primaryid$caseid$caseversion$i_f_code$event_dt$mfr_dt$init_fda_dt$fda_dt$rept_cod$auth_num$mfr_num$mfr_sndr$lit_ref$age$age_cod$age_grp$sex$e_sub$wt$wt_cod$rept_dt$to_mfr$occp_cod$reporter_country$occr_country
100289774$10028977$4$F$$20250729$20140321$20250806$EXP$$PHHY2014IN032993$GLAXOSMITHKLINE$Patelln DR, Dosi VR, Shah CP, Joshi SH. Widespread bullous fixed drug eruption. BMJ Case Reports. 2014;1-3$53$YR$$M$Y$$$20250805$$MD$IN$IN
1078729226$10787292$26$F$20150116$20250918$20150211$20250926$EXP$$CA-ROCHE-1535957$ROCHE$$51$YR$A$F$Y$$$20250926$$CN$CA$CA
111462422$11146242$2$F$20121013$20250728$20150528$20250805$EXP$$PHHY2015MX060265$NOVARTIS$$68$YR$$F$Y$73$KG$20250805$$CN$MX$MX
120429906$12042990$6$F$20160107$20170612$20160208$20250709$EXP$$JP-SA-2016SA017771$SANOFI AVENTIS$$54$YR$A$F$Y$74$KG$20250710$$MD$JP$JP
120984983$12098498$3$F$$20160209$20160222$20250810$PER$$US-AstraZeneca-2016SE14433$ALEXION PHARMACEUTICALS$$75$YR$E$F$Y$73.028$KG$20250810$$$US$US
128724082$12872408$2$F$20140601$20250914$20161021$20250916$EXP$$US-MUNDIPHARMA DS AND PHARMACOVIGILANCE-USA-2016-0133989$PURDUE$$$$$M$Y$$$20250916$$CN$US$US
130932869$13093286$9$F$$20250711$20170106$20250716$EXP$$AU-PFIZER INC-2017004390$PFIZER$Tabet, E.. Opioid-induced transient secondary hypoadrenalism: Are some clinically significant cases being overlooked?. Endocrine Reviews. 2015;36(2)$18$YR$$F$Y$46$KG$20250716$$HP$AU$AU
132340786$13234078$6$F$20170202$20240801$20170215$20250715$EXP$$PHHY2017CO020740$NOVARTIS$$59$YR$$F$Y$48$KG$20250715$$CN$CO$CO
137398815$13739881$5$F$$20250822$20170711$20250903$EXP$$EU-AUROBINDO-AUR-APL-2017-37190$AUROBINDO$Harmark L. Pregabalin and visual colour distortions. Lareb. WHO Pharmaceuticals newsletter.. 2017;3:19-23$$$A$M$Y$$$20250903$$MD$EU$EU
138806013$13880601$3$F$$20250731$20170818$20250808$EXP$$EU-TEVA-797218GER$TEVA$Tountopoulou M, Weschke B, Kaindl AM. Lacosamide Lowers Valproate and Levetiracetam Levels. Neuropediatrics 2017;48(3):188-189.; Tountopoulou M, Roggenkamp V, Weschke B, Kaindl AM. Lacosamide Lowers Valproate and Levetiracetam Levels. Neuropediatrics 2017; 48 (Suppl.) (1): (plus Poster).; Tountopoulou M, Weschke B, Kaindl AM. Lacosamide Lowers Valproate and Levetiracetam Levels. Neuropediatrics 2017;48(3):188-189.$14$YR$$$Y$$$20250808$$MD$EU$EU
139282123$13928212$3$F$$20250901$20170901$20250915$EXP$AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2017-00565$AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2017-00565$ALKEM$Sharma M.. Parvovirus B19 induced pure red cell aplasia after 11 years unrelated allogeneic bone marrow transplantation. International Journal of Laboratory Hematology. 2017;39 (2):104-105$76$YR$$M$Y$$$20250915$$MD$AU$AU
139400183$13940018$3$F$$20250819$20170906$20250901$EXP$$US-AUROBINDO-AUR-APL-2017-39776$AUROBINDO$Patel MG, Quddus S.. Acute fibrinous and organizing pneumonia in a lung transplant patient managed without calcineurin inhibitors.. American Journal of Respiratory and Critical Care Medicine. 2017;195$60$YR$$F$Y$$$20250901$$HP$US$US
144261993$14426199$3$F$20160101$20250822$20180123$20250829$EXP$$EU-SA-2018SA016207$SANOFI AVENTIS$Vincent N, Miroslav I, Jaroslav B.. Management of patients with kidney rupture and bleeding into retroperitoneum.. clin urology.. 2017;13:136-40$64$YR$A$F$Y$$$20250829$$HP$EU$EU
146792669$14679266$9$F$20180301$20250826$20180326$20250828$PER$$US-PFIZER INC-2018122075$PFIZER$$48$YR$$M$Y$149$KG$20250828$$CN$US$US
148544778$14854477$8$F$$20250729$20180507$20250804$EXP$CA-MLMSERVICE-20180423-1153752-1$CA-PFIZER INC-2018184897$PFIZER$Haubrich, K.. Successful treatment of chronic norovirus gastroenteritis with nitazoxanide in a pediatric kidney transplant recipient.. Pediatric Transplantation.. 2018;10.1111/petr.13186$13$YR$$M$Y$$$20250804$$PH$CA$CA
149515208$14951520$8$F$20170401$20190828$20180530$20250918$EXP$$PHJP2018JP011548$NOVARTIS$$70$YR$$F$Y$$$20250918$$HP$JP$JP
150131879$15013187$9$F$$20241212$20180614$20250803$EXP$$EU-ALEXION PHARMACEUTICALS INC-A201807235$ALEXION PHARMACEUTICALS$Calbi V, Fumagalli F, Penati R, Consiglieri G, Migliavacca M, Redaelli D. Defibrotide prophylaxis and adjustment of busulfan schedule to prevent veno-occlusive disease and thrombotic microangiopathy in an infant with a membrane cofactor protein gene mutation and metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy (hsc-gt). Bone marrow transplantation. 2017;52(1):431-432$8$MON$I$$Y$$$20250803$$$EU$EU
151350882$15135088$2$F$20180501$20250806$20180712$20250812$EXP$$US-VERTEX PHARMACEUTICALS-2018-004700$VERTEX$$49$YR$$F$Y$45$KG$20250812$$HP$US$US
151706353$15170635$3$F$$20250624$20180720$20250708$EXP$$EU-AUROBINDO-AUR-APL-2018-036896$AUROBINDO$Hoeltzenbein M., Tissen-Diabate T., Fietz A.-K., Zinke S., Kayser A., Meister R. at al.. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.. Pregnancy Hypertens. 2018;13:65-71$$$N$M$Y$$$20250708$$MD$EU$EU
152537184$15253718$4$F$$20250630$20180808$20250709$EXP$$CA-ASTELLAS-2018US034715$ASTELLAS$$53$YR$A$M$Y$$$20250709$$HP$CA$CA
1529742241$15297422$41$F$$20250909$20180820$20250912$EXP$$CA-NAPPMUNDI-CAN-2018-0008915$PURDUE$$36$YR$$F$Y$$$20250912$$MD$CA$CA
153050754$15305075$4$F$$20250626$20180822$20250709$EXP$$EU-AUROBINDO-AUR-APL-2018-042554$AUROBINDO$Sousa B.,Tavares N.,. Lynfocytic colitis (Clinical case).. Biomedical and Biopharmaceutical Research. 2018;15(1):50-4$67$YR$$F$Y$97.6$KG$20250709$$MD$EU$EU
153196952$15319695$2$F$$20250704$20180827$20250717$EXP$$EU-AUROBINDO-AUR-APL-2018-043126$AUROBINDO$Degasperi E, De Nicola S, Rumi M, D^Ambrosio R.. HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.. Journal of Hepatology.. 2016;65(5):1058-59$$$A$$Y$$$20250717$$HP$EU$EU
153503392$15350339$2$F$$20250703$20180905$20250717$EXP$$EU-AUROBINDO-AUR-APL-2018-043938$AUROBINDO$Quattrocchi C.C, Alexandre A.M, Tonini G. Errante Y, Grasso R.F, Zobel B.B.. Brain microischemic phenomena in a woman receiving bevacizumab treatment: A case report.. Journal of Medical Case Reports. 2011;5:84$37$YR$$F$Y$$$20250717$$HP$EU$EU
154724003$15472400$3$F$20150101$20250702$20181008$20250715$EXP$$US-AUROBINDO-AUR-APL-2018-048166$AUROBINDO$Mor LT, Holley K.. A Case Report of Anticoagulation Management in Acquired Hemophilia Associated With Levofloxacin. .. Journal of Pharmacy Practice.. 2018;33(3):378-381$78$YR$$F$Y$$$20250715$$HP$US$US
155158142$15515814$2$F$$20250731$20181017$20250814$EXP$$EU-AUROBINDO-AUR-APL-2018-050779$AUROBINDO$Serafim A., Ferreira A., Company R., Carneiro A., Agostini P., Figueiredo T.. Caracter?sticas Ecogr?ficas do Hidradenoma Ap?crino Cut?neo: Descri??o de um Caso Cl?nico.. Acta Radiol?gica Portuguesa.. 2018;30(2):39-41$82$YR$$M$Y$$$20250814$$MD$EU$EU
155346622$15534662$2$F$$20250708$20181022$20250721$EXP$$US-AUROBINDO-AUR-APL-2018-050813$AUROBINDO$Nissly T, Levy R.. Buprenorphine to treat opioid use disorder: A practical guide.. Journal of Family Practice. 2018;67(9):544-548$55$YR$$M$Y$$$20250721$$MD$US$US
155467542$15546754$2$F$$20250705$20181024$20250718$EXP$$US-MYLANLABS-2018M1076704$AUROBINDO$Yetto TO, Burns C.. Linear IgA bullous dermatosis associated with ulcerative proctitis: Treatment challenge.. Dermatol-Online-J. 2018;24(7):14$58$YR$$M$Y$$$20250718$$MD$US$US
155600852$15560085$2$F$$20250705$20181029$20250718$EXP$$GB-AUROBINDO-AUR-APL-2018-052446$AUROBINDO$Wilson C, Duckers J, Rajenderkumar D.. Unusual discovery of a vestibular schwannoma following eradication therapy for Mycobacterium abscessus.. BMJ-Case-Rep. 2018$4$DEC$$M$Y$$$20250718$$MD$GB$GB
155784503$15578450$3$F$$20250620$20181102$20250701$EXP$$EU-AUROBINDO-AUR-APL-2018-053326$AUROBINDO$Xipell M, Losno RA, Garcia-Vidal C, Rovira M, Alejo-Cancho I, Puig de la Bellacasa J, et al.. Clinical features and outcome in patients with mucormycosis in a tertiary hospital (2012-2016).. Revista Iberoamericana de Micologia. 2018$53$YR$$M$Y$$$20250701$$MD$EU$EU
156885832$15688583$2$F$$20250709$20181205$20250722$EXP$$GB-AUROBINDO-08-AUR-03018$AUROBINDO$lodge J Peter A, Dasgupta D, Prasad KR, Attia M, Toogood GJ, Davies M.. Emergency subtotal hepatectomy: A new concept for acetaminophen induced acute liver failure temporary hepatic support by auxiliary orthotopic liver transplantation enables long term success. Annalsof surgery. 2008;247 (2):238 - 49$41$YR$$M$Y$71$KG$20250722$$MD$GB$GB
157546482$15754648$2$F$$20250822$20181224$20250901$EXP$$EU-ROCHE-2228321$ROCHE$Balazs S, Alexandra A, Akos K, Csilla C, Ibolya C. The role of CMR in the evaluation of acute mixed cardiac allograft rejection.. Cardiologica Hungarica.. 2018;48:44-51. doi:10.26430/CHUNGARICA.2018.48.1.44.$$$A$$Y$$$20250901$$HP$EU$EU
157741902$15774190$2$F$$20250625$20181229$20250709$EXP$$EU-AUROBINDO-AUR-APL-2018-063651$AUROBINDO$Bonnet U, Strasser J, Scherbaum N.. Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population.. Addictive Behaviors. 2018;90:265-71$73$YR$$F$Y$$$20250709$$HP$EU$EU
157786842$15778684$2$F$$20250625$20181231$20250710$EXP$$US-AUROBINDO-AUR-APL-2018-061354$AUROBINDO$Short RG, Tailor TD.. Case 260: Endobronchial posttransplantation lymphoproliferative disease.. Radiology.. 2018;289(3)::876-880.$31$YR$$F$Y$$$20250710$$MD$US$US
157875062$15787506$2$F$$20250714$20190103$20250725$EXP$$US-MYLANLABS-2018M1097654$AUROBINDO$Bishop-Freeman SC, Hensel EM, Feaster MS, Winecker RE.. Degradation of Bupropion: Implications for Interpretation of Postmortem Case Data.. J-Anal-Toxicol. 2018;42(8):525-536$36$YR$$M$Y$$$20250725$$HP$US$US
157957362$15795736$2$F$$20250714$20190107$20250724$EXP$$US-MYLANLABS-2018M1097690$AUROBINDO$Bishop-Freeman SC, Hensel EM, Feaster MS, Winecker RE. Degradation of Bupropion: Implications for Interpretation of Postmortem Case Data.. J-Anal-Toxicol. 2018;42(8):525-536$30$YR$$M$Y$$$20250724$$HP$US$US
158520222$15852022$2$F$$20250910$20190122$20250924$EXP$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2018-06154$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2018-06154$ALKEM$Diestelmann M, Zangl A, Herrle I, Koch E, et al.. MDPV in forensic routine cases: Psychotic and aggressive behavior in relation to plasma concentrations. Forensic Science International. 2018;283:72-84$37$YR$$M$Y$$$20250924$$HP$EU$EU
159225323$15922532$3$F$$20250714$20190206$20250728$EXP$$EU-AUROBINDO-AUR-APL-2018-056136$AUROBINDO$Mendes T, Costa R, Pereira M, Costa V, Araujo E, Barbosa M et al.. Hepatite fulminante com disfun??o multi-org?nica em doente com depend?ncia alco?lica (Fulminant hepatitis with multi-organ dysfunction in a patient with alcohol dependence).. Medicina Interna. (Internal medicine). 2017;23:1$42$YR$$F$Y$$$20250728$$MD$EU$EU
159605732$15960573$2$F$$20250828$20190214$20250911$EXP$$EU-AUROBINDO-AUR-APL-2019-007483$AUROBINDO$Iacusso C, Morini F, Capolupo I, Dotta A, Bagolan P, Parisi F,  et al.. Lung Transplantation for Late-Onset Pulmonary Hypertension in a Patient with Congenital Diaphragmatic Hernia.. European J Pediatr Surg Rep. 2018;6(1):e100-e103$10$YR$$F$Y$$$20250911$$MD$EU$EU
159891082$15989108$2$F$$20250709$20190221$20250723$EXP$$EU-AUROBINDO-AUR-APL-2019-008591$AUROBINDO$Havlinova A, Kodet O, Prochazkova I, Sukova T, Stork J.. Klinicky pripad: Strouzkovite utvary periungvalne. Strucny prehled./Clinical case: Periungual clove-like formations. Brief overview. Ces-slov Derm.. 2018;93(5):186-9$68$YR$$F$Y$$$20250723$$MD$EU$EU
1601105712$16011057$12$F$20180208$20250918$20190227$20250923$EXP$$JP-ABBVIE-19P-087-2682524-00$ABBVIE$$46$YR$$M$Y$61$KG$20250923$$MD$JP$JP
160435815$16043581$5$F$$20250814$20190306$20250822$EXP$$US-TAKEDA-2019TUS011105$TAKEDA$$$$$M$Y$$$20250822$$$US$US
161158602$16115860$2$F$$20250702$20190326$20250703$EXP$$EU-AUROBINDO-AUR-APL-2019-015062$AUROBINDO$Garcia-Carretero R.. Bacteraemia and multiple liver abscesses due to Fusobacterium nucleatum in a patient with oropharyngeal malignancy.  2019;12(1):Article Number e228237. DOI: 10.1136/bcr-2018-228237.. BMJ Case Reports. 2019;12(1):e228237$92$YR$$F$Y$$$20250703$$MD$EU$EU
1615636313$16156363$13$F$20170420$20250804$20190404$20250806$EXP$$EU-SA-2017SA148451$SANOFI AVENTIS$$40$YR$A$F$Y$55$KG$20250806$$MD$EU$EU
161624012$16162401$2$F$$20250713$20190405$20250723$EXP$$EU-AUROBINDO-AUR-APL-2019-018026$AUROBINDO$Quarteroni L, Pluchart H, Faure C, Briault A, Chanoine S, Claustre J, et al.. PT027: Foscarnet use in multidrug-resistant cytomegalovirus in lung-transplanted patient: is it a feasible option?. International Journal of Clinical Pharmacy.. 2019;41 (1):378$67$YR$$M$Y$$$20250723$$MD$EU$EU
161624492$16162449$2$F$20160101$20250723$20190405$20250804$EXP$$EU-AUROBINDO-AUR-APL-2019-017862$AUROBINDO$Silva M, Ferreira F, Joosten A, Pereira L, Campante F. IGG4 pancreatitis - a rare cause of diabetes mellitus. Revista Portuguesa de Diabetes. 2019;14(1):47-122$73$YR$$M$Y$$$20250804$$HP$EU$EU
162345872$16234587$2$F$$20250711$20190424$20250723$EXP$$US-MYLANLABS-2019M1037962$AUROBINDO$Chakrabarti S, Sara J, Lobo R, Eiring R, Finnes H, Mitchell J, et al.. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.. Clin-Colorectal-Cancer. 2019;18(1):52-57$36$YR$$M$Y$$$20250723$$MD$US$US
162588512$16258851$2$F$$20250711$20190501$20250723$EXP$$EU-AUROBINDO-AUR-APL-2019-024035$AUROBINDO$Kreuzer P, Landgrebe M, Wittmann M, Schecklmann M, Poeppl TB, Hajak G, et al.. Hypothermia Associated With Antipsychotic Drug Use: A Clinical Case Series and Review of Current Literature. J Clin Pharmacol. 2011;52:1090-1097$51$YR$$F$Y$$$20250723$$MD$EU$EU
162631022$16263102$2$F$$20250708$20190502$20250722$EXP$$EU-AUROBINDO-AUR-APL-2019-023853$AUROBINDO$Antonietta R.,Paolo A.,Sara P.,Franco N.,Georgios A.,Liliana C.,et al... Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.. JOURNAL OF HEPATOLOGY.. 2018;69 (2):345-352$75$YR$$$Y$$$20250722$$HP$EU$EU
162742752$16274275$2$F$$20250708$20190504$20250721$EXP$$EU-AUROBINDO-AUR-APL-2019-024159$AUROBINDO$Lauterbach M.. Clinical toxicology of beta-blocker overdose in adults. Basic-Clin-Pharmacol-Toxicol. 2019;125:178?186$$$A$$Y$$$20250721$$MD$EU$EU
163086223$16308622$3$F$$20250711$20190514$20250723$EXP$$GB-AUROBINDO-AUR-APL-2019-026298$AUROBINDO$Reyhani Calvo A, Rajagopal S, Panagiotopoulos S, Rubino F. Marginal ulcer after gastric bypass: An underestimated complication. Surgical Endoscopy. 2018;32(2):S579$59$YR$$F$Y$$$20250723$$HP$GB$GB
163420182$16342018$2$F$$20250724$20190522$20250728$EXP$$EU-UCBSA-2019011474$UCB$Duat Rodriguez A, Cantarin Extremera V, Garcia Fernandez M, Garcia Penas JJ, Ruiz-Falco Rojasa ML. Induccion de crisis de ausencia atipica durante el tratamiento con perampanel [Induced atypical absence seizures during treatment with perampanel]. An Pediatr (Barc). 2019;346-348$38$MON$$F$Y$$$20250728$$MD$EU$EU
1636023511$16360235$11$F$20160101$20250731$20190528$20250807$EXP$$BR-BIOGEN-2017BI00448316$BIOGEN$$$$$M$Y$74$KG$20250807$$CN$BR$BR
163709012$16370901$2$F$$20250829$20190530$20250912$EXP$$EU-AUROBINDO-AUR-APL-2019-029968$AUROBINDO$Dias D, Santos R, Leite V.. Efficacy of chemotherapy with GEMOX in a case of Follicular Thyroid Cancer. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo. 2019;89$$$A$M$Y$$$20250912$$MD$EU$EU
163762482$16376248$2$F$$20250712$20190531$20250723$EXP$$EU-AUROBINDO-AUR-APL-2019-005258$AUROBINDO$Pinho DGQ, Brue A, Kapanski G, Granel B, Benyamine A.. Efficacite du rtituximab dans le traitment de la cascularite urticarienne hypocomeplementemiante  prpros d? une obsercation.. REVUE DE MEDECINE INTERNE.. 2018;39 (2018):A103-A235$19$YR$$F$Y$$$20250723$$HP$EU$EU
164129592$16412959$2$F$$20250702$20190611$20250715$EXP$$EU-AUROBINDO-AUR-APL-2019-032311$AUROBINDO$Mangia A., Piazzolla V., Giannelli A., Visaggi E., Minerva N., Palmieri V. et al... SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience... PLoS ONE. 2019;14(5):1-14$$$A$$Y$$$20250715$$HP$EU$EU
164304207$16430420$7$F$$20250711$20190614$20250721$EXP$$EU-AUROBINDO-AUR-APL-2019-033208$AUROBINDO$Czlonkowska A,  Dzieiyc-Jaworska K, Klysz B, Barbara RO, Litwin T. Difficulties in diagnosis and treatment of Wilson disease -A case series of five patients. Annals of Translational Medicine. 2019;7(suppl.2):S73$23$YR$$F$Y$$$20250721$$MD$EU$EU
164374553$16437455$3$F$$20250708$20190615$20250720$EXP$$EU-AUROBINDO-AUR-APL-2019-034466$AUROBINDO$Castel M, Cotten C, Deschamps-Huvier A, Commin MH, Marguet F, Jardin F et al.. Primary central nervous system lymphoma following immunotherapy for metastatic melanoma. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 2019;1-6$59$YR$$M$Y$$$20250720$$HP$EU$EU
164442603$16444260$3$F$20180501$20250703$20190618$20250715$EXP$$EU-AUROBINDO-AUR-APL-2019-034388$AUROBINDO$Domenico C, Antonella I, Benedetto C, Gallelli L.. Panitumumab Induced Forearm Panniculitis In Two Women With Metastatic Colon Cancer. Current Drug Safety. 2019;14:1-5$44$YR$$F$Y$$$20250715$$HP$EU$EU
164721374$16472137$4$F$20121021$20250708$20190625$20250722$EXP$$EU-AUROBINDO-AUR-APL-2019-035512$AUROBINDO$Marcello T, Elisa R, Laura F, Anna P, Alberto DV, Francesca B, et al.. Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents.. Springer Science+Business Media, LLC, part of Springer Nature.. 2019$79$YR$$M$Y$$$20250722$$MD$EU$EU
165273795$16527379$5$F$20180301$20250826$20190704$20250923$EXP$$EU-TAKEDA-2019TUS041219$TAKEDA$$15$DY$$M$Y$$$20250923$$MD$EU$EU
165301632$16530163$2$F$$20250708$20190704$20250718$EXP$$EU-AUROBINDO-AUR-APL-2019-037476$AUROBINDO$Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Europ. 2019;118:178-186$$$A$F$Y$$$20250718$$HP$EU$EU
166501092$16650109$2$F$$20250815$20190731$20250825$EXP$$EU-CELLTRION INC.-2019RO023167$CELLTRION$$$$$$Y$$$20250825$$CN$EU$EU
166598093$16659809$3$F$20190101$20250903$20190802$20250909$EXP$$CA-TAKEDA-2019TUS045999$TAKEDA$$$$$F$Y$75$KG$20250909$$$CA$CA
168207155$16820715$5$F$$20250910$20190918$20250918$EXP$$CA-TAKEDA-2019TUS045554$TAKEDA$$$$$M$Y$$$20250918$$MD$CA$CA
168837084$16883708$4$F$$20250616$20191004$20250701$EXP$$CA-AUROBINDO-AUR-APL-2019-063501$AUROBINDO$Tremblay F, Chapdelaine H, Lavoie A, Berthiaume Y, Sabbah L, Bernstein SC, et al... Toxic epidermal necrolysis in a patient with cystic fibrosis.. J-Allergy-Clin-Immunol-Pract.. 2016;4(3):526-528$42$YR$$M$Y$$$20250701$$MD$CA$CA
168959145$16895914$5$F$$20250805$20191008$20250813$EXP$$CA-MYLANLABS-2019M1094314$MYLAN$Lewin A, Quach C, Rigourd V, Picaud J-C, Perreault T, Frange P, et al. Bacillus cereus infection in neonates and the absence of evidence for the role of banked human milk: Case reports and literature review. Infect-Control-Hosp-Epidemiol 2019;40(7):787-793.$$$N$$Y$$$20250813$$$CA$CA
169128414$16912841$4$F$20160101$20250811$20191014$20250822$EXP$$EU-AUROBINDO-AUR-APL-2019-061556$AUROBINDO$Witkos A, Copija A, Ikora-Skrabaka M, Nowakowska-Zajdel E.. Interval treatment of chronic myeloid leukaemia in patient with breast cancer undergoing palliative chemotherapy.. Onkologia w Praktyce Klinicznej - Edukacja.. 2018;4:B22$51$YR$$F$Y$$$20250822$$MD$EU$EU
169504602$16950460$2$F$20180101$20250813$20191023$20250926$EXP$$US-SUNOVION-2019SUN004478$SUNOVION$$69$YR$$F$Y$78.186$KG$20250822$$$US$US
169822782$16982278$2$F$$20250812$20191101$20250821$EXP$$EU-AUROBINDO-AUR-APL-2019-070679$AUROBINDO$Magallanes Gamboa JO, Notario Barba V, Marcos S?nchez F.. Dolor en el miembro inferior.. REV CLIN MED FAM.. 2019;12(3):155-159$83$YR$$F$Y$$$20250821$$HP$EU$EU
170290892$17029089$2$F$$20250811$20191114$20250822$EXP$$EU-AUROBINDO-AUR-APL-2019-072399$AUROBINDO$Vida A, Lemos C, Vieira A, Vieira P, Dias G, Braz?o M.. Lombalgia, calafrios e febre - nem tudo ? o que parece. Congressos Nacionais 25CNMI19. 2019$71$YR$$M$Y$$$20250822$$MD$EU$EU
170292193$17029219$3$F$$20250627$20191114$20250705$EXP$$EU-AUROBINDO-AUR-APL-2019-072214$AUROBINDO$Rodrigues C, Naia L, Vasconcelos A, Vidal I, Cunha B, Simoes R, et al.. Aneurisma da aorta ascendente: relembrar para nao escapar. Medicina Interna - Congressos Nacionais 25CNMI19. 2019$89$YR$$M$Y$$$20250705$$MD$EU$EU
1705309618$17053096$18$F$$20250902$20191120$20250908$PER$$US-PFIZER INC-2019495947$PFIZER$$73$YR$$F$Y$56.7$KG$20250908$$CN$US$US
170735072$17073507$2$F$$20250811$20191126$20250825$EXP$$EU-AUROBINDO-AUR-APL-2019-074392$AUROBINDO$Esteves A, Carvoeiro A, Ribeiro M, Felgueiras P, Guerra D, Rodrigues C.. Estenose da art?ria renal bilateral- o diagn?stico ?bvio (BILATERAL RENAL ARTERY STENOSIS - THE OBVIOUS DIAGNOSIS). Medicina Interna - Congressos Nacionais 25CNMI19. 2019$76$YR$$F$Y$$$20250825$$MD$EU$EU
171305703$17130570$3$F$$20250812$20191209$20250818$EXP$$CA-PURDUE-CAN-2019-0010454$PURDUE$$75$YR$$F$Y$$$20250818$$CN$CA$CA
171328582$17132858$2$F$$20250708$20191210$20250718$EXP$$EU-AUROBINDO-AUR-APL-2019-103663$AUROBINDO$Jaholkowski P, Niewiadomska J, Wci?rka J, Kowalski M, ?witaj P. Clozapine-induced myocarditis during valproic acid treatment: case report.. POLISH PSYCHIATRY.. 2019;53(5):997-1002$22$YR$$M$Y$$$20250718$$MD$EU$EU
171671172$17167117$2$F$$20250627$20191218$20250710$EXP$$US-AUROBINDO-AUR-APL-2019-104220$AUROBINDO$Tariq T, Dawdy J, Goyal S, Mohamad B, Singh M, Mutchnick M, et al.. Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD.. ACG Case Reports Journal.. 2019;6(7):1-3$56$YR$$M$Y$$$20250710$$MD$US$US
1719240638$17192406$38$F$20191028$20250709$20191223$20250715$EXP$$CA-CELLTRION INC.-2019CA025072$CELLTRION$$$$$$Y$$$20250715$$CN$CA$CA
171932574$17193257$4$F$20191112$20250830$20191223$20250904$EXP$$US-SHIRE-US201944414$TAKEDA$$16$YR$$M$Y$$$20250904$$$US$US
172024082$17202408$2$F$$20250724$20191226$20250729$EXP$$CA-MYLANLABS-2019M1127015$MYLAN$$83$YR$$F$Y$$$20250729$$$CA$CA
1721976915$17219769$15$F$$20250924$20191231$20250929$EXP$$US-SHIRE-US201945039$TAKEDA$$$$A$F$Y$65.76$KG$20250929$$$US$US
172398962$17239896$2$F$$20250626$20200106$20250709$EXP$$GB-AUROBINDO-AUR-APL-2020-000125$AUROBINDO$Quinn L, Shepherd L, Kauser S, Johnson B, Lawson A, Bates A. Adrenal insufficiency from steroid-containing complementary therapy:Importance of detailed history. Endocrinology, Diabetes and Metabolism Case Reports. 2019;19(1)$62$YR$$F$Y$$$20250709$$HP$GB$GB
172630256$17263025$6$F$$20250723$20200113$20250729$PER$$US-PFIZER INC-2019443655$PFIZER$$65$YR$$M$Y$97$KG$20250729$$CN$US$US
1732409719$17324097$19$F$20210101$20250701$20200127$20250711$EXP$$BR-GLAXOSMITHKLINE-BR2020AMR012597$GLAXOSMITHKLINE$$$$$F$Y$60$KG$20250711$$$BR$BR
173753017$17375301$7$F$$20250628$20200205$20250707$EXP$$EU-MYLANLABS-2020M1012741$MYLAN$Andreani G, Fadda G, Gned D, Dragani M, Cavallo G, Monticone V, et al., Rhino-orbital-cerebral mucormycosis after allogeneic hematopoietic stem cell transplantation and isavuconazole therapeutic drug monitoring during intestinal graft versus host disease. Article Number e2019061, Mediterr. J. Hematol. Infect. Dis., 2019, 11(1), 1-6$59$YR$$M$Y$$$20250703$$MD$EU$EU
174116512$17411651$2$F$$20250630$20200213$20250711$EXP$$EU-AUROBINDO-AUR-APL-2020-006777$AUROBINDO$Van Lanschot Hubrecht WJ, Be WKM, Fredriks IM, Dalman JE.. Mix-up of medication in spinal anaesthetics (Verwisseling van medicatie bij spinale anesthesie). Ned Tijdschr Geneeskd. (NED JOURNAL OF MEDICINE). 2019;163:D3192$53$YR$$F$Y$$$20250711$$HP$EU$EU
174182982$17418298$2$F$$20250811$20200214$20250821$PER$$US-UNITED THERAPEUTICS-UNT-2018-012841$UNITED THERAPEUTICS$$$$$F$Y$110.66$KG$20250821$$$US$US
174384415$17438441$5$F$20120101$20250813$20200220$20250826$EXP$$EU-AUROBINDO-AUR-APL-2020-008613$AUROBINDO$Casper M., Reichert M., Gr?nhage F., Lammert F... Long-term ribavirin therapy as a treatment option in chronic hepatitis E virus infection. Annual Meeting of the German Association for the Study of the Liver (GASL). 2020$73$YR$$M$Y$$$20250826$$MD$EU$EU
174391662$17439166$2$F$$20250619$20200220$20250701$EXP$$EU-AUROBINDO-AUR-APL-2020-008706$AUROBINDO$Yuste J, de Cerio A, Rifon J, Moreno C, Panizo M, Inoges S. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients. ANTIVIRAL THERAPY. 2019;24:313-319$$$E$M$Y$$$20250701$$HP$EU$EU
174664552$17466455$2$F$20180101$20250725$20200227$20250806$EXP$$EU-AUROBINDO-AUR-APL-2020-009573$AUROBINDO$Herncirova Lucia.. Treating a patient with chronic heart failure and decreased ejection fraction.. ACTA MEDICINAE. 2019;8(15):60-3$60$YR$$M$Y$$$20250806$$HP$EU$EU
174742523$17474252$3$F$$20250619$20200228$20250704$EXP$$US-MYLANLABS-2020M1021612$AUROBINDO$Lingamaneni P, Desai PM, Mathew M, Moturi KR, Gupta S.. Tumor lysis syndrome in a patient with gastric adenocarcinoma.. Am-J-Gastroenterol. 2019;114 (Suppl.):S1492-S1493$48$YR$$M$Y$$$20250704$$MD$US$US
174864152$17486415$2$F$$20250721$20200303$20250801$EXP$$EU-AUROBINDO-AUR-APL-2019-036244$AUROBINDO$Piccioni AL. Outpatient management of nausea and vomiting in the multi-day therapy of acute myeloid leukemia in the elderly. Use of granisetron in slow-release transdermal formulation, a clinical case. Recent Progress in Medicine. 2019;110(3):e10-e13$64$YR$$F$Y$$$20250801$$HP$EU$EU
175317526$17531752$6$F$$20201116$20200311$20250707$PER$$NVSC2020US065688$NOVARTIS$$$$$F$Y$$$20250707$$CN$US$US
1754971922$17549719$22$F$20240102$20250703$20200317$20250708$EXP$$US-SHIRE-US202010049$TAKEDA$$71$YR$$F$Y$113$KG$20250708$$$US$US
1755998736$17559987$36$F$20220919$20250923$20200319$20250928$EXP$$US-SHIRE-US202010294$TAKEDA$$76$YR$$F$Y$78$KG$20250928$$$US$US
175645973$17564597$3$F$$20250626$20200320$20250711$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-240633$RANBAXY$$$$E$F$Y$$$20250711$$CN$US$US
175966192$17596619$2$F$$20250618$20200330$20250703$EXP$$US-AUROBINDO-AUR-APL-2020-015063$AUROBINDO$Tang AA, Lin AL.. Purtscher-like retinopathy in adult-onset Still^s disease, complicated by treatment-related central serous chorioretinopathy.. American Journal of Ophthalmology Case Reports.. 2020;18:10063$53$YR$$F$Y$$$20250703$$HP$US$US
176886622$17688662$2$F$20190901$20250711$20200421$20250711$EXP$$EU-JNJFOC-20200416793$JOHNSON AND JOHNSON$$30$YR$A$M$Y$115$KG$20250711$$CN$EU$EU
177093552$17709355$2$F$20120101$20250619$20200426$20250704$EXP$$EU-AUROBINDO-AUR-APL-2020-019999$AUROBINDO$Di Battista ME, Dell^Acqua C, Galimberti D, Serpente M, Boccaletto F, Gallucci M. A case of bipolar disorder developing into atypical parkinsonism and presenting with frontotemporal asymmetrical brain degeneration. A TREDEM Registry Case Report. Bipolar Disorders. 2020;22(2):201-203$67$YR$$M$Y$$$20250704$$HP$EU$EU
177351392$17735139$2$F$20200402$20200406$20200501$20250703$PER$$US-RADIUS HEALTH INC.-2020US001300$RADIUS PHARM$$71$YR$$F$Y$$$20250704$$CN$US$US
177575167$17757516$7$F$20160101$20250805$20200507$20250808$PER$$US-GILEAD-2020-0464223$GILEAD$$$$A$M$Y$102.04$KG$20250808$$LW$US$US
177685192$17768519$2$F$$20250618$20200512$20250703$EXP$$EU-AUROBINDO-AUR-APL-2020-024177$AUROBINDO$de Campos D, Teixeira R, Saleiro C, Botelho A, Goncalves L. A Spleen Complication After an Acute Myocardial Infarction. JACC: Case Reports. 2020;2(4):619-620$63$YR$$M$Y$$$20250703$$MD$EU$EU
177688313$17768831$3$F$$20250908$20200512$20250922$EXP$$EU-AUROBINDO-AUR-APL-2020-022417$AUROBINDO$Freund W. Neurological casuistry: Depressed and always tired again. NEUROTRANSMITTER. 2020;31(4)$19$YR$$F$Y$$$20250922$$HP$EU$EU
177775844$17777584$4$F$$20250808$20200513$20250819$EXP$$EU-TEVA-2020-FR-1233871$TEVA$Vukusic S, Hellwig K, Truffinet P, Benamor M, Strattman S, Afsar S, et al. Pregnancy outcomes in female partners of male patients treated with teriflunomide or leflunomide (an in vivo precursor of teriflunomide). Mult-Scler-J 2019;25 (Suppl. 2):620.; Vukusic S, Hellwig K, Truffinet P, Benamor M, Strattman S, Afsar S, et al. Pregnancy outcomes in female partners of male patients treated with teriflunomide or leflunomide (an in vivo precursor of teriflunomide). Mult-Scler-J 2019;25 (Suppl. 2):620.$$$$$Y$$$20250819$$HP$EU$EU
177961414$17796141$4$F$20131212$20250728$20200517$20250804$EXP$$CA-ROCHE-2602200$ROCHE$$64$YR$A$F$Y$$$20250804$$MD$CA$CA
178116512$17811651$2$F$20180306$20200513$20200521$20250709$EXP$$PHHY2018NL057110$NOVARTIS$$54$YR$$F$Y$$$20250709$$HP$EU$EU
178840503$17884050$3$F$$20250702$20200611$20250715$EXP$$EU-MYLANLABS-2020M1055199$AUROBINDO$Penel-Page M, Plesa A, Girard S, Marceau-Renaut A, Renard C, Bertrand Y.. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.. Pediatr-Blood-Cancer. 2020;67:6$17$YR$$M$Y$$$20250715$$MD$EU$EU
179139702$17913970$2$F$$20250707$20200619$20250708$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029828$BOEHRINGER INGELHEIM$$53$YR$A$F$Y$$$20250708$$MD$CA$CA
1792605155$17926051$55$F$20201024$20250912$20200623$20250917$EXP$$US-SHIRE-US202020335$TAKEDA$$31$YR$$F$Y$49$KG$20250917$$$US$US
179330162$17933016$2$F$$20250813$20200624$20250826$EXP$$EU-AUROBINDO-AUR-APL-2020-030631$AUROBINDO$Alonso-Claudio G, Moralejo-Alonso L.. Herramientas para garantizar la continuidad asistencial en el paciente pluripatol?gico cr?nico. (Tools to ensure continuity of care for chronic multi-pathological patients). Revista Espa?ola de Casos Cl?nicos en Medicina Interna.. 2020;5 (Supl 1):3-5$78$YR$$M$Y$51.5$KG$20250826$$HP$EU$EU
179808455$17980845$5$F$$20250618$20200704$20250701$EXP$$EU-AUROBINDO-AUR-APL-2020-031748$AUROBINDO$Mas Serrano M, Perez-Sanchez J, Portela Sanchez S, et al.. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.. Journal Neurological Science.. 2020;415:116944$78$YR$$M$Y$$$20250701$$HP$EU$EU
1799247215$17992472$15$F$20230519$20250912$20200708$20250917$EXP$$US-SHIRE-US202021829$TAKEDA$$74$YR$$F$Y$73$KG$20250917$$$US$US
180390832$18039083$2$F$$20250618$20200718$20250703$EXP$$EU-AUROBINDO-AUR-APL-2020-035266$AUROBINDO$van Berlo-van de Laar IRF, Vermeij CG, van den Elsen-Hutten M, de Meijer A, Taxis K, Jansman FGA.. Extracorporeal treatment of metforminassociated lactic acidosis in clinical practice: a retrospective cohort study.. European Journal of Clinical Pharmacology. 2020;76(6):815-820$82$YR$$F$Y$$$20250703$$PH$EU$EU
180764244$18076424$4$F$20250101$20250811$20200727$20250826$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR140111$GLAXOSMITHKLINE$$64$YR$$F$Y$$$20250826$$$CA$CA
1811472514$18114725$14$F$20181002$20250807$20200805$20250814$EXP$$EU-ROCHE-2195172$ROCHE$$52$YR$A$F$Y$67$KG$20250814$$CN$EU$EU
181601544$18160154$4$F$$20250621$20200818$20250706$EXP$$EU-AUROBINDO-AUR-APL-2020-038906$AUROBINDO$Bivolaru S, Voinea OC, Arbune M.. ^To be or not to be?: How real is the diagnosis of COVID-19 infection.. Romanian Journal of Infectious Diseases.. 2020;23 (2):139-143.$38$YR$$M$Y$$$20250706$$MD$EU$EU
1818939135$18189391$35$F$20190905$20250627$20200824$20250701$EXP$$US-SHIRE-US202027309$TAKEDA$$36$YR$$F$Y$145$KG$20250701$$$US$US
1821009410$18210094$10$F$20191118$20250819$20200829$20250822$EXP$$EU-ABBVIE-20K-062-3546535-00$ABBVIE$$54$YR$$M$Y$78$KG$20250822$$MD$EU$EU
1822122839$18221228$39$F$20240101$20250916$20200902$20250924$EXP$$US-SHIRE-US202028079$TAKEDA$$80$YR$$F$Y$102$KG$20250924$$$US$US
182428633$18242863$3$F$20200101$20250714$20200908$20250721$EXP$$JP-FERRINGPH-2020FE06187$FERRING$$$$$$Y$$$20250721$$PH$JP$JP
1825455419$18254554$19$F$$20250729$20200910$20250801$EXP$$US-SHIRE-US202029300$TAKEDA$$$$$F$Y$72.56$KG$20250801$$$US$US
182545725$18254572$5$F$$20250902$20200910$20250909$EXP$$US-SHIRE-US202029421$TAKEDA$$$$$F$Y$54$KG$20250909$$$US$US
182768917$18276891$7$F$20200105$20250819$20200917$20250822$EXP$$EU-ABBVIE-20K-062-3570328-00$ABBVIE$$81$YR$$M$Y$80$KG$20250822$$MD$EU$EU
182826055$18282605$5$F$$20250319$20200918$20250803$EXP$$CA-AstraZeneca-2020SF16499$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$$$20250803$$$CA$CA
184030314$18403031$4$F$$20250808$20201020$20250819$EXP$$EU-AUROBINDO-AUR-APL-2020-052621$AUROBINDO$Joana Couto, Rosana Maia, Jos? Carvalho, Marta Matos Pereira, Pedro Moura, Maria Moyano Perez . e.tal. S?NDROME SEROTONIN?RGICO - UMA ENTIDADE A N?O ESQUECER (SEROTONERGIC SYNDROME - AN ENTITY NOT TO BE FORGOTTEN). Medicina interna$54$YR$$F$Y$$$20250819$$MD$EU$EU
184197345$18419734$5$F$$20250924$20201023$20250929$EXP$$CA-AstraZeneca-2020SF36872$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$69$KG$20250929$$MD$CA$CA
184554389$18455438$9$F$20201026$20250820$20201102$20250826$EXP$$CA-TAKEDA-2018TUS032205$TAKEDA$$45$YR$$F$Y$$$20250826$$MD$CA$CA
184768352$18476835$2$F$$20250808$20201107$20250821$EXP$$EU-AUROBINDO-AUR-APL-2020-054861$AUROBINDO$Taibi A, Bardet MS,  Fontanier SD, Deluche E, Fredon F, Christou N, et al.. Managing chemotherapy extravasation in totally implantable central venous access: Use of subcutaneous wash-out technique.. The Journal of Vascular Access.. 2020;21(5):723-31$65$YR$$F$Y$$$20250821$$HP$EU$EU
184873243$18487324$3$F$$20250902$20201110$20250912$EXP$$CA-CELLTRION INC.-2020CA030642$CELLTRION$$$$$$Y$$$20250912$$HP$CA$CA
184891202$18489120$2$F$$20250830$20201111$20250912$EXP$$EU-AUROBINDO-AUR-APL-2020-055424$AUROBINDO$Veloso RR, Simas A, Amorim N, Rodrigues M, Silveira A, Cardoso J et. al. ORTHOSTATIC HYPOTENSION AS A PRIMARY SYMPTOM, A DIAGNOSTIC CHALLENGE. 26th National Congress of Internal Medicine. Journal of the Portuguese Society of Internal Medicine.. 2020;27:508$51$YR$$F$Y$$$20250912$$MD$EU$EU
184953622$18495362$2$F$20170101$20250623$20201112$20250702$EXP$$EU-SA-2020SA294905$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250702$$HP$EU$EU
1851709218$18517092$18$F$20221126$20250807$20201118$20250808$EXP$$US-TAKEDA-2020TUS047018$TAKEDA$$66$YR$$F$Y$77$KG$20250808$$$US$US
186042475$18604247$5$F$20200803$20250717$20201211$20250721$EXP$$EU-ROCHE-2725662$ROCHE$$64$YR$A$M$Y$$$20250721$$MD$EU$EU
186245212$18624521$2$F$20130515$20250723$20201216$20250725$EXP$$US-PURDUE-USA-2020-0184267$PURDUE$$$$E$M$Y$$$20250725$$CN$US$US
1868282813$18682828$13$F$20200301$20220218$20201230$20250707$EXP$$NVSC2020US339632$NOVARTIS$$57$YR$$M$Y$$$20250707$$CN$US$US
186927623$18692762$3$F$$20250830$20210104$20250912$EXP$$EU-AUROBINDO-AUR-APL-2020-063956$AUROBINDO$Englert I. Diphenhydramin-overdose: Anticholinergic symptoms, EEG-findings in the course and drug treatment of a gerontopsychiatric patient. Psychiatrische Praxis, Supplement. 2004;31(1):S145-6$76$YR$$M$Y$$$20250912$$MD$EU$EU
187219612$18721961$2$F$20180413$20250721$20210111$20250731$EXP$$EU-AUROBINDO-AUR-APL-2021-000439$AUROBINDO$Diaz C. En farmacia tambi?n se detectan arritmias. Farmac?uticos Comunitarios. 2020;12 (supl 2):13$71$YR$$F$Y$$$20250731$$PH$EU$EU
1876011820$18760118$20$F$20201124$20250811$20210120$20250822$EXP$$GB-ADVANZ PHARMA-202101000209$ADVANZ PHARMA$$$$$$Y$$$20250822$$MD$GB$GB
1878670357$18786703$57$F$20201221$20250922$20210126$20250929$EXP$$BR-TAKEDA-2020TUS060000$TAKEDA$$49$YR$$F$Y$61$KG$20250929$$$BR$BR
188068784$18806878$4$F$20190101$20250723$20210129$20250730$EXP$$CO-ABBVIE-19K-036-2986234-00$ABBVIE$$59$YR$$F$Y$$$20250730$$CN$CO$CO
1888054511$18880545$11$F$20210201$20250801$20210211$20250805$EXP$$US-TAKEDA-US202034013$TAKEDA$$44$YR$$F$Y$$$20250805$$$US$US
188819072$18881907$2$F$20210109$20250708$20210211$20250711$EXP$$EU-GILEAD-2021-0516893$GILEAD$$84$YR$E$M$Y$$$20250711$$MD$EU$EU
1890303114$18903031$14$F$20210218$20250825$20210217$20250901$EXP$$CA-TAKEDA-2021TUS008201$TAKEDA$$75$YR$$M$Y$$$20250901$$MD$CA$CA
189245593$18924559$3$F$$20210209$20210223$20250810$EXP$$US-AstraZeneca-2021A051316$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
189783174$18978317$4$F$20210201$20210329$20210307$20250704$EXP$$US-GLENMARK PHARMACEUTICALS-2021GMK052020$GLENMARK$$$$$$Y$$$20250704$$CN$US$US
190159937$19015993$7$F$$20240923$20210316$20250711$EXP$$CA-GLAXOSMITHKLINE-CACH2021012084$Haleon PLC$$53$YR$$M$Y$$$20250710$$HP$CA$CA
190416652$19041665$2$F$$20250918$20210323$20250924$EXP$$CA-ROCHE-2791611$ROCHE$$50$YR$A$F$Y$47$KG$20250924$$HP$CA$CA
190614642$19061464$2$F$$20250616$20210326$20250701$EXP$$EU-AUROBINDO-AUR-APL-2021-011800$AUROBINDO$Rigouzzo A, Tessier V, Jonard M, Laplace J-P. Maternal deaths due to infections in France 2013-2015. Gynecol-Obstet-Fertil-Senol. 2021;49(1):53-59$28$YR$$F$Y$$$20250701$$MD$EU$EU
190890162$19089016$2$F$$20250728$20210403$20250808$EXP$$US-LUPIN PHARMACEUTICALS INC.-2021-04001$LUPIN$Cicci C, Feldman R, Stanton M, Theobald J. Outcomes of benzonatate exposures reported to a single U.S. poison center: A 20-year review. Clinical toxicology (Philadelphia). 2020;58(11):1113-1114$63$YR$$F$Y$$$20250808$$$US$US
191323904$19132390$4$F$$20250707$20210414$20250717$EXP$$EU-AUROBINDO-AUR-APL-2018-043900$AUROBINDO$Sisinni L, Torrent M, Pardo N, Pineda M, Coll M, Gort L et al.. Hematopoietic stem cell transplantation for mucopolysaccharidosis VII.. Bone marrow transplantation. 2014;49:S315-S316$2$YR$$F$Y$$$20250717$$MD$EU$EU
191367622$19136762$2$F$$20210401$20210414$20250731$EXP$$US-SUNOVION-2021SUN001214$SUNOVION$$$$$$Y$$$20250731$$HP$US$US
1919730841$19197308$41$F$20210302$20250627$20210429$20250703$EXP$$CO-TAKEDA-CO201939795$TAKEDA$$49$YR$$M$Y$60$KG$20250703$$$CO$CO
1921764716$19217647$16$F$$20250721$20210505$20250728$EXP$$US-TAKEDA-US202021339$TAKEDA$$$$$M$Y$29.48$KG$20250728$$$US$US
192336492$19233649$2$F$20210114$20250702$20210507$20250709$EXP$EU-MPA-2021-028170$EU-TAKEDA-2021TUS028322$TAKEDA$$36$YR$$M$Y$$$20250709$$MD$EU$EU
192381889$19238188$9$F$$20250714$20210510$20250717$EXP$$CA-TAKEDA-2019TUS039859$TAKEDA$$$$$F$Y$57.6$KG$20250717$$$CA$CA
1924006012$19240060$12$F$$20250625$20210511$20250702$EXP$$CA-CELLTRION INC.-2021CA006101$CELLTRION$$$$$$Y$$$20250702$$HP$CA$CA
193017702$19301770$2$F$20161018$20250725$20210524$20250728$PER$$US-PURDUE-USA-2020-0177790$PURDUE$$$$A$F$Y$$$20250728$$CN$US$US
193524902$19352490$2$F$$20250819$20210601$20250831$PER$$US-SA-2021SA180011$SANOFI AVENTIS$$$$A$F$Y$80.73$KG$20250831$$MD$US$US
1937675713$19376757$13$F$20201106$20250918$20210604$20250927$PER$$CO-TAKEDA-CO201912450$TAKEDA$$21$YR$$F$Y$57$KG$20250927$$$CO$CO
194334622$19433462$2$F$$20250912$20210618$20250926$EXP$$CA-AUROBINDO-AUR-APL-2021-025081$AUROBINDO$Unknown. Unknown. Unknown$46$YR$$F$Y$$$20250926$$HP$CA$CA
194446262$19444626$2$F$$20250623$20210621$20250707$EXP$$US-MYLANLABS-2021M1035993$AUROBINDO$Sidlak AM, Koivisto KO, Marino RT, Abesamis MG.. Serotonin toxicity from isolated bupropion overdoses.. Clin-Toxicol-(Phila). 2020;58(12):1347-1349$20$YR$$F$Y$$$20250707$$HP$US$US
1947723925$19477239$25$F$20180101$20250721$20210630$20250725$EXP$$US-OTSUKA-2021_021549$OTSUKA$$$$$M$Y$129.27$KG$20250725$$CN$US$US
195608194$19560819$4$F$20210101$20211023$20210715$20250710$EXP$$NVSC2021EG155769$NOVARTIS$$29$YR$$M$Y$$$20250710$$CN$EG$EG
1958178216$19581782$16$F$20180302$20250903$20210720$20250910$EXP$$CA-TAKEDA-2018TUS005739$TAKEDA$$67$YR$$F$Y$$$20250910$$$CA$CA
195900482$19590048$2$F$$20250910$20210721$20250916$PER$$US-SA-2021SA234532$SANOFI AVENTIS$$49$YR$A$F$Y$63.5$KG$20250917$$MD$US$US
196537743$19653774$3$F$20210101$20250717$20210803$20250722$PER$$US-AMGEN-USASP2021113415$AMGEN$$64$YR$A$F$Y$$$20250722$$HP$US$US
196547952$19654795$2$F$$20250626$20210804$20250709$EXP$$EU-AUROBINDO-AUR-APL-2021-032922$AUROBINDO$Lagoutte-Renosi J, Richeval C, Phanithavong M, Wiart JF, Castex E, Gaulier JM. Hair analysis can support the follow-up addiction care after acute New Psychoactive Substances intoxication: Illustration by two cases. Drug testing and analysis.. 2021;13:227-234$32$YR$$M$Y$$$20250709$$HP$EU$EU
196548407$19654840$7$F$20180405$20250909$20210804$20250913$EXP$$JP-ABBVIE-20P-087-3670384-00$ABBVIE$$41$YR$$M$Y$84$KG$20250913$$MD$JP$JP
196730414$19673041$4$F$20210701$20210901$20210809$20250722$EXP$$NVSC2021CN174422$NOVARTIS$$$$$M$Y$$$20250722$$CN$CN$CN
196772816$19677281$6$F$20201116$20250630$20210810$20250707$EXP$$NVSJ2020JP012912$NOVARTIS$$18$YR$$M$Y$53.2$KG$20250707$$MD$JP$JP
196862685$19686268$5$F$20170101$20250703$20210811$20250709$EXP$$EU-MYLANLABS-2021M1050076$MYLAN$Kurczych K, Makulska A, Jastrz?bska I. Zaburzenia psychotyczne jako dzia?anie niepo??dane stosowania lewetiracetamu lub odstawienia lek?w normotymicznych (Psychotic disorders as an adverse effect of levetiracetam  or discontinuation of mood stabilising drugs). FARMAKOTERAPIA W PSYCHIATRII I NEUROLOGII (Institute of Psychiatry and Neurolog). 2020;36(2):155-163$34$YR$$M$Y$$$20250709$$MD$EU$EU
197099543$19709954$3$F$$20250902$20210817$20250909$PER$$US-BIOGEN-2021BI01039996$BIOGEN$$$$$F$Y$$$20250909$$CN$US$US
197112424$19711242$4$F$20210811$20250827$20210816$20250828$PER$$US-TAKEDA-2021TUS050563$TAKEDA$$68$YR$$F$Y$$$20250828$$$US$US
197331182$19733118$2$F$$20250808$20210823$20250818$EXP$$EU-CELLTRION INC.-2021FR011089$CELLTRION$Urbain F, Puyade M, Labeyrie C, Maubeuge N, Puma A, Cintas P, et al.. Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.. J-Neurol. 2021;268(4):1536-1539$$$$$Y$$$20250818$$HP$EU$EU
197464198$19746419$8$F$$20250708$20210825$20250715$EXP$$BR-TAKEDA-2021TUS052827$TAKEDA$$$$$M$Y$$$20250715$$$BR$BR
197493412$19749341$2$F$$20250911$20210826$20250923$EXP$JP-MACLEODS PHARMACEUTICALS US LTD-MAC2021032435$JP-MACLEODS PHARMACEUTICALS US LTD-MAC2021032435$MACLEODS$Nishiyori R, Goto-Umeki M, Hasegawa A, Hama N, Nishida H, Daa T, et al.A case of Stevens-Johnson syndrome-like eruption suggesting clinical importance of body temperature and serum levels of receptor-interacting kinase 3.Journal of Cutaneous Immunology and Allergy.2021;1-3$$$$$Y$$$20250923$$MD$JP$JP
197634275$19763427$5$F$20210803$20250828$20210830$20250903$EXP$$CA-TAKEDA-2021TUS029416$TAKEDA$$70$YR$$F$Y$$$20250903$$$CA$CA
197696383$19769638$3$F$$20250827$20210831$20250903$EXP$$EU-MYLANLABS-2021M1056521$MYLAN$Paul LD, Welter-Luedeke J, Penzel S, Zangl A, Graw M., Alpha-Pyrrolidinopentiothiophenone (-PVT): A forensic case study including plasma concentrations, Forensic Sci Int, 2021, 321, 110721$39$YR$$M$Y$$$20250902$$$EU$EU
1984642713$19846427$13$F$20250314$20250904$20210917$20250909$EXP$$US-TAKEDA-US202003462$TAKEDA$$31$YR$$F$Y$$$20250909$$$US$US
198535082$19853508$2$F$$20210909$20210919$20250806$EXP$$NVSC2021DE207940$NOVARTIS$$52$YR$$F$Y$$$20250806$$MD$EU$EU
1985591212$19855912$12$F$20210813$20250717$20210920$20250722$EXP$$CN-DSJP-DSE-2021-130330$DAIICHI$$75$YR$$F$Y$43$KG$20250722$$MD$CN$CN
198790615$19879061$5$F$20210125$20250819$20210923$20250903$EXP$$EU-AVERITAS PHARMA, INC.-2021-269899$AVERITAS$$59$YR$$F$Y$$$20250903$$MD$EU$EU
198987619$19898761$9$F$20210825$20250805$20210929$20250811$EXP$$EU-ABBVIE-21K-056-4096645-00$ABBVIE$$59$YR$$M$Y$70$KG$20250811$$MD$EU$EU
199112952$19911295$2$F$20200401$20250808$20211004$20250818$EXP$$EU-CELLTRION INC.-2021FR013166$CELLTRION$Mouren D, Goyard C, Catherinot E, Givel C, Chabrol A, Tcherakian C, et. al.. COVID-19 and Pneumocystis jirovecii. Back to the basics (Letter). Respiratory Medicine and Research 2021. 2021;79:unknown$$$$$Y$$$20250818$$HP$EU$EU
199207682$19920768$2$F$20000101$20250626$20211006$20250709$EXP$$GB-AUROBINDO-AUR-APL-2021-041078$AUROBINDO$Williams F, Lenihan F, Rowe A. Continuing clozapine treatment after a diagnosis of cardiomyopathy. Irish Journal of Psychological Medicine. 2021;38(3):227-31$42$YR$$M$Y$$$20250709$$MD$GB$GB
199802525$19980252$5$F$20180828$20250814$20211021$20250828$EXP$$EU-TEVA-2021-DE-1966044$TEVA$$$$A$F$Y$$$20250828$$CN$EU$EU
200065024$20006502$4$F$$20250626$20211028$20250702$EXP$$CA-GLAXOSMITHKLINE-CA2021220117$GLAXOSMITHKLINE$$$$$M$Y$$$20250702$$$CA$CA
2003489822$20034898$22$F$20210805$20250812$20211104$20250819$EXP$$CA-TAKEDA-2021TUS049785$TAKEDA$$60$YR$$F$Y$84$KG$20250819$$$CA$CA
2005801112$20058011$12$F$$20250828$20211111$20250903$EXP$$US-PFIZER INC-202101550637$PFIZER$$72$YR$$F$Y$$$20250903$$CN$US$US
2007027411$20070274$11$F$$20250909$20211115$20250911$EXP$$CA-PFIZER INC-202101487716$PFIZER$$51$YR$$M$Y$$$20250911$$HP$CA$CA
200907925$20090792$5$F$$20250723$20211119$20250728$EXP$$US-TAKEDA-2021TUS034826$TAKEDA$$$$$F$Y$$$20250728$$$US$US
201207663$20120766$3$F$$20250710$20211126$20250717$EXP$$CA-CELLTRION INC.-2021CA015764$CELLTRION$$$$$$Y$$$20250718$$HP$CA$CA
201377775$20137777$5$F$$20250904$20211202$20250912$EXP$$CA-CELLTRION INC.-2021CA016117$CELLTRION$$$$$$Y$$$20250912$$HP$CA$CA
202351475$20235147$5$F$$20250708$20211227$20250716$EXP$$CA-CELLTRION INC.-2021CA017513$CELLTRION$$$$$$Y$$$20250716$$CN$CA$CA
203533926$20353392$6$F$20250709$20250903$20220119$20250915$PER$$US-BIOMARINAP-US-2022-140782$BIOMARIN$$14$YR$$F$Y$53.52$KG$20250915$$$US$US
2041087332$20410873$32$F$$20250911$20220201$20250919$EXP$$CA-PURDUE-USA-2022-0291043$PURDUE$$65$YR$$F$Y$34$KG$20250919$$HP$CA$CA
2045172911$20451729$11$F$$20250916$20220209$20250922$EXP$$CA-TAKEDA-2020TUS018497$TAKEDA$$$$$F$Y$$$20250922$$MD$CA$CA
204720324$20472032$4$F$$20220704$20220214$20250710$EXP$$US-GW PHARMA-202202USGW00555$JAZZ$Tanvir A, Scazo AC. Non-convulsive status epilepticus in the setting of cannabidiol adjunctive therapy. Epileptic disorder. 2022;24 (4):1-8$63$YR$$M$Y$$$20250710$$MD$US$US
204822194$20482219$4$F$$20250617$20220216$20250701$EXP$$CA-APOTEX-2022AP003276$APOTEX$$53$YR$$F$Y$$$20250701$$HP$CA$CA
204858786$20485878$6$F$20200101$20250807$20220217$20250819$PER$$BR-TAKEDA-BR202021739$TAKEDA$$$$$F$Y$78$KG$20250819$$$BR$BR
2048597410$20485974$10$F$$20250626$20220217$20250702$EXP$$CA-PFIZER INC-202200222287$PFIZER$$31$YR$$F$Y$$$20250702$$HP$CA$CA
2048691023$20486910$23$F$20220209$20250904$20220217$20250908$EXP$$US-TAKEDA-2022TUS007307$TAKEDA$$60$YR$$M$Y$$$20250908$$$US$US
204935862$20493586$2$F$$20250828$20220221$20250911$EXP$$CA-AUROBINDO-AUR-APL-2022-004978$AUROBINDO$$50$YR$$F$Y$$$20250911$$HP$CA$CA
205049292$20504929$2$F$$20250820$20220223$20250902$EXP$$EU-AUROBINDO-AUR-APL-2019-109533$AUROBINDO$Gamier A, Fila M, Chalard F, Daltry A, Piette JC, Kwon T, et al.. Lethal cerebral histoplasmosis in systemic lupus.. DEFAULT RECORD.. 2019;1$$$C$F$Y$$$20250902$$HP$EU$EU
205274448$20527444$8$F$20220127$20250918$20220228$20250927$EXP$$JP-JAZZ-2022-JP-004242$JAZZ$$12$YR$$M$Y$34.6$KG$20250927$$MD$JP$JP
2053903627$20539036$27$F$$20250826$20220302$20250830$EXP$$CA-PURDUE-USA-2022-0291724$PURDUE$$43$YR$$F$Y$96$KG$20250830$$HP$CA$CA
205552052$20555205$2$F$$20250929$20220304$20250930$PER$$US-PURDUE-USA-2020-0284679$PURDUE$$$$$F$Y$$$20250930$$CN$US$US
2056643218$20566432$18$F$20240624$20250812$20220308$20250818$EXP$$US-TAKEDA-2021TUS021863$TAKEDA$$71$YR$$F$Y$111$KG$20250818$$$US$US
205911713$20591171$3$F$20220306$20250728$20220314$20250729$EXP$$US-TAKEDA-2021TUS040285$TAKEDA$$1$YR$$M$Y$$$20250729$$$US$US
205950023$20595002$3$F$20211201$20250813$20220315$20250818$EXP$$US-UCBSA-2021061761$UCB$$69$YR$$F$Y$147$KG$20250818$$CN$US$US
206093916$20609391$6$F$$20250808$20220317$20250819$EXP$$EU-CELLTRION INC.-2022IT002842$CELLTRION$D^Arena G, La Penna A, Crocamo A, Ametrano M, Di Palma A, Avino D, et al.. SARS-COV2 Infection in Vaccinated Patients: Look for Clinical History and Test Humoral Immunity. Indian J Hematol Blood Transfus. 2022;38(1):207-209$$$$$Y$$$20250819$$HP$EU$EU
206520524$20652052$4$F$20200727$20250719$20220330$20250724$EXP$$CA-JNJFOC-20220353834$JOHNSON AND JOHNSON$$9$YR$C$M$Y$44$KG$20250724$$HP$CA$CA
206630145$20663014$5$F$20220101$20220627$20220401$20250710$EXP$$US-GW PHARMA-202202USGW00843$JAZZ$$10$YR$$M$Y$$$20250710$$CN$US$US
206665037$20666503$7$F$20181001$20250731$20220403$20250811$PER$$US-SA-2022SA112609$SANOFI AVENTIS$$44$YR$A$M$Y$84.82$KG$20250811$$MD$US$US
206901128$20690112$8$F$20221102$20250819$20220408$20250825$EXP$$US-TAKEDA-2022TUS015002$TAKEDA$$67$YR$$F$Y$$$20250825$$$US$US
207064062$20706406$2$F$$20250828$20220413$20250905$PER$$US-INCYTE CORPORATION-2022IN003434$INCYTE$$71$YR$$$Y$$$20250905$$$US$
2072374522$20723745$22$F$20210101$20250718$20220419$20250724$EXP$$CA-CELLTRION INC.-2021CA018200$CELLTRION$$$$$$Y$$$20250724$$MD$CA$CA
2072635618$20726356$18$F$20230407$20250924$20220419$20250930$EXP$$US-JAZZ-2021-US-015140$JAZZ$$79$YR$$F$Y$$$20250930$$MD$US$US
207749855$20774985$5$F$20210331$20250819$20220502$20250829$PER$$EU-TAKEDA-2021TUS055796$TAKEDA$Devos T, Deeren D, Theunissen K, Selleslag D, Bailly B, Havelange V, et al. Real-world outcomes in patients with philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry. Hematology. 2025;30 (1):2534196$30$YR$$M$Y$$$20250829$$MD$EU$EU
207772023$20777202$3$F$$20250627$20220503$20250703$PER$$US-SA-2022SA154808$SANOFI AVENTIS$$82$YR$E$M$Y$$$20250703$$MD$US$US
207778143$20777814$3$F$$20250728$20220503$20250804$EXP$$CA-TAKEDA-2022TUS029194$TAKEDA$$$$$M$Y$$$20250804$$$CA$CA
2078349319$20783493$19$F$20220425$20250818$20220504$20250822$EXP$$CA-PFIZER INC-202200629820$PFIZER$$57$YR$$M$Y$83$KG$20250822$$HP$CA$CA
207941523$20794152$3$F$$20250916$20220506$20250922$EXP$$EU-AUROBINDO-AUR-APL-2022-015398$AUROBINDO$Rademacher JG, Glaubitz S, Zechel S, Oettler M, Tampe B, Schmidt J et.al. Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data. Clinical and Experimental Rheumatology. 2022;40(2):320-8$72$YR$$M$Y$$$20250922$$MD$EU$EU
2080189716$20801897$16$F$$20250910$20220509$20250912$EXP$$US-TAKEDA-2020TUS053182$TAKEDA$$$$$F$Y$$$20250912$$$US$US
208028648$20802864$8$F$20250102$20250725$20220509$20250729$EXP$$US-PFIZER INC-202200676649$PFIZER$$73$YR$$F$Y$$$20250729$$CN$US$US
208158214$20815821$4$F$20220322$20250910$20220511$20250923$PER$$US-AGIOS-2204US03047$AGIOS PHARMACEUTICALS$$22$YR$$F$Y$$$20250923$$CN$US$US
208351862$20835186$2$F$20220501$20250804$20220516$20250813$PER$$US-SA-2022SA172688$SANOFI AVENTIS$$42$YR$A$F$Y$$$20250813$$MD$US$US
208451134$20845113$4$F$20230101$20250911$20220518$20250916$EXP$$CA-TAKEDA-2019TUS070890$TAKEDA$$$$$M$Y$$$20250916$$$CA$CA
208547852$20854785$2$F$$20250722$20220520$20250724$PER$$US-PFIZER INC-2021606176$PFIZER$$56$YR$$M$Y$$$20250724$$HP$US$US
208625555$20862555$5$F$20200824$20250904$20220523$20250905$EXP$$US-SHIRE-US202029138$TAKEDA$$60$YR$$F$Y$$$20250905$$$US$US
208726114$20872611$4$F$$20220927$20220525$20250710$EXP$$US-GW PHARMA-2022-US-017458$JAZZ$$$$$F$Y$$$20250710$$MD$US$US
2092464911$20924649$11$F$$20250829$20220607$20250903$PER$$US-PFIZER INC-202200799912$PFIZER$$66$YR$$F$Y$$$20250903$$CN$US$US
209888014$20988801$4$F$$20250822$20220621$20250826$EXP$$CA-TAKEDA-2022TUS011641$TAKEDA$$$$$F$Y$$$20250826$$MD$CA$CA
210004156$21000415$6$F$20210830$20250814$20220623$20250818$EXP$$US-SHIRE-US201900301$TAKEDA$$76$YR$$M$Y$$$20250818$$$US$US
210339083$21033908$3$F$$20220628$20220701$20250710$EXP$$US-GW PHARMA-2022-US-022182$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
210421675$21042167$5$F$20210913$20250922$20220705$20250926$EXP$$NVSC2021IN228562$NOVARTIS$$66$YR$$F$Y$$$20250926$$CN$IN$IN
210522808$21052280$8$F$$20250808$20220707$20250813$EXP$$CA-PFIZER INC-202101352298$PFIZER$$30$YR$$F$Y$52$KG$20250813$$HP$CA$CA
210563056$21056305$6$F$$20250708$20220708$20250721$EXP$$EU-AUROBINDO-AUR-APL-2022-024547$AUROBINDO$Makinen VN, Hansen KB, Knudsen ST. Acute benzodiazepine withdrawal delirium. Ugeskrift for laeger.[Danish].. 2022;184(23):1-3$51$YR$$M$Y$$$20250721$$MD$EU$EU
210591307$21059130$7$F$$20221213$20220708$20250710$EXP$$US-GW PHARMA-2022-US-022334$JAZZ$$$$$M$Y$29.478$KG$20250710$$CN$US$US
210823163$21082316$3$F$20210101$20250624$20220714$20250703$EXP$EU-AFSSAPS-MP20222109$EU-TEVA-2022-FR-2053559$TEVA$$56$YR$$M$Y$75.6$KG$20250703$$MD$EU$EU
210824113$21082411$3$F$$20220707$20220714$20250710$EXP$$US-GW PHARMA-2022-US-023177$JAZZ$$$$$F$Y$$$20250710$$CN$US$US
2109943515$21099435$15$F$20220101$20250730$20220719$20250806$EXP$$IN-PFIZER INC-PV202200021039$PFIZER$$74$YR$$M$Y$50.75$KG$20250806$$CN$IN$IN
211079132$21107913$2$F$$20250714$20220720$20250717$PER$$US-SA-2022SA285551$SANOFI AVENTIS$$50$YR$A$M$Y$$$20250717$$MD$US$US
2111990814$21119908$14$F$20210701$20250721$20220722$20250724$EXP$$EU-PFIZER INC-202101275936$PFIZER$$81$YR$$M$Y$$$20250724$$HP$EU$EU
2112959125$21129591$25$F$$20250805$20220726$20250812$EXP$$US-TAKEDA-2022TUS042324$TAKEDA$$$$$F$Y$45$KG$20250812$$$US$US
211338033$21133803$3$F$$20250725$20220726$20250801$EXP$$CA-TAKEDA-2022TUS049991$TAKEDA$$$$$F$Y$60$KG$20250801$$$CA$CA
211512963$21151296$3$F$$20250724$20220730$20250805$EXP$$EU-AUROBINDO-AUR-APL-2022-029527$AUROBINDO$PEREZ M. Caso cl?nico: cefalea por toma de anticonceptivos combinados y abuso de f?rmacos analg?sicos e introducci?n de tratamiento preventivo de migra?as (Clinical case: headache due to taking combined contraceptives and abuse of analgesic drugs and introduction of preventive treatment for migraine headaches). Farmacia Comunitaria. 2022;14(Supl 1. Cong:32-32$24$YR$$F$Y$$$20250805$$PH$EU$EU
2118298922$21182989$22$F$20220101$20250716$20220808$20250721$EXP$$CA-CELLTRION INC.-2022CA006826$CELLTRION$$$$$$Y$$$20250721$$MD$CA$CA
211919495$21191949$5$F$20220315$20250818$20220809$20250821$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170739$BOEHRINGER INGELHEIM$$79$YR$E$M$Y$90$KG$20250821$$MD$EU$EU
212114243$21211424$3$F$$20250626$20220815$20250709$EXP$$NVSC2022DK166754$NOVARTIS$Risum M, Overgaard UM, Rubek N, Haastrup E, Hare R, Helweg-Larsen J et al. Disseminated fusariosis with cerebral involvement in a patient with acute myeloid leukemia: successful outcome with intrathecal and systemic antifungal treatment. JOURNAL OF INFECTION AND CHEMOTHERAPY. 2022;28(9):1324-8$49$YR$$F$Y$$$20250709$$HP$EU$EU
212131853$21213185$3$F$20220101$20250820$20220815$20250827$EXP$$US-ABBVIE-22K-163-4223257-00$ABBVIE$$57$YR$$F$Y$$$20250827$$CN$US$US
212180004$21218000$4$F$20221101$20250715$20220816$20250721$PER$$US-BIOMARINAP-US-2022-144917$BIOMARIN$$19$YR$$M$Y$$$20250721$$MD$US$US
212415022$21241502$2$F$$20250716$20220823$20250723$EXP$$CA-APOTEX-2022AP011430$APOTEX$$72$YR$$F$Y$$$20250723$$HP$CA$CA
2124330812$21243308$12$F$20220202$20250819$20220823$20250822$EXP$$CA-TAKEDA-2022TUS009292$TAKEDA$$35$YR$$M$Y$$$20250822$$$CA$CA
2125772111$21257721$11$F$20211217$20250918$20220826$20250925$EXP$$CO-TAKEDA-2021TUS081185$TAKEDA$$67$YR$$F$Y$42$KG$20250925$$$CO$CO
2126756923$21267569$23$F$20220822$20250818$20220829$20250821$EXP$$GB-MYLANLABS-2022M1089171$MYLAN$$38$YR$$M$Y$$$20250821$$$GB$GB
212754993$21275499$3$F$$20220824$20220831$20250710$EXP$$US-GW PHARMA-2022-US-027930$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
2127850011$21278500$11$F$20200323$20250811$20220831$20250819$EXP$$CA-CELLTRION INC.-2019CA025129$CELLTRION$$$$$$Y$$$20250819$$MD$CA$CA
212895703$21289570$3$F$20211210$20220830$20220902$20250710$EXP$$US-GW PHARMA-2022-US-028356$JAZZ$$23$YR$$F$Y$$$20250710$$CN$US$US
212940963$21294096$3$F$20220823$20220826$20220905$20250710$EXP$EU-AFSSAPS-CN20221699$EU-GW PHARMA-2022-FR-028011$JAZZ$$12$YR$$F$Y$24$KG$20250710$$PH$EU$EU
2134632320$21346323$20$F$20220101$20250711$20220917$20250718$EXP$$CA-CELLTRION INC.-2022CA014573$CELLTRION$$$$$$Y$$$20250718$$CN$CA$CA
213468324$21346832$4$F$20200309$20240424$20220918$20250708$EXP$$NVSC2020AT139006$NOVARTIS$$81$YR$$F$Y$63$KG$20250708$$MD$EU$EU
213924962$21392496$2$F$20220101$20250624$20220929$20250701$EXP$$US-ABBVIE-4132419$ABBVIE$$50$YR$$F$Y$$$20250701$$CN$US$US
213967214$21396721$4$F$20200513$20250819$20220930$20250825$EXP$$EU-PFIZER INC-2021304116$PFIZER$$59$YR$$F$Y$$$20250825$$HP$EU$EU
214060703$21406070$3$F$20220801$20250617$20221004$20250701$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-357205$RANBAXY$$$$A$M$Y$70$KG$20250701$$HP$EU$EU
214081793$21408179$3$F$$20220930$20221004$20250710$EXP$$US-GW PHARMA-2022-US-031244$JAZZ$$$$$F$Y$$$20250710$$CN$US$US
214088114$21408811$4$F$$20221018$20221004$20250710$EXP$$US-GW PHARMA-2022-US-031328$JAZZ$$$$$M$Y$9.9$KG$20250710$$CN$US$US
214356439$21435643$9$F$$20250909$20221010$20250911$EXP$$US-PFIZER INC-PV202200079013$PFIZER$$63$YR$$F$Y$$$20250911$$CN$US$US
214417335$21441733$5$F$20250301$20250715$20221011$20250719$PER$$US-SA-2022SA413852$SANOFI AVENTIS$$41$YR$A$F$Y$$$20250719$$MD$US$US
2146716912$21467169$12$F$20250430$20250805$20221017$20250812$EXP$$CA-TAKEDA-2022TUS028057$TAKEDA$$71$YR$$F$Y$$$20250812$$MD$CA$CA
214933083$21493308$3$F$$20221018$20221021$20250710$EXP$$US-GW PHARMA-2022-US-033156$JAZZ$$$$$M$Y$45$KG$20250710$$CN$US$US
215357232$21535723$2$F$$20250801$20221101$20250806$PER$$US-ABBVIE-4175213$ABBVIE$$$$A$M$Y$$$20250806$$CN$US$US
215538763$21553876$3$F$20210601$20250808$20221104$20250812$PER$$EU-TAKEDA-2022TUS080342$TAKEDA$$81$YR$$F$Y$$$20250812$$$EU$EU
215570633$21557063$3$F$$20221031$20221104$20250710$EXP$$US-GW PHARMA-2022-US-034216$JAZZ$$$$$F$Y$48.8$KG$20250710$$CN$US$US
215572822$21557282$2$F$$20250806$20221105$20250817$EXP$$EU-AUROBINDO-AUR-APL-2022-046682$AUROBINDO$Martins B, Pinto J, Araujo D.. PLEURAL EFFUSION SECONDARY TO DASATINIB TREATMENT  WHEN TO SUSPECT?.. 37 Congresso de Pneumologia. 2021;SC2:94$72$YR$$F$Y$$$20250817$$HP$EU$EU
215587494$21558749$4$F$$20250908$20221107$20250920$EXP$$EU-AUROBINDO-AUR-APL-2022-046915$AUROBINDO$Maria J, Magdalena A, Emil D, Ana C, Enrique C. Results of our experience in the use of D-VMP in patients with multiple myeloma.. Hematologia y Hemoterapia.. 2022;462-463$74$YR$$M$Y$$$20250920$$MD$EU$EU
2157969814$21579698$14$F$20250730$20250804$20221110$20250811$EXP$$US-TAKEDA-2022TUS083710$TAKEDA$$68$YR$$F$Y$40.518$KG$20250811$$$US$US
215860133$21586013$3$F$$20221108$20221111$20250710$EXP$$US-JAZZ-2022-US-034921$JAZZ$$$$$M$Y$58.9$KG$20250710$$CN$US$US
215881323$21588132$3$F$$20250805$20221114$20250816$EXP$$EU-AUROBINDO-AUR-APL-2022-047628$AUROBINDO$Pozzi M, Buzzi R, Hayek A,Portran P, Schweizer R, Jean Luc M.. Veno-arterial extracorporeal membrane oxygenation for drug intoxications: A single center, 14-year experience.. J Card Surg. 2022;37:1512?1519$$$A$$Y$$$20250816$$MD$EU$EU
216320653$21632065$3$F$$20250729$20221123$20250812$EXP$$EU-AUROBINDO-AUR-APL-2022-037893$AUROBINDO$Velosa A, Silva B, Oliveira-Maia AJ, Bugalho P, Barahona?correa B.. Mania Ap?s Estimula??o do N?cleo Subtal?mico na Doen?a de Parkinson (Mania Following Subthalamic Nucleus Stimulation for Parkinson?s Disease).. Psilogos. 2019;17(1/2):132-138$62$YR$$F$Y$$$20250812$$MD$EU$EU
216415424$21641542$4$F$$20250729$20221125$20250812$EXP$$EU-AUROBINDO-AUR-APL-2022-049350$AUROBINDO$Konopasek P, Srankov? M, Krejcov? V, Amaratunga S, Zieg J. Severe hypertension in a three-year-old boy... PEDIATRICS FOR PRACTICE... 2022;23(5):351-354$3$YR$$M$Y$3.6$KG$20250812$$MD$EU$EU
216444563$21644456$3$F$20221121$20221123$20221125$20250710$EXP$$US-GW PHARMA-2022-US-036190$JAZZ$$1$YR$$F$Y$$$20250710$$CN$US$US
216513822$21651382$2$F$20201030$20250901$20221128$20250905$EXP$$EU-MYLANLABS-2020M1099088$MYLAN$$57$YR$$M$Y$83.5$KG$20250905$$MD$EU$EU
2168412921$21684129$21$F$20220207$20250818$20221205$20250825$EXP$$BR-TAKEDA-BR201925106$TAKEDA$$8$YR$$M$Y$30$KG$20250825$$$BR$BR
2168799621$21687996$21$F$20220125$20250722$20221206$20250730$EXP$$CA-OTSUKA-2022_003829$OTSUKA$$38$YR$$F$Y$$$20250730$$MD$CA$CA
217043692$21704369$2$F$$20221129$20221209$20250703$EXP$$US-STERISCIENCE B.V.-2022-ST-000186$Steriscience PTE$Goertemoeller S, Kaiser N, Behrman A, Yin S. Iatrogenic administration of ondansetron during neonatal circumcision. Clin-Toxicol-(Phila). 2022;60 (Suppl. 2):65-66$2$DY$$M$Y$$$20250703$$HP$US$US
217317515$21731751$5$F$20240401$20250922$20221215$20250929$EXP$$US-SA-2022SA505840$SANOFI AVENTIS$$77$YR$E$M$Y$$$20250929$$CN$US$US
217320742$21732074$2$F$$20221206$20221215$20250703$EXP$$EU-STERISCIENCE B.V.-2022-ST-000243$Steriscience PTE$Santoro F, Monitillo F, Raimondo P, Lopizzo A, Brindicci G, Gilio M, et al. QTc Interval Prolongation and Life-Threatening Arrhythmias during Hospitalization in Patients with Coronavirus Disease 2019 (COVID-19): Results from a Multicenter Prospective Registry. Clin-Infect-Dis. 2021;73(11):E4031-E4038$74$YR$$F$Y$$$20250703$$HP$EU$EU
217352633$21735263$3$F$$20221209$20221215$20250710$EXP$$US-GW PHARMA-2022-US-037709$JAZZ$$$$$F$Y$24.5$KG$20250710$$CN$US$US
217377374$21737737$4$F$$20250804$20221216$20250817$EXP$$EU-AUROBINDO-AUR-APL-2022-051021$AUROBINDO$Kint N, Delforge M. Plasma cell leukaemia with an indolent clinical presentation.. BJH HEMATOCASE. 2022;13:277-80$72$YR$$F$Y$$$20250817$$MD$EU$EU
217440692$21744069$2$F$$20250724$20221218$20250805$EXP$$EU-AUROBINDO-AUR-APL-2022-053067$AUROBINDO$Baranowski M, Zygielo N, Knapp M,  Sobkowicz B,  Lisowska A. The patient with severe heart failure secondary to functional mitral regurgitation. Folia Cardiologica. 2022;17(5):300-302$59$YR$$M$Y$$$20250805$$MD$EU$EU
217524162$21752416$2$F$$20250709$20221220$20250722$EXP$$EU-AUROBINDO-AUR-APL-2022-054991$AUROBINDO$Mayerova M,  Libor Ustohal. N?kter? m?n? ?ast? ne??douc? ??inky antipsychotik (Some less common side effects of antipsychotics). PAEHLEDOV~ tL?NKY (PSYCHIATRY FOR PRACTICE). 2022;23(3):144- 149$17$YR$$F$Y$$$20250722$$MD$EU$EU
2177080514$21770805$14$F$20220901$20250912$20221223$20250918$EXP$$EU-ABBVIE-4247645$ABBVIE$$71$YR$$M$Y$$$20250918$$CN$EU$EU
217773087$21777308$7$F$20221118$20250711$20221226$20250718$EXP$$US-UCBSA-2022067051$UCB$$6$YR$$F$Y$20$KG$20250718$$CN$US$US
217795564$21779556$4$F$20221216$20221222$20221226$20250710$EXP$$US-GW PHARMA-2022-US-038401$JAZZ$$49$YR$$F$Y$$$20250710$$CN$US$US
217844402$21784440$2$F$20181018$20250828$20221227$20250904$EXP$$CA-TAKEDA-2018TUS032480$TAKEDA$$42$YR$$F$Y$$$20250904$$$CA$CA
217977642$21797764$2$F$$20221221$20221230$20250703$EXP$$US-STERISCIENCE B.V.-2022-ST-000466$Steriscience PTE$Lowry S, Karnsakul W, Mogayzel P, Oshima K.. Evaluating cytochrome P450 enzyme metabolisms and drug-to-drug interaction for drug-induced liver injury in cystic fibrosis patients taking CFTR modulators. Hepatology. 2022;76 (Suppl. 1):S1455-S1456$19$YR$$$Y$$$20250703$$HP$US$US
218002713$21800271$3$F$20221225$20250818$20221230$20250820$PER$$US-PFIZER INC-PV202200132671$PFIZER$$74$YR$$F$Y$67.13$KG$20250820$$HP$US$US
2183019316$21830193$16$F$20230911$20250923$20230106$20250929$EXP$$CA-TAKEDA-2023TUS001090$TAKEDA$$21$YR$$F$Y$95.7$KG$20250929$$$CA$CA
218313056$21831305$6$F$$20250716$20230106$20250730$EXP$$CA-GLENMARK PHARMACEUTICALS-2023GMK077546$GLENMARK$$$$$M$Y$$$20250730$$MD$CA$CA
218314636$21831463$6$F$$20250821$20230106$20250827$EXP$$US-PFIZER INC-PV202200133838$PFIZER$$73$YR$$F$Y$$$20250827$$CN$US$US
218346494$21834649$4$F$20200414$20250821$20230108$20250827$EXP$$US-ABBVIE-22K-163-4233337-00$ABBVIE$$56$YR$$M$Y$$$20250827$$CN$US$US
218374577$21837457$7$F$20210101$20250917$20230109$20250925$EXP$$US-PFIZER INC-PV202300002937$PFIZER$$54$YR$$F$Y$$$20250925$$HP$US$US
218473694$21847369$4$F$$20250903$20230111$20250915$EXP$$US-Accord-294511$ACCORD$Benavente K, Kozai L, Silangcruz K, Banerjee D. The risks of rejection vs. infection: Ramsay Hunt syndrome, Gradenigo syndrome, and varicella meningoencephalitis in a heart transplant patient. European Heart Journal - Case Reports. 2023;7(8):1-4.$64$YR$A$M$Y$$$20250915$$MD$US$US
218564942$21856494$2$F$20221216$20221216$20230112$20250830$PER$$US-AMGEN-USASP2022220742$AMGEN$$86$YR$E$F$Y$$$20250830$$CN$US$US
218764678$21876467$8$F$$20250813$20230118$20250822$EXP$$EU-CELLTRION INC.-2023DE000648$CELLTRION$Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S et.al.. Clinical features of hepatitis E infections in patients with hematologic disorders. Haematologica. 2022;107 (12):2870-83$$$$$Y$$$20250822$$HP$EU$EU
2188620210$21886202$10$F$$20250827$20230119$20250903$EXP$2021A794630$CA-AstraZeneca-2021A794630$ALEXION PHARMACEUTICALS$$41$YR$A$F$Y$$$20250903$$$CA$CA
218906123$21890612$3$F$$20230116$20230120$20250710$EXP$$US-GW PHARMA-2023-US-001091$JAZZ$$$$$M$Y$25.6$KG$20250710$$CN$US$US
218977882$21897788$2$F$20220131$20250806$20230123$20250813$PER$$US-SA-2023SA023804$SANOFI AVENTIS$$10$YR$C$F$Y$31.8$KG$20250813$$MD$US$US
219086428$21908642$8$F$20210108$20250715$20230125$20250718$EXP$$GB-BAXTER-2023BAX010437$BAXTER$$$$A$M$Y$$$20250718$$CN$GB$GB
219212873$21921287$3$F$20230112$20230124$20230127$20250710$EXP$$US-JAZZ-2023-US-001731$JAZZ$$31$YR$$M$Y$$$20250710$$CN$US$US
219352606$21935260$6$F$$20250917$20230201$20250925$EXP$$US-TAKEDA-2022TUS004268$TAKEDA$$$$$F$Y$$$20250925$$$US$US
219625569$21962556$9$F$20230107$20250915$20230207$20250919$EXP$$CA-TAKEDA-2023TUS012302$TAKEDA$$61$YR$$F$Y$$$20250919$$$CA$CA
219792723$21979272$3$F$20230101$20230407$20230210$20250715$EXP$$NVSC2023US025800$NOVARTIS$$75$YR$$M$Y$$$20250715$$CN$US$US
219919823$21991982$3$F$$20230209$20230214$20250710$EXP$$US-GW PHARMA-2023-US-003360$JAZZ$$$$$F$Y$64$KG$20250710$$CN$US$US
220094584$22009458$4$F$$20250923$20230220$20250930$EXP$$US-AMGEN-USASP2023026911$AMGEN$Abdallah A.. Efficacy and Safety of Daratumumab,Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience. Clinical Lymphoma, Myeloma and Leukemia. 2025$$$$$Y$$$20250930$$MD$US$US
220416236$22041623$6$F$20230216$20250812$20230227$20250819$EXP$$US-TAKEDA-2023TUS020588$TAKEDA$$15$YR$$M$Y$$$20250819$$$US$US
220453823$22045382$3$F$20230204$20230310$20230228$20250722$EXP$$NVSC2023US040313$NOVARTIS$$$$$M$Y$$$20250722$$MD$US$US
220566282$22056628$2$F$$20230216$20230302$20250801$EXP$$CA-NOVOPROD-1028013$NOVO NORDISK$$$$N$$Y$$$20250801$$MD$CA$CA
220630178$22063017$8$F$20220317$20250826$20230306$20250902$EXP$$JP-ROCHE-3293689$ROCHE$$75$YR$E$M$Y$$$20250902$$MD$JP$JP
220715413$22071541$3$F$$20230301$20230307$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-004971$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
220833802$22083380$2$F$$20250715$20230310$20250728$EXP$$EU-AUROBINDO-AUR-APL-2023-010132$AUROBINDO$Comolli S, Del Vecchio L, De Micheli V, Tucci B, D^Amico M, Fumagalli G, et al. [Possible vaccine-induced immune thrombotic thrombocytopenia in a patient with diabetes and chronic kidney disease or random association?]. G-Ital-Nefrol. 2022;39No. 6$75$YR$$M$Y$$$20250728$$HP$EU$EU
220963373$22096337$3$F$20210101$20250806$20230315$20250812$EXP$$JP-AMGEN-JPNSP2023041573$AMGEN$Najima Y.; Sadaga Y.; Watanabe D. et al.. Ponatinib/blinatumomab combination for relapsed Ph+ acute leukemia as a bridging therapy to allo-SCT. Japanese Society for Transplantation and Cellular Therapy. 2023;272$60$YR$A$M$Y$$$20250812$$HP$JP$JP
221068442$22106844$2$F$20230101$20250708$20230317$20250716$PER$$US-SA-2023SA084537$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250716$$MD$US$US
221079613$22107961$3$F$20230101$20250805$20230317$20250811$EXP$$US-BIOGEN-2023BI01193619$BIOGEN$$$$$F$Y$$$20250811$$CN$US$US
221447983$22144798$3$F$$20250827$20230328$20250904$EXP$$CA-CELLTRION INC.-2023CA006012$CELLTRION$$$$$$Y$$$20250904$$HP$CA$CA
221571154$22157115$4$F$20230301$20230522$20230330$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-006972$JAZZ$$6$YR$$F$Y$$$20250710$$CN$US$US
2216336010$22163360$10$F$20210522$20250722$20230401$20250728$EXP$$CO-TAKEDA-2020TUS045582$TAKEDA$$18$YR$$F$Y$44$KG$20250728$$$CO$CO
221785656$22178565$6$F$20230301$20250722$20230405$20250730$PER$$US-SA-2023SA107009$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250730$$MD$US$US
221811283$22181128$3$F$$20250724$20230406$20250801$EXP$$JP-ASTELLAS-2023JP004193$ASTELLAS$$65$YR$E$M$Y$$$20250801$$MD$JP$JP
221823687$22182368$7$F$20241101$20250903$20230406$20250908$EXP$$CA-TAKEDA-2023TUS034428$TAKEDA$$64$YR$$F$Y$$$20250908$$$CA$CA
222034832$22203483$2$F$$20250916$20230412$20250917$EXP$$EU-MYLANLABS-2023M1037782$MYLAN$$49$YR$$F$Y$$$20250917$$$EU$EU
222259643$22225964$3$F$$20250624$20230419$20250708$EXP$$EU-AUROBINDO-AUR-APL-2023-030707$AUROBINDO$Simeoli R, Cairoli S, Cocciadiferro D, Agolini E, Marano M, Lancella L, et al. Combined approach between therapeutic drug monitoring (TDM) and pharmacogenetics for the application of personalized medicine in clinical practice. [Italian]. Biochim-Clin. 2022;46(4):E31-E34$5$YR$$M$Y$$$20250708$$HP$EU$EU
222339853$22233985$3$F$$20250808$20230420$20250820$PER$$US-ROCHE-3133289$ROCHE$$$$E$M$Y$$$20250820$$CN$US$US
222441015$22244101$5$F$$20250905$20230424$20250911$EXP$$US-SA-2023SA125716$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250911$$CN$US$US
2224517310$22245173$10$F$$20250904$20230424$20250918$EXP$$CA-AUROBINDO-AUR-APL-2022-032038$AUROBINDO$Massey V, Martel V, Nguyen DK, Busque L, Chapdelaine H, Keezer MR. Acute central nervous system graft-versus-host-disease after liver transplantation. Transpl-Immunol. 2022;70:101521$63$YR$$M$Y$$$20250918$$HP$CA$CA
222510262$22251026$2$F$$20250801$20230425$20250814$EXP$$GB-TAKEDA-2021TUS081208$TAKEDA$$$$$F$Y$$$20250814$$$GB$GB
222549723$22254972$3$F$$20250819$20230426$20250828$EXP$$CA-CELLTRION INC.-2023CA008385$CELLTRION$$$$$$Y$$$20250828$$HP$CA$CA
222617189$22261718$9$F$$20250728$20230428$20250805$EXP$$CA-GLAXOSMITHKLINE-CACH2023018361$Haleon PLC$$50$YR$$F$Y$68$KG$20250804$$HP$CA$CA
222666423$22266642$3$F$20230416$20230426$20230428$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-009533$JAZZ$$10$YR$$M$Y$$$20250710$$CN$US$US
222703547$22270354$7$F$$20250801$20230501$20250805$PER$$US-PFIZER INC-PV202300075656$PFIZER$$34$YR$$F$Y$$$20250805$$CN$US$US
222836758$22283675$8$F$$20250721$20230504$20250724$EXP$$CA-MYLANLABS-2023M1043314$MYLAN$$43$YR$$F$Y$68$KG$20250724$$$CA$CA
2229305017$22293050$17$F$20230101$20250714$20230508$20250721$EXP$$CA-CELLTRION INC.-2023CA003163$CELLTRION$$$$$$Y$$$20250721$$MD$CA$CA
223015504$22301550$4$F$$20250829$20230510$20250912$EXP$$EU-AUROBINDO-AUR-APL-2023-000573$AUROBINDO$Pelissier-Alicot AL, Fabresse N, Sastre C, Baillif-Couniou V, Becam J, Leonetti G.. Deaths related to the combination of pregabalin and other drugs of abuse: About two cases.. Analytical and Clinical Toxicology. 2022;34 (3):S153-S154$30$YR$$M$Y$$$20250912$$MD$EU$EU
223126542$22312654$2$F$20230418$20250617$20230512$20250702$PER$$US-TEVA-2023-US-2881447$TEVA$$37$YR$$F$Y$$$20250702$$CN$US$US
223148803$22314880$3$F$20230427$20230510$20230512$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-010397$JAZZ$$18$YR$$F$Y$$$20250710$$CN$US$US
223176443$22317644$3$F$$20230510$20230515$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-007448$JAZZ$$$$$F$Y$93$KG$20250710$$HP$US$US
2231789219$22317892$19$F$20230101$20250912$20230515$20250922$EXP$$CA-CELLTRION INC.-2023CA002538$CELLTRION$$$$$$Y$$$20250922$$HP$CA$CA
223180843$22318084$3$F$20210101$20230518$20230515$20250801$EXP$$CA-NOVOPROD-1061760$NOVO NORDISK$$65$YR$$F$Y$68$KG$20250801$$CN$CA$CA
223209399$22320939$9$F$20230101$20250724$20230515$20250804$PER$$US-SA-2023SA148032$SANOFI AVENTIS$$73$YR$E$F$Y$$$20250804$$CN$US$US
223252963$22325296$3$F$$20250820$20230516$20250822$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2023-062292$BRISTOL-MYERS SQUIBB COMPANY$$84$YR$E$M$Y$71.21$KG$20250822$$HP$US$US
223260313$22326031$3$F$20230505$20230513$20230516$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-010652$JAZZ$$18$YR$$F$Y$$$20250710$$CN$US$US
223374893$22337489$3$F$20230512$20230512$20230518$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-010654$JAZZ$$34$YR$$M$Y$$$20250710$$CN$US$US
223405235$22340523$5$F$$20230628$20230518$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-010626$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
2235029712$22350297$12$F$20190718$20250717$20230522$20250722$EXP$$CA-TAKEDA-2019TUS044587$TAKEDA$$64$YR$$M$Y$$$20250722$$$CA$CA
223555678$22355567$8$F$20220101$20250910$20230523$20250917$EXP$$CA-TAKEDA-2022TUS013905$TAKEDA$$62$YR$$M$Y$$$20250917$$PH$CA$CA
223559542$22355954$2$F$$20230511$20230523$20250709$EXP$$US-GLENMARK PHARMACEUTICALS-2023GMK081886$GLENMARK$$$$$$Y$$$20250709$$CN$US$US
223705323$22370532$3$F$$20230522$20230526$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-011304$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
223870393$22387039$3$F$20230425$20230525$20230531$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-011413$JAZZ$$17$YR$$M$Y$$$20250710$$CN$US$US
223872552$22387255$2$F$$20250625$20230531$20250709$EXP$$US-AUROBINDO-AUR-APL-2023-039367$AUROBINDO$Soussan L, Aggarwal S, Malat G, Kelepouris E, Doyle AM.. Kidney Recovery after Three Years of Dialysis for Hepatorenal Syndrome Type I. J-Am-Soc-Nephrol. 2016;27381A$51$YR$$M$Y$$$20250709$$HP$US$US
2239242714$22392427$14$F$20230712$20250918$20230601$20250922$EXP$$CA-TAKEDA-2022TUS090970$TAKEDA$$52$YR$$F$Y$$$20250922$$$CA$CA
225286363$22528636$3$F$20230531$20230601$20230607$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-011990$JAZZ$$31$YR$$M$Y$104.3$KG$20250710$$CN$US$US
225876932$22587693$2$F$$20250715$20230612$20250728$EXP$$US-AUROBINDO-AUR-APL-2023-040564$AUROBINDO$Skelton K, Bliss S.. Persistent Hypertriglyceridemia After Omission of Lipid From Parenteral Nutrition.. Journal of Parenteral and Enteral Nutrition.. 2023;47 (S2):S204-5$53$YR$$F$Y$72$KG$20250728$$PH$US$US
225877773$22587777$3$F$$20230608$20230612$20250710$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-012514$JAZZ$$$$$M$Y$$$20250710$$CN$US$US
226237753$22623775$3$F$$20250731$20230621$20250805$EXP$$CA-AUROBINDO-AUR-APL-2022-057711$AUROBINDO$Zai G, Dembo J, Levitsky N, Richter MA. Misophonia: A Detailed Case Series and Literature Review.. Primary Care Companion for CNS Disorders.. 2022;24(5):3124, 21cr03124$37$YR$$M$Y$$$20250805$$MD$CA$CA
2262568919$22625689$19$F$$20250911$20230621$20250916$EXP$$US-TAKEDA-2021TUS053993$TAKEDA$$$$$F$Y$115$KG$20250916$$$US$US
2262841711$22628417$11$F$$20250812$20230622$20250814$EXP$$CA-TAKEDA-2022TUS103834$TAKEDA$$$$$F$Y$$$20250814$$$CA$CA
226289074$22628907$4$F$20220326$20250819$20230622$20250822$EXP$$SA-SA-2023SA189460$SANOFI AVENTIS$Shendi AM, Aly AA, Alsaad KO, Shah Y, Ali TZ, Broering DC, et al.. Thrombotic microangiopathy after kidney transplantation: lessons from a transplant tourist.. Journal of Nephrology. 2023;36(4):1191-5$45$YR$A$M$Y$$$20250822$$MD$SA$SA
226319035$22631903$5$F$$20230719$20230623$20250903$PER$$NVSC2023US140107$NOVARTIS$$$$$M$Y$87.09$KG$20250903$$MD$US$US
226416233$22641623$3$F$20220326$20250819$20230626$20250822$EXP$$SA-PFIZER INC-202300228800$PFIZER$Shendi, A.. Thrombotic microangiopathy after kidney transplantation: lessons from a transplant tourist. Journal of Nephrology. 2023;36(4):1191-5$45$YR$$M$Y$$$20250822$$MD$SA$SA
226488397$22648839$7$F$$20250923$20230628$20250930$EXP$$US-TAKEDA-2023TUS060889$TAKEDA$$$$$F$Y$$$20250930$$$US$US
2266994410$22669944$10$F$20240613$20250919$20230704$20250925$EXP$$US-TAKEDA-US202026272$TAKEDA$$62$YR$$F$Y$$$20250925$$$US$US
226804126$22680412$6$F$20230602$20250819$20230707$20250827$EXP$$CA-TAKEDA-2023TUS066273$TAKEDA$$37$YR$$M$Y$$$20250827$$$CA$CA
226842317$22684231$7$F$20230101$20250710$20230709$20250721$PER$$US-VERTEX PHARMACEUTICALS-2023-009635$VERTEX$$$$$$Y$$$20250721$$CN$US$US
226996462$22699646$2$F$$20250926$20230713$20250930$EXP$$CA-ROCHE-3386234$ROCHE$$70$YR$E$F$Y$55$KG$20250930$$HP$CA$CA
227095274$22709527$4$F$$20250818$20230717$20250822$EXP$$CA-ROCHE-3387576$ROCHE$$47$YR$A$F$Y$210$KG$20250822$$HP$CA$CA
227137142$22713714$2$F$20230601$20250703$20230717$20250711$EXP$EU-SEMPA-2023-012449$EU-TEVA-2023-SE-2907727$TEVA$$37$YR$$F$Y$$$20250711$$MD$EU$EU
227146148$22714614$8$F$$20250805$20230718$20250818$EXP$$CA-THEA-2022000475$Thea Pharma$$75$YR$$F$Y$70$KG$20250818$$HP$CA$CA
2271623614$22716236$14$F$20230501$20250902$20230718$20250904$EXP$$CA-TAKEDA-2023TUS019338$TAKEDA$$72$YR$$F$Y$$$20250904$$$CA$CA
227170595$22717059$5$F$$20250818$20230718$20250820$PER$$US-PFIZER INC-PV202300123076$PFIZER$$75$YR$$F$Y$52.2$KG$20250820$$MD$US$US
2272316414$22723164$14$F$20230101$20250807$20230719$20250822$EXP$$CA-GSK-CA2023AMR070593$GLAXOSMITHKLINE$$$$$F$Y$$$20250822$$$CA$CA
227326862$22732686$2$F$20230217$20230220$20230720$20250715$PER$$US-NOVOPROD-1039202$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
227343842$22734384$2$F$20230615$20250630$20230721$20250703$PER$$US-SA-2023SA219891$SANOFI AVENTIS$$11$YR$C$M$Y$$$20250703$$MD$US$US
227434992$22743499$2$F$$20250810$20230724$20250815$EXP$$EU-BAUSCH-BL-2023-011260$BAUSCH AND LOMB$$69$YR$E$$Y$$$20250815$$MD$EU$EU
227461904$22746190$4$F$20210702$20250630$20230725$20250701$EXP$$US-TAKEDA-2021TUS042292$TAKEDA$$62$YR$$M$Y$74$KG$20250701$$$US$US
227476257$22747625$7$F$20231120$20250826$20230725$20250901$EXP$$US-TAKEDA-2023TUS040744$TAKEDA$$77$YR$$F$Y$$$20250901$$$US$US
227570773$22757077$3$F$20230101$20230720$20230727$20250829$PER$$NVSC2023US161414$NOVARTIS$$70$YR$$F$Y$$$20250829$$CN$US$US
227573904$22757390$4$F$20230701$20250721$20230727$20250730$EXP$$US-UCBSA-2023034337$UCB$$16$YR$$F$Y$58.05$KG$20250730$$CN$US$US
2276142418$22761424$18$F$$20250924$20230728$20250929$EXP$$US-PFIZER INC-PV202300048183$PFIZER$$65$YR$$F$Y$$$20250929$$CN$US$US
227702385$22770238$5$F$$20250822$20230801$20250903$EXP$$CA-ROCHE-3396638$ROCHE$$57$YR$A$M$Y$$$20250903$$HP$CA$CA
228111972$22811197$2$F$$20230808$20230810$20250725$EXP$$JP-DSJP-DSJ-2023-125766$DAIICHI$$60$YR$$F$Y$$$20250725$$MD$JP$JP
228121674$22812167$4$F$20230101$20250905$20230811$20250916$PER$$US-SA-2023SA243527$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250917$$MD$US$US
228128104$22812810$4$F$20230101$20250805$20230811$20250813$EXP$EU-AFSSAPS-LM2023000419$EU-TEVA-2023-FR-2915284$TEVA$$73$YR$$F$Y$77$KG$20250813$$PH$EU$EU
228176894$22817689$4$F$20230730$20250715$20230813$20250718$EXP$$US-BEH-2023161917$CSL BEHRING$$64$YR$A$M$Y$$$20250718$$HP$US$US
228228003$22822800$3$F$20230809$20250917$20230815$20250923$EXP$$US-ASTELLAS-2023US024132$ASTELLAS$$72$YR$E$M$Y$72.57$KG$20250923$$CN$US$US
228234313$22823431$3$F$$20250721$20230815$20250729$EXP$$CA-TAKEDA-2023TUS058007$TAKEDA$$$$$F$Y$90$KG$20250729$$$CA$CA
228289853$22828985$3$F$$20230818$20230816$20250901$EXP$$NVSC2023US174590$NOVARTIS$$$$$M$Y$98.7$KG$20250901$$CN$US$US
228349747$22834974$7$F$20230101$20250820$20230818$20250825$PER$$US-SA-2023SA249872$SANOFI AVENTIS$$54$YR$A$M$Y$$$20250826$$MD$US$US
228430412$22843041$2$F$20230728$20250723$20230821$20250805$EXP$GB-MHRA-ADR 28086214$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2023-08797$ALKEM$$22$YR$$F$Y$16$KG$20250805$$MD$GB$GB
228461395$22846139$5$F$$20250919$20230821$20250929$EXP$$CA-CELLTRION INC.-2023CA016393$CELLTRION$$$$$$Y$$$20250929$$HP$CA$CA
228494012$22849401$2$F$$20230821$20230822$20250903$PER$$NVSC2023US182270$NOVARTIS$$$$$M$Y$104.33$KG$20250903$$MD$US$US
228588159$22858815$9$F$20230801$20250730$20230824$20250811$EXP$$US-ELI_LILLY_AND_COMPANY-US202308014295$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250811$$CN$US$US
228703663$22870366$3$F$20230724$20250818$20230827$20250822$EXP$$US-ABBVIE-5382911$ABBVIE$$66$YR$$M$Y$$$20250822$$MD$US$US
228717642$22871764$2$F$$20230806$20230828$20250909$PER$$US-CHATTEMPRD-2023OHG003454$CHATTEM$$$$A$$Y$$$20250909$$CN$US$US
2291040012$22910400$12$F$20240401$20250804$20230906$20250807$EXP$$US-SANDOZ INC.-NVSC2022US284338$SANDOZ$$76$YR$$F$Y$92.063$KG$20250807$$CN$US$US
229226232$22922623$2$F$$20240829$20230908$20250905$PER$$US-FARMAPROD-202303-0682$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250814$$CN$US$US
2292481915$22924819$15$F$20221214$20250807$20230908$20250812$EXP$$US-SANDOZ INC.-NVSC2022US162764$SANDOZ$$63$YR$$M$Y$106.12$KG$20250812$$CN$US$US
229322362$22932236$2$F$$20250918$20230912$20250929$EXP$$JP-MALLINCKRODT-MNK202304305$MALLINCKRODT$$58$YR$A$M$Y$85$KG$20250929$$HP$JP$JP
229366822$22936682$2$F$$20250725$20230912$20250801$PER$$US-INCYTE CORPORATION-2023IN009326$INCYTE$$46$YR$$$Y$$$20250801$$$US$
2294558312$22945583$12$F$20201223$20250909$20230914$20250912$EXP$$MX-TAKEDA-2021TUS000362$TAKEDA$$3$YR$$M$Y$23$KG$20250912$$$MX$MX
229583775$22958377$5$F$$20240514$20230919$20250930$PER$$US-SECURA BIO, INC.-2023-SECUR-US000100$SECURA BIO$$$$$$Y$$$20250930$$HP$US$US
229668365$22966836$5$F$20230101$20250714$20230921$20250716$PER$$US-PFIZER INC-PV202300157450$PFIZER$$54$YR$$F$Y$$$20250716$$HP$US$US
229871766$22987176$6$F$20230925$20250916$20230926$20250919$EXP$$US-TAKEDA-2023TUS092376$TAKEDA$$36$YR$$F$Y$136.91$KG$20250919$$$US$US
2299318612$22993186$12$F$$20250630$20230927$20250708$EXP$$CA-SANDOZ INC.-NVSC2022CA223691$SANDOZ$$39$YR$$F$Y$119$KG$20250708$$HP$CA$CA
229939204$22993920$4$F$$20250718$20230927$20250722$EXP$$CA-SANDOZ INC.-SDZ2023CA034157$SANDOZ$$45$YR$$M$Y$$$20250722$$MD$CA$CA
229954554$22995455$4$F$$20240815$20230927$20250803$EXP$$CA-AstraZeneca-2021A597927$ALEXION PHARMACEUTICALS$$75$YR$E$F$Y$$$20250803$$$CA$CA
230110424$23011042$4$F$$20250913$20230929$20250918$EXP$$EU-BAUSCH-BL-2023-014289$BAUSCH AND LOMB$Flaksa M. Vyuziti Cresemby pri lecbe tezke nekrotizujici aspergilove pneumonie u mlade pacientky s astmatem. Antiinfectives News. 2023 Dec;14 (2): 14-18.$42$YR$A$F$Y$$$20250918$$MD$EU$EU
2301425511$23014255$11$F$20210101$20250714$20231002$20250723$EXP$$US-CATALYST PHARMACEUTICALS, INC-US-CATA-23-00119$CATALYST PHARMA$$$$$M$Y$$$20250723$$CN$US$US
230265782$23026578$2$F$$20250908$20231004$20250919$EXP$$CA-AUROBINDO-AUR-APL-2023-061150$AUROBINDO$$37$YR$$M$Y$$$20250919$$HP$CA$CA
230367362$23036736$2$F$$20250725$20231006$20250729$EXP$$US-SA-2023SA304030$SANOFI AVENTIS$$$$E$F$Y$$$20250729$$MD$US$US
230424413$23042441$3$F$$20250701$20231008$20250709$EXP$$CA-CELLTRION INC.-2023CA019106$CELLTRION$$$$$$Y$$$20250709$$HP$CA$CA
230442284$23044228$4$F$$20250715$20231009$20250718$EXP$$US-TAKEDA-2023TUS095977$TAKEDA$$$$$F$Y$$$20250718$$$US$US
230509665$23050966$5$F$20230901$20250813$20231010$20250822$PER$$US-SA-2023SA303962$SANOFI AVENTIS$$53$YR$A$M$Y$81.65$KG$20250822$$HP$US$US
230535614$23053561$4$F$20231025$20250908$20231011$20250914$EXP$$US-ABBVIE-5444236$ABBVIE$$55$YR$$F$Y$97$KG$20250914$$CN$US$US
230567572$23056757$2$F$20201201$20250827$20231012$20250829$EXP$$US-CHEPLA-2021002351$CHEPLAPHARM$$53$YR$$F$Y$97.155$KG$20250829$$MD$COUNTRY NOT SPECIFIED$US
230630493$23063049$3$F$20200101$20250618$20231013$20250703$EXP$$EU-AUROBINDO-AUR-APL-2023-056755$AUROBINDO$Saleh K, Arbab A, Ghez D, Bigenwald C, Cotteret S, Marzac C, et.al. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.. Immunotherapy. 2023;15(6):401-407$56$YR$$M$Y$$$20250703$$HP$EU$EU
230678747$23067874$7$F$20181023$20250903$20231016$20250908$EXP$$CA-TAKEDA-2018TUS032961$TAKEDA$$18$YR$$M$Y$$$20250908$$$CA$CA
230761937$23076193$7$F$$20250828$20231017$20250904$EXP$$CA-TAKEDA-2023TUS081469$TAKEDA$$$$$F$Y$78.2$KG$20250904$$$CA$CA
230770973$23077097$3$F$20210620$20250717$20231018$20250721$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2023-146317$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$F$Y$88.7$KG$20250721$$HP$US$US
230876722$23087672$2$F$$20250808$20231020$20250813$PER$$US-JNJFOC-20231028210$JOHNSON AND JOHNSON$$$$$F$Y$$$20250814$$HP$US$US
230883473$23088347$3$F$20171020$20250723$20231020$20250729$EXP$$CA-TAKEDA-2017TUS020127$TAKEDA$$55$YR$$F$Y$$$20250729$$MD$CA$CA
231074772$23107477$2$F$$20250805$20231026$20250816$EXP$$EU-AUROBINDO-AUR-APL-2023-065080$AUROBINDO$Ciriello GD, Colonna D, Papaccioli G, Correra A, Romeo E, Palladino MT et al.. Triple Antiarrhythmic Therapy in Newborns with Refractory  Atrioventricular Reentrant Tachycardia. Pediatric Cardiology. 2023;40:1040?1049$$$N$F$Y$$$20250816$$HP$EU$EU
231257153$23125715$3$F$20230101$20250815$20231030$20250826$PER$$US-SA-2023SA332582$SANOFI AVENTIS$$17$YR$T$F$Y$$$20250826$$MD$US$US
231358334$23135833$4$F$$20250808$20231101$20250818$EXP$$EU-CELLTRION INC.-2023IT020751$CELLTRION$Michelerio A, Tomasini C, Fiandrino G, De Amici Ma, Varettoni M, Defrancesco I, et.al. Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin^s B lymphoma: a single center prospective clinico-pathological study. Frontiers in Medicine. 2023;10:1-10.$$$$$Y$$$20250818$$HP$EU$EU
231359913$23135991$3$F$$20250903$20231102$20250912$EXP$$CA-SA-2023SA332355$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250912$$HP$CA$CA
231691373$23169137$3$F$20231020$20250722$20231110$20250724$EXP$$CN-CHEPLA-2023013933$CHEPLAPHARM$$66$YR$$F$Y$53$KG$20250724$$MD$COUNTRY NOT SPECIFIED$CN
231750483$23175048$3$F$20230101$20250724$20231112$20250730$EXP$$US-ABBVIE-5490311$ABBVIE$$48$YR$$F$Y$$$20250730$$CN$US$US
231760312$23176031$2$F$$20231025$20231113$20250909$PER$$US-CHATTEMPRD-2023OHG013098$CHATTEM$$$$$F$Y$$$20250909$$CN$US$US
231784749$23178474$9$F$$20250722$20231113$20250723$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2023-161898$BRISTOL-MYERS SQUIBB COMPANY$Sugawara Y, et al. A case of bullous pemphigoid 6 years after nivolumab initiation. The 908th Tokyo Regional Meeting of the Japanese Dermatological Association. 2023;16.$82$YR$E$F$Y$$$20250723$$MD$JP$JP
231799082$23179908$2$F$$20250716$20231114$20250724$EXP$$US-ROCHE-3340172$ROCHE$$76$YR$E$F$Y$$$20250724$$CN$US$US
231801872$23180187$2$F$20240101$20250905$20231114$20250910$EXP$$US-ABBVIE-5488572$ABBVIE$$71$YR$$M$Y$$$20250910$$CN$US$US
2318422012$23184220$12$F$20211104$20250909$20231115$20250917$EXP$$CA-CELLTRION INC.-2021CA019156$CELLTRION$$$$$$Y$$$20250917$$HP$CA$CA
231969923$23196992$3$F$$20250814$20231117$20250820$EXP$$EU-MYLANLABS-2023M1121682$MYLAN$Quintero V, Bueno-Sanchez D, Mozo-Del-Castillo Y, Urtasun-Erburu A, Sisinni L, Lopez-Duarte M et al. Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Hypocellular Bone Marrow Failure. Transplant Cell Ther. 2023;29(10):621.e1-6$11$YR$$F$Y$$$20250820$$$EU$EU
232101624$23210162$4$F$20230101$20241024$20231121$20250810$EXP$$US-ALXN-A202306750AA$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$US$US
2321851710$23218517$10$F$20230101$20250902$20231122$20250910$EXP$$JP-Eisai-EC-2023-153032$EISAI$Osawa T. Clinical perspectives in metastatic renal cell carcinoma treatment strategies.. Clinical perspectives in metastatic renal cell carcinoma treatment strategies..$61$YR$A$M$Y$$$20250910$$MD$JP$JP
232203374$23220337$4$F$$20241031$20231123$20250816$PER$$US-ALXN-202311USA001378US$ALEXION PHARMACEUTICALS$$87$YR$E$F$Y$$$20250816$$$US$US
232368784$23236878$4$F$$20250804$20231128$20250805$EXP$$CA-TAKEDA-2023TUS114139$TAKEDA$$$$$M$Y$$$20250805$$$CA$CA
232452753$23245275$3$F$$20250916$20231130$20250923$EXP$$CA-SANDOZ INC.-NVSC2023CA055601$SANDOZ$$60$YR$$M$Y$$$20250923$$CN$CA$CA
232495664$23249566$4$F$20250101$20250815$20231201$20250820$EXP$$GB-SANDOZ INC.-SDZ2023GB061139$SANDOZ$$$$$F$Y$$$20250820$$CN$GB$GB
232568793$23256879$3$F$20231124$20250711$20231204$20250717$EXP$$CN-BIOGEN-2023BI01237926$BIOGEN$$4$YR$$F$Y$16.5$KG$20250717$$MD$CN$CN
232624573$23262457$3$F$$20241008$20231205$20250810$PER$$US-ALXN-202312USA000056US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$US$US
232938542$23293854$2$F$20220101$20250826$20231213$20250911$EXP$$US-KYOWAKIRIN-2023KK019727$KYOWA$$$$$$Y$$$20250911$$HP$US$US
233174975$23317497$5$F$20240321$20250829$20231219$20250905$PER$$US-ROCHE-3404443$ROCHE$$17$YR$T$M$Y$74.84$KG$20250905$$CN$US$US
233246114$23324611$4$F$20250430$20250902$20231221$20250908$EXP$$CA-TAKEDA-2023TUS121433$TAKEDA$$54$YR$$F$Y$$$20250908$$$CA$CA
233342247$23334224$7$F$20230101$20250820$20231223$20250828$PER$$US-SA-2023SA351026$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250828$$MD$US$US
233355015$23335501$5$F$20230925$20250626$20231225$20250702$EXP$$BR-TAKEDA-2023TUS122316$TAKEDA$$26$YR$$M$Y$$$20250702$$$BR$BR
233355703$23335570$3$F$20231218$20250708$20231225$20250714$EXP$$US-UCBSA-2022057639$UCB$$18$YR$$F$Y$124.3$KG$20250714$$CN$US$US
233376922$23337692$2$F$$20231211$20231226$20250901$EXP$$US-TEVA-VS-3137544$TEVA$Gilmore RM, Abernathy KM, Shultes KC, Eplin DD, Orton L, Kassim AA, et al. Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia. Blood 2022; 140 (Suppl. 1) 2386-2388.$$$$$Y$$$20250901$$HP$US$US
2334538413$23345384$13$F$20240911$20250916$20231228$20250919$EXP$$US-JAZZ PHARMACEUTICALS-2023-US-025376$JAZZ$$38$YR$$M$Y$$$20250919$$$US$US
2335020710$23350207$10$F$20230101$20250908$20231229$20250917$EXP$$US-UCBSA-2023054631$UCB$$$$$F$Y$45$KG$20250917$$CN$US$US
233516303$23351630$3$F$$20250915$20231229$20250922$EXP$$US-BIOGEN-2023BI01242535$BIOGEN$$$$$F$Y$$$20250922$$CN$US$US
233663007$23366300$7$F$20180320$20250905$20240104$20250910$EXP$$NVSC2020IT289506$NOVARTIS$$62$YR$$F$Y$110$KG$20250910$$MD$EU$EU
233765556$23376555$6$F$$20240910$20240108$20250911$EXP$$CA-SANDOZ INC.-SDZ2024CA001007$SANDOZ$$52$YR$$F$Y$$$20250911$$HP$CA$CA
233875246$23387524$6$F$20230324$20250729$20240110$20250804$EXP$$US-PFIZER INC-PV202400003310$PFIZER$$42$YR$$F$Y$101.59$KG$20250804$$MD$US$US
233960765$23396076$5$F$$20250908$20240112$20250909$EXP$$US-GILEAD-2024-0658187$GILEAD$$30$YR$A$M$Y$$$20250909$$MD$US$US
233966003$23396600$3$F$$20250919$20240112$20250929$EXP$$BR-TAKEDA-2023TUS035865$TAKEDA$$65$YR$$F$Y$$$20250929$$$BR$BR
234094575$23409457$5$F$20231120$20250716$20240117$20250723$EXP$$CA-OTSUKA-2023_030467$OTSUKA$$33$YR$$M$Y$$$20250723$$PH$CA$CA
234174704$23417470$4$F$$20240724$20240118$20250927$EXP$$CA-SA-2024SA014963$SANOFI AVENTIS$$40$YR$A$F$Y$96$KG$20250926$$HP$CA$CA
234294284$23429428$4$F$20110101$20250818$20240122$20250821$EXP$$US-PURDUE PHARMA-USA-2024-0307199$PURDUE$$$$$F$Y$$$20250821$$CN$US$US
234368903$23436890$3$F$$20250923$20240124$20250930$EXP$$CA-ASTELLAS-2024US002033$ASTELLAS$Unk. Unk. Unk Unk;Unk:Unk.$45$YR$A$M$Y$$$20250930$$PH$CA$CA
234411452$23441145$2$F$20240123$20250821$20240125$20250825$EXP$$US-TAKEDA-US201815833$TAKEDA$$84$YR$$M$Y$$$20250825$$$US$US
234428094$23442809$4$F$20230301$20250813$20240125$20250826$EXP$$EU-ANIPHARMA-2024-FR-000023$ANI$$67$YR$$M$Y$85$KG$20250826$$CN$EU$EU
2344592211$23445922$11$F$20240913$20250724$20240126$20250729$EXP$$US-TAKEDA-2023TUS027446$TAKEDA$$65$YR$$F$Y$89$KG$20250729$$$US$US
234554086$23455408$6$F$20231106$20250725$20240130$20250804$EXP$$GB-TAKEDA-2023TUS103740$TAKEDA$$44$YR$$F$Y$$$20250804$$$GB$GB
234566045$23456604$5$F$$20250830$20240130$20250901$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2024-014132$BRISTOL-MYERS SQUIBB COMPANY$Hori K, et al. Two cases of acute hepatic failure after nivolumab administration in severe irAE liver disorder. The 73rd Koshinetsu Division Meeting of the Japanese Society of Gastroenterology. 2023;89.$71$YR$E$F$Y$$$20250902$$MD$JP$JP
234603252$23460325$2$F$$20250827$20240131$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-425880$RANBAXY$Balsam P, Grabowski M. The cardiovascular safety of etoricoxib. Medycyna Faktow. 2023;16(1):99-104$60$YR$$F$Y$$$20250911$$HP$EU$EU
234708112$23470811$2$F$20231220$20250709$20240202$20250718$EXP$CH-SM-2024-10144$NVSC2024CH019085$NOVARTIS$$67$YR$$M$Y$$$20250718$$MD$CH$CH
234817113$23481711$3$F$20231201$20250807$20240205$20250813$EXP$$BR-TAKEDA-2024TUS009879$TAKEDA$$79$YR$$F$Y$$$20250813$$$BR$BR
234828852$23482885$2$F$$20250714$20240205$20250728$EXP$$US-DAIICHI SANKYO, INC.-DSU-2024-104768$DAIICHI$$$$$F$Y$$$20250728$$HP$US$US
234991544$23499154$4$F$20210209$20250910$20240208$20250917$EXP$$GB-CIPLA LTD.-2024GB01139$CIPLA$$$$$$Y$$$20250917$$MD$GB$GB
235035829$23503582$9$F$20240202$20250417$20240208$20250810$EXP$$US-ALXN-202402USA000300US$ALEXION PHARMACEUTICALS$$85$YR$E$F$Y$60$KG$20250810$$PH$US$US
235069642$23506964$2$F$20240104$20240129$20240209$20250807$EXP$$NVSC2024KZ005132$NOVARTIS$$11$MON$$$Y$9.355$KG$20250807$$MD$KZ$KZ
235151403$23515140$3$F$20230126$20250703$20240213$20250710$EXP$$EU-JNJFOC-20230223819$JOHNSON AND JOHNSON$$87$YR$E$M$Y$77.5$KG$20250711$$MD$EU$EU
235194263$23519426$3$F$20230801$20250731$20240213$20250805$PER$$US-SA-2024SA043971$SANOFI AVENTIS$$80$YR$E$M$Y$$$20250805$$CN$US$US
235203465$23520346$5$F$$20250625$20240214$20250702$EXP$$CA-GSK-CA2023082974$GLAXOSMITHKLINE$$$$$F$Y$$$20250702$$$CA$CA
235236073$23523607$3$F$20240301$20250910$20240214$20250916$EXP$$IN-PFIZER INC-PV202400020501$PFIZER$$49$YR$$M$Y$$$20250916$$CN$IN$IN
235257553$23525755$3$F$20240209$20250806$20240215$20250812$EXP$$AE-TAKEDA-2024TUS012934$TAKEDA$$$$$$Y$$$20250812$$$AE$AE
235261772$23526177$2$F$$20250827$20240215$20250829$EXP$$US-SA-2024SA052872$SANOFI AVENTIS$$26$YR$A$F$Y$$$20250829$$MD$US$US
235368402$23536840$2$F$$20250328$20240219$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-003985$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
235463092$23546309$2$F$20240101$20250625$20240220$20250701$EXP$$US-SA-2024SA058438$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250701$$MD$US$US
235552772$23555277$2$F$$20240219$20240222$20250710$EXP$$EU-SANDOZ INC.-SDZ2024DE017263$SANDOZ$$$$$M$Y$$$20250710$$HP$EU$EU
2356536013$23565360$13$F$20240101$20250902$20240226$20250908$EXP$$US-SA-2024SA062858$SANOFI AVENTIS$$34$YR$A$M$Y$79.55$KG$20250908$$MD$US$US
235731072$23573107$2$F$20231207$20250623$20240227$20250701$EXP$$EU-CELLTRION INC.-2024ES004640$CELLTRION$$$$$$Y$$$20250701$$PH$EU$EU
235748465$23574846$5$F$20240218$20250807$20240228$20250814$EXP$$JP-AMGEN-JPNSP2024036016$AMGEN$$72$YR$E$M$Y$38$KG$20250813$$MD$JP$JP
235759723$23575972$3$F$20230519$20250717$20240228$20250721$EXP$$EU-PFIZER INC-202400034365$PFIZER$$53$YR$$F$Y$65$KG$20250721$$MD$EU$EU
235884297$23588429$7$F$$20250816$20240302$20250829$EXP$$EU-AUROBINDO-AUR-APL-2024-009106$AUROBINDO$Woro? J, Siwek M. Intensification of secondary sensitization and hyperalgesia in a patient with pancreatic cancer accompanied by depression and insomnia.(Nasilenie sensytyzacji i hiperalgezji  wt?rnej u pacjenta chorego na nowotw?r trzustki  z towarzysz?c? depresj? i bezsenno?ci?.). Medycyna Practical Psychiatria/ PSYCHOPHARMACOLOGY IN PRACTICE. 2024;1(96):31-32$41$YR$$M$Y$$$20250829$$MD$EU$EU
235938597$23593859$7$F$20230818$20250814$20240305$20250818$EXP$$CN-AMGEN-CHNNI2024044725$AMGEN$$69$YR$E$F$Y$70$KG$20250818$$MD$CN$CN
235966154$23596615$4$F$20240101$20250918$20240305$20250924$EXP$$US-SA-2024SA072900$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250924$$MD$US$US
236012972$23601297$2$F$$20250623$20240306$20250703$EXP$$US-STRIDES ARCOLAB LIMITED-2024SP002589$STRIDES$Reed HD, Do H, Weller E, Farrar JE, Gamper C, Lau BW, et al.. Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry.. Blood. 2023;142 (Suppl. 1):5662 abstr. 509$$$$M$Y$$$20250703$$HP$US$US
236017184$23601718$4$F$20240305$20250721$20240306$20250728$EXP$$US-SHIRE-US202019102$TAKEDA$$63$YR$$F$Y$$$20250728$$$US$US
236119393$23611939$3$F$20130101$20250701$20240308$20250707$EXP$$EU-ORGANON-2008PRT000884$ORGANON$Pinto PV, Nunes AT, Santos C, Martins P, Machado AP, Montenegro N.. Pregnancy in chronic kidney disease: from peritoneal dialysis to hemodialysis. Acta Obstet Ginecol Port.. 2016;10(3):194-200$25$YR$$F$Y$$$20250707$$MD$EU$EU
236147854$23614785$4$F$20230101$20250918$20240311$20250923$EXP$$US-ABBVIE-5496736$ABBVIE$$69$YR$$F$Y$$$20250923$$CN$US$US
236225173$23622517$3$F$20240101$20250912$20240312$20250922$PER$$US-SA-2024SA075692$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250922$$MD$US$US
236279113$23627911$3$F$$20250716$20240313$20250723$PER$$JP-Eisai-EC-2024-161296$EISAI$Sano S. Consideration of Lenvatinib + Pembrolizumab Combination Therapy - Based on the Experience at Yamagata University. Endometrial Cancer Clinical Seminar in Yamagata.$68$YR$E$F$Y$$$20250723$$MD$JP$JP
236336043$23633604$3$F$20210101$20250723$20240314$20250726$PER$$US-SA-2024SA081726$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250726$$MD$US$US
236361772$23636177$2$F$20231201$20240313$20240315$20250715$EXP$$NVSC2024HN056215$NOVARTIS$$67$YR$$F$Y$$$20250715$$CN$HN$HN
236495176$23649517$6$F$20240206$20250701$20240319$20250709$EXP$$NVSC2024FR054624$NOVARTIS$$$$E$F$Y$$$20250709$$MD$EU$EU
236545445$23654544$5$F$$20250924$20240320$20250930$EXP$$CA-SANDOZ INC.-SDZ2024CA029088$SANDOZ$$$$A$F$Y$$$20250930$$HP$CA$CA
236561569$23656156$9$F$20240528$20250922$20240321$20250927$EXP$$CA-JNJFOC-20231169098$JOHNSON AND JOHNSON$$70$YR$E$F$Y$68$KG$20250927$$HP$CA$CA
236569362$23656936$2$F$$20240728$20240321$20250806$EXP$$GB-NORDICGR-055351$NORDIC PHARMA$$$$A$M$Y$$$20250806$$MD$GB$GB
236616222$23661622$2$F$$20250822$20240322$20250829$EXP$$CA-TAKEDA-2024TUS006481$TAKEDA$$$$$M$Y$$$20250829$$$CA$CA
236628852$23662885$2$F$$20250617$20240322$20250701$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-437354$RANBAXY$Nersesjan M, Wagner M, Dalhoff KP, Petersen TS Bogevig S, Horwitz H. Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report. Br J Clin Pharmacol. 2024;Mar 7:Online ahead of print$$$$F$Y$$$20250701$$HP$EU$EU
236679902$23667990$2$F$$20240321$20240325$20250904$EXP$$CA-SANDOZ INC.-SDZ2024CA031630$SANDOZ$$$$$F$Y$$$20250904$$MD$CA$CA
236685225$23668522$5$F$$20241011$20240325$20250810$EXP$$CA-AstraZeneca-2024A068766$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
236697114$23669711$4$F$$20250924$20240325$20250929$EXP$$IN-PFIZER INC-2021373839$PFIZER$$52$YR$$F$Y$65$KG$20250929$$CN$IN$IN
236705953$23670595$3$F$20230201$20250904$20240326$20250913$EXP$$AU-CELLTRION INC.-2024AU007212$CELLTRION$$$$$$Y$$$20250913$$MD$AU$AU
236712653$23671265$3$F$20230101$20250909$20240326$20250916$PER$$US-BIOGEN-2023BI01241634$BIOGEN$$$$$F$Y$$$20250916$$CN$US$US
236838563$23683856$3$F$20231201$20250702$20240328$20250708$EXP$$US-UCBSA-2023060867$UCB$$13$YR$$$Y$46.9$KG$20250708$$MD$US$US
236966843$23696684$3$F$$20250626$20240402$20250704$EXP$$CA-GSK-CA2024AMR040142$GLAXOSMITHKLINE$$33$YR$$F$Y$57$KG$20250704$$$CA$CA
237039285$23703928$5$F$20200103$20250627$20240403$20250703$EXP$$MX-TAKEDA-MX202003503$TAKEDA$$17$YR$$M$Y$37$KG$20250703$$MD$MX$MX
237224306$23722430$6$F$20240308$20250923$20240409$20250926$EXP$$JP-AstraZeneca-2024A082440$ALEXION PHARMACEUTICALS$$79$YR$E$M$Y$48$KG$20250926$$MD$JP$JP
237440443$23744044$3$F$20250701$20250814$20240415$20250818$PER$$US-SA-2024SA112081$SANOFI AVENTIS$$53$YR$A$F$Y$71.21$KG$20250818$$MD$US$US
237441333$23744133$3$F$$20250730$20240415$20250807$PER$$US-SA-2024SA109432$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250807$$MD$US$US
237454642$23745464$2$F$20220401$20250710$20240416$20250717$PER$$US-SA-2024SA109015$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250717$$MD$US$US
237661763$23766176$3$F$20210701$20250819$20240422$20250826$EXP$$NVSC2021IN171540$NOVARTIS$$51$YR$$F$Y$$$20250826$$CN$IN$IN
237693614$23769361$4$F$20200101$20250710$20240422$20250716$EXP$$CO-BIOGEN-2022BI01148718$BIOGEN$$$$$F$Y$56$KG$20250716$$CN$CO$CO
237768172$23776817$2$F$$20250909$20240424$20250930$EXP$$CA-AUROBINDO-AUR-APL-2024-018556$AUROBINDO$Beaufils C, Proulx C, Blincoe A, Teira P, Bittencourt H, Cellot S, et al. Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis. Front-Med. 2023$3$YR$$F$Y$$$20250919$$HP$CA$CA
237788654$23778865$4$F$$20250912$20240424$20250920$EXP$$US-ABBVIE-5731862$ABBVIE$$60$YR$$F$Y$$$20250920$$CN$US$US
237820632$23782063$2$F$$20250910$20240425$20250919$EXP$$CA-AUROBINDO-AUR-APL-2024-019398$AUROBINDO$$70$YR$$M$Y$$$20250919$$HP$CA$CA
237901944$23790194$4$F$$20250820$20240426$20250825$EXP$$US-GILEAD-2024-0670680$GILEAD$$80$YR$E$M$Y$$$20250825$$MD$US$US
237926442$23792644$2$F$20230701$20250923$20240429$20250929$PER$$US-SA-2024SA127595$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250929$$CN$US$US
237946664$23794666$4$F$$20250723$20240429$20250731$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2024-065706$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250801$$MD$JP$JP
238050082$23805008$2$F$20240427$20250702$20240502$20250707$EXP$$US-ABBVIE-5738620$ABBVIE$$68$YR$$M$Y$$$20250707$$CN$US$US
238079884$23807988$4$F$20240404$20250825$20240502$20250902$EXP$$JP-ROCHE-3552726$ROCHE$$6$DEC$A$M$Y$56.6$KG$20250902$$MD$JP$JP
238102496$23810249$6$F$20191030$20250825$20240502$20250904$EXP$$EU-TEVA-VS-3189400$TEVA$$63$YR$$F$Y$73$KG$20250904$$MD$EU$EU
238112795$23811279$5$F$20240101$20250827$20240502$20250904$EXP$$CA-PFIZER INC-202300353070$PFIZER$$64$YR$$F$Y$$$20250904$$HP$CA$CA
238158613$23815861$3$F$$20250624$20240503$20250701$EXP$$CA-SANDOZ INC.-NVSC2022CA265276$SANDOZ$$$$$M$Y$74$KG$20250701$$MD$CA$CA
238175577$23817557$7$F$20250609$20250701$20240505$20250704$PER$$US-AMGEN-USASP2024086185$AMGEN$$48$YR$A$F$Y$$$20250704$$HP$US$US
238191952$23819195$2$F$$20240430$20240506$20250910$EXP$$US-CHATTEMPRD-2024OHG015520$CHATTEM$$$$$F$Y$$$20250910$$CN$US$US
238225096$23822509$6$F$$20250917$20240506$20250922$EXP$$CA-PFIZER INC-202400099241$PFIZER$$49$YR$$M$Y$115$KG$20250922$$HP$CA$CA
238314342$23831434$2$F$$20250728$20240508$20250805$EXP$$ZA-ABBVIE-5749885$ABBVIE$$59$YR$$M$Y$$$20250805$$CN$ZA$ZA
238318103$23831810$3$F$20240301$20241022$20240508$20250803$EXP$$EU-AstraZeneca-2024A108204$ALEXION PHARMACEUTICALS$$42$YR$A$M$Y$87$KG$20250803$$MD$EU$EU
238328932$23832893$2$F$$20250903$20240508$20250910$PER$$US-SA-2024SA136398$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250910$$HP$US$US
238582433$23858243$3$F$$20241205$20240515$20250810$PER$$US-ALXN-202405USA000440US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
238584703$23858470$3$F$$20250919$20240515$20250924$EXP$$CA-PFIZER INC-202400107631$PFIZER$$70$YR$$M$Y$$$20250924$$HP$CA$CA
238600132$23860013$2$F$20250101$20250731$20240515$20250807$PER$$US-SA-2024SA145737$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250807$$MD$US$US
238633237$23863323$7$F$20240515$20250813$20240516$20250819$EXP$$US-UCBSA-2024022247$UCB$$10$YR$$F$Y$42$KG$20250819$$CN$US$US
238646563$23864656$3$F$20230101$20250703$20240516$20250711$PER$$US-SA-2024SA145997$SANOFI AVENTIS$$68$YR$E$F$Y$76.372$KG$20250711$$HP$US$US
238754367$23875436$7$F$20250422$20250709$20240520$20250715$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-077662$BRISTOL-MYERS SQUIBB COMPANY$$53$YR$A$M$Y$$$20250715$$CN$US$US
238854812$23885481$2$F$$20240513$20240522$20250908$PER$$US-CHATTEMPRD-2024OHG017039$CHATTEM$$3$YR$C$M$Y$$$20250908$$CN$US$US
238869164$23886916$4$F$20230601$20250920$20240523$20250925$EXP$$US-ABBVIE-5713866$ABBVIE$$60$YR$$F$Y$$$20250925$$CN$US$US
2388962514$23889625$14$F$20240913$20250909$20240523$20250911$EXP$$US-TAKEDA-2024TUS051356$TAKEDA$$72$YR$$F$Y$109$KG$20250911$$$US$US
238979802$23897980$2$F$20240101$20250908$20240524$20250917$PER$$US-SA-2024SA150938$SANOFI AVENTIS$$29$YR$A$M$Y$$$20250917$$CN$US$US
238979993$23897999$3$F$20240401$20250623$20240524$20250701$PER$$US-SA-2024SA151706$SANOFI AVENTIS$$39$YR$A$M$Y$$$20250702$$MD$US$US
238980773$23898077$3$F$$20250710$20240524$20250723$PER$$US-SA-2024SA155826$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250723$$CN$US$US
239061152$23906115$2$F$20140101$20250904$20240527$20250909$EXP$$US-ABBVIE-5182787$ABBVIE$$60$YR$$M$Y$$$20250909$$CN$US$US
239076175$23907617$5$F$$20250714$20240528$20250717$EXP$$US-TAKEDA-2024TUS051809$TAKEDA$$$$$M$Y$$$20250717$$$US$US
239096582$23909658$2$F$20240301$20250923$20240528$20250930$EXP$$CN-AMGEN-CHNSP2024062066$AMGEN$$68$YR$E$F$Y$$$20250930$$CN$CN$CN
239114712$23911471$2$F$$20250717$20240528$20250724$PER$$US-SA-2024SA155079$SANOFI AVENTIS$$$$A$M$Y$105$KG$20250724$$MD$US$US
239129755$23912975$5$F$$20250623$20240529$20250701$EXP$$CA-SANDOZ INC.-SDZ2024CA052339$SANDOZ$$44$YR$$F$Y$$$20250701$$HP$CA$CA
239150402$23915040$2$F$20200101$20250725$20240529$20250728$EXP$$US-PFIZER INC-PV202400069967$PFIZER$$54$YR$$F$Y$$$20250728$$HP$US$US
239183907$23918390$7$F$20240513$20250819$20240530$20250821$EXP$$BR-TAKEDA-2024TUS052730$TAKEDA$$35$YR$$F$Y$$$20250821$$$BR$BR
2392712514$23927125$14$F$20240101$20250728$20240531$20250807$EXP$$US-UNITED THERAPEUTICS-UNT-2024-001630$UNITED THERAPEUTICS$$$$$F$Y$64.399$KG$20250807$$$US$US
239283682$23928368$2$F$20240201$20240320$20240531$20250703$PER$$US-RADIUS HEALTH INC.-2024US001867$RADIUS PHARM$$80$YR$$F$Y$$$20250704$$CN$US$US
239293862$23929386$2$F$$20240405$20240601$20250703$PER$$US-RADIUS HEALTH INC.-2024US002313$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
239296852$23929685$2$F$$20240312$20240601$20250703$PER$$US-RADIUS HEALTH INC.-2024US001602$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
239296862$23929686$2$F$20240419$20240422$20240601$20250703$PER$$US-RADIUS HEALTH INC.-2024US002715$RADIUS PHARM$$66$YR$$M$Y$$$20250704$$MD$US$US
239391175$23939117$5$F$20220101$20250627$20240604$20250703$EXP$$US-ABBVIE-5783016$ABBVIE$$42$YR$$F$Y$$$20250703$$CN$US$US
239401002$23940100$2$F$$20250723$20240605$20250904$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-437017$RANBAXY$$$$E$F$Y$$$20250904$$CN$US$US
239410294$23941029$4$F$$20241007$20240605$20250810$PER$$US-ALXN-202405USA002120US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250810$$$US$US
239422365$23942236$5$F$20240501$20250909$20240605$20250919$PER$$US-Calliditas-2024CAL00874$CALLIDITAS THERAPEUTICS AB$$44$YR$A$M$Y$50.3$KG$20250919$$CN$US$US
2394898515$23948985$15$F$20240513$20250828$20240607$20250903$EXP$$CA-TAKEDA-2024TUS049046$TAKEDA$$12$YR$$M$Y$$$20250903$$$CA$CA
239500503$23950050$3$F$$20250625$20240607$20250709$EXP$$EU-AUROBINDO-AUR-APL-2024-027314$AUROBINDO$$$$$M$Y$$$20250709$$MD$EU$EU
239530135$23953013$5$F$20240423$20250908$20240608$20250914$EXP$$EU-JNJFOC-20240588026$JOHNSON AND JOHNSON$$54$YR$A$M$Y$77$KG$20250914$$HP$EU$EU
239541284$23954128$4$F$$20250910$20240609$20250915$PER$$US-BAUSCHBL-2024BNL028118$BAUSCH AND LOMB$$69$YR$$M$Y$$$20250915$$CN$US$US
239553227$23955322$7$F$20120101$20250912$20240610$20250916$EXP$$US-GILEAD-2024-0676229$GILEAD$$40$YR$A$F$Y$$$20250916$$LW$US$US
239595304$23959530$4$F$$20250725$20240611$20250730$EXP$$US-AMGEN-USASP2024113531$AMGEN$$$$E$F$Y$$$20250730$$HP$US$US
239644112$23964411$2$F$$20250910$20240612$20250916$EXP$$US-ELI_LILLY_AND_COMPANY-US202406001531$ELI LILLY AND COMPANY$$63$YR$A$M$Y$$$20250916$$CN$US$US
239666358$23966635$8$F$20231002$20250731$20240612$20250807$EXP$$EU-TAKEDA-2023TUS095835$TAKEDA$$68$YR$$M$Y$78$KG$20250807$$$EU$EU
239710582$23971058$2$F$$20250702$20240613$20250703$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-449362$RANBAXY$Aoki KC, Bartos G, Skopit S. Hydroxychloroquine-Induced Nonthrombocytopenic Purpura: A Case series. J Drugs Dermatol. 2024;MAY; 23 (5):e124-e126$73$YR$$F$Y$$$20250703$$HP$US$US
239713386$23971338$6$F$20221201$20250719$20240613$20250723$EXP$$CA-PFIZER INC-202201296203$PFIZER$$21$YR$$M$Y$109.3$KG$20250723$$MD$CA$CA
2397434014$23974340$14$F$20230614$20250626$20240614$20250703$EXP$$CA-CELLTRION INC.-2023CA013544$CELLTRION$$$$$$Y$$$20250703$$HP$CA$CA
239748364$23974836$4$F$20240217$20240924$20240614$20250803$EXP$$CH-ALXN-202406EEA000631CH$ALEXION PHARMACEUTICALS$$40$YR$A$F$Y$$$20250803$$MD$CH$CH
239841086$23984108$6$F$20240603$20250703$20240618$20250715$EXP$$US-UCBSA-2024007323$UCB$$16$YR$$M$Y$46.1$KG$20250715$$CN$US$US
239846893$23984689$3$F$$20240617$20240618$20250709$EXP$$NVSC2024US126386$NOVARTIS$$$$$$Y$$$20250709$$HP$US$US
239861744$23986174$4$F$20240301$20250801$20240618$20250808$EXP$$US-MYOVANT SCIENCES GMBH-2024MYSCI0300873$SUNOVION$$76$YR$$M$Y$$$20250807$$$US$US
239874183$23987418$3$F$$20240927$20240618$20250810$PER$$US-ALXN-202406USA000590US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
239897593$23989759$3$F$20230818$20250725$20240619$20250801$EXP$$CA-OTSUKA-2024_016885$OTSUKA$$87$YR$$M$Y$49$KG$20250801$$HP$CA$CA
239915883$23991588$3$F$$20240927$20240619$20250816$PER$$US-ALXN-202406USA000648US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250816$$$US$US
239916622$23991662$2$F$$20240528$20240619$20250813$PER$$US-Ascend Therapeutics US, LLC-2158320$ASCEND THERAPEUTICS US, LLC$$$$$$Y$$$20250813$$$US$US
239965513$23996551$3$F$$20240927$20240620$20250816$PER$$US-ALXN-202406USA000726US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250816$$$US$US
240026303$24002630$3$F$$20241009$20240623$20250810$PER$$US-ALXN-202406USA001174US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
240075418$24007541$8$F$20240101$20250711$20240625$20250719$EXP$$CA-CELLTRION INC.-2024CA011022$CELLTRION$$$$$$Y$$$20250719$$HP$CA$CA
240081962$24008196$2$F$$20240620$20240625$20250825$EXP$$AU-SANDOZ INC.-SDZ2024AU059394$SANDOZ$$$$$$Y$$$20250825$$HP$AU$AU
240193685$24019368$5$F$20240501$20250710$20240627$20250715$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-102585$BRISTOL-MYERS SQUIBB COMPANY$$46$YR$A$F$Y$$$20250715$$MD$US$US
240268195$24026819$5$F$20240527$20250908$20240628$20250918$EXP$$US-SAREPTA THERAPEUTICS INC.-SRP2024-004774$SAREPTA THERAPEUTICS$$20$YR$$M$Y$109.3$KG$20250918$$CN$US$US
240285745$24028574$5$F$20240621$20250925$20240628$20250929$PER$$US-ROCHE-10000011620$ROCHE$$45$YR$A$M$Y$$$20250929$$CN$US$US
240304679$24030467$9$F$20231209$20250606$20240628$20250808$EXP$$GB-MYLANLABS-2024M1058265$MYLAN$$73$YR$$F$Y$$$20250807$$$GB$GB
240323073$24032307$3$F$20221223$20250715$20240630$20250718$EXP$$JP-AMGEN-JPNNI2024127702$AMGEN$$75$YR$E$M$Y$70.8$KG$20250718$$MD$JP$JP
240386673$24038667$3$F$20240605$20240606$20240702$20250810$PER$$US-AstraZeneca-2024A132479$ALEXION PHARMACEUTICALS$$59$YR$A$F$Y$$$20250810$$$US$US
240511452$24051145$2$F$$20250829$20240704$20250906$PER$$US-SA-2024SA190523$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250906$$MD$US$US
240579853$24057985$3$F$$20250725$20240707$20250804$EXP$$NVSC2024IT135701$NOVARTIS$Zaccheddu E, Zappu A, Barella S, Clemente MG, Orecchia V, Pilia MP et. al.. Unplanned pregnancy in women with beta-thalassaemia treated with luspatercept.. BRITISH JOURNAL OF HAEMATOLOGY. 2024;204 (6):2505-7$28$YR$$F$Y$$$20250804$$HP$EU$EU
240609466$24060946$6$F$20250131$20250917$20240708$20250926$EXP$$CA-BEH-2024174960$CSL BEHRING$$74$YR$E$F$Y$36$KG$20250926$$HP$CA$CA
240675732$24067573$2$F$20170101$20250905$20240710$20250915$EXP$$EU-CELLTRION INC.-2020NL034621$CELLTRION$Brinkman TK, Hubers AAM, van der Veek PPJ, Scholten EM, Gelinck LBS. Ileocolitis in a immunecompromised patient. Crohn^s disease or an infection after all?. Ned Tijdschr Geneeskd. 2020;164:D4813$$$$$Y$$$20250915$$MD$EU$EU
240758405$24075840$5$F$$20250708$20240710$20250903$EXP$$CA-SANDOZ INC.-NVSC2022CA013012$SANDOZ$$60$YR$$F$Y$$$20250903$$CN$CA$CA
240759507$24075950$7$F$20200401$20250821$20240710$20250826$EXP$$AU-BAUSCHBL-2024BNL029653$BAUSCH AND LOMB$Thorburn S, Majumdar A, Smibert O. Chronic hepatitis E masquerading as allograft rejection in a liver transplant recipient. Transplant Infectious Diseases. 2024;26:1-3. doi:10.1111/tid.14303$41$YR$$M$Y$$$20250827$$HP$AU$AU
240807243$24080724$3$F$$20241106$20240711$20250802$EXP$$JP-AstraZeneca-2024A033902$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$JP$JP
240828243$24082824$3$F$20240703$20250729$20240712$20250806$30DAY$$EU-SANDOZ INC.-SDZ2024IT064593$SANDOZ$$14$YR$$M$Y$52$KG$20250806$$CN$EU$EU
240837776$24083777$6$F$$20250905$20240712$20250911$EXP$$CA-TAKEDA-2024TUS070907$TAKEDA$$$$$F$Y$$$20250911$$$CA$CA
240882715$24088271$5$F$$20250818$20240715$20250825$EXP$$US-TAKEDA-2024TUS059562$TAKEDA$$$$$M$Y$117$KG$20250825$$$US$US
240974792$24097479$2$F$20240407$20250806$20240716$20250820$EXP$EU-AFSSAPS-NC2024000778$EU-SK LIFE SCIENCE, INC-SKPVG-2024-001574$SK LIFE SCIENCE$$$$$$Y$$$20250820$$MD$EU$EU
240986612$24098661$2$F$$20241118$20240716$20250715$PER$$US-NOVOPROD-1175897$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
240997002$24099700$2$F$20240301$20240719$20240716$20250715$PER$$US-NOVOPROD-1216504$NOVO NORDISK$$44$YR$$F$Y$$$20250715$$CN$US$US
241016762$24101676$2$F$20240515$20240723$20240717$20250715$PER$$US-NOVOPROD-1228605$NOVO NORDISK$$54$YR$$F$Y$$$20250715$$CN$US$US
241017232$24101723$2$F$20240101$20240910$20240717$20250715$PER$$US-NOVOPROD-1219736$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
241021352$24102135$2$F$$20240813$20240717$20250715$PER$$US-NOVOPROD-1153658$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
241023892$24102389$2$F$20240401$20240714$20240717$20250715$PER$$US-NOVOPROD-1234954$NOVO NORDISK$$63$YR$$F$Y$$$20250715$$CN$US$US
241153402$24115340$2$F$$20241003$20240721$20250718$PER$$US-NOVOPROD-1218239$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
241154102$24115410$2$F$20240413$20240718$20240721$20250718$PER$$US-NOVOPROD-1213259$NOVO NORDISK$$33$YR$$F$Y$$$20250718$$CN$US$US
241159165$24115916$5$F$$20250915$20240721$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-115117$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$F$Y$56.25$KG$20250916$$$US$US
241212549$24121254$9$F$$20250919$20240722$20250924$30DAY$$US-PFIZER INC-202400217130$PFIZER$$12$YR$$M$Y$$$20250924$$CN$US$US
241226538$24122653$8$F$$20250908$20240723$20250919$EXP$$EU-AUROBINDO-AUR-APL-2024-036387$AUROBINDO$Sitina M, Sramek V. Euglykemicka ketoacidoza asociovana se SGLT2 inhibitory a DPP4 inhibitory ? rozbor kazuistik (Euglycemic ketoacidosis associated with SGLT2 inhibitors and DPP4 inhibitors ? analysis of case reports). Anesteziologie a intenzivni medicina (Anesthesiology and intensive care medicine. 2024;35(2):116-21$70$YR$$F$Y$$$20250919$$MD$EU$EU
241260808$24126080$8$F$20240101$20250729$20240723$20250804$EXP$$CA-JNJFOC-20240656738$JOHNSON AND JOHNSON$$23$YR$A$F$Y$$$20250804$$HP$CA$CA
241315933$24131593$3$F$$20250822$20240724$20250901$EXP$$EU-TEVA-VS-3222261$TEVA$Campos S., Conceicao V., Vieira N., Arez L. LYELL SYNDROME - A MATERIAL ADVERSE EFFECT. Congresses of the Portuguese Society of Internal Medicine: 30th National Congress of Internal Medicine - Book of abstracts. 2024 May: 637. PO-0272 - (4498); Campos S., Conceicao V., Vieira N., Arez L. LYELL SYNDROME - A MATERIAL ADVERSE EFFECT. Congresses of the Portuguese Society of Internal Medicine: 30th National Congress of Internal Medicine - Book of abstracts. 2024 May: 637. PO-0272 - (4498)$20$YR$$M$Y$$$20250829$$MD$EU$EU
241365732$24136573$2$F$$20250909$20240725$20250912$EXP$$CA-APOTEX-2024AP008541$APOTEX$$$$$M$Y$$$20250912$$MD$CA$CA
241373782$24137378$2$F$20240605$20250826$20240725$20250830$EXP$EU-AFSSAPS-AN2024000920$EU-ORGANON-O2407FRA002268$ORGANON$$53$YR$$F$Y$48.5$KG$20250830$$MD$EU$EU
241413392$24141339$2$F$$20250927$20240726$20250930$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2024RR-458892$RANBAXY$Louisy A, Rochefort J, Plantier F, Kervarrec T, Quilhot P, Agbo Godeau S, et al. ^Plasma cell gingivitis^ encompasses multiple entities: a retrospective series of 37 cases. Eur J Dermatol. 2023;33 (2):109-120$83$YR$$M$Y$$$20250930$$HP$EU$EU
241478055$24147805$5$F$20240101$20250915$20240729$20250917$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-022351$BOEHRINGER INGELHEIM$$66$YR$E$M$Y$$$20250917$$$US$US
241519302$24151930$2$F$20240321$20240816$20240730$20250728$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-004495$SAREPTA THERAPEUTICS$$9$YR$$M$Y$$$20250728$$HP$US$US
241559104$24155910$4$F$$20250725$20240731$20250801$EXP$$NVSC2024GR155348$NOVARTIS$Tsotridou E. Encephalopathy Syndrome in an adolescent with Systemic Lupus Nephritis. 62ND PANHELLENIC PEDIATRIC CONGRESS. 2024$10$YR$$F$Y$$$20250801$$HP$EU$EU
241641062$24164106$2$F$$20250811$20240801$20250820$EXP$$RU-TEVA-VS-3226165$TEVA$Sergeeva NS, Karmakova TA, Savchina VV, Deshkina TI, Karpenko EYu, Bolotina LV, et al. DYNAMICS OF URINARY KIM-1 AS A BIOMARKER OF ACUTE KIDNEY INJURY IN CANCER PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY. [Russian]. Sib-Onkol-Zhur 2023; 22 (4): 44-54.; Sergeeva NS, Karmakova TA, Savchina VV, Deshkina TI, Karpenko EYu, Bolotina LV, et al. DYNAMICS OF URINARY KIM-1 AS A BIOMARKER OF ACUTE KIDNEY INJURY IN CANCER PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY. [Russian]. Sib-Onkol-Zhur 2...$60$YR$$M$Y$$$20250820$$HP$RU$RU
241686004$24168600$4$F$$20241217$20240802$20250802$EXP$$JP-AstraZeneca-2024A173328$ALEXION PHARMACEUTICALS$$78$YR$E$F$Y$$$20250802$$MD$JP$JP
241703894$24170389$4$F$$20250625$20240803$20250704$EXP$$CA-TEVA-VS-3226794$TEVA$$65$YR$$F$Y$34$KG$20250704$$HP$CA$CA
241744453$24174445$3$F$20240101$20250813$20240805$20250821$PER$$US-SA-2024SA226171$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250821$$MD$US$US
241749765$24174976$5$F$20190201$20250826$20240805$20250829$EXP$$US-SHIRE-US201905081$TAKEDA$$61$YR$$F$Y$$$20250829$$$US$US
241750712$24175071$2$F$$20250804$20240805$20250807$EXP$$EU-SANDOZ INC.-SDZ2024FR070434$SANDOZ$$18$YR$$F$Y$$$20250807$$HP$EU$EU
241763802$24176380$2$F$$20250918$20240806$20250926$EXP$$CA-AUROBINDO-AUR-APL-2024-038735$AUROBINDO$$48$YR$$M$Y$$$20250926$$HP$CA$CA
2417819210$24178192$10$F$20240702$20250816$20240806$20250818$30DAY$$US-PFIZER INC-PV202400081092$PFIZER$$14$YR$$M$Y$53$KG$20250818$$MD$US$US
241828323$24182832$3$F$20240709$20241031$20240807$20250809$EXP$$EU-AstraZeneca-2024A172752$ALEXION PHARMACEUTICALS$$85$YR$E$M$Y$68$KG$20250809$$$EU$EU
241849422$24184942$2$F$20240718$20250623$20240807$20250701$PER$$JP-Eisai-EC-2024-171198$EISAI$$71$YR$E$F$Y$$$20250701$$MD$JP$JP
241896004$24189600$4$F$$20240923$20240808$20250816$PER$$US-ALXN-202408USA000150US$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250816$$$US$US
241896672$24189667$2$F$$20250806$20240808$20250807$EXP$$US-PFIZER INC-202400232273$PFIZER$$$$$$Y$$$20250807$$CN$US$US
241976882$24197688$2$F$$20250721$20240811$20250726$PER$$US-SA-2024SA232902$SANOFI AVENTIS$$$$A$F$Y$84.36$KG$20250726$$MD$US$US
242054243$24205424$3$F$$20240805$20240813$20250810$EXP$$US-AstraZeneca-2024A178149$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
242097412$24209741$2$F$20240215$20250630$20240814$20250708$EXP$EU-AFSSAPS-RE2024000781$EU-PFIZER INC-202400234448$PFIZER$$54$YR$$F$Y$67$KG$20250708$$MD$EU$EU
242099172$24209917$2$F$$20250414$20240814$20250812$PER$$US-AMRYT PHARMACEUTICALS DAC-AEGR007315$CHIESI$$$$$F$Y$80.739$KG$20250812$$CN$US$US
242100143$24210014$3$F$$20250819$20240814$20250822$EXP$$IN-PFIZER INC-202400235337$PFIZER$Gupta, D.. Rare complications of heart transplant: Autopsy findings. Indian Journal of Pathology and Microbiology. 2024;67(3):624-627$33$YR$$M$Y$$$20250822$$MD$IN$IN
242122595$24212259$5$F$20240601$20250724$20240815$20250730$EXP$$EU-CELLTRION INC.-2024GR019302$CELLTRION$$$$$$Y$$$20250730$$CN$EU$EU
242137694$24213769$4$F$$20241030$20240815$20250809$EXP$$EU-ALXN-202408EEA000820PL$ALEXION PHARMACEUTICALS$$45$YR$A$F$Y$$$20250809$$MD$EU$EU
242195723$24219572$3$F$20230801$20250728$20240816$20250804$EXP$$US-ELI_LILLY_AND_COMPANY-US202408007477$ELI LILLY AND COMPANY$$29$YR$A$F$Y$$$20250804$$LW$US$US
242226573$24222657$3$F$20240101$20250815$20240819$20250822$PER$$US-SA-2024SA243113$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250822$$MD$US$US
242229504$24222950$4$F$20181010$20250904$20240819$20250909$EXP$$CA-TAKEDA-2018TUS027140$TAKEDA$$39$YR$$F$Y$$$20250909$$$CA$CA
242229797$24222979$7$F$20240101$20250728$20240819$20250807$EXP$$US-INSMED, INC.-2024-02496-US$INSMED$$$$$F$Y$$$20250807$$CN$US$US
242266873$24226687$3$F$$20241018$20240820$20250810$PER$$US-ALXN-202408USA000965US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$US$US
2422977410$24229774$10$F$20231028$20250710$20240820$20250714$EXP$$NVSC2023BR264316$NOVARTIS$$49$YR$$F$Y$$$20250714$$CN$BR$BR
242308995$24230899$5$F$20250601$20250722$20240821$20250729$EXP$$BR-TAKEDA-2023TUS004520$TAKEDA$$70$YR$$F$Y$$$20250729$$$BR$BR
242332566$24233256$6$F$$20250710$20240821$20250717$EXP$$CA-OTSUKA-2024_007715$OTSUKA$$$$$F$Y$$$20250717$$MD$CA$CA
242405377$24240537$7$F$$20250904$20240822$20250909$EXP$$US-Blueprint Medicines Corporation-SP-US-2024-001653$BLUEPRINT MEDICINES$$48$YR$A$F$Y$$$20250909$$CN$US$US
242407653$24240765$3$F$$20250707$20240823$20250717$EXP$CA-HEALTHCANVIG-03605216$CA-NOVOPROD-1269449$NOVO NORDISK$$39$YR$$F$Y$$$20250717$$CN$CA$CA
242436454$24243645$4$F$$20250623$20240823$20250707$EXP$EU-EMA-DD-20240809-7482655-095404$EU-GILEAD-2024-0684022$GILEAD$Hernani R, Sancho A, Amata P, Hernandez P, Perez A, Pinana J, et al. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Current Research in Translational Medicine. 2021;69(4):1 to 5. doi:10.1016/j.retram.2021.103304$56$YR$A$M$Y$$$20250707$$HP$EU$EU
242495863$24249586$3$F$$20250804$20240826$20250811$PER$$US-SA-2024SA246112$SANOFI AVENTIS$$$$A$F$Y$$$20250811$$MD$US$US
242496974$24249697$4$F$20250101$20250908$20240826$20250915$EXP$$US-SA-2024SA244214$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250915$$MD$US$US
242503472$24250347$2$F$$20250818$20240826$20250827$EXP$$CA-SANDOZ INC.-PHHY2018CA061543$SANDOZ$$68$YR$$F$Y$$$20250827$$HP$CA$CA
242504784$24250478$4$F$$20241003$20240826$20250816$PER$$US-ALXN-202408USA001528US$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250816$$$US$US
242524352$24252435$2$F$20231217$20250318$20240827$20250820$PER$$US-Accord-401797$ACCORD$$79$YR$E$M$Y$$$20250820$$CN$US$US
242524598$24252459$8$F$20230217$20250903$20240827$20250912$EXP$$CA-CELLTRION INC.-2022CA012286$CELLTRION$$$$$$Y$$$20250912$$MD$CA$CA
242545803$24254580$3$F$$20240926$20240827$20250810$PER$$US-ALXN-202408USA001353US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$US$US
242547033$24254703$3$F$20240101$20250714$20240827$20250717$PER$$US-BIOGEN-2024BI01279357$BIOGEN$$$$$F$Y$$$20250717$$CN$US$US
242548033$24254803$3$F$$20250129$20240827$20250810$PER$$US-AstraZeneca-2024A193069$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
242555213$24255521$3$F$20240801$20250812$20240827$20250820$PER$$US-SA-2024SA247081$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250820$$MD$US$US
242567633$24256763$3$F$$20240920$20240828$20250810$PER$$US-AstraZeneca-2024A188599$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
242589573$24258957$3$F$20240805$20241003$20240828$20250816$PER$$US-AstraZeneca-2024A179278$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$$$20250816$$$US$US
242589998$24258999$8$F$$20250918$20240828$20250923$PER$$US-PFIZER INC-PV202300122052$PFIZER$$84$YR$$F$Y$56.6$KG$20250923$$CN$US$US
242599692$24259969$2$F$$20250724$20240828$20250730$PER$$US-SA-2024SA248113$SANOFI AVENTIS$$34$YR$A$F$Y$$$20250730$$CN$US$US
2426067910$24260679$10$F$$20250822$20240828$20250903$EXP$$CA-AstraZeneca-2024A091311$ALEXION PHARMACEUTICALS$$66$YR$E$M$Y$$$20250903$$$CA$CA
242611312$24261131$2$F$$20250721$20240829$20250723$EXP$$CA-ROCHE-10000063967$ROCHE$$42$YR$A$F$Y$$$20250723$$HP$CA$CA
242637513$24263751$3$F$20240801$20250827$20240829$20250903$EXP$$US-PFIZER INC-PV202400112095$PFIZER$$75$YR$$M$Y$$$20250903$$HP$US$US
242641514$24264151$4$F$$20250924$20240829$20250929$EXP$$CA-PFIZER INC-202400245763$PFIZER$$80$YR$$M$Y$$$20250929$$HP$CA$CA
242696532$24269653$2$F$20240101$20250910$20240830$20250923$EXP$$US-CORCEPT THERAPEUTICS INC.-US-2024CRT002382$CORCEPT$$$$$$Y$$$20250923$$MD$US$US
242709479$24270947$9$F$20240801$20250716$20240831$20250729$EXP$$EU-AUROBINDO-AUR-APL-2024-042400$AUROBINDO$$67$YR$$M$Y$82$KG$20250729$$MD$EU$EU
242721393$24272139$3$F$20240829$20250717$20240902$20250723$PER$$US-AMGEN-USASP2024174475$AMGEN$$87$YR$E$M$Y$$$20250723$$HP$US$US
242732892$24273289$2$F$$20250822$20240902$20250901$PER$$US-VERTEX PHARMACEUTICALS-2024-013711$VERTEX$$$$$$Y$$$20250901$$CN$US$US
242757233$24275723$3$F$$20240926$20240903$20250810$PER$$US-ALXN-202408USA002124US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250810$$$US$US
242798802$24279880$2$F$$20240830$20240904$20250908$PER$$US-CHATTEMPRD-2024OHG030340$CHATTEM$$$$$F$Y$$$20250908$$CN$US$US
242802158$24280215$8$F$$20250725$20240904$20250729$EXP$$EU-SANDOZ INC.-SDZ2024ES076945$SANDOZ$$36$YR$$F$Y$83.3$KG$20250729$$PH$EU$EU
242835423$24283542$3$F$$20250725$20240904$20250801$PER$$US-SMPA-2024SPA002201$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
2428509112$24285091$12$F$20240101$20250704$20240905$20250712$EXP$$CA-CELLTRION INC.-2024CA018615$CELLTRION$$$$$$Y$$$20250712$$MD$CA$CA
242872623$24287262$3$F$$20250603$20240905$20250803$EXP$$JP-AstraZeneca-2024A196997$ALEXION PHARMACEUTICALS$$7$DEC$E$M$Y$$$20250803$$MD$JP$JP
242880426$24288042$6$F$$20250628$20240905$20250718$PER$$US-SMPA-2024SPA001339$SUNOVION$$$$$$Y$$$20250718$$CN$US$US
242886503$24288650$3$F$$20250814$20240906$20250820$EXP$EU-SYNOPTIS-048b/048d-L-012$EU-GSK-PL2024104917$GLAXOSMITHKLINE$Woron J, Siwek M. Sore throat as an adverse consequence of drug interactions used in the treatment of a patient with depression and obesity. Medycyna Praktyczna-Psychiatry. 2024;04:37-39$31$YR$$F$Y$$$20250820$$MD$EU$EU
242904642$24290464$2$F$$20250626$20240906$20250708$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-466093$RANBAXY$Zhang PL, Metcalf BD, Khan S, Abukhaled J, Zafar K, Li W, et al. Hydralazine use can be associated with IgM-dominated immune complex-mediated glomerulonephritis. Ultrastruct Pathol. 2024;48 (4):317-322$67$YR$$F$Y$$$20250708$$HP$US$US
242918703$24291870$3$F$$20241008$20240906$20250809$EXP$$US-ALXN-202408USA002233US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250809$$$US$US
242942352$24294235$2$F$20240501$20240709$20240906$20250905$PER$$US-FARMAPROD-202405-1936$DOMPE FARMACEUTICI$$55$YR$A$M$Y$$$20250817$$MD$US$US
242942612$24294261$2$F$20240616$20240708$20240906$20250905$PER$$US-FARMAPROD-202406-2292$DOMPE FARMACEUTICI$$76$YR$E$F$Y$$$20250815$$CN$US$US
242979453$24297945$3$F$$20250811$20240909$20250814$EXP$$US-ROCHE-10000012051$ROCHE$$76$YR$E$F$Y$$$20250814$$MD$US$US
243004913$24300491$3$F$$20241025$20240910$20250810$PER$$US-ALXN-202409USA000413US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$US$US
243005283$24300528$3$F$$20250128$20240910$20250816$PER$$US-AstraZeneca-2024A201484$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
243020133$24302013$3$F$$20250805$20240910$20250817$EXP$$EU-AUROBINDO-AUR-APL-2023-067670$AUROBINDO$Quintero V, Bueno-S?nchez D, Mozo-Del-Castillo Y, Urtasun-Erburu A, Sisinni L, L?pez-Duarte M et al.. Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Hypocellular Bone Marrow Failure.. Transplantation and Cellular Therapy. 2023;29(10):e1-621.e6$11$YR$$F$Y$$$20250817$$MD$EU$EU
243036758$24303675$8$F$20140101$20250710$20240910$20250714$PER$$US-GILEAD-2024-0686794$GILEAD$$43$YR$A$M$Y$$$20250714$$LW$US$US
243041435$24304143$5$F$20240816$20241011$20240910$20250809$EXP$$JP-ALXN-202409JPN000172JP$ALEXION PHARMACEUTICALS$$74$YR$E$F$Y$$$20250809$$MD$JP$JP
243046582$24304658$2$F$$20250702$20240910$20250710$EXP$$US-SMPA-2024MYSCI0700717$SUNOVION$$$$$$Y$$$20250710$$CN$US$US
243088403$24308840$3$F$$20250825$20240911$20250827$PER$$US-PFIZER INC-202400253346$PFIZER$$80$YR$$F$Y$$$20250827$$CN$US$US
243111093$24311109$3$F$20220801$20250909$20240912$20250920$PER$$US-SA-2024SA080770$SANOFI AVENTIS$$70$YR$E$M$Y$$$20250920$$CN$US$US
243144903$24314490$3$F$$20241017$20240913$20250816$PER$$US-ALXN-202409USA000735US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250816$$$US$US
243154932$24315493$2$F$$20250713$20240913$20250904$EXP$$US-JNJFOC-20240923463$JOHNSON AND JOHNSON$Ayoobkhan MD FS, Suleman MD N, Iftikhar MD A, Qureshi MD R, Wesson MD W, Mushtaq MD MU, et al. Immune Effector Cell-Associated Hemophagocytic LymphohistiocytosisLike Syndrome in Relapsed and Refractory Multiple Myeloma Using the FAERS Database. Clin Lymphoma Myeloma Leuk. 2024;$$$$$Y$$$20250904$$MD$US$US
243175212$24317521$2$F$$20250725$20240913$20250729$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-141428$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$M$Y$$$20250729$$CN$US$US
243177745$24317774$5$F$20201201$20240909$20240913$20250904$EXP$$EU-SANDOZ INC.-NVSC2021PL142238$SANDOZ$$49$YR$$M$Y$$$20250904$$MD$EU$EU
243212433$24321243$3$F$$20241203$20240916$20250816$PER$$US-AstraZeneca-2024A207942$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
243219497$24321949$7$F$$20241213$20240916$20250812$EXP$$US-AstraZeneca-2024A205341$ALEXION PHARMACEUTICALS$$$$$F$Y$96.162$KG$20250812$$MD$US$US
243229412$24322941$2$F$$20250723$20240916$20250805$EXP$PH-MLMSERVICE-20240827-PI173858-00079-1$PH-STRIDES ARCOLAB LIMITED-2024SP011497$STRIDES$Ajon ARS, Camara PT.. Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Due to Multiple Anti-Epileptic Drug Hypersensitivity. Cureus. 2024;16(7):e65417$41$YR$$F$Y$$$20250805$$MD$PH$PH
243239132$24323913$2$F$$20240912$20240916$20250916$EXP$$CA-SANDOZ INC.-SDZ2024CA080029$SANDOZ$$$$$M$Y$$$20250916$$CN$CA$CA
243256033$24325603$3$F$$20240909$20240917$20250810$EXP$$ZA-AstraZeneca-2024A205353$ALEXION PHARMACEUTICALS$$56$YR$$F$Y$$$20250810$$$ZA$ZA
243262963$24326296$3$F$$20240911$20240917$20250809$EXP$$ZA-AstraZeneca-2024A209055$ALEXION PHARMACEUTICALS$$81$YR$$F$Y$$$20250809$$$ZA$ZA
243264087$24326408$7$F$20240101$20250910$20240917$20250922$EXP$$US-INSMED, INC.-2024-02433-US$INSMED$$$$$F$Y$$$20250922$$CN$US$US
243269833$24326983$3$F$$20241011$20240917$20250810$EXP$2024A206901$EU-AstraZeneca-2024A206901$ALEXION PHARMACEUTICALS$$65$YR$E$M$Y$82$KG$20250810$$MD$EU$EU
243280293$24328029$3$F$$20241028$20240917$20250810$PER$$US-ALXN-202409USA001211US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
243295252$24329525$2$F$20240807$20250814$20240917$20250818$EXP$$US-Eisai-EC-2024-174341$EISAI$$77$YR$E$F$Y$56.6$KG$20250818$$MD$US$US
243297505$24329750$5$F$20241101$20250725$20240917$20250730$PER$$US-SA-2024SA266933$SANOFI AVENTIS$$37$YR$A$M$Y$$$20250730$$MD$US$US
243300523$24330052$3$F$$20240912$20240917$20250809$EXP$$US-AstraZeneca-2024A210839$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
243303823$24330382$3$F$$20240913$20240918$20250803$EXP$$US-AstraZeneca-2024A210142$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
243308483$24330848$3$F$20230703$20240912$20240918$20250804$EXP$$EU-AstraZeneca-2024A209952$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$63$KG$20250804$$MD$EU$EU
243313623$24331362$3$F$20240725$20240914$20240918$20250803$EXP$$CN-AstraZeneca-2024A211553$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$$$20250803$$$CN$CN
243314103$24331410$3$F$$20240913$20240918$20250809$EXP$$US-AstraZeneca-2024A211751$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
243333012$24333301$2$F$20240912$20250813$20240918$20250814$PER$$US-PFIZER INC-202400256044$PFIZER$$24$YR$$$Y$$$20250814$$CN$US$US
243334834$24333483$4$F$20140904$20250909$20240918$20250913$EXP$$EU-ABBVIE-15P-013-1353183-00$ABBVIE$$53$YR$$M$Y$$$20250913$$MD$EU$EU
243342703$24334270$3$F$20230517$20241021$20240918$20250803$EXP$$EU-ALXN-202409EEA000016IT$ALEXION PHARMACEUTICALS$$48$YR$A$F$Y$72$KG$20250803$$MD$EU$EU
243346095$24334609$5$F$$20250918$20240918$20250925$EXP$$US-SMPA-2024SPA001868$SUNOVION$$69$YR$$M$Y$$$20250924$$$US$US
243397243$24339724$3$F$20240601$20250923$20240919$20250930$EXP$$US-Calliditas-2024CAL01682$CALLIDITAS THERAPEUTICS AB$$54$YR$A$F$Y$$$20250930$$CN$US$US
243422192$24342219$2$F$$20250815$20240920$20250821$EXP$$US-JAZZ PHARMACEUTICALS-2024-US-015344$JAZZ$$$$$F$Y$8.7$KG$20250821$$$US$US
243433425$24343342$5$F$20240816$20250718$20240920$20250725$EXP$$US-STEMLINE THERAPEUTICS B.V.-2024-STML-US004932$STEMLINE THERAPEUTICS$$$$$$Y$$$20250725$$CN$US$US
243466125$24346612$5$F$20230101$20250820$20240921$20250827$EXP$$US-ABBVIE-5931132$ABBVIE$$59$YR$$M$Y$$$20250827$$CN$US$US
243535254$24353525$4$F$$20250909$20240923$20250911$EXP$$US-PFIZER INC-PV202400123770$PFIZER$$43$YR$$F$Y$$$20250911$$HP$US$US
243566958$24356695$8$F$$20250919$20240924$20250925$EXP$$CA-APOTEX-2024AP010648$APOTEX$$30$YR$$F$Y$99$KG$20250925$$HP$CA$CA
243604283$24360428$3$F$$20250703$20240925$20250704$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-151032$BRISTOL-MYERS SQUIBB COMPANY$$54$YR$A$F$Y$$$20250704$$HP$US$US
243616812$24361681$2$F$$20250808$20240925$20250821$EXP$$US-AUROBINDO-AUR-APL-2024-045471$AUROBINDO$Reddy TP, Barrios R, Bernicker E, Qian W, Chang J, Safdar Z. Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension. Pulmonary circulation. 2024;14(3):e12426 (1-8)$52$YR$$F$Y$$$20250821$$MD$US$US
243620754$24362075$4$F$$20250724$20240925$20250801$EXP$$NVSC2024CA189054$NOVARTIS$D^Souza R, Soete E, Silversides CK, Zaffar N, Van Mieghem T, Van Cleemput J, et al. Pregnancy Outcomes Following Cardiac Transplantation. J OBSTET GYNAECOL CAN. 2018;40(5):566-71$$$A$F$Y$$$20250801$$HP$CA$CA
243630583$24363058$3$F$$20250625$20240925$20250717$PER$$US-SMPA-2024SPA002434$SUNOVION$$$$$$Y$$$20250717$$CN$US$US
2436499510$24364995$10$F$20241212$20250829$20240926$20250903$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-152396$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$68.1$KG$20250903$$CN$US$US
243671925$24367192$5$F$20240101$20250812$20240926$20250821$EXP$$JP-UNITED THERAPEUTICS-UNT-2024-027473$UNITED THERAPEUTICS$$92$YR$$F$Y$$$20250821$$$JP$JP
2436867010$24368670$10$F$20230313$20250722$20240926$20250723$EXP$$KR-ABBVIE-5938582$ABBVIE$$50$YR$$M$Y$85$KG$20250723$$MD$KR$KR
243735282$24373528$2$F$$20240718$20240927$20250919$EXP$$US-VIVUS LLC-2023V1001046$VIVUS$$$$$$Y$$$20250903$$CN$US$US
243743634$24374363$4$F$$20250825$20240927$20250904$EXP$$US-OTSUKA PHARMACEUTICAL NETHERLANDS B.V.-AUR-006778$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250904$$CN$US$US
243785962$24378596$2$F$20240601$20240910$20240930$20250915$PER$$US-ENDO USA, INC.-2024-003068$ENDO$$94$YR$$F$Y$$$20250915$$CN$US$US
243798972$24379897$2$F$$20240920$20240930$20250816$PER$$US-ASTRAZENECA-202409USA004802US$ALEXION PHARMACEUTICALS$$70$YR$E$M$Y$$$20250816$$$US$US
243813492$24381349$2$F$$20240919$20241001$20250809$EXP$$AU-ASTRAZENECA-202409OCE002293AU$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$AU$AU
243828884$24382888$4$F$$20250924$20241001$20250929$EXP$$CA-APOTEX-2024AP011336$APOTEX$$69$YR$$F$Y$$$20250929$$HP$CA$CA
243829553$24382955$3$F$$20241008$20241001$20250809$EXP$$TR-ALXN-202409TUR001261TR$ALEXION PHARMACEUTICALS$$$$A$F$Y$63$KG$20250809$$MD$TR$TR
243844342$24384434$2$F$$20240918$20241001$20250810$PER$$US-ASTRAZENECA-202409USA002609US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
243857372$24385737$2$F$$20240917$20241001$20250816$EXP$$US-ASTRAZENECA-202409USA006658US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
243873542$24387354$2$F$$20240920$20241002$20250810$EXP$$US-ASTRAZENECA-202409USA003887US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
243878972$24387897$2$F$$20240923$20241002$20250803$EXP$$CA-ASTRAZENECA-202409CAN007585CA$ALEXION PHARMACEUTICALS$$79$YR$E$M$Y$$$20250803$$$CA$CA
243880982$24388098$2$F$20240710$20240925$20241002$20250802$EXP$$US-ASTRAZENECA-202409USA007077US$ALEXION PHARMACEUTICALS$$69$YR$E$M$Y$$$20250802$$$US$US
243881242$24388124$2$F$$20240918$20241002$20250810$EXP$$US-ASTRAZENECA-202409USA002232US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
243889303$24388930$3$F$20240101$20240919$20241002$20250803$EXP$$GB-ASTRAZENECA-202409GBR003452GB$ALEXION PHARMACEUTICALS$$63$YR$A$M$Y$$$20250803$$MD$GB$GB
243890402$24389040$2$F$20240920$20240923$20241002$20250803$EXP$$CN-ASTRAZENECA-202409CHN006128CN$ALEXION PHARMACEUTICALS$$67$YR$E$F$Y$55$KG$20250803$$$CN$CN
243904783$24390478$3$F$20230101$20250825$20241003$20250901$PER$$US-SA-2024SA279773$SANOFI AVENTIS$$11$YR$C$M$Y$$$20250901$$HP$US$US
243905312$24390531$2$F$20240226$20240926$20241003$20250807$EXP$$NVSC2024RO192595$NOVARTIS$$61$YR$$F$Y$$$20250807$$MD$EU$EU
243918975$24391897$5$F$$20240923$20241003$20250910$PER$$NVSC2024US191265$NOVARTIS$$59$YR$$F$Y$$$20250910$$MD$US$US
243924792$24392479$2$F$20240905$20241031$20241003$20250809$EXP$$EU-AstraZeneca-2024A213416$ALEXION PHARMACEUTICALS$$70$YR$E$F$Y$65$KG$20250809$$MD$EU$EU
243931842$24393184$2$F$$20240919$20241003$20250810$EXP$$SG-ASTRAZENECA-202409ASI003810SG$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$SG$SG
243936662$24393666$2$F$$20240919$20241003$20250803$EXP$$US-ASTRAZENECA-202409USA003170US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
243942943$24394294$3$F$20240901$20250812$20241004$20250818$EXP$$JP-ABBVIE-5948114$ABBVIE$$40$YR$$M$Y$$$20250818$$MD$JP$JP
243951862$24395186$2$F$$20240919$20241004$20250816$EXP$$CN-ASTRAZENECA-202409CHN002199CN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$CN$CN
243952582$24395258$2$F$20240717$20241002$20241004$20250809$EXP$$TR-ALXN-202410TUR000362TR$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$MD$TR$TR
243965402$24396540$2$F$20240901$20250701$20241004$20250703$PER$$US-AMGEN-USASP2024196494$AMGEN$$50$YR$A$F$Y$$$20250702$$HP$US$US
243982792$24398279$2$F$$20240909$20241004$20250810$EXP$$US-ASTRAZENECA-202409USA012223US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
243990552$24399055$2$F$20240101$20250909$20241004$20250918$PER$$US-UNITED THERAPEUTICS-UNT-2024-030755$UNITED THERAPEUTICS$$$$$F$Y$$$20250918$$$US$US
243992502$24399250$2$F$$20240920$20241004$20250816$EXP$$US-ASTRAZENECA-202409USA003961US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
243992972$24399297$2$F$20240902$20240923$20241004$20250809$EXP$$US-ASTRAZENECA-202409USA007736US$ALEXION PHARMACEUTICALS$$77$YR$E$F$Y$$$20250809$$$US$US
243997322$24399732$2$F$$20240912$20241005$20250810$EXP$$JP-AstraZeneca-2024A211181$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$JP$JP
243999662$24399966$2$F$$20240925$20241005$20250809$EXP$$CA-ASTRAZENECA-202409CAN007395CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
244015692$24401569$2$F$20240101$20250730$20241007$20250806$EXP$$GB-UCBSA-2024044785$UCB$$$$$F$Y$$$20250806$$CN$GB$GB
244028252$24402825$2$F$20240906$20250910$20241007$20250923$EXP$$EU-CIPLA LTD.-2024ES10773$CIPLA$$$$$$Y$$$20250923$$MD$EU$EU
244039643$24403964$3$F$$20240926$20241007$20250802$EXP$$JP-ASTRAZENECA-202409GLO011703JP$ALEXION PHARMACEUTICALS$$$$A$$Y$$$20250802$$MD$JP$JP
244054632$24405463$2$F$$20241004$20241007$20250816$PER$$US-ASTRAZENECA-202410USA001743US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
244054712$24405471$2$F$$20240919$20241007$20250803$EXP$$US-ASTRAZENECA-202409USA003147US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
244069472$24406947$2$F$20240801$20250908$20241007$20250918$PER$$US-SA-2024SA281572$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250918$$MD$US$US
244069714$24406971$4$F$20230502$20250904$20241007$20250911$EXP$$BR-TAKEDA-2022TUS005921$TAKEDA$$60$YR$$F$Y$$$20250911$$$BR$BR
244092512$24409251$2$F$$20240927$20241008$20250803$EXP$$MY-ASTRAZENECA-202409ASI009497MY$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$MY$MY
244113183$24411318$3$F$$20241001$20241008$20250809$EXP$$JP-ASTRAZENECA-202410GLO001362JP$ALEXION PHARMACEUTICALS$$67$YR$E$M$Y$$$20250809$$MD$JP$JP
244127356$24412735$6$F$20040601$20250710$20241008$20250714$EXP$$US-GILEAD-2024-0689975$GILEAD$$35$YR$A$M$Y$$$20250714$$LW$US$US
244156992$24415699$2$F$$20250718$20241009$20250726$EXP$$JP-AMGEN-JPNSP2024196993$AMGEN$$85$YR$E$F$Y$$$20250726$$PH$JP$JP
244157247$24415724$7$F$$20250924$20241009$20250930$EXP$$US-TAKEDA-2024TUS056503$TAKEDA$$$$A$M$Y$71$KG$20250930$$$US$US
244191812$24419181$2$F$20240825$20240930$20241009$20250810$EXP$$US-ASTRAZENECA-202409USA013445US$ALEXION PHARMACEUTICALS$$84$YR$E$M$Y$$$20250810$$$US$US
244219083$24421908$3$F$20240801$20240923$20241010$20250802$EXP$$EU-ASTRAZENECA-202409EEA005423PL$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$EU$EU
244224182$24422418$2$F$20190101$20250722$20241010$20250723$EXP$$EU-SANDOZ INC.-NVSC2023DE028325$SANDOZ$$37$YR$$M$Y$$$20250723$$MD$EU$EU
244237767$24423776$7$F$20241007$20250701$20241010$20250708$PER$$EU-TAKEDA-2024TUS099324$TAKEDA$$$$E$M$Y$$$20250708$$$EU$EU
244257594$24425759$4$F$20230914$20250718$20241011$20250801$EXP$$CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-413561$RANBAXY$$25$YR$A$F$Y$$$20250801$$CN$CA$CA
244279262$24427926$2$F$$20240930$20241011$20250802$EXP$$AU-ASTRAZENECA-202409GLO013015AU$ALEXION PHARMACEUTICALS$Malherbe J.A.J, Misko J, Jayawardena N.K, Rawlins M.D.M, Manning L, Purtill D. Safety of intramuscular tixagevimab-cilgavimab (Evusheld) administration in patients at risk of iatrogenic haematoma due to haematological disorders. Journal of Oncology Pharmacy Practice. 2024;1-6$31$YR$A$M$Y$$$20250802$$$AU$AU
244295262$24429526$2$F$20240828$20241004$20241012$20250803$EXP$$US-ASTRAZENECA-202410USA004015US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
244295442$24429544$2$F$$20240930$20241012$20250810$EXP$$US-ASTRAZENECA-202409USA013707US$ALEXION PHARMACEUTICALS$$58$YR$A$F$Y$$$20250810$$$US$US
244298212$24429821$2$F$$20241001$20241012$20250810$PER$$US-ASTRAZENECA-202410USA002806US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
244321663$24432166$3$F$$20250909$20241014$20250919$EXP$$EU-TAKEDA-2024TUS100994$TAKEDA$Cuschera F, Vekemans M, Oprea E. Guillain-barre syndrome following autologous stem cell transplantation for the treatment of multiple myeloma: a myth. 2024;24.0:S106. doi:10.1016/S2152-2650(24)02013-5$65$YR$$M$Y$$$20250919$$$EU$EU
244328382$24432838$2$F$$20240917$20241014$20250803$EXP$$US-AstraZeneca-2024A213109$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$
244334727$24433472$7$F$20241003$20250910$20241014$20250919$EXP$$US-UCBSA-2024049547$UCB$$5$YR$$F$Y$18.6$KG$20250919$$CN$US$US
244357934$24435793$4$F$$20250826$20241015$20250905$EXP$$US-UCBSA-2024051674$UCB$$$$$M$Y$24$KG$20250905$$MD$US$US
244361362$24436136$2$F$$20241003$20241015$20250803$EXP$$US-ASTRAZENECA-202410USA004057US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
244398323$24439832$3$F$20241001$20250626$20241015$20250702$EXP$$KR-JNJFOC-20241027174$JOHNSON AND JOHNSON$$70$YR$E$M$Y$$$20250702$$HP$KR$KR
244398583$24439858$3$F$$20241014$20241015$20250812$EXP$$CA-ASTRAZENECA-202410CAN006342CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250812$$$CA$CA
244401772$24440177$2$F$20241007$20241008$20241016$20250809$EXP$$EU-ASTRAZENECA-202410EEA004529RO$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$EU$EU
244411023$24441102$3$F$20231123$20250721$20241016$20250725$PER$$US-ROCHE-3468300$ROCHE$$47$YR$A$M$Y$$$20250725$$CN$US$US
244431892$24443189$2$F$$20250725$20241016$20250806$EXP$EU-EMA-DD-20241007-7482831-133827$EU-RDY-SPO/ROU/24/0014978$DR REDDYS$Apetrei-Corduneanu O, Radu R, Apetrei A, Ureche CG, T?nas? A, Bostan MM, Artene BA, Burlacu A, St?tescu C. Cardio-oncological challenge in the age of modern tumor treatment. Romanian Journal of Cardiology. 2019;29(2):127-128.$63$YR$A$M$Y$$$20250806$$HP$EU$EU
244437072$24443707$2$F$$20241007$20241016$20250809$EXP$$US-ASTRAZENECA-202410USA003889US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
244444752$24444475$2$F$$20250709$20241016$20250709$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-473273$RANBAXY$Xiaoyun F, Jingzhu W, Li Z, Yijie W, Yongde P, Fang L, Yufan W. Clinical management of hyperthyroidism complicated with liver failure. Clin J Endocrinol Metab. 2023;Jul; 39 (7):611-15$21$YR$$F$Y$$$20250709$$HP$CN$CN
244451832$24445183$2$F$$20241003$20241016$20250809$EXP$EU-AFSSAPS-MP2024001468$EU-ASTRAZENECA-202409GLO012858FR$ALEXION PHARMACEUTICALS$$70$YR$E$M$Y$70$KG$20250809$$MD$EU$EU
244452672$24445267$2$F$$20240923$20241016$20250803$EXP$$US-ASTRAZENECA-202409USA005623US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
244452933$24445293$3$F$$20240413$20241016$20250816$PER$$US-ASTRAZENECA-202404USA002519US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
244500153$24450015$3$F$20240101$20250915$20241017$20250918$EXP$$US-SA-2024SA298124$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250918$$MD$US$US
244501862$24450186$2$F$$20240923$20241017$20250803$EXP$$CN-ASTRAZENECA-202409GLO007885CN$ALEXION PHARMACEUTICALS$Zhao C., Fei C., Chen R., Liu Y., Zhang H.. Comparison of clinical outcomes between ticagrelor and clopidogrel in patients with acute coronary syndrome and left ventricle dysfunction undergoing percutaneous coronary intervention: An observational study.. Medicine. 2024;103(36):e39620$$$$$Y$$$20250803$$MD$CN$CN
244502933$24450293$3$F$$20240917$20241017$20250803$PER$$EU-AstraZeneca-2024A212619$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$EU$EU
244606213$24460621$3$F$$20241224$20241018$20250802$EXP$$EU-ASTRAZENECA-202410EEA013220FR$ALEXION PHARMACEUTICALS$$64$YR$A$M$Y$66.2$KG$20250802$$MD$EU$EU
244632074$24463207$4$F$20240701$20240917$20241018$20250816$PER$$US-AstraZeneca-2024A212515$ALEXION PHARMACEUTICALS$$59$YR$A$M$Y$$$20250816$$$US$US
244661233$24466123$3$F$20250427$20250731$20241018$20250807$EXP$$CA-TAKEDA-2024TUS104323$TAKEDA$$44$YR$$F$Y$$$20250807$$$CA$CA
244681674$24468167$4$F$20230101$20250919$20241018$20250924$EXP$$US-PFIZER INC-PV202400134782$PFIZER$$57$YR$$F$Y$$$20250924$$HP$US$US
244685012$24468501$2$F$$20240930$20241018$20250803$EXP$GB-MHRA-MED-202409271424381580-VFKQY$GB-ASTRAZENECA-202409GLO013735GB$ALEXION PHARMACEUTICALS$$24$YR$A$M$Y$79$KG$20250803$$$GB$GB
245247334$24524733$4$F$$20250205$20241019$20250810$PER$$US-ASTRAZENECA-202409USA003179US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
245267112$24526711$2$F$$20240923$20241021$20250810$PER$$US-ASTRAZENECA-202409USA005309US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
245275193$24527519$3$F$$20241223$20241021$20250810$EXP$$US-ASTRAZENECA-202409USA014196US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
245282344$24528234$4$F$20231111$20241018$20241021$20250809$EXP$$US-ASTRAZENECA-202410USA015467US$ALEXION PHARMACEUTICALS$$66$YR$E$M$Y$$$20250809$$MD$US$US
245292822$24529282$2$F$$20241016$20241021$20250810$EXP$$JP-ASTRAZENECA-202410JPN011641JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$MD$JP$JP
245295883$24529588$3$F$20240530$20241129$20241021$20250812$EXP$$EU-BEH-2024177397$CSL BEHRING$$57$YR$A$F$Y$70$KG$20250812$$CN$CN$EU
245305852$24530585$2$F$$20241017$20241021$20250803$EXP$$US-ASTRAZENECA-202410USA013753US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
245318603$24531860$3$F$20240915$20241230$20241022$20250803$EXP$$US-ASTRAZENECA-202410USA012395US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
245324962$24532496$2$F$$20241011$20241022$20250802$EXP$$JP-ASTRAZENECA-202410GLO014508JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250802$$PH$JP$JP
245341862$24534186$2$F$$20250728$20241022$20250730$EXP$$CA-HALEON-2201368$Haleon PLC$$44$YR$$F$Y$$$20250730$$HP$CA$CA
245347503$24534750$3$F$20240401$20250103$20241022$20250809$EXP$$EG-ASTRAZENECA-202410NAF012238EG$ALEXION PHARMACEUTICALS$$63$YR$$F$Y$$$20250809$$$EG$EG
245371703$24537170$3$F$20240101$20250826$20241022$20250903$PER$$US-SA-2024SA300033$SANOFI AVENTIS$$10$YR$C$F$Y$$$20250903$$MD$US$US
245394414$24539441$4$F$20240101$20250721$20241023$20250726$EXP$$CA-CELLTRION INC.-2024CA025793$CELLTRION$$$$$$Y$$$20250726$$HP$CA$CA
245399442$24539944$2$F$$20241015$20241023$20250809$EXP$$US-ASTRAZENECA-202410USA010958US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
245399532$24539953$2$F$$20241017$20241023$20250809$EXP$$US-ASTRAZENECA-202410USA014000US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$MD$US$US
245404232$24540423$2$F$$20241009$20241023$20250803$EXP$$JP-ASTRAZENECA-202410GLO007222JP$ALEXION PHARMACEUTICALS$$80$YR$E$M$Y$$$20250803$$MD$JP$JP
245404753$24540475$3$F$$20241114$20241023$20250809$EXP$$JP-ASTRAZENECA-202410GLO014325JP$ALEXION PHARMACEUTICALS$$44$YR$A$F$Y$$$20250809$$MD$JP$JP
245404927$24540492$7$F$20180801$20250617$20241023$20250809$EXP$$JP-ASTRAZENECA-202410GLO014434JP$ALEXION PHARMACEUTICALS$Nakagawa M, et al.. P3-5 Rapidly advanced multiple myeloma in a patient with lung adenocarcinoma on EGFR-TKI treatment: Case Report.. The 50th Annual Meeting of the Japanese Society of Myeloma. 2025;128-$69$YR$E$M$Y$76$KG$20250809$$MD$JP$JP
245411362$24541136$2$F$$20241008$20241023$20250802$EXP$$US-ASTRAZENECA-202410USA004995US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
245432622$24543262$2$F$$20241014$20241024$20250802$EXP$$ZA-ASTRAZENECA-202409SSA005480ZA$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$$$20250802$$$ZA$ZA
245433013$24543301$3$F$20201005$20250625$20241024$20250703$EXP$$CA-TAKEDA-2020TUS027611$TAKEDA$$45$YR$$M$Y$$$20250703$$$CA$CA
245450863$24545086$3$F$$20241205$20241024$20250810$EXP$$AU-ASTRAZENECA-202410OCE018987AU$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$AU$AU
245451763$24545176$3$F$$20250918$20241024$20250926$EXP$$US-TEVA-VS-3179490$TEVA$$69$YR$$F$Y$$$20250926$$CN$US$US
245460174$24546017$4$F$$20250714$20241024$20250715$EXP$$CA-SANDOZ INC.-SDZ2024CA088537$SANDOZ$$44$YR$$F$Y$$$20250715$$HP$CA$CA
245471772$24547177$2$F$$20241009$20241025$20250809$EXP$$US-ASTRAZENECA-202410USA007818US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245475742$24547574$2$F$$20241021$20241025$20250808$EXP$$US-PADAGIS-2024PAD01677$PADAGIS$Masood H,Waghela R,Amini S,Fan C,Abraham BP. Efficacy of Ustekinumab Intravenously q12 Weeks for Maintenance Therapy for Crohn^s Disease. ACG Case Reports Journal. 2024;11(10):e01520$$$$$Y$$$20250808$$HP$US$US
245479243$24547924$3$F$$20250729$20241025$20250801$EXP$$US-SMPA-2024SPA004208$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
245484255$24548425$5$F$20231101$20250713$20241025$20250719$EXP$$CA-CELLTRION INC.-2024CA000622$CELLTRION$$$$$$Y$$$20250719$$HP$CA$CA
245492623$24549262$3$F$$20241231$20241025$20250803$EXP$$US-ALXN-202410USA017476US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$PH$US$US
245494932$24549493$2$F$20241001$20241014$20241025$20250810$PER$$US-ASTRAZENECA-202410GLO016193US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
245500954$24550095$4$F$$20250828$20241025$20250902$EXP$$EU-SANDOZ INC.-SDZ2024ES089154$SANDOZ$$64$YR$$F$Y$$$20250902$$HP$EU$EU
245501884$24550188$4$F$20240701$20250918$20241025$20250923$PER$$US-PFIZER INC-PV202400137914$PFIZER$$51$YR$$F$Y$$$20250923$$HP$US$US
245503862$24550386$2$F$$20241021$20241025$20250803$EXP$$US-ASTRAZENECA-202410USA017375US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$US$US
245510692$24551069$2$F$$20241018$20241025$20250802$EXP$$JP-ASTRAZENECA-202410GLO016785JP$ALEXION PHARMACEUTICALS$Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. [In Process] Lung Cancer. 2024;197:Article Number 107988$$$$$Y$$$20250802$$$JP$JP
245513112$24551311$2$F$$20241009$20241025$20250809$EXP$$US-ASTRAZENECA-202410USA008044US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
245514162$24551416$2$F$$20241018$20241026$20250809$EXP$$US-ASTRAZENECA-202410USA015118US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
245514972$24551497$2$F$$20241007$20241026$20250816$PER$$US-ASTRAZENECA-202410USA005424US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
245518652$24551865$2$F$$20241016$20241026$20250816$PER$$US-ASTRAZENECA-202410USA012692US$ALEXION PHARMACEUTICALS$$82$YR$E$M$Y$$$20250816$$$US$US
245519912$24551991$2$F$$20241008$20241026$20250802$EXP$$US-ASTRAZENECA-202410USA007027US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
245521122$24552112$2$F$$20241009$20241026$20250802$EXP$$US-ASTRAZENECA-202410USA008368US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$US$US
245521662$24552166$2$F$$20241024$20241026$20250816$PER$$US-ASTRAZENECA-202410USA021373US$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250816$$MD$US$US
245526072$24552607$2$F$20240917$20241016$20241026$20250809$EXP$$US-ASTRAZENECA-202410USA012593US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245527432$24552743$2$F$$20241009$20241027$20250809$EXP$$US-ASTRAZENECA-202410USA007876US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245527912$24552791$2$F$$20241009$20241027$20250803$EXP$$US-ASTRAZENECA-202410USA007953US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
245548404$24554840$4$F$$20250820$20241028$20250826$EXP$$US-TAKEDA-2024TUS108165$TAKEDA$$$$$F$Y$$$20250826$$MD$US$US
245548912$24554891$2$F$$20241018$20241028$20250809$EXP$$US-ASTRAZENECA-202410USA015516US$ALEXION PHARMACEUTICALS$$$$$F$Y$76.657$KG$20250809$$$US$US
245549022$24554902$2$F$$20241003$20241028$20250810$EXP$$JP-ASTRAZENECA-202410GLO004247JP$ALEXION PHARMACEUTICALS$$41$YR$A$M$Y$$$20250810$$PH$JP$
245573414$24557341$4$F$20240507$20250904$20241028$20250915$EXP$$NVSC2024DE133622$NOVARTIS$$$$A$M$Y$130$KG$20250915$$MD$EU$EU
245577562$24557756$2$F$$20250829$20241028$20250908$PER$$US-SMPA-2024SPA004198$SUNOVION$$76$YR$$M$Y$$$20250908$$$US$US
245606432$24560643$2$F$20231010$20241022$20241029$20250803$EXP$$US-ASTRAZENECA-202410USA018431US$ALEXION PHARMACEUTICALS$$90$YR$E$F$Y$$$20250803$$$US$US
245616172$24561617$2$F$$20241018$20241029$20250809$EXP$$JP-ASTRAZENECA-202410GLO016781JP$ALEXION PHARMACEUTICALS$Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. [In Process] Lung Cancer. 2024;197:Article Number 107988$$$$$Y$$$20250809$$$JP$JP
245639383$24563938$3$F$20240801$20250626$20241030$20250701$EXP$$US-ABBVIE-5978598$ABBVIE$$57$YR$$F$Y$$$20250701$$CN$US$US
245654312$24565431$2$F$20190402$20250624$20241030$20250708$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2024RR-476408$RANBAXY$$50$YR$$M$Y$$$20250708$$PH$EU$EU
245660582$24566058$2$F$$20241022$20241030$20250809$EXP$$VN-ASTRAZENECA-202410ASI018604VN$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$VN$VN
245661382$24566138$2$F$$20241023$20241030$20250810$PER$$US-ASTRAZENECA-202410USA020057US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
245665832$24566583$2$F$$20241022$20241030$20250803$EXP$$US-ASTRAZENECA-202410USA019991US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
245670782$24567078$2$F$$20241025$20241030$20250809$EXP$$US-ASTRAZENECA-202410USA022822US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245672732$24567273$2$F$$20241023$20241030$20250802$EXP$$US-ASTRAZENECA-202410USA019724US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
245672792$24567279$2$F$20241001$20241011$20241030$20250810$PER$$US-ASTRAZENECA-202410USA022499US$ALEXION PHARMACEUTICALS$$76$YR$$M$Y$$$20250810$$$US$US
245673852$24567385$2$F$$20241022$20241030$20250802$EXP$$US-ASTRAZENECA-202410USA018276US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
245674032$24567403$2$F$$20241023$20241030$20250816$PER$$US-ASTRAZENECA-202410USA019765US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
245681166$24568116$6$F$20230412$20250909$20241031$20250918$EXP$$CA-CELLTRION INC.-2023CA011057$CELLTRION$$$$$$Y$$$20250918$$CN$CA$CA
245682042$24568204$2$F$$20241022$20241031$20250810$PER$$US-ASTRAZENECA-202410USA018594US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
245684073$24568407$3$F$20240101$20250910$20241031$20250916$EXP$$US-ABBVIE-5743419$ABBVIE$$70$YR$$M$Y$$$20250916$$CN$US$US
245704662$24570466$2$F$20240101$20241021$20241031$20250703$PER$$US-BAUSCHBL-2024BNL036303$BAUSCH AND LOMB$$76$YR$$F$Y$$$20250704$$CN$US$US
245706712$24570671$2$F$20240912$20240919$20241031$20250810$EXP$$CN-ASTRAZENECA-202409CHN003428CN$ALEXION PHARMACEUTICALS$$48$YR$A$M$Y$70$KG$20250810$$$CN$CN
245720733$24572073$3$F$$20250326$20241101$20250810$PER$$US-ASTRAZENECA-202410USA021102US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
245725803$24572580$3$F$$20250226$20241101$20250816$PER$$US-ASTRAZENECA-202311USA002144US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$MD$US$US
245729543$24572954$3$F$$20241217$20241101$20250810$EXP$$JP-ASTRAZENECA-202410GLO023455JP$ALEXION PHARMACEUTICALS$$$$E$$Y$$$20250810$$MD$JP$JP
245749563$24574956$3$F$$20241126$20241104$20250810$EXP$$JP-ASTRAZENECA-202410GLO023084JP$ALEXION PHARMACEUTICALS$$$$E$$Y$$$20250810$$MD$JP$JP
245755042$24575504$2$F$$20241014$20241104$20250803$EXP$$US-ASTRAZENECA-202410USA010685US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
245758032$24575803$2$F$$20250724$20241104$20250730$PER$$US-LUPIN PHARMACEUTICALS INC.-2024-10614$LUPIN$$$$$$Y$$$20250730$$$US$US
245760282$24576028$2$F$$20250723$20241104$20250919$PER$$US-TRAVERE-2024TVT01058$TRAVERE THERAPEUTICS$$$$$M$Y$$$20250919$$CN$US$US
245777802$24577780$2$F$$20241017$20241104$20250809$EXP$$US-ASTRAZENECA-202410USA013502US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245781003$24578100$3$F$$20250302$20241104$20250816$PER$$US-ASTRAZENECA-202410USA025324US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
245785455$24578545$5$F$20230518$20250924$20241105$20250930$PER$$CO-TAKEDA-2022TUS001239$TAKEDA$$21$YR$$F$Y$76$KG$20250930$$$CO$CO
245786852$24578685$2$F$$20241104$20241105$20250816$PER$$US-ASTRAZENECA-202411USA001046US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
245797193$24579719$3$F$$20241118$20241105$20250809$EXP$$US-ASTRAZENECA-202410USA011174US$ALEXION PHARMACEUTICALS$$$$$M$Y$79.374$KG$20250809$$$US$US
245805302$24580530$2$F$20240629$20241015$20241105$20250803$EXP$$US-ASTRAZENECA-202410USA010619US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
245828422$24582842$2$F$20230101$20241028$20241106$20250802$EXP$GB-MHRA-MED-202410261516218130-SHKWB$GB-ASTRAZENECA-202410GLO024762GB$ALEXION PHARMACEUTICALS$$73$YR$E$F$Y$$$20250802$$$GB$GB
245833832$24583383$2$F$20240319$20250909$20241106$20250917$PER$$KR-TAKEDA-2024TUS110899$TAKEDA$$68$YR$$M$Y$70$KG$20250917$$MD$KR$KR
245840882$24584088$2$F$$20240926$20241106$20250803$EXP$$EU-ASTRAZENECA-202409EEA008188PL$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$MD$EU$EU
245840902$24584090$2$F$$20240926$20241106$20250803$EXP$$CN-ASTRAZENECA-202409CHN007390CN$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$CN$CN
245844092$24584409$2$F$$20241029$20241106$20250803$EXP$$US-ASTRAZENECA-202410USA012748US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
245851356$24585135$6$F$20241023$20250730$20241106$20250805$PER$$BR-TAKEDA-2024TUS085731$TAKEDA$$46$YR$$F$Y$68$KG$20250805$$$BR$BR
245853213$24585321$3$F$20240923$20250926$20241106$20250930$EXP$$AU-BRISTOL-MYERS SQUIBB COMPANY-2024-170753$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250930$$$AU$AU
245855307$24585530$7$F$$20250919$20241106$20250925$EXP$$US-SMPA-2024SPA004472$SUNOVION$$76$YR$$M$Y$92.98$KG$20250924$$MD$US$US
245858522$24585852$2$F$$20241017$20241106$20250810$EXP$$ID-ASTRAZENECA-202410ASI014241ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$ID$ID
245871952$24587195$2$F$$20241018$20241107$20250809$EXP$$ZA-ASTRAZENECA-202410SSA014789ZA$ALEXION PHARMACEUTICALS$$92$YR$E$M$Y$$$20250809$$$ZA$ZA
245898232$24589823$2$F$$20241023$20241107$20250803$EXP$$ZA-ASTRAZENECA-202410SSA019500ZA$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$$$20250803$$$ZA$ZA
245898352$24589835$2$F$$20241022$20241107$20250809$EXP$$US-ASTRAZENECA-202410USA018435US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245898392$24589839$2$F$$20241104$20241107$20250816$PER$$US-ASTRAZENECA-202411USA001214US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
245903323$24590332$3$F$$20241129$20241107$20250810$EXP$$JP-ASTRAZENECA-202410GLO018019JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$MD$JP$JP
245911722$24591172$2$F$$20241104$20241108$20250803$EXP$$US-ASTRAZENECA-202411USA001234US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
245916098$24591609$8$F$20241030$20241119$20241108$20250903$EXP$$EU-BIOGEN-2024BI01289503$BIOGEN$$20$YR$$M$Y$60.2$KG$20250903$$MD$EU$EU
245918692$24591869$2$F$20241030$20241031$20241108$20250809$EXP$$CO-ASTRAZENECA-202410SAM028261CO$ALEXION PHARMACEUTICALS$$35$YR$A$M$Y$113$KG$20250809$$$CO$CO
245918832$24591883$2$F$$20241023$20241108$20250803$EXP$$ZA-ASTRAZENECA-202410SSA019517ZA$ALEXION PHARMACEUTICALS$$78$YR$E$M$Y$$$20250803$$$ZA$ZA
245929382$24592938$2$F$$20240607$20241108$20250810$EXP$$KZ-AstraZeneca-2024A136954$ALEXION PHARMACEUTICALS$$54$YR$A$F$Y$$$20250810$$MD$KZ$KZ
245931513$24593151$3$F$$20250624$20241108$20250701$EXP$$CA-TAKEDA-2024TUS111615$TAKEDA$$$$$F$Y$$$20250701$$$CA$CA
245936154$24593615$4$F$20231201$20250909$20241108$20250917$EXP$$CA-ASTRAZENECA-202410CAN027997CA$ALEXION PHARMACEUTICALS$$83$YR$$F$Y$$$20250917$$$CA$CA
245946012$24594601$2$F$20241030$20250917$20241108$20250920$EXP$$US-ABBVIE-5988452$ABBVIE$$57$YR$$F$Y$$$20250920$$CN$US$US
245954982$24595498$2$F$20240930$20241024$20241109$20250803$EXP$$CN-ASTRAZENECA-202410CHN022051CN$ALEXION PHARMACEUTICALS$$68$YR$E$F$Y$$$20250803$$$CN$CN
245956452$24595645$2$F$$20241011$20241109$20250809$EXP$$US-ASTRAZENECA-202410USA015785US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
245959652$24595965$2$F$$20241024$20241109$20250809$EXP$$CN-ASTRAZENECA-202410CHN020671CN$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250809$$$CN$CN
245959672$24595967$2$F$$20241017$20241109$20250809$EXP$$ZA-ASTRAZENECA-202409SSA005369ZA$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$$$20250809$$$ZA$ZA
245962062$24596206$2$F$20241013$20241023$20241110$20250809$EXP$$BR-ASTRAZENECA-202410SAM021479BR$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$BR$BR
245988843$24598884$3$F$$20250807$20241110$20250814$EXP$$JP-ASTRAZENECA-202410GLO029085JP$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$$$20250814$$MD$JP$JP
245995933$24599593$3$F$20240101$20250804$20241110$20250813$PER$$US-SA-2024SA271088$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250813$$MD$US$US
246006234$24600623$4$F$20240101$20250902$20241110$20250910$PER$$US-SA-2024SA316293$SANOFI AVENTIS$$37$YR$A$F$Y$$$20250910$$MD$US$US
246010402$24601040$2$F$$20241023$20241110$20250810$EXP$$ID-ASTRAZENECA-202410ASI019106ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$ID$ID
246019132$24601913$2$F$20241028$20250903$20241111$20250905$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-061833$BOEHRINGER INGELHEIM$$39$YR$A$M$Y$$$20250905$$MD$US$US
246024182$24602418$2$F$$20241009$20241111$20250803$EXP$$CN-ASTRAZENECA-202410CHN006544CN$ALEXION PHARMACEUTICALS$$51$YR$A$M$Y$$$20250803$$$CN$CN
246024292$24602429$2$F$$20241104$20241111$20250809$EXP$$RU-ASTRAZENECA-202411RUS002042RU$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$RU$RU
246028393$24602839$3$F$$20250714$20241111$20250723$EXP$$JP-ROCHE-10000126924$ROCHE$Onishi M, Onishi M Y. 75 A case of follicular lymphoma in which peripheral nerve disorder aggravated occurred during maintenance therapy with obinutuzumab.. The 248th Kinki Regional Meeting of the Japanese Society of Internal Medicine.. 2025;$76$YR$E$M$Y$85$KG$20250723$$MD$JP$JP
246045532$24604553$2$F$$20241018$20241111$20250810$EXP$$US-ASTRAZENECA-202410USA014911US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
246050372$24605037$2$F$$20241009$20241111$20250810$EXP$$TW-ASTRAZENECA-202410ASI024163TW$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$TW$TW
246057373$24605737$3$F$20241108$20250206$20241111$20250816$PER$$US-ASTRAZENECA-202411USA005375US$ALEXION PHARMACEUTICALS$$48$YR$A$F$Y$$$20250816$$$US$US
246062072$24606207$2$F$$20241108$20241112$20250803$EXP$$ZA-ASTRAZENECA-202411SSA005023ZA$ALEXION PHARMACEUTICALS$$91$YR$E$F$Y$$$20250803$$$ZA$ZA
246065962$24606596$2$F$$20241011$20241112$20250810$EXP$$US-ASTRAZENECA-202410USA016012US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
246069652$24606965$2$F$$20241023$20241112$20250803$EXP$$US-ASTRAZENECA-202410USA020078US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$MD$US$US
246069912$24606991$2$F$20240522$20241108$20241112$20250809$EXP$EU-AEMPS-1589028$EU-ASTRAZENECA-202411GLO005097ES$ALEXION PHARMACEUTICALS$$68$YR$E$F$Y$$$20250809$$PH$EU$EU
246073202$24607320$2$F$20220331$20250626$20241112$20250711$EXP$$US-COOPERSURGICAL, INC.-2024CPS003341$COOPERSURGICAL$$32$YR$$F$Y$113.38$KG$20250711$$CN$US$US
246081222$24608122$2$F$$20241031$20241112$20250809$EXP$$EU-ASTRAZENECA-202410EEA027813SK$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$MD$EU$EU
246094222$24609422$2$F$$20241104$20241112$20250809$EXP$$EU-ASTRAZENECA-202411EEA001096DE$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$EU$EU
246094442$24609444$2$F$$20241104$20241112$20250816$PER$$US-ASTRAZENECA-202411USA002624US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
246102862$24610286$2$F$$20241104$20241112$20250802$EXP$$CA-ASTRAZENECA-202411CAN001892CA$ALEXION PHARMACEUTICALS$$80$YR$E$M$Y$$$20250802$$$CA$CA
246104743$24610474$3$F$$20250709$20241112$20250723$PER$$US-SMPA-2024SPA004695$SUNOVION$$$$$$Y$$$20250723$$CN$US$US
246107602$24610760$2$F$$20250811$20241112$20250814$EXP$$GB-SANDOZ INC.-SDZ2024GB094137$SANDOZ$$$$$M$Y$$$20250814$$CN$GB$GB
246112232$24611223$2$F$$20241028$20241113$20250803$EXP$$US-ASTRAZENECA-202410USA024276US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
246112422$24611242$2$F$20240321$20241101$20241113$20250803$EXP$EU-MINISAL02-1008844$EU-ASTRAZENECA-202411GLO000594IT$ALEXION PHARMACEUTICALS$$83$YR$E$F$Y$84$KG$20250803$$PH$EU$
246129682$24612968$2$F$$20241108$20241113$20250803$EXP$$JP-AstraZeneca-2024A041834$ALEXION PHARMACEUTICALS$$$$A$$Y$$$20250803$$MD$JP$JP
246129712$24612971$2$F$20241103$20241106$20241113$20250805$EXP$$CN-ASTRAZENECA-202411CHN003816CN$ALEXION PHARMACEUTICALS$$66$YR$E$M$Y$60$KG$20250805$$$CN$CN
246129912$24612991$2$F$$20241028$20241113$20250810$EXP$$US-ASTRAZENECA-202410USA024539US$ALEXION PHARMACEUTICALS$$70$YR$E$M$Y$$$20250810$$$US$US
246136782$24613678$2$F$$20240913$20241113$20250802$EXP$$US-AstraZeneca-2024A185457$ALEXION PHARMACEUTICALS$$89$YR$E$M$Y$82.993$KG$20250802$$$US$US
246136882$24613688$2$F$$20241024$20241113$20250809$EXP$$US-ASTRAZENECA-202410USA026806US$ALEXION PHARMACEUTICALS$$$$$F$Y$83$KG$20250809$$$US$US
246149063$24614906$3$F$$20241011$20241113$20250809$EXP$$US-ASTRAZENECA-202410USA015771US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246149103$24614910$3$F$20241030$20241206$20241113$20250809$EXP$$US-ASTRAZENECA-202411USA002270US$ALEXION PHARMACEUTICALS$$60$YR$A$M$Y$84.009$KG$20250809$$$US$US
246149182$24614918$2$F$20241007$20241024$20241113$20250809$EXP$$US-ASTRAZENECA-202410USA022391US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246157664$24615766$4$F$20240101$20250820$20241113$20250828$PER$$US-SA-2024SA326845$SANOFI AVENTIS$$84$YR$E$F$Y$$$20250828$$HP$US$US
246162054$24616205$4$F$$20250902$20241113$20250907$PER$$US-SA-2024SA325341$SANOFI AVENTIS$$$$A$F$Y$$$20250907$$HP$US$US
246172732$24617273$2$F$20240601$20241108$20241114$20250809$EXP$$US-ASTRAZENECA-202411USA005392US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$US$US
246176022$24617602$2$F$$20250709$20241114$20250709$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2024RR-478095$RANBAXY$$20$YR$$F$Y$$$20250709$$HP$EU$EU
246179212$24617921$2$F$$20241112$20241114$20250816$PER$$US-ASTRAZENECA-202411USA008659US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
246192652$24619265$2$F$$20250903$20241114$20250908$EXP$$CA-TAKEDA-2024TUS113543$TAKEDA$$$$$M$Y$$$20250908$$$CA$CA
246210112$24621011$2$F$$20241113$20241114$20250816$PER$$US-ASTRAZENECA-202410USA020065US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
246211304$24621130$4$F$20250801$20250827$20241114$20250829$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-056997$BOEHRINGER INGELHEIM$$78$YR$E$M$Y$$$20250829$$$CA$CA
246220572$24622057$2$F$$20241111$20241114$20250809$EXP$$US-ASTRAZENECA-202411USA006931US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$MD$US$US
246227953$24622795$3$F$20240901$20250522$20241115$20250816$PER$$US-ASTRAZENECA-202409USA011541US$ALEXION PHARMACEUTICALS$$64$YR$$M$Y$$$20250816$$$US$US
246228592$24622859$2$F$$20241029$20241115$20250803$EXP$$US-ASTRAZENECA-202410USA025845US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
246231892$24623189$2$F$20241020$20241107$20241115$20250803$EXP$$CN-ASTRAZENECA-202411CHN004930CN$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250803$$$CN$CN
246232642$24623264$2$F$$20240920$20241115$20250810$PER$$US-ASTRAZENECA-202409USA003771US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
246249365$24624936$5$F$20170101$20250718$20241115$20250723$EXP$$EU-SANDOZ INC.-SDZ2024FR095313$SANDOZ$$48$YR$$F$Y$$$20250723$$CN$EU$EU
246258682$24625868$2$F$$20250218$20241115$20250825$PER$$US-ANIPHARMA-2024-US-058168$ANI$$$$$F$Y$$$20250825$$HP$US$US
246259672$24625967$2$F$20240606$20241204$20241115$20250808$PER$$US-ANIPHARMA-2024-US-040501$ANI$$63$YR$$F$Y$$$20250808$$CN$US$US
246261202$24626120$2$F$20190128$20241107$20241115$20250803$EXP$$EU-ASTRAZENECA-202411GLO011208DE$ALEXION PHARMACEUTICALS$$21$YR$A$F$Y$60$KG$20250803$$$EU$EU
246261953$24626195$3$F$20240101$20250905$20241115$20250912$PER$$US-SA-2024SA323040$SANOFI AVENTIS$$18$YR$A$M$Y$$$20250912$$HP$US$US
246265952$24626595$2$F$20230701$20250625$20241115$20250701$PER$$US-SA-2024SA329128$SANOFI AVENTIS$$25$YR$A$F$Y$$$20250702$$HP$US$US
246267723$24626772$3$F$20240319$20241128$20241115$20250716$PER$$US-NOVOPROD-1284549$NOVO NORDISK$$80$YR$$F$Y$$$20250715$$CN$US$US
246274722$24627472$2$F$$20241112$20241116$20250803$EXP$$US-ASTRAZENECA-202411USA008890US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
246276482$24627648$2$F$20241111$20241112$20241116$20250810$PER$$US-ASTRAZENECA-202411USA008622US$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$$$20250810$$$US$US
246277172$24627717$2$F$$20241107$20241116$20250809$EXP$$EU-ASTRAZENECA-202411GLO009435NL$ALEXION PHARMACEUTICALS$$47$YR$A$F$Y$90$KG$20250809$$$EU$EU
246290033$24629003$3$F$$20241112$20241118$20250809$EXP$$US-ASTRAZENECA-202411USA008441US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246292033$24629203$3$F$20240909$20250425$20241118$20250816$PER$$US-ASTRAZENECA-202409USA013358US$ALEXION PHARMACEUTICALS$$86$YR$E$F$Y$$$20250816$$MD$US$US
246294755$24629475$5$F$20230101$20250916$20241118$20250919$EXP$$EU-SANDOZ INC.-SDZ2024FR095336$SANDOZ$$75$YR$$M$Y$$$20250919$$HP$EU$EU
246295702$24629570$2$F$$20241107$20241118$20250803$EXP$$ZA-ASTRAZENECA-202411SSA003988ZA$ALEXION PHARMACEUTICALS$$77$YR$E$M$Y$$$20250803$$$ZA$ZA
246309253$24630925$3$F$20241031$20241216$20241118$20250810$EXP$$JP-ASTRAZENECA-202411GLO009227JP$ALEXION PHARMACEUTICALS$$75$YR$E$F$Y$$$20250810$$MD$JP$JP
246321432$24632143$2$F$20241017$20241108$20241118$20250810$EXP$$US-ASTRAZENECA-202411USA005726US$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$$$20250810$$$US$US
246323765$24632376$5$F$$20250813$20241118$20250821$EXP$$NVSC2024CA220153$NOVARTIS$$71$YR$$M$Y$$$20250821$$HP$CA$CA
246334412$24633441$2$F$$20250920$20241118$20250929$PER$$US-SA-2024SA330240$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250929$$HP$US$US
246341023$24634102$3$F$20241001$20241211$20241119$20250810$EXP$$TH-ASTRAZENECA-202411ASI002885TH$ALEXION PHARMACEUTICALS$$67$YR$E$M$Y$83.4$KG$20250810$$$TH$TH
246342353$24634235$3$F$$20241210$20241119$20250803$EXP$$US-ASTRAZENECA-202411USA008509US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250803$$$US$US
246344882$24634488$2$F$20250625$20250626$20241119$20250702$EXP$$US-UCBSA-2024059323$UCB$$17$YR$$F$Y$48.6$KG$20250702$$MD$US$US
246350502$24635050$2$F$$20241116$20241119$20250816$PER$$US-ASTRAZENECA-202411USA013855US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
246372172$24637217$2$F$$20241105$20241119$20250703$EXP$$NP-STERISCIENCE B.V.-2024-ST-001874$Steriscience PTE$Khadka J, Bhattarai P, Adhikari A, Acharya R, Rayamajhi P. Myasthenic crisis-induced Takotsubo cardiomyopathy: a case report. Ann-Med-Surgery. 2024;86 (3):1704-1707$31$YR$$F$Y$$$20250703$$MD$NP$NP
246374523$24637452$3$F$20220221$20241210$20241119$20250810$EXP$$JP-ASTRAZENECA-202411GLO012415JP$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$69$KG$20250810$$MD$JP$JP
246401612$24640161$2$F$$20241112$20241120$20250803$EXP$$CA-ASTRAZENECA-202411CAN007893CA$ALEXION PHARMACEUTICALS$$65$YR$E$F$Y$34$KG$20250803$$$CA$CA
246402053$24640205$3$F$$20250922$20241120$20250923$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-180999$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$F$Y$$$20250923$$$US$US
246403302$24640330$2$F$$20241112$20241120$20250809$EXP$$GB-ASTRAZENECA-202411GBR009675GB$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$GB$GB
246420122$24642012$2$F$20240101$20250805$20241120$20250911$PER$$US-BAYER-2024A164371$BAYER HEALTHCARE PHARMACEUTICALS INC.$$19$YR$A$F$Y$$$20250911$$CN$US$US
246443382$24644338$2$F$20241001$20250917$20241120$20250925$PER$$US-SA-2024SA335823$SANOFI AVENTIS$$85$YR$E$F$Y$$$20250925$$HP$US$US
246446564$24644656$4$F$20241007$20250828$20241121$20250906$EXP$$JP-UNITED THERAPEUTICS-UNT-2024-033033$UNITED THERAPEUTICS$$73$YR$$M$Y$63$KG$20250906$$$JP$JP
246446617$24644661$7$F$$20250801$20241121$20250806$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2024-PIM-007150$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250806$$CN$US$US
246465573$24646557$3$F$$20241213$20241121$20250810$EXP$$JP-ASTRAZENECA-202411GLO011189JP$ALEXION PHARMACEUTICALS$$71$YR$E$M$Y$$$20250810$$MD$JP$JP
246466533$24646653$3$F$20240905$20241119$20241121$20250810$EXP$$JP-ASTRAZENECA-202411GLO006067JP$ALEXION PHARMACEUTICALS$$73$YR$E$F$Y$53$KG$20250810$$MD$JP$JP
246478593$24647859$3$F$$20241205$20241121$20250909$EXP$$US-FARMAPROD-202408-3006$DOMPE FARMACEUTICI$$$$E$M$Y$95.25$KG$20250817$$MD$US$US
246490922$24649092$2$F$20240101$20250722$20241121$20250801$PER$$US-SA-2024SA337446$SANOFI AVENTIS$$11$MON$I$M$Y$$$20250801$$MD$US$US
246491602$24649160$2$F$20250101$20250626$20241121$20250702$PER$$US-SA-2024SA336947$SANOFI AVENTIS$$33$YR$A$F$Y$$$20250702$$HP$US$US
246495833$24649583$3$F$20241129$20250123$20241121$20250810$EXP$$JP-ASTRAZENECA-202411GLO013994JP$ALEXION PHARMACEUTICALS$$61$YR$A$F$Y$$$20250810$$MD$JP$JP
246505222$24650522$2$F$$20241113$20241122$20250803$EXP$$US-ASTRAZENECA-202411USA010258US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
246511232$24651123$2$F$$20241118$20241122$20250802$EXP$$US-ASTRAZENECA-202411USA013165US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
246522192$24652219$2$F$$20241118$20241122$20250810$PER$$US-ASTRAZENECA-202411USA016011US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
2465316911$24653169$11$F$20210601$20250911$20241122$20250916$PER$$US-PFIZER INC-202400304605$PFIZER$$67$YR$$F$Y$$$20250916$$CN$US$US
246535694$24653569$4$F$$20250806$20241122$20250922$PER$$US-TRAVERE-2024TVT01178$TRAVERE THERAPEUTICS$$35$YR$A$F$Y$$$20250922$$CN$US$US
246543893$24654389$3$F$20241022$20241031$20241122$20250803$EXP$$US-ASTRAZENECA-202410USA030752US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
246551682$24655168$2$F$$20241115$20241123$20250809$EXP$$US-ASTRAZENECA-202411USA012069US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246560385$24656038$5$F$20240101$20250627$20241124$20250708$PER$$US-SA-2024SA339646$SANOFI AVENTIS$$67$YR$E$F$Y$$$20250708$$HP$US$US
246574363$24657436$3$F$20250418$20250714$20241125$20250722$EXP$$US-BEH-2024185842$CSL BEHRING$$54$YR$A$F$Y$$$20250722$$HP$US$US
246596423$24659642$3$F$$20250814$20241125$20250819$EXP$$SG-PFIZER INC-PV202400151218$PFIZER$Andres, J.. Sequential Development of Immune Checkpoint Inhibitor-Induced Acute Tubulointerstitial Nephritis (ICI-ATIN) following Stevens-Johnson Syndrome (SJS)-Like Reaction in Patient on Pembrolizumab and Meropenem: A Common Drug Trigger?. Journal of the American Society of Nephrology. 2024;35:522-523$71$YR$$M$Y$$$20250819$$HP$SG$SG
246602692$24660269$2$F$$20241121$20241125$20250809$EXP$$US-ASTRAZENECA-202411USA018548US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246636433$24663643$3$F$20250501$20250722$20241126$20250724$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-184363$BRISTOL-MYERS SQUIBB COMPANY$$49$YR$A$F$Y$$$20250724$$HP$US$US
246639602$24663960$2$F$20240802$20250630$20241126$20250710$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2024RR-480421$RANBAXY$$39$YR$$F$Y$$$20250710$$PH$EU$EU
246640213$24664021$3$F$$20250718$20241126$20250725$EXP$$CA-APOTEX-2024AP017671$APOTEX$$78$YR$$F$Y$$$20250725$$HP$CA$CA
246684964$24668496$4$F$20240101$20250711$20241127$20250719$EXP$$US-UNITED THERAPEUTICS-UNT-2024-037237$UNITED THERAPEUTICS$$$$$F$Y$60.771$KG$20250719$$$US$US
246703004$24670300$4$F$$20250911$20241127$20250916$EXP$$CA-MYLANLABS-2024M1105279$MYLAN$$59$YR$$F$Y$54$KG$20250916$$$CA$CA
246705232$24670523$2$F$$20250812$20241127$20250821$PER$$US-INCYTE CORPORATION-2024IN012378$INCYTE$$63$YR$$$Y$72.562$KG$20250821$$$US$
246749043$24674904$3$F$20231201$20250909$20241128$20250914$EXP$$NVSC2024EG227573$NOVARTIS$$55$YR$$F$Y$95$KG$20250914$$CN$EG$EG
246772582$24677258$2$F$20240930$20241121$20241129$20250802$EXP$$US-ASTRAZENECA-202411USA021711US$ALEXION PHARMACEUTICALS$$55$YR$A$F$Y$$$20250802$$$US$US
246774422$24677442$2$F$$20241120$20241129$20250810$EXP$$US-ASTRAZENECA-202411USA016026US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
246788033$24678803$3$F$$20250911$20241129$20250919$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2024-186746$BRISTOL-MYERS SQUIBB COMPANY$$84$YR$E$M$Y$$$20250919$$MD$JP$JP
246791532$24679153$2$F$$20241122$20241129$20250810$EXP$$US-ASTRAZENECA-202411USA018967US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$MD$US$US
246798192$24679819$2$F$20241028$20241122$20241129$20250802$EXP$$US-ASTRAZENECA-202411USA018851US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$US$US
246802552$24680255$2$F$20241010$20241125$20241129$20250810$EXP$$CO-ASTRAZENECA-202411SAM020680CO$ALEXION PHARMACEUTICALS$$30$YR$A$F$Y$$$20250810$$$CO$CO
246802732$24680273$2$F$20241027$20241126$20241129$20250809$EXP$$US-ASTRAZENECA-202411USA022135US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
246804122$24680412$2$F$$20241121$20241129$20250810$EXP$$JP-ASTRAZENECA-202411GLO020990JP$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$$$20250810$$MD$JP$JP
246804382$24680438$2$F$$20241119$20241129$20250803$EXP$$US-ASTRAZENECA-202411USA014720US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
246804602$24680460$2$F$$20241122$20241129$20250803$EXP$$ZA-ASTRAZENECA-202411SSA018149ZA$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$$$20250803$$$ZA$ZA
246807902$24680790$2$F$20241007$20241018$20241129$20250803$EXP$$TH-ASTRAZENECA-202410ASI014249TH$ALEXION PHARMACEUTICALS$$7$YR$C$F$Y$18$KG$20250803$$MD$TH$TH
246812473$24681247$3$F$$20250806$20241129$20250807$PER$$US-PFIZER INC-202400310535$PFIZER$$43$YR$$F$Y$$$20250807$$CN$US$US
246821032$24682103$2$F$20240724$20241118$20241130$20250803$EXP$GB-MHRA-MIDB-a709a7a3-01f3-45aa-8ff6-04f1f8969a02$GB-ASTRAZENECA-202411GLO013819GB$ALEXION PHARMACEUTICALS$$32$YR$A$F$Y$$$20250803$$PH$GB$GB
246829783$24682978$3$F$20241114$20250109$20241201$20250810$PER$$US-ASTRAZENECA-202411USA020467US$ALEXION PHARMACEUTICALS$$73$YR$E$M$Y$$$20250810$$$US$US
246832982$24683298$2$F$$20241126$20241201$20250802$EXP$$BR-ASTRAZENECA-202411SAM021446BR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$BR$BR
246848273$24684827$3$F$$20241128$20241202$20250802$EXP$$CA-ASTRAZENECA-202411CAN022183CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$CA$CA
246859697$24685969$7$F$$20250806$20241202$20250808$PER$$US-PFIZER INC-202400302942$PFIZER$$79$YR$$F$Y$$$20250808$$CN$US$US
246867502$24686750$2$F$$20241126$20241202$20250809$EXP$$JP-ASTRAZENECA-202411GLO025851JP$ALEXION PHARMACEUTICALS$Miki A, et al.. 073 A case of hypertrophic obstructive cardiomyopathy aggravated by alcohol consumption and dapagliflozin.. Joint Regional Meeting of the 164th Tokai Branch/149th Hokuriku Branch of the Japanese Circulation Society. 2024;93-$67$YR$E$F$Y$$$20250809$$MD$JP$JP
246879852$24687985$2$F$$20250808$20241202$20250816$PER$$US-SA-2024SA351887$SANOFI AVENTIS$$48$YR$A$M$Y$$$20250816$$HP$US$US
246884543$24688454$3$F$$20250731$20241202$20250804$EXP$$US-BEIGENE-BGN-2024-019408$BEIGENE$$50$YR$$$Y$$$20250804$$$US$US
246887892$24688789$2$F$$20241125$20241203$20250802$EXP$$US-ASTRAZENECA-202411USA020809US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
246892582$24689258$2$F$$20241127$20241203$20250803$EXP$$EU-ASTRAZENECA-202411GLO025651FR$ALEXION PHARMACEUTICALS$$85$YR$E$M$Y$$$20250803$$$EU$EU
246903423$24690342$3$F$20241120$20250702$20241203$20250707$PER$$US-SA-2024SA355654$SANOFI AVENTIS$$6$YR$C$F$Y$19.27$KG$20250707$$MD$US$US
246910492$24691049$2$F$20241031$20241126$20241203$20250803$EXP$$EU-ASTRAZENECA-202411GLO026475IT$ALEXION PHARMACEUTICALS$$25$YR$A$F$Y$$$20250803$$PH$EU$EU
246920832$24692083$2$F$$20241118$20241203$20250809$EXP$$US-ASTRAZENECA-202411USA013334US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
246933163$24693316$3$F$20241012$20250418$20241203$20250802$EXP$$CN-ASTRAZENECA-202411GLO020924CN$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$$$20250802$$MD$CN$CN
246933172$24693317$2$F$$20241202$20241203$20250810$PER$$US-ASTRAZENECA-202412USA000568US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
246937583$24693758$3$F$20241018$20250717$20241204$20250729$PER$$US-GLK-002400$GLAUKOS$$33$YR$$$Y$$$20250729$$MD$US$US
246940393$24694039$3$F$20241202$20250703$20241204$20250710$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2024-PIM-007739$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20250711$$CN$US$US
246943322$24694332$2$F$$20250618$20241204$20250701$EXP$$EU-AUROBINDO-AUR-APL-2024-057804$AUROBINDO$Zeltner N, Lohmeyer J, Kouidri K, Helwig N, Ajib S, Lang F et al.. Case report: Relapse of hemophagocytic lymphohistiocytosis (HLH) after allogeneic hematopoietic cell transplantation in a patient with acute myeloid leukaemia.. Oncol Res Treat.. 2024;47(Suppl 2):262$49$YR$$M$Y$$$20250701$$MD$EU$EU
246946176$24694617$6$F$20181010$20250708$20241204$20250710$EXP$$CA-JNJFOC-20241167610$JOHNSON AND JOHNSON$$59$YR$A$F$Y$$$20250710$$CN$CA$CA
246966364$24696636$4$F$20241113$20250618$20241204$20250810$EXP$$JP-ASTRAZENECA-202411GLO026861JP$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$36$KG$20250810$$MD$JP$JP
246977743$24697774$3$F$20241101$20250725$20241204$20250819$PER$$US-SA-2024SA356571$SANOFI AVENTIS$$4$YR$C$M$Y$$$20250819$$MD$US$US
246978662$24697866$2$F$20240101$20250804$20241204$20250811$PER$$US-SA-2024SA354842$SANOFI AVENTIS$$7$YR$C$F$Y$$$20250811$$HP$US$US
246984602$24698460$2$F$$20241128$20241204$20250803$EXP$$EU-ASTRAZENECA-202411EEA025996DE$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
246989045$24698904$5$F$20240903$20250722$20241205$20250729$EXP$$GB-CELLTRION INC.-2024GB030564$CELLTRION$$$$$$Y$$$20250729$$PH$GB$GB
246989142$24698914$2$F$$20241129$20241205$20250810$EXP$$EU-ASTRAZENECA-202411EEA026021ES$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$EU$EU
246989552$24698955$2$F$$20241203$20241205$20250809$EXP$$ID-ASTRAZENECA-202412ASI000927ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$ID$ID
246989822$24698982$2$F$$20241202$20241205$20250802$EXP$$US-ASTRAZENECA-202412USA001534US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
246990103$24699010$3$F$20241122$20241227$20241205$20250809$EXP$$US-ASTRAZENECA-202411USA023459US$ALEXION PHARMACEUTICALS$$77$YR$E$M$Y$81.633$KG$20250809$$$US$US
247010339$24701033$9$F$$20250814$20241205$20250818$PER$$CA-TAKEDA-2024TUS116847$TAKEDA$$$$$F$Y$$$20250818$$$CA$CA
247018913$24701891$3$F$20250201$20250702$20241205$20250709$PER$$US-SA-2024SA358121$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250709$$MD$US$US
247025053$24702505$3$F$20241107$20250630$20241205$20250702$EXP$$JP-GILEAD-2024-0693375$GILEAD$$29$YR$A$M$Y$75.4$KG$20250702$$HP$JP$JP
247028472$24702847$2$F$20240816$20250906$20241205$20250910$EXP$$CA-SANDOZ INC.-SDZ2024CA075147$SANDOZ$$49$YR$$F$Y$$$20250910$$CN$CA$CA
247045062$24704506$2$F$20241009$20250724$20241206$20250804$EXP$$EU-AUROBINDO-AUR-APL-2024-058804$AUROBINDO$$77$YR$$M$Y$$$20250804$$MD$EU$EU
247057612$24705761$2$F$20241126$20241129$20241206$20250803$EXP$$CO-ASTRAZENECA-202411SAM025405CO$ALEXION PHARMACEUTICALS$$66$YR$E$F$Y$$$20250803$$$CO$CO
247058192$24705819$2$F$$20241203$20241206$20250809$EXP$$US-ASTRAZENECA-202412USA001278US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
247062607$24706260$7$F$20241219$20250710$20241206$20250722$EXP$$CN-NOVOPROD-1326296$NOVO NORDISK$$$$$M$Y$92.5$KG$20250722$$CN$CN$CN
247086133$24708613$3$F$$20241202$20241207$20250809$EXP$$JP-ASTRAZENECA-202412GLO002376JP$ALEXION PHARMACEUTICALS$Nagai Y, Ohta H, Amari H, Tahara H, Masuda K, Maeda Y. A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment. Thoracic Cancer. 2025;16 (1):e15501$66$YR$E$F$Y$$$20250809$$$JP$JP
247094642$24709464$2$F$$20241202$20241209$20250803$EXP$$US-ASTRAZENECA-202412USA001427US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
247094932$24709493$2$F$$20241202$20241209$20250809$EXP$$EU-ASTRAZENECA-202412EEA001075IT$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$EU$
247097202$24709720$2$F$$20250731$20241209$20250808$EXP$$US-SA-2024SA358108$SANOFI AVENTIS$$59$YR$A$F$Y$$$20250808$$MD$US$US
247097234$24709723$4$F$$20241227$20241209$20250810$PER$$US-ASTRAZENECA-202412USA003568US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250810$$$US$US
247110622$24711062$2$F$$20241125$20241209$20250721$EXP$$CA-UCBSA-2024063313$UCB$$44$YR$$F$Y$$$20250721$$MD$CA$CA
247118702$24711870$2$F$$20241205$20241209$20250810$PER$$US-ASTRAZENECA-202412USA003941US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$PH$US$US
247130022$24713002$2$F$$20241202$20241209$20250810$EXP$$US-ASTRAZENECA-202412USA001573US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
247140045$24714004$5$F$20200420$20250626$20241209$20250708$EXP$$EU-BIOGEN-2024BI01278720$BIOGEN$$47$YR$$F$Y$76$KG$20250708$$MD$EU$EU
247143982$24714398$2$F$$20241202$20241209$20250810$EXP$$US-ASTRAZENECA-202412USA000482US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
247171242$24717124$2$F$$20241120$20241210$20250803$EXP$$IL-ASTRAZENECA-202411ISR015673IL$ALEXION PHARMACEUTICALS$$16$YR$T$M$Y$$$20250803$$MD$IL$IL
247174663$24717466$3$F$20241130$20250905$20241210$20250910$EXP$$US-ABBVIE-6033585$ABBVIE$$77$YR$$F$Y$$$20250910$$CN$US$US
247185912$24718591$2$F$20240101$20250731$20241210$20250811$PER$$US-SA-2024SA362870$SANOFI AVENTIS$$47$YR$A$M$Y$$$20250811$$HP$US$US
247189922$24718992$2$F$20240210$20240822$20241210$20250809$EXP$$EU-AstraZeneca-2023A260439$ALEXION PHARMACEUTICALS$$48$YR$A$M$Y$$$20250809$$$EU$EU
247198722$24719872$2$F$$20241205$20241211$20250803$EXP$$US-ASTRAZENECA-202412USA004456US$ALEXION PHARMACEUTICALS$$$$$F$Y$63.1$KG$20250803$$$US$US
247218473$24721847$3$F$$20241218$20241211$20250809$EXP$2024CP16544$EU-ASTRAZENECA-202412GLO008121PT$ALEXION PHARMACEUTICALS$Certal M, Mimoso D, Marques BR, Cerqueira E, Exposito B.. Bradycardia, Renal Failure, Atrioventricular (AV) Nodal Blockers, Shock, and Hyperkalemia (BRASH) Syndrome: A Confounder in the Clinical Practice.. Cureus.. 2024;16(10):e72793$83$YR$E$F$Y$$$20250809$$$EU$EU
247223952$24722395$2$F$$20241204$20241211$20250803$EXP$$JP-ASTRAZENECA-202412GLO005460JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$MD$JP$
247243062$24724306$2$F$20241001$20250714$20241212$20250721$PER$$US-SA-2024SA365977$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250721$$HP$US$US
2472670811$24726708$11$F$20241124$20250922$20241212$20250930$PER$$US-UNITED THERAPEUTICS-UNT-2024-038667$UNITED THERAPEUTICS$$61$YR$$F$Y$$$20250930$$$US$US
247276222$24727622$2$F$20240716$20250716$20241212$20250721$EXP$$CA-TAKEDA-2024TUS072455$TAKEDA$$86$YR$$M$Y$$$20250721$$$CA$CA
247286552$24728655$2$F$20241004$20241204$20241212$20250809$EXP$$JP-ASTRAZENECA-202410GLO005752JP$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250809$$MD$JP$JP
247288652$24728865$2$F$20241003$20241212$20241212$20250816$PER$$US-ASTRAZENECA-202412USA010141US$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$90.249$KG$20250816$$$US$US
247290902$24729090$2$F$$20241205$20241213$20250816$PER$$US-ASTRAZENECA-202412USA003953US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
247296902$24729690$2$F$20240927$20241212$20241213$20250902$EXP$$US-ASTRAZENECA-202412USA010145US$ALEXION PHARMACEUTICALS$$32$YR$A$F$Y$$$20250902$$MD$US$US
247299172$24729917$2$F$$20250731$20241213$20250807$EXP$$CA-TEVA-VS-3275055$TEVA$$44$YR$$F$Y$68$KG$20250807$$HP$CA$CA
247319314$24731931$4$F$$20250711$20241213$20250715$EXP$$US-PFIZER INC-PV202400162798$PFIZER$$$$A$F$Y$$$20250715$$LW$US$US
247325962$24732596$2$F$$20241211$20241213$20250809$EXP$$TW-ASTRAZENECA-202412ASI008356TW$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$TW$TW
247347642$24734764$2$F$$20250623$20241214$20250701$EXP$$CA-CELLTRION INC.-2024CA031291$CELLTRION$$$$$$Y$$$20250701$$MD$CA$CA
247350952$24735095$2$F$$20241211$20241215$20250803$EXP$$EU-ASTRAZENECA-202412EEA011072AT$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250803$$MD$EU$EU
247366523$24736652$3$F$20241207$20241223$20241216$20250809$EXP$$US-ASTRAZENECA-202412USA010003US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
247371872$24737187$2$F$20241203$20250912$20241216$20250918$EXP$$CA-TAKEDA-CA201914207$TAKEDA$$63$YR$$F$Y$$$20250918$$$CA$CA
247372164$24737216$4$F$20241104$20250314$20241216$20250722$EXP$$EU-BRISTOL-MYERS SQUIBB COMPANY-2024-192088$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$$$20250723$$HP$EU$EU
247374512$24737451$2$F$$20241211$20241216$20250803$EXP$$US-ASTRAZENECA-202412USA009027US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
247378324$24737832$4$F$$20250828$20241216$20250829$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2024-194789$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$$$20250829$$CN$US$US
247384284$24738428$4$F$20240401$20250725$20241216$20250730$EXP$$CA-PFIZER INC-202300298876$PFIZER$$44$YR$$F$Y$$$20250730$$MD$CA$CA
247398343$24739834$3$F$20241001$20250728$20241216$20250802$PER$$US-SA-2024SA367179$SANOFI AVENTIS$$30$YR$A$M$Y$$$20250802$$HP$US$US
247404082$24740408$2$F$$20241216$20241216$20250816$PER$$US-ASTRAZENECA-202412USA012367US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
247411813$24741181$3$F$$20241210$20241217$20250816$PER$$US-ASTRAZENECA-202412USA007514US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
247416252$24741625$2$F$$20241210$20241217$20250816$PER$$US-ASTRAZENECA-202412USA007918US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$MD$US$US
247419332$24741933$2$F$$20241209$20241217$20250809$EXP$$US-ASTRAZENECA-202412USA007606US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$US$US
247420122$24742012$2$F$$20241209$20241217$20250809$EXP$$US-ASTRAZENECA-202412USA006051US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
247421542$24742154$2$F$$20241209$20241217$20250802$EXP$$US-ASTRAZENECA-202412USA007618US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$US$US
247435982$24743598$2$F$$20241209$20241217$20250809$EXP$$CN-ASTRAZENECA-202412CHN006975CN$ALEXION PHARMACEUTICALS$$59$YR$A$F$Y$65$KG$20250809$$$CN$CN
247443152$24744315$2$F$$20241209$20241217$20250809$EXP$$US-ASTRAZENECA-202412USA007595US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$US$US
247445993$24744599$3$F$$20241223$20241217$20250809$EXP$$JP-ASTRAZENECA-202412GLO011748JP$ALEXION PHARMACEUTICALS$$55$YR$A$M$Y$$$20250809$$MD$JP$JP
247464532$24746453$2$F$$20241207$20241218$20250802$EXP$$CN-ASTRAZENECA-202412GLO007074CN$ALEXION PHARMACEUTICALS$Chen Z, Meng Q.. A Long-Term Survival Case of Osimertinib-Resistant Lung Adenocarcinoma With Pleural MetastasesResponding to High-Dose Aumolertinib Plus Anlotinib. 2024 ASIA CONGRESS OF THE EUROPEAN SOCIETY FOR MEDICALONCOLOGY (ESMO). 2024$61$YR$A$M$Y$$$20250802$$$CN$CN
247476882$24747688$2$F$$20250916$20241218$20250922$EXP$$EU-ROCHE-1412695$ROCHE$Le Saux O, You B and Freyer G. Antiangiogenic therapy in patients with HER2-positive Metastatic breast cancer: A case series. Clinical Breast Cancer 2014 Jan 01;14(3):E89-e94.$51$YR$A$F$Y$$$20250922$$HP$EU$EU
247482102$24748210$2$F$20240101$20250709$20241218$20250714$PER$$US-PFIZER INC-PV202400163911$PFIZER$$35$YR$$F$Y$$$20250714$$HP$US$US
247485122$24748512$2$F$$20250908$20241218$20250915$EXP$$CA-ROCHE-10000155243$ROCHE$$40$YR$A$F$Y$96$KG$20250915$$HP$CA$CA
247489623$24748962$3$F$20241001$20241226$20241218$20250802$EXP$$TW-ASTRAZENECA-202412ASI007159TW$ALEXION PHARMACEUTICALS$$69$YR$E$M$Y$67$KG$20250802$$$TW$TW
247492413$24749241$3$F$20241025$20250707$20241218$20250810$EXP$$KR-ASTRAZENECA-202412KOR006756KR$ALEXION PHARMACEUTICALS$$92$YR$E$M$Y$$$20250810$$$KR$KR
247492662$24749266$2$F$$20241218$20241218$20250816$PER$$US-ASTRAZENECA-202412USA015157US$ALEXION PHARMACEUTICALS$$51$YR$A$F$Y$$$20250816$$$US$US
247511632$24751163$2$F$$20250630$20241219$20250709$EXP$CA-HEALTHCANVIG-E2B_07467770$CA-NOVOPROD-1337122$NOVO NORDISK$$13$YR$$F$Y$$$20250709$$HP$CA$CA
247517722$24751772$2$F$$20241216$20241219$20250810$PER$$US-ASTRAZENECA-202412USA012679US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
247522823$24752282$3$F$20241201$20250730$20241219$20250807$EXP$$CA-CELLTRION INC.-2024CA031482$CELLTRION$$$$$$Y$$$20250807$$HP$CA$CA
247529392$24752939$2$F$$20241211$20241219$20250809$EXP$$MY-ASTRAZENECA-202412ASI009266MY$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$MY$MY
247539802$24753980$2$F$$20250627$20241219$20250717$PER$$US-SMPA-2024SPA005710$SUNOVION$$$$$$Y$$$20250717$$CN$US$US
247546842$24754684$2$F$$20241211$20241219$20250809$EXP$$JP-ASTRAZENECA-202412GLO011840JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$JP$JP
247548562$24754856$2$F$$20250825$20241219$20250902$PER$$US-ELI_LILLY_AND_COMPANY-US202412012296$ELI LILLY AND COMPANY$$41$YR$A$F$Y$$$20250902$$CN$US$US
247563932$24756393$2$F$$20241217$20241220$20250803$EXP$$US-ASTRAZENECA-202412USA014204US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
247570672$24757067$2$F$$20241218$20241220$20250816$PER$$US-ASTRAZENECA-202412USA015376US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
247605973$24760597$3$F$20240806$20241217$20241220$20250803$EXP$$ZA-ASTRAZENECA-202412SSA013648ZA$ALEXION PHARMACEUTICALS$$80$YR$E$M$Y$$$20250803$$$ZA$ZA
247608747$24760874$7$F$20240101$20250729$20241220$20250804$EXP$$US-SA-2024SA375956$SANOFI AVENTIS$$34$YR$A$M$Y$$$20250804$$MD$US$US
247614053$24761405$3$F$$20240722$20241220$20250803$EXP$$US-ASTRAZENECA-202407GLO002472US$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$$$20250803$$$US$US
247618222$24761822$2$F$$20241217$20241221$20250803$EXP$$US-ASTRAZENECA-202412USA016352US$ALEXION PHARMACEUTICALS$David D. Gummin, James B. Mowry, Michael C. Beuhler, Daniel A. Spyker, Laura J. Rivers, Ryan Feldman, Kaitlyn Brown, Nathaniel P.T. Pham, Alvin C. Bronstein + Carol DesLauriers. 2023 Annual Report of the National Poison Data System? (NPDS) from America?s Poison Centers?: 41st Annual Report. Clinical Toxicology. 2024;1:235$33$YR$A$M$Y$$$20250803$$$US$US
247626262$24762626$2$F$$20241218$20241221$20250809$EXP$$US-ASTRAZENECA-202412USA015387US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
247642004$24764200$4$F$$20250916$20241223$20250924$EXP$$CA-CELLTRION INC.-2024CA032545$CELLTRION$$$$$$Y$$$20250924$$HP$CA$CA
247654952$24765495$2$F$$20241216$20241223$20250810$EXP$$US-ASTRAZENECA-202412USA012451US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
247657632$24765763$2$F$20241128$20241219$20241223$20250803$EXP$$US-ASTRAZENECA-202412USA016547US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$MD$US$US
247660775$24766077$5$F$$20250610$20241223$20250707$PER$$US-SMPA-2024SPA005830$SUNOVION$$$$$$Y$$$20250707$$CN$US$US
247673264$24767326$4$F$20241212$20250804$20241223$20250807$EXP$$GB-MYLANLABS-2024M1097141$MYLAN$$$$$M$Y$$$20250807$$MD$GB$GB
247673842$24767384$2$F$$20241216$20241223$20250810$EXP$$EU-ASTRAZENECA-202412EEA007063FR$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250810$$MD$EU$EU
247698032$24769803$2$F$$20241217$20241224$20250810$EXP$$ZA-ASTRAZENECA-202412SSA013439ZA$ALEXION PHARMACEUTICALS$$67$YR$E$F$Y$$$20250810$$$ZA$ZA
247715714$24771571$4$F$20241201$20250618$20241224$20250714$PER$$US-GSK-US2024161339$GLAXOSMITHKLINE$$58$YR$$F$Y$$$20250714$$$US$US
247730524$24773052$4$F$20240712$20250804$20241225$20250806$EXP$$US-ABBVIE-6063175$ABBVIE$$$$$M$Y$10$KG$20250806$$HP$US$US
247738852$24773885$2$F$20240801$20241218$20241225$20250809$EXP$EU-AFSSAPS-LY2024001262$EU-ASTRAZENECA-202408GLO002605FR$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$67$KG$20250809$$$EU$EU
247739573$24773957$3$F$$20241220$20241225$20250809$EXP$$US-ASTRAZENECA-202412USA018125US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
247741373$24774137$3$F$20241101$20250925$20241225$20250930$PER$$US-SA-2024SA379964$SANOFI AVENTIS$$47$YR$A$F$Y$$$20250930$$HP$US$US
247742993$24774299$3$F$20230101$20250813$20241225$20250819$PER$$US-SA-2024SA377161$SANOFI AVENTIS$$48$YR$A$M$Y$$$20250819$$HP$US$US
247753963$24775396$3$F$20241212$20250805$20241226$20250811$EXP$$US-BAXTER-2024BAX029835$BAXTER$$39$YR$$F$Y$61.2$KG$20250811$$HP$US$US
247760662$24776066$2$F$20240726$20250627$20241226$20250710$EXP$$JP-GSK-JP2024162667$GLAXOSMITHKLINE$$$$$F$Y$$$20250710$$MD$JP$JP
247781452$24778145$2$F$$20241223$20241226$20250809$EXP$$US-ASTRAZENECA-202412USA019109US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
247790002$24779000$2$F$$20241223$20241226$20250802$EXP$$US-ASTRAZENECA-202412USA019338US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
247840122$24784012$2$F$20240608$20241225$20241227$20250809$EXP$$CN-ASTRAZENECA-202412CHN022028CN$ALEXION PHARMACEUTICALS$$65$YR$E$M$Y$65$KG$20250809$$$CN$CN
247857842$24785784$2$F$20241201$20250826$20241229$20250902$PER$$US-SA-2024SA379343$SANOFI AVENTIS$$55$YR$A$F$Y$$$20250902$$HP$US$US
247858452$24785845$2$F$20241002$20241224$20241229$20250810$EXP$$US-ASTRAZENECA-202412USA020440US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
247858662$24785866$2$F$20241208$20241220$20241229$20250803$EXP$$CO-ASTRAZENECA-202412SAM019584CO$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$65$KG$20250803$$$CO$CO
247862053$24786205$3$F$20241127$20250724$20241229$20250730$EXP$$US-UCBSA-2024067731$UCB$$15$YR$$M$Y$31$KG$20250730$$HP$US$US
247867395$24786739$5$F$$20250903$20241230$20250918$EXP$$US-INSMED, INC.-2024-05142-US$INSMED$$$$$F$Y$$$20250918$$CN$US$US
247878152$24787815$2$F$$20241205$20241230$20250809$EXP$$JP-ASTRAZENECA-202412GLO021470JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$PH$JP$
247892082$24789208$2$F$20241210$20241223$20241230$20250810$EXP$$CN-ASTRAZENECA-202412CHN020320CN$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$$$20250810$$$CN$CN
247915405$24791540$5$F$20241210$20250502$20241231$20250710$PER$$US-BEH-2024188860$CSL BEHRING$$72$YR$E$M$Y$$$20250710$$CN$US$US
247921738$24792173$8$F$$20250902$20241231$20250906$EXP$$CA-TAKEDA-2024TUS130472$TAKEDA$$$$$F$Y$$$20250906$$$CA$CA
247922613$24792261$3$F$$20250630$20241231$20250710$EXP$$SG-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-487136$RANBAXY$Lau WK, Chee D. Loss of consciousness following a central neuraxial block -a case report. Region Anesth Pain Med. 2024;49(Suppl.):A200 (P089)$33$YR$$F$Y$$$20250710$$HP$SG$SG
247923382$24792338$2$F$20241208$20241226$20241231$20250809$EXP$$US-ASTRAZENECA-202412USA022521US$ALEXION PHARMACEUTICALS$$94$YR$E$$Y$$$20250809$$$US$US
247945073$24794507$3$F$$20241223$20241231$20250803$EXP$$RU-ASTRAZENECA-202412RUS021247RU$ALEXION PHARMACEUTICALS$Pribylov SA, Maslova TA, Pribylov VS, Leonidova KO, Pribylova NN, Kuts AP. Long-COVID, severe course, with congenital bronchiectasis, Williams?Campbell syndrome. Case report. Terapevticheskii Arkhiv. 2024;96(11):1089-1095$$$$F$Y$30$KG$20250803$$MD$RU$RU
247955532$24795553$2$F$20241030$20241227$20241231$20250810$PER$$US-ASTRAZENECA-202412GLO025534US$ALEXION PHARMACEUTICALS$$5$DY$N$F$Y$$$20250810$$$US$US
247971852$24797185$2$F$$20250626$20250101$20250702$PER$$US-SA-2024SA385399$SANOFI AVENTIS$$85$YR$E$M$Y$$$20250702$$MD$US$US
247990304$24799030$4$F$20240101$20250821$20250102$20250828$PER$$US-SA-2024SA384606$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250828$$HP$US$US
247991122$24799112$2$F$$20250718$20250102$20250721$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-000481$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$M$Y$$$20250721$$CN$US$US
247992942$24799294$2$F$$20250925$20250102$20250929$EXP$$US-PFIZER INC-PV202400168239$PFIZER$$73$YR$$F$Y$$$20250929$$CN$US$US
248011412$24801141$2$F$20240101$20250915$20250102$20250916$EXP$EU-AFSSAPS-RE2024001305$EU-Eisai-EC-2024-181303$EISAI$$71$YR$E$M$Y$58.3$KG$20250916$$MD$EU$EU
248035862$24803586$2$F$$20250714$20250103$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202501000360$ELI LILLY AND COMPANY$$67$YR$E$F$Y$$$20250722$$CN$US$US
248044983$24804498$3$F$20240501$20250224$20250103$20250909$EXP$$EU-UCBSA-2024045560$UCB$$54$YR$$M$Y$142$KG$20250909$$MD$EU$EU
248048142$24804814$2$F$$20250813$20250103$20250822$PER$$US-SA-2025SA002021$SANOFI AVENTIS$$$$A$M$Y$$$20250822$$HP$US$US
248049852$24804985$2$F$$20250716$20250103$20250721$PER$$US-SA-2025SA000955$SANOFI AVENTIS$$$$A$F$Y$$$20250721$$MD$US$US
248096892$24809689$2$F$20241201$20250813$20250106$20250815$EXP$$EU-ABBVIE-6071443$ABBVIE$$67$YR$$M$Y$$$20250815$$CN$EU$EU
248117028$24811702$8$F$20240101$20250830$20250106$20250903$EXP$$IN-PFIZER INC-PV202500000612$PFIZER$$78$YR$$F$Y$$$20250903$$CN$IN$IN
248131933$24813193$3$F$$20250801$20250107$20250806$EXP$$EU-JNJFOC-20241289829$JOHNSON AND JOHNSON$$57$YR$A$M$Y$69$KG$20250806$$MD$EU$EU
248135432$24813543$2$F$$20250103$20250107$20250803$EXP$$US-ASTRAZENECA-202501USA002234US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$US$US
248142762$24814276$2$F$$20250103$20250107$20250803$EXP$$US-ASTRAZENECA-202501USA001103US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
248144588$24814458$8$F$20241101$20250704$20250107$20250708$EXP$$NVSC2025GB001470$NOVARTIS$$56$YR$$M$Y$$$20250708$$CN$GB$GB
248167832$24816783$2$F$$20250106$20250107$20250809$EXP$$US-ASTRAZENECA-202501USA002740US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
248186934$24818693$4$F$20240901$20250728$20250108$20250805$EXP$$NVSC2024FR216051$NOVARTIS$$45$YR$$F$Y$$$20250805$$MD$EU$EU
248204477$24820447$7$F$20250822$20250908$20250108$20250917$EXP$$US-UCBSA-2025000968$UCB$$44$YR$$F$Y$102.6$KG$20250917$$CN$US$US
248205526$24820552$6$F$20240824$20250701$20250108$20250703$EXP$$IN-ASTELLAS-2025-AER-000558$ASTELLAS$$68$YR$E$F$Y$$$20250703$$CN$IN$IN
248210433$24821043$3$F$20240101$20250806$20250108$20250814$PER$$US-SA-2025SA003073$SANOFI AVENTIS$$29$YR$A$F$Y$$$20250815$$HP$US$US
248213192$24821319$2$F$20250501$20250623$20250108$20250702$PER$$US-SA-2025SA004482$SANOFI AVENTIS$$44$YR$A$M$Y$$$20250702$$HP$US$US
248217704$24821770$4$F$20240101$20250703$20250108$20250710$PER$$US-SA-2025SA003673$SANOFI AVENTIS$$38$YR$A$F$Y$$$20250710$$HP$US$US
248218903$24821890$3$F$20240101$20250811$20250108$20250819$PER$$US-SA-2025SA005769$SANOFI AVENTIS$$4$YR$C$F$Y$$$20250819$$HP$US$US
248223242$24822324$2$F$$20250103$20250108$20250816$PER$$US-ASTRAZENECA-202501USA001080US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$US$US
248224069$24822406$9$F$20240927$20250911$20250108$20250917$EXP$$CA-TAKEDA-2024TUS097459$TAKEDA$$51$YR$$F$Y$72$KG$20250917$$$CA$CA
248226302$24822630$2$F$$20250909$20250109$20250918$PER$$US-ABBVIE-6076946$ABBVIE$$$$A$F$Y$$$20250918$$CN$US$US
248242943$24824294$3$F$$20250905$20250109$20250916$PER$$US-SMPA-2025SPA000115$SUNOVION$$74$YR$$M$Y$$$20250915$$$US$US
248243322$24824332$2$F$20240301$20250103$20250109$20250810$EXP$$US-ASTRAZENECA-202501USA002873US$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$$$20250810$$$US$US
248246662$24824666$2$F$$20250829$20250109$20250904$EXP$$US-MYLANLABS-2025M1001360$MYLAN$Lafazanos Y, David R, Asado N, Gonzalez M, Ehrenpreis ED. A Case of Pembrolizumab-Induced Duodenitis Mimicking Celiac Disease. Am-J-Gastroenterol 2024; 119 (Suppl. 10) S3038-S3039 abstr. S4814.$64$YR$$F$Y$$$20250904$$$US$US
248256666$24825666$6$F$20240101$20250715$20250109$20250717$PER$$US-PFIZER INC-202400298074$PFIZER$$58$YR$$F$Y$$$20250717$$HP$US$US
248267982$24826798$2$F$$20250106$20250109$20250803$EXP$$US-ASTRAZENECA-202501USA002605US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
248268393$24826839$3$F$$20241228$20250109$20250810$EXP$$EU-ASTRAZENECA-202412GLO026923ES$ALEXION PHARMACEUTICALS$$$$I$$Y$$$20250810$$$EU$EU
248283214$24828321$4$F$20241201$20250815$20250109$20250820$EXP$$US-SA-2025SA006540$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250820$$HP$US$US
248285123$24828512$3$F$20250101$20250801$20250110$20250916$PER$$US-GSK-US2025000331$GLAXOSMITHKLINE$$34$YR$$F$Y$$$20250916$$$US$US
248288852$24828885$2$F$20241227$20241230$20250110$20250810$PER$$US-ASTRAZENECA-202412GLO026964US$ALEXION PHARMACEUTICALS$$93$YR$E$M$Y$$$20250810$$$US$
248289622$24828962$2$F$20240401$20250107$20250110$20250803$EXP$$US-ASTRAZENECA-202501USA004196US$ALEXION PHARMACEUTICALS$$71$YR$$$Y$$$20250803$$MD$US$US
248289852$24828985$2$F$20241226$20250106$20250110$20250802$EXP$$US-ASTRAZENECA-202501USA002817US$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$$$20250802$$$US$US
248302892$24830289$2$F$20241201$20250107$20250110$20250803$EXP$$BR-ASTRAZENECA-202501SAM005745BR$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$78$KG$20250803$$$BR$BR
248305063$24830506$3$F$20241225$20250204$20250110$20250809$EXP$$US-ASTRAZENECA-202501USA001602US$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$$$20250809$$$US$US
248307732$24830773$2$F$20240401$20250818$20250110$20250819$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-488689$RANBAXY$$70$YR$$F$Y$$$20250819$$MD$US$US
248311862$24831186$2$F$$20250109$20250110$20250809$EXP$$US-ASTRAZENECA-202501USA006160US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
248322032$24832203$2$F$$20250107$20250110$20250809$EXP$$US-ASTRAZENECA-202501GLO006766US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
248335783$24833578$3$F$20240601$20250325$20250113$20250803$EXP$$US-ASTRAZENECA-202501USA006188US$ALEXION PHARMACEUTICALS$$94$YR$E$F$Y$$$20250803$$$US$US
248345073$24834507$3$F$$20250106$20250113$20250803$EXP$$US-ASTRAZENECA-202501USA002836US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$MD$US$US
248352032$24835203$2$F$20250102$20250108$20250113$20250803$EXP$$EU-ASTRAZENECA-202501EEA004425ES$ALEXION PHARMACEUTICALS$$75$YR$E$F$Y$$$20250803$$$EU$EU
2483641210$24836412$10$F$20250201$20250926$20250113$20250929$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-004494$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$F$Y$$$20250929$$$US$US
248366542$24836654$2$F$$20250702$20250113$20250716$EXP$$US-AUROBINDO-AUR-APL-2025-001311$AUROBINDO$Sadjadi R, Cogdell E, Mostafa M, Anatelli F, Ackerman L, Han MAT. Watch Out for Off-Label Weight Loss Medication Use: Zonisamide-Induced Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Drug Induced Liver Injury.. The American College of Gastroenterology. 2024;119 (Suppl.)(10:S2854$55$YR$$F$Y$$$20250716$$MD$US$US
248367632$24836763$2$F$$20250107$20250113$20250810$PER$$US-ASTRAZENECA-202501USA003379US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
248377382$24837738$2$F$$20250106$20250113$20250802$EXP$$US-ALXN-202501USA002194US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250802$$$US$US
248379732$24837973$2$F$$20250106$20250113$20250810$EXP$$US-ASTRAZENECA-202501USA002765US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
248388582$24838858$2$F$$20250110$20250114$20250802$EXP$$CA-ASTRAZENECA-202501CAN007375CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$MD$CA$CA
248391332$24839133$2$F$$20250110$20250114$20250802$EXP$$ZA-ASTRAZENECA-202501SSA006726ZA$ALEXION PHARMACEUTICALS$$77$YR$E$M$Y$$$20250802$$$ZA$ZA
248399812$24839981$2$F$$20250110$20250114$20250816$PER$$US-ASTRAZENECA-202501USA007408US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
248402192$24840219$2$F$$20250110$20250114$20250810$EXP$$US-ASTRAZENECA-202501GLO006626US$ALEXION PHARMACEUTICALS$Gupta S.R., Channen L., Habr F.. Gastric Neuroendocrine Tumor Induced by Long-Term PPI Use. American Journal of Gastroenterology. 2024;119:10:Supplement (S3251-)$50$YR$A$M$Y$$$20250810$$MD$US$US
248405607$24840560$7$F$$20250809$20250114$20250811$EXP$$CA-PFIZER INC-202500005595$PFIZER$$34$YR$$M$Y$$$20250811$$HP$CA$CA
248436633$24843663$3$F$$20250108$20250115$20250809$EXP$$EU-ASTRAZENECA-202501EEA005922FR$ALEXION PHARMACEUTICALS$$71$YR$E$M$Y$$$20250809$$$EU$EU
248437132$24843713$2$F$20210528$20250109$20250115$20250803$EXP$$EU-AstraZeneca-2024A142142$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$MD$EU$EU
248441922$24844192$2$F$$20250711$20250115$20250717$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-001630$BOEHRINGER INGELHEIM$$74$YR$E$M$Y$$$20250717$$$CA$CA
248441942$24844194$2$F$$20250110$20250115$20250809$EXP$$US-ASTRAZENECA-202501USA007205US$ALEXION PHARMACEUTICALS$$$$$F$Y$72.17$KG$20250809$$$US$US
248446923$24844692$3$F$$20250318$20250115$20250829$PER$$US-CHATTEMPRD-2025OHG000658$CHATTEM$$$$$M$Y$$$20250829$$CN$US$US
248460012$24846001$2$F$20241101$20250108$20250115$20250803$EXP$$EU-ASTRAZENECA-202501GLO010879SE$ALEXION PHARMACEUTICALS$$55$YR$A$F$Y$$$20250803$$$EU$EU
248460352$24846035$2$F$$20250114$20250115$20250809$EXP$$KR-ASTRAZENECA-202501KOR009379KR$ALEXION PHARMACEUTICALS$$60$YR$A$$Y$$$20250809$$$KR$KR
248477982$24847798$2$F$$20250702$20250116$20250707$EXP$$CA-JNJFOC-20250122883$JOHNSON AND JOHNSON$$$$$M$Y$$$20250707$$HP$CA$CA
248479713$24847971$3$F$20250110$20250718$20250116$20250722$EXP$$US-TAKEDA-2025TUS004040$TAKEDA$$74$YR$$F$Y$$$20250722$$$US$US
248495032$24849503$2$F$$20250808$20250116$20250820$EXP$$EU-TEVA-VS-3286377$TEVA$Lakatos F A, K?d?r L, Schmidt P, K?nig J, Br?dy A, Mensch K F. Prosthetic care and management of patients with MRONJ with different microbiological backgrounds. Fogorvosi Szemle. 2024; 117(2): 86-99.; Lakatos F A, K?d?r L, Schmidt P, K?nig J, Br?dy A, Mensch K F. Prosthetic care and management of patients with MRONJ with different microbiological backgrounds. Fogorvosi Szemle. 2024; 117(2): 86-99.$73$YR$$F$Y$$$20250820$$MD$EU$EU
248501812$24850181$2$F$20241214$20250109$20250116$20250803$EXP$$EU-ASTRAZENECA-202501GLO012189IT$ALEXION PHARMACEUTICALS$$41$YR$A$F$Y$$$20250803$$MD$EU$EU
248524632$24852463$2$F$$20250114$20250116$20250810$PER$$US-ASTRAZENECA-202501USA010509US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
248529192$24852919$2$F$$20250110$20250116$20250816$PER$$US-ASTRAZENECA-202501USA007242US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
248538494$24853849$4$F$$20240820$20250117$20250828$PER$$US-ENDO USA, INC.-2024-003306$ENDO$$$$$F$Y$$$20250828$$CN$US$US
248540973$24854097$3$F$$20250114$20250117$20250809$EXP$$MY-ASTRAZENECA-202501ASI009419MY$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$$$20250809$$PH$MY$MY
248541552$24854155$2$F$$20250116$20250117$20250810$PER$$US-ASTRAZENECA-202501USA012932US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
248543102$24854310$2$F$$20250114$20250117$20250803$EXP$$CN-ASTRAZENECA-202501GLO009619CN$ALEXION PHARMACEUTICALS$Xiang Y, Wang J, Yang W, Feng X, Ni J, Zhang X. EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China. Translational Lung Cancer Research. 2024;13(12):3500-12$52$YR$A$M$Y$$$20250803$$MD$CN$CN
248552862$24855286$2$F$20241226$20250110$20250117$20250809$EXP$$CN-ASTRAZENECA-202501GLO013433CN$ALEXION PHARMACEUTICALS$$23$YR$A$M$Y$75$KG$20250809$$MD$CN$CN
248555983$24855598$3$F$20240101$20250630$20250117$20250704$EXP$$US-UCBSA-2024066138$UCB$$$$$F$Y$82.64$KG$20250704$$CN$US$US
248579132$24857913$2$F$20241210$20250110$20250117$20250804$EXP$$EU-ASTRAZENECA-202501GLO013689ES$ALEXION PHARMACEUTICALS$$89$YR$E$M$Y$$$20250804$$PH$EU$EU
248598553$24859855$3$F$20240624$20250825$20250119$20250903$PER$$US-SA-2025SA016113$SANOFI AVENTIS$$1$YR$I$M$Y$$$20250903$$HP$US$US
248604582$24860458$2$F$$20250113$20250120$20250816$PER$$US-ASTRAZENECA-202501USA009036US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
248608893$24860889$3$F$$20250416$20250120$20250816$PER$$US-ASTRAZENECA-202501USA010484US$ALEXION PHARMACEUTICALS$$6$YR$C$F$Y$$$20250816$$$US$US
248636922$24863692$2$F$$20250115$20250120$20250810$EXP$$JP-ASTRAZENECA-202410GLO031070JP$ALEXION PHARMACEUTICALS$$64$YR$A$M$Y$$$20250810$$MD$JP$JP
248646612$24864661$2$F$$20250812$20250120$20250821$PER$$US-SA-2025SA017131$SANOFI AVENTIS$$21$YR$A$F$Y$$$20250821$$HP$US$US
248651252$24865125$2$F$$20250114$20250121$20250810$EXP$$AU-ASTRAZENECA-202501OCE009492AU$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$AU$AU
248688802$24868880$2$F$20250107$20250117$20250121$20250809$EXP$$CN-ASTRAZENECA-202501CHN015160CN$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250809$$$CN$CN
248703564$24870356$4$F$20250201$20250709$20250121$20250716$PER$$US-SA-2025SA018927$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250716$$HP$US$US
248707312$24870731$2$F$$20250115$20250121$20250810$PER$$US-ASTRAZENECA-202501USA015243US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
248713802$24871380$2$F$$20250115$20250122$20250816$PER$$US-ASTRAZENECA-202501USA011512US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
248734873$24873487$3$F$20241201$20250818$20250122$20250825$EXP$$US-UCBSA-2025003278$UCB$$33$YR$$F$Y$$$20250825$$HP$US$US
248758422$24875842$2$F$20241021$20250120$20250122$20250809$EXP$EU-AFSSAPS-ST2025000037$EU-ASTRAZENECA-202501GLO015088FR$ALEXION PHARMACEUTICALS$$54$YR$A$F$Y$69.8$KG$20250809$$MD$EU$EU
248760419$24876041$9$F$20250101$20250707$20250123$20250716$EXP$$US-UNITED THERAPEUTICS-UNT-2025-002252$UNITED THERAPEUTICS$$84$YR$$M$Y$99.773$KG$20250716$$$US$US
248769535$24876953$5$F$20241226$20250811$20250123$20250821$EXP$$CA-UCBSA-2025003683$UCB$$23$YR$$F$Y$$$20250821$$CN$CA$CA
248770683$24877068$3$F$20250101$20250812$20250123$20250818$EXP$$CL-JNJFOC-20250148535$JOHNSON AND JOHNSON$$63$YR$A$F$Y$$$20250818$$CN$CL$CL
248798833$24879883$3$F$20250118$20250718$20250123$20250801$EXP$$CA-TAKEDA-2024TUS021683$TAKEDA$$37$YR$$F$Y$$$20250801$$$CA$CA
248801075$24880107$5$F$$20250808$20250123$20250815$EXP$$IN-TAKEDA-2025TUS006613$TAKEDA$$$$$M$Y$$$20250815$$$IN$IN
248803912$24880391$2$F$$20250119$20250123$20250816$PER$$US-ASTRAZENECA-202501USA017441US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
248807622$24880762$2$F$$20250121$20250123$20250803$EXP$$ZA-ASTRAZENECA-202501SSA016339ZA$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250803$$$ZA$ZA
2488091112$24880911$12$F$20241218$20250916$20250124$20250919$EXP$$EU-ASTRAZENECA-202409GLO015065ES$ALEXION PHARMACEUTICALS$$41$YR$A$F$Y$$$20250919$$$EU$EU
248826903$24882690$3$F$$20250704$20250124$20250718$EXP$US-MLMSERVICE-20250110-PI225339-00030-6$US-STRIDES ARCOLAB LIMITED-2025SP000939$Unknown Manufacturer$Tsao LR, Li L, Robertson PA, Irani RA, Otani IM.. Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity evaluations in pregnancy: A case series of initiating low-dose aspirin.. Ann-Allergy-Asthma-Immunol. 2025;134(1):95-97$3$DEC$$F$Y$$$20250718$$MD$US$US
248830882$24883088$2$F$$20250121$20250124$20250810$EXP$$JP-ASTRAZENECA-202501GLO020263JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$PH$JP$JP
248833104$24883310$4$F$$20250711$20250124$20250725$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-490194$RANBAXY$$75$YR$$M$Y$$$20250725$$HP$AU$AU
248842194$24884219$4$F$$20250228$20250124$20250803$EXP$$US-ASTRAZENECA-202501USA012902US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250803$$$US$US
248859922$24885992$2$F$20240909$20250702$20250125$20250714$EXP$EU-SEMPA-2024-009164$EU-Accord-465843$ACCORD$$34$YR$A$M$Y$$$20250714$$MD$EU$EU
248868932$24886893$2$F$$20250630$20250127$20250704$EXP$$JP-ASTELLAS-2025-AER-004013$ASTELLAS$$6$DEC$A$$Y$$$20250704$$MD$JP$JP
248881844$24888184$4$F$20250118$20250318$20250127$20250803$EXP$$US-ASTRAZENECA-202501USA018121US$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$$$20250803$$$US$US
248883742$24888374$2$F$20250112$20250724$20250127$20250802$EXP$$EU-AUROBINDO-AUR-APL-2025-003885$AUROBINDO$$86$YR$$F$Y$57$KG$20250803$$MD$EU$EU
248895543$24889554$3$F$$20250122$20250127$20250913$EXP$$GB-UCBSA-2025004526$UCB$Forbes H, Madley-Dowd P, Ahlqvist V, Campbell J, Davies NM, Liebling R, et.al. First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study. Journal of Neurology, Neurosurgery and Psychiatry. 2024;00:1-11$$$$F$Y$$$20250913$$MD$GB$GB
248900192$24890019$2$F$$20250121$20250127$20250809$EXP$$US-ASTRAZENECA-202501USA016459US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
248900988$24890098$8$F$20250119$20250814$20250127$20250815$30DAY$$US-PFIZER INC-202500015599$PFIZER$$13$YR$$F$Y$$$20250815$$MD$US$US
248905773$24890577$3$F$20241105$20250310$20250127$20250803$EXP$$US-ASTRAZENECA-202501USA018000US$ALEXION PHARMACEUTICALS$$31$YR$A$M$Y$$$20250803$$PH$US$US
248939443$24893944$3$F$$20250616$20250128$20250710$PER$$US-SMPA-2025SPA000517$SUNOVION$$$$$$Y$$$20250710$$CN$US$US
248945542$24894554$2$F$$20250710$20250128$20250724$PER$$US-SMPA-2025SPA000531$SUNOVION$$$$$$Y$$$20250724$$HP$US$US
248950573$24895057$3$F$20241119$20250710$20250128$20250717$EXP$$GB-MYLANLABS-2024M1105194$MYLAN$$$$$F$Y$$$20250717$$$GB$GB
248981755$24898175$5$F$20240101$20250908$20250129$20250916$EXP$$US-BEH-2024173967$CSL BEHRING$$77$YR$E$F$Y$61.36$KG$20250916$$CN$US$US
248986943$24898694$3$F$20250106$20250605$20250129$20250809$EXP$$JP-ASTRAZENECA-202501GLO021857JP$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$36$KG$20250809$$MD$JP$JP
248989092$24898909$2$F$$20250122$20250129$20250809$EXP$$US-ASTRAZENECA-202501USA018751US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
248995142$24899514$2$F$$20250122$20250129$20250809$EXP$$US-ASTRAZENECA-202501USA018622US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
249004422$24900442$2$F$20250126$20250126$20250129$20250809$EXP$$CN-ASTRAZENECA-202501CHN022215CN$ALEXION PHARMACEUTICALS$$61$YR$A$F$Y$52$KG$20250809$$$CN$CN
249006652$24900665$2$F$20250113$20250124$20250129$20250809$EXP$$EU-ASTRAZENECA-202501EEA020649ES$ALEXION PHARMACEUTICALS$$73$YR$E$F$Y$$$20250809$$PH$EU$EU
249035234$24903523$4$F$20240221$20250909$20250130$20250916$EXP$$BR-TAKEDA-2024TUS019509$TAKEDA$$46$YR$$F$Y$$$20250916$$$BR$BR
249036882$24903688$2$F$20241201$20250123$20250130$20250809$EXP$$US-ASTRAZENECA-202501USA020820US$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$$$20250809$$$US$US
249064092$24906409$2$F$$20250129$20250130$20250807$EXP$$BR-ABBVIE-6110900$ABBVIE$$$$$F$Y$$$20250807$$MD$BR$BR
249083382$24908338$2$F$20241117$20250127$20250131$20250802$EXP$$US-ASTRAZENECA-202501022768US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
249084422$24908442$2$F$$20250127$20250131$20250810$EXP$$US-ASTRAZENECA-202501023847US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249084462$24908446$2$F$$20250128$20250131$20250803$EXP$$US-ASTRAZENECA-202501024709US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250803$$$US$US
249087582$24908758$2$F$20240601$20250717$20250131$20250725$EXP$$JP-JNJFOC-20250118736$JOHNSON AND JOHNSON$$42$YR$A$M$Y$$$20250725$$HP$JP$JP
249089042$24908904$2$F$$20250129$20250131$20250803$EXP$$US-ASTRAZENECA-202501025606US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$PH$US$US
249100912$24910091$2$F$20250101$20250127$20250131$20250810$EXP$$JP-ASTRAZENECA-202501GLO027304JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$MD$JP$JP
249104824$24910482$4$F$$20250212$20250131$20250803$EXP$$EU-ASTRAZENECA-202501GLO023706SE$ALEXION PHARMACEUTICALS$$86$YR$E$M$Y$$$20250803$$$EU$EU
249107582$24910758$2$F$20240509$20250123$20250131$20250803$EXP$$AU-ASTRAZENECA-202501GLO027207AU$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$AU$AU
249111743$24911174$3$F$$20250609$20250131$20250704$PER$$US-SMPA-2025SPA000990$SUNOVION$$$$$$Y$$$20250704$$CN$US$US
249125965$24912596$5$F$20250102$20250804$20250131$20250807$EXP$$JP-shionogi-202500001147$SHIONOGI$$23$YR$A$F$Y$30.8$KG$20250807$$MD$JP$JP
249126422$24912642$2$F$$20250703$20250131$20250715$EXP$$US-MEITHEAL-2025MPLIT00033$MEITHEAL PHARMACEUTICALS$Ailawadi S, et al. .A Fatal Case of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Post-Autologous Stem Cell Transplant.American Journal of Gastroenterology.oct-2024;119 (10):S2826$62$YR$A$M$Y$$$20250715$$MD$US$US
249126942$24912694$2$F$$20250123$20250131$20250816$PER$$US-ASTRAZENECA-202501020967US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$MD$US$US
249130672$24913067$2$F$$20250127$20250201$20250809$EXP$$US-ASTRAZENECA-202501022740US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
249145522$24914552$2$F$$20250909$20250203$20250921$PER$$US-SA-2025SA030277$SANOFI AVENTIS$$21$YR$A$M$Y$102$KG$20250921$$MD$US$US
249152252$24915225$2$F$$20250709$20250203$20250722$EXP$$US-AUROBINDO-AUR-APL-2025-004330$AUROBINDO$Alleyasin T, Wilder E, Nhu Q. A Case of Autoimmune Enteropathy Treated With Vedolizumab. J-Gastroenterol. 2024;119 (Suppl. 10):S2989$34$YR$$M$Y$$$20250722$$MD$US$US
249153523$24915352$3$F$$20250224$20250203$20250803$EXP$$US-ASTRAZENECA-202501028046US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
249167882$24916788$2$F$20241217$20250127$20250203$20250809$EXP$$EU-ASTRAZENECA-202501EEA025299IE$ALEXION PHARMACEUTICALS$$71$YR$E$F$Y$$$20250809$$$EU$EU
249174977$24917497$7$F$20231225$20250904$20250203$20250908$EXP$$US-PAREXEL-2021-KAM-US003532$TAKEDA$$73$YR$$M$Y$109$KG$20250908$$$US$US
249185522$24918552$2$F$$20250130$20250203$20250810$PER$$US-ASTRAZENECA-202501026690US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
249185822$24918582$2$F$$20250128$20250203$20250816$PER$$US-ASTRAZENECA-202501025321US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$MD$US$US
249189577$24918957$7$F$20221005$20250701$20250204$20250707$EXP$$US-UCBSA-2024047556$UCB$$11$YR$$F$Y$58.4$KG$20250707$$CN$US$US
249191623$24919162$3$F$$20250616$20250204$20250810$PER$$US-ASTRAZENECA-202501026482US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
249223714$24922371$4$F$$20241218$20250204$20250810$30DAY$$US-ASTRAZENECA-202411USA002587US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249233542$24923354$2$F$$20250130$20250204$20250809$EXP$$US-ASTRAZENECA-202501027611US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
249237912$24923791$2$F$$20250201$20250204$20250803$EXP$$US-ASTRAZENECA-202502USA000876US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
249266194$24926619$4$F$$20250902$20250205$20250911$EXP$$CA-CELLTRION INC.-2025CA003501$CELLTRION$$$$$$Y$$$20250911$$HP$CA$CA
249275452$24927545$2$F$$20250131$20250205$20250810$PER$$US-ASTRAZENECA-202501028050US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249282742$24928274$2$F$$20250129$20250205$20250816$PER$$US-ASTRAZENECA-202501USA025428US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$MD$US$US
249290702$24929070$2$F$$20241014$20250205$20250803$EXP$$VN-ASTRAZENECA-202410ASI009836VN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$VN$VN
249300353$24930035$3$F$$20250818$20250205$20250825$EXP$$CA-SANDOZ INC.-SDZ2025CA006940$SANDOZ$$61$YR$$F$Y$70$KG$20250825$$HP$CA$CA
249306022$24930602$2$F$$20250304$20250205$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007745$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
249314202$24931420$2$F$20241201$20250703$20250205$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007560$AURINIA PHARMACEUTICALS$$41$YR$$M$Y$$$20250804$$CN$US$US
249331272$24933127$2$F$$20250205$20250206$20250810$PER$$US-ASTRAZENECA-202502002526US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$MD$US$US
249337373$24933737$3$F$$20250717$20250206$20250723$EXP$$EU-EXELIXIS-CABO-24073861$EXELIXIS$$57$YR$$M$Y$$$20250723$$MD$EU$EU
249339242$24933924$2$F$$20250728$20250206$20250731$EXP$$NVSC2025GB019718$NOVARTIS$$$$$F$Y$$$20250731$$CN$GB$GB
249353802$24935380$2$F$$20250130$20250206$20250809$EXP$$ZA-ASTRAZENECA-202501026204ZA$ALEXION PHARMACEUTICALS$$89$YR$E$M$Y$$$20250809$$$ZA$ZA
249354983$24935498$3$F$20240101$20250821$20250206$20250825$EXP$$US-ABBVIE-6119125$ABBVIE$$44$YR$$M$Y$$$20250825$$CN$US$US
249385343$24938534$3$F$$20250803$20250206$20250812$PER$$US-SA-2025SA035507$SANOFI AVENTIS$$44$YR$A$F$Y$154.2$KG$20250813$$MD$US$US
249386312$24938631$2$F$$20250811$20250206$20250819$PER$$US-SA-2025SA036080$SANOFI AVENTIS$$42$YR$A$M$Y$$$20250819$$MD$US$US
249394302$24939430$2$F$$20250205$20250206$20250809$EXP$$US-ASTRAZENECA-202502002485US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
249395682$24939568$2$F$$20250205$20250206$20250809$EXP$$US-ASTRAZENECA-202502002207US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
249396258$24939625$8$F$20210101$20250722$20250207$20250725$EXP$$US-GILEAD-2025-0701883$GILEAD$$45$YR$A$M$Y$$$20250725$$LW$US$US
249419433$24941943$3$F$20250127$20250707$20250207$20250716$EXP$$US-SAREPTA THERAPEUTICS INC.-SRP2025-005578$SAREPTA THERAPEUTICS$$16$YR$$M$Y$71.5$KG$20250716$$MD$US$US
249422445$24942244$5$F$20240801$20250821$20250207$20250827$PER$$JP-Eisai-EC-2025-183445$EISAI$$71$YR$E$F$Y$80$KG$20250827$$MD$JP$JP
249426112$24942611$2$F$20250101$20250820$20250207$20250828$PER$$US-SA-2025SA036895$SANOFI AVENTIS$$16$YR$T$M$Y$$$20250828$$HP$US$US
249435464$24943546$4$F$$20250301$20250207$20250810$PER$$US-ASTRAZENECA-202410USA002652US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$US$US
249443724$24944372$4$F$20231001$20250913$20250208$20250923$EXP$$CA-CELLTRION INC.-2024CA006591$CELLTRION$$$$$$Y$$$20250923$$CN$CA$CA
249447583$24944758$3$F$20250202$20250703$20250208$20250710$EXP$$CA-CELLTRION INC.-2025CA003608$CELLTRION$$$$$$Y$$$20250711$$CN$CA$CA
249448323$24944832$3$F$$20250210$20250208$20250802$EXP$$CA-ASTRAZENECA-202502003723CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$CA$CA
2494483310$24944833$10$F$20250101$20250913$20250208$20250922$EXP$$CA-CELLTRION INC.-2025CA004006$CELLTRION$$$$$$Y$$$20250922$$HP$CA$CA
249451142$24945114$2$F$$20250206$20250208$20250802$EXP$$US-ASTRAZENECA-202502003760US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
249451713$24945171$3$F$20250101$20250718$20250208$20250724$PER$$US-SA-2025SA038094$SANOFI AVENTIS$$46$YR$A$M$Y$$$20250724$$MD$US$US
249453242$24945324$2$F$$20250131$20250209$20250803$EXP$$CA-ASTRAZENECA-202501CAN028816CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$CA$CA
249473242$24947324$2$F$$20250207$20250210$20250803$EXP$$HN-ASTRAZENECA-202502004983HN$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$HN$HN
249479352$24947935$2$F$$20250701$20250210$20250709$EXP$$CA-CELLTRION INC.-2025CA003422$CELLTRION$$$$$$Y$$$20250709$$MD$CA$CA
249518104$24951810$4$F$$20250819$20250210$20250901$EXP$$CA-GLENMARK PHARMACEUTICALS-2025GMK097754$GLENMARK$$$$$F$Y$$$20250901$$HP$CA$CA
249520794$24952079$4$F$20250117$20250728$20250210$20250801$EXP$$JP-Eisai-EC-2025-183787$EISAI$$85$YR$E$F$Y$54.2$KG$20250801$$MD$JP$JP
249522694$24952269$4$F$20241108$20250827$20250210$20250904$EXP$$US-ELI_LILLY_AND_COMPANY-US202411007739$ELI LILLY AND COMPANY$$85$YR$E$M$Y$65.306$KG$20250904$$CN$US$US
249528582$24952858$2$F$20241001$20250829$20250211$20250907$PER$$US-SA-2025SA039993$SANOFI AVENTIS$$21$YR$A$F$Y$$$20250908$$HP$US$US
249538372$24953837$2$F$$20250828$20250211$20250905$PER$$US-SA-2025SA040556$SANOFI AVENTIS$$79$YR$E$F$Y$$$20250905$$CN$US$US
249539103$24953910$3$F$20241227$20250305$20250211$20250803$EXP$$US-ASTRAZENECA-202502001286US$ALEXION PHARMACEUTICALS$$30$YR$A$F$Y$$$20250803$$$US$US
249540602$24954060$2$F$$20250206$20250211$20250803$EXP$$US-ASTRAZENECA-202502004901US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
249552322$24955232$2$F$20250110$20250204$20250211$20250802$EXP$$EU-ASTRAZENECA-202502GLO006978ES$ALEXION PHARMACEUTICALS$$78$YR$E$M$Y$$$20250802$$MD$EU$EU
249553292$24955329$2$F$$20250207$20250211$20250809$EXP$$US-ASTRAZENECA-202502004565US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250809$$$US$US
249563974$24956397$4$F$$20250825$20250211$20250901$EXP$$CA-GSK-CA2025AMR016797$GLAXOSMITHKLINE$$43$YR$$F$Y$68$KG$20250901$$$CA$CA
249572023$24957202$3$F$$20250210$20250211$20250809$EXP$$CL-ASTRAZENECA-202502006405CL$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CL$CL
249574172$24957417$2$F$$20250210$20250211$20250803$EXP$$US-ASTRAZENECA-202502006011US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
249575052$24957505$2$F$$20250205$20250212$20250810$PER$$US-ASTRAZENECA-202502002502US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249583395$24958339$5$F$$20250828$20250212$20250829$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-020999$BRISTOL-MYERS SQUIBB COMPANY$$50$YR$A$F$Y$$$20250829$$HP$US$US
249592252$24959225$2$F$$20250805$20250212$20250814$EXP$GB-MHRA-MED-202502030946032360-FRJVC$GB-862174955-ML2025-00627$Unknown Manufacturer$$60$YR$A$$Y$$$20250814$$CN$GB$GB
249596215$24959621$5$F$20241228$20250821$20250212$20250826$EXP$$EU-PFIZER INC-PV202500015776$PFIZER$$71$YR$$F$Y$$$20250826$$MD$EU$EU
249613812$24961381$2$F$20250201$20250211$20250212$20250809$EXP$$US-ASTRAZENECA-202502007570US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$US$US
249615952$24961595$2$F$$20250211$20250212$20250809$EXP$$TW-ASTRAZENECA-202502006927TW$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$TW$TW
249623583$24962358$3$F$$20250711$20250212$20250716$EXP$$US-ELI_LILLY_AND_COMPANY-US202502008177$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250716$$CN$US$US
249629882$24962988$2$F$$20250701$20250213$20250709$PER$$US-SA-2025SA041456$SANOFI AVENTIS$$82$YR$E$M$Y$$$20250710$$HP$US$US
249631622$24963162$2$F$$20250918$20250213$20250926$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-019262$BRISTOL-MYERS SQUIBB COMPANY$$8$DEC$E$M$Y$$$20250926$$PH$JP$JP
249635152$24963515$2$F$$20250211$20250213$20250803$EXP$$US-ASTRAZENECA-202502007402US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
249646589$24964658$9$F$20250101$20250715$20250213$20250723$PER$$US-UNITED THERAPEUTICS-UNT-2025-004644$UNITED THERAPEUTICS$$$$$F$Y$64.853$KG$20250723$$$US$US
249650943$24965094$3$F$$20250826$20250213$20250827$PER$$US-PFIZER INC-202500032526$PFIZER$$25$YR$$F$Y$$$20250827$$CN$US$US
249656014$24965601$4$F$$20250707$20250213$20250715$EXP$$TR-AMGEN-TURSP2025002616$AMGEN$$$$$M$Y$$$20250715$$CN$TR$TR
249667955$24966795$5$F$20241122$20250922$20250213$20250923$EXP$EU-AFSSAPS-NC2024001721$EU-LUNDBECK-DKLU4010731$LUNDBECK$$59$YR$A$F$Y$80$KG$20250923$$MD$EU$EU
249672063$24967206$3$F$20240101$20250527$20250213$20250810$PER$$US-ASTRAZENECA-202501USA011486US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250810$$$US$US
249681402$24968140$2$F$20211123$20250901$20250214$20250909$EXP$EU-AFSSAPS-PA2025000098$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-119081$ZYDUS PHARM$$$$$$Y$$$20250909$$PH$EU$EU
249683713$24968371$3$F$20250212$20250224$20250214$20250810$PER$$US-ASTRAZENECA-202502008417US$ALEXION PHARMACEUTICALS$$10$YR$C$F$Y$$$20250810$$$US$US
249687192$24968719$2$F$$20250213$20250214$20250809$EXP$$US-ASTRAZENECA-202502010196US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
249704963$24970496$3$F$$20250202$20250214$20250810$PER$$US-ASTRAZENECA-202501025770US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249705742$24970574$2$F$$20130403$20250214$20250810$PER$$US-AstraZeneca-2013SE22140$ALEXION PHARMACEUTICALS$$64$YR$A$M$Y$$$20250810$$$US$
249709942$24970994$2$F$$20250213$20250214$20250809$EXP$$US-ASTRAZENECA-202502010082US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
249716533$24971653$3$F$20221206$20250303$20250214$20250810$EXP$$JP-ASTRAZENECA-202502GLO006790JP$ALEXION PHARMACEUTICALS$$87$YR$E$F$Y$$$20250810$$MD$JP$JP
249717362$24971736$2$F$$20250210$20250214$20250810$PER$$US-ASTRAZENECA-202502USA007411US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
249718862$24971886$2$F$20090925$20091207$20250214$20250816$PER$$CA-AstraZeneca-2009SE29178$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$MD$CA$
249719033$24971903$3$F$$20250728$20250214$20250803$EXP$$US-SA-2025SA042866$SANOFI AVENTIS$$19$YR$A$F$Y$$$20250803$$MD$US$US
249719202$24971920$2$F$20120101$20130813$20250214$20250810$PER$$US-AstraZeneca-2013SE63169$ALEXION PHARMACEUTICALS$$93$YR$E$F$Y$49.895$KG$20250810$$$US$
249721982$24972198$2$F$$20110804$20250214$20250810$PER$$US-AstraZeneca-2011SE46796$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$54.9$KG$20250810$$$US$
249723539$24972353$9$F$20250101$20250806$20250215$20250813$PER$$US-UNITED THERAPEUTICS-UNT-2025-004010$UNITED THERAPEUTICS$$86$YR$$M$Y$83.9$KG$20250813$$$US$US
249723822$24972382$2$F$20210208$20240115$20250215$20250810$PER$$KR-AstraZeneca-2024A014675$ALEXION PHARMACEUTICALS$$61$YR$A$F$Y$$$20250810$$PH$KR$KR
249724532$24972453$2$F$20140101$20150408$20250215$20250816$EXP$$US-AstraZeneca-2015SE34198$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$72.575$KG$20250816$$$US$
249724572$24972457$2$F$$20180226$20250215$20250810$PER$$US-AstraZeneca-2018SE25730$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249724662$24972466$2$F$$20191022$20250215$20250816$EXP$$US-AstraZeneca-2019SF51664$ALEXION PHARMACEUTICALS$$89$YR$E$F$Y$$$20250816$$$US$US
249761412$24976141$2$F$$20250210$20250217$20250803$EXP$$US-ASTRAZENECA-202502006473US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
249761982$24976198$2$F$20150401$20150717$20250217$20250810$PER$$US-AstraZeneca-2015SE71760$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$62.142$KG$20250810$$$US$
249788127$24978812$7$F$$20250916$20250218$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-024113$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$M$Y$$$20250916$$$US$US
249790002$24979000$2$F$20161001$20181219$20250218$20250810$PER$$US-AstraZeneca-2016SE93458$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$77.111$KG$20250810$$$US$US
249791444$24979144$4$F$20250101$20250709$20250218$20250714$EXP$$US-ABBVIE-6135950$ABBVIE$$40$YR$$M$Y$90.718$KG$20250714$$CN$US$US
249795477$24979547$7$F$20241201$20250922$20250218$20250929$EXP$$CA-SAMSUNG BIOEPIS-SB-2025-05523$SAMSUNG BIOEPIS$$71$YR$E$M$Y$$$20250929$$CN$CA$CA
249798592$24979859$2$F$20221128$20221201$20250218$20250810$PER$$GB-AstraZeneca-2022A394901$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$GB$GB
249812144$24981214$4$F$20240220$20250313$20250218$20250803$EXP$$EU-ALXN-202402EEA002150DK$ALEXION PHARMACEUTICALS$$7$YR$C$F$Y$21$KG$20250803$$MD$EU$EU
249812152$24981215$2$F$20250101$20250217$20250218$20250810$EXP$$US-ASTRAZENECA-202502013057US$ALEXION PHARMACEUTICALS$$73$YR$$M$Y$$$20250810$$PH$US$US
249828483$24982848$3$F$20250117$20250117$20250218$20250802$PER$$EU-ASTRAZENECA-202501EEA013778RO$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$109$KG$20250802$$MD$EU$EU
249830034$24983003$4$F$$20250416$20250218$20250809$EXP$$CA-ASTRAZENECA-202502010025CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$CA$CA
249830112$24983011$2$F$$20250212$20250218$20250810$EXP$$CA-ASTRAZENECA-202501CAN007483CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$CA$CA
249836574$24983657$4$F$20230424$20250911$20250219$20250919$PER$$US-BIOGEN-2023BI01227172$BIOGEN$$59$YR$$F$Y$$$20250919$$CN$US$US
249841023$24984102$3$F$20250117$20250826$20250219$20250829$EXP$$BR-JNJFOC-20250162656$JOHNSON AND JOHNSON$$68$YR$E$F$Y$72$KG$20250829$$CN$BR$BR
249846012$24984601$2$F$20241204$20250811$20250219$20250820$PER$$US-SMPA-2025SPA000972$SUNOVION$$42$YR$$F$Y$$$20250814$$$US$US
2498471417$24984714$17$F$20250101$20250826$20250219$20250910$EXP$$CA-ASTELLAS-2025-AER-009994$ASTELLAS$$71$YR$E$F$Y$$$20250911$$HP$CA$CA
249848582$24984858$2$F$$20250212$20250219$20250809$EXP$$US-ASTRAZENECA-202502008898US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$PH$US$US
249849485$24984948$5$F$20250123$20250808$20250219$20250813$EXP$$GB-AMGEN-GBRNI2025031241$AMGEN$$78$YR$E$F$Y$$$20250813$$MD$GB$GB
249864452$24986445$2$F$$20250212$20250219$20250803$EXP$$US-ASTRAZENECA-202502008950US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
249869495$24986949$5$F$$20250708$20250219$20250709$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-024754$BRISTOL-MYERS SQUIBB COMPANY$$79$YR$E$F$Y$$$20250709$$CN$US$US
249877452$24987745$2$F$$20250213$20250219$20250816$PER$$US-ASTRAZENECA-202502010408US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$US$US
249880712$24988071$2$F$20190101$20250905$20250220$20250916$EXP$$US-NOVOPROD-1368688$NOVO NORDISK$$68$YR$$M$Y$127$KG$20250916$$CN$US$US
249882914$24988291$4$F$20250104$20250310$20250220$20250802$EXP$$US-ASTRAZENECA-202502012870US$ALEXION PHARMACEUTICALS$$73$YR$E$M$Y$81.633$KG$20250802$$$US$US
249899762$24989976$2$F$$20020625$20250220$20250816$PER$$US-AstraZeneca-2002UW08911$ALEXION PHARMACEUTICALS$$42$YR$A$M$Y$$$20250816$$MD$US$
249903892$24990389$2$F$$20250218$20250220$20250802$EXP$$US-ASTRAZENECA-202502014156US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
249907962$24990796$2$F$$20250217$20250220$20250810$EXP$$US-ASTRAZENECA-202502USA015084US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
249911623$24991162$3$F$20240101$20250814$20250220$20250818$PER$$US-PFIZER INC-PV202500019482$PFIZER$$74$YR$$M$Y$$$20250818$$HP$US$US
249913012$24991301$2$F$20201001$20250212$20250220$20250803$EXP$$EU-ASTRAZENECA-202502GLO016046DE$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250803$$MD$EU$EU
249913072$24991307$2$F$$20250825$20250220$20250901$PER$$US-BIOGEN-2025BI01301302$BIOGEN$$$$$F$Y$$$20250901$$CN$US$US
249924703$24992470$3$F$$20250215$20250220$20250809$EXP$$JP-ASTRAZENECA-202502GLO015968JP$ALEXION PHARMACEUTICALS$$10$DEC$E$M$Y$41$KG$20250809$$MD$JP$JP
249926512$24992651$2$F$20241119$20250718$20250221$20250728$EXP$$JP-AMGEN-JPNSP2024257488$AMGEN$$84$YR$E$F$Y$55$KG$20250728$$MD$JP$JP
249926922$24992692$2$F$$20250216$20250221$20250816$PER$$US-ASTRAZENECA-202502014801US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
249927752$24992775$2$F$20241225$20250214$20250221$20250802$EXP$$BR-ASTRAZENECA-202502011646BR$ALEXION PHARMACEUTICALS$$80$YR$E$F$Y$36$KG$20250802$$$BR$BR
249932772$24993277$2$F$$20250903$20250221$20250911$EXP$$US-SMPA-2024MYSCI0300437$SUNOVION$$70$YR$$M$Y$$$20250908$$$US$US
249941622$24994162$2$F$$20250219$20250221$20250816$PER$$US-ASTRAZENECA-202502016957US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$MD$US$US
249943942$24994394$2$F$$20250218$20250221$20250809$EXP$$ID-ASTRAZENECA-202502014618ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$ID$ID
249952955$24995295$5$F$20231215$20250718$20250221$20250728$EXP$$JP-Merz Pharmaceuticals GmbH-2025020000029$MERZ$$$$$$Y$$$20250728$$HP$JP$JP
249974642$24997464$2$F$$20250217$20250222$20250810$PER$$US-ASTRAZENECA-202502USA016840US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
249978542$24997854$2$F$$20250826$20250222$20250902$PER$$US-SA-2025SA043320$SANOFI AVENTIS$$57$YR$A$F$Y$60$KG$20250902$$HP$US$US
249986414$24998641$4$F$$20250805$20250222$20250811$PER$$US-SA-2025SA043244$SANOFI AVENTIS$$10$YR$C$F$Y$$$20250811$$HP$US$US
250000272$25000027$2$F$20250201$20250626$20250222$20250704$PER$$US-SA-2025SA050164$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250704$$HP$US$US
250003583$25000358$3$F$20250101$20250721$20250222$20250724$PER$$US-SA-2025SA051687$SANOFI AVENTIS$$25$YR$A$F$Y$79.55$KG$20250724$$HP$US$US
250004073$25000407$3$F$20250218$20250818$20250222$20250820$PER$$US-SA-2025SA051271$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250820$$MD$US$US
250008642$25000864$2$F$20250101$20250808$20250222$20250813$PER$$US-SA-2025SA050390$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250813$$HP$US$US
250040892$25004089$2$F$20240718$20250710$20250224$20250721$EXP$$US-RECORDATI RARE DISEASE INC.-2024005764$RECORDATI$$40$YR$$F$Y$108.84$KG$20250721$$CN$US$US
250063292$25006329$2$F$$20250218$20250224$20250803$EXP$$US-ASTRAZENECA-202502014624US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250072199$25007219$9$F$20250210$20250916$20250225$20250925$EXP$$US-ORPHANEU-2025001174$RECORDATI$$73$YR$$F$Y$44.898$KG$20250925$$CN$US$US
250072672$25007267$2$F$$20250626$20250225$20250709$EXP$$CA-APOTEX-2025AP002255$APOTEX$$76$YR$$M$Y$$$20250709$$MD$CA$CA
250077004$25007700$4$F$20250101$20250715$20250225$20250723$EXP$$JP-BAUSCH-BL-2025-001351$BAUSCH AND LOMB$$77$YR$E$F$Y$36.4$KG$20250723$$PH$JP$JP
250087723$25008772$3$F$$20250806$20250225$20250807$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-027311$BRISTOL-MYERS SQUIBB COMPANY$$59$YR$A$F$Y$$$20250807$$HP$US$US
250098772$25009877$2$F$$20250218$20250225$20250803$EXP$$CN-ASTRAZENECA-202502GLO016623CN$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250803$$MD$CN$CN
250099932$25009993$2$F$$20241213$20250225$20250803$EXP$$US-ASTRAZENECA-202412USA015545US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250099992$25009999$2$F$$20250217$20250225$20250809$EXP$$ZA-ASTRAZENECA-202502SSA012304ZA$ALEXION PHARMACEUTICALS$$82$YR$E$F$Y$$$20250809$$$ZA$ZA
250111184$25011118$4$F$20250201$20250827$20250226$20250903$EXP$$AR-EMD Serono-2025008815$EMD SERONO INC$$12$YR$T$F$Y$$$20250903$$$AR$AR
250122712$25012271$2$F$$20250219$20250226$20250803$EXP$$US-ASTRAZENECA-202502015353US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250133803$25013380$3$F$$20250718$20250226$20250815$PER$$US-GSK-US2025021259$GLAXOSMITHKLINE$$$$$M$Y$$$20250815$$$US$US
250148302$25014830$2$F$20250101$20250701$20250226$20250706$EXP$$US-SA-2025SA057986$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250706$$HP$US$US
250148763$25014876$3$F$20230420$20250704$20250226$20250715$EXP$$JP-MSD-M2023-17851$MERCK SHARP + DOHME LLC$$65$YR$$F$Y$$$20250715$$MD$JP$JP
250151303$25015130$3$F$$20250831$20250226$20250910$PER$$US-SMPA-2024MYSCI0501024$SUNOVION$$94$YR$$M$Y$$$20250909$$MD$US$US
250170713$25017071$3$F$20241113$20250924$20250227$20250930$EXP$$JP-MSD-M2024-52043$MERCK SHARP + DOHME LLC$$68$YR$$F$Y$49$KG$20250930$$MD$JP$JP
250177152$25017715$2$F$20250207$20250714$20250227$20250723$PER$EU-AEMPS-1632709$EU-IDORSIA-009350-2025-ES$IDORSIA PHARMACEUTICALS$$22$YR$$M$Y$$$20250723$$MD$EU$EU
250179322$25017932$2$F$$20250220$20250227$20250802$EXP$$VN-ASTRAZENECA-202502017984VN$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$VN$VN
250193682$25019368$2$F$20230301$20250707$20250227$20250717$EXP$$US-ELI_LILLY_AND_COMPANY-US202502016536$ELI LILLY AND COMPANY$$57$YR$A$F$Y$68$KG$20250717$$LW$US$US
250194802$25019480$2$F$$20250220$20250227$20250802$EXP$$ZA-ASTRAZENECA-202502016445ZA$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$$$20250802$$$ZA$ZA
250196062$25019606$2$F$20250201$20250811$20250227$20250815$EXP$$US-BIOMARINAP-US-2025-164048$BIOMARIN$$39$YR$$F$Y$100$KG$20250815$$$US$US
250200103$25020010$3$F$20250205$20250804$20250227$20250812$EXP$$CO-SANDOZ INC.-SDZ2025CO012383$SANDOZ$$89$YR$$F$Y$52$KG$20250812$$CN$CO$CO
250208663$25020866$3$F$$20250903$20250227$20250909$EXP$$CA-JNJFOC-20250254589$JOHNSON AND JOHNSON$$13$YR$T$F$Y$$$20250909$$CN$CA$CA
250209083$25020908$3$F$$20250218$20250227$20250717$EXP$$JP-NOVEN PHARMACEUTICALS, INC.-2025-NOV-JP000508$NOVEN$$6$DEC$$F$Y$$$20250717$$HP$JP$JP
250217524$25021752$4$F$$20250718$20250228$20250728$EXP$$GB-TAKEDA-2025TUS018357$TAKEDA$$$$$F$Y$$$20250728$$$GB$GB
250219214$25021921$4$F$20250101$20250915$20250228$20250921$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-030270$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$$$20250921$$$US$US
250221132$25022113$2$F$20250207$20250220$20250228$20250810$EXP$$CN-ASTRAZENECA-202502CHN018746CN$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$68$KG$20250810$$$CN$CN
250221252$25022125$2$F$$20250225$20250228$20250809$EXP$$US-ASTRAZENECA-202502USA021146US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
250232052$25023205$2$F$$20250221$20250228$20250803$EXP$$US-ASTRAZENECA-202502019598US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250239975$25023997$5$F$20190101$20250812$20250228$20250821$EXP$$EU-PFM-2025-00897$PIERRE FABRE MEDICAMENT$$9$YR$$M$Y$29.5$KG$20250821$$$EU$EU
250243522$25024352$2$F$20250122$20250220$20250228$20250802$EXP$EU-AFSSAPS-LY2025000229$EU-ASTRAZENECA-202502GLO016265FR$ALEXION PHARMACEUTICALS$$16$YR$T$F$Y$37$KG$20250802$$MD$EU$EU
250248613$25024861$3$F$$20250801$20250228$20250804$30DAY$$US-JNJFOC-20250230674$JOHNSON AND JOHNSON$$$$$$Y$$$20250805$$CN$US$US
250255432$25025543$2$F$$20250723$20250228$20250801$EXP$$CA-UCBSA-2025010637$UCB$$43$YR$$F$Y$70$KG$20250801$$HP$CA$CA
250266383$25026638$3$F$20241101$20250729$20250301$20250804$EXP$$US-ABBVIE-6152635$ABBVIE$$63$YR$$F$Y$$$20250804$$CN$US$US
250284347$25028434$7$F$$20250812$20250302$20250816$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-004980$JAZZ$$$$$F$Y$$$20250816$$MD$US$US
250290342$25029034$2$F$$20250227$20250303$20250816$PER$$US-ASTRAZENECA-202502USA025857US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
250295922$25029592$2$F$20240101$20250624$20250303$20250701$PER$$US-SA-2025SA058358$SANOFI AVENTIS$$34$YR$A$M$Y$70$KG$20250702$$HP$US$US
250298796$25029879$6$F$20200101$20241202$20250303$20250802$EXP$$JP-AstraZeneca-2024A197340$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$60$KG$20250802$$MD$JP$JP
250300242$25030024$2$F$$20250227$20250303$20250803$EXP$$RU-ASTRAZENECA-200502RUS000001RU$ALEXION PHARMACEUTICALS$$$$T$M$Y$$$20250803$$MD$RU$RU
250305782$25030578$2$F$20241201$20250225$20250303$20250803$EXP$$JP-ASTRAZENECA-202412GLO011781JP$ALEXION PHARMACEUTICALS$$8$DEC$E$M$Y$$$20250803$$MD$JP$JP
250321144$25032114$4$F$$20250728$20250303$20250801$EXP$$US-SMPA-2025SPA002414$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
250325273$25032527$3$F$20240101$20250103$20250303$20250827$PER$$US-UCBSA-2024057678$UCB$$$$$F$Y$$$20250827$$HP$US$US
250326123$25032612$3$F$$20250630$20250303$20250703$PER$$US-PFIZER INC-202500045814$PFIZER$$10$YR$$M$Y$30.3$KG$20250703$$CN$US$US
250326622$25032662$2$F$$20250224$20250303$20250809$EXP$$JP-ASTRAZENECA-202502GLO026253JP$ALEXION PHARMACEUTICALS$$57$YR$A$M$Y$$$20250809$$MD$JP$JP
250330947$25033094$7$F$20250201$20250730$20250303$20250801$EXP$$CA-PFIZER INC-202500044376$PFIZER$$9$YR$$F$Y$$$20250801$$MD$CA$CA
250332502$25033250$2$F$20250124$20250219$20250303$20250917$EXP$$CN-009507513-2257033$MERCK SHARP + DOHME LLC$$39$YR$$F$Y$52$KG$20250917$$HP$CN$CN
250338492$25033849$2$F$$20250228$20250303$20250810$PER$$US-ASTRAZENECA-202502USA025507US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
250347413$25034741$3$F$$20250226$20250304$20250825$PER$$US-CHATTEMPRD-2025OHG005480$CHATTEM$$$$$M$Y$$$20250825$$CN$US$US
250356612$25035661$2$F$20250301$20250303$20250304$20250810$PER$$US-ASTRAZENECA-202503USA000328US$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$$$20250810$$$US$US
250365125$25036512$5$F$20220706$20250901$20250304$20250905$EXP$$EU-MYLANLABS-2025M1017340$MYLAN$$75$YR$$M$Y$80$KG$20250905$$$EU$EU
250385772$25038577$2$F$20250210$20250228$20250304$20250802$EXP$$CN-ASTRAZENECA-202502CHN025954CN$ALEXION PHARMACEUTICALS$$57$YR$A$F$Y$40$KG$20250802$$$CN$CN
250409463$25040946$3$F$$20250805$20250305$20250806$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-032127$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$F$Y$$$20250806$$CN$US$US
250418332$25041833$2$F$$20250226$20250305$20250810$EXP$$JP-ASTRAZENECA-202502GLO026526JP$ALEXION PHARMACEUTICALS$Ito M, et al.. 27 A case of anti-AQP4 antibody-positive neuromyelitis optica which occurred during the treatment with an anti-PD-L1 antibody, durvalumab.. The 171st Tokai Hokuriku Regional Meeting of Japanese Society of Neurology.. 2025;Not Reported:30-$76$YR$E$F$Y$$$20250810$$MD$JP$JP
250432944$25043294$4$F$$20250912$20250305$20250915$PER$$US-TAKEDA-2025TUS023292$TAKEDA$$$$$F$Y$$$20250915$$$US$US
250441312$25044131$2$F$$20250922$20250306$20250930$EXP$$EU-IPCA LABORATORIES LIMITED-IPC-2025-HR-000492$IPCA$Jasmin Hamzic, Katja Kudrna-prasek and Ivan Gornik. Metformin poisoning and metformin associated lactacidosis. Acta Med Croatica. 2020;74 (1):123-6$$$$$Y$$$20250930$$HP$EU$EU
250443313$25044331$3$F$20250120$20250805$20250306$20250812$EXP$EU-INFARMED-F202502-740$EU-VIIV HEALTHCARE-PT2025025564$VIIV$$62$YR$$M$Y$58$KG$20250812$$PH$EU$EU
250443562$25044356$2$F$$20250303$20250306$20250803$EXP$$US-ASTRAZENECA-202503USA000513US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
250452553$25045255$3$F$$20250321$20250306$20250803$EXP$$CA-ASTRAZENECA-202502016874CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$CA$CA
250454742$25045474$2$F$20250227$20250227$20250306$20250810$EXP$$EU-ASTRAZENECA-202502EEA023375AT$ALEXION PHARMACEUTICALS$$80$YR$E$F$Y$120$KG$20250810$$$EU$EU
250459322$25045932$2$F$20240403$20250703$20250306$20250711$EXP$$CA-Amarin Pharma, Inc-2024AMR000344$AMARIN$$60$YR$A$F$Y$$$20250711$$CN$CA$CA
250463166$25046316$6$F$$20250922$20250306$20250929$EXP$$JP-ALNYLAM PHARMACEUTICALS, INC.-ALN-2023-004923$ALNYLAM PHARMACEUTICALS$$90$YR$$$Y$34.8$KG$20250926$$MD$COUNTRY NOT SPECIFIED$JP
250464805$25046480$5$F$20250210$20250528$20250306$20250810$EXP$$JP-ASTRAZENECA-202502008243JP$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250810$$MD$JP$JP
250464883$25046488$3$F$20240101$20250624$20250306$20250702$EXP$$JP-MSD-M2024-17457$MERCK SHARP + DOHME LLC$$64$YR$$F$Y$$$20250702$$MD$JP$JP
250474362$25047436$2$F$20250201$20250829$20250306$20250904$EXP$EU-AFSSAPS-PA2025000224$EU-PFIZER INC-202500048516$PFIZER$$39$YR$$M$Y$87$KG$20250904$$MD$EU$EU
250480423$25048042$3$F$$20250304$20250306$20250809$EXP$$US-ASTRAZENECA-202503USA001436US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
250480786$25048078$6$F$20250201$20250626$20250306$20250701$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-002005$ACADIA PHARMACEUTICALS$$8$YR$$F$Y$$$20250701$$CN$US$US
250483923$25048392$3$F$$20250304$20250307$20250803$EXP$$US-ASTRAZENECA-202503USA001202US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$MD$US$US
250486992$25048699$2$F$20220207$20250710$20250307$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202502020019$ELI LILLY AND COMPANY$$27$YR$A$F$Y$272$KG$20250716$$LW$US$US
250490213$25049021$3$F$20240201$20250716$20250307$20250717$EXP$$US-ARGENX-2025-ARGX-US002296$ARGENX BVBA$$$$$$Y$$$20250717$$CN$US$US
250491613$25049161$3$F$20250101$20250819$20250307$20250826$EXP$$JP-GALDERMA-JP2025000883$GALDERMA$$$$$$Y$$$20250826$$MD$JP$JP
250502832$25050283$2$F$$20250609$20250307$20250704$EXP$$CA-ATNAHS-ATNAHS20241100749$Atnahs Healthcare$$64$YR$$F$Y$$$20250704$$HP$CA$CA
250505032$25050503$2$F$20250208$20250305$20250307$20250803$EXP$$US-ASTRAZENECA-202503USA002295US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250505875$25050587$5$F$20250201$20250831$20250307$20250904$EXP$$CA-CELLTRION INC.-2025CA006820$CELLTRION$$$$$$Y$$$20250904$$CN$CA$CA
250514612$25051461$2$F$$20250304$20250307$20250810$EXP$$ZA-ASTRAZENECA-202503SSA002118ZA$ALEXION PHARMACEUTICALS$$90$YR$E$M$Y$$$20250810$$$ZA$ZA
250516076$25051607$6$F$$20250716$20250307$20250718$30DAY$$US-PFIZER INC-202500049134$PFIZER$$15$YR$$M$Y$$$20250718$$HP$US$US
250529255$25052925$5$F$$20250919$20250307$20250927$PER$$US-SA-2024SA202645$SANOFI AVENTIS$$92$YR$E$F$Y$$$20250926$$MD$US$US
250529693$25052969$3$F$$20250818$20250307$20250826$PER$$US-SA-2025SA000262$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250826$$CN$US$US
250542892$25054289$2$F$$20250731$20250307$20250806$PER$$US-SA-2025SA065941$SANOFI AVENTIS$$2$YR$C$M$Y$$$20250806$$HP$US$US
250548432$25054843$2$F$$20250303$20250308$20250803$EXP$$EU-ASTRAZENECA-202503EEA001105FR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
250563863$25056386$3$F$$20250304$20250310$20250802$EXP$$EU-ASTRAZENECA-202503EEA001169ES$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250802$$$EU$EU
250565762$25056576$2$F$$20250306$20250310$20250803$EXP$$US-ASTRAZENECA-202503USA003661US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250571472$25057147$2$F$$20250303$20250310$20250810$EXP$$GB-ASTRAZENECA-202503GBR000345GB$ALEXION PHARMACEUTICALS$$45$YR$A$M$Y$$$20250810$$$GB$GB
250587816$25058781$6$F$20241202$20250818$20250310$20250822$EXP$$EU-ABBVIE-6033184$ABBVIE$$87$YR$$M$Y$$$20250822$$CN$EU$EU
250595343$25059534$3$F$$20250812$20250310$20250814$EXP$$CA-TAKEDA-2024TUS116910$TAKEDA$$$$$F$Y$$$20250814$$MD$CA$CA
250598832$25059883$2$F$$20250303$20250310$20250809$EXP$$US-ASTRAZENECA-202503USA002307US$ALEXION PHARMACEUTICALS$$73$YR$E$M$Y$$$20250809$$$US$US
250611032$25061103$2$F$$20250306$20250310$20250803$EXP$$US-ASTRAZENECA-202503USA003667US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
250619012$25061901$2$F$20250219$20250812$20250311$20250815$EXP$$US-ABBVIE-6166230$ABBVIE$$46$YR$$F$Y$$$20250815$$CN$US$US
250625412$25062541$2$F$20250201$20250305$20250311$20250809$EXP$$CA-ASTRAZENECA-202502001351CA$ALEXION PHARMACEUTICALS$$4$YR$C$M$Y$$$20250809$$$CA$CA
250633163$25063316$3$F$20250308$20250827$20250311$20250828$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-014158$BOEHRINGER INGELHEIM$$72$YR$E$F$Y$$$20250828$$$US$US
250637263$25063726$3$F$$20250403$20250311$20250707$EXP$$US-BEH-2025198160$CSL BEHRING$$$$A$M$Y$$$20250707$$CN$US$US
250637362$25063736$2$F$$20250303$20250311$20250802$EXP$$CA-ASTRAZENECA-202501CAN010225CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$CA$CA
250650132$25065013$2$F$$20250307$20250311$20250803$EXP$$GB-ASTRAZENECA-202503GBR006339GB$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$GB$GB
250655065$25065506$5$F$20250319$20250705$20250311$20250722$PER$$US-SMPA-2025SPA002439$SUNOVION$$$$$$Y$$$20250722$$CN$US$US
250661003$25066100$3$F$$20250811$20250312$20250813$EXP$$US-TAKEDA-2025TUS025561$TAKEDA$$69$YR$$F$Y$78$KG$20250813$$$US$US
250666694$25066669$4$F$20210614$20250829$20250312$20250905$EXP$$US-CHATTEMPRD-2025OHG006570$CHATTEM$$41$YR$A$F$Y$$$20250905$$LW$US$US
250670492$25067049$2$F$$20250305$20250312$20250803$EXP$$US-ASTRAZENECA-202503USA002470US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
250681793$25068179$3$F$$20250701$20250312$20250702$PER$$US-PFIZER INC-PV202500029620$PFIZER$$75$YR$$F$Y$$$20250702$$CN$US$US
250689652$25068965$2$F$$20250703$20250312$20250709$PER$$US-SA-2025SA071035$SANOFI AVENTIS$$$$E$F$Y$112.27$KG$20250709$$MD$US$US
250691655$25069165$5$F$20250101$20250802$20250312$20250807$PER$$US-SA-2025SA070966$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250807$$MD$US$US
250702747$25070274$7$F$20240906$20250911$20250312$20250916$PER$$EU-TAKEDA-2025TUS025752$TAKEDA$$$$E$M$Y$$$20250916$$$EU$EU
250704163$25070416$3$F$20240801$20250724$20250312$20250801$EXP$$EU-ALNYLAM PHARMACEUTICALS, INC.-ALN-2025-001682$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20250801$$CN$EU$EU
250704862$25070486$2$F$20250101$20250819$20250312$20250829$PER$$US-SA-2025SA072247$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250829$$HP$US$US
250712353$25071235$3$F$20250201$20250826$20250312$20250827$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-031950$BRISTOL-MYERS SQUIBB COMPANY$$44$YR$A$F$Y$$$20250827$$HP$US$US
250716212$25071621$2$F$$20250306$20250313$20250810$EXP$EU-AFSSAPS-PV2025000151$EU-ASTRAZENECA-202502GLO027423FR$ALEXION PHARMACEUTICALS$$81$YR$E$F$Y$62$KG$20250810$$PH$EU$EU
250716462$25071646$2$F$20250708$20250715$20250313$20250718$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-034690$BRISTOL-MYERS SQUIBB COMPANY$$47$YR$A$M$Y$$$20250718$$HP$US$US
250717022$25071702$2$F$20250202$20250818$20250313$20250821$EXP$EU-INFARMED-B202502-782$NVSC2025PT041765$NOVARTIS$$38$YR$$F$Y$$$20250821$$MD$EU$EU
250722353$25072235$3$F$$20250715$20250313$20250720$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-02124$LUPIN$$$$$$Y$$$20250720$$$US$US
250726942$25072694$2$F$$20250311$20250313$20250802$EXP$$CA-ASTRAZENECA-202503CAN007941CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$CA$CA
250729943$25072994$3$F$20250101$20250807$20250313$20250814$PER$$US-SA-2025SA069439$SANOFI AVENTIS$$52$YR$A$M$Y$52.27$KG$20250815$$MD$US$US
250731332$25073133$2$F$20231125$20250307$20250313$20250802$EXP$EU-AFSSAPS-NC2025000314$EU-ASTRAZENECA-202503GLO009377FR$ALEXION PHARMACEUTICALS$$58$YR$A$F$Y$49$KG$20250802$$MD$EU$EU
250735832$25073583$2$F$20230930$20250305$20250313$20250809$EXP$$JP-ALXN-A202312852$ALEXION PHARMACEUTICALS$$69$YR$E$F$Y$45.8$KG$20250809$$MD$JP$JP
250745702$25074570$2$F$$20250307$20250313$20250803$EXP$$US-ASTRAZENECA-202503USA006201US$ALEXION PHARMACEUTICALS$$$$$F$Y$53.5$KG$20250803$$$US$US
250746933$25074693$3$F$$20250402$20250313$20250816$PER$$US-ASTRAZENECA-202503USA004800US$ALEXION PHARMACEUTICALS$$74$YR$E$F$Y$$$20250816$$MD$US$US
250747752$25074775$2$F$20250310$20250312$20250313$20250810$EXP$$MY-ASTRAZENECA-202503ASI008692MY$ALEXION PHARMACEUTICALS$$42$YR$A$F$Y$$$20250810$$$MY$MY
250747822$25074782$2$F$20250101$20250919$20250313$20250925$PER$$US-SA-2025SA074403$SANOFI AVENTIS$$84$YR$E$F$Y$$$20250925$$HP$US$US
250752732$25075273$2$F$20250228$20250716$20250313$20250718$EXP$$CA-GILEAD-2025-0706079$GILEAD$$19$YR$A$M$Y$79$KG$20250718$$HP$CA$CA
250754042$25075404$2$F$$20250828$20250313$20250902$PER$$US-PFIZER INC-PV202500030305$PFIZER$$48$YR$$F$Y$$$20250902$$HP$US$US
250759933$25075993$3$F$20241101$20250314$20250313$20250803$EXP$$CA-ASTRAZENECA-202503CAN009170CA$ALEXION PHARMACEUTICALS$$77$YR$$F$Y$$$20250803$$$CA$CA
250767012$25076701$2$F$$20250702$20250313$20250708$EXP$$US-RADIUS HEALTH INC.-2025US002175$RADIUS PHARM$$$$$F$Y$$$20250708$$CN$US$US
250793892$25079389$2$F$$20250310$20250314$20250802$EXP$$CN-ASTRAZENECA-202503CHN005628CN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$CN$CN
250795862$25079586$2$F$20240322$20250905$20250314$20250911$EXP$$JP-GILEAD-2025-0706895$GILEAD$$67$YR$E$F$Y$$$20250911$$MD$JP$JP
250797554$25079755$4$F$20250211$20250423$20250314$20250803$EXP$$EU-ASTRAZENECA-202502016600FR$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$$$20250803$$MD$EU$EU
250802992$25080299$2$F$20240101$20250710$20250315$20250715$EXP$$CA-ABBVIE-6173865$ABBVIE$$25$YR$$M$Y$$$20250715$$CN$CA$CA
250807943$25080794$3$F$20240301$20250825$20250315$20250829$EXP$$US-ABBVIE-6171882$ABBVIE$$70$YR$$F$Y$$$20250829$$CN$US$US
250827872$25082787$2$F$20231208$20250708$20250317$20250714$EXP$$CA-TAKEDA-2023TUS095479$TAKEDA$$46$YR$$F$Y$$$20250714$$$CA$CA
250843255$25084325$5$F$20220510$20250715$20250317$20250721$PER$$US-SA-2025SA075210$SANOFI AVENTIS$$12$YR$T$F$Y$56.236$KG$20250721$$MD$US$US
250848193$25084819$3$F$20250101$20250827$20250317$20250831$EXP$$CA-JNJFOC-20250332404$JOHNSON AND JOHNSON$$69$YR$E$F$Y$$$20250831$$HP$CA$CA
250848823$25084882$3$F$$20250408$20250317$20250803$EXP$$EU-ASTRAZENECA-202503EEA007166ES$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
250852618$25085261$8$F$20250605$20250910$20250317$20250919$EXP$$US-BAYER-2025A032893$BAYER HEALTHCARE PHARMACEUTICALS INC.$$68$YR$E$F$Y$77.914$KG$20250919$$CN$US$US
250868862$25086886$2$F$$20250719$20250318$20250722$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-498902$RANBAXY$Torii A, Oki M, Iida H, Yamada A, Kogure Y, Kitagawa C et al. The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study. Pulm Pharmacol Ther. 2024;85:102297;1-6$67$YR$$M$Y$$$20250722$$HP$JP$JP
250869972$25086997$2$F$$20250625$20250318$20250701$30DAY$$US-SANDOZ INC.-SDZ2025US016176$SANDOZ$$$$$M$Y$$$20250701$$CN$US$US
250871102$25087110$2$F$$20250314$20250318$20250809$EXP$$US-ASTRAZENECA-202503USA011508US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$US$US
250871432$25087143$2$F$$20250314$20250318$20250809$EXP$$TW-ASTRAZENECA-202503ASI011102TW$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$TW$TW
250872592$25087259$2$F$20240905$20250701$20250318$20250709$EXP$$EU-CELLTRION INC.-2025FI007540$CELLTRION$$$$$$Y$$$20250709$$MD$EU$EU
250879522$25087952$2$F$20250302$20250606$20250318$20250703$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000173$DECIPHERA PHARMACEUTICALS$$54$YR$A$F$Y$$$20250703$$CN$US$US
250883433$25088343$3$F$20250314$20250902$20250318$20250919$PER$$US-RDY-USA/2025/03/003962$DR REDDYS$$16$YR$T$F$Y$44.6$KG$20250919$$MD$US$US
250889352$25088935$2$F$$20250313$20250318$20250810$PER$$US-ASTRAZENECA-202503USA010395US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
250891074$25089107$4$F$20250101$20250703$20250318$20250716$EXP$$US-AVADEL CNS PHARMACEUTICALS, LLC-2025AVA00449$AVADEL CNS PHARMACEUTICALS, LLC$$$$$F$Y$$$20250716$$CN$US$US
250892222$25089222$2$F$20240101$20250314$20250318$20250809$EXP$$EU-ASTRAZENECA-202503EEA011860BG$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250809$$MD$EU$EU
250892294$25089229$4$F$$20250627$20250318$20250703$EXP$$US-INCYTE CORPORATION-2025IN002747$INCYTE$$$$$$Y$$$20250703$$MD$US$
250901763$25090176$3$F$$20250721$20250318$20250731$EXP$$CA-ROCHE-10000231169$ROCHE$$65$YR$E$F$Y$34$KG$20250731$$CN$CA$CA
250905893$25090589$3$F$$20250226$20250318$20250816$EXP$$IL-ASTRAZENECA-202502GLO027795IL$ALEXION PHARMACEUTICALS$Loewenstein I, Urtreger NO, Schwartz D, Zubkov A, Ingbir M.. Acute Tubular Necrosis Attributed to High-Dose Everolimus with High-Potency Bisphosphonates for Advanced Breast Cancer: A Case Report.. Nephron.. 2025;149 (6):333-338$69$YR$E$F$Y$$$20250816$$$IL$IL
250914573$25091457$3$F$20250101$20250925$20250318$20250930$PER$$US-SA-2025SA077217$SANOFI AVENTIS$$61$YR$A$F$Y$75.45$KG$20250930$$MD$US$US
250916824$25091682$4$F$20250101$20250915$20250318$20250920$PER$$US-SA-2025SA078128$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250920$$HP$US$US
250922232$25092223$2$F$20250306$20250311$20250319$20250803$EXP$$GB-ASTRAZENECA-202503GBR008512GB$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250803$$$GB$GB
250922783$25092278$3$F$20231109$20250324$20250319$20250803$EXP$$EU-ASTRAZENECA-202503GLO010992FR$ALEXION PHARMACEUTICALS$$8$DY$N$M$Y$2.56$KG$20250803$$MD$EU$EU
250924052$25092405$2$F$$20250314$20250319$20250803$EXP$$EU-ASTRAZENECA-202503EEA011424SE$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250803$$MD$EU$EU
250925622$25092562$2$F$20220101$20250707$20250319$20250710$PER$$US-SA-2025SA078585$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250710$$HP$US$US
250933593$25093359$3$F$20250203$20250822$20250319$20250827$EXP$$JP-ASTELLAS-2025-AER-009153$ASTELLAS$$8$DEC$E$M$Y$$$20250828$$MD$JP$JP
250935542$25093554$2$F$$20250315$20250319$20250803$EXP$$US-ASTRAZENECA-202503USA012807US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250803$$$US$US
250937462$25093746$2$F$$20250816$20250319$20250821$PER$$US-SA-2025SA080085$SANOFI AVENTIS$$39$YR$A$M$Y$$$20250821$$CN$US$US
250939252$25093925$2$F$$20250909$20250319$20250910$PER$$US-TAKEDA-2024TUS033049$TAKEDA$$$$$M$Y$$$20250910$$$US$US
250943932$25094393$2$F$20250101$20250701$20250319$20250707$PER$$US-SA-2025SA078659$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250707$$HP$US$US
250993062$25099306$2$F$$20250313$20250320$20250803$EXP$$EU-ASTRAZENECA-202503EEA009878IT$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
250993172$25099317$2$F$20250204$20250313$20250320$20250810$EXP$$US-ASTRAZENECA-202503USA011673US$ALEXION PHARMACEUTICALS$$70$YR$E$F$Y$86.168$KG$20250810$$$US$US
251011522$25101152$2$F$20241101$20250707$20250320$20250711$EXP$$US-ABBVIE-6179605$ABBVIE$$67$YR$$F$Y$$$20250711$$CN$US$US
251012112$25101211$2$F$$20250804$20250320$20250812$PER$$US-PHARMING-PHAUS2025000382$PHARMING GROUP$$$$$$Y$$$20250812$$CN$US$US
251014843$25101484$3$F$20250101$20250729$20250320$20250804$PER$$US-SA-2025SA080508$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250804$$MD$US$US
251017532$25101753$2$F$$20250818$20250320$20250820$EXP$$US-PFIZER INC-PV202500033063$PFIZER$$66$YR$$F$Y$$$20250820$$HP$US$US
251035842$25103584$2$F$$20250724$20250321$20250728$PER$$US-LEO Pharma-378497$LEO PHARM$$45$YR$$F$Y$$$20250728$$PH$US$US
251039253$25103925$3$F$$20250711$20250321$20250715$EXP$$US-ABBVIE-6186527$ABBVIE$$$$A$F$Y$63.502$KG$20250715$$CN$US$US
251041232$25104123$2$F$$20250630$20250321$20250716$PER$$US-009507513-2258809$MERCK SHARP + DOHME LLC$$$$$F$Y$100$KG$20250716$$CN$US$US
251052772$25105277$2$F$$20250318$20250321$20250810$EXP$$US-ASTRAZENECA-202503USA014615US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
251065782$25106578$2$F$20250318$20250319$20250321$20250802$EXP$$US-ASTRAZENECA-202503USA016309US$ALEXION PHARMACEUTICALS$$63$YR$A$F$Y$$$20250802$$MD$US$US
251066732$25106673$2$F$$20250315$20250321$20250803$EXP$$US-ASTRAZENECA-202503GLO015498US$ALEXION PHARMACEUTICALS$Kumanayaka D.D. Singh R. Kiwan C.M. Correia J. Suleiman A.. DOUBLE EDGED SWORD: CAN LIFE SAVING AND LESSRESISTANT CANCER TREATMENT, THIRD GENERATIONTYROSINE KINASE INHIBITORS ALSO RAPIDLYACCELERATE THE PROGRESSION OF AORTIC STENOSIS. Journal of the American College of Cardiology. 2025;85 (12):3739$77$YR$E$F$Y$$$20250803$$$US$US
251069823$25106982$3$F$$20250421$20250321$20250802$EXP$$EU-ASTRAZENECA-202503EEA015576IT$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250802$$MD$EU$EU
251072403$25107240$3$F$$20250415$20250321$20250809$EXP$$US-ASTRAZENECA-202503USA011544US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250809$$$US$US
251078852$25107885$2$F$20250201$20250718$20250322$20250723$PER$$US-SA-2025SA080636$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250723$$HP$US$US
251086132$25108613$2$F$20250315$20250827$20250322$20250902$PER$$US-ABBVIE-6188009$ABBVIE$$33$YR$$F$Y$$$20250902$$HP$US$US
251087622$25108762$2$F$20250101$20250916$20250322$20250922$EXP$$EU-ABBVIE-6162465$ABBVIE$$56$YR$$M$Y$$$20250922$$CN$EU$EU
251092112$25109211$2$F$20250101$20250716$20250323$20250722$PER$$US-SA-2025SA083036$SANOFI AVENTIS$$53$YR$A$M$Y$101$KG$20250722$$MD$US$US
251102192$25110219$2$F$20250307$20250321$20250324$20250803$EXP$EU-AFSSAPS-TS2025000271$EU-ASTRAZENECA-202503GLO018146FR$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250803$$MD$EU$EU
251131572$25113157$2$F$$20250317$20250324$20250809$EXP$$RU-ASTRAZENECA-202503RUS015998RU$ALEXION PHARMACEUTICALS$$$$C$F$Y$$$20250809$$$RU$RU
251135362$25113536$2$F$20240901$20250731$20250324$20250805$EXP$$GB-ABBVIE-6188977$ABBVIE$$$$$M$Y$$$20250805$$MD$GB$GB
251138473$25113847$3$F$20250319$20250415$20250324$20250810$EXP$$EU-ASTRAZENECA-202503EEA018181FR$ALEXION PHARMACEUTICALS$$66$YR$E$F$Y$$$20250810$$MD$EU$EU
251138532$25113853$2$F$$20250317$20250324$20250810$EXP$$CA-ASTRAZENECA-202503CAN012310CA$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$$$20250810$$$CA$CA
251139872$25113987$2$F$$20250320$20250324$20250810$EXP$$US-ASTRAZENECA-202503USA017164US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$US$US
251142873$25114287$3$F$20250101$20250903$20250324$20250909$PER$$US-SA-2025SA083066$SANOFI AVENTIS$$33$YR$A$M$Y$$$20250909$$HP$US$US
251153522$25115352$2$F$20241201$20250902$20250324$20250905$EXP$$CA-JNJFOC-20250344732$JOHNSON AND JOHNSON$$39$YR$A$F$Y$$$20250905$$HP$CA$CA
251163662$25116366$2$F$20250304$20250317$20250325$20250809$EXP$$CO-ASTRAZENECA-202503SAM012976CO$ALEXION PHARMACEUTICALS$$91$YR$E$F$Y$68$KG$20250809$$$CO$CO
251171693$25117169$3$F$$20250912$20250325$20250926$PER$$US-SMPA-2025SPA000457$SUNOVION$$80$YR$$M$Y$76.644$KG$20250923$$MD$US$US
251172912$25117291$2$F$20250904$20250919$20250325$20250930$PER$$US-Ipsen Biopharmaceuticals, Inc.-2025-06208$IPSEN BIOPHARMACEUTICALS, INC.$$51$YR$A$F$Y$$$20250930$$$US$US
251181362$25118136$2$F$$20250715$20250325$20250721$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-02104$LUPIN$$$$$$Y$$$20250721$$$US$US
251182922$25118292$2$F$20240301$20250318$20250325$20250810$EXP$EU-AFSSAPS-LY2025000063$EU-ASTRAZENECA-202501GLO030026FR$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$85$KG$20250810$$MD$EU$EU
251183985$25118398$5$F$20250608$20250703$20250325$20250708$EXP$$US-TAKEDA-2022TUS095528$TAKEDA$$72$YR$$F$Y$64$KG$20250708$$$US$US
251189492$25118949$2$F$20250101$20250820$20250325$20250825$PER$$US-SA-2025SA084906$SANOFI AVENTIS$$78$YR$E$F$Y$57.27$KG$20250825$$HP$US$US
251196874$25119687$4$F$$20250401$20250325$20250802$EXP$$US-ASTRAZENECA-202503USA018354US$ALEXION PHARMACEUTICALS$$85$YR$E$F$Y$29.478$KG$20250802$$$US$US
251197192$25119719$2$F$$20250318$20250325$20250809$EXP$$JP-ASTRAZENECA-202503GLO019446JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$MD$JP$JP
251207633$25120763$3$F$20250101$20250910$20250325$20250916$EXP$$US-ABBVIE-6184662$ABBVIE$$42$YR$$M$Y$69.853$KG$20250916$$CN$US$US
251217322$25121732$2$F$$20250318$20250326$20250802$EXP$$CA-AstraZeneca-2020SF34769$ALEXION PHARMACEUTICALS$$71$YR$E$F$Y$$$20250802$$$CA$CA
251228044$25122804$4$F$$20250822$20250326$20250905$PER$$US-GRUNENTHAL-2025-104178$AVERITAS$$$$E$F$Y$$$20250905$$CN$US$US
251236922$25123692$2$F$20250101$20250319$20250326$20250809$EXP$$EU-ASTRAZENECA-202503EEA015740FR$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$EU$EU
251241172$25124117$2$F$$20250319$20250326$20250802$EXP$$US-ASTRAZENECA-202503USA015972US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
251241852$25124185$2$F$$20250708$20250326$20250723$PER$$US-SMPA-2025SPA002541$SUNOVION$$$$$$Y$$$20250723$$CN$US$US
251244182$25124418$2$F$$20250319$20250326$20250802$EXP$$US-ASTRAZENECA-202503USA015761US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
251245685$25124568$5$F$$20250721$20250326$20250724$EXP$$US-ROCHE-10000035470$ROCHE$$79$YR$E$F$Y$$$20250724$$CN$US$US
251251362$25125136$2$F$$20250325$20250326$20250803$EXP$$US-ASTRAZENECA-202503USA021608US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$US$US
251273563$25127356$3$F$20240801$20250818$20250327$20250821$EXP$$US-ABBVIE-6194257$ABBVIE$$58$YR$$M$Y$106$KG$20250821$$CN$US$US
251277752$25127775$2$F$$20250320$20250327$20250803$EXP$$US-ASTRAZENECA-202503USA018610US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
251280362$25128036$2$F$$20250721$20250327$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-045589$BRISTOL-MYERS SQUIBB COMPANY$$72$YR$E$M$Y$87.54$KG$20250722$$CN$US$US
251288984$25128898$4$F$$20250819$20250327$20250822$EXP$$US-SA-2025SA088208$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250822$$HP$US$US
251294823$25129482$3$F$20250101$20250911$20250327$20250915$EXP$$US-PFIZER INC-PV202500036269$PFIZER$$57$YR$$F$Y$$$20250915$$HP$US$US
251295072$25129507$2$F$$20250324$20250327$20250810$EXP$$US-ASTRAZENECA-202503USA021757US$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$$$20250810$$$US$US
251299083$25129908$3$F$20250101$20250710$20250327$20250716$PER$$US-SA-2025SA088050$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250717$$HP$US$US
251300762$25130076$2$F$$20250320$20250327$20250802$EXP$$BR-ASTRAZENECA-202503SAM017531BR$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$BR$BR
251302082$25130208$2$F$20240101$20250729$20250327$20250807$EXP$$US-UNITED THERAPEUTICS-UNT-2025-001904$UNITED THERAPEUTICS$$$$$M$Y$107.03$KG$20250807$$$US$US
251334733$25133473$3$F$20250325$20250617$20250328$20250810$PER$$US-ASTRAZENECA-202503USA021963US$ALEXION PHARMACEUTICALS$$57$YR$A$F$Y$$$20250810$$$US$US
251335267$25133526$7$F$20241229$20250723$20250328$20250729$EXP$$CA-JNJFOC-20241289708$JOHNSON AND JOHNSON$$53$YR$A$F$Y$88.5$KG$20250728$$HP$CA$CA
251346512$25134651$2$F$20250128$20250709$20250328$20250711$EXP$EU-AFSSAPS-LL2025000272$EU-MYLANLABS-2025M1025569$MYLAN$$84$YR$$F$Y$74$KG$20250711$$PH$EU$EU
251351996$25135199$6$F$20241007$20250826$20250328$20250902$EXP$$CO-MIRUM PHARMACEUTICALS, INC.-CO-MIR-24-00939$Unknown Manufacturer$$$$$$Y$$$20250902$$CN$CO$CO
251355033$25135503$3$F$20240101$20250905$20250328$20250916$EXP$$CA-UCBSA-2025016538$UCB$$$$$F$Y$$$20250916$$HP$CA$CA
251356092$25135609$2$F$$20250322$20250328$20250809$EXP$$JP-ASTRAZENECA-202503GLO023407JP$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250809$$MD$JP$JP
251361312$25136131$2$F$$20250325$20250328$20250809$EXP$$TW-ASTRAZENECA-202503ASI020759TW$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$TW$TW
251365862$25136586$2$F$20250320$20250324$20250328$20250809$EXP$$US-ASTRAZENECA-202503USA020490US$ALEXION PHARMACEUTICALS$$58$YR$A$F$Y$$$20250809$$$US$US
251377203$25137720$3$F$$20250702$20250329$20250711$EXP$$EU-MACLEODS PHARMA-MAC2025052318$MACLEODS$Heiloo.S.J, Broek. D.V., Los. M, Hunting. C.B..Acute renal insufficiency due to rhabdomyolysis when taking abiraterone and rosuvastatin in a patient with metastatic prostate carcinoma.Nederlands Tijdschrift voor oncologie.MAR-2025;22(2):19-22$$$$$Y$$$20250711$$MD$EU$EU
251388372$25138837$2$F$20021230$20250324$20250331$20250810$EXP$EU-GREOF-202500284$EU-ASTRAZENECA-202503GLO023439GR$ALEXION PHARMACEUTICALS$$44$YR$A$M$Y$79$KG$20250810$$MD$EU$EU
251391662$25139166$2$F$$20250327$20250331$20250803$EXP$$US-ASTRAZENECA-202503USA024450US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$US$US
251395725$25139572$5$F$$20250630$20250331$20250704$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-003390$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250704$$CN$US$US
251411883$25141188$3$F$20250301$20250714$20250331$20250718$EXP$$US-BIOMARINAP-US-2025-164908$BIOMARIN$$39$YR$$F$Y$$$20250718$$MD$US$US
251414034$25141403$4$F$20240101$20250915$20250331$20250922$PER$$US-SA-2025SA087711$SANOFI AVENTIS$$2$YR$C$M$Y$$$20250922$$HP$US$US
251419772$25141977$2$F$20220901$20250807$20250331$20250813$EXP$$CA-TAKEDA-2022TUS070908$TAKEDA$$23$YR$$F$Y$$$20250813$$$CA$CA
251431392$25143139$2$F$$20250729$20250401$20250801$PER$$US-SA-2025SA090633$SANOFI AVENTIS$$$$C$F$Y$$$20250802$$MD$US$US
251441682$25144168$2$F$20250201$20250327$20250401$20250816$PER$$US-ASTRAZENECA-202503USA023979US$ALEXION PHARMACEUTICALS$$77$YR$$F$Y$$$20250816$$$US$US
251455714$25145571$4$F$20240101$20250725$20250401$20250725$EXP$$CA-PFIZER INC-202400278344$PFIZER$$47$YR$$F$Y$$$20250725$$MD$CA$CA
251459563$25145956$3$F$20240819$20250403$20250401$20250803$EXP$$JP-ASTRAZENECA-202503GLO006761JP$ALEXION PHARMACEUTICALS$Kido R, et al.. O-078 A case of type 1 diabetes mellitus with euglycemic ketoacidosis due to trouble with a pump and an overdose of oral SGLT2 inhibitor.. The 62nd Kanto-Koshinetsu Regional Meeting of the Japan Diabetes Society. 2025;96-.$59$YR$A$F$Y$51$KG$20250803$$MD$JP$JP
251464942$25146494$2$F$$20250701$20250401$20250704$EXP$$EU-JNJFOC-20250376605$JOHNSON AND JOHNSON$$$$$M$Y$$$20250704$$CN$EU$EU
251468093$25146809$3$F$$20250523$20250401$20250810$EXP$$TR-ASTRAZENECA-202503TUR021023TR$ALEXION PHARMACEUTICALS$$$$C$F$Y$$$20250810$$MD$TR$TR
251477822$25147782$2$F$20240105$20241113$20250402$20250810$EXP$$US-ASTRAZENECA-202405USA002412US$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$82.086$KG$20250810$$$US$US
251478013$25147801$3$F$20250328$20250423$20250402$20250816$PER$$US-ASTRAZENECA-202503USA027096US$ALEXION PHARMACEUTICALS$$39$YR$A$F$Y$$$20250816$$$US$US
251481712$25148171$2$F$$20250331$20250402$20250816$PER$$US-ASTRAZENECA-202503USA027372US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$MD$US$US
251487722$25148772$2$F$$20250804$20250402$20250812$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-02461$LUPIN$$$$$$Y$$$20250812$$$US$US
251496372$25149637$2$F$20250323$20250329$20250402$20250803$EXP$$US-ASTRAZENECA-202503USA025884US$ALEXION PHARMACEUTICALS$$27$YR$A$M$Y$77.11$KG$20250803$$$US$US
251496442$25149644$2$F$$20250326$20250402$20250803$EXP$$US-ASTRAZENECA-202503USA023137US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
251507064$25150706$4$F$20250101$20250903$20250402$20250909$PER$$US-SA-2025SA090893$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250909$$HP$US$US
251518742$25151874$2$F$$20250323$20250402$20250803$EXP$$CN-ASTRAZENECA-202503GLO028134CN$ALEXION PHARMACEUTICALS$Zhang H, Hou F, Liu L, Zhao W, Qu Y, Zhou R, Wang T, Ye Y, Chai X. Durable response to Olaparib in EGFR and somatic BRCA2- mutated lung adenocarcinoma with leptomeningeal metastases: a case report. Frontiers in Oncology. 2025$67$YR$E$F$Y$$$20250803$$$CN$CN
251518822$25151882$2$F$$20250724$20250402$20250730$PER$$US-SMPA-2025SPA003747$SUNOVION$$$$$$Y$$$20250730$$CN$US$US
251520522$25152052$2$F$20231001$20250707$20250402$20250710$EXP$$EU-MYLANLABS-2025M1026832$MYLAN$$54$YR$$F$Y$$$20250710$$$EU$EU
251532762$25153276$2$F$$20250819$20250403$20250821$EXP$$CA-APOTEX-2025AP003925$APOTEX$$63$YR$$F$Y$$$20250821$$HP$CA$CA
251533402$25153340$2$F$$20250812$20250403$20250820$EXP$$CA-BIOCON BIOLOGICS LIMITED-BBL2025001786$BIOCON$$$$$$Y$$$20250820$$HP$CA$CA
251547292$25154729$2$F$$20250718$20250403$20250728$EXP$$EU-TEVA-VS-3315370$TEVA$van Willigen WW, Schreurs DA, Speetjens FM, Kapiteijn E, Badrising UA. [Neurological side-effects associated with immune checkpoint inhibitors]. [Dutch]. Ned-Tijdschr-Geneeskd 2025; 169 (0):.; van Willigen WW, Schreurs DA, Speetjens FM, Kapiteijn E, Badrising UA. [Neurological side-effects associated with immune checkpoint inhibitors]. [Dutch]. Ned-Tijdschr-Geneeskd 2025; 169 (0):.$65$YR$$M$Y$$$20250728$$HP$EU$EU
251549492$25154949$2$F$$20250702$20250403$20250707$EXP$$US-ABBVIE-6205540$ABBVIE$$$$E$F$Y$$$20250707$$CN$US$US
251549962$25154996$2$F$20250326$20250327$20250403$20250802$EXP$$EU-ASTRAZENECA-202503EEA023885FR$ALEXION PHARMACEUTICALS$$61$YR$A$F$Y$$$20250802$$MD$EU$EU
251557923$25155792$3$F$$20250704$20250403$20250710$30DAY$$CO-PFIZER INC-202500065906$PFIZER$$$$C$M$Y$$$20250710$$CN$CO$CO
251559724$25155972$4$F$20230101$20250714$20250403$20250721$EXP$$CO-BIOGEN-2024BI01270051$BIOGEN$$$$$F$Y$52$KG$20250721$$CN$CO$CO
251563692$25156369$2$F$$20250327$20250403$20250803$EXP$$CA-ASTRAZENECA-202503CAN025370CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$CA$CA
251563765$25156376$5$F$20180101$20250818$20250403$20250822$PER$$US-BIOGEN-2018BI00561563$BIOGEN$$$$$M$Y$$$20250822$$CN$US$US
251564332$25156433$2$F$$20250627$20250403$20250704$PER$$US-SA-2025SA093723$SANOFI AVENTIS$$$$E$F$Y$$$20250704$$MD$US$US
251567092$25156709$2$F$$20250707$20250403$20250709$EXP$$CA-PFIZER INC-202500069034$PFIZER$$28$YR$$F$Y$$$20250709$$HP$CA$CA
251577932$25157793$2$F$20250101$20250714$20250403$20250720$EXP$$US-ABBVIE-6206349$ABBVIE$$74$YR$$M$Y$$$20250720$$CN$US$US
251578683$25157868$3$F$20250101$20250806$20250404$20250912$EXP$$US-ABBVIE-6204872$ABBVIE$$73$YR$$M$Y$79$KG$20250912$$CN$US$US
251583223$25158322$3$F$20250101$20250901$20250404$20250905$EXP$$US-SA-2025SA094044$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250905$$MD$US$US
251587232$25158723$2$F$$20250328$20250404$20250803$EXP$$IN-ASTRAZENECA-202503GLO027617IN$ALEXION PHARMACEUTICALS$Ratan C, Rajeev M, Krishnan K, Jayamohanan H, Kartha N, Vijayan M. Assessment of potential drug?drug interactions in hospitalized cancer patients. Journal of Oncology Pharmacy Practice. 2025;31 (2):256-265$$$$$Y$$$20250803$$$IN$IN
251590892$25159089$2$F$$20250328$20250404$20250809$EXP$$CA-AstraZeneca-2020SF10326$ALEXION PHARMACEUTICALS$$55$YR$A$M$Y$$$20250809$$$CA$CA
251601152$25160115$2$F$20250206$20250331$20250404$20250803$EXP$$US-ASTRAZENECA-202503USA027834US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
251606493$25160649$3$F$$20250417$20250404$20250816$PER$$US-ASTRAZENECA-202504USA002463US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$MD$US$US
251610272$25161027$2$F$$20250402$20250404$20250803$EXP$$US-ASTRAZENECA-202504USA001456US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
251613134$25161313$4$F$$20250704$20250404$20250714$EXP$$EU-VERTEX PHARMACEUTICALS-2025-005153$VERTEX$Bonnel A, Bihouee T, Ribault M, Driessen M, Grevent D, Foissac F, et al.. First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study. J Cyst Fibros. 2025$$$I$M$Y$4$KG$20250714$$MD$EU$EU
251625703$25162570$3$F$$20250626$20250404$20250711$EXP$$AU-HARROW-HAR-2025-AU-00057$Harrow Health$$$$A$M$Y$$$20250711$$CN$AU$AU
251628665$25162866$5$F$20250328$20250820$20250404$20250828$EXP$$US-Blueprint Medicines Corporation-2025-AER-00635$BLUEPRINT MEDICINES$$53$YR$A$F$Y$$$20250828$$MD$US$US
251633942$25163394$2$F$$20250401$20250404$20250809$EXP$$US-ASTRAZENECA-202503USA014132US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
251637922$25163792$2$F$20250101$20250725$20250405$20250731$PER$$US-SA-2025SA097161$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250731$$HP$US$US
251642082$25164208$2$F$$20250401$20250405$20250810$PER$$US-ASTRAZENECA-202504USA002046US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$MD$US$US
251652122$25165212$2$F$$20250331$20250407$20250809$EXP$$CA-ASTRAZENECA-202503CAN027880CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$CA$CA
251663592$25166359$2$F$20250226$20250715$20250407$20250718$EXP$$US-JNJFOC-20250379815$JOHNSON AND JOHNSON$$$$$M$Y$$$20250718$$MD$US$US
251664592$25166459$2$F$$20250403$20250407$20250810$EXP$$US-ASTRAZENECA-202504USA002082US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
251665102$25166510$2$F$20240412$20250805$20250407$20250813$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-049700$BRISTOL-MYERS SQUIBB COMPANY$$55$YR$A$F$Y$50$KG$20250813$$PH$JP$JP
251670372$25167037$2$F$20250328$20250915$20250407$20250921$EXP$$US-UCBSA-2025019731$UCB$$13$YR$$M$Y$37.7$KG$20250921$$MD$US$US
251676703$25167670$3$F$$20250507$20250407$20250809$EXP$$US-ASTRAZENECA-202504USA002532US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
251682882$25168288$2$F$$20250804$20250407$20250812$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-02764$LUPIN$$61$YR$$$Y$61.224$KG$20250812$$$US$US
251692033$25169203$3$F$20240201$20250521$20250407$20250803$EXP$$JP-ASTRAZENECA-202504GLO003760JP$ALEXION PHARMACEUTICALS$$82$YR$E$M$Y$$$20250803$$MD$JP$JP
251697095$25169709$5$F$20250101$20250729$20250407$20250803$EXP$$CA-ABBVIE-6179524$ABBVIE$$56$YR$$F$Y$69$KG$20250803$$CN$CA$CA
251701035$25170103$5$F$20250101$20250625$20250407$20250701$EXP$$US-ABBVIE-6161014$ABBVIE$$25$YR$$F$Y$$$20250701$$CN$US$US
251706622$25170662$2$F$$20250804$20250408$20250812$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-02553$LUPIN$$57$YR$$$Y$90$KG$20250812$$$US$US
251709942$25170994$2$F$$20250623$20250408$20250716$PER$$US-SMPA-2025SPA002990$SUNOVION$$$$$$Y$$$20250716$$CN$US$US
251713473$25171347$3$F$$20250916$20250408$20250919$PER$$US-CHATTEMPRD-2025OHG009746$CHATTEM$$$$$M$Y$$$20250919$$CN$US$US
251725462$25172546$2$F$$20250401$20250408$20250809$EXP$$JP-ASTRAZENECA-202504GLO003745JP$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250809$$MD$JP$JP
251727792$25172779$2$F$$20250404$20250408$20250809$EXP$$US-ASTRAZENECA-202504USA003251US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$MD$US$US
251738994$25173899$4$F$20080729$20250716$20250408$20250722$EXP$$US-SA-2025SA099770$SANOFI AVENTIS$$22$YR$A$M$Y$$$20250722$$MD$US$US
251743532$25174353$2$F$$20250819$20250408$20250822$EXP$$CA-JNJFOC-20250407802$JOHNSON AND JOHNSON$$16$YR$T$F$Y$44$KG$20250822$$HP$CA$CA
251743792$25174379$2$F$20250305$20250326$20250408$20250709$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ3010$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250709$$MD$US$US
251744042$25174404$2$F$$20250821$20250408$20250826$EXP$$US-JAZZ PHARMACEUTICALS-2024-US-016169$JAZZ$$$$$F$Y$$$20250826$$MD$US$US
251747782$25174778$2$F$$20250407$20250408$20250803$EXP$$US-ASTRAZENECA-202504USA004679US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250803$$$US$US
251748164$25174816$4$F$$20250820$20250408$20250821$PER$$US-PFIZER INC-202500072200$PFIZER$$69$YR$$F$Y$$$20250821$$HP$US$US
251751542$25175154$2$F$$20250402$20250408$20250709$PER$$US-TG THERAPEUTICS INC.-TGT004439$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
251759562$25175956$2$F$20250101$20250404$20250409$20250809$EXP$$EU-ASTRAZENECA-202504EEA003015FR$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250809$$MD$EU$EU
251759813$25175981$3$F$20250405$20250717$20250409$20250721$PER$$NVSC2025US057940$NOVARTIS$$33$YR$$M$Y$$$20250721$$CN$US$US
251763125$25176312$5$F$20250331$20250414$20250409$20250816$PER$$US-ASTRAZENECA-202503USA027012US$ALEXION PHARMACEUTICALS$$75$YR$E$F$Y$$$20250816$$$US$US
251767162$25176716$2$F$20250304$20250715$20250409$20250718$EXP$$US-JNJFOC-20250387166$JOHNSON AND JOHNSON$$41$YR$A$M$Y$$$20250718$$HP$US$US
251771283$25177128$3$F$20250101$20250402$20250409$20250803$EXP$EU-JAZMP-NCPHV-2025SI0439_0439$EU-ASTRAZENECA-202504GLO000894SI$ALEXION PHARMACEUTICALS$$85$YR$E$M$Y$$$20250803$$MD$EU$EU
251779052$25177905$2$F$20250216$20250402$20250409$20250802$EXP$CH-SM-2025-01894$CH-ASTRAZENECA-202504GLO001651CH$ALEXION PHARMACEUTICALS$$43$YR$A$F$Y$72.1$KG$20250802$$MD$CH$CH
251781915$25178191$5$F$20250225$20250414$20250409$20250802$PER$$CA-ASTRAZENECA-202504CAN002323CA$ALEXION PHARMACEUTICALS$$57$YR$A$F$Y$100$KG$20250802$$$CA$CA
251813212$25181321$2$F$20250406$20250407$20250410$20250810$PER$$US-ASTRAZENECA-202504USA004442US$ALEXION PHARMACEUTICALS$$89$YR$E$M$Y$$$20250810$$$US$US
251822812$25182281$2$F$20230101$20250602$20250410$20250701$EXP$$US-KINIKSA PHARMACEUTICALS LTD.-2024KPU000821$KINIKSA PHARMACEUTICALS$$$$$M$Y$$$20250630$$CN$US$US
251826912$25182691$2$F$$20250807$20250410$20250815$EXP$$JP-TEVA-VS-3318903$TEVA$Hiromi Ito, et al., 3 cases of pneumocystis pneumonia during breast cancer dose-dense EC therapy, The 14th Annual Meeting of Japanese Society of pharmaceutical oncology 2025 (2025.3.15,16); Hiromi Ito, et al., 3 cases of pneumocystis pneumonia during breast cancer dose-dense?EC therapy, The 14th Annual Meeting of Japanese Society of pharmaceutical oncology 2025 (2025.3.15,16)$40$YR$$F$Y$$$20250815$$HP$JP$JP
251835818$25183581$8$F$20240101$20250908$20250410$20250922$EXP$$CO-SA-2024SA157290$SANOFI AVENTIS$$35$YR$A$F$Y$56$KG$20250922$$MD$CO$CO
251836184$25183618$4$F$$20250703$20250410$20250709$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-003960$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250709$$CN$US$US
251842033$25184203$3$F$$20250506$20250410$20250809$EXP$$CA-ASTRAZENECA-202504CAN002541CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
251844853$25184485$3$F$$20250903$20250410$20250904$PER$$US-PFIZER INC-PV202500043013$PFIZER$$61$YR$$F$Y$$$20250904$$HP$US$US
251852042$25185204$2$F$20231213$20250811$20250410$20250814$EXP$$CA-JNJFOC-20231240814$JOHNSON AND JOHNSON$$14$YR$T$M$Y$65$KG$20250814$$HP$CA$CA
251864522$25186452$2$F$$20250408$20250411$20250810$PER$$US-ASTRAZENECA-202504USA005732US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250810$$$US$US
251867183$25186718$3$F$20220101$20250717$20250411$20250722$EXP$$US-ABBVIE-6168473$ABBVIE$$66$YR$$F$Y$65.771$KG$20250722$$CN$US$US
251870122$25187012$2$F$$20250407$20250411$20250803$EXP$$US-ASTRAZENECA-202504USA005661US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
251872902$25187290$2$F$$20250404$20250411$20250802$EXP$$US-ASTRAZENECA-202504USA003236US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
251876143$25187614$3$F$$20250710$20250411$20250714$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-054159$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$$$20250714$$CN$US$US
251879192$25187919$2$F$$20250709$20250411$20250716$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-004092$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250716$$CN$US$US
251879635$25187963$5$F$20250115$20250821$20250411$20250902$EXP$$EU-AUROBINDO-AUR-APL-2025-018301$AUROBINDO$$57$YR$$F$Y$83$KG$20250902$$MD$EU$EU
251881722$25188172$2$F$20240901$20250408$20250411$20250802$EXP$$EU-ASTRAZENECA-202504EEA005559RO$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$MD$EU$EU
251886182$25188618$2$F$$20250404$20250411$20250816$PER$$US-ASTRAZENECA-202504USA003508US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
251886654$25188665$4$F$$20250729$20250411$20250806$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-054023$BRISTOL-MYERS SQUIBB COMPANY$$57$YR$A$F$Y$$$20250806$$MD$JP$JP
251894842$25189484$2$F$20250214$20250409$20250411$20250809$EXP$$US-ASTRAZENECA-202504USA007496US$ALEXION PHARMACEUTICALS$$69$YR$E$M$Y$$$20250809$$$US$US
251896593$25189659$3$F$20250410$20250604$20250411$20250810$PER$$US-ASTRAZENECA-202504USA008702US$ALEXION PHARMACEUTICALS$$68$YR$E$F$Y$$$20250810$$$US$US
251897042$25189704$2$F$20250407$20250710$20250411$20250710$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-052514$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$F$Y$58.97$KG$20250710$$CN$US$US
251899612$25189961$2$F$$20250408$20250411$20250809$EXP$$CA-ASTRAZENECA-202504CAN006102CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$CA$CA
251902516$25190251$6$F$20250101$20250815$20250411$20250825$EXP$$US-UCBSA-2025021235$UCB$$$$$F$Y$$$20250822$$CN$US$US
251907112$25190711$2$F$$20250710$20250411$20250710$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-053128$BRISTOL-MYERS SQUIBB COMPANY$Park M, Suh S, Kincaid C, Yale K, Mesinkovska NA. Alopecia as an adverse event of immune checkpoint inhibitor therapies: clinical evidence and outcomes. Journal of Drugs in Dermatology. 2025 Mar 01;24(3):255-60. doi:10.36849/JDD.7828.$72$YR$E$M$Y$$$20250710$$HP$US$US
251924583$25192458$3$F$$20250722$20250414$20250723$PER$$NVSC2025US060857$NOVARTIS$$$$$M$Y$$$20250723$$CN$US$US
251928427$25192842$7$F$$20250917$20250414$20250919$EXP$$EU-MYLANLABS-2025M1031456$MYLAN$Pimenta G, Martins A, De Sousa L, Carvalho T, Chorao M, Weigert A. Atypical Primary Central Nervous System Post -Transplant Lymphoproliferative Disorder. Portuguese Kidney Journal. 2025;1(39): 58-63.$42$YR$$F$Y$$$20250919$$$EU$EU
251929052$25192905$2$F$$20250708$20250414$20250710$EXP$$US-ABBVIE-6221835$ABBVIE$$$$A$F$Y$$$20250710$$CN$US$US
251933673$25193367$3$F$$20250710$20250414$20250810$PER$$US-ASTRAZENECA-202504USA004734US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
251933692$25193369$2$F$20250330$20250410$20250414$20250810$EXP$$US-ASTRAZENECA-202504USA008766US$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250810$$$US$US
251934302$25193430$2$F$$20250408$20250414$20250810$EXP$$US-ASTRAZENECA-202504USA006978US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
251934332$25193433$2$F$$20250407$20250414$20250809$EXP$$US-ASTRAZENECA-202504USA004285US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
251934953$25193495$3$F$$20250414$20250414$20250802$EXP$$CA-ASTRAZENECA-202504CAN007000CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$CA$CA
251935013$25193501$3$F$20250408$20250505$20250414$20250803$EXP$$IL-ASTRAZENECA-202504ISR005438IL$ALEXION PHARMACEUTICALS$$90$YR$E$F$Y$$$20250803$$$IL$IL
251935413$25193541$3$F$20250205$20250417$20250414$20250803$EXP$$JP-ASTRAZENECA-202502GLO006668JP$ALEXION PHARMACEUTICALS$$3$MON$I$F$Y$6$KG$20250803$$MD$JP$JP
251935422$25193542$2$F$20250101$20250407$20250414$20250809$EXP$$JP-ASTRAZENECA-202504GLO010545JP$ALEXION PHARMACEUTICALS$$57$YR$A$M$Y$$$20250809$$MD$JP$JP
251935522$25193552$2$F$$20250407$20250414$20250803$EXP$$US-ASTRAZENECA-202504USA004839US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
251937185$25193718$5$F$20240610$20250620$20250414$20250703$EXP$$EU-ABBVIE-5800028$ABBVIE$$61$YR$$M$Y$78$KG$20250703$$MD$EU$EU
251943072$25194307$2$F$20250101$20250703$20250414$20250708$PER$$US-SA-2025SA105914$SANOFI AVENTIS$$34$YR$A$M$Y$$$20250708$$HP$US$US
251943497$25194349$7$F$20250101$20250826$20250414$20250829$EXP$$EU-ABBVIE-6204227$ABBVIE$$57$YR$$M$Y$$$20250829$$CN$EU$EU
251946976$25194697$6$F$$20250715$20250414$20250723$EXP$$JP-JNJFOC-20250416389$JOHNSON AND JOHNSON$$4$DEC$A$F$Y$$$20250723$$CN$JP$JP
251951005$25195100$5$F$20250101$20250904$20250415$20250909$EXP$$US-ABBVIE-6230447$ABBVIE$$73$YR$$F$Y$$$20250909$$CN$US$US
251952142$25195214$2$F$$20250627$20250415$20250703$PER$$US-SA-2025SA103384$SANOFI AVENTIS$$$$A$M$Y$88.64$KG$20250703$$CN$US$US
251953762$25195376$2$F$$20250904$20250415$20250910$PER$$US-SA-2025SA015319$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250910$$CN$US$US
251955122$25195512$2$F$20250301$20250731$20250415$20250805$PER$$US-SA-2025SA104169$SANOFI AVENTIS$$2$YR$C$M$Y$$$20250805$$HP$US$US
251959442$25195944$2$F$20250201$20250714$20250415$20250722$EXP$$AR-JNJFOC-20250413520$JOHNSON AND JOHNSON$$40$YR$A$M$Y$70$KG$20250723$$CN$AR$AR
251970562$25197056$2$F$$20250408$20250415$20250809$EXP$$ZA-ASTRAZENECA-202504SSA005557ZA$ALEXION PHARMACEUTICALS$$78$YR$E$F$Y$$$20250809$$$ZA$ZA
251973685$25197368$5$F$20250401$20250711$20250415$20250719$EXP$$US-UNITED THERAPEUTICS-UNT-2025-011618$UNITED THERAPEUTICS$$28$YR$$F$Y$54.422$KG$20250719$$PH$US$US
251985093$25198509$3$F$20241107$20250602$20250415$20250803$EXP$$US-ASTRAZENECA-202504USA007061US$ALEXION PHARMACEUTICALS$$85$YR$E$M$Y$78.458$KG$20250803$$$US$US
251987172$25198717$2$F$20241102$20250722$20250415$20250730$EXP$$JP-MSD-2411JPN001332J$MERCK SHARP + DOHME LLC$$8$DEC$$F$Y$45$KG$20250730$$MD$JP$JP
251990522$25199052$2$F$20250101$20250701$20250415$20250704$EXP$$US-UCBSA-2025021586$UCB$$$$$F$Y$$$20250704$$HP$US$US
251992102$25199210$2$F$$20250408$20250415$20250803$EXP$$US-ASTRAZENECA-202504USA005936US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
251998423$25199842$3$F$20240101$20250821$20250415$20250826$EXP$$US-ABBVIE-6221838$ABBVIE$$73$YR$$M$Y$95$KG$20250826$$CN$US$US
252007702$25200770$2$F$20240913$20250821$20250415$20250829$EXP$$US-TAKEDA-2024TUS079684$TAKEDA$$60$YR$$F$Y$$$20250829$$$US$US
252031302$25203130$2$F$$20250409$20250416$20250803$EXP$$US-ASTRAZENECA-202504USA007256US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
252033222$25203322$2$F$20240516$20250409$20250416$20250809$EXP$$US-ASTRAZENECA-202504USA011222US$ALEXION PHARMACEUTICALS$$68$YR$E$F$Y$$$20250809$$$US$US
252036732$25203673$2$F$$20250801$20250416$20250807$PER$$US-SA-2025SA109415$SANOFI AVENTIS$$81$YR$E$F$Y$48.18$KG$20250807$$MD$US$US
252039483$25203948$3$F$$20250414$20250416$20250809$EXP$$US-ASTRAZENECA-202504USA011680US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$US$US
252042834$25204283$4$F$$20250728$20250416$20250731$30DAY$$AR-JNJFOC-20250416493$JOHNSON AND JOHNSON$$$$$$Y$$$20250731$$PH$AR$AR
252047292$25204729$2$F$20250401$20250409$20250416$20250809$EXP$$JP-ASTRAZENECA-202504GLO010476JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$JP$JP
252050723$25205072$3$F$20250413$20250417$20250416$20250803$EXP$$SG-ASTRAZENECA-202504ASI012136SG$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$SG$SG
252061224$25206122$4$F$20250101$20250912$20250417$20250920$EXP$$JP-UNITED THERAPEUTICS-UNT-2025-012585$UNITED THERAPEUTICS$$66$YR$$M$Y$$$20250920$$$JP$JP
252065472$25206547$2$F$$20250909$20250417$20250912$EXP$$TH-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-503885$RANBAXY$Chatproedprai S, Tiasiri N, Chantawarangkul K, Wananukul S. Pediatric drug reaction with eosinophilia and systemic symptoms: A 12-year retrospective study in a tertiary center. J Dermatol. 2024;51:509-517$$$C$$Y$$$20250912$$HP$TH$TH
252067623$25206762$3$F$$20250623$20250417$20250704$EXP$$US-ASTELLAS-2025-AER-019468$ASTELLAS$$$$$F$Y$$$20250704$$MD$US$US
252070486$25207048$6$F$20230101$20250804$20250417$20250813$EXP$$US-INSMED-2023-04511-USAA$INSMED$$$$$M$Y$$$20250814$$CN$US$US
252070592$25207059$2$F$20250407$20250410$20250417$20250809$EXP$$PA-ASTRAZENECA-202504CAM008318PA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$PA$PA
252073552$25207355$2$F$$20250623$20250417$20250710$PER$$US-PHARMING-PHAUS2025000517$PHARMING GROUP$$$$$$Y$$$20250710$$CN$US$US
252078693$25207869$3$F$20240701$20250702$20250417$20250708$EXP$$CA-BIOGEN-2024BI01277774$BIOGEN$$34$YR$$F$Y$$$20250708$$CN$CA$CA
252080742$25208074$2$F$$20250411$20250417$20250809$EXP$$US-ASTRAZENECA-202504USA009769US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
252089062$25208906$2$F$$20250815$20250417$20250819$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-055842$BRISTOL-MYERS SQUIBB COMPANY$$60$YR$A$F$Y$$$20250819$$CN$US$US
252089303$25208930$3$F$$20250910$20250417$20250912$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-055889$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$F$Y$70.31$KG$20250912$$$US$US
252090142$25209014$2$F$20250401$20250731$20250417$20250803$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-056193$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$F$Y$58.97$KG$20250804$$HP$US$US
252098232$25209823$2$F$20250407$20250730$20250417$20250808$EXP$$JP-JAZZ PHARMACEUTICALS-2025-JP-009756$JAZZ$$48$YR$$M$Y$55.3$KG$20250808$$MD$JP$JP
252111914$25211191$4$F$20241128$20250627$20250417$20250701$EXP$$JP-Taiho Oncology Inc-2025-003916$TAIHO ONCOLOGY INC$$74$YR$E$M$Y$56.9$KG$20250701$$MD$JP$JP
252112772$25211277$2$F$$20250708$20250417$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202504007572$ELI LILLY AND COMPANY$$71$YR$E$F$Y$$$20250714$$MD$US$US
252116942$25211694$2$F$$20250411$20250418$20250802$EXP$$US-ASTRAZENECA-202504USA009952US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250802$$$US$US
252117732$25211773$2$F$20221014$20250822$20250418$20250902$PER$$US-ELI_LILLY_AND_COMPANY-US202504011084$ELI LILLY AND COMPANY$$50$YR$A$F$Y$206$KG$20250902$$LW$US$US
252119652$25211965$2$F$20210101$20250714$20250418$20250716$EXP$GB-EMA-DD-20250220-7483181-080018$GB-SANDOZ INC.-SDZ2025GB023285$SANDOZ$$$$$F$Y$$$20250716$$CN$GB$GB
252122352$25212235$2$F$$20250415$20250418$20250816$PER$$US-ASTRAZENECA-202504USA014446US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
252149686$25214968$6$F$20250314$20250807$20250418$20250807$30DAY$$TR-PFIZER INC-PV202500041788$PFIZER$$49$YR$$F$Y$64$KG$20250807$$CN$TR$TR
252153202$25215320$2$F$$20250411$20250418$20250803$EXP$$US-ASTRAZENECA-202504GLO015710US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$$US$US
252154362$25215436$2$F$$20250328$20250418$20250721$PER$$US-PHATHOM PHARMACEUTICALS INC.-2025PHT00545$Phathom Pharmaceuticals$$$$$F$Y$$$20250721$$CN$US$US
252157252$25215725$2$F$$20250709$20250418$20250711$EXP$$US-BIOMARINAP-US-2025-165177$BIOMARIN$$11$YR$$F$Y$$$20250711$$$US$US
252162293$25216229$3$F$$20250809$20250418$20250809$EXP$$US-ASTRAZENECA-202504USA015107US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250809$$$US$US
252164615$25216461$5$F$20250101$20250625$20250418$20250703$PER$$US-SA-2025SA112442$SANOFI AVENTIS$$11$YR$C$F$Y$$$20250703$$HP$US$US
252171734$25217173$4$F$20250410$20250728$20250419$20250804$EXP$$CA-TAKEDA-2025TUS016742$TAKEDA$$31$YR$$F$Y$$$20250804$$$CA$CA
252172942$25217294$2$F$$20250623$20250420$20250721$PER$$US-GSK-US2025037860$GLAXOSMITHKLINE$$$$$M$Y$$$20250721$$$US$US
252174522$25217452$2$F$$20250808$20250420$20250813$PER$$US-SA-2025SA113221$SANOFI AVENTIS$$6$YR$C$F$Y$$$20250813$$MD$US$US
252184966$25218496$6$F$20250302$20250709$20250421$20250713$EXP$$JP-GSK-JP2025046351$GLAXOSMITHKLINE$$$$$F$Y$$$20250713$$MD$JP$JP
252188813$25218881$3$F$20250328$20250903$20250421$20250903$PER$$NVSC2025US065082$NOVARTIS$$37$YR$$F$Y$$$20250904$$CN$US$US
252189702$25218970$2$F$$20250414$20250421$20250809$EXP$$EU-ASTRAZENECA-202504EEA011203DE$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$EU$EU
252194052$25219405$2$F$$20250909$20250421$20250917$PER$$US-ELI_LILLY_AND_COMPANY-US202504017078$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250917$$CN$US$US
252194182$25219418$2$F$20250401$20250716$20250421$20250724$EXP$$US-CELLTRION INC.-2025US011492$CELLTRION$$$$$$Y$$$20250724$$CN$US$US
252199973$25219997$3$F$20250401$20250721$20250421$20250730$PER$$US-TAKEDA-2025TUS037555$TAKEDA$$25$YR$$F$Y$$$20250730$$$US$US
252203143$25220314$3$F$20250101$20250828$20250421$20250910$EXP$$US-IBSA PHARMA INC.-2025IBS000237$IBSA INSTITUT BIOCHIMIQUE$$$$$$Y$$$20250910$$CN$US$US
252217142$25221714$2$F$$20250731$20250421$20250804$PER$$US-SA-2025SA113471$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250804$$HP$US$US
252225772$25222577$2$F$20250405$20250417$20250421$20250809$EXP$$CO-ASTRAZENECA-202504SAM015678CO$ALEXION PHARMACEUTICALS$$14$YR$T$F$Y$25$KG$20250809$$$CO$CO
252225834$25222583$4$F$20241201$20250807$20250421$20250811$EXP$$CA-JNJFOC-20230464813$JOHNSON AND JOHNSON$$66$YR$E$M$Y$$$20250811$$HP$CA$CA
252235805$25223580$5$F$$20250805$20250422$20250808$EXP$$CA-JNJFOC-20250205445$JOHNSON AND JOHNSON$$65$YR$E$M$Y$$$20250808$$HP$CA$CA
252236332$25223633$2$F$$20250417$20250422$20250810$PER$$CN-ASTRAZENECA-202503CHN005085CN$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250810$$$CN$CN
252245092$25224509$2$F$$20250725$20250422$20250806$EXP$$EU-UCBSA-2025023495$UCB$$5$YR$$F$Y$20.5$KG$20250806$$CN$EU$EU
252245922$25224592$2$F$$20250418$20250422$20250802$EXP$$US-ASTRAZENECA-202504USA016378US$ALEXION PHARMACEUTICALS$$$$E$$Y$$$20250802$$$US$US
252252832$25225283$2$F$$20250418$20250422$20250809$EXP$$US-ASTRAZENECA-202504USA016231US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$US$US
252260073$25226007$3$F$20250401$20250707$20250422$20250714$PER$$US-SA-2025SA040597$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250714$$HP$US$US
252261292$25226129$2$F$20240712$20250415$20250422$20250810$EXP$$US-ASTRAZENECA-202504USA012744US$ALEXION PHARMACEUTICALS$$51$YR$A$F$Y$$$20250810$$$US$US
252263422$25226342$2$F$20240408$20250729$20250422$20250801$EXP$$US-JNJFOC-20250424667$JOHNSON AND JOHNSON$$$$E$M$Y$$$20250801$$HP$US$US
252263552$25226355$2$F$$20250414$20250422$20250809$EXP$$JP-ASTRAZENECA-202504GLO015639JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$JP$JP
252266503$25226650$3$F$$20250515$20250422$20250803$EXP$$US-ASTRAZENECA-202409USA015082US$ALEXION PHARMACEUTICALS$$36$YR$A$F$Y$$$20250803$$$US$US
252267642$25226764$2$F$20250406$20250414$20250422$20250803$EXP$$US-ASTRAZENECA-202504USA011545US$ALEXION PHARMACEUTICALS$$43$YR$A$F$Y$$$20250803$$$US$US
252270753$25227075$3$F$$20250515$20250422$20250809$EXP$$US-ASTRAZENECA-202504USA012774US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250809$$$US$US
252271763$25227176$3$F$20250407$20250923$20250422$20250930$PER$$US-BIOMARINAP-US-2025-165256$BIOMARIN$$32$YR$$F$Y$151.47$KG$20250930$$$US$US
252272822$25227282$2$F$$20250415$20250422$20250809$EXP$$CA-ASTRAZENECA-202504CAN012901CA$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$113$KG$20250809$$$CA$CA
252277643$25227764$3$F$20250101$20250805$20250423$20250811$PER$$US-SA-2025SA116431$SANOFI AVENTIS$$4$YR$C$M$Y$$$20250811$$HP$US$US
252282032$25228203$2$F$$20250704$20250423$20250707$PER$$NVSC2025US066172$NOVARTIS$$$$$$Y$$$20250707$$MD$US$US
252285093$25228509$3$F$20250404$20250509$20250423$20250809$EXP$$EU-ASTRAZENECA-202504EEA014148RO$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$84$KG$20250809$$MD$EU$EU
252307252$25230725$2$F$20250701$20250715$20250423$20250720$PER$$US-SA-2025SA116590$SANOFI AVENTIS$$61$YR$A$M$Y$100.45$KG$20250721$$MD$US$US
252311992$25231199$2$F$$20250416$20250423$20250809$EXP$$US-ASTRAZENECA-202504USA014324US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
252323912$25232391$2$F$20250101$20250919$20250423$20250927$PER$$US-SA-2025SA116673$SANOFI AVENTIS$$46$YR$A$M$Y$$$20250926$$HP$US$US
252327992$25232799$2$F$$20250723$20250424$20250807$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-504731$RANBAXY$Achando P, Paradela AM. MALA (METFORMIN-ASSOCIATED LACTIC ACIDOSIS) - ABOUT TWO CASES IN CENTRO HOSPITALAR BAIXO VOUGA. Clin Chem Lab Med. 2024;Apr 12-13;63(3):eA82-eA83;P71$84$YR$$F$Y$$$20250807$$MD$EU$EU
252329105$25232910$5$F$20250414$20250917$20250424$20250926$EXP$$US-UCBSA-2025023932$UCB$$41$YR$$F$Y$145$KG$20250926$$MD$US$US
252330663$25233066$3$F$$20250421$20250424$20250809$EXP$$CA-AstraZeneca-2024A190839$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
252332054$25233205$4$F$20250501$20250817$20250424$20250822$EXP$$US-SMPA-2025SPA004623$SUNOVION$$70$YR$$M$Y$$$20250821$$$US$US
252345442$25234544$2$F$$20250417$20250424$20250802$EXP$$US-ASTRAZENECA-202504USA017649US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
252357392$25235739$2$F$$20250723$20250424$20250723$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-060624$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250723$$CN$US$US
252358162$25235816$2$F$20200910$20250801$20250424$20250807$EXP$$NVSC2023IN278379$NOVARTIS$$33$YR$$M$Y$$$20250807$$CN$IN$IN
252365272$25236527$2$F$$20250909$20250424$20250911$PER$$US-PFIZER INC-PV202500048307$PFIZER$$47$YR$$F$Y$$$20250911$$HP$US$US
252374092$25237409$2$F$$20250901$20250425$20250903$EXP$$JP-ASTELLAS-2025-AER-022749$ASTELLAS$$8$DEC$E$M$Y$$$20250903$$MD$JP$JP
252377632$25237763$2$F$$20250807$20250425$20250827$PER$$US-UCBSA-2025016150$UCB$$$$$F$Y$77$KG$20250827$$CN$US$US
252378513$25237851$3$F$20250123$20250827$20250425$20250829$EXP$$CA-CELLTRION INC.-2025CA003308$CELLTRION$$$$$$Y$$$20250829$$HP$CA$CA
252381322$25238132$2$F$20250423$20250423$20250425$20250802$EXP$$US-ASTRAZENECA-202504USA020204US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
252394532$25239453$2$F$20230508$20250715$20250425$20250717$PER$$US-GILEAD-2025-0711604$GILEAD$$39$YR$A$M$Y$$$20250717$$LW$US$US
252398142$25239814$2$F$$20250418$20250425$20250809$EXP$$US-ASTRAZENECA-202504USA016141US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250809$$$US$US
252400856$25240085$6$F$$20250724$20250425$20250728$30DAY$$US-PFIZER INC-202500085677$PFIZER$$13$YR$$F$Y$$$20250728$$CN$US$US
252404403$25240440$3$F$$20250418$20250425$20250802$EXP$$EU-ASTRAZENECA-202504EEA019595AT$ALEXION PHARMACEUTICALS$Hemmlich B, Sanchez-Alamo B, Schirmer JH, Bert A, Blockmans D, Cid MC, Holle JU, Hollinger N, et. al.. Eular recommendations for the management of ANCA-associated vascultis: 2022 update. Not provided$$$$F$Y$$$20250802$$MD$EU$EU
252411582$25241158$2$F$20240101$20250402$20250425$20250701$PER$$US-KENVUE-20250400445$Kenvue$$86$YR$$F$Y$$$20250701$$CN$US$US
252412632$25241263$2$F$$20250624$20250425$20250705$EXP$$JP-009507513-2277860$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250705$$MD$JP$JP
252428112$25242811$2$F$$20250421$20250427$20250802$EXP$$US-ASTRAZENECA-202504USA021048US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
252429702$25242970$2$F$20250421$20250421$20250428$20250803$EXP$$JP-ASTRAZENECA-202504GLO019165JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$MD$JP$JP
252434752$25243475$2$F$20241010$20250731$20250428$20250806$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-053975$BOEHRINGER INGELHEIM$$77$YR$E$F$Y$$$20250806$$$CA$CA
252439332$25243933$2$F$$20250422$20250428$20250803$EXP$$US-ASTRAZENECA-202504USA018967US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
252440782$25244078$2$F$20250318$20250422$20250428$20250802$EXP$$EU-ASTRAZENECA-202504EEA018782IE$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250802$$$EU$EU
252458592$25245859$2$F$$20250422$20250428$20250810$EXP$$ZA-ASTRAZENECA-202504SSA018371ZA$ALEXION PHARMACEUTICALS$$63$YR$A$F$Y$$$20250810$$$ZA$ZA
252485352$25248535$2$F$20210101$20250715$20250429$20250729$EXP$GB-EMA-DD-20250220-7483181-080018$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-04229$ALKEM$$$$$F$Y$$$20250729$$CN$GB$GB
252487392$25248739$2$F$$20250421$20250429$20250721$PER$$US-BEH-2025202782$CSL BEHRING$$79$YR$E$F$Y$73.016$KG$20250721$$CN$US$US
252493982$25249398$2$F$$20250719$20250429$20250722$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-505068$RANBAXY$Edagawa T, Iwagami H, Akamatsu T, Nakano S, Wakita M, Konishi T, et al. Clinicopathological Features of Methotrexate-associated Lymphoproliferative Disorders in the Gastrointestinal Tract. Intern Med. 2025;64 (5):687-693$89$YR$$F$Y$$$20250722$$HP$JP$JP
252495372$25249537$2$F$$20250422$20250429$20250809$EXP$$SA-ASTRAZENECA-202504MES019398SA$ALEXION PHARMACEUTICALS$$30$YR$A$F$Y$$$20250809$$$SA$SA
252499892$25249989$2$F$$20250425$20250429$20250802$EXP$$CN-ASTRAZENECA-202504CHN021957CN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$CN$CN
252502152$25250215$2$F$$20250424$20250429$20250809$EXP$$US-ASTRAZENECA-202504USA021267US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
252502804$25250280$4$F$20250101$20250806$20250429$20250812$EXP$$CA-UCBSA-2025024746$UCB$$$$$F$Y$$$20250812$$CN$CA$CA
252507902$25250790$2$F$$20250422$20250429$20250809$EXP$$EU-ASTRAZENECA-202504GLO020793IT$ALEXION PHARMACEUTICALS$Di Bari S, Izzo F, Bresciani L, Mancarella G, Garattini S, Gasperin A, Di Trento D, Grimaldi A, Parente A, Marocco R, Carraro A, Kertusha B, Tieghi T, Del Borgo C, Vita S, Guardiani M, Pasquazzi C, Spagnoli A, Alunni Fegatelli D and Lichtner M. Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience. Frontiers in Immunology. 2025;16$67$YR$E$F$Y$$$20250809$$$EU$EU
252512552$25251255$2$F$20231214$20250725$20250429$20250728$PER$$US-GILEAD-2025-0711811$GILEAD$$57$YR$A$M$Y$$$20250728$$LW$US$US
252515673$25251567$3$F$20250325$20250617$20250429$20250708$PER$$US-TRAVERE-2025TVT00428$TRAVERE THERAPEUTICS$$47$YR$A$F$Y$$$20250708$$CN$US$US
252530802$25253080$2$F$20250410$20250428$20250430$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000315$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$CN$US$US
252536345$25253634$5$F$20240101$20250813$20250430$20250819$EXP$$US-SMPA-2025SPA004118$SUNOVION$$75$YR$$M$Y$$$20250818$$$US$US
252536385$25253638$5$F$$20250719$20250430$20250728$EXP$$US-SMPA-2025SPA004903$SUNOVION$$$$$$Y$$$20250728$$CN$US$US
252541382$25254138$2$F$$20250424$20250430$20250810$EXP$$BR-ASTRAZENECA-202504SAM021429BR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$BR$BR
252544902$25254490$2$F$$20250423$20250430$20250816$PER$$US-ASTRAZENECA-202504USA021442US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250816$$$US$US
252556364$25255636$4$F$20240519$20250814$20250430$20250905$EXP$$EU-SERVIER-S24007419$SERVIER$$$$$$Y$$$20250905$$MD$EU$EU
252561123$25256112$3$F$20250402$20250804$20250430$20250813$PER$$US-SMPA-2025SPA004157$SUNOVION$$61$YR$$M$Y$$$20250812$$$US$US
252563323$25256332$3$F$$20250827$20250430$20250903$EXP$$US-TAKEDA-2025TUS041294$TAKEDA$$$$$F$Y$$$20250903$$$US$US
252573432$25257343$2$F$20250101$20250703$20250430$20250708$EXP$$CA-ABBVIE-6253362$ABBVIE$$68$YR$$M$Y$$$20250708$$CN$CA$CA
252580363$25258036$3$F$$20250722$20250501$20250723$EXP$$NVSC2025GB066829$NOVARTIS$$$$$F$Y$$$20250723$$CN$GB$GB
252584402$25258440$2$F$20240701$20250926$20250501$20250926$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-505273$RANBAXY$$95$YR$$F$Y$$$20250926$$HP$AU$AU
252589154$25258915$4$F$20250401$20250921$20250501$20250930$EXP$$KR-Eisai-EC-2025-188213$EISAI$$82$YR$E$F$Y$49$KG$20250930$$MD$KR$KR
252596744$25259674$4$F$20240101$20250813$20250501$20250818$EXP$$US-UCBSA-2025023078$UCB$$$$$F$Y$$$20250818$$CN$US$US
252598542$25259854$2$F$20250424$20250425$20250501$20250803$EXP$$CO-ASTRAZENECA-202504SAM022831CO$ALEXION PHARMACEUTICALS$$73$YR$E$F$Y$50$KG$20250803$$$CO$CO
252602562$25260256$2$F$20250401$20250813$20250501$20250821$EXP$$US-UCBSA-2025025342$UCB$$26$YR$$F$Y$$$20250821$$HP$US$US
252603582$25260358$2$F$$20250428$20250501$20250802$EXP$$US-ASTRAZENECA-202504USA024140US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
252611872$25261187$2$F$20250101$20250918$20250501$20250920$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-062854$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$M$Y$$$20250920$$$US$US
252621364$25262136$4$F$20250429$20250715$20250502$20250716$EXP$$NVSC2025US071345$NOVARTIS$$81$YR$$M$Y$77.6$KG$20250716$$HP$US$US
252624962$25262496$2$F$20250426$20250429$20250502$20250809$EXP$$US-ASTRAZENECA-202504USA025416US$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250809$$PH$US$US
252627713$25262771$3$F$20250101$20250818$20250502$20250821$PER$$US-BAUSCHBL-2025BNL007397$BAUSCH AND LOMB$$86$YR$$F$Y$$$20250822$$CN$US$US
252631902$25263190$2$F$$20250428$20250502$20250816$PER$$US-ASTRAZENECA-202504USA023947US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$US$US
252637923$25263792$3$F$20250401$20250806$20250502$20250813$EXP$$CA-CELLTRION INC.-2025CA013027$CELLTRION$$$$$$Y$$$20250813$$HP$CA$CA
252643452$25264345$2$F$$20250424$20250502$20250822$EXP$$US-JNJFOC-20250433916$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20250822$$MD$US$US
252649422$25264942$2$F$$20250429$20250502$20250809$EXP$$CN-ASTRAZENECA-202504GLO026239CN$ALEXION PHARMACEUTICALS$Lu Y, Fang D, Guo J and Huang H.. Partial transformation from non-small cell lung cancer to small cell lung cancer: a case report and literatures review. Frontiers in Oncology. 2025;15$33$YR$A$F$Y$$$20250809$$$CN$CN
252662412$25266241$2$F$$20250428$20250504$20250809$EXP$$CA-ASTRAZENECA-202504CAN023976CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
252662893$25266289$3$F$$20250829$20250504$20250902$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-063944$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$F$Y$$$20250902$$CN$US$US
252665565$25266556$5$F$20250413$20250917$20250505$20250926$EXP$$CA-ASTRAZENECA-202504CAN025562CA$ALEXION PHARMACEUTICALS$$59$YR$A$M$Y$$$20250926$$$CA$CA
252665702$25266570$2$F$$20250430$20250505$20250809$EXP$$ZA-ASTRAZENECA-202504SSA026685ZA$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250809$$$ZA$ZA
252666022$25266602$2$F$$20250428$20250505$20250809$EXP$$CA-ASTRAZENECA-202504CAN024503CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$CA$CA
252666973$25266697$3$F$20250523$20250528$20250505$20250809$EXP$$CA-ASTRAZENECA-202504CAN027353CA$ALEXION PHARMACEUTICALS$$66$YR$E$F$Y$$$20250809$$$CA$CA
252668972$25266897$2$F$$20250430$20250505$20250810$PER$$US-ASTRAZENECA-202504USA008211US$ALEXION PHARMACEUTICALS$$78$YR$E$M$Y$$$20250810$$PH$US$US
252669202$25266920$2$F$$20250428$20250505$20250809$EXP$$US-ASTRAZENECA-202504GBR024051US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$$US$GB
252671103$25267110$3$F$$20250827$20250505$20250902$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-004978$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250902$$CN$US$US
252671133$25267113$3$F$20250330$20250829$20250505$20250904$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-005016$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20250904$$CN$US$US
252673186$25267318$6$F$20250502$20250820$20250505$20250826$PER$$US-BIOVITRUM-2025-US-006159$BIOVITRUM$$59$YR$$M$Y$$$20250826$$CN$US$US
252674042$25267404$2$F$20250307$20250701$20250505$20250709$EXP$$NVSC2025ES070883$NOVARTIS$$22$YR$$M$Y$60$KG$20250709$$MD$EU$EU
252675542$25267554$2$F$$20250428$20250505$20250809$EXP$$US-ASTRAZENECA-202504USA024457US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
252680062$25268006$2$F$$20250430$20250505$20250804$EXP$$US-ASTRAZENECA-202504USA027702US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250804$$MD$US$US
252681292$25268129$2$F$20231002$20250430$20250505$20250809$EXP$$JP-ASTRAZENECA-202504GLO028294JP$ALEXION PHARMACEUTICALS$Tsumura H, et al.. P33-3 Retrospective review of Durvalumab + Gemcitabine + Cisplatin combination therapy for unresectable advanced or recurrent biliary cancer in our hospital.. Journal of Japan Biliary Association. 2024;38 (3):563-$8$DEC$E$M$Y$$$20250809$$MD$JP$JP
252684603$25268460$3$F$20250101$20250828$20250505$20250902$EXP$$US-SA-2025SA123178$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250902$$HP$US$US
252687502$25268750$2$F$20250101$20250711$20250505$20250716$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-010985$JAZZ$$51$YR$$F$Y$$$20250716$$$US$US
252697013$25269701$3$F$20250101$20250528$20250505$20250810$EXP$$US-ASTRAZENECA-202504USA015195US$ALEXION PHARMACEUTICALS$$71$YR$E$F$Y$$$20250810$$MD$US$US
252708622$25270862$2$F$$20250429$20250506$20250809$EXP$$CA-ASTRAZENECA-202504CAN027128CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$CA$CA
252721852$25272185$2$F$20250201$20250430$20250506$20250803$EXP$$CA-ASTRAZENECA-202504CAN027207CA$ALEXION PHARMACEUTICALS$$81$YR$$M$Y$$$20250803$$$CA$CA
252721882$25272188$2$F$$20250502$20250506$20250810$EXP$$US-ASTRAZENECA-202505USA001076US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$US$US
252724533$25272453$3$F$$20250903$20250506$20250908$EXP$$US-BIOVITRUM-2025-US-006279$BIOVITRUM$$75$YR$$M$Y$$$20250908$$CN$US$US
252730102$25273010$2$F$$20250716$20250506$20250730$PER$$US-SMPA-2025SPA004303$SUNOVION$$$$$$Y$$$20250730$$CN$US$US
252740422$25274042$2$F$20250422$20250730$20250506$20250806$PER$$US-SYNDAX PHARMACEUTICALS, INC.-2025US000390$SYNDAX$$61$YR$$F$Y$97.959$KG$20250806$$CN$US$US
252748203$25274820$3$F$$20250708$20250506$20250710$EXP$$US-PFIZER INC-PV202500053597$PFIZER$$$$A$F$Y$$$20250710$$LW$US$US
252754743$25275474$3$F$20250101$20250822$20250506$20250828$EXP$$US-ABBVIE-6261716$ABBVIE$$70$YR$$M$Y$$$20250828$$CN$US$US
252758492$25275849$2$F$20250322$20250530$20250507$20250805$PER$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00301$AIMMUNE$$$$$$Y$$$20250805$$HP$US$US
252767332$25276733$2$F$20250311$20250430$20250507$20250803$EXP$$CN-ASTRAZENECA-202505CHN000451CN$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$$$20250803$$$CN$CN
252769712$25276971$2$F$$20250811$20250507$20250820$PER$$US-SMPA-2025SPA004382$SUNOVION$$81$YR$$M$Y$$$20250819$$$US$US
252770542$25277054$2$F$$20250505$20250507$20250816$PER$$US-ASTRAZENECA-202505USA002257US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
252770722$25277072$2$F$20250101$20250501$20250507$20250803$EXP$EU-AFSSAPS-BX2025000634$EU-ASTRAZENECA-202505GLO000056FR$ALEXION PHARMACEUTICALS$$69$YR$E$F$Y$51$KG$20250803$$MD$EU$EU
252798643$25279864$3$F$$20250804$20250507$20250805$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-066262$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$F$Y$$$20250806$$CN$US$US
252802222$25280222$2$F$$20250505$20250507$20250810$EXP$$US-ASTRAZENECA-202505USA002241US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
252805222$25280522$2$F$$20250505$20250508$20250803$EXP$$AU-ASTRAZENECA-202505OCE001470AU$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250803$$MD$AU$AU
252806182$25280618$2$F$$20250506$20250508$20250816$PER$$US-ASTRAZENECA-202505USA002961US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
252806803$25280680$3$F$20250101$20250628$20250508$20250707$EXP$$CA-CELLTRION INC.-2025CA013595$CELLTRION$$$$$$Y$$$20250707$$HP$CA$CA
252812985$25281298$5$F$20201201$20250703$20250508$20250708$EXP$GB-BRISTOL-MYERS SQUIBB COMPANY-2025-046996$GB-SANDOZ INC.-SDZ2025GB025091$SANDOZ$$79$YR$$M$Y$$$20250708$$HP$GB$GB
252813142$25281314$2$F$$20250626$20250508$20250703$EXP$$US-GRAVITIPHARMA-GRA-2504-US-LIT-0259$GRAVITI PHARMACEUTICALS PRIVATE LIMITED$Sze AH, Pola AS, Smith AG, Vora J, Greenage MP.A Case of Clozapine Induced Mania-Like Symptoms in the Treatment of Schizophrenia.Psychopharmacol-Bull.2025;55 (3):56-59$47$YR$A$M$Y$$$20250703$$MD$US$US
252814093$25281409$3$F$20250426$20250626$20250508$20250704$EXP$$JP-AMGEN-JPNSP2025087028$AMGEN$$$$$$Y$$$20250704$$MD$JP$JP
252814553$25281455$3$F$$20250506$20250508$20250809$EXP$$US-ASTRAZENECA-202505USA003162US$ALEXION PHARMACEUTICALS$$$$$F$Y$103$KG$20250809$$$US$US
252818733$25281873$3$F$$20250815$20250508$20250825$EXP$$EU-CELLTRION INC.-2025DE013095$CELLTRION$Fick F, Kaschner K, Banys-Paluchowski M, Schiemenz C, Belousova V, Rody A, et al.. Bilateral papilledema and vision loss under adjuvant chemotherapy with Carboplatin and Doxetaxel - a rare presentation of central neurotoxicity. Geburtshilfe und Frauenheilkunde. 2024;84(10):122-3$$$$$Y$$$20250825$$HP$EU$EU
252836633$25283663$3$F$$20250425$20250508$20250918$EXP$$MX-NOVOPROD-1422576$NOVO NORDISK$$$$$M$Y$$$20250918$$CN$MX$MX
252848742$25284874$2$F$$20250506$20250508$20250816$PER$$US-ASTRAZENECA-202505USA004601US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$MD$US$US
252854372$25285437$2$F$20240101$20250717$20250509$20250722$EXP$$US-ABBVIE-6029433$ABBVIE$$65$YR$$M$Y$$$20250722$$CN$US$US
252856632$25285663$2$F$$20250506$20250509$20250810$EXP$$US-ASTRAZENECA-202505USA002889US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
252861262$25286126$2$F$$20250507$20250509$20250803$EXP$$US-ASTRAZENECA-202505USA004476US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
252862924$25286292$4$F$20250310$20250805$20250509$20250813$EXP$EU-INFARMED-F202504-954$EU-JNJFOC-20250508959$JOHNSON AND JOHNSON$$27$YR$A$M$Y$70$KG$20250813$$PH$EU$EU
252862973$25286297$3$F$$20250708$20250509$20250717$PER$$US-ROCHE-10000272267$ROCHE$$$$A$F$Y$$$20250717$$CN$US$US
252864072$25286407$2$F$20250422$20250507$20250509$20250806$EXP$$US-ASTRAZENECA-202505USA004513US$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$$$20250806$$$US$US
252877872$25287787$2$F$$20250715$20250509$20250721$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-005310$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250721$$CN$US$US
252879892$25287989$2$F$$20250704$20250509$20250708$EXP$$JP-ABBVIE-6275466$ABBVIE$$$$E$$Y$$$20250708$$MD$JP$JP
252879952$25287995$2$F$$20250630$20250509$20250704$EXP$$US-UCBSA-2025026612$UCB$$$$$F$Y$$$20250704$$HP$US$US
252896432$25289643$2$F$20250425$20250624$20250509$20250702$EXP$$BR-BAYER-2025A059576$BAYER HEALTHCARE PHARMACEUTICALS INC.$$57$YR$A$F$Y$$$20250702$$CN$BR$BR
252897274$25289727$4$F$$20250709$20250509$20250710$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-067499$BRISTOL-MYERS SQUIBB COMPANY$$73$YR$E$F$Y$$$20250710$$CN$US$US
252899862$25289986$2$F$$20250508$20250509$20250810$PER$$US-ASTRAZENECA-202505USA005443US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
252900092$25290009$2$F$$20250709$20250509$20250710$EXP$$NVSC2025US073985$NOVARTIS$$$$$F$Y$$$20250710$$MD$US$US
252904902$25290490$2$F$$20250506$20250510$20250803$EXP$$US-ASTRAZENECA-202505USA002971US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$US$US
252906842$25290684$2$F$20250401$20250723$20250510$20250729$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-025603$BOEHRINGER INGELHEIM$$80$YR$E$F$Y$97.3$KG$20250729$$$US$US
252912322$25291232$2$F$20250211$20250822$20250510$20250829$PER$$US-SA-2025SA120357$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250829$$HP$US$US
252913112$25291311$2$F$20250101$20250722$20250510$20250727$PER$$US-SA-2025SA119091$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250727$$MD$US$US
252914002$25291400$2$F$20250401$20250721$20250510$20250727$PER$$US-SA-2025SA117261$SANOFI AVENTIS$$16$YR$T$F$Y$$$20250727$$MD$US$US
252928402$25292840$2$F$$20250711$20250510$20250716$PER$$US-SA-2025SA122748$SANOFI AVENTIS$$9$YR$C$F$Y$$$20250716$$HP$US$US
252928992$25292899$2$F$20250101$20250730$20250510$20250806$PER$$US-SA-2025SA122597$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250806$$HP$US$US
252934232$25293423$2$F$20250401$20250902$20250510$20250909$PER$$US-SA-2025SA124515$SANOFI AVENTIS$$1$YR$I$M$Y$$$20250909$$HP$US$US
252937682$25293768$2$F$20250401$20250630$20250510$20250705$PER$$US-SA-2025SA123511$SANOFI AVENTIS$$17$YR$T$M$Y$$$20250705$$MD$US$US
252949352$25294935$2$F$$20250819$20250511$20250825$PER$$US-SA-2025SA128792$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250825$$HP$US$US
252953402$25295340$2$F$$20250905$20250511$20250914$PER$$US-SA-2025SA130098$SANOFI AVENTIS$$15$YR$T$M$Y$$$20250914$$HP$US$US
252957453$25295745$3$F$20250101$20250829$20250511$20250904$PER$$US-SA-2025SA130608$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250904$$HP$US$US
252957764$25295776$4$F$20250528$20250716$20250511$20250723$PER$$US-SA-2025SA133252$SANOFI AVENTIS$$80$YR$E$F$Y$52.27$KG$20250723$$MD$US$US
252959674$25295967$4$F$20250101$20250731$20250511$20250808$PER$$US-SA-2025SA126715$SANOFI AVENTIS$$55$YR$A$F$Y$$$20250808$$HP$US$US
252976373$25297637$3$F$$20250901$20250511$20250912$EXP$CH-SM-2025-03496$CH-ABBVIE-6275422$ABBVIE$$22$YR$$$Y$64$KG$20250910$$PH$CH$CH
252986162$25298616$2$F$$20250508$20250512$20250803$EXP$$US-ASTRAZENECA-202505USA005594US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$MD$US$US
252987522$25298752$2$F$20250416$20250627$20250512$20250710$EXP$$EU-MELINTA THERAPEUTICS, LLC-ES-MLNT-25-00117$Unknown Manufacturer$$$$$$Y$$$20250710$$MD$EU$EU
252991082$25299108$2$F$20250401$20250729$20250512$20250804$EXP$$US-ABBVIE-6250050$ABBVIE$$63$YR$$F$Y$$$20250804$$CN$US$US
252993002$25299300$2$F$$20250508$20250512$20250803$EXP$$US-ASTRAZENECA-202505USA006576US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
252994802$25299480$2$F$20240819$20250507$20250512$20250810$EXP$$JP-ASTRAZENECA-202504GLO022987JP$ALEXION PHARMACEUTICALS$$84$YR$E$M$Y$68$KG$20250810$$MD$JP$JP
253000262$25300026$2$F$20250101$20250727$20250512$20250804$EXP$$US-BEH-2025204174$CSL BEHRING$$34$YR$A$F$Y$$$20250804$$HP$US$US
253005248$25300524$8$F$20250422$20250709$20250512$20250717$30DAY$$US-PFIZER INC-202500094837$PFIZER$$13$YR$$F$Y$36.281$KG$20250717$$MD$US$US
253008632$25300863$2$F$20250502$20250505$20250512$20250816$PER$$US-ASTRAZENECA-202505USA001723US$ALEXION PHARMACEUTICALS$$57$YR$A$$Y$$$20250816$$$US$US
253020672$25302067$2$F$20250101$20250630$20250512$20250704$EXP$$US-ABBVIE-6269869$ABBVIE$$61$YR$$F$Y$$$20250704$$CN$US$US
253020872$25302087$2$F$20250316$20250507$20250512$20250810$EXP$$US-ASTRAZENECA-202505USA004306US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
253025293$25302529$3$F$$20250623$20250512$20250702$EXP$$NVSC2025AU075829$NOVARTIS$$$$N$F$Y$$$20250702$$MD$AU$AU
253027072$25302707$2$F$$20250508$20250512$20250810$EXP$$US-ASTRAZENECA-202505USA005666US$ALEXION PHARMACEUTICALS$$$$$F$Y$71$KG$20250810$$$US$US
253037302$25303730$2$F$$20250507$20250513$20250803$EXP$$AU-ASTRAZENECA-202505OCE003508AU$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$AU$AU
253042852$25304285$2$F$$20250710$20250513$20250716$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-005564$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250716$$CN$US$US
253050282$25305028$2$F$20241001$20250709$20250513$20250714$EXP$$IL-PFIZER INC-PV202500055984$PFIZER$$12$YR$$M$Y$$$20250714$$MD$IL$IL
253061253$25306125$3$F$$20250715$20250513$20250720$30DAY$$US-SANDOZ INC.-SDZ2025US029027$SANDOZ$$$$$F$Y$$$20250720$$CN$US$US
253073684$25307368$4$F$20250501$20250709$20250513$20250711$EXP$$US-ABBVIE-6278891$ABBVIE$$70$YR$$M$Y$$$20250711$$CN$US$US
253074452$25307445$2$F$$20240608$20250513$20250810$EXP$$US-ALXN-202404USA000971US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250810$$$US$US
253076023$25307602$3$F$20250201$20250909$20250513$20250909$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-069149$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$F$Y$$$20250909$$$US$US
253078705$25307870$5$F$20250121$20250704$20250513$20250810$EXP$EU-PEI-CADR2025335896$EU-ASTRAZENECA-202505GLO006195DE$ALEXION PHARMACEUTICALS$$54$YR$A$F$Y$72$KG$20250810$$MD$EU$EU
253082734$25308273$4$F$20250101$20250821$20250513$20250825$EXP$$US-SA-2025SA030276$SANOFI AVENTIS$$78$YR$E$F$Y$$$20250825$$HP$US$US
253085323$25308532$3$F$20250601$20250630$20250513$20250707$PER$$US-SA-2025SA132602$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250707$$HP$US$US
253085412$25308541$2$F$20250101$20250730$20250513$20250804$PER$$US-SA-2025SA135330$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250804$$CN$US$US
253087573$25308757$3$F$20250101$20250724$20250513$20250801$PER$$US-SA-2025SA134669$SANOFI AVENTIS$$52$YR$A$M$Y$$$20250801$$HP$US$US
253091865$25309186$5$F$$20250911$20250513$20250922$PER$$US-SMPA-2025SPA005217$SUNOVION$$65$YR$$M$Y$$$20250920$$$US$US
253100245$25310024$5$F$20250401$20250711$20250514$20250717$EXP$$JP-ASTELLAS-2025-AER-020832$ASTELLAS$$6$DEC$A$M$Y$$$20250717$$HP$JP$JP
253103254$25310325$4$F$$20250903$20250514$20250908$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-005516$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250908$$CN$US$US
253107492$25310749$2$F$$20250924$20250514$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-069562$BRISTOL-MYERS SQUIBB COMPANY$$53$YR$A$M$Y$$$20250926$$$US$US
253111164$25311116$4$F$20240509$20250915$20250514$20250917$EXP$$NVSC2025CO076614$NOVARTIS$$61$YR$$F$Y$60$KG$20250917$$CN$CO$CO
253111223$25311122$3$F$$20250811$20250514$20250824$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-03951$LUPIN$$$$$$Y$$$20250824$$PH$US$US
253113743$25311374$3$F$$20250908$20250514$20250918$PER$$US-SMPA-2025SPA004868$SUNOVION$$82$YR$$M$Y$$$20250912$$$US$US
253114222$25311422$2$F$$20250820$20250514$20250830$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-03898$LUPIN$$$$$$Y$$$20250830$$$US$US
253115552$25311555$2$F$20250101$20250818$20250514$20250820$EXP$$NVSC2024US204012$NOVARTIS$$90$YR$$M$Y$$$20250820$$CN$US$US
253118762$25311876$2$F$20250601$20250801$20250514$20250807$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-005625$ACADIA PHARMACEUTICALS$$51$YR$$F$Y$$$20250807$$CN$US$US
253128364$25312836$4$F$$20250706$20250514$20250710$EXP$$PE-PFIZER INC-PV202500056584$PFIZER$$75$YR$$F$Y$$$20250710$$CN$PE$PE
253138945$25313894$5$F$20250501$20250809$20250514$20250811$30DAY$$EU-PFIZER INC-PV202500055774$PFIZER$$9$YR$$F$Y$23$KG$20250811$$CN$EU$EU
253145832$25314583$2$F$$20250814$20250514$20250820$EXP$$EU-MYLANLABS-2025M1039852$MYLAN$$$$$F$Y$$$20250820$$MD$EU$EU
253149352$25314935$2$F$$20250819$20250514$20250825$PER$$US-SA-2025SA136192$SANOFI AVENTIS$$$$E$F$Y$71.82$KG$20250825$$MD$US$US
253149752$25314975$2$F$20250501$20250626$20250514$20250703$PER$$US-SA-2025SA137177$SANOFI AVENTIS$$66$YR$E$M$Y$67.73$KG$20250703$$MD$US$US
253150412$25315041$2$F$20250101$20250814$20250514$20250821$PER$$US-SA-2025SA137486$SANOFI AVENTIS$$22$YR$A$M$Y$$$20250821$$HP$US$US
253158302$25315830$2$F$$20250508$20250515$20250803$EXP$$CA-ASTRAZENECA-202505CAN000956CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$CA$CA
253158962$25315896$2$F$$20250509$20250515$20250809$EXP$$BR-ASTRAZENECA-202505SAM006502BR$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$BR$BR
253172272$25317227$2$F$20240730$20250814$20250515$20250818$EXP$$US-ABBVIE-6279374$ABBVIE$$56$YR$$F$Y$121$KG$20250818$$MD$US$US
253172632$25317263$2$F$$20250815$20250515$20250822$EXP$$US-TAKEDA-US201805360$TAKEDA$$$$$F$Y$57$KG$20250822$$$US$US
253177253$25317725$3$F$20250101$20250814$20250515$20250820$EXP$$US-CIPLA LTD.-2025US05478$CIPLA$$$$$$Y$$$20250820$$CN$US$US
253177535$25317753$5$F$20250813$20250820$20250515$20250822$PER$$NVSC2025US078487$NOVARTIS$$46$YR$$M$Y$$$20250823$$HP$US$US
253183857$25318385$7$F$20250416$20250927$20250515$20250929$EXP$$US-PFIZER INC-202500070369$PFIZER$$67$YR$$M$Y$62.6$KG$20250929$$CN$US$US
253187513$25318751$3$F$20241008$20250926$20250515$20250930$EXP$$JP-shionogi-202500005008$SHIONOGI$$76$YR$E$M$Y$90$KG$20250930$$MD$JP$JP
253190862$25319086$2$F$$20250801$20250515$20250808$EXP$$US-BIOGEN-2025BI01310905$BIOGEN$$$$$F$Y$$$20250808$$HP$US$US
253191832$25319183$2$F$$20250509$20250515$20250807$PER$$US-ABBVIE-6279473$ABBVIE$$$$$F$Y$$$20250807$$HP$US$US
253202333$25320233$3$F$20250401$20250814$20250515$20250821$EXP$$MX-BIOMARINAP-MX-2025-165905$BIOMARIN$$$$I$F$Y$6$KG$20250821$$$MX$MX
253204932$25320493$2$F$20250414$20250813$20250515$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-070365$BRISTOL-MYERS SQUIBB COMPANY$$37$YR$A$$Y$$$20250813$$HP$US$US
253216152$25321615$2$F$$20250513$20250516$20250803$EXP$$EU-ASTRAZENECA-202505EEA010797IE$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$$EU$EU
253222094$25322209$4$F$20240101$20250815$20250516$20250911$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000457$DECIPHERA PHARMACEUTICALS$$85$YR$E$F$Y$$$20250911$$MD$US$US
253223073$25322307$3$F$20250124$20250711$20250516$20250718$EXP$$MX-ROCHE-10000283609$ROCHE$$40$YR$A$M$Y$76.1$KG$20250718$$CN$MX$MX
253247562$25324756$2$F$$20250812$20250516$20250813$EXP$$US-JNJFOC-20250513752$JOHNSON AND JOHNSON$$67$YR$E$M$Y$$$20250814$$PH$US$US
253248965$25324896$5$F$$20250710$20250516$20250716$30DAY$$CO-PFIZER INC-PV202500058030$PFIZER$$$$T$M$Y$$$20250716$$CN$CO$CO
253258974$25325897$4$F$20250511$20250715$20250516$20250718$PER$$AR-PFIZER INC-202500099054$PFIZER$$40$YR$$F$Y$$$20250718$$CN$AR$AR
253262242$25326224$2$F$$20250725$20250516$20250818$EXP$$US-GALDERMA-US2025006029$GALDERMA$$$$$$Y$$$20250818$$MD$US$US
253262942$25326294$2$F$20250413$20250523$20250516$20250813$PER$$US-GALDERMA-US2025006335$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
253274026$25327402$6$F$$20250826$20250517$20250910$EXP$$EU-AUROBINDO-AUR-APL-2025-022729$AUROBINDO$St?tzle J. From High Blood Pressure via Pediatrics to Geriatrics. Deutsche Apotheker Zeitung (German pharmacist newspaper). 2025;165(14):46-49$86$YR$$F$Y$$$20250910$$MD$EU$EU
253284003$25328400$3$F$20250101$20250918$20250518$20250926$EXP$$CO-JNJFOC-20250515857$JOHNSON AND JOHNSON$$58$YR$A$F$Y$54$KG$20250926$$CN$CO$CO
253285393$25328539$3$F$$20250723$20250519$20250731$PER$$US-SA-2025SA140990$SANOFI AVENTIS$$14$YR$T$M$Y$87.18$KG$20250731$$MD$US$US
253292582$25329258$2$F$20250101$20250806$20250519$20250812$EXP$$US-ABBVIE-6282811$ABBVIE$$52$YR$$F$Y$96$KG$20250812$$CN$US$US
253295392$25329539$2$F$$20250515$20250519$20250809$EXP$$ZA-ASTRAZENECA-202505SSA012844ZA$ALEXION PHARMACEUTICALS$$86$YR$E$F$Y$$$20250809$$$ZA$ZA
253296882$25329688$2$F$$20250516$20250519$20250810$EXP$$ZA-ASTRAZENECA-202505SSA013213ZA$ALEXION PHARMACEUTICALS$$40$YR$A$F$Y$$$20250810$$$ZA$ZA
253297602$25329760$2$F$20250303$20250514$20250519$20250803$EXP$$US-ASTRAZENECA-202505USA012348US$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250803$$MD$US$US
253303222$25330322$2$F$20250508$20250515$20250519$20250803$EXP$$CN-ASTRAZENECA-202505CHN012773CN$ALEXION PHARMACEUTICALS$$84$YR$E$F$Y$81$KG$20250803$$$CN$CN
253304773$25330477$3$F$20250514$20250709$20250519$20250715$EXP$$JP-ASTELLAS-2025-AER-026354$ASTELLAS$$67$YR$E$F$Y$$$20250715$$HP$JP$JP
253306282$25330628$2$F$$20250703$20250519$20250704$PER$$NVSC2025US079603$NOVARTIS$$$$$F$Y$$$20250704$$HP$US$US
253314322$25331432$2$F$$20250714$20250519$20250715$EXP$$CA-PFIZER INC-202400260666$PFIZER$$69$YR$$M$Y$$$20250715$$HP$CA$CA
253320222$25332022$2$F$$20250804$20250519$20250807$PER$$US-JNJFOC-20250514413$JOHNSON AND JOHNSON$$79$YR$E$F$Y$61$KG$20250807$$CN$US$US
253323154$25332315$4$F$$20250912$20250519$20250922$PER$$US-GSK-US2025AMR056235$GLAXOSMITHKLINE$$$$$M$Y$$$20250922$$$US$US
253342803$25334280$3$F$$20250820$20250520$20250830$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04162$LUPIN$$41$YR$$$Y$122.45$KG$20250830$$$US$US
253354093$25335409$3$F$20250418$20250516$20250520$20250809$EXP$$CN-ASTRAZENECA-202505CHN014165CN$ALEXION PHARMACEUTICALS$$59$YR$A$F$Y$$$20250809$$$CN$CN
253355532$25335553$2$F$$20250902$20250520$20250910$EXP$$CA-CELLTRION INC.-2025CA014804$CELLTRION$$$$$$Y$$$20250910$$HP$CA$CA
253357632$25335763$2$F$$20250625$20250520$20250703$30DAY$$EU-JNJFOC-20250516793$JOHNSON AND JOHNSON$$$$$$Y$$$20250703$$HP$EU$EU
253358872$25335887$2$F$20250201$20250709$20250520$20250721$EXP$$US-GLENMARK PHARMACEUTICALS-2025GMK100160$GLENMARK$$$$$$Y$$$20250722$$CN$US$US
253360622$25336062$2$F$20250101$20250722$20250520$20250730$EXP$$US-CATALYSTPHARMACEUTICALPARTNERS-US-CATA-25-00702$CATALYST PHARMA$$$$$$Y$$$20250730$$CN$US$US
253361316$25336131$6$F$$20250629$20250520$20250702$30DAY$$US-PFIZER INC-202500103545$PFIZER$$9$YR$$F$Y$$$20250702$$CN$US$US
253363042$25336304$2$F$20240110$20250624$20250520$20250701$EXP$$US-UCBSA-2025029161$UCB$$81$YR$$M$Y$$$20250701$$CN$US$US
253363635$25336363$5$F$$20250707$20250520$20250710$30DAY$$US-PFIZER INC-202500099685$PFIZER$$10$YR$$F$Y$$$20250710$$HP$US$US
253373993$25337399$3$F$20240801$20250818$20250520$20250818$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-070044$BRISTOL-MYERS SQUIBB COMPANY$Ishigouoka T, et al. A case of steroid-dependent immune-related adverse event after neoadjuvant chemotherapy with nivolumab + chemotherapy. The 129th Hokkaido Branch Annual Meeting of the Japanese Respiratory Society (The 2nd Joint Hokkaido Regional Meeting of 5 Respiratory-Related Societies). 2025;15.$59$YR$A$M$Y$$$20250818$$MD$JP$JP
253379443$25337944$3$F$$20250630$20250520$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-072604$BRISTOL-MYERS SQUIBB COMPANY$$68$YR$E$$Y$$$20250702$$CN$US$US
253382793$25338279$3$F$$20250520$20250520$20250810$PER$$US-ASTRAZENECA-202505USA015001US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
253388032$25338803$2$F$$20250716$20250520$20250718$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-069120$BRISTOL-MYERS SQUIBB COMPANY$$67$YR$E$M$Y$$$20250718$$CN$US$US
253391202$25339120$2$F$$20250613$20250521$20250826$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-01802$AMNEAL$$$$$F$Y$58.957$KG$20250826$$CN$US$US
253391624$25339162$4$F$20250101$20250603$20250521$20250701$PER$$US-MALLINCKRODT-MNK202502986$MALLINCKRODT$$76$YR$E$F$Y$$$20250701$$CN$US$US
253392213$25339221$3$F$$20250724$20250521$20250725$EXP$$NVSC2025US047855$NOVARTIS$$$$$F$Y$$$20250725$$CN$US$US
253393392$25339339$2$F$$20250519$20250521$20250813$EXP$$EU-ASTRAZENECA-202505EEA014373DE$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250813$$PH$EU$EU
253395293$25339529$3$F$20250101$20250811$20250521$20250818$EXP$$US-SA-2025SA144448$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250818$$CN$US$US
253395802$25339580$2$F$$20250520$20250521$20250809$EXP$$VN-ASTRAZENECA-202505ASI014800VN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$VN$VN
253396323$25339632$3$F$20250509$20250910$20250521$20250918$EXP$$CA-CELLTRION INC.-2025CA014866$CELLTRION$$$$$$Y$$$20250918$$HP$CA$CA
253396502$25339650$2$F$$20250509$20250521$20250810$EXP$$US-ASTRAZENECA-202505USA011138US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
253397182$25339718$2$F$$20250730$20250521$20250731$PER$$US-TAKEDA-2025TUS047267$TAKEDA$$$$$F$Y$64$KG$20250731$$$US$US
253403432$25340343$2$F$$20250820$20250521$20250829$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04182$LUPIN$$41$YR$$$Y$$$20250829$$$US$US
253405682$25340568$2$F$$20250515$20250521$20250810$PER$$US-ASTRAZENECA-202505USA012295US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
253408213$25340821$3$F$20250601$20250723$20250521$20250801$PER$$US-SMPA-2025SPA005246$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
253412556$25341255$6$F$20240101$20250908$20250521$20250919$EXP$$EU-AUROBINDO-AUR-APL-2025-025190$AUROBINDO$Jaroslaw Woro?, Tomasz Drygalski, Tomasz Lonc, Magdalena Kocot-K?pska, Jerzy Wordliczek. Prescription machines as a  measurable threat to the patient during  pharmacological treatment, what does it  mean for the Emergency Medical Services  and Hospital Emergency Departments.. Anesthesiology and Emergency Medicine. 2025;19:44-50$48$YR$$F$Y$$$20250919$$MD$EU$EU
253419925$25341992$5$F$$20250908$20250521$20250908$PER$$US-PFIZER INC-202400304783$PFIZER$$62$YR$$M$Y$$$20250908$$CN$US$US
253425562$25342556$2$F$20250408$20250410$20250521$20250820$PER$$US-CATALYST PHARMACEUTICALS-US-CATA-25-00543$CATALYST PHARMA$$7$YR$$M$Y$25.397$KG$20250820$$CN$US$US
253432193$25343219$3$F$$20250711$20250521$20250715$30DAY$$CO-PFIZER INC-PV202500055274$PFIZER$$$$$F$Y$$$20250715$$CN$CO$CO
253444003$25344400$3$F$20250509$20250526$20250521$20250810$EXP$$CN-ASTRAZENECA-202505CHN013984CN$ALEXION PHARMACEUTICALS$$71$YR$E$M$Y$$$20250810$$$CN$CN
253446155$25344615$5$F$20250429$20250812$20250522$20250815$PER$$MX-BIOMARINAP-MX-2025-165741$BIOMARIN$$29$YR$$F$Y$29.4$KG$20250815$$$MX$MX
253452473$25345247$3$F$$20250714$20250522$20250721$EXP$$US-SMPA-2025SPA006167$SUNOVION$$$$$$Y$$$20250721$$CN$US$US
253453123$25345312$3$F$20250101$20250801$20250522$20250806$EXP$$US-BIOGEN-2025BI01311761$BIOGEN$$$$$M$Y$$$20250806$$CN$US$US
253455382$25345538$2$F$$20250818$20250522$20250818$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-072612$BRISTOL-MYERS SQUIBB COMPANY$$8$DEC$E$F$Y$$$20250818$$MD$JP$JP
253473003$25347300$3$F$20250514$20250721$20250522$20250724$EXP$$MX-ELI_LILLY_AND_COMPANY-MX202505016957$ELI LILLY AND COMPANY$$82$YR$E$F$Y$46$KG$20250724$$CN$MX$MX
253475103$25347510$3$F$20250407$20250610$20250522$20250810$EXP$$JP-ASTRAZENECA-202505GLO017971JP$ALEXION PHARMACEUTICALS$$75$YR$E$M$Y$$$20250810$$MD$JP$JP
253479794$25347979$4$F$20241230$20250725$20250522$20250813$EXP$$EU-ABBVIE-6290455$ABBVIE$$74$YR$$F$Y$68$KG$20250813$$MD$EU$EU
253479836$25347983$6$F$20250101$20250822$20250522$20250827$EXP$$CA-PFIZER INC-202500097556$PFIZER$$14$YR$$F$Y$$$20250827$$HP$CA$CA
253481442$25348144$2$F$$20250701$20250522$20250704$PER$$US-Taiho Oncology Inc-2025-005340$TAIHO ONCOLOGY INC$$53$YR$A$M$Y$$$20250704$$CN$US$US
253482872$25348287$2$F$20250324$20250514$20250522$20250809$EXP$$JP-ASTRAZENECA-202505GLO007316JP$ALEXION PHARMACEUTICALS$$36$YR$A$F$Y$$$20250809$$MD$JP$JP
253485622$25348562$2$F$20250519$20250721$20250522$20250725$PER$$US-BIOGEN-2025BI01311755$BIOGEN$$30$YR$$M$Y$$$20250725$$CN$US$US
253491812$25349181$2$F$20250101$20250724$20250522$20250730$PER$$US-SA-2025SA145790$SANOFI AVENTIS$$52$YR$A$M$Y$$$20250730$$MD$US$US
253491822$25349182$2$F$20250101$20250819$20250522$20250823$PER$$US-SA-2025SA146256$SANOFI AVENTIS$$10$YR$C$M$Y$$$20250823$$HP$US$US
253496613$25349661$3$F$20250501$20250814$20250522$20250821$EXP$$US-EMD Serono-2025017602$EMD SERONO INC$$82$YR$E$M$Y$$$20250821$$$US$US
253503124$25350312$4$F$20250101$20250915$20250523$20250923$EXP$$US-SA-2025SA147025$SANOFI AVENTIS$$61$YR$A$F$Y$90$KG$20250923$$MD$US$US
253511172$25351117$2$F$$20250828$20250523$20250905$EXP$$CA-CELLTRION INC.-2024CA026286$CELLTRION$$$$$$Y$$$20250905$$HP$CA$CA
253518613$25351861$3$F$20250101$20250811$20250523$20250815$EXP$$US-ABBVIE-6289898$ABBVIE$$86$YR$$F$Y$$$20250815$$CN$US$US
253526246$25352624$6$F$$20250818$20250523$20250827$EXP$$US-RDY-USA/2025/05/007208$DR REDDYS$$67$YR$E$F$Y$69.85$KG$20250827$$CN$US$US
253530886$25353088$6$F$20250601$20250729$20250523$20250807$PER$$US-MALLINCKRODT-MNK202503001$MALLINCKRODT$$67$YR$$M$Y$$$20250806$$CN$US$US
253534862$25353486$2$F$$20250514$20250523$20250810$EXP$$CA-ASTRAZENECA-202503CAN017093CA$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250810$$$CA$CA
253539502$25353950$2$F$20250510$20250625$20250523$20250702$PER$$US-SA-2025SA148269$SANOFI AVENTIS$$10$YR$C$F$Y$$$20250702$$HP$US$US
253539982$25353998$2$F$20250418$20250718$20250523$20250723$PER$$US-SA-2025SA146489$SANOFI AVENTIS$$9$YR$C$M$Y$$$20250723$$HP$US$US
253545012$25354501$2$F$$20250624$20250523$20250702$EXP$$JP-009507513-2288636$MERCK SHARP + DOHME LLC$$4$DEC$$F$Y$$$20250702$$MD$JP$JP
253548032$25354803$2$F$$20250910$20250524$20250915$EXP$$US-ABBVIE-6291866$ABBVIE$$$$E$F$Y$$$20250915$$CN$US$US
253562504$25356250$4$F$20241202$20250718$20250526$20250723$EXP$$CA-UCBSA-2024063430$UCB$$67$YR$$F$Y$$$20250723$$CN$CA$CA
253564892$25356489$2$F$20250513$20250516$20250526$20250810$PER$$US-ASTRAZENECA-202505USA017539US$ALEXION PHARMACEUTICALS$$78$YR$E$M$Y$$$20250810$$$US$US
253577362$25357736$2$F$20230101$20250724$20250526$20250730$PER$$US-SA-2025SA147993$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250730$$HP$US$US
253578303$25357830$3$F$$20250922$20250526$20250926$PER$$EU-TAKEDA-2025TUS049031$TAKEDA$$$$E$F$Y$$$20250926$$$EU$EU
253591593$25359159$3$F$20241019$20250919$20250526$20250927$EXP$$EU-SA-2025SA145353$SANOFI AVENTIS$$68$YR$E$M$Y$106.5$KG$20250926$$MD$EU$EU
253596422$25359642$2$F$$20250919$20250526$20250923$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-075358$BRISTOL-MYERS SQUIBB COMPANY$$68$YR$E$M$Y$$$20250923$$$US$US
253601462$25360146$2$F$20241101$20250709$20250527$20250717$EXP$$US-ROCHE-10000199297$ROCHE$$69$YR$E$F$Y$$$20250717$$CN$US$US
253602175$25360217$5$F$20250401$20250722$20250527$20250726$EXP$$EU-ASTRAZENECA-202504GLO029084IT$ALEXION PHARMACEUTICALS$$65$YR$E$F$Y$64$KG$20250726$$$EU$EU
253607014$25360701$4$F$20220101$20250611$20250527$20250809$EXP$$MX-ASTRAZENECA-202505MEX019253MX$ALEXION PHARMACEUTICALS$$51$YR$A$F$Y$55$KG$20250809$$$MX$MX
253612173$25361217$3$F$$20250811$20250527$20250813$EXP$$CA-TAKEDA-2025TUS048383$TAKEDA$$$$$M$Y$$$20250813$$$CA$CA
253614922$25361492$2$F$$20250522$20250527$20250809$EXP$$US-ASTRAZENECA-202505USA020125US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
253618512$25361851$2$F$20250101$20250806$20250527$20250813$EXP$$US-ABBVIE-6273211$ABBVIE$$$$E$F$Y$$$20250813$$CN$US$US
253619492$25361949$2$F$$20250702$20250527$20250710$EXP$$CA-CELLTRION INC.-2025CA015390$CELLTRION$$$$$$Y$$$20250710$$HP$CA$CA
253619533$25361953$3$F$20240101$20250621$20250527$20250706$EXP$$EU-AUROBINDO-AUR-APL-2025-026603$AUROBINDO$Woron J, Drygalski T, Lonc T, Kocot-K?pska M, Wordliczek J. Prescription machines as a measurable threat to the patient during pharmacological treatment, what does it mean for the Emergency Medical Services and Hospital Emergency Departments.. Anestezjologia I Ratownictwo. 2025;19(1):44-50.$56$YR$$F$Y$$$20250706$$MD$EU$EU
253632082$25363208$2$F$$20250715$20250527$20250724$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202505022047$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250724$$CN$EU$JP
253636023$25363602$3$F$20250101$20250716$20250527$20250721$30DAY$$IL-PFIZER INC-PV202500051136$PFIZER$$5$YR$$M$Y$$$20250721$$HP$IL$IL
2536361311$25363613$11$F$20250101$20250709$20250527$20250718$30DAY$$US-PFIZER INC-202500106900$PFIZER$$10$YR$$F$Y$$$20250718$$CN$US$US
253636207$25363620$7$F$20250508$20250829$20250527$20250903$30DAY$$US-PFIZER INC-202500100509$PFIZER$$9$YR$$F$Y$$$20250903$$CN$US$US
253637072$25363707$2$F$$20250523$20250527$20250802$EXP$$US-ASTRAZENECA-202505USA020526US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250802$$$US$US
253637813$25363781$3$F$$20250718$20250527$20250718$30DAY$$CO-PFIZER INC-202500102940$PFIZER$$$$T$M$Y$$$20250718$$CN$CO$CO
253638523$25363852$3$F$20250101$20250610$20250527$20250724$EXP$$US-UNITED THERAPEUTICS-UNT-2025-017980$UNITED THERAPEUTICS$$$$$M$Y$95.238$KG$20250724$$$US$US
253640922$25364092$2$F$$20250630$20250527$20250703$PER$$US-HALEON-2244177$Haleon PLC$$$$$$Y$$$20250703$$CN$US$US
253641522$25364152$2$F$$20250523$20250527$20250809$EXP$$BR-ASTRAZENECA-202505SAM020454BR$ALEXION PHARMACEUTICALS$$63$YR$A$F$Y$$$20250809$$$BR$BR
253649872$25364987$2$F$20250501$20250826$20250527$20250904$PER$$US-SA-2025SA149603$SANOFI AVENTIS$$44$YR$A$M$Y$140.91$KG$20250904$$MD$US$US
253650292$25365029$2$F$$20250625$20250527$20250704$PER$$US-SA-2025SA149762$SANOFI AVENTIS$$$$$F$Y$$$20250704$$CN$US$US
253656852$25365685$2$F$$20250807$20250527$20250808$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-072217$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$M$Y$$$20250808$$CN$US$US
253657142$25365714$2$F$20250501$20250521$20250527$20250803$EXP$$AE-ASTRAZENECA-202505MES016899AE$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$AE$AE
253661922$25366192$2$F$$20250727$20250528$20250731$EXP$$EU-ROCHE-10000294447$ROCHE$Staubach P, Bilo B, Fluhr JW, Krause K, Kulthanan K, Salman A, et al.. UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities. JOURNAL OF DERMATOLOGICAL TREATMENT. 2025;35 (1):1-6. doi:10.1080/09546634.2024.2329784.$$$$$Y$$$20250731$$HP$EU$EU
253662242$25366224$2$F$$20250729$20250528$20250731$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-075618$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$$$20250731$$CN$US$US
253666853$25366685$3$F$20240930$20250614$20250528$20250802$EXP$$EU-ASTRAZENECA-202505EEA000769FR$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$EU$EU
253666872$25366687$2$F$20250328$20250526$20250528$20250810$EXP$$EU-ASTRAZENECA-202505EEA021061RO$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$EU$EU
253667434$25366743$4$F$20250427$20250702$20250528$20250809$EXP$$CN-ASTRAZENECA-202505CHN019337CN$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250809$$MD$CN$CN
253676142$25367614$2$F$20250404$20250529$20250528$20250827$PER$$US-CELLTRION INC.-2025US010511$CELLTRION$$$$$$Y$$$20250827$$CN$US$US
253679162$25367916$2$F$20240606$20250716$20250528$20250721$EXP$$US-ABBVIE-6296084$ABBVIE$$74$YR$$F$Y$$$20250721$$CN$US$US
253680255$25368025$5$F$20250101$20250924$20250528$20250925$EXP$$US-PFIZER INC-202500107864$PFIZER$$44$YR$$F$Y$$$20250925$$PH$US$US
253680383$25368038$3$F$20250527$20250904$20250528$20250905$PER$$NVSC2025US085494$NOVARTIS$$$$$M$Y$$$20250905$$CN$US$US
253680612$25368061$2$F$$20250710$20250528$20250710$PER$$NVSC2025US085445$NOVARTIS$$$$$$Y$$$20250710$$MD$US$US
253688502$25368850$2$F$20250127$20250705$20250528$20250709$EXP$$JP-PFIZER INC-PV202500019932$PFIZER$$57$YR$$F$Y$50$KG$20250709$$MD$JP$JP
253689913$25368991$3$F$$20250815$20250528$20250829$30DAY$$US-CIPLA LTD.-2024US10576$CIPLA$$$$$$Y$$$20250829$$CN$US$US
253695373$25369537$3$F$$20250923$20250528$20250925$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-072483$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$$$20250925$$$US$US
253699054$25369905$4$F$$20250710$20250528$20250714$EXP$$NVSC2025BR044046$NOVARTIS$$$$$F$Y$39$KG$20250714$$CN$BR$BR
253704233$25370423$3$F$20250705$20250729$20250528$20250804$PER$$US-SA-2025SA150448$SANOFI AVENTIS$$84$YR$E$M$Y$$$20250804$$MD$US$US
253706143$25370614$3$F$20250302$20250801$20250528$20250805$EXP$$US-TAKEDA-2025TUS024850$TAKEDA$$14$YR$$F$Y$76.6$KG$20250805$$$US$US
253706563$25370656$3$F$$20250912$20250528$20250924$30DAY$$US-SANDOZ INC.-SDZ2025US035724$SANDOZ$$$$$F$Y$$$20250924$$CN$US$US
253707232$25370723$2$F$20250519$20250521$20250528$20250803$EXP$$US-ASTRAZENECA-202505USA018693US$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250803$$$US$US
253709623$25370962$3$F$$20250523$20250528$20250803$EXP$$EU-ASTRAZENECA-202505EEA019723FR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
253710032$25371003$2$F$20250506$20250613$20250528$20250715$PER$$US-GLK-000644$GLAUKOS$$$$$$Y$$$20250715$$MD$US$US
253714482$25371448$2$F$20250523$20250626$20250529$20250702$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-006294$ACADIA PHARMACEUTICALS$$87$YR$$M$Y$$$20250702$$CN$US$US
253715022$25371502$2$F$$20250912$20250529$20250920$PER$$NVSC2025US085331$NOVARTIS$$$$$$Y$$$20250920$$HP$US$US
253718612$25371861$2$F$$20250825$20250529$20250825$EXP$$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-074659$BRISTOL-MYERS SQUIBB COMPANY$Idoudi S, Masson AD, Gandon C, Battistella M, Caillat-Zucman S, Pinel S, et al. Immune checkpoint inhibitors induced subcutaneous panniculitis-like T-cell lymphoma. Annales de Dermatologie et de Venereologie. 2025;152(3):1-3. doi:10.1016/j.annder.2025.103366.$67$YR$E$F$Y$$$20250825$$HP$EU$EU
253719123$25371912$3$F$$20250821$20250529$20250827$EXP$$US-SMPA-2025SPA006269$SUNOVION$$63$YR$$M$Y$$$20250826$$$US$US
253719922$25371992$2$F$$20250527$20250529$20250809$EXP$$EU-ASTRAZENECA-202505EEA022567BG$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$EU$EU
253722722$25372272$2$F$$20250821$20250529$20250830$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04422$LUPIN$$$$$$Y$$$20250830$$$US$US
253726684$25372668$4$F$20250101$20250630$20250529$20250710$PER$$US-UNITED THERAPEUTICS-UNT-2025-018238$UNITED THERAPEUTICS$$$$$M$Y$80.272$KG$20250710$$$US$US
253728722$25372872$2$F$20230401$20250820$20250529$20250826$EXP$$US-ABBVIE-5787426$ABBVIE$$70$YR$$F$Y$75$KG$20250826$$CN$US$US
253730892$25373089$2$F$20250330$20250527$20250529$20250827$PER$$US-CELLTRION INC.-2025US011840$CELLTRION$$$$$$Y$$$20250827$$HP$US$US
253745445$25374544$5$F$20250101$20250808$20250529$20250818$EXP$$US-UCBSA-2025031626$UCB$$40$YR$$F$Y$$$20250818$$CN$US$US
253746783$25374678$3$F$20250419$20250702$20250529$20250708$EXP$$JP-PFIZER INC-PV202500064701$PFIZER$$85$YR$$F$Y$$$20250708$$PH$JP$JP
253759492$25375949$2$F$20250101$20250806$20250529$20250811$PER$$US-SA-2025SA153316$SANOFI AVENTIS$$40$YR$A$M$Y$$$20250811$$HP$US$US
253762572$25376257$2$F$20250420$20250523$20250529$20250809$EXP$EU-INFARMED-T202505-67$EU-ASTRAZENECA-202505GLO024585PT$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$88$KG$20250809$$PH$EU$EU
2537628911$25376289$11$F$20250526$20250925$20250529$20250928$EXP$$CA-JNJFOC-20250532847$JOHNSON AND JOHNSON$$12$YR$T$M$Y$35$KG$20250928$$HP$CA$CA
253781033$25378103$3$F$$20250806$20250530$20250811$EXP$$US-ABBVIE-6305155$ABBVIE$$$$E$F$Y$63$KG$20250811$$CN$US$US
253784972$25378497$2$F$20241118$20250723$20250530$20250729$EXP$$BR-TAKEDA-2024TUS090862$TAKEDA$$73$YR$$F$Y$$$20250729$$$BR$BR
253795182$25379518$2$F$20250101$20250818$20250530$20250827$EXP$$JP-009507513-2288998$MERCK SHARP + DOHME LLC$$6$DEC$$F$Y$$$20250827$$MD$JP$JP
253795812$25379581$2$F$$20250828$20250530$20250828$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-077940$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$F$Y$$$20250828$$CN$US$US
253800513$25380051$3$F$20250515$20250619$20250530$20250701$EXP$$US-FARMAPROD-202505-1704$DOMPE FARMACEUTICI$$88$YR$E$F$Y$$$20250701$$MD$US$US
253802882$25380288$2$F$20250101$20250903$20250530$20250910$PER$$US-SA-2025SA153469$SANOFI AVENTIS$$80$YR$E$F$Y$74.09$KG$20250910$$MD$US$US
253804202$25380420$2$F$20250101$20250905$20250530$20250911$PER$$US-SA-2025SA152490$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250911$$HP$US$US
253804572$25380457$2$F$20250101$20250710$20250530$20250714$PER$$US-SA-2025SA153910$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250714$$CN$US$US
253805132$25380513$2$F$20250501$20250716$20250530$20250722$PER$$US-SA-2025SA154393$SANOFI AVENTIS$$15$YR$T$M$Y$$$20250722$$HP$US$US
253807292$25380729$2$F$$20250828$20250530$20250828$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-077349$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$F$Y$$$20250828$$CN$US$US
253834152$25383415$2$F$$20250704$20250602$20250708$30DAY$$CA-JNJFOC-20250538588$JOHNSON AND JOHNSON$$$$$$Y$$$20250708$$HP$CA$CA
253836152$25383615$2$F$20180615$20250910$20250602$20250913$EXP$$EU-ABBVIE-6301235$ABBVIE$$52$YR$$F$Y$$$20250913$$CN$EU$EU
253839342$25383934$2$F$$20250808$20250602$20250813$EXP$$EU-ANIPHARMA-023025$ANI$$27$YR$A$M$Y$$$20250813$$HP$EU$EU
253847895$25384789$5$F$20250101$20250718$20250602$20250721$30DAY$$GB-PFIZER INC-202500110205$PFIZER$$$$$M$Y$$$20250721$$PH$GB$GB
253848103$25384810$3$F$20250501$20250707$20250602$20250710$30DAY$$US-PFIZER INC-202500107555$PFIZER$$15$YR$$M$Y$$$20250710$$HP$US$US
253853292$25385329$2$F$$20250529$20250602$20250810$EXP$$CN-ASTRAZENECA-202505CHN024760CN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$CN$CN
253853562$25385356$2$F$$20250703$20250602$20250708$EXP$$EU-MYLANLABS-2025M1045693$MYLAN$Woron J, Drygalski T, Lonc T, Kepska K M, Wordliczek J.. Prescription machines as a measurable threat to the patient during pharmacological treatment, what does it mean for the Emergency Medical Services and Hospital Emergency Departments. Anestezjologia i Ratownictwo. 2025;19:44-50.$58$YR$$F$Y$$$20250708$$MD$EU$EU
253859822$25385982$2$F$$20250808$20250602$20250822$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-509745$RANBAXY$Medina-Caliz I, Sanabria-Cabrera J, Villanueva-Paz M, Aukstikalne L, Stephens C, Robles-Diaz M, et al. Characterization of drug induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. Archives of Toxicology. 2024;98:303-325$53$YR$$F$Y$$$20250822$$HP$EU$EU
253867162$25386716$2$F$20250101$20250722$20250602$20250728$PER$$US-SA-2025SA155795$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250728$$HP$US$US
253867893$25386789$3$F$20250101$20250722$20250602$20250725$PER$$US-SA-2025SA155687$SANOFI AVENTIS$$38$YR$A$F$Y$$$20250725$$MD$US$US
253874132$25387413$2$F$$20250630$20250602$20250701$EXP$$NVSJ2025JP005904$NOVARTIS$$75$YR$$$Y$$$20250702$$MD$JP$JP
253876142$25387614$2$F$$20250527$20250603$20250809$EXP$$US-ASTRAZENECA-202505USA024279US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
253876642$25387664$2$F$20250101$20250714$20250603$20250717$EXP$$CA-ABBVIE-6307980$ABBVIE$$73$YR$$M$Y$98$KG$20250717$$CN$CA$CA
253880655$25388065$5$F$20250101$20250818$20250603$20250825$EXP$$CA-UCBSA-2025021063$UCB$$$$$F$Y$$$20250825$$CN$CA$CA
253887162$25388716$2$F$$20250529$20250603$20250803$EXP$$ZA-ASTRAZENECA-202505SSA026090ZA$ALEXION PHARMACEUTICALS$$59$YR$A$M$Y$$$20250803$$$ZA$ZA
253893162$25389316$2$F$$20250626$20250603$20250704$30DAY$$US-AMGEN-USASP2025107039$AMGEN$$$$$$Y$$$20250704$$HP$US$US
253896542$25389654$2$F$20250522$20250707$20250603$20250714$PER$$US-ROCHE-10000297912$ROCHE$$8$YR$C$M$Y$26.31$KG$20250714$$CN$US$US
253897343$25389734$3$F$$20250722$20250603$20250723$EXP$$US-INCYTE CORPORATION-2025IN005891$INCYTE$$65$YR$$$Y$80.726$KG$20250723$$$US$US
253899902$25389990$2$F$20250401$20250715$20250603$20250715$PER$$US-BAYER-2025A072928$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250715$$CN$US$US
253902812$25390281$2$F$$20250726$20250603$20250728$EXP$$CA-PFIZER INC-202500112491$PFIZER$$59$YR$$F$Y$108.84$KG$20250728$$CN$CA$CA
253902832$25390283$2$F$$20250711$20250603$20250714$EXP$$EU-PFIZER INC-202500110847$PFIZER$$74$YR$$M$Y$$$20250714$$MD$EU$EU
253903732$25390373$2$F$20250528$20250704$20250603$20250708$PER$$US-PFIZER INC-202500111654$PFIZER$$14$YR$$M$Y$$$20250708$$CN$US$US
253903742$25390374$2$F$20250529$20250702$20250603$20250702$PER$$US-JNJFOC-20250537350$JOHNSON AND JOHNSON$$61$YR$A$$Y$$$20250702$$CN$US$US
253914803$25391480$3$F$20140701$20250526$20250603$20250803$EXP$$RU-ASTRAZENECA-202409RUS010932RU$ALEXION PHARMACEUTICALS$Marchenko MV, Klimova OU, Anikina EV, Lapina AV, Rudakova TA, Ksenzova TI. Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy. Oncohematology. 2024;19 (3):68-78$24$YR$A$F$Y$$$20250803$$$RU$RU
253916622$25391662$2$F$$20250604$20250603$20250701$PER$$US-KENVUE-20250508408$Kenvue$$$$$M$Y$$$20250701$$CN$US$US
253917212$25391721$2$F$$20240914$20250603$20250809$EXP$$JP-ASTRAZENECA-202409GLO015102JP$ALEXION PHARMACEUTICALS$Niimi K.. Initial and recurrent treatment options in empathizing with the ovarian cancer patients.. The 71st Annual Meeting of the Northern Japan Society of Obstetrics and Gynecology Sponsored Seminar.. 2024;0-.$$$A$F$Y$$$20250809$$MD$JP$JP
253917622$25391762$2$F$20250221$20250508$20250603$20250803$EXP$$EG-ASTRAZENECA-202505NAF005082EG$ALEXION PHARMACEUTICALS$$57$YR$A$M$Y$80$KG$20250803$$$EG$EG
253919014$25391901$4$F$$20250724$20250603$20250729$30DAY$$CO-PFIZER INC-202500113212$PFIZER$$$$$F$Y$$$20250729$$CN$CO$CO
253925613$25392561$3$F$20250101$20250731$20250603$20250805$PER$$US-SA-2025SA156564$SANOFI AVENTIS$$72$YR$E$M$Y$$$20250805$$MD$US$US
253926632$25392663$2$F$$20250529$20250603$20250809$EXP$$US-ASTRAZENECA-202505USA025632US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
253929072$25392907$2$F$20250517$20250528$20250604$20250809$EXP$$CN-ASTRAZENECA-202505CHN025020CN$ALEXION PHARMACEUTICALS$$77$YR$E$F$Y$46$KG$20250809$$$CN$CN
253929762$25392976$2$F$$20250528$20250604$20250809$EXP$$US-ASTRAZENECA-202505USA025952US$ALEXION PHARMACEUTICALS$$$$$F$Y$73$KG$20250809$$$US$US
253932742$25393274$2$F$20230627$20250714$20250604$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202505024469$ELI LILLY AND COMPANY$$74$YR$E$F$Y$133$KG$20250722$$LW$US$US
253933082$25393308$2$F$$20250602$20250604$20250809$EXP$$US-ASTRAZENECA-202506USA000439US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
253935553$25393555$3$F$20250625$20250725$20250604$20250801$PER$$US-SMPA-2025SPA005867$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
253939592$25393959$2$F$20240927$20250709$20250604$20250709$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-074570$BOEHRINGER INGELHEIM$$47$YR$A$M$Y$75.2$KG$20250709$$PH$JP$JP
253945532$25394553$2$F$$20250603$20250604$20250816$PER$$US-ASTRAZENECA-202506USA001350US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
253949422$25394942$2$F$20250401$20250922$20250604$20250929$EXP$$US-UCBSA-2025032052$UCB$$61$YR$$F$Y$$$20250929$$HP$US$US
253951172$25395117$2$F$20241006$20250827$20250604$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-510561$RANBAXY$$83$YR$$F$Y$33.35$KG$20250911$$MD$EU$EU
253952222$25395222$2$F$$20250808$20250604$20250812$30DAY$$CA-JNJFOC-20250603372$JOHNSON AND JOHNSON$$36$YR$A$M$Y$$$20250812$$CN$CA$CA
253954402$25395440$2$F$20250101$20250711$20250604$20250722$EXP$$US-UCBSA-2025032519$UCB$$$$$F$Y$83$KG$20250722$$HP$US$US
253955443$25395544$3$F$$20250903$20250604$20250903$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-079215$BRISTOL-MYERS SQUIBB COMPANY$$53$YR$A$F$Y$$$20250903$$MD$JP$JP
253956222$25395622$2$F$$20250620$20250604$20250701$EXP$$JP-STERISCIENCE B.V.-2025-ST-001043$Steriscience PTE$Ashimoto T, Minamiguchi H, Kanazaki M, Fukunaga R, Abe K, Kumode M, et al.. [Complete response of musculoskeletal chronic GVHD achieved with extracorporeal photopheresis therapy]. [Japanese].. Rinsho-Ketsueki. 2025;66 (4):228-232$48$YR$$M$Y$$$20250701$$HP$JP$JP
253958192$25395819$2$F$$20250826$20250604$20250828$EXP$$GB-JNJFOC-20250602019$JOHNSON AND JOHNSON$$$$$M$Y$$$20250828$$CN$GB$GB
253958643$25395864$3$F$$20250630$20250604$20250709$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-073966$BOEHRINGER INGELHEIM$$64$YR$A$M$Y$$$20250709$$MD$JP$JP
253963363$25396336$3$F$20250601$20250711$20250604$20250715$EXP$$US-PFIZER INC-PV202500066430$PFIZER$$84$YR$$M$Y$$$20250715$$PH$US$US
253971963$25397196$3$F$20250101$20250709$20250604$20250710$PER$$US-KARYOPHARM-2025KPT100340$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20250710$$CN$US$US
253979435$25397943$5$F$$20250612$20250604$20250821$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-079531$BRISTOL-MYERS SQUIBB COMPANY$$79$YR$E$M$Y$$$20250821$$CN$US$US
253990342$25399034$2$F$$20250528$20250605$20250810$PER$$US-ASTRAZENECA-202505USA025112US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
253991597$25399159$7$F$20250101$20250917$20250605$20250926$EXP$$US-UNITED THERAPEUTICS-UNT-2025-019067$UNITED THERAPEUTICS$$$$$M$Y$65.76$KG$20250926$$$US$US
253996702$25399670$2$F$$20250603$20250605$20250809$EXP$$IN-ASTRAZENECA-202506IND000902IN$ALEXION PHARMACEUTICALS$$54$YR$A$F$Y$70$KG$20250809$$$IN$IN
253996774$25399677$4$F$$20250711$20250605$20250719$EXP$$CA-CELLTRION INC.-2025CA017410$CELLTRION$$$$$$Y$$$20250719$$HP$CA$CA
253998313$25399831$3$F$$20250630$20250605$20250702$PER$$US-JNJFOC-20250537345$JOHNSON AND JOHNSON$$$$$M$Y$$$20250702$$CN$US$US
253999664$25399966$4$F$20150601$20250702$20250605$20250708$PER$$US-GILEAD-2025-0715992$GILEAD$$60$YR$A$M$Y$$$20250708$$LW$US$US
254000013$25400001$3$F$$20250625$20250605$20250701$PER$$US-SYNDAX PHARMACEUTICALS, INC.-2025US000464$SYNDAX$$$$$F$Y$61.088$KG$20250701$$CN$US$US
254001766$25400176$6$F$20250315$20250825$20250605$20250901$PER$$AR-TAKEDA-2025TUS026818$TAKEDA$$24$YR$$M$Y$60$KG$20250901$$$AR$AR
254005422$25400542$2$F$$20250623$20250605$20250703$EXP$$VE-ROCHE-10000300490$ROCHE$$$$$$Y$$$20250703$$MD$VE$VE
254007722$25400772$2$F$20250508$20250604$20250605$20250803$EXP$$US-ASTRAZENECA-202506USA002187US$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$$$20250803$$$US$US
254009632$25400963$2$F$20250401$20250702$20250605$20250708$PER$$US-VIIV HEALTHCARE-US2025AMR070031$VIIV$$56$YR$$M$Y$$$20250708$$MD$US$US
254010774$25401077$4$F$$20250829$20250605$20250925$PER$$US-MALLINCKRODT-MNK202502719$MALLINCKRODT$$$$$M$Y$$$20250925$$CN$US$US
254011592$25401159$2$F$$20250723$20250605$20250728$30DAY$$EU-PFIZER INC-202500114523$PFIZER$$$$$F$Y$$$20250728$$CN$EU$EU
254015193$25401519$3$F$$20250702$20250605$20250707$EXP$$AR-MYLANLABS-2025M1047438$MYLAN$$$$$F$Y$$$20250707$$MD$AR$AR
254016612$25401661$2$F$$20250530$20250605$20250809$EXP$$NZ-ASTRAZENECA-202505GLO028783NZ$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$NZ$NZ
254018152$25401815$2$F$20250101$20250923$20250605$20250924$PER$$US-PFIZER INC-202500115292$PFIZER$$59$YR$$F$Y$$$20250924$$HP$US$US
254020414$25402041$4$F$$20250915$20250605$20250923$PER$$NVSC2025US089870$NOVARTIS$$$$$$Y$$$20250923$$HP$US$US
254020932$25402093$2$F$$20250701$20250605$20250704$PER$$US-GSK-US2025068855$GLAXOSMITHKLINE$$$$$M$Y$$$20250704$$$US$US
254022433$25402243$3$F$$20250626$20250605$20250707$30DAY$$EU-UCBSA-2025033183$UCB$$$$A$M$Y$$$20250707$$CN$EU$EU
254024032$25402403$2$F$$20240319$20250605$20250810$PER$$US-AstraZeneca-2024A028542$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
254025703$25402570$3$F$20250516$20250816$20250605$20250821$EXP$$NVSC2025FR084001$NOVARTIS$$60$YR$$M$Y$$$20250821$$CN$EU$EU
254030362$25403036$2$F$20250101$20250822$20250605$20250828$PER$$US-SA-2025SA157643$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250828$$HP$US$US
254032012$25403201$2$F$20250101$20250911$20250605$20250918$PER$$US-SA-2025SA159494$SANOFI AVENTIS$$67$YR$E$M$Y$$$20250919$$HP$US$US
254036782$25403678$2$F$$20250613$20250605$20250715$PER$$US-TLM-TLM-2025-01329$TOLMAR$$$$$$Y$$$20250708$$PH$US$US
254037833$25403783$3$F$20250521$20250701$20250606$20250810$PER$$US-ASTRAZENECA-202506USA002261US$ALEXION PHARMACEUTICALS$$71$YR$E$F$Y$$$20250810$$MD$US$US
254042872$25404287$2$F$$20250603$20250606$20250802$EXP$$US-ASTRAZENECA-202506USA001910US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
254044573$25404457$3$F$20240101$20250726$20250606$20250730$EXP$$CA-CELLTRION INC.-2024CA012456$CELLTRION$$$$$$Y$$$20250730$$HP$CA$CA
254047562$25404756$2$F$20250405$20250808$20250606$20250818$EXP$$US-SA-2025SA159688$SANOFI AVENTIS$$6$YR$C$M$Y$$$20250818$$HP$US$US
254052834$25405283$4$F$20250518$20250721$20250606$20250731$PER$$US-SMPA-2025SPA006397$SUNOVION$$$$$$Y$$$20250731$$CN$US$US
254056543$25405654$3$F$20231102$20250916$20250606$20250925$EXP$$CN-ROCHE-10000299598$ROCHE$$65$YR$E$F$Y$55$KG$20250925$$MD$CN$CN
254066472$25406647$2$F$$20250904$20250606$20250904$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-080142$BRISTOL-MYERS SQUIBB COMPANY$Blum SM, Ouyang B, Zubiri L, Leonard D, Slowikowski K, Wang M, et al. Tumor location as a risk factor for severe immune-related adverse events. Journal for ImmunoTherapy of Cancer. 2025 May 15;13(5):1-7. doi:10.1136/jitc-2024-011312.$9$DEC$E$$Y$$$20250904$$HP$US$US
254070063$25407006$3$F$20250501$20250721$20250606$20250729$EXP$$US-BIOCODEX2-2025000637$BIOCODEX$$38$YR$$F$Y$72.6$KG$20250728$$MD$US$US
254074322$25407432$2$F$$20250709$20250606$20250729$30DAY$$CL-JNJFOC-20250535630$JOHNSON AND JOHNSON$$$$$$Y$$$20250729$$PH$CL$CL
254079172$25407917$2$F$$20250710$20250606$20250711$PER$$US-JNJFOC-20250607241$JOHNSON AND JOHNSON$$$$$$Y$$$20250711$$CN$US$US
254081993$25408199$3$F$20250101$20250811$20250606$20250819$PER$$US-SA-2025SA160608$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250819$$HP$US$US
254085012$25408501$2$F$$20250812$20250606$20250818$EXP$$EU-ELI_LILLY_AND_COMPANY-DE202506000860$ELI LILLY AND COMPANY$$65$YR$E$F$Y$123$KG$20250818$$CN$EU$EU
254106342$25410634$2$F$20241126$20250705$20250609$20250711$EXP$$JP-GENMAB-2025-00263$GENMAB$Sekiguchi Y, Tsutsumi H, Kudo M, Maseki N, Iizaki Y, Kawamura M, et al. Use of Epcoritamab in 19 patients in actual clinical practice: a report from a single facility. The Japanese Society of Lymphoma Research. 2025;P-006$77$YR$$M$Y$$$20250711$$MD$JP$JP
254117056$25411705$6$F$20240322$20250725$20250609$20250805$EXP$$JP-JNJFOC-20250607733$JOHNSON AND JOHNSON$$83$YR$E$F$Y$$$20250805$$PH$JP$JP
254124482$25412448$2$F$$20250703$20250609$20250716$PER$$US-MALLINCKRODT-MNK202501056$MALLINCKRODT$$$$$F$Y$$$20250715$$CN$US$US
254127333$25412733$3$F$$20250709$20250609$20250710$30DAY$$US-PFIZER INC-202500111603$PFIZER$$13$YR$$M$Y$$$20250710$$CN$US$US
254127355$25412735$5$F$20250601$20250709$20250609$20250710$30DAY$$US-PFIZER INC-202500115226$PFIZER$$16$YR$$M$Y$$$20250710$$CN$US$US
254134642$25413464$2$F$$20250718$20250609$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202506004919$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250728$$CN$US$US
254135512$25413551$2$F$$20250604$20250609$20250816$PER$$US-ASTRAZENECA-202506USA002436US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$US$US
254135922$25413592$2$F$$20250603$20250609$20250810$EXP$$US-ASTRAZENECA-202506USA001384US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$GB
254137842$25413784$2$F$$20250722$20250609$20250723$PER$$US-ASTRAZENECA-202505USA002985US$ALEXION PHARMACEUTICALS$$71$YR$E$M$Y$$$20250723$$$US$US
254138662$25413866$2$F$$20250710$20250609$20250710$PER$$US-PFIZER INC-202500115266$PFIZER$$30$YR$$M$Y$$$20250710$$CN$US$US
254141482$25414148$2$F$20250603$20250604$20250609$20250802$EXP$$CO-ASTRAZENECA-202506SAM003077CO$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$MD$CO$CO
254142614$25414261$4$F$$20250712$20250609$20250715$30DAY$$US-PFIZER INC-202500111894$PFIZER$$59$YR$$F$Y$$$20250715$$CN$US$US
254143383$25414338$3$F$$20250721$20250609$20250723$PER$$US-SA-2025SA161246$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250723$$CN$US$US
254144362$25414436$2$F$$20250709$20250609$20250710$PER$$NVSC2025US091841$NOVARTIS$$$$$$Y$$$20250710$$HP$US$US
254145563$25414556$3$F$20250101$20250922$20250609$20250930$PER$$US-SA-2025SA161335$SANOFI AVENTIS$$1$YR$I$F$Y$$$20250930$$HP$US$US
254150962$25415096$2$F$20250601$20250714$20250609$20250716$30DAY$$AR-JNJFOC-20250604846$JOHNSON AND JOHNSON$$75$YR$E$F$Y$67$KG$20250716$$CN$AR$AR
254151172$25415117$2$F$20250603$20250711$20250609$20250715$30DAY$$US-JNJFOC-20250603205$JOHNSON AND JOHNSON$$53$YR$A$M$Y$$$20250715$$CN$US$US
254156342$25415634$2$F$$20250904$20250610$20250905$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-080550$BRISTOL-MYERS SQUIBB COMPANY$$5$DEC$A$F$Y$$$20250905$$MD$JP$JP
254161083$25416108$3$F$20250603$20250728$20250610$20250806$PER$$US-ROCHE-10000304791$ROCHE$$62$YR$A$F$Y$$$20250806$$CN$US$US
254163352$25416335$2$F$20100401$20250707$20250610$20250709$PER$$US-BIOGEN-2025BI01313364$BIOGEN$$43$YR$$F$Y$$$20250709$$CN$US$US
254163463$25416346$3$F$20250101$20250627$20250610$20250704$EXP$$US-AMGEN-USASL2025018916$AMGEN$$58$YR$A$M$Y$$$20250703$$MD$US$US
254166043$25416604$3$F$$20250611$20250610$20250813$PER$$US-ASTRAZENECA-202506USA004195US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250813$$$US$US
254169263$25416926$3$F$$20250826$20250610$20250827$PER$$AE-ASTRAZENECA-202501GLO018841AE$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250827$$$AE$AE
254180854$25418085$4$F$$20250711$20250610$20250716$30DAY$$US-PFIZER INC-202500116484$PFIZER$$16$YR$$F$Y$$$20250716$$CN$US$US
254181522$25418152$2$F$$20250603$20250610$20250810$EXP$$JP-ASTRAZENECA-202506GLO004943JP$ALEXION PHARMACEUTICALS$$85$YR$E$M$Y$$$20250810$$MD$JP$JP
254182633$25418263$3$F$20250511$20250922$20250610$20250930$EXP$$CA-TAKEDA-2022TUS026785$TAKEDA$$39$YR$$F$Y$$$20250930$$$CA$CA
254185133$25418513$3$F$20241108$20250728$20250610$20250805$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-081471$BRISTOL-MYERS SQUIBB COMPANY$$33$YR$A$F$Y$36$KG$20250806$$MD$JP$JP
254188412$25418841$2$F$$20250814$20250610$20250822$EXP$$EU-CLINIGEN-CLI2025000067$CLINIGEN$$$$$$Y$$$20250822$$HP$EU$EU
254190464$25419046$4$F$$20250904$20250610$20250908$30DAY$$GB-PFIZER INC-202500116482$PFIZER$$19$YR$$M$Y$$$20250908$$CN$GB$GB
254192972$25419297$2$F$20250114$20250909$20250610$20250915$EXP$$GB-MYLANLABS-2024M1083225$MYLAN$$$$$M$Y$$$20250915$$MD$GB$GB
254200962$25420096$2$F$20250411$20250902$20250610$20250903$EXP$$EU-JNJFOC-20250605417$JOHNSON AND JOHNSON$$$$A$M$Y$$$20250903$$MD$EU$EU
254201092$25420109$2$F$$20250731$20250610$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202506004987$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250805$$CN$US$US
254201552$25420155$2$F$$20250606$20250610$20250802$EXP$$US-ASTRAZENECA-202506USA004267US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
254207362$25420736$2$F$$20250630$20250611$20250707$EXP$$US-KYOWAKIRIN-2025KK010905$KYOWA$$$$$$Y$$$20250707$$PH$US$US
254207444$25420744$4$F$$20250903$20250611$20250904$EXP$$US-ABBVIE-6321398$ABBVIE$$69$YR$$M$Y$$$20250904$$CN$US$US
254209753$25420975$3$F$$20250623$20250611$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506004262$ELI LILLY AND COMPANY$$62$YR$A$F$Y$$$20250701$$CN$US$US
254212884$25421288$4$F$20250101$20250915$20250611$20250924$EXP$$US-UCBSA-2025033955$UCB$$$$$F$Y$98.88$KG$20250924$$HP$US$US
254216372$25421637$2$F$20250101$20250724$20250611$20250729$EXP$$US-ABBVIE-6312947$ABBVIE$$62$YR$$F$Y$$$20250729$$CN$US$US
254216872$25421687$2$F$20250528$20250908$20250611$20250915$EXP$$UA-SANDOZ INC.-SDZ2025UA038530$SANDOZ$$$$$F$Y$$$20250915$$CN$UA$UA
254226202$25422620$2$F$$20250714$20250611$20250717$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-006800$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250717$$CN$US$US
254227002$25422700$2$F$$20250724$20250611$20250724$PER$$NVSC2025US092443$NOVARTIS$$60$YR$$M$Y$$$20250724$$MD$US$US
254235242$25423524$2$F$20250201$20250721$20250611$20250728$EXP$$EU-ELI_LILLY_AND_COMPANY-FR202506002281$ELI LILLY AND COMPANY$$14$YR$T$M$Y$85$KG$20250728$$MD$EU$EU
254240292$25424029$2$F$20250601$20250715$20250611$20250718$EXP$$US-ASCENDIS PHARMA-2025US009780$ASCENDIS PHARMA$$$$$$Y$$$20250718$$CN$US$US
254243192$25424319$2$F$20250101$20250722$20250611$20250728$PER$$US-SA-2025SA164346$SANOFI AVENTIS$$22$YR$A$F$Y$$$20250728$$HP$US$US
254246782$25424678$2$F$$20250702$20250611$20250705$PER$$US-SA-2025SA165476$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250705$$CN$US$US
254251232$25425123$2$F$$20250711$20250611$20250711$PER$$US-PFIZER INC-202500118204$PFIZER$$14$YR$$M$Y$$$20250711$$CN$US$US
254255853$25425585$3$F$20250401$20250828$20250611$20250902$EXP$$JP-AMGEN-JPNSP2025112679$AMGEN$$8$DEC$E$M$Y$$$20250902$$MD$JP$JP
254256182$25425618$2$F$$20250605$20250611$20250809$EXP$$US-ASTRAZENECA-202506USA003478US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$MD$US$US
254263743$25426374$3$F$20250509$20250715$20250612$20250721$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-006912$ACADIA PHARMACEUTICALS$$13$YR$$F$Y$34.467$KG$20250721$$CN$US$US
254264993$25426499$3$F$20250101$20250827$20250612$20250902$EXP$$US-SA-2025SA164940$SANOFI AVENTIS$$68$YR$E$M$Y$$$20250902$$HP$US$US
254266672$25426667$2$F$20250602$20250630$20250612$20250703$EXP$$JP-ROCHE-10000307815$ROCHE$$74$YR$E$F$Y$$$20250703$$PH$JP$JP
254267355$25426735$5$F$20250101$20250818$20250612$20250827$EXP$$CA-CELLTRION INC.-2025CA018428$CELLTRION$$$$$$Y$$$20250827$$HP$CA$CA
254269392$25426939$2$F$$20250825$20250612$20250903$EXP$$EU-ROCHE-10000306515$ROCHE$$$$$$Y$$$20250903$$HP$EU$EU
254270484$25427048$4$F$20250101$20250728$20250612$20250731$EXP$$US-ABBVIE-6321312$ABBVIE$$41$YR$$F$Y$$$20250731$$CN$US$US
254270622$25427062$2$F$$20250905$20250612$20250912$EXP$$US-SMPA-2025SPA006258$SUNOVION$$71$YR$$M$Y$$$20250911$$$US$US
254280932$25428093$2$F$20250226$20250611$20250612$20250809$EXP$$US-ASTRAZENECA-202506USA008350US$ALEXION PHARMACEUTICALS$$82$YR$E$M$Y$$$20250809$$$US$US
254281532$25428153$2$F$20240910$20250901$20250612$20250908$EXP$EU-AFSSAPS-CN2024000887$EU-GRUNENTHAL-2025-108154$AVERITAS$$34$YR$$F$Y$75$KG$20250905$$CN$EU$EU
254282534$25428253$4$F$20250101$20250709$20250612$20250715$PER$$US-SA-2025SA165416$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250715$$HP$US$US
254282775$25428277$5$F$$20250911$20250612$20250923$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-006805$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250923$$CN$US$US
254282793$25428279$3$F$20250419$20250722$20250612$20250730$EXP$$JP-ARGENX-2025-ARGX-JP005300AA$ARGENX BVBA$$$$$$Y$$$20250730$$MD$JP$JP
254296243$25429624$3$F$20250517$20250717$20250612$20250718$EXP$$EU-ASTRAZENECA-202506EEA004318IT$ALEXION PHARMACEUTICALS$$37$YR$A$F$Y$46$KG$20250718$$MD$EU$EU
254301372$25430137$2$F$$20250808$20250612$20250819$EXP$EU-Desitin-2024-01750$EU-TORRENT-00028810$TORRENT PHARMA INC.$$$$N$$Y$$$20250819$$HP$EU$EU
254303042$25430304$2$F$$20250725$20250612$20250728$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-083785$BRISTOL-MYERS SQUIBB COMPANY$$49$YR$A$F$Y$$$20250728$$CN$US$US
254308302$25430830$2$F$20240101$20250609$20250612$20250809$EXP$$US-ASTRAZENECA-202505USA023937US$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250809$$$US$US
254310013$25431001$3$F$20240101$20250630$20250612$20250709$EXP$$EU-ABBVIE-6323488$ABBVIE$Barbosa A, Marques JR, Silva CD. Gravidez inesperada: relato de caso. Revista Portuguesa de Medicina Geral e Familiar. 2025:14(41): S47-S47.; Barbosa A, Marques JR, Silva CD. Gravidez inesperada: relato de caso. Revista Portuguesa de Medicina Geral e Familiar.. 2025 Mar;14(41): S47-S47.$33$YR$$F$Y$$$20250709$$HP$EU$EU
254311812$25431181$2$F$20250606$20250609$20250613$20250803$EXP$$US-ASTRAZENECA-202506USA007306US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250803$$$US$US
254314422$25431442$2$F$$20250609$20250613$20250803$EXP$$EU-ASTRAZENECA-202506EEA006713PL$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250803$$MD$EU$EU
254323273$25432327$3$F$20250612$20250826$20250613$20250903$EXP$$CA-SANDOZ INC.-SDZ2025CA040993$SANDOZ$$21$MON$$M$Y$11.6$KG$20250903$$MD$CA$CA
254325262$25432526$2$F$20250605$20250626$20250613$20250702$EXP$$CA-SAMSUNG BIOEPIS-SB-2025-01605$SAMSUNG BIOEPIS$$67$YR$E$F$Y$$$20250702$$CN$CA$CA
254325813$25432581$3$F$20250101$20250723$20250613$20250725$EXP$$US-SA-2025SA143605$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250725$$CN$US$US
254325832$25432583$2$F$20250101$20250718$20250613$20250724$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-014544$JAZZ$$72$YR$$M$Y$111$KG$20250724$$$US$US
254326954$25432695$4$F$20250601$20250715$20250613$20250724$30DAY$$US-AMGEN-USASP2025113251$AMGEN$$81$YR$E$M$Y$116$KG$20250724$$HP$US$US
254328902$25432890$2$F$$20250611$20250613$20250810$EXP$$US-ASTRAZENECA-202506USA008256US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250810$$MD$US$US
254329082$25432908$2$F$20240812$20250912$20250613$20250924$EXP$$KR-SMPA-2025SPA007367$SUNOVION$$83$YR$$M$Y$79$KG$20250920$$$KR$KR
254333022$25433302$2$F$$20250612$20250613$20250810$PER$$US-ASTRAZENECA-202506USA009705US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
254341906$25434190$6$F$20250608$20250829$20250613$20250903$EXP$$US-PFIZER INC-202500118041$PFIZER$$13$YR$$F$Y$$$20250903$$CN$US$US
254345612$25434561$2$F$$20250826$20250613$20250829$PER$$US-SA-2025SA167000$SANOFI AVENTIS$$7$YR$C$M$Y$$$20250829$$MD$US$US
254345672$25434567$2$F$20201225$20250707$20250613$20250709$EXP$$US-TAKEDA-2021TUS020508$TAKEDA$$69$YR$$M$Y$$$20250709$$$US$US
254347442$25434744$2$F$20240101$20250811$20250613$20250819$PER$$US-SA-2025SA168063$SANOFI AVENTIS$$79$YR$E$F$Y$$$20250819$$HP$US$US
254351172$25435117$2$F$20250501$20250721$20250613$20250730$EXP$$US-PHARMING-PHAUS2025000827$PHARMING GROUP$$$$$$Y$$$20250730$$CN$US$US
254352472$25435247$2$F$20230301$20250617$20250613$20250702$EXP$$US-PARI RESPIRATORY EQUIPMENT, INC.-2025PAR00046$PARI RESPIRATORY EQUIPMENT$$11$YR$$F$Y$$$20250702$$HP$US$US
254354612$25435461$2$F$$20250611$20250613$20250803$EXP$$GB-ASTRAZENECA-202506GBR009155GB$ALEXION PHARMACEUTICALS$$78$YR$E$M$Y$$$20250803$$$GB$GB
254355993$25435599$3$F$20250603$20250715$20250613$20250716$PER$$US-JNJFOC-20250604998$JOHNSON AND JOHNSON$$50$YR$A$F$Y$$$20250717$$CN$US$US
254357182$25435718$2$F$$20250725$20250613$20250729$EXP$$CA-TAKEDA-2025TUS054771$TAKEDA$$54$YR$$M$Y$$$20250729$$$CA$CA
254360982$25436098$2$F$$20250612$20250614$20250802$EXP$$US-ASTRAZENECA-202506USA009674US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$$US$US
254361213$25436121$3$F$$20250625$20250614$20250701$EXP$$US-009507513-2291215$MERCK SHARP + DOHME LLC$$$$$F$Y$56.699$KG$20250701$$CN$US$US
254363362$25436336$2$F$$20250708$20250614$20250711$EXP$$CA-TEVA-VS-3340717$TEVA$$80$YR$$M$Y$69$KG$20250711$$HP$CA$CA
254364032$25436403$2$F$20250412$20250612$20250614$20250803$EXP$$US-ASTRAZENECA-202506USA009807US$ALEXION PHARMACEUTICALS$$87$YR$E$M$Y$$$20250803$$$US$US
254364102$25436410$2$F$$20250611$20250614$20250810$PER$$US-ASTRAZENECA-202506USA010021US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
254364342$25436434$2$F$20250314$20250611$20250614$20250802$EXP$$BR-ASTRAZENECA-202506SAM008327BR$ALEXION PHARMACEUTICALS$$59$YR$A$F$Y$$$20250802$$$BR$BR
254374823$25437482$3$F$$20250710$20250616$20250716$EXP$$JP-ASTELLAS-2025-AER-031638$ASTELLAS$$7$DEC$$M$Y$$$20250716$$MD$JP$JP
254377382$25437738$2$F$$20250820$20250616$20250829$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04740$LUPIN$$19$MON$$$Y$12.245$KG$20250829$$$US$US
254377463$25437746$3$F$20230701$20250827$20250616$20250903$EXP$$EU-EMD Serono-2025029620$EMD SERONO INC$$7$YR$C$F$Y$17$KG$20250903$$$EU$EU
254377752$25437775$2$F$20250101$20250828$20250616$20250904$PER$$US-SA-2025SA169400$SANOFI AVENTIS$$17$YR$T$F$Y$$$20250904$$HP$US$US
254395212$25439521$2$F$20250610$20250611$20250616$20250803$EXP$$CO-ASTRAZENECA-202506SAM008612CO$ALEXION PHARMACEUTICALS$$63$YR$A$M$Y$62$KG$20250803$$$CO$CO
254395802$25439580$2$F$20250101$20250811$20250616$20250820$PER$$US-SA-2025SA169537$SANOFI AVENTIS$$85$YR$E$M$Y$$$20250820$$MD$US$US
254400675$25440067$5$F$20250611$20250807$20250616$20250811$30DAY$$EU-PFIZER INC-PV202500071002$PFIZER$$15$YR$$M$Y$47$KG$20250811$$CN$EU$EU
254400992$25440099$2$F$20240101$20250717$20250616$20250722$EXP$$CA-PFIZER INC-202400096278$PFIZER$$69$YR$$F$Y$$$20250722$$HP$CA$CA
254401793$25440179$3$F$$20250725$20250616$20250730$30DAY$$GB-PFIZER INC-PV202500026759$PFIZER$$32$YR$$M$Y$$$20250730$$HP$GB$GB
254403343$25440334$3$F$20250613$20250701$20250616$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-085213$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$$$20250702$$CN$US$US
254418242$25441824$2$F$20240101$20250620$20250616$20250707$PER$$US-MYLANLABS-2025M1047700$MYLAN$$$$$F$Y$86.18$KG$20250703$$$US$US
254418563$25441856$3$F$$20250709$20250616$20250809$EXP$$US-ASTRAZENECA-202504USA029181US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$PH$US$US
254419703$25441970$3$F$20250410$20250824$20250616$20250827$EXP$$JP-DSJP-DS-2025-146675-JPAA$DAIICHI$$77$YR$$F$Y$51.2$KG$20250827$$MD$JP$JP
254419842$25441984$2$F$20241226$20250714$20250616$20250718$EXP$$NVSC2025BR095564$NOVARTIS$$50$YR$$F$Y$97$KG$20250718$$CN$BR$BR
254423233$25442323$3$F$20250418$20250702$20250616$20250707$EXP$EU-AFSSAPS-TO2025000895$EU-ABBVIE-6323580$ABBVIE$$50$YR$$F$Y$74$KG$20250707$$MD$EU$EU
254423253$25442325$3$F$20250612$20250619$20250616$20250703$EXP$$CA-HLS-202501594$HLS THERAPEUTICS$$57$YR$A$F$Y$$$20250703$$PH$CA$CA
254423472$25442347$2$F$$20250701$20250616$20250707$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007052$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250707$$CN$US$US
254428882$25442888$2$F$20250606$20250820$20250617$20250826$EXP$$NVSC2025US093358$NOVARTIS$$38$YR$$F$Y$$$20250826$$CN$US$US
254438212$25443821$2$F$20250712$20250721$20250617$20250723$EXP$$IN-ROCHE-10000307957$ROCHE$$80$YR$E$F$Y$50$KG$20250723$$CN$IN$IN
254443412$25444341$2$F$20250101$20250806$20250617$20250812$EXP$$US-UCBSA-2025025647$UCB$$$$$F$Y$81.633$KG$20250812$$HP$US$US
254444294$25444429$4$F$20250304$20250811$20250617$20250815$EXP$$CO-BRISTOL-MYERS SQUIBB COMPANY-2025-039757$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$85$KG$20250815$$CN$CO$CO
254445593$25444559$3$F$20250605$20250905$20250617$20250909$EXP$$EU-ASTRAZENECA-202506GLO011246ES$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250909$$MD$EU$EU
254446792$25444679$2$F$$20240112$20250617$20250810$PER$$US-ASTRAZENECA-202401GLO002457US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
254449183$25444918$3$F$20250521$20250905$20250617$20250912$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-084663$BRISTOL-MYERS SQUIBB COMPANY$$82$YR$E$M$Y$76.29$KG$20250912$$PH$US$US
254454222$25445422$2$F$$20250611$20250617$20250803$EXP$$EU-ASTRAZENECA-202506EEA011888FR$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250803$$MD$EU$EU
254454982$25445498$2$F$20250518$20250825$20250617$20250826$EXP$$EU-JNJFOC-20250607804$JOHNSON AND JOHNSON$$57$YR$A$F$Y$109$KG$20250826$$MD$EU$EU
254458422$25445842$2$F$$20250916$20250617$20250922$EXP$$CO-SANDOZ INC.-SDZ2025CO041981$SANDOZ$$$$$M$Y$45$KG$20250922$$CN$CO$CO
254460532$25446053$2$F$20250101$20250717$20250617$20250723$EXP$$GB-VERTEX PHARMACEUTICALS-2025-009709$VERTEX$$$$$F$Y$$$20250723$$CN$GB$GB
254461852$25446185$2$F$20250501$20250616$20250617$20250809$EXP$$US-ASTRAZENECA-202506USA012511US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
254466342$25446634$2$F$$20250714$20250617$20250717$EXP$$CA-TAKEDA-2025TUS055058$TAKEDA$$50$YR$$F$Y$$$20250717$$$CA$CA
254467808$25446780$8$F$20250613$20250815$20250617$20250818$30DAY$$US-PFIZER INC-202500082006$PFIZER$$8$YR$$M$Y$24.6$KG$20250818$$MD$US$US
254468963$25446896$3$F$$20250718$20250617$20250718$30DAY$$US-PFIZER INC-202500106205$PFIZER$$41$YR$$M$Y$$$20250718$$CN$US$US
254470503$25447050$3$F$$20250918$20250617$20250924$EXP$$EU-ASTRAZENECA-202506EEA011875FR$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250924$$MD$EU$EU
254471602$25447160$2$F$20250101$20250722$20250617$20250729$PER$$US-SA-2025SA170515$SANOFI AVENTIS$$70$YR$E$M$Y$86.36$KG$20250730$$HP$US$US
254472192$25447219$2$F$20250101$20250818$20250617$20250824$PER$$US-SA-2025SA170205$SANOFI AVENTIS$$17$YR$T$F$Y$$$20250824$$HP$US$US
254474922$25447492$2$F$20250611$20250627$20250617$20250703$PER$$US-AMGEN-USASP2025116501$AMGEN$$60$YR$A$M$Y$$$20250703$$HP$US$US
254476123$25447612$3$F$20250502$20250701$20250617$20250915$EXP$$EU-ASTRAZENECA-202505EEA024992FR$ALEXION PHARMACEUTICALS$$80$YR$E$M$Y$75$KG$20250915$$MD$EU$EU
254476483$25447648$3$F$$20250826$20250617$20250901$EXP$$CA-TAKEDA-2025TUS052009AA$TAKEDA$$$$$M$Y$$$20250901$$$CA$CA
254477673$25447767$3$F$$20250721$20250617$20250723$EXP$$CA-PFIZER INC-202500121418$PFIZER$$$$$F$Y$96$KG$20250723$$HP$CA$CA
254480313$25448031$3$F$20250613$20250916$20250617$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-085691$BRISTOL-MYERS SQUIBB COMPANY$$50$YR$A$M$Y$129.8$KG$20250916$$PH$US$US
254484252$25448425$2$F$20250101$20250903$20250618$20250905$EXP$$US-ABBVIE-6326372$ABBVIE$$54$YR$$M$Y$$$20250905$$CN$US$US
254487783$25448778$3$F$$20250613$20250618$20250809$EXP$$US-ASTRAZENECA-202506USA010706US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
254488602$25448860$2$F$20250711$20250716$20250618$20250717$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-086034$BRISTOL-MYERS SQUIBB COMPANY$$82$YR$E$M$Y$66.59$KG$20250717$$HP$US$US
254489713$25448971$3$F$$20250822$20250618$20250828$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-007172$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250828$$CN$US$US
254493003$25449300$3$F$20250101$20250825$20250618$20250829$PER$$US-UNITED THERAPEUTICS-UNT-2025-019824$UNITED THERAPEUTICS$$$$$M$Y$$$20250829$$$US$US
254495102$25449510$2$F$$20250808$20250618$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-086620$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$F$Y$$$20250812$$CN$US$US
254500282$25450028$2$F$20250101$20250625$20250618$20250704$PER$$US-UNITED THERAPEUTICS-UNT-2025-007323$UNITED THERAPEUTICS$$$$$F$Y$$$20250704$$$US$US
254504013$25450401$3$F$20241021$20250717$20250618$20250724$EXP$EU-PFIZER INC-202500113709$EU-ROCHE-10000309957$ROCHE$Jesus A,  Spontaneous Low-Output Hemoperitoneum Secondary to Immunotherapy - A Rare Adverse Effect [Abstract number: 0154]. 31 Degree Celsius Congresso Nacional de Medicina Interna. 2025;$60$YR$A$M$Y$$$20250724$$HP$EU$EU
254505482$25450548$2$F$$20250820$20250618$20250821$EXP$$NVSC2025US097119$NOVARTIS$$$$$M$Y$$$20250821$$CN$US$US
254511964$25451196$4$F$20250616$20250916$20250618$20250918$PER$$EU-TAKEDA-2025TUS055360$TAKEDA$$31$YR$$M$Y$73$KG$20250918$$MD$EU$EU
254513662$25451366$2$F$20250101$20250611$20250618$20250803$EXP$$EU-ASTRAZENECA-202501GLO028542PT$ALEXION PHARMACEUTICALS$$2$MON$I$M$Y$$$20250803$$MD$EU$EU
254517792$25451779$2$F$20250101$20250707$20250618$20250712$PER$$US-SA-2025SA170663$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250712$$HP$US$US
254522352$25452235$2$F$20250413$20250908$20250618$20250909$EXP$$US-BAYER-2025A077604$BAYER HEALTHCARE PHARMACEUTICALS INC.$$84$YR$E$M$Y$$$20250909$$CN$US$US
254523952$25452395$2$F$$20250916$20250618$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-086963$BRISTOL-MYERS SQUIBB COMPANY$$88$YR$E$F$Y$$$20250916$$$US$US
254529152$25452915$2$F$20180417$20250723$20250618$20250730$EXP$$JP-Eisai-EC-2018-041738$EISAI$$$$E$M$Y$57$KG$20250730$$MD$JP$JP
254529522$25452952$2$F$20240301$20250609$20250618$20250929$EXP$$JP-MSD-M2024-46279$MERCK SHARP + DOHME LLC$$6$DEC$$F$Y$$$20250929$$MD$JP$JP
254530762$25453076$2$F$$20250730$20250618$20250808$PER$$US-MALLINCKRODT-MNK202503106$MALLINCKRODT$$$$$M$Y$$$20250807$$CN$US$US
254531224$25453122$4$F$20250501$20250925$20250618$20250929$EXP$$JP-ASTELLAS-2025-AER-032382$ASTELLAS$$85$YR$E$M$Y$$$20250929$$MD$JP$JP
254532632$25453263$2$F$$20250822$20250618$20250829$EXP$$JP-AMGEN-JPNSP2025119397$AMGEN$$7$DEC$E$F$Y$$$20250828$$HP$JP$JP
254534552$25453455$2$F$20250606$20250616$20250619$20250803$EXP$$TH-ASTRAZENECA-202506ASI012927TH$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$$$20250803$$$TH$TH
254535472$25453547$2$F$$20250617$20250619$20250809$EXP$$US-ASTRAZENECA-202506USA013461US$ALEXION PHARMACEUTICALS$$89$YR$E$$Y$$$20250809$$$US$US
254536432$25453643$2$F$20241201$20250715$20250619$20250724$EXP$$CH-NOVOPROD-1456206$NOVO NORDISK$Giordani, Ilaria;Sykiotis, Gerasimos P. Letter: Amiodarone-Induced Thyrotoxicosis Following Semaglutide-Associated Weight Loss. Thyroid : official journal of the American Thyroid Association. 2025$56$YR$$F$Y$98$KG$20250724$$HP$CH$CH
254537773$25453777$3$F$20250611$20250711$20250619$20250722$EXP$$JP-ASTRAZENECA-202506GLO014195JP$ALEXION PHARMACEUTICALS$$69$YR$E$F$Y$47$KG$20250722$$MD$JP$JP
254538012$25453801$2$F$$20250617$20250619$20250809$EXP$$US-ASTRAZENECA-202506USA013636US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
254538282$25453828$2$F$20230727$20250707$20250619$20250719$EXP$$EU-AUROBINDO-AUR-APL-2025-029752$AUROBINDO$$66$YR$$M$Y$61.2$KG$20250719$$MD$EU$EU
254540112$25454011$2$F$20240101$20250701$20250619$20250703$EXP$$RU-009507513-2295453$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250703$$MD$RU$RU
254541583$25454158$3$F$$20250905$20250619$20250916$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04996$LUPIN$$33$YR$$$Y$81.633$KG$20250916$$$US$US
254551382$25455138$2$F$$20250701$20250619$20250918$PER$$US-ALVOGEN-2025098046$ALVOGEN$$$$$F$Y$$$20250918$$HP$US$US
254555092$25455509$2$F$$20250911$20250619$20250922$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04976$LUPIN$$89$YR$$$Y$86.168$KG$20250922$$$US$US
254556882$25455688$2$F$$20250707$20250619$20250708$PER$$US-BAUSCHBL-2025BNL010774$BAUSCH AND LOMB$$$$$M$Y$$$20250708$$CN$US$US
254557022$25455702$2$F$20240901$20250822$20250619$20250829$EXP$$CN-ROCHE-10000249545$ROCHE$$83$YR$E$M$Y$56.8$KG$20250829$$MD$CN$CN
254559653$25455965$3$F$20210701$20250703$20250619$20250710$EXP$$EU-SANDOZ INC.-SDZ2025DE042717$SANDOZ$$80$YR$$F$Y$$$20250710$$MD$EU$EU
254562053$25456205$3$F$20250616$20250916$20250619$20250922$EXP$$JP-009507513-2297661$MERCK SHARP + DOHME LLC$$86$YR$$F$Y$$$20250922$$MD$JP$JP
254563312$25456331$2$F$$20250801$20250619$20250802$PER$$NVSC2025US097567$NOVARTIS$$$$$F$Y$$$20250802$$CN$US$US
254564104$25456410$4$F$20240528$20250908$20250619$20250917$EXP$$JP-JNJFOC-20250624240$JOHNSON AND JOHNSON$Ogisu T, Takayama T, Katano T, Murao D, Tanaka H, Yamaguchi E, et al.. P43-2 A case of pulmonary Lomentspora prolificansosis diagnosed by bronchoscopy accompanied by Crohn^s Disease being treated with infliximab.. The Journal of the Japan Society for Respiratory Endoscopy. 2025;47:S367$76$YR$E$F$Y$$$20250917$$MD$JP$JP
254565122$25456512$2$F$20250430$20250618$20250619$20250703$EXP$$EU-Ipsen Biopharmaceuticals, Inc.-2025-14353$IPSEN BIOPHARMACEUTICALS, INC.$$14$YR$T$F$Y$28.1$KG$20250703$$$EU$EU
254565452$25456545$2$F$$20250625$20250619$20250701$PER$$US-Taiho Oncology Inc-2025-006430$TAIHO ONCOLOGY INC$$38$YR$A$F$Y$$$20250701$$CN$US$US
254568552$25456855$2$F$20250101$20250721$20250619$20250728$PER$$US-SA-2025SA173550$SANOFI AVENTIS$$3$YR$C$F$Y$$$20250728$$HP$US$US
254571032$25457103$2$F$$20250722$20250619$20250729$PER$$US-SA-2025SA172598$SANOFI AVENTIS$$$$A$F$Y$70.45$KG$20250729$$HP$US$US
254572592$25457259$2$F$$20250630$20250619$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202409005940$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250704$$CN$US$US
254578464$25457846$4$F$20250617$20250731$20250620$20250805$EXP$$CA-ASTRAZENECA-202506CAN013632CA$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$$$20250805$$$CA$CA
254585362$25458536$2$F$$20250625$20250620$20250701$EXP$$JP-AMGEN-JPNSP2025120330$AMGEN$$75$YR$E$M$Y$$$20250701$$PH$JP$JP
254585413$25458541$3$F$$20250916$20250620$20250920$PER$$NVSC2025US094267$NOVARTIS$$$$$M$Y$$$20250920$$CN$US$US
254588552$25458855$2$F$$20250616$20250620$20250803$EXP$$JP-ASTRAZENECA-202506GLO015458JP$ALEXION PHARMACEUTICALS$$7$DEC$E$M$Y$$$20250803$$MD$JP$JP
254590862$25459086$2$F$20250101$20250908$20250620$20250915$PER$$US-SA-2025SA173726$SANOFI AVENTIS$$57$YR$A$M$Y$$$20250915$$MD$US$US
254591255$25459125$5$F$20250626$20250725$20250620$20250806$PER$$US-ROCHE-10000315967$ROCHE$$42$YR$A$M$Y$71.67$KG$20250806$$CN$US$US
254593312$25459331$2$F$20250606$20250623$20250620$20250701$PER$$US-AMGEN-USASP2025120188$AMGEN$$5$YR$C$F$Y$19.7$KG$20250701$$PH$US$US
254596913$25459691$3$F$$20250829$20250620$20250905$EXP$$US-AMGEN-USASP2025121045$AMGEN$$$$$F$Y$$$20250904$$CN$US$US
254599092$25459909$2$F$$20250725$20250620$20250730$30DAY$$EU-JNJFOC-20250615721$JOHNSON AND JOHNSON$$$$$$Y$$$20250730$$PH$EU$EU
254599493$25459949$3$F$$20250711$20250620$20250721$EXP$$US-ROCHE-10000313108$ROCHE$$$$E$M$Y$$$20250721$$CN$US$US
254602932$25460293$2$F$$20250828$20250620$20250908$PER$$US-SMPA-2025SPA006788$SUNOVION$$94$YR$$M$Y$$$20250905$$$US$US
254604382$25460438$2$F$20250326$20250812$20250620$20250819$EXP$$US-TERSERA THERAPEUTICS LLC-2025TRS002313$TERSERA THERAPEUTICS$$$$$$Y$$$20250819$$MD$US$US
254608863$25460886$3$F$20210801$20250725$20250620$20250801$EXP$$NVSC2025IL095607$NOVARTIS$$20$YR$$F$Y$$$20250801$$MD$IL$IL
254612342$25461234$2$F$$20250623$20250620$20250707$EXP$$US-INDIVIOR US-INDV-143909-2024$RECKITT BENCKISER$$$$$$Y$$$20250707$$LW$US$US
254612512$25461251$2$F$$20250610$20250620$20250816$PER$$US-ASTRAZENECA-202506USA008217US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$MD$US$US
254612532$25461253$2$F$20250505$20250621$20250620$20250705$EXP$$EU-AUROBINDO-AUR-APL-2025-029715$AUROBINDO$$58$YR$$M$Y$71$KG$20250705$$MD$EU$EU
254614282$25461428$2$F$$20250616$20250620$20250803$EXP$$JP-ASTRAZENECA-202506GLO015599JP$ALEXION PHARMACEUTICALS$$$$A$$Y$$$20250803$$MD$JP$JP
254624604$25462460$4$F$20250101$20250921$20250620$20250929$EXP$$JP-ARGENX-2025-ARGX-JP000988AA$ARGENX BVBA$$$$$$Y$$$20250929$$CN$JP$JP
254625492$25462549$2$F$20250615$20250617$20250620$20250810$EXP$$GB-ASTRAZENECA-202506GBR014690GB$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250810$$$GB$GB
254627403$25462740$3$F$$20250822$20250620$20250826$PER$$US-PFIZER INC-202500124541$PFIZER$$20$YR$$F$Y$$$20250826$$MD$US$US
254627603$25462760$3$F$20250523$20250703$20250620$20250715$PER$$US-AMGEN-USASP2025115069$AMGEN$$12$YR$T$F$Y$$$20250714$$HP$US$US
254627713$25462771$3$F$$20250630$20250620$20250810$EXP$$CA-ASTRAZENECA-202506GLO015577CA$ALEXION PHARMACEUTICALS$$53$YR$A$M$Y$$$20250810$$$CA$CA
254631232$25463123$2$F$$20250616$20250620$20250810$EXP$$US-ASTRAZENECA-202506USA012498US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
254634142$25463414$2$F$$20250717$20250620$20250728$30DAY$$EU-JNJFOC-20250614864$JOHNSON AND JOHNSON$$56$YR$A$F$Y$$$20250728$$PH$EU$EU
254634543$25463454$3$F$20250618$20250826$20250620$20250827$PER$$US-ASTRAZENECA-202506USA015054US$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$$$20250827$$$US$US
254636152$25463615$2$F$20240729$20250822$20250620$20250828$EXP$$CA-SANDOZ INC.-SDZ2024CA070009$SANDOZ$$38$YR$$F$Y$$$20250828$$MD$CA$CA
254636253$25463625$3$F$20230104$20250829$20250620$20250904$EXP$$US-ASTRAZENECA-202506USA012098US$ALEXION PHARMACEUTICALS$$77$YR$E$F$Y$64.8$KG$20250904$$MD$US$US
254636392$25463639$2$F$20250501$20250630$20250620$20250912$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-089046$REGENERON$$$$$F$Y$$$20250912$$CN$US$US
254636412$25463641$2$F$$20250624$20250620$20250708$EXP$$CA-HLS-202501486$HLS THERAPEUTICS$$$$E$F$Y$$$20250708$$MD$CA$CA
254640582$25464058$2$F$$20250626$20250621$20250702$EXP$$JP-ASTELLAS-2025-AER-033598$ASTELLAS$$$$E$$Y$$$20250702$$MD$JP$JP
254644343$25464434$3$F$$20250806$20250621$20250811$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-077117$BOEHRINGER INGELHEIM$$34$YR$A$F$Y$$$20250811$$$CA$CA
254645652$25464565$2$F$$20250618$20250621$20250810$PER$$US-ASTRAZENECA-202506USA015030US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$US$US
254649822$25464982$2$F$20231215$20250626$20250622$20250702$EXP$EU-SANDOZ-SDZ2025DE038987$EU-RDY-DEU/2025/06/008801$DR REDDYS$$61$YR$A$F$Y$$$20250702$$HP$EU$EU
254650452$25465045$2$F$20250101$20250725$20250622$20250729$EXP$$CO-ASTELLAS-2025-AER-025423$ASTELLAS$$80$YR$E$M$Y$78$KG$20250729$$CN$CO$CO
254652272$25465227$2$F$20241101$20250630$20250622$20250701$EXP$EU-MINISAL02-1045159$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-087719$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$60$KG$20250701$$MD$EU$EU
254656742$25465674$2$F$$20250819$20250623$20250822$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007331$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250822$$CN$US$US
254657662$25465766$2$F$$20250715$20250623$20250718$PER$$US-BIOGEN-2016BI00250250$BIOGEN$$$$$F$Y$$$20250718$$CN$US$US
254659533$25465953$3$F$20250101$20250618$20250623$20250803$EXP$$EU-ASTRAZENECA-202506EEA015636DE$ALEXION PHARMACEUTICALS$$57$YR$A$M$Y$$$20250803$$MD$EU$EU
254659972$25465997$2$F$20250613$20250619$20250623$20250810$EXP$$CN-ASTRAZENECA-202506CHN016695CN$ALEXION PHARMACEUTICALS$$84$YR$E$M$Y$67.5$KG$20250810$$$CN$CN
254662542$25466254$2$F$$20250704$20250623$20250720$PER$$US-RDY-USA/2025/05/007282$DR REDDYS$$64$YR$A$M$Y$$$20250720$$CN$US$US
254663062$25466306$2$F$$20250618$20250623$20250810$PER$$US-ASTRAZENECA-202506USA017646US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$MD$US$US
254666142$25466614$2$F$$20250618$20250623$20250802$EXP$$US-ASTRAZENECA-202506USA015212US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
254666872$25466687$2$F$$20250620$20250623$20250802$EXP$$EU-ASTRAZENECA-202506EEA017101BG$ALEXION PHARMACEUTICALS$$47$YR$A$F$Y$$$20250802$$MD$EU$EU
254669172$25466917$2$F$$20250829$20250623$20250903$PER$$NVSC2025US096931$NOVARTIS$$$$$M$Y$$$20250903$$MD$US$US
254673182$25467318$2$F$20250601$20250725$20250623$20250731$EXP$$US-BIOGEN-2025BI01313865$BIOGEN$$67$YR$$F$Y$$$20250731$$CN$US$US
254673652$25467365$2$F$$20250820$20250623$20250821$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-088742$BRISTOL-MYERS SQUIBB COMPANY$$50$YR$A$F$Y$$$20250821$$CN$US$US
254673822$25467382$2$F$$20250620$20250623$20250809$EXP$$US-ASTRAZENECA-202506USA017887US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
254675003$25467500$3$F$$20250807$20250623$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202506018790$ELI LILLY AND COMPANY$$57$YR$A$F$Y$117$KG$20250818$$CN$US$US
254675956$25467595$6$F$$20250917$20250623$20250917$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-087634$BRISTOL-MYERS SQUIBB COMPANY$$42$YR$A$M$Y$$$20250917$$$US$US
254686332$25468633$2$F$20250101$20250919$20250623$20250929$PER$$US-SA-2025SA176145$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250929$$CN$US$US
254693252$25469325$2$F$$20250619$20250623$20250810$PER$$US-ASTRAZENECA-202506USA017703US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
254697172$25469717$2$F$$20250625$20250623$20250701$EXP$$US-ELI_LILLY_AND_COMPANY-US202506018853$ELI LILLY AND COMPANY$$$$E$M$Y$$$20250701$$CN$US$US
254698672$25469867$2$F$$20250708$20250623$20250721$EXP$$CA-HLS-202501524$HLS THERAPEUTICS$$43$YR$A$F$Y$$$20250721$$$CA$CA
254701782$25470178$2$F$20250501$20250923$20250623$20250929$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-089105$BRISTOL-MYERS SQUIBB COMPANY$$47$YR$A$F$Y$$$20250929$$$US$US
254706782$25470678$2$F$$20250722$20250624$20250925$PER$$US-GSK-US2025072612$GLAXOSMITHKLINE$$$$$F$Y$$$20250924$$$US$US
254707643$25470764$3$F$$20250831$20250624$20250905$EXP$$US-BIOGEN-2025BI01314514$BIOGEN$$$$$F$Y$46.81$KG$20250905$$MD$US$US
254708042$25470804$2$F$20250424$20250623$20250624$20250810$EXP$EU-AFSSAPS-SE2025000516$EU-ASTRAZENECA-202506GLO018391FR$ALEXION PHARMACEUTICALS$$68$YR$E$F$Y$65.5$KG$20250810$$MD$EU$EU
254709042$25470904$2$F$20230301$20250618$20250624$20250703$EXP$CN-MLMSERVICE-20250603-PI524827-00306-1$CN-ALKEM LABORATORIES LIMITED-CN-ALKEM-2025-06265$ALKEM$Wang X, You Y, Chen S, Wang P, Zeng S, Zhuang L, Wang M, Lai G, Yu Z, Yu G and Wen W. Isavuconazole as an optimal treatment option for multiple pathogens induced severe pneumonia in immunocompromised hosts: a case series report. Frontiers in Medicine. 2025;12:1565071$73$YR$$M$Y$$$20250703$$MD$CN$CN
254710512$25471051$2$F$20250601$20250716$20250624$20250720$EXP$$CA-ABBVIE-6333994$ABBVIE$$59$YR$$F$Y$$$20250720$$CN$CA$CA
254712492$25471249$2$F$$20250612$20250624$20250703$PER$$US-TLM-TLM-2025-03639$TOLMAR$$$$$M$Y$$$20250702$$PH$US$US
254713162$25471316$2$F$20250501$20250624$20250624$20250701$EXP$$US-ABBVIE-6336862$ABBVIE$$66$YR$$F$Y$52.163$KG$20250701$$CN$US$US
254718392$25471839$2$F$$20250701$20250624$20250726$PER$$US-TLM-TLM-2025-02104$TOLMAR$$71$YR$E$M$Y$96.162$KG$20250712$$HP$US$US
254721087$25472108$7$F$$20250815$20250624$20250822$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-006599$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250822$$CN$US$US
254722382$25472238$2$F$$20250708$20250624$20250807$PER$$US-UniquePharma-US-2025UPLSPO00083$UNIQUE PHARMACEUTICALS$$$$$F$Y$$$20250807$$PH$US$US
254723072$25472307$2$F$20250505$20250709$20250624$20250808$EXP$$US-ASTRAZENECA-202506USA018683US$ALEXION PHARMACEUTICALS$$83$YR$E$M$Y$$$20250808$$MD$US$US
254724372$25472437$2$F$20250225$20250714$20250624$20250724$EXP$$JP-RADIUS HEALTH INC.-2025JP001969$RADIUS PHARM$$75$YR$$F$Y$$$20250724$$MD$JP$JP
254725294$25472529$4$F$20250301$20250703$20250624$20250821$EXP$$EU-Accord-491090$ACCORD$$65$YR$E$M$Y$58$KG$20250821$$MD$EU$EU
254727033$25472703$3$F$$20250911$20250624$20250923$PER$$US-SMPA-2025SPA006907$SUNOVION$$73$YR$$M$Y$$$20250922$$$US$US
254728372$25472837$2$F$$20250620$20250624$20250923$PER$$US-JNJFOC-20250627735$JOHNSON AND JOHNSON$$$$$$Y$$$20250923$$MD$US$US
254728392$25472839$2$F$20250306$20250624$20250624$20250819$EXP$$EU-Accord-491827$ACCORD$$52$YR$A$F$Y$49$KG$20250819$$MD$EU$EU
254731872$25473187$2$F$20250529$20250620$20250624$20250802$EXP$$CN-ASTRAZENECA-202506CHN016957CN$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$CN$CN
254734295$25473429$5$F$$20250919$20250624$20250923$30DAY$$US-PFIZER INC-202500124570$PFIZER$$6$YR$$M$Y$$$20250923$$HP$US$US
254735044$25473504$4$F$$20250724$20250624$20250724$30DAY$$US-PFIZER INC-202500122670$PFIZER$$12$YR$$M$Y$$$20250724$$CN$US$US
254736383$25473638$3$F$$20250629$20250624$20250701$PER$$US-PFIZER INC-202500126291$PFIZER$$23$YR$$M$Y$$$20250701$$MD$US$US
254743032$25474303$2$F$20250613$20250727$20250624$20250801$30DAY$$US-AMGEN-USASL2025119096$AMGEN$$43$YR$A$M$Y$115.65$KG$20250731$$PH$US$US
254744562$25474456$2$F$$20250620$20250624$20250802$EXP$$US-ASTRAZENECA-202506USA017369US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250802$$PH$US$US
254744582$25474458$2$F$$20250620$20250624$20250701$PER$$US-KENVUE-20250610029$Kenvue$$$$$$Y$$$20250701$$CN$US$US
254745872$25474587$2$F$20250101$20250731$20250624$20250812$PER$$US-SA-2025SA178024$SANOFI AVENTIS$$28$YR$A$M$Y$$$20250813$$MD$US$US
254746172$25474617$2$F$20250101$20250716$20250624$20250721$PER$$US-SA-2025SA176825$SANOFI AVENTIS$$75$YR$E$M$Y$$$20250722$$HP$US$US
254750223$25475022$3$F$$20250702$20250624$20250711$EXP$$CA-TAKEDA-2025TUS050454$TAKEDA$$$$$M$Y$$$20250711$$MD$CA$CA
254751274$25475127$4$F$$20250728$20250624$20250729$EXP$$CA-TEVA-VS-3342701$TEVA$$43$YR$$M$Y$$$20250729$$MD$CA$CA
254752482$25475248$2$F$20200101$20250826$20250624$20250904$EXP$AU-PERRIGO-25AU007479$AU-PERRIGO-25AU007479$GALPHARM INTERNATIONAL$Haggan M.. Transitions of care saw medicines, condition missed. Australian Journal of Pharmacy. 2025;1-9$47$YR$$F$Y$$$20250904$$CN$AU$AU
254759002$25475900$2$F$$20250822$20250625$20250902$EXP$$CA-ABBVIE-6341052$ABBVIE$$55$YR$$M$Y$$$20250902$$CN$CA$CA
254760532$25476053$2$F$$20250716$20250625$20250722$EXP$$JP-GSK-JP2025JPN076612$GLAXOSMITHKLINE$$81$YR$$M$Y$$$20250722$$MD$JP$JP
254765034$25476503$4$F$20250611$20250826$20250625$20250827$PER$$US-ASTRAZENECA-202506USA018900US$ALEXION PHARMACEUTICALS$$61$YR$A$F$Y$$$20250827$$$US$US
254768052$25476805$2$F$20250101$20250624$20250625$20250810$PER$$US-ASTRAZENECA-202506USA020569US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
254768162$25476816$2$F$20250418$20250902$20250625$20250912$EXP$$US-KYOWAKIRIN-2025KK011821$KYOWA$$$$$$Y$$$20250912$$HP$US$US
254768332$25476833$2$F$20241231$20250627$20250625$20250710$EXP$$EU-AUROBINDO-AUR-APL-2025-030847$AUROBINDO$$70$YR$$M$Y$76$KG$20250710$$MD$EU$EU
254768934$25476893$4$F$$20250716$20250625$20250729$EXP$$EU-AUROBINDO-AUR-APL-2025-030824$AUROBINDO$Filipe CB Cabral TC,Ambrosio AR, Oliveira ID,Grilo A  et al.. Sarcoma de Kaposi Iatrog?nico-Um Caso Incomum./PA No. 0464 Iatrogenic Kaposi Sarcoma - An Uncommon Case./Iatrogenic Kaposi^s Sarcoma - An Unusual Case. Portuguese Journal of Internal Medicine. 31st National Congress of Internal Medi. 2025;370$53$YR$$M$Y$$$20250729$$MD$EU$EU
254770999$25477099$9$F$20250708$20250918$20250625$20250923$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007461$ACADIA PHARMACEUTICALS$$74$YR$$M$Y$$$20250923$$CN$US$US
254772282$25477228$2$F$20250614$20250620$20250625$20250803$EXP$GB-MHRA-MED-202506201516482820-FJHSZ$GB-ASTRAZENECA-202506GLO018257GB$ALEXION PHARMACEUTICALS$$81$YR$E$F$Y$50$KG$20250803$$$GB$GB
254774773$25477477$3$F$$20250624$20250625$20250810$EXP$$GB-ASTRAZENECA-202506GBR018634GB$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250810$$$GB$GB
254775002$25477500$2$F$20250509$20250618$20250625$20250803$EXP$EU-AFSSAPS-NT2025000499$EU-ASTRAZENECA-202506GLO019449FR$ALEXION PHARMACEUTICALS$$36$YR$A$F$Y$62$KG$20250803$$MD$EU$EU
254775472$25477547$2$F$20250407$20250826$20250625$20250902$EXP$$US-ABBVIE-6339936$ABBVIE$$49$YR$$F$Y$69$KG$20250902$$CN$US$US
254776813$25477681$3$F$$20250731$20250625$20250804$EXP$$EU-ASTRAZENECA-202506EEA018364FR$ALEXION PHARMACEUTICALS$$72$YR$E$M$Y$$$20250804$$MD$EU$EU
254777254$25477725$4$F$20250619$20250908$20250625$20250912$EXP$$EU-ABBVIE-6338314$ABBVIE$$69$YR$$F$Y$101$KG$20250912$$MD$EU$EU
254779562$25477956$2$F$$20250610$20250625$20250813$EXP$$EU-AUROBINDO-AUR-APL-2021-032577$AUROBINDO$Figueiredo C, Valerio P, Sousa H, Gois M, Nolasco F. Kidney graft dysfunction in a patient with SARS-CoV-2 pneumonia - Not everything is COVID 19.. Port J Nephrol Hypert. 2021;35(1):59-62$46$YR$$M$Y$$$20250813$$HP$EU$EU
254784272$25478427$2$F$$20250722$20250625$20250801$EXP$$US-AUROBINDO-AUR-APL-2025-032371$AUROBINDO$Sathya S, Cely C, Ruiz RM, Vera-Arroyo A.. Case of a 56 Year-Old Postop CABG Patient with Hypoxemic Respiratory Failure and Subsequent Improvement with Methylprednisolone.. Anesth-Analg. 2017;127 (Suppl.)(5):526-528$56$YR$$M$Y$$$20250801$$HP$US$US
254784562$25478456$2$F$20250101$20250722$20250625$20250731$PER$$US-MYLANLABS-2025M1052751$MYLAN$$$$$F$Y$65.7$KG$20250731$$$US$US
254786082$25478608$2$F$$20250702$20250625$20250709$EXP$$CH-BEIGENE-BGN-2025-008413$BEIGENE$$68$YR$$$Y$$$20250709$$MD$CH$CH
254791452$25479145$2$F$20250607$20250627$20250625$20250708$EXP$$BR-GUERBET / LLC-BR-20250150$GUERBET$$18$YR$A$F$Y$48$KG$20250708$$PH$BR$BR
254792132$25479213$2$F$$20250625$20250625$20250704$EXP$$EU-VANTIVE-2025VAN002831$Vantive US Healthcare$$$$$M$Y$$$20250704$$MD$EU$EU
254793952$25479395$2$F$$20250808$20250625$20250813$EXP$$CA-SA-2025SA176367$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250813$$HP$CA$CA
254794892$25479489$2$F$20250101$20250911$20250625$20250917$PER$$US-SA-2025SA175491$SANOFI AVENTIS$$$$A$F$Y$$$20250917$$HP$US$US
254796203$25479620$3$F$20250601$20250708$20250625$20250715$PER$$US-SA-2025SA177946$SANOFI AVENTIS$$84$YR$E$M$Y$$$20250715$$HP$US$US
254801282$25480128$2$F$20250501$20250722$20250625$20250731$EXP$$US-NOVOPROD-1452225$NOVO NORDISK$$77$YR$$F$Y$$$20250731$$PH$US$US
254803792$25480379$2$F$$20250730$20250625$20250806$EXP$$CA-PFIZER INC-202500127007$PFIZER$$14$YR$$F$Y$43$KG$20250806$$PH$CA$CA
254813002$25481300$2$F$20220601$20250617$20250626$20250701$EXP$$EU-AUROBINDO-AUR-APL-2025-031339$AUROBINDO$$16$YR$$M$Y$$$20250701$$CN$EU$EU
254815302$25481530$2$F$20250406$20250701$20250626$20250711$EXP$AU-TGA-0000840169$AU-NOVOPROD-1461954$NOVO NORDISK$$51$YR$$F$Y$$$20250711$$CN$AU$AU
254816662$25481666$2$F$$20250725$20250626$20250922$PER$$US-AUROBINDO-AUR-APL-2025-020955$AUROBINDO$$$$$$Y$$$20250922$$PH$US$US
254819452$25481945$2$F$$20250708$20250626$20250715$EXP$$US-UNITED THERAPEUTICS-UNT-2025-021636$UNITED THERAPEUTICS$$$$$F$Y$$$20250715$$$US$US
254821465$25482146$5$F$20250501$20250905$20250626$20250916$EXP$$US-NOVOPROD-1464553$NOVO NORDISK$$12$YR$$F$Y$81$KG$20250916$$MD$US$US
254823133$25482313$3$F$$20250902$20250626$20250911$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05384$LUPIN$$31$YR$$$Y$52.154$KG$20250911$$$US$US
254826672$25482667$2$F$$20250707$20250626$20250711$PER$$NVSC2025US101392$NOVARTIS$$$$$$Y$$$20250711$$HP$US$US
254827212$25482721$2$F$$20250708$20250626$20250716$EXP$$AU-BAUSCH-BL-2025-007908$BAUSCH AND LOMB$Lee Z, Brennan C, Marshman G. Bilateral Palmar Rash With Azathioprine Rechallenge. The Australasian journal of dermatology. 2025;1-2. doi:10.1111/ajd.14550.$80$YR$E$M$Y$$$20250716$$MD$AU$AU
254827752$25482775$2$F$$20250716$20250626$20250722$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007529$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250722$$CN$US$US
254829002$25482900$2$F$$20250825$20250626$20250829$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007587$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250829$$CN$US$US
254830352$25483035$2$F$20250424$20250708$20250626$20250710$EXP$$CO-BAYER-2025A084865$BAYER HEALTHCARE PHARMACEUTICALS INC.$$23$YR$A$M$Y$$$20250710$$CN$CO$CO
254833533$25483353$3$F$$20250703$20250626$20250708$EXP$$US-Taiho Oncology Inc-2025-006607$TAIHO ONCOLOGY INC$$54$YR$A$F$Y$90.26$KG$20250708$$CN$US$US
254834586$25483458$6$F$$20250917$20250626$20250918$30DAY$$US-PFIZER INC-202500127513$PFIZER$$14$YR$$M$Y$$$20250918$$CN$US$US
254835612$25483561$2$F$$20250710$20250626$20250715$EXP$$CA-TEVA-VS-3345356$TEVA$$66$YR$$M$Y$$$20250715$$HP$CA$CA
254835942$25483594$2$F$20250621$20250626$20250626$20250701$PER$$US-AMGEN-USASP2025124111$AMGEN$$76$YR$E$F$Y$$$20250701$$CN$US$US
254839643$25483964$3$F$20250322$20250729$20250626$20250731$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-090921$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$$$20250731$$CN$US$US
254840842$25484084$2$F$$20250618$20250626$20250717$PER$$US-BEH-2025210025$CSL BEHRING$$76$YR$E$F$Y$65.76$KG$20250717$$CN$US$US
254842132$25484213$2$F$20250501$20250807$20250626$20250819$PER$$US-SA-2025SA179316$SANOFI AVENTIS$$22$YR$A$M$Y$$$20250819$$HP$US$US
254844162$25484416$2$F$$20250916$20250626$20250918$PER$$US-JNJFOC-20250625260$JOHNSON AND JOHNSON$$$$$F$Y$$$20250918$$CN$US$US
254853153$25485315$3$F$$20250730$20250626$20250806$30DAY$$US-MYLANLABS-2025M1052642$MYLAN$$$$$$Y$$$20250806$$PH$US$US
254853492$25485349$2$F$$20250718$20250626$20250721$EXP$$EU-SANDOZ INC.-NVSC2020ES031697$SANDOZ$$$$A$$Y$$$20250721$$MD$EU$EU
254854552$25485455$2$F$20250526$20250722$20250626$20250728$EXP$$JP-ASTELLAS-2025-AER-033924$ASTELLAS$$73$YR$E$M$Y$$$20250728$$MD$JP$JP
254855362$25485536$2$F$$20250815$20250626$20250819$EXP$$EU-MYLANLABS-2025M1052610$MYLAN$Van Hove K, D?heygere E, Vanderdonckt P, D?heygere F. An unusual cause of neurological symptoms. Tijdschrift voor Geneeskunde en Gezondheidszorg. 2025;81:484-92.$54$YR$$M$Y$$$20250819$$$EU$EU
254856202$25485620$2$F$20240101$20250618$20250626$20250702$EXP$$JP-009507513-2298238$MERCK SHARP + DOHME LLC$$86$YR$$M$Y$$$20250702$$MD$JP$JP
254862732$25486273$2$F$20250505$20250711$20250626$20250716$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202506022247$ELI LILLY AND COMPANY$$65$YR$E$M$Y$$$20250716$$CN$JP$JP
254865033$25486503$3$F$20250601$20250905$20250627$20250916$EXP$$US-NOVOPROD-1463480$NOVO NORDISK$$87$YR$$M$Y$99.773$KG$20250916$$MD$US$US
254865914$25486591$4$F$$20250719$20250627$20250730$EXP$$EU-AUROBINDO-AUR-APL-2025-031776$AUROBINDO$Bosic V, Seitz B, Abdin AD.. Letrozole-induced central serous chorioretinopathy.. OPHTHALMOLOGIE (Ophthalmology). 2025$62$YR$$F$Y$$$20250730$$HP$EU$EU
254867896$25486789$6$F$$20250709$20250627$20250807$EXP$$EU-AUROBINDO-AUR-APL-2025-031861$AUROBINDO$Teixeira D,  M?boto D, Rodrigues AF.. S?ndrome dos Ductos Biliares Evanescentes.. Livro de Resumos - 31? Congresso Nacional de Medicina Interna.. 2025;915$79$YR$$M$Y$$$20250807$$MD$EU$EU
254871352$25487135$2$F$20250601$20250621$20250627$20250706$EXP$$EU-AUROBINDO-AUR-APL-2025-031539$AUROBINDO$$1$MON$$M$Y$$$20250706$$MD$EU$EU
254872492$25487249$2$F$$20250710$20250627$20250714$EXP$$JP-GSK-JP2025JPN077190$GLAXOSMITHKLINE$$93$YR$$M$Y$$$20250714$$PH$JP$JP
254873242$25487324$2$F$$20250911$20250627$20250922$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05275$LUPIN$$67$YR$$$Y$$$20250922$$$US$US
254879092$25487909$2$F$$20250630$20250627$20250702$EXP$$EU-SANDOZ INC.-NVSC2019DE034799$SANDOZ$$14$YR$$M$Y$$$20250702$$HP$EU$EU
254881422$25488142$2$F$$20250812$20250627$20250818$EXP$$US-ELI_LILLY_AND_COMPANY-US202506019522$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250818$$CN$US$US
254884062$25488406$2$F$$20250721$20250627$20250725$PER$$US-BAYER-2025A085444$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250725$$CN$US$US
254884443$25488444$3$F$20250501$20250728$20250627$20250807$EXP$$US-UCBSA-2025038638$UCB$$35$YR$$F$Y$$$20250807$$HP$US$US
254884522$25488452$2$F$$20250709$20250627$20250718$EXP$$US-OTSUKA PHARMACEUTICAL NETHERLANDS B.V.-AUR-008439$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250718$$CN$US$US
254885362$25488536$2$F$20250613$20250716$20250627$20250725$EXP$$AR-AKCEA THERAPEUTICS, INC.-2025IS001944$AKCEA THERAPEUTICS$$$$$$Y$$$20250725$$HP$AR$AR
254887043$25488704$3$F$$20250730$20250627$20250730$PER$$US-PFIZER INC-202500116560$PFIZER$$59$YR$$M$Y$73$KG$20250730$$CN$US$US
254891002$25489100$2$F$20250501$20250807$20250627$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202506020657$ELI LILLY AND COMPANY$$35$YR$A$M$Y$$$20250813$$CN$US$US
254894222$25489422$2$F$20250501$20250902$20250627$20250907$PER$$US-SA-2025SA179760$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250907$$MD$US$US
254897552$25489755$2$F$$20250623$20250627$20250917$EXP$$EU-SANDOZ INC.-PHHY2019CZ133831$SANDOZ$$$$A$$Y$$$20250917$$MD$EU$EU
254899253$25489925$3$F$20250101$20250827$20250628$20250902$PER$$US-SA-2025SA181660$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250902$$HP$US$US
254899282$25489928$2$F$20250606$20250709$20250627$20250721$EXP$$US-ADMA BIOLOGICS INC.-US-2025ADM000187$ADMA BIOLOGICS$$48$YR$$M$Y$$$20250721$$HP$US$US
254900772$25490077$2$F$20241229$20250708$20250628$20250714$EXP$EU-AFSSAPS-TO2025000212$EU-CELLTRION INC.-2025FR020185$CELLTRION$$$$$$Y$$$20250714$$PH$EU$EU
254904502$25490450$2$F$20241101$20250808$20250628$20250813$EXP$$US-ABBVIE-6068077$ABBVIE$$50$YR$$F$Y$$$20250813$$CN$US$US
254905773$25490577$3$F$20250601$20250722$20250628$20250725$PER$$US-SA-2025SA180670$SANOFI AVENTIS$$59$YR$A$F$Y$105.67$KG$20250725$$MD$US$US
254915202$25491520$2$F$20250127$20250718$20250629$20250722$EXP$$CN-ABBVIE-6343477$ABBVIE$$45$YR$$F$Y$$$20250722$$MD$CN$CN
254915882$25491588$2$F$20250101$20250910$20250629$20250915$EXP$$US-ABBVIE-6343325$ABBVIE$$74$YR$$F$Y$$$20250915$$CN$US$US
254916404$25491640$4$F$$20250918$20250629$20250925$EXP$$US-TAKEDA-2025TUS057115$TAKEDA$$38$YR$$M$Y$$$20250925$$$US$US
254918592$25491859$2$F$$20250620$20250630$20250701$EXP$$NVSC2025BR101295$NOVARTIS$$$$$F$Y$$$20250701$$MD$BR$BR
254920062$25492006$2$F$$20250709$20250630$20250805$PER$$US-TLM-TLM-2025-04003$TOLMAR$$$$$$Y$$$20250711$$HP$US$US
254923002$25492300$2$F$$20250707$20250630$20250802$PER$$US-TLM-TLM-2025-02773$TOLMAR$$$$E$M$Y$88.415$KG$20250712$$HP$US$US
254923303$25492330$3$F$20250601$20250807$20250630$20250812$EXP$$JP-ABBVIE-6347953$ABBVIE$$80$YR$$F$Y$$$20250812$$PH$JP$JP
254925463$25492546$3$F$$20250911$20250630$20250922$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05515$LUPIN$$61$YR$$$Y$48.98$KG$20250922$$$US$US
254929592$25492959$2$F$$20250605$20250630$20250702$PER$$US-TRAVERE-2025TVT00788$TRAVERE THERAPEUTICS$$41$YR$A$F$Y$$$20250702$$CN$US$US
254936292$25493629$2$F$20250422$20250626$20250630$20250702$EXP$EU-AFSSAPS-GR2025000940$EU-ASTELLAS-2025-AER-035193$ASTELLAS$$64$YR$A$F$Y$70$KG$20250702$$PH$EU$EU
254937362$25493736$2$F$$20250722$20250630$20250724$PER$$US-ELI_LILLY_AND_COMPANY-US202506025121$ELI LILLY AND COMPANY$$26$YR$A$$Y$$$20250724$$CN$US$US
254939115$25493911$5$F$20250101$20250818$20250630$20250821$PER$$IL-PFIZER INC-PV202500063018$PFIZER$$12$YR$$M$Y$$$20250821$$HP$IL$IL
254939852$25493985$2$F$$20250825$20250630$20250829$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-007620$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250829$$CN$US$US
254939962$25493996$2$F$20100101$20250630$20250630$20250701$EXP$$US-PFIZER INC-PV202500077222$PFIZER$$$$$F$Y$$$20250701$$LW$US$US
254940562$25494056$2$F$$20250626$20250630$20250707$30DAY$$US-JNJFOC-20250633855$JOHNSON AND JOHNSON$$$$$$Y$$$20250707$$CN$US$US
254944083$25494408$3$F$$20250829$20250630$20250910$EXP$$US-ASTELLAS-2025-AER-033771$ASTELLAS$$$$A$F$Y$$$20250910$$MD$US$US
254947592$25494759$2$F$20190311$20250627$20250630$20250708$EXP$$CO-SANDOZ INC.-SDZ2025CO045300$SANDOZ$$45$YR$$M$Y$88.2$KG$20250708$$CN$CO$CO
254949375$25494937$5$F$$20250730$20250630$20250805$EXP$$CA-TEVA-VS-3344569$TEVA$$43$YR$$F$Y$68$KG$20250805$$HP$CA$CA
254949992$25494999$2$F$$20250822$20250630$20250904$EXP$$JP-ROCHE-10000323886$ROCHE$$57$YR$A$M$Y$74.2$KG$20250904$$MD$JP$JP
254952073$25495207$3$F$20250616$20250823$20250630$20250825$EXP$$CA-PFIZER INC-202500057586$PFIZER$$71$YR$$M$Y$68.1$KG$20250825$$MD$CA$CA
254957272$25495727$2$F$20250625$20250819$20250630$20250826$PER$$US-SA-2025SA183111$SANOFI AVENTIS$$70$YR$E$F$Y$$$20250826$$HP$US$US
254957362$25495736$2$F$20250101$20250718$20250630$20250723$PER$$US-SA-2025SA183313$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250723$$CN$US$US
254960152$25496015$2$F$20250627$20250806$20250630$20250807$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092252$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$74.39$KG$20250807$$CN$US$US
254965132$25496513$2$F$20220101$20250708$20250630$20250713$EXP$$US-ABBVIE-6346510$ABBVIE$$70$YR$$F$Y$62.1$KG$20250713$$CN$US$US
254966082$25496608$2$F$20250622$20250814$20250630$20250819$EXP$$EU-ABBVIE-6349728$ABBVIE$$73$YR$$M$Y$72$KG$20250819$$MD$EU$EU
254967581$25496758$1$I$$20250626$20250701$20250701$EXP$$US-JNJFOC-20250633526$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20250701$$HP$US$US
254968112$25496811$2$F$20250301$20250818$20250701$20250822$EXP$$US-ABBVIE-6342404$ABBVIE$$80$YR$$M$Y$$$20250822$$CN$US$US
254968631$25496863$1$I$$20250625$20250701$20250701$EXP$$EG-HALEON-2249639$Haleon PLC$$$$$$Y$$$20250630$$CN$EG$EG
254969161$25496916$1$I$$20250625$20250701$20250701$PER$$US-TAKEDA-2025TUS059102$TAKEDA$$$$$$Y$$$20250701$$$US$US
254970461$25497046$1$I$$20250624$20250701$20250701$PER$$US-SA-2025SA183212$SANOFI AVENTIS$$64$YR$A$M$Y$$$20250701$$CN$US$US
254970481$25497048$1$I$$20250630$20250701$20250701$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092507$BRISTOL-MYERS SQUIBB COMPANY$$68$YR$E$M$Y$$$20250701$$CN$US$US
254970571$25497057$1$I$$20250626$20250701$20250701$EXP$$US-ABBVIE-6349152$ABBVIE$$$$A$F$Y$$$20250701$$CN$US$US
254971841$25497184$1$I$$20250625$20250701$20250701$EXP$$CA-UCBSA-2025038932$UCB$$$$$F$Y$$$20250701$$CN$CA$CA
254972271$25497227$1$I$$20250622$20250701$20250701$EXP$$US-AVET LIFESCIENCES LTD-2025-AVET-000211$EMCURE PHARMACEUTICALS LTD$Cantley ME, Coleman C, Morgan RM, Reddy N, Sertich SA, Villano JL.. Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity. Cancer Chemotherapy and Pharmacology. 2025;95(1):61$25$YR$$F$Y$$$20250701$$HP$US$US
254972411$25497241$1$I$$20250626$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506024960$ELI LILLY AND COMPANY$$33$YR$A$F$Y$$$20250701$$CN$US$US
254972902$25497290$2$F$20250618$20250721$20250701$20250729$EXP$$US-AMGEN-USASP2025126537$AMGEN$$76$YR$E$F$Y$$$20250728$$CN$US$US
254973471$25497347$1$I$$20250618$20250701$20250701$EXP$$EU-UNICHEM LABORATORIES LIMITED-UNI-2025-ES-002593$UNICHEM$Fernandez-Gines FD, Rodriguez-Cuadros TB, Nieto-Guindo P and Molina-Cuadrado E. Toxic epidermal necrolysis resulting in a fatal outcome caused by use of lamotrigine.. European Journal Hospital Pharm. 2017;24(1):A121$$$$$Y$$$20250701$$HP$EU$EU
254973921$25497392$1$I$$20250402$20250701$20250701$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-503147$RANBAXY$$$$I$F$Y$$$20250701$$CN$US$US
254974081$25497408$1$I$$20250528$20250701$20250701$EXP$$SA-ALKEM LABORATORIES LIMITED-ES-ALKEM-2019-03154$ALKEM$Ng JA, Goldberg N and Tafreshi MJ. Clopidogrel-induced hepatotoxicity and fever. Pharmacotherapy. 2006;26(7):1023-6$59$YR$$F$Y$$$20250701$$HP$SA$SA
254974551$25497455$1$I$$20250617$20250701$20250701$EXP$$US-CIPLA LTD.-2025US07740$CIPLA$Tirado D, Kennedy CL, Horowitz BZ.. In response to: High dose insulin is an inodilator, not an antidote in the poisoned patient. EMA - Emergency Medicine Australasia.. 2025;37(3):e70059$$$$$Y$$$20250701$$MD$US$US
254975401$25497540$1$I$$20250623$20250701$20250701$EXP$$CA-CELLTRION INC.-2025CA020442$CELLTRION$$$$$$Y$$$20250701$$MD$CA$CA
254975661$25497566$1$I$20200804$20250624$20250701$20250701$EXP$EU-MPA-2020-004974$EU-ORGANON-2009SWE003163$ORGANON$$25$YR$$F$Y$$$20250701$$MD$EU$EU
254975671$25497567$1$I$20250226$20250624$20250701$20250701$EXP$EU-MINISAL02-1043788$EU-TEVA-VS-3347026$TEVA$$41$YR$$M$Y$64$KG$20250701$$MD$EU$EU
254976941$25497694$1$I$$20250627$20250701$20250701$PER$$US-AMGEN-USASP2025128557$AMGEN$$$$$F$Y$$$20250701$$CN$US$US
254977002$25497700$2$F$$20250623$20250701$20250708$EXP$$TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2025-06557$ALKEM$Kavak Sinanoglu G, Yavrum F.. Aripiprazole-Related Acute Myopia: A Case Report. Journal of Clinical Psychopharmacology. 2025;00(00):1-2$27$YR$$F$Y$$$20250708$$MD$TR$TR
254977011$25497701$1$I$$20250616$20250701$20250701$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-06675$ALKEM$Neumann MA, Sieg N, Garcia Borrega J, Huser C, Caspers M, Shimabukuro-Vornhagen A, Boll B, Kochanek M, Eichenauer DA, Naendrup JH.. Overdosing of direct oral anticoagulants. Medical Clinic - Intensive care and emergency medicine. 2025;120(5):426-433$66$YR$$F$Y$$$20250701$$HP$EU$EU
254977241$25497724$1$I$20230101$20250619$20250701$20250701$EXP$GB-MHRA-MED-202506172108032450-HNRBK$GB-STRIDES ARCOLAB LIMITED-2025SP007727$STRIDES$$40$YR$$F$Y$$$20250701$$MD$GB$GB
254977661$25497766$1$I$$20250616$20250701$20250701$PER$$US-ROCHE-10000326117$ROCHE$Guliani A, Leung A, Shah S. When Immunotherapy Meets Infection: A Case of Ocrelizumab-induced Pneumocystis Jirovecii Pneumonia. Am J Respir Crit Care Med. 2025;211:A4570.$50$YR$A$F$Y$$$20250701$$HP$US$US
254977851$25497785$1$I$$20250627$20250701$20250701$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092585$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250701$$CN$US$US
254978592$25497859$2$F$$20250728$20250701$20250730$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007597$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250730$$CN$US$US
254978731$25497873$1$I$20250623$20250627$20250701$20250701$EXP$$EU-ABBVIE-6351295$ABBVIE$$60$YR$$M$Y$$$20250701$$HP$EU$EU
254979421$25497942$1$I$20240825$20240911$20250701$20250701$PER$$US-CPL-004622$CADILA$$$$$F$Y$$$20250701$$CN$US$US
254979472$25497947$2$F$$20250725$20250701$20250801$EXP$$JP-BAXTER-2025BAX017528$BAXTER$$25$YR$$M$Y$$$20250801$$HP$JP$JP
254980351$25498035$1$I$$20250623$20250701$20250701$EXP$$CA-TEVA-VS-3345624$TEVA$$59$YR$$M$Y$$$20250701$$MD$CA$CA
254980911$25498091$1$I$$20250623$20250701$20250701$EXP$$CA-CELLTRION INC.-2025CA020498$CELLTRION$$$$$$Y$$$20250701$$HP$CA$CA
254981201$25498120$1$I$$20250627$20250701$20250701$EXP$$US-GILEAD-2025-0718927$GILEAD$$70$YR$E$M$Y$$$20250701$$CN$US$US
254981511$25498151$1$I$$20250625$20250701$20250701$PER$$US-HALEON-2249352$Haleon PLC$$$$$F$Y$$$20250701$$CN$US$US
254981551$25498155$1$I$20250109$20250624$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506023514$ELI LILLY AND COMPANY$$$$$F$Y$$$20250701$$CN$US$US
254981701$25498170$1$I$$20250617$20250701$20250701$EXP$$GB-AUROBINDO-AUR-APL-2025-031924$AUROBINDO$$$$$$Y$$$20250701$$HP$GB$GB
254982241$25498224$1$I$20250601$20250627$20250701$20250701$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092099$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$74.84$KG$20250701$$CN$US$US
254983061$25498306$1$I$$20250630$20250701$20250701$PER$$US-JNJFOC-20250637663$JOHNSON AND JOHNSON$$$$$$Y$$$20250701$$HP$US$US
254983071$25498307$1$I$20250617$20250618$20250701$20250701$PER$$US-MYLANLABS-2025M1053649$MYLAN$$72$YR$$M$Y$$$20250627$$$US$US
254983201$25498320$1$I$20250626$20250627$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506026664$ELI LILLY AND COMPANY$$23$YR$A$F$Y$$$20250701$$CN$US$US
254983231$25498323$1$I$$20250627$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506026919$ELI LILLY AND COMPANY$$71$YR$E$M$Y$$$20250701$$CN$US$US
254985291$25498529$1$I$20250320$20250321$20250701$20250701$PER$$US-CHIESI-2025CHF01991$CHIESI$$12$YR$$F$Y$34.001$KG$20250701$$HP$US$US
254985592$25498559$2$F$20240901$20250924$20250701$20250924$EXP$$US-BAYER-2025A085630$BAYER HEALTHCARE PHARMACEUTICALS INC.$$51$YR$A$M$Y$$$20250924$$CN$US$US
254985851$25498585$1$I$20250401$20250623$20250701$20250701$EXP$$US-CHATTEMPRD-2025OHG019591$CHATTEM$$$$$F$Y$$$20250701$$LW$US$US
254985882$25498588$2$F$$20250625$20250701$20250723$PER$$US-TLM-TLM-2025-01688$TOLMAR$$$$$$Y$$$20250708$$HP$US$US
254985891$25498589$1$I$20250624$20250625$20250701$20250701$EXP$$US-JNJFOC-20250632525$JOHNSON AND JOHNSON$$46$YR$A$F$Y$$$20250701$$HP$US$US
254986602$25498660$2$F$$20250916$20250701$20250925$EXP$$US-ASTELLAS-2023US019448$ASTELLAS$$22$YR$A$F$Y$$$20250925$$CN$US$US
254986672$25498667$2$F$20240411$20250708$20250701$20250708$EXP$EU-GREOF-202500946$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-080128$BOEHRINGER INGELHEIM$$65$YR$E$M$Y$75$KG$20250708$$$EU$EU
254986761$25498676$1$I$20210101$20250619$20250701$20250701$EXP$EU-AEMPS-1699504$EU-AMGEN-ESPSP2025121963$AMGEN$$58$YR$A$F$Y$$$20250701$$MD$EU$EU
254986921$25498692$1$I$$20250617$20250701$20250701$EXP$$IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-514001$RANBAXY$Benoliel Berman T, Bauer M, Moscovici S, Lossos A. Diagnostic clues in herpes encephalitis following radiation therapy. J Neurol Sci. 2025;470 (0):123394 (1-6)$36$YR$$F$Y$$$20250701$$HP$IL$IL
254987481$25498748$1$I$$20250623$20250701$20250701$EXP$$EU-MYLANLABS-2025M1055000$MYLAN$$$$$$Y$$$20250701$$$EU$EU
254988072$25498807$2$F$$20250902$20250701$20250917$EXP$$CA-GSK-CA2025AMR080557$GLAXOSMITHKLINE$$43$YR$$F$Y$96$KG$20250917$$$CA$CA
254988161$25498816$1$I$$20250623$20250701$20250701$EXP$$EU-SANDOZ INC.-PHHY2019DE028206$SANDOZ$$55$YR$$M$Y$$$20250701$$MD$EU$EU
254988713$25498871$3$F$$20250730$20250701$20250804$PER$$US-BAUSCHBL-2025BNL011433$BAUSCH AND LOMB$$75$YR$$F$Y$$$20250804$$CN$US$US
254988741$25498874$1$I$$20250520$20250701$20250701$PER$$US-CHIESI-2025CHF03466$CHIESI$$13$YR$$M$Y$$$20250701$$HP$US$US
254988801$25498880$1$I$$20250627$20250701$20250701$EXP$$CN-TAKEDA-2025TUS058039$TAKEDA$$$$$M$Y$$$20250701$$$CN$CN
254989764$25498976$4$F$20250401$20250805$20250701$20250806$PER$$US-PFIZER INC-202500131298$PFIZER$$26$YR$$F$Y$55.34$KG$20250806$$CN$US$US
254990371$25499037$1$I$$20250623$20250701$20250701$EXP$$EU-CELLTRION INC.-2025GR020981$CELLTRION$$$$$$Y$$$20250701$$MD$EU$EU
254990981$25499098$1$I$$20250616$20250701$20250701$PER$$US-EPICPHARMA-US-2025EPCSPO00760$EPIC PHARM$$$$$F$Y$$$20250701$$PH$US$US
254991061$25499106$1$I$20250523$20250627$20250701$20250701$EXP$EU-AFSSAPS-AN2025000804$EU-009507513-2301279$MERCK SHARP + DOHME LLC$$63$YR$$M$Y$$$20250701$$MD$EU$EU
254991461$25499146$1$I$$20250623$20250701$20250701$EXP$$EU-MYLANLABS-2025M1054997$MYLAN$Staropoli N, Scionti F, Farenza V, Falcone F, Luciano F, Renne M, et al. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience. Biomed-Pharmacother 2024; 174.$59$YR$$F$Y$$$20250701$$$EU$EU
254992513$25499251$3$F$20250609$20250915$20250701$20250917$PER$$US-GRUNENTHAL-2025-108802$AVERITAS$$47$YR$$F$Y$$$20250917$$CN$US$US
254993731$25499373$1$I$$20250626$20250701$20250701$EXP$$US-PFIZER INC-PV202500078049$PFIZER$$46$YR$$F$Y$$$20250701$$CN$US$US
254993821$25499382$1$I$20250609$20250627$20250701$20250701$EXP$GB-MHRA-MED-202506271408064420-YHDLQ$GB-PFIZER INC-202500130866$PFIZER$$$$$$Y$$$20250701$$CN$GB$GB
254994051$25499405$1$I$20250414$20250623$20250701$20250701$EXP$EU-AEMPS-1702085$EU-PFIZER INC-202500126687$PFIZER$$73$YR$$M$Y$$$20250701$$MD$EU$EU
254994311$25499431$1$I$20200601$20250630$20250701$20250701$PER$$US-BAYER-2025A086977$BAYER HEALTHCARE LLC$$$$$$Y$$$20250701$$CN$US$US
254995101$25499510$1$I$$20250701$20250701$20250701$DIR$FDA-CDER-CTU-2025-43480$$FDA-CTU$$72$YR$$F$N$$$20250701$N$$US$
254995111$25499511$1$I$$20250624$20250701$20250701$PER$$US-AMGEN-USASP2025124912$AMGEN$$56$YR$A$M$Y$$$20250701$$CN$US$US
254995731$25499573$1$I$$20250624$20250701$20250701$EXP$$JP-JNJFOC-20250700506$JOHNSON AND JOHNSON$Nakata M, Shirai O, Morishima T, Hosono I. 23 A case of ulcerative colitis developing miliary tuberculosis after the introduction of anti-TNF-? antibodies. The 142nd Meeting of the Tokai Branch of the Japanese Society of Gastroenterolog. 2025;81$69$YR$E$M$Y$$$20250701$$MD$JP$JP
254995811$25499581$1$I$$20250617$20250701$20250701$PER$$US-ROCHE-10000316238$ROCHE$$$$E$$Y$$$20250701$$HP$US$US
254995902$25499590$2$F$$20250703$20250701$20250715$PER$$US-LUNDBECK-DKLU4016342$LUNDBECK$$$$$F$Y$$$20250715$$PH$US$US
254995951$25499595$1$I$$20250627$20250701$20250701$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092434$BRISTOL-MYERS SQUIBB COMPANY$$57$YR$A$M$Y$$$20250701$$CN$US$US
254996191$25499619$1$I$$20250626$20250701$20250701$EXP$$CN-FERRINGPH-2025FE03334$FERRING$$$$$$Y$$$20250701$$CN$CN$CN
254996932$25499693$2$F$$20250630$20250701$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-092874$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$F$Y$$$20250702$$HP$US$US
254997402$25499740$2$F$$20250630$20250701$20250701$PER$$US-GILEAD-2025-0719127$GILEAD$$$$$$Y$$$20250701$$LW$US$US
254997721$25499772$1$I$$20250619$20250701$20250701$PER$$US-INCYTE CORPORATION-2025IN007148$INCYTE$$$$$$Y$$$20250701$$$US$
254997841$25499784$1$I$$20250701$20250701$20250701$DIR$FDA-CDER-CTU-2025-43528$$FDA-CTU$$55$YR$$F$N$$$20250701$N$CN$US$
254998632$25499863$2$F$20241201$20250807$20250701$20250814$EXP$$US-ABBVIE-6349217$ABBVIE$$74$YR$$M$Y$$$20250814$$CN$US$US
254998701$25499870$1$I$20231101$20250626$20250701$20250701$EXP$$CA-ABBVIE-6263976$ABBVIE$$62$YR$$M$Y$$$20250701$$CN$CA$CA
255000221$25500022$1$I$$20250628$20250701$20250701$EXP$$CN-INCYTE CORPORATION-2025IN007155$INCYTE$$9$YR$$$Y$$$20250701$$$CN$
255000761$25500076$1$I$$20250625$20250701$20250701$EXP$$BR-SANDOZ INC.-SDZ2025BR045427$SANDOZ$$$$$F$Y$$$20250701$$CN$BR$BR
255001831$25500183$1$I$20250603$20250701$20250701$20250701$DIR$FDA-CDER-CTU-2025-43601$$FDA-CTU$$34$YR$$M$N$224$LBS$20250701$N$PH$US$
255002651$25500265$1$I$$20250701$20250701$20250701$DIR$FDA-CDER-CTU-2025-43612$$FDA-CTU$$61$YR$$F$N$$$20250701$N$$US$
255002891$25500289$1$I$$20250620$20250701$20250701$EXP$$EU-AUROBINDO-AUR-APL-2025-032308$AUROBINDO$Marc Xipellto, Ricardo Arturo Losno, Carolina Garcia-Vidal, Montserrat Rovira, Izaskun Alejo-Cancho, Jorge Puig de la Bellacasa. Clinical characteristics and evolution of patients diagnosed with  mucormycosis in a tertiary hospital (2012-2016). Rev Iberoam Micol.. 2018;35(3):162?166$54$YR$$M$Y$$$20250701$$HP$EU$EU
255005014$25500501$4$F$20250806$20250815$20250701$20250822$EXP$$CO-AMGEN-COLSL2025127635$AMGEN$$80$YR$E$M$Y$$$20250822$$CN$CO$CO
255005201$25500520$1$I$$20250627$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506027005$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250701$$CN$US$US
255005924$25500592$4$F$20250613$20250808$20250701$20250828$EXP$$CL-SANDOZ INC.-SDZ2025CL046040$SANDOZ$$66$YR$$F$Y$$$20250828$$CN$CL$CL
255006034$25500603$4$F$20250601$20250726$20250701$20250801$EXP$$JP-Eisai-EC-2025-192203$EISAI$$76$YR$E$M$Y$$$20250801$$MD$JP$JP
255006101$25500610$1$I$20250516$20250625$20250701$20250701$EXP$$US-ABBVIE-6347579$ABBVIE$$52$YR$$M$Y$$$20250701$$CN$US$US
255006301$25500630$1$I$$20250620$20250701$20250701$EXP$$US-SPRINGWORKS THERAPEUTICS-SW-002458$SPRINGWORKS THERAPEUTIC$$$$$M$Y$$$20250701$$CN$US$US
255006841$25500684$1$I$$20250625$20250701$20250701$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-016049$JAZZ$$$$$M$Y$$$20250701$$CN$US$US
255007482$25500748$2$F$$20250908$20250701$20250913$EXP$$JP-ABBVIE-6348557$ABBVIE$$22$YR$$M$Y$$$20250913$$PH$JP$JP
255007911$25500791$1$I$$20250630$20250701$20250701$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-2025-092568$BRISTOL-MYERS SQUIBB COMPANY$$47$YR$A$F$Y$$$20250701$$PH$CA$CA
255008341$25500834$1$I$$20250626$20250701$20250701$PER$$US-MALLINCKRODT-MNK202503990$MALLINCKRODT$$$$$M$Y$$$20250630$$CN$US$US
255008771$25500877$1$I$20210101$20250623$20250701$20250701$EXP$$BR-BAYER-2025A084417$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$M$Y$$$20250701$$CN$BR$BR
255009011$25500901$1$I$20250602$20250620$20250701$20250701$EXP$$EU-ROCHE-10000321679$ROCHE$$86$YR$E$F$Y$$$20250701$$MD$EU$EU
255009442$25500944$2$F$20250630$20250809$20250701$20250812$EXP$$US-ABBVIE-6352406$ABBVIE$$63$YR$$F$Y$$$20250812$$CN$US$US
255010041$25501004$1$I$$20250624$20250701$20250701$EXP$GB-MHRA-MED-202506241643209470-GTWZN$GB-ELI_LILLY_AND_COMPANY-GB202506023278$ELI LILLY AND COMPANY$$74$YR$E$F$Y$114$KG$20250701$$CN$GB$GB
255011271$25501127$1$I$20240726$20250625$20250701$20250701$PER$$US-SA-2025SA183993$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250702$$MD$US$US
255011331$25501133$1$I$20250101$20250625$20250701$20250701$PER$$US-SA-2025SA184044$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250702$$HP$US$US
255013421$25501342$1$I$20250101$20250626$20250701$20250701$PER$$US-SA-2025SA184713$SANOFI AVENTIS$$53$YR$A$F$Y$$$20250702$$HP$US$US
255013991$25501399$1$I$20250627$20250627$20250701$20250701$PER$$US-SA-2025SA184527$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250702$$HP$US$US
255014131$25501413$1$I$20250601$20250627$20250701$20250701$PER$$US-SA-2025SA184463$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250702$$HP$US$US
255014411$25501441$1$I$$20250628$20250701$20250701$PER$$US-SA-2025SA184560$SANOFI AVENTIS$$$$$$Y$$$20250702$$MD$US$US
255014431$25501443$1$I$$20250630$20250701$20250701$PER$$US-SA-2025SA185600$SANOFI AVENTIS$$25$YR$A$F$Y$$$20250702$$HP$US$US
255014491$25501449$1$I$$20250620$20250701$20250701$PER$$US-ELI_LILLY_AND_COMPANY-US202506022036$ELI LILLY AND COMPANY$$29$YR$A$F$Y$$$20250701$$MD$US$US
255014511$25501451$1$I$$20250617$20250701$20250701$PER$$US-009507513-2302189$MERCK SHARP + DOHME LLC$Olney KB, Pai MP, Stadler LP, Burgess DS. Evaluation of High-dose Daptomycin in Children With Methicillin-resistant Staphylococcus aureus Bacteremia. A Case Series. The Pediatric Infectious Disease Journal, 15-April-2025. ().$5$YR$$M$Y$15.2$KG$20250701$$PH$US$US
255015571$25501557$1$I$$20250618$20250701$20250701$EXP$$EU-Norvium Bioscience LLC-080339$Norvium Bioscience$Fernandez-Gordon Sanchez FM, Gomez Labrador C, Wong Becerra L, Paz Fernandez BA, Martinez Aguilar AP, Castano-Milla C. Active microscopic colitis precipitated by fluoxetine. Rev Esp Enferm Dig. 2025 Jun;117(6):350-351. doi: 10.17235/reed.2024.10336/2024.$41$YR$A$F$Y$$$20250702$$HP$EU$EU
255016002$25501600$2$F$20241201$20250709$20250701$20250723$EXP$$IN-CIPLA LTD.-2025IN07793$CIPLA$$$$$$Y$$$20250723$$CN$IN$IN
255016031$25501603$1$I$20250501$20250624$20250701$20250701$EXP$$EU-JNJFOC-20250633353$JOHNSON AND JOHNSON$$31$YR$A$F$Y$$$20250702$$HP$EU$EU
255016253$25501625$3$F$20250101$20250729$20250701$20250731$EXP$$US-ABBVIE-6349332$ABBVIE$$75$YR$$M$Y$64.863$KG$20250731$$CN$US$US
255016342$25501634$2$F$$20250718$20250701$20250721$PER$$US-ABBVIE-6349681$ABBVIE$$$$A$F$Y$$$20250721$$CN$US$US
255016601$25501660$1$I$20250501$20250627$20250701$20250701$EXP$$US-SA-2025SA184655$SANOFI AVENTIS$$$$E$F$Y$$$20250702$$CN$US$US
255016861$25501686$1$I$20241101$20250623$20250701$20250701$EXP$$US-ABBVIE-4267517$ABBVIE$$69$YR$$F$Y$$$20250701$$CN$US$US
255017911$25501791$1$I$$20250627$20250702$20250702$EXP$GB-MHRA-MED-202506271122087670-DSKWL$GB-ROCHE-10000325199$ROCHE$$$$$M$Y$$$20250702$$HP$GB$GB
255018471$25501847$1$I$$20250623$20250702$20250702$EXP$$KR-SA-2023SA397470$SANOFI AVENTIS$$79$YR$E$M$Y$$$20250702$$CN$KR$KR
255018651$25501865$1$I$20250515$20250623$20250702$20250702$EXP$EU-HALMED-300090032$EU-TEVA-VS-3344948$TEVA$$15$YR$$F$Y$$$20250702$$MD$EU$EU
255019601$25501960$1$I$$20250619$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202506019332$ELI LILLY AND COMPANY$$54$YR$A$F$Y$$$20250702$$CN$US$US
255019621$25501962$1$I$$20250611$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202506011832$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250702$$CN$US$US
255019842$25501984$2$F$20250529$20250827$20250702$20250921$PER$$US-GSK-US2025080499$GLAXOSMITHKLINE$$68$YR$$F$Y$$$20250921$$$US$US
255020332$25502033$2$F$20250602$20250805$20250702$20250813$EXP$EU-BFARM-25004502$EU-SA-2025SA185874$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250813$$MD$EU$EU
255020912$25502091$2$F$20240923$20250704$20250702$20250711$EXP$$EU-CELLTRION INC.-2025FR020455$CELLTRION$$$$$$Y$$$20250711$$MD$EU$EU
255020951$25502095$1$I$20250619$20250625$20250702$20250702$EXP$$CN-JNJFOC-20250633521$JOHNSON AND JOHNSON$$72$YR$E$F$Y$40$KG$20250702$$HP$CN$CN
255021612$25502161$2$F$$20250701$20250702$20250708$PER$$US-GSK-US2025070115$GLAXOSMITHKLINE$$$$$F$Y$$$20250708$$$US$US
255021791$25502179$1$I$$20250625$20250702$20250702$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007683$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250702$$CN$US$US
255021831$25502183$1$I$$20250625$20250702$20250702$PER$$US-ROCHE-10000325586$ROCHE$$$$$$Y$$$20250702$$MD$US$US
255022351$25502235$1$I$$20250624$20250702$20250702$EXP$GB-MHRA-MED-202506241427065280-KDCHR$GB-TEVA-VS-3345370$TEVA$$$$$M$Y$$$20250702$$HP$GB$GB
255022401$25502240$1$I$$20250630$20250702$20250702$PER$$US-ABBVIE-6353013$ABBVIE$$$$A$M$Y$$$20250702$$CN$US$US
255022541$25502254$1$I$$20250701$20250702$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-093181$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$F$Y$$$20250702$$PH$US$US
255022962$25502296$2$F$$20250627$20250702$20250707$EXP$$BR-TAKEDA-2025TUS058676$TAKEDA$$$$$F$Y$$$20250707$$$BR$BR
255023061$25502306$1$I$$20250626$20250702$20250702$EXP$$EU-ROCHE-10000324299$ROCHE$Garcia-Castillo M, Garcia-Castillo M, Sierra-Mencia A, Caronna E, Toledo-Alfocea D, Jaimes A, et al. Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies. Journal of Neurology. 2025-Jun-01;272 (6):1-12. doi:10.1007/s00415-025-13177-y.$$$$F$Y$$$20250702$$HP$EU$EU
255023322$25502332$2$F$20250815$20250821$20250702$20250828$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007659$ACADIA PHARMACEUTICALS$$74$YR$$F$Y$$$20250828$$CN$US$US
255023331$25502333$1$I$20250415$20250624$20250702$20250702$EXP$GB-MHRA-MED-202506241958176870-KPDRZ$GB-TEVA-VS-3347683$TEVA$$58$YR$$F$Y$69$KG$20250702$$CN$GB$GB
255023471$25502347$1$I$$20250624$20250702$20250702$PER$$US-BAUSCHBL-2025BNL011418$BAUSCH AND LOMB$$$$$$Y$$$20250702$$CN$US$US
255024311$25502431$1$I$20210101$20250623$20250702$20250702$EXP$$US-NOVOPROD-1465068$NOVO NORDISK$$$$E$F$Y$$$20250702$$CN$US$US
255026081$25502608$1$I$$20250417$20250702$20250702$PER$$US-STERISCIENCE B.V.-2025-ST-000819$Steriscience PTE$Ali SA, Jafri S-M.. Unmasking the Complexity: A Case Report of Severe Refeeding Syndrome in a Post-Liver Transplant Patient With Pharyngeal Squamous Cell Carcinoma.. Am-J-Gastroenterol. 2023;118 (Suppl.) (10):S2314 abstr. S3536.$57$YR$$F$Y$$$20250702$$MD$US$US
255026571$25502657$1$I$20250604$20250617$20250702$20250702$EXP$$EU-AUROBINDO-AUR-APL-2025-032228$AUROBINDO$$60$YR$$F$Y$66$KG$20250702$$MD$EU$EU
255026762$25502676$2$F$$20250620$20250702$20250707$EXP$$EU-SANDOZ INC.-PHHY2019IT219281$SANDOZ$$48$YR$$F$Y$$$20250707$$HP$EU$EU
255027231$25502723$1$I$$20250624$20250702$20250702$PER$$US-ABBVIE-6345468$ABBVIE$$$$$F$Y$$$20250702$$CN$US$US
255027331$25502733$1$I$$20250626$20250702$20250702$EXP$$GB-ABBVIE-6350062$ABBVIE$$$$A$M$Y$$$20250702$$CN$GB$GB
255027661$25502766$1$I$$20250625$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202506024388$ELI LILLY AND COMPANY$$36$YR$A$F$Y$$$20250702$$CN$US$US
255027941$25502794$1$I$20250605$20250618$20250702$20250702$EXP$$CN-adr44030518216-HPR2025000340$SHENZHEN TECHDOW PHARMACEUTICAL$$70$YR$E$M$Y$51$KG$20250702$$MD$CN$CN
255029391$25502939$1$I$$20250624$20250702$20250702$EXP$$AU-CELLTRION INC.-2025AU020688$CELLTRION$$$$$$Y$$$20250702$$HP$AU$AU
255029841$25502984$1$I$20250625$20250625$20250702$20250702$EXP$$US-JNJFOC-20250633486$JOHNSON AND JOHNSON$$34$YR$A$F$Y$$$20250702$$HP$US$US
255030031$25503003$1$I$20250619$20250626$20250702$20250702$EXP$$CN-SANDOZ INC.-SDZ2025CN045814$SANDOZ$$79$YR$$M$Y$$$20250702$$HP$CN$CN
255030441$25503044$1$I$$20250626$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202506025623$ELI LILLY AND COMPANY$$51$YR$A$F$Y$$$20250702$$CN$US$US
255031111$25503111$1$I$$20250625$20250702$20250702$EXP$$CN-SA-2025SA182680$SANOFI AVENTIS$$6$YR$C$M$Y$$$20250702$$HP$CN$CN
255031181$25503118$1$I$$20250612$20250702$20250702$EXP$$CA-GSK-CA2025AMR075428$GLAXOSMITHKLINE$$80$YR$$F$Y$69$KG$20250702$$$CA$CA
255032381$25503238$1$I$20250203$20250625$20250702$20250702$EXP$GB-MHRA-MED-202506251801535670-MYCTF$GB-TEVA-VS-3345842$TEVA$$72$YR$$M$Y$117$KG$20250702$$PH$GB$GB
255032671$25503267$1$I$$20250626$20250702$20250702$EXP$$CN-SANDOZ INC.-SDZ2025CN041365$SANDOZ$$$$$F$Y$$$20250702$$CN$CN$CN
255032751$25503275$1$I$$20250627$20250702$20250702$EXP$GB-MHRA-MED-202506271244098580-HDVRN$GB-MYLANLABS-2025M1054861$MYLAN$$72$YR$$$Y$$$20250702$$$GB$GB
255033121$25503312$1$I$$20250224$20250702$20250702$PER$$US-AUROBINDO-AUR-APL-2025-012275$AUROBINDO$$$$$F$Y$$$20250702$$CN$US$US
255033791$25503379$1$I$20250629$20250630$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202507001300$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250702$$CN$US$US
255033891$25503389$1$I$$20250625$20250702$20250702$EXP$$EU-VANTIVE-2025VAN002970$Vantive US Healthcare$$$$$F$Y$$$20250702$$HP$EU$EU
255034153$25503415$3$F$20250619$20250714$20250702$20250722$EXP$$US-UNITED THERAPEUTICS-UNT-2025-022578$UNITED THERAPEUTICS$$54$YR$$F$Y$89.796$KG$20250722$$$US$US
255035121$25503512$1$I$20250601$20250617$20250702$20250702$PER$$US-CHATTEMPRD-2025OHG020306$CHATTEM$$65$YR$$M$Y$$$20250702$$CN$US$US
255036632$25503663$2$F$20250613$20250708$20250702$20250709$PER$$US-ABBVIE-6353329$ABBVIE$$24$YR$$F$Y$$$20250709$$CN$US$US
255037194$25503719$4$F$$20250725$20250702$20250729$EXP$$GB-PFIZER INC-PV202500049224$PFIZER$$15$YR$$F$Y$$$20250729$$PH$GB$GB
255037511$25503751$1$I$$20250523$20250702$20250702$EXP$$GB-ROCHE-10000323105$ROCHE$$$$$$Y$$$20250702$$HP$GB$GB
255037721$25503772$1$I$20250601$20250630$20250701$20250701$DIR$FDA-CDER-CTU-2025-43675$$FDA-CTU$$78$YR$$M$N$$$20250630$N$CN$US$
255038401$25503840$1$I$20240401$20250626$20250702$20250702$EXP$$EU-SANDOZ INC.-SDZ2025RO045264$SANDOZ$$72$YR$$F$Y$$$20250702$$MD$EU$EU
255039231$25503923$1$I$$20250625$20250702$20250702$PER$$NVSC2025US102537$NOVARTIS$$$$$M$Y$$$20250702$$MD$US$US
255039911$25503991$1$I$$20250701$20250702$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-093434$BRISTOL-MYERS SQUIBB COMPANY$$54$YR$A$F$Y$$$20250702$$CN$US$US
255040331$25504033$1$I$20250106$20250624$20250702$20250702$EXP$GB-MHRA-MED-202506241330459420-VZPTY$GB-TEVA-VS-3345320$TEVA$$18$YR$$M$Y$99$KG$20250702$$MD$GB$GB
255040631$25504063$1$I$$20241120$20250702$20250702$PER$$US-GLENMARK PHARMACEUTICALS-2024GMK095857$GLENMARK$$$$$$Y$$$20250702$$CN$US$US
255041592$25504159$2$F$$20250902$20250702$20250911$PER$$US-SMPA-2025SPA007191$SUNOVION$$80$YR$$M$Y$$$20250910$$$US$US
255041972$25504197$2$F$$20250627$20250702$20250718$PER$$US-SMPA-2025SPA007778$SUNOVION$$$$$$Y$$$20250718$$CN$US$US
255042471$25504247$1$I$20250601$20250625$20250702$20250702$EXP$$US-UNITED THERAPEUTICS-UNT-2025-022341$UNITED THERAPEUTICS$$65$YR$$F$Y$63.492$KG$20250702$$$US$US
255043491$25504349$1$I$20250701$20250701$20250701$20250701$DIR$762529$$FDA-CTU$$86$YR$$F$N$$$20250701$N$$US$
255043651$25504365$1$I$$20250630$20250702$20250702$EXP$$CA-PFIZER INC-202500131746$PFIZER$$75$YR$$M$Y$$$20250702$$HP$CA$CA
255044061$25504406$1$I$$20250701$20250702$20250702$PER$$US-HALEON-2250409$Haleon PLC$$$$$$Y$$$20250702$$CN$US$US
255044643$25504464$3$F$20250607$20250710$20250702$20250714$PER$$AR-MYLANLABS-2025M1055595$MYLAN$$57$YR$$M$Y$$$20250714$$$AR$AR
255045051$25504505$1$I$$20250626$20250702$20250702$EXP$$AU-PFIZER INC-202500133090$PFIZER$$50$YR$$M$Y$$$20250702$$MD$AU$AU
255045121$25504512$1$I$$20250630$20250702$20250702$EXP$$TR-PFIZER INC-PV202500078596$PFIZER$$$$$F$Y$$$20250702$$MD$TR$TR
255045221$25504522$1$I$$20250626$20250702$20250702$EXP$$GB-PFIZER INC-202500129786$PFIZER$$57$YR$$F$Y$$$20250702$$CN$GB$GB
255045641$25504564$1$I$20250101$20250623$20250702$20250702$PER$$US-UNITED THERAPEUTICS-UNT-2025-022256$UNITED THERAPEUTICS$$$$$F$Y$63.492$KG$20250702$$PH$US$US
255045981$25504598$1$I$20250101$20250509$20250702$20250702$PER$$US-ARDELYX-2025ARDX003406$ARDELYX$$$$$M$Y$$$20250702$$CN$US$US
255046771$25504677$1$I$20250619$20250625$20250702$20250702$EXP$$US-UNITED THERAPEUTICS-UNT-2025-022235$UNITED THERAPEUTICS$$68$YR$$F$Y$$$20250702$$$US$US
255048671$25504867$1$I$$20250622$20250702$20250702$PER$$US-INCYTE CORPORATION-2025IN006849$INCYTE$$$$$$Y$$$20250702$$$US$US
255049841$25504984$1$I$20250604$20250616$20250702$20250702$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2025-006077$SAREPTA THERAPEUTICS$$19$YR$$M$Y$54.88$KG$20250702$$HP$US$US
255049991$25504999$1$I$20240101$20240901$20250702$20250702$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-004812$SAREPTA THERAPEUTICS$$$$$M$Y$$$20250702$$HP$US$US
255050771$25505077$1$I$$20250624$20250702$20250702$EXP$$US-PURDUE-USA-2025-0318582$PURDUE$Blanton A M, Parikh P, Zhou S, Mohamed M, Ufret-Vincenty R L, Mancini R.. Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms. American Journal of Ophthalmology Case Reports. 2025;39$21$YR$$M$Y$$$20250702$$HP$US$US
255051241$25505124$1$I$$20250630$20250702$20250702$EXP$$JP-Eisai-EC-2025-192619$EISAI$$$$E$M$Y$$$20250702$$MD$JP$JP
255051361$25505136$1$I$$20241120$20250702$20250702$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-005301$SAREPTA THERAPEUTICS$$$$$M$Y$59.86$KG$20250702$$HP$US$US
255052002$25505200$2$F$20240902$20250710$20250702$20250717$EXP$$JP-JAZZ PHARMACEUTICALS-2025-JP-016450$JAZZ$$63$YR$$F$Y$$$20250717$$MD$JP$JP
255052461$25505246$1$I$$20250403$20250702$20250702$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2025-005860$SAREPTA THERAPEUTICS$$$$$M$Y$50.794$KG$20250702$$HP$US$US
255052841$25505284$1$I$20250530$20250603$20250702$20250702$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2025-006072$SAREPTA THERAPEUTICS$$23$YR$$M$Y$49.44$KG$20250702$$HP$US$US
255053331$25505333$1$I$$20250618$20250702$20250702$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-06844$ALKEM$Adjailia EB, Grasshoff H, Schinke S, Fourlakis K, Jendrek ST, Lamprecht P, Riemekasten G, Humrich JY.. Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases. Rheumatic + Musculoskeletal Diseases (RMD) Open. 2025;11(2):1-7$32$YR$$F$Y$$$20250702$$HP$EU$EU
255054071$25505407$1$I$$20250624$20250702$20250702$PER$$US-ELI_LILLY_AND_COMPANY-US202507000684$ELI LILLY AND COMPANY$$73$YR$E$F$Y$66.667$KG$20250702$$CN$US$US
255054601$25505460$1$I$$20250623$20250702$20250702$EXP$$US-ALCON LABORATORIES-ALC2025US003267$ALCON$Claiborne M, GribbleK, PetriniT. Flushing Out the Cause: Anticholinergic Toxicity from Atropine Eye Drops. American Journal of Health-System Pharmacy. 2021;59(12):1282-1501$44$YR$$M$Y$$$20250702$$HP$US$US
255055141$25505514$1$I$$20250625$20250702$20250702$EXP$$US-BAUSCHBL-2025BNL011515$BAUSCH AND LOMB$$$$E$F$Y$$$20250702$$MD$US$US
255055221$25505522$1$I$$20250626$20250702$20250702$PER$$US-ALNYLAM PHARMACEUTICALS, INC.-ALN-2025-004091$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20250702$$CN$US$US
255055421$25505542$1$I$20250404$20250630$20250702$20250702$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-093312$BRISTOL-MYERS SQUIBB COMPANY$$59$YR$A$F$Y$$$20250702$$HP$US$US
255055861$25505586$1$I$$20250620$20250702$20250702$EXP$$EU-SANDOZ INC.-PHHY2018RO095233$SANDOZ$$11$YR$$F$Y$$$20250702$$MD$EU$EU
255055911$25505591$1$I$20250227$20250407$20250702$20250702$PER$$US-VERONA PHARMA-VER-004446$VERONA PHARMA$$76$YR$$F$Y$$$20250702$$CN$US$US
255056361$25505636$1$I$$20250428$20250702$20250702$PER$$US-VERONA PHARMA-VER-005098$VERONA PHARMA$$$$$$Y$$$20250702$$CN$US$US
255058402$25505840$2$F$$20250630$20250702$20250706$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-016392$JAZZ$$$$$F$Y$$$20250706$$CN$US$US
255058422$25505842$2$F$$20250627$20250702$20250703$EXP$$US-AMGEN-USASP2025128532$AMGEN$$$$A$F$Y$$$20250703$$HP$US$US
255058632$25505863$2$F$20250701$20250725$20250702$20250731$PER$$US-ABBVIE-6346206$ABBVIE$$63$YR$$F$Y$$$20250731$$CN$US$US
255058801$25505880$1$I$20250101$20250630$20250702$20250702$EXP$EU-AFSSAPS-AVPO2025000138$EU-ETHYPHARM-2025001930$ETHYPHARM$$$$A$M$Y$$$20250702$$MD$EU$
255060781$25506078$1$I$$20250422$20250702$20250702$PER$$US-RADIUS HEALTH INC.-2025US001064$RADIUS PHARM$$$$$F$Y$$$20250702$$CN$US$US
255060851$25506085$1$I$20241206$20241209$20250702$20250702$PER$$US-RADIUS HEALTH INC.-2024US010119$RADIUS PHARM$$62$YR$$F$Y$$$20250702$$CN$US$US
255061011$25506101$1$I$$20250625$20250702$20250702$PER$$US-SA-2025SA184286$SANOFI AVENTIS$$$$A$F$Y$$$20250702$$HP$US$US
255061181$25506118$1$I$20250618$20250626$20250702$20250702$PER$$US-SA-2025SA185785$SANOFI AVENTIS$$3$YR$C$M$Y$$$20250702$$HP$US$US
255061421$25506142$1$I$20250101$20250626$20250702$20250702$PER$$US-SA-2025SA185060$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250702$$HP$US$US
255062131$25506213$1$I$$20250626$20250702$20250702$PER$$US-SA-2025SA185761$SANOFI AVENTIS$$30$YR$A$F$Y$89.55$KG$20250702$$MD$US$US
255062191$25506219$1$I$$20250626$20250702$20250702$PER$$US-SA-2025SA185187$SANOFI AVENTIS$$$$A$F$Y$$$20250702$$HP$US$US
255063061$25506306$1$I$20250601$20250627$20250702$20250702$PER$$US-SA-2025SA185413$SANOFI AVENTIS$$19$YR$A$F$Y$$$20250702$$HP$US$US
255063701$25506370$1$I$$20250630$20250702$20250702$PER$$US-SA-2025SA185626$SANOFI AVENTIS$$67$YR$E$M$Y$$$20250702$$HP$US$US
255063911$25506391$1$I$20250611$20250616$20250702$20250702$PER$$US-009507513-2296724$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250702$$CN$US$US
255063931$25506393$1$I$$20250630$20250702$20250702$PER$$US-SA-2025SA186322$SANOFI AVENTIS$$66$YR$E$$Y$$$20250702$$CN$US$US
255064241$25506424$1$I$$20250630$20250702$20250702$PER$$US-SA-2025SA186389$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250702$$CN$US$US
255064821$25506482$1$I$20241120$20241127$20250702$20250702$PER$$US-PERRIGO-24US011097$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250702$$CN$US$US
255067311$25506731$1$I$$20250625$20250702$20250702$PER$$US-BIOMARINAP-US-2025-166831$BIOMARIN$$5$YR$$F$Y$12$KG$20250702$$$US$US
255067341$25506734$1$I$20250505$20250630$20250702$20250702$EXP$$EU-APELLIS-2025-APL-0001353$APELLIS PHARMACEUTICALS$$$$$$Y$$$20250702$$MD$EU$EU
255067441$25506744$1$I$$20250623$20250702$20250702$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-2025-089419$BRISTOL-MYERS SQUIBB COMPANY$$43$YR$A$F$Y$68$KG$20250702$$HP$CA$CA
255067671$25506767$1$I$$20250324$20250702$20250702$PER$$US-RADIUS HEALTH INC.-2024US007699$RADIUS PHARM$$$$$F$Y$$$20250702$$CN$US$US
255068131$25506813$1$I$20250201$20250228$20250702$20250702$PER$$US-RADIUS HEALTH INC.-2025US001865$RADIUS PHARM$$70$YR$$F$Y$$$20250702$$CN$US$US
255068261$25506826$1$I$20250101$20250502$20250702$20250702$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25046023$RADIUS PHARM$$$$$F$Y$$$20250702$$CN$US$US
255068291$25506829$1$I$$20250311$20250702$20250702$PER$$US-RADIUS HEALTH INC.-2025US002389$RADIUS PHARM$$$$$F$Y$$$20250702$$CN$US$US
255069851$25506985$1$I$$20250624$20250702$20250702$EXP$$JP-JNJFOC-20250700521$JOHNSON AND JOHNSON$$8$DEC$E$F$Y$$$20250703$$PH$JP$JP
255070161$25507016$1$I$$20250630$20250702$20250702$EXP$$AU-BAUSCHBL-2025BNL011703$BAUSCH AND LOMB$$12$YR$$F$Y$$$20250703$$CN$AU$AU
255070651$25507065$1$I$$20250623$20250702$20250702$PER$$US-ABBVIE-6341581$ABBVIE$$$$$$Y$$$20250702$$CN$US$US
255070801$25507080$1$I$$20250627$20250702$20250702$EXP$$US-ABBVIE-6350908$ABBVIE$$$$A$F$Y$$$20250702$$CN$US$US
255071651$25507165$1$I$20250101$20250627$20250703$20250703$EXP$$US-ABBVIE-6350267$ABBVIE$$52$YR$$M$Y$$$20250703$$CN$US$US
255071931$25507193$1$I$20250625$20250630$20250703$20250703$PER$$US-AMGEN-USASP2025129275$AMGEN$$$$$$Y$$$20250702$$PH$US$US
255072091$25507209$1$I$20241024$20241110$20250703$20250703$EXP$GB-MHRA-MED-202411090901049320-DKSNJ$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2024-24533$ALKEM$$65$YR$$F$Y$76$KG$20250703$$CN$GB$GB
255072771$25507277$1$I$$20250618$20250703$20250703$PER$$US-NOVITIUMPHARMA-2025USNVP01477$NOVITIUM PHARMA$$79$YR$E$F$Y$$$20250703$$HP$US$US
255072841$25507284$1$I$$20250609$20250703$20250703$PER$$US-NOVITIUMPHARMA-2025USNVP01377$NOVITIUM PHARMA$$$$$F$Y$$$20250703$$CN$US$US
255075191$25507519$1$I$$20241017$20250703$20250703$PER$$US-LUPIN EUROPE GMBH-2024-10513$LUPIN$$$$$$Y$$$20250703$$$US$US
255075431$25507543$1$I$$20250627$20250703$20250703$PER$$US-ELI_LILLY_AND_COMPANY-US202507000279$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250703$$CN$US$US
255075642$25507564$2$F$$20250702$20250703$20250710$EXP$US-MLMSERVICE-20250619-PI547854-00108-1$US-RDY-USA/2025/06/009499$DR REDDYS$Newlin A, Yu H, Mullen M. Clozapine Withdrawal Catatonia Successfully Treated with Olanzapine: A Case Report. Journal of the Academy of Consultation-Liaison Psychiatry. 2025. DOI: 10.1016/j.jaclp.2025.06.003.$50$YR$A$F$Y$$$20250710$$MD$US$US
255076001$25507600$1$I$$20250618$20250703$20250703$EXP$$CA-APOTEX-2025AP008659$APOTEX$$48$YR$$F$Y$$$20250703$$HP$CA$CA
255076322$25507632$2$F$$20250711$20250703$20250721$EXP$$US-TEVA-VS-3347837$TEVA$Ossewaarde-van Norel J, Spaide RF. SEVERE RECURRENCE AND RETINAL INFLAMMATORY INFILTRATION AFTER CESSATION OF IMMUNOSUPPRESSION FOR MULTIFOCAL CHOROIDITIS AND PANUVEITIS. Retin-Cases-Brief-Rep 2025; 19 (3): 289-293.; Ossewaarde-van Norel J, Spaide RF. SEVERE RECURRENCE AND RETINAL INFLAMMATORY INFILTRATION AFTER CESSATION OF IMMUNOSUPPRESSION FOR MULTIFOCAL CHOROIDITIS AND PANUVEITIS. Retin-Cases-Brief-Rep 2025; 19 (3): 289-293.$$$A$F$Y$$$20250721$$MD$US$US
255076981$25507698$1$I$20250501$20250627$20250703$20250703$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007717$ACADIA PHARMACEUTICALS$$76$YR$$F$Y$$$20250703$$CN$US$US
255077241$25507724$1$I$20250611$20250626$20250703$20250703$EXP$EU-NOMAADVRE-PASRAPP-2025-Vw3ngm$EU-GSK-NO2025080855$GLAXOSMITHKLINE$$41$YR$$F$Y$$$20250703$$$EU$EU
255077861$25507786$1$I$20250101$20250630$20250703$20250703$EXP$$US-ABBVIE-6352143$ABBVIE$$71$YR$$F$Y$$$20250703$$CN$US$US
255078071$25507807$1$I$$20250625$20250703$20250703$PER$$US-APOTEX-2025AP009300$APOTEX$Barritt IV AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database. The American Journal of Gastroenterology. 2025;120 (6):1307-1313$$$A$$Y$$$20250703$$MD$US$US
255078201$25507820$1$I$$20250619$20250703$20250703$EXP$$EU-ROCHE-10000320493$ROCHE$$$$$F$Y$$$20250703$$MD$EU$EU
255078491$25507849$1$I$$20250609$20250703$20250703$PER$$US-ITALFARMACO SPA-2179837$ITALFARMACO SPA$$$$$M$Y$$$20250703$$MD$US$US
255078521$25507852$1$I$20240101$20250630$20250703$20250703$EXP$$US-UCBSA-2025039916$UCB$$$$$F$Y$$$20250703$$CN$US$US
255079051$25507905$1$I$$20250606$20250703$20250703$PER$$US-SMPA-2025SPA007279$SUNOVION$$$$$$Y$$$20250703$$CN$US$US
255079711$25507971$1$I$$20250625$20250703$20250703$PER$$US-APOTEX-2025AP009303$APOTEX$Barritt IV AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database. The American Journal of Gastroenterology. 2025;120 (6):1307-1313$$$A$$Y$$$20250703$$MD$US$US
255080031$25508003$1$I$$20250618$20250703$20250703$EXP$$EU-ALKEM LABORATORIES LIMITED-ES-ALKEM-2025-06792$ALKEM$Celada-Sendino M, Fernandez-de la Varga M, Ordieres-Diaz C, Alvarez-Posadilla M, Huergo-Fernandez A, Amor-Martin P. Beyond dabigatran: recognizing direct oral anticoagulants as a cause of exfoliative esophagitis. Revista Espanola de Enfermedades Digestivas. 2025;unk:unk$86$YR$$F$Y$$$20250703$$HP$EU$EU
255080651$25508065$1$I$$20250627$20250703$20250703$EXP$$CA-ABBVIE-6350731$ABBVIE$$$$E$M$Y$$$20250703$$CN$CA$CA
255081321$25508132$1$I$$20250626$20250703$20250703$EXP$$CA-TLM-TLM-2025-04151$TOLMAR$$$$E$M$Y$$$20250703$$HP$CA$CA
255081521$25508152$1$I$$20250626$20250703$20250703$EXP$$EU-CELLTRION INC.-2025PT020837$CELLTRION$Oliveira D.. Systemic lupus erythematosus induced by anti-tumor necrosis factor? therapy in inamma diseases: a case series. Reumatismo. 2024;76 (4):286-290$$$$$Y$$$20250703$$HP$EU$EU
255081891$25508189$1$I$$20250630$20250703$20250703$PER$$US-ELI_LILLY_AND_COMPANY-US202507001630$ELI LILLY AND COMPANY$$$$$M$Y$$$20250703$$CN$US$US
255082471$25508247$1$I$20250616$20250626$20250703$20250703$EXP$$CN-CHEPLA-2025007943$CHEPLAPHARM$$61$YR$$F$Y$60$KG$20250703$$HP$COUNTRY NOT SPECIFIED$CN
255082701$25508270$1$I$20250628$20250630$20250703$20250703$EXP$$AU-ABBVIE-6351529$ABBVIE$$66$YR$$M$Y$$$20250703$$CN$AU$AU
255082911$25508291$1$I$20250101$20250626$20250703$20250703$EXP$$US-BIOGEN-2025BI01315585$BIOGEN$$$$$F$Y$$$20250703$$CN$US$US
255083742$25508374$2$F$$20250629$20250703$20250816$PER$$US-ASTRAZENECA-202506USA025661US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
255083912$25508391$2$F$$20250630$20250703$20250810$PER$$US-ASTRAZENECA-202506USA025076US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
255083921$25508392$1$I$$20250625$20250703$20250703$EXP$$US-ROCHE-10000323363$ROCHE$$$$$$Y$$$20250703$$CN$US$US
255084792$25508479$2$F$20250101$20250703$20250703$20250917$PER$$US-ARDELYX-2025ARDX003687$ARDELYX$$$$$M$Y$$$20250917$$PH$US$US
255085113$25508511$3$F$$20250811$20250703$20250812$EXP$$US-ASTRAZENECA-202506USA025365US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250812$$$US$US
255086021$25508602$1$I$$20250619$20250703$20250703$EXP$GB-MHRA-MIDB-80d35d2b-8762-40d4-a2e6-f08f4d0618f1$GB-AMAROX PHARMA-AMR2025GB03428$HETERO$$72$YR$$F$Y$$$20250703$$PH$GB$GB
255086211$25508621$1$I$$20250625$20250703$20250703$PER$$US-APOTEX-2025AP009310$APOTEX$Barritt IV AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database. The American Journal of Gastroenterology. 2025;120 (6):1307-1313$$$A$$Y$$$20250703$$MD$US$US
255086292$25508629$2$F$$20250627$20250703$20250705$EXP$$CA-CELLTRION INC.-2025CA021532$CELLTRION$$$$$$Y$$$20250705$$HP$CA$CA
255086811$25508681$1$I$20250101$20250618$20250703$20250703$PER$$US-KENVUE-20250609909$Kenvue$$$$$F$Y$$$20250703$$CN$US$US
255086982$25508698$2$F$20250301$20250821$20250703$20250913$PER$$US-GRANULES-US-2025GRASPO00338$GRANULES PHARMACEUTICALS INC$$32$YR$A$F$Y$135$KG$20250913$$CN$US$US
255087851$25508785$1$I$$20250703$20250703$20250703$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-094112$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250703$$HP$US$US
255088021$25508802$1$I$$20250627$20250703$20250703$EXP$$JP-DSJP-DS-2025-150418-JP$DAIICHI$$9$DEC$$F$Y$$$20250703$$MD$JP$JP
255088391$25508839$1$I$$20250627$20250703$20250703$PER$$US-AMGEN-USASP2025128817$AMGEN$$$$$F$Y$$$20250703$$HP$US$US
255089071$25508907$1$I$20250515$20250618$20250703$20250703$EXP$$GB-AUROBINDO-AUR-APL-2025-032103$AUROBINDO$$73$YR$$M$Y$80$KG$20250703$$MD$GB$GB
255090191$25509019$1$I$$20250701$20250703$20250703$PER$$US-ELI_LILLY_AND_COMPANY-US202507002533$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250703$$CN$US$US
255090691$25509069$1$I$$20250626$20250703$20250703$EXP$$US-GSK-US2025AMR081522$GLAXOSMITHKLINE$$$$$M$Y$$$20250703$$$US$US
255091501$25509150$1$I$20240619$20250627$20250703$20250703$EXP$$EU-ABBVIE-5812325$ABBVIE$$73$YR$$F$Y$$$20250703$$CN$EU$EU
255091595$25509159$5$F$20250709$20250724$20250703$20250729$EXP$$EU-ABBVIE-6307975$ABBVIE$$64$YR$$M$Y$$$20250729$$CN$EU$EU
255093372$25509337$2$F$20250630$20250802$20250703$20250804$PER$$US-PFIZER INC-202500109931$PFIZER$$10$YR$$M$Y$24.9$KG$20250804$$HP$US$US
255093622$25509362$2$F$$20250909$20250703$20250915$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007763$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250915$$CN$US$US
255094912$25509491$2$F$$20250911$20250703$20250923$EXP$$EU-AMAROX PHARMA-AMR2025DE03488$HETERO$$$$$F$Y$1.924$KG$20250923$$HP$EU$EU
255096061$25509606$1$I$$20250630$20250703$20250703$PER$$US-HALEON-2250431$Haleon PLC$$86$YR$$F$Y$$$20250703$$CN$US$US
255096382$25509638$2$F$$20250706$20250703$20250707$PER$$US-GSK-US2025071438$GLAXOSMITHKLINE$$$$$M$Y$$$20250707$$$US$US
255096451$25509645$1$I$$20250609$20250703$20250703$PER$$US-Innogenix, LLC-2179855$INNOGENIX, LLC$$$$$$Y$$$20250703$$$US$US
255096471$25509647$1$I$$20250630$20250703$20250703$EXP$$AU-BAUSCHBL-2025BNL011652$BAUSCH AND LOMB$$39$YR$$M$Y$$$20250703$$CN$AU$AU
255096631$25509663$1$I$20250625$20250702$20250702$20250702$DIR$762801$$FDA-CTU$$60$YR$$M$N$$$20250702$Y$PH$US$
255097131$25509713$1$I$20250527$20250625$20250703$20250703$PER$$CA-TAKEDA-2025TUS056576$TAKEDA$$74$YR$$M$Y$$$20250703$$$CA$CA
255097381$25509738$1$I$20250306$20250624$20250703$20250703$EXP$EU-AFSSAPS-RS2025000600$EU-TEVA-VS-3345339$TEVA$$80$YR$$M$Y$$$20250703$$MD$EU$EU
255097711$25509771$1$I$20230101$20250626$20250703$20250703$EXP$$US-ABBVIE-5532616$ABBVIE$$76$YR$$F$Y$$$20250703$$CN$US$US
255098461$25509846$1$I$20250625$20250701$20250703$20250703$EXP$$CN-ROCHE-10000328014$ROCHE$$68$YR$E$M$Y$65$KG$20250703$$HP$CN$CN
255099661$25509966$1$I$20210809$20250623$20250703$20250703$EXP$$EU-TEVA-VS-3348248$TEVA$$21$YR$$F$Y$60$KG$20250703$$MD$EU$EU
255100051$25510005$1$I$20241001$20250626$20250703$20250703$EXP$CH-SM-2025-05251$CH-REGENERON PHARMACEUTICALS, INC.-2025-106069$REGENERON$$75$YR$$M$Y$$$20250703$$MD$CH$CH
255100111$25510011$1$I$20230101$20250626$20250703$20250703$EXP$GB-MHRA-MED-202506261859148170-KZYMJ$GB-REGENERON PHARMACEUTICALS, INC.-2025-105612$REGENERON$$66$YR$$F$Y$$$20250703$$CN$GB$GB
255100421$25510042$1$I$$20250702$20250702$20250702$DIR$762759$$FDA-CTU$$$$$$N$$$20250702$N$$US$
255101361$25510136$1$I$20240101$20240418$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US002683$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255101431$25510143$1$I$$20250703$20250703$20250703$DIR$FDA-CDER-CTU-2025-44226$$FDA-CTU$$62$YR$$M$N$$$20250703$N$$US$
255102751$25510275$1$I$$20250618$20250703$20250703$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI08209$NEUROCRINE BIOSCIENCES$$$$$$Y$$$20250703$$HP$US$US
255102781$25510278$1$I$20250628$20250701$20250703$20250703$EXP$$EU-ABBVIE-6355334$ABBVIE$$68$YR$$M$Y$$$20250703$$CN$EU$EU
255103142$25510314$2$F$$20250626$20250703$20250809$EXP$$EU-ASTRAZENECA-202506GLO026382PT$ALEXION PHARMACEUTICALS$Sampaio E et al.. Polypharmacy in the elderly the importance of systematic medication review. Portuguese Journal of Internal Medicine 31st National Congress of Clinical Medicine. Abstract of Congress.. 2025;394$81$YR$E$M$Y$$$20250809$$$EU$EU
255104641$25510464$1$I$$20240515$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003432$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255104671$25510467$1$I$20240507$20240516$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003455$RADIUS PHARM$$68$YR$$F$Y$65.669$KG$20250703$$CN$US$US
255105051$25510505$1$I$20250301$20250630$20250703$20250703$EXP$$US-ABBVIE-6353087$ABBVIE$$52$YR$$F$Y$$$20250703$$CN$US$US
255105741$25510574$1$I$20240728$20240802$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US005982$RADIUS PHARM$$88$YR$$F$Y$$$20250703$$CN$US$US
255106021$25510602$1$I$20240501$20240517$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003504$RADIUS PHARM$$56$YR$$F$Y$$$20250703$$MD$US$US
255106101$25510610$1$I$$20250627$20250703$20250703$EXP$$US-ABBVIE-6351061$ABBVIE$$$$E$M$Y$$$20250703$$CN$US$US
255106481$25510648$1$I$20240501$20240522$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003589$RADIUS PHARM$$54$YR$$F$Y$$$20250703$$CN$US$US
255106591$25510659$1$I$$20250620$20250703$20250703$PER$$US-ELI_LILLY_AND_COMPANY-US202506020433$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250703$$CN$US$US
255106951$25510695$1$I$$20250619$20250703$20250703$EXP$$EU-Renata Limited-2179866$RENATA LIMITED$Full text$75$YR$$F$Y$$$20250703$$$EU$EU
255107171$25510717$1$I$$20240806$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006082$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255107281$25510728$1$I$20240701$20240805$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006104$RADIUS PHARM$$63$YR$$F$Y$27.574$KG$20250703$$CN$US$US
255107611$25510761$1$I$$20240523$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003620$RADIUS PHARM$$$$$M$Y$$$20250703$$CN$US$US
255108081$25510808$1$I$20231101$20240525$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003702$RADIUS PHARM$$71$YR$$F$Y$$$20250703$$CN$US$US
255108211$25510821$1$I$$20250626$20250703$20250703$EXP$GB-MHRA-MED-202506262257504520-HNMKY$GB-TEVA-VS-3347813$TEVA$$$$$$Y$$$20250703$$CN$GB$GB
255108481$25510848$1$I$20240808$20240809$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006206$RADIUS PHARM$$65$YR$$F$Y$$$20250703$$CN$US$US
255108811$25510881$1$I$$20250623$20250703$20250703$EXP$$CA-NORDICGR-063109$NORDIC PHARMA$$60$YR$$F$Y$$$20250703$$CN$CA$CA
255108871$25510887$1$I$$20250607$20250703$20250703$PER$$US-SMPA-2025SPA007293$SUNOVION$$$$$$Y$$$20250703$$CN$US$US
255109452$25510945$2$F$20250601$20250701$20250703$20250802$EXP$$US-ASTRAZENECA-202507USA000199US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250802$$$US$US
255109701$25510970$1$I$$20240528$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003779$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255110991$25511099$1$I$20240523$20240530$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US003912$RADIUS PHARM$$82$YR$$F$Y$$$20250703$$CN$US$US
255111991$25511199$1$I$$20250623$20250703$20250703$PER$$US-INCYTE CORPORATION-2025IN006885$INCYTE$$56$YR$$$Y$99.773$KG$20250703$$$US$
255112341$25511234$1$I$$20250701$20250703$20250703$PER$$US-ALKERMES INC.-ALK-2025-001763$ALKERMES$$$$$F$Y$$$20250703$$MD$US$US
255112481$25511248$1$I$$20250625$20250703$20250703$PER$$US-APOTEX-2025AP009317$APOTEX$Barritt IV AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database. The American Journal of Gastroenterology. 2025;120 (6):1307-1313$$$A$$Y$$$20250703$$MD$US$US
255112621$25511262$1$I$$20240816$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006500$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255112741$25511274$1$I$20241001$20240822$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006654$RADIUS PHARM$$57$YR$$F$Y$$$20250703$$CN$US$US
255113041$25511304$1$I$20240601$20240829$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006970$RADIUS PHARM$$79$YR$$F$Y$$$20250703$$CN$US$US
255113081$25511308$1$I$$20240816$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006508$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255114171$25511417$1$I$20240827$20240828$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006930$RADIUS PHARM$$63$YR$$F$Y$$$20250703$$CN$US$US
255115551$25511555$1$I$20250101$20250701$20250703$20250703$EXP$$US-ABBVIE-6355987$ABBVIE$$66$YR$$F$Y$$$20250703$$CN$US$US
255116051$25511605$1$I$$20250701$20250703$20250703$PER$$US-ELI_LILLY_AND_COMPANY-US202507000585$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250703$$CN$US$US
255116581$25511658$1$I$20240608$20240610$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004173$RADIUS PHARM$$73$YR$$F$Y$57.143$KG$20250703$$CN$US$US
255116731$25511673$1$I$20240306$20240822$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006722$RADIUS PHARM$$68$YR$$F$Y$$$20250703$$CN$US$US
255117141$25511714$1$I$$20240904$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007244$RADIUS PHARM$$$$$M$Y$$$20250703$$CN$US$US
255117481$25511748$1$I$$20240821$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006692$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255117571$25511757$1$I$$20240612$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004229$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255117901$25511790$1$I$$20240823$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US006781$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255117981$25511798$1$I$$20240620$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004526$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255119131$25511913$1$I$$20240910$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007402$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255120331$25512033$1$I$$20240927$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007572$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255120441$25512044$1$I$$20240917$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007621$RADIUS PHARM$$$$$M$Y$$$20250703$$MD$US$US
255122161$25512216$1$I$20250430$20250626$20250703$20250703$EXP$$US-Calliditas-2025CAL01215$CALLIDITAS THERAPEUTICS AB$$79$YR$E$F$Y$$$20250703$$CN$US$US
255122361$25512236$1$I$20250612$20250624$20250703$20250703$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202506022797$ELI LILLY AND COMPANY$$72$YR$E$M$Y$63$KG$20250703$$CN$CN$CN
255122552$25512255$2$F$20250611$20250709$20250703$20250716$PER$$US-ABBVIE-6356026$ABBVIE$$29$YR$$F$Y$$$20250716$$MD$US$US
255123141$25512314$1$I$$20240928$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007981$RADIUS PHARM$$$$$F$Y$54$KG$20250703$$CN$US$US
255123281$25512328$1$I$20240930$20241001$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007988$RADIUS PHARM$$70$YR$$F$Y$$$20250703$$CN$US$US
255123551$25512355$1$I$$20240702$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004904$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255123791$25512379$1$I$$20240716$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US005287$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255123921$25512392$1$I$20240601$20240702$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004908$RADIUS PHARM$$71$YR$$F$Y$$$20250703$$CN$US$US
255124912$25512491$2$F$$20250912$20250703$20250915$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-094383$BRISTOL-MYERS SQUIBB COMPANY$$51$YR$A$F$Y$$$20250915$$$US$US
255126401$25512640$1$I$$20241002$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US008298$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255126481$25512648$1$I$20241031$20240719$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US005502$RADIUS PHARM$$68$YR$$F$Y$$$20250703$$CN$US$US
255127341$25512734$1$I$$20240704$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US004989$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255127491$25512749$1$I$$20240910$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US007465$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255128251$25512825$1$I$$20250626$20250703$20250703$EXP$$AU-AMGEN-AUSSP2025127261$AMGEN$Jung K.; Sivadas S.D.; Fitzgerald X. et al.. Long-term clinical outcomes of bevacizumab for treatment of stereotactic radio surgery-induced radiation necrosis in patients with brain metastases. Journal of Neuro-Oncology. 2025;1 - 10$$$$$Y$$$20250703$$HP$AU$AU
255128325$25512832$5$F$20250629$20250822$20250703$20250827$30DAY$$US-PFIZER INC-202500131951$PFIZER$$13$YR$$M$Y$44.91$KG$20250827$$CN$US$US
255128724$25512872$4$F$20250620$20250820$20250703$20250825$30DAY$$EU-PFIZER INC-PV202500078000$PFIZER$$13$YR$$F$Y$34$KG$20250825$$CN$EU$EU
255129471$25512947$1$I$20241007$20250703$20250703$20250703$DIR$FDA-CDER-CTU-2025-44280$$FDA-CTU$$$$$$N$$$20250703$N$MD$US$
255130241$25513024$1$I$$20250627$20250703$20250703$EXP$GB-MHRA-MED-202506271257572980-LFQYC$GB-ELI_LILLY_AND_COMPANY-GB202507001254$ELI LILLY AND COMPANY$$$$$F$Y$$$20250703$$CN$GB$GB
255131741$25513174$1$I$$20240710$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US005330$RADIUS PHARM$$$$A$F$Y$$$20250703$$CN$US$US
255132041$25513204$1$I$20240601$20240709$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US005317$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255134331$25513433$1$I$20250101$20250627$20250703$20250703$PER$$US-SA-2025SA187301$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250703$$MD$US$US
255134401$25513440$1$I$20230401$20250627$20250703$20250703$PER$$US-SA-2025SA186917$SANOFI AVENTIS$$4$YR$C$F$Y$$$20250703$$HP$US$US
255134511$25513451$1$I$20250101$20250627$20250703$20250703$PER$$US-SA-2025SA186182$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250703$$MD$US$US
255134671$25513467$1$I$$20250627$20250703$20250703$PER$$US-SA-2025SA184635$SANOFI AVENTIS$$9$YR$C$F$Y$$$20250703$$CN$US$US
255136761$25513676$1$I$20241101$20241111$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009256$RADIUS PHARM$$59$YR$$F$Y$$$20250703$$CN$US$US
255137061$25513706$1$I$$20250627$20250703$20250703$PER$$US-SA-2025SA187072$SANOFI AVENTIS$$$$A$F$Y$58.18$KG$20250703$$MD$US$US
255138031$25513803$1$I$$20241120$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009575$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255138151$25513815$1$I$$20250628$20250703$20250703$PER$$US-SA-2025SA187820$SANOFI AVENTIS$$$$T$M$Y$$$20250703$$HP$US$US
255138161$25513816$1$I$20250501$20250628$20250703$20250703$PER$$US-SA-2025SA187113$SANOFI AVENTIS$$19$YR$A$F$Y$$$20250703$$HP$US$US
255138831$25513883$1$I$20240101$20250630$20250703$20250703$PER$$US-SA-2025SA186563$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250703$$HP$US$US
255138921$25513892$1$I$$20250630$20250703$20250703$PER$$US-SA-2025SA187610$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250703$$HP$US$US
255139031$25513903$1$I$20241201$20250701$20250703$20250703$PER$$US-SA-2025SA187751$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250703$$CN$US$US
255139391$25513939$1$I$$20250701$20250703$20250703$PER$$US-SA-2025SA187003$SANOFI AVENTIS$$$$A$$Y$$$20250703$$CN$US$US
255140361$25514036$1$I$20241001$20241125$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009695$RADIUS PHARM$$60$YR$$F$Y$$$20250703$$CN$US$US
255140621$25514062$1$I$$20241125$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009701$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255140671$25514067$1$I$20240101$20241129$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009812$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255140911$25514091$1$I$20241101$20241127$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US009799$RADIUS PHARM$$68$YR$$M$Y$$$20250703$$CN$US$US
255141381$25514138$1$I$20250101$20250626$20250703$20250703$PER$$US-ABBVIE-6349294$ABBVIE$$$$$$Y$$$20250703$$CN$US$US
255142861$25514286$1$I$$20241209$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US010162$RADIUS PHARM$$$$$F$Y$68.027$KG$20250703$$CN$US$US
255142891$25514289$1$I$$20241219$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US010486$RADIUS PHARM$$$$$F$Y$$$20250703$$MD$US$US
255144081$25514408$1$I$20241231$20250402$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000080$RADIUS PHARM$$73$YR$$F$Y$$$20250703$$CN$US$US
255145471$25514547$1$I$$20250116$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000350$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255145931$25514593$1$I$20250101$20250116$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000440$RADIUS PHARM$$75$YR$$F$Y$$$20250703$$CN$US$US
255145981$25514598$1$I$$20250120$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000489$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255146151$25514615$1$I$$20250121$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000522$RADIUS PHARM$$$$$M$Y$$$20250703$$CN$US$US
255146311$25514631$1$I$20241001$20250505$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000578$RADIUS PHARM$$68$YR$$F$Y$$$20250703$$CN$US$US
255146431$25514643$1$I$20250101$20250325$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000539$RADIUS PHARM$$62$YR$$F$Y$$$20250703$$CN$US$US
255146481$25514648$1$I$20250123$20250123$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000622$RADIUS PHARM$$67$YR$$F$Y$$$20250703$$CN$US$US
255146511$25514651$1$I$20250101$20250123$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000584$RADIUS PHARM$$70$YR$$F$Y$$$20250703$$CN$US$US
255146961$25514696$1$I$$20250129$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2025US000770$RADIUS PHARM$$$$$F$Y$$$20250703$$CN$US$US
255147782$25514778$2$F$$20250718$20250703$20250723$EXP$$US-009507513-2296750$MERCK SHARP + DOHME LLC$$6$DEC$$F$Y$$$20250723$$MD$US$US
255148661$25514866$1$I$$20231127$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2023US006154$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255149041$25514904$1$I$$20240228$20250703$20250703$PER$$US-RADIUS HEALTH INC.-2024US001641$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255149071$25514907$1$I$20250627$20250627$20250703$20250703$EXP$$US-JNJFOC-20250636162$JOHNSON AND JOHNSON$$37$YR$A$M$Y$$$20250704$$MD$US$US
255149671$25514967$1$I$$20250423$20250703$20250703$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25047591$RADIUS PHARM$$$$$M$Y$$$20250704$$CN$US$US
255150781$25515078$1$I$$20250702$20250703$20250703$EXP$$US-JNJFOC-20250702791$JOHNSON AND JOHNSON$$$$$F$Y$$$20250704$$HP$US$US
255151122$25515112$2$F$$20250721$20250703$20250725$PER$$US-SA-2025SA188784$SANOFI AVENTIS$$$$A$F$Y$62.27$KG$20250725$$CN$US$US
255152051$25515205$1$I$20250201$20250701$20250703$20250703$EXP$$EU-ABBVIE-6355512$ABBVIE$$67$YR$$M$Y$$$20250703$$CN$EU$EU
255153291$25515329$1$I$$20250622$20250704$20250704$EXP$$US-Accord-492811$ACCORD$Jagadish A, Notta S, Bakeler S, Joseph D. Pleural Effusion and Anasarca Associated With Pioglitazone. J Pharm Technol. 2025 Jun 14:87551225251348838. doi: 10.1177/87551225251348838$81$YR$E$M$Y$$$20250704$$MD$US$US
255153791$25515379$1$I$20250625$20250625$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202506024744$ELI LILLY AND COMPANY$$31$YR$A$F$Y$$$20250704$$CN$US$US
255153852$25515385$2$F$$20250627$20250704$20250809$EXP$$US-ASTRAZENECA-202506USA023627US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250809$$$US$US
255154001$25515400$1$I$$20250624$20250704$20250704$EXP$$GB-TEVA-VS-3347539$TEVA$$72$YR$$F$Y$80$KG$20250704$$MD$GB$GB
255154061$25515406$1$I$$20200701$20250704$20250704$EXP$$EU-ABBVIE-6348622$ABBVIE$$15$MON$$M$Y$10$KG$20250704$$MD$EU$EU
255154581$25515458$1$I$$20250623$20250704$20250704$EXP$CA-MHPD-001129648$CA-Accord-492292$ACCORD$$56$YR$A$F$Y$$$20250704$$MD$CA$CA
255154651$25515465$1$I$$20250625$20250704$20250704$PER$$US-ABBVIE-6350769$ABBVIE$$64$YR$$M$Y$$$20250704$$MD$US$US
255154761$25515476$1$I$$20250701$20250704$20250704$PER$$US-SA-2025SA187392$SANOFI AVENTIS$$$$A$F$Y$$$20250704$$CN$US$US
255155111$25515511$1$I$$20250627$20250704$20250704$PER$$US-SA-2025SA188053$SANOFI AVENTIS$$$$E$F$Y$75$KG$20250704$$HP$US$US
255155382$25515538$2$F$$20250710$20250704$20250714$EXP$$GB-TEVA-VS-3348361$TEVA$Anpalagan J, Oo K-N, Bingham S. UNCOVERING THE DRIVER OF A FATAL DISEASE. Rheumatol-Adv-Pract 2024; 8 (Suppl. 1) i23 (plus Poster) abstr. P03.; Anpalagan J, Oo K-N, Bingham S. UNCOVERING THE DRIVER OF A FATAL DISEASE. Rheumatol-Adv-Pract 2024; 8 (Suppl. 1) i23 (plus Poster) abstr. P03.$65$YR$$F$Y$$$20250714$$HP$GB$GB
255156051$25515605$1$I$20250626$20250627$20250704$20250704$PER$$US-BEH-2025211096$CSL BEHRING$$74$YR$E$F$Y$$$20250704$$HP$US$US
255156411$25515641$1$I$$20250701$20250704$20250704$EXP$$US-SMPA-2025SPA008432$SUNOVION$$$$$$Y$$$20250704$$CN$US$US
255156521$25515652$1$I$20211221$20250630$20250704$20250704$EXP$EU-AEMPS-1702381$EU-ORGANON-O2507ESP000051$ORGANON$$81$YR$$F$Y$$$20250704$$MD$EU$EU
255157651$25515765$1$I$20250601$20250630$20250704$20250704$EXP$$JP-ASTELLAS-2025-AER-035881$ASTELLAS$$$$E$$Y$$$20250704$$PH$JP$JP
255160104$25516010$4$F$$20250828$20250704$20250908$EXP$$CA-NOVOPROD-1468520$NOVO NORDISK$$48$YR$$F$Y$81$KG$20250908$$PH$CA$CA
255160181$25516018$1$I$$20250625$20250704$20250704$EXP$$CO-NOVOPROD-1467466$NOVO NORDISK$$61$YR$$F$Y$$$20250704$$CN$CO$CO
255160191$25516019$1$I$$20250625$20250704$20250704$EXP$GB-MHRA-MED-202506250851174860-FZSBC$GB-NOVOPROD-1466268$NOVO NORDISK$$63$YR$$F$Y$$$20250704$$HP$GB$GB
255160961$25516096$1$I$$20250624$20250704$20250704$EXP$$US-SPECGX-T202501156$SPECGX$Li K, Azizolli A. Treating urinary tract infection (UTI) and treatment-resistant depression in the setting of multidrug-resistant infection and drug-drug interaction: A focus on methylphenidate and linezolid interaction. Am J Health-Syst Pharm. 2025;82(1):S2688$77$YR$$F$Y$$$20250704$$HP$US$US
255161291$25516129$1$I$$20250211$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US001465$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255161301$25516130$1$I$$20250218$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US001462$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255161911$25516191$1$I$20241223$20250219$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US001567$RADIUS PHARM$$89$YR$$F$Y$$$20250704$$CN$US$US
255162441$25516244$1$I$20250101$20250225$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US001756$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255163471$25516347$1$I$20250304$20250305$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US002026$RADIUS PHARM$$85$YR$$F$Y$$$20250704$$CN$US$US
255163551$25516355$1$I$$20250702$20250704$20250704$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-080961$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250704$$$US$US
255163791$25516379$1$I$20250601$20250701$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507002332$ELI LILLY AND COMPANY$$$$$F$Y$$$20250704$$CN$US$US
255164001$25516400$1$I$$20250306$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US002105$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255164781$25516478$1$I$20250101$20250321$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US002183$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255165131$25516513$1$I$$20250306$20250704$20250704$PER$$US-RADIUS HEALTH INC.-2025US002251$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255165521$25516552$1$I$$20250625$20250704$20250704$PER$$US-ABBVIE-6350367$ABBVIE$$$$$F$Y$$$20250704$$CN$US$US
255166201$25516620$1$I$20250301$20250320$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25045782$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255167171$25516717$1$I$$20250619$20250704$20250704$EXP$$GB-AUROBINDO-AUR-APL-2025-032132$AUROBINDO$$55$YR$$F$Y$$$20250704$$HP$GB$GB
255167371$25516737$1$I$$20250317$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25045965$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$COUNTRY NOT SPECIFIED$US
255167501$25516750$1$I$$20250317$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25045940$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255170181$25517018$1$I$$20250324$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25046817$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255170541$25517054$1$I$20241101$20250408$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25046639$RADIUS PHARM$$69$YR$$F$Y$$$20250704$$CN$US$US
255171001$25517100$1$I$$20250328$20250704$20250704$PER$$US-STRIDES ARCOLAB LIMITED-2025SP004394$STRIDES$$$$$$Y$$$20250704$$CN$US$US
255171161$25517116$1$I$20250101$20250408$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25046865$RADIUS PHARM$$$$$F$Y$$$20250704$$CN$US$US
255171781$25517178$1$I$20250604$20250630$20250704$20250704$EXP$$US-SA-2025SA187835$SANOFI AVENTIS$$80$YR$E$F$Y$$$20250704$$HP$US$US
255172271$25517227$1$I$$20250627$20250704$20250704$EXP$$TR-AMGEN-TURSP2025128179$AMGEN$Ozbay E.; Sabanci S.; Kucuk M. et.al.. Hemorrhagic complications in premature infants treated with intravitreal bevacizumab. International Ophthalmology. 2025;45 (1):1-8$$$I$$Y$$$20250704$$HP$TR$TR
255172311$25517231$1$I$20250501$20250630$20250704$20250704$EXP$$BR-JNJFOC-20250700592$JOHNSON AND JOHNSON$$49$YR$A$F$Y$$$20250704$$CN$BR$BR
255172631$25517263$1$I$$20250627$20250704$20250704$EXP$$ZA-ROCHE-10000325245$ROCHE$$$$$M$Y$$$20250704$$MD$ZA$ZA
255172871$25517287$1$I$20250618$20250619$20250704$20250704$PER$$US-TLM-TLM-2025-03949$TOLMAR$$$$$$Y$$$20250703$$HP$US$US
255173291$25517329$1$I$20250401$20250416$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25047217$RADIUS PHARM$$64$YR$$M$Y$$$20250704$$CN$US$US
255173451$25517345$1$I$20250415$20250416$20250704$20250704$PER$$US-RADIUS HEALTH INC.-US-RADIUS-25047214$RADIUS PHARM$$65$YR$$F$Y$$$20250704$$CN$US$US
255174131$25517413$1$I$$20250625$20250704$20250704$PER$$US-APOTEX-2025AP009473$APOTEX$Barritt IV AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH. Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database. The American Journal of Gastroenterology. 2025;120 (6):1307-1313$$$A$$Y$$$20250704$$MD$US$US
255174391$25517439$1$I$$20250605$20250704$20250704$PER$$US-GSK-US2025070685$GLAXOSMITHKLINE$$$$$F$Y$$$20250704$$$US$US
255174511$25517451$1$I$$20250702$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507003329$ELI LILLY AND COMPANY$$36$YR$A$F$Y$$$20250704$$CN$US$US
255174881$25517488$1$I$20250201$20250619$20250704$20250704$EXP$$EU-AUROBINDO-AUR-APL-2025-032811$AUROBINDO$$14$YR$$M$Y$$$20250704$$PH$EU$EU
255175314$25517531$4$F$20250725$20250918$20250704$20250925$EXP$$CA-TAKEDA-2025TUS060339$TAKEDA$$18$YR$$M$Y$$$20250925$$$CA$CA
255175541$25517554$1$I$$20250703$20250704$20250704$PER$$US-JNJFOC-20250704379$JOHNSON AND JOHNSON$$$$$F$Y$$$20250704$$HP$US$US
255175632$25517563$2$F$20250620$20250623$20250704$20250810$EXP$$CN-ASTRAZENECA-202506CHN019626CN$ALEXION PHARMACEUTICALS$$60$YR$A$M$Y$51$KG$20250810$$$CN$CN
255176001$25517600$1$I$$20250620$20250704$20250704$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-515100$RANBAXY$Dormegny-Jeanjean LC, Mainberger OAE, de Crespin de BillyC, Obrecht A, Danila V, Erb A, et al. Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression. Encephale. 2024;50 (2):137-142$$$$$Y$$$20250704$$HP$EU$EU
255177472$25517747$2$F$20250623$20250625$20250704$20250809$EXP$$CA-ASTRAZENECA-202506CAN022587CA$ALEXION PHARMACEUTICALS$$81$YR$E$M$Y$$$20250809$$$CA$CA
255177612$25517761$2$F$$20250623$20250704$20250816$PER$$US-ASTRAZENECA-202506USA019081US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
255177953$25517795$3$F$20250101$20250915$20250704$20250925$EXP$$US-ASTRAZENECA-202506USA021629US$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$99.8$KG$20250925$$$US$US
255178212$25517821$2$F$20250616$20250626$20250704$20250809$EXP$$EU-ASTRAZENECA-202506EEA025166IE$ALEXION PHARMACEUTICALS$$42$YR$A$F$Y$$$20250809$$$EU$EU
255178672$25517867$2$F$$20250625$20250704$20250810$EXP$$BR-ASTRAZENECA-202506SAM019369BR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$BR$BR
255179932$25517993$2$F$20250626$20250717$20250704$20250722$PER$$US-AMGEN-USASP2025129366$AMGEN$$$$A$M$Y$$$20250722$$CN$US$US
255180491$25518049$1$I$$20241011$20250704$20250704$PER$$US-TARO PHARMACEUTICALS USA INC.-2024TAR01983$TARO$$$$$$Y$$$20250704$$CN$US$US
255181663$25518166$3$F$$20250912$20250704$20250920$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05661$LUPIN$$$$$$Y$$$20250920$$$US$US
255181752$25518175$2$F$$20250702$20250704$20250816$PER$$US-ASTRAZENECA-202507USA001185US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
255182181$25518218$1$I$$20250624$20250704$20250704$EXP$$CN-TAKEDA-2025TUS060623$TAKEDA$$$$$$Y$$$20250704$$MD$CN$CN
255183192$25518319$2$F$20250401$20250711$20250704$20250717$EXP$$US-ABBVIE-6269838$ABBVIE$$78$YR$$M$Y$$$20250717$$CN$US$US
255183271$25518327$1$I$$20250702$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507003269$ELI LILLY AND COMPANY$$52$YR$A$F$Y$$$20250704$$CN$US$US
255183662$25518366$2$F$$20250627$20250704$20250816$PER$$US-ASTRAZENECA-202506USA025677US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
255183931$25518393$1$I$20250530$20250620$20250704$20250704$EXP$$CN-Hisun Pharmaceuticals USA Inc.-000490$HISUN PHARMACEUTICALS USA INC$$75$YR$E$F$Y$55$KG$20250704$$HP$CN$CN
255184221$25518422$1$I$$20250606$20250704$20250704$PER$$US-GSK-US2025071356$GLAXOSMITHKLINE$$$$$F$Y$$$20250704$$$US$US
255184621$25518462$1$I$$20250609$20250704$20250704$PER$$US-SMPA-2025SPA007444$SUNOVION$$$$$$Y$$$20250704$$CN$US$US
255185151$25518515$1$I$20250101$20250624$20250704$20250704$EXP$$US-JNJFOC-20250630269$JOHNSON AND JOHNSON$$35$YR$A$F$Y$$$20250704$$HP$US$US
255185221$25518522$1$I$$20250624$20250704$20250704$EXP$$JP-862174955-ML2025-03207$UNKNOWN$Katsuki H, Yamada T, Ayukawa K. Prolonged QRS duration in patients with acute poisoning occurs both xenobiotics and with low level of potassium: a single-center retrospective case control study. The Journal of Toxicological Sciences. 2025 Jan 10;50(3): 117-123.$24$YR$A$M$Y$$$20250704$$HP$JP$JP
255185301$25518530$1$I$20250502$20250702$20250704$20250704$PER$$US-BIOGEN-2025BI01310080$BIOGEN$$48$YR$$F$Y$$$20250704$$CN$US$US
255185361$25518536$1$I$$20250605$20250704$20250704$30DAY$$US-VEROBIOTECH-2025USVEROSPO00213$VERO BIOTECH$$$$A$M$Y$$$20250704$$CN$US$US
255186271$25518627$1$I$$20250630$20250704$20250704$EXP$$AZ-TAKEDA-2025TUS060673$TAKEDA$$$$$F$Y$$$20250704$$MD$AZ$AZ
255186511$25518651$1$I$$20250701$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507002491$ELI LILLY AND COMPANY$$$$$F$Y$$$20250704$$CN$US$US
255187361$25518736$1$I$20180601$20250626$20250704$20250704$EXP$EU-MPA-2019-000411$EU-KENVUE-20250611524$Kenvue$$$$$$Y$$$20250704$$HP$EU$EU
255187781$25518778$1$I$20150701$20250630$20250704$20250704$EXP$$EU-SANDOZ INC.-PHHY2017CZ196097$SANDOZ$$22$YR$$M$Y$$$20250704$$MD$EU$EU
255187853$25518785$3$F$$20250922$20250704$20250930$EXP$$CA-SANDOZ INC.-SDZ2025CA046533$SANDOZ$$43$YR$$F$Y$96$KG$20250930$$HP$CA$CA
255189083$25518908$3$F$$20250714$20250704$20250716$EXP$$JP-SA-2025SA185433$SANOFI AVENTIS$$70$YR$E$F$Y$$$20250717$$MD$JP$JP
255189271$25518927$1$I$20250627$20250702$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507002954$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250704$$HP$US$US
255189301$25518930$1$I$$20250628$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507001136$ELI LILLY AND COMPANY$$$$$$Y$$$20250704$$CN$US$US
255189334$25518933$4$F$20250601$20250708$20250704$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507002518$ELI LILLY AND COMPANY$$44$YR$A$F$Y$$$20250722$$CN$US$US
255189451$25518945$1$I$$20250620$20250704$20250704$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-514695$RANBAXY$Citation Nicoli F, Citro F, Giannese D, Cattani R, Bianchi C. A case of type 1 diabetes mellitus and advanced chronic kidney disease in pregnancy: Which glucose monitoring system is the most accurate?. Acta Diabetol. 2024;61(3):389-392$34$YR$$F$Y$$$20250704$$HP$EU$EU
255189771$25518977$1$I$20250619$20250701$20250704$20250704$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007023$ACADIA PHARMACEUTICALS$$83$YR$$F$Y$$$20250704$$CN$US$US
255189991$25518999$1$I$$20250624$20250704$20250704$EXP$$EU-ASTELLAS-2025-AER-034904$ASTELLAS$$63$YR$A$F$Y$$$20250704$$MD$EU$EU
255190221$25519022$1$I$$20250627$20250704$20250704$PER$$US-ROCHE-10000325708$ROCHE$$$$A$F$Y$$$20250704$$CN$US$US
255190331$25519033$1$I$$20250630$20250704$20250704$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007868$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250704$$CN$US$US
255190801$25519080$1$I$$20250701$20250704$20250704$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007867$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250704$$CN$US$US
255190961$25519096$1$I$$20250626$20250704$20250704$EXP$$JP-JAZZ PHARMACEUTICALS-2025-JP-016630$JAZZ$$$$$F$Y$$$20250704$$MD$JP$JP
255191541$25519154$1$I$$20250627$20250704$20250704$PER$$US-AMGEN-USASP2025128501$AMGEN$$$$A$F$Y$$$20250704$$HP$US$US
255192031$25519203$1$I$$20250702$20250704$20250704$PER$$US-ELI_LILLY_AND_COMPANY-US202507003239$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250704$$CN$US$US
255192322$25519232$2$F$20250601$20250707$20250704$20250806$30DAY$$US-AMGEN-USASP2025123121$AMGEN$$84$YR$E$M$Y$103$KG$20250805$$HP$US$US
255192641$25519264$1$I$$20250702$20250704$20250704$EXP$$US-JNJFOC-20250702907$JOHNSON AND JOHNSON$$61$YR$A$F$Y$$$20250704$$HP$US$US
255192701$25519270$1$I$$20250620$20250704$20250704$EXP$$CA-APOTEX-2025AP008718$APOTEX$$65$YR$$F$Y$$$20250704$$MD$CA$CA
255193561$25519356$1$I$$20250626$20250704$20250704$EXP$$CA-TEVA-VS-3347959$TEVA$$13$YR$$M$Y$37$KG$20250704$$HP$CA$CA
255194011$25519401$1$I$$20250621$20250704$20250704$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-015453$JAZZ$$$$$F$Y$$$20250704$$MD$US$US
255194531$25519453$1$I$20250501$20250630$20250704$20250704$EXP$$US-GSK-US2025081787$GLAXOSMITHKLINE$$$$$F$Y$$$20250704$$$US$US
255195342$25519534$2$F$20250615$20250710$20250704$20250716$EXP$$CN-KENVUE-20250612130$Kenvue$$$$$$Y$$$20250716$$HP$CN$CN
255195461$25519546$1$I$20220503$20250625$20250704$20250704$EXP$$US-TEVA-VS-3346030$TEVA$$39$YR$$F$Y$$$20250704$$CN$US$US
255196451$25519645$1$I$$20250702$20250704$20250704$PER$$US-ABBVIE-6356663$ABBVIE$$$$$$Y$$$20250704$$HP$US$US
255199441$25519944$1$I$$20250630$20250704$20250704$PER$$US-SA-2025SA187977$SANOFI AVENTIS$$88$YR$E$M$Y$$$20250704$$MD$US$US
255199711$25519971$1$I$20250101$20250630$20250704$20250704$EXP$$US-BAUSCH-BH-2025-014168$BAUSCH AND LOMB$$81$YR$$F$Y$$$20250704$$HP$US$US
255199991$25519999$1$I$20250701$20250702$20250704$20250704$PER$$US-SA-2025SA188162$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250704$$CN$US$US
255201541$25520154$1$I$$20250702$20250704$20250704$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-2025-093794$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250704$$HP$CA$CA
255202051$25520205$1$I$20231128$20250630$20250704$20250704$EXP$EU-AFSSAPS-ST2025000735$EU-GSK-FR2025082305$GLAXOSMITHKLINE$$68$YR$$F$Y$70$KG$20250704$$MD$EU$EU
255202471$25520247$1$I$$20250630$20250704$20250704$EXP$$RS-SANDOZ INC.-SDZ2025RS046753$SANDOZ$Karisik E., Stanojevic-Ristic Z., Jevtic M., Rasic J., Maric M., Popovic M.. Ceftriaxone-Induced Pancytopenia: A Case Report. Hematology Reports. 2025;17, 30:1-8$72$YR$$F$Y$$$20250704$$HP$RS$RS
255202561$25520256$1$I$$20250624$20250704$20250704$EXP$$CA-TEVA-VS-3346896$TEVA$$89$YR$$M$Y$$$20250704$$PH$CA$CA
255202671$25520267$1$I$$20250703$20250704$20250704$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-095052$BRISTOL-MYERS SQUIBB COMPANY$$67$YR$E$F$Y$$$20250704$$CN$US$US
255204311$25520431$1$I$20240105$20250628$20250704$20250704$EXP$GB-MHRA-MED-202506280327423910-QHJBW$GB-ELI_LILLY_AND_COMPANY-GB202506026954$ELI LILLY AND COMPANY$$45$YR$A$F$Y$100$KG$20250704$$CN$GB$GB
255204921$25520492$1$I$20250528$20250630$20250704$20250704$EXP$$CN-PFIZER INC-PV202500078259$PFIZER$$24$YR$$F$Y$44$KG$20250704$$HP$CN$CN
255205613$25520561$3$F$20250626$20250912$20250704$20250922$EXP$$CO-TAKEDA-2025TUS060326$TAKEDA$$43$YR$$M$Y$$$20250922$$$CO$CO
255206343$25520634$3$F$20250702$20250711$20250705$20250716$30DAY$$US-SANDOZ INC.-SDZ2025US046939$SANDOZ$$12$YR$$$Y$$$20250716$$CN$US$US
255206521$25520652$1$I$20240110$20250625$20250705$20250705$PER$$US-UNITED THERAPEUTICS-UNT-2025-022357$UNITED THERAPEUTICS$$78$YR$$F$Y$90.249$KG$20250705$$$US$US
255206581$25520658$1$I$20250101$20250630$20250705$20250705$PER$$US-SA-2025SA188111$SANOFI AVENTIS$$26$YR$A$F$Y$$$20250705$$HP$US$US
255206622$25520662$2$F$$20250701$20250705$20250816$PER$$US-ASTRAZENECA-202507USA002863US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250816$$$US$US
255206843$25520684$3$F$20250101$20250826$20250705$20250831$EXP$$US-SA-2025SA188044$SANOFI AVENTIS$$64$YR$A$M$Y$$$20250831$$HP$US$US
255207441$25520744$1$I$20250619$20250620$20250705$20250705$EXP$$GB-AUROBINDO-AUR-APL-2025-032314$AUROBINDO$$87$YR$$M$Y$80$KG$20250705$$HP$GB$GB
255207892$25520789$2$F$$20250815$20250705$20250818$PER$$NVSC2025US105493$NOVARTIS$$$$$M$Y$$$20250818$$CN$US$US
255208641$25520864$1$I$20250601$20250627$20250705$20250705$PER$$US-SA-2025SA187920$SANOFI AVENTIS$$63$YR$A$F$Y$73.18$KG$20250705$$MD$US$US
255208881$25520888$1$I$20250623$20250626$20250705$20250705$EXP$$US-ORPHANEU-2025004688$RECORDATI$$43$YR$$F$Y$67.574$KG$20250705$$CN$US$US
255209351$25520935$1$I$20250101$20250701$20250705$20250705$PER$$US-SA-2025SA189169$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250705$$HP$US$US
255210221$25521022$1$I$$20250626$20250705$20250705$EXP$$US-APOTEX-2025AP009241$APOTEX$Xu EJ, Steele DJR, Fenves AZ.. Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review. Kidney Medicine. 2025;7 (7): 101030:1-6$61$YR$$M$Y$$$20250705$$MD$US$US
255211392$25521139$2$F$20250501$20250710$20250705$20250719$EXP$$US-UNITED THERAPEUTICS-UNT-2025-022862$UNITED THERAPEUTICS$$80$YR$$M$Y$82.54$KG$20250719$$$US$US
255212101$25521210$1$I$20250601$20250701$20250705$20250705$PER$$US-ELI_LILLY_AND_COMPANY-US202507002424$ELI LILLY AND COMPANY$$51$YR$A$F$Y$$$20250705$$HP$US$US
255212261$25521226$1$I$20250623$20250701$20250705$20250705$PER$$US-SA-2025SA188799$SANOFI AVENTIS$$37$YR$A$M$Y$$$20250705$$HP$US$US
255213781$25521378$1$I$20250401$20250612$20250705$20250705$PER$$US-TRAVERE-2025TVT00952$TRAVERE THERAPEUTICS$$55$YR$A$M$Y$$$20250706$$CN$US$US
255213991$25521399$1$I$$20250703$20250706$20250706$PER$$US-ELI_LILLY_AND_COMPANY-US202507005038$ELI LILLY AND COMPANY$$$$$M$Y$$$20250705$$CN$US$US
255214511$25521451$1$I$$20250622$20250706$20250706$EXP$$AU-Suven-000029$SUVEN PHARMACEUTICALS LIMITED$Mannolini K, Flanagan N, Brushett K, McCartney B. Reverse Takotsubo cardiomyopathy at caesarean section following administration of glycopyrrolate for bradycardia secondary to high spinal block. BMJ Case Rep. 2025 Jun 19;18(6):e265777. doi: 10.1136/bcr-2025-265777.$4$DEC$A$F$Y$$$20250705$$HP$AU$AU
255215831$25521583$1$I$20250514$20250620$20250706$20250706$PER$$US-RDY-USA/2025/06/009300$DR REDDYS$$47$YR$A$$Y$$$20250706$$CN$US$US
255216242$25521624$2$F$$20250702$20250706$20250816$PER$$US-ASTRAZENECA-202507USA000998US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
255217471$25521747$1$I$$20250623$20250706$20250706$EXP$$US-Ipsen Biopharmaceuticals, Inc.-2025-14859$IPSEN BIOPHARMACEUTICALS, INC.$$69$YR$E$M$Y$120$KG$20250706$$$US$US
255217882$25521788$2$F$$20250904$20250706$20250914$PER$$US-SA-2025SA189063$SANOFI AVENTIS$$$$E$M$Y$$$20250914$$HP$US$US
255218481$25521848$1$I$20250624$20250701$20250706$20250706$EXP$$EU-ABBVIE-6357412$ABBVIE$$70$YR$$M$Y$$$20250706$$CN$EU$EU
255218592$25521859$2$F$$20250806$20250706$20250813$EXP$$US-ABBVIE-6356848$ABBVIE$$$$A$F$Y$$$20250813$$CN$US$US
255218891$25521889$1$I$20250701$20250701$20250706$20250706$EXP$$US-ABBVIE-6318410$ABBVIE$$69$YR$$F$Y$$$20250706$$CN$US$US
255219111$25521911$1$I$$20250623$20250706$20250706$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-089601$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250707$$CN$US$US
255219501$25521950$1$I$$20250702$20250706$20250706$PER$$US-ABBVIE-6356976$ABBVIE$$$$$$Y$$$20250706$$HP$US$US
255220883$25522088$3$F$$20250911$20250707$20250916$PER$$NVSC2025US101543$NOVARTIS$$$$$F$Y$$$20250916$$CN$US$US
255221201$25522120$1$I$$20250701$20250707$20250707$EXP$$GB-AMGEN-GBRSP2025130219$AMGEN$$$$$F$Y$$$20250706$$CN$GB$GB
255221241$25522124$1$I$20241201$20250702$20250707$20250707$EXP$$US-ABBVIE-6357022$ABBVIE$$70$YR$$F$Y$$$20250707$$CN$US$US
255221411$25522141$1$I$$20250701$20250707$20250707$PER$$US-ROCHE-10000328518$ROCHE$$$$A$F$Y$$$20250707$$CN$US$US
255221801$25522180$1$I$$20250626$20250707$20250707$PER$$US-ROCHE-10000325146$ROCHE$$$$A$M$Y$$$20250707$$CN$US$US
255221843$25522184$3$F$20230101$20250703$20250707$20250810$EXP$$EU-ASTRAZENECA-202507EEA001758RO$ALEXION PHARMACEUTICALS$$69$YR$E$M$Y$$$20250810$$MD$EU$EU
255222051$25522205$1$I$20221201$20250702$20250707$20250707$EXP$$US-ABBVIE-6357045$ABBVIE$$47$YR$$F$Y$$$20250707$$CN$US$US
255222191$25522219$1$I$$20250625$20250707$20250707$EXP$$US-NOVOPROD-1459034$NOVO NORDISK$$$$$F$Y$$$20250707$$CN$US$US
255222291$25522229$1$I$$20250701$20250707$20250707$PER$$US-ELI_LILLY_AND_COMPANY-US202507002115$ELI LILLY AND COMPANY$$74$YR$E$F$Y$$$20250707$$CN$US$US
255222361$25522236$1$I$$20250702$20250707$20250707$PER$$US-ELI_LILLY_AND_COMPANY-US202507003058$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250707$$CN$US$US
255222941$25522294$1$I$$20250627$20250707$20250707$EXP$$CA-TEVA-VS-3347192$TEVA$$$$$$Y$$$20250707$$HP$CA$CA
255223971$25522397$1$I$$20250704$20250707$20250707$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-081025$BOEHRINGER INGELHEIM$$$$$$Y$$$20250707$$MD$JP$JP
255224171$25522417$1$I$20241001$20250115$20250707$20250707$EXP$$EU-ALKEM LABORATORIES LIMITED-FR-ALKEM-2024-26930$ALKEM$$70$YR$$F$Y$$$20250707$$MD$EU$EU
255224591$25522459$1$I$20250606$20250626$20250707$20250707$EXP$$CN-ROCHE-10000323579$ROCHE$$36$YR$A$F$Y$$$20250707$$HP$CN$CN
255225441$25522544$1$I$$20250318$20250707$20250707$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2025001632$BIOCON$$$$$$Y$$$20250707$$PH$US$US
255225541$25522554$1$I$20250624$20250702$20250707$20250707$PER$$US-ABBVIE-6356027$ABBVIE$$39$YR$$M$Y$99.79$KG$20250707$$CN$US$US
255226332$25522633$2$F$$20250701$20250707$20250810$EXP$$GB-ASTRAZENECA-202505GBR026250GB$ALEXION PHARMACEUTICALS$$50$YR$A$M$Y$$$20250810$$$GB$GB
255226631$25522663$1$I$$20250704$20250707$20250707$EXP$$US-ROCHE-10000331111$ROCHE$$$$C$M$Y$$$20250707$$CN$US$US
255227871$25522787$1$I$$20250617$20250707$20250707$PER$$US-Ipsen Biopharmaceuticals, Inc.-2025-14787$IPSEN BIOPHARMACEUTICALS, INC.$$$$$$Y$$$20250707$$MD$US$US
255228561$25522856$1$I$20250101$20250630$20250707$20250707$EXP$EU-BAUSCH-BH-2025-014152$EU-BAUSCH-BH-2025-014152$BAUSCH AND LOMB$$85$YR$$F$Y$$$20250707$$CN$EU$EU
255229221$25522922$1$I$20250101$20250702$20250707$20250707$EXP$$GB-UCBSA-2025040759$UCB$$$$$F$Y$$$20250707$$CN$GB$GB
255229401$25522940$1$I$$20250701$20250707$20250707$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007904$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250707$$CN$US$US
255230622$25523062$2$F$$20250714$20250707$20250727$EXP$$US-GLENMARK PHARMACEUTICALS-2025GMK101460$GLENMARK$$$$$$Y$$$20250727$$CN$US$US
255231062$25523106$2$F$20250604$20250804$20250707$20250805$PER$$US-GSK-US2025071932$GLAXOSMITHKLINE$$63$YR$$M$Y$$$20250805$$$US$US
255231792$25523179$2$F$$20250707$20250707$20250714$PER$$US-SMPA-2025SPA007419$SUNOVION$$$$$$Y$$$20250714$$CN$US$US
255232001$25523200$1$I$$20250702$20250707$20250707$EXP$$US-GSK-US2025AMR084369$GLAXOSMITHKLINE$$$$$F$Y$$$20250707$$$US$US
255232751$25523275$1$I$$20250627$20250707$20250707$PER$$US-VIIV HEALTHCARE-US2025AMR083980$VIIV$$$$$M$Y$$$20250707$$$US$US
255233081$25523308$1$I$$20250523$20250707$20250707$PER$$US-TAKEDA-2025TUS059877$TAKEDA$$$$$F$Y$$$20250707$$$US$US
255233881$25523388$1$I$20250404$20250624$20250707$20250707$EXP$EU-AEMPS-1700053$EU-HIKMA PHARMACEUTICALS USA INC.-ES-H14001-25-08084$HIKMA$$79$YR$$M$Y$66$KG$20250703$$MD$EU$EU
255235341$25523534$1$I$$20250701$20250707$20250707$EXP$$US-SANDOZ INC.-SDZ2025US046974$SANDOZ$$$$$F$Y$$$20250707$$CN$US$US
255236121$25523612$1$I$$20250610$20250707$20250707$PER$$US-SMPA-2025SPA007475$SUNOVION$$$$$$Y$$$20250707$$CN$US$US
255236151$25523615$1$I$$20250610$20250707$20250707$PER$$US-SMPA-2025SPA007523$SUNOVION$$$$$$Y$$$20250707$$CN$US$US
255236461$25523646$1$I$$20250610$20250707$20250707$PER$$US-SMPA-2025SPA007466$SUNOVION$$$$$$Y$$$20250707$$CN$US$US
255236852$25523685$2$F$$20250808$20250707$20250818$EXP$$JP-UCBSA-2025040186$UCB$$26$YR$$M$Y$$$20250818$$PH$JP$JP
255237241$25523724$1$I$20250219$20250707$20250707$20250707$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-081137$BOEHRINGER INGELHEIM$$78$YR$E$M$Y$63.9$KG$20250707$$PH$JP$JP
255237771$25523777$1$I$$20250630$20250707$20250707$EXP$$JP-ROCHE-10000329108$ROCHE$Sekine Y, Otsuki T, Oguma K, Kikuchi M, Kobayashi S, Yaguchi T. A Case of pneumocystis pneumonia that developed during maintenance therapy with bevacizumab + olaparib for Stage IVB ovarian cancer [Abstract number:O-54]. The 157th Meeting of the Tohoku Society of Obstetrics and Gynecology. 2025;58.$45$YR$A$F$Y$$$20250707$$MD$JP$JP
255238411$25523841$1$I$$20250701$20250707$20250707$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-007926$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250707$$CN$US$US
255238691$25523869$1$I$20250703$20250703$20250703$20250703$DIR$FDA-CDER-CTU-2025-44518$$FDA-CTU$$23$YR$$F$N$$$20250703$N$$US$
255238811$25523881$1$I$$20250701$20250707$20250707$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202507002738$ELI LILLY AND COMPANY$$$$$$Y$$$20250707$$CN$JP$JP
255238821$25523882$1$I$$20250626$20250707$20250707$EXP$$US-ELI_LILLY_AND_COMPANY-US202504022928$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250707$$CN$US$US
255240251$25524025$1$I$$20250702$20250707$20250707$PER$$US-ROCHE-10000329530$ROCHE$$$$$$Y$$$20250707$$CN$US$US
255241001$25524100$1$I$$20250623$20250707$20250707$EXP$EU-EMA-DD-20240830-7482643-153734$EU-STRIDES PHARMA UK LTD.-2025SP007902$STRIDES$Khanafer N, Neuraz A, Benet T, Cour M, Persat F, Labussiere H et al. Acute graft-versus-host disease, invasive aspergillosis and Clostridium difficile colitis after peripheral blood stem cell transplantation: A complex network of causalities and a challenge for prevention. ANAEROBE. 2015;33:98-100$58$YR$$M$Y$$$20250707$$HP$EU$EU
255241482$25524148$2$F$20250101$20250905$20250707$20250918$EXP$$EU-UCBSA-2025040025$UCB$$$$$F$Y$93$KG$20250918$$MD$EU$EU
255241621$25524162$1$I$$20250626$20250707$20250707$EXP$$EU-MYLANLABS-2025M1055422$MYLAN$Mapelli M, Mantegazza V, Fusini L, Cefalu C, Gripari P, Vignati C, et al. ^Who let the clot out?^: a case of a mitralvalve annulus thrombosis resolved by directanticoagulants. Eur-Heart-J-Suppl 2019; 21 (Suppl.) E127-E130.$75$YR$$M$Y$$$20250704$$$EU$EU
255242201$25524220$1$I$$20250623$20250707$20250707$EXP$$US-AUROBINDO-AUR-APL-2025-031052$AUROBINDO$Kim S, Chen K, Stull W. Fluconazole-induced drug rash with eosinophilia and systemic symptoms syndrome. J Med Case Rep. 2025;19:257$19$YR$$F$Y$$$20250707$$HP$US$US
255243081$25524308$1$I$20250501$20250624$20250707$20250707$PER$$US-COSETTE-CP2025US000606$COSETTE PHARMACEUTICALS INC$$46$YR$A$F$Y$$$20250707$$CN$US$US
255243981$25524398$1$I$20250501$20250701$20250707$20250707$EXP$EU-HALMED-300090164$EU-TEVA-VS-3349330$TEVA$$$$A$F$Y$$$20250707$$MD$EU$EU
255244492$25524449$2$F$$20250724$20250707$20250730$EXP$$US-TAKEDA-2025TUS059516$TAKEDA$$$$$M$Y$$$20250730$$$US$US
255245131$25524513$1$I$$20250625$20250707$20250707$EXP$$EU-SANDOZ INC.-NVSC2020PL171307$SANDOZ$$60$YR$$M$Y$$$20250707$$HP$EU$EU
255245192$25524519$2$F$$20250714$20250707$20250721$EXP$$JP-AMGEN-JPNSP2025129545$AMGEN$Hirose S.; Cho T.; Ito A.. Investigation on the Prognosis of Cases Using Corticosteroid Agents for Adverse Events During Atezolizumab plus Bevacizumab Combination Therapy. Acta Hepatologica Japonica. 2025;66 (1):MO-39$$$$$Y$$$20250721$$HP$JP$JP
255245775$25524577$5$F$20250820$20250827$20250707$20250904$EXP$$US-GILEAD-2025-0712479$GILEAD$$25$YR$A$F$Y$$$20250904$$HP$US$US
255246161$25524616$1$I$20250625$20250701$20250707$20250707$PER$$NVSC2025US105549$NOVARTIS$$79$YR$$F$Y$65.32$KG$20250707$$HP$US$US
255246291$25524629$1$I$20250625$20250702$20250707$20250707$EXP$RU-RZN-3052090$RU-BAYER-2025A088617$BAYER HEALTHCARE PHARMACEUTICALS INC.$$47$YR$A$F$Y$$$20250707$$MD$RU$RU
255246711$25524671$1$I$$20250701$20250707$20250707$EXP$$US-PFIZER INC-202500133983$PFIZER$Klein, S.. Anxiety, vocalization, and agitation following peripheral nerve block with ropivacaine. Regional Anesthesia and Pain Medicine. 1999;24 (2):175-178$76$YR$$F$Y$50$KG$20250707$$HP$US$US
255247001$25524700$1$I$$20250703$20250704$20250704$DIR$FDA-CDER-CTU-2025-44441$$FDA-CTU$$92$YR$$F$N$$$20250703$N$CN$US$
255247301$25524730$1$I$20250612$20250624$20250707$20250707$EXP$$US-009507513-2300010$MERCK SHARP + DOHME LLC$$$$E$F$Y$58$KG$20250707$$MD$US$US
255247951$25524795$1$I$$20250703$20250707$20250707$PER$$US-PFIZER INC-PV202500080270$PFIZER$$55$YR$$M$Y$$$20250707$$CN$US$US
255248831$25524883$1$I$20010101$20250623$20250707$20250707$EXP$$US-PFIZER INC-2011051643$PFIZER$$36$YR$$F$Y$$$20250707$$CN$US$US
255248871$25524887$1$I$$20250626$20250707$20250707$EXP$GB-MHRA-MED-202506261127149620-HJYCD$GB-PERRIGO-25GB008060$GALPHARM INTERNATIONAL$$34$YR$$F$Y$44$KG$20250707$$CN$GB$GB
255249031$25524903$1$I$$20250630$20250707$20250707$EXP$$EU-MYLANLABS-2025M1056712$MYLAN$Mendes J, Savka L, Baltazar AM, et al. Chronic diarrhea and its therapeutic challenges in hospitalized patients. In: Congresses of the Portuguese Society of Internal Medicine: 31st National Congress of Internal Medicine ? Abstracts book. May 2025: 423.$67$YR$$M$Y$$$20250705$$MD$EU$EU
255250231$25525023$1$I$$20250702$20250707$20250707$PER$$US-SA-2025SA190739$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250707$$MD$US$US
255251451$25525145$1$I$20250101$20250702$20250707$20250707$PER$$US-SA-2025SA190010$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250707$$HP$US$US
255251531$25525153$1$I$$20250706$20250706$20250706$DIR$763192$$FDA-CTU$$$$$$N$$$20250706$N$CN$US$
255251721$25525172$1$I$$20250630$20250707$20250707$PER$$US-INCYTE CORPORATION-2025IN007192$INCYTE$$78$YR$$$Y$$$20250707$$$US$
255251792$25525179$2$F$20250101$20250801$20250707$20250806$PER$$US-SA-2025SA190263$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250806$$HP$US$US
255254641$25525464$1$I$20250209$20250703$20250707$20250707$EXP$$EU-ABBVIE-6357459$ABBVIE$$38$YR$$F$Y$$$20250707$$MD$EU$EU
255255221$25525522$1$I$$20250630$20250707$20250707$EXP$$CN-PFIZER INC-PV202500078211$PFIZER$$$$A$F$Y$$$20250707$$HP$CN$CN
255255541$25525554$1$I$20250101$20250626$20250707$20250707$EXP$$US-ELI_LILLY_AND_COMPANY-US202506026122$ELI LILLY AND COMPANY$$81$YR$E$F$Y$$$20250707$$CN$US$US
255256121$25525612$1$I$20250423$20250702$20250707$20250707$EXP$EU-AEMPS-1702221$EU-SA-2025SA190637$SANOFI AVENTIS$$60$YR$A$F$Y$75$KG$20250707$$MD$EU$EU
255256181$25525618$1$I$$20250707$20250707$20250707$DIR$763233$$FDA-CTU$$$$$F$N$$$20250707$N$CN$US$
255256201$25525620$1$I$20171102$20250701$20250707$20250707$EXP$EU-BFARM-25004614$EU-PFIZER INC-202500132460$PFIZER$$$$$$Y$$$20250707$$CN$EU$EU
255257381$25525738$1$I$$20250702$20250707$20250707$EXP$$JP-BAYER-2025A082753$BAYER HEALTHCARE PHARMACEUTICALS INC.$$77$YR$E$M$Y$$$20250707$$PH$JP$JP
255257662$25525766$2$F$$20250702$20250707$20250810$EXP$$CA-ASTRAZENECA-202507CAN002144CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$CA$CA
255257802$25525780$2$F$$20250808$20250707$20250813$PER$$US-SA-2025SA186078$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250813$$HP$US$US
255258263$25525826$3$F$20250627$20250825$20250707$20250903$EXP$$US-BAYER-2025A087981$BAYER HEALTHCARE PHARMACEUTICALS INC.$$27$YR$A$M$Y$$$20250903$$CN$US$US
255260502$25526050$2$F$$20250701$20250707$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507001572$ELI LILLY AND COMPANY$$71$YR$E$$Y$$$20250716$$CN$US$US
255261071$25526107$1$I$$20250704$20250707$20250707$EXP$$JP-BAYER-2025A088836$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$$Y$$$20250707$$MD$JP$JP
255261112$25526111$2$F$20250629$20250701$20250707$20250809$EXP$$CN-ASTRAZENECA-202507CHN000743CN$ALEXION PHARMACEUTICALS$$54$YR$A$F$Y$45$KG$20250809$$$CN$CN
255261211$25526121$1$I$20250619$20250626$20250707$20250707$PER$$US-BAYER-2025A085566$BAYER HEALTHCARE PHARMACEUTICALS INC.$$69$YR$E$M$Y$$$20250707$$HP$US$US
255261813$25526181$3$F$20250101$20250819$20250707$20250822$PER$$US-JNJFOC-20250704254$JOHNSON AND JOHNSON$$60$YR$A$M$Y$70.3$KG$20250822$$CN$US$US
255262493$25526249$3$F$20241126$20250812$20250707$20250814$EXP$$KR-PFIZER INC-202500132835$PFIZER$$1$YR$$M$Y$$$20250814$$PH$KR$KR
255263631$25526363$1$I$$20250705$20250707$20250707$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-095580$BRISTOL-MYERS SQUIBB COMPANY$$85$YR$E$M$Y$77.11$KG$20250707$$CN$US$US
255265192$25526519$2$F$20250102$20250819$20250707$20250821$EXP$$EU-SANDOZ INC.-SDZ2025DE047139$SANDOZ$$71$YR$$F$Y$51$KG$20250821$$HP$EU$EU
255265721$25526572$1$I$$20250702$20250707$20250707$PER$$US-MALLINCKRODT-MNK202504119$MALLINCKRODT$$$$$F$Y$$$20250704$$CN$US$US
255266621$25526662$1$I$$20250704$20250707$20250707$EXP$$CN-PFIZER INC-PV202500080306$PFIZER$$$$E$M$Y$$$20250707$$CN$CN$CN
255266712$25526671$2$F$$20250623$20250707$20250708$EXP$$US-PFM-2025-03105$PIERRE FABRE MEDICAMENT$Corda R, Chrisomalis-Dring S, Crook S, Shawber C.J, Wu J.K, Chai, P. J. Propranolol treatment for chylothorax after congenital cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery. 2022;163(5):1630-41$$$$$Y$3$KG$20250708$$$US$US
255269471$25526947$1$I$$20250704$20250707$20250707$PER$$US-ABBVIE-6359500$ABBVIE$$$$$F$Y$$$20250707$$HP$US$US
255269821$25526982$1$I$20250701$20250702$20250707$20250707$30DAY$$US-SANDOZ INC.-SDZ2025US046870$SANDOZ$$$$$F$Y$$$20250707$$CN$US$US
255269881$25526988$1$I$$20250703$20250708$20250708$EXP$$US-ABBVIE-6357720$ABBVIE$$$$E$F$Y$$$20250708$$CN$US$US
255269961$25526996$1$I$$20250630$20250708$20250708$EXP$$US-GSK-US2025081871$GLAXOSMITHKLINE$$$$$F$Y$$$20250708$$PH$US$US
255270051$25527005$1$I$$20250623$20250708$20250708$EXP$$EU-ABBVIE-6358754$ABBVIE$$84$YR$$M$Y$$$20250708$$CN$EU$EU
255270221$25527022$1$I$$20250703$20250708$20250708$EXP$$US-GSK-US2025AMR084059$GLAXOSMITHKLINE$$$$$F$Y$$$20250708$$$US$US
255270431$25527043$1$I$$20250703$20250708$20250708$EXP$$CA-ABBVIE-6358995$ABBVIE$$62$YR$$M$Y$$$20250708$$CN$CA$CA
255271781$25527178$1$I$20250505$20250519$20250708$20250708$PER$$US-TLM-TLM-2025-02054$TOLMAR$$45$YR$A$F$Y$66.2$KG$20250708$$HP$US$US
255271921$25527192$1$I$20250101$20250606$20250708$20250708$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-125165$ZYDUS PHARM$$$$$$Y$$$20250708$$CN$US$US
255272021$25527202$1$I$20241101$20250701$20250708$20250708$EXP$$US-ABBVIE-6354779$ABBVIE$$64$YR$$F$Y$$$20250708$$CN$US$US
255272933$25527293$3$F$20250101$20250908$20250708$20250912$EXP$$CA-ABBVIE-6359116$ABBVIE$$53$YR$$F$Y$$$20250912$$CN$CA$CA
255273331$25527333$1$I$$20250610$20250708$20250708$PER$$US-GSK-US2025AMR076333$GLAXOSMITHKLINE$$$$$F$Y$$$20250708$$$US$US
255273943$25527394$3$F$$20250815$20250708$20250822$EXP$$US-SMPA-2025SPA007657$SUNOVION$$68$YR$$M$Y$$$20250822$$$US$US
255274182$25527418$2$F$$20250707$20250708$20250710$EXP$$US-TAKEDA-2025TUS056487$TAKEDA$$$$$M$Y$$$20250710$$MD$US$US
255274501$25527450$1$I$20250601$20250625$20250708$20250708$EXP$CN-NMPA-3204021053296202500022$CN-NOVOPROD-1468759$NOVO NORDISK$$34$YR$$M$Y$$$20250708$$HP$CN$CN
255275012$25527501$2$F$20250624$20250714$20250708$20250723$EXP$$CN-NOVOPROD-1469761$NOVO NORDISK$$$$$F$Y$$$20250723$$CN$CN$CN
255275821$25527582$1$I$20250627$20250702$20250708$20250708$EXP$$US-KYOWAKIRIN-2025KK013156$KYOWA$$$$$$Y$$$20250708$$HP$US$US
255275841$25527584$1$I$20250518$20250626$20250708$20250708$EXP$EU-AEMPS-1695303$EU-Accord-493181$ACCORD$$78$YR$E$F$Y$$$20250708$$MD$EU$EU
255277391$25527739$1$I$20250703$20250703$20250708$20250708$EXP$$US-JNJFOC-20250706235$JOHNSON AND JOHNSON$$58$YR$A$F$Y$$$20250708$$HP$US$US
255277542$25527754$2$F$20250416$20250704$20250708$20250717$EXP$$EU-AUROBINDO-AUR-APL-2025-023449$AUROBINDO$$$$A$F$Y$$$20250717$$MD$EU$EU
255279021$25527902$1$I$20250604$20250701$20250708$20250708$EXP$$US-SANDOZ INC.-SDZ2025US040670$SANDOZ$$75$YR$$F$Y$$$20250708$$PH$US$US
255279122$25527912$2$F$20250605$20250729$20250708$20250730$PER$$NVSC2025US105598$NOVARTIS$$$$$F$Y$$$20250730$$HP$US$US
255280231$25528023$1$I$$20250102$20250708$20250708$PER$$US-STRIDES ARCOLAB LIMITED-2025SP000279$STRIDES$Mazhude T, Zahra T.. Refractory Hyperinsulinemic Hypoglycemia as a Complication of Roux-en-Y Gastric Bypass Surgery. Cureus. 2024;16(9):e69037$5$DEC$$F$Y$$$20250708$$HP$US$US
255280811$25528081$1$I$20201230$20250624$20250708$20250708$EXP$$EU-AUROBINDO-AUR-APL-2025-033436$AUROBINDO$$19$YR$$F$Y$47$KG$20250708$$MD$EU$EU
255280862$25528086$2$F$$20250729$20250708$20250806$PER$$US-UNITED THERAPEUTICS-UNT-2025-023251$UNITED THERAPEUTICS$$$$$F$Y$37.642$KG$20250806$$$US$US
255280981$25528098$1$I$$20250102$20250708$20250708$PER$$US-STRIDES ARCOLAB LIMITED-2025SP000283$STRIDES$Elfil M, Lookian PP, Kumari K, Aladawi M, Jedras M, Phillips SM et.al.. Reversible cerebral vasoconstriction syndrome due to teprotumumab: two case reports. Oxford Medical Case Reports. 2024;8:333-336$71$YR$$F$Y$$$20250708$$HP$US$US
255281481$25528148$1$I$$20250623$20250708$20250708$EXP$$CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-515250$RANBAXY$From  A, Dumont T, Singh S, Duigenan S, Flaxman T. Navigating Complexity: Advanced Visualization for M?llerian Anomalies and its implications for diagnoses and surgical planning. J Pediatr Adolesc Gynecol. 2025;19 Jun:21, Abs 33$15$YR$$F$Y$$$20250708$$HP$CA$CA
255282161$25528216$1$I$$20250630$20250708$20250708$EXP$$US-RIGEL-20250700014$RIGEL PHARMACEUTICALS$$$$$M$Y$$$20250708$$CN$US$US
255282361$25528236$1$I$$20250624$20250708$20250708$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-515280$RANBAXY$Matsubara D, Komatsu S, Konishi T, Ito S, Takeda R, Ogawa S, et al. Pancreaticopleural Fistula in a Patient with Metastatic Gastric Cancer. Gan To Kagaku Ryoho. 2025;52 (3):237-239$69$YR$$F$Y$$$20250708$$HP$JP$JP
255283111$25528311$1$I$20210726$20250623$20250708$20250708$EXP$$US-COOPERSURGICAL, INC.-2025CPS005225$COOPERSURGICAL$$39$YR$$F$Y$65.76$KG$20250708$$CN$US$US
255284051$25528405$1$I$20240901$20250630$20250708$20250708$PER$$US-ROCHE-10000327727$ROCHE$$36$YR$A$F$Y$74.84$KG$20250708$$CN$US$US
255284841$25528484$1$I$$20250630$20250708$20250708$EXP$$US-AMGEN-USASP2025129632$AMGEN$Jannat-khah D.; Reid P.; Suarez-almazor M. et al.. ORAL GLUCOCORTICOID TREATMENT FOR CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS DO NOT AFFECT PROGRESSION FREE SURVIVAL: A RADIOS REGISTRY COHORT STUDY DJKlTHE 5000 CHARACTERS FOR REGULAR SUBMISSIONS. Annals of the Rheumatic Diseases. 2025;84 (SUPPL_1):1290-1291$$$$$Y$$$20250708$$HP$US$US
255285461$25528546$1$I$20250331$20250701$20250708$20250708$EXP$$JP-ROCHE-10000331696$ROCHE$$58$YR$A$M$Y$71.2$KG$20250708$$MD$JP$JP
255286122$25528612$2$F$$20250707$20250708$20250709$PER$$US-ABBVIE-6360780$ABBVIE$$$$$$Y$$$20250709$$HP$US$US
255286472$25528647$2$F$$20250707$20250708$20250810$PER$$US-ASTRAZENECA-202507USA004170US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250810$$$US$US
255286871$25528687$1$I$20250702$20250703$20250708$20250708$EXP$$US-JNJFOC-20250706183$JOHNSON AND JOHNSON$$55$YR$A$F$Y$$$20250708$$HP$US$US
255287021$25528702$1$I$20250704$20250707$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507005926$ELI LILLY AND COMPANY$$58$YR$A$M$Y$$$20250708$$CN$US$US
255287061$25528706$1$I$$20250701$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507002133$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250708$$CN$US$US
255287331$25528733$1$I$20230901$20250707$20250708$20250708$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-081397$BOEHRINGER INGELHEIM$$88$YR$E$M$Y$$$20250708$$$US$US
255288103$25528810$3$F$20241012$20250724$20250708$20250804$EXP$$EU-AUROBINDO-AUR-APL-2025-033631$AUROBINDO$$72$YR$$M$Y$64$KG$20250804$$MD$EU$EU
255289141$25528914$1$I$$20250625$20250708$20250708$PER$$US-ROCHE-10000323267$ROCHE$$$$A$F$Y$$$20250708$$CN$US$US
255289291$25528929$1$I$20250601$20250630$20250708$20250708$PER$$US-ABBVIE-6355304$ABBVIE$$27$YR$$F$Y$$$20250708$$HP$US$US
255289381$25528938$1$I$20250629$20250707$20250707$20250707$DIR$763336$$FDA-CTU$$28$YR$$F$N$155.25$KG$20250707$N$CN$US$
255290341$25529034$1$I$$20250707$20250708$20250708$PER$$US-ABBVIE-6360669$ABBVIE$$$$$$Y$$$20250708$$CN$US$US
255291081$25529108$1$I$20250703$20250703$20250708$20250708$EXP$$IN-009507513-2304984$MERCK SHARP + DOHME LLC$$46$YR$$F$Y$$$20250708$$HP$IN$IN
255291331$25529133$1$I$20250527$20250701$20250708$20250708$EXP$$GB-MYLANLABS-2025M1055499$MYLAN$$$$$F$Y$$$20250704$$PH$GB$GB
255291343$25529134$3$F$20250616$20250714$20250708$20250718$EXP$$EU-MYLANLABS-2025M1051924$MYLAN$$$$$F$Y$$$20250718$$$EU$EU
255291462$25529146$2$F$$20250707$20250708$20250810$PER$$US-ASTRAZENECA-202507USA003191US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250810$$$US$US
255291991$25529199$1$I$20250626$20250626$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202506026121$ELI LILLY AND COMPANY$$$$$M$Y$$$20250708$$CN$US$US
255292741$25529274$1$I$20250401$20250707$20250708$20250708$PER$$US-BAYER-2025A089419$BAYER HEALTHCARE LLC$$64$YR$A$F$Y$$$20250708$$CN$US$US
255293731$25529373$1$I$20250614$20250707$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507006495$ELI LILLY AND COMPANY$$62$YR$A$F$Y$$$20250708$$CN$US$US
255294991$25529499$1$I$$20250706$20250708$20250708$EXP$$US-GSK-US2025AMR084740$GLAXOSMITHKLINE$$$$$F$Y$$$20250708$$$US$US
255295821$25529582$1$I$20240501$20250703$20250708$20250708$EXP$$EU-PFIZER INC-202500134409$PFIZER$$$$N$F$Y$2.4$KG$20250708$$MD$EU$EU
255297801$25529780$1$I$$20250626$20250708$20250708$EXP$GB-MHRA-MED-202506261059186610-YGRPH$GB-ELI_LILLY_AND_COMPANY-GB202506025770$ELI LILLY AND COMPANY$$34$YR$A$M$Y$84$KG$20250708$$CN$GB$GB
255298002$25529800$2$F$20250531$20250805$20250708$20250818$EXP$$EU-AUROBINDO-AUR-APL-2025-033408$AUROBINDO$$2$YR$$F$Y$13$KG$20250818$$CN$EU$EU
255298402$25529840$2$F$$20250716$20250708$20250722$EXP$$CA-AMGEN-CANSP2025132216$AMGEN$Carmona A.. LOW INCIDENCE OF NEONATALINFECTION WITH TNF AND NON-TNF BIOLOGIC DMARD USE IN THE SECOND AND THIRD TRIMESTERS OF PREGNANCY. Annals of the Rheumatic Diseases. 2025;84(Suppi 1):1631$$$$$Y$$$20250722$$HP$CA$CA
255298411$25529841$1$I$20250501$20250625$20250708$20250708$EXP$$GB-FDC-2025GBSPO00286$FDC LIMITED$$80$YR$E$M$Y$$$20250708$$CN$GB$GB
255298671$25529867$1$I$20250405$20250708$20250708$20250708$DIR$763470$$FDA-CTU$$79$YR$$F$N$59.4$KG$20250708$Y$CN$US$
255298991$25529899$1$I$$20250703$20250708$20250708$EXP$$EU-INCYTE CORPORATION-2025IN007367$INCYTE$$$$$$Y$$$20250708$$MD$EU$EU
255299291$25529929$1$I$$20250707$20250708$20250708$EXP$$CA-PFIZER INC-202500137173$PFIZER$$7$YR$$M$Y$$$20250708$$HP$CA$CA
255299722$25529972$2$F$20250617$20250711$20250708$20250805$PER$$US-MRZWEB-2025060000247$MERZ$$$$$$Y$$$20250805$$HP$US$US
255299772$25529977$2$F$$20250815$20250708$20250815$EXP$$CN-PFIZER INC-PV202500080322$PFIZER$$22$YR$$M$Y$$$20250815$$CN$CN$CN
255300881$25530088$1$I$20250101$20250630$20250708$20250708$EXP$$NVSC2025DE107624$NOVARTIS$$$$A$F$Y$$$20250708$$CN$EU$EU
255301111$25530111$1$I$$20250701$20250708$20250708$EXP$$US-TAKEDA-2025TUS060592$TAKEDA$$$$$F$Y$66.58$KG$20250708$$$US$US
255301411$25530141$1$I$20210101$20220404$20250708$20250708$EXP$$US-NOVOPROD-907348$NOVO NORDISK$$$$$F$Y$$$20250708$$CN$US$US
255301451$25530145$1$I$20250623$20250630$20250708$20250708$EXP$$EU-UCBSA-2025040545$UCB$$$$A$M$Y$$$20250708$$PH$EU$EU
255301761$25530176$1$I$$20250702$20250708$20250708$PER$$US-TAKEDA-2025TUS060675$TAKEDA$$$$$F$Y$81$KG$20250708$$$US$US
255302224$25530222$4$F$20250708$20250813$20250708$20250819$30DAY$$US-JNJFOC-20250708543$JOHNSON AND JOHNSON$$66$YR$E$M$Y$$$20250819$$PH$US$US
255303222$25530322$2$F$$20250710$20250708$20250713$PER$$US-SA-2025SA190074$SANOFI AVENTIS$$21$YR$A$M$Y$$$20250713$$HP$US$US
255303372$25530337$2$F$20250101$20250819$20250708$20250825$PER$$US-SA-2025SA185891$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250825$$HP$US$US
255303711$25530371$1$I$20250101$20250702$20250708$20250708$PER$$US-SA-2025SA190104$SANOFI AVENTIS$$7$YR$C$F$Y$27.211$KG$20250708$$HP$US$US
255303862$25530386$2$F$20250702$20250702$20250708$20250710$PER$$US-SA-2025SA189591$SANOFI AVENTIS$$27$YR$A$M$Y$$$20250710$$MD$US$US
255304031$25530403$1$I$$20250701$20250708$20250708$PER$$US-SA-2025SA191396$SANOFI AVENTIS$$14$YR$T$M$Y$$$20250708$$CN$US$US
255304422$25530442$2$F$$20250725$20250708$20250801$PER$$US-SA-2025SA190835$SANOFI AVENTIS$$$$A$F$Y$92.73$KG$20250801$$MD$US$US
255304881$25530488$1$I$20250101$20250703$20250708$20250708$PER$$US-SA-2025SA191225$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250708$$HP$US$US
255304921$25530492$1$I$$20250703$20250708$20250708$PER$$US-SA-2025SA190620$SANOFI AVENTIS$$$$A$F$Y$$$20250708$$HP$US$US
255305091$25530509$1$I$$20250703$20250708$20250708$PER$$US-SA-2025SA191532$SANOFI AVENTIS$$$$E$F$Y$$$20250708$$MD$US$US
255305362$25530536$2$F$20250101$20250821$20250708$20250829$PER$$US-SA-2025SA190621$SANOFI AVENTIS$$6$MON$I$M$Y$$$20250829$$HP$US$US
255306203$25530620$3$F$20220301$20250630$20250708$20250714$EXP$$JP-Eisai-EC-2022-112689$EISAI$$68$YR$E$F$Y$$$20250714$$MD$JP$JP
255306462$25530646$2$F$20250101$20250814$20250708$20250822$PER$$US-SA-2025SA192122$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250822$$MD$US$US
255306561$25530656$1$I$20241120$20250701$20250708$20250708$EXP$$KR-PFIZER INC-202500132827$PFIZER$$2$YR$$F$Y$$$20250708$$HP$KR$KR
255306611$25530661$1$I$$20250630$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507001182$ELI LILLY AND COMPANY$$58$YR$A$M$Y$$$20250708$$CN$US$US
255307872$25530787$2$F$20230619$20250722$20250708$20250728$PER$$US-VERTEX PHARMACEUTICALS-2025-011001$VERTEX$$12$YR$$F$Y$$$20250728$$MD$US$US
255308271$25530827$1$I$20250301$20250626$20250708$20250708$EXP$$GB-CIPLA (EU) LIMITED-2025GB08163$CIPLA$$$$$$Y$$$20250708$$CN$GB$GB
255308391$25530839$1$I$$20250702$20250708$20250708$EXP$EU-FAMHP-DHH-N2025-124871$EU-TEVA-VS-3349743$TEVA$$75$YR$$F$Y$$$20250708$$MD$EU$EU
255308891$25530889$1$I$$20250702$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507003858$ELI LILLY AND COMPANY$$62$YR$A$F$Y$$$20250708$$CN$US$US
255309661$25530966$1$I$$20250703$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507004294$ELI LILLY AND COMPANY$$54$YR$A$M$Y$$$20250708$$CN$US$US
255309834$25530983$4$F$20250601$20250718$20250708$20250724$30DAY$$AR-PFIZER INC-202500133826$PFIZER$$9$YR$$F$Y$$$20250724$$CN$AR$AR
255310062$25531006$2$F$20250101$20250828$20250708$20250909$PER$$US-TEVA-VS-3348911$TEVA$$$$$$Y$$$20250909$$CN$US$US
255310921$25531092$1$I$$20250708$20250708$20250708$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096139$BRISTOL-MYERS SQUIBB COMPANY$$61$YR$A$M$Y$$$20250708$$HP$US$US
255311571$25531157$1$I$$20250703$20250708$20250708$PER$$US-ELI_LILLY_AND_COMPANY-US202507005103$ELI LILLY AND COMPANY$$37$YR$A$$Y$$$20250708$$CN$US$US
255312732$25531273$2$F$20250101$20250823$20250708$20250831$EXP$$US-009507513-2300548$MERCK SHARP + DOHME LLC$$62$YR$$F$Y$$$20250831$$CN$US$US
255313192$25531319$2$F$$20250702$20250708$20250816$PER$$US-ASTRAZENECA-202507USA003889US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250816$$$US$US
255314331$25531433$1$I$20250101$20250707$20250708$20250708$EXP$$US-ABBVIE-6361149$ABBVIE$$76$YR$$F$Y$$$20250708$$CN$US$US
255314871$25531487$1$I$$20250708$20250708$20250708$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096331$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$F$Y$61.69$KG$20250709$$CN$US$US
255315663$25531566$3$F$20250101$20250723$20250709$20250729$EXP$$EU-ABBVIE-6302482$ABBVIE$$78$YR$$F$Y$$$20250729$$CN$EU$EU
255315771$25531577$1$I$20230104$20250703$20250709$20250709$EXP$$EU-AMGEN-ITASP2025132278$AMGEN$$76$YR$E$M$Y$$$20250708$$MD$EU$EU
255315821$25531582$1$I$$20250701$20250709$20250709$PER$$US-SA-2025SA191788$SANOFI AVENTIS$$78$YR$E$F$Y$$$20250709$$CN$US$US
255316281$25531628$1$I$20241120$20250707$20250709$20250709$PER$$US-ABBVIE-6360640$ABBVIE$$55$YR$$M$Y$$$20250709$$MD$US$US
255317421$25531742$1$I$$20250317$20250709$20250709$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ3081$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250709$$HP$US$US
255317613$25531761$3$F$20240101$20250715$20250709$20250720$EXP$$CA-Ipsen Biopharmaceuticals, Inc.-2025-01851$IPSEN BIOPHARMACEUTICALS, INC.$$76$YR$E$F$Y$$$20250720$$MD$CA$CA
255317892$25531789$2$F$$20250708$20250709$20250716$EXP$$EU-CELLTRION INC.-2025GR006852$CELLTRION$Tsafis, K.. D2T AxSpA How we proceed?. 4th PANHELLENIC SUMMER SYMPOSIUM ON MUSCULOSKELETAL HEALTH. 2024$$$$$Y$$$20250716$$MD$EU$EU
255317961$25531796$1$I$20230601$20250630$20250709$20250709$PER$$US-Ipsen Biopharmaceuticals, Inc.-2025-15940$IPSEN BIOPHARMACEUTICALS, INC.$$74$YR$E$F$Y$$$20250709$$$US$US
255318761$25531876$1$I$20250618$20250627$20250709$20250709$EXP$GB-MHRA-MED-202506271228028920-DTRZP$GB-ELI_LILLY_AND_COMPANY-GB202507001257$ELI LILLY AND COMPANY$$$$$F$Y$67$KG$20250709$$CN$GB$GB
255318951$25531895$1$I$$20250612$20250709$20250709$PER$$US-SMPA-2025SPA007562$SUNOVION$$$$$$Y$$$20250709$$CN$US$US
255319301$25531930$1$I$$20250409$20250709$20250709$PER$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-03337$HIKMA$$$$$F$Y$$$20250708$$CN$US$US
255319331$25531933$1$I$$20250704$20250709$20250709$EXP$$NVSJ2025JP007087$NOVARTIS$$$$$$Y$$$20250709$$PH$JP$JP
255319381$25531938$1$I$$20250421$20250709$20250709$PER$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-03736$HIKMA$$$$$F$Y$$$20250708$$CN$US$US
255320411$25532041$1$I$20250628$20250702$20250709$20250709$EXP$$US-UNITED THERAPEUTICS-UNT-2025-023325$UNITED THERAPEUTICS$$58$YR$$F$Y$61.224$KG$20250709$$$US$US
255321311$25532131$1$I$20250101$20250707$20250709$20250709$PER$$US-SA-2025SA192530$SANOFI AVENTIS$$46$YR$A$M$Y$$$20250709$$CN$US$US
255321531$25532153$1$I$$20250626$20250709$20250709$EXP$$US-APOTEX-2025AP009238$APOTEX$Walton H, Khan S. Interaction Between Oxcarbazepine and Long-Acting Aripiprazole Leading to Relapse of Bipolar Disorder. Primary Care Companion for CNS Disorders. 2025;27(2):24cr03877:1-2$45$YR$$F$Y$$$20250709$$MD$US$US
255321891$25532189$1$I$$20250629$20250709$20250709$PER$$US-GSK-US2025AMR081618$GLAXOSMITHKLINE$$$$$M$Y$$$20250709$$$US$US
255322202$25532220$2$F$$20250804$20250709$20250812$EXP$$BR-NOVOPROD-1469637$NOVO NORDISK$$66$YR$$F$Y$85$KG$20250812$$CN$BR$BR
255322671$25532267$1$I$20250516$20250630$20250709$20250709$EXP$EU-SEMPA-2025-004704$EU-NOVOPROD-1469165$NOVO NORDISK$$57$YR$$M$Y$76$KG$20250709$$MD$EU$EU
255323232$25532323$2$F$20250627$20250714$20250709$20250723$PER$$US-AVET LIFESCIENCES LTD-2025-AVET-000220$EMCURE PHARMACEUTICALS LTD$$$$$$Y$$$20250723$$CN$US$US
255323771$25532377$1$I$$20250630$20250709$20250709$EXP$$US-AMGEN-USASP2025131625$AMGEN$Jannat-khah D.; Reid P.; Suarez-almazor M. et al.. ORAL GLUCOCORTICOID TREATMENT FOR CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS DO NOT AFFECT PROGRESSION FREE SURVIVAL: A RADIOS REGISTRY COHORT STUDY DJKlTHE 5000 CHARACTERS FOR REGULAR SUBMISSIONS. Annals of the Rheumatic Diseases. 2025;84 (SUPPL_1):1290-1291$$$$$Y$$$20250709$$HP$US$US
255324031$25532403$1$I$$20250625$20250709$20250709$EXP$EU-LRB-01070095$EU-AUROBINDO-AUR-APL-2025-033588$AUROBINDO$$39$YR$$M$Y$80$KG$20250709$$CN$EU$EU
255324131$25532413$1$I$$20250612$20250709$20250709$PER$$US-SMPA-2025SPA007567$SUNOVION$$$$$$Y$$$20250709$$CN$US$US
255324901$25532490$1$I$$20250703$20250709$20250709$PER$$US-SA-2025SA192503$SANOFI AVENTIS$$78$YR$E$$Y$$$20250709$$CN$US$US
255325781$25532578$1$I$$20250630$20250709$20250709$EXP$$CN-BEIGENE-BGN-2025-010702$BEIGENE$$71$YR$$$Y$$$20250709$$$CN$CN
255325832$25532583$2$F$$20250704$20250709$20250816$PER$$US-ASTRAZENECA-202507USA004370US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250816$$$US$US
255326043$25532604$3$F$20240101$20250911$20250709$20250917$EXP$$EU-ABBVIE-6029238$ABBVIE$$74$YR$$M$Y$$$20250917$$CN$EU$EU
255326642$25532664$2$F$20250625$20250804$20250709$20250807$EXP$$EU-ASTELLAS-2025-AER-036627$ASTELLAS$$63$YR$A$F$Y$$$20250807$$MD$EU$EU
255326741$25532674$1$I$$20250629$20250709$20250709$PER$$US-P+L Developments of Newyork Corporation-2180160$PL DEVELOPMENTS$$$$$$Y$$$20250709$$$US$US
255326941$25532694$1$I$20250708$20250708$20250709$20250709$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096505$BRISTOL-MYERS SQUIBB COMPANY$$81$YR$E$F$Y$$$20250709$$HP$US$US
255327121$25532712$1$I$$20250707$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507006848$ELI LILLY AND COMPANY$$67$YR$E$M$Y$$$20250709$$CN$US$US
255327591$25532759$1$I$20250609$20250627$20250709$20250709$EXP$EU-MINISAL02-1045505$EU-HIKMA PHARMACEUTICALS-IT-H14001-25-08168$HIKMA$$89$YR$$F$Y$$$20250709$$MD$EU$EU
255328051$25532805$1$I$20250101$20250622$20250709$20250709$PER$$US-LUNDBECK-DKLU4016354$LUNDBECK$$44$YR$A$F$Y$$$20250709$$CN$US$US
255328065$25532806$5$F$20250101$20250813$20250709$20250826$EXP$$US-UNITED THERAPEUTICS-UNT-2025-023292$UNITED THERAPEUTICS$$$$$F$Y$82.993$KG$20250823$$$US$US
255328202$25532820$2$F$20240501$20250708$20250709$20250723$EXP$$EU-ASTRAZENECA-202507EEA004711RO$ALEXION PHARMACEUTICALS$$42$YR$A$M$Y$$$20250723$$MD$EU$EU
255328341$25532834$1$I$20250505$20250630$20250709$20250709$EXP$EU-AFSSAPS-TS2025000637$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-125765$ZYDUS PHARM$$$$$$Y$$$20250709$$MD$EU$EU
255329101$25532910$1$I$$20250625$20250709$20250709$EXP$$CA-APOTEX-2025AP009040$APOTEX$$$$$F$Y$$$20250709$$MD$CA$CA
255329162$25532916$2$F$20250621$20250724$20250709$20250731$30DAY$$CN-JNJFOC-20250631303$JOHNSON AND JOHNSON$$$$$$Y$$$20250731$$PH$CN$CN
255329361$25532936$1$I$20250602$20250702$20250709$20250709$PER$$US-ABBVIE-6355907$ABBVIE$$61$YR$$F$Y$$$20250709$$CN$US$US
255329601$25532960$1$I$$20250705$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507005902$ELI LILLY AND COMPANY$$$$$$Y$$$20250709$$CN$US$US
255329721$25532972$1$I$$20250707$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507006125$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250709$$CN$US$US
255329861$25532986$1$I$$20250709$20250709$20250709$EXP$$EU-JNJFOC-20250709755$JOHNSON AND JOHNSON$$$$I$$Y$$$20250709$$CN$EU$EU
255329941$25532994$1$I$$20250625$20250709$20250709$EXP$$US-AUROBINDO-AUR-APL-2023-042175$AUROBINDO$Comstock G, Kaiser S, Heard K, Wang GS. Significance of temperature in antimuscarinic toxicity: a case-control study. Clin-Toxicol-(Phila). 2022;60(9):1070-1072$$$$$Y$$$20250709$$HP$US$US
255330671$25533067$1$I$$20250624$20250709$20250709$EXP$$CH-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-515820$RANBAXY$Fischer A, Kloos S, Remde H, Dischinger U, Pamporaki C, Timmers HJLM, et al. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. Eur J Endocrinol. 2023;189 (5):546-565$$$$$Y$$$20250709$$HP$CH$CH
255331341$25533134$1$I$$20250626$20250709$20250709$EXP$$US-AUROBINDO-AUR-APL-2025-034153$AUROBINDO$Stewart D, Lee S, Patel T.. Turmeric-Warfarin Interaction Resulting in Supratherapeutic INR, Bleeding, and Hospitalization.. American Journal of Health-System Pharmacy.. 2025;82(Suppl 1):S2697.$54$YR$$F$Y$$$20250709$$HP$US$US
255332361$25533236$1$I$$20250626$20250709$20250709$EXP$$US-AUROBINDO-AUR-APL-2025-034145$AUROBINDO$Petmanson B, Sanchez K, Ritz L.. Clozapine-Induced Myocarditis: A Pharmacist-Driven Intervention. American Journal of Health-System Pharmacy.. 2025;82(Supplement 1:S487$35$YR$$M$Y$$$20250709$$PH$US$US
255333032$25533303$2$F$20231001$20250715$20250709$20250730$EXP$$US-CIPLA LTD.-2025US08097$CIPLA$$$$$$Y$$$20250730$$HP$US$US
255334091$25533409$1$I$$20250613$20250709$20250709$PER$$US-SMPA-2025SPA007677$SUNOVION$$$$$$Y$$$20250709$$CN$US$US
255334781$25533478$1$I$20250617$20250701$20250709$20250709$EXP$EU-AFSSAPS-GR2025000946$EU-TEVA-VS-3349085$TEVA$$18$YR$$M$Y$$$20250709$$MD$EU$EU
255334821$25533482$1$I$$20250707$20250709$20250709$PER$$EU-Blueprint Medicines Corporation-2025-AER-01466$BLUEPRINT MEDICINES$$$$$$Y$$$20250709$$CN$EU$EU
255335181$25533518$1$I$$20250707$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507006931$ELI LILLY AND COMPANY$$$$$$Y$$$20250709$$CN$US$US
255335352$25533535$2$F$20221015$20250716$20250709$20250721$EXP$$HN-BAYER-2025A089365$BAYER HEALTHCARE PHARMACEUTICALS INC.$$32$YR$A$F$Y$$$20250721$$CN$HN$HN
255335921$25533592$1$I$20250101$20250708$20250709$20250709$PER$$US-PFIZER INC-PV202500081888$PFIZER$$28$YR$$F$Y$$$20250709$$CN$US$US
255336392$25533639$2$F$20250101$20250708$20250709$20250710$EXP$$PR-ABBVIE-6362442$ABBVIE$$35$YR$$F$Y$83.914$KG$20250710$$CN$PR$US
255336891$25533689$1$I$20250624$20250703$20250709$20250709$EXP$$CO-REGENERON PHARMACEUTICALS, INC.-2025-109923$REGENERON$$$$$F$Y$$$20250709$$HP$CO$CO
255337231$25533723$1$I$$20250703$20250709$20250709$PER$$US-SA-2025SA192261$SANOFI AVENTIS$$$$A$F$Y$$$20250709$$MD$US$US
255337331$25533733$1$I$$20250703$20250709$20250709$PER$$US-SA-2025SA192700$SANOFI AVENTIS$$$$C$F$Y$88.18$KG$20250709$$HP$US$US
255337361$25533736$1$I$$20250703$20250709$20250709$PER$$US-SA-2025SA192637$SANOFI AVENTIS$$58$YR$A$$Y$$$20250709$$CN$US$US
255337841$25533784$1$I$$20250707$20250709$20250709$PER$$US-SA-2025SA192436$SANOFI AVENTIS$$67$YR$E$F$Y$$$20250709$$CN$US$US
255338431$25533843$1$I$$20250701$20250709$20250709$EXP$$CA-BIOCON BIOLOGICS LIMITED-BBL2025003522$BIOCON$$$$$$Y$$$20250709$$CN$CA$CA
255338792$25533879$2$F$$20250710$20250709$20250716$EXP$GB-MHRA-MED-202506301546191090-BFTPW$GB-PERRIGO-25GB008168$GALPHARM INTERNATIONAL$$59$YR$$$Y$$$20250716$$CN$GB$GB
255339691$25533969$1$I$$20250707$20250709$20250709$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096144$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$82.1$KG$20250709$$CN$US$US
255340131$25534013$1$I$20250601$20250708$20250708$20250708$DIR$763554$$FDA-CTU$$64$YR$$F$N$126$KG$20250708$Y$CN$US$
255340421$25534042$1$I$$20250703$20250709$20250709$EXP$$CA-TEVA-VS-3349475$TEVA$$80$YR$$M$Y$$$20250709$$HP$CA$CA
255340891$25534089$1$I$20250623$20250702$20250709$20250709$EXP$$CN-009507513-2303934$MERCK SHARP + DOHME LLC$$92$YR$$F$Y$$$20250709$$HP$CN$CN
255341401$25534140$1$I$$20250605$20250709$20250709$EXP$$CN-ROCHE-10000331747$ROCHE$$80$YR$E$M$Y$$$20250709$$CN$CN$CN
255341761$25534176$1$I$$20250626$20250709$20250709$EXP$$EU-AUROBINDO-AUR-APL-2025-033887$AUROBINDO$Castelli B, Fonte C, Tellini M, Di Nicola M, Guidi M, Giunti L,Tirinnanzi B, Marzano C, Buccoliero AM, D^Incerti L, Giordano F, Scagnet M, Tintori V, Genitori L, Sardi I et al... Gemcitabine-oxaliplatin as a bridge therapy toward autologous hematopoietic stem cell transplantation in infant-type brain tumors... Frontiers in Oncology.. 2025;15: 1476411:1-7.$24$MON$$F$Y$$$20250709$$MD$EU$EU
255342061$25534206$1$I$$20250630$20250709$20250709$EXP$$US-AMGEN-USASP2025131709$AMGEN$Noss E.; Ling I.; Marciniak S. et al.. SAFETY, TOLERABILITY, AND ACTIVITY OF JNJ-67484703 IN PARTICIPANTS WITH ACTIVE RBEUMATOID ARTERITIS: RESULTS OF A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTIPLE-DOSE PHASE 1B STUDY. Annals of the Rheumatic Diseases. 2025;84 (SUPPL_1):794-795$$$$$Y$$$20250709$$HP$US$US
255342091$25534209$1$I$$20250626$20250709$20250709$EXP$$US-AUROBINDO-AUR-APL-2025-034138$AUROBINDO$Adair AK, Spishock S.. Prolonged Discrepancy in Methotrexate Level Assays After Glucarpidase Administration. American Journal of Health-System Pharmacy. 2025;82(Supplement1:S2506$15$YR$$F$Y$$$20250709$$HP$US$US
255342273$25534227$3$F$$20250831$20250709$20250902$30DAY$$CO-PFIZER INC-202500134623$PFIZER$$$$C$M$Y$$$20250902$$CN$CO$CO
255342311$25534231$1$I$$20250707$20250709$20250709$EXP$$US-SA-2025SA191940$SANOFI AVENTIS$$72$YR$E$M$Y$$$20250709$$CN$US$US
255344461$25534446$1$I$$20250702$20250709$20250709$EXP$GB-MHRA-TPP30407792C10709288YC1751360012070$GB-TORRENT-00041834$TORRENT PHARMA INC.$$60$YR$A$F$Y$65$KG$20250709$$PH$GB$GB
255344492$25534449$2$F$20250630$20250707$20250709$20250714$EXP$$GB-UCBSA-2025040219$UCB$$32$YR$$F$Y$$$20250714$$CN$GB$GB
255345711$25534571$1$I$$20250702$20250709$20250709$EXP$$CA-VER-202500137$VERITY PHARMACEUTICALS INC.$$81$YR$E$M$Y$$$20250709$$CN$CA$CA
255346531$25534653$1$I$20250326$20250708$20250709$20250709$EXP$EU-AFSSAPS-PP2025000688$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-096463$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$F$Y$56.8$KG$20250709$$MD$EU$EU
255347031$25534703$1$I$$20250707$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507006343$ELI LILLY AND COMPANY$$$$$F$Y$$$20250709$$CN$US$US
255349211$25534921$1$I$20210601$20250708$20250709$20250709$EXP$EU-AFSSAPS-AVBX20220108$EU-SANDOZ INC.-NVSC2022FR064567$SANDOZ$$81$YR$$M$Y$$$20250709$$PH$EU$EU
255350081$25535008$1$I$$20250702$20250709$20250709$PER$$US-ABBVIE-6363338$ABBVIE$$$$$$Y$$$20250709$$CN$US$US
255350091$25535009$1$I$$20250704$20250709$20250709$EXP$$EU-AMGEN-ITASP2025133240$AMGEN$Locatelli F.; Bufalo F.D.; Becilli M. et.al.. Point-of-Care, Fresh CAR T Cells for Pediatric/Young Adults First, Very High-Risk Relapse or Relapsed/Refractory BCP-ALL. Blood Advances. 2025;1-29$$$$$Y$$$20250709$$HP$EU$EU
255350192$25535019$2$F$$20250707$20250709$20250809$EXP$$US-ASTRAZENECA-202507USA004855US$ALEXION PHARMACEUTICALS$$$$E$$Y$$$20250809$$$US$US
255351241$25535124$1$I$$20250514$20250709$20250709$PER$$US-BIOCRYST PHARMACEUTICALS, INC.-2025BCR00638$BIOCRYST PHARMACEUTICALS$$$$$$Y$$$20250709$$CN$US$US
255351531$25535153$1$I$$20250708$20250709$20250709$DIR$FDA-CDER-CTU-2025-45227$$FDA-CTU$$$$$M$N$$$20250708$N$CN$US$
255351762$25535176$2$F$$20250725$20250709$20250730$EXP$$CA-SANDOZ INC.-SDZ2025CA047850$SANDOZ$$78$YR$$F$Y$$$20250730$$HP$CA$CA
255351841$25535184$1$I$20250101$20250604$20250709$20250709$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ6813$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250709$$CN$US$US
255351971$25535197$1$I$20250101$20250604$20250709$20250709$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ6846$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250709$$CN$US$US
255353251$25535325$1$I$$20250609$20250709$20250709$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000705$DECIPHERA PHARMACEUTICALS$$66$YR$A$M$Y$$$20250709$$CN$US$US
255353301$25535330$1$I$20250601$20250704$20250709$20250709$EXP$$TW-DSJP-DS-2025-151472-TW$DAIICHI$$88$YR$$F$Y$67$KG$20250709$$PH$TW$TW
255353381$25535338$1$I$$20250709$20250709$20250709$DIR$FDA-CDER-CTU-2025-45231$$FDA-CTU$$21$YR$$F$N$$$20250709$N$$US$
255355001$25535500$1$I$20250502$20250502$20250709$20250709$PER$$US-BOTANIX PHARMACEUTICALS-2025BOT00140$BOTANIX PHARMACEUTICALS$$17$YR$$M$Y$$$20250709$$CN$US$US
255355041$25535504$1$I$$20250508$20250709$20250709$PER$$US-BOTANIX PHARMACEUTICALS-2025BOT00161$BOTANIX PHARMACEUTICALS$$$$$F$Y$$$20250709$$CN$US$US
255355251$25535525$1$I$20250408$20250416$20250709$20250709$PER$$US-BOTANIX PHARMACEUTICALS-2025BOT00100$BOTANIX PHARMACEUTICALS$$$$$$Y$$$20250709$$HP$US$US
255355271$25535527$1$I$$20250418$20250709$20250709$PER$$US-BOTANIX PHARMACEUTICALS-2025BOT00109$BOTANIX PHARMACEUTICALS$$$$$F$Y$$$20250709$$CN$US$US
255355471$25535547$1$I$$20250610$20250709$20250709$PER$$US-BOTANIX PHARMACEUTICALS-2025BOT00194$BOTANIX PHARMACEUTICALS$$$$$$Y$$$20250709$$HP$US$US
255356231$25535623$1$I$$20250701$20250709$20250709$EXP$$US-ALNYLAM PHARMACEUTICALS, INC.-ALN-2025-004208$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20250709$$CN$US$US
255356651$25535665$1$I$20250703$20250705$20250709$20250709$PER$$US-MTPC-MTPA2025-0012520$Unknown Manufacturer$$$$A$M$Y$$$20250709$$CN$US$US
255357441$25535744$1$I$20250611$20250708$20250709$20250709$EXP$$CL-PFIZER INC-PV202500081731$PFIZER$$50$YR$$F$Y$$$20250709$$CN$CL$CL
255357502$25535750$2$F$$20250704$20250709$20250716$EXP$$CA-PFIZER INC-202500137121$PFIZER$$78$YR$$F$Y$$$20250716$$HP$CA$CA
255357521$25535752$1$I$20250614$20250708$20250709$20250709$EXP$$CL-PFIZER INC-PV202500081744$PFIZER$$47$YR$$F$Y$$$20250709$$CN$CL$CL
255357841$25535784$1$I$$20250704$20250709$20250709$EXP$$GB-TAKEDA-2025TUS061968$TAKEDA$$$$$F$Y$$$20250709$$$GB$GB
255358341$25535834$1$I$$20250708$20250709$20250709$PER$$US-PFIZER INC-202500138890$PFIZER$$15$YR$$F$Y$$$20250709$$HP$US$US
255358952$25535895$2$F$20250101$20250723$20250709$20250729$EXP$$US-ABBVIE-6362427$ABBVIE$$66$YR$$F$Y$$$20250728$$CN$US$US
255359161$25535916$1$I$20250601$20250708$20250709$20250709$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096661$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$F$Y$68.49$KG$20250709$$CN$US$US
255359671$25535967$1$I$$20250703$20250709$20250709$EXP$$CA-TEVA-VS-3349209$TEVA$$$$$$Y$$$20250709$$HP$CA$CA
255359701$25535970$1$I$$20250707$20250709$20250709$PER$$US-SA-2025SA192772$SANOFI AVENTIS$$59$YR$A$M$Y$$$20250709$$CN$US$US
255359811$25535981$1$I$$20250625$20250709$20250709$PER$$US-Calliditas-2025CAL01903$CALLIDITAS THERAPEUTICS AB$$69$YR$E$F$Y$$$20250709$$CN$US$US
255360173$25536017$3$F$$20250723$20250709$20250822$EXP$$US-GILEAD-2025-0719906$GILEAD$$70$YR$E$M$Y$$$20250822$$MD$US$US
255360321$25536032$1$I$20250101$20250331$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT004851$TG THERAPEUTICS$$$$$$Y$$$20250709$$HP$US$US
255361431$25536143$1$I$20250320$20250424$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT004992$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255361451$25536145$1$I$20250415$20250424$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT004995$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255361752$25536175$2$F$20250303$20250708$20250709$20250710$PER$$NVSC2025US109439$NOVARTIS$$60$YR$$F$Y$$$20250710$$HP$US$US
255361891$25536189$1$I$20250401$20250506$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005054$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255361901$25536190$1$I$20240412$20250505$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005050$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255361921$25536192$1$I$20240101$20250608$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005055$TG THERAPEUTICS$$$$$$Y$$$20250709$$MD$US$US
255362541$25536254$1$I$$20250522$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005185$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255362571$25536257$1$I$$20250708$20250709$20250709$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096560$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$M$Y$$$20250709$$CN$US$US
255363421$25536342$1$I$20250526$20250616$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005343$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255363791$25536379$1$I$20250214$20250617$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005348$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255363901$25536390$1$I$$20241126$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005413$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255363931$25536393$1$I$$20250619$20250709$20250709$PER$$US-TG THERAPEUTICS INC.-TGT005402$TG THERAPEUTICS$$$$$$Y$$$20250709$$CN$US$US
255365081$25536508$1$I$20250707$20250707$20250709$20250709$PER$$US-BIOGEN-2025BI01316500$BIOGEN$$$$$M$Y$$$20250709$$CN$US$US
255365371$25536537$1$I$$20250708$20250709$20250709$PER$$US-ELI_LILLY_AND_COMPANY-US202507007987$ELI LILLY AND COMPANY$$59$YR$A$M$Y$$$20250709$$CN$US$US
255366611$25536661$1$I$20250701$20250708$20250709$20250709$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-096376$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$$$20250710$$PH$US$US
255366921$25536692$1$I$$20250701$20250709$20250709$EXP$$EU-NOVITIUMPHARMA-2025ESNVP01550$NOVITIUM PHARMA$Xabier Larrea Urtaran.Patient with allergy to first-line anti-tuberculosis drugs.Revista Espanola de Quimioterapia.23-FEB-2024;37 (2):196-198$60$YR$A$F$Y$$$20250710$$HP$EU$EU
255368783$25536878$3$F$20250702$20250724$20250710$20250729$EXP$$JP-TAKEDA-2025TJP006825$TAKEDA$$5$DEC$$M$Y$$$20250729$$MD$JP$JP
255369931$25536993$1$I$$20250707$20250710$20250710$EXP$$EU-AMGEN-ESPNI2025133569$AMGEN$$$$E$F$Y$53$KG$20250709$$MD$EU$EU
255370361$25537036$1$I$20250621$20250628$20250710$20250710$EXP$$CN-KENVUE-20250700446$Kenvue$$$$$$Y$$$20250710$$HP$CN$CN
255370772$25537077$2$F$$20250819$20250710$20250826$EXP$$US-SMPA-2025SPA007709$SUNOVION$$73$YR$$M$Y$$$20250825$$$US$US
255370801$25537080$1$I$$20250616$20250710$20250710$PER$$US-SMPA-2025SPA007713$SUNOVION$$$$$$Y$$$20250710$$CN$US$US
255370911$25537091$1$I$20250101$20250701$20250710$20250710$PER$$US-TEVA-VS-3350301$TEVA$$77$YR$$F$Y$$$20250710$$CN$US$US
255371181$25537118$1$I$$20250703$20250710$20250710$EXP$$US-GSK-US2025AMR085395$GLAXOSMITHKLINE$$$$$F$Y$$$20250710$$$US$US
255371251$25537125$1$I$$20250421$20250710$20250710$PER$$US-STALCOR-2025-AER-01187$STALLERGENES$$$$T$F$Y$$$20250710$$CN$US$US
255371341$25537134$1$I$$20250707$20250710$20250710$PER$$US-ELI_LILLY_AND_COMPANY-US202507006328$ELI LILLY AND COMPANY$$$$$$Y$$$20250710$$MD$US$US
255371871$25537187$1$I$$20250628$20250710$20250710$EXP$$CA-TLM-TLM-2025-04335$TOLMAR$$79$YR$E$M$Y$$$20250708$$CN$CA$CA
255371921$25537192$1$I$20250619$20250702$20250710$20250710$PER$$US-009507513-2303705$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250710$$HP$US$US
255373321$25537332$1$I$$20250630$20250710$20250710$EXP$CA-HEALTHCANVIG-E2B_07068129$CA-NOVOPROD-1472589$NOVO NORDISK$$48$YR$$F$Y$$$20250710$$CN$CA$CA
255374332$25537433$2$F$20250623$20250923$20250710$20250927$EXP$$GB-Ipsen Biopharmaceuticals, Inc.-2025-15952$IPSEN BIOPHARMACEUTICALS, INC.$$74$YR$E$F$Y$$$20250927$$$GB$GB
255374461$25537446$1$I$$20250618$20250710$20250710$EXP$$US-GSK-US2025076526$GLAXOSMITHKLINE$$$$$M$Y$$$20250710$$$US$US
255374701$25537470$1$I$$20250704$20250710$20250710$EXP$$CN-PANGEAPHARMA-2025PAN00008$Pangea Pharmaceuticals$Yin G, Li Z, Zhang S, Wang X, Yang J, Cai H, et al.Analysis of the Efficacy and Safety of Intratymapanic Dexamethasone for Treating Meniere^s Disease: A Randomized Controlled Trial..Ear, Nose + Throat Journal.JUL-2025;104 (7):431-437$$$$M$Y$$$20250710$$MD$CN$CN
255375963$25537596$3$F$20250101$20250829$20250710$20250904$EXP$$JP-AMGEN-JPNSP2025135602$AMGEN$$83$YR$E$F$Y$56.3$KG$20250904$$MD$JP$JP
255376131$25537613$1$I$$20250626$20250710$20250710$EXP$$CN-Nexus Pharma-000428$NEXUS PHARMACEUTICALS$Ouyang L, Zhang W, Wang Z. Target bronchus determination in giant emphysematous bullae: A case report. Medicine (Baltimore). 2025 Jun 20;104(25):e43003. doi: 10.1097/MD.0000000000043003$67$YR$E$M$Y$$$20250710$$HP$CN$CN
255376671$25537667$1$I$$20250630$20250710$20250710$EXP$$US-TEVA-VS-3348186$TEVA$$$$$$Y$$$20250710$$HP$US$US
255376811$25537681$1$I$$20250708$20250710$20250710$EXP$$EU-TAKEDA-2025TUS048685$TAKEDA$Dziwak J. Ciezka polineuropatia czuciowo-ruchowa w przebiegu eozynofilowej ziarniniakowatosci z zapaleniem naczyn-opis przypadku. Polski Przeglad Neurologiczny. 2025;1:35-42. doi:10.5603/ppn.102241$72$YR$$F$Y$$$20250710$$MD$EU$EU
255377841$25537784$1$I$$20250702$20250710$20250710$EXP$$EU-JNJFOC-20250705396$JOHNSON AND JOHNSON$$$$$M$Y$$$20250710$$MD$EU$EU
255378001$25537800$1$I$20230117$20230420$20250710$20250710$EXP$$CO-ASTELLAS-2023US007806$ASTELLAS$$29$YR$A$F$Y$57$KG$20250710$$CN$CO$CO
255378031$25537803$1$I$$20250703$20250710$20250710$PER$$US-ROCHE-10000330346$ROCHE$$$$A$F$Y$$$20250710$$CN$US$US
255378561$25537856$1$I$$20250702$20250710$20250710$PER$$US-ELI_LILLY_AND_COMPANY-US202507004504$ELI LILLY AND COMPANY$$47$YR$A$M$Y$$$20250710$$CN$US$US
255378892$25537889$2$F$$20250705$20250710$20250809$EXP$$IN-ASTRAZENECA-202507IND003015IN$ALEXION PHARMACEUTICALS$$51$YR$A$F$Y$68$KG$20250809$$$IN$IN
255379061$25537906$1$I$$20250709$20250710$20250710$EXP$$IN-ROCHE-10000333914$ROCHE$$48$YR$A$F$Y$$$20250710$$CN$IN$IN
255379301$25537930$1$I$$20250630$20250710$20250710$EXP$$IN-LUPIN PHARMACEUTICALS INC.-2025-05814$LUPIN$Anand AB, Parimoo A, Sabnis GR. Electrocardiogram challenge: Mechanisms of arrhythmogenesis in patients with drug-induced long QT. Heart Rhythm Case Reports. 2024;10(12):967-970$22$YR$$$Y$$$20250710$$MD$IN$IN
255379312$25537931$2$F$20250625$20250625$20250710$20250721$PER$$US-CSL-2025-003690$CSL Plasma$$31$YR$$F$Y$$$20250721$$HP$US$US
255379431$25537943$1$I$$20250709$20250710$20250710$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-082137$BOEHRINGER INGELHEIM$$82$YR$E$F$Y$$$20250710$$$US$US
255379791$25537979$1$I$20250301$20250627$20250710$20250710$EXP$GB-MHRA-MED-202506251623181940-MGPBS$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-07068$ALKEM$$56$YR$$M$Y$81$KG$20250710$$CN$GB$GB
255379802$25537980$2$F$$20250821$20250710$20250904$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-07051$ALKEM$$35$YR$$M$Y$$$20250904$$CN$EU$EU
255380321$25538032$1$I$$20250705$20250710$20250710$PER$$US-ROCHE-10000331478$ROCHE$$$$A$F$Y$$$20250710$$CN$US$US
255380901$25538090$1$I$$20250707$20250710$20250710$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05964$LUPIN$$77$YR$$$Y$99.773$KG$20250710$$$US$US
255381241$25538124$1$I$20250620$20250627$20250710$20250710$EXP$$GB-AUROBINDO-AUR-APL-2025-034129$AUROBINDO$$44$YR$$F$Y$6$KG$20250710$$CN$GB$GB
255381971$25538197$1$I$$20250625$20250710$20250710$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-515986$RANBAXY$Eifer M, Sutherland DEK, Goncalves I, Buteau JP, Au L, Azad AA, et al. Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series. j nucl med. 2025;66 (4):579-584$65$YR$$M$Y$$$20250710$$HP$AU$AU
255382372$25538237$2$F$$20250723$20250710$20250801$PER$$US-SMPA-2025SPA007803$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
255382601$25538260$1$I$20250612$20250707$20250710$20250710$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008086$ACADIA PHARMACEUTICALS$$78$YR$$M$Y$$$20250710$$CN$US$US
255382851$25538285$1$I$$20250703$20250710$20250710$EXP$$JP-GSK-JP2025086737$GLAXOSMITHKLINE$$$$A$F$Y$$$20250710$$MD$JP$JP
255382961$25538296$1$I$20250615$20250708$20250710$20250710$PER$$US-ELI_LILLY_AND_COMPANY-US202507007792$ELI LILLY AND COMPANY$$37$YR$A$M$Y$$$20250710$$CN$US$US
255383341$25538334$1$I$$20250617$20250710$20250710$PER$$US-SMPA-2025SPA007852$SUNOVION$$$$$$Y$$$20250710$$CN$US$US
255383531$25538353$1$I$$20250617$20250710$20250710$PER$$US-SMPA-2025SPA007871$SUNOVION$$$$$$Y$$$20250710$$CN$US$US
255383811$25538381$1$I$20240511$20250702$20250710$20250710$EXP$EU-MINISAL02-1027830$EU-CELLTRION INC.-2025IT021689$CELLTRION$$$$$$Y$$$20250710$$MD$EU$EU
255384171$25538417$1$I$20250515$20250702$20250710$20250710$PER$$US-VIIV HEALTHCARE-US2025083892$VIIV$$33$YR$$M$Y$$$20250710$$MD$US$US
255384501$25538450$1$I$20250119$20250627$20250710$20250710$EXP$$EU-AUROBINDO-AUR-APL-2025-034187$AUROBINDO$$40$YR$$M$Y$76$KG$20250710$$MD$EU$EU
255386221$25538622$1$I$$20250630$20250710$20250710$EXP$$EU-AMGEN-PRTSP2025132694$AMGEN$Pinto Oliveira C.; Vilafanha C.; Barcelos A. et al.. DRUG-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED WITH TUMOR NECROSIS FACTOR-ALPHA INHIBITORS: A RETROSPECTIVE STUDY USING REAL-WORLD DATA FROM THE EUDRAVIGILANCE DATABASE. Annals of the Rheumatic Diseases. 2025;84 (SUPPL_1):643-644$$$$$Y$$$20250710$$HP$EU$EU
255386532$25538653$2$F$20230301$20250715$20250710$20250722$PER$$US-SA-2025SA190734$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250722$$HP$US$US
255386822$25538682$2$F$$20250708$20250710$20250715$PER$$US-SA-2025SA193543$SANOFI AVENTIS$$84$YR$E$F$Y$$$20250715$$CN$US$US
255386891$25538689$1$I$$20250707$20250710$20250710$PER$$US-SA-2025SA193360$SANOFI AVENTIS$$$$T$F$Y$57$KG$20250710$$HP$US$US
255387022$25538702$2$F$20250101$20250812$20250710$20250818$PER$$US-SA-2025SA192525$SANOFI AVENTIS$$57$YR$A$M$Y$$$20250818$$MD$US$US
255387882$25538788$2$F$20250707$20250903$20250710$20250908$PER$$US-SA-2025SA194672$SANOFI AVENTIS$$67$YR$E$F$Y$108.84$KG$20250908$$MD$US$US
255389222$25538922$2$F$$20250721$20250710$20250722$EXP$EU-LRB-01070529$EU-009507513-2303443$MERCK SHARP + DOHME LLC$$7$YR$$M$Y$23$KG$20250722$$CN$EU$EU
255389603$25538960$3$F$20250702$20250814$20250710$20250815$30DAY$$US-PFIZER INC-202500134104$PFIZER$$14$YR$$F$Y$45.36$KG$20250815$$HP$US$US
255390101$25539010$1$I$$20250708$20250710$20250710$PER$$US-SA-2025SA193948$SANOFI AVENTIS$$71$YR$E$F$Y$$$20250710$$MD$US$US
255390662$25539066$2$F$$20250704$20250710$20250810$EXP$$BR-ASTRAZENECA-202507SAM002740BR$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250810$$$BR$BR
255390911$25539091$1$I$$20250703$20250710$20250710$EXP$GB-MHRA-MIDB-6f588753-440d-4edc-a92f-30b8f2243141$GB-TORRENT-00041811$TORRENT PHARMA INC.$$67$YR$E$F$Y$$$20250710$$PH$GB$GB
255390951$25539095$1$I$$20250702$20250710$20250710$EXP$$US-TORRENT-00014400$TORRENT PHARMA INC.$$49$YR$A$M$Y$$$20250710$$HP$US$US
255391891$25539189$1$I$20250701$20250701$20250710$20250710$EXP$$PH-ABBVIE-6362996$ABBVIE$$24$YR$$F$Y$$$20250710$$CN$PH$PH
255392061$25539206$1$I$$20250707$20250710$20250710$PER$$US-ELI_LILLY_AND_COMPANY-US202507007582$ELI LILLY AND COMPANY$$$$$F$Y$$$20250710$$CN$US$US
255392751$25539275$1$I$20250707$20250707$20250710$20250710$EXP$$US-BAYER-2025A090609$BAYER HEALTHCARE PHARMACEUTICALS INC.$$85$YR$E$M$Y$$$20250710$$CN$US$US
255393681$25539368$1$I$$20250707$20250710$20250710$EXP$$CA-NORDICGR-063175$NORDIC PHARMA$$73$YR$$M$Y$109$KG$20250710$$HP$CA$CA
255393821$25539382$1$I$20250101$20250707$20250710$20250710$PER$$US-AMGEN-USASP2025134157$AMGEN$$65$YR$E$M$Y$$$20250710$$CN$US$US
255393923$25539392$3$F$$20250807$20250710$20250819$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-05774$LUPIN$$74$YR$$$Y$69.388$KG$20250819$$$US$US
255394161$25539416$1$I$$20250709$20250710$20250710$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-097060$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$F$Y$$$20250710$$CN$US$US
255395301$25539530$1$I$20250625$20250630$20250710$20250710$EXP$GB-MHRA-MED-202506301607568830-VHLWJ$GB-ELI_LILLY_AND_COMPANY-GB202507001232$ELI LILLY AND COMPANY$$28$YR$A$F$Y$84$KG$20250709$$CN$GB$GB
255396121$25539612$1$I$$20250704$20250710$20250710$EXP$$BR-SANDOZ INC.-SDZ2025BR048075$SANDOZ$$$$$M$Y$$$20250710$$CN$BR$BR
255396163$25539616$3$F$$20250826$20250710$20250829$EXP$$GB-TEVA-VS-3350790$TEVA$$56$YR$$F$Y$85$KG$20250829$$MD$GB$GB
255398012$25539801$2$F$20250101$20250708$20250710$20250711$EXP$$US-SA-2025SA193421$SANOFI AVENTIS$$36$YR$A$F$Y$$$20250711$$HP$US$US
255399521$25539952$1$I$$20250626$20250710$20250710$PER$$US-LUNDBECK-DKLU4016480$LUNDBECK$$19$YR$A$F$Y$$$20250710$$CN$US$US
255400281$25540028$1$I$20250327$20250331$20250710$20250710$PER$$US-THEA-2025000849$Thea Pharma$$61$YR$$F$Y$$$20250710$$CN$US$US
255401901$25540190$1$I$$20250710$20250710$20250710$DIR$763966$$FDA-CTU$$$$$$N$$$20250710$N$CN$US$
255402711$25540271$1$I$20250502$20250709$20250710$20250710$EXP$$MA-PFIZER INC-202500139037$PFIZER$$$$$M$Y$$$20250710$$CN$MA$MA
255402881$25540288$1$I$$20250703$20250710$20250710$PER$$US-SA-2025SA192055$SANOFI AVENTIS$$$$T$M$Y$$$20250710$$HP$US$US
255405041$25540504$1$I$$20250704$20250710$20250710$EXP$$EU-ABBVIE-6363049$ABBVIE$Wang D, Vela Serrano D, Camacho-Arteaga L. Concurrent interstitial pneumonia and acute hepatitis induced by mesalazine. BMJ case reports. 2025;18(7).doi:10.1136/bcr-2025-266199$$$E$M$Y$$$20250710$$MD$EU$EU
255405221$25540522$1$I$20250709$20250709$20250709$20250709$DIR$FDA-CDER-CTU-2025-45618$$FDA-CTU$$66$YR$$M$N$85.4$KG$20250709$N$PH$US$
255405432$25540543$2$F$$20250825$20250710$20250930$PER$$US-TRAVERE-2025TVT01032$TRAVERE THERAPEUTICS$$$$$M$Y$$$20250930$$CN$US$US
255405921$25540592$1$I$$20250507$20250710$20250710$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ4858$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250710$$MD$US$US
255406832$25540683$2$F$20240926$20250725$20250710$20250804$EXP$EU-AFSSAPS-PC2025000528$EU-ELI_LILLY_AND_COMPANY-FR202507006856$ELI LILLY AND COMPANY$$51$YR$A$M$Y$86.5$KG$20250804$$CN$EU$EU
255408721$25540872$1$I$20250703$20250708$20250710$20250710$PER$$US-ELI_LILLY_AND_COMPANY-US202507008217$ELI LILLY AND COMPANY$$$$$M$Y$$$20250710$$CN$US$US
255409551$25540955$1$I$$20250710$20250710$20250710$DIR$FDA-CDER-CTU-2025-45705$$FDA-CTU$$$$$$N$$$20250710$N$CN$US$
255410592$25541059$2$F$$20250708$20250710$20250711$EXP$$US-ABBVIE-6363560$ABBVIE$$$$A$F$Y$$$20250711$$CN$US$US
255411193$25541119$3$F$20250702$20250903$20250710$20250905$30DAY$$US-AMGEN-USASP2025132807$AMGEN$$54$YR$A$F$Y$$$20250905$$HP$US$US
255412581$25541258$1$I$20250516$20250707$20250711$20250711$EXP$EU-AEMPS-1717792$EU-ORGANON-O2507ESP000701$ORGANON$$$$E$F$Y$$$20250711$$HP$EU$EU
255412801$25541280$1$I$20250101$20250708$20250711$20250711$PER$$US-SA-2025SA193212$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250711$$MD$US$US
255412972$25541297$2$F$$20250808$20250711$20250815$EXP$$CA-ROCHE-10000334367$ROCHE$$44$YR$A$F$Y$$$20250815$$MD$CA$CA
255413201$25541320$1$I$$20250708$20250711$20250711$EXP$$CA-ABBVIE-6363209$ABBVIE$$$$A$F$Y$$$20250711$$MD$CA$CA
255413272$25541327$2$F$20250101$20250808$20250711$20250811$EXP$$CA-ABBVIE-6364665$ABBVIE$$78$YR$$M$Y$81.3$KG$20250811$$CN$CA$CA
255414051$25541405$1$I$$20250710$20250711$20250711$EXP$$AU-ABBVIE-6365125$ABBVIE$$81$YR$$F$Y$$$20250711$$HP$AU$AU
255414332$25541433$2$F$$20250710$20250711$20250715$PER$$US-HALEON-2250923$Haleon PLC$$$$$$Y$$$20250715$$CN$US$US
255414641$25541464$1$I$$20250703$20250711$20250711$EXP$$EU-UCBSA-2025041370$UCB$$35$YR$$F$Y$$$20250711$$MD$EU$EU
255414931$25541493$1$I$20250516$20250519$20250711$20250711$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-01979$AMNEAL$$$$$M$Y$$$20250711$$CN$US$US
255415681$25541568$1$I$$20250507$20250711$20250711$EXP$$EU-ALKEM LABORATORIES LIMITED-ES-ALKEM-2025-05120$ALKEM$Soto-Insuga V, Gonzalez-Alguacil E, Ballara-Petitbo M, Lamagrande-Casanova N, Duat-Rodriguez A, Benitez-Provedo C, Cardenal-Munoz E, Garcia-Penas JJ.. Efficacy of Stiripentol Beyond Dravet Syndrome: A Retrospective Medical Record Review of Patients with Drug-Resistant Epilepsies. Neurol Ther. 2025;unk:unk$$$$$Y$$$20250710$$HP$EU$EU
255416331$25541633$1$I$$20250707$20250711$20250711$PER$$US-SA-2025SA195306$SANOFI AVENTIS$$$$E$M$Y$80.91$KG$20250711$$HP$US$US
255416531$25541653$1$I$20250701$20250701$20250711$20250711$EXP$GB-MHRA-MED-202507010847493890-ZYGKR$GB-Accord-493829$ACCORD$$52$YR$A$M$Y$75$KG$20250711$$MD$GB$GB
255417191$25541719$1$I$$20250707$20250711$20250711$EXP$$EU-JNJFOC-20250710469$JOHNSON AND JOHNSON$$$$$$Y$$$20250711$$MD$EU$EU
255417201$25541720$1$I$$20250708$20250711$20250711$PER$$US-ELI_LILLY_AND_COMPANY-US202507007828$ELI LILLY AND COMPANY$$28$YR$A$F$Y$$$20250711$$CN$US$US
255417471$25541747$1$I$20241201$20250701$20250711$20250711$EXP$GB-MHRA-MED-202506282249432070-NGFJW$GB-NOVOPROD-1471669$NOVO NORDISK$$$$$$Y$$$20250711$$CN$GB$GB
255417621$25541762$1$I$$20250701$20250711$20250711$EXP$$US-REVANCE THERAPEUTICS INC.-US-REV-2025-000415$REVANCE THERAPEUTICS$$$$$$Y$$$20250711$$HP$US$US
255417821$25541782$1$I$20250619$20250630$20250711$20250711$EXP$GB-MHRA-MED-202506261357009510-WMYQZ$GB-IPCA LABORATORIES LIMITED-IPC-2025-GB-001816$IPCA$$$$$$Y$$$20250711$$PH$GB$GB
255418141$25541814$1$I$20250601$20250708$20250711$20250711$EXP$$US-UCBSA-2025042170$UCB$$38$YR$$M$Y$$$20250711$$HP$US$US
255418691$25541869$1$I$$20250703$20250711$20250711$EXP$$CL-EMD Serono-2025034264$EMD SERONO INC$$$$E$M$Y$$$20250711$$$CL$CL
255419081$25541908$1$I$20250620$20250620$20250711$20250711$PER$$US-ELI_LILLY_AND_COMPANY-US202506001710$ELI LILLY AND COMPANY$$43$YR$A$F$Y$$$20250711$$CN$US$US
255419101$25541910$1$I$20250101$20250706$20250711$20250711$PER$$US-UNITED THERAPEUTICS-UNT-2025-023360$UNITED THERAPEUTICS$$$$$M$Y$68.027$KG$20250711$$$US$US
255420581$25542058$1$I$$20250703$20250711$20250711$EXP$$US-NOVOPROD-1474579$NOVO NORDISK$$$$$F$Y$101$KG$20250711$$CN$US$US
255420811$25542081$1$I$20120301$20250626$20250711$20250711$EXP$$US-COOPERSURGICAL, INC.-2025CPS005311$COOPERSURGICAL$$32$YR$$F$Y$86.168$KG$20250711$$CN$US$US
255421711$25542171$1$I$$20250625$20250711$20250711$PER$$US-Hibrow Healthcare Private Ltd-2180310$Hibrow Healthcare$$$$$$Y$$$20250711$$$US$US
255421862$25542186$2$F$$20250708$20250711$20250809$EXP$$US-ASTRAZENECA-202507USA005449US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
255422482$25542248$2$F$$20250717$20250711$20250728$EXP$$US-TEVA-VS-3349531$TEVA$Kavalauskas RJ, Kelley JL, Norris Z, Scott BJ. Daptomycin Pneumonitis Secondary to the Treatment of Osteomyelitis - A Case Report. Am-J-Health-Syst-Pharm 2025; 82 (Suppl. 1) S1827 (plus Poster).; Kavalauskas RJ, Kelley JL, Norris Z, Scott BJ. Daptomycin Pneumonitis Secondary to the Treatment of Osteomyelitis - A Case Report. Am-J-Health-Syst-Pharm 2025; 82 (Suppl. 1) S1827 (plus Poster).$78$YR$$M$Y$$$20250728$$PH$US$US
255423461$25542346$1$I$20250423$20250703$20250711$20250711$EXP$EU-AEMPS-1702221$EU-HIKMA PHARMACEUTICALS USA INC.-ES-H14001-25-08407$HIKMA$$60$YR$$F$Y$75$KG$20250711$$MD$EU$EU
255424151$25542415$1$I$$20250708$20250711$20250711$PER$$NVSC2025US110269$NOVARTIS$$$$$M$Y$$$20250711$$CN$US$US
255425021$25542502$1$I$20250613$20250708$20250711$20250711$EXP$$US-ABBVIE-6362850$ABBVIE$$56$YR$$M$Y$$$20250711$$CN$US$US
255425621$25542562$1$I$$20250627$20250711$20250711$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-515793$RANBAXY$$$$A$M$Y$$$20250711$$HP$EU$EU
255426281$25542628$1$I$$20250709$20250711$20250711$EXP$$US-BIOGEN-2025BI01316659$BIOGEN$$$$$F$Y$$$20250711$$CN$US$US
255426661$25542666$1$I$20250707$20250707$20250711$20250711$EXP$$US-ABBVIE-6361953$ABBVIE$$63$YR$$M$Y$$$20250711$$CN$US$US
255428263$25542826$3$F$20250211$20250723$20250711$20250729$EXP$$EU-ASTRAZENECA-202506GLO027485DE$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250729$$$EU$EU
255429281$25542928$1$I$$20250707$20250711$20250711$PER$$US-CHATTEMPRD-2025OHG021125$CHATTEM$$$$$$Y$$$20250711$$CN$US$US
255430211$25543021$1$I$$20250707$20250711$20250711$PER$$US-AMGEN-USASP2025135308$AMGEN$$$$$$Y$4.5$KG$20250711$$CN$US$US
255430651$25543065$1$I$$20250629$20250711$20250711$EXP$$TW-Accord-494016$ACCORD$Yu SC, Tong SS, Chen YL, Cheng YF, Lin JC, et al. Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer. PLoS One. 2025 Jun 26;20(6):e0326056. doi: 10.1371/journal.pone.0326056.$$$$$Y$$$20250711$$HP$TW$TW
255430801$25543080$1$I$$20250201$20250711$20250711$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK097756$GLENMARK$$$$$$Y$$$20250711$$CN$US$US
255430811$25543081$1$I$$20250216$20250711$20250711$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK098149$GLENMARK$$$$$F$Y$$$20250711$$CN$US$US
255431101$25543110$1$I$$20250120$20250711$20250711$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK097373$GLENMARK$$$$$$Y$$$20250711$$CN$US$US
255431841$25543184$1$I$$20250703$20250711$20250711$PER$$US-009507513-2304572$MERCK SHARP + DOHME LLC$Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, et al. Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica 2025; 110(6): 1436-1442. doi 0.3324/haematol.2024.286675$57$YR$$F$Y$$$20250711$$HP$US$US
255432211$25543221$1$I$$20250705$20250711$20250711$PER$$US-ROCHE-10000331669$ROCHE$$$$A$F$Y$$$20250711$$CN$US$US
255433121$25543312$1$I$20250619$20250710$20250711$20250711$EXP$EU-NMA-2025-SP0370$EU-HALEON-2251923$Haleon PLC$$59$YR$$F$Y$77$KG$20250711$$PH$EU$EU
255433301$25543330$1$I$$20250703$20250711$20250711$EXP$$US-MYLANLABS-2025M1057705$MYLAN$Jesudasen S, Keller B, Michel E, Nandavaram S. Navigating dual battles: lung transplant success amidst incidental advanced cancer on explant. J-Heart-Lung-Transplant 2025; 44 (Suppl.) (4): S745 abstr. 1592.$60$YR$$F$Y$$$20250711$$$US$US
255434171$25543417$1$I$$20250702$20250711$20250711$PER$$US-INCYTE CORPORATION-2025IN007304$INCYTE$$67$YR$$$Y$88.6$KG$20250711$$$US$US
255435571$25543557$1$I$$20250626$20250711$20250711$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-514842$RANBAXY$Handlos P, Handlosova K, Zidlik V, Gebauerova V, Uvira M. Aorto-pericardial fistula in an intravenous drug addict with infective endocarditis of the aortic valve. Cardiovasc Pathol. 2025;Jun 22:Online ahead of print$31$YR$$F$Y$$$20250711$$HP$EU$EU
255436031$25543603$1$I$20250217$20250627$20250711$20250711$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-516707$RANBAXY$$52$YR$$F$Y$$$20250711$$MD$EU$EU
255436821$25543682$1$I$$20250710$20250711$20250711$EXP$$CA-SANDOZ INC.-SDZ2025CA048986$SANDOZ$$$$$$Y$$$20250711$$HP$CA$CA
255436891$25543689$1$I$$20250707$20250711$20250711$PER$$US-AMGEN-USASP2025133841$AMGEN$$$$A$F$Y$$$20250711$$HP$US$US
255436921$25543692$1$I$$20250710$20250710$20250710$DIR$764060$$FDA-CTU$$$$$M$N$67.5$KG$20250710$N$CN$US$
255437181$25543718$1$I$$20250701$20250711$20250711$EXP$$CA-HIKMA PHARMACEUTICALS-CA-H14001-25-08352$HIKMA$$57$YR$$M$Y$$$20250711$$HP$CA$CA
255437353$25543735$3$F$20250501$20250904$20250711$20250909$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-017010$JAZZ$$38$YR$$F$Y$$$20250909$$MD$US$US
255437391$25543739$1$I$$20250711$20250711$20250711$DIR$FDA-CDER-CTU-2025-45820$$FDA-CTU$$$$$$N$$$20250711$$CN$US$
255438071$25543807$1$I$$20250702$20250711$20250711$EXP$$IN-ANIPHARMA-023433$ANI$$12$YR$T$F$Y$$$20250711$$HP$IN$IN
255438101$25543810$1$I$20250429$20250703$20250711$20250711$EXP$GB-MHRA-MED-202507021527383500-NYLDP$GB-TORRENT-00041871$TORRENT PHARMA INC.$$56$YR$A$M$Y$84$KG$20250711$$PH$GB$GB
255438201$25543820$1$I$20240124$20250707$20250711$20250711$EXP$$EU-SANDOZ INC.-SDZ2024DE056375$SANDOZ$$54$YR$$F$Y$69.9$KG$20250711$$HP$EU$EU
255438221$25543822$1$I$20230819$20250702$20250711$20250711$EXP$$CN-ANIPHARMA-023426$ANI$$68$YR$E$M$Y$$$20250711$$HP$CN$CN
255438561$25543856$1$I$$20250710$20250711$20250711$PER$$US-PFIZER INC-202500140415$PFIZER$$60$YR$$M$Y$$$20250711$$MD$US$US
255440171$25544017$1$I$$20250620$20250711$20250711$PER$$US-FMCRTG-FMC-2506-000993$FRESENIUS MEDICAL CARE$$40$YR$A$F$Y$$$20250711$$HP$US$US
255440821$25544082$1$I$20250708$20250710$20250711$20250711$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-097963$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250711$$PH$US$US
255440851$25544085$1$I$20250627$20250701$20250711$20250711$EXP$GB-MHRA-MED-202507011113538810-YNZGJ$GB-ELI_LILLY_AND_COMPANY-GB202507002122$ELI LILLY AND COMPANY$$24$YR$A$M$Y$125$KG$20250711$$CN$GB$GB
255440971$25544097$1$I$20250601$20250629$20250711$20250711$EXP$GB-MHRA-MED-202506291742208780-LFWRK$GB-ELI_LILLY_AND_COMPANY-GB202506026803$ELI LILLY AND COMPANY$$29$YR$A$$Y$63$KG$20250711$$CN$GB$GB
255441852$25544185$2$F$$20250704$20250711$20250714$EXP$$EU-AMGEN-FRASP2025132790$AMGEN$Maureille A.; Vauleon E.; Meyronet D. et al.. Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases. Neuro-Oncology Advances. 2025;7 (1):1 -9$45$YR$A$M$Y$$$20250714$$MD$EU$EU
255442412$25544241$2$F$$20250717$20250711$20250722$EXP$$US-PFIZER INC-PV202500082419$PFIZER$$$$A$F$Y$$$20250722$$LW$US$US
255442521$25544252$1$I$$20250711$20250711$20250711$DIR$764110$$FDA-CTU$$$$$$N$$$20250711$N$$US$
255443752$25544375$2$F$$20250708$20250711$20250722$EXP$$EU-PFIZER INC-202500139060$PFIZER$Semeraro, P.. NEXT GENERATION SEQUENCING ANALYSIS IDENTIFIES HIGH FREQUENCY OF GENETIC VARIANTS POTENTIALLY LINKED TO INBORN ERRORS OF IMMUNITY IN COMMON VARIABLE IMMUNODEFICIENCY PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY RHEUMATIC DISEASES. Annals of the Rheumatic Diseases. 2025;84:1333-1334$$$A$$Y$$$20250722$$HP$EU$EU
255445381$25544538$1$I$20250710$20250711$20250711$20250711$DIR$FDA-CDER-CTU-2025-45942$$FDA-CTU$$76$YR$$M$N$$$20250711$N$$US$
255445601$25544560$1$I$$20250707$20250711$20250711$EXP$$EU-BAYER-2025A089773$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250711$$CN$EU$EU
255445624$25544562$4$F$20250512$20250811$20250711$20250821$EXP$$EU-CATALYSTPHARMACEUTICALPARTNERS-DE-CATA-25-00986$CATALYST PHARMA$$6$YR$$M$Y$$$20250821$$MD$EU$EU
255446342$25544634$2$F$$20250820$20250711$20250826$PER$$US-SA-2025SA195308$SANOFI AVENTIS$$78$YR$E$F$Y$$$20250826$$CN$US$US
255446482$25544648$2$F$$20250721$20250711$20250724$PER$$US-SA-2025SA193494$SANOFI AVENTIS$$$$A$M$Y$81.36$KG$20250724$$HP$US$US
255446901$25544690$1$I$20250101$20250708$20250711$20250711$PER$$US-SA-2025SA195298$SANOFI AVENTIS$$11$YR$C$M$Y$$$20250711$$HP$US$US
255447251$25544725$1$I$$20250708$20250711$20250711$PER$$US-SA-2025SA194985$SANOFI AVENTIS$$$$A$F$Y$$$20250711$$HP$US$US
255447601$25544760$1$I$20250601$20250708$20250711$20250711$PER$$US-SA-2025SA195598$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250711$$HP$US$US
255447991$25544799$1$I$$20250708$20250711$20250711$PER$$US-SA-2025SA196056$SANOFI AVENTIS$$$$A$F$Y$52.73$KG$20250711$$MD$US$US
255448041$25544804$1$I$20250601$20250708$20250711$20250711$PER$$US-SA-2025SA195608$SANOFI AVENTIS$$82$YR$E$M$Y$$$20250711$$MD$US$US
255448262$25544826$2$F$$20250715$20250711$20250718$PER$$US-SA-2025SA195648$SANOFI AVENTIS$$$$A$F$Y$$$20250718$$MD$US$US
255448341$25544834$1$I$$20250708$20250711$20250711$PER$$US-SA-2025SA194946$SANOFI AVENTIS$$9$YR$C$M$Y$$$20250711$$CN$US$US
255448442$25544844$2$F$20250101$20250804$20250711$20250811$PER$$US-SA-2025SA194676$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250811$$HP$US$US
255449821$25544982$1$I$20250702$20250704$20250711$20250711$EXP$$TH-GUERBET / LLC-TH-20250036$GUERBET$$87$YR$E$M$Y$$$20250711$$HP$TH$TH
255450561$25545056$1$I$$20250702$20250711$20250711$EXP$$US-ELI_LILLY_AND_COMPANY-US202507002985$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250711$$CN$US$US
255451971$25545197$1$I$20190710$20250707$20250711$20250711$EXP$EU-MPA-2019-005065$EU-MYE-2019M1120826AA$MYLAN$$53$YR$$F$Y$$$20250711$$MD$EU$EU
255453601$25545360$1$I$$20250702$20250711$20250711$EXP$$CN-B. Braun Medical Inc.-CN-BBM-202502636$B. BRAUN MEDICAL INC.$Wang J. Emergency management of ceftriaxone-induced Type II Kounis syndrome. Medicine?. 2025 Jun 02;1-5. doi:10.1097/MD.0000000000042917.$73$YR$E$M$Y$$$20250711$$$CN$CN
255453661$25545366$1$I$$20250702$20250711$20250711$EXP$$JP-JAZZ PHARMACEUTICALS-2025-JP-016962$JAZZ$$80$YR$$M$Y$$$20250711$$MD$JP$JP
255453811$25545381$1$I$$20250626$20250711$20250711$EXP$$US-The Proactiv LLC-2180365$PROACTIV$$$$$F$Y$$$20250711$$$US$US
255454001$25545400$1$I$20250501$20250710$20250711$20250711$EXP$$JP-PFIZER INC-202500139843$PFIZER$$$$A$M$Y$$$20250711$$MD$JP$JP
255454761$25545476$1$I$$20250630$20250711$20250711$PER$$US-INCYTE CORPORATION-2025IN007223$INCYTE$$$$$$Y$$$20250711$$PH$US$US
255454981$25545498$1$I$$20250703$20250711$20250711$EXP$$IN-GE HEALTHCARE-2025CSU009008$GE HEALTHCARE$$$$$$Y$$$20250711$$HP$IN$IN
255455311$25545531$1$I$$20250709$20250711$20250711$PER$$US-ELI_LILLY_AND_COMPANY-US202507008567$ELI LILLY AND COMPANY$$$$$$Y$$$20250711$$CN$US$US
255456052$25545605$2$F$20220101$20250708$20250711$20250716$EXP$$EU-CELLTRION INC.-2025IE022090$CELLTRION$Cosgrove N, Fitzpatrick O, Grogan L, Hennessy B, Furney S, Toomey S.. Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples. Frontiers in Oncology. 2024;14:1-9$$$$$Y$$$20250716$$HP$EU$EU
255456171$25545617$1$I$20250101$20250708$20250712$20250712$PER$$US-SA-2025SA194426$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250712$$PH$US$US
255458053$25545805$3$F$20250101$20250814$20250712$20250826$EXP$$US-UNITED THERAPEUTICS-UNT-2025-021443$UNITED THERAPEUTICS$$$$$M$Y$68.027$KG$20250823$$$US$US
255458851$25545885$1$I$20250101$20250703$20250712$20250712$PER$$US-UNITED THERAPEUTICS-UNT-2025-023449$UNITED THERAPEUTICS$$$$$F$Y$53.061$KG$20250712$$$US$US
255458941$25545894$1$I$$20250630$20250712$20250712$EXP$$US-AUROBINDO-AUR-APL-2025-035108$AUROBINDO$Coyne BM, Ishaq SM, Thota A, Thakkar B.. Treatment for a rare case of phenazopyridine-induced methemoglobinemia: a case report and mini-review.. Front-Med. 2025$67$YR$$M$Y$$$20250712$$HP$US$US
255459651$25545965$1$I$$20250625$20250712$20250712$PER$$US-GSK-US2025AMR081678$GLAXOSMITHKLINE$$$$$M$Y$$$20250712$$$US$US
255460301$25546030$1$I$20250630$20250709$20250712$20250712$EXP$$US-UNITED THERAPEUTICS-UNT-2025-023024$UNITED THERAPEUTICS$$78$YR$$F$Y$50.794$KG$20250712$$$US$US
255460431$25546043$1$I$$20250707$20250712$20250712$EXP$$US-TAKEDA-2025TUS061998$TAKEDA$$$$$F$Y$$$20250712$$$US$US
255460451$25546045$1$I$20250101$20250708$20250712$20250712$PER$$US-SA-2025SA196673$SANOFI AVENTIS$$17$YR$T$M$Y$$$20250712$$CN$US$US
255460811$25546081$1$I$$20250710$20250712$20250712$PER$$US-ELI_LILLY_AND_COMPANY-US202507010787$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250712$$CN$US$US
255461691$25546169$1$I$20250101$20250630$20250713$20250713$30DAY$$US-UCBSA-2025042327$UCB$$$$$F$Y$$$20250713$$CN$US$US
255461741$25546174$1$I$$20250702$20250713$20250713$EXP$EU-LRB-01071404$EU-JUBILANT CADISTA PHARMACEUTICALS-2025NL000771$Unknown Manufacturer$$77$YR$$F$Y$65$KG$20250713$$CN$EU$EU
255461941$25546194$1$I$20250524$20250701$20250713$20250713$EXP$$EU-AUROBINDO-AUR-APL-2025-034690$AUROBINDO$$36$YR$$M$Y$69$KG$20250713$$MD$EU$EU
255462141$25546214$1$I$$20250626$20250713$20250713$EXP$$US-NEBO-699508$PHARMACOSMOS A/S$$50$YR$$F$Y$$$20250713$$HP$US$US
255462731$25546273$1$I$$20250709$20250713$20250713$PER$$US-SA-2025SA196219$SANOFI AVENTIS$$67$YR$E$F$Y$$$20250713$$MD$US$US
255462891$25546289$1$I$$20250702$20250713$20250713$PER$$US-ELI_LILLY_AND_COMPANY-US202507002955$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250713$$CN$US$US
255463001$25546300$1$I$$20250707$20250713$20250713$PER$$US-SA-2025SA194501$SANOFI AVENTIS$$17$YR$T$M$Y$$$20250713$$HP$US$US
255463011$25546301$1$I$20250707$20250708$20250713$20250713$PER$$US-ELI_LILLY_AND_COMPANY-US202506005240$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250713$$CN$US$US
255463182$25546318$2$F$20241110$20250721$20250713$20250728$EXP$EU-CADRBFARM-2025337045$EU-BIOGEN-2025BI01316640$BIOGEN$$46$YR$$F$Y$104$KG$20250728$$CN$EU$EU
255463642$25546364$2$F$20150101$20250709$20250713$20250721$EXP$$US-RDY-USA/2025/07/010145$DR REDDYS$Ricciardi FL, Melnitsky JL, Peleg SB, Govil P, Kantrowitz JT. Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia. The Journal of clinical psychiatry. 2025;86(3):25cr15857. DOI:10.4088/JCP.25cr15857.$$$A$M$Y$$$20250721$$MD$US$US
255464042$25546404$2$F$$20250912$20250713$20250926$EXP$$US-CIPLA (EU) LIMITED-2025US08363$CIPLA$$$$$$Y$$$20250926$$CN$US$US
255464141$25546414$1$I$20180301$20250707$20250713$20250713$PER$$US-SA-2025SA195392$SANOFI AVENTIS$$52$YR$A$F$Y$$$20250713$$HP$US$US
255464251$25546425$1$I$20250601$20250708$20250713$20250713$EXP$$US-GSK-US2025AMR087909$GLAXOSMITHKLINE$$42$YR$$F$Y$$$20250713$$$US$US
255464391$25546439$1$I$$20250707$20250713$20250713$PER$$US-SA-2025SA195616$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250713$$HP$US$US
255465661$25546566$1$I$20240101$20250708$20250713$20250713$EXP$$US-ABBVIE-6323705$ABBVIE$$33$YR$$F$Y$127$KG$20250713$$CN$US$US
255466291$25546629$1$I$$20250710$20250713$20250713$EXP$$US-JNJFOC-20250712100$JOHNSON AND JOHNSON$$73$YR$E$M$Y$$$20250714$$HP$US$US
255466621$25546662$1$I$20250626$20250710$20250713$20250713$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-097885$BRISTOL-MYERS SQUIBB COMPANY$$94$YR$E$F$Y$70.31$KG$20250714$$HP$US$US
255467361$25546736$1$I$20250601$20250707$20250714$20250714$EXP$EU-AEMPS-1716314$EU-TEVA-VS-3351183$TEVA$$36$YR$$F$Y$$$20250714$$MD$EU$EU
255468041$25546804$1$I$$20250710$20250714$20250714$EXP$$JP-009507513-2307856$MERCK SHARP + DOHME LLC$$78$YR$$F$Y$$$20250714$$MD$JP$JP
255468811$25546881$1$I$$20250428$20250714$20250714$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-04277$ALKEM$Glassner A, Dubrall D, Wurpts G, Deck P, Weindl G, Heubach CA, Yazdi AS, Sachs B. Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions. Frontiers in Allergy. 2025;6:1532775$57$YR$$M$Y$$$20250714$$MD$EU$EU
255469601$25546960$1$I$20250504$20250708$20250714$20250714$EXP$EU-AFSSAPS-PO2025000670$EU-BAXTER-2025BAX018110$BAXTER$$61$YR$$F$Y$46$KG$20250714$$MD$EU$EU
255470201$25547020$1$I$20250501$20250710$20250714$20250714$EXP$$JP-ASTELLAS-2025-AER-027847$ASTELLAS$$8$DEC$E$M$Y$$$20250714$$MD$JP$JP
255471031$25547103$1$I$$20250708$20250714$20250714$PER$$US-GSK-US2025AMR088259$GLAXOSMITHKLINE$$$$$F$Y$$$20250714$$$US$US
255471111$25547111$1$I$20240506$20250708$20250714$20250714$EXP$EU-FIMEA-202502617$EU-ABBVIE-6365531$ABBVIE$$52$YR$$F$Y$$$20250714$$CN$EU$EU
255471531$25547153$1$I$$20250708$20250714$20250714$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06048$LUPIN$$33$YR$$$Y$$$20250714$$MD$US$US
255472274$25547227$4$F$$20250828$20250714$20250903$PER$$US-BIOVITRUM-2025-US-009507$BIOVITRUM$$$$$F$Y$$$20250903$$CN$US$US
255472531$25547253$1$I$$20250704$20250714$20250714$EXP$GB-BRISTOL-MYERS SQUIBB COMPANY-2025-094271$GB-ASPEN-GLO2025GB005876$ASPEN$$$$$$Y$$$20250714$$HP$GB$GB
255472921$25547292$1$I$$20250710$20250714$20250714$EXP$$US-ASTRAZENECA-202507USA007925US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250714$$$US$US
255473273$25547327$3$F$$20250716$20250714$20250808$EXP$$EU-AUROBINDO-AUR-APL-2025-032386$AUROBINDO$Car??o E, Pereira R, Canelas C, Salvador F.. O dilema da Iatrogenia - um caso de hemorragia no idoso. 31? CONGRESSO NACIONAL DE MEDICINA INTERNA. 2025;1043-1043.$85$YR$$F$Y$$$20250808$$HP$EU$EU
255473471$25547347$1$I$$20250703$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507004788$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250714$$CN$US$US
255474701$25547470$1$I$20250707$20250707$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507011311$ELI LILLY AND COMPANY$$$$$F$Y$$$20250714$$CN$US$US
255474901$25547490$1$I$$20250711$20250714$20250714$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-098301$BRISTOL-MYERS SQUIBB COMPANY$$74$YR$E$M$Y$$$20250714$$HP$US$US
255475411$25547541$1$I$20250601$20250709$20250714$20250714$EXP$$US-ABBVIE-6365247$ABBVIE$$49$YR$$F$Y$$$20250714$$CN$US$US
255475461$25547546$1$I$$20250709$20250714$20250714$EXP$$US-ABBVIE-6366005$ABBVIE$$$$A$M$Y$$$20250714$$CN$US$US
255475491$25547549$1$I$20250101$20250709$20250714$20250714$30DAY$$US-SANDOZ INC.-SDZ2025US048558$SANDOZ$$$$$F$Y$$$20250714$$CN$US$US
255476892$25547689$2$F$20250704$20250807$20250714$20250815$PER$$US-ELI_LILLY_AND_COMPANY-US202507005953$ELI LILLY AND COMPANY$$35$YR$A$F$Y$$$20250815$$CN$US$US
255477042$25547704$2$F$$20250916$20250714$20250922$EXP$$JP-ROCHE-10000335564$ROCHE$Hasegawa T,  Study on cases of T0 lung cancer in our hospital. [Abstract number: O4-5]. The 34th Annual Meeting of Japanese Society of Strategies for Cancer Research and Therapy. 2025;60:$74$YR$E$M$Y$$$20250922$$MD$JP$JP
255477481$25547748$1$I$$20250710$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507009793$ELI LILLY AND COMPANY$$$$$$Y$$$20250714$$CN$US$US
255478921$25547892$1$I$$20250708$20250714$20250714$PER$$US-ROCHE-10000333505$ROCHE$$$$$M$Y$$$20250714$$MD$US$US
255479161$25547916$1$I$$20250707$20250714$20250714$EXP$EU-EMA-DD-20180423-negievprod-115717$EU-CHEPLA-2025008406$CHEPLAPHARM$Goulas A, Raikos N, Krokos D, Mastrogianni O, Orphanidis A, Zisopoulos K, et al. Fatal intoxication with antidepressants: a case with many culprits. Forensic Science, Medicine and Pathology. 2018;14:225-228. doi: 10.1007/s12024-018-9960-3.$25$YR$$M$Y$$$20250714$$HP$COUNTRY NOT SPECIFIED$EU
255480241$25548024$1$I$20250603$20250701$20250714$20250714$EXP$$EU-AUROBINDO-AUR-APL-2025-034910$AUROBINDO$$82$YR$$M$Y$90$KG$20250714$$PH$EU$EU
255480261$25548026$1$I$20250626$20250710$20250714$20250714$EXP$$US-TAKEDA-2024TUS120206$TAKEDA$$73$YR$$F$Y$$$20250714$$$US$US
255481013$25548101$3$F$$20250714$20250714$20250731$PER$$US-ASTRAZENECA-202507USA008577US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250731$$$US$US
255482171$25548217$1$I$20250709$20250709$20250714$20250714$EXP$$US-JNJFOC-20250712007$JOHNSON AND JOHNSON$$37$YR$A$F$Y$$$20250714$$HP$US$US
255482731$25548273$1$I$$20250701$20250714$20250714$EXP$$GB-INTERCEPT-PM2025001469$INTERCEPT PHARMACEUTICALS$$$$E$F$Y$$$20250714$$CN$GB$GB
255482751$25548275$1$I$20210101$20250704$20250714$20250714$EXP$EU-AFSSAPS-AVBX2025000552$EU-TEVA-VS-3350592$TEVA$$26$YR$$F$Y$$$20250714$$PH$EU$EU
255484611$25548461$1$I$$20250604$20250714$20250714$PER$$US-GLENMARK PHARMACEUTICALS-2024GMK094612$GLENMARK$$$$$$Y$$$20250714$$HP$US$US
255484711$25548471$1$I$$20250204$20250714$20250714$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK097789$GLENMARK$$$$$$Y$$$20250714$$CN$US$US
255484761$25548476$1$I$$20250625$20250714$20250714$PER$$US-GSK-US2025079939$GLAXOSMITHKLINE$$$$$F$Y$$$20250714$$MD$US$US
255486051$25548605$1$I$20250706$20250708$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507008189$ELI LILLY AND COMPANY$$77$YR$E$F$Y$$$20250714$$CN$US$US
255486231$25548623$1$I$$20250709$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507009266$ELI LILLY AND COMPANY$$$$$M$Y$$$20250714$$CN$US$US
255487241$25548724$1$I$$20250703$20250714$20250714$EXP$GB-MHRA-MED-202507021918588460-WCHDQ$GB-ELI_LILLY_AND_COMPANY-GB202507004699$ELI LILLY AND COMPANY$$$$$$Y$$$20250714$$CN$GB$GB
255488061$25548806$1$I$$20250707$20250714$20250714$EXP$$SY-ANIPHARMA-023536$ANI$$66$YR$E$F$Y$$$20250714$$HP$SY$SY
255488171$25548817$1$I$$20250707$20250714$20250714$EXP$$JP-CHEPLA-2025008492$CHEPLAPHARM$Adachi T, Matsuda T, Misaki Y, Ishida T, Sakaguchi T, Suga T, et al.. O7-4: A Case of Extensive Pulmonary Embolism in a Young Adult Patient with Severe Intellectual Disability Undergoing Mechanical Ventilation Due to Influenza Pneumonia. The 38th Annual Meeting of Japanese Society of Emergency Pediatrics. 2025$22$YR$$F$Y$$$20250714$$MD$COUNTRY NOT SPECIFIED$JP
255488791$25548879$1$I$$20250711$20250711$20250711$DIR$FDA-CDER-CTU-2025-46011$$FDA-CTU$$73$YR$$M$N$$$20250711$N$$US$
255488981$25548898$1$I$20250530$20250709$20250714$20250714$EXP$EU-AFSSAPS-GR2025001013$EU-CHEPLA-2025008443$CHEPLAPHARM$$56$YR$$M$Y$100$KG$20250714$$PH$COUNTRY NOT SPECIFIED$EU
255489071$25548907$1$I$$20250702$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507003900$ELI LILLY AND COMPANY$$50$YR$A$$Y$$$20250714$$CN$US$US
255489711$25548971$1$I$$20250710$20250714$20250714$PER$$US-BAYER-2025A091765$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250714$$MD$US$US
255489801$25548980$1$I$$20250709$20250714$20250714$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008189$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250714$$HP$US$US
255490251$25549025$1$I$20241201$20250709$20250714$20250714$EXP$$JP-BEH-2025212178$CSL BEHRING$$$$$$Y$$$20250714$$CN$JP$JP
255490681$25549068$1$I$20250201$20250707$20250714$20250714$EXP$$EU-TEVA-VS-3350951$TEVA$$$$$F$Y$2.4$KG$20250714$$MD$EU$EU
255490901$25549090$1$I$20250101$20250708$20250714$20250714$EXP$$US-SA-2025SA196778$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250714$$HP$US$US
255490981$25549098$1$I$$20250707$20250714$20250714$PER$$US-AMGEN-USASP2025134183$AMGEN$$$$A$M$Y$$$20250714$$CN$US$US
255491352$25549135$2$F$$20250717$20250714$20250721$EXP$$US-PFIZER INC-PV202500082739$PFIZER$Bdair, H.. Steroid Is the Mysterious Drug. American Journal of Respiratory and Critical Care Medicine. 2025;211:A5541$80$YR$$F$Y$$$20250721$$MD$US$US
255492362$25549236$2$F$20250620$20250918$20250714$20250925$EXP$$AU-BEH-2025211380$CSL BEHRING$$88$YR$E$M$Y$62$KG$20250925$$PH$AU$AU
255493292$25549329$2$F$$20250808$20250714$20250814$PER$$US-MALLINCKRODT-MNK202504084$MALLINCKRODT$$$$$F$Y$$$20250813$$CN$US$US
255493921$25549392$1$I$$20250708$20250714$20250714$EXP$$CA-LUNDBECK-DKLU4016883$LUNDBECK$$51$YR$A$F$Y$$$20250714$$CN$CA$CA
255495181$25549518$1$I$20250101$20250709$20250714$20250714$PER$$US-PFIZER INC-202500140286$PFIZER$$54$YR$$F$Y$$$20250714$$HP$US$US
255496342$25549634$2$F$20250701$20250808$20250714$20250811$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-098491$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$F$Y$$$20250811$$PH$US$US
255496441$25549644$1$I$$20250711$20250714$20250714$PER$$US-ABBVIE-6369300$ABBVIE$$$$E$F$Y$$$20250714$$CN$US$US
255496461$25549646$1$I$$20250703$20250714$20250714$PER$$US-INCYTE CORPORATION-2025IN007372$INCYTE$$43$YR$$$Y$$$20250714$$$US$
255496961$25549696$1$I$20250706$20250710$20250714$20250714$PER$$US-BAYER-2025A091459$BAYER HEALTHCARE LLC$$$$$M$Y$$$20250714$$CN$US$US
255497283$25549728$3$F$$20250818$20250714$20250820$PER$$US-HALEON-2252241$Haleon PLC$$$$$M$Y$$$20250820$$CN$US$US
255498291$25549829$1$I$$20250324$20250714$20250714$PER$$US-NOVOPROD-1399750$NOVO NORDISK$$55$YR$$F$Y$237$KG$20250714$$CN$US$US
255498991$25549899$1$I$20250101$20250205$20250714$20250714$PER$$US-NOVOPROD-1368621$NOVO NORDISK$$$$$M$Y$$$20250714$$CN$US$US
255499901$25549990$1$I$$20250709$20250714$20250714$EXP$$NVSC2025DE111076$NOVARTIS$$$$$F$Y$$$20250714$$CN$EU$EU
255500031$25550003$1$I$20250505$20250709$20250714$20250714$EXP$$EU-ABBVIE-6368896$ABBVIE$$19$YR$$F$Y$$$20250714$$MD$EU$EU
255500082$25550008$2$F$20250710$20250716$20250714$20250721$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-017143$JAZZ$$37$YR$$F$Y$$$20250721$$$US$US
255500581$25550058$1$I$$20250703$20250714$20250714$PER$$US-INCYTE CORPORATION-2025IN007397$INCYTE$$3$MON$$$Y$$$20250714$$$US$US
255500921$25550092$1$I$20250711$20250711$20250711$20250711$DIR$FDA-CDER-CTU-2025-46222$$FDA-CTU$$$$$$N$$$20250711$N$CN$US$
255502991$25550299$1$I$20250227$20250708$20250714$20250714$EXP$$US-TORRENT-00014406$TORRENT PHARMA INC.$$35$YR$A$M$Y$99$KG$20250714$$CN$US$US
255503691$25550369$1$I$$20250709$20250714$20250714$EXP$$US-ABBVIE-6366314$ABBVIE$$$$A$F$Y$$$20250714$$CN$US$US
255503791$25550379$1$I$20250101$20250603$20250714$20250714$PER$$US-YILING-2025YPSPO0013$YILING PHARMACEUTICAL LTD$$73$YR$E$F$Y$$$20250714$$CN$US$US
255504781$25550478$1$I$20250601$20250709$20250714$20250714$PER$$US-SA-2025SA197119$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250714$$MD$US$US
255506021$25550602$1$I$$20250709$20250714$20250714$PER$$US-SA-2025SA197430$SANOFI AVENTIS$$$$A$F$Y$$$20250714$$HP$US$US
255506231$25550623$1$I$$20250710$20250714$20250714$PER$$US-SA-2025SA197619$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250714$$CN$US$US
255506341$25550634$1$I$20100101$20250710$20250714$20250714$PER$$US-SA-2025SA196177$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250714$$HP$US$US
255506431$25550643$1$I$$20250710$20250714$20250714$PER$$US-SA-2025SA197436$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250714$$CN$US$US
255506491$25550649$1$I$$20250710$20250714$20250714$PER$$US-SA-2025SA197483$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250714$$CN$US$US
255507362$25550736$2$F$20250707$20250708$20250714$20250718$EXP$$CA-HLS-202501814$HLS THERAPEUTICS$$26$YR$A$F$Y$125$KG$20250718$$MD$CA$CA
255507551$25550755$1$I$$20250708$20250714$20250714$PER$$US-ELI_LILLY_AND_COMPANY-US202507008853$ELI LILLY AND COMPANY$$32$YR$A$F$Y$$$20250714$$CN$US$US
255507662$25550766$2$F$20250601$20250717$20250714$20250722$EXP$$US-ABBVIE-6342007$ABBVIE$$74$YR$$F$Y$104.32$KG$20250722$$CN$US$US
255507721$25550772$1$I$$20250408$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00557$INTRA-CELLULAR THERAPIES$$$$A$F$Y$$$20250714$$HP$US$US
255508651$25550865$1$I$20250101$20250613$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT01102$INTRA-CELLULAR THERAPIES$$$$$F$Y$$$20250714$$MD$US$US
255509691$25550969$1$I$$20250501$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00757$INTRA-CELLULAR THERAPIES$$$$A$F$Y$$$20250714$$HP$US$US
255509851$25550985$1$I$$20250521$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00905$INTRA-CELLULAR THERAPIES$$$$A$F$Y$$$20250714$$HP$US$US
255509901$25550990$1$I$$20250528$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00963$INTRA-CELLULAR THERAPIES$$$$$M$Y$$$20250714$$HP$US$US
255510171$25551017$1$I$$20250515$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00838$INTRA-CELLULAR THERAPIES$$$$A$F$Y$$$20250714$$HP$US$US
255510621$25551062$1$I$$20250320$20250714$20250714$PER$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT00441$INTRA-CELLULAR THERAPIES$$$$$M$Y$$$20250714$$CN$US$US
255511271$25551127$1$I$$20250710$20250714$20250714$PER$$US-SA-2025SA197738$SANOFI AVENTIS$$$$$F$Y$$$20250714$$PH$US$US
255511395$25551139$5$F$20250512$20250903$20250714$20250909$EXP$$AR-TAKEDA-2025TUS057862$TAKEDA$$83$YR$$F$Y$$$20250909$$$AR$AR
255511651$25551165$1$I$$20250703$20250714$20250714$EXP$$US-RDY-USA/2025/07/010183$DR REDDYS$Jesudasen S, Keller B, Michel E, Nandavaram S. Navigating Dual Battles: Lung Transplant Success Amidst Incidental Advanced Cancer on Explant. J Heart Lung Transplant. 2025;44(4): S745. DOI: 10.1016/j.healun.2025.02.1607.$60$YR$A$F$Y$$$20250714$$HP$US$US
255512791$25551279$1$I$$20250708$20250714$20250714$PER$$US-ABBVIE-6364425$ABBVIE$$$$A$M$Y$$$20250714$$CN$US$US
255512821$25551282$1$I$$20250704$20250714$20250714$EXP$$CA-TEVA-VS-3349594$TEVA$$4$YR$$F$Y$16$KG$20250714$$PH$CA$CA
255512891$25551289$1$I$$20250702$20250714$20250714$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI08876$NEUROCRINE BIOSCIENCES$$$$$F$Y$$$20250714$$HP$US$US
255513101$25551310$1$I$$20250710$20250714$20250714$PER$$US-SA-2025SA196019$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250714$$HP$US$US
255513632$25551363$2$F$$20250630$20250714$20250726$PER$$US-Ipsen Biopharmaceuticals, Inc.-2025-05736$IPSEN BIOPHARMACEUTICALS, INC.$$$$$F$Y$52.16$KG$20250726$$$US$US
255515524$25551552$4$F$$20250813$20250714$20250813$30DAY$$US-PFIZER INC-202400079450$PFIZER$$17$YR$$M$Y$$$20250813$$CN$US$US
255515544$25551554$4$F$20250709$20250905$20250714$20250910$30DAY$$US-PFIZER INC-202500139329$PFIZER$$11$YR$$M$Y$$$20250910$$CN$US$US
255515831$25551583$1$I$20250703$20250711$20250714$20250714$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-098620$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$F$Y$52.16$KG$20250714$$PH$US$US
255515871$25551587$1$I$$20240103$20250714$20250714$EXP$$NVSC2024TG001686$NOVARTIS$$$$$F$Y$$$20250714$$MD$TG$TG
255516091$25551609$1$I$$20250704$20250714$20250714$EXP$$IN-DSJP-DS-2025-152761-IN$DAIICHI$$56$YR$$F$Y$71$KG$20250714$$CN$IN$IN
255516571$25551657$1$I$20250616$20250630$20250714$20250714$PER$$US-Calliditas-2025CAL01955$CALLIDITAS THERAPEUTICS AB$$77$YR$E$F$Y$$$20250714$$CN$US$US
255517651$25551765$1$I$$20250630$20250714$20250714$EXP$$US-BEXIMCO-2025BEX00041$BEXIMCO PHARMACEUTICALS$Xu E.J, Steele D.J.R, Fenves A.Z. Hypomagnesemia With METFORMIN Use in Diabetes Mellitus: A Case and Narrative Review. Kidney Medicine. 2025;(7)7:1-6$61$YR$$M$Y$$$20250710$$HP$US$US
255519932$25551993$2$F$20250101$20250909$20250714$20250918$EXP$$US-UCBSA-2025042591$UCB$$$$$F$Y$113.37$KG$20250918$$HP$US$US
255520521$25552052$1$I$$20250710$20250715$20250715$EXP$$EU-ABBVIE-6370063$ABBVIE$$$$A$F$Y$$$20250715$$MD$EU$EU
255520861$25552086$1$I$20250702$20250707$20250715$20250715$EXP$$US-AMGEN-USASP2025134441$AMGEN$$65$YR$E$F$Y$$$20250714$$CN$US$US
255521391$25552139$1$I$20250101$20250710$20250715$20250715$EXP$$US-ABBVIE-6367104$ABBVIE$$70$YR$$M$Y$$$20250715$$CN$US$US
255521451$25552145$1$I$$20250709$20250715$20250715$EXP$$US-ROCHE-10000060341$ROCHE$$$$A$M$Y$$$20250715$$CN$US$US
255521492$25552149$2$F$20250101$20250916$20250715$20250922$PER$$US-SA-2025SA197663$SANOFI AVENTIS$$58$YR$A$F$Y$$$20250922$$MD$US$US
255521781$25552178$1$I$$20250708$20250715$20250715$PER$$US-ABBVIE-6364657$ABBVIE$$$$$$Y$$$20250715$$HP$US$US
255521871$25552187$1$I$$20250710$20250715$20250715$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-082413$BOEHRINGER INGELHEIM$$$$$M$Y$$$20250715$$MD$EU$EU
255522561$25552256$1$I$$20250704$20250715$20250715$EXP$$CA-TEVA-VS-3349825$TEVA$$35$YR$$F$Y$54.431$KG$20250714$$MD$CA$CA
255522762$25552276$2$F$$20250913$20250715$20250919$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06133$LUPIN$$80$YR$$$Y$$$20250919$$PH$US$US
255523402$25552340$2$F$20250101$20250716$20250715$20250723$EXP$$JP-JNJFOC-20250351864$JOHNSON AND JOHNSON$$73$YR$E$$Y$$$20250723$$PH$JP$JP
255523891$25552389$1$I$20250616$20250705$20250715$20250715$EXP$$CO-NOVOPROD-1475943$NOVO NORDISK$$82$YR$$M$Y$58$KG$20250715$$CN$CO$CO
255523991$25552399$1$I$20240429$20250707$20250715$20250715$EXP$$KR-009507513-2304921$MERCK SHARP + DOHME LLC$$$$A$F$Y$71.1$KG$20250715$$PH$KR$KR
255524461$25552446$1$I$20250616$20250618$20250715$20250715$PER$$US-009507513-2298007$MERCK SHARP + DOHME LLC$$86$YR$$F$Y$$$20250715$$CN$US$US
255524522$25552452$2$F$$20250707$20250715$20250715$PER$$US-GSK-US2025084968$GLAXOSMITHKLINE$$$$$F$Y$$$20250715$$$US$US
255524951$25552495$1$I$20250401$20250709$20250715$20250715$EXP$$US-UCBSA-2025042721$UCB$$56$YR$$M$Y$$$20250715$$CN$US$US
255525311$25552531$1$I$$20250711$20250715$20250715$PER$$US-ASTRAZENECA-202507USA008919US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250715$$PH$US$US
255525431$25552543$1$I$$20250110$20250715$20250715$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-490562$RANBAXY$$$$$$Y$$$20250715$$HP$US$US
255525551$25552555$1$I$$20250710$20250715$20250715$PER$$US-ROCHE-10000334959$ROCHE$Mccrary M, Singla R, Desai A. Eosinophilic Fasciitis With Pulmonary Granulomas: A Mimicker of Sarcoidosis [Abstract: A7489]. American Journal of Respiratory and Critical Care Medicine. 2025-May-01;211: doi:10.1164/ajrccm.2025.211.Abstracts.A7489.$60$YR$A$F$Y$$$20250715$$HP$US$US
255526451$25552645$1$I$$20250709$20250715$20250715$EXP$$JP-ASTELLAS-2025-AER-037905$ASTELLAS$$$$$M$Y$$$20250715$$PH$JP$JP
255526901$25552690$1$I$$20250611$20250715$20250715$PER$$US-TLM-TLM-2025-03528$TOLMAR$$$$$M$Y$$$20250712$$MD$US$US
255527922$25552792$2$F$$20250714$20250715$20250716$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06045$LUPIN$$48$YR$$$Y$143.76$KG$20250716$$$US$US
255528701$25552870$1$I$$20250709$20250715$20250715$EXP$$EU-BEIGENE-BGN-2025-011299$BEIGENE$$$$$$Y$$$20250715$$MD$EU$EU
255529271$25552927$1$I$$20250709$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011469$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250715$$CN$US$US
255529481$25552948$1$I$$20250711$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011779$ELI LILLY AND COMPANY$$$$$$Y$$$20250715$$CN$US$US
255529521$25552952$1$I$$20250714$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507012812$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250715$$CN$US$US
255529701$25552970$1$I$$20250710$20250715$20250715$EXP$$US-SA-2025SA181511$SANOFI AVENTIS$$82$YR$E$M$Y$$$20250715$$MD$US$US
255530131$25553013$1$I$20250629$20250709$20250715$20250715$EXP$CN-NMPACDR-4417011006520202500175$CN-BAXTER-2025BAX018143$BAXTER$$63$YR$$F$Y$66.9$KG$20250715$$MD$CN$CN
255530512$25553051$2$F$20250707$20250714$20250715$20250717$EXP$$CN-ABBVIE-6367692$ABBVIE$$68$YR$$F$Y$$$20250717$$MD$CN$CN
255531651$25553165$1$I$20250710$20250710$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011898$ELI LILLY AND COMPANY$$$$$M$Y$$$20250715$$CN$US$US
255531761$25553176$1$I$$20250622$20250715$20250715$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0015602$RECKITT BENCKISER$$90$YR$$M$Y$$$20250715$$CN$US$US
255531911$25553191$1$I$$20250709$20250715$20250715$EXP$$CN-JNJFOC-20250711655$JOHNSON AND JOHNSON$$$$$$Y$$$20250715$$CN$CN$CN
255532051$25553205$1$I$$20250702$20250715$20250715$EXP$$EU-AUROBINDO-AUR-APL-2021-001121$AUROBINDO$Giglio F, Xue E, Lazzari L, Greco R, Clerici TD, Marktel S, et al.. Prophylaxis with defibrotide in adults at very high risk of veno-occlusive disease: Results in 11 patients.. Bone Marrow Transplant.. 2019;54:255-56$$$A$$Y$$$20250715$$MD$EU$EU
255532171$25553217$1$I$20250710$20250710$20250715$20250715$PER$$US-JNJFOC-20250714260$JOHNSON AND JOHNSON$$$$$$Y$$$20250715$$PH$US$US
255532921$25553292$1$I$$20250709$20250715$20250715$EXP$$US-ABBVIE-6365735$ABBVIE$$$$A$M$Y$$$20250715$$CN$US$US
255533261$25553326$1$I$$20250701$20250715$20250715$PER$$US-GSK-US2025AMR083293$GLAXOSMITHKLINE$$$$$F$Y$$$20250715$$$US$US
255533371$25553337$1$I$$20250127$20250715$20250715$PER$$US-AUROBINDO-AUR-APL-2025-006368$AUROBINDO$$$$A$F$Y$$$20250715$$MD$US$US
255533441$25553344$1$I$20250714$20250714$20250715$20250715$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-099129$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$M$Y$$$20250715$$CN$US$US
255534121$25553412$1$I$$20250621$20250715$20250715$PER$$US-SMPA-2025SPA008421$SUNOVION$$$$$$Y$$$20250715$$CN$US$US
255534531$25553453$1$I$$20250619$20250715$20250715$PER$$US-SMPA-2025SPA007934$SUNOVION$$$$$$Y$$$20250715$$CN$US$US
255534761$25553476$1$I$$20250619$20250715$20250715$PER$$US-SMPA-2025SPA007945$SUNOVION$$$$$$Y$$$20250715$$CN$US$US
255534901$25553490$1$I$$20250709$20250715$20250715$EXP$$TW-AMGEN-TWNSP2025137043$AMGEN$Wu, C.. Risk factors and reasons for romosozumab nonadherence in a case-control study. Scientific Reports. 2025;15 (1):01-09$$$$$Y$$$20250715$$HP$TW$TW
255536421$25553642$1$I$$20250623$20250715$20250715$PER$$US-KENVUE-20250610369$Kenvue$$$$$M$Y$$$20250715$$CN$US$US
255537421$25553742$1$I$$20250711$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011213$ELI LILLY AND COMPANY$$54$YR$A$F$Y$$$20250715$$CN$US$US
255538671$25553867$1$I$20250519$20250714$20250714$20250714$DIR$764609$$FDA-CTU$$71$YR$$F$N$58$KG$20250714$N$HP$US$
255538731$25553873$1$I$$20250714$20250714$20250714$DIR$764472$$FDA-CTU$$$$$F$N$$$20250714$N$CN$US$
255538911$25553891$1$I$20250701$20250710$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011171$ELI LILLY AND COMPANY$$70$YR$E$F$Y$$$20250715$$CN$US$US
255539131$25553913$1$I$20250710$20250711$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011589$ELI LILLY AND COMPANY$$33$YR$A$$Y$$$20250715$$HP$US$US
255540001$25554000$1$I$$20250630$20250715$20250715$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-516246$RANBAXY$Rito S, Faim D, Dias J, Reis I,Francisco A, Da Silva AM, et al. Paediatric pulmonary arterial hypertension: an unusual course of a severe case. Cardiol Young. 2024;34(Suppl. 2):S1942-S1943/ PP-826$13$YR$$F$Y$$$20250715$$HP$EU$EU
255540561$25554056$1$I$20250224$20250630$20250715$20250715$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-516328$RANBAXY$$63$YR$$F$Y$$$20250715$$MD$EU$EU
255541084$25554108$4$F$20250101$20250912$20250715$20250915$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-099230$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$F$Y$$$20250915$$$US$US
255541591$25554159$1$I$$20250714$20250714$20250714$DIR$764541$$FDA-CTU$$60$YR$$F$N$89$KG$20250714$N$CN$EU$
255542001$25554200$1$I$$20250310$20250715$20250715$EXP$$US-VIIV HEALTHCARE-US2025AMR085114$VIIV$$$$$M$Y$$$20250715$$$US$US
255542551$25554255$1$I$$20250714$20250714$20250714$DIR$FDA-CDER-CTU-2025-46483$$FDA-CTU$$74$YR$$M$N$78.93$KG$20250714$N$$US$
255543701$25554370$1$I$$20241114$20250715$20250715$PER$$US-NOVOPROD-1251240$NOVO NORDISK$$73$YR$$F$Y$167$KG$20250715$$CN$US$US
255544731$25554473$1$I$20240601$20240708$20250715$20250715$PER$$US-NOVOPROD-1254573$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255544801$25554480$1$I$20240501$20240627$20250715$20250715$PER$$US-NOVOPROD-1251474$NOVO NORDISK$$72$YR$$F$Y$$$20250715$$CN$US$US
255545351$25554535$1$I$$20250711$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011716$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250715$$CN$US$US
255545441$25554544$1$I$20240701$20240724$20250715$20250715$PER$$US-NOVOPROD-1256471$NOVO NORDISK$$77$YR$$F$Y$$$20250715$$MD$US$US
255545621$25554562$1$I$$20241010$20250715$20250715$PER$$US-NOVOPROD-1256580$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255546131$25554613$1$I$20250604$20250701$20250715$20250715$PER$$US-Calliditas-2025CAL01682$CALLIDITAS THERAPEUTICS AB$$83$YR$E$F$Y$$$20250715$$CN$US$US
255546331$25554633$1$I$20240501$20240709$20250715$20250715$PER$$US-NOVOPROD-1257736$NOVO NORDISK$$68$YR$$F$Y$$$20250715$$CN$US$US
255548141$25554814$1$I$$20250530$20250715$20250715$PER$$US-NOVOPROD-1260249$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255548301$25554830$1$I$20240501$20240618$20250715$20250715$PER$$US-NOVOPROD-1259853$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255548382$25554838$2$F$20250619$20250929$20250715$20250930$EXP$EU-ROCHE-10000323940$EU-SANDOZ INC.-SDZ2025FR049593$SANDOZ$$58$YR$$F$Y$65$KG$20250930$$MD$EU$EU
255549984$25554998$4$F$20250701$20250902$20250715$20250903$30DAY$$US-PFIZER INC-202500139591$PFIZER$$10$YR$$M$Y$$$20250903$$HP$US$US
255550101$25555010$1$I$$20250714$20250714$20250714$DIR$FDA-CDER-CTU-2025-46372$$FDA-CTU$$66$YR$$M$N$$$20250714$N$$US$
255550384$25555038$4$F$$20250814$20250715$20250815$30DAY$$US-PFIZER INC-202500140482$PFIZER$$12$YR$$F$Y$$$20250815$$CN$US$US
255550392$25555039$2$F$20250101$20250911$20250715$20250911$EXP$$CA-PFIZER INC-202500141237$PFIZER$$78$YR$$M$Y$$$20250911$$HP$CA$CA
255550795$25555079$5$F$20250708$20250917$20250715$20250917$30DAY$$CO-PFIZER INC-PV202500082799$PFIZER$$11$YR$$F$Y$$$20250917$$CN$CO$CO
255552054$25555205$4$F$20170523$20250912$20250715$20250916$PER$$US-GILEAD-2025-0720594$GILEAD$$35$YR$A$F$Y$$$20250916$$LW$US$US
255553041$25555304$1$I$$20250709$20250715$20250715$EXP$$EU-EMD Serono-2025035234$EMD SERONO INC$$93$YR$E$F$Y$$$20250715$$MD$EU$EU
255553191$25555319$1$I$20240603$20240603$20250715$20250715$PER$$US-NOVOPROD-1237938$NOVO NORDISK$$48$YR$$F$Y$$$20250715$$CN$US$US
255554211$25555421$1$I$20230705$20240608$20250715$20250715$PER$$US-NOVOPROD-1241983$NOVO NORDISK$$77$YR$$F$Y$$$20250715$$CN$US$US
255555181$25555518$1$I$20240101$20240611$20250715$20250715$PER$$US-NOVOPROD-1243629$NOVO NORDISK$$80$YR$$M$Y$$$20250715$$CN$US$US
255555561$25555556$1$I$20240614$20240614$20250715$20250715$PER$$US-NOVOPROD-1244764$NOVO NORDISK$$57$YR$$F$Y$$$20250715$$CN$US$US
255556311$25555631$1$I$20230628$20241010$20250715$20250715$PER$$US-NOVOPROD-1246386$NOVO NORDISK$$35$YR$$M$Y$101.59$KG$20250715$$CN$US$US
255557421$25555742$1$I$20250528$20250710$20250715$20250715$EXP$$US-VANTIVE-2025VAN003191$Vantive US Healthcare$$67$YR$$F$Y$$$20250715$$HP$US$US
255557651$25555765$1$I$20250713$20250715$20250715$20250715$DIR$FDA-CDER-CTU-2025-46627$$FDA-CTU$$19$YR$$F$N$65.2$KG$20250715$N$PH$US$
255558221$25555822$1$I$20250101$20250703$20250715$20250715$PER$$US-SA-2025SA197237$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250715$$CN$US$US
255559801$25555980$1$I$$20250709$20250715$20250715$PER$$US-SA-2025SA198026$SANOFI AVENTIS$$$$A$M$Y$100.6$KG$20250715$$MD$US$US
255560062$25556006$2$F$$20250813$20250715$20250818$PER$$US-SA-2025SA198435$SANOFI AVENTIS$$70$YR$E$F$Y$$$20250818$$CN$US$US
255560241$25556024$1$I$20250501$20250710$20250715$20250715$PER$$US-SA-2025SA197697$SANOFI AVENTIS$$$$A$F$Y$$$20250715$$HP$US$US
255561501$25556150$1$I$$20250710$20250715$20250715$PER$$US-SA-2025SA198078$SANOFI AVENTIS$$$$A$F$Y$$$20250715$$HP$US$US
255561711$25556171$1$I$$20250710$20250715$20250715$PER$$US-SA-2022SA353957$SANOFI AVENTIS$$67$YR$E$M$Y$$$20250715$$MD$US$US
255562941$25556294$1$I$20250610$20250703$20250715$20250715$EXP$GB-MHRA-MED-202506261521109470-NGQTS$GB-ELI_LILLY_AND_COMPANY-GB202507003700$ELI LILLY AND COMPANY$$53$YR$A$F$Y$78$KG$20250715$$CN$GB$GB
255562971$25556297$1$I$20250605$20250703$20250715$20250715$EXP$GB-MHRA-MED-202507021556111760-BQTHN$GB-ELI_LILLY_AND_COMPANY-GB202507003718$ELI LILLY AND COMPANY$$$$$F$Y$$$20250715$$CN$GB$GB
255563311$25556331$1$I$$20241028$20250715$20250715$PER$$US-NOVOPROD-1348910$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255564571$25556457$1$I$20240813$20250204$20250715$20250715$PER$$US-NOVOPROD-1278503$NOVO NORDISK$$60$YR$$F$Y$$$20250715$$CN$US$US
255565291$25556529$1$I$20250101$20250710$20250715$20250715$PER$$US-SA-2025SA199891$SANOFI AVENTIS$$19$YR$A$F$Y$$$20250715$$HP$US$US
255565381$25556538$1$I$$20240809$20250715$20250715$PER$$US-NOVOPROD-1315506$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
255565431$25556543$1$I$$20241104$20250715$20250715$PER$$US-NOVOPROD-1315264$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255565621$25556562$1$I$20241201$20250109$20250715$20250715$PER$$US-NOVOPROD-1375933$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255565941$25556594$1$I$$20250709$20250715$20250715$EXP$$US-PFIZER INC-202500139863$PFIZER$Yenepalli, A.. Fixed, High-dose Bivalirudin - A Novel Solution to a Fatal Problem.. American Journal of Respiratory and Critical Care Medicine. 2025;211:10.1164/ajrccm.2025.211.Abstr$77$YR$$M$Y$$$20250715$$HP$US$US
255566001$25556600$1$I$$20250708$20250715$20250715$EXP$$NVSC2025DE111922$NOVARTIS$$62$YR$$F$Y$$$20250715$$PH$EU$EU
255567752$25556775$2$F$20180101$20250306$20250715$20250716$PER$$US-NOVOPROD-1265779$NOVO NORDISK$$61$YR$$M$Y$90.703$KG$20250715$$CN$US$US
255568171$25556817$1$I$20250507$20250711$20250715$20250715$EXP$$CA-ABBVIE-6371282$ABBVIE$$62$YR$$M$Y$$$20250715$$CN$CA$CA
255568251$25556825$1$I$20240207$20240731$20250715$20250715$PER$$US-NOVOPROD-1265980$NOVO NORDISK$$70$YR$$M$Y$$$20250715$$CN$US$US
255568501$25556850$1$I$$20250714$20250714$20250714$DIR$764575$$FDA-CTU$$$$$M$N$$$20250714$N$CN$US$
255568582$25556858$2$F$20231006$20250204$20250715$20250715$PER$$US-NOVOPROD-1266268$NOVO NORDISK$$27$YR$$F$Y$79.819$KG$20250715$$CN$US$US
255569182$25556918$2$F$$20250821$20250715$20250822$EXP$$AU-SANDOZ INC.-SDZ2025AU049683$SANDOZ$$48$YR$$M$Y$$$20250822$$MD$AU$AU
255569291$25556929$1$I$20240718$20240801$20250715$20250715$PER$$US-NOVOPROD-1266445$NOVO NORDISK$$67$YR$$M$Y$$$20250715$$CN$US$US
255569341$25556934$1$I$20250101$20250707$20250715$20250715$EXP$$EU-TEVA-VS-3345869$TEVA$$39$YR$$F$Y$$$20250715$$CN$EU$EU
255569361$25556936$1$I$20250627$20250711$20250715$20250715$PER$$US-ELI_LILLY_AND_COMPANY-US202507011678$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250715$$CN$US$US
255570092$25557009$2$F$$20240823$20250715$20250718$PER$$US-NOVOPROD-1276030$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255570301$25557030$1$I$$20250709$20250715$20250715$PER$$US-INCYTE CORPORATION-2025IN007644$INCYTE$$$$$$Y$$$20250715$$$US$US
255570601$25557060$1$I$$20240816$20250715$20250715$PER$$US-NOVOPROD-1310628$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255570951$25557095$1$I$$20250715$20250715$20250715$DIR$FDA-CDER-CTU-2025-46697$$FDA-CTU$$51$YR$$F$N$$$20250715$N$$US$
255571521$25557152$1$I$$20250707$20250715$20250715$EXP$$CA-TEVA-VS-3350609$TEVA$$80$YR$$F$Y$$$20250715$$CN$CA$CA
255571891$25557189$1$I$$20241213$20250715$20250715$PER$$US-NOVOPROD-1311621$NOVO NORDISK$$$$$M$Y$$$20250715$$HP$US$US
255572091$25557209$1$I$$20250714$20250715$20250715$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-099405$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$F$Y$$$20250715$$CN$US$US
255572661$25557266$1$I$$20250714$20250715$20250715$PER$$US-SA-2025SA199914$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250715$$CN$US$US
255573021$25557302$1$I$$20241002$20250715$20250715$PER$$US-NOVOPROD-1346513$NOVO NORDISK$$56$YR$$F$Y$$$20250715$$CN$US$US
255573151$25557315$1$I$$20250226$20250715$20250715$PER$$US-NOVOPROD-1373555$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255573561$25557356$1$I$$20250124$20250715$20250715$PER$$US-NOVOPROD-1373880$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255573741$25557374$1$I$$20241120$20250715$20250715$PER$$US-NOVOPROD-1374100$NOVO NORDISK$$$$$$Y$$$20250715$$MD$US$US
255574961$25557496$1$I$20230601$20250115$20250715$20250715$PER$$US-NOVOPROD-1266987$NOVO NORDISK$$55$YR$$F$Y$109.75$KG$20250715$$CN$US$US
255575001$25557500$1$I$$20250708$20250715$20250715$EXP$$EU-PFIZER INC-202500139941$PFIZER$Podlecka-Pietowska, A.. Rituximab Treatment in Patients with Neuromyelitis Optica- 10-Year Follow-up.. POLSKI PRZEGLAD NEUROLOGICZNY. 2024;Supl. A:A48-A49$$$A$$Y$$$20250715$$HP$EU$EU
255575651$25557565$1$I$20231006$20250115$20250715$20250715$PER$$US-NOVOPROD-1267184$NOVO NORDISK$$39$YR$$M$Y$111.15$KG$20250715$$CN$US$US
255575801$25557580$1$I$$20240827$20250715$20250715$PER$$US-NOVOPROD-1276625$NOVO NORDISK$$$$$$Y$$$20250715$$MD$US$US
255578391$25557839$1$I$$20250714$20250715$20250715$EXP$$KR-PFIZER INC-202500142526$PFIZER$$9$DEC$$$Y$$$20250715$$MD$KR$KR
255578541$25557854$1$I$$20241101$20250715$20250715$PER$$US-NOVOPROD-1313654$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255579021$25557902$1$I$20250501$20250523$20250715$20250715$PER$$US-NOVOPROD-1451337$NOVO NORDISK$$80$YR$$F$Y$$$20250715$$CN$US$US
255579431$25557943$1$I$$20250529$20250715$20250715$PER$$US-NOVOPROD-1451845$NOVO NORDISK$$$$$F$Y$$$20250715$$MD$US$US
255579621$25557962$1$I$$20250709$20250715$20250715$PER$$US-ABBVIE-6364418$ABBVIE$$$$E$M$Y$$$20250715$$HP$US$US
255579891$25557989$1$I$$20250714$20250715$20250715$EXP$$NVSC2025CN112331$NOVARTIS$$68$YR$$F$Y$$$20250715$$CN$CN$CN
255580971$25558097$1$I$$20250707$20250715$20250715$EXP$$EU-AMGEN-BELSP2025134207$AMGEN$Vermeire S.; Greef I. D.; Bislenghi G. et al.. No Increased Risk of Venous Thromboembolism or Infectious Complications after Janus Kinase Inhibitor Exposure in Patients with Ulcerative Colitis Undergoing Surgery. Digestive Diseases. 2025;43 (3):289-299$$$$$Y$$$20250715$$HP$EU$EU
255582211$25558221$1$I$$20250508$20250715$20250715$PER$$US-NOVOPROD-1428658$NOVO NORDISK$$45$YR$$$Y$$$20250715$$CN$US$US
255582261$25558226$1$I$20250331$20250421$20250715$20250715$PER$$US-NOVOPROD-1431143$NOVO NORDISK$$69$YR$$M$Y$$$20250715$$CN$US$US
255582451$25558245$1$I$20250505$20250507$20250715$20250715$PER$$US-NOVOPROD-1430325$NOVO NORDISK$$$$E$F$Y$$$20250715$$HP$US$US
255583071$25558307$1$I$20250331$20250507$20250715$20250715$PER$$US-NOVOPROD-1444444$NOVO NORDISK$$$$A$$Y$$$20250715$$CN$US$US
255583711$25558371$1$I$20250628$20250708$20250715$20250715$30DAY$$US-SANDOZ INC.-SDZ2025US048313$SANDOZ$$49$YR$$F$Y$$$20250715$$CN$US$US
255583752$25558375$2$F$20241201$20250226$20250715$20250715$PER$$US-NOVOPROD-1411307$NOVO NORDISK$$73$YR$$F$Y$$$20250715$$CN$US$US
255583961$25558396$1$I$$20250220$20250715$20250715$PER$$US-NOVOPROD-1411488$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255584071$25558407$1$I$$20250414$20250715$20250715$PER$$US-NOVOPROD-1411528$NOVO NORDISK$$53$YR$$$Y$$$20250715$$CN$US$US
255584371$25558437$1$I$$20250603$20250715$20250715$PER$$US-IBO-202500124$INTRABIO$$2$YR$C$F$Y$16$KG$20250715$$MD$US$US
255584521$25558452$1$I$20241101$20250508$20250715$20250715$PER$$US-NOVOPROD-1434856$NOVO NORDISK$$60$YR$$F$Y$$$20250715$$CN$US$US
255585221$25558522$1$I$20250422$20250422$20250715$20250715$PER$$US-NOVOPROD-1436463$NOVO NORDISK$$69$YR$$F$Y$$$20250715$$CN$US$US
255586461$25558646$1$I$$20250225$20250715$20250715$PER$$US-NOVOPROD-1412132$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255586481$25558648$1$I$$20250226$20250715$20250715$PER$$US-NOVOPROD-1411814$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255587881$25558788$1$I$20250401$20250430$20250715$20250715$PER$$US-NOVOPROD-1438658$NOVO NORDISK$$43$YR$$F$Y$$$20250715$$CN$US$US
255588341$25558834$1$I$$20250519$20250715$20250715$PER$$US-NOVOPROD-1449794$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255588471$25558847$1$I$$20250521$20250715$20250715$PER$$US-NOVOPROD-1450349$NOVO NORDISK$$$$A$$Y$$$20250715$$MD$US$US
255588781$25558878$1$I$$20250522$20250715$20250715$PER$$US-NOVOPROD-1450256$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255589301$25558930$1$I$20250520$20250520$20250715$20250715$PER$$US-NOVOPROD-1442395$NOVO NORDISK$$63$YR$$M$Y$$$20250715$$CN$US$US
255589401$25558940$1$I$$20250510$20250715$20250715$PER$$US-NOVOPROD-1442518$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255589831$25558983$1$I$$20250507$20250715$20250715$PER$$US-NOVOPROD-1442937$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255589842$25558984$2$F$20250501$20250825$20250715$20250904$EXP$$US-NOVOPROD-1443411$NOVO NORDISK$$69$YR$$F$Y$$$20250904$$CN$US$US
255590571$25559057$1$I$20250522$20250529$20250715$20250715$PER$$US-NOVOPROD-1453246$NOVO NORDISK$$68$YR$$F$Y$$$20250715$$CN$US$US
255590591$25559059$1$I$20250101$20250313$20250715$20250715$PER$$US-NOVOPROD-1392334$NOVO NORDISK$$79$YR$$M$Y$$$20250715$$CN$US$US
255591181$25559118$1$I$20250114$20241217$20250715$20250715$PER$$US-NOVOPROD-1393144$NOVO NORDISK$$60$YR$$F$Y$$$20250715$$CN$US$US
255591281$25559128$1$I$20250411$20250414$20250715$20250715$PER$$US-NOVOPROD-1415958$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255591361$25559136$1$I$20240101$20250106$20250715$20250715$PER$$US-NOVOPROD-1392864$NOVO NORDISK$$80$YR$$M$Y$$$20250715$$CN$US$US
255591471$25559147$1$I$20250308$20250311$20250715$20250715$PER$$US-NOVOPROD-1415991$NOVO NORDISK$$63$YR$$$Y$$$20250715$$CN$US$US
255592551$25559255$1$I$20250214$20250319$20250715$20250715$PER$$US-NOVOPROD-1394824$NOVO NORDISK$$52$YR$$$Y$$$20250715$$CN$US$US
255593071$25559307$1$I$$20250317$20250715$20250715$PER$$US-NOVOPROD-1416900$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255593521$25559352$1$I$20241215$20241219$20250715$20250715$PER$$US-NOVOPROD-1395033$NOVO NORDISK$$65$YR$$M$Y$$$20250715$$CN$US$US
255593561$25559356$1$I$20241217$20241217$20250715$20250715$PER$$US-NOVOPROD-1395280$NOVO NORDISK$$68$YR$$F$Y$$$20250715$$CN$US$US
255595131$25559513$1$I$20221001$20250325$20250715$20250715$PER$$US-NOVOPROD-1397481$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255595141$25559514$1$I$$20250121$20250715$20250715$PER$$US-NOVOPROD-1397456$NOVO NORDISK$$$$A$$Y$$$20250715$$CN$US$US
255595231$25559523$1$I$$20250306$20250715$20250715$PER$$US-NOVOPROD-1419026$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255595492$25559549$2$F$$20250324$20250715$20250718$PER$$US-NOVOPROD-1419524$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255595931$25559593$1$I$20250131$20250404$20250715$20250715$PER$$US-NOVOPROD-1398999$NOVO NORDISK$$73$YR$$F$Y$$$20250715$$CN$US$US
255596791$25559679$1$I$$20250121$20250715$20250715$PER$$US-NOVOPROD-1399881$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255596911$25559691$1$I$20250107$20250114$20250715$20250715$PER$$US-NOVOPROD-1400344$NOVO NORDISK$$69$YR$$F$Y$$$20250715$$CN$US$US
255596951$25559695$1$I$20241101$20250114$20250715$20250715$PER$$US-NOVOPROD-1400394$NOVO NORDISK$$67$YR$$M$Y$$$20250715$$CN$US$US
255597621$25559762$1$I$$20250327$20250715$20250715$PER$$US-NOVOPROD-1420293$NOVO NORDISK$$70$YR$$$Y$$$20250715$$CN$US$US
255597861$25559786$1$I$20240705$20250512$20250715$20250715$PER$$US-NOVOPROD-1401699$NOVO NORDISK$$68$YR$$F$Y$$$20250715$$CN$US$US
255599211$25559921$1$I$20250101$20250715$20250715$20250715$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-083254$BOEHRINGER INGELHEIM$$62$YR$A$F$Y$$$20250715$$$US$US
255600131$25560013$1$I$$20250303$20250715$20250715$PER$$US-NOVOPROD-1386937$NOVO NORDISK$$$$$M$Y$$$20250715$$PH$US$US
255600591$25560059$1$I$$20250404$20250715$20250715$PER$$US-NOVOPROD-1405613$NOVO NORDISK$$46$YR$$$Y$$$20250715$$CN$US$US
255601771$25560177$1$I$$20250410$20250715$20250715$PER$$US-NOVOPROD-1423619$NOVO NORDISK$$49$YR$$F$Y$$$20250715$$CN$US$US
255601871$25560187$1$I$$20241212$20250715$20250715$PER$$US-NOVOPROD-1387461$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255602651$25560265$1$I$20250101$20250306$20250715$20250715$PER$$US-NOVOPROD-1388863$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255602941$25560294$1$I$20250501$20250627$20250715$20250715$PER$$US-NOVOPROD-1424020$NOVO NORDISK$$54$YR$$M$Y$$$20250715$$CN$US$US
255602991$25560299$1$I$$20250122$20250715$20250715$PER$$US-NOVOPROD-1424130$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255603301$25560330$1$I$$20250403$20250715$20250715$PER$$US-NOVOPROD-1406988$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255603571$25560357$1$I$$20250421$20250715$20250715$PER$$US-NOVOPROD-1407633$NOVO NORDISK$$$$$F$Y$$$20250715$$MD$US$US
255603951$25560395$1$I$20250407$20250408$20250715$20250715$PER$$US-NOVOPROD-1407926$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255604041$25560404$1$I$$20250407$20250715$20250715$PER$$US-NOVOPROD-1408580$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255605351$25560535$1$I$$20250414$20250715$20250715$PER$$US-NOVOPROD-1409192$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255605671$25560567$1$I$20240101$20250414$20250715$20250715$PER$$US-NOVOPROD-1426441$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255606551$25560655$1$I$$20250710$20250715$20250715$EXP$$US-ABBVIE-6366975$ABBVIE$$$$E$M$Y$$$20250715$$CN$US$US
255607131$25560713$1$I$20241001$20250128$20250715$20250715$PER$$US-NOVOPROD-1403256$NOVO NORDISK$$66$YR$$F$Y$$$20250715$$CN$US$US
255607751$25560775$1$I$$20250428$20250715$20250715$PER$$US-NOVOPROD-1421702$NOVO NORDISK$$38$YR$$$Y$$$20250715$$CN$US$US
255607791$25560779$1$I$$20250328$20250715$20250715$PER$$US-NOVOPROD-1421795$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255608221$25560822$1$I$$20250407$20250715$20250715$PER$$US-NOVOPROD-1422338$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255608853$25560885$3$F$20250101$20250902$20250715$20250908$PER$$US-SA-2025SA198634$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250908$$HP$US$US
255608881$25560888$1$I$20241001$20250711$20250715$20250715$EXP$$US-ABBVIE-6370533$ABBVIE$$57$YR$$M$Y$$$20250715$$CN$US$US
255609101$25560910$1$I$$20250403$20250715$20250715$PER$$US-NOVOPROD-1404771$NOVO NORDISK$$81$YR$$F$Y$$$20250715$$CN$US$US
255610191$25561019$1$I$20250101$20250709$20250715$20250715$EXP$$US-ABBVIE-6347389$ABBVIE$$56$YR$$F$Y$$$20250715$$CN$US$US
255610521$25561052$1$I$20240731$20240826$20250715$20250715$PER$$US-NOVOPROD-1316914$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255610711$25561071$1$I$$20241007$20250715$20250715$PER$$US-NOVOPROD-1349298$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255612161$25561216$1$I$20250704$20250707$20250716$20250716$EXP$$CN-GSK-CN2025APC085245$GLAXOSMITHKLINE$$8$YR$$M$Y$20$KG$20250716$$$CN$CN
255612571$25561257$1$I$20250101$20250711$20250716$20250716$PER$$US-ABBVIE-6370172$ABBVIE$$$$A$F$Y$$$20250716$$MD$US$US
255612761$25561276$1$I$20240401$20240710$20250716$20250716$PER$$US-NOVOPROD-1267875$NOVO NORDISK$$59$YR$$F$Y$$$20250715$$CN$US$US
255613001$25561300$1$I$20250101$20250710$20250716$20250716$PER$$US-SA-2025SA198582$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250716$$HP$US$US
255613211$25561321$1$I$$20241022$20250716$20250716$PER$$US-NOVOPROD-1377902$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255614351$25561435$1$I$$20240814$20250716$20250716$PER$$US-NOVOPROD-1318045$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255615352$25561535$2$F$20250614$20250710$20250716$20250813$EXP$$CA-ASTRAZENECA-202507CAN007684CA$ALEXION PHARMACEUTICALS$$59$YR$A$$Y$$$20250813$$$CA$CA
255615751$25561575$1$I$$20241010$20250716$20250716$PER$$US-NOVOPROD-1352314$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255615771$25561577$1$I$$20241009$20250716$20250716$PER$$US-NOVOPROD-1352219$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255616381$25561638$1$I$$20250710$20250716$20250716$EXP$$ZA-ASTRAZENECA-202507SSA007373ZA$ALEXION PHARMACEUTICALS$$43$YR$A$M$Y$$$20250716$$$ZA$ZA
255616472$25561647$2$F$$20250711$20250716$20250718$EXP$$NVSC2025US110995$NOVARTIS$$35$YR$$F$Y$$$20250718$$MD$US$US
255616731$25561673$1$I$20231122$20250714$20250716$20250716$EXP$EU-AFSSAPS-LL2025001268$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-098547$BRISTOL-MYERS SQUIBB COMPANY$$61$YR$A$M$Y$$$20250716$$MD$EU$EU
255617841$25561784$1$I$20250101$20250711$20250716$20250716$PER$$US-SA-2025SA199680$SANOFI AVENTIS$$$$T$M$Y$$$20250716$$HP$US$US
255618441$25561844$1$I$20210101$20250221$20250716$20250716$PER$$US-NOVOPROD-1282818$NOVO NORDISK$$41$YR$$F$Y$95.238$KG$20250715$$CN$US$US
255618451$25561845$1$I$$20240906$20250716$20250716$PER$$US-NOVOPROD-1283911$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255619022$25561902$2$F$$20250718$20250716$20250730$EXP$$CA-TEVA-VS-3350615$TEVA$Jiang SX, Xiong W, Shahidi N. A CASE OF COLONIC MALAKOPLAKIA PRESENTING AS A LARGE CECAL MASS : NOT EVERY POLYP HAS TO LOOK LIKE A NAIL. J-Can-Assoc-Gastroenterol 2023; 6 (Suppl. 1) 71-72 abstr. A132 A132 A132 .; Jiang SX, Xiong W, Shahidi N. A CASE OF COLONIC MALAKOPLAKIA PRESENTING AS A LARGE CECAL MASS : NOT EVERY POLYP HAS TO LOOK LIKE A NAIL. J-Can-Assoc-Gastroenterol 2023; 6 (Suppl. 1) 71-72 abstr. A132 A132 A132 .$80$YR$$M$Y$$$20250730$$HP$CA$CA
255619091$25561909$1$I$$20250715$20250716$20250716$PER$$US-JNJFOC-20250718059$JOHNSON AND JOHNSON$$$$$$Y$$$20250716$$HP$US$US
255619451$25561945$1$I$$20250530$20250716$20250716$PER$$US-NOVOPROD-1319956$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255619581$25561958$1$I$$20240823$20250716$20250716$PER$$US-NOVOPROD-1320187$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
255619701$25561970$1$I$$20250708$20250716$20250716$EXP$$US-GSK-US2025AMR088417$GLAXOSMITHKLINE$$$$$F$Y$$$20250716$$$US$US
255620801$25562080$1$I$$20250709$20250716$20250716$EXP$$EU-ASTELLAS-2025-AER-037789$ASTELLAS$$23$YR$A$F$Y$$$20250716$$MD$EU$EU
255620841$25562084$1$I$20240912$20241115$20250716$20250716$PER$$US-NOVOPROD-1322570$NOVO NORDISK$$55$YR$$F$Y$$$20250715$$HP$US$US
255621071$25562107$1$I$$20240826$20250716$20250716$PER$$US-NOVOPROD-1321917$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255622261$25562226$1$I$$20250106$20250716$20250716$PER$$US-NOVOPROD-1354223$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
255622601$25562260$1$I$$20241016$20250716$20250716$PER$$US-NOVOPROD-1354919$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255622771$25562277$1$I$$20250530$20250716$20250716$PER$$US-NOVOPROD-1290630$NOVO NORDISK$$$$A$$Y$$$20250715$$CN$US$US
255623152$25562315$2$F$20220729$20250219$20250716$20250716$PER$$US-NOVOPROD-1290951$NOVO NORDISK$$60$YR$$M$Y$97.5$KG$20250715$$CN$US$US
255623311$25562331$1$I$$20240924$20250716$20250716$PER$$US-NOVOPROD-1291762$NOVO NORDISK$$62$YR$$M$Y$$$20250715$$MD$US$US
255623541$25562354$1$I$20220601$20250227$20250716$20250716$PER$$US-NOVOPROD-1291779$NOVO NORDISK$$40$YR$$M$Y$90.71$KG$20250715$$CN$US$US
255624262$25562426$2$F$20210601$20250916$20250716$20250926$EXP$$US-NOVOPROD-1382561$NOVO NORDISK$$56$YR$$M$Y$206.38$KG$20250926$$CN$US$US
255624331$25562433$1$I$$20250228$20250716$20250716$PER$$US-NOVOPROD-1382562$NOVO NORDISK$$63$YR$$$Y$$$20250715$$CN$US$US
255624651$25562465$1$I$$20241227$20250716$20250716$PER$$US-NOVOPROD-1382925$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255624691$25562469$1$I$$20250623$20250716$20250716$PER$$US-NOVOPROD-1383411$NOVO NORDISK$$75$YR$$M$Y$63.5$KG$20250715$$MD$US$US
255625321$25562532$1$I$$20240712$20250716$20250716$PER$$US-NOVOPROD-1268662$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255625741$25562574$1$I$20221226$20250127$20250716$20250716$PER$$US-NOVOPROD-1268928$NOVO NORDISK$$51$YR$$M$Y$81.633$KG$20250715$$CN$US$US
255626141$25562614$1$I$20220214$20250123$20250716$20250716$PER$$US-NOVOPROD-1269172$NOVO NORDISK$$29$YR$$M$Y$104.31$KG$20250715$$CN$US$US
255626361$25562636$1$I$$20250711$20250716$20250716$PER$$US-ASTRAZENECA-202507USA010707US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250716$$$US$US
255627671$25562767$1$I$20250101$20250710$20250716$20250716$PER$$US-UNITED THERAPEUTICS-UNT-2025-021094$UNITED THERAPEUTICS$$$$$F$Y$83.9$KG$20250716$$$US$US
255627891$25562789$1$I$$20240723$20250716$20250716$PER$$US-NOVOPROD-1286501$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255628141$25562814$1$I$$20241015$20250716$20250716$PER$$US-NOVOPROD-1323189$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255628801$25562880$1$I$20220101$20240830$20250716$20250716$PER$$US-NOVOPROD-1324704$NOVO NORDISK$$64$YR$$F$Y$$$20250715$$CN$US$US
255628912$25562891$2$F$$20250813$20250716$20250814$PER$$US-ASTRAZENECA-202506USA017316US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250814$$$US$US
255629251$25562925$1$I$20241201$20250204$20250716$20250716$PER$$US-NOVOPROD-1355970$NOVO NORDISK$$66$YR$$F$Y$$$20250715$$CN$US$US
255629411$25562941$1$I$$20250114$20250716$20250716$PER$$US-NOVOPROD-1356143$NOVO NORDISK$$45$YR$$M$Y$$$20250715$$MD$US$US
255629612$25562961$2$F$$20250709$20250716$20250722$EXP$$US-AUROBINDO-AUR-APL-2025-035318$AUROBINDO$Hungler C, Laurore K, Grillo C, Clements S. Tripping or Triggered? Differential Diagnosis and Management of Hallucination Persistent Perception Disorder: A Clinical Case Report. Am-J-HealthSyst-Pharm. 2025;82 (Suppl. 1):S2695$$$$M$Y$$$20250722$$HP$US$US
255630071$25563007$1$I$$20241119$20250716$20250716$PER$$US-NOVOPROD-1378761$NOVO NORDISK$$$$$$Y$$$20250715$$MD$US$US
255630201$25563020$1$I$20250101$20250709$20250716$20250716$EXP$$US-ABBVIE-6366446$ABBVIE$$47$YR$$F$Y$$$20250716$$CN$US$US
255630291$25563029$1$I$$20241120$20250716$20250716$PER$$US-NOVOPROD-1379012$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255630301$25563030$1$I$20241024$20241114$20250716$20250716$PER$$US-NOVOPROD-1379037$NOVO NORDISK$$65$YR$$M$Y$$$20250715$$CN$US$US
255630721$25563072$1$I$$20250710$20250716$20250716$EXP$$US-UCBSA-2025042907$UCB$$$$$$Y$$$20250716$$CN$US$US
255630831$25563083$1$I$$20241230$20250716$20250716$PER$$US-NOVOPROD-1379919$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255631571$25563157$1$I$20240916$20240917$20250716$20250716$PER$$US-NOVOPROD-1287423$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
255632091$25563209$1$I$20240301$20241101$20250716$20250716$PER$$US-NOVOPROD-1355781$NOVO NORDISK$$77$YR$$F$Y$$$20250715$$CN$US$US
255632321$25563232$1$I$$20250703$20250716$20250716$EXP$GB-MHRA-MED-202507022200215190-NTYMP$GB-AMAROX PHARMA-AMR2025GB03746$HETERO$$29$YR$$F$Y$$$20250716$$CN$GB$GB
255632701$25563270$1$I$$20250620$20250716$20250716$PER$$US-GSK-US2025077811$GLAXOSMITHKLINE$$$$$M$Y$$$20250716$$$US$US
255632861$25563286$1$I$20250630$20250714$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507012695$ELI LILLY AND COMPANY$$$$$F$Y$$$20250716$$CN$US$US
255635041$25563504$1$I$20231101$20241028$20250716$20250716$PER$$US-NOVOPROD-1356923$NOVO NORDISK$$50$YR$$M$Y$$$20250715$$CN$US$US
255635121$25563512$1$I$$20250707$20250716$20250716$PER$$US-Ipsen Biopharmaceuticals, Inc.-2025-16869$IPSEN BIOPHARMACEUTICALS, INC.$$$$$F$Y$$$20250716$$$US$US
255635351$25563535$1$I$$20250715$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507014127$ELI LILLY AND COMPANY$$60$YR$A$M$Y$$$20250716$$CN$US$US
255635831$25563583$1$I$$20250117$20250716$20250716$PER$$US-NOVOPROD-1357618$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255636051$25563605$1$I$$20240917$20250716$20250716$PER$$US-NOVOPROD-1288876$NOVO NORDISK$$$$$F$Y$$$20250715$$MD$US$US
255636771$25563677$1$I$20240701$20240726$20250716$20250716$PER$$US-NOVOPROD-1289747$NOVO NORDISK$$74$YR$$F$Y$$$20250715$$CN$US$US
255637541$25563754$1$I$20250616$20250617$20250716$20250716$PER$$US-TLM-TLM-2025-03718$TOLMAR$$70$YR$E$M$Y$116.8$KG$20250712$$HP$US$US
255637702$25563770$2$F$$20250729$20250716$20250805$PER$$JP-BEIGENE-BGN-2025-011528$BEIGENE$$77$YR$$$Y$$$20250805$$PH$JP$JP
255637941$25563794$1$I$20250528$20250617$20250716$20250716$PER$$US-TLM-TLM-2025-03661$TOLMAR$$70$YR$E$$Y$70.307$KG$20250715$$CN$US$US
255638021$25563802$1$I$$20250711$20250716$20250716$EXP$$US-ASTRAZENECA-202507USA009010US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250716$$$US$US
255638391$25563839$1$I$20240906$20240906$20250716$20250716$PER$$US-NOVOPROD-1328437$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255638811$25563881$1$I$20250712$20250714$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507013609$ELI LILLY AND COMPANY$$64$YR$A$$Y$$$20250716$$CN$US$US
255639361$25563936$1$I$$20240903$20250716$20250716$PER$$US-NOVOPROD-1327319$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255639641$25563964$1$I$$20250704$20250716$20250716$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-125848$ZYDUS PHARM$Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, et al.. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia.. Clin-Lymphoma-Myeloma-Leuk. 2024;24(11):783-788$$$$$Y$$$20250716$$HP$US$US
255639982$25563998$2$F$20250627$20250819$20250716$20250821$PER$$US-JNJFOC-20250712934$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20250821$$PH$US$US
255640741$25564074$1$I$$20241022$20250716$20250716$PER$$US-NOVOPROD-1358321$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255641041$25564104$1$I$$20241014$20250716$20250716$PER$$US-NOVOPROD-1358821$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255641552$25564155$2$F$$20250711$20250716$20250716$PER$$US-GILEAD-2025-0720729$GILEAD$$$$$$Y$$$20250716$$LW$US$US
255641601$25564160$1$I$20250101$20250710$20250716$20250716$PER$$US-AMGEN-USASP2025137400$AMGEN$$68$YR$E$F$Y$$$20250716$$HP$US$US
255641931$25564193$1$I$20241108$20250704$20250716$20250716$EXP$$EU-CIPLA LTD.-2025FR08484$CIPLA$$$$$$Y$$$20250716$$MD$EU$EU
255642381$25564238$1$I$$20240828$20250716$20250716$PER$$US-NOVOPROD-1291873$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255642683$25564268$3$F$20220625$20250220$20250716$20250716$PER$$US-NOVOPROD-1292175$NOVO NORDISK$$35$YR$$F$Y$75.74$KG$20250715$$HP$US$US
255642851$25564285$1$I$$20240926$20250716$20250716$PER$$US-NOVOPROD-1292367$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255643431$25564343$1$I$$20250715$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507014160$ELI LILLY AND COMPANY$$63$YR$A$M$Y$$$20250716$$CN$US$US
255643981$25564398$1$I$$20240909$20250716$20250716$PER$$US-NOVOPROD-1330184$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255645361$25564536$1$I$$20250622$20250716$20250716$PER$$US-SMPA-2025SPA008034$SUNOVION$$$$$$Y$$$20250716$$CN$US$US
255646022$25564602$2$F$$20250905$20250716$20250910$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008225$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250910$$CN$US$US
255646271$25564627$1$I$20250629$20250714$20250716$20250716$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-099609$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$M$Y$66.5$KG$20250716$$PH$US$US
255647121$25564712$1$I$20240927$20241105$20250716$20250716$PER$$US-NOVOPROD-1294556$NOVO NORDISK$$$$$F$Y$77.551$KG$20250715$$HP$US$US
255647841$25564784$1$I$20250616$20250715$20250715$20250715$DIR$FDA-CDER-CTU-2025-46741$$FDA-CTU$$51$YR$$M$N$$$20250715$N$HP$US$
255648681$25564868$1$I$$20241204$20250716$20250716$PER$$US-NOVOPROD-1332753$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255649421$25564942$1$I$20250706$20250712$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507012995$ELI LILLY AND COMPANY$$54$YR$A$F$Y$$$20250716$$CN$US$US
255649431$25564943$1$I$20250713$20250714$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507012754$ELI LILLY AND COMPANY$$41$YR$A$F$Y$$$20250716$$CN$US$US
255649591$25564959$1$I$$20240904$20250716$20250716$PER$$US-NOVOPROD-1332797$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255650521$25565052$1$I$$20250102$20250716$20250716$PER$$US-NOVOPROD-1360936$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255651211$25565121$1$I$20250303$20250702$20250716$20250716$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-516522$RANBAXY$$36$YR$$M$Y$$$20250716$$MD$EU$EU
255651441$25565144$1$I$$20250701$20250716$20250716$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-516840$RANBAXY$Wang J, Hou X, Zhang J, Ren B, Lu B. Guillain-Barre Syndrome Secondary to herpes Zoster: A Rare Case Report of Death and Literature Review. Case Rep Dermatol. 2025;17:118-122$68$YR$$M$Y$$$20250716$$HP$CN$CN
255651731$25565173$1$I$$20240726$20250716$20250716$PER$$US-NOVOPROD-1296225$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255652371$25565237$1$I$20250714$20250714$20250716$20250716$EXP$$CN-VANTIVE-2025VAN003245$Vantive US Healthcare$$$$$F$Y$$$20250716$$CN$CN$CN
255652902$25565290$2$F$$20250707$20250716$20250720$EXP$$TR-STRIDES ARCOLAB LIMITED-2025SP008771$STRIDES$Arikoglu T, Tokmeci N, Demirhan A, Ozhan AK, Yalaki AI, Akbey V, et al. Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children. Int-J-Clin-Pharm. 2024;46 (6):1294-1306$5$YR$$$Y$$$20250720$$HP$TR$TR
255652922$25565292$2$F$$20250707$20250716$20250720$EXP$$TR-STRIDES ARCOLAB LIMITED-2025SP008759$STRIDES$Arikoglu T, Tokmeci N, Demirhan A, Ozhan AK, Yalaki AI, Akbey V, et al. Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children.. Int-J-Clin-Pharm. 2024;46 (6):1294-1306$9$YR$$$Y$$$20250720$$HP$TR$TR
255653271$25565327$1$I$$20240913$20250716$20250716$PER$$US-NOVOPROD-1334409$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255653521$25565352$1$I$$20241031$20250716$20250716$PER$$US-NOVOPROD-1361529$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255653731$25565373$1$I$$20241025$20250716$20250716$PER$$US-NOVOPROD-1362848$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255654141$25565414$1$I$20240301$20241031$20250716$20250716$PER$$US-NOVOPROD-1361614$NOVO NORDISK$$52$YR$$F$Y$$$20250715$$CN$US$US
255654621$25565462$1$I$20240901$20241025$20250716$20250716$PER$$US-NOVOPROD-1362067$NOVO NORDISK$$$$E$$Y$$$20250715$$CN$US$US
255655251$25565525$1$I$$20241129$20250716$20250716$PER$$US-NOVOPROD-1300013$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255655281$25565528$1$I$20240321$20241223$20250716$20250716$PER$$US-NOVOPROD-1299816$NOVO NORDISK$$73$YR$$F$Y$82.5$KG$20250715$$CN$US$US
255655941$25565594$1$I$$20250625$20250716$20250716$PER$$US-GLK-000659$GLAUKOS$$$$$$Y$$$20250716$$MD$US$US
255656051$25565605$1$I$20240429$20241206$20250716$20250716$PER$$US-NOVOPROD-1335422$NOVO NORDISK$$87$YR$$M$Y$$$20250715$$CN$US$US
255658211$25565821$1$I$$20250711$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507012505$ELI LILLY AND COMPANY$$52$YR$A$F$Y$$$20250716$$CN$US$US
255658241$25565824$1$I$$20250714$20250716$20250716$PER$$US-ELI_LILLY_AND_COMPANY-US202507012479$ELI LILLY AND COMPANY$$62$YR$A$F$Y$$$20250716$$CN$US$US
255658482$25565848$2$F$$20250718$20250716$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507012885$ELI LILLY AND COMPANY$$45$YR$A$M$Y$$$20250722$$CN$US$US
255659181$25565918$1$I$$20250711$20250716$20250716$PER$$US-PFIZER INC-202500094056$PFIZER$$60$YR$$M$Y$$$20250716$$CN$US$US
255659253$25565925$3$F$$20250807$20250716$20250812$PER$$US-PFIZER INC-202500143791$PFIZER$$50$YR$$F$Y$$$20250812$$MD$US$US
255659283$25565928$3$F$$20250718$20250716$20250722$PER$$US-PFIZER INC-202500141217$PFIZER$$$$$F$Y$$$20250722$$PH$US$US
255659763$25565976$3$F$20230508$20250221$20250716$20250716$PER$$US-NOVOPROD-1269481$NOVO NORDISK$$63$YR$$F$Y$97.959$KG$20250715$$CN$US$US
255660291$25566029$1$I$20250501$20250707$20250716$20250716$PER$EU-MINISAL02-1048047$EU-Eisai-EC-2025-192773$EISAI$$61$YR$A$F$Y$$$20250716$$MD$EU$EU
255660321$25566032$1$I$20250630$20250708$20250716$20250716$EXP$$CN-COHERUS ONCOLOGY-2025-COH-CN000648$COHERUS$$$$$$Y$$$20250716$$HP$CN$CN
255660521$25566052$1$I$20231006$20240802$20250716$20250716$PER$$US-NOVOPROD-1302631$NOVO NORDISK$$58$YR$$F$Y$$$20250715$$CN$US$US
255660851$25566085$1$I$$20250708$20250716$20250716$PER$$JP-Eisai-EC-2025-193020$EISAI$Hiroya Yamaguchi. A Case of Hepatocellular Carcinoma with Acute Liver Disorder and Heterogeneous Tumor Effects After Atezolizumab + Bevacizumab Combination Therapy. liver. 2025; 66(S1): SS10-3-.$73$YR$E$M$Y$$$20250716$$MD$JP$JP
255661503$25566150$3$F$20250710$20250804$20250716$20250806$30DAY$$US-PFIZER INC-202500141381$PFIZER$$14$YR$$F$Y$$$20250806$$CN$US$US
255661761$25566176$1$I$$20240801$20250716$20250716$PER$$US-NOVOPROD-1303393$NOVO NORDISK$$$$$M$Y$$$20250715$$CN$US$US
255662842$25566284$2$F$$20250801$20250716$20250807$EXP$$RS-SA-2025SA198894$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250807$$CN$RS$RS
255664021$25566402$1$I$20250501$20250708$20250716$20250716$PER$$US-SA-2025SA200153$SANOFI AVENTIS$$35$YR$A$M$Y$72.57$KG$20250716$$MD$US$US
255664721$25566472$1$I$20241020$20241030$20250716$20250716$PER$$US-NOVOPROD-1366169$NOVO NORDISK$$76$YR$$F$Y$$$20250715$$CN$US$US
255664771$25566477$1$I$20240101$20250710$20250716$20250716$PER$$US-SA-2025SA199336$SANOFI AVENTIS$$$$E$M$Y$$$20250716$$MD$US$US
255665153$25566515$3$F$20250101$20250904$20250716$20250909$PER$$US-SA-2025SA199682$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250909$$HP$US$US
255665491$25566549$1$I$$20250711$20250716$20250716$PER$$US-SA-2025SA198132$SANOFI AVENTIS$$$$A$$Y$$$20250716$$HP$US$US
255665891$25566589$1$I$$20250711$20250716$20250716$PER$$US-SA-2025SA200392$SANOFI AVENTIS$$$$I$M$Y$$$20250716$$HP$US$US
255666381$25566638$1$I$$20250714$20250716$20250716$PER$$US-SA-2025SA200084$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250716$$CN$US$US
255667711$25566771$1$I$$20240716$20250716$20250716$PER$$US-NOVOPROD-1262961$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255668514$25566851$4$F$$20250816$20250716$20250818$30DAY$$US-PFIZER INC-202500131498$PFIZER$$11$YR$$M$Y$$$20250818$$CN$US$US
255668732$25566873$2$F$$20250821$20250716$20250826$30DAY$$EU-PFIZER INC-202500143560$PFIZER$$$$$$Y$$$20250826$$HP$EU$EU
255668921$25566892$1$I$$20240806$20250716$20250716$PER$$US-NOVOPROD-1304244$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255670731$25567073$1$I$$20250716$20250716$20250716$DIR$FDA-CDER-CTU-2025-46949$$FDA-CTU$$54$YR$$F$N$81.65$KG$20250716$N$$US$
255670922$25567092$2$F$20250710$20250724$20250716$20250805$PER$$US-BAYER-2025A091457$BAYER HEALTHCARE PHARMACEUTICALS INC.$$56$YR$A$M$Y$$$20250805$$PH$US$US
255671051$25567105$1$I$20240701$20240731$20250716$20250716$PER$$US-NOVOPROD-1304551$NOVO NORDISK$$55$YR$$F$Y$$$20250715$$CN$US$US
255671681$25567168$1$I$$20240924$20250716$20250716$PER$$US-NOVOPROD-1338557$NOVO NORDISK$$$$$$Y$$$20250715$$CN$US$US
255672181$25567218$1$I$20230201$20250401$20250716$20250716$PER$$US-NOVOPROD-1338771$NOVO NORDISK$$55$YR$$F$Y$74.84$KG$20250715$$CN$US$US
255673281$25567328$1$I$$20250203$20250716$20250716$PER$$US-NOVOPROD-1367920$NOVO NORDISK$$$$A$M$Y$$$20250715$$CN$US$US
255673351$25567335$1$I$$20250207$20250716$20250716$PER$$US-NOVOPROD-1367615$NOVO NORDISK$$56$YR$$$Y$$$20250715$$CN$US$US
255674001$25567400$1$I$$20240621$20250716$20250716$PER$$US-NOVOPROD-1263461$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255675432$25567543$2$F$20250711$20250711$20250716$20250718$EXP$$US-ABBVIE-6370294$ABBVIE$$69$YR$$F$Y$$$20250718$$CN$US$US
255675911$25567591$1$I$20230801$20240812$20250716$20250716$PER$$US-NOVOPROD-1271832$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255676481$25567648$1$I$20240214$20240717$20250716$20250716$PER$$US-NOVOPROD-1272371$NOVO NORDISK$$68$YR$$F$Y$$$20250715$$CN$US$US
255676501$25567650$1$I$$20250716$20250716$20250716$DIR$764902$$FDA-CTU$$$$$$N$$$20250716$$CN$US$
255676761$25567676$1$I$20250417$20250716$20250716$20250716$DIR$764930$$FDA-CTU$$42$YR$$F$N$54.3$KG$20250716$N$HP$US$
255677481$25567748$1$I$20240311$20240909$20250716$20250716$PER$$US-NOVOPROD-1273409$NOVO NORDISK$$73$YR$$M$Y$$$20250715$$CN$US$US
255677641$25567764$1$I$20240723$20240730$20250716$20250716$PER$$US-NOVOPROD-1306350$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255678323$25567832$3$F$$20250805$20250716$20250820$PER$$US-BRIDGEBIO-25US000967$BridgeBio Pharma$$$$$$Y$$$20250820$$CN$US$US
255678351$25567835$1$I$20240416$20241220$20250716$20250716$PER$$US-NOVOPROD-1342146$NOVO NORDISK$$$$A$F$Y$$$20250715$$CN$US$US
255678491$25567849$1$I$20240101$20250708$20250716$20250716$EXP$$EU-AMGEN-FRASP2025135156$AMGEN$Delrue M.; Daher M.; Percheron V. et al.. Pulmonary cement embolism following cement-augmented pedicle screw fixation in a patient with metastatic vertebral compression fracture A case report and management. Journal of Vascular Surgery Cases and Innovative Techniques. 2025;11 (4):1-5$61$YR$A$F$Y$$$20250716$$MD$EU$EU
255679742$25567974$2$F$$20241106$20250716$20250716$PER$$US-NOVOPROD-1369105$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255679961$25567996$1$I$$20250709$20250716$20250716$EXP$$TR-GSK-TR2025GSK088897$GLAXOSMITHKLINE$Bektas AB, Gochasanoglu BK. Efficacy of electroconvulsive therapy (ECT) in a treatment-resistant bipolar mixed state with metabolic comorbidity. Dusunen Adam J Psychiatr Neurol Sci. 2025;38:107-108$39$YR$$M$Y$$$20250716$$$TR$TR
255680251$25568025$1$I$$20250715$20250716$20250716$PER$$US-GILEAD-2025-0720836$GILEAD$$$$$$Y$$$20250716$$HP$US$US
255680811$25568081$1$I$20240617$20240626$20250716$20250716$PER$$US-NOVOPROD-1265302$NOVO NORDISK$$78$YR$$F$Y$$$20250715$$CN$US$US
255681031$25568103$1$I$$20250708$20250716$20250716$EXP$$EU-BIOGEN-2025BI01316846$BIOGEN$$$$$$Y$$$20250716$$MD$EU$EU
255681421$25568142$1$I$$20250708$20250716$20250716$PER$$US-BEH-2025212583$CSL BEHRING$$$$$F$Y$$$20250716$$PH$US$US
255681741$25568174$1$I$$20240627$20250716$20250716$PER$$US-PERRIGO-24US006198$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255682021$25568202$1$I$20240425$20240718$20250716$20250716$PER$$US-PERRIGO-24US006847$GALPHARM INTERNATIONAL$$78$YR$$M$Y$$$20250716$$CN$US$US
255682272$25568227$2$F$$20250812$20250716$20250818$EXP$$JP-AMGEN-JPNSP2025138733$AMGEN$Horikawa H.. Two cases of renal-limited ANCA-associated vasculitis treated with avacopan from the induction phase [in Japanese].. ANCA-associated vasculitis Expert Seminar. 2025$83$YR$E$F$Y$$$20250818$$MD$JP$JP
255682551$25568255$1$I$20240701$20240729$20250716$20250716$PER$$US-PERRIGO-24US007198$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250716$$CN$US$US
255682891$25568289$1$I$$20240822$20250716$20250716$PER$$US-PERRIGO-24US007918$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250716$$CN$US$US
255682901$25568290$1$I$20240401$20240816$20250716$20250716$PER$$US-PERRIGO-24US007804$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250716$$CN$US$US
255682916$25568291$6$F$20240101$20250915$20250716$20250920$EXP$$NVSC2025DE112526$NOVARTIS$$59$YR$$M$Y$89$KG$20250920$$CN$EU$EU
255683511$25568351$1$I$$20240904$20250716$20250716$PER$$US-PERRIGO-24US008398$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255683811$25568381$1$I$20240918$20240920$20250716$20250716$PER$$US-PERRIGO-24US008997$GALPHARM INTERNATIONAL$$78$YR$$M$Y$81.633$KG$20250716$$CN$US$US
255684161$25568416$1$I$20240901$20241003$20250716$20250716$PER$$US-PERRIGO-24US009407$GALPHARM INTERNATIONAL$$68$YR$$F$Y$95.238$KG$20250716$$CN$US$US
255684811$25568481$1$I$$20241018$20250716$20250716$PER$$US-NOVOPROD-1308237$NOVO NORDISK$$58$YR$$F$Y$$$20250715$$HP$US$US
255684911$25568491$1$I$$20241017$20250716$20250716$PER$$US-PERRIGO-24US010246$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255685031$25568503$1$I$$20241108$20250716$20250716$PER$$US-PERRIGO-24US010560$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255685443$25568544$3$F$20200901$20250311$20250716$20250718$PER$$US-NOVOPROD-1309418$NOVO NORDISK$$46$YR$$F$Y$87.075$KG$20250718$$CN$US$US
255686042$25568604$2$F$20210101$20241217$20250716$20250718$PER$$US-PERRIGO-24US011624$GALPHARM INTERNATIONAL$$$$$F$Y$59.864$KG$20250718$$CN$US$US
255686352$25568635$2$F$20240601$20250715$20250716$20250722$EXP$$EU-MYLANLABS-2025M1059801$MYLAN$$$$$F$Y$$$20250722$$MD$EU$EU
255687201$25568720$1$I$$20250114$20250716$20250716$PER$$US-PERRIGO-25US000918$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255687271$25568727$1$I$$20250115$20250716$20250716$PER$$US-PERRIGO-25US000941$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255687441$25568744$1$I$$20241219$20250716$20250716$PER$$US-NOVOPROD-1344087$NOVO NORDISK$$26$YR$$$Y$$$20250715$$CN$US$US
255687791$25568779$1$I$$20250126$20250716$20250716$PER$$US-PERRIGO-25US001961$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255687971$25568797$1$I$20241001$20250125$20250716$20250716$PER$$US-PERRIGO-25US001854$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255688341$25568834$1$I$20250321$20250404$20250716$20250716$EXP$$US-NOVOPROD-1478804$NOVO NORDISK$$$$$F$Y$$$20250715$$CN$US$US
255688691$25568869$1$I$$20250317$20250716$20250716$PER$$US-PERRIGO-25US003494$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250716$$CN$US$US
255688921$25568892$1$I$20250402$20250410$20250716$20250716$PER$$US-PERRIGO-25US004740$GALPHARM INTERNATIONAL$$82$YR$$F$Y$49.887$KG$20250716$$CN$US$US
255689281$25568928$1$I$$20250421$20250716$20250716$PER$$US-PERRIGO-25US005306$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255689651$25568965$1$I$$20250520$20250716$20250716$PER$$US-PERRIGO-25US006728$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255689831$25568983$1$I$$20250505$20250716$20250716$PER$$US-PERRIGO-25US005873$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250716$$CN$US$US
255689971$25568997$1$I$$20250702$20250716$20250716$PER$$US-RDY-USA/2025/07/010162$DR REDDYS$$$$$$Y$$$20250716$$MD$US$US
255690161$25569016$1$I$$20250604$20250716$20250716$PER$$US-PERRIGO-25US007272$GALPHARM INTERNATIONAL$$$$$M$Y$$$20250716$$CN$US$US
255690451$25569045$1$I$$20250704$20250716$20250716$EXP$GB-MHRA-MED-202507042312461680-YFWRP$GB-ELI_LILLY_AND_COMPANY-GB202507005569$ELI LILLY AND COMPANY$$40$YR$A$F$Y$73$KG$20250716$$CN$GB$GB
255690881$25569088$1$I$20250201$20250210$20250716$20250716$PER$$US-NOVOPROD-1412563$NOVO NORDISK$$70$YR$$M$Y$$$20250715$$CN$US$US
255691041$25569104$1$I$20241217$20241218$20250716$20250716$PER$$US-SUNNY-2024ALO00588$Alora Pharma$$21$YR$$F$Y$45.359$KG$20250716$$PH$US$US
255691161$25569116$1$I$20230501$20250211$20250716$20250716$PER$$US-NOVOPROD-1268584$NOVO NORDISK$$68$YR$$F$Y$90.703$KG$20250715$$CN$US$US
255693211$25569321$1$I$$20250709$20250716$20250716$PER$$NVSC2025US110323$NOVARTIS$$$$$$Y$$$20250716$$HP$US$US
255694221$25569422$1$I$$20250703$20250716$20250716$PER$$US-BIOMARINAP-US-2025-167142$BIOMARIN$$$$A$M$Y$$$20250716$$$US$US
255694471$25569447$1$I$$20250715$20250716$20250716$PER$$US-ASTRAZENECA-202507USA011575US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250716$$$US$US
255694831$25569483$1$I$$20250709$20250716$20250716$EXP$$TW-AMGEN-TWNSP2025137240$AMGEN$Wu, C.. Risk factors and reasons for romosozumab nonadherence in a case-control study. Scientific Reports. 2025;15 (1):01-09$$$$$Y$$$20250716$$HP$TW$TW
255694891$25569489$1$I$20230806$20250714$20250716$20250716$EXP$$EU-SANDOZ INC.-SDZ2025FR049637$SANDOZ$$70$YR$$F$Y$$$20250716$$HP$EU$EU
255695541$25569554$1$I$20240101$20250714$20250716$20250716$EXP$$US-ABBVIE-6371341$ABBVIE$$84$YR$$F$Y$$$20250716$$CN$US$US
255696433$25569643$3$F$20250101$20250808$20250717$20250815$EXP$$US-UCBSA-2025038397$UCB$$$$$F$Y$$$20250815$$MD$US$US
255697982$25569798$2$F$20250211$20250731$20250717$20250812$EXP$$EU-MACLEODS PHARMA-MAC2025054052$MACLEODS$$$$$$Y$$$20250812$$HP$EU$EU
255698291$25569829$1$I$20040202$20250707$20250717$20250717$EXP$EU-AFSSAPS-PB2025000754$EU-TEVA-VS-3350953$TEVA$$89$YR$$F$Y$$$20250717$$PH$EU$EU
255698502$25569850$2$F$$20250806$20250717$20250813$EXP$$JP-009507513-2305746$MERCK SHARP + DOHME LLC$$7$DEC$$F$Y$$$20250813$$MD$JP$JP
255699231$25569923$1$I$20250704$20250707$20250717$20250717$EXP$CN-NMPA-3702131013825202500186$CN-NOVOPROD-1475971$NOVO NORDISK$$66$YR$$F$Y$65$KG$20250717$$HP$CN$CN
255699301$25569930$1$I$$20250707$20250717$20250717$EXP$CA-HEALTHCANVIG-E2B_07901186$CA-NOVOPROD-1476433$NOVO NORDISK$$72$YR$$M$Y$$$20250717$$CN$CA$CA
255699382$25569938$2$F$$20250806$20250717$20250814$EXP$$JP-009507513-2305745$MERCK SHARP + DOHME LLC$$7$DEC$$M$Y$$$20250814$$MD$JP$JP
255699581$25569958$1$I$20250101$20250714$20250717$20250717$EXP$EU-AFSSAPS-LL2025001251$EU-ASTRAZENECA-202507GLO009666FR$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250717$$MD$EU$EU
255699821$25569982$1$I$$20250713$20250717$20250717$EXP$$US-GSK-US2025AMR089945$GLAXOSMITHKLINE$$$$$F$Y$$$20250717$$$US$US
255700811$25570081$1$I$20250101$20250711$20250717$20250717$PER$$US-UNITED THERAPEUTICS-UNT-2025-024303$UNITED THERAPEUTICS$$$$$M$Y$109.75$KG$20250717$$$US$US
255700991$25570099$1$I$20250601$20250715$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507013835$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250717$$CN$US$US
255701261$25570126$1$I$20250712$20250714$20250717$20250717$EXP$$US-UCBSA-2025043324$UCB$$26$YR$$F$Y$$$20250717$$CN$US$US
255701321$25570132$1$I$$20250704$20250717$20250717$EXP$$GB-AUROBINDO-AUR-APL-2025-035536$AUROBINDO$$$$$M$Y$111$KG$20250717$$PH$GB$GB
255701341$25570134$1$I$$20250708$20250717$20250717$PER$$US-APOTEX-2025AP009873$APOTEX$Longardner K, Satpathy Y, Litvan I, Haubenberger D.. Impact of clinical neurophysiological assessment on diagnosis and management of tremor disorders. Clinical Neurophysiology Practice. 2025;10:188-201$71$YR$$F$Y$$$20250717$$HP$US$US
255701421$25570142$1$I$20250601$20250616$20250717$20250717$PER$$US-KENVUE-20250703530$Kenvue$$66$YR$$F$Y$$$20250717$$CN$US$US
255702234$25570223$4$F$20250101$20250815$20250717$20250818$EXP$$US-KARYOPHARM-2025KPT100499$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20250818$$CN$US$US
255703012$25570301$2$F$20250710$20250714$20250717$20250718$EXP$$US-UCBSA-2025043227$UCB$$4$YR$$F$Y$$$20250718$$HP$US$US
255703371$25570337$1$I$$20250711$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507013594$ELI LILLY AND COMPANY$$78$YR$E$M$Y$$$20250717$$CN$US$US
255703941$25570394$1$I$$20250710$20250717$20250717$EXP$GB-MHRA-MED-202507090922383410-MWRFN$GB-RDY-GBR/2025/07/010472$DR REDDYS$$8$YR$C$F$Y$$$20250717$$CN$GB$GB
255704591$25570459$1$I$$20250716$20250717$20250717$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100132$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250717$$HP$US$US
255705411$25570541$1$I$$20250710$20250717$20250717$EXP$$CA-CELLTRION INC.-2025CA023318$CELLTRION$$$$$$Y$$$20250717$$CN$CA$CA
255705521$25570552$1$I$20190101$20250716$20250717$20250717$EXP$EU-DKMA-WBS-0100210$EU-ROCHE-3355581$ROCHE$$43$YR$A$F$Y$77$KG$20250717$$CN$EU$EU
255705591$25570559$1$I$20210101$20250710$20250717$20250717$EXP$$JP-MSD-M2022-43234$MERCK SHARP + DOHME LLC$$87$YR$$F$Y$$$20250717$$MD$JP$JP
255706042$25570604$2$F$20250601$20250723$20250717$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507014161$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250730$$CN$US$US
255706061$25570606$1$I$$20250710$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507009885$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250717$$HP$US$US
255706171$25570617$1$I$20250623$20250711$20250717$20250717$EXP$CN-NMPACDR-6523011569378202500053$CN-BAXTER-2025BAX018265$BAXTER$$45$YR$$F$Y$51$KG$20250717$$MD$CN$CN
255706451$25570645$1$I$$20250710$20250717$20250717$EXP$$CA-CELLTRION INC.-2025CA023201$CELLTRION$$$$$$Y$$$20250717$$HP$CA$CA
255706461$25570646$1$I$$20250625$20250717$20250717$PER$$US-EMD Serono-2025032588$EMD SERONO INC$$86$YR$E$M$Y$$$20250717$$$US$US
255706782$25570678$2$F$$20250815$20250717$20250828$PER$$US-GSK-US2025077874$GLAXOSMITHKLINE$$$$$F$Y$$$20250828$$$US$US
255707521$25570752$1$I$$20250708$20250717$20250717$PER$$US-BIOGEN-2025BI01317341$BIOGEN$$$$$$Y$$$20250717$$HP$US$US
255707881$25570788$1$I$$20250702$20250717$20250717$EXP$$EU-AZURITY PHARMACEUTICALS, INC.-AZR202507-001863$AZURITY PHARMACEUTICALS$Desport PC, Santos MF, DeCastro CL. Corticosteroid-induced neuropsychiatric effects: A rare case of persistent bipolar disorder. Psiq Biol. 2025;32:1-3$49$YR$$F$Y$$$20250717$$HP$EU$EU
255708831$25570883$1$I$$20250710$20250717$20250717$EXP$$US-JNJFOC-20250717302$JOHNSON AND JOHNSON$$4$DEC$A$M$Y$$$20250717$$HP$US$US
255709111$25570911$1$I$20250101$20250714$20250717$20250717$EXP$$EU-ABBVIE-6334169$ABBVIE$$51$YR$$F$Y$$$20250717$$MD$EU$EU
255709661$25570966$1$I$$20250506$20250717$20250717$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-00484$AMNEAL$$$$$$Y$$$20250717$$CN$US$US
255710321$25571032$1$I$$20250625$20250717$20250717$PER$$US-SMPA-2025SPA008140$SUNOVION$$$$$$Y$$$20250717$$CN$US$US
255710351$25571035$1$I$20250211$20250707$20250717$20250717$EXP$$EU-BIOCON-BCN-2025-000212$BIOCON$$$$A$M$Y$$$20250717$$HP$EU$EU
255710412$25571041$2$F$20250117$20250731$20250717$20250811$EXP$$US-ASTELLAS-2025-AER-037479$ASTELLAS$$56$YR$A$F$Y$$$20250811$$CN$US$US
255710441$25571044$1$I$$20250625$20250717$20250717$PER$$US-SMPA-2025SPA008157$SUNOVION$$$$$$Y$$$20250717$$CN$US$US
255710641$25571064$1$I$$20250715$20250717$20250717$PER$$US-ABBVIE-6375479$ABBVIE$$$$$$Y$$$20250717$$CN$US$US
255711221$25571122$1$I$$20250714$20250717$20250717$EXP$$US-ADIENNEP-2025AD000465$ADIENNE PHARMA + BIOTECH$Diaz Garcia BI, Johnson B, Peek G, Bleiweis M, Rackauskas M, Stukov Y et al. Rapidly Progressive Lung Disease in a 9-Year-Old. Am J Respir Crit Care Med. 2025;211:A2351. DOI: 10.1164/ajrccm.2025.211.Abstracts.A2351$$$C$M$Y$$$20250715$$MD$US$
255711491$25571149$1$I$20230401$20250709$20250717$20250717$EXP$$CN-ANIPHARMA-023568$ANI$$36$YR$A$F$Y$$$20250717$$HP$CN$CN
255711711$25571171$1$I$$20250627$20250717$20250717$PER$$US-SMPA-2025SPA005450$SUNOVION$$$$$$Y$$$20250717$$CN$US$US
255712411$25571241$1$I$20200101$20250708$20250717$20250717$EXP$$EU-AMGEN-ITASP2025135439$AMGEN$Gentile G.. Management of fertility preservation in young female patients with gastrointestinal cancer: A case series and systematic literature review. Current Problems in Cancer. 2025;57:1-9$23$YR$A$F$Y$$$20250717$$HP$EU$EU
255712501$25571250$1$I$20250715$20250715$20250717$20250717$EXP$$US-JNJFOC-20250717870$JOHNSON AND JOHNSON$$33$YR$A$F$Y$$$20250717$$HP$US$US
255713021$25571302$1$I$$20250703$20250717$20250717$EXP$$RS-HIKMA PHARMACEUTICALS USA INC.-RS-H14001-25-08421$HIKMA$Karisik E, Stanojevic-Ristic Z, Jevtic M, Rasic J, Maric M, Popovic M. Karisik E, Stanojevic-Ristic Z, Jevtic M, Rasic J, Maric M, Popovic M. Ceftriaxone-Induced Pancytopenia: A Case Report. Hematology reports. 2025;17(3):30$72$YR$$F$Y$$$20250717$$MD$RS$RS
255713371$25571337$1$I$$20250711$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507012641$ELI LILLY AND COMPANY$$39$YR$A$F$Y$$$20250717$$CN$US$US
255714151$25571415$1$I$$20250702$20250717$20250717$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-517008$RANBAXY$Martinez-Gil M, Hussain MW, Theut LR, Miller M, Ezekpo A, Dachman WD. Fever of unknown origin: Unravelling the mystery of Q fever and coccidioidomycosis coinfection - Case report. ID Cases. 2025;40 (0):no pagination$72$YR$$M$Y$$$20250717$$HP$US$US
255714751$25571475$1$I$$20250716$20250716$20250716$DIR$FDA-CDER-CTU-2025-47020$$FDA-CTU$$67$YR$$M$N$$$20250716$N$$US$
255715142$25571514$2$F$20250615$20250731$20250717$20250805$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008329$ACADIA PHARMACEUTICALS$$69$YR$$F$Y$$$20250805$$CN$US$US
255715871$25571587$1$I$$20250617$20250717$20250717$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-125731$ZYDUS PHARM$$$$$$Y$$$20250717$$CN$US$US
255716481$25571648$1$I$20250101$20250711$20250717$20250717$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-075198$BOEHRINGER INGELHEIM$$72$YR$E$F$Y$80$KG$20250717$$$EU$EU
255717051$25571705$1$I$$20240910$20250717$20250717$PER$$US-STRIDES ARCOLAB LIMITED-2024SP011825$STRIDES$Chen CB, Chugh S, Rao D.. Iron Pill-Induced Gastritis in a Pediatric Patient Taking Ferrous Sulfate Tablets.. J-Pediatr-Pharmacol-Ther. 2024;29 (4):425-428$$$$M$Y$$$20250717$$MD$US$US
255717101$25571710$1$I$$20250714$20250717$20250717$EXP$$EU-PFIZER INC-PV202500084179$PFIZER$Angelis, N.. Diffuse nocardiosis in a patient with an underlying malignancy. 24th PANHELLENIC CONGRESS ON INFECTIONS, Book of proceedings. 2025;108$72$YR$$F$Y$$$20250717$$MD$EU$EU
255718313$25571831$3$F$$20250826$20250717$20250903$EXP$$JP-PFIZER INC-PV202500083600$PFIZER$$75$YR$$F$Y$$$20250903$$MD$JP$JP
255719511$25571951$1$I$$20250707$20250717$20250717$EXP$$US-LUPIN PHARMACEUTICALS INC.-2025-06128$LUPIN$Tahir H, Waheed RI, Ahmed M. Unrecognized steroid exposure: tawon liar induced adrenal insufficiency. South Dakota Medicine. 2025;78 (5):s37-s38$65$YR$$M$Y$$$20250717$$$US$US
255719591$25571959$1$I$$20250707$20250717$20250717$EXP$$TR-STRIDES ARCOLAB LIMITED-2025SP008766$STRIDES$Arikoglu T, Tokmeci N, Demirhan A, Ozhan AK, Yalaki AI, Akbey V, et al.. Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children.. Int-J-Clin-Pharm. 2024;46 (6):1294-1306$5$YR$$$Y$$$20250717$$HP$TR$TR
255720952$25572095$2$F$$20250716$20250717$20250724$PER$$US-PFIZER INC-202500144390$PFIZER$$$$A$M$Y$$$20250724$$CN$US$US
255721091$25572109$1$I$20250101$20250714$20250717$20250717$EXP$$US-ABBVIE-6372449$ABBVIE$$52$YR$$F$Y$$$20250717$$CN$US$US
255721271$25572127$1$I$20250301$20250711$20250717$20250717$EXP$$US-UCBSA-2025019768$UCB$$55$YR$$M$Y$$$20250717$$CN$US$US
255722071$25572207$1$I$$20250714$20250717$20250717$EXP$$JP-GILEAD-2025-0720857$GILEAD$$69$YR$E$M$Y$$$20250717$$MD$JP$JP
255722511$25572251$1$I$20250101$20250708$20250717$20250717$PER$$US-UNITED THERAPEUTICS-UNT-2025-023754$UNITED THERAPEUTICS$$$$$F$Y$$$20250717$$$US$US
255722701$25572270$1$I$$20250709$20250717$20250717$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25051071$RADIUS PHARM$$$$$F$Y$$$20250717$$CN$US$US
255723251$25572325$1$I$$20250716$20250717$20250717$EXP$$IN-ASTRAZENECA-202507IND012122IN$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$48$KG$20250717$$$IN$IN
255724131$25572413$1$I$20250101$20250714$20250717$20250717$EXP$$US-PFIZER INC-202500142925$PFIZER$$64$YR$$F$Y$$$20250717$$PH$US$US
255725002$25572500$2$F$$20250825$20250717$20250828$PER$$US-LUNDBECK-DKLU4016668$LUNDBECK$$58$YR$A$F$Y$$$20250828$$CN$US$US
255725035$25572503$5$F$$20250917$20250717$20250925$PER$$CO-PFIZER INC-PV202500084995$PFIZER$$$$$M$Y$$$20250925$$CN$CO$CO
255725142$25572514$2$F$20240101$20250804$20250717$20250806$EXP$$EU-PFIZER INC-202500142343$PFIZER$$53$YR$$F$Y$57$KG$20250806$$CN$EU$EU
255725321$25572532$1$I$20221001$20250709$20250717$20250717$EXP$$EU-Blueprint Medicines Corporation-2025-AER-01506$BLUEPRINT MEDICINES$$70$YR$E$F$Y$$$20250717$$MD$EU$EU
255725431$25572543$1$I$$20250702$20250717$20250717$PER$$US-LUNDBECK-DKLU4016731$LUNDBECK$$$$$$Y$$$20250717$$CN$US$US
255726091$25572609$1$I$$20250709$20250717$20250717$EXP$$CN-ASTELLAS-2025-AER-038570$ASTELLAS$Zhong J, Luo Q, Han Q. Delayed viral clearance accompanied by early impaired humoral and virus-specific T- cell response in patients with coronavirus disease 2019 and interstitial lung disease. Vaccines. 2025;13(6): 1-14. doi:10.3390/vaccines13060655.$55$YR$A$F$Y$$$20250717$$HP$CN$CN
255726731$25572673$1$I$$20250708$20250717$20250717$PER$$US-SA-2025SA198586$SANOFI AVENTIS$$$$$M$Y$$$20250717$$HP$US$US
255726911$25572691$1$I$$20250710$20250717$20250717$PER$$US-SA-2025SA197240$SANOFI AVENTIS$$22$YR$A$M$Y$$$20250717$$CN$US$US
255727191$25572719$1$I$$20250710$20250717$20250717$PER$$US-SA-2025SA201549$SANOFI AVENTIS$$$$T$M$Y$61.4$KG$20250717$$MD$US$US
255727461$25572746$1$I$20250606$20250710$20250717$20250717$PER$$US-SA-2025SA201101$SANOFI AVENTIS$$27$YR$A$F$Y$$$20250717$$HP$US$US
255727631$25572763$1$I$$20250715$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507014572$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250717$$CN$US$US
255727691$25572769$1$I$20250401$20250715$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507015508$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250717$$CN$US$US
255727871$25572787$1$I$20250701$20250711$20250717$20250717$PER$$US-SA-2025SA201243$SANOFI AVENTIS$$11$YR$C$M$Y$$$20250717$$HP$US$US
255728142$25572814$2$F$$20250812$20250717$20250823$PER$$US-SA-2025SA202531$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250823$$HP$US$US
255728481$25572848$1$I$$20250711$20250717$20250717$PER$$US-SA-2025SA198482$SANOFI AVENTIS$$$$A$F$Y$$$20250717$$HP$US$US
255729581$25572958$1$I$$20250714$20250717$20250717$PER$$US-SA-2025SA202537$SANOFI AVENTIS$$$$A$F$Y$58$KG$20250717$$MD$US$US
255729901$25572990$1$I$20250601$20250714$20250717$20250717$PER$$US-SA-2025SA202496$SANOFI AVENTIS$$35$YR$A$F$Y$$$20250717$$HP$US$US
255729951$25572995$1$I$$20250714$20250717$20250717$PER$$US-SA-2025SA200545$SANOFI AVENTIS$$58$YR$A$F$Y$$$20250717$$CN$US$US
255730111$25573011$1$I$$20250715$20250717$20250717$PER$$US-SA-2025SA201824$SANOFI AVENTIS$$$$A$M$Y$$$20250717$$HP$US$US
255731381$25573138$1$I$20250711$20250716$20250717$20250717$EXP$$GB-AMERICAN REGENT INC-2025002781$AMERICAN REGENT$$91$YR$$F$Y$57$KG$20250717$$HP$GB$GB
255731811$25573181$1$I$20250716$20250716$20250716$20250716$DIR$764992$$FDA-CTU$$32$YR$$F$N$$$20250716$N$HP$US$
255732192$25573219$2$F$$20250722$20250717$20250725$EXP$$US-ABBVIE-6372818$ABBVIE$$$$A$F$Y$$$20250725$$CN$US$US
255732821$25573282$1$I$$20250716$20250717$20250717$EXP$$CN-TAKEDA-2025TUS064360$TAKEDA$$$$$F$Y$$$20250717$$$CN$CN
255733312$25573331$2$F$20250701$20250804$20250717$20250807$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100625$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$46.27$KG$20250807$$HP$US$US
255733412$25573341$2$F$20250101$20250903$20250717$20250908$EXP$$US-ABBVIE-6364360$ABBVIE$$61$YR$$F$Y$$$20250908$$CN$US$US
255733429$25573342$9$F$$20250927$20250717$20250929$30DAY$$US-PFIZER INC-202500143815$PFIZER$$13$YR$$M$Y$$$20250929$$HP$US$US
255734323$25573432$3$F$20250713$20250904$20250717$20250904$30DAY$$EU-PFIZER INC-202500141956$PFIZER$$$$$F$Y$$$20250904$$CN$EU$EU
255734791$25573479$1$I$20250101$20250705$20250717$20250717$PER$$US-INSUD PHARMA-2507US05546$INSUD PHARMA$$$$$$Y$$$20250717$$CN$US$US
255734952$25573495$2$F$$20250816$20250717$20250818$PER$$US-PFIZER INC-202500143716$PFIZER$$9$YR$$M$Y$$$20250818$$CN$US$US
255736321$25573632$1$I$$20250710$20250717$20250717$EXP$$US-AMGEN-USASP2025137684$AMGEN$Toy B.C.; Li J.; Yu K. et al.. A case of refractory idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN) responsive to infliximab and mycophenolate mofetil. Retinal Cases + Brief Reports. 2025;1-22$24$YR$A$M$Y$$$20250717$$MD$US$US
255736421$25573642$1$I$$20250715$20250717$20250717$EXP$$US-SA-2025SA202800$SANOFI AVENTIS$$71$YR$E$F$Y$$$20250717$$CN$US$US
255736491$25573649$1$I$20250610$20250716$20250717$20250717$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100743$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$M$Y$86.18$KG$20250717$$HP$US$US
255737561$25573756$1$I$$20250709$20250717$20250717$EXP$GB-MHRA-MED-202507090931322960-LNTZW$GB-ELI_LILLY_AND_COMPANY-GB202507009502$ELI LILLY AND COMPANY$$64$YR$A$M$Y$$$20250717$$CN$GB$GB
255738081$25573808$1$I$20250530$20250611$20250717$20250717$EXP$$US-BRACCO-2025US03893$BRACCO$$$$$F$Y$$$20250717$$CN$US$US
255738331$25573833$1$I$$20250710$20250717$20250717$EXP$$US-UCBSA-2025042876$UCB$$$$$F$Y$$$20250717$$CN$US$US
255738692$25573869$2$F$$20250812$20250717$20250815$PER$$US-MALLINCKRODT-MNK202504201$MALLINCKRODT$$$$$F$Y$$$20250814$$CN$US$US
255738951$25573895$1$I$$20250710$20250717$20250717$EXP$$US-MYLANLABS-2025M1059822$MYLAN$Mahajan A, Vatti T, Coulter A, Khawam E, Howland M. Palliative ECT for Catatonia in a Terminal Cancer Patient: A Case Report. J-Acad-Consult-Liaison-Psychiatry 2024; 65 (3): 315-316.$78$YR$$M$Y$$$20250717$$$US$US
255739401$25573940$1$I$$20250714$20250717$20250717$PER$$US-ASTRAZENECA-202507USA011947US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250717$$$US$US
255739521$25573952$1$I$20160301$20250708$20250717$20250717$EXP$$EU-ANIPHARMA-2025-DE-000032$ANI$$82$YR$$F$Y$56$KG$20250717$$MD$EU$EU
255739581$25573958$1$I$$20250702$20250717$20250717$PER$$JP-JOURNEY MEDICAL CORPORATION-2025JNY00117$JOURNEY MEDICAL CORPORATION$Kazusa Miyahara, Atsuko Nagaoka, Hiroko Sato, Mizuki Hino, Hiroaki Tomita, Yasuto Kunii. Minocycline as a causative agent of manic episode: A case report and brief postmortem brain analysis. Psychiatry and Clinical Neurosciences ? 2025 Japanese Society of Psychiatry and. 2025$3$DEC$$F$Y$$$20250717$$HP$JP$JP
255739711$25573971$1$I$$20250711$20250717$20250717$EXP$$KR-009507513-2309350$MERCK SHARP + DOHME LLC$$$$$M$Y$$$20250717$$CN$KR$KR
255739871$25573987$1$I$$20250716$20250717$20250717$EXP$$CA-ABBVIE-6375974$ABBVIE$$43$YR$$F$Y$$$20250717$$HP$CA$CA
255740491$25574049$1$I$$20250613$20250717$20250717$PER$$US-FMCRTG-FMC-2506-000991$FRESENIUS MEDICAL CARE$$$$$F$Y$$$20250717$$HP$US$US
255740743$25574074$3$F$$20250801$20250717$20250811$PER$$US-JNJFOC-20250717861$JOHNSON AND JOHNSON$$$$$$Y$$$20250811$$CN$US$US
255741031$25574103$1$I$$20250714$20250717$20250717$PER$$US-ELI_LILLY_AND_COMPANY-US202507012801$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250717$$CN$US$US
255741614$25574161$4$F$$20250910$20250717$20250911$30DAY$$PR-PFIZER INC-202500142639$PFIZER$$12$YR$$F$Y$$$20250911$$CN$PR$PR
255742961$25574296$1$I$20250709$20250709$20250717$20250717$EXP$$US-JNJFOC-20250713212$JOHNSON AND JOHNSON$$48$YR$A$M$Y$$$20250718$$HP$US$US
255743252$25574325$2$F$$20250806$20250717$20250817$30DAY$$CN-JNJFOC-20250719245$JOHNSON AND JOHNSON$$$$$$Y$$$20250818$$HP$CN$CN
255744531$25574453$1$I$$20250711$20250717$20250717$EXP$$JP-009507513-2308368$MERCK SHARP + DOHME LLC$$67$YR$$F$Y$$$20250717$$MD$JP$JP
255745161$25574516$1$I$$20250709$20250718$20250718$EXP$$US-Difgen-012080$DIFGEN PHARMACEUTICALS LLC$Boley S, Chakraborty A, Strand A, Gooley B and LeRoy J. Utilization of full-agonist therapy for severe precipitated opioid withdrawal: A case series and retrospective analysis. Am J Emerg Med. 2025 Aug:94:192-196. Doi: 10.1016/j.ajem.2025.04.052.$27$YR$A$M$Y$$$20250711$$MD$US$US
255745631$25574563$1$I$20250303$20250716$20250718$20250718$EXP$EU-AFSSAPS-NY2025000470$EU-ABBVIE-6376717$ABBVIE$$24$YR$$M$Y$$$20250718$$MD$EU$EU
255746081$25574608$1$I$$20250706$20250718$20250718$EXP$$IN-Accord-494526$ACCORD$Periasamy K, Goyal S, Kumar S, Chandran V, Kumar R. Extended field chemoradiation in M1a bladder carcinoma: A case report. J Cancer Res Ther. 2025 Apr 1;21(3):725-729. doi: 10.4103/jcrt.jcrt_2393_23.$59$YR$A$M$Y$$$20250718$$MD$IN$IN
255746311$25574631$1$I$$20250715$20250718$20250718$PER$$US-ABBVIE-6375091$ABBVIE$$$$A$$Y$$$20250718$$HP$US$US
255746671$25574667$1$I$$20250709$20250718$20250718$EXP$$US-AVET LIFESCIENCES LTD-2025-AVET-000231$EMCURE PHARMACEUTICALS LTD$Massad F, Calcagno T, Issa R, Tomaszewski K, Reese J, Starling RC, et.al.. Tacrolimus-Induced Thrombotic Microangiopathy in Orthotopic Heart Transplant Patients: A Case Series and Review of Literature. JACC Case Rep. 2025;30(17):103790$37$YR$$M$Y$$$20250718$$MD$US$US
255747421$25574742$1$I$20250601$20250715$20250718$20250718$EXP$$US-ABBVIE-6375335$ABBVIE$$62$YR$$F$Y$$$20250718$$CN$US$US
255747592$25574759$2$F$$20250805$20250718$20250812$PER$$US-JNJFOC-20250716726$JOHNSON AND JOHNSON$$$$E$M$Y$$$20250812$$CN$US$US
255748593$25574859$3$F$20250707$20250820$20250718$20250825$30DAY$$US-JNJFOC-20250706858$JOHNSON AND JOHNSON$$64$YR$A$F$Y$103$KG$20250825$$CN$US$US
255748881$25574888$1$I$$20250714$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507013509$ELI LILLY AND COMPANY$$64$YR$A$F$Y$$$20250718$$CN$US$US
255750451$25575045$1$I$20250501$20250714$20250718$20250718$PER$$US-SA-2025SA202366$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250718$$HP$US$US
255750521$25575052$1$I$$20250704$20250718$20250718$EXP$$EU-AZURITY PHARMACEUTICALS, INC.-AZR202507-001936$AZURITY PHARMACEUTICALS$D^hoore P, Terryn J. BACLOFEN INDUCED ENCEPHALOPATHY - A Study of two cases with review of literature. Clin. Neurophysiol. Pract.. 2025;10:218-21$18$YR$$F$Y$$$20250718$$HP$EU$EU
255750561$25575056$1$I$20250101$20250714$20250718$20250718$PER$$US-SA-2025SA201193$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250718$$HP$US$US
255750871$25575087$1$I$$20250709$20250718$20250718$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-097081$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250718$$CN$JP$JP
255751012$25575101$2$F$20250501$20250916$20250718$20250923$PER$$US-SA-2025SA201839$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250923$$HP$US$US
255751131$25575113$1$I$$20250709$20250718$20250718$PER$$US-BEIGENE-BGN-2025-011693$BEIGENE$$$$$$Y$$$20250718$$MD$US$US
255751502$25575150$2$F$20250628$20250716$20250718$20250730$PER$$US-SMPA-2025SPA008375$SUNOVION$$$$$$Y$$$20250730$$CN$US$US
255752241$25575224$1$I$$20250716$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507015354$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250718$$CN$US$US
255753111$25575311$1$I$$20250708$20250718$20250718$EXP$CA-MHPD-001130481$CA-Accord-494009$ACCORD$$62$YR$A$M$Y$119$KG$20250718$$HP$CA$CA
255753291$25575329$1$I$$20250711$20250718$20250718$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25051117$RADIUS PHARM$$$$$F$Y$$$20250718$$CN$US$US
255753791$25575379$1$I$$20250716$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507015357$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250718$$CN$US$US
255754171$25575417$1$I$$20250714$20250718$20250718$EXP$$US-BAXTER-2025BAX018435$BAXTER$$82$YR$$F$Y$$$20250718$$HP$US$US
255754331$25575433$1$I$$20250711$20250718$20250718$PER$$US-GSK-US2025AMR089654$GLAXOSMITHKLINE$$$$$F$Y$$$20250718$$$US$US
255754992$25575499$2$F$$20250815$20250718$20250819$PER$$US-BAUSCHBL-2025BNL012621$BAUSCH AND LOMB$$42$YR$$F$Y$$$20250819$$MD$US$US
255755121$25575512$1$I$$20250714$20250718$20250718$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06292$LUPIN$$57$YR$$$Y$169.62$KG$20250718$$$US$US
255755691$25575569$1$I$$20250628$20250718$20250718$30DAY$$US-BECTON DICKINSON-US-BD-25-000342$BECTON DICKINSON$$$$$$Y$$$20250718$$CN$US$US
255756371$25575637$1$I$$20250711$20250718$20250718$EXP$$EU-ANIPHARMA-023625$ANI$$$$$$Y$$$20250718$$HP$EU$EU
255756462$25575646$2$F$$20250822$20250718$20250902$PER$$US-SMPA-2025SPA008186$SUNOVION$$56$YR$$M$Y$$$20250901$$$US$US
255756471$25575647$1$I$$20250625$20250718$20250718$PER$$US-SMPA-2025SPA008165$SUNOVION$$$$$$Y$$$20250718$$CN$US$US
255756971$25575697$1$I$$20250715$20250718$20250718$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100716$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$$$20250718$$HP$US$US
255757021$25575702$1$I$20250601$20250715$20250718$20250718$EXP$$US-ABBVIE-6375319$ABBVIE$$38$YR$$F$Y$$$20250718$$CN$US$US
255757271$25575727$1$I$$20250628$20250718$20250718$PER$$US-SMPA-2025SPA008324$SUNOVION$$$$$$Y$$$20250718$$CN$US$US
255757871$25575787$1$I$$20250715$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507014251$ELI LILLY AND COMPANY$$65$YR$E$M$Y$$$20250718$$CN$US$US
255758841$25575884$1$I$20250630$20250715$20250718$20250718$EXP$$CA-ABBVIE-6374464$ABBVIE$$48$YR$$F$Y$$$20250718$$CN$CA$CA
255759071$25575907$1$I$$20250714$20250718$20250718$PER$$US-TEVA-VS-3352743$TEVA$$70$YR$$M$Y$$$20250718$$CN$US$US
255759322$25575932$2$F$$20250717$20250718$20250729$EXP$$EU-AUROBINDO-AUR-APL-2025-035857$AUROBINDO$Pawlowska A, Kwella N, Zbrzezniak-Suszczewicz J, Knysak M, Stompor T.. First Use of Maribavir in Poland to treat Refractory CMV Disease in a Patient After Kidney Transplantation.. Transplantation Proceedings.. 2025;57 (3):427-429.$39$YR$$$Y$$$20250729$$HP$EU$EU
255759631$25575963$1$I$$20250711$20250718$20250718$EXP$$US-GSK-US2025AMR090534$GLAXOSMITHKLINE$$$$$F$Y$$$20250718$$$US$US
255759891$25575989$1$I$$20250627$20250718$20250718$PER$$US-GSK-US2025AMR081539$GLAXOSMITHKLINE$$$$$F$Y$$$20250718$$$US$US
255760261$25576026$1$I$20220922$20250716$20250718$20250718$PER$$US-SA-2025SA203095$SANOFI AVENTIS$$10$YR$C$M$Y$93$KG$20250718$$CN$US$US
255760651$25576065$1$I$$20250714$20250718$20250718$PER$$US-SA-2025SA203120$SANOFI AVENTIS$$$$E$M$Y$95.45$KG$20250718$$MD$US$US
255760951$25576095$1$I$20250601$20250715$20250718$20250718$PER$$US-SA-2025SA203428$SANOFI AVENTIS$$42$YR$A$F$Y$76.18$KG$20250718$$MD$US$US
255761031$25576103$1$I$20250716$20250716$20250718$20250718$PER$$US-SA-2025SA203396$SANOFI AVENTIS$$40$YR$A$M$Y$$$20250718$$CN$US$US
255761571$25576157$1$I$$20250716$20250718$20250718$PER$$US-SA-2025SA204520$SANOFI AVENTIS$$2$YR$C$F$Y$$$20250718$$CN$US$US
255762631$25576263$1$I$$20250707$20250718$20250718$EXP$$JP-MACLEODS PHARMA-MAC2025054068$MACLEODS$Sakurai H, Okamoto T, Hamaya T, Kodama H, Fujita N, Yamamoto H, et.al.A Case of Delayed Refractory Mycobacterium mageritense Abdominal Wall Abscess in a Kidney Transplant Recipient.IJU Case Reports.9 MAY 2025;8(4):369-372$$$$$Y$$$20250718$$HP$JP$JP
255762731$25576273$1$I$$20250712$20250718$20250718$PER$$US-SA-2025SA201554$SANOFI AVENTIS$$81$YR$E$M$Y$$$20250718$$CN$US$US
255763083$25576308$3$F$20250701$20250829$20250718$20250901$PER$$US-AMGEN-USASP2025140423$AMGEN$$77$YR$E$F$Y$$$20250901$$CN$US$US
255763231$25576323$1$I$$20250622$20250718$20250718$PER$$US-GSK-US2025AMR081106$GLAXOSMITHKLINE$$$$$F$Y$$$20250718$$$US$US
255763311$25576331$1$I$20231201$20250708$20250718$20250718$EXP$$CN-862174955-ML2025-03542$Unknown Manufacturer$Xie Y, Wu D, Jin P, Mao L, Zhen J, Zhang W. Case Report: Synergistic central nervous system depression of baclofen and pregabalin: clinical pharmacist-driven case analysis and case review. Frontiers in Pharmacology. 2025 Jun 05;16: 01-08. doi:10.3389/fphar.2025.1598971.$68$YR$E$F$Y$65$KG$20250718$$HP$CN$CN
255764041$25576404$1$I$$20250716$20250718$20250718$EXP$$US-ORGANON-O2507USA001698$ORGANON$$$$$F$Y$$$20250718$$CN$US$US
255764311$25576431$1$I$20210101$20250708$20250718$20250718$EXP$$EU-AMGEN-ITASP2025136458$AMGEN$Shahini, E.. Case Report: Disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum. Frontiers in Immunology. 2025;16:1-9$50$YR$A$M$Y$$$20250718$$HP$EU$EU
255764781$25576478$1$I$$20250715$20250718$20250718$PER$$US-SA-2025SA204066$SANOFI AVENTIS$$$$A$F$Y$62.73$KG$20250718$$MD$US$US
255765041$25576504$1$I$20250714$20250715$20250718$20250718$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008333$ACADIA PHARMACEUTICALS$$82$YR$$F$Y$$$20250718$$CN$US$US
255765161$25576516$1$I$20250708$20250716$20250718$20250718$EXP$$AU-MYLANLABS-2025M1060695$MYLAN$$52$YR$$M$Y$$$20250718$$$AU$AU
255765631$25576563$1$I$$20250714$20250718$20250718$PER$$US-SA-2025SA203467$SANOFI AVENTIS$$$$A$F$Y$$$20250718$$HP$US$US
255766041$25576604$1$I$$20250709$20250718$20250718$PER$$US-ROCHE-10000334385$ROCHE$$$$E$F$Y$$$20250718$$CN$US$US
255766091$25576609$1$I$$20250712$20250718$20250718$PER$$US-ROCHE-10000337090$ROCHE$$$$A$F$Y$$$20250718$$CN$US$US
255766691$25576669$1$I$$20250708$20250718$20250718$EXP$$TR-ENDO USA, INC.-2025-001607$ENDO$Daye M, Temiz SA, Arslan S, Yosunkaya A, Gumus S, Uyanik O, et al.. Toxic Epidermal Necrolysis in a Patient with Allopurinol, Colchicine and Alcohol Use. Journal of Emergency Medicine Case Reports. 2020;11(3):65-67$33$YR$$M$Y$$$20250718$$HP$TR$TR
255767381$25576738$1$I$$20250709$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507009933$ELI LILLY AND COMPANY$$$$A$M$Y$$$20250718$$CN$US$US
255767431$25576743$1$I$20250615$20250703$20250718$20250718$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-515340$RANBAXY$$$$$F$Y$$$20250718$$CN$GB$GB
255767781$25576778$1$I$$20250704$20250718$20250718$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-517759$RANBAXY$$$$$M$Y$$$20250718$$CN$EU$EU
255769593$25576959$3$F$$20250723$20250718$20250728$EXP$$CA-PFIZER INC-202300445403$PFIZER$$32$YR$$M$Y$$$20250728$$MD$CA$CA
255770931$25577093$1$I$$20250717$20250717$20250717$DIR$765120$$FDA-CTU$$$$$$N$$$20250717$N$$US$
255771531$25577153$1$I$$20250706$20250718$20250718$EXP$$US-Norvium Bioscience LLC-080401$Norvium Bioscience$Casey TJ, Mehr BP. A novel case of aripiprazole and clomipramine-induced toxic megacolon: enough to drive anyone mad. J Surg Case Rep. 2025 Jun 23;2025(6):rjaf265. doi: 10.1093/jscr/rjaf265$49$YR$A$M$Y$$$20250718$$HP$US$US
255771991$25577199$1$I$$20250714$20250718$20250718$EXP$$US-ASTRAZENECA-202507USA010007US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250718$$$US$US
255772151$25577215$1$I$20221101$20250717$20250718$20250718$EXP$$EU-ABBVIE-4339909$ABBVIE$$57$YR$$F$Y$$$20250718$$MD$EU$EU
255772401$25577240$1$I$$20250717$20250717$20250717$DIR$765122$$FDA-CTU$$$$$$N$$$20250717$N$CN$US$
255772491$25577249$1$I$20250701$20250716$20250718$20250718$PER$$US-SA-2025SA203924$SANOFI AVENTIS$$71$YR$E$F$Y$$$20250718$$CN$US$US
255772591$25577259$1$I$20250709$20250710$20250718$20250718$EXP$$CO-TAKEDA-2025TUS063732$TAKEDA$$19$YR$$M$Y$64$KG$20250718$$$CO$CO
255772731$25577273$1$I$$20250715$20250718$20250718$EXP$$US-GILEAD-2025-0721216$GILEAD$$$$E$F$Y$$$20250718$$CN$US$US
255773321$25577332$1$I$$20250709$20250718$20250718$PER$$US-JNJFOC-20250721423$JOHNSON AND JOHNSON$$$$$$Y$$$20250718$$PH$US$US
255773921$25577392$1$I$20250508$20250715$20250718$20250718$EXP$$US-AMGEN-USASP2025140999$AMGEN$$84$YR$E$F$Y$$$20250718$$CN$US$US
255773981$25577398$1$I$20250701$20250715$20250718$20250718$PER$$US-SA-2025SA202991$SANOFI AVENTIS$$40$YR$A$F$Y$81.82$KG$20250718$$MD$US$US
255774001$25577400$1$I$$20250711$20250718$20250718$EXP$$AU-SAMSUNG BIOEPIS-SB-2025-24275$SAMSUNG BIOEPIS$$$$$F$Y$72$KG$20250718$$PH$AU$AU
255774441$25577444$1$I$$20250516$20250718$20250718$PER$$US-NOVOPROD-1445853$NOVO NORDISK$$$$$M$Y$$$20250718$$CN$US$US
255775301$25577530$1$I$$20250717$20250718$20250718$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101247$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$86.64$KG$20250718$$CN$US$US
255775471$25577547$1$I$$20250716$20250718$20250718$PER$$US-SA-2025SA204336$SANOFI AVENTIS$$$$$F$Y$$$20250718$$CN$US$US
255775551$25577555$1$I$$20240718$20250718$20250718$PER$$US-NOVOPROD-1261960$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255776111$25577611$1$I$$20240822$20250718$20250718$PER$$US-NOVOPROD-1277785$NOVO NORDISK$$$$A$$Y$$$20250718$$CN$US$US
255776701$25577670$1$I$$20240911$20250718$20250718$PER$$US-NOVOPROD-1284015$NOVO NORDISK$$$$$M$Y$$$20250718$$MD$US$US
255777071$25577707$1$I$20231001$20241018$20250718$20250718$PER$$US-NOVOPROD-1355460$NOVO NORDISK$$67$YR$$F$Y$$$20250718$$CN$US$US
255778401$25577840$1$I$20241001$20250227$20250718$20250718$PER$$US-NOVOPROD-1382012$NOVO NORDISK$$75$YR$$F$Y$$$20250718$$CN$US$US
255779021$25577902$1$I$20211101$20250218$20250718$20250718$PER$$US-NOVOPROD-1419204$NOVO NORDISK$$74$YR$$F$Y$$$20250718$$CN$US$US
255779491$25577949$1$I$20170101$20250707$20250718$20250718$EXP$$US-INDIVIOR US-INDV-153975-2024$RECKITT BENCKISER$$$$$$Y$$$20250718$$LW$US$US
255779643$25577964$3$F$20250701$20250730$20250718$20250801$30DAY$$US-PFIZER INC-202500143865$PFIZER$$48$YR$$M$Y$$$20250801$$CN$US$US
255779681$25577968$1$I$$20250710$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507010169$ELI LILLY AND COMPANY$$52$YR$A$$Y$$$20250718$$CN$US$US
255779931$25577993$1$I$$20250716$20250718$20250718$EXP$$US-PFIZER INC-PV202500085609$PFIZER$$5$DEC$$F$Y$$$20250718$$LW$US$US
255780051$25578005$1$I$$20250714$20250718$20250718$30DAY$$US-PFIZER INC-202500142557$PFIZER$$$$$$Y$$$20250718$$MD$US$US
255780061$25578006$1$I$$20250716$20250718$20250718$EXP$$US-PFIZER INC-PV202500085714$PFIZER$$$$A$F$Y$$$20250718$$LW$US$US
255780442$25578044$2$F$$20250728$20250718$20250730$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101348$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$$$20250730$$CN$US$US
255780792$25578079$2$F$20220101$20250716$20250718$20250722$PER$$US-BIOGEN-2025BI01316704$BIOGEN$$$$$F$Y$$$20250722$$CN$US$US
255781004$25578100$4$F$$20250815$20250718$20250819$30DAY$$US-PFIZER INC-202500144918$PFIZER$$$$$$Y$$$20250819$$PH$US$US
255781281$25578128$1$I$20250224$20250714$20250718$20250718$EXP$$US-UCBSA-2025043101$UCB$$67$YR$$M$Y$$$20250718$$HP$US$US
255781332$25578133$2$F$$20250717$20250718$20250724$EXP$$US-PFIZER INC-PV202500084662$PFIZER$Skrehot, H.. Docetaxel-induced pigmentary maculopathy.. RETINAL Cases + Brief Reports. 2024;10.1097/ICB.0000000000001617$79$YR$$M$Y$$$20250724$$HP$US$US
255782262$25578226$2$F$$20250717$20250718$20250724$EXP$$US-TORRENT-00014420$TORRENT PHARMA INC.$$23$YR$A$F$Y$$$20250724$$MD$US$US
255782521$25578252$1$I$$20250703$20250718$20250718$PER$$US-INCYTE CORPORATION-2025IN007622$INCYTE$$3$MON$$$Y$4.7$KG$20250718$$MD$US$US
255782721$25578272$1$I$20250101$20250709$20250718$20250718$PER$$US-INSUD PHARMA-2507US05731$INSUD PHARMA$$$$$$Y$$$20250718$$CN$US$US
255782782$25578278$2$F$20240904$20250801$20250718$20250810$EXP$$JP-AMGEN-JPNSP2025138636$AMGEN$$70$YR$E$M$Y$$$20250810$$MD$JP$JP
255783021$25578302$1$I$20250714$20250714$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507013925$ELI LILLY AND COMPANY$$68$YR$E$M$Y$$$20250718$$CN$US$US
255784052$25578405$2$F$20230101$20250715$20250718$20250722$EXP$$US-BIOGEN-2025BI01317577$BIOGEN$$$$$F$Y$$$20250722$$CN$US$US
255784081$25578408$1$I$$20250715$20250718$20250718$EXP$$CA-TAKEDA-2025TUS064145$TAKEDA$$$$$F$Y$$$20250718$$$CA$CA
255784281$25578428$1$I$20211016$20220111$20250718$20250718$EXP$$AR-SANDOZ INC.-NVSC2021AR297414$SANDOZ$$61$YR$$F$Y$$$20250718$$MD$AR$AR
255785084$25578508$4$F$20250101$20250918$20250718$20250923$PER$$US-MALLINCKRODT-MNK202504320$MALLINCKRODT$$54$YR$A$M$Y$$$20250923$$CN$US$US
255785381$25578538$1$I$$20250716$20250718$20250718$PER$$US-PURDUE PHARMA-USA-2025-0319000$PURDUE$$38$YR$$F$Y$$$20250718$$CN$US$US
255785891$25578589$1$I$20230815$20250711$20250718$20250718$EXP$EU-AFSSAPS-MA2025000874$EU-RDY-FRA/2025/07/010511$DR REDDYS$$68$YR$E$F$Y$$$20250718$$HP$EU$EU
255786371$25578637$1$I$$20250717$20250718$20250718$30DAY$$US-SANDOZ INC.-SDZ2025US051040$SANDOZ$$57$YR$$F$Y$$$20250718$$CN$US$US
255786631$25578663$1$I$20250707$20250707$20250718$20250718$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202507006834$ELI LILLY AND COMPANY$$$$$F$Y$$$20250718$$CN$CN$CN
255787071$25578707$1$I$20231101$20250704$20250718$20250718$EXP$$MA-SANDOZ INC.-SDZ2025MA048098$SANDOZ$Sagara M,Mohamed A O, Assad HE, Kanta S, Marbouh KE, Mekhakh O et al. Article : Rheumatoid polyarthritis and Tabetic arthropathy: between control of inflammation andinfectious risk with anti-TNF? - Clinical study and review of the literature. Revue Marocaine de Rhumatologie. 2025;Q2$$$A$M$Y$$$20250718$$MD$MA$MA
255788101$25578810$1$I$$20250716$20250718$20250718$PER$$US-ABBVIE-6377400$ABBVIE$$$$$$Y$$$20250718$$HP$US$US
255788131$25578813$1$I$20250601$20250716$20250718$20250718$PER$$US-ABBVIE-6378287$ABBVIE$$51$YR$$M$Y$$$20250718$$CN$US$US
255788281$25578828$1$I$$20250717$20250718$20250718$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101277$BRISTOL-MYERS SQUIBB COMPANY$$58$YR$A$F$Y$$$20250718$$HP$US$US
255788531$25578853$1$I$$20250716$20250718$20250718$PER$$US-SA-2025SA204108$SANOFI AVENTIS$$51$YR$A$M$Y$$$20250718$$CN$US$US
255788711$25578871$1$I$20250420$20250716$20250718$20250718$EXP$CH-JNJFOC-20250722344$CH-JNJFOC-20250722344$JOHNSON AND JOHNSON$$84$YR$$M$Y$120$KG$20250718$$PH$CH$CH
255788721$25578872$1$I$$20250710$20250718$20250718$PER$$US-ELI_LILLY_AND_COMPANY-US202507014155$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250717$$CN$US$US
255789892$25578989$2$F$20210120$20250712$20250718$20250725$EXP$$AU-TEVA-VS-3352571$TEVA$$74$YR$$F$Y$$$20250725$$MD$AU$AU
255790083$25579008$3$F$20250601$20250820$20250718$20250820$30DAY$$US-PFIZER INC-202500140718$PFIZER$$15$YR$$M$Y$$$20250820$$CN$US$US
255790092$25579009$2$F$$20250730$20250718$20250805$30DAY$$JP-PFIZER INC-202500145696$PFIZER$$$$T$M$Y$$$20250805$$CN$JP$JP
255790143$25579014$3$F$$20250820$20250718$20250820$30DAY$$US-PFIZER INC-202500139407$PFIZER$$9$YR$$M$Y$$$20250820$$CN$US$US
255790631$25579063$1$I$$20200518$20250718$20250718$EXP$$EU-SANDOZ INC.-NVSC2020NL186702$SANDOZ$$$$$$Y$$$20250718$$CN$EU$EU
255790911$25579091$1$I$20250501$20250710$20250718$20250718$EXP$$US-TEVA-VS-3351673$TEVA$$66$YR$$F$Y$$$20250718$$CN$US$US
255791291$25579129$1$I$$20250711$20250718$20250718$PER$$US-INCYTE CORPORATION-2025IN007691$INCYTE$$55$YR$$$Y$$$20250718$$$US$
255791531$25579153$1$I$$20250714$20250718$20250718$PER$$US-ABBVIE-6373460$ABBVIE$$40$YR$$F$Y$$$20250718$$HP$US$US
255791951$25579195$1$I$20240619$20240628$20250718$20250718$PER$$US-NOVOPROD-1253221$NOVO NORDISK$$66$YR$$M$Y$$$20250718$$CN$US$US
255791991$25579199$1$I$$20240701$20250718$20250718$PER$$US-NOVOPROD-1253887$NOVO NORDISK$$$$$M$Y$$$20250718$$CN$US$US
255792501$25579250$1$I$20240501$20240610$20250718$20250718$PER$$US-NOVOPROD-1242210$NOVO NORDISK$$17$YR$$M$Y$$$20250718$$CN$US$US
255793242$25579324$2$F$$20240708$20250718$20250718$PER$$US-NOVOPROD-1256987$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255793451$25579345$1$I$20240704$20240709$20250718$20250718$PER$$US-NOVOPROD-1257479$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255793521$25579352$1$I$$20240708$20250718$20250718$PER$$US-NOVOPROD-1257582$NOVO NORDISK$$$$$M$Y$$$20250718$$CN$US$US
255793951$25579395$1$I$$20240618$20250718$20250718$PER$$US-NOVOPROD-1264284$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255794701$25579470$1$I$20230628$20250116$20250718$20250718$PER$$US-NOVOPROD-1268471$NOVO NORDISK$$52$YR$$F$Y$74.842$KG$20250718$$CN$US$US
255795281$25579528$1$I$$20240716$20250718$20250718$PER$$US-NOVOPROD-1271351$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255795891$25579589$1$I$20250301$20250714$20250718$20250718$PER$$US-SA-2025SA202782$SANOFI AVENTIS$$16$YR$T$F$Y$$$20250718$$HP$US$US
255796141$25579614$1$I$20250617$20250711$20250718$20250718$EXP$$CN-PURDUE-USA-2025-0319035$PURDUE$$66$YR$$M$Y$60$KG$20250718$$HP$CN$CN
255796201$25579620$1$I$$20240825$20250718$20250718$PER$$US-NOVOPROD-1277290$NOVO NORDISK$$$$$$Y$$$20250718$$CN$US$US
255796561$25579656$1$I$$20240905$20250718$20250718$PER$$US-NOVOPROD-1280999$NOVO NORDISK$$$$A$F$Y$$$20250718$$MD$US$US
255796631$25579663$1$I$20240901$20241025$20250718$20250718$PER$$US-NOVOPROD-1282598$NOVO NORDISK$$42$YR$$M$Y$$$20250718$$CN$US$US
255797101$25579710$1$I$20240706$20240914$20250718$20250718$PER$$US-NOVOPROD-1287533$NOVO NORDISK$$39$YR$$F$Y$$$20250718$$CN$US$US
255797231$25579723$1$I$20240831$20240924$20250718$20250718$PER$$US-NOVOPROD-1290054$NOVO NORDISK$$40$YR$$F$Y$$$20250718$$CN$US$US
255797431$25579743$1$I$20240927$20241001$20250718$20250718$PER$$US-NOVOPROD-1294976$NOVO NORDISK$$60$YR$$F$Y$$$20250718$$CN$US$US
255797661$25579766$1$I$$20241004$20250718$20250718$PER$$US-NOVOPROD-1297147$NOVO NORDISK$$$$$F$Y$$$20250718$$HP$US$US
255801391$25580139$1$I$$20241216$20250718$20250718$PER$$US-NOVOPROD-1340530$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255802191$25580219$1$I$20240906$20240924$20250718$20250718$PER$$US-NOVOPROD-1345187$NOVO NORDISK$$43$YR$$F$Y$$$20250718$$CN$US$US
255802232$25580223$2$F$20240926$20240927$20250718$20250718$PER$$US-NOVOPROD-1345593$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255802331$25580233$1$I$$20250103$20250718$20250718$PER$$US-NOVOPROD-1347902$NOVO NORDISK$$$$A$M$Y$$$20250718$$CN$US$US
255802711$25580271$1$I$20240928$20241002$20250718$20250718$PER$$US-NOVOPROD-1349816$NOVO NORDISK$$17$YR$$F$Y$$$20250718$$CN$US$US
255803721$25580372$1$I$$20250108$20250718$20250718$PER$$US-NOVOPROD-1394935$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255803811$25580381$1$I$$20250108$20250718$20250718$PER$$US-NOVOPROD-1394502$NOVO NORDISK$$$$$F$Y$$$20250718$$MD$US$US
255804261$25580426$1$I$20250227$20250325$20250718$20250718$PER$$US-NOVOPROD-1399795$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255804671$25580467$1$I$$20250109$20250718$20250718$PER$$US-NOVOPROD-1404309$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255804781$25580478$1$I$$20250117$20250718$20250718$PER$$US-NOVOPROD-1405140$NOVO NORDISK$$$$$F$Y$$$20250718$$HP$US$US
255805171$25580517$1$I$$20250206$20250718$20250718$PER$$US-NOVOPROD-1406374$NOVO NORDISK$$$$$M$Y$$$20250718$$MD$US$US
255805531$25580553$1$I$20240101$20250716$20250718$20250718$PER$$US-NOVOPROD-1411977$NOVO NORDISK$$$$$F$Y$102.04$KG$20250718$$HP$US$US
255806021$25580602$1$I$$20250221$20250718$20250718$PER$$US-NOVOPROD-1418474$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255806221$25580622$1$I$$20250330$20250718$20250718$PER$$US-NOVOPROD-1425460$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255806311$25580631$1$I$20250225$20250225$20250718$20250718$PER$$US-NOVOPROD-1426590$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255806381$25580638$1$I$$20250310$20250718$20250718$PER$$US-NOVOPROD-1427626$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255806461$25580646$1$I$$20250226$20250718$20250718$PER$$US-NOVOPROD-1427846$NOVO NORDISK$$$$A$$Y$$$20250718$$CN$US$US
255807461$25580746$1$I$$20240905$20250718$20250718$PER$$US-NOVOPROD-1328260$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255807581$25580758$1$I$$20241230$20250718$20250718$PER$$US-NOVOPROD-1327865$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255807671$25580767$1$I$$20250303$20250718$20250718$PER$$US-NOVOPROD-1432576$NOVO NORDISK$$$$$$Y$$$20250718$$CN$US$US
255808061$25580806$1$I$$20250320$20250718$20250718$PER$$US-NOVOPROD-1433686$NOVO NORDISK$$31$YR$$F$Y$$$20250718$$CN$US$US
255808231$25580823$1$I$$20250515$20250718$20250718$PER$$US-NOVOPROD-1436019$NOVO NORDISK$$26$YR$$F$Y$$$20250718$$HP$US$US
255810041$25581004$1$I$$20250113$20250718$20250718$PER$$US-NOVOPROD-1353057$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255810721$25581072$1$I$$20250506$20250718$20250718$PER$$US-NOVOPROD-1455470$NOVO NORDISK$$$$$M$Y$$$20250718$$CN$US$US
255810822$25581082$2$F$20250517$20250522$20250718$20250718$PER$$US-NOVOPROD-1456229$NOVO NORDISK$$51$YR$$M$Y$$$20250718$$CN$US$US
255811011$25581101$1$I$$20250522$20250718$20250718$PER$$US-NOVOPROD-1456218$NOVO NORDISK$$$$A$F$Y$$$20250718$$PH$US$US
255811511$25581151$1$I$20250103$20250102$20250718$20250718$PER$$US-NOVOPROD-1358317$NOVO NORDISK$$59$YR$$F$Y$$$20250718$$CN$US$US
255811531$25581153$1$I$20241118$20241202$20250718$20250718$PER$$US-NOVOPROD-1358309$NOVO NORDISK$$54$YR$$M$Y$$$20250718$$CN$US$US
255812191$25581219$1$I$$20250131$20250718$20250718$PER$$US-NOVOPROD-1364703$NOVO NORDISK$$$$$M$Y$$$20250718$$MD$US$US
255812421$25581242$1$I$$20250131$20250718$20250718$PER$$US-NOVOPROD-1367752$NOVO NORDISK$$$$$M$Y$$$20250718$$CN$US$US
255813141$25581314$1$I$$20241113$20250718$20250718$PER$$US-NOVOPROD-1375114$NOVO NORDISK$$$$A$F$Y$$$20250718$$CN$US$US
255813801$25581380$1$I$$20240611$20250718$20250718$PER$$US-NOVOPROD-1377595$NOVO NORDISK$$$$$$Y$$$20250718$$CN$US$US
255813821$25581382$1$I$$20241113$20250718$20250718$PER$$US-NOVOPROD-1377301$NOVO NORDISK$$32$YR$$F$Y$$$20250718$$MD$US$US
255814151$25581415$1$I$20250224$20250602$20250718$20250718$PER$$US-NOVOPROD-1381083$NOVO NORDISK$$52$YR$$M$Y$$$20250718$$CN$US$US
255814391$25581439$1$I$$20250219$20250718$20250718$PER$$US-NOVOPROD-1382256$NOVO NORDISK$$$$$F$Y$$$20250718$$CN$US$US
255814662$25581466$2$F$$20241205$20250718$20250718$PER$$US-NOVOPROD-1385038$NOVO NORDISK$$$$$F$Y$$$20250718$$HP$US$US
255815291$25581529$1$I$20250201$20250224$20250719$20250719$PER$$US-NOVOPROD-1390456$NOVO NORDISK$$76$YR$$F$Y$$$20250718$$CN$US$US
255816291$25581629$1$I$$20250710$20250719$20250719$EXP$$CA-CELLTRION INC.-2025CA023236$CELLTRION$$$$$$Y$$$20250719$$HP$CA$CA
255817102$25581710$2$F$20250101$20250812$20250719$20250821$PER$$US-SA-2025SA203957$SANOFI AVENTIS$$$$A$F$Y$$$20250821$$MD$US$US
255817551$25581755$1$I$20250701$20250716$20250719$20250719$EXP$$US-UNITED THERAPEUTICS-UNT-2025-023964$UNITED THERAPEUTICS$$52$YR$$F$Y$89.796$KG$20250719$$$US$US
255818282$25581828$2$F$$20250829$20250719$20250905$EXP$$CA-CELLTRION INC.-2025CA023443$CELLTRION$$$$$$Y$$$20250905$$HP$CA$CA
255818291$25581829$1$I$20230824$20250709$20250719$20250719$EXP$$EU-AUROBINDO-AUR-APL-2025-036775$AUROBINDO$$49$YR$$F$Y$$$20250719$$HP$EU$EU
255818351$25581835$1$I$$20250715$20250719$20250719$PER$$US-ELI_LILLY_AND_COMPANY-US202507015219$ELI LILLY AND COMPANY$$$$$$Y$$$20250719$$HP$US$US
255818971$25581897$1$I$20221201$20250707$20250719$20250719$EXP$$CN-PBT-010615$PANACEA BIOTEC PHARMA LIMITED$Zhang J, Su J, Yu X, Yue W, Chen J, Xu L. Nirmatrelvir/ritonavir in heart transplant recipients with COVID-19: A case report on pharmaceutical care and drug interaction management. Medicine (Baltimore). 2025 Jun 27;104(26):e43122. doi: 10.1097/MD.0000000000043122.$65$YR$E$M$Y$$$20250719$$MD$CN$CN
255819181$25581918$1$I$20250601$20250711$20250719$20250719$EXP$$JP-AMGEN-JPNSP2025137685$AMGEN$$8$DEC$E$$Y$$$20250719$$MD$JP$JP
255820642$25582064$2$F$20250801$20250923$20250719$20250927$PER$$US-SA-2025SA204111$SANOFI AVENTIS$$1$YR$I$M$Y$$$20250927$$HP$US$US
255822431$25582243$1$I$$20250717$20250719$20250719$PER$$NVSC2025US114556$NOVARTIS$$$$$$Y$$$20250719$$CN$US$US
255822572$25582257$2$F$$20250811$20250719$20250811$EXP$$US-ASTRAZENECA-202507USA011662US$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250811$$$US$US
255823211$25582321$1$I$$20250707$20250720$20250720$EXP$$EU-AUROBINDO-AUR-APL-2025-036632$AUROBINDO$Kotnik N, Diercks G F H, Jalving H, Hospers G, Oosting S F, Meijer J M, et.al.. Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum. JAAD Case Rep. 2025;61:100-6$63$YR$$M$Y$$$20250720$$MD$EU$EU
255823361$25582336$1$I$$20250707$20250720$20250720$EXP$$US-AUROBINDO-AUR-APL-2025-036285$AUROBINDO$Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Sasaki k, et al.. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia.. Clin-Lymphoma-Myeloma-Leuk. 2024;24(11):783-788$24$YR$$M$Y$$$20250720$$MD$US$US
255823571$25582357$1$I$$20250707$20250720$20250720$EXP$$TR-STRIDES ARCOLAB LIMITED-2025OS000105$Unknown Manufacturer$Arikoglu T, Tokmeci N, Demirhan A, Ozhan AK, Yalaki AI, Akbey V, et al. Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children. Int-J-Clin-Pharm. 2024;46 (6):1294-1306$3$YR$$$Y$$$20250720$$HP$TR$TR
255823882$25582388$2$F$$20250707$20250720$20250808$EXP$$CA-ASTRAZENECA-202505CAN022765CA$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250808$$$CA$CA
255823891$25582389$1$I$$20250714$20250720$20250720$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06265$LUPIN$$65$YR$$$Y$$$20250720$$$US$US
255824881$25582488$1$I$$20250711$20250720$20250720$EXP$$US-RDY-USA/2025/07/010685$DR REDDYS$Eggleston R, Dupuy-McCauley K. A CASE OF MEDICATION-RELATED CENTRAL APNEA DURING WAKEFULNESS. Sleep. 2025;48: A635-6. DOI: 10.1093/sleep/zsaf090.1484.$60$YR$A$M$Y$$$20250720$$HP$US$US
255825311$25582531$1$I$$20250707$20250720$20250720$EXP$$CN-TEYRO-2025-TY-000565$Teyro Labs$Yang Q, Huang Y, Zhang K, Lan Q, Liang J, Xu H, et al..Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD-1 Inhibitor as Later-Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study..MedComm.2025;6:e70174$$$$$Y$$$20250720$$HP$CN$CN
255825481$25582548$1$I$20250601$20250715$20250720$20250720$EXP$$US-UCBSA-2025044012$UCB$$25$YR$$F$Y$$$20250720$$HP$US$US
255825652$25582565$2$F$20250401$20250818$20250720$20250827$EXP$$US-009507513-2308890$MERCK SHARP + DOHME LLC$$63$YR$$M$Y$$$20250827$$CN$US$US
255825813$25582581$3$F$20250709$20250908$20250720$20250915$PER$$US-GSK-US2025088926$GLAXOSMITHKLINE$$85$YR$$F$Y$$$20250915$$$US$US
255826021$25582602$1$I$$20250709$20250720$20250720$PER$$US-GSK-US2025087698$GLAXOSMITHKLINE$$$$$F$Y$$$20250720$$$US$US
255826203$25582620$3$F$20250717$20250829$20250720$20250901$PER$$US-JNJFOC-20250723061$JOHNSON AND JOHNSON$$63$YR$A$F$Y$$$20250901$$HP$US$US
255826641$25582664$1$I$$20250709$20250720$20250720$PER$$US-RDY-USA/2025/07/010577$DR REDDYS$Rubenstein AI, Chung J, Rosenbach M. Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab. JAAD Case Rep. 2025;61: 154-6. DOI: 10.1016/j.jdcr.2025.03.028.$$$A$F$Y$$$20250720$$HP$US$US
255826681$25582668$1$I$$20250715$20250720$20250720$PER$$US-SA-2025SA202125$SANOFI AVENTIS$$28$YR$A$M$Y$$$20250720$$CN$US$US
255826961$25582696$1$I$20250101$20250716$20250720$20250720$PER$$US-ELI_LILLY_AND_COMPANY-US202507015697$ELI LILLY AND COMPANY$$82$YR$E$M$Y$$$20250720$$CN$US$US
255828211$25582821$1$I$$20250711$20250720$20250720$EXP$$CN-BEIGENE-BGN-2025-011442$BEIGENE$$59$YR$$$Y$64$KG$20250720$$$CN$CN
255829091$25582909$1$I$$20250716$20250720$20250720$PER$$US-ABBVIE-6378801$ABBVIE$$$$$$Y$$$20250720$$CN$US$US
255829141$25582914$1$I$$20250716$20250720$20250720$EXP$$US-ABBVIE-6376004$ABBVIE$$$$A$F$Y$$$20250720$$CN$US$US
255829292$25582929$2$F$$20250722$20250720$20250728$EXP$$GB-ABBVIE-6372671$ABBVIE$$$$E$F$Y$$$20250728$$CN$GB$GB
255829391$25582939$1$I$20250628$20250707$20250721$20250721$EXP$$US-ETON PHARMACEUTICALS, INC-2025ETO000295$ETON PHARMACEUTICALS, INC$$$$$$Y$$$20250718$$CN$US$US
255829481$25582948$1$I$$20250716$20250721$20250721$EXP$$US-ABBVIE-6377004$ABBVIE$$$$E$F$Y$$$20250721$$CN$US$US
255830331$25583033$1$I$$20250714$20250721$20250721$PER$$US-SA-2025SA023142$SANOFI AVENTIS$$$$C$F$Y$$$20250721$$MD$US$US
255830461$25583046$1$I$20250708$20250708$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507007327$ELI LILLY AND COMPANY$$$$$$Y$$$20250721$$CN$US$US
255831351$25583135$1$I$$20250716$20250721$20250721$PER$$US-SA-2025SA204482$SANOFI AVENTIS$$$$A$F$Y$$$20250721$$HP$US$US
255831531$25583153$1$I$20250101$20250716$20250721$20250721$EXP$$US-ABBVIE-6376040$ABBVIE$$42$YR$$F$Y$$$20250721$$CN$US$US
255831592$25583159$2$F$20240201$20250731$20250721$20250805$EXP$$US-ABBVIE-6376073$ABBVIE$$55$YR$$F$Y$108.86$KG$20250805$$CN$US$US
255831771$25583177$1$I$$20250710$20250721$20250721$EXP$$US-GSK-US2025AMR090204$GLAXOSMITHKLINE$$$$$F$Y$54.875$KG$20250721$$$US$US
255831981$25583198$1$I$$20250711$20250721$20250721$EXP$$GB-TEVA-VS-3353881$TEVA$$67$YR$$F$Y$62$KG$20250721$$MD$GB$GB
255832351$25583235$1$I$20250101$20250716$20250721$20250721$PER$$US-SA-2025SA205074$SANOFI AVENTIS$$22$YR$A$F$Y$$$20250721$$HP$US$US
255832391$25583239$1$I$$20250715$20250721$20250721$EXP$$US-ARGENX-2025-ARGX-US009306$ARGENX BVBA$$$$$$Y$$$20250721$$CN$US$US
255832861$25583286$1$I$20250701$20250716$20250721$20250721$PER$$US-AMGEN-USASP2025141214$AMGEN$$53$YR$A$M$Y$$$20250720$$HP$US$US
255832881$25583288$1$I$20250101$20250714$20250721$20250721$EXP$EU-BASGAGES-2025-004491$EU-TEVA-VS-3352945$TEVA$$67$YR$$M$Y$$$20250721$$PH$EU$EU
255833821$25583382$1$I$20250625$20250709$20250721$20250721$EXP$3401011513273202500352$CN-Accord-495251$ACCORD$$69$YR$E$F$Y$49$KG$20250721$$MD$CN$CN
255833831$25583383$1$I$$20250709$20250721$20250721$PER$$US-APOTEX-2025AP010254$APOTEX$Lee H, Kaushish A, Han J, Lucas C, Peery M, Brigle K, Mann H.. Single-Center Experience Assessing Use of the Andromeda Regimen for AL in Ethnic Minorities. Blood. 2024;144:7864-7865$$$A$$Y$$$20250721$$HP$US$US
255834061$25583406$1$I$$20250709$20250721$20250721$EXP$$US-APOTEX-2025AP010107$APOTEX$Sidhu R, Embry E, Xiong J, Prasad S, Naik M. Refractory Gemcitabine-Induced Pneumonitis in Metastatic Testicular Cancer. American Journal of Respiratory and Critical Care Medicine. 2025;211:1-4$30$YR$$M$Y$$$20250721$$HP$US$US
255834211$25583421$1$I$$20250707$20250721$20250721$EXP$$EU-STRIDES ARCOLAB LIMITED-2025OS000176$Unknown Manufacturer$Dathe K, Benndorf C, Bergner S, Schaefer C. Do Major Pharmacovigilance Databases Support Evidence of Second Trimester NSAID and Third Trimester Paracetamol Fetotoxicity?.. Pharmaceuticals. 2024;17 (12):1592$$$$F$Y$$$20250721$$HP$EU$EU
255834391$25583439$1$I$$20250717$20250721$20250721$EXP$$GB-AMGEN-GBRSP2025142636$AMGEN$$$$$F$Y$$$20250721$$HP$GB$GB
255834901$25583490$1$I$20250217$20250709$20250721$20250721$EXP$EU-AFSSAPS-CN2025000591$EU-Accord-494894$ACCORD$$66$YR$E$F$Y$71$KG$20250721$$HP$EU$EU
255835341$25583534$1$I$$20250709$20250721$20250721$EXP$$EU-NOVOPROD-1477894$NOVO NORDISK$$80$YR$$F$Y$84$KG$20250721$$CN$EU$EU
255835642$25583564$2$F$20250101$20250715$20250721$20250724$EXP$$JP-NOVOPROD-1478640$NOVO NORDISK$$62$YR$$M$Y$$$20250724$$PH$JP$JP
255836061$25583606$1$I$20230101$20250708$20250721$20250721$EXP$$EU-AMGEN-ROUSP2025142210$AMGEN$Michelini S., Civita R., Mancino S., Harpa M.. Advanced heart failure treatment - from left ventricular assist device to cardiac transplantation.. Acta Medica Marisiensis. 2025;71(Suppl 1):23-4$46$YR$A$M$Y$$$20250721$$CN$EU$EU
255837281$25583728$1$I$$20250715$20250721$20250721$PER$$US-SA-2025SA204068$SANOFI AVENTIS$$77$YR$E$M$Y$$$20250721$$CN$US$US
255837341$25583734$1$I$$20250715$20250721$20250721$PER$$US-SA-2025SA202792$SANOFI AVENTIS$$96$YR$E$F$Y$$$20250721$$CN$US$US
255837651$25583765$1$I$20250101$20250711$20250721$20250721$EXP$$US-Rigel Pharmaceuticals, Inc.-20250700110$RIGEL PHARMACEUTICALS$$$$$F$Y$$$20250721$$CN$US$US
255837711$25583771$1$I$20250101$20250717$20250721$20250721$PER$$US-ABBVIE-6378572$ABBVIE$$$$$M$Y$$$20250721$$CN$US$US
255837861$25583786$1$I$20250701$20250715$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507015682$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250721$$MD$US$US
255838121$25583812$1$I$$20241127$20250721$20250721$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2024008766$BIOCON$$$$$$Y$$$20250721$$PH$US$US
255838131$25583813$1$I$$20241122$20250721$20250721$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2024008770$BIOCON$$$$$$Y$$$20250721$$PH$US$US
255838811$25583881$1$I$20250501$20250716$20250721$20250721$PER$$US-SA-2025SA204971$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250721$$CN$US$US
255839031$25583903$1$I$20200101$20250716$20250721$20250721$EXP$$US-SA-2025SA203937$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250721$$CN$US$US
255839581$25583958$1$I$$20250717$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507016655$ELI LILLY AND COMPANY$$$$$$Y$$$20250721$$CN$US$US
255839691$25583969$1$I$$20250708$20250721$20250721$EXP$SY-MLMSERVICE-20241014-PI225915-00166-2$SY-STRIDES ARCOLAB LIMITED-2024SP013887$STRIDES$Alshwayyat S, Hanifa H, Amro AM, Alshwayyat M, Odat RM, Mahmoud LM, et al.. From flank pain to splenic abscess: a complex case of infective endocarditis with literature review.. BMC Cardiovascular Disorders.. 2024;24(1):520$20$YR$$F$Y$$$20250721$$MD$SY$SY
255840122$25584012$2$F$$20250718$20250721$20250724$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101568$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$$$20250724$$CN$US$US
255840621$25584062$1$I$$20250717$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507016816$ELI LILLY AND COMPANY$$40$YR$A$M$Y$$$20250721$$CN$US$US
255841741$25584174$1$I$$20240909$20250721$20250721$PER$$US-AUROBINDO-AUR-APL-2024-045778$AUROBINDO$$75$YR$$M$Y$$$20250721$$CN$US$US
255841791$25584179$1$I$$20250717$20250721$20250721$EXP$$CA-SANDOZ INC.-SDZ2025CA042753$SANDOZ$$10$YR$$F$Y$$$20250721$$HP$CA$CA
255842471$25584247$1$I$20240501$20250710$20250721$20250721$EXP$$EU-AUROBINDO-AUR-APL-2025-036679$AUROBINDO$$33$YR$$F$Y$110$KG$20250721$$CN$EU$EU
255843051$25584305$1$I$$20250626$20250721$20250721$PER$US-MLMSERVICE-20250620-PI550030-00217-1$US-RDY-USA/2025/07/009581$DR REDDYS$Grabenhorst C, Zhong C. Metformin^s Dark Side: A Case Report on Nightmares Triggered by a Common Diabetes Drug. American Journal of Health-System Pharmacy. 2025;82(1):S2376. DOI:10.1093/ajhp/zxae345.$76$YR$E$M$Y$$$20250721$$PH$US$US
255844791$25584479$1$I$$20250717$20250721$20250721$PER$$US-BIOGEN-2021BI01008643$BIOGEN$$$$$M$Y$$$20250721$$CN$US$US
255845001$25584500$1$I$20250101$20250709$20250721$20250721$PER$$US-SA-2025SA198410$SANOFI AVENTIS$$52$YR$A$F$Y$109.09$KG$20250721$$HP$US$US
255847141$25584714$1$I$20250527$20250711$20250721$20250721$EXP$EU-AFSSAPS-TS2025000654$EU-TEVA-VS-3352537$TEVA$$36$YR$$F$Y$60$KG$20250721$$MD$EU$EU
255847541$25584754$1$I$20110101$20250714$20250721$20250721$EXP$$CN-SA-2025SA201111$SANOFI AVENTIS$Ding Y.. Pulmonary Artery Thrombosis and Ulcerative Colitis.. American Journal of Respiratory and Critical Care Medicine. 2025;211:unk$58$YR$A$M$Y$$$20250721$$HP$CN$CN
255847671$25584767$1$I$$20250714$20250721$20250721$EXP$$US-BAXTER-2025BAX018334$BAXTER$$66$YR$$M$Y$$$20250721$$HP$US$US
255848521$25584852$1$I$$20250707$20250721$20250721$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-125942$ZYDUS PHARM$Xu EJ, Steele DJR, Fenves AZ.. Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review.. Kidney-Med. 2025;7 Issue 7$$$$$Y$$$20250721$$MD$US$US
255848841$25584884$1$I$20250101$20250624$20250721$20250721$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-125898$ZYDUS PHARM$$$$$$Y$$$20250721$$CN$US$US
255849122$25584912$2$F$$20250906$20250721$20250909$EXP$$EU-ASTELLAS-2025-AER-039780$ASTELLAS$$64$YR$A$M$Y$$$20250909$$MD$EU$EU
255849581$25584958$1$I$$20250717$20250721$20250721$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101483$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$62.14$KG$20250721$$CN$US$US
255849612$25584961$2$F$$20250730$20250721$20250805$PER$$US-BEH-2025212396$CSL BEHRING$$$$A$M$Y$$$20250805$$HP$US$US
255850101$25585010$1$I$$20250714$20250721$20250721$EXP$$US-ROCHE-10000339433$ROCHE$Vaghela M, Pandya D, Chandran A. A Rare Case of Stevens-Johnson Syndrome Triggered by Aeromonas Hydrophila Bacteremia in a Patient With Diffuse B-cell Lymphoma [Abstract: A1635]. American Journal of Respiratory and Critical Care Medicine. 2025-May-01;211: doi:10.1164/ajrccm.2025.211.Abstracts.A1635.$56$YR$A$F$Y$$$20250721$$HP$US$US
255850181$25585018$1$I$20250702$20250710$20250721$20250721$EXP$$US-MYLANLABS-2025M1058805$MYLAN$$56$YR$$M$Y$$$20250721$$$US$US
255850421$25585042$1$I$$20250714$20250721$20250721$EXP$US-MLMSERVICE-20250707-PI528199-00275-3$US-CHEPLA-2025008802$CHEPLAPHARM$Restrepo JA, Rosenbaum BL, Harris D, Gift T, Freudenreich O. Clozapine in solid organ transplant: a literature review and case series. Journal of the Academy of Consultation-Liaison Psychiatry. 2025. DOI:10.1016/j.jaclp.2025.05.007.$29$YR$$M$Y$$$20250721$$MD$COUNTRY NOT SPECIFIED$US
255850762$25585076$2$F$$20250901$20250721$20250908$EXP$$US-ROCHE-10000341084$ROCHE$Iyengar V, Chicola J, Joseph A, Okwali M, Truong R, Bapodra N. Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2024-Nov-05;144:2336. doi:10.1182/blood-2024-202741.$$$$$Y$$$20250908$$HP$US$US
255851151$25585115$1$I$20250715$20250716$20250721$20250721$PER$$US-VIIV HEALTHCARE-US2025091844$VIIV$$$$A$M$Y$$$20250721$$$US$US
255851221$25585122$1$I$$20250712$20250721$20250721$EXP$$GB-ACORDA THERAPEUTICS IRELAND LIMITED-ACO_178412_2025$MERZ$$$$$$Y$$$20250721$$CN$GB$GB
255851761$25585176$1$I$20250718$20250718$20250718$20250718$DIR$765293$$FDA-CTU$$64$YR$$M$N$66.15$KG$20250718$N$PH$US$
255852551$25585255$1$I$20250601$20250715$20250721$20250721$PER$$US-SA-2025SA205574$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250721$$HP$US$US
255853021$25585302$1$I$$20250714$20250721$20250721$EXP$$US-UNICHEM LABORATORIES LIMITED-UNI-2025-US-002790$UNICHEM$Flathers E, Cecchini A, Curow T and Sill JW.. Amiodarone induced thyrotoxicosis leading to fulminant cardiogenic shock. American journal of respiratory and critical care medicine. 2025;211:A1651$$$$$Y$$$20250721$$HP$US$US
255853201$25585320$1$I$$20250717$20250721$20250721$EXP$$US-JNJFOC-20250721127$JOHNSON AND JOHNSON$$$$$$Y$$$20250721$$HP$US$US
255854721$25585472$1$I$$20250715$20250721$20250721$EXP$$US-BAYER-2025A094676$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$E$F$Y$$$20250721$$CN$US$US
255854881$25585488$1$I$$20250717$20250721$20250721$EXP$$US-JNJFOC-20250721769$JOHNSON AND JOHNSON$$4$DEC$A$M$Y$$$20250721$$HP$US$US
255854971$25585497$1$I$$20250718$20250718$20250718$DIR$765294$$FDA-CTU$$$$$$N$$$20250718$N$CN$US$
255855752$25585575$2$F$20250623$20250827$20250721$20250904$PER$$US-SA-2025SA205121$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250904$$MD$US$US
255856611$25585661$1$I$$20250716$20250721$20250721$EXP$$CA-PFIZER INC-202500145510$PFIZER$$86$YR$$M$Y$$$20250721$$HP$CA$CA
255857081$25585708$1$I$$20250716$20250721$20250721$EXP$$JP-PFIZER INC-202500144312$PFIZER$$9$DEC$$F$Y$$$20250721$$PH$JP$JP
255858111$25585811$1$I$$20250718$20250718$20250718$DIR$765418$$FDA-CTU$$$$$M$N$64.8$KG$20250718$N$CN$US$
255858431$25585843$1$I$$20250714$20250721$20250721$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100143$BRISTOL-MYERS SQUIBB COMPANY$Hu J, Ali A, Takahashi T, Hughes AV. Clotting and bleeding - a rare case of catastrophic trousseau syndrome. American Journal of Respiratory and Critical Care Medicine. 2025 May 01;211:A5897.$59$YR$A$M$Y$$$20250721$$HP$US$US
255859021$25585902$1$I$$20250716$20250721$20250721$PER$$US-BAYER-2025A095172$BAYER HEALTHCARE LLC$$$$$F$Y$$$20250721$$CN$US$US
255859731$25585973$1$I$$20250708$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507007528$ELI LILLY AND COMPANY$$57$YR$A$M$Y$$$20250721$$CN$US$US
255860461$25586046$1$I$$20250717$20250721$20250721$PER$$US-BAYER-2025A095434$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250721$$CN$US$US
255860971$25586097$1$I$$20250717$20250721$20250721$PER$$US-INCYTE CORPORATION-2025IN007894$INCYTE$$$$$$Y$$$20250721$$$US$US
255860991$25586099$1$I$$20250715$20250721$20250721$EXP$$CA-APOTEX-2025AP010186$APOTEX$$84$YR$$F$Y$68$KG$20250721$$PH$CA$CA
255861311$25586131$1$I$$20250717$20250721$20250721$PER$$US-SA-2025SA204725$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250721$$HP$US$US
255861361$25586136$1$I$$20250714$20250721$20250721$EXP$$US-MYLANLABS-2025M1059312$MYLAN$$$$$$Y$$$20250721$$LW$US$US
255861771$25586177$1$I$20240201$20250708$20250721$20250721$EXP$$EU-COSETTE-CP2025ES000695$COSETTE PHARMACEUTICALS INC$$33$YR$A$M$Y$$$20250721$$PH$EU$EU
255862557$25586255$7$F$$20250911$20250721$20250911$30DAY$$US-PFIZER INC-202500145660$PFIZER$$15$YR$$M$Y$$$20250911$$CN$US$US
255862903$25586290$3$F$$20250818$20250721$20250821$30DAY$$US-PFIZER INC-202500144989$PFIZER$$$$$$Y$$$20250821$$PH$US$US
255863696$25586369$6$F$20250101$20250903$20250721$20250905$EXP$$US-KARYOPHARM-2025KPT100508$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20250905$$CN$US$US
255863971$25586397$1$I$$20250721$20250721$20250721$DIR$FDA-CDER-CTU-2025-47810$$FDA-CTU$$1$YR$$M$N$$$20250721$N$$US$
255864031$25586403$1$I$20250717$20250721$20250721$20250721$DIR$FDA-CDER-CTU-2025-47840$$FDA-CTU$$76$YR$$F$N$$$20250721$Y$PH$US$
255864212$25586421$2$F$$20250724$20250721$20250803$EXP$$JP-AMGEN-JPNSP2025142102$AMGEN$$$$$F$Y$$$20250803$$MD$JP$JP
255864952$25586495$2$F$$20250730$20250721$20250801$PER$$US-PFIZER INC-PV202500086350$PFIZER$$39$YR$$F$Y$67.69$KG$20250801$$MD$US$US
255865141$25586514$1$I$$20250714$20250721$20250721$EXP$$US-ELI_LILLY_AND_COMPANY-US202507014254$ELI LILLY AND COMPANY$$63$YR$A$$Y$$$20250721$$LW$US$US
255865391$25586539$1$I$20210910$20250717$20250721$20250721$EXP$$US-SA-2021SA362726$SANOFI AVENTIS$$68$YR$E$M$Y$101.8$KG$20250721$$MD$US$US
255865711$25586571$1$I$20250424$20250714$20250721$20250721$EXP$EU-MINISAL02-1048027$EU-TEVA-VS-3353677$TEVA$$55$YR$$F$Y$$$20250721$$PH$EU$EU
255866701$25586670$1$I$$20250716$20250721$20250721$PER$$US-LUNDBECK-DKLU4017202$LUNDBECK$$$$$$Y$$$20250721$$HP$US$US
255867201$25586720$1$I$$20250716$20250721$20250721$EXP$$CA-PFIZER INC-202500145316$PFIZER$$41$YR$$F$Y$$$20250721$$HP$CA$CA
255867601$25586760$1$I$$20250717$20250721$20250721$30DAY$$US-PFIZER INC-202500145701$PFIZER$$27$YR$$F$Y$$$20250721$$HP$US$US
255869261$25586926$1$I$20250101$20250602$20250721$20250721$PER$$US-PHATHOM PHARMACEUTICALS INC.-2025PHT01400$Phathom Pharmaceuticals$$60$YR$$M$Y$$$20250721$$CN$US$US
255870731$25587073$1$I$$20250602$20250721$20250721$PER$$US-PHATHOM PHARMACEUTICALS INC.-2025PHT01075$Phathom Pharmaceuticals$$$$$F$Y$$$20250721$$CN$US$US
255871561$25587156$1$I$20250708$20250721$20250721$20250721$DIR$765560$$FDA-CTU$$57$YR$$F$N$60.75$KG$20250721$Y$MD$US$
255872401$25587240$1$I$$20250721$20250721$20250721$DIR$765581$$FDA-CTU$$$$$$N$$$20250721$N$CN$US$
255873631$25587363$1$I$20250714$20250721$20250721$20250721$DIR$765559$$FDA-CTU$$34$YR$$F$N$76.5$KG$20250721$N$CN$US$
255873821$25587382$1$I$$20250714$20250721$20250721$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-100086$BRISTOL-MYERS SQUIBB COMPANY$Patel N, Hassan S, Gandhamaneni S, Al-Ahmad R, Philip L, Morrison L, et al. A case of cardiac tamponade following catheter ablation for atrial fibrillation while on continuous anticoagulation. American Journal of Respiratory and Critical Care Medicine. 2025 May 01;211:A5824.$72$YR$E$F$Y$$$20250721$$HP$US$US
255874332$25587433$2$F$$20250722$20250721$20250728$EXP$$AE-PFIZER INC-PV202500086445$PFIZER$Saleem, A.. Disseminated Saprochaete capitata Fungemia in Acute Myeloid Leukemia: A Case Report and Literature Review From the United Arab Emirates. Cureus. 2025;17(6):e85898$49$YR$$M$Y$$$20250728$$HP$AE$AE
255874411$25587441$1$I$$20250708$20250721$20250721$PER$$US-ALNYLAM PHARMACEUTICALS, INC.-ALN-2025-004341$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20250721$$CN$US$US
255874841$25587484$1$I$$20250709$20250721$20250721$PER$$US-PHARMING-PHAUS2025000999$PHARMING GROUP$$$$$$Y$$$20250721$$CN$US$US
255875391$25587539$1$I$$20250718$20250721$20250721$EXP$$GB-PFIZER INC-202500146262$PFIZER$$$$$M$Y$$$20250721$$CN$GB$GB
255875401$25587540$1$I$20210101$20250716$20250721$20250721$EXP$$EU-PFIZER INC-202500144151$PFIZER$$54$YR$$F$Y$$$20250721$$MD$EU$EU
255876431$25587643$1$I$20250101$20250709$20250721$20250721$PER$$US-MALLINCKRODT-MNK202500909$MALLINCKRODT$$46$YR$A$F$Y$$$20250718$$CN$US$US
255876851$25587685$1$I$$20250717$20250721$20250721$PER$$NVSC2025US114047$NOVARTIS$$$$$$Y$$$20250721$$HP$US$US
255877081$25587708$1$I$$20250716$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507016839$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250721$$CN$US$US
255877141$25587714$1$I$$20250718$20250721$20250721$EXP$$US-ABBVIE-6379130$ABBVIE$$$$E$F$Y$$$20250721$$CN$US$US
255878172$25587817$2$F$20250626$20250731$20250721$20250806$EXP$$US-DSJP-DS-2025-150155-US$DAIICHI$$55$YR$$F$Y$$$20250806$$HP$US$US
255878651$25587865$1$I$20250101$20250711$20250721$20250721$EXP$$US-PRINSTON PHARMACEUTICAL INC.-2025PRN00230$PRINSTON PHARMACEUTICAL$$$$$M$Y$71.668$KG$20250721$$CN$US$US
255879122$25587912$2$F$$20250826$20250721$20250829$PER$$US-TAKEDA-2025TUS064902$TAKEDA$$$$$F$Y$64$KG$20250829$$$US$US
255879261$25587926$1$I$$20250715$20250721$20250721$EXP$$CN-BEIGENE-BGN-2025-011643$BEIGENE$$66$YR$$$Y$43$KG$20250721$$$CN$CN
255879382$25587938$2$F$20250701$20250825$20250721$20250831$EXP$$US-ABBVIE-6377058$ABBVIE$$53$YR$$F$Y$$$20250831$$CN$US$US
255879411$25587941$1$I$$20250715$20250721$20250721$PER$$US-ELI_LILLY_AND_COMPANY-US202507016114$ELI LILLY AND COMPANY$$15$YR$T$F$Y$$$20250721$$CN$US$US
255880011$25588001$1$I$$20250716$20250721$20250721$EXP$$CA-ABBVIE-6378386$ABBVIE$$$$A$M$Y$$$20250721$$PH$CA$CA
255880201$25588020$1$I$$20250710$20250721$20250721$PER$$US-Bion-015141$BIONPHARMA INC.$$30$YR$A$F$Y$$$20250722$$HP$US$US
255880412$25588041$2$F$20250101$20250707$20250722$20250725$EXP$$CA-CURRAX PHARMACEUTICALS LLC-CA-2025CUR001059$CURRAX PHARMACEUTICALS$$47$YR$$F$Y$$$20250725$$CN$CA$CA
255881052$25588105$2$F$20250101$20250722$20250722$20250724$EXP$$CO-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-084200$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250724$$$CO$CO
255881101$25588110$1$I$20250709$20250710$20250722$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507009864$ELI LILLY AND COMPANY$$50$YR$A$$Y$$$20250722$$CN$US$US
255881251$25588125$1$I$20250625$20250716$20250722$20250722$EXP$$CA-ABBVIE-6378398$ABBVIE$$60$YR$$F$Y$$$20250722$$CN$CA$CA
255881301$25588130$1$I$$20250712$20250722$20250722$EXP$$US-GSK-US2025AMR090046$GLAXOSMITHKLINE$$$$$F$Y$$$20250722$$$US$US
255881481$25588148$1$I$20250718$20250718$20250722$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101979$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$F$Y$$$20250722$$CN$US$US
255881861$25588186$1$I$$20250715$20250722$20250722$EXP$$AU-CELLTRION INC.-2025AU023747$CELLTRION$$$$$$Y$$$20250722$$HP$AU$AU
255882261$25588226$1$I$$20250415$20250722$20250722$EXP$$US-PRINSTON PHARMACEUTICAL INC.-2025PRN00131$PRINSTON PHARMACEUTICAL$$$$$M$Y$$$20250718$$CN$US$US
255882311$25588231$1$I$$20240717$20250722$20250722$EXP$$US-PRINSTON PHARMACEUTICAL INC.-2024PRN00280$PRINSTON PHARMACEUTICAL$$$$$F$Y$$$20250718$$CN$US$US
255882381$25588238$1$I$$20250710$20250722$20250722$EXP$GB-MHRA-MED-202507011248307940-RNPKV$GB-Accord-495069$ACCORD$$$$$$Y$$$20250722$$MD$GB$GB
255883102$25588310$2$F$20250416$20250719$20250722$20250730$EXP$$EU-AUROBINDO-AUR-APL-2025-035859$AUROBINDO$$56$YR$$M$Y$$$20250730$$MD$EU$EU
255883611$25588361$1$I$20250625$20250717$20250722$20250722$EXP$EU-MINISAL02-1048725$EU-TEVA-VS-3354367$TEVA$$66$YR$$M$Y$$$20250722$$MD$EU$EU
255883911$25588391$1$I$20250710$20250717$20250722$20250722$EXP$GB-MHRA-MED-202507171019156710-PKDSY$GB-TEVA-VS-3354328$TEVA$$65$YR$$M$Y$70$KG$20250722$$HP$GB$GB
255885331$25588533$1$I$$20250708$20250722$20250722$EXP$$IN-STRIDES ARCOLAB LIMITED-2025SP009213$STRIDES$Kaur U, Lahari TSS, Jaiswal S, Chakrabarti SS.. Duloxetine-induced neuropsychiatric symptoms in a nonagenarian with chronic Pregabalin intake.. Acta-Neurol-Belg. 2025$96$YR$$M$Y$$$20250722$$HP$IN$IN
255885781$25588578$1$I$$20250716$20250722$20250722$EXP$$US-JNJFOC-20250719914$JOHNSON AND JOHNSON$$$$$M$Y$$$20250722$$HP$US$US
255886512$25588651$2$F$$20250725$20250722$20250728$30DAY$$US-ELI_LILLY_AND_COMPANY-US202507019448$ELI LILLY AND COMPANY$$$$$F$Y$$$20250728$$CN$US$US
255887501$25588750$1$I$$20250716$20250722$20250722$PER$$US-UNITED THERAPEUTICS-UNT-2025-024859$UNITED THERAPEUTICS$$$$$F$Y$69.841$KG$20250722$$$US$US
255887601$25588760$1$I$$20250715$20250722$20250722$EXP$$US-SMPA-2025SPA009182$SUNOVION$$$$$$Y$$$20250722$$CN$US$US
255888432$25588843$2$F$20241001$20250805$20250722$20250811$EXP$$GB-UCBSA-2025000073$UCB$$74$YR$$F$Y$$$20250811$$HP$GB$GB
255889191$25588919$1$I$$20250715$20250722$20250722$EXP$$JP-GSK-JP2025JPN090492$GLAXOSMITHKLINE$$$$$F$Y$$$20250722$$PH$JP$JP
255889461$25588946$1$I$$20250715$20250722$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507016386$ELI LILLY AND COMPANY$$$$$$Y$$$20250722$$CN$US$US
255889881$25588988$1$I$20190101$20250708$20250722$20250722$EXP$$US-COOPERSURGICAL, INC.-2025CPS005501$COOPERSURGICAL$$38$YR$$F$Y$158.73$KG$20250722$$CN$US$US
255890082$25589008$2$F$20241001$20250804$20250722$20250808$EXP$$US-ABBVIE-6379965$ABBVIE$$26$YR$$F$Y$63.502$KG$20250808$$CN$US$US
255890711$25589071$1$I$20250701$20250714$20250722$20250722$EXP$$AE-ASTRAZENECA-202507MES009826AE$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250722$$$AE$AE
255891021$25589102$1$I$20100101$20250708$20250722$20250722$EXP$$US-COOPERSURGICAL, INC.-2025CPS005510$COOPERSURGICAL$$21$YR$$F$Y$86.168$KG$20250722$$CN$US$US
255891641$25589164$1$I$$20250707$20250722$20250722$EXP$$US-CHURCH AND DWIGHT CO., INC-2025-CDW-01193$CHURCH + DWIGHT$$92$YR$$M$Y$$$20250722$$CN$US$US
255892006$25589200$6$F$20250701$20250919$20250722$20250927$PER$$US-UNITED THERAPEUTICS-UNT-2025-024278$UNITED THERAPEUTICS$$64$YR$$M$Y$78.005$KG$20250927$$$US$US
255893111$25589311$1$I$20250524$20250709$20250722$20250722$EXP$$EU-AUROBINDO-AUR-APL-2025-036107$AUROBINDO$$28$YR$$F$Y$$$20250722$$MD$EU$EU
255893671$25589367$1$I$$20250716$20250722$20250722$EXP$$EU-AMGEN-DNKSP2025141892$AMGEN$Lauridsen Kb.. Sex differences in treatment response in patients withrheumatoid arthritis treated with tumour necrosis factor inhibitor: a cohort study from the DANBIO registry. Scandinavian Journal of Rheumatology. 2025;54 (4):252-262$$$$$Y$$$20250722$$HP$EU$EU
255893741$25589374$1$I$$20250709$20250722$20250722$EXP$$US-AUROBINDO-AUR-APL-2025-036548$AUROBINDO$Kongala BP, Bhattarai M, Ammar H.. A Case of Takotsubo Cardiomyopathy Triggered by Human Metapneumovirus. Cureus. 2025;17(5):e84977$59$YR$$F$Y$$$20250722$$MD$US$US
255894511$25589451$1$I$$20250716$20250722$20250722$EXP$$US-SANDOZ INC.-SDZ2025US050679$SANDOZ$$$$$$Y$$$20250722$$CN$US$US
255894961$25589496$1$I$20250716$20250716$20250722$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-101863$BRISTOL-MYERS SQUIBB COMPANY$$32$YR$A$M$Y$$$20250722$$CN$US$US
255895141$25589514$1$I$$20250702$20250722$20250722$PER$$US-SMPA-2025SPA008515$SUNOVION$$$$$$Y$$$20250722$$CN$US$US
255896801$25589680$1$I$$20250702$20250722$20250722$PER$$US-SMPA-2025SPA008563$SUNOVION$$$$$$Y$$$20250722$$CN$US$US
255896971$25589697$1$I$$20250710$20250722$20250722$EXP$$US-AMGEN-USASP2025137472$AMGEN$Pennington K.M.; Kommaraju K.; Alsharif M. et.al.. Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation. Clinical Transplantation. 2025;39 (6):1-6$51$YR$A$F$Y$$$20250722$$HP$US$US
255897043$25589704$3$F$$20250824$20250722$20250903$PER$$US-SMPA-2025SPA008573$SUNOVION$$68$YR$$M$Y$$$20250902$$$US$US
255897081$25589708$1$I$$20250707$20250722$20250722$EXP$$TR-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-517556$RANBAXY$Katran ZY, Bulut I, Saydin F, Yavuz D, Cosar ND, Katran M. The cause of perioperative hypersensitivity in adults and consequences of subsequent anesthesia. Allergol Immunopathol. 2025;53 (2):113-123$72$YR$$F$Y$$$20250722$$HP$TR$TR
255897492$25589749$2$F$$20250805$20250722$20250820$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-517676$RANBAXY$Itoh A, Shibuya K, Kimura N, Fukasawa M, Kawai S, Igarashi T. Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involving nanoliposomal irinotecan with fluorouracil and folinic acid. Clin J Gastroenterol. 2025;Jul 4:Online ahead of print$67$YR$$F$Y$$$20250820$$HP$JP$JP
255897521$25589752$1$I$20250305$20250707$20250722$20250722$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-517854$RANBAXY$$43$YR$$F$Y$90$KG$20250722$$MD$EU$EU
255897721$25589772$1$I$$20250707$20250722$20250722$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-517807$RANBAXY$Agrawal S, Hutson SD, Johnson EF, Alavi A. Cytomegalovirus-induced cutaneous ulcers: A case series. JAAD Case Rep. 2025;61 (0):123-128$55$YR$$M$Y$$$20250722$$MD$US$US
255897871$25589787$1$I$20250711$20250711$20250722$20250722$EXP$$US-IMMUNOCORE, LTD-2025-IMC-004430$IMMUNOCORE$$74$YR$$M$Y$$$20250722$$CN$US$US
255898631$25589863$1$I$$20250715$20250722$20250722$EXP$$GB-TEVA-VS-3354645$TEVA$$53$YR$$F$Y$69$KG$20250722$$MD$GB$GB
255899391$25589939$1$I$$20250709$20250722$20250722$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202507-002056$AZURITY PHARMACEUTICALS$Ahmed M, Mian M, Parchuri V, Hossain T, Weaver M, Tahir S et al.. The role of pre-anesthesia testing in identifying risk for delayed gastric emptying and aspiration: A case report.. Am J Respir Crit Care Med. 2025;211:A5704$68$YR$$F$Y$$$20250722$$HP$US$US
255899962$25589996$2$F$20250610$20250901$20250722$20250910$30DAY$$US-NOVOPROD-1479581$NOVO NORDISK$$54$YR$$F$Y$$$20250910$$CN$US$US
255900571$25590057$1$I$20250701$20250711$20250722$20250722$PER$$US-BAUSCH-BH-2025-014780$BAUSCH AND LOMB$$$$$F$Y$$$20250722$$CN$US$US
255901231$25590123$1$I$20250719$20250721$20250722$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507019576$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250722$$CN$US$US
255901342$25590134$2$F$$20250805$20250722$20250813$EXP$$US-TEVA-VS-3352855$TEVA$Wieschhaus KJ, Fallah T, Burcham P, Kissling K, Harriman C, Leaman A, et al. Routine Voriconazole Prophylaxis in Heart Transplant Recipients and Incidence of Non-Melanoma Skin Cancer. J-Heart-Lung-Transplant 2025; 44 (Suppl.) (4): S640 abstr. 1367.; Wieschhaus KJ, Fallah T, Burcham P, Kissling K, Harriman C, Leaman A, et al. Routine Voriconazole Prophylaxis in Heart Transplant Recipients and Incidence of Non-Melanoma Skin Cancer. J-Heart-Lung-Transplant 2025; 44 (Suppl.) (4): S640 abstr. 1367.$$$A$$Y$$$20250813$$HP$US$US
255901551$25590155$1$I$20250626$20250717$20250722$20250722$PER$$US-VIIV HEALTHCARE-US2025091945$VIIV$$$$$M$Y$$$20250722$$MD$US$US
255902262$25590226$2$F$$20250731$20250722$20250801$EXP$$EU-TEVA-VS-3353139$TEVA$Reiter N, Otte HR, Dalhoff K, Wamberg CA, Petersen TS, Meyhoff CS. Respiratory Failure Requiring Mechanical Ventilation Among Patients Receiving Chlordiazepoxide for Alcohol Withdrawal Symptoms. Acta-Anaesthesiol-Scand 2025; 69 (6): 1-8.; Reiter N, Otte HR, Dalhoff K, Wamberg CA, Petersen TS, Meyhoff CS. Respiratory Failure Requiring Mechanical Ventilation Among Patients Receiving Chlordiazepoxide for Alcohol Withdrawal Symptoms. Acta-Anaesthesiol-Scand 2025; 69 (6): 1-8.$$$$$Y$$$20250801$$HP$EU$EU
255902322$25590232$2$F$20250421$20250822$20250722$20250827$EXP$$JP-GILEAD-2025-0721241$GILEAD$$63$YR$A$F$Y$$$20250827$$MD$JP$JP
255902811$25590281$1$I$$20250721$20250721$20250721$DIR$765729$$FDA-CTU$$$$$F$N$$$20250721$N$$US$
255903541$25590354$1$I$20250617$20250624$20250722$20250722$PER$$US-GALDERMA-US2025011007$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255903911$25590391$1$I$20250101$20250626$20250722$20250722$PER$$US-GALDERMA-US2025011378$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255904461$25590446$1$I$20250101$20250630$20250722$20250722$PER$$US-GALDERMA-US2025011714$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255905301$25590530$1$I$$20250718$20250722$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507018555$ELI LILLY AND COMPANY$$60$YR$A$$Y$$$20250722$$CN$US$US
255906001$25590600$1$I$20250625$20250626$20250722$20250722$PER$$US-GSK-US2025080493$GLAXOSMITHKLINE$$72$YR$$M$Y$$$20250722$$$US$US
255906591$25590659$1$I$20250601$20250717$20250722$20250722$PER$$US-GSK-US2025091893$GLAXOSMITHKLINE$$88$YR$$F$Y$$$20250722$$$US$US
255906741$25590674$1$I$20220101$20250714$20250722$20250722$EXP$EU-GREOF-202501098$EU-KOWA-25EU001228$KOWA PHARM$$$$$$Y$$$20250722$$HP$EU$EU
255907472$25590747$2$F$$20250723$20250722$20250807$EXP$$US-TORRENT-00014427$TORRENT PHARMA INC.$$8$DEC$E$M$Y$$$20250807$$PH$US$US
255907561$25590756$1$I$$20250721$20250722$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-102520$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$$$20250722$$CN$US$US
255908581$25590858$1$I$20250101$20250710$20250722$20250722$EXP$$US-UCBSA-2025040881$UCB$$$$A$M$Y$$$20250722$$CN$US$US
255908851$25590885$1$I$20250715$20250721$20250722$20250722$EXP$$CN-BAYER-2025A097197$BAYER HEALTHCARE PHARMACEUTICALS INC.$$71$YR$E$M$Y$55$KG$20250722$$HP$CN$CN
255909421$25590942$1$I$20250626$20250717$20250722$20250722$EXP$$US-ASTRAZENECA-202507USA014211US$ALEXION PHARMACEUTICALS$$10$YR$C$F$Y$$$20250722$$$US$US
255909781$25590978$1$I$20250210$20250715$20250722$20250722$EXP$$IN-PFIZER INC-PV202500038473$PFIZER$$50$YR$$M$Y$74$KG$20250722$$CN$IN$IN
255909961$25590996$1$I$$20250717$20250722$20250722$EXP$$IN-PFIZER INC-PV202400102582$PFIZER$$50$YR$$M$Y$$$20250722$$CN$IN$IN
255910081$25591008$1$I$$20250717$20250722$20250722$EXP$$IN-PFIZER INC-PV202400038038$PFIZER$$50$YR$$M$Y$$$20250722$$CN$IN$IN
255910181$25591018$1$I$20250601$20250718$20250722$20250722$EXP$$MA-PFIZER INC-202500146869$PFIZER$$$$$F$Y$$$20250722$$CN$MA$MA
255910461$25591046$1$I$20250101$20250718$20250722$20250722$PER$$US-BAYER-2025A096636$BAYER HEALTHCARE PHARMACEUTICALS INC.$$28$YR$A$F$Y$$$20250722$$CN$US$US
255910731$25591073$1$I$20250619$20250715$20250722$20250722$EXP$EU-AFSSAPS-BX2025001040$EU-FreseniusKabi-FK202509770$FRESENIUS KABI$$74$YR$E$F$Y$48$KG$20250722$$MD$EU$EU
255911211$25591121$1$I$20250501$20250620$20250722$20250722$EXP$$US-SANDOZ INC.-SDZ2025US051638$SANDOZ$$52$YR$$M$Y$$$20250722$$MD$US$US
255911271$25591127$1$I$20250101$20250716$20250722$20250722$EXP$$US-ABBVIE-6376136$ABBVIE$$77$YR$$F$Y$$$20250722$$CN$US$US
255911452$25591145$2$F$$20250730$20250722$20250807$EXP$$US-TEVA-VS-3352594$TEVA$Solodiuk JC, Donado C, Wickerham L, Goodyear L, Hayes J, Mortell RE, et al. Development and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessment Instrument for Monitoring Iatrogenic Withdrawal Symptoms in Children Receiving an Alpha-2 Agonist. Pediatr-Crit-Care-Med 2025; 26 (1): e67-e76.; Solodiuk JC, Donado C, Wickerham L, Goodyear L, Hayes J, Mortell RE, et al. Development and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessmen...$19$YR$$M$Y$$$20250807$$HP$US$US
255911741$25591174$1$I$$20250711$20250722$20250722$EXP$$US-ELI_LILLY_AND_COMPANY-US202507011853$ELI LILLY AND COMPANY$$57$YR$A$M$Y$$$20250722$$HP$US$US
255912111$25591211$1$I$20250721$20250722$20250722$20250722$DIR$765818$$FDA-CTU$$$$$$N$$$20250722$N$CN$US$
255912663$25591266$3$F$20250326$20250728$20250722$20250810$EXP$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00660$AIMMUNE$$$$$$Y$$$20250810$$HP$US$US
255913011$25591301$1$I$20250721$20250721$20250722$20250722$EXP$$US-JNJFOC-20250725463$JOHNSON AND JOHNSON$$28$YR$A$F$Y$$$20250722$$HP$US$US
255913251$25591325$1$I$$20250722$20250722$20250722$DIR$765841$$FDA-CTU$$$$$$N$$$20250722$N$CN$US$
255913581$25591358$1$I$$20250721$20250722$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-102265$BRISTOL-MYERS SQUIBB COMPANY$$46$YR$A$M$Y$$$20250722$$CN$US$US
255913662$25591366$2$F$20160101$20250505$20250722$20250909$EXP$$BR-Ipsen Biopharmaceuticals, Inc.-2025-14608$IPSEN BIOPHARMACEUTICALS, INC.$$$$A$$Y$$$20250909$$$BR$BR
255914421$25591442$1$I$20250609$20250716$20250722$20250722$EXP$EU-AEMPS-1720295$EU-TEVA-VS-3354360$TEVA$$73$YR$$F$Y$$$20250722$$MD$EU$EU
255914771$25591477$1$I$20230101$20250717$20250722$20250722$EXP$$PH-009507513-2304PHL006704$MERCK SHARP + DOHME LLC$$$$$M$Y$$$20250722$$MD$PH$PH
255918081$25591808$1$I$$20250424$20250722$20250722$PER$$US-VANDA PHARMACEUTICALS, INC-2025TASUS007573$VANDA PHARMACEUTICALS$$$$$F$Y$46.077$KG$20250722$$CN$US$US
255918781$25591878$1$I$$20250715$20250722$20250722$EXP$$US-TAKEDA-2025TUS064598$TAKEDA$$$$$M$Y$$$20250722$$$US$US
255918931$25591893$1$I$$20250717$20250722$20250722$EXP$$CN-JNJFOC-20250723083$JOHNSON AND JOHNSON$$$$$$Y$$$20250722$$MD$CN$CN
255921331$25592133$1$I$20250715$20250716$20250722$20250722$EXP$$US-MALLINCKRODT-MNK202504393$MALLINCKRODT$$72$YR$E$M$Y$$$20250722$$CN$US$US
255921472$25592147$2$F$20250710$20250717$20250722$20250723$EXP$$EU-ABBVIE-6381228$ABBVIE$$75$YR$$F$Y$$$20250723$$CN$EU$EU
255922611$25592261$1$I$$20250718$20250722$20250722$30DAY$$CN-ASTRAZENECA-202503CHN002866CN$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$$$20250722$$$CN$CN
255923461$25592346$1$I$$20250717$20250722$20250722$PER$$US-ASTRAZENECA-202507USA014671US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250722$$$US$US
255923591$25592359$1$I$$20250714$20250722$20250722$EXP$$US-AMGEN-USASP2025140875$AMGEN$Joo E.; Robinson R.; Golts E. et al.. ^HHV-8 Negative^ Cutaneous Kaposi^s Sarcoma Following Lung Transplantation. American Journal of Respiratory and Critical Care Medicine. 2025;211:A6004$69$YR$E$M$Y$$$20250722$$HP$US$US
255924391$25592439$1$I$$20250715$20250722$20250722$EXP$$TR-BAUSCH-BL-2025-007441$BAUSCH AND LOMB$Benli S, Yetkin MF, Mirza M. Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case. Journal of child neurology. 2025 Apr 19;1-4. doi:10.1177/08830738251340278.$$$A$F$Y$$$20250722$$MD$TR$TR
255925151$25592515$1$I$$20250710$20250722$20250722$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI09186$NEUROCRINE BIOSCIENCES$$$$$$Y$$$20250722$$HP$US$US
255925821$25592582$1$I$$20250715$20250722$20250722$PER$$US-ASTRAZENECA-202507USA013514US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250722$$$US$US
255926051$25592605$1$I$20250715$20250715$20250722$20250722$PER$$US-SA-2025SA205999$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250722$$PH$US$US
255926112$25592611$2$F$20250101$20250905$20250722$20250913$PER$$US-SA-2025SA208293$SANOFI AVENTIS$$67$YR$E$M$Y$$$20250913$$HP$US$US
255926482$25592648$2$F$$20250721$20250722$20250727$PER$$US-SA-2025SA205660$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250727$$CN$US$US
255926891$25592689$1$I$$20250716$20250722$20250722$PER$$US-SA-2025SA205674$SANOFI AVENTIS$$$$$M$Y$$$20250722$$PH$US$US
255926931$25592693$1$I$20250701$20250715$20250722$20250722$PER$$US-SA-2025SA204225$SANOFI AVENTIS$$46$YR$A$F$Y$67.27$KG$20250722$$HP$US$US
255927791$25592779$1$I$20250704$20250716$20250722$20250722$PER$$US-SA-2025SA205613$SANOFI AVENTIS$$14$YR$T$F$Y$$$20250722$$HP$US$US
255928451$25592845$1$I$$20250716$20250722$20250722$PER$$US-SA-2025SA208025$SANOFI AVENTIS$$17$YR$T$M$Y$$$20250722$$HP$US$US
255929281$25592928$1$I$$20250718$20250722$20250722$PER$$US-JNJFOC-20250723377$JOHNSON AND JOHNSON$$$$$M$Y$$$20250722$$CN$US$US
255929661$25592966$1$I$20250601$20250717$20250722$20250722$PER$$US-SA-2025SA208532$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250722$$HP$US$US
255930122$25593012$2$F$20250718$20250829$20250722$20250903$PER$$US-SA-2025SA209411$SANOFI AVENTIS$$53$YR$A$F$Y$$$20250903$$CN$US$US
255930221$25593022$1$I$$20250718$20250722$20250722$PER$$US-SA-2025SA208776$SANOFI AVENTIS$$30$YR$A$F$Y$$$20250722$$CN$US$US
255930281$25593028$1$I$$20250718$20250722$20250722$PER$$US-SA-2025SA209026$SANOFI AVENTIS$$51$YR$A$F$Y$$$20250722$$CN$US$US
255930571$25593057$1$I$20250701$20250717$20250722$20250722$PER$$US-MALLINCKRODT-MNK202504413$MALLINCKRODT$$31$YR$A$M$Y$$$20250721$$CN$US$US
255930782$25593078$2$F$$20250818$20250722$20250821$EXP$$JP-DSJP-DS-2025-153633-JPAA$DAIICHI$Miwa M, Kimura K, Okada M, Nishida M, Nishihara K, Yasunari R, et al.. EP24-159 A case of pseudocirrhosis during breast cancer liver metastasis treatment. The 33rd Annual Meeting of the Japanese Breast Cancer Society. 2025;1445$61$YR$$F$Y$$$20250821$$MD$JP$JP
255931081$25593108$1$I$20250701$20250718$20250722$20250722$PER$$US-ELI_LILLY_AND_COMPANY-US202507018070$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250722$$PH$US$US
255931921$25593192$1$I$$20250717$20250722$20250722$PER$$US-ABBVIE-6378722$ABBVIE$$$$$F$Y$$$20250722$$CN$US$US
255933221$25593322$1$I$20250101$20250620$20250722$20250722$PER$$US-GALDERMA-US2025010874$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255933701$25593370$1$I$20250623$20250624$20250722$20250722$PER$$US-GALDERMA-US2025011030$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255933791$25593379$1$I$$20250701$20250722$20250722$PER$$US-GALDERMA-US2025011708$GALDERMA$$$$$$Y$$$20250722$$CN$US$US
255933931$25593393$1$I$20171124$20250715$20250722$20250722$EXP$$US-ASTRAZENECA-202507GLO012428US$ALEXION PHARMACEUTICALS$$65$YR$E$M$Y$$$20250722$$LW$US$US
255934691$25593469$1$I$20250328$20250718$20250722$20250722$EXP$$US-ASTRAZENECA-202507USA015458US$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$$$20250722$$MD$US$US
255935133$25593513$3$F$20250605$20250904$20250722$20250908$EXP$$JP-ASTRAZENECA-202507JPN014889JP$ALEXION PHARMACEUTICALS$$6$DEC$A$M$Y$72$KG$20250908$$PH$JP$JP
255935191$25593519$1$I$20250301$20250718$20250722$20250722$EXP$$US-ABBVIE-6380099$ABBVIE$$52$YR$$F$Y$$$20250722$$CN$US$US
255935841$25593584$1$I$$20250722$20250722$20250722$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-102706$BRISTOL-MYERS SQUIBB COMPANY$$42$YR$A$F$Y$$$20250723$$HP$US$US
255936112$25593611$2$F$$20250722$20250722$20250730$EXP$$JP-AMGEN-JPNSP2025144903$AMGEN$$$$$$Y$$$20250730$$PH$JP$JP
255936517$25593651$7$F$20220101$20250903$20250722$20250910$EXP$$US-AMGEN-USASP2025143722$AMGEN$$65$YR$E$M$Y$101$KG$20250909$$LW$US$US
255936631$25593663$1$I$20250224$20250715$20250722$20250722$EXP$$US-ASTRAZENECA-202507GLO012401US$ALEXION PHARMACEUTICALS$$65$YR$E$M$Y$$$20250722$$LW$US$US
255938281$25593828$1$I$20250707$20250715$20250723$20250723$EXP$$US-Ipsen Biopharmaceuticals, Inc.-2025-17711$IPSEN BIOPHARMACEUTICALS, INC.$$36$YR$A$F$Y$72$KG$20250723$$MD$US$US
255938401$25593840$1$I$20150101$20250717$20250723$20250723$EXP$$BR-BIOGEN-2025BI01317927$BIOGEN$$$$$F$Y$60$KG$20250723$$HP$BR$BR
255938872$25593887$2$F$$20250829$20250723$20250904$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008482$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250904$$CN$US$US
255939761$25593976$1$I$20250630$20250721$20250723$20250723$EXP$$US-ASTRAZENECA-202507USA016688US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250723$$$US$US
255941551$25594155$1$I$$20250715$20250723$20250723$EXP$$US-TAKEDA-2025TUS064337$TAKEDA$$$$$F$Y$$$20250723$$$US$US
255942091$25594209$1$I$$20250702$20250723$20250723$PER$$US-GSK-US2025083144$GLAXOSMITHKLINE$$$$$M$Y$$$20250723$$$US$US
255943321$25594332$1$I$20220101$20250717$20250723$20250723$EXP$$US-SANDOZ INC.-SDZ2025US051955$SANDOZ$$$$$M$Y$$$20250723$$MD$US$US
255943791$25594379$1$I$$20250721$20250723$20250723$PER$$US-ABBVIE-6382701$ABBVIE$$$$E$F$Y$$$20250723$$CN$US$US
255944271$25594427$1$I$$20250716$20250723$20250723$PER$$US-SA-2025SA210584$SANOFI AVENTIS$$69$YR$E$F$Y$63.18$KG$20250723$$HP$US$US
255944921$25594492$1$I$20250216$20250715$20250723$20250723$EXP$EU-AFSSAPS-PP2025000782$EU-BAXTER-2025BAX018388$BAXTER$$19$YR$$F$Y$68$KG$20250723$$MD$EU$EU
255946281$25594628$1$I$$20250714$20250723$20250723$EXP$$US-AMGEN-USASP2025140605$AMGEN$Gangaraju R.; Bhatia S.; Kenzik K.. Venous-Thromboembolism in Elderly Patients with Diffuse Large B Cell Lymphoma. Blood. 2020;136 (SUPPL.1):4$$$$$Y$$$20250723$$MD$US$US
255946763$25594676$3$F$20250101$20250801$20250723$20250807$EXP$$EU-ABBVIE-6380848$ABBVIE$$79$YR$$F$Y$$$20250807$$HP$EU$EU
255947061$25594706$1$I$20250601$20250719$20250723$20250723$PER$$US-SA-2025SA210193$SANOFI AVENTIS$$54$YR$A$M$Y$$$20250723$$HP$US$US
255947081$25594708$1$I$20250710$20250717$20250723$20250723$PER$$US-SA-2025SA208092$SANOFI AVENTIS$$9$YR$C$M$Y$$$20250723$$HP$US$US
255947371$25594737$1$I$20250628$20250710$20250723$20250723$PER$$US-Emmaus Medical, Inc.-EMM202507-000111$EMMAUS LIFE SCIENCES$$30$YR$A$M$Y$$$20250723$$CN$US$
255947891$25594789$1$I$20250626$20250710$20250723$20250723$EXP$$EU-AUROBINDO-AUR-APL-2025-036587$AUROBINDO$$23$YR$$F$Y$68$KG$20250723$$MD$EU$EU
255948001$25594800$1$I$$20250710$20250723$20250723$EXP$$EU-AUROBINDO-AUR-APL-2025-036864$AUROBINDO$$30$YR$$M$Y$$$20250723$$HP$EU$EU
255948031$25594803$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507020282$ELI LILLY AND COMPANY$$73$YR$E$F$Y$$$20250723$$CN$US$US
255948332$25594833$2$F$$20250811$20250723$20250814$EXP$EU-EMA-DD-20250716-7482689-071047$EU-SANDOZ INC.-SDZ2025PT051728$SANDOZ$$28$YR$$F$Y$$$20250814$$MD$EU$EU
255948532$25594853$2$F$$20250721$20250723$20250724$30DAY$$US-SANDOZ INC.-SDZ2025US051539$SANDOZ$$$$$F$Y$$$20250724$$CN$US$US
255948682$25594868$2$F$$20250726$20250723$20250806$EXP$$US-UCBSA-2025044563$UCB$$$$$M$Y$$$20250806$$HP$US$US
255949171$25594917$1$I$$20250715$20250723$20250723$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126183$ZYDUS PHARM$Moskowitz A, Advani RH, Ganesan N, Chang T, Hancock H, Davey T, et al. Front-Line Treatment of Extranodal NK/T-Cell Lymphoma. Blood. 2024;144 (1):3068-3069$$$$$Y$$$20250723$$MD$US$US
255949561$25594956$1$I$20250619$20250715$20250723$20250723$EXP$EU-AFSSAPS-AN2025000880$EU-TEVA-VS-3353537$TEVA$$69$YR$$F$Y$77$KG$20250723$$PH$EU$EU
255949612$25594961$2$F$$20250714$20250723$20250806$EXP$$TW-EXELIXIS-EXL-2025-010012$EXELIXIS$$26$YR$$F$Y$$$20250806$$MD$TW$TW
255950081$25595008$1$I$$20250716$20250723$20250723$PER$$US-VIIV HEALTHCARE-US2025AMR093091$VIIV$$$$$M$Y$$$20250723$$MD$US$US
255950511$25595051$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507019666$ELI LILLY AND COMPANY$$$$$$Y$$$20250723$$CN$US$US
255950721$25595072$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507020288$ELI LILLY AND COMPANY$$41$YR$A$M$Y$$$20250723$$CN$US$US
255951031$25595103$1$I$$20250708$20250723$20250723$EXP$$JO-SUN PHARMA MIDDLE EAST FZ-LLC-2025RR-518529$RANBAXY$Alshwayyat S, Hanifa H, Amro AM, Alshwayyat M, Odat RM, Mahmoud LM, et al. From flank pain to splenic abscess a complex case of infective endocarditis with literature review. BMC Cardiovasc Disord. 2024;24 (1):520$20$YR$$F$Y$$$20250723$$HP$JO$JO
255951081$25595108$1$I$$20250707$20250723$20250723$PER$$US-SMPA-2025SPA008722$SUNOVION$$$$$$Y$$$20250723$$CN$US$US
255952411$25595241$1$I$20250101$20250708$20250723$20250723$EXP$$EU-TEVA-VS-3351090$TEVA$$73$YR$$F$Y$$$20250723$$CN$EU$EU
255952463$25595246$3$F$$20250808$20250723$20250819$EXP$$US-UNICHEM LABORATORIES LIMITED-UNI-2025-US-002804$UNICHEM$$$$$$Y$$$20250819$$CN$US$US
255952691$25595269$1$I$$20250708$20250723$20250723$PER$$US-SMPA-2025SPA008783$SUNOVION$$$$$$Y$$$20250723$$CN$US$US
255953261$25595326$1$I$$20250718$20250723$20250723$EXP$$HN-JNJFOC-20250725788$JOHNSON AND JOHNSON$$83$YR$E$M$Y$$$20250723$$CN$HN$HN
255954841$25595484$1$I$$20250707$20250723$20250723$PER$$US-SMPA-2025SPA008744$SUNOVION$$$$$$Y$$$20250723$$CN$US$US
255955352$25595535$2$F$20250715$20250725$20250723$20250729$PER$$JP-TAKEDA-2025TJP007318$TAKEDA$$58$YR$$M$Y$$$20250729$$MD$JP$JP
255955461$25595546$1$I$20250627$20250714$20250723$20250723$EXP$GB-MHRA-MED-202507110940005840-GLDWT$GB-AMAROX PHARMA-AMR2025GB04055$HETERO$$71$YR$$F$Y$44$KG$20250723$$CN$GB$GB
255955981$25595598$1$I$$20250717$20250723$20250723$PER$$US-ABBVIE-6378360$ABBVIE$$$$$$Y$$$20250723$$MD$US$US
255957121$25595712$1$I$$20250716$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507015268$ELI LILLY AND COMPANY$$61$YR$A$$Y$$$20250723$$CN$US$US
255957151$25595715$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507019258$ELI LILLY AND COMPANY$$74$YR$E$F$Y$$$20250723$$CN$US$US
255957171$25595717$1$I$$20250716$20250723$20250723$EXP$$US-VELOXIS PHARMACEUTICALS, INC.-2025-VEL-00367$VELOXIS PHARMACEUTICALS$Noor A, Yong S, Vagts C.. The hemorrhagic veil: Kaposi Sarcoma in the lungs and its pulmonary manifestations.. American Journal of Respiratory and Critical Care Medicine.. 2025;211:A2777$69$YR$$M$Y$$$20250723$$MD$US$US
255957481$25595748$1$I$$20250722$20250722$20250722$DIR$765976$$FDA-CTU$$$$$F$N$$$20250722$N$CN$US$
255958061$25595806$1$I$20250722$20250722$20250722$20250722$DIR$FDA-CDER-CTU-2025-48326$$FDA-CTU$$58$YR$$F$N$$$20250722$N$PH$US$
255958401$25595840$1$I$20250624$20250715$20250723$20250723$EXP$$US-BAXTER-2025BAX018402$BAXTER$$57$YR$$M$Y$77$KG$20250723$$HP$US$US
255958893$25595889$3$F$20250625$20250819$20250723$20250826$PER$$EU-Eisai-EC-2025-193373$EISAI$$73$YR$E$F$Y$78$KG$20250826$$$EU$EU
255959132$25595913$2$F$20231123$20250801$20250723$20250812$EXP$EU-MINISAL02-1048781$EU-ELI_LILLY_AND_COMPANY-IT202507011862$ELI LILLY AND COMPANY$$87$YR$E$F$Y$$$20250812$$CN$EU$EU
255959311$25595931$1$I$20250701$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507020580$ELI LILLY AND COMPANY$$$$$$Y$$$20250723$$CN$US$US
255959481$25595948$1$I$20250113$20250713$20250723$20250723$EXP$GB-MHRA-MED-202507131043452470-MDSRQ$GB-ELI_LILLY_AND_COMPANY-GB202507012054$ELI LILLY AND COMPANY$$32$YR$A$F$Y$63$KG$20250723$$CN$GB$GB
255959501$25595950$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507019672$ELI LILLY AND COMPANY$$$$$F$Y$$$20250723$$CN$US$US
255960261$25596026$1$I$20250717$20250722$20250723$20250723$DIR$FDA-CDER-CTU-2025-48343$$FDA-CTU$$51$YR$$M$N$101$KG$20250722$N$$US$
255960292$25596029$2$F$$20250721$20250723$20250801$EXP$$EU-AUROBINDO-AUR-APL-2025-037103$AUROBINDO$Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Duong TA, Ingen-Housz-Oro S, et al.. Systemic involvement of acute generalized exanthematous pustulosis: A retrospective study on 58 patients. British Journal of Dermatology. 2013;169(6):1223-32$27$YR$$F$Y$$$20250801$$HP$EU$EU
255960751$25596075$1$I$20250101$20250715$20250723$20250723$PER$$US-SA-2025SA204618$SANOFI AVENTIS$$11$YR$C$F$Y$$$20250723$$HP$US$US
255960961$25596096$1$I$20250523$20250717$20250723$20250723$PER$$US-SA-2025SA209659$SANOFI AVENTIS$$50$YR$A$F$Y$$$20250723$$HP$US$US
255961541$25596154$1$I$20250101$20250718$20250723$20250723$PER$$US-SA-2025SA210941$SANOFI AVENTIS$$32$YR$A$M$Y$$$20250723$$HP$US$US
255962571$25596257$1$I$20230520$20250721$20250723$20250723$EXP$$EU-MYLANLABS-2025M1061818$MYLAN$$28$YR$$F$Y$$$20250723$$$EU$EU
255962592$25596259$2$F$20250627$20250721$20250723$20250729$EXP$$PK-MYLANLABS-2025M1061385$MYLAN$$20$YR$$F$Y$24.5$KG$20250729$$MD$PK$PK
255963061$25596306$1$I$$20250704$20250723$20250723$PER$$US-KENVUE-20250702440$Kenvue$$$$$F$Y$$$20250723$$CN$US$US
255963201$25596320$1$I$20250528$20250710$20250723$20250723$EXP$EU-MINISAL02-1042615$EU-Axellia-005634$XELLIA PHARMACEUTICALS$$60$YR$A$F$Y$55$KG$20250723$$PH$EU$EU
255963871$25596387$1$I$$20250711$20250723$20250723$PER$$US-KENVUE-20250705429$Kenvue$$$$$F$Y$$$20250723$$CN$US$US
255964981$25596498$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507019657$ELI LILLY AND COMPANY$$70$YR$E$F$Y$$$20250723$$CN$US$US
255965151$25596515$1$I$$20250715$20250723$20250723$EXP$$CA-MERZ PHARMACEUTICALS LLC-ACO_178459_2025$MERZ$$$$$M$Y$$$20250723$$HP$CA$CA
255966611$25596661$1$I$20250721$20250722$20250722$20250722$DIR$765932$$FDA-CTU$$62$YR$$F$N$57.15$KG$20250722$N$CN$US$
255967591$25596759$1$I$$20250721$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507020513$ELI LILLY AND COMPANY$$57$YR$A$M$Y$$$20250723$$CN$US$US
255968121$25596812$1$I$$20250717$20250723$20250723$EXP$$AU-AMGEN-AUSSP2025142464$AMGEN$$$$$$Y$$$20250723$$MD$AU$AU
255968253$25596825$3$F$20250716$20250822$20250723$20250822$30DAY$$US-PFIZER INC-202500145740$PFIZER$$12$YR$$M$Y$$$20250822$$CN$US$US
255969491$25596949$1$I$$20250717$20250723$20250723$PER$$US-ROCHE-10000342115$ROCHE$$$$T$F$Y$$$20250723$$CN$US$US
255970761$25597076$1$I$$20250717$20250723$20250723$EXP$$VN-009507513-2311340$MERCK SHARP + DOHME LLC$$64$YR$$M$Y$$$20250723$$MD$VN$VN
255972321$25597232$1$I$20240614$20240617$20250723$20250723$PER$$US-LANTHEUS MEDICAL IMAGING-LMI-2024-01879$PROGENICS PHARMACEUTICALS$$$$$$Y$$$20250716$$CN$US$US
255972851$25597285$1$I$20250101$20250718$20250723$20250723$EXP$$US-VERTEX PHARMACEUTICALS-2025-011975$VERTEX$$$$C$M$Y$$$20250723$$CN$US$US
255973263$25597326$3$F$$20250815$20250723$20250819$30DAY$$US-PFIZER INC-202500148253$PFIZER$$$$$$Y$$$20250819$$HP$US$US
255973305$25597330$5$F$$20250818$20250723$20250822$30DAY$$US-PFIZER INC-202500148254$PFIZER$$$$$$Y$$$20250822$$HP$US$US
255973324$25597332$4$F$$20250815$20250723$20250825$30DAY$$US-PFIZER INC-202500148248$PFIZER$$$$$$Y$$$20250825$$HP$US$US
255973743$25597374$3$F$$20250815$20250723$20250819$30DAY$$US-PFIZER INC-202500148339$PFIZER$$$$$$Y$$$20250819$$HP$US$US
255974121$25597412$1$I$$20250723$20250723$20250723$DIR$766045$$FDA-CTU$$$$$$N$$$20250723$N$CN$US$
255974364$25597436$4$F$$20250818$20250723$20250820$30DAY$$US-PFIZER INC-202500148257$PFIZER$$$$$$Y$$$20250820$$HP$US$US
255976691$25597669$1$I$$20250723$20250723$20250723$DIR$766038$$FDA-CTU$$$$$$N$$$20250723$$CN$US$
255976911$25597691$1$I$20250715$20250718$20250723$20250723$EXP$$GB-Ipsen Biopharmaceuticals, Inc.-2025-17844$IPSEN BIOPHARMACEUTICALS, INC.$$71$YR$E$M$Y$$$20250723$$$GB$GB
255977022$25597702$2$F$20250708$20250710$20250723$20250801$EXP$GB-MHRA-MED-202507091317472540-NBMWY$GB-B. Braun Medical Inc.-GB-BBM-202502690$B. BRAUN MEDICAL INC.$$$$$F$Y$$$20250801$$$GB$GB
255977122$25597712$2$F$20250719$20250721$20250723$20250728$PER$$US-BAUSCHBL-2025BNL012838$BAUSCH AND LOMB$$$$$F$Y$$$20250729$$CN$US$US
255977971$25597797$1$I$$20250721$20250723$20250723$EXP$$TR-GSK-TR2025GSK093487$GLAXOSMITHKLINE$Aykut TS, Recep D, Munise D, Arzu A, ?lkay O. A Case of Bupropion-Induced Toxic Epidermal Necrolysis (TEN). Annals of Clinical Case Reports. 2017;2:1396$38$YR$$F$Y$$$20250723$$$TR$TR
255978123$25597812$3$F$$20250815$20250723$20250819$30DAY$$US-PFIZER INC-202500148304$PFIZER$$$$$$Y$$$20250819$$HP$US$US
255978163$25597816$3$F$$20250815$20250723$20250819$30DAY$$US-PFIZER INC-202500148310$PFIZER$$$$$$Y$$$20250819$$HP$US$US
255978791$25597879$1$I$$20250722$20250723$20250723$PER$$NVSC2025US117048$NOVARTIS$$$$$$Y$$$20250723$$HP$US$US
255979491$25597949$1$I$20250709$20250718$20250723$20250723$PER$$CN-Eisai-EC-2025-193614$EISAI$$39$YR$A$F$Y$62.9$KG$20250723$$$CN$CN
255979581$25597958$1$I$$20250717$20250723$20250723$EXP$EU-AFSSAPS-AVMA2025000389$EU-MYLANLABS-2025M1060870$MYLAN$$18$YR$$M$Y$$$20250723$$PH$EU$EU
255980202$25598020$2$F$$20250825$20250723$20250828$EXP$$US-AMGEN-USASP2025140524$AMGEN$$$$$F$Y$$$20250827$$MD$US$US
255980311$25598031$1$I$$20250716$20250723$20250723$EXP$$US-UCBSA-2025044554$UCB$$$$$F$Y$$$20250723$$HP$US$US
255981982$25598198$2$F$$20250721$20250723$20250724$PER$$US-009507513-2311653$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250724$$HP$US$US
255982181$25598218$1$I$$20250722$20250723$20250723$PER$$US-SHIRE-US202013521$TAKEDA$$$$$M$Y$$$20250723$$$US$US
255982652$25598265$2$F$$20250721$20250723$20250725$EXP$$US-ABBVIE-6322790$ABBVIE$$61$YR$$F$Y$$$20250725$$CN$US$US
255983362$25598336$2$F$20250705$20250910$20250723$20250912$EXP$$CA-PFIZER INC-202500149088$PFIZER$$88$YR$$M$Y$$$20250912$$HP$CA$CA
255983941$25598394$1$I$20250701$20250722$20250723$20250723$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-103168$BRISTOL-MYERS SQUIBB COMPANY$$50$YR$A$M$Y$$$20250723$$PH$US$US
255983981$25598398$1$I$$20250721$20250723$20250723$PER$$US-SA-2025SA210743$SANOFI AVENTIS$$59$YR$A$F$Y$$$20250724$$CN$US$US
255984701$25598470$1$I$$20250715$20250723$20250723$PER$$US-DAIICHI SANKYO, INC.-DS-2025-153953-US$DAIICHI$$84$YR$$F$Y$$$20250723$$PH$US$US
255984882$25598488$2$F$20250601$20250727$20250723$20250807$EXP$$IL-ELI_LILLY_AND_COMPANY-IL202507014413$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250807$$CN$IL$IL
255984931$25598493$1$I$$20250701$20250723$20250723$PER$$US-009507513-2304236$MERCK SHARP + DOHME LLC$Waliany S, Hung Y, Rous F, Luo F, Capelletti M, Ressler S, et al. Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies. Clinical Lung Cancer 2025-07-01 26 (5): 354-363.e5$58$YR$$F$Y$$$20250723$$HP$US$US
255984991$25598499$1$I$$20250717$20250723$20250723$EXP$$US-ORGANON-O2507USA001769$ORGANON$Kuzel T, Burton T, Rayyan E.. Refractory Status Epilepticus Resulting from Immune Effector Cell associated Neurotoxicity Syndrome. Am J Respir Crit Care Med. 2025;211:A3954$49$YR$$M$Y$$$20250723$$HP$US$US
255985061$25598506$1$I$$20250722$20250723$20250723$PER$$US-ELI_LILLY_AND_COMPANY-US202507020808$ELI LILLY AND COMPANY$$33$YR$A$$Y$$$20250723$$CN$US$US
255985401$25598540$1$I$20250715$20250718$20250723$20250723$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-083034$BOEHRINGER INGELHEIM$$89$YR$E$F$Y$$$20250723$$PH$JP$JP
255986181$25598618$1$I$$20250722$20250723$20250723$PER$$PR-BRISTOL-MYERS SQUIBB COMPANY-2025-103238$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$96.16$KG$20250724$$CN$PR$PR
255986261$25598626$1$I$$20250721$20250723$20250723$PER$$US-ABBVIE-6382587$ABBVIE$$$$$F$Y$$$20250723$$HP$US$US
255987161$25598716$1$I$$20250721$20250724$20250724$PER$$US-ABBVIE-6382989$ABBVIE$$$$A$M$Y$$$20250724$$CN$US$US
255988621$25598862$1$I$$20250716$20250724$20250724$PER$$US-ROCHE-10000340768$ROCHE$$$$$$Y$$$20250724$$CN$US$US
255988691$25598869$1$I$$20250716$20250724$20250724$PER$$US-ROCHE-10000340773$ROCHE$$$$$$Y$$$20250724$$CN$US$US
255988811$25598881$1$I$20250301$20250721$20250724$20250724$PER$$US-GSK-US2025093141$GLAXOSMITHKLINE$$69$YR$$F$Y$$$20250724$$$US$US
255988851$25598885$1$I$$20250717$20250724$20250724$EXP$$US-BIOGEN-2025BI01317839$BIOGEN$$$$$F$Y$$$20250724$$HP$US$US
255989951$25598995$1$I$20230101$20250716$20250724$20250724$PER$$US-ELI_LILLY_AND_COMPANY-US202507015858$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250724$$CN$US$US
255990271$25599027$1$I$$20250717$20250724$20250724$EXP$$NVSC2025AU116975$NOVARTIS$$$$$M$Y$$$20250724$$HP$AU$AU
255991322$25599132$2$F$$20250905$20250724$20250910$EXP$$CA-JNJFOC-20250724600$JOHNSON AND JOHNSON$$$$N$F$Y$$$20250910$$HP$CA$CA
255991651$25599165$1$I$20231201$20250717$20250724$20250724$EXP$$EU-ABBVIE-6383363$ABBVIE$$62$YR$$M$Y$$$20250724$$MD$EU$EU
255993162$25599316$2$F$20250709$20250827$20250724$20250903$EXP$$JP-ROCHE-10000345881$ROCHE$$56$YR$A$F$Y$$$20250903$$MD$JP$JP
255994121$25599412$1$I$20250320$20250716$20250724$20250724$EXP$EU-AFSSAPS-LL2025001154$EU-Accord-495789$ACCORD$$59$YR$A$F$Y$$$20250724$$MD$EU$EU
255994241$25599424$1$I$$20250715$20250724$20250724$EXP$$US-NOVOPROD-1481247$NOVO NORDISK$$49$YR$$$Y$$$20250724$$CN$US$US
255995213$25599521$3$F$20250711$20250807$20250724$20250822$EXP$$EU-BEH-2025213675$CSL BEHRING$$33$YR$A$F$Y$$$20250822$$PH$EU$EU
255995281$25599528$1$I$$20250716$20250724$20250724$EXP$EU-AMGEN-ITASP2025061343$EU-CELLTRION INC.-2025IT023975$CELLTRION$Bonfante F.P.; Romano A.; Covelli C. et. al.. Trastuzumab (immune checkpoint inhibitors) drug induced liver injury. Italian Journal of Medicine. 2024;72$$$$$Y$$$20250724$$HP$EU$EU
255996071$25599607$1$I$$20250718$20250724$20250724$EXP$$US-ABBVIE-6381242$ABBVIE$$$$$F$Y$$$20250724$$CN$US$US
255996171$25599617$1$I$$20250721$20250724$20250724$PER$$US-ABBVIE-6382869$ABBVIE$$$$$$Y$$$20250724$$HP$US$US
255997574$25599757$4$F$20250912$20250923$20250724$20250926$PER$$US-GILEAD-2025-0721600$GILEAD$$59$YR$A$M$Y$$$20250926$$HP$US$US
255998111$25599811$1$I$20250703$20250709$20250724$20250724$EXP$$CN-Accord-494216$ACCORD$$46$YR$A$F$Y$57$KG$20250724$$MD$CN$CN
255998451$25599845$1$I$$20250714$20250724$20250724$EXP$$US-AMGEN-USASP2025141309$AMGEN$Nguyen J.; Kumar A.; Xu H. et al. Severe Disseminated Histoplasmosis With Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Patient. American Journal of Respiratory and Critical Care Medicine. 2025;211:A5912-A5912$76$YR$E$F$Y$$$20250724$$HP$US$US
255999171$25599917$1$I$$20250718$20250724$20250724$EXP$$US-UCBSA-2025044846$UCB$$$$$M$Y$$$20250724$$CN$US$US
255999401$25599940$1$I$$20250711$20250724$20250724$PER$$US-SMPA-2025SPA007427$SUNOVION$$$$$$Y$$$20250724$$CN$US$US
255999961$25599996$1$I$20250624$20250709$20250724$20250724$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126167$ZYDUS PHARM$$$$$$Y$$$20250724$$CN$US$US
256000161$25600016$1$I$$20241230$20250724$20250724$EXP$$EU-ALKEM LABORATORIES LIMITED-NL-ALKEM-2024-26836$ALKEM$den Besten-Bertholee D, Wegner I, Touw DJ, Horst PGJ, Mian P.. Lamotrigine Use in Lactating Women: Passage into Breast Milk and Infant Exposure: Grand Round/A Case Study. Ther Drug Monit. 2024;00(00):1-3$35$YR$$F$Y$$$20250724$$HP$EU$EU
256000311$25600031$1$I$$20240726$20250724$20250724$EXP$$EU-ALKEM LABORATORIES LIMITED-AT-ALKEM-2024-17462$ALKEM$Egger C, Muehlbacher M, Grohmann R, et al.. Clozapine intoxication in a patient with Lamotrigine-induced rash. Pharmacopsychiatry. 2010;43(1):35-36$$$$$Y$$$20250724$$HP$EU$EU
256000491$25600049$1$I$$20241108$20250724$20250724$EXP$$CN-ALKEM LABORATORIES LIMITED-CN-ALKEM-2024-24502$ALKEM$Huang H, Liao Y, Yu Y, Qin H, Wei YZ, Cao L. Adult-onset neuronal ceroid lipofuscinosis misdiagnosed as autoimmune encephalitis and normal-pressure hydrocephalus: A 10-year case report and case-based review. Medicine. 2024;103:43 (e40248)$36$YR$$F$Y$$$20250724$$MD$CN$CN
256001281$25600128$1$I$20250627$20250714$20250724$20250724$EXP$GB-MHRA-MED-202507110940005840-GLDWT$GB-862174955-ML2025-03556$Unknown Manufacturer$$71$YR$E$F$Y$44$KG$20250724$$CN$GB$GB
256001472$25600147$2$F$20250709$20250728$20250724$20250730$PER$$US-AMGEN-USASP2025144544$AMGEN$$30$YR$A$F$Y$$$20250730$$MD$US$US
256001841$25600184$1$I$$20250721$20250724$20250724$PER$$US-ELI_LILLY_AND_COMPANY-US202507020478$ELI LILLY AND COMPANY$$48$YR$A$M$Y$$$20250724$$CN$US$US
256001881$25600188$1$I$20250710$20250716$20250724$20250724$EXP$$US-CATALYSTPHARMACEUTICALPARTNERS-US-CATA-25-01031$CATALYST PHARMA$$31$YR$$F$Y$$$20250724$$CN$US$US
256001981$25600198$1$I$$20250705$20250724$20250724$PER$$US-Axsome Therapeutics, Inc.-AXS202507-001209$AXSOME THERAPEUTICS, INC.$$63$YR$A$F$Y$$$20250724$$CN$US$
256002201$25600220$1$I$$20250715$20250724$20250724$PER$$US-Axsome Therapeutics, Inc.-AXS202507-001280$AXSOME THERAPEUTICS, INC.$$6$DEC$A$M$Y$$$20250724$$MD$US$
256002601$25600260$1$I$$20250709$20250724$20250724$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202507-002088$AZURITY PHARMACEUTICALS$Noureldin SM, Mckell J. Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Complicated by Extensive Subcutaneous Emphysema, Pneumomediastinum, and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2025;211$66$YR$$M$Y$$$20250724$$HP$US$US
256002861$25600286$1$I$$20250709$20250724$20250724$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202507-002108$AZURITY PHARMACEUTICALS$Hartz W, Jariwala M, Rigsby D, Pinches RS, Patel E, Kinniry P. Iatrogenic immunosuppression, disseminated histoplasmosis, and COVID-19 leading to hemophagocytic lymphohistiocytosis. Am J Respir Crit Care Med. 2025;211$54$YR$$F$Y$$$20250724$$HP$US$US
256002961$25600296$1$I$$20250709$20250724$20250724$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202507-002110$AZURITY PHARMACEUTICALS$Shahzad M, Khan MA, Amin MK, Sarfraz Z, Zulfiqar F, Qasim H et al. Efficacy of ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review. Blood. 2024;144 Suppl 1$30$YR$$M$Y$$$20250724$$HP$US$US
256003912$25600391$2$F$$20250910$20250724$20250922$PER$$US-SMPA-2025SPA008884$SUNOVION$$67$YR$$M$Y$$$20250920$$$US$US
256003972$25600397$2$F$20250114$20250826$20250724$20250903$EXP$$EU-BIOTEST-015812$BIOTEST$$74$YR$$F$Y$$$20250903$$MD$EU$EU
256004261$25600426$1$I$20250601$20250624$20250724$20250724$PER$$US-NKFPHARMA-2025MPSPO00237$NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL$$85$YR$$F$Y$$$20250724$$CN$US$US
256004281$25600428$1$I$20250417$20250718$20250724$20250724$EXP$$EU-REGENERON PHARMACEUTICALS, INC.-2025-117863$REGENERON$$77$YR$$F$Y$$$20250724$$MD$EU$EU
256005122$25600512$2$F$20250101$20250806$20250724$20250813$EXP$$JP-UCBSA-2025045019$UCB$$$$$$Y$$$20250813$$MD$JP$JP
256005133$25600513$3$F$20250101$20250919$20250724$20250929$EXP$$US-UCBSA-2025044962$UCB$$$$$M$Y$$$20250929$$CN$US$US
256005151$25600515$1$I$$20250723$20250723$20250723$DIR$FDA-CDER-CTU-2025-48719$$FDA-CTU$$77$YR$$F$N$$$20250723$N$$US$
256005411$25600541$1$I$$20250723$20250724$20250724$EXP$$CA-SANDOZ INC.-SDZ2025CA052531$SANDOZ$$81$YR$$F$Y$$$20250724$$CN$CA$CA
256005532$25600553$2$F$$20250721$20250724$20250728$EXP$$US-SA-2025SA210054$SANOFI AVENTIS$$79$YR$E$M$Y$$$20250728$$MD$US$US
256005772$25600577$2$F$$20250723$20250724$20250729$PER$$US-ELI_LILLY_AND_COMPANY-US202507021544$ELI LILLY AND COMPANY$$62$YR$A$M$Y$$$20250729$$CN$US$US
256005861$25600586$1$I$20250717$20250723$20250724$20250724$PER$$US-ELI_LILLY_AND_COMPANY-US202507021994$ELI LILLY AND COMPANY$$56$YR$A$M$Y$$$20250724$$CN$US$US
256006252$25600625$2$F$$20250801$20250724$20250814$EXP$$EU-TEVA-VS-3353352$TEVA$Zweegman S, van de DonkNWCJ. Supportive care in myeloma-when treating the clone alone is not enough. Hematology 2024; 2024 (1): 569-581.; Zweegman S, van de DonkNWCJ. Supportive care in myeloma-when treating the clone alone is not enough. Hematology 2024; 2024 (1): 569-581.$50$YR$$F$Y$$$20250814$$HP$EU$EU
256006411$25600641$1$I$$20250713$20250724$20250724$EXP$$IN-Accord-495620$ACCORD$Shah MM, Ghoghara PK, Dhanani S, Patel K, Nair PA. Acute accidental methotrexate poisoning: Fatal consequences - An Indian experience. Indian J Pharmacol. 2025 May 1;57(3):196-199. doi: 10.4103/ijp.ijp_363_24.$59$YR$A$F$Y$$$20250724$$HP$IN$IN
256006811$25600681$1$I$20210128$20250709$20250724$20250724$DIR$FDA-CDER-CTU-2025-48761$$FDA-CTU$$69$YR$$M$N$88$KG$20250709$N$$US$
256006841$25600684$1$I$20250616$20250716$20250724$20250724$EXP$EU-AFSSAPS-LL2025001245$EU-HIKMA PHARMACEUTICALS USA INC.-FR-H14001-25-08720$HIKMA$$$$$$Y$$$20250724$$PH$EU$EU
256006931$25600693$1$I$$20250716$20250724$20250724$PER$$US-SA-2025SA193564$SANOFI AVENTIS$$$$A$F$Y$112.47$KG$20250724$$HP$US$US
256007041$25600704$1$I$$20250712$20250724$20250724$EXP$$EU-AUROBINDO-AUR-APL-2019-002444$AUROBINDO$Genebat M, Vera F, Hernandez-Quero J, Domingo P, Guardiola J, Martinez-Madrid O, et al. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Research. 2014;104:59-61$$$A$$Y$$$20250724$$MD$EU$EU
256007522$25600752$2$F$20250601$20250805$20250724$20250812$PER$$US-SA-2025SA211602$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250813$$HP$US$US
256007711$25600771$1$I$$20250718$20250724$20250724$EXP$$US-ASTRAZENECA-202507USA016877US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250724$$$US$US
256008101$25600810$1$I$$20250720$20250724$20250724$PER$$US-SA-2025SA211557$SANOFI AVENTIS$$$$A$M$Y$$$20250724$$HP$US$US
256008241$25600824$1$I$20250601$20250721$20250724$20250724$PER$$US-SA-2025SA211722$SANOFI AVENTIS$$70$YR$E$M$Y$$$20250724$$HP$US$US
256008251$25600825$1$I$20250701$20250720$20250724$20250724$PER$$US-SA-2025SA211637$SANOFI AVENTIS$$41$YR$A$F$Y$$$20250724$$HP$US$US
256008391$25600839$1$I$$20250722$20250724$20250724$PER$$US-SA-2025SA212018$SANOFI AVENTIS$$52$YR$A$M$Y$$$20250724$$CN$US$US
256008512$25600851$2$F$$20250722$20250724$20250728$PER$$US-SA-2025SA208945$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250728$$CN$US$US
256009661$25600966$1$I$20250601$20250722$20250724$20250724$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-103804$BRISTOL-MYERS SQUIBB COMPANY$$72$YR$E$F$Y$54.43$KG$20250724$$CN$US$US
256011792$25601179$2$F$20250404$20250721$20250724$20250805$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-517733$RANBAXY$$90$YR$$M$Y$$$20250805$$MD$EU$EU
256012131$25601213$1$I$$20250717$20250724$20250724$EXP$$US-ASTRAZENECA-202507USA014330US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250724$$$US$US
256012621$25601262$1$I$$20250714$20250724$20250724$EXP$$US-AMGEN-USASP2025142069$AMGEN$Missak C.; Nair S.; George G. et al.. Mutations of the COPA Gene: A New Entity With an Expanding Phenotype. American Journal of Respiratory and Critical Care Medicine. 2025;211:A5516$21$YR$A$M$Y$$$20250724$$HP$US$US
256012741$25601274$1$I$20230801$20250714$20250724$20250724$EXP$$IR-STRIDES ARCOLAB LIMITED-2025SP009163$STRIDES$Jahani Z, Latifian M, Ahmadi P, Esmaeili S.. Fatal case of streptococcal prosthetic valve endocarditis caused by Streptococcus mitis in patient with tetralogy fallot disorder: a case report.. J-Cardiothorac-Surg. 2025;20$30$YR$$F$Y$$$20250724$$HP$IR$IR
256012771$25601277$1$I$$20250721$20250724$20250724$EXP$EU-EMA-DD-20250716-7482643-120458$EU-LABORATORIOS LICONSA S.A.-2507PL05950$INSUD PHARMA$Woron J., Siwek M.. Pancreatitis as a consequence of the association of sertraline with medicinal products used in the non-operative treatment of obesity. Medycyna praktyczna - Psychiatria. 2023;94(5):43-45$29$YR$$M$Y$$$20250724$$MD$EU$EU
256012931$25601293$1$I$$20250704$20250724$20250724$PER$$US-Apozeal Pharmaceuticals-2181106$Apozeal Pharmaceuticals$$$$$$Y$$$20250724$$$US$US
256015121$25601512$1$I$$20250717$20250724$20250724$PER$$US-SA-2025SA211696$SANOFI AVENTIS$$$$A$M$Y$125$KG$20250724$$MD$US$US
256015311$25601531$1$I$20250508$20250715$20250724$20250724$EXP$EU-AFSSAPS-BX2025001011$EU-TEVA-VS-3353906$TEVA$$67$YR$$M$Y$60$KG$20250724$$MD$EU$EU
256015581$25601558$1$I$20250601$20250718$20250724$20250724$PER$$US-SA-2025SA212362$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250724$$HP$US$US
256016411$25601641$1$I$20250426$20250718$20250724$20250724$EXP$EU-AFSSAPS-LY2025001029$EU-UCBSA-2025044392$UCB$$32$YR$$F$Y$59$KG$20250724$$MD$EU$EU
256016511$25601651$1$I$20250516$20250722$20250724$20250724$EXP$$AR-ABBVIE-6385242$ABBVIE$$91$YR$$F$Y$$$20250724$$CN$AR$AR
256017571$25601757$1$I$20240102$20250721$20250724$20250724$EXP$$CA-PFIZER INC-202300434683$PFIZER$$81$YR$$M$Y$78$KG$20250724$$MD$CA$CA
256017601$25601760$1$I$20250701$20250715$20250724$20250724$EXP$$JP-PFIZER INC-202500148672$PFIZER$$$$$F$Y$$$20250724$$HP$JP$JP
256018343$25601834$3$F$$20250822$20250724$20250827$30DAY$$US-PFIZER INC-202500115012$PFIZER$$10$YR$$M$Y$$$20250827$$HP$US$US
256018641$25601864$1$I$$20250710$20250724$20250724$PER$$US-COSETTE-CP2025US000684$COSETTE PHARMACEUTICALS INC$$53$YR$A$F$Y$$$20250724$$CN$US$US
256018665$25601866$5$F$$20250816$20250724$20250825$30DAY$$US-PFIZER INC-202500145924$PFIZER$$36$YR$$M$Y$61.46$KG$20250825$$HP$US$US
256018871$25601887$1$I$$20250722$20250724$20250724$PER$$US-BAYER-2025A098361$BAYER HEALTHCARE LLC$$91$YR$E$F$Y$$$20250724$$CN$US$US
256019151$25601915$1$I$20250101$20250718$20250724$20250724$PER$$US-SA-2025SA211560$SANOFI AVENTIS$$6$YR$C$M$Y$$$20250724$$MD$US$US
256019481$25601948$1$I$$20250723$20250724$20250724$PER$$US-PFIZER INC-202500149477$PFIZER$$$$$F$Y$$$20250724$$CN$US$US
256020111$25602011$1$I$20220616$20250711$20250724$20250724$EXP$$ZA-CIPLA LTD.-2025ZA08868$CIPLA$Naidoo A, Waalewijn H, Naidoo K, Letsoalo M, Cromhout G, Sewnarain L et.al.. Pharmacokinetics and safety of Dolutegravir in children receiving Rifampicin tuberculosis treatment in South Africa (ORCHID): A prospective cohort study. Lancet HIV. 2025;12:e273 to e282$$$$$Y$$$20250724$$MD$ZA$ZA
256021061$25602106$1$I$$20250709$20250724$20250724$EXP$$US-RECORDATI RARE DISEASE INC.-2025005078$RECORDATI$$$$$$Y$$$20250724$$MD$US$US
256021691$25602169$1$I$20250324$20250717$20250724$20250724$EXP$$JP-ASTRAZENECA-202506GLO011405JP$ALEXION PHARMACEUTICALS$$65$YR$E$M$Y$$$20250724$$MD$JP$JP
256021961$25602196$1$I$$20250714$20250724$20250724$EXP$$EU-TEVA-VS-3348251$TEVA$Keikes L, van Sandwijk MS, Kooi E-J, Gittelbauer M, van Dijk K. Extensive and recurrent infection caused by Medicopsis romeroi in two immunocompromised patients. Med-Mycol-Case-Reports 2025; 48.; Keikes L, van Sandwijk MS, Kooi EJ, Gittelbauer M, van Dijk K. Extensive and recurrent infection caused by Medicopsis romeroi in two immunocompromised patients. Med Mycol Case Rep. 2025 May 8;48:100706. doi: 10.1016/j.mmcr.2025.100706. PMID: 40487190; PMCID: PMC12142340.$49$YR$$M$Y$$$20250724$$HP$EU$EU
256022031$25602203$1$I$$20250721$20250724$20250724$PER$$US-SA-2025SA211865$SANOFI AVENTIS$$$$A$F$Y$$$20250724$$HP$US$US
256023651$25602365$1$I$20250101$20250723$20250724$20250724$PER$$US-PFIZER INC-202500149553$PFIZER$$59$YR$$F$Y$$$20250724$$PH$US$US
256024511$25602451$1$I$$20250723$20250724$20250724$PER$$US-PFIZER INC-PV202500089185$PFIZER$$21$YR$$F$Y$$$20250724$$HP$US$US
256024781$25602478$1$I$20250601$20250721$20250724$20250724$PER$$US-SA-2025SA212028$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250724$$MD$US$US
256024821$25602482$1$I$$20250724$20250724$20250724$DIR$766273$$FDA-CTU$$$$$$N$$$20250724$$CN$US$
256024901$25602490$1$I$20250717$20250723$20250724$20250724$PER$$US-KARYOPHARM-2025KPT100535$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20250724$$CN$US$US
256025022$25602502$2$F$$20250808$20250724$20250814$PER$$US-TEVA-VS-3355305$TEVA$$66$YR$$F$Y$$$20250814$$CN$US$US
256025132$25602513$2$F$$20250724$20250724$20250729$EXP$$US-PFIZER INC-202500149275$PFIZER$Badran, S.. B-Cell Lymphoma Presenting as a Pancreatic Mass. Journal of medical cases. 2025;16(6):226-231$64$YR$$F$Y$$$20250729$$MD$US$US
256025401$25602540$1$I$$20250722$20250724$20250724$EXP$$CA-PFIZER INC-202500148204$PFIZER$$49$YR$$F$Y$90$KG$20250724$$HP$CA$CA
256025581$25602558$1$I$$20250714$20250724$20250724$EXP$$EU-TEVA-VS-3353757$TEVA$$63$YR$$F$Y$$$20250724$$CN$EU$EU
256025592$25602559$2$F$$20250808$20250724$20250813$EXP$$JP-ASTRAZENECA-202507JPN018802JP$ALEXION PHARMACEUTICALS$$90$YR$E$M$Y$$$20250813$$PH$JP$JP
256026581$25602658$1$I$$20250716$20250724$20250724$PER$$US-ROCHE-10000341776$ROCHE$$$$A$F$Y$$$20250724$$PH$US$US
256026861$25602686$1$I$$20250723$20250724$20250724$PER$$US-PURDUE PHARMA-USA-2025-0319174$PURDUE$$27$YR$$M$Y$$$20250724$$CN$US$US
256027161$25602716$1$I$20250718$20250724$20250724$20250724$PER$$US-BAYER-2025A098984$BAYER HEALTHCARE LLC$$71$YR$E$F$Y$$$20250724$$CN$US$US
256027371$25602737$1$I$20250101$20250715$20250724$20250724$EXP$$CN-009507513-2309954$MERCK SHARP + DOHME LLC$$69$YR$$F$Y$65$KG$20250724$$HP$CN$CN
256028041$25602804$1$I$20250617$20250722$20250724$20250724$PER$$US-SA-2025SA212373$SANOFI AVENTIS$$25$YR$A$F$Y$$$20250724$$CN$US$US
256029411$25602941$1$I$20250523$20250718$20250724$20250724$EXP$EU-DKMA-31017139$EU-MYLANLABS-2025M1061069$MYLAN$$86$YR$$F$Y$78$KG$20250724$$MD$EU$EU
256030851$25603085$1$I$$20250723$20250724$20250724$EXP$$CN-PFIZER INC-PV202500088703$PFIZER$$$$A$F$Y$$$20250724$$CN$CN$CN
256031651$25603165$1$I$$20250722$20250724$20250724$EXP$$NVSC2025US116916$NOVARTIS$$$$$F$Y$$$20250724$$CN$US$US
256031882$25603188$2$F$$20250730$20250724$20250805$EXP$$BR-009507513-2310261$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250805$$MD$BR$BR
256032293$25603229$3$F$20250711$20250820$20250724$20250822$EXP$$US-AMERICAN REGENT INC-2025002841$AMERICAN REGENT$$4$DEC$$F$Y$$$20250822$$MD$US$US
256032311$25603231$1$I$$20250723$20250724$20250724$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-103992$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$M$Y$$$20250724$$CN$US$US
256034051$25603405$1$I$20240203$20250721$20250724$20250724$EXP$EU-AFSSAPS-RE2025000647$EU-ELI_LILLY_AND_COMPANY-FR202507020236$ELI LILLY AND COMPANY$$54$YR$A$M$Y$$$20250724$$CN$EU$EU
256034341$25603434$1$I$20250401$20250721$20250724$20250724$PER$$US-SA-2025SA213895$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250725$$HP$US$US
256035241$25603524$1$I$$20250716$20250724$20250724$PER$$US-APOTEX-2025AP010470$APOTEX$Nyabuto E, Fenstermaker RA, Qiu J. Secondary IDH-mutant gliosarcoma in a patient with prior IDH-mutant grade 2 astrocytoma. Journal of Neuropathology and Experimental Neurology. 2025;84 (7):655-657$31$YR$$F$Y$$$20250724$$MD$US$US
256035791$25603579$1$I$$20250620$20250725$20250725$PER$$US-ENDO USA, INC.-2025-001514$ENDO$$$$$F$Y$$$20250725$$CN$US$US
256036043$25603604$3$F$20250624$20250724$20250725$20250807$EXP$$CN-EVIVE BIOTECHNOLOGY IRELAND LIMITED-EVI-CN-2025-000101$Evive Biotechnology$$27$YR$$F$Y$80$KG$20250807$$MD$CN$CN
256036141$25603614$1$I$20141001$20250718$20250725$20250725$EXP$$EU-CELLTRION INC.-2025BG024403$CELLTRION$Emin S, Boyadzhieval V, Stoilov N. TREAT TO TARGET - CASE SERIES OF PATIENTS WITH RHEUMATOID ARTHRITIS AND NO RADIOGRAPHIC PROGRESSION AT LONG-TERM FOLLOW UP. RHEUMATOLOGY. 2024;XXXII:72-75$$$$$Y$$$20250725$$HP$EU$EU
256036301$25603630$1$I$$20250721$20250725$20250725$EXP$$US-SANDOZ INC.-SDZ2025US052456$SANDOZ$$$$$M$Y$$$20250725$$CN$US$US
256036862$25603686$2$F$20241111$20250728$20250725$20250805$EXP$$CA-CELLTRION INC.-2024CA028896$CELLTRION$$$$$$Y$$$20250805$$CN$CA$CA
256037492$25603749$2$F$$20250806$20250725$20250811$EXP$$US-INTERCEPT-PM2025001529$INTERCEPT PHARMACEUTICALS$$$$$F$Y$$$20250811$$HP$US$US
256038261$25603826$1$I$20250401$20250514$20250725$20250725$PER$$US-STALCOR-2025-AER-01912$STALLERGENES$$4$YR$C$F$Y$$$20250725$$CN$US$US
256038281$25603828$1$I$$20250718$20250725$20250725$30DAY$$US-SANDOZ INC.-SDZ2025US051714$SANDOZ$$$$$F$Y$$$20250725$$CN$US$US
256038323$25603832$3$F$$20250805$20250725$20250820$PER$$US-GSK-US2025AMR081247$GLAXOSMITHKLINE$$$$$F$Y$$$20250820$$$US$US
256038461$25603846$1$I$$20250718$20250725$20250725$EXP$$US-SANDOZ INC.-SDZ2025US052051$SANDOZ$$$$$M$Y$$$20250725$$MD$US$US
256038501$25603850$1$I$$20250716$20250725$20250725$PER$$US-ROCHE-10000340889$ROCHE$$80$YR$E$M$Y$$$20250725$$CN$US$US
256039181$25603918$1$I$$20241007$20250725$20250725$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-2024-108436$BRISTOL-MYERS SQUIBB COMPANY$$29$YR$A$M$Y$$$20250725$$MD$GB$GB
256039411$25603941$1$I$20250629$20250721$20250725$20250725$EXP$EU-AFSSAPS-TS2025000722$EU-SANDOZ INC.-SDZ2025FR052647$SANDOZ$$66$YR$$F$Y$$$20250725$$MD$EU$EU
256039592$25603959$2$F$$20250804$20250725$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202507020900$ELI LILLY AND COMPANY$$$$$F$Y$$$20250806$$CN$US$US
256040221$25604022$1$I$$20250716$20250725$20250725$EXP$$US-NOVOPROD-1483044$NOVO NORDISK$$$$A$F$Y$$$20250725$$CN$US$US
256040441$25604044$1$I$$20250723$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507022360$ELI LILLY AND COMPANY$$$$$$Y$$$20250725$$CN$US$US
256040451$25604045$1$I$20250718$20250721$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507019340$ELI LILLY AND COMPANY$$33$YR$A$F$Y$$$20250725$$CN$US$US
256040652$25604065$2$F$20241001$20250807$20250725$20250818$EXP$$US-NOVOPROD-1484015$NOVO NORDISK$$$$$F$Y$$$20250818$$CN$US$US
256041171$25604117$1$I$$20250710$20250725$20250725$EXP$$US-COOPERSURGICAL, INC.-2025CPS005587$COOPERSURGICAL$$$$$F$Y$62.87$KG$20250725$$CN$US$US
256041271$25604127$1$I$$20250722$20250725$20250725$EXP$$US-ABBVIE-6384380$ABBVIE$$$$E$M$Y$$$20250725$$CN$US$US
256041371$25604137$1$I$20250601$20250715$20250725$20250725$EXP$GB-MHRA-MED-202507152259518370-ZNTMK$GB-AMAROX PHARMA-AMR2025GB04080$HETERO$$61$YR$$F$Y$73$KG$20250725$$CN$GB$GB
256041441$25604144$1$I$20230518$20250711$20250725$20250725$EXP$$ZA-CIPLA LTD.-2025ZA08883$CIPLA$Naidoo A, Waalewijn H, Naidoo K, Letsoalo M, Cromhout G, Sewnarain L et al.. Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study. Lancet HIV. 2025;12:e273 to e282$$$$$Y$$$20250725$$HP$ZA$ZA
256042192$25604219$2$F$$20250807$20250725$20250906$PER$$US-GSK-US2025AMR081542$GLAXOSMITHKLINE$$$$$M$Y$$$20250906$$$US$US
256042391$25604239$1$I$$20250724$20250725$20250725$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-085222$BOEHRINGER INGELHEIM$$$$A$$Y$$$20250725$$MD$US$US
256042741$25604274$1$I$$20250714$20250725$20250725$EXP$$JP-ROCHE-10000341814$ROCHE$Aoishi Y, Naito K. A case of cytomegalovirus enterocolitis which developed during bevacizumab + paclitaxel therapy for breast cancer. [Abstract number: EP24-247]. The 33rd Annual Meeting of the Japanese Breast Cancer Society. 2025;1489.$7$DEC$E$F$Y$$$20250725$$MD$JP$JP
256042821$25604282$1$I$$20250710$20250725$20250725$EXP$$US-Norvium Bioscience LLC-080435$Norvium Bioscience$Friederich L, Mata D, Bishop-Freeman S. Tizanidine in Postmortem Forensic Cases. J Anal Toxicol. 2025 Jun 17:bkaf056. doi: 10.1093/jat/bkaf056.$42$YR$A$M$Y$$$20250725$$HP$US$US
256043271$25604327$1$I$$20250721$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507020592$ELI LILLY AND COMPANY$$$$$$Y$$$20250725$$CN$US$US
256043701$25604370$1$I$$20250708$20250725$20250725$PER$$US-ASTRAZENECA-202507USA020997US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250725$$$US$US
256044091$25604409$1$I$$20250709$20250725$20250725$PER$$US-SMPA-2025SPA008955$SUNOVION$$$$$$Y$$$20250725$$CN$US$US
256044171$25604417$1$I$20250528$20250721$20250725$20250725$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008524$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$$$20250725$$CN$US$US
256044331$25604433$1$I$20250722$20250722$20250725$20250725$PER$$US-JNJFOC-20250729039$JOHNSON AND JOHNSON$$$$$$Y$$$20250725$$MD$US$US
256044411$25604441$1$I$20250101$20250718$20250725$20250725$EXP$$US-BEH-2025213659$CSL BEHRING$$10$YR$C$M$Y$$$20250725$$HP$US$US
256044541$25604454$1$I$20250626$20250718$20250725$20250725$EXP$EU-ROCHE-10000342643$EU-ROCHE-10000342643$ROCHE$$85$YR$E$M$Y$$$20250725$$PH$EU$EU
256045551$25604555$1$I$$20250707$20250725$20250725$PER$$US-ASTRAZENECA-202507USA003729US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250725$$$US$US
256045631$25604563$1$I$$20250716$20250725$20250725$PER$$US-009507513-2309976$MERCK SHARP + DOHME LLC$Javed H, Sheikh M, Clark A, Arif A, Balasubramanian V. The Phourth Pathway in PAH: Experience in the^ Underserved^ Central Valley of California. American Journal of Respiratory and Critical Care Medicine. 2025, 211: A6466.$45$YR$$F$Y$$$20250725$$HP$US$US
256046251$25604625$1$I$$20250626$20250725$20250725$PER$$US-GSK-US2025080559$GLAXOSMITHKLINE$$$$$F$Y$$$20250725$$$US$US
256046301$25604630$1$I$$20250714$20250725$20250725$EXP$$GB-AUROBINDO-AUR-APL-2025-036945$AUROBINDO$$58$YR$$F$Y$$$20250725$$CN$GB$GB
256048041$25604804$1$I$20250316$20250723$20250725$20250725$EXP$$US-ASTRAZENECA-202507USA019600US$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$$$20250725$$$US$US
256048111$25604811$1$I$$20250721$20250725$20250725$EXP$$US-ABBVIE-6382169$ABBVIE$$$$A$F$Y$$$20250725$$CN$US$US
256048212$25604821$2$F$20250101$20250829$20250725$20250905$30DAY$$US-SANDOZ INC.-SDZ2025US052984$SANDOZ$$$$$$Y$$$20250905$$CN$US$US
256048691$25604869$1$I$$20250710$20250725$20250725$EXP$$US-Norvium Bioscience LLC-080444$Norvium Bioscience$Friederich L, Mata D, Bishop-Freeman S. Tizanidine in Postmortem Forensic Cases. J Anal Toxicol. 2025 Jun 17:bkaf056. doi: 10.1093/jat/bkaf056.$69$YR$E$F$Y$$$20250725$$HP$US$US
256049382$25604938$2$F$20250827$20250827$20250725$20250905$EXP$$CA-TEVA-VS-3339738$TEVA$$68$YR$$M$Y$78$KG$20250905$$HP$CA$CA
256049511$25604951$1$I$20250702$20250715$20250725$20250725$EXP$$GB-TEVA-VS-3354085$TEVA$$16$YR$$M$Y$$$20250725$$HP$GB$GB
256049981$25604998$1$I$20250715$20250717$20250725$20250725$EXP$$CH-OCTA-2025000623$OCTAPHARMA$$16$YR$T$M$Y$$$20250725$$MD$CH$CH
256050041$25605004$1$I$20170101$20250718$20250725$20250725$EXP$EU-MINISAL02-1046882$EU-SAMSUNG BIOEPIS-SB-2025-24899$SAMSUNG BIOEPIS$$54$YR$A$M$Y$$$20250725$$MD$EU$EU
256050081$25605008$1$I$$20250721$20250725$20250725$PER$$US-ROCHE-10000344505$ROCHE$$$$$$Y$$$20250725$$CN$US$US
256050501$25605050$1$I$20230515$20250717$20250725$20250725$EXP$$CN-JNJFOC-20250722466$JOHNSON AND JOHNSON$$34$YR$A$M$Y$$$20250725$$MD$CN$CN
256051391$25605139$1$I$$20250717$20250725$20250725$EXP$$US-RDY-USA/2025/07/011140$DR REDDYS$Brandon W, Belt H, Shen K, Cardenas C. A Case of Massive Pleural Effusion Due to Azacitidine Therapy. Am J Respir Crit Care Med. 2025;211: DOI: 10.1164/ajrccm.2025.211.Abstracts.A1924.$39$YR$A$F$Y$$$20250725$$HP$US$US
256053991$25605399$1$I$$20250724$20250724$20250724$DIR$FDA-CDER-CTU-2025-49078$$FDA-CTU$$$$$F$N$$$20250724$N$CN$US$
256054251$25605425$1$I$20250714$20250716$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507016109$ELI LILLY AND COMPANY$$81$YR$E$$Y$$$20250725$$CN$US$US
256054311$25605431$1$I$$20250724$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507023891$ELI LILLY AND COMPANY$$34$YR$A$F$Y$$$20250725$$CN$US$US
256054531$25605453$1$I$20250720$20250721$20250725$20250725$PER$$US-ABBVIE-6382313$ABBVIE$$17$YR$$F$Y$72.574$KG$20250725$$CN$US$US
256054661$25605466$1$I$$20250721$20250725$20250725$EXP$$GB-MYLANLABS-2025M1061769$MYLAN$$$$$$Y$$$20250725$$$GB$GB
256056271$25605627$1$I$20250101$20250722$20250725$20250725$PER$$US-SA-2025SA213934$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250725$$CN$US$US
256057271$25605727$1$I$20250101$20250721$20250725$20250725$PER$$US-SA-2025SA213071$SANOFI AVENTIS$$52$YR$A$F$Y$$$20250725$$HP$US$US
256058501$25605850$1$I$$20250722$20250725$20250725$PER$$US-SA-2025SA212914$SANOFI AVENTIS$$21$YR$A$M$Y$$$20250725$$CN$US$US
256058531$25605853$1$I$20250602$20250717$20250725$20250725$EXP$EU-AFSSAPS-LM2025000498$EU-TEVA-VS-3354475$TEVA$$63$YR$$M$Y$$$20250725$$MD$EU$EU
256058631$25605863$1$I$$20250723$20250725$20250725$PER$$US-TAKEDA-2025TUS066375$TAKEDA$$$$$M$Y$$$20250725$$$US$US
256058841$25605884$1$I$$20250722$20250725$20250725$PER$$US-SA-2025SA213442$SANOFI AVENTIS$$$$A$M$Y$168.18$KG$20250725$$MD$US$US
256058931$25605893$1$I$20250525$20250714$20250725$20250725$EXP$$EU-AUROBINDO-AUR-APL-2025-037201$AUROBINDO$$71$YR$$F$Y$89$KG$20250725$$MD$EU$EU
256058982$25605898$2$F$20250701$20250728$20250725$20250804$PER$$US-BAYER-2025A097468$BAYER HEALTHCARE PHARMACEUTICALS INC.$$18$YR$A$F$Y$$$20250804$$CN$US$US
256059021$25605902$1$I$20250428$20250717$20250725$20250725$EXP$EU-AFSSAPS-AVMA2025000406$EU-TEVA-VS-3354924$TEVA$$25$YR$$F$Y$$$20250725$$PH$EU$EU
256059271$25605927$1$I$20250523$20250716$20250725$20250725$EXP$EU-AFSSAPS-AVLY2025000255$EU-TEVA-VS-3354056$TEVA$$43$YR$$M$Y$$$20250725$$MD$EU$EU
256059971$25605997$1$I$$20250714$20250725$20250725$EXP$$JP-STRIDES ARCOLAB LIMITED-2025SP009191$STRIDES$Mori K, Shirai T, Mutoh T, Inoue J, Fujishima F, Kubo S, et al. Drug-induced liver injury related to avacopan therapy. Rheumatology. 2025;64 (5):2533-2540$75$YR$$F$Y$$$20250725$$HP$JP$JP
256060692$25606069$2$F$20250110$20250711$20250725$20250725$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-518639$RANBAXY$$74$YR$$M$Y$$$20250725$$HP$AU$AU
256060831$25606083$1$I$$20250721$20250725$20250725$PER$$US-ABBVIE-6384513$ABBVIE$$$$$$Y$$$20250725$$CN$US$US
256060841$25606084$1$I$$20250718$20250725$20250725$EXP$$US-SMPA-2025SPA009342$SUNOVION$$$$$$Y$$$20250725$$CN$US$US
256061971$25606197$1$I$$20250724$20250725$20250725$PER$$US-PFIZER INC-202500150232$PFIZER$$59$YR$$F$Y$$$20250725$$CN$US$US
256062153$25606215$3$F$$20250913$20250725$20250915$PER$$US-PFIZER INC-202500148586$PFIZER$$$$$F$Y$$$20250915$$MD$US$US
256063461$25606346$1$I$20250601$20250721$20250725$20250725$PER$$US-SA-2025SA214037$SANOFI AVENTIS$$15$YR$T$M$Y$$$20250725$$HP$US$US
256063741$25606374$1$I$$20240430$20250725$20250725$EXP$$US-RECORDATI RARE DISEASE INC.-2024003333$RECORDATI$$$$$$Y$$$20250725$$PH$US$US
256064433$25606443$3$F$20250101$20250818$20250725$20250828$PER$$US-ABBVIE-6380014$ABBVIE$$65$YR$$F$Y$61.23$KG$20250828$$CN$US$US
256064671$25606467$1$I$$20250717$20250725$20250725$EXP$$CA-CELLTRION INC.-2025CA024954$CELLTRION$$$$$$Y$$$20250725$$HP$CA$CA
256065401$25606540$1$I$20250601$20250722$20250725$20250725$PER$$US-SA-2025SA213686$SANOFI AVENTIS$$72$YR$E$F$Y$$$20250725$$CN$US$US
256065851$25606585$1$I$$20250715$20250725$20250725$EXP$$EU-AMGEN-ESPSP2025140086$AMGEN$Latras-cortes I.; Saez Hortelano J.C.; Suarez-alvarez P. et al.. Persistence and Efficacy of Ustekinumab in Crohn^s Disease After Anti-TNF Failure: An Observational Study. Digestive Diseases and Sciences. 2025;70 (6):2081-2086$$$$$Y$$$20250725$$HP$EU$EU
256065952$25606595$2$F$20250701$20250807$20250725$20250808$EXP$$US-JNJFOC-20250728624$JOHNSON AND JOHNSON$$44$YR$A$M$Y$$$20250808$$CN$US$US
256066131$25606613$1$I$$20250717$20250725$20250725$EXP$$US-ABBVIE-6379392$ABBVIE$$$$E$F$Y$$$20250725$$CN$US$US
256066261$25606626$1$I$$20250714$20250725$20250725$EXP$$US-AMGEN-USASP2025141904$AMGEN$Lurain K.; Ramaswami R.; Widell A. et al.. Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R-2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142). Blood. 2020;136 (SUPPL_1):8-9$29$YR$A$M$Y$$$20250725$$MD$US$US
256066341$25606634$1$I$20241101$20250724$20250724$20250724$DIR$766496$$FDA-CTU$$46$YR$$F$N$126$KG$20250724$N$CN$US$
256067241$25606724$1$I$20240101$20250721$20250725$20250725$PER$$US-SA-2025SA213900$SANOFI AVENTIS$$25$YR$A$M$Y$$$20250725$$CN$US$US
256067321$25606732$1$I$$20250702$20250725$20250725$PER$$US-009507513-2303301$MERCK SHARP + DOHME LLC$Manivannan M, Oladinni D, Petronic-Rosic V, Albrecht J. Angioinvasive Scopulariopsis infection. JAAD Case Reports 2025; 61: 75-77. doi: 10.1016/j.jdcr.2024.10.024$49$YR$$M$Y$$$20250725$$MD$US$US
256067331$25606733$1$I$$20250714$20250725$20250725$EXP$$US-AMGEN-USASP2025142484$AMGEN$Schuetz S.; Gardner T.. Which Tissue Is the Issue? A Meandering Path to Diagnosis. American Journal of Respiratory and Critical Care Medicine. 2025;211:A7018$57$YR$A$M$Y$$$20250725$$HP$US$US
256068523$25606852$3$F$20250101$20250804$20250725$20250807$EXP$$US-ABBVIE-6384201$ABBVIE$$54$YR$$F$Y$70$KG$20250807$$CN$US$US
256068531$25606853$1$I$$20250724$20250725$20250725$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-104362$BRISTOL-MYERS SQUIBB COMPANY$$60$YR$A$M$Y$$$20250725$$HP$US$US
256068651$25606865$1$I$20250101$20250717$20250725$20250725$PER$$US-AMGEN-USASP2025143732$AMGEN$$$$A$M$Y$$$20250725$$MD$US$US
256069151$25606915$1$I$$20250725$20250725$20250725$DIR$766525$$FDA-CTU$$$$$$N$$$20250725$N$$US$
256069552$25606955$2$F$20250101$20250801$20250725$20250805$PER$$US-AMGEN-USASP2025144579$AMGEN$$66$YR$E$$Y$$$20250805$$CN$US$US
256070141$25607014$1$I$$20250717$20250725$20250725$EXP$$AU-ELI_LILLY_AND_COMPANY-AU202507015561$ELI LILLY AND COMPANY$$$$$F$Y$$$20250725$$MD$AU$AU
256070251$25607025$1$I$$20250723$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507022560$ELI LILLY AND COMPANY$$49$YR$A$F$Y$$$20250725$$CN$US$US
256070491$25607049$1$I$$20250717$20250725$20250725$EXP$$US-ELI_LILLY_AND_COMPANY-US202507017789$ELI LILLY AND COMPANY$$$$$F$Y$$$20250725$$CN$US$US
256071081$25607108$1$I$$20250722$20250725$20250725$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06616$LUPIN$$64$YR$$$Y$67.12$KG$20250725$$$US$US
256072222$25607222$2$F$20250717$20250730$20250725$20250806$PER$$US-AMGEN-USASP2025146736$AMGEN$$$$$F$Y$$$20250806$$HP$US$US
256072251$25607225$1$I$$20250711$20250725$20250725$EXP$$US-JUBILANT CADISTA PHARMACEUTICALS-2025JUB00084$JUBILANT$Ryhal R., Daloul R., Nashar K., Sureshkumar K.K. Progressive Dysphagia in Kidney Transplant Recipient: An Unusual Cause. Journal of the American Society of Nephrology. 2023;34(622)$49$YR$$M$Y$$$20250725$$HP$US$US
256072951$25607295$1$I$$20250721$20250725$20250725$EXP$$US-ABBVIE-6382067$ABBVIE$$$$A$F$Y$$$20250725$$CN$US$US
256073771$25607377$1$I$$20250720$20250725$20250725$EXP$$GB-REGENERON PHARMACEUTICALS, INC.-2025-117974$REGENERON$$71$YR$$F$Y$$$20250725$$CN$GB$GB
256074921$25607492$1$I$$20230807$20250725$20250725$30DAY$$EU-SANDOZ INC.-SDZ2023FR012589$SANDOZ$$12$YR$$M$Y$$$20250725$$CN$EU$EU
256075413$25607541$3$F$$20250806$20250725$20250807$EXP$$EU-AstraZeneca-2024A070601$ALEXION PHARMACEUTICALS$Diaz Diaz D, Olmos Mata C, Palencia Herrejon E et al. Adult respiratory distress syndrome (ARDS) due to omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS): Case report and review of the literature. Revista Espanola de Anestesiologia y Reanimacion. 2024;1607:1-8$52$YR$A$F$Y$$$20250807$$$EU$EU
256075421$25607542$1$I$20240601$20250723$20250725$20250725$EXP$$US-PFIZER INC-PV202500089316$PFIZER$$66$YR$$M$Y$$$20250725$$MD$US$US
256075692$25607569$2$F$20240101$20250717$20250725$20250728$EXP$$RU-Eisai-EC-2025-193572$EISAI$$66$YR$E$M$Y$$$20250728$$MD$RU$RU
256076481$25607648$1$I$20250703$20250724$20250725$20250725$PER$$US-ABBVIE-6387925$ABBVIE$$46$YR$$F$Y$$$20250725$$CN$US$US
256076581$25607658$1$I$$20250721$20250725$20250725$PER$$US-BIOGEN-2025BI01317906$BIOGEN$$$$$F$Y$$$20250725$$CN$US$US
256077111$25607711$1$I$$20250715$20250725$20250725$EXP$$US-ASTRAZENECA-202507GLO012440US$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$125.17$KG$20250725$$LW$US$US
256077401$25607740$1$I$20250718$20250718$20250725$20250725$PER$$US-ELI_LILLY_AND_COMPANY-US202507022136$ELI LILLY AND COMPANY$$33$YR$A$F$Y$$$20250725$$CN$US$US
256077881$25607788$1$I$$20250716$20250725$20250725$EXP$US-MLMSERVICE-20250710-PI575603-00057-1$US-RDY-USA/2025/07/010876$DR REDDYS$Nudelman BG, Valencia Uribe J, Bhattar K, Krishnaswamy S. Acute Respiratory Failure Secondary to Statin-induced Anti-HMG CoA Reductase Myopathy: A Rare Complication With Diagnostic Challenges. American Journal of Respiratory and Critical Care Medicine. 2025;211:A5931. DOI:10.1164/ajrccm.2025.211.Abstracts.A5931.$74$YR$E$F$Y$$$20250725$$MD$US$US
256078201$25607820$1$I$$20250716$20250725$20250725$PER$$US-APOTEX-2025AP010501$APOTEX$Gutierrez AYH, Kherallah K, Rodriguez I, Chen A, Chen E, Worswick S. Investigating the relationship between lactose intolerance and doxycycline-induced GI disturbances. Journal of Investigative Dermatology. 2025;145 (8):S40$$$$$Y$$$20250725$$HP$US$US
256078291$25607829$1$I$$20250722$20250725$20250725$PER$$JP-Eisai-EC-2025-193730$EISAI$Okimasa Saito. A Case of Pharyngocutaneous Fistula from Anaplastic Thyroid Carcinoma Closed with Fascia Lata and Pectoralis Major Myocutaneous Flap. The 75th Annual Meeting of the Japan Broncho-Esophagological Society, Program and Abstracts/The 75th Annual Meeting of the Japan Broncho-Esophagological Society(Hybrid), Conference Abstracts. 2024: 114-.$49$YR$A$F$Y$$$20250725$$MD$JP$JP
256078511$25607851$1$I$$20250719$20250725$20250725$EXP$$CA-TAKEDA-2025TUS064309$TAKEDA$$$$$F$Y$$$20250725$$$CA$CA
256078591$25607859$1$I$$20250724$20250725$20250725$PER$$NVSC2025US118417$NOVARTIS$$$$$$Y$$$20250725$$HP$US$US
256079711$25607971$1$I$20250604$20250717$20250725$20250725$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202507017218$ELI LILLY AND COMPANY$$63$YR$A$F$Y$75$KG$20250725$$CN$CN$CN
256080071$25608007$1$I$$20250724$20250725$20250725$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-104106$BRISTOL-MYERS SQUIBB COMPANY$$67$YR$E$F$Y$$$20250725$$CN$US$US
256080241$25608024$1$I$$20250721$20250725$20250725$PER$$US-MALLINCKRODT-MNK202504485$MALLINCKRODT$$61$YR$A$F$Y$$$20250724$$CN$US$US
256080541$25608054$1$I$$20250724$20250725$20250725$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-104622$BRISTOL-MYERS SQUIBB COMPANY$$46$YR$A$M$Y$$$20250725$$HP$US$US
256080652$25608065$2$F$20250621$20250910$20250725$20250930$PER$$US-RDY-USA/2025/07/011001$DR REDDYS$$21$YR$A$M$Y$73$KG$20250930$$MD$US$US
256080744$25608074$4$F$$20250917$20250725$20250923$EXP$$IN-PFIZER INC-202500148941$PFIZER$$64$YR$$M$Y$$$20250923$$CN$IN$IN
256080941$25608094$1$I$20250401$20250721$20250725$20250725$EXP$EU-MINISAL02-1049046$EU-FreseniusKabi-FK202510045$FRESENIUS KABI$$61$YR$A$F$Y$$$20250725$$PH$EU$EU
256081251$25608125$1$I$20250101$20250716$20250725$20250725$EXP$$US-TEVA-VS-3348195$TEVA$$71$YR$$F$Y$$$20250725$$CN$US$US
256082291$25608229$1$I$$20250718$20250725$20250725$PER$$US-ABBVIE-6382420$ABBVIE$$$$$$Y$$$20250725$$HP$US$US
256082341$25608234$1$I$$20250724$20250725$20250725$EXP$$US-PAIPHARMA-2025-US-035373$PHARMACEUTICAL ASSOC$Cheema M, Idoko R, Uddin A, Ghuman ZJ, Iftikhar A.Amantadine-induced hypoglycemia in a patient without a history of diabetes mellitus..American Journal of Respiratory and Critical Care Medicine.2025;211A3844.$72$YR$$M$Y$$$20250725$$HP$US$US
256083892$25608389$2$F$20250613$20250722$20250726$20250730$EXP$$US-UNITED THERAPEUTICS-UNT-2025-025270$UNITED THERAPEUTICS$$7$YR$$M$Y$19.955$KG$20250730$$$US$US
256084851$25608485$1$I$20240201$20250722$20250726$20250726$EXP$$EU-ASTRAZENECA-202507EEA017817RO$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250726$$MD$EU$EU
256085015$25608501$5$F$$20250911$20250726$20250922$EXP$$EU-AUROBINDO-AUR-APL-2025-037626$AUROBINDO$Gon?alves VBC, Alves NF. Fen?meno de Raynaud secund?rio ? toma de betabloqueador: relato de caso (Raynaud^s phenomenon secondary to beta-blocker use: case report). Rev Port Med Geral Fam. 2025;41:268-72$64$YR$$F$Y$$$20250922$$MD$EU$EU
256085141$25608514$1$I$$20250709$20250726$20250726$PER$$US-EPICPHARMA-US-2025EPCSPO00818$EPIC PHARM$$55$YR$A$F$Y$$$20250726$$CN$US$US
256085591$25608559$1$I$$20250716$20250726$20250726$EXP$$VN-Accord-495744$ACCORD$An PM, Nguyen Van D, Hoang Huu H, Ha Son B, Le Duc N. Successful Use of Veno-venous ECMO in Severe Calcium Channel Blocker Overdose: A Case Report. American Journal of Respiratory and Critical Care Medicine. 2025;211:A3873. DOI:10.1164/ajrccm.2025.211.Abstracts.A3873.$70$YR$E$M$Y$$$20250726$$MD$VN$VN
256086151$25608615$1$I$$20250723$20250726$20250726$EXP$$US-ASTRAZENECA-202507USA019757US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250726$$$US$US
256086161$25608616$1$I$20250701$20250722$20250726$20250726$PER$$US-SA-2025SA214340$SANOFI AVENTIS$$69$YR$E$M$Y$$$20250726$$HP$US$US
256087122$25608712$2$F$$20250903$20250726$20250909$PER$$US-SA-2025SA213995$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250909$$HP$US$US
256088231$25608823$1$I$20220901$20250722$20250726$20250726$EXP$EU-MINISAL02-1049897$EU-ASTRAZENECA-202507GLO017725IT$ALEXION PHARMACEUTICALS$$59$YR$A$M$Y$125$KG$20250726$$$EU$EU
256088431$25608843$1$I$20250101$20250723$20250726$20250726$PER$$US-SA-2025SA214783$SANOFI AVENTIS$$11$YR$C$F$Y$$$20250726$$HP$US$US
256088811$25608881$1$I$$20250701$20250726$20250726$PER$$US-GSK-US2025AMR084189$GLAXOSMITHKLINE$$$$$M$Y$$$20250726$$$US$US
256089271$25608927$1$I$20250719$20250722$20250726$20250726$PER$$US-SA-2025SA212580$SANOFI AVENTIS$$33$YR$A$M$Y$$$20250726$$MD$US$US
256090511$25609051$1$I$20250101$20250723$20250726$20250726$PER$$US-SA-2025SA214734$SANOFI AVENTIS$$18$YR$A$M$Y$$$20250727$$HP$US$US
256090591$25609059$1$I$$20250624$20250726$20250726$PER$$US-009507513-2312655$MERCK SHARP + DOHME LLC$Ronsley R, Bradford MC, Crotty EE, Vitanza NA, Runco DV, Stevens J, et al. Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children^s Hospital experience. Neuro-Oncology Practice. 2025 June 01. 12 (3): 489-97.; Ronsley R, Bradford MC, Crotty EE, Vitanza NA, Runco DV, Stevens J, et al. Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children^s Hospital experie...$$$C$M$Y$$$20250726$$MD$US$US
256091261$25609126$1$I$$20250722$20250727$20250727$PER$$US-SA-2025SA212734$SANOFI AVENTIS$$68$YR$E$M$Y$$$20250727$$CN$US$US
256091541$25609154$1$I$$20250721$20250727$20250727$PER$$US-ELI_LILLY_AND_COMPANY-US202507020587$ELI LILLY AND COMPANY$$73$YR$E$$Y$$$20250727$$CN$US$US
256093591$25609359$1$I$20250324$20250724$20250727$20250727$EXP$$CA-HLS-202501935$HLS THERAPEUTICS$$$$A$$Y$$$20250727$$HP$CA$CA
256093671$25609367$1$I$20250701$20250722$20250727$20250727$PER$$US-ELI_LILLY_AND_COMPANY-US202507021606$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250727$$CN$US$US
256093881$25609388$1$I$20250701$20250722$20250727$20250727$EXP$$NVSC2025US095091$NOVARTIS$$65$YR$$M$Y$$$20250727$$CN$US$US
256094031$25609403$1$I$20250711$20250722$20250727$20250727$PER$$US-ELI_LILLY_AND_COMPANY-US202507021238$ELI LILLY AND COMPANY$$$$$F$Y$$$20250727$$CN$US$US
256094051$25609405$1$I$$20250718$20250727$20250727$PER$$US-ELI_LILLY_AND_COMPANY-US202507018919$ELI LILLY AND COMPANY$$78$YR$E$F$Y$$$20250727$$CN$US$US
256094741$25609474$1$I$$20250723$20250727$20250727$EXP$$US-ABBVIE-5794328$ABBVIE$$$$E$F$Y$$$20250727$$CN$US$US
256095022$25609502$2$F$$20250808$20250727$20250817$EXP$$CA-ABBVIE-6388037$ABBVIE$$74$YR$$M$Y$$$20250817$$HP$CA$CA
256095311$25609531$1$I$$20250722$20250727$20250727$EXP$$US-ASTRAZENECA-202507USA018630US$ALEXION PHARMACEUTICALS$$$$$F$Y$90.264$KG$20250727$$$US$US
256096032$25609603$2$F$20221101$20250819$20250728$20250822$EXP$$JP-ABBVIE-6388197$ABBVIE$$73$YR$$M$Y$$$20250822$$MD$JP$JP
256096081$25609608$1$I$20250101$20250720$20250728$20250728$EXP$$IL-AMGEN-ISRSP2025145909$AMGEN$$58$YR$A$F$Y$$$20250727$$HP$IL$IL
256096401$25609640$1$I$20250707$20250722$20250728$20250728$EXP$$US-BIOGEN-2025BI01318262$BIOGEN$$70$YR$$F$Y$$$20250728$$CN$US$US
256097331$25609733$1$I$$20250721$20250728$20250728$EXP$$US-JNJFOC-20250725827$JOHNSON AND JOHNSON$$$$$F$Y$$$20250728$$PH$US$US
256097741$25609774$1$I$20190201$20250721$20250728$20250728$EXP$$CA-TAKEDA-2019TUS006348$TAKEDA$$55$YR$$F$Y$$$20250728$$$CA$CA
256098451$25609845$1$I$$20250717$20250728$20250728$EXP$$US-ASTRAZENECA-202507USA014177US$ALEXION PHARMACEUTICALS$$$$$F$Y$104.32$KG$20250728$$$US$US
256099493$25609949$3$F$$20250917$20250728$20250925$EXP$$US-SMPA-2025SPA009373$SUNOVION$$78$YR$$M$Y$$$20250924$$$US$US
256099901$25609990$1$I$$20250722$20250728$20250728$PER$$US-BIOGEN-2025BI01318052$BIOGEN$$$$$F$Y$$$20250728$$CN$US$US
256100583$25610058$3$F$$20250916$20250728$20250923$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06270$LUPIN$$65$YR$$$Y$$$20250923$$$US$US
256100721$25610072$1$I$20250531$20250724$20250728$20250728$EXP$$US-ROCHE-10000347977$ROCHE$$76$YR$E$M$Y$$$20250728$$CN$US$US
256101091$25610109$1$I$20250601$20250721$20250728$20250728$EXP$$US-UCBSA-2025045463$UCB$$72$YR$$F$Y$$$20250728$$HP$US$US
256101682$25610168$2$F$20250627$20250724$20250728$20250728$EXP$$JP-TAKEDA-2025TJP007554$TAKEDA$$9$DEC$$$Y$$$20250728$$MD$JP$JP
256101801$25610180$1$I$20240101$20241206$20250728$20250728$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-005367$SAREPTA THERAPEUTICS$$$$$M$Y$$$20250728$$HP$US$US
256102481$25610248$1$I$$20250513$20250728$20250728$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2025-006002$SAREPTA THERAPEUTICS$$$$$M$Y$34.47$KG$20250728$$PH$US$US
256102653$25610265$3$F$20250423$20250729$20250728$20250805$EXP$$CA-UCBSA-2025045406$UCB$$74$YR$$F$Y$$$20250805$$CN$CA$CA
256102891$25610289$1$I$20250101$20250722$20250728$20250728$EXP$$US-SA-2025SA214057$SANOFI AVENTIS$$77$YR$E$M$Y$65.3$KG$20250728$$MD$US$US
256103001$25610300$1$I$$20250725$20250728$20250728$PER$$US-ASTRAZENECA-202507USA021784US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250728$$$US$US
256103321$25610332$1$I$$20250721$20250728$20250728$PER$$US-AMGEN-USASP2025145190$AMGEN$$$$E$F$Y$$$20250728$$CN$US$US
256103731$25610373$1$I$20250413$20250723$20250728$20250728$EXP$EU-AFSSAPS-LL2025000705$EU-CELLTRION INC.-2025FR024899$CELLTRION$$$$$$Y$$$20250728$$MD$EU$EU
256103791$25610379$1$I$$20250720$20250728$20250728$EXP$$RU-ROCHE-10000344882$ROCHE$$$$$F$Y$$$20250728$$CN$RU$RU
256103882$25610388$2$F$$20250819$20250728$20250821$PER$$US-JNJFOC-20250730115$JOHNSON AND JOHNSON$$60$YR$A$M$Y$$$20250821$$CN$US$US
256104051$25610405$1$I$$20250714$20250728$20250728$EXP$$TR-EPICPHARMA-TR-2025EPCLIT00833$EPIC PHARM$Dogukan Kocyigit.A case of bupropion overdose: Bupropion intoxication and/ or serotonin syndrome?.Psychiatria Danubina.07-NOV-2024;37:97-101$19$YR$A$F$Y$50$KG$20250728$$HP$TR$TR
256104971$25610497$1$I$$20250718$20250728$20250728$EXP$$US-AMGEN-USASP2025144033$AMGEN$Boe D. M.; Nguyen P. L.; Varipapa R. J.; et al. Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) and CMV Reactivation With Pulmonary Involvement in a Renal Transplant Patient With Well Controlled HIV. American Journal of Respiratory and Critical Care Medicine. 2025;211:A3957-A3957$39$YR$A$M$Y$$$20250728$$HP$US$US
256105233$25610523$3$F$20240101$20250815$20250728$20250818$EXP$$GB-MYLANLABS-2025M1062873$MYLAN$$62$YR$$M$Y$83$KG$20250817$$MD$GB$GB
256105511$25610551$1$I$$20250716$20250728$20250728$EXP$CA-MHPD-E2B_07802569$CA-Accord-495217$ACCORD$$36$YR$A$M$Y$$$20250728$$HP$CA$CA
256105761$25610576$1$I$20250601$20250725$20250728$20250728$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-104789$BRISTOL-MYERS SQUIBB COMPANY$$47$YR$A$F$Y$$$20250728$$HP$US$US
256105961$25610596$1$I$$20250716$20250728$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202507015624$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250728$$CN$US$US
256107022$25610702$2$F$$20250828$20250728$20250903$EXP$$US-TAKEDA-2025TUS055246$TAKEDA$$$$$F$Y$$$20250903$$$US$US
256108081$25610808$1$I$$20250718$20250728$20250728$EXP$$US-AMGEN-USASP2025144077$AMGEN$Shahid A.; Barrios C.R.. A Complex Case of Birt-Hogg-Dube Syndrome With Coexisting Granulomatous Lung Disease in a Young Male. American Journal of Respiratory and Critical Care Medicine. 2025;211:A5998$20$YR$A$M$Y$$$20250728$$HP$US$US
256108991$25610899$1$I$$20250714$20250728$20250728$EXP$$US-IPCA LABORATORIES LIMITED-IPC-2025-US-001928$IPCA$Rao A, Montgomery A and Jagana R. A case of hydroxychloroquine associated catatonia in SLE. Am J Respir Crit Care Med. 2025;211:A3856$$$$$Y$$$20250728$$HP$US$US
256109051$25610905$1$I$$20250714$20250728$20250728$EXP$$US-AMGEN-USASP2025142376$AMGEN$Piatek C.; Rodriguez R.D.; Choudhry Z. et.al.. Qualitative Examination of Treatment Experiences Among Individuals Living with Warm Autoimmune Hemolytic Anemia (wAIHA). Blood. 2024;144 (SUPPL_1):7721-7722$$$$$Y$$$20250728$$MD$US$US
256109131$25610913$1$I$20250725$20250725$20250725$20250725$DIR$766625$$FDA-CTU$$84$YR$$F$N$$$20250725$N$$US$
256109543$25610954$3$F$$20250813$20250728$20250814$EXP$$US-INCYTE CORPORATION-2025IN007890$INCYTE$$$$$$Y$$$20250814$$$US$US
256109701$25610970$1$I$20250605$20250715$20250728$20250728$EXP$$US-BEH-2025213517$CSL BEHRING$$45$YR$A$M$Y$$$20250728$$CN$US$US
256110012$25611001$2$F$$20250724$20250728$20250804$EXP$$EU-AUROBINDO-AUR-APL-2025-038001$AUROBINDO$Kayal D, Vedrine E, Goursaud C, Sellier-Leclerc A-L, Acquaviva-Bourdain C, Bertholet-Thomas A, et al.. Unveiling atypical diagnoses: when whole-genome analysis performed for refractory infantile hypomagnesemia reveals primary hyperoxaluria. Pediatr-Nephrol. 2024;4085-87$1$MON$$M$Y$$$20250804$$HP$EU$EU
256110511$25611051$1$I$$20250722$20250728$20250728$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-103784$BRISTOL-MYERS SQUIBB COMPANY$$81$YR$E$M$Y$77.11$KG$20250728$$CN$US$US
256111591$25611159$1$I$$20250715$20250728$20250728$EXP$$CA-AUROBINDO-AUR-APL-2023-033604$AUROBINDO$Dsouza, A, Christensen CR, Hussain MW. The effect of occipital nerve block on post traumatic headache  following concussion: A retrospective chart review. Headache. 2022;62 (suppl 1):168$$$$$Y$$$20250728$$HP$CA$CA
256112071$25611207$1$I$20250722$20250725$20250725$20250725$DIR$FDA-CDER-CTU-2025-49436$$FDA-CTU$$72$YR$$M$N$$$20250725$N$PH$US$
256112691$25611269$1$I$20250307$20250312$20250728$20250728$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2025-005748$SAREPTA THERAPEUTICS$$21$YR$$M$Y$$$20250728$$HP$US$US
256113681$25611368$1$I$$20250723$20250728$20250728$PER$$NVSC2025US118343$NOVARTIS$$$$$M$Y$$$20250728$$HP$US$US
256114081$25611408$1$I$$20250722$20250728$20250728$EXP$$GB-Ipsen Biopharmaceuticals, Inc.-2025-18265$IPSEN BIOPHARMACEUTICALS, INC.$Fattah MA, Chapple C, Breeman S, Gorrod HB, Cooper D, Kuppanda P, et al. Invasive urodynamic investigations in the  management of women with refractory  overactive bladder symptoms: FUTURE, a  superiority RCT and economic evaluation. National institute for health care and research. 2025 Jul;29(27): 1-139. doi:10.3310/UKYW4923.$$$$F$Y$$$20250728$$$GB$GB
256115691$25611569$1$I$20250508$20250723$20250728$20250728$EXP$$CH-GILEAD-2025-0722098$GILEAD$$49$YR$A$M$Y$$$20250728$$HP$CH$CH
256115953$25611595$3$F$$20250805$20250728$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202507025017$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250806$$CN$US$US
256115961$25611596$1$I$$20250722$20250728$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202507021540$ELI LILLY AND COMPANY$$54$YR$A$$Y$$$20250728$$CN$US$US
256116081$25611608$1$I$20250723$20250723$20250728$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202507022465$ELI LILLY AND COMPANY$$76$YR$E$F$Y$$$20250728$$CN$US$US
256116591$25611659$1$I$$20250725$20250725$20250725$DIR$766545$$FDA-CTU$$$$$F$N$59.4$KG$20250725$N$CN$US$
256117311$25611731$1$I$$20250715$20250728$20250728$PER$$US-GSK-US2025AMR092598$GLAXOSMITHKLINE$$$$$$Y$$$20250728$$$US$US
256117421$25611742$1$I$$20250726$20250728$20250728$EXP$$JP-ASTRAZENECA-202410GLO021785JP$ALEXION PHARMACEUTICALS$$$$E$$Y$$$20250728$$MD$JP$JP
256117731$25611773$1$I$$20250723$20250728$20250728$EXP$$US-ASTRAZENECA-202507USA019698US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250728$$$US$US
256118481$25611848$1$I$$20250724$20250728$20250728$PER$$US-PFIZER INC-PV202500090164$PFIZER$$45$YR$$F$Y$$$20250728$$CN$US$US
256119491$25611949$1$I$$20250723$20250728$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202507023483$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250728$$CN$US$US
256120552$25612055$2$F$20250717$20250729$20250728$20250801$30DAY$$US-AMGEN-USASP2025145336$AMGEN$$52$YR$A$F$Y$$$20250801$$PH$US$US
256121401$25612140$1$I$19951114$20250728$20250728$20250728$EXP$EU-EMA-DD-20250724-7482699-080604$EU-FERRINGPH-1997FE00314$FERRING$$$$$$Y$$$20250728$$MD$EU$EU
256121591$25612159$1$I$$20250722$20250728$20250728$PER$$US-SA-2025SA213973$SANOFI AVENTIS$$2$YR$C$F$Y$$$20250728$$HP$US$US
256121671$25612167$1$I$20241101$20250725$20250728$20250728$EXP$$US-TAKEDA-2025TUS067208$TAKEDA$$53$YR$$F$Y$$$20250728$$$US$US
256122041$25612204$1$I$$20250724$20250728$20250728$PER$$US-SA-2025SA218148$SANOFI AVENTIS$$20$YR$A$M$Y$$$20250728$$CN$US$US
256122182$25612218$2$F$$20250806$20250728$20250813$EXP$$CA-TAKEDA-2025TUS066068$TAKEDA$$$$$M$Y$$$20250813$$$CA$CA
256122351$25612235$1$I$20250401$20250722$20250728$20250728$PER$$US-SA-2025SA215451$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250728$$HP$US$US
256122392$25612239$2$F$20250101$20250725$20250728$20250813$PER$$US-SA-2025SA218524$SANOFI AVENTIS$$10$YR$C$M$Y$36.3$KG$20250813$$MD$US$US
256123011$25612301$1$I$$20250725$20250725$20250725$DIR$766744$$FDA-CTU$$$$$$N$$$20250725$N$$US$
256124801$25612480$1$I$$20250722$20250728$20250728$EXP$$MY-MYLANLABS-2025M1062768$MYLAN$$56$YR$$F$Y$$$20250728$$PH$MY$MY
256125351$25612535$1$I$$20250726$20250726$20250726$DIR$FDA-CDER-CTU-2025-49413$$FDA-CTU$$77$YR$$M$N$$$20250726$N$CN$US$
256125511$25612551$1$I$20250605$20250722$20250728$20250728$EXP$EU-MINISAL02-1049608$EU-FreseniusKabi-FK202510163$FRESENIUS KABI$$54$YR$A$M$Y$$$20250728$$PH$EU$EU
256125761$25612576$1$I$$20250723$20250728$20250728$PER$$US-SA-2025SA215515$SANOFI AVENTIS$$$$A$F$Y$$$20250728$$HP$US$US
256126391$25612639$1$I$20250724$20250724$20250728$20250728$EXP$$US-ABBVIE-6387328$ABBVIE$$33$YR$$F$Y$$$20250728$$CN$US$US
256126523$25612652$3$F$$20250919$20250728$20250924$30DAY$$CO-PFIZER INC-PV202500088848$PFIZER$$$$$M$Y$$$20250924$$CN$CO$CO
256126561$25612656$1$I$$20250723$20250728$20250728$EXP$$US-PFIZER INC-PV202500089291$PFIZER$$$$$F$Y$$$20250728$$LW$US$US
256127282$25612728$2$F$20250818$20250818$20250728$20250820$EXP$$CA-TAKEDA-2025TUS066598$TAKEDA$$76$YR$$M$Y$$$20250820$$$CA$CA
256127781$25612778$1$I$$20250723$20250728$20250728$PER$$NVSC2025US117797$NOVARTIS$$$$$F$Y$$$20250728$$CN$US$US
256128371$25612837$1$I$$20250723$20250728$20250728$PER$$US-SA-2025SA132525$SANOFI AVENTIS$$$$A$F$Y$$$20250728$$CN$US$US
256128791$25612879$1$I$20250718$20250726$20250728$20250728$EXP$GB-MHRA-MED-202507261325184400-WVLQB$GB-MYLANLABS-2025M1063948$MYLAN$$68$YR$$F$Y$$$20250728$$PH$GB$GB
256129071$25612907$1$I$$20250725$20250728$20250728$DIR$FDA-CDER-CTU-2025-49437$$FDA-CTU$$$$$M$N$$$20250725$N$CN$US$
256129271$25612927$1$I$$20250726$20250726$20250726$DIR$766903$$FDA-CTU$$$$$F$N$$$20250726$N$CN$US$
256129423$25612942$3$F$20250616$20250716$20250728$20250812$EXP$EU-AFSSAPS-AVPO2025000174$EU-ATNAHS-2025-PMNV-FR000086$Atnahs Healthcare$$$$$$Y$$$20250812$$MD$EU$EU
256129481$25612948$1$I$$20250716$20250728$20250728$EXP$$TR-SCIEGENP-2025SCLIT00179$SCIEGEN PHARMACEUTICALS INC$Kocyigit D, et al..A case of bupropion overdose: Bupropion intoxication  and/or serotonin syndrome?.Psychiatria Danubina.JAN-2025;37 (1):97-101$19$YR$A$F$Y$50$KG$20250728$$HP$TR$TR
256129731$25612973$1$I$$20250723$20250728$20250728$EXP$$US-BIOGEN-2025BI01318265$BIOGEN$$$$$M$Y$$$20250728$$CN$US$US
256130032$25613003$2$F$20250715$20250807$20250728$20250819$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008439$ACADIA PHARMACEUTICALS$$70$YR$$M$Y$$$20250819$$CN$US$US
256131172$25613117$2$F$20250101$20250723$20250728$20250812$30DAY$$EU-PFIZER INC-202500118339$PFIZER$$54$YR$$F$Y$106$KG$20250812$$CN$EU$EU
256131221$25613122$1$I$20201130$20250726$20250726$20250726$DIR$766905$$FDA-CTU$$33$YR$$F$N$58.5$KG$20250726$$CN$US$
256131502$25613150$2$F$$20250724$20250728$20250731$EXP$$NVSC2025BR118819$NOVARTIS$$$$$F$Y$$$20250731$$MD$BR$BR
256132701$25613270$1$I$$20250723$20250728$20250728$EXP$$GB-INCYTE CORPORATION-2025IN008195$INCYTE$$$$$$Y$$$20250728$$PH$GB$GB
256132951$25613295$1$I$$20250722$20250728$20250728$EXP$$US-AMGEN-USASP2025146281$AMGEN$$70$YR$E$M$Y$$$20250728$$HP$US$US
256133171$25613317$1$I$$20250728$20250728$20250728$DIR$FDA-CDER-CTU-2025-49655$$FDA-CTU$$64$YR$$M$N$$$20250728$N$$US$
256133671$25613367$1$I$20250711$20250727$20250727$20250727$DIR$766948$$FDA-CTU$$59$YR$$F$N$114.75$KG$20250727$N$CN$US$
256134071$25613407$1$I$20250722$20250728$20250728$20250728$DIR$767056$$FDA-CTU$$$$$M$N$$$20250728$N$CN$US$
256134652$25613465$2$F$$20250728$20250728$20250801$PER$$US-GILEAD-2025-0721817$GILEAD$$61$YR$A$F$Y$$$20250801$$HP$US$US
256134711$25613471$1$I$$20250728$20250728$20250728$DIR$767091$$FDA-CTU$$$$$$N$$$20250728$N$$US$
256134761$25613476$1$I$$20250714$20250728$20250728$EXP$$US-CIPLA LTD.-2025US09053$CIPLA$Ahmed T, Lodhi SH, Haigh PJ, Sorrell VL.. The many faces of takotsubo syndrome: A review.. Current Problems in Cardiology.. 2024;49 (3);102421$$$$$Y$$$20250728$$MD$US$US
256134811$25613481$1$I$20250401$20250714$20250728$20250728$EXP$$EU-CIPLA LTD.-2025IT08937$CIPLA$$$$$$Y$$$20250728$$MD$EU$EU
256134821$25613482$1$I$20250627$20250714$20250728$20250728$EXP$$EU-CIPLA (EU) LIMITED-2025ES08996$CIPLA$$$$$$Y$$$20250728$$MD$EU$EU
256135021$25613502$1$I$$20250728$20250728$20250728$DIR$766989$$FDA-CTU$$18$YR$$F$N$90$KG$20250728$N$CN$US$
256136671$25613667$1$I$20250725$20250728$20250728$20250728$DIR$767099$$FDA-CTU$$75$YR$$M$N$81$KG$20250728$N$MD$US$
256137151$25613715$1$I$20241010$20250728$20250728$20250728$DIR$767106$$FDA-CTU$$78$YR$$F$N$71.1$KG$20250728$N$CN$US$
256137161$25613716$1$I$20250101$20250723$20250728$20250728$PER$$US-SA-2025SA215332$SANOFI AVENTIS$$11$YR$C$M$Y$$$20250728$$CN$US$US
256137211$25613721$1$I$20250701$20250725$20250728$20250728$EXP$GB-MHRA-MED-202507250844133470-VYBZD$GB-PFIZER INC-202500150775$PFIZER$$53$YR$$M$Y$104$KG$20250728$$HP$GB$GB
256137641$25613764$1$I$20220501$20250721$20250728$20250728$EXP$$RU-TAKEDA-2025TUS066338$TAKEDA$Aleshina OA, Akezheva KA, Eroshenkov DYu, Vasilyeva AN, Shchekina AE, Nalbandyan SA et al. Efficacy of chimeric antigen receptor T-cell therapy after therapy with a bispecific monoclonal antibody (CD19/CD3) in a patient with relapsed Ph-positive acute lymphoblastic leukemia with a massive extramedullary component. Russian Journal of Hematology and Transfusiology. 2024;69(4):474-83. doi:https://doi.org/10.35754/0234-5730-2024-69-4-474-483$28$YR$$M$Y$$$20250728$$MD$RU$RU
256137711$25613771$1$I$$20250721$20250728$20250728$EXP$$NVSC2025KR117526$NOVARTIS$$$$$$Y$$$20250728$$MD$KR$KR
256137981$25613798$1$I$$20250724$20250728$20250728$PER$$US-HALEON-2254439$Haleon PLC$$93$YR$$F$Y$$$20250728$$CN$US$US
256138201$25613820$1$I$$20250723$20250728$20250728$PER$$US-ELI_LILLY_AND_COMPANY-US202507022555$ELI LILLY AND COMPANY$$62$YR$A$$Y$$$20250728$$CN$US$US
256138211$25613821$1$I$$20250717$20250728$20250728$EXP$$US-ELI_LILLY_AND_COMPANY-US202507016926$ELI LILLY AND COMPANY$$$$$$Y$$$20250728$$CN$US$US
256138691$25613869$1$I$20250720$20250726$20250726$20250726$DIR$766816$$FDA-CTU$$71$YR$$F$N$$$20250726$N$CN$US$
256139211$25613921$1$I$20250513$20250725$20250728$20250728$EXP$$KR-TAKEDA-2025TUS066963$TAKEDA$$35$YR$$M$Y$$$20250728$$$KR$KR
256139951$25613995$1$I$$20250717$20250728$20250728$EXP$$US-MACLEODS PHARMA-MAC2025054282$MACLEODS$Mccormack L, Hountras P..Pregnancy Unmasking Pulmonary Veno-occlusive Disease Variant Pulmonary Hypertension.American Journal of Respiratory and Critical Care Medicine.2025;211:A6480$$$$$Y$$$20250728$$MD$US$US
256140091$25614009$1$I$$20250725$20250728$20250728$PER$$NVSC2025US119495$NOVARTIS$$$$$$Y$$$20250728$$HP$US$US
256140192$25614019$2$F$$20250901$20250728$20250903$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202507017708$ELI LILLY AND COMPANY$$43$YR$A$F$Y$40$KG$20250903$$CN$CN$CN
256140801$25614080$1$I$20210901$20250728$20250728$20250728$EXP$EU-URPL-DML-MLP.4401.2.13211.2021$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-085551$BOEHRINGER INGELHEIM$$58$YR$A$M$Y$98$KG$20250728$$$EU$EU
256141191$25614119$1$I$$20250408$20250728$20250728$EXP$$EU-DSJP-DS-2025-135735-RO$DAIICHI$$76$YR$$F$Y$$$20250728$$MD$EU$EU
256141811$25614181$1$I$$20250721$20250728$20250728$EXP$$CN-JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.-H2025225231$JIANGSU HENGRUI$$75$YR$$$Y$61$KG$20250728$$MD$CN$CN
256142111$25614211$1$I$20250717$20250725$20250728$20250728$EXP$$US-ASTRAZENECA-202507USA021806US$ALEXION PHARMACEUTICALS$$67$YR$E$F$Y$$$20250728$$MD$US$US
256142901$25614290$1$I$20250101$20250722$20250728$20250728$PER$$US-SA-2025SA215444$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250729$$HP$US$US
256143231$25614323$1$I$20250101$20250722$20250728$20250728$PER$$US-AMGEN-USASP2025146365$AMGEN$$$$E$F$Y$$$20250728$$MD$US$US
256144711$25614471$1$I$$20250724$20250729$20250729$EXP$$US-ASTRAZENECA-202507USA020951US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250729$$$US$US
256144921$25614492$1$I$$20250721$20250729$20250729$EXP$$CN-ANIPHARMA-023821$ANI$$53$YR$A$F$Y$$$20250728$$HP$CN$CN
256145031$25614503$1$I$$20250721$20250729$20250729$EXP$$CN-ANIPHARMA-023758$ANI$$53$YR$A$F$Y$$$20250728$$HP$CN$CN
256145171$25614517$1$I$$20250716$20250729$20250729$EXP$CA-MHPD-E2B_07790852$CA-Accord-495147$ACCORD$$29$YR$A$M$Y$$$20250728$$MD$CA$CA
256148672$25614867$2$F$$20250822$20250729$20250826$30DAY$$EU-JNJFOC-20250714976$JOHNSON AND JOHNSON$$52$YR$A$F$Y$$$20250826$$PH$EU$EU
256148851$25614885$1$I$$20250723$20250729$20250729$EXP$$MX-ASTRAZENECA-202507MEX020986MX$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250729$$MD$MX$MX
256148871$25614887$1$I$$20250721$20250729$20250729$EXP$EU-MINISAL02-1049577$EU-ABBVIE-6384343$ABBVIE$$24$YR$$$Y$$$20250727$$PH$EU$EU
256149611$25614961$1$I$$20250724$20250729$20250729$EXP$$US-ABBVIE-6389567$ABBVIE$$$$E$F$Y$$$20250728$$CN$US$US
256149711$25614971$1$I$$20250717$20250729$20250729$PER$$US-TAKEDA-2025TUS064868$TAKEDA$$$$$F$Y$$$20250729$$$US$US
256149991$25614999$1$I$$20250717$20250729$20250729$EXP$$CA-TLM-TLM-2025-04880$TOLMAR$$$$E$M$Y$$$20250723$$CN$CA$CA
256150501$25615050$1$I$$20250715$20250729$20250729$EXP$$US-ENDO USA, INC.-2025-001642$ENDO$Koch K, Chittal A, Rane R, Dumont TL. Fluoxetine Induced Chronic Eosinophilic Pneumonia Leading to Usual Interstitial Pneumonia (UIP) Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2025;211:A6055$76$YR$$F$Y$$$20250729$$HP$US$US
256151071$25615107$1$I$$20250715$20250729$20250729$EXP$$US-STRIDES ARCOLAB LIMITED-2025OS000267$Unknown Manufacturer$Mufarrih S, Lusby H, Watson P.. Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in a patient with leprosy.. BMJ-Case-Rep. 2024;17 (9)$4$DEC$$M$Y$$$20250729$$HP$US$US
256152191$25615219$1$I$20250301$20250717$20250729$20250729$EXP$EU-SEMPA-2025-005187$EU-NOVOPROD-1482114$NOVO NORDISK$$60$YR$$F$Y$105$KG$20250729$$CN$EU$EU
256153391$25615339$1$I$$20250728$20250729$20250729$EXP$$ID-ASTRAZENECA-202507ASI022673ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250729$$$ID$ID
256153691$25615369$1$I$$20250728$20250729$20250729$EXP$$US-TAKEDA-2025TUS059965$TAKEDA$$$$$M$Y$$$20250729$$$US$US
256154012$25615401$2$F$20250723$20250724$20250729$20250731$PER$$US-ABBVIE-6389922$ABBVIE$$$$$$Y$$$20250731$$CN$US$US
256154112$25615411$2$F$$20250812$20250729$20250821$PER$$US-SMPA-2025SPA009052$SUNOVION$$75$YR$$M$Y$$$20250819$$$US$US
256154491$25615449$1$I$20250702$20250717$20250729$20250729$PER$$US-ELI_LILLY_AND_COMPANY-US202507017057$ELI LILLY AND COMPANY$$$$$$Y$$$20250729$$CN$US$US
256156452$25615645$2$F$$20250819$20250729$20250826$EXP$$JP-ASTRAZENECA-202507JPN019000JP$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250826$$MD$JP$JP
256156501$25615650$1$I$$20250716$20250729$20250729$EXP$$EU-AUROBINDO-AUR-APL-2025-037859$AUROBINDO$Hock S, Tako LM, Knake S, von Podewils F, Langenbruch L, Kovac S, et.al.. Occurrence and treatment of depression symptoms and anxiety in patients with epilepsy: Findings from a German multicentre cross-sectional study. Epilepsy + behavior. 2025;173:1-6$$$A$$Y$$$20250729$$HP$EU$EU
256156651$25615665$1$I$20250718$20250721$20250729$20250729$EXP$CN-NMPACDR-3706011027023202500803$CN-GE HEALTHCARE-2025CSU009858$GE HEALTHCARE$$71$YR$$M$Y$65$KG$20250729$$HP$CN$CN
256157071$25615707$1$I$20250318$20250723$20250729$20250729$EXP$$JP-GSK-JP2025JPN094279$GLAXOSMITHKLINE$$69$YR$$M$Y$61.7$KG$20250729$$MD$JP$JP
256158141$25615814$1$I$$20250724$20250729$20250729$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-105264$BRISTOL-MYERS SQUIBB COMPANY$$$$E$M$Y$$$20250729$$MD$JP$JP
256158241$25615824$1$I$$20250725$20250729$20250729$PER$$US-ELI_LILLY_AND_COMPANY-US202507025094$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250729$$CN$US$US
256158391$25615839$1$I$$20250724$20250729$20250729$EXP$$US-ABBVIE-6389619$ABBVIE$$$$E$F$Y$$$20250729$$CN$US$US
256158435$25615843$5$F$20250717$20250828$20250729$20250904$EXP$$CA-ASTELLAS-2025-AER-041051$ASTELLAS$$70$YR$E$F$Y$55$KG$20250904$$HP$CA$CA
256158941$25615894$1$I$$20250718$20250729$20250729$EXP$$CO-EXELAPHARMA-2025EXLA00133$EXELA PHARMA SCIENCES$John Jairo Cardeno-S anchez^a, Mariana Montoya-Castillo^b, Juan Ricardo Cadavid-Castrillon^c, Luis Felipe Higuita-Guti^errez.Foscarnet-induced penile ulcer in a patient with cytomegalovirus  coinfection refractory to ganciclovir and Clostridioides difficile: A  case report.IDCases.06-JUL-2025;41 (2025) e02315:1-5$39$YR$A$M$Y$$$20250729$$HP$CO$CO
256159081$25615908$1$I$$20250724$20250729$20250729$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-085642$BOEHRINGER INGELHEIM$$$$$M$Y$$$20250729$$$US$US
256159821$25615982$1$I$$20250725$20250729$20250729$EXP$$US-ASTRAZENECA-202507USA022072US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250729$$$US$US
256160272$25616027$2$F$$20250820$20250729$20250820$PER$$US-ASTRAZENECA-202507USA020759US$ALEXION PHARMACEUTICALS$$19$YR$A$M$Y$$$20250820$$PH$US$US
256160661$25616066$1$I$$20250715$20250729$20250729$PER$$US-SMPA-2025SPA009158$SUNOVION$$$$$$Y$$$20250729$$CN$US$US
256160931$25616093$1$I$$20250717$20250729$20250729$EXP$$GB-GLENMARK PHARMACEUTICALS-2025GMK102336$GLENMARK$$91$YR$$F$Y$72$KG$20250729$$MD$GB$GB
256161771$25616177$1$I$20230601$20250716$20250729$20250729$EXP$$EU-AUROBINDO-AUR-APL-2025-037722$AUROBINDO$$60$YR$$M$Y$$$20250729$$MD$EU$EU
256162291$25616229$1$I$20250622$20250721$20250729$20250729$EXP$EU-AFSSAPS-AN2025000962$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-126504$ZYDUS PHARM$$$$$$Y$$$20250729$$PH$EU$EU
256162441$25616244$1$I$20250722$20250724$20250729$20250729$EXP$GB-MHRA-MED-202507241634308290-NQVFC$GB-SANDOZ INC.-SDZ2025GB053423$SANDOZ$$66$YR$$M$Y$91$KG$20250729$$CN$GB$GB
256162451$25616245$1$I$$20250630$20250729$20250729$30DAY$$US-VEROBIOTECH-2025USVEROSPO00233$VERO BIOTECH$$$$$$Y$$$20250729$$HP$US$US
256162561$25616256$1$I$$20250723$20250729$20250729$EXP$$GB-AMGEN-GBRSP2025148993$AMGEN$$82$YR$E$F$Y$$$20250729$$CN$GB$GB
256163071$25616307$1$I$$20250714$20250729$20250729$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519044$RANBAXY$Wasa J, Katagiri H, Murata H, Toki S, Ito K, Takahashi M. Ifosfamide, Carboplatin, and Etoposide as Neoadjuvant Chemotherapy in Patients With Neurofibromatosis Type I?related Malignant Peripheral Nerve Sheath Tumors. In Vivo. 2025;39(4):2267-2276$37$YR$$F$Y$$$20250729$$MD$JP$JP
256163251$25616325$1$I$$20250714$20250729$20250729$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519178$RANBAXY$Vani S, Kapu S, Pothala R, Kumar C. Monochorionic-Monoamniotic Twins Discordant for Anencephaly: Story of Expectant Management. J Obstet Gynecol India. 2025;75(suppl 1):S613-S615$$$N$F$Y$1.58$KG$20250729$$MD$IN$IN
256163551$25616355$1$I$$20250714$20250729$20250729$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-518944$RANBAXY$Du Z, Zhang Y-H, Sun L. Challenges and Limitations of Extracorporeal Membrane Oxygenation Therapy in Severe Paraquat Poisoning: An Analysis of Unsuccessful Cases. Arch Bronconeumol. 2024;60:431-432$43$YR$$M$Y$$$20250729$$HP$CN$CN
256163611$25616361$1$I$$20250714$20250729$20250729$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-518851$RANBAXY$Liu Q, Wang Q, Tan H, Zhang W, Wang B, Jin T, et al. Renal-Limited Thrombotic Microangiopathy induced  by Fruquintinib and Tislelizumab: A Case Report. Nephrology. 2025;30:e70067 (1-7)$60$YR$$F$Y$$$20250729$$HP$CN$CN
256163642$25616364$2$F$$20250828$20250729$20250829$30DAY$$JP-JNJFOC-20250731685$JOHNSON AND JOHNSON$$$$$$Y$$$20250829$$CN$JP$JP
256164052$25616405$2$F$20230901$20250801$20250729$20250814$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-508210$RANBAXY$Munoz NP, Vest P, Peres M, Ponsin P, Hejl C. Voluntary self-poisoning with metformin and antiretroviral therapy drugs. Ann Biol Clin. 2025;Mar-Apr;83 (2):211-219$67$YR$$M$Y$$$20250814$$HP$EU$EU
256164141$25616414$1$I$20250709$20250716$20250729$20250729$EXP$$GB-AUROBINDO-AUR-APL-2025-037830$AUROBINDO$$65$YR$$F$Y$$$20250729$$PH$GB$GB
256164451$25616445$1$I$20250621$20250715$20250729$20250729$EXP$EU-AEMPS-1719653$EU-HIKMA PHARMACEUTICALS-ES-H14001-25-08695$HIKMA$$54$YR$$F$Y$60$KG$20250729$$PH$EU$EU
256165071$25616507$1$I$$20250724$20250729$20250729$PER$$US-ELI_LILLY_AND_COMPANY-US202507024036$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250729$$CN$US$US
256165531$25616553$1$I$20250227$20250725$20250725$20250725$DIR$FDA-CDER-CTU-2025-49780$$FDA-CTU$$49$YR$$M$N$105.69$KG$20250725$N$HP$US$
256165881$25616588$1$I$20250606$20250725$20250725$20250725$DIR$FDA-CDER-CTU-2025-49825$$FDA-CTU$$70$YR$$F$N$63.5$KG$20250725$N$PH$US$
256166361$25616636$1$I$20250719$20250721$20250729$20250729$EXP$$US-ALCON LABORATORIES-ALC2025US003698$ALCON$$$$$F$Y$$$20250729$$CN$US$US
256166992$25616699$2$F$$20250728$20250729$20250729$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-105654$BRISTOL-MYERS SQUIBB COMPANY$$34$YR$A$M$Y$79.38$KG$20250729$$CN$US$US
256168801$25616880$1$I$20250101$20250710$20250729$20250729$PER$$US-Eisai-EC-2025-193069$EISAI$$70$YR$E$M$Y$$$20250729$$$US$US
256169631$25616963$1$I$$20250717$20250729$20250729$EXP$$US-AUROBINDO-AUR-APL-2025-038018$AUROBINDO$Katsev B, Campagna G, Liu JC.. Ahmed glaucoma valve implantation in a case of volatile intraocular  pressure and preoperative hypotony. Am-J-Ophthalmol-Case-Rep. 2025;38:102285$71$YR$$M$Y$$$20250729$$HP$US$US
256170001$25617000$1$I$$20250714$20250729$20250729$EXP$$IN-CADILA HEALTHCARE LIMITED-IN-ZYDUS-126711$ZYDUS PHARM$Kaur U, Lahari TSS, Jaiswal S, Chakrabarti SS. Duloxetine-induced neuropsychiatric symptoms in a nonagenarian with chronic Pregabalin intake. Acta-Neurol-Belg. 2025$$$$$Y$$$20250729$$MD$IN$IN
256170181$25617018$1$I$20250626$20250724$20250729$20250729$EXP$CH-SM-2025-05954$CH-SANDOZ INC.-SDZ2025CH053669$SANDOZ$$82$YR$$M$Y$63$KG$20250729$$MD$CH$CH
256170544$25617054$4$F$20250401$20250904$20250729$20250913$PER$$US-ELI_LILLY_AND_COMPANY-US202507021485$ELI LILLY AND COMPANY$$78$YR$E$F$Y$$$20250913$$CN$US$US
256170731$25617073$1$I$$20250725$20250729$20250729$EXP$$CA-APOTEX-2025AP010829$APOTEX$$64$YR$$F$Y$$$20250729$$PH$CA$CA
256171251$25617125$1$I$20250710$20250728$20250728$20250728$DIR$FDA-CDER-CTU-2025-49806$$FDA-CTU$$73$YR$$F$N$$$20250728$Y$PH$US$
256172041$25617204$1$I$$20250722$20250729$20250729$EXP$$CA-JNJFOC-20250731009$JOHNSON AND JOHNSON$$56$YR$A$M$Y$$$20250729$$HP$CA$CA
256172111$25617211$1$I$20250701$20250725$20250729$20250729$EXP$$JP-009507513-2313148$MERCK SHARP + DOHME LLC$$6$DEC$$M$Y$$$20250729$$MD$JP$JP
256172351$25617235$1$I$$20250724$20250729$20250729$PER$$US-PFIZER INC-PV202500089583$PFIZER$$44$YR$$F$Y$$$20250729$$HP$US$US
256173241$25617324$1$I$20250714$20250727$20250727$20250727$DIR$766925$$FDA-CTU$$81$YR$$M$N$$$20250727$N$CN$US$
256173671$25617367$1$I$$20250724$20250729$20250729$EXP$GB-MHRA-MED-202507241301308750-HDZMC$GB-MYLANLABS-2025M1063207$MYLAN$$27$YR$$M$Y$110$KG$20250729$$$GB$GB
256173811$25617381$1$I$$20250724$20250729$20250729$EXP$$CN-AMGEN-CHNSP2025148325$AMGEN$Jiang S.; Li C.; Li L. et al.. Effect of moderate-dose statins combined with PCSK 9 inhibitors on coronary plaques in patients with acute coronary syndrome. Journal of Clinical Cardiology (China). 2025;41 (5):352-256$$$$$Y$$$20250729$$HP$CN$CN
256173841$25617384$1$I$$20250723$20250729$20250729$PER$EU-MINISAL02-1049682$EU-BRACCO-2025IT05036$BRACCO$$$$$F$Y$$$20250728$$HP$EU$EU
256173991$25617399$1$I$$20250723$20250729$20250729$PER$$US-AMGEN-USASP2025148303$AMGEN$$$$A$F$Y$$$20250729$$MD$US$US
256175091$25617509$1$I$$20250721$20250729$20250729$EXP$$US-AMGEN-USASP2025145822$AMGEN$Sharma Y.; Myer A.S.; Seccurro D.A et.al. Outcomes following the use of HBsAg-positive liver allografts in HBsAg-negative recipients. Liver Transplantation. 2025;31 (7):870-876$$$$$Y$$$20250729$$MD$US$US
256175231$25617523$1$I$$20250715$20250729$20250729$PER$$US-SMPA-2025SPA009177$SUNOVION$$$$$$Y$$$20250729$$CN$US$US
256176022$25617602$2$F$20250701$20250919$20250729$20250929$EXP$$US-STEMLINE THERAPEUTICS B.V.-2025-STML-US000982$STEMLINE THERAPEUTICS$$$$$$Y$$$20250929$$HP$US$US
256176371$25617637$1$I$$20250729$20250729$20250729$DIR$767225$$FDA-CTU$$$$$$N$$$20250729$$CN$US$
256176401$25617640$1$I$$20250729$20250729$20250729$DIR$767268$$FDA-CTU$$$$$$N$$$20250729$N$CN$US$
256176651$25617665$1$I$$20250728$20250729$20250729$EXP$$US-SA-2025SA220348$SANOFI AVENTIS$$76$YR$E$M$Y$$$20250729$$CN$US$US
256176901$25617690$1$I$20250724$20250724$20250729$20250729$EXP$$AR-PFIZER INC-202500151890$PFIZER$$$$$M$Y$$$20250729$$CN$AR$AR
256177011$25617701$1$I$20250724$20250725$20250729$20250729$EXP$$CA-PFIZER INC-202500150982$PFIZER$$77$YR$$M$Y$$$20250729$$HP$CA$CA
256177821$25617782$1$I$20240101$20250723$20250729$20250729$EXP$$US-ABBVIE-6387919$ABBVIE$$59$YR$$F$Y$$$20250729$$CN$US$US
256177861$25617786$1$I$20250101$20250726$20250729$20250729$PER$$US-009507513-2313456$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250729$$CN$US$US
256178302$25617830$2$F$20250501$20250902$20250729$20250903$EXP$$NVSC2025AU105659$NOVARTIS$$62$YR$$F$Y$$$20250903$$MD$AU$AU
256180661$25618066$1$I$$20250723$20250729$20250729$PER$$US-ROCHE-10000347412$ROCHE$$$$A$F$Y$$$20250729$$CN$US$US
256181222$25618122$2$F$$20250922$20250729$20250928$PER$$US-SA-2025SA215121$SANOFI AVENTIS$$$$A$F$Y$$$20250928$$MD$US$US
256181471$25618147$1$I$$20250723$20250729$20250729$PER$$US-SA-2025SA219106$SANOFI AVENTIS$$$$E$F$Y$$$20250729$$MD$US$US
256181542$25618154$2$F$20250601$20250731$20250729$20250806$PER$$US-SA-2025SA219094$SANOFI AVENTIS$$61$YR$A$F$Y$113.64$KG$20250806$$MD$US$US
256181571$25618157$1$I$$20250723$20250729$20250729$PER$$US-SA-2025SA219364$SANOFI AVENTIS$$$$A$F$Y$$$20250729$$MD$US$US
256181761$25618176$1$I$$20250729$20250729$20250729$DIR$767259$$FDA-CTU$$$$$$N$$$20250729$$CN$US$
256181781$25618178$1$I$20250101$20250723$20250729$20250729$PER$$US-SA-2025SA214711$SANOFI AVENTIS$$68$YR$E$M$Y$$$20250729$$CN$US$US
256181981$25618198$1$I$$20250723$20250729$20250729$PER$$US-SA-2025SA218498$SANOFI AVENTIS$$$$A$M$Y$$$20250729$$HP$US$US
256182482$25618248$2$F$20250101$20250918$20250729$20250924$PER$$US-SA-2025SA219302$SANOFI AVENTIS$$1$YR$I$F$Y$$$20250924$$HP$US$US
256182902$25618290$2$F$20250101$20250925$20250729$20250930$PER$$US-SA-2025SA218672$SANOFI AVENTIS$$87$YR$E$M$Y$$$20250930$$HP$US$US
256183191$25618319$1$I$$20250724$20250729$20250729$PER$$US-SA-2025SA219153$SANOFI AVENTIS$$92$YR$E$F$Y$$$20250729$$HP$US$US
256183261$25618326$1$I$$20250724$20250729$20250729$PER$$US-SA-2025SA214596$SANOFI AVENTIS$$84$YR$E$F$Y$$$20250729$$CN$US$US
256183681$25618368$1$I$$20250724$20250729$20250729$PER$$US-SA-2025SA219105$SANOFI AVENTIS$$$$E$M$Y$$$20250729$$HP$US$US
256183771$25618377$1$I$20250612$20250725$20250729$20250729$PER$$US-SA-2025SA220193$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250729$$HP$US$US
256184031$25618403$1$I$$20250725$20250729$20250729$PER$$US-SA-2025SA219627$SANOFI AVENTIS$$51$YR$A$M$Y$$$20250729$$PH$US$US
256184331$25618433$1$I$$20250728$20250729$20250729$PER$$US-SA-2025SA220810$SANOFI AVENTIS$$75$YR$E$F$Y$$$20250729$$CN$US$US
256184841$25618484$1$I$$20250722$20250729$20250729$EXP$$MY-FreseniusKabi-FK202510221$FRESENIUS KABI$$56$YR$A$F$Y$$$20250729$$PH$MY$MY
256185172$25618517$2$F$20250601$20250827$20250729$20250904$30DAY$$EU-PFIZER INC-202500147310$PFIZER$$8$YR$$M$Y$26$KG$20250904$$PH$EU$EU
256185743$25618574$3$F$$20250815$20250729$20250819$30DAY$$US-PFIZER INC-202500152167$PFIZER$$$$$$Y$$$20250819$$PH$US$US
256186167$25618616$7$F$$20250926$20250729$20250929$30DAY$$US-PFIZER INC-202500151433$PFIZER$$58$YR$$F$Y$47.63$KG$20250929$$CN$US$US
256186293$25618629$3$F$$20250815$20250729$20250819$30DAY$$US-PFIZER INC-202500152175$PFIZER$$$$$$Y$$$20250819$$PH$US$US
256187452$25618745$2$F$20250701$20250730$20250729$20250731$EXP$$US-SANDOZ INC.-SDZ2025US054088$SANDOZ$$100$YR$$F$Y$$$20250731$$HP$US$US
256187871$25618787$1$I$20250330$20250723$20250729$20250729$PER$$US-SA-2025SA218704$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250729$$HP$US$US
256187931$25618793$1$I$20250101$20250722$20250729$20250729$EXP$$EU-AMGEN-ESPSP2025145705$AMGEN$$$$$M$Y$$$20250729$$PH$EU$EU
256188241$25618824$1$I$$20250725$20250729$20250729$PER$$US-JNJFOC-20250731920$JOHNSON AND JOHNSON$$$$$$Y$$$20250729$$PH$US$US
256188355$25618835$5$F$20180101$20250828$20250729$20250902$EXP$EU-MSNLABS-2025MSNLIT01939$EU-SANDOZ INC.-SDZ2025CZ053975$SANDOZ$$36$YR$$F$Y$$$20250902$$MD$EU$EU
256188501$25618850$1$I$20250707$20250722$20250729$20250729$PER$$US-AMGEN-USASP2025146034$AMGEN$$57$YR$A$F$Y$$$20250729$$CN$US$US
256189141$25618914$1$I$20250717$20250721$20250729$20250729$EXP$$US-ASTRAZENECA-202507USA021966US$ALEXION PHARMACEUTICALS$$10$YR$C$M$Y$$$20250729$$$US$US
256189331$25618933$1$I$20250707$20250729$20250729$20250729$DIR$767309$$FDA-CTU$$18$YR$$F$N$85.05$KG$20250729$N$CN$US$
256190522$25619052$2$F$20230101$20250728$20250729$20250801$EXP$$EU-MYLANLABS-2025M1063499$MYLAN$Pinheiro CS, Pinheiro GM, Mo?o R. Between remission and lymphoma: the impact of methotrexate. Presented at: Oncological Diseases Session; Local Health Unit of Matosinhos; PA No. 1538$71$YR$$M$Y$$$20250801$$MD$EU$EU
256190861$25619086$1$I$$20250724$20250729$20250729$EXP$GB-MHRA-MED-202507241601540840-PKSMZ$GB-MYLANLABS-2025M1063306$MYLAN$$76$YR$$F$Y$47$KG$20250729$$PH$GB$GB
256191721$25619172$1$I$20250629$20250724$20250729$20250729$EXP$$CA-ABBVIE-6389943$ABBVIE$$49$YR$$M$Y$$$20250729$$CN$CA$CA
256191981$25619198$1$I$$20250728$20250729$20250729$PER$$US-ABBVIE-6391919$ABBVIE$$$$E$F$Y$$$20250729$$CN$US$US
256192071$25619207$1$I$$20250725$20250729$20250729$PER$$US-ELI_LILLY_AND_COMPANY-US202507026003$ELI LILLY AND COMPANY$$$$$F$Y$$$20250729$$CN$US$US
256192331$25619233$1$I$20250724$20250724$20250729$20250729$PER$$US-ABBVIE-6389471$ABBVIE$$$$$F$Y$$$20250729$$CN$US$US
256192611$25619261$1$I$$20250722$20250729$20250729$EXP$$TW-AMGEN-TWNSP2025146030$AMGEN$Hsu, TJ. Evaluating the Efficacy and Safety of Kinesiology Tape Wrapping as Adjunct Therapy for Epidermal Growth Factor Receptor - Induced Paronychia. Dermatologic Therapy. 2025;2025 (1):1-12$$$$$Y$$$20250729$$HP$TW$TW
256194251$25619425$1$I$20250101$20250724$20250729$20250729$PER$$US-ABBVIE-6390008$ABBVIE$$$$$M$Y$$$20250729$$CN$US$US
256195211$25619521$1$I$20250724$20250724$20250729$20250729$PER$$JP-Eisai-EC-2025-194062$EISAI$$53$YR$A$M$Y$$$20250729$$MD$JP$JP
256197252$25619725$2$F$20241201$20250724$20250729$20250826$PER$$US-ASTRAZENECA-202507GLO025359US$ALEXION PHARMACEUTICALS$$5$MON$I$$Y$$$20250826$$$US$US
256197411$25619741$1$I$20250722$20250725$20250729$20250729$EXP$$US-ASTRAZENECA-202507USA022141US$ALEXION PHARMACEUTICALS$$78$YR$E$F$Y$62.142$KG$20250729$$$US$US
256197801$25619780$1$I$$20250724$20250729$20250729$EXP$$US-ABBVIE-6389570$ABBVIE$$$$$F$Y$$$20250729$$CN$US$US
256197853$25619785$3$F$20250711$20250818$20250729$20250822$30DAY$$US-AMGEN-USASL2025147546$AMGEN$$$$$F$Y$$$20250822$$PH$US$US
256198191$25619819$1$I$$20250723$20250730$20250730$EXP$$US-JNJFOC-20250735565$JOHNSON AND JOHNSON$$45$YR$A$M$Y$$$20250730$$CN$US$US
256198221$25619822$1$I$$20250728$20250730$20250730$PER$$US-GILEAD-2025-0722631$GILEAD$$$$$$Y$$$20250729$$LW$US$US
256199131$25619913$1$I$20250710$20250724$20250730$20250730$EXP$EU-BASGAGES-2025-004930$EU-SA-2025SA217856$SANOFI AVENTIS$$33$YR$A$M$Y$$$20250730$$MD$EU$EU
256199391$25619939$1$I$$20250718$20250730$20250730$EXP$GB-MHRA-MED-202507180813163470-CGJWP$GB-Accord-496029$ACCORD$$63$YR$A$F$Y$53$KG$20250730$$CN$GB$GB
256199451$25619945$1$I$$20250723$20250730$20250730$PER$$US-ROCHE-10000347120$ROCHE$$$$$$Y$$$20250730$$CN$US$US
256200151$25620015$1$I$$20250724$20250730$20250730$EXP$$CA-ASTRAZENECA-202507CAN022319CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250730$$$CA$CA
256200381$25620038$1$I$$20250723$20250730$20250730$PER$$US-ABBVIE-6387257$ABBVIE$$$$$F$Y$$$20250730$$CN$US$US
256200471$25620047$1$I$$20250728$20250730$20250730$EXP$$US-ASTRAZENECA-202507USA023344US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250730$$PH$US$US
256200711$25620071$1$I$20250701$20250722$20250730$20250730$PER$$US-AMGEN-USASP2025145764$AMGEN$$$$$F$Y$$$20250729$$HP$US$US
256201231$25620123$1$I$$20241104$20250730$20250730$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202410-000988$AZURITY PHARMACEUTICALS$$$$$F$Y$$$20250730$$HP$US$US
256201451$25620145$1$I$$20241028$20250730$20250730$EXP$$US-AZURITY PHARMACEUTICALS, INC.-AZR202410-001004$AZURITY PHARMACEUTICALS$$$$$F$Y$$$20250730$$HP$US$US
256202271$25620227$1$I$20250101$20250723$20250730$20250730$EXP$$EU-CELLTRION INC.-2025GR025360$CELLTRION$$$$$$Y$$$20250730$$CN$EU$EU
256203082$25620308$2$F$$20250910$20250730$20250916$PER$$US-BIOVITRUM-2025-US-007770$BIOVITRUM$$58$YR$$F$Y$$$20250916$$CN$US$US
256203251$25620325$1$I$$20250729$20250730$20250730$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-086141$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250730$$$US$US
256203562$25620356$2$F$20250501$20250806$20250730$20250826$PER$$US-009507513-2303770$MERCK SHARP + DOHME LLC$$36$YR$$M$Y$$$20250826$$CN$US$US
256203711$25620371$1$I$20240117$20250718$20250730$20250730$EXP$$EU-AUROBINDO-AUR-APL-2025-037957$AUROBINDO$$66$YR$$M$Y$$$20250730$$MD$EU$EU
256203801$25620380$1$I$$20250723$20250730$20250730$PER$$US-ROCHE-10000346930$ROCHE$$$$E$F$Y$$$20250730$$CN$US$US
256204202$25620420$2$F$20200101$20250816$20250730$20250828$EXP$$EU-AUROBINDO-AUR-APL-2025-038895$AUROBINDO$$43$YR$$M$Y$$$20250828$$CN$EU$EU
256204382$25620438$2$F$20250702$20250820$20250730$20250901$EXP$$EU-AUROBINDO-AUR-APL-2025-038247$AUROBINDO$$54$YR$$F$Y$$$20250901$$MD$EU$EU
256204401$25620440$1$I$$20250723$20250730$20250730$PER$$US-ASTRAZENECA-202507USA019721US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250730$$$US$US
256204701$25620470$1$I$$20250717$20250730$20250730$PER$$US-GSK-US2025AMR096355$GLAXOSMITHKLINE$$$$$$Y$$$20250730$$$US$US
256204831$25620483$1$I$$20250725$20250730$20250730$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008714$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250730$$CN$US$US
256206731$25620673$1$I$20250421$20250718$20250730$20250730$EXP$$GB-AUROBINDO-AUR-APL-2025-037731$AUROBINDO$$85$YR$$M$Y$79$KG$20250730$$PH$GB$GB
256207253$25620725$3$F$20250101$20250922$20250730$20250928$EXP$$US-ABBVIE-6390892$ABBVIE$$71$YR$$F$Y$$$20250928$$CN$US$US
256207991$25620799$1$I$20250424$20250718$20250730$20250730$EXP$EU-AFSSAPS-AM2025000486$EU-Accord-496763$ACCORD$$71$YR$E$M$Y$57$KG$20250730$$MD$EU$EU
256208631$25620863$1$I$$20250725$20250730$20250730$EXP$$US-ABBVIE-6391217$ABBVIE$$$$$F$Y$$$20250730$$MD$US$US
256208711$25620871$1$I$$20250724$20250730$20250730$PER$$US-AMGEN-USASP2025147979$AMGEN$$$$A$F$Y$$$20250730$$HP$US$US
256209561$25620956$1$I$20241007$20241119$20250730$20250730$EXP$$US-AMNEAL-2024-AMRX-04336$AMNEAL$$62$YR$$F$Y$79$KG$20250730$$MD$US$US
256210601$25621060$1$I$$20250721$20250730$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507019995$ELI LILLY AND COMPANY$$$$A$M$Y$$$20250730$$CN$US$US
256211341$25621134$1$I$$20250718$20250730$20250730$EXP$$VN-ROCHE-10000345251$ROCHE$$$$A$F$Y$$$20250730$$MD$VN$VN
256211571$25621157$1$I$$20250630$20250730$20250730$30DAY$$US-SANDOZ INC.-SDZ2025US054510$SANDOZ$$$$$F$Y$$$20250730$$PH$US$US
256211721$25621172$1$I$20230527$20250724$20250730$20250730$EXP$$US-ABBVIE-5307768$ABBVIE$$58$YR$$F$Y$$$20250730$$CN$US$US
256211992$25621199$2$F$20250721$20250801$20250730$20250811$PER$$US-ABBVIE-6385376$ABBVIE$$57$YR$$M$Y$50.34$KG$20250811$$MD$US$US
256212252$25621225$2$F$$20250924$20250730$20250930$EXP$$CA-TAKEDA-2025TUS042460$TAKEDA$$50$YR$$M$Y$$$20250930$$$CA$CA
256212272$25621227$2$F$$20250729$20250730$20250801$PER$$NVSC2025US119940$NOVARTIS$$$$$$Y$$$20250801$$MD$US$US
256212282$25621228$2$F$20250725$20250908$20250730$20250910$PER$$US-JNJFOC-20250732294$JOHNSON AND JOHNSON$$67$YR$E$F$Y$$$20250910$$PH$US$US
256212401$25621240$1$I$$20250728$20250730$20250730$EXP$$NVSC2025CA120213$NOVARTIS$$46$YR$$F$Y$$$20250730$$PH$CA$CA
256212521$25621252$1$I$$20250729$20250730$20250730$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-106175$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250730$$MD$US$US
256213861$25621386$1$I$20250701$20250722$20250730$20250730$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-103540$BRISTOL-MYERS SQUIBB COMPANY$$$$$M$Y$$$20250730$$MD$JP$JP
256214551$25621455$1$I$$20250716$20250730$20250730$EXP$$ID-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519521$RANBAXY$Prasetyo YB, Wati TP. The Effectiveness of Slow Deep Breathing as a Pain Management Intervention in Coronary Heart Disease: A Case Report. NamikKemal tip derg. 2025;Jun;13 (2):184-188$57$YR$$F$Y$$$20250730$$HP$ID$ID
256214782$25621478$2$F$$20250721$20250730$20250805$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519108$RANBAXY$Xiao A, Fakih M. Response to anti-EGFR therapy in chemo-refractory right-sided RAS wild-type metastatic colorectal cancer: a case report and literature review. J Gastrointest Oncol. 2025;16 (1):292-300$70$YR$$M$Y$$$20250805$$HP$US$US
256214891$25621489$1$I$$20250715$20250730$20250730$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519226$RANBAXY$Valerio P, Soares E, Abrantes C, Gois M, Sousa H, Farinha A, et al. Oral Anticoagulant-Related Nephropathy: A New Cause for an Old Entity. Indian J Nephrol. 2025;35 (1):113-114$70$YR$$M$Y$$$20250730$$HP$EU$EU
256216611$25621661$1$I$20250726$20250728$20250730$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507026807$ELI LILLY AND COMPANY$$54$YR$A$M$Y$$$20250730$$CN$US$US
256216671$25621667$1$I$20250101$20250724$20250730$20250730$EXP$$US-ABBVIE-6393150$ABBVIE$$66$YR$$M$Y$$$20250730$$CN$US$US
256216741$25621674$1$I$$20250723$20250730$20250730$PER$$US-ROCHE-10000347148$ROCHE$$$$$F$Y$$$20250730$$CN$US$US
256217051$25621705$1$I$$20250725$20250730$20250730$PER$$US-ROCHE-10000349330$ROCHE$$$$A$F$Y$$$20250730$$CN$US$US
256217511$25621751$1$I$20250728$20250729$20250730$20250730$PER$$US-ABBVIE-6393859$ABBVIE$$74$YR$$M$Y$86.182$KG$20250730$$CN$US$US
256218191$25621819$1$I$$20250723$20250730$20250730$EXP$$US-ABBVIE-6388686$ABBVIE$$$$$F$Y$$$20250730$$CN$US$US
256218501$25621850$1$I$$20250729$20250729$20250729$DIR$FDA-CDER-CTU-2025-50275$$FDA-CTU$$81$YR$$F$N$$$20250729$N$HP$US$
256218551$25621855$1$I$$20250724$20250730$20250730$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008690$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250730$$CN$US$US
256219281$25621928$1$I$$20250716$20250730$20250730$EXP$$US-Appco Pharma LLC-2181502$APPCO PHARMA LLC$Initial$84$YR$$F$Y$$$20250730$$PH$US$US
256219441$25621944$1$I$20181205$20250725$20250730$20250730$EXP$$KR-CHEPLA-2023001950$CHEPLAPHARM$$49$YR$$F$Y$81.4$KG$20250730$$MD$COUNTRY NOT SPECIFIED$KR
256219621$25621962$1$I$20210101$20250728$20250730$20250730$EXP$$US-ABBVIE-6391973$ABBVIE$$55$YR$$M$Y$$$20250730$$CN$US$US
256219821$25621982$1$I$20250721$20250728$20250730$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507026325$ELI LILLY AND COMPANY$$$$$$Y$$$20250730$$CN$US$US
256220772$25622077$2$F$$20250722$20250730$20250801$EXP$$CN-AMGEN-CHNSP2025147044$AMGEN$Han Zhongchao. Salvage treatment of steroid-refractory acute GVHD with the off-the-shelf product of human umbilical cord mesenchymal stromal cells: a multicenter, open label, phase Ib/IIa trial. Stem Cell Research + Therapy. 2025;16 (1):1-14$$$$$Y$$$20250801$$HP$CN$CN
256221651$25622165$1$I$$20250723$20250730$20250730$EXP$GB-MHRA-EMIS-693-7b402836-7ef1-461b-b4aa-17c379a80d73$GB-RDY-GBR/2025/07/011318$DR REDDYS$$64$YR$A$F$Y$70$KG$20250730$$MD$GB$GB
256221811$25622181$1$I$$20250725$20250730$20250730$PER$$US-ABBVIE-6391812$ABBVIE$$$$$$Y$$$20250730$$CN$US$US
256221891$25622189$1$I$20241025$20250709$20250730$20250730$PER$$US-MALLINCKRODT-MNK202504291$MALLINCKRODT$$$$$$Y$$$20250730$$HP$US$US
256222001$25622200$1$I$20250525$20250729$20250729$20250729$DIR$FDA-CDER-CTU-2025-50377$$FDA-CTU$$37$YR$$F$N$62$KG$20250729$Y$CN$JO$
256222411$25622241$1$I$$20241105$20250730$20250730$PER$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-24-10422$HIKMA$$31$YR$$M$Y$$$20250730$$CN$US$US
256222921$25622292$1$I$$20250725$20250730$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507025143$ELI LILLY AND COMPANY$$46$YR$A$$Y$$$20250730$$LW$US$US
256223451$25622345$1$I$$20250722$20250730$20250730$EXP$$CN-BEIGENE-BGN-2025-012197$BEIGENE$$51$YR$$$Y$71$KG$20250730$$$CN$CN
256223893$25622389$3$F$$20250828$20250730$20250903$EXP$$EU-SANDOZ INC.-SDZ2025CZ041374$SANDOZ$$42$YR$$M$Y$$$20250903$$MD$EU$EU
256224051$25622405$1$I$20250101$20250724$20250730$20250730$EXP$$CA-UCBSA-2025037292$UCB$$$$$F$Y$$$20250730$$CN$CA$CA
256224101$25622410$1$I$$20250722$20250730$20250730$EXP$$CN-BEIGENE-BGN-2025-012204$BEIGENE$$47$YR$$$Y$60$KG$20250730$$$CN$CN
256224282$25622428$2$F$20250601$20250826$20250730$20250911$PER$$US-APOTEX-2025AP009224$APOTEX$$$$$F$Y$$$20250911$$CN$US$US
256224581$25622458$1$I$$20250728$20250730$20250730$PER$$US-ELI_LILLY_AND_COMPANY-US202507026685$ELI LILLY AND COMPANY$$63$YR$A$M$Y$$$20250730$$CN$US$US
256224601$25622460$1$I$$20250722$20250730$20250730$EXP$$JP-AMGEN-JPNSP2025146192$AMGEN$$$$$$Y$$$20250730$$MD$JP$JP
256225261$25622526$1$I$20250501$20250725$20250730$20250730$EXP$$CN-ORGANON-O2507CHN002540$ORGANON$$25$YR$$F$Y$$$20250730$$MD$CN$CN
256225442$25622544$2$F$$20250808$20250730$20250811$EXP$$EU-TEVA-VS-3355593$TEVA$Veiga R, Cotrim N, Coelho C, Andrade B, Domingues K. A hard pill to swallow - statin-induced necrotizing autoimmune myopathy manifesting as dysphagia. Cor-Vasa 2024; 66 (6): 620-622.; Veiga R, Cotrim N, Coelho C, Andrade B, Domingues K. A hard pill to swallow - statin-induced necrotizing autoimmune myopathy manifesting as dysphagia. Cor-Vasa 2024; 66 (6): 620-622.$70$YR$$M$Y$$$20250811$$HP$EU$EU
256225631$25622563$1$I$$20250728$20250730$20250730$PER$$US-PFIZER INC-202500152233$PFIZER$$67$YR$$M$Y$$$20250730$$MD$US$US
256226051$25622605$1$I$$20250721$20250730$20250730$EXP$$US-NOVOPROD-1484556$NOVO NORDISK$$53$YR$$$Y$$$20250730$$CN$US$US
256226071$25622607$1$I$20230101$20250718$20250730$20250730$EXP$$US-NOVOPROD-1486810$NOVO NORDISK$$72$YR$$F$Y$$$20250730$$CN$US$US
256226641$25622664$1$I$$20250717$20250730$20250730$PER$$US-GSK-US2025AMR094423$GLAXOSMITHKLINE$$$$$F$Y$$$20250730$$$US$US
256226801$25622680$1$I$20250726$20250729$20250729$20250729$DIR$767414$$FDA-CTU$$65$YR$$M$N$74.5$KG$20250729$N$PH$US$
256227841$25622784$1$I$$20250720$20250730$20250730$EXP$$US-MARINUS PHARMACEUTICALS, INC.-MAR2025000171$MARINUS PHARMACEUTICALS$$$$$$Y$$$20250730$$CN$US$US
256228341$25622834$1$I$$20250724$20250730$20250730$EXP$$CA-TAKEDA-2025TUS067239$TAKEDA$$$$$M$Y$$$20250730$$$CA$CA
256228701$25622870$1$I$20240701$20240703$20250730$20250730$PER$$US-PERRIGO-24US006373$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250730$$CN$US$US
256229081$25622908$1$I$20240101$20240905$20250730$20250730$PER$$US-PERRIGO-24US008488$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250730$$CN$US$US
256229571$25622957$1$I$20240101$20241219$20250730$20250730$PER$$US-PERRIGO-24US011704$GALPHARM INTERNATIONAL$$81$YR$$M$Y$72.562$KG$20250730$$CN$US$US
256229701$25622970$1$I$20240101$20241222$20250730$20250730$PER$$US-PERRIGO-24US011959$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250730$$CN$US$US
256230851$25623085$1$I$20250506$20250725$20250730$20250730$EXP$$ZA-SA-2025SA219433$SANOFI AVENTIS$$84$YR$E$F$Y$$$20250730$$HP$ZA$ZA
256231401$25623140$1$I$20250714$20250724$20250730$20250730$EXP$$NVSC2025CN119265$NOVARTIS$$44$YR$$M$Y$60$KG$20250730$$HP$CN$CN
256231691$25623169$1$I$$20250725$20250730$20250730$EXP$$IN-PFIZER INC-PV202500090854$PFIZER$Mehta, P.. Catastrophic Outcomes: Rapid Multi-Organ Failure from Paraquat Poisoning- A Case Report. Nigerian Medical Journal. 2025;66(2):811-817$19$YR$$M$Y$$$20250730$$HP$IN$IN
256232011$25623201$1$I$20250729$20250730$20250730$20250730$DIR$767496$$FDA-CTU$$$$$$N$$$20250730$N$CN$US$
256232531$25623253$1$I$$20250723$20250730$20250730$PER$$US-INSUD PHARMA-2507US06078$INSUD PHARMA$$$$$$Y$$$20250730$$CN$US$US
256233491$25623349$1$I$$20250717$20250730$20250730$PER$$US-TEVA-VS-3354197$TEVA$$43$YR$$F$Y$$$20250730$$CN$US$US
256234541$25623454$1$I$$20250725$20250730$20250730$PER$$US-BAYER-2025A100120$BAYER HEALTHCARE LLC$$77$YR$E$F$Y$77.1$KG$20250730$$CN$US$US
256234671$25623467$1$I$$20250725$20250730$20250730$EXP$$US-LUNDBECK-DKLU4017598$LUNDBECK$$23$YR$A$M$Y$$$20250730$$CN$US$US
256235111$25623511$1$I$20250701$20250728$20250730$20250730$PER$$US-ABBVIE-6391933$ABBVIE$$$$$$Y$$$20250730$$CN$US$US
256236741$25623674$1$I$20220301$20250729$20250730$20250730$EXP$$JP-SANDOZ INC.-SDZ2025JP054437$SANDOZ$$69$YR$$M$Y$$$20250730$$MD$JP$JP
256237011$25623701$1$I$$20250724$20250730$20250730$EXP$$US-ELI_LILLY_AND_COMPANY-US202507023409$ELI LILLY AND COMPANY$$46$YR$A$$Y$$$20250730$$LW$US$US
256237281$25623728$1$I$20250720$20250730$20250730$20250730$DIR$767557$$FDA-CTU$$75$YR$$M$N$95.4$KG$20250730$N$HP$US$
256237861$25623786$1$I$$20250726$20250730$20250730$EXP$$IN-PFIZER INC-PV202500026726$PFIZER$$47$YR$$M$Y$$$20250730$$CN$IN$IN
256237961$25623796$1$I$20250401$20250519$20250730$20250730$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000355$Tarsus Pharmaceuticals$$$$$$Y$$$20250730$$PH$US$US
256238141$25623814$1$I$20250501$20250725$20250730$20250730$PER$$US-ABBVIE-6391754$ABBVIE$$41$YR$$F$Y$$$20250730$$HP$US$US
256238581$25623858$1$I$$20250729$20250730$20250730$PER$$NVSC2025US120712$NOVARTIS$$$$$$Y$$$20250730$$HP$US$US
256238751$25623875$1$I$20250508$20250509$20250730$20250730$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000427$Tarsus Pharmaceuticals$$$$$$Y$$$20250730$$CN$US$US
256239101$25623910$1$I$$20250728$20250730$20250730$EXP$$US-PFIZER INC-PV202500091018$PFIZER$$$$A$F$Y$$$20250730$$LW$US$US
256239461$25623946$1$I$20250725$20250725$20250730$20250730$PER$$US-ABBVIE-6391912$ABBVIE$$35$YR$$F$Y$$$20250730$$MD$US$US
256240111$25624011$1$I$$20250724$20250730$20250730$PER$$US-SA-2025SA220422$SANOFI AVENTIS$$31$YR$A$M$Y$84.55$KG$20250730$$MD$US$US
256241231$25624123$1$I$$20250724$20250730$20250730$EXP$$US-MYLANLABS-2025M1064477$MYLAN$Short NJ, Loghavi S, Yilmaz M, Karrar O, Jabbour JE, DiNardo CD, et al. Long-term survival outcomes and cytogenetic/molecular patterns of relapse in adults with FLT3-mutated aml receiving frontline triplet therapy with a hypomethylating agent, Venetoclax and FLT3 inhibitor. Blood 2024; 144 (Suppl. 1) 220.$$$A$$Y$$$20250730$$MD$US$US
256241501$25624150$1$I$20250101$20250725$20250730$20250730$PER$$US-SA-2025SA221379$SANOFI AVENTIS$$29$YR$A$F$Y$53.5$KG$20250730$$MD$US$US
256241541$25624154$1$I$$20250725$20250730$20250730$PER$$US-SA-2025SA221107$SANOFI AVENTIS$$$$A$M$Y$$$20250730$$HP$US$US
256242453$25624245$3$F$$20250903$20250730$20250911$PER$$US-MALLINCKRODT-MNK202504469$MALLINCKRODT$$$$$M$Y$$$20250911$$CN$US$US
256243732$25624373$2$F$20250725$20250730$20250730$20250804$PER$$US-AMGEN-USASP2025149215$AMGEN$$73$YR$E$M$Y$$$20250804$$CN$US$US
256243871$25624387$1$I$$20250725$20250730$20250730$EXP$$US-VERTEX PHARMACEUTICALS DOOEL SKOPJ-2023-006414$VERTEX$$$$$M$Y$51$KG$20250730$$MD$US$US
256243901$25624390$1$I$$20250726$20250730$20250730$EXP$$US-GILEAD-2025-0722382$GILEAD$$$$$F$Y$$$20250730$$MD$US$US
256244011$25624401$1$I$$20250115$20250730$20250730$EXP$$NVSJ2025JP001038$NOVARTIS$Saito Y, Terasaki Y, Kashiwada T, Tanaka T, Takei H, Kimura G, et al. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis. Journal of Nippon Medical School. 2024;91:207-217$$$$$Y$$$20250730$$HP$JP$JP
256244262$25624426$2$F$20250921$20250923$20250730$20250929$EXP$$US-SA-2025SA221525$SANOFI AVENTIS$$51$YR$A$M$Y$$$20250929$$MD$US$US
256246111$25624611$1$I$20250723$20250729$20250730$20250730$EXP$$US-ASTRAZENECA-202507USA024874US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250730$$$US$US
256246641$25624664$1$I$$20250722$20250730$20250730$EXP$$US-APOTEX-2025AP010759$APOTEX$Ekladios H, Fitzsimmons A, Singh A.. 120. RARE BUT LIFE THREATENING PSYCHOTROPIC-INDUCED NEUTROPENIA IN OLDER ADULTS: A CASE REPORT. American Journal of Geriatric Psychiatry. 2025;33 (Suppl. 10):S88-S89$72$YR$$M$Y$$$20250730$$HP$US$US
256246761$25624676$1$I$$20250728$20250730$20250730$PER$$US-SA-2025SA220656$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250731$$CN$US$US
256246981$25624698$1$I$$20250723$20250730$20250730$PER$$US-AMGEN-USASP2025148573$AMGEN$$$$$$Y$$$20250730$$HP$US$US
256249171$25624917$1$I$$20250717$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507017855$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250731$$CN$US$US
256249271$25624927$1$I$20250726$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507026339$ELI LILLY AND COMPANY$$44$YR$A$$Y$$$20250731$$CN$US$US
256249391$25624939$1$I$20250701$20250723$20250731$20250731$PER$$US-SA-2025SA219838$SANOFI AVENTIS$$38$YR$A$F$Y$$$20250731$$HP$US$US
256249452$25624945$2$F$20210101$20250902$20250731$20250904$EXP$$EU-TEVA-VS-3355543$TEVA$Aranda Rubio Y, Pallardo Rodil B, Gomez Pavon FJ. Lymphocytic colitis associated with duloxetine. Rev-Esp-Geriatr-Gerontol 2025; 60 (1):.; Aranda Rubio Y, Pallardo Rodil B, Gomez Pavon FJ. Lymphocytic colitis associated with duloxetine. Rev-Esp-Geriatr-Gerontol 2025; 60 (1):.$85$YR$$F$Y$$$20250904$$HP$EU$EU
256249791$25624979$1$I$20250629$20250728$20250731$20250731$EXP$$CN-ASTRAZENECA-202507CHN024273CN$ALEXION PHARMACEUTICALS$$60$YR$A$M$Y$72$KG$20250731$$$CN$CN
256249921$25624992$1$I$20250712$20250721$20250731$20250731$PER$$US-ROCHE-10000345257$ROCHE$$24$YR$A$M$Y$$$20250731$$CN$US$US
256250481$25625048$1$I$$20250729$20250731$20250731$PER$$US-ASTRAZENECA-202507USA024878US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250731$$$US$US
256251551$25625155$1$I$20240903$20250725$20250731$20250731$EXP$EU-PEI-CADR2025337528$EU-ROCHE-10000350531$ROCHE$$54$YR$A$F$Y$56$KG$20250731$$CN$EU$EU
256251741$25625174$1$I$$20250725$20250731$20250731$EXP$$EU-CELLTRION INC.-2025FR025439$CELLTRION$Cognard J.. Indications, efficacy, safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort.. Rheumatology. 2025$$$$$Y$$$20250731$$HP$EU$EU
256252221$25625222$1$I$20240901$20250722$20250731$20250731$EXP$$US-UNITED THERAPEUTICS-UNT-2024-031798$UNITED THERAPEUTICS$$33$YR$$F$Y$70.748$KG$20250731$$$US$US
256252881$25625288$1$I$$20250725$20250731$20250731$PER$$US-BIOGEN-2022BI01088902$BIOGEN$$$$$F$Y$$$20250731$$CN$US$US
256252992$25625299$2$F$20250721$20250814$20250731$20250820$EXP$$US-SMPA-2025SPA009755$SUNOVION$$66$YR$$M$Y$$$20250819$$$US$US
256253502$25625350$2$F$20250401$20250826$20250731$20250830$PER$$US-UNITED THERAPEUTICS-UNT-2025-014584$UNITED THERAPEUTICS$$70$YR$$F$Y$69.841$KG$20250830$$$US$US
256254391$25625439$1$I$20250514$20250522$20250731$20250731$EXP$$EU-ROCHE-10000293344$ROCHE$$71$YR$E$M$Y$$$20250731$$MD$EU$EU
256254991$25625499$1$I$$20250721$20250731$20250731$EXP$$GB-AUROBINDO-AUR-APL-2025-038638$AUROBINDO$$62$YR$$F$Y$85$KG$20250731$$CN$GB$GB
256255141$25625514$1$I$20250728$20250729$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507028169$ELI LILLY AND COMPANY$$78$YR$E$M$Y$$$20250731$$CN$US$US
256255422$25625542$2$F$$20250803$20250731$20250815$EXP$$US-AUROBINDO-AUR-APL-2025-038716$AUROBINDO$Berg M, Strand A, Garrett ND, Keric A, Wilkinson J.. Rivastigmine as an alternative treatment for anticholinergic toxidrome in light of the physostigmine shortage: A case series. Am-J-Emerg-Med. 2025;94:144-147$$$A$$Y$$$20250815$$MD$US$US
256255681$25625568$1$I$$20250723$20250731$20250731$EXP$$US-BAXTER-2025BAX018886$BAXTER$$52$YR$$M$Y$$$20250731$$HP$US$US
256256161$25625616$1$I$$20250717$20250731$20250731$EXP$$CN-Lyne Laboratories Inc.-2181572$LYNE LABORATORIES$Full text$61$YR$$F$Y$$$20250731$$$CN$CN
256256241$25625624$1$I$$20250723$20250731$20250731$PER$$US-ABBVIE-6393619$ABBVIE$$$$A$$Y$$$20250731$$CN$US$US
256256692$25625669$2$F$$20250825$20250731$20250901$EXP$$CA-JNJFOC-20250730918$JOHNSON AND JOHNSON$$24$YR$A$F$Y$$$20250902$$HP$CA$CA
256256951$25625695$1$I$20250601$20250724$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507023930$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250731$$CN$US$US
256257031$25625703$1$I$20250728$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507027872$ELI LILLY AND COMPANY$$27$YR$A$F$Y$$$20250731$$CN$US$US
256257271$25625727$1$I$$20250725$20250731$20250731$EXP$$TR-ANIPHARMA-023862$ANI$$5$YR$C$$Y$$$20250731$$HP$TR$TR
256257771$25625777$1$I$20250301$20250724$20250731$20250731$EXP$$BR-EMD Serono-2025037927$EMD SERONO INC$$56$YR$A$F$Y$$$20250731$$$BR$BR
256258551$25625855$1$I$20250701$20250722$20250731$20250731$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000891$DECIPHERA PHARMACEUTICALS$$81$YR$E$F$Y$$$20250731$$CN$US$US
256258792$25625879$2$F$20250101$20250826$20250731$20250901$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25051615$RADIUS PHARM$$$$$F$Y$$$20250901$$CN$US$US
256258861$25625886$1$I$20250512$20250719$20250731$20250731$EXP$GB-MHRA-MED-202507192002416080-STLWH$GB-GLENMARK PHARMACEUTICALS-2025GMK102398$GLENMARK$$71$YR$$F$Y$55$KG$20250731$$CN$GB$GB
256258891$25625889$1$I$$20250729$20250731$20250731$EXP$$US-ASTRAZENECA-202507USA024626US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250731$$MD$US$US
256258952$25625895$2$F$20250501$20250731$20250731$20250811$EXP$$MX-ROCHE-10000350154$ROCHE$$$$A$M$Y$50$KG$20250811$$CN$MX$MX
256259151$25625915$1$I$20240901$20250725$20250731$20250731$EXP$$US-ABBVIE-6391967$ABBVIE$$32$YR$$M$Y$$$20250731$$CN$US$US
256260221$25626022$1$I$20250101$20250721$20250731$20250731$EXP$$US-NOVOPROD-1485430$NOVO NORDISK$$60$YR$$M$Y$$$20250731$$CN$US$US
256260391$25626039$1$I$$20241105$20250731$20250731$PER$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-24-10591$HIKMA$$19$YR$$M$Y$$$20250731$$HP$US$US
256260811$25626081$1$I$$20250722$20250731$20250731$EXP$$US-UCBSA-2025046738$UCB$Hernandez-Diaz S, Quinn M, Conant S, Lyons A, Paik H, Ward J, et.al. Use of Antiseizure Medications Early in Pregnancy and the Risk of Major Malformations in the Newborn. Neurology. 2025;105(3):e213786(1-11)$$$A$F$Y$$$20250731$$HP$US$US
256260941$25626094$1$I$$20250722$20250731$20250731$EXP$$EU-NOVOPROD-1485116$NOVO NORDISK$$$$$M$Y$122$KG$20250731$$MD$EU$EU
256262011$25626201$1$I$20250714$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507028427$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250731$$CN$US$US
256262391$25626239$1$I$$20250722$20250731$20250731$PER$$US-GSK-US2025093784$GLAXOSMITHKLINE$$$$$F$Y$$$20250731$$MD$US$US
256262691$25626269$1$I$20250501$20250717$20250731$20250731$PER$$US-SMPA-2025SPA009356$SUNOVION$$$$$$Y$$$20250731$$CN$US$US
256263311$25626331$1$I$$20250717$20250731$20250731$PER$$US-SMPA-2025SPA009305$SUNOVION$$$$$$Y$$$20250731$$CN$US$US
256263391$25626339$1$I$$20250716$20250731$20250731$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519611$RANBAXY$Al-Nabolsi A, Tripathi V, Darany G, Khan O. Immune Thrombocytopenic Purpura: A Case of Risperidone-induced Immune Thrombocytopenia Purpura. Am J Respir Crit Care Med. 2025;211 (0):1, C32$49$YR$$F$Y$$$20250731$$HP$US$US
256263441$25626344$1$I$$20250716$20250731$20250731$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519526$RANBAXY$Xie H, Wang Y, Tian X. Acute Interstitial Lung Disease as a Result of Combination Medication of Abemaciclib and Fluconazole. Am J Respir Crit Care Med. 2025;211 (0):A1928$75$YR$$F$Y$$$20250731$$HP$CN$CN
256263451$25626345$1$I$$20250716$20250731$20250731$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-519617$RANBAXY$Hossain S, Perez R,Patten E, Majeed I, Vadde R, Reddy N. Pet Positive Pulmonary Nodule Secondary to ANCA Induced. Am J Respir Crit Care Med. 2025;211(0):1/A80-2$62$YR$$F$Y$$$20250731$$HP$US$US
256264221$25626422$1$I$20250131$20250717$20250731$20250731$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519388$RANBAXY$$48$YR$$M$Y$$$20250731$$HP$AU$AU
256264381$25626438$1$I$$20250717$20250731$20250731$EXP$$AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519334$RANBAXY$$$$$$Y$$$20250731$$HP$AU$AU
256264421$25626442$1$I$$20250717$20250731$20250731$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-519876$RANBAXY$Ranger R, Jamil S, Fuhrer G. Hydralazine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Presenting as Pulmonary-Renal Syndrome. Am J Respir Crit Care Med. 2025;211(0):A1925$56$YR$$M$Y$$$20250731$$HP$US$US
256264671$25626467$1$I$$20250730$20250731$20250731$EXP$$JP-ABBVIE-6395569$ABBVIE$$80$YR$$$Y$$$20250731$$MD$JP$JP
256264791$25626479$1$I$20250506$20250723$20250731$20250731$EXP$$GB-TEVA-VS-3356512$TEVA$$72$YR$$M$Y$82$KG$20250731$$MD$GB$GB
256264811$25626481$1$I$20210101$20250728$20250731$20250731$EXP$$US-ABBVIE-6391994$ABBVIE$$54$YR$$M$Y$$$20250731$$CN$US$US
256264831$25626483$1$I$$20250721$20250731$20250731$EXP$$JP-NOVITIUMPHARMA-2025JPNVP01822$NOVITIUM PHARMA$Kentaro Mori.Drug-induced liver injury related to avacopan therapy.Rheumatology.13-DEC-2024;64:2533-2540$78$YR$E$M$Y$$$20250731$$HP$JP$JP
256265091$25626509$1$I$20250501$20250722$20250731$20250731$EXP$$EU-AUROBINDO-AUR-APL-2025-038907$AUROBINDO$$21$YR$$M$Y$$$20250731$$PH$EU$EU
256265501$25626550$1$I$20250101$20250711$20250731$20250731$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126251$ZYDUS PHARM$$$$$$Y$$$20250731$$CN$US$US
256265561$25626556$1$I$$20250705$20250731$20250731$PER$$US-Norvium Bioscience LLC-080409$Norvium Bioscience$$$$$F$Y$$$20250731$$CN$US$US
256265821$25626582$1$I$$20250721$20250731$20250731$EXP$$US-AUROBINDO-AUR-APL-2025-038761$AUROBINDO$Abadir S, Ipalawatte H, Takher J.. A Rare Case of Valsartan-Induced Angioedema.. Cureus. 2025;17(6):e85623$77$YR$$M$Y$$$20250731$$MD$US$US
256266001$25626600$1$I$20240801$20250721$20250731$20250731$EXP$$EU-AUROBINDO-AUR-APL-2025-038524$AUROBINDO$Giommoni E... A case of long-term response to nal-IRI + 5-FU/LV... Real Life Experience in Onco-Hematology Clinical Cases 2025. 2025$59$YR$$M$Y$$$20250731$$MD$EU$EU
256266991$25626699$1$I$20250705$20250728$20250731$20250731$EXP$$JP-ROCHE-10000337113$ROCHE$$80$YR$E$F$Y$$$20250731$$MD$JP$JP
256267112$25626711$2$F$$20250505$20250731$20250804$EXP$$US-ORGANON-O2507USA001349$ORGANON$$$$A$$Y$$$20250804$$HP$US$US
256267211$25626721$1$I$20250301$20250725$20250731$20250731$EXP$$CA-TAKEDA-2025TUS003308$TAKEDA$$49$YR$$M$Y$$$20250731$$$CA$CA
256267631$25626763$1$I$$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507027529$ELI LILLY AND COMPANY$$30$YR$A$F$Y$$$20250731$$CN$US$US
256268041$25626804$1$I$$20250730$20250730$20250730$DIR$FDA-CDER-CTU-2025-50608$$FDA-CTU$$71$YR$$F$N$103.42$KG$20250730$N$$US$
256268631$25626863$1$I$$20250722$20250731$20250731$EXP$$TR-UCBSA-2025038229$UCB$$$$$$Y$$$20250731$$MD$TR$TR
256268714$25626871$4$F$20250610$20250916$20250731$20250923$EXP$$EU-ABBVIE-6391450$ABBVIE$$68$YR$$F$Y$48$KG$20250923$$MD$EU$EU
256268722$25626872$2$F$$20250816$20250731$20250821$EXP$$US-ABBVIE-6392028$ABBVIE$$$$E$F$Y$$$20250821$$CN$US$US
256269951$25626995$1$I$$20250725$20250731$20250731$EXP$$JP-ANIPHARMA-023892$ANI$$68$YR$E$M$Y$$$20250731$$HP$JP$JP
256270091$25627009$1$I$$20250717$20250731$20250731$EXP$$EU-CPL-005562$CADILA$Elleisy M, Resch I, Yurdakul O, Huebner NA, Shariat S. Acute kidney injury in a cancer patient exposed to relugolix and abiraterone. Urol Int. 2025 Jul 12:1-6. doi: 10.1159/000547373.$72$YR$E$M$Y$$$20250731$$MD$EU$EU
256271221$25627122$1$I$$20250723$20250731$20250731$EXP$$US-MYLANLABS-2025M1064254$MYLAN$$58$YR$$F$Y$$$20250731$$$US$US
256271541$25627154$1$I$20250729$20250730$20250730$20250730$DIR$767572$$FDA-CTU$$29$YR$$M$N$90$KG$20250730$N$CN$US$
256271791$25627179$1$I$$20250725$20250731$20250731$EXP$$US-INCYTE CORPORATION-2025IN008207$INCYTE$$75$YR$$$Y$$$20250731$$$US$US
256271921$25627192$1$I$20250625$20250722$20250731$20250731$EXP$EU-AFSSAPS-AM2025000542$EU-HIKMA PHARMACEUTICALS USA INC.-FR-H14001-25-08873$HIKMA$$35$YR$$M$Y$80$KG$20250731$$MD$EU$EU
256272071$25627207$1$I$20250601$20250729$20250731$20250731$EXP$$CN-009507513-2314765$MERCK SHARP + DOHME LLC$$44$YR$$F$Y$55$KG$20250731$$HP$CN$CN
256272681$25627268$1$I$20250726$20250728$20250731$20250731$PER$$US-Blueprint Medicines Corporation-2025-AER-01663$BLUEPRINT MEDICINES$$20$YR$A$M$Y$$$20250731$$CN$US$US
256273191$25627319$1$I$$20250728$20250731$20250731$EXP$$US-PFIZER INC-PV202500091399$PFIZER$$$$$F$Y$$$20250731$$LW$US$US
256273511$25627351$1$I$$20250724$20250731$20250731$EXP$GB-MHRA-MED-202507241635082410-CVFJH$GB-TEVA-VS-3357456$TEVA$$$$$$Y$$$20250731$$MD$GB$GB
256273851$25627385$1$I$20250403$20250722$20250731$20250731$EXP$$GB-AUROBINDO-AUR-APL-2025-038893$AUROBINDO$$63$YR$$F$Y$70$KG$20250731$$CN$GB$GB
256274285$25627428$5$F$$20250905$20250731$20250905$PER$$US-PFIZER INC-202500149681$PFIZER$$9$YR$$M$Y$$$20250905$$CN$US$US
256274374$25627437$4$F$$20250831$20250731$20250903$30DAY$$US-PFIZER INC-202500153217$PFIZER$$11$YR$$F$Y$$$20250903$$CN$US$US
256275391$25627539$1$I$20250501$20250722$20250731$20250731$EXP$$US-BEH-2025214253$CSL BEHRING$$74$YR$E$$Y$67.12$KG$20250731$$CN$US$US
256275871$25627587$1$I$20250714$20250722$20250731$20250731$EXP$$US-BAYER-2025A097809$BAYER HEALTHCARE PHARMACEUTICALS INC.$$59$YR$A$M$Y$$$20250731$$HP$US$US
256275931$25627593$1$I$$20250603$20250731$20250731$EXP$$CL-ASTRAZENECA-202506GLO027945CL$ALEXION PHARMACEUTICALS$$4$MON$I$F$Y$$$20250731$$$CL$CL
256276191$25627619$1$I$20250717$20250730$20250731$20250731$EXP$$US-JNJFOC-20250737368$JOHNSON AND JOHNSON$$62$YR$A$F$Y$$$20250731$$CN$US$US
256276543$25627654$3$F$$20250923$20250731$20250930$PER$$US-BIOMARINAP-US-2025-167734$BIOMARIN$$22$YR$$M$Y$$$20250930$$MD$US$US
256276801$25627680$1$I$$20250731$20250731$20250731$DIR$767686$$FDA-CTU$$$$$$N$$$20250731$N$$US$
256277191$25627719$1$I$$20250721$20250731$20250731$PER$$US-SMPA-2025SPA009391$SUNOVION$$$$$$Y$$$20250731$$CN$US$US
256277272$25627727$2$F$20250720$20250822$20250731$20250902$PER$$US-SMPA-2025SPA009387$SUNOVION$$74$YR$$M$Y$$$20250901$$$US$US
256278252$25627825$2$F$$20250725$20250731$20250917$EXP$$EU-BAYER-2025A100936$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250917$$HP$EU$EU
256278311$25627831$1$I$$20250725$20250731$20250731$EXP$$EU-EMD Serono-2025038341$EMD SERONO INC$$$$$F$Y$$$20250731$$MD$EU$EU
256278761$25627876$1$I$$20250729$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507028056$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250731$$CN$US$US
256279151$25627915$1$I$20250707$20250707$20250731$20250731$PER$$US-THERATECHNOLOGIES INC.-2025-THE-TES-000176$Unknown Manufacturer$$$$$$Y$$$20250731$$CN$US$US
256279341$25627934$1$I$20250730$20250731$20250731$20250731$DIR$767678$$FDA-CTU$$$$$$N$$$20250731$N$CN$US$
256281151$25628115$1$I$$20250728$20250731$20250731$EXP$$US-ABBVIE-6393272$ABBVIE$$$$A$F$Y$$$20250731$$CN$US$US
256281522$25628152$2$F$$20250728$20250731$20250811$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-07867$ALKEM$Schultze-Florey CR, Thol FR, Aleksandrova K, Stoyanov K, Gutierrez Jauregui R, Arseniev L, Leise J, Klob S, Heidel FH, Tiede A.. Anti-CD19 CAR-T cell therapy for acquired hemophilia A. Leukemia. 2025;39(4):980-982$39$YR$$M$Y$$$20250811$$HP$EU$EU
256282362$25628236$2$F$20250715$20250729$20250731$20250804$EXP$$US-Eisai-EC-2025-193450$EISAI$$75$YR$E$F$Y$85$KG$20250804$$$US$US
256283381$25628338$1$I$$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507028904$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250731$$CN$US$US
256283621$25628362$1$I$$20250729$20250731$20250731$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-106120$BRISTOL-MYERS SQUIBB COMPANY$$74$YR$E$M$Y$$$20250731$$CN$US$US
256284751$25628475$1$I$$20250730$20250731$20250731$EXP$$US-TAKEDA-2024TUS099947$TAKEDA$$$$$M$Y$$$20250731$$$US$US
256284981$25628498$1$I$20250711$20250730$20250731$20250731$EXP$GB-MHRA-MED-202507300339105260-BKQMJ$GB-SANDOZ INC.-SDZ2025GB054494$SANDOZ$$69$YR$$M$Y$24$KG$20250731$$CN$GB$GB
256286101$25628610$1$I$$20250520$20250731$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000473$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$PH$US$US
256286661$25628666$1$I$$20250602$20250731$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000516$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$PH$US$US
256286701$25628670$1$I$$20250523$20250731$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000490$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$PH$US$US
256287051$25628705$1$I$20250101$20250728$20250731$20250731$PER$$US-BAUSCHBL-2025BNL013186$BAUSCH AND LOMB$$$$$M$Y$$$20250731$$CN$US$US
256287531$25628753$1$I$$20250610$20250731$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000558$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$PH$US$US
256287611$25628761$1$I$20250618$20250618$20250731$20250731$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000596$Tarsus Pharmaceuticals$$$$$$Y$$$20250731$$CN$US$US
256287781$25628778$1$I$20250101$20250729$20250731$20250731$PER$$US-BAUSCHBL-2025BNL013308$BAUSCH AND LOMB$$82$YR$$F$Y$$$20250731$$CN$US$US
256288421$25628842$1$I$20250701$20250723$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507023002$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250731$$CN$US$US
256288801$25628880$1$I$20250425$20250425$20250731$20250731$PER$$US-MALLINCKRODT-MNK202501766$MALLINCKRODT$$61$YR$$F$Y$$$20250730$$CN$US$US
256289031$25628903$1$I$$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507010516$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250731$$CN$US$US
256289931$25628993$1$I$$20250724$20250731$20250731$PER$$US-SA-2025SA222167$SANOFI AVENTIS$$$$E$F$Y$86.36$KG$20250731$$HP$US$US
256290361$25629036$1$I$20250101$20250725$20250731$20250731$PER$$US-SA-2025SA220973$SANOFI AVENTIS$$50$YR$A$M$Y$$$20250731$$MD$US$US
256290631$25629063$1$I$$20250725$20250731$20250731$PER$$US-SA-2025SA221214$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250731$$HP$US$US
256290801$25629080$1$I$20250701$20250725$20250731$20250731$PER$$US-SA-2025SA220736$SANOFI AVENTIS$$37$YR$A$M$Y$$$20250731$$MD$US$US
256291961$25629196$1$I$$20250728$20250731$20250731$PER$$US-SA-2025SA221386$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250731$$CN$US$US
256291991$25629199$1$I$$20250728$20250731$20250731$PER$$US-SA-2025SA222296$SANOFI AVENTIS$$79$YR$E$M$Y$$$20250731$$CN$US$US
256292261$25629226$1$I$$20250728$20250731$20250731$PER$$US-SA-2025SA221603$SANOFI AVENTIS$$$$E$F$Y$$$20250731$$MD$US$US
256292801$25629280$1$I$$20250723$20250731$20250731$EXP$$CA-UCBSA-2025045502$UCB$$40$YR$$F$Y$96$KG$20250731$$HP$CA$CA
256293841$25629384$1$I$$20250731$20250731$20250731$DIR$767720$$FDA-CTU$$$$$$N$$$20250731$N$CN$US$
256294301$25629430$1$I$$20250724$20250731$20250731$PER$$US-MALLINCKRODT-MNK202504583$MALLINCKRODT$$39$YR$A$M$Y$$$20250730$$CN$US$US
256294661$25629466$1$I$$20250729$20250731$20250731$EXP$$US-PFIZER INC-PV202500091930$PFIZER$$$$A$F$Y$$$20250731$$LW$US$US
256294832$25629483$2$F$20250101$20250825$20250731$20250903$EXP$$US-VERTEX PHARMACEUTICALS-2025-010450$VERTEX$$$$$M$Y$$$20250903$$CN$US$US
256294941$25629494$1$I$$20250723$20250731$20250731$PER$$US-INCYTE CORPORATION-2025IN008178$INCYTE$$$$$$Y$$$20250730$$MD$US$US
256295211$25629521$1$I$$20250707$20250731$20250731$PER$$US-MALLINCKRODT-MNK202504181$MALLINCKRODT$$$$$M$Y$$$20250730$$CN$US$US
256295681$25629568$1$I$20250601$20250722$20250731$20250731$EXP$EU-AEMPS-1720223$EU-NOVOPROD-1486400$NOVO NORDISK$$62$YR$$F$Y$73$KG$20250731$$CN$EU$EU
256295701$25629570$1$I$$20250722$20250731$20250731$EXP$$US-NOVOPROD-1486761$NOVO NORDISK$$$$$F$Y$$$20250731$$CN$US$US
256296391$25629639$1$I$20250714$20250718$20250731$20250731$EXP$$US-FMCRTG-FMC-2507-001162$FRESENIUS MEDICAL CARE$$58$YR$A$M$Y$$$20250731$$HP$US$US
256296762$25629676$2$F$20250110$20250730$20250731$20250807$EXP$$NVSC2025FR048150$NOVARTIS$$$$E$M$Y$$$20250807$$MD$EU$EU
256297201$25629720$1$I$$20250728$20250731$20250731$PER$$US-ELI_LILLY_AND_COMPANY-US202507028238$ELI LILLY AND COMPANY$$64$YR$A$F$Y$$$20250731$$CN$US$US
256297451$25629745$1$I$20250101$20250722$20250731$20250731$PER$$US-ABBVIE-6386200$ABBVIE$$$$A$M$Y$$$20250731$$PH$US$US
256297471$25629747$1$I$$20250726$20250731$20250731$EXP$$CA-TEVA-VS-3357085$TEVA$$56$YR$$M$Y$$$20250731$$PH$CA$CA
256298514$25629851$4$F$20250701$20250819$20250731$20250825$EXP$$CA-ABBVIE-6394651$ABBVIE$$45$YR$$F$Y$$$20250825$$CN$CA$CA
256298671$25629867$1$I$$20250724$20250731$20250731$EXP$$CN-BEIGENE-BGN-2025-012371$BEIGENE$$61$YR$$$Y$48$KG$20250731$$$CN$CN
256298721$25629872$1$I$$20250728$20250731$20250731$PER$$US-TAKEDA-2025TUS067404$TAKEDA$$$$$F$Y$93$KG$20250731$$$US$US
256299181$25629918$1$I$20250504$20250731$20250731$20250731$EXP$EU-JNJFOC-20250738908$EU-JNJFOC-20250738908$JOHNSON AND JOHNSON$$50$YR$A$M$Y$110$KG$20250801$$MD$EU$EU
256299211$25629921$1$I$20250101$20250726$20250731$20250731$PER$$US-SA-2025SA185233$SANOFI AVENTIS$$17$YR$T$M$Y$$$20250801$$CN$US$US
256300001$25630000$1$I$$20250729$20250801$20250801$PER$$US-ELI_LILLY_AND_COMPANY-US202507028234$ELI LILLY AND COMPANY$$44$YR$A$$Y$$$20250731$$LW$US$US
256300311$25630031$1$I$$20250728$20250801$20250801$EXP$$BR-JNJFOC-20250737179$JOHNSON AND JOHNSON$$57$YR$A$F$Y$$$20250801$$CN$BR$BR
256301791$25630179$1$I$20220701$20250720$20250801$20250801$EXP$$PE-Accord-496897$ACCORD$Rioja P, Valencia G, Morante Z, Cruz R, Vidaurre T, Neciosup S. Primary Mediastinal Germ Cell Tumor With Bone Marrow Infiltration: A Case Report and Literature Review. Cancer Rep (Hoboken). 2025 Jul;8(7):e70282. doi: 10.1002/cnr2.70282.$28$YR$A$M$Y$$$20250801$$HP$PE$PE
256304091$25630409$1$I$$20250723$20250801$20250801$PER$$US-SMPA-2025SPA009546$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
256304981$25630498$1$I$$20250724$20250801$20250801$PER$$US-APOTEX-2025AP010993$APOTEX$Gitto M, Sartori S, Vogel B, Leone PP, Smith K, Bay B, et al.. Potent P2Y12 Inhibitors vs Clopidogrel in Cancer Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology. 2025;41 (7):1241-1250$$$A$$Y$$$20250801$$MD$US$US
256305401$25630540$1$I$$20250729$20250801$20250801$PER$$US-ELI_LILLY_AND_COMPANY-US202507028538$ELI LILLY AND COMPANY$$76$YR$E$M$Y$$$20250801$$PH$US$US
256305481$25630548$1$I$$20250731$20250801$20250801$EXP$$CA-SANDOZ INC.-SDZ2025CA055098$SANDOZ$$47$YR$$F$Y$$$20250801$$HP$CA$CA
256305552$25630555$2$F$20250701$20250805$20250801$20250814$EXP$$US-NOVOPROD-1489207$NOVO NORDISK$$68$YR$$F$Y$$$20250814$$CN$US$US
256306451$25630645$1$I$20250101$20250724$20250801$20250801$EXP$$US-UCBSA-2025030264$UCB$$$$$F$Y$$$20250801$$CN$US$US
256307352$25630735$2$F$20250101$20250819$20250801$20250825$PER$$US-SA-2025SA223369$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250825$$HP$US$US
256307361$25630736$1$I$20250101$20250728$20250801$20250801$PER$$US-SA-2025SA223725$SANOFI AVENTIS$$7$YR$C$M$Y$$$20250801$$HP$US$US
256307561$25630756$1$I$$20250723$20250801$20250801$PER$$US-SMPA-2025SPA009499$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
256307721$25630772$1$I$$20250728$20250801$20250801$PER$$US-ABBVIE-6395072$ABBVIE$$$$$$Y$$$20250801$$MD$US$US
256308432$25630843$2$F$20240101$20250725$20250801$20250805$EXP$$US-UCBSA-2025022124$UCB$$$$$M$Y$90.249$KG$20250805$$HP$US$US
256308901$25630890$1$I$20250705$20250730$20250801$20250801$PER$$US-AMGEN-USASP2025152159$AMGEN$$81$YR$E$F$Y$$$20250801$$CN$US$US
256308931$25630893$1$I$$20250729$20250801$20250801$PER$$US-ELI_LILLY_AND_COMPANY-US202507029293$ELI LILLY AND COMPANY$$64$YR$A$F$Y$$$20250801$$CN$US$US
256308951$25630895$1$I$$20250721$20250801$20250801$EXP$$US-LUPIN PHARMACEUTICALS INC.-2025-06718$LUPIN$Akoto A, Pence R, Mudrakola V. Heart failure and suicide: A complex polysubstance overdose. American Journal of Respiratory and Critical Care Medicine. 2025;211;A3836:1$39$YR$$F$Y$$$20250801$$$US$US
256309061$25630906$1$I$20231108$20250723$20250801$20250801$PER$$US-NEBO-701950$PHARMACOSMOS A/S$$53$YR$$M$Y$$$20250801$$HP$US$US
256310011$25631001$1$I$20250408$20250410$20250801$20250801$30DAY$$EU-PHARMAESSENTIA CORPORATION-FR-2025-PEC-007156$PHARMAESSENTIA$$$$$$Y$$$20250801$$CN$EU$EU
256310351$25631035$1$I$$20250722$20250801$20250801$EXP$$GB-AUROBINDO-AUR-APL-2025-038633$AUROBINDO$$71$YR$$F$Y$$$20250801$$PH$GB$GB
256310621$25631062$1$I$$20250723$20250801$20250801$EXP$$US-AVET LIFESCIENCES LTD-2025-AVET-000241$EMCURE PHARMACEUTICALS LTD$Kumar A, Jain R, Kamath MY.. A Case of Cutaneous Kaposi Sarcoma in a Patient Post?Heart Transplantation. JACC Case Rep. 2025;30(19):104162$69$YR$$M$Y$$$20250801$$MD$US$US
256311251$25631125$1$I$$20250724$20250801$20250801$PER$$US-APOTEX-2025AP010832$APOTEX$Gomez-Villegas SI, Andrews E, Mostaghimi A, Sun Y-P, Loscalzo J. Caving In to Pressure. The New England Journal of Medicine. 2025;393:73-79$64$YR$$M$Y$$$20250801$$MD$US$US
256312001$25631200$1$I$$20250730$20250801$20250801$PER$$US-ABBVIE-6397214$ABBVIE$$$$$F$Y$$$20250801$$CN$US$US
256314581$25631458$1$I$$20250723$20250801$20250801$EXP$$US-Rigel Pharmaceuticals, Inc.-20250700206$RIGEL PHARMACEUTICALS$$$$$F$Y$$$20250801$$CN$US$US
256314701$25631470$1$I$20250528$20250730$20250801$20250801$EXP$GB-MHRA-MED-202507301112579500-LGTFZ$GB-ASTRAZENECA-202507GLO026665GB$ALEXION PHARMACEUTICALS$$76$YR$E$M$Y$67$KG$20250801$$$GB$GB
256317621$25631762$1$I$$20250723$20250801$20250801$EXP$$JP-009507513-2313107$MERCK SHARP + DOHME LLC$$63$YR$$$Y$$$20250801$$MD$JP$JP
256317802$25631780$2$F$$20250729$20250801$20250805$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06670$LUPIN$$$$$$Y$$$20250805$$$US$US
256317972$25631797$2$F$20250228$20250718$20250801$20250814$EXP$$GB-AZURITY PHARMACEUTICALS, INC.-AZR202507-002336$AZURITY PHARMACEUTICALS$$51$YR$$F$Y$62$KG$20250814$$CN$GB$GB
256318721$25631872$1$I$20240101$20250723$20250801$20250801$EXP$$US-CATALYST PHARMACEUTICALS, INC-US-CATA-25-01086$CATALYST PHARMA$$$$$F$Y$83.9$KG$20250801$$CN$US$US
256319171$25631917$1$I$20210101$20250729$20250801$20250801$EXP$$EU-DSJP-DS-2025-156279-DE$DAIICHI$$86$YR$$F$Y$57$KG$20250801$$CN$EU$EU
256320404$25632040$4$F$20250101$20250828$20250801$20250905$EXP$$US-009507513-2312309$MERCK SHARP + DOHME LLC$$$$$F$Y$26.8$KG$20250905$$PH$US$US
256320652$25632065$2$F$$20250724$20250801$20250815$EXP$$JP-009507513-2314787$MERCK SHARP + DOHME LLC$$73$YR$$M$Y$$$20250815$$MD$JP$JP
256320891$25632089$1$I$20250725$20250726$20250801$20250801$EXP$$TH-ASTRAZENECA-202507ASI022534TH$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250801$$$TH$TH
256321411$25632141$1$I$$20250730$20250731$20250731$DIR$FDA-CDER-CTU-2025-50953$$FDA-CTU$$$$$M$N$$$20250730$N$CN$US$
256321837$25632183$7$F$20250701$20250922$20250801$20250923$30DAY$$US-PFIZER INC-202500152452$PFIZER$$15$YR$$M$Y$$$20250923$$CN$US$US
256321893$25632189$3$F$$20250807$20250801$20250811$30DAY$$US-JNJFOC-20250731640$JOHNSON AND JOHNSON$$$$$$Y$$$20250811$$HP$US$US
256323231$25632323$1$I$$20250730$20250801$20250801$EXP$$NVSC2025US121783$NOVARTIS$$$$$M$Y$$$20250801$$MD$US$US
256323341$25632334$1$I$20250721$20250723$20250801$20250801$EXP$$CN-KENVUE-20250710143$Kenvue$$$$$$Y$$$20250801$$HP$CN$CN
256323441$25632344$1$I$20250622$20250710$20250801$20250801$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000619$Tarsus Pharmaceuticals$$$$$$Y$$$20250801$$CN$US$US
256323821$25632382$1$I$20250601$20250626$20250801$20250801$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000637$Tarsus Pharmaceuticals$$$$$$Y$$$20250801$$MD$US$US
256324001$25632400$1$I$$20250628$20250801$20250801$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000640$Tarsus Pharmaceuticals$$$$$$Y$$$20250801$$PH$US$US
256324111$25632411$1$I$$20250724$20250801$20250801$EXP$$US-MYLANLABS-2025M1064471$MYLAN$Ray L, Kaster MJ. Recurrent Chylothorax Refractory to Conservative Management. Am-J-Respir-Crit-Care-Med 2025; 211 A2081 (plus Poster).$76$YR$$M$Y$$$20250801$$$US$US
256324571$25632457$1$I$20250227$20250724$20250801$20250801$EXP$$US-ASTRAZENECA-202507USA025140US$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$$$20250801$$$US$
256324721$25632472$1$I$$20250725$20250801$20250801$EXP$$EU-MYLANLABS-2025M1064399$MYLAN$$$$E$M$Y$$$20250731$$MD$EU$EU
256327382$25632738$2$F$20250708$20250729$20250801$20250806$EXP$$US-ALVOGEN-2025098411$ALVOGEN$$$$$F$Y$$$20250806$$CN$US$US
256327751$25632775$1$I$20250101$20250130$20250801$20250801$PER$$US-IGSA-BIG0032918$GRIFOLS$$20$YR$$F$Y$$$20250801$$HP$US$US
256327881$25632788$1$I$20250208$20250210$20250801$20250801$PER$$US-IGSA-BIG0033089$GRIFOLS$$59$YR$$F$Y$79.365$KG$20250801$$CN$US$US
256327961$25632796$1$I$$20250723$20250801$20250801$PER$$US-TAKEDA-2025TUS066758$TAKEDA$$$$$F$Y$96$KG$20250801$$$US$US
256329781$25632978$1$I$$20250728$20250801$20250801$EXP$$CA-FreseniusKabi-FK202510636$FRESENIUS KABI$$35$YR$A$F$Y$$$20250801$$HP$CA$CA
256330051$25633005$1$I$$20250730$20250801$20250801$PER$$US-PFIZER INC-PV202500092486$PFIZER$$69$YR$$F$Y$$$20250801$$MD$US$US
256330291$25633029$1$I$$20250728$20250801$20250801$EXP$$KW-ADIENNEP-2025AD000561$ADIENNE PHARMA + BIOTECH$Alsharidah S, Elhussein A, Al-Herz W. Haploidentical stem cell transplantation in DOCK8 deficiency: a case report of successful outcomes. Blood Coagul Fibrinolysis. 2025;36(5):199-203. DOI: 10.1097/MBC.0000000000001351$$$C$F$Y$$$20250728$$MD$KW$
256331671$25633167$1$I$20250309$20250718$20250801$20250801$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-520261$RANBAXY$$68$YR$$F$Y$63$KG$20250801$$HP$EU$EU
256331811$25633181$1$I$$20250718$20250801$20250801$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519821$RANBAXY$Panse M, Sapone J, Kaur P. Unlikely Diagnosis of Pulmonary Embolism in Setting of Coumadin Failure. Am J Respir Crit Care Med. 2025;211:A4383$86$YR$$M$Y$$$20250801$$HP$US$US
256331822$25633182$2$F$$20250722$20250801$20250806$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519815$RANBAXY$Cohen ES, Hooker AB, Wiendels NJ, Abdolrahimi Raeni R, Verburg N.. Seizures in pregnancy: not always eclamptic seizures. Ned Tijdschr Geneeskd. 2023;167:1-7/D7467$38$YR$$F$Y$$$20250806$$HP$EU$EU
256331881$25633188$1$I$$20250718$20250801$20250801$EXP$$PR-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-520310$RANBAXY$Diaz Mayor DJ. The Danger Within: How Hormone Supplementation Can Lead to Certain Demise.. Am-J-Respir-Crit-Care-Med. 2025;211 (0):no pagination$69$YR$$M$Y$$$20250801$$HP$PR$PR
256331891$25633189$1$I$$20250718$20250801$20250801$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-519227$RANBAXY$$$$A$F$Y$$$20250801$$CN$US$US
256333182$25633318$2$F$20250704$20250829$20250801$20250905$PER$$US-UNITED THERAPEUTICS-UNT-2025-026090$UNITED THERAPEUTICS$$60$YR$$F$Y$$$20250905$$$US$US
256333511$25633351$1$I$$20250718$20250801$20250801$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-520173$RANBAXY$Arnous MG, Singh N, Reddy A, MacBruce D.. A Rare Finding of Secondary Spontanous Pneumothorax (SSP) During Tyrosine Kinase Inhibitor Treatment of a Patient With Metastatic Synovial Sarcoma. Am J Respir Crit Care Med. 2025;211 (0):A2750$51$YR$$M$Y$$$20250801$$HP$US$US
256334293$25633429$3$F$20250716$20250804$20250801$20250807$PER$$US-PFIZER INC-202500155026$PFIZER$$$$$F$Y$$$20250807$$CN$US$US
256334361$25633436$1$I$20250706$20250731$20250731$20250731$DIR$767812$$FDA-CTU$$34$YR$$F$N$$$20250731$Y$HP$US$
256334371$25633437$1$I$20250709$20250731$20250731$20250731$DIR$767814$$FDA-CTU$$37$YR$$F$N$$$20250731$Y$HP$US$
256334602$25633460$2$F$$20250831$20250801$20250901$PER$$US-PFIZER INC-202500153052$PFIZER$$13$YR$$M$Y$$$20250901$$CN$US$US
256334831$25633483$1$I$$20250726$20250801$20250801$PER$$US-SMPA-2025SPA009763$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
256334921$25633492$1$I$$20250725$20250801$20250801$PER$$US-SMPA-2025SPA009695$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
256335401$25633540$1$I$20250101$20250730$20250801$20250801$EXP$$US-JNJFOC-20250732080$JOHNSON AND JOHNSON$$5$DEC$A$F$Y$$$20250801$$CN$US$US
256335821$25633582$1$I$20230101$20250721$20250801$20250801$EXP$$IN-PFIZER INC-202500152861$PFIZER$Kakkar, D.. A tertiary care centre experience with Elranatamab: A report of three cases. Leukemia Research Reports. 2024;21:1-4$5$DEC$$M$Y$$$20250801$$MD$IN$IN
256335941$25633594$1$I$20250225$20250729$20250801$20250801$EXP$EU-AFSSAPS-PC2025000593$EU-MYLANLABS-2025M1064443$MYLAN$$86$YR$$F$Y$67$KG$20250801$$MD$EU$EU
256336121$25633612$1$I$$20250801$20250801$20250801$DIR$767899$$FDA-CTU$$$$$$N$$$20250801$N$CN$US$
256336541$25633654$1$I$$20250801$20250801$20250801$DIR$767844$$FDA-CTU$$39$YR$$M$N$108$KG$20250801$N$CN$US$
256336581$25633658$1$I$$20250730$20250801$20250801$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107065$BRISTOL-MYERS SQUIBB COMPANY$$61$YR$A$F$Y$$$20250801$$CN$US$US
256336861$25633686$1$I$$20250801$20250801$20250801$DIR$767883$$FDA-CTU$$$$$$N$$$20250801$N$$US$
256337052$25633705$2$F$20250717$20250830$20250801$20250909$30DAY$$US-MYLANLABS-2025M1062387$MYLAN$$43$YR$$F$Y$$$20250909$$$US$US
256337191$25633719$1$I$$20250725$20250801$20250801$PER$$US-GSK-US2025096227$GLAXOSMITHKLINE$$$$$F$Y$$$20250801$$$US$US
256337952$25633795$2$F$20250726$20250826$20250801$20250828$EXP$$JP-PFIZER INC-PV202500092162$PFIZER$$80$YR$$$Y$$$20250828$$MD$JP$JP
256338191$25633819$1$I$20250726$20250726$20250801$20250801$PER$$US-SA-2025SA222638$SANOFI AVENTIS$$40$YR$A$M$Y$$$20250801$$MD$US$US
256338701$25633870$1$I$$20250730$20250801$20250801$PER$$US-SA-2025SA222905$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250801$$CN$US$US
256340821$25634082$1$I$20240116$20250721$20250801$20250801$EXP$EU-MINISAL02-1050046$EU-ELI_LILLY_AND_COMPANY-IT202507020351$ELI LILLY AND COMPANY$$79$YR$E$F$Y$$$20250801$$CN$EU$EU
256341031$25634103$1$I$20250501$20250725$20250801$20250801$EXP$$BR-JNJFOC-20250735534$JOHNSON AND JOHNSON$$69$YR$E$M$Y$85$KG$20250801$$CN$BR$BR
256341051$25634105$1$I$$20250729$20250801$20250801$EXP$$US-SMPA-2025SPA009961$SUNOVION$$$$$$Y$$$20250801$$CN$US$US
256342041$25634204$1$I$$20250728$20250801$20250801$PER$$US-ABBVIE-6394437$ABBVIE$$$$$F$Y$$$20250801$$MD$US$US
256342401$25634240$1$I$$20250730$20250801$20250801$PER$$US-ELI_LILLY_AND_COMPANY-US202507029710$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250801$$CN$US$US
256343021$25634302$1$I$$20250730$20250801$20250801$PER$$US-ABBVIE-6396000$ABBVIE$$26$YR$$$Y$$$20250801$$CN$US$US
256343341$25634334$1$I$$20250729$20250801$20250801$PER$$US-MALLINCKRODT-MNK202504681$MALLINCKRODT$$$$A$F$Y$$$20250731$$CN$US$US
256343591$25634359$1$I$$20250703$20250801$20250801$PER$$US-GSK-US2025AMR085560$GLAXOSMITHKLINE$$$$$F$Y$$$20250801$$$US$US
256343632$25634363$2$F$$20250812$20250801$20250821$EXP$$US-ARDELYX-2025ARDX005657$ARDELYX$$74$YR$$F$Y$$$20250821$$CN$US$US
256343868$25634386$8$F$20250301$20250813$20250801$20250819$EXP$$US-Ipsen Biopharmaceuticals, Inc.-2025-18720$IPSEN BIOPHARMACEUTICALS, INC.$$33$YR$A$F$Y$$$20250819$$$US$US
256345441$25634544$1$I$$20250722$20250801$20250801$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000722$Tarsus Pharmaceuticals$$$$$$Y$$$20250801$$CN$US$US
256345552$25634555$2$F$$20250710$20250801$20250814$PER$$US-TARSUS PHARMACEUTICALS-TSP-US-2025-000677$Tarsus Pharmaceuticals$$$$$$Y$$$20250814$$PH$US$US
256346501$25634650$1$I$$20250725$20250801$20250801$EXP$$JP-MALLINCKRODT-MNK202504604$MALLINCKRODT$Motoji Y, Kitamura T, Mishima T, Fukuzumi M, Kondo R, Tamura Y, Ishikawa S, Sugimoto A, Aiso K, Miyaji K.Inhaled nitric oxide therapy is effective in improving right ventricular function in patients receiving ECPELLA support.Gen Thorac Cardiovasc Surg.20-JUL-2025$73$YR$E$F$Y$$$20250801$$HP$JP$JP
256346701$25634670$1$I$$20250722$20250801$20250801$EXP$$GB-ELI_LILLY_AND_COMPANY-GB202507021302$ELI LILLY AND COMPANY$$76$YR$E$F$Y$$$20250801$$CN$GB$GB
256348301$25634830$1$I$20250519$20250730$20250801$20250801$EXP$EU-AFSSAPS-RS2025000715$EU-MYLANLABS-2025M1064792$MYLAN$$63$YR$$M$Y$87$KG$20250801$$MD$EU$EU
256349731$25634973$1$I$$20250730$20250801$20250801$EXP$$US-PFIZER INC-PV202500092349$PFIZER$$$$A$F$Y$$$20250801$$LW$US$US
256350191$25635019$1$I$$20250730$20250801$20250801$PER$$US-BIOMARINAP-US-2025-167801$BIOMARIN$$5$YR$$$Y$$$20250801$$$US$US
256350451$25635045$1$I$$20250729$20250801$20250801$EXP$$US-ELI_LILLY_AND_COMPANY-US202507028086$ELI LILLY AND COMPANY$$$$$F$Y$$$20250801$$CN$US$US
256350851$25635085$1$I$$20250707$20250802$20250802$PER$$US-ASTRAZENECA-202507USA028155US$ALEXION PHARMACEUTICALS$$73$YR$E$$Y$$$20250802$$$US$US
256351131$25635113$1$I$$20250723$20250802$20250802$PER$$US-GSK-US2025AMR098630$GLAXOSMITHKLINE$$$$$$Y$$$20250802$$$US$US
256353001$25635300$1$I$20250731$20250731$20250802$20250802$PER$$US-ASTRAZENECA-202507USA027411US$ALEXION PHARMACEUTICALS$$38$YR$A$F$Y$$$20250802$$$US$US
256353701$25635370$1$I$$20250722$20250802$20250802$EXP$CA-MHPD-001133507$CA-Accord-496520$ACCORD$$78$YR$E$F$Y$89$KG$20250802$$MD$CA$CA
256354491$25635449$1$I$20250101$20250716$20250802$20250802$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126551$ZYDUS PHARM$$$$$$Y$$$20250802$$CN$US$US
256354551$25635455$1$I$$20250716$20250802$20250802$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126474$ZYDUS PHARM$$$$$$Y$$$20250802$$CN$US$US
256354601$25635460$1$I$20250714$20250714$20250802$20250802$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126773$ZYDUS PHARM$$$$$$Y$$$20250802$$CN$US$US
256355091$25635509$1$I$$20250724$20250802$20250802$EXP$$US-APOTEX-2025AP011090$APOTEX$Gitto M, Sartori S, Vogel B, Leone PP, Smith K, Bay B, et al.. Potent P2Y12 Inhibitors vs Clopidogrel in Cancer Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology. 2025;41 (7):1241-1250$$$A$$Y$$$20250802$$MD$US$US
256355561$25635556$1$I$20240601$20250721$20250802$20250802$EXP$EU-AFSSAPS-SE2025000500$EU-Accord-492022$ACCORD$$52$YR$A$F$Y$$$20250802$$PH$EU$EU
256355641$25635564$1$I$20250728$20250729$20250802$20250802$PER$$US-ELI_LILLY_AND_COMPANY-US202507028533$ELI LILLY AND COMPANY$$28$YR$A$F$Y$$$20250802$$CN$US$US
256355712$25635571$2$F$20250601$20250826$20250802$20250904$EXP$$US-UNITED THERAPEUTICS-UNT-2025-026446$UNITED THERAPEUTICS$$74$YR$$F$Y$$$20250904$$$US$US
256355731$25635573$1$I$20250101$20250729$20250802$20250802$PER$$US-SA-2025SA224496$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250802$$HP$US$US
256355791$25635579$1$I$$20250722$20250802$20250802$EXP$$US-KOANAAP-SML-US-2025-00348$SHILPA MEDICARE$Chaudhary HA, Cannon TL, Winer A. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature. Drugs-RD. 2024;24(3): 395-403. doi:10.1007/s40268-024-00475-5.$$$$M$Y$$$20250802$$MD$US$US
256355831$25635583$1$I$$20250728$20250802$20250802$PER$$US-ELI_LILLY_AND_COMPANY-US202507026101$ELI LILLY AND COMPANY$$76$YR$E$F$Y$$$20250802$$CN$US$US
256356401$25635640$1$I$$20250725$20250802$20250802$EXP$$TR-ANIPHARMA-023878$ANI$$15$YR$T$$Y$$$20250802$$HP$TR$TR
256356581$25635658$1$I$$20250703$20250802$20250802$EXP$$US-GSK-US2025AMR084505$GLAXOSMITHKLINE$$52$YR$$F$Y$$$20250802$$$US$US
256358001$25635800$1$I$$20250731$20250802$20250802$PER$$US-ELI_LILLY_AND_COMPANY-US202508000180$ELI LILLY AND COMPANY$$37$YR$A$F$Y$$$20250802$$CN$US$US
256358091$25635809$1$I$20250731$20250731$20250802$20250802$PER$$US-ELI_LILLY_AND_COMPANY-US202508000579$ELI LILLY AND COMPANY$$$$$$Y$$$20250802$$CN$US$US
256358161$25635816$1$I$$20250731$20250802$20250802$PER$$US-ELI_LILLY_AND_COMPANY-US202508000336$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250802$$CN$US$US
256358561$25635856$1$I$$20250724$20250802$20250802$EXP$$GB-AUROBINDO-AUR-APL-2025-039601$AUROBINDO$$$$$M$Y$$$20250803$$HP$GB$GB
256359031$25635903$1$I$20250101$20250723$20250802$20250802$EXP$$EU-AUROBINDO-AUR-APL-2025-039076$AUROBINDO$$62$YR$$F$Y$$$20250803$$CN$EU$EU
256359041$25635904$1$I$20250402$20250723$20250802$20250802$EXP$$EU-AUROBINDO-AUR-APL-2025-039073$AUROBINDO$$70$YR$$M$Y$$$20250803$$MD$EU$EU
256359131$25635913$1$I$20250527$20250723$20250802$20250802$EXP$$EU-AUROBINDO-AUR-APL-2025-039023$AUROBINDO$$23$YR$$F$Y$77$KG$20250803$$PH$EU$EU
256359471$25635947$1$I$20250601$20250729$20250803$20250803$PER$$US-SA-2025SA224212$SANOFI AVENTIS$$29$YR$A$M$Y$$$20250803$$MD$US$US
256359801$25635980$1$I$20250501$20250728$20250803$20250803$PER$$US-SA-2025SA223782$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250803$$HP$US$US
256360511$25636051$1$I$$20250730$20250803$20250803$PER$$US-ELI_LILLY_AND_COMPANY-US202508000215$ELI LILLY AND COMPANY$$$$$$Y$$$20250803$$HP$US$US
256361421$25636142$1$I$$20250721$20250803$20250803$EXP$$GB-CIPLA (EU) LIMITED-2025GB09364$CIPLA$$$$$$Y$$$20250803$$MD$GB$GB
256361501$25636150$1$I$$20250729$20250803$20250803$PER$$US-SA-2025SA222974$SANOFI AVENTIS$$$$$$Y$$$20250803$$CN$US$US
256362221$25636222$1$I$$20250723$20250803$20250803$PER$$US-RDY-USA/2025/07/011450$DR REDDYS$Nesseler JP, Silos KD, Peony O, Singh A, Belen P, Kamrava MR, et al. Dynamic cardiac changes in low cardiovascular risk patients with triple negative breast cancer treated with chemo-immunotherapy. Cardio-Oncology. 2025;62(11): Doi: 10.1186/s40959-025-00361-2.$69$YR$E$F$Y$$$20250803$$HP$US$US
256362431$25636243$1$I$$20250723$20250803$20250803$PER$$US-RDY-USA/2025/07/011547$DR REDDYS$Shrestha B, Bohra N, Sherpa c, Gabreily I. Acute Hypomagnesemic Hypocalcemia. J Bone Miner Res. 2022;37: 327.$66$YR$E$M$Y$$$20250803$$HP$US$US
256362562$25636256$2$F$$20250818$20250803$20250829$EXP$$US-TEVA-VS-3358019$TEVA$Ali AA, Saavedra P, White G, Bali SD. Polymicrobial Pneumonia in a Patient With Human Immunodeficiency Virus. Am-J-Respir-Crit-Care-Med 2025; 211 A1595.; Ali AA, Saavedra P, White G, Bali SD. Polymicrobial Pneumonia in a Patient With Human Immunodeficiency Virus. Am-J-Respir-Crit-Care-Med 2025; 211 A1595.$35$YR$$F$Y$$$20250829$$HP$US$US
256363202$25636320$2$F$$20250828$20250803$20250901$EXP$$JP-JNJFOC-20250800079$JOHNSON AND JOHNSON$KATAGAI K. : Characteristics of each antipsychotic and reasons for selection; About LAI; LURASIDONE HYDROCHLORIDE/BLONANSERIN tape/PALIPERIDONE PALMITATE; A case related to PALIPERIDONE PALMITATE TRI.$32$YR$A$F$Y$$$20250902$$MD$JP$JP
256363551$25636355$1$I$$20250730$20250803$20250803$EXP$$CA-ABBVIE-6339000$ABBVIE$$$$A$M$Y$$$20250803$$CN$CA$CA
256364191$25636419$1$I$$20250731$20250803$20250803$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107557$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$M$Y$$$20250804$$CN$US$US
256364712$25636471$2$F$$20250729$20250803$20250811$PER$$NVSC2025US118069$NOVARTIS$$$$$M$Y$$$20250811$$CN$US$US
256365141$25636514$1$I$20250101$20250729$20250804$20250804$PER$$US-SA-2025SA223507$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250804$$HP$US$US
256365882$25636588$2$F$20240101$20250824$20250804$20250829$EXP$$US-ABBVIE-6393860$ABBVIE$$54$YR$$F$Y$57$KG$20250829$$CN$US$US
256366071$25636607$1$I$$20250725$20250804$20250804$PER$$US-ABBVIE-6391055$ABBVIE$$$$$F$Y$$$20250804$$CN$US$US
256366081$25636608$1$I$$20250729$20250804$20250804$PER$$US-ROCHE-10000351493$ROCHE$$$$$$Y$$$20250804$$CN$US$US
256366541$25636654$1$I$$20250723$20250804$20250804$EXP$GB-MHRA-MED-202507232203047140-TFYZL$GB-Accord-496958$ACCORD$$55$YR$A$F$Y$72$KG$20250804$$CN$GB$GB
256366592$25636659$2$F$20241001$20250808$20250804$20250812$EXP$$EU-ASTRAZENECA-202507EEA025704FR$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$$$20250812$$MD$EU$EU
256367721$25636772$1$I$$20250723$20250804$20250804$EXP$GB-MHRA-EMIS-2939-ba526fcc-f271-4571-89c8-3c2fe82667df$GB-Accord-496989$ACCORD$$87$YR$E$M$Y$78$KG$20250804$$PH$GB$GB
256368001$25636800$1$I$$20250728$20250804$20250804$PER$$US-SA-2025SA223196$SANOFI AVENTIS$$$$A$M$Y$70.45$KG$20250804$$HP$US$US
256368061$25636806$1$I$$20250728$20250804$20250804$PER$$US-SA-2025SA223212$SANOFI AVENTIS$$$$A$F$Y$$$20250804$$HP$US$US
256368441$25636844$1$I$20240801$20240820$20250804$20250804$EXP$$US-CIPLA LTD.-2024US08685$CIPLA$$$$$$Y$$$20250804$$CN$US$US
256368511$25636851$1$I$$20250730$20250804$20250804$PER$$US-ROCHE-10000352716$ROCHE$$$$A$F$Y$86.64$KG$20250804$$CN$US$US
256368521$25636852$1$I$$20250730$20250804$20250804$PER$$US-ROCHE-10000352522$ROCHE$$$$E$M$Y$$$20250804$$CN$US$US
256369012$25636901$2$F$$20250722$20250804$20250808$PER$$JP-ASTRAZENECA-202507JPN023925JP$ALEXION PHARMACEUTICALS$$67$YR$E$F$Y$$$20250808$$MD$JP$JP
256369241$25636924$1$I$$20250731$20250804$20250804$PER$$US-ELI_LILLY_AND_COMPANY-US202508000288$ELI LILLY AND COMPANY$$70$YR$E$M$Y$$$20250804$$CN$US$US
256369452$25636945$2$F$20240101$20250825$20250804$20250828$EXP$$EU-ASTRAZENECA-202507GLO025875CZ$ALEXION PHARMACEUTICALS$Simunkova M. Labyrintem komorbidit: cesta pacienta - od praktickych lekaru ke specialistum a zpet. Medical Tribune. 2025;21(10):B6-B8$70$YR$E$F$Y$85$KG$20250828$$MD$EU$EU
256369561$25636956$1$I$20180601$20250304$20250804$20250804$PER$$US-Accord-469637$ACCORD$$55$YR$A$F$Y$$$20250804$$HP$US$US
256369631$25636963$1$I$$20250729$20250804$20250804$EXP$$US-UPSHER-SMITH LABORATORIES, LLC-20250701051$UPSHER SMITH LABORATORIES$$$$$$Y$$$20250804$$$US$US
256369993$25636999$3$F$20250729$20250902$20250804$20250908$PER$$US-JNJFOC-20250738193$JOHNSON AND JOHNSON$$82$YR$E$M$Y$$$20250908$$CN$US$US
256370181$25637018$1$I$20250711$20250728$20250804$20250804$EXP$EU-AFSSAPS-PA2025000687$EU-ASTELLAS-2025-AER-041374$ASTELLAS$$21$YR$A$F$Y$61.8$KG$20250804$$PH$EU$EU
256370891$25637089$1$I$$20250731$20250804$20250804$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107764$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$M$Y$$$20250804$$HP$US$US
256371031$25637103$1$I$$20250730$20250804$20250804$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008829$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256371771$25637177$1$I$20250510$20250724$20250804$20250804$EXP$$EU-AUROBINDO-AUR-APL-2025-039209$AUROBINDO$$76$YR$$M$Y$$$20250804$$MD$EU$EU
256372251$25637225$1$I$20250718$20250725$20250804$20250804$PER$$US-ABBVIE-6390225$ABBVIE$$63$YR$$M$Y$$$20250804$$CN$US$US
256373931$25637393$1$I$$20250722$20250804$20250804$EXP$$TR-Guardian Drug Company-2181769$GUARDIAN DRUG COMPANY$Full text$16$YR$$$Y$$$20250804$$$TR$TR
256374032$25637403$2$F$$20250828$20250804$20250908$EXP$$JP-INSMED, INC.-2025-03011-JP$INSMED$$61$YR$$M$Y$$$20250908$$MD$JP$JP
256375861$25637586$1$I$20240501$20250801$20250804$20250804$EXP$EU-MINISAL02-1051495$EU-UCBSA-2025047996$UCB$$24$YR$$M$Y$52$KG$20250804$$MD$EU$EU
256375911$25637591$1$I$$20240819$20250804$20250804$PER$$US-STRIDES ARCOLAB LIMITED-2024SP010548$STRIDES$Maresch KJ.. Arytenoid Dislocation and Vocal Cord Immobility After Emergent Fiberoptic Intubation: A Case Report.. AANA-J. 2020;88 (6):459-463$53$YR$$M$Y$$$20250804$$HP$US$US
256377031$25637703$1$I$$20250730$20250804$20250804$PER$$US-ELI_LILLY_AND_COMPANY-US202507030446$ELI LILLY AND COMPANY$$61$YR$A$M$Y$$$20250804$$CN$US$US
256377281$25637728$1$I$$20250728$20250804$20250804$PER$$US-ABBVIE-6393615$ABBVIE$$$$$$Y$$$20250804$$HP$US$US
256377391$25637739$1$I$$20250723$20250804$20250804$PER$$US-CHATTEMPRD-2025OHG023248$CHATTEM$$$$A$$Y$$$20250804$$CN$US$US
256378991$25637899$1$I$$20250731$20250804$20250804$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107804$BRISTOL-MYERS SQUIBB COMPANY$$92$YR$E$F$Y$$$20250804$$CN$US$US
256379251$25637925$1$I$$20250731$20250804$20250804$PER$$US-TAKEDA-2025TUS068689$TAKEDA$$$$$F$Y$62.494$KG$20250804$$$US$US
256380501$25638050$1$I$$20250728$20250804$20250804$PER$$US-ABBVIE-6392421$ABBVIE$$$$$$Y$$$20250804$$MD$US$US
256381111$25638111$1$I$$20250731$20250804$20250804$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107357$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$$$20250804$$CN$US$US
256381171$25638117$1$I$$20250721$20250804$20250804$EXP$GB-MHRA-MED-202507211637118300-YJTQR$GB-GLENMARK PHARMACEUTICALS-2025GMK102462$GLENMARK$$87$YR$$F$Y$$$20250804$$PH$GB$GB
256381322$25638132$2$F$20250701$20250804$20250804$20250808$PER$$US-VIIV HEALTHCARE-US2025098241$VIIV$$45$YR$$M$Y$$$20250808$$PH$US$US
256382051$25638205$1$I$$20250708$20250804$20250804$PER$$US-GSK-US2025AMR088741$GLAXOSMITHKLINE$$$$$F$Y$$$20250804$$$US$US
256382531$25638253$1$I$$20250724$20250804$20250804$EXP$$EU-AUROBINDO-AUR-APL-2025-036516$AUROBINDO$Molteni C, Gemignani N, Bottanelli M, Bradanini L, Conti F, Morena V etal. Un caso di osteomielite peritrocanterica da Pseudomonas aeruginosa DTR. (A case of peritrochanteric osteomyelitis caused by Pseudomonas aeruginosa DTR). Journal of HIV and Ageing.. 2025;10:35-36$65$YR$$M$Y$$$20250804$$MD$EU$EU
256383121$25638312$1$I$$20250730$20250804$20250804$EXP$$EU-MYLANLABS-2025M1064853$MYLAN$Teixeira RL, da Silva Vieira R, Saavedra MJ, Polido-Pereira J, Moura RA, Alcobia I, Fonseca JE, Rom?o VC. Structured and prompt treatment of early arthritis in clinical practice leverages window of opportunity and leads to excellent clinical outcomes: an innovative retrospective cohort study. Clin Rheumatol. 2024 Oct 29. Epub ahead of print. PMID: 39472411.$88$YR$$M$Y$$$20250802$$MD$EU$EU
256383301$25638330$1$I$$20250714$20250804$20250804$PER$$US-GSK-US2025AMR090747$GLAXOSMITHKLINE$$$$$F$Y$$$20250804$$$US$US
256383411$25638341$1$I$$20250801$20250804$20250804$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-108052$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250804$$MD$US$US
256383421$25638342$1$I$20250711$20250730$20250804$20250804$EXP$$CN-PFIZER INC-PV202500092256$PFIZER$$26$YR$$F$Y$70$KG$20250804$$HP$CN$CN
256383921$25638392$1$I$20250731$20250801$20250801$20250801$DIR$FDA-CDER-CTU-2025-51168$$FDA-CTU$$71$YR$$F$N$$$20250801$Y$HP$US$
256383981$25638398$1$I$$20250212$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007974$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256384131$25638413$1$I$20250401$20250424$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008672$AURINIA PHARMACEUTICALS$$26$YR$$M$Y$$$20250804$$CN$US$US
256385111$25638511$1$I$20250621$20250728$20250804$20250804$EXP$EU-AFSSAPS-NC2025001094$EU-MYLANLABS-2025M1064904$MYLAN$$29$YR$$F$Y$$$20250802$$MD$EU$EU
256385141$25638514$1$I$$20250728$20250804$20250804$EXP$$GB-MYLANLABS-2025M1064699$MYLAN$$$$$F$Y$$$20250802$$MD$GB$GB
256385651$25638565$1$I$$20250707$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-009266$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256385911$25638591$1$I$$20250213$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007988$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256386691$25638669$1$I$$20250311$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008258$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$MD$US$US
256387141$25638714$1$I$$20250708$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008266$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256387411$25638741$1$I$$20250731$20250804$20250804$PER$$US-ELI_LILLY_AND_COMPANY-US202508000803$ELI LILLY AND COMPANY$$49$YR$A$M$Y$$$20250804$$CN$US$US
256388211$25638821$1$I$$20250625$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-009186$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256388391$25638839$1$I$$20250128$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007841$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256388401$25638840$1$I$$20250130$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007852$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256388411$25638841$1$I$$20250128$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007835$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256388801$25638880$1$I$$20250801$20250802$20250802$DIR$FDA-CDER-CTU-2025-51199$$FDA-CTU$$77$YR$$F$N$$$20250801$N$$US$
256389521$25638952$1$I$$20250207$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007925$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256389771$25638977$1$I$20250210$20250220$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007914$AURINIA PHARMACEUTICALS$$21$YR$$F$Y$$$20250804$$CN$US$US
256389831$25638983$1$I$20250601$20250731$20250804$20250804$EXP$EU-CZSUKL-25002107$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-107358$BRISTOL-MYERS SQUIBB COMPANY$$51$YR$A$M$Y$77$KG$20250804$$PH$EU$EU
256389861$25638986$1$I$$20250225$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-007844$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256390491$25639049$1$I$$20250312$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008271$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256390511$25639051$1$I$$20250317$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008329$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256392131$25639213$1$I$20250220$20250515$20250804$20250804$PER$$US-OTSUKA PHARMACEUTICAL NETHERLANDS B.V.-AUR-007905$AURINIA PHARMACEUTICALS$$42$YR$$F$Y$$$20250804$$CN$US$US
256392511$25639251$1$I$$20250731$20250804$20250804$PER$$US-ROCHE-10000353745$ROCHE$$$$A$F$Y$$$20250804$$CN$US$US
256392561$25639256$1$I$$20250605$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-009001$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256393231$25639323$1$I$20250508$20250729$20250804$20250804$EXP$$GB-MYLANLABS-2025M1064655$MYLAN$$78$YR$$F$Y$55$KG$20250802$$$GB$GB
256395111$25639511$1$I$20250602$20250723$20250804$20250804$PER$$US-BAYER-2025A101770$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$$Y$$$20250804$$HP$US$US
256395331$25639533$1$I$20241226$20250723$20250804$20250804$EXP$EU-AFSSAPS-TS2025000759$EU-ELI_LILLY_AND_COMPANY-FR202507021719$ELI LILLY AND COMPANY$$65$YR$E$M$Y$102$KG$20250804$$CN$EU$EU
256396011$25639601$1$I$$20250726$20250804$20250804$EXP$$CA-BIOCON BIOLOGICS LIMITED-BBL2025004177$BIOCON$$$$$$Y$$$20250804$$MD$CA$CA
256396041$25639604$1$I$$20250320$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008343$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256396821$25639682$1$I$20250101$20250729$20250804$20250804$PER$$US-CHATTEMPRD-2025OHG023390$CHATTEM$$$$I$M$Y$$$20250804$$CN$US$US
256397061$25639706$1$I$20241227$20250725$20250804$20250804$EXP$$CN-TAKEDA-2025TUS068773$TAKEDA$$73$YR$$M$Y$47.5$KG$20250804$$$CN$CN
256398761$25639876$1$I$$20250527$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008777$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256398832$25639883$2$F$$20250910$20250804$20250915$EXP$$JP-OTSUKA-2025_018647$OTSUKA$$10$DEC$$F$Y$$$20250915$$MD$JP$JP
256399381$25639938$1$I$$20250617$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-009129$AURINIA PHARMACEUTICALS$$$$$M$Y$$$20250804$$CN$US$US
256399861$25639986$1$I$20250201$20250616$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-008010$AURINIA PHARMACEUTICALS$$61$YR$$F$Y$$$20250804$$CN$US$US
256400021$25640002$1$I$$20250716$20250804$20250804$PER$$US-AURINIA PHARMACEUTICALS INC.-AUR-009165$AURINIA PHARMACEUTICALS$$$$$F$Y$$$20250804$$CN$US$US
256400672$25640067$2$F$$20250922$20250804$20250923$30DAY$$US-PFIZER INC-PV202500090176$PFIZER$$$$$$Y$$$20250923$$HP$US$US
256400801$25640080$1$I$$20250731$20250804$20250804$EXP$$US-ABBVIE-6397774$ABBVIE$$$$A$M$Y$$$20250804$$CN$US$US
256400921$25640092$1$I$$20250725$20250804$20250804$EXP$GB-MHRA-MIDB-0c7fe3e2-38ec-4030-a935-32780774af07$GB-TORRENT-00042225$TORRENT PHARMA INC.$$89$YR$E$F$Y$58$KG$20250804$$PH$GB$GB
256401131$25640113$1$I$$20250730$20250804$20250804$PER$$US-BAYER-2025A102690$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250804$$CN$US$US
256401601$25640160$1$I$20250101$20250730$20250804$20250804$EXP$$CA-ABBVIE-6399204$ABBVIE$$84$YR$$F$Y$$$20250804$$CN$CA$CA
256402571$25640257$1$I$$20250804$20250804$20250804$DIR$FDA-CDER-CTU-2025-51322$$FDA-CTU$$75$YR$$F$N$$$20250804$N$$US$
256402662$25640266$2$F$$20250801$20250804$20250807$PER$$US-ABBVIE-6399981$ABBVIE$$$$$$Y$$$20250807$$HP$US$US
256404441$25640444$1$I$$20250731$20250804$20250804$EXP$$US-PFIZER INC-PV202500092954$PFIZER$$$$$F$Y$$$20250804$$LW$US$US
256404521$25640452$1$I$$20250729$20250804$20250804$EXP$$IR-MYLANLABS-2025M1066034$MYLAN$Abbasi B, Elyasi F, Aliyali M. Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol. Clin-Case-Rep 2025; 13 (7): 1-6.$53$YR$$M$Y$$$20250804$$$IR$IR
256404771$25640477$1$I$$20250801$20250804$20250804$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-107949$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$81.65$KG$20250804$$MD$US$US
256405071$25640507$1$I$$20250731$20250804$20250804$PER$$US-ABBVIE-6398378$ABBVIE$$$$$$Y$$$20250804$$CN$US$US
256405092$25640509$2$F$$20250731$20250804$20250806$PER$$US-ABBVIE-6399375$ABBVIE$$$$$$Y$$$20250806$$HP$US$US
256405101$25640510$1$I$$20250725$20250804$20250804$PER$$US-INSUD PHARMA-2507US06234$INSUD PHARMA$$$$$$Y$$$20250804$$CN$US$US
256405261$25640526$1$I$20250101$20250730$20250804$20250804$EXP$$US-BIOMARINAP-US-2025-167810$BIOMARIN$$15$YR$$F$Y$$$20250804$$$US$US
256405461$25640546$1$I$20250604$20250604$20250804$20250804$30DAY$$US-SANDOZ INC.-SDZ2025US055455$SANDOZ$$$$$F$Y$$$20250804$$CN$US$US
256405871$25640587$1$I$$20250630$20250804$20250804$PER$$US-RDY-USA/2025/07/009907$DR REDDYS$$67$YR$E$F$Y$73.48$KG$20250804$$CN$US$US
256406141$25640614$1$I$$20250721$20250804$20250804$EXP$$CL-Pharmobedient-000034$PHARMOBEDIENT CONSULTING, LLC$Uribe G, Fica A, Teneb E, Onat M, Galvez L, Toro N, et al. Combined Use of Meropenem, Linezolid, and Quinolones for Non-Drug-Resistant Tuberculosis in Critically Ill Patients and Other Settings: A Descriptive Series. Rev Med Chil. 2025 Jul;153(7):492-504. doi: 10.4067/s0034-98872025000700492.$$$$M$Y$$$20250804$$HP$CL$CL
256406511$25640651$1$I$$20250729$20250804$20250804$EXP$GB-MHRA-MED-202507291144491040-BGHPW$GB-TEVA-VS-3358526$TEVA$$$$$F$Y$$$20250804$$HP$GB$GB
256406591$25640659$1$I$$20250724$20250804$20250804$EXP$GB-MHRA-MED-202507241407143450-PGYCF$GB-ELI_LILLY_AND_COMPANY-GB202507024224$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250804$$CN$GB$GB
256407381$25640738$1$I$$20250726$20250804$20250804$EXP$$US-ELI_LILLY_AND_COMPANY-US202507026531$ELI LILLY AND COMPANY$$70$YR$E$$Y$$$20250804$$LW$US$US
256407681$25640768$1$I$$20250725$20250804$20250804$PER$$US-ABBVIE-6398395$ABBVIE$$$$$F$Y$$$20250804$$HP$US$US
256407721$25640772$1$I$$20250729$20250804$20250804$EXP$$JP-OTSUKA-2025_018434$OTSUKA$$$$$M$Y$$$20250804$$CN$JP$JP
256409201$25640920$1$I$$20250722$20250804$20250804$EXP$$CA-ASTRAZENECA-202501CAN021321CA$ALEXION PHARMACEUTICALS$$74$YR$E$F$Y$$$20250804$$$CA$CA
256409921$25640992$1$I$$20250728$20250804$20250804$PER$$US-SA-2025SA223912$SANOFI AVENTIS$$56$YR$A$$Y$$$20250804$$CN$US$US
256410081$25641008$1$I$20250101$20250729$20250804$20250804$PER$$US-SA-2025SA226741$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250804$$HP$US$US
256410171$25641017$1$I$20250101$20250729$20250804$20250804$PER$$US-SA-2025SA225261$SANOFI AVENTIS$$16$YR$T$M$Y$$$20250804$$HP$US$US
256410231$25641023$1$I$$20250730$20250804$20250804$PER$$US-SA-2025SA226753$SANOFI AVENTIS$$$$A$M$Y$100$KG$20250804$$MD$US$US
256410431$25641043$1$I$20250101$20250730$20250804$20250804$PER$$US-SA-2025SA225117$SANOFI AVENTIS$$58$YR$A$M$Y$$$20250804$$HP$US$US
256411831$25641183$1$I$20250101$20250730$20250804$20250804$PER$$US-SA-2025SA227202$SANOFI AVENTIS$$59$YR$A$F$Y$$$20250804$$HP$US$US
256411962$25641196$2$F$$20250812$20250804$20250818$PER$$US-SA-2025SA225219$SANOFI AVENTIS$$24$YR$A$M$Y$$$20250818$$CN$US$US
256412191$25641219$1$I$$20250731$20250804$20250804$PER$$US-SA-2025SA224262$SANOFI AVENTIS$$$$E$M$Y$$$20250804$$HP$US$US
256412331$25641233$1$I$$20250731$20250804$20250804$PER$$US-SA-2025SA226243$SANOFI AVENTIS$$62$YR$A$F$Y$$$20250804$$CN$US$US
256414673$25641467$3$F$20250101$20250909$20250804$20250923$PER$$US-MALLINCKRODT-MNK202504289$MALLINCKRODT$$$$$F$Y$$$20250922$$CN$US$US
256414722$25641472$2$F$$20250825$20250804$20250829$PER$$US-MALLINCKRODT-MNK202504505$MALLINCKRODT$$$$$F$Y$$$20250828$$CN$US$US
256414791$25641479$1$I$20250701$20250730$20250804$20250804$PER$$US-MALLINCKRODT-MNK202504697$MALLINCKRODT$$74$YR$$F$Y$$$20250801$$CN$US$US
256414911$25641491$1$I$$20250730$20250804$20250804$EXP$$CA-PFIZER INC-202500155302$PFIZER$$85$YR$$M$Y$$$20250804$$HP$CA$CA
256416671$25641667$1$I$20250801$20250801$20250804$20250804$EXP$$EU-GILEAD-2025-0723083$GILEAD$$$$$F$Y$$$20250804$$MD$EU$EU
256416771$25641677$1$I$$20250730$20250804$20250804$PER$$NVSC2025US123239$NOVARTIS$$$$$$Y$$$20250805$$HP$US$US
256418941$25641894$1$I$$20250728$20250804$20250804$PER$$US-AMGEN-USASP2025150280$AMGEN$$$$$$Y$$$20250804$$CN$US$US
256419262$25641926$2$F$20250701$20250912$20250804$20250919$PER$$US-SA-2025SA224970$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250919$$HP$US$US
256419451$25641945$1$I$$20250730$20250804$20250804$EXP$$JP-SANDOZ INC.-SDZ2025JP055283$SANDOZ$Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, et al. Phase I study of neoadjuvant chemotherapy with nivolumab for locally advanced esophageal carcinoma (JCOG1804E). The 79th Annual Meeting of the Japan Esophageal Society (Abstracts). 2025;SY12-1$$$$$Y$$$20250804$$MD$JP$JP
256419571$25641957$1$I$$20250721$20250804$20250804$EXP$$CL-Norvium Bioscience LLC-080477$Norvium Bioscience$Uribe G, Fica A, Teneb E, Onat M, Galvez L, Toro N, et al. Combined Use of Meropenem, Linezolid, and Quinolones for Non-Drug-Resistant Tuberculosis in Critically Ill Patients and Other Settings: A Descriptive Series. Rev Med Chil. 2025 Jul;153(7):492-504. doi: 10.4067/s0034-98872025000700492.$$$$M$Y$$$20250805$$HP$CL$CL
256419821$25641982$1$I$$20250730$20250805$20250805$EXP$$GB-ABBVIE-6398035$ABBVIE$$$$A$F$Y$$$20250805$$CN$GB$GB
256419941$25641994$1$I$$20250727$20250805$20250805$EXP$$EU-JNJFOC-20250733345$JOHNSON AND JOHNSON$Sobotkova T, Hugo J, Salavec M, Kojanova M, Tichy M, Necas M, et al. Efficacy, Safety, and Drug Survival During the First Year of Biologic Therapy for Psoriasis in Elderly Versus Younger Patients. International Journal of Dermatology. 2025 August 01;:1401-1408. doi: 10.1111/ijd.17814$$$$$Y$$$20250805$$HP$EU$EU
256420015$25642001$5$F$20250101$20250908$20250805$20250917$PER$$US-UNITED THERAPEUTICS-UNT-2025-026315$UNITED THERAPEUTICS$$$$$M$Y$56.689$KG$20250917$$$US$US
256420691$25642069$1$I$20250711$20250730$20250805$20250805$EXP$GB-MHRA-MED-202507300339105260-BKQMJ$GB-TEVA-VS-3358620$TEVA$$69$YR$$M$Y$24$KG$20250805$$CN$GB$GB
256420961$25642096$1$I$$20250731$20250805$20250805$EXP$$VN-ASTRAZENECA-202507ASI027362VN$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250805$$MD$VN$VN
256421191$25642119$1$I$$20250731$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202504013488$ELI LILLY AND COMPANY$$$$$M$Y$$$20250805$$MD$US$US
256422731$25642273$1$I$20250701$20250729$20250805$20250805$PER$$US-SA-2025SA225021$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250805$$MD$US$US
256423211$25642321$1$I$20230101$20250731$20250805$20250805$PER$$US-SA-2025SA227381$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250805$$HP$US$US
256423631$25642363$1$I$$20250725$20250805$20250805$EXP$$US-BEH-2025214241$CSL BEHRING$$$$E$M$Y$$$20250805$$HP$US$US
256423791$25642379$1$I$$20250725$20250805$20250805$PER$$US-NOVITIUMPHARMA-2025USNVP01896$NOVITIUM PHARMA$$$$$F$Y$$$20250805$$CN$US$US
256425201$25642520$1$I$20250717$20250724$20250805$20250805$EXP$$GB-LAURUS LABS LIMITED-2025LAU000048$LAURUS LABS LIMITED$$25$YR$$F$Y$$$20250805$$HP$GB$GB
256425491$25642549$1$I$$20250804$20250805$20250805$EXP$$CA-TEVA-VS-3359639$TEVA$$47$YR$$F$Y$$$20250805$$HP$CA$CA
256425791$25642579$1$I$20130101$20250724$20250805$20250805$EXP$$CO-TLM-23CO043133$TOLMAR$$89$YR$E$M$Y$$$20250726$$CN$CO$CO
256425901$25642590$1$I$20250501$20250729$20250805$20250805$EXP$$US-UCBSA-2025047702$UCB$$$$$M$Y$$$20250805$$MD$US$US
256426363$25642636$3$F$20250101$20250807$20250805$20250818$EXP$$US-ABBVIE-6398806$ABBVIE$$61$YR$$F$Y$163.29$KG$20250818$$CN$US$US
256427361$25642736$1$I$$20250723$20250805$20250805$EXP$$US-LUPIN PHARMACEUTICALS INC.-2025-06762$LUPIN$Beyerle T, Permann A, Grindlay-Beckort K, Converse E, Shetty M. Boldly bradycardic: A case report of Brash Syndrome in the setting of HFpEF. American Journal of Respiratory and Critical Care Medicine. 2025;211:A1697$67$YR$$F$Y$$$20250805$$$US$US
256427392$25642739$2$F$20250205$20250801$20250805$20250807$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008886$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20250807$$CN$US$US
256427531$25642753$1$I$$20250731$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202508001669$ELI LILLY AND COMPANY$$74$YR$E$F$Y$$$20250805$$CN$US$US
256428271$25642827$1$I$20230104$20250728$20250805$20250805$EXP$$EU-CELLTRION INC.-2025CZ025807$CELLTRION$$$$$$Y$$$20250805$$MD$EU$EU
256429111$25642911$1$I$$20250721$20250805$20250805$EXP$$US-AMGEN-USASP2025146963$AMGEN$Chandrasekhar S.. Intralesional talimogene laherparepvec for treatment of advanced merkel cell carcinoma. Journal of Investigative Dermatology. 2025;145 (8):S41$$$$$Y$$$20250805$$HP$US$US
256429481$25642948$1$I$$20250804$20250805$20250805$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-108567$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250805$$HP$US$US
256430011$25643001$1$I$$20250715$20250805$20250805$PER$$US-KENVUE-20250706295$Kenvue$$$$$$Y$$$20250805$$CN$US$US
256431712$25643171$2$F$20250601$20250922$20250805$20250925$PER$$US-ELI_LILLY_AND_COMPANY-US202508000633$ELI LILLY AND COMPANY$$71$YR$E$F$Y$$$20250925$$CN$US$US
256433381$25643338$1$I$$20250731$20250805$20250805$PER$$US-JNJFOC-20250801099$JOHNSON AND JOHNSON$$$$$F$Y$$$20250805$$HP$US$US
256433621$25643362$1$I$$20250721$20250805$20250805$EXP$$TR-PURACAP-TR-2025EPCLIT00899$PURACAP PHARMACEUTICAL LLC$Tugba Arikoglu.Diagnostic evaluation of hypersensitivity reactions to arylpropionic  acid derivatives: a descriptive observational study focusing on clinical  characteristics and potential risk factors in children.International Journal of Clinical Pharmacy.11-JUN-2024;46:1294-1306$5$YR$C$$Y$$$20250805$$HP$TR$TR
256433911$25643391$1$I$$20250801$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202508002455$ELI LILLY AND COMPANY$$$$$$Y$$$20250805$$CN$US$US
256433921$25643392$1$I$$20250331$20250805$20250805$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-502952$RANBAXY$$$$$F$Y$$$20250805$$CN$US$US
256434281$25643428$1$I$20230101$20250731$20250805$20250805$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-086746$BOEHRINGER INGELHEIM$$68$YR$E$M$Y$$$20250805$$$US$US
256434421$25643442$1$I$$20250724$20250805$20250805$EXP$$CN-Accord-497123$ACCORD$Yao Y, Chen LI, Cao X, Xiao H, Tong J. Brivudine as a successful treatment for herpes zoster combined with chickenpox. Postepy Dermatologii i Alergologii. 2025;42(3):322-4. DOI: 10.5114/ada.2025.149542$47$YR$A$F$Y$$$20250805$$MD$CN$CN
256434921$25643492$1$I$$20250728$20250805$20250805$EXP$$JP-CELLTRION INC.-2025JP026072$CELLTRION$Yamagishi A, Kaiho T, Yotsukura J, Ikeda J, Baba T. Bilateral Multiple Chalazia After Adalimumab Therapy for Uveitis Associated With Generalized Pustular Psoriasis: A Case Report. Cureus. 2025;17(6):e86646$$$$$Y$$$20250805$$HP$JP$JP
256435161$25643516$1$I$$20250731$20250805$20250805$EXP$$US-SA-2025SA225077$SANOFI AVENTIS$$$$A$F$Y$$$20250805$$MD$US$US
256435551$25643555$1$I$20250626$20250728$20250805$20250805$EXP$EU-AFSSAPS-AN2025000951$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-126798$ZYDUS PHARM$$$$$$Y$$$20250805$$PH$EU$EU
256436041$25643604$1$I$20250725$20250731$20250805$20250805$EXP$$GB-MYLANLABS-2025M1065437$MYLAN$$75$YR$$F$Y$88$KG$20250805$$$GB$GB
256437661$25643766$1$I$$20250731$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202508001699$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250805$$CN$US$US
256438231$25643823$1$I$20250725$20250731$20250805$20250805$PER$$US-ROCHE-10000353714$ROCHE$$$$T$F$Y$$$20250805$$CN$US$US
256438531$25643853$1$I$$20250729$20250805$20250805$PER$$NVSC2025US121198$NOVARTIS$$$$$F$Y$$$20250805$$CN$US$US
256438811$25643881$1$I$$20250728$20250805$20250805$EXP$$US-GSK-US2025AMR098783$GLAXOSMITHKLINE$$$$$F$Y$$$20250805$$$US$US
256440661$25644066$1$I$$20250730$20250805$20250805$EXP$$US-GSK-US2025AMR099631$GLAXOSMITHKLINE$$$$$F$Y$$$20250805$$$US$US
256440961$25644096$1$I$20250412$20250803$20250803$20250803$DIR$767834$$FDA-CTU$$50$YR$$F$N$126$KG$20250803$N$CN$US$
256441281$25644128$1$I$$20250729$20250805$20250805$EXP$$US-ANIPHARMA-023925$ANI$$40$YR$A$M$Y$$$20250805$$HP$US$US
256441301$25644130$1$I$$20250728$20250805$20250805$EXP$$US-ANIPHARMA-023921$ANI$$40$YR$A$F$Y$$$20250805$$HP$US$US
256441821$25644182$1$I$20250423$20250725$20250805$20250805$EXP$$EU-AUROBINDO-AUR-APL-2025-039613$AUROBINDO$$85$YR$$M$Y$70$KG$20250805$$MD$EU$EU
256441971$25644197$1$I$$20250708$20250805$20250805$PER$$US-GSK-US2025AMR088414$GLAXOSMITHKLINE$$$$$F$Y$$$20250805$$$US$US
256443201$25644320$1$I$$20250106$20250805$20250805$EXP$$AU-ALXN-202412OCE005788AU$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250805$$MD$AU$AU
256444044$25644404$4$F$$20250916$20250805$20250917$30DAY$$US-PFIZER INC-202500152706$PFIZER$$13$YR$$F$Y$37.188$KG$20250917$$CN$US$US
256444641$25644464$1$I$$20250804$20250805$20250805$PER$$US-BAYER-2025A103362$BAYER HEALTHCARE LLC$$$$$$Y$$$20250805$$CN$US$US
256445401$25644540$1$I$$20250725$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202507024895$ELI LILLY AND COMPANY$$50$YR$A$$Y$$$20250805$$LW$US$US
256445662$25644566$2$F$$20250804$20250805$20250807$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06952$LUPIN$$$$$$Y$$$20250807$$$US$US
256445861$25644586$1$I$$20250722$20250805$20250805$EXP$$US-GLANDPHARMA-US-2025GLNLIT01646$GLAND PHARMA LTD$Jeremy Richard Brozyna.Omalizumab pretreatment in a case of pediatric carboplatin desensitization.Pediatric Allergy and Immunology.15-JUN-2025;36:1-4$57$MON$C$M$Y$$$20250805$$HP$US$US
256446261$25644626$1$I$$20250804$20250804$20250804$DIR$FDA-CDER-CTU-2025-51454$$FDA-CTU$$14$YR$$F$N$90.72$KG$20250804$N$$US$
256446461$25644646$1$I$$20250725$20250805$20250805$PER$$US-ROCHE-10000350205$ROCHE$$$$A$F$Y$$$20250805$$CN$US$US
256447591$25644759$1$I$$20250730$20250805$20250805$PER$$US-SA-2025SA227836$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250805$$HP$US$US
256447681$25644768$1$I$20250701$20250730$20250805$20250805$PER$$US-SA-2025SA224023$SANOFI AVENTIS$$4$YR$C$F$Y$$$20250805$$HP$US$US
256448191$25644819$1$I$20250701$20250731$20250805$20250805$PER$$US-SA-2025SA228556$SANOFI AVENTIS$$40$YR$A$M$Y$$$20250805$$HP$US$US
256448411$25644841$1$I$$20250730$20250805$20250805$PER$$US-SA-2025SA226818$SANOFI AVENTIS$$$$A$F$Y$$$20250805$$MD$US$US
256448531$25644853$1$I$$20250731$20250805$20250805$PER$$US-SA-2025SA227516$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250805$$CN$US$US
256448682$25644868$2$F$$20250916$20250805$20250919$PER$$US-SA-2025SA227851$SANOFI AVENTIS$$16$YR$T$F$Y$$$20250919$$CN$US$US
256449231$25644923$1$I$$20250801$20250805$20250805$PER$$US-SA-2025SA227945$SANOFI AVENTIS$$86$YR$E$F$Y$$$20250805$$CN$US$US
256449731$25644973$1$I$20241206$20250801$20250805$20250805$EXP$$US-Eisai-EC-2025-194375$EISAI$$78$YR$E$M$Y$$$20250805$$$US$US
256450221$25645022$1$I$20250731$20250731$20250805$20250805$PER$$US-BAYER-2025A103715$BAYER HEALTHCARE PHARMACEUTICALS INC.$$26$YR$A$F$Y$$$20250805$$MD$US$US
256450801$25645080$1$I$20230404$20250730$20250805$20250805$EXP$$JP-MSD-M2023-23947$MERCK SHARP + DOHME LLC$$67$YR$$M$Y$$$20250805$$MD$JP$JP
256452882$25645288$2$F$20250731$20250801$20250805$20250806$EXP$$CA-PFIZER INC-202500156095$PFIZER$$40$YR$$M$Y$$$20250806$$HP$CA$CA
256452971$25645297$1$I$20250101$20250801$20250805$20250805$EXP$$US-ABBVIE-6400177$ABBVIE$$57$YR$$F$Y$$$20250805$$CN$US$US
256452981$25645298$1$I$20250801$20250801$20250805$20250805$PER$$US-BAYER-2025A102727$BAYER HEALTHCARE LLC$$88$YR$E$F$Y$$$20250805$$CN$US$US
256453181$25645318$1$I$$20250728$20250805$20250805$EXP$$EU-UCBSA-2025047338$UCB$$$$A$M$Y$$$20250805$$MD$EU$EU
256453331$25645333$1$I$$20250804$20250804$20250804$DIR$768224$$FDA-CTU$$$$$M$N$$$20250804$N$CN$US$
256453561$25645356$1$I$$20250728$20250805$20250805$EXP$$CA-SANDOZ INC.-NVSC2020CA085156$SANDOZ$$$$$M$Y$$$20250805$$CN$CA$CA
256453942$25645394$2$F$$20250808$20250805$20250815$EXP$$NVSJ2025JP007909$NOVARTIS$Makoto Naganuma. Cytoaphresis Therapy for Inflammatory Bowel Disease. Stomach and Intestine. 2024;59:1463-1471$4$DEC$$M$Y$$$20250815$$HP$JP$JP
256454381$25645438$1$I$$20250724$20250805$20250805$EXP$GB-MHRA-MED-202507241409104640-YDJHB$GB-ELI_LILLY_AND_COMPANY-GB202507024240$ELI LILLY AND COMPANY$$$$$F$Y$75$KG$20250805$$CN$GB$GB
256454812$25645481$2$F$$20250807$20250805$20250812$EXP$$EU-MYLANLABS-2025M1065308$MYLAN$$$$$F$Y$$$20250812$$$EU$EU
256455551$25645555$1$I$20250730$20250805$20250805$20250805$DIR$768382$$FDA-CTU$$89$YR$$M$N$$$20250805$N$HP$US$
256457141$25645714$1$I$$20250729$20250805$20250805$PER$$NVSC2025US122445$NOVARTIS$$$$$$Y$$$20250805$$HP$US$US
256457441$25645744$1$I$20250713$20250731$20250805$20250805$EXP$$CN-PFIZER INC-PV202500092809$PFIZER$$5$YR$$F$Y$17$KG$20250805$$HP$CN$CN
256459511$25645951$1$I$$20250805$20250805$20250805$DIR$768394$$FDA-CTU$$$$$$N$$$20250805$N$$US$
256459551$25645955$1$I$20250805$20250805$20250805$20250805$DIR$768397$$FDA-CTU$$68$YR$$F$N$72$KG$20250805$N$CN$US$
256460011$25646001$1$I$$20250804$20250805$20250805$PER$$US-ELI_LILLY_AND_COMPANY-US202508003108$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250805$$CN$US$US
256460291$25646029$1$I$20250727$20250801$20250805$20250805$EXP$$NVSC2025CN123710$NOVARTIS$$70$YR$$F$Y$36$KG$20250805$$HP$CN$CN
256460421$25646042$1$I$$20250805$20250805$20250805$DIR$768402$$FDA-CTU$$$$$$N$$$20250805$$CN$US$
256461461$25646146$1$I$$20250728$20250805$20250805$EXP$$US-NOVOPROD-1489350$NOVO NORDISK$$53$YR$$$Y$$$20250805$$CN$US$US
256461791$25646179$1$I$20250725$20250725$20250805$20250805$EXP$$CA-ABBVIE-6399644$ABBVIE$$43$YR$$M$Y$$$20250805$$CN$CA$CA
256461971$25646197$1$I$20220101$20250729$20250805$20250805$EXP$$US-NOVOPROD-1490161$NOVO NORDISK$$53$YR$$$Y$$$20250805$$CN$US$US
256462411$25646241$1$I$20250601$20250801$20250805$20250805$EXP$$US-ABBVIE-6400498$ABBVIE$$60$YR$$F$Y$$$20250805$$CN$US$US
256462531$25646253$1$I$$20250801$20250805$20250805$EXP$$US-ABBVIE-6400102$ABBVIE$$30$YR$$F$Y$$$20250805$$CN$US$US
256462982$25646298$2$F$$20250804$20250805$20250808$EXP$$GB-PFIZER INC-202500156925$PFIZER$$32$YR$$M$Y$$$20250808$$CN$GB$GB
256463131$25646313$1$I$20250711$20250729$20250805$20250805$EXP$$CN-TAKEDA-2025TUS069459$TAKEDA$$78$YR$$F$Y$38$KG$20250805$$$CN$CN
256463241$25646324$1$I$20250730$20250730$20250805$20250805$PER$$US-INSUD PHARMA-2507US06275$INSUD PHARMA$$$$$$Y$$$20250805$$CN$US$US
256463461$25646346$1$I$$20250722$20250805$20250805$EXP$$US-SCIEGENP-2025SCLIT00190$SCIEGEN PHARMACEUTICALS INC$Rink DE, et al..Diagnostic Confounders in Brain Death A Woman with Unexplained Coma and Brainstem Areflexia.Annals of the American Thoracic Society.aug-2024;21 (8):1204-8$60$YR$A$F$Y$$$20250805$$MD$US$US
256463901$25646390$1$I$20250120$20250724$20250805$20250805$EXP$$NVSC2025FR107217$NOVARTIS$$$$A$F$Y$$$20250805$$MD$EU$EU
256464861$25646486$1$I$$20250730$20250805$20250805$EXP$$GB-009507513-2315398$MERCK SHARP + DOHME LLC$$$$A$F$Y$$$20250805$$HP$GB$GB
256466501$25646650$1$I$$20250801$20250805$20250805$PER$$US-JNJFOC-20250800212$JOHNSON AND JOHNSON$$$$$$Y$$$20250805$$CN$US$US
256466561$25646656$1$I$20250520$20250730$20250805$20250805$EXP$EU-DKMA-31018089$EU-GE HEALTHCARE-2025CSU010267$GE HEALTHCARE$$60$YR$$F$Y$75$KG$20250806$$MD$EU$EU
256467621$25646762$1$I$$20250730$20250805$20250805$PER$$NVSC2025US123242$NOVARTIS$$$$$$Y$$$20250806$$HP$US$US
256469052$25646905$2$F$$20250812$20250805$20250818$EXP$$US-TEVA-VS-3358299$TEVA$Upreti H, Mora A. As Many Diseases as They Please: A Case of Respiratory Failure Due to Overlap of Differentiation Syndrome and Staphylococcal Pneumonia. Am-J-Respir-Crit-Care-Med 2025; 211 A6095.; Upreti H, Mora A. As Many Diseases as They Please: A Case of Respiratory Failure Due to Overlap of Differentiation Syndrome and Staphylococcal Pneumonia. Am-J-Respir-Crit-Care-Med 2025; 211 A6095.$49$YR$$F$Y$$$20250818$$HP$US$US
256469521$25646952$1$I$20250101$20250728$20250805$20250805$EXP$$US-UNITED THERAPEUTICS-UNT-2025-025123$UNITED THERAPEUTICS$$$$$M$Y$58.503$KG$20250805$$$US$US
256470391$25647039$1$I$$20250728$20250806$20250806$EXP$$EU-BAUSCH-BL-2024-004824$BAUSCH AND LOMB$Szlauer-Stefanska A, Kaminska-Winciorek G, UNKNOWN. Patient with chronic cutaneous and mucosal form of graft versus host disease. POSTGRADUATE DERMATOLOGY [DERMATOLOGIA PO DYPLOMIE]. 2024;$30$YR$A$M$Y$$$20250806$$HP$EU$EU
256470751$25647075$1$I$20250726$20250805$20250806$20250806$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-108999$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$$$20250806$$HP$US$US
256471271$25647127$1$I$20241018$20250801$20250806$20250806$EXP$EU-BFARM-25005423$EU-AMGEN-DEUSP2025153863$AMGEN$$50$YR$A$F$Y$$$20250805$$MD$EU$EU
256471701$25647170$1$I$$20250731$20250806$20250806$EXP$$AU-TAKEDA-2025TUS069493$TAKEDA$$$$$F$Y$$$20250806$$MD$AU$AU
256473021$25647302$1$I$$20250725$20250806$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202507026469$ELI LILLY AND COMPANY$$66$YR$E$$Y$$$20250806$$LW$US$US
256473261$25647326$1$I$20250728$20250729$20250806$20250806$EXP$$CN-ROCHE-10000351356$ROCHE$$59$YR$A$M$Y$$$20250806$$CN$CN$CN
256474012$25647401$2$F$20250617$20250808$20250806$20250818$EXP$$AR-TAKEDA-2025TUS057302$TAKEDA$$49$YR$$M$Y$$$20250818$$$AR$AR
256474061$25647406$1$I$20240101$20250730$20250806$20250806$PER$$US-SA-2025SA226799$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250806$$HP$US$US
256474111$25647411$1$I$20250101$20250729$20250806$20250806$PER$$US-SA-2025SA224803$SANOFI AVENTIS$$10$YR$C$F$Y$33.11$KG$20250806$$MD$US$US
256474931$25647493$1$I$20250725$20250725$20250806$20250806$PER$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00702$AIMMUNE$$$$$$Y$$$20250806$$CN$US$US
256475221$25647522$1$I$20250701$20250730$20250806$20250806$PER$$US-ABBVIE-6399053$ABBVIE$$$$$F$Y$$$20250806$$MD$US$US
256475861$25647586$1$I$20250723$20250729$20250806$20250806$EXP$$US-UCBSA-2025047631$UCB$$35$YR$$F$Y$56.2$KG$20250806$$MD$US$US
256476281$25647628$1$I$20250729$20250730$20250806$20250806$PER$$US-ASTRAZENECA-202507USA026092US$ALEXION PHARMACEUTICALS$$76$YR$E$F$Y$$$20250806$$$US$US
256476991$25647699$1$I$$20250801$20250806$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202508002206$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250806$$CN$US$US
256477591$25647759$1$I$$20250618$20250806$20250806$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2025-06878$ALKEM$Cicci CD, Theobald J, Stanton M, Feldman R. Outcomes of benzonatate exposures reported to a single United States poison center: a 20-year review. Clinical Toxicology. 2025;unk:1-7$33$YR$$F$Y$$$20250806$$HP$US$US
256477691$25647769$1$I$$20250729$20250806$20250806$EXP$$US-KOANAAP-SML-US-2025-00365$SHILPA MEDICARE$McPherson AZ, Miller M, Rytlewski K, Bacon S, Voyer K. Magnusiomyces clavatus fungemiatreated with combination antifungals including isavuconazole and flucytosine in a pediatricpatient with Fanconi anemia and recent umbilical cord blood allogenic transplant. AM J HEALTH-SYST PHARM. 2025 Jan 08;82(1): S1206-S1207. doi:10.1093/ajhp/zxae345.$4$YR$C$F$Y$12$KG$20250806$$MD$US$US
256479521$25647952$1$I$$20250801$20250806$20250806$PER$$US-ABBVIE-6400936$ABBVIE$$$$$$Y$$$20250806$$HP$US$US
256480481$25648048$1$I$$20250723$20250806$20250806$EXP$$EU-STRIDES ARCOLAB LIMITED-2025SP009706$STRIDES$Bolt P, Adamovic I, Horacek M, Brinar IV, Gulin T.. From diagnosis to treatment of minimal change disease in pregnancy.. EN Case Rep. 2025;14:374-380$33$YR$$F$Y$$$20250806$$HP$EU$EU
256480951$25648095$1$I$$20250730$20250806$20250806$PER$$US-LEO Pharma-381846$LEO PHARM$$25$YR$$M$Y$$$20250806$$PH$US$US
256481011$25648101$1$I$$20250727$20250806$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202507026609$ELI LILLY AND COMPANY$$55$YR$A$$Y$$$20250806$$CN$US$US
256481481$25648148$1$I$$20250805$20250806$20250806$PER$$US-ASTRAZENECA-202508USA002226US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250806$$$US$US
256482282$25648228$2$F$$20250820$20250806$20250825$PER$$US-SA-2025SA229018$SANOFI AVENTIS$$50$YR$A$M$Y$$$20250825$$CN$US$US
256482542$25648254$2$F$$20250822$20250806$20250918$EXP$$US-TLM-TLM-2025-04619$TOLMAR$$$$$$Y$$$20250918$$HP$US$US
256482641$25648264$1$I$$20250731$20250806$20250806$EXP$$JP-AMGEN-JPNSP2025153235$AMGEN$Shinozaki E.; Fukuda K.; Osumi H. et al.. Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. International Journal of Clinical Oncology. 2025;1-10$$$$$Y$$$20250806$$HP$JP$JP
256483081$25648308$1$I$20241015$20250712$20250806$20250806$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0012886$RECKITT BENCKISER$$$$$M$Y$$$20250806$$CN$US$US
256483691$25648369$1$I$20250430$20250726$20250806$20250806$EXP$GB-MHRA-MED-202507251622525380-GTYNV$GB-AMAROX PHARMA-AMR2025GB04365$HETERO$$61$YR$$F$Y$$$20250806$$CN$GB$GB
256483731$25648373$1$I$$20250725$20250806$20250806$PER$$US-ROCHE-10000349338$ROCHE$$$$A$M$Y$$$20250806$$CN$US$US
256484911$25648491$1$I$20250801$20250801$20250806$20250806$EXP$$ID-ASTRAZENECA-202508ASI000612ID$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250806$$MD$ID$ID
256485491$25648549$1$I$20250325$20250801$20250806$20250806$EXP$$US-GILEAD-2025-0723392$GILEAD$$57$YR$A$F$Y$$$20250806$$HP$US$US
256485692$25648569$2$F$20250427$20250818$20250806$20250822$EXP$$US-ABBVIE-6400028$ABBVIE$$44$YR$$M$Y$$$20250822$$CN$US$US
256485751$25648575$1$I$$20250722$20250806$20250806$EXP$$JP-GLANDPHARMA-JP-2025GLNLIT01643$GLAND PHARMA LTD$Daisuke Himeji.Pneumocystis pneumonia in a patient receiving nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A case report.Internal Medicine.26-JUN-2025;1-5$78$YR$E$M$Y$$$20250806$$HP$JP$JP
256485921$25648592$1$I$20250709$20250804$20250806$20250806$EXP$$US-ABBVIE-6402508$ABBVIE$$73$YR$$F$Y$$$20250806$$HP$US$US
256486451$25648645$1$I$20250101$20250723$20250806$20250806$PER$$US-009507513-2312341$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250806$$CN$US$US
256488181$25648818$1$I$$20250724$20250806$20250806$PER$$US-APOTEX-2025AP011042$APOTEX$Gitto M, Sartori S, Vogel B, Leone PP, Smith K, Bay B, et al.. Potent P2Y12 Inhibitors vs Clopidogrel in Cancer Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology. 2025;41 (7):1241-1250$$$A$$Y$$$20250806$$MD$US$US
256489561$25648956$1$I$$20250729$20250806$20250806$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06853$LUPIN$$38$YR$$$Y$$$20250806$$$US$US
256489991$25648999$1$I$$20250726$20250806$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202507028955$ELI LILLY AND COMPANY$$$$$$Y$$$20250806$$CN$US$US
256491231$25649123$1$I$20250805$20250805$20250805$20250805$DIR$FDA-CDER-CTU-2025-51972$$FDA-CTU$$32$YR$$F$N$62.6$KG$20250805$Y$$US$
256492191$25649219$1$I$$20250801$20250806$20250806$EXP$$EU-AMGEN-ITASP2025153629$AMGEN$Grimaldi, F.. Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center. Cancers. 2025;17 (13):1-15$$$$$Y$$$20250806$$HP$EU$EU
256492972$25649297$2$F$$20250820$20250806$20250901$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-06924$LUPIN$$63$YR$$$Y$70.295$KG$20250901$$$US$US
256493321$25649332$1$I$$20250716$20250806$20250806$PER$$US-009507513-2310019$MERCK SHARP + DOHME LLC$Al-Nabolsi A., Hubbard C., Marchewka T.C., Shatila M. A Case of Purulent Pericarditis Due to Actinomyces From an Odontogenic Focus. American Journal of Respiratory and Critical Care Medicine 2025 May 1. 211.$39$YR$$M$Y$$$20250806$$HP$US$US
256493791$25649379$1$I$20250626$20250801$20250806$20250806$EXP$$GB-MYLANLABS-2025M1065846$MYLAN$$81$YR$$F$Y$74$KG$20250806$$PH$GB$GB
256494271$25649427$1$I$$20250722$20250806$20250806$EXP$$TR-AptaPharma Inc.-2181914$APTAPHARMA INC.$Full text$5$YR$$$Y$$$20250806$$$TR$TR
256494311$25649431$1$I$$20250731$20250806$20250806$EXP$$EU-SAMSUNG BIOEPIS-SB-2025-26660$SAMSUNG BIOEPIS$$$$$F$Y$$$20250806$$CN$EU$EU
256494501$25649450$1$I$20250415$20250725$20250806$20250806$EXP$$BR-VIIV HEALTHCARE-BR2025AMR099131$VIIV$$$$$M$Y$$$20250806$$$BR$BR
256494605$25649460$5$F$20250213$20250827$20250806$20250904$30DAY$$US-PFIZER INC-202500155414$PFIZER$$38$YR$$M$Y$59.87$KG$20250904$$HP$US$US
256494952$25649495$2$F$$20250927$20250806$20250930$EXP$$TR-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-518359$RANBAXY$Babacan A. Cold-associated laryngopharyngeal dysesthesia syndrome after oxaliplatin treatment. J Oncol Pharm Pract. 2024;30 (7):1245-1248$77$YR$$F$Y$$$20250930$$HP$TR$TR
256495021$25649502$1$I$$20250725$20250806$20250806$EXP$AU-TGA-839201$AU-Accord-496744$ACCORD$$57$YR$A$F$Y$$$20250806$$HP$AU$AU
256495221$25649522$1$I$$20250805$20250806$20250806$PER$$US-JNJFOC-20250804506$JOHNSON AND JOHNSON$$$$$$Y$$$20250806$$CN$US$US
256495751$25649575$1$I$$20250725$20250806$20250806$EXP$AU-TGA-835643$AU-Accord-496916$ACCORD$$48$YR$A$F$Y$$$20250806$$HP$AU$AU
256496461$25649646$1$I$$20250729$20250806$20250806$PER$$US-ROCHE-10000351385$ROCHE$$$$A$F$Y$$$20250806$$CN$US$US
256496831$25649683$1$I$20250715$20250715$20250806$20250806$PER$$US-009507513-2309551$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250806$$PH$US$US
256496991$25649699$1$I$20250101$20250801$20250806$20250806$EXP$$US-ABBVIE-6399794$ABBVIE$$70$YR$$M$Y$$$20250806$$CN$US$US
256497341$25649734$1$I$$20250725$20250806$20250806$EXP$$EU-MACLEODS PHARMA-MAC2025054478$MACLEODS$$$$$$Y$$$20250806$$HP$EU$EU
256498161$25649816$1$I$$20250805$20250806$20250806$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-109385$BRISTOL-MYERS SQUIBB COMPANY$$86$YR$E$$Y$$$20250806$$CN$US$US
256498471$25649847$1$I$20250801$20250804$20250806$20250806$PER$$US-ELI_LILLY_AND_COMPANY-US202508003929$ELI LILLY AND COMPANY$$81$YR$E$$Y$$$20250806$$CN$US$US
256498561$25649856$1$I$$20250801$20250806$20250806$EXP$$US-AMGEN-USASP2025154478$AMGEN$$26$YR$A$F$Y$$$20250806$$HP$US$US
256499421$25649942$1$I$$20250805$20250806$20250806$PER$$US-BAYER-2025A104061$BAYER HEALTHCARE LLC$$81$YR$E$F$Y$$$20250806$$CN$US$US
256499881$25649988$1$I$20250529$20250729$20250806$20250806$EXP$$US-EMD Serono-2025036755$EMD SERONO INC$$51$YR$A$F$Y$$$20250806$$$US$US
256500571$25650057$1$I$$20250805$20250806$20250806$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-109153$BRISTOL-MYERS SQUIBB COMPANY$$56$YR$A$F$Y$$$20250806$$HP$US$US
256501021$25650102$1$I$$20250805$20250806$20250806$PER$$US-BEH-2025215309$CSL BEHRING$$$$E$M$Y$$$20250806$$PH$US$US
256501141$25650114$1$I$$20250806$20250806$20250806$DIR$FDA-CDER-CTU-2025-52120$$FDA-CTU$$53$YR$$M$N$$$20250806$N$CN$US$
256502041$25650204$1$I$$20250731$20250806$20250806$EXP$$US-NOVOPROD-1491999$NOVO NORDISK$$86$YR$$$Y$$$20250806$$CN$US$US
256502441$25650244$1$I$20220101$20250804$20250806$20250806$EXP$$US-ABBVIE-6402721$ABBVIE$$57$YR$$F$Y$$$20250806$$CN$US$US
256503011$25650301$1$I$20250528$20250728$20250806$20250806$EXP$EU-MINISAL02-1050263$EU-FreseniusKabi-FK202510611$FRESENIUS KABI$$75$YR$E$M$Y$$$20250806$$HP$EU$EU
256503081$25650308$1$I$$20250805$20250805$20250805$DIR$768473$$FDA-CTU$$$$$$N$$$20250805$$CN$US$
256503133$25650313$3$F$20250804$20250826$20250806$20250902$EXP$$US-JNJFOC-20250805277$JOHNSON AND JOHNSON$$57$YR$A$M$Y$90.72$KG$20250902$$MD$US$US
256503341$25650334$1$I$$20250727$20250806$20250806$EXP$$US-ELI_LILLY_AND_COMPANY-US202507026823$ELI LILLY AND COMPANY$$79$YR$E$$Y$$$20250806$$LW$US$US
256503791$25650379$1$I$$20250727$20250806$20250806$EXP$$US-ELI_LILLY_AND_COMPANY-US202507026976$ELI LILLY AND COMPANY$$59$YR$A$$Y$$$20250806$$LW$US$US
256504022$25650402$2$F$$20250819$20250806$20250828$EXP$$US-TEVA-VS-3358282$TEVA$McCarty K, Zheng S, Simms-Waldrip T, Shliakhtsitsava K. Fibroblast Growth Factor Receptor 1 Rearranged Myeloproliferative Neoplasm (MLN-FGFR1) in a Pediatric Patient; Challenging Diagnosis and Treatment Approach. Blood 2024; 144 (Suppl. 1) 6671.; McCarty K, Zheng S, Simms-Waldrip T, Shliakhtsitsava K. Fibroblast Growth Factor Receptor 1 Rearranged Myeloproliferative Neoplasm (MLN-FGFR1) in a Pediatric Patient; Challenging Diagnosis and Treatment Approach. Blood 2024; 144 (Suppl. 1) 6671.$16$YR$$F$Y$$$20250828$$HP$US$US
256504291$25650429$1$I$$20250729$20250806$20250806$PER$$US-JNJFOC-20250805428$JOHNSON AND JOHNSON$$$$$M$Y$$$20250806$$HP$US$US
256504321$25650432$1$I$20250722$20250804$20250806$20250806$EXP$EU-INFARMED-T202507-1140$EU-FreseniusKabi-FK202510885$FRESENIUS KABI$$35$YR$A$F$Y$70$KG$20250806$$MD$EU$EU
256505601$25650560$1$I$20250706$20250728$20250806$20250806$EXP$$GB-TEVA-VS-3358944$TEVA$$$$$$Y$$$20250806$$CN$GB$GB
256505851$25650585$1$I$$20250802$20250806$20250806$EXP$$GB-VANTIVE-2025VAN003525$Vantive US Healthcare$$$$$M$Y$58.5$KG$20250806$$HP$GB$GB
256506772$25650677$2$F$20250701$20250826$20250806$20250901$PER$$US-SA-2025SA226817$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250901$$CN$US$US
256508711$25650871$1$I$20250101$20250804$20250806$20250806$PER$$US-SA-2025SA229866$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250806$$HP$US$US
256508811$25650881$1$I$20220101$20250802$20250806$20250806$PER$$US-SA-2025SA229906$SANOFI AVENTIS$$39$YR$A$M$Y$$$20250806$$HP$US$US
256509061$25650906$1$I$20250719$20250731$20250806$20250806$EXP$$CN-AMGEN-CHNSP2025153758$AMGEN$$61$YR$A$F$Y$63$KG$20250806$$HP$CN$CN
256509111$25650911$1$I$$20250804$20250806$20250806$PER$$US-SA-2025SA229352$SANOFI AVENTIS$$$$C$F$Y$21.36$KG$20250806$$MD$US$US
256509981$25650998$1$I$20241001$20250731$20250806$20250806$EXP$$GT-SA-2025SA229701$SANOFI AVENTIS$$88$YR$E$F$Y$$$20250806$$MD$GT$GT
256510131$25651013$1$I$$20250621$20250806$20250806$PER$$US-PFIZER INC-202500127399$PFIZER$$$$$F$Y$$$20250806$$CN$US$US
256510581$25651058$1$I$20250415$20250731$20250806$20250806$EXP$$US-TEVA-VS-3359128$TEVA$$36$YR$$F$Y$73$KG$20250806$$CN$US$US
256510871$25651087$1$I$20230813$20250806$20250806$20250806$EXP$EU-BASGAGES-2025-004882$EU-BAYER-2025A104513$BAYER HEALTHCARE PHARMACEUTICALS INC.$$42$YR$A$M$Y$$$20250806$$CN$EU$EU
256516321$25651632$1$I$$20250723$20250806$20250806$EXP$$TR-SLATERUN-2025SRLIT00127$SLATE RUN$Arikoglu T, et al..Diagnostic evaluation of hypersensitivity reactions to arylpropionic  acid derivatives: a descriptive observational study focusing on clinical  characteristics and potential risk factors in children.International Journal of Clinical Pharmacy.11-jun-2024;46 (6):1294-1306$5$YR$C$$Y$$$20250806$$HP$TR$TR
256517551$25651755$1$I$$20240816$20250806$20250806$PER$$US-EVOKE PHARMA, INC.-2024EVO000068$EVOKE PHARMA$$$$$F$Y$$$20250805$$HP$US$US
256517761$25651776$1$I$20250101$20250424$20250806$20250806$PER$$US-EVOKE PHARMA, INC.-2025EVO000025$EVOKE PHARMA$$$$$$Y$$$20250806$$CN$US$US
256518121$25651812$1$I$$20250804$20250806$20250806$EXP$CA-HEALTHCANVIG-001130906$CA-PURDUE-USA-2025-0319506$PURDUE$$42$YR$$M$Y$122$KG$20250806$$HP$CA$CA
256519961$25651996$1$I$$20250728$20250806$20250806$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2024SPA005991$SUNOVION$$65$YR$$M$Y$$$20250806$$$US$US
256520011$25652001$1$I$20250701$20250729$20250806$20250806$EXP$$CA-JNJFOC-20250801379$JOHNSON AND JOHNSON$$$$$M$Y$$$20250807$$CN$CA$CA
256520111$25652011$1$I$20220712$20250805$20250806$20250806$EXP$$US-JNJFOC-20250433536$JOHNSON AND JOHNSON$$$$E$F$Y$$$20250807$$HP$US$US
256520891$25652089$1$I$$20250727$20250806$20250806$EXP$$US-ABBVIE-6403573$ABBVIE$Posligua A, Shahwan KT, Carr DR. Facial Necrotizing Fasciitis After Mohs Micrographic Surgery. Dermatologic Surgery. 2025;725-727. doi: 10.1097/DSS.000000000000459.$73$YR$$M$Y$$$20250806$$MD$US$US
256522001$25652200$1$I$$20250804$20250807$20250807$PER$$US-SA-2025SA229636$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250807$$HP$US$US
256522331$25652233$1$I$$20250804$20250807$20250807$PER$$US-ABBVIE-6403281$ABBVIE$$$$E$M$Y$$$20250807$$CN$US$US
256522861$25652286$1$I$$20250729$20250807$20250807$EXP$$US-NOVOPROD-1491367$NOVO NORDISK$$$$$F$Y$$$20250807$$CN$US$US
256523871$25652387$1$I$$20250723$20250807$20250807$EXP$$US-GSK-US2025AMR095870$GLAXOSMITHKLINE$$$$$F$Y$$$20250807$$$US$US
256524101$25652410$1$I$$20250727$20250807$20250807$EXP$$US-Accord-498552$ACCORD$Sulaiman A, Leppla I. The Identification and Challenges of Dopamine Dysregulation Syndrome: A Case Report. Cureus. 2025;17(6):e86547. DOI: 10.7759/cureus.86547.$48$YR$A$M$Y$$$20250807$$MD$US$US
256525332$25652533$2$F$$20250817$20250807$20250822$EXP$$US-TEVA-VS-3358471$TEVA$Hren MG, Khattri S. Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series. Ann-Rheum-Dis 2024; 83 (10): 1392-1393.; Hren MG, Khattri S. Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series. Ann-Rheum-Dis 2024; 83 (10): 1392-1393.; Hren MG, Khattri S. Treatment of recalcitrant psoriasis and psoriatic arthritis with a ...$50$YR$$F$Y$$$20250822$$HP$US$US
256525492$25652549$2$F$$20250817$20250807$20250821$EXP$$US-TEVA-VS-3358349$TEVA$Mopuru NN, Banda SV, Kallakuri K, Apedo MY. Daptomycin-induced Pneumonitis in the Treatment of Osteomyelitis: A Case Report. Am-J-Respir-Crit-Care-Med 2025; 211 A1904.; Mopuru NN, Banda SV, Kallakuri K, Apedo MY. Daptomycin-induced Pneumonitis in the Treatment of Osteomyelitis: A Case Report. Am-J-Respir-Crit-Care-Med 2025; 211 A1904.$82$YR$$M$Y$$$20250821$$HP$US$US
256525551$25652555$1$I$$20250729$20250807$20250807$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA009019$SUNOVION$$85$YR$$M$Y$$$20250806$$$US$US
256525621$25652562$1$I$20240316$20250727$20250807$20250807$EXP$GB-MHRA-MED-202507271544047390-RKGCS$GB-Accord-497650$ACCORD$$59$YR$A$M$Y$106$KG$20250807$$CN$GB$GB
256525802$25652580$2$F$$20250807$20250807$20250818$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA009241$SUNOVION$$63$YR$$M$Y$$$20250814$$$US$US
256526331$25652633$1$I$$20250528$20250807$20250807$PER$$US-AUROBINDO-AUR-APL-2025-028292$AUROBINDO$$$$$$Y$$$20250807$$HP$US$US
256526652$25652665$2$F$20241002$20250804$20250807$20250828$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000889$DECIPHERA PHARMACEUTICALS$$56$YR$A$M$Y$$$20250828$$CN$US$US
256526751$25652675$1$I$$20250804$20250807$20250807$PER$$US-ELI_LILLY_AND_COMPANY-US202508003093$ELI LILLY AND COMPANY$$32$YR$A$$Y$$$20250807$$CN$US$US
256527051$25652705$1$I$$20250802$20250807$20250807$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008910$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250807$$CN$US$US
256527202$25652720$2$F$$20250903$20250807$20250910$EXP$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2024SPA000618$SUNOVION$$82$YR$$M$Y$$$20250909$$$US$US
256527301$25652730$1$I$$20250801$20250807$20250807$EXP$$US-VIIV HEALTHCARE-US2025099501$VIIV$$$$$$Y$$$20250807$$PH$US$US
256528001$25652800$1$I$$20250805$20250807$20250807$PER$$US-ABBVIE-6403763$ABBVIE$$$$$$Y$$$20250807$$CN$US$US
256528071$25652807$1$I$20250728$20250731$20250807$20250807$EXP$$US-BIOGEN-2025BI01319513$BIOGEN$$23$YR$$F$Y$$$20250807$$CN$US$US
256528114$25652811$4$F$$20250812$20250807$20250820$EXP$$US-GSK-US2025AMR098782$GLAXOSMITHKLINE$$$$$F$Y$$$20250820$$$US$US
256528851$25652885$1$I$20250710$20250725$20250807$20250807$EXP$GB-MHRA-MED-202507241009168250-QYHZG$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-08227$ALKEM$$$$$F$Y$$$20250806$$PH$GB$GB
256531112$25653111$2$F$$20250923$20250807$20250926$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-008962$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250926$$CN$US$US
256532151$25653215$1$I$$20250730$20250807$20250807$EXP$EU-URPL-DML-MLP.4401.1.3194.2021$EU-KENVUE-20250800185$Kenvue$$$$$$Y$$$20250807$$MD$EU$EU
256532293$25653229$3$F$$20250923$20250807$20250929$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-008953$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250929$$CN$US$US
256532661$25653266$1$I$$20250804$20250807$20250807$PER$$US-ELI_LILLY_AND_COMPANY-US202508003358$ELI LILLY AND COMPANY$$$$$$Y$$$20250807$$CN$US$US
256532781$25653278$1$I$$20250326$20250807$20250807$PER$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-02958$HIKMA$$24$YR$$F$Y$$$20250807$$CN$US$US
256533041$25653304$1$I$$20250708$20250807$20250807$PER$$US-GSK-US2025AMR088106$GLAXOSMITHKLINE$$$$$F$Y$$$20250807$$$US$US
256533941$25653394$1$I$$20250724$20250807$20250807$EXP$$US-ALEMBIC PHARMACUETICALS LIMITED-2025SCAL000977$ALEMBIC$Barab H.. 61. DIFFICULTIES IN EVALUATING LITHIUM TOXICITY IN A PATIENT WITH NUMEROUS MEDICAL COMORBIDITIES. American Journal of Geriatric Psychiatry. 2025;33:10 Sup (S45)$$$$$Y$$$20250807$$HP$US$US
256534631$25653463$1$I$20250728$20250729$20250807$20250807$EXP$$GB-AUROBINDO-AUR-APL-2025-040037$AUROBINDO$$53$YR$$F$Y$$$20250807$$HP$GB$GB
256535721$25653572$1$I$20250109$20250115$20250807$20250807$PER$$US-Techdow-2025Techdow000037$SHENZHEN TECHDOW PHARMACEUTICAL$$64$YR$A$$Y$$$20250806$$PH$US$US
256535941$25653594$1$I$$20250801$20250807$20250807$PER$$NVSC2025US123001$NOVARTIS$$$$$$Y$$$20250807$$CN$US$US
256536352$25653635$2$F$20250519$20250916$20250807$20250919$EXP$EU-AFSSAPS-RN2025000680$EU-Orion Corporation ORION PHARMA-25_00036001$ORION$$92$YR$E$M$Y$$$20250919$$MD$EU$
256536881$25653688$1$I$$20250725$20250807$20250807$EXP$$CA-MYLANLABS-2025M1063626$MYLAN$$$$$F$Y$$$20250726$$$CA$CA
256536991$25653699$1$I$20250709$20250731$20250807$20250807$EXP$$CN-TAKEDA-2025TUS070082$TAKEDA$$59$YR$$M$Y$$$20250807$$$CN$CN
256537482$25653748$2$F$$20250908$20250807$20250922$PER$$NVSC2025US124973$NOVARTIS$$$$$M$Y$$$20250922$$CN$US$US
256537602$25653760$2$F$20250717$20250813$20250807$20250922$EXP$$EU-ASTRAZENECA-202508EEA003223PL$ALEXION PHARMACEUTICALS$$73$YR$E$M$Y$94$KG$20250904$$MD$EU$EU
256537711$25653771$1$I$$20250725$20250807$20250807$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI09845$NEUROCRINE BIOSCIENCES$$38$YR$$M$Y$$$20250807$$HP$US$US
256538121$25653812$1$I$$20250801$20250807$20250807$PER$$US-SA-2025SA229540$SANOFI AVENTIS$$$$A$F$Y$$$20250807$$HP$US$US
256538921$25653892$1$I$$20250731$20250807$20250807$PER$$US-CHATTEMPRD-2025OHG023967$CHATTEM$$$$$$Y$$$20250807$$CN$US$US
256538991$25653899$1$I$$20250728$20250807$20250807$EXP$$US-Fourrts (India) Laboratories Pvt. Ltd.-2182031$Fourrts (India) Laboratories$Souce document$60$YR$$F$Y$$$20250807$$$US$US
256539521$25653952$1$I$$20250805$20250807$20250807$PER$$US-SA-2025SA229968$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250807$$CN$US$US
256540271$25654027$1$I$$20250730$20250807$20250807$EXP$$TW-MYLANLABS-2025M1065349$MYLAN$$50$YR$$M$Y$$$20250807$$$TW$TW
256541021$25654102$1$I$$20250724$20250807$20250807$EXP$$TR-ASCENT-2025ASLIT00147$ASCENT PHARMACEUTICALS INC$Arikoglu T, et al..Diagnostic evaluation of hypersensitivity reactions to arylpropionic acid derivatives: a descriptive observational study focusing on clinical characteristics and potential risk factors in children.International Journal of Clinical Pharmacy.11-jun-2024;46 (6):1294-1306$9$YR$C$$Y$$$20250807$$HP$TR$TR
256541541$25654154$1$I$$20250801$20250807$20250807$EXP$$GB-MYLANLABS-2025M1049022$MYLAN$$$$$F$Y$$$20250807$$PH$GB$GB
256541881$25654188$1$I$20250101$20250805$20250807$20250807$PER$$US-SA-2025SA230933$SANOFI AVENTIS$$38$YR$A$F$Y$$$20250807$$CN$US$US
256542791$25654279$1$I$$20250717$20250807$20250807$EXP$$US-GALDERMA-US2025012954$GALDERMA$$$$$$Y$$$20250807$$CN$US$US
256542832$25654283$2$F$20250731$20250807$20250807$20250811$EXP$$EU-BAXTER-2025BAX019415$BAXTER$$12$YR$$M$Y$$$20250811$$PH$EU$EU
256543271$25654327$1$I$20250601$20250805$20250807$20250807$PER$$US-JNJFOC-20250805080$JOHNSON AND JOHNSON$$77$YR$$M$Y$$$20250807$$CN$US$US
256543661$25654366$1$I$$20250804$20250807$20250807$PER$$US-JNJFOC-20250802990$JOHNSON AND JOHNSON$$$$$$Y$$$20250807$$CN$US$US
256543911$25654391$1$I$20250801$20250805$20250807$20250807$PER$$US-SA-2025SA231289$SANOFI AVENTIS$$1$YR$I$F$Y$13.605$KG$20250807$$HP$US$US
256545201$25654520$1$I$$20250728$20250806$20250806$DIR$FDA-CDER-CTU-2025-52212$$FDA-CTU$$$$$M$N$$$20250728$N$HP$US$
256545351$25654535$1$I$$20250806$20250806$20250806$DIR$FDA-CDER-CTU-2025-52225$$FDA-CTU$$98$YR$$F$N$$$20250806$N$$US$
256546401$25654640$1$I$20241201$20250731$20250807$20250807$EXP$$CO-UCBSA-2025048283$UCB$$$$A$M$Y$$$20250807$$CN$CO$CO
256547491$25654749$1$I$$20250723$20250807$20250807$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-521244$RANBAXY$Jassal T, Kharade V, Das S, Gupta M. Case report of an adult with rhabdomyosarcoma of lung with ovarian metastases or the other way around: Do^s and don?ts with review of literature. J Cancer Res Ther. 2025;21(3):762-766.$52$YR$$F$Y$$$20250807$$HP$IN$IN
256547641$25654764$1$I$$20250723$20250807$20250807$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-521062$RANBAXY$Sturm L, Haas N, Flemmer A, Kley A, Schmidt S, Pattathu J. From Simple Medical History to Complex Diagnosis-A Rare Case of Sertraline-induced PPHN. Thorac Cardiovasc Surg. 2025;72:S77-S103$$$N$$Y$$$20250807$$HP$EU$EU
256547671$25654767$1$I$$20250723$20250807$20250807$EXP$$IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-520037$RANBAXY$Friedman-Korn T, Benoliel-Berman T, Doufish D, Shifman T,Medvedovsky M, Ekstein D. Levetiracetam-induced seizure aggravation-case series and literature review. Seizure. 2025;129(0):77-83$75$YR$$M$Y$$$20250807$$HP$IL$IL
256547721$25654772$1$I$20230411$20250723$20250807$20250807$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-520379$RANBAXY$$59$YR$$F$Y$68$KG$20250807$$MD$EU$EU
256548171$25654817$1$I$20230613$20250723$20250807$20250807$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-520717$RANBAXY$$29$YR$$F$Y$96$KG$20250807$$PH$EU$EU
256548561$25654856$1$I$$20250724$20250807$20250807$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-521366$RANBAXY$Liberko M. Pemigatinib in the treatment of FGFR2+ cholangiocarcinoma - miracles happen. Clinical Oncology. 2025;38(3):233-234$58$YR$$F$Y$$$20250807$$MD$EU$EU
256548781$25654878$1$I$$20250804$20250807$20250807$PER$$US-SA-2025SA228689$SANOFI AVENTIS$$75$YR$E$F$Y$$$20250807$$CN$US$US
256549221$25654922$1$I$20241101$20250730$20250807$20250807$EXP$GB-MHRA-MED-202507291121165870-ZKBGV$GB-TORRENT-00042248$TORRENT PHARMA INC.$$67$YR$E$F$Y$54$KG$20250807$$CN$GB$GB
256549371$25654937$1$I$$20250730$20250807$20250807$EXP$$US-AUROBINDO-AUR-APL-2024-046759$AUROBINDO$Lee JZ, Tan MC, Karikalan S, Deshmukh AJ, Srivathsan K, Shen WK, et al.. Causes of Early Mortality After Ventricular Tachycardia Ablation in Patients With Reduced Ejection Fraction. JACC: CLINICAL ELECTROPHYSIOLOGY. 2023;9(6):824-832$50$YR$$M$Y$$$20250807$$MD$US$US
256549592$25654959$2$F$$20250817$20250807$20250821$EXP$$US-TEVA-VS-3358358$TEVA$Abushamma A, Shah S, Ejaz A, Pande A. DMARDs Associated Cavitary Lung Pleuro-pulmonary Disease. Am-J-Respir-Crit-Care-Med 2025; 211.; Abushamma A, Shah S, Ejaz A, Pande A. DMARDs Associated Cavitary Lung Pleuro-pulmonary Disease. Am-J-Respir-Crit-Care-Med 2025; 211.$67$YR$$$Y$$$20250821$$HP$US$US
256549711$25654971$1$I$20250417$20250730$20250807$20250807$EXP$EU-ADIENNEP-2025AD000574$EU-ADIENNEP-2025AD000574$ADIENNE PHARMA + BIOTECH$$53$YR$$F$Y$$$20250731$$MD$EU$EU
256549721$25654972$1$I$20250601$20250804$20250807$20250807$PER$$US-SA-2025SA230398$SANOFI AVENTIS$$32$YR$A$F$Y$$$20250807$$HP$US$US
256550161$25655016$1$I$20250101$20250717$20250807$20250807$EXP$$US-GALDERMA-US2025012959$GALDERMA$$$$$$Y$$$20250807$$CN$US$US
256550431$25655043$1$I$20250101$20250805$20250807$20250807$EXP$GB-MHRA-MED-202508051709591140-TRNZH$GB-PFIZER INC-202500157781$PFIZER$$$$$M$Y$$$20250807$$CN$GB$GB
256550662$25655066$2$F$$20250829$20250807$20250905$PER$$US-SA-2025SA230345$SANOFI AVENTIS$$10$YR$C$M$Y$$$20250905$$HP$US$US
256551201$25655120$1$I$$20250805$20250807$20250807$EXP$$CA-PFIZER INC-202500158569$PFIZER$$69$YR$$M$Y$$$20250807$$HP$CA$CA
256551391$25655139$1$I$20250704$20250801$20250807$20250807$EXP$EU-AEMPS-1737235$EU-TEVA-VS-3359266$TEVA$$87$YR$$M$Y$58.2$KG$20250807$$MD$EU$EU
256551442$25655144$2$F$20250725$20250815$20250807$20250819$EXP$$US-REVANCE THERAPEUTICS INC.-US-REV-2025-000471$REVANCE THERAPEUTICS$$$$$$Y$$$20250819$$HP$US$US
256551841$25655184$1$I$$20250806$20250806$20250806$DIR$768696$$FDA-CTU$$$$$$N$$$20250806$N$CN$US$
256551941$25655194$1$I$20250806$20250806$20250806$20250806$DIR$768726$$FDA-CTU$$68$YR$$M$N$51.8$KG$20250806$N$PH$US$
256553551$25655355$1$I$20250101$20250806$20250807$20250807$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-110073$BRISTOL-MYERS SQUIBB COMPANY$$28$YR$A$M$Y$$$20250807$$HP$US$US
256553681$25655368$1$I$$20240920$20250807$20250807$EXP$$KR-ASTRAZENECA-202409KOR001698KR$ALEXION PHARMACEUTICALS$$60$YR$A$M$Y$$$20250807$$MD$KR$KR
256554571$25655457$1$I$20250707$20250801$20250807$20250807$EXP$$US-AGIOS-2508US04406$AGIOS PHARMACEUTICALS$$67$YR$$F$Y$$$20250807$$CN$US$US
256555143$25655514$3$F$20250730$20250924$20250807$20250930$EXP$$JP-MYLANLABS-2025M1065179$MYLAN$$62$YR$$F$Y$$$20250930$$PH$JP$JP
256555181$25655518$1$I$$20250807$20250807$20250807$DIR$FDA-CDER-CTU-2025-52398$$FDA-CTU$$87$YR$$F$N$$$20250807$N$$US$
256555542$25655554$2$F$$20250827$20250807$20250828$30DAY$$JP-JNJFOC-20250807231$JOHNSON AND JOHNSON$$$$$$Y$$$20250828$$PH$JP$JP
256558392$25655839$2$F$$20250827$20250807$20250829$EXP$$JP-OTSUKA-2025_017345$OTSUKA$$10$DEC$$$Y$$$20250829$$PH$JP$JP
256559331$25655933$1$I$$20250726$20250807$20250807$EXP$$US-ELI_LILLY_AND_COMPANY-US202507026133$ELI LILLY AND COMPANY$$65$YR$E$$Y$$$20250807$$LW$US$US
256559481$25655948$1$I$$20250806$20250807$20250807$PER$$US-ELI_LILLY_AND_COMPANY-US202508006140$ELI LILLY AND COMPANY$$47$YR$A$$Y$$$20250807$$CN$US$US
256559711$25655971$1$I$$20250805$20250807$20250807$PER$$US-SA-2025SA231144$SANOFI AVENTIS$$$$A$M$Y$$$20250807$$CN$US$US
256559931$25655993$1$I$$20250803$20250807$20250807$EXP$$AU-Taiho Oncology Inc-2025-008219$TAIHO ONCOLOGY INC$$$$E$$Y$$$20250807$$HP$AU$AU
256560213$25656021$3$F$20200101$20250822$20250807$20250826$EXP$$EU-SA-2025SA230718$SANOFI AVENTIS$Fabianova J.. Coordination of clinical oncology, radiation oncology and surgery in the treatment of a patient with tumours in GIT.. Farmakoterapie.. 2022;18:756-60$48$YR$A$M$Y$$$20250826$$$COUNTRY NOT SPECIFIED$EU
256560241$25656024$1$I$$20250805$20250807$20250807$EXP$$US-ASTRAZENECA-202508USA002673US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250807$$$US$US
256560521$25656052$1$I$$20250712$20250807$20250807$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0011933$RECKITT BENCKISER$$60$YR$$F$Y$$$20250807$$CN$US$US
256560592$25656059$2$F$$20250819$20250807$20250822$30DAY$$CO-PFIZER INC-202500154663$PFIZER$$$$T$F$Y$$$20250822$$CN$CO$CO
256560621$25656062$1$I$20221112$20250805$20250807$20250807$EXP$$US-PFIZER INC-PV202500094846$PFIZER$$$$$F$Y$$$20250807$$LW$US$US
256560751$25656075$1$I$$20250804$20250807$20250807$EXP$$US-ASTRAZENECA-202508USA001119US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250807$$$US$US
256561651$25656165$1$I$20250721$20250805$20250807$20250807$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-087638$BOEHRINGER INGELHEIM$$74$YR$E$M$Y$$$20250807$$MD$EU$EU
256562111$25656211$1$I$$20250701$20250807$20250807$PER$$US-TRAVERE-2025TVT01080$TRAVERE THERAPEUTICS$$$$$M$Y$$$20250807$$CN$US$US
256562311$25656231$1$I$20250604$20250731$20250807$20250807$EXP$$NVSC2025CN123106$NOVARTIS$$40$YR$$F$Y$$$20250807$$HP$CN$CN
256562941$25656294$1$I$20250627$20250806$20250807$20250807$EXP$$US-ASTRAZENECA-202508USA003322US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250807$$$US$US
256562991$25656299$1$I$$20250804$20250807$20250807$30DAY$$US-SANDOZ INC.-SDZ2025US056101$SANDOZ$$$$$F$Y$$$20250807$$CN$US$US
256563501$25656350$1$I$$20250806$20250807$20250807$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-109896$BRISTOL-MYERS SQUIBB COMPANY$$72$YR$E$M$Y$$$20250807$$CN$US$US
256564831$25656483$1$I$$20250730$20250807$20250807$EXP$$US-ELI_LILLY_AND_COMPANY-US202508004488$ELI LILLY AND COMPANY$$54$YR$A$$Y$$$20250807$$LW$US$US
256565231$25656523$1$I$$20250729$20250807$20250807$PER$$US-BEH-2025214582$CSL BEHRING$$$$A$F$Y$$$20250807$$HP$US$US
256566011$25656601$1$I$20250723$20250807$20250807$20250807$EXP$EU-AFSSAPS-LY2025001290$EU-ASTRAZENECA-202508GLO004107FR$ALEXION PHARMACEUTICALS$$73$YR$E$M$Y$62$KG$20250807$$PH$EU$EU
256567801$25656780$1$I$20250425$20250430$20250807$20250807$PER$$US-MALLINCKRODT-MNK202502665$MALLINCKRODT$$24$YR$A$F$Y$$$20250807$$CN$US$US
256567811$25656781$1$I$$20250501$20250807$20250807$PER$$US-MALLINCKRODT-MNK202502663$MALLINCKRODT$$54$YR$A$M$Y$$$20250807$$CN$US$US
256568011$25656801$1$I$$20250806$20250807$20250807$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-087808$BOEHRINGER INGELHEIM$$59$YR$A$M$Y$$$20250807$$PH$CA$CA
256568531$25656853$1$I$20250804$20250805$20250807$20250807$EXP$$US-BAUSCHBL-2025BNL013747$BAUSCH AND LOMB$$66$YR$$F$Y$$$20250808$$CN$US$US
256569301$25656930$1$I$$20250726$20250807$20250807$PER$$US-TRAVERE-2025TVT01300$TRAVERE THERAPEUTICS$$$$$F$Y$$$20250804$$CN$US$US
256569961$25656996$1$I$20250101$20250730$20250807$20250807$EXP$$US-NOVOPROD-1493528$NOVO NORDISK$$$$$F$Y$$$20250808$$CN$US$US
256570061$25657006$1$I$20250717$20250730$20250807$20250807$EXP$$BR-NOVOPROD-1492284$NOVO NORDISK$$45$YR$$F$Y$74$KG$20250808$$CN$BR$BR
256570631$25657063$1$I$$20250806$20250807$20250807$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-110163$BRISTOL-MYERS SQUIBB COMPANY$$73$YR$E$F$Y$47.17$KG$20250808$$HP$US$US
256571961$25657196$1$I$$20250717$20250808$20250808$EXP$GB-UCBSA-2025038663$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-07181$ALKEM$$16$YR$$F$Y$$$20250808$$MD$GB$GB
256572161$25657216$1$I$$20250724$20250808$20250808$EXP$$US-GSK-US2025AMR096590$GLAXOSMITHKLINE$$$$$F$Y$$$20250808$$$US$US
256572801$25657280$1$I$$20250806$20250808$20250808$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-109953$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250808$$CN$US$US
256573101$25657310$1$I$$20250728$20250808$20250808$EXP$AU-TGA-840786$AU-Accord-497302$ACCORD$$76$YR$E$F$Y$$$20250808$$HP$AU$AU
256573291$25657329$1$I$$20250804$20250808$20250808$EXP$$GB-TEVA-VS-3360756$TEVA$$64$YR$$F$Y$63$KG$20250808$$HP$GB$GB
256574221$25657422$1$I$20220302$20250804$20250808$20250808$EXP$$EU-BAXTER-2025BAX019295$BAXTER$$56$YR$$M$Y$71$KG$20250808$$MD$EU$EU
256574983$25657498$3$F$$20250813$20250808$20250814$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-110115$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250814$$CN$US$US
256575371$25657537$1$I$20250730$20250805$20250808$20250808$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-008956$ACADIA PHARMACEUTICALS$$81$YR$$M$Y$$$20250808$$CN$US$US
256575761$25657576$1$I$20250616$20250729$20250808$20250808$EXP$$GB-862174955-ML2025-03900$Unknown Manufacturer$$71$YR$E$F$Y$77$KG$20250808$$HP$GB$GB
256575771$25657577$1$I$20250617$20250728$20250808$20250808$EXP$EU-AFSSAPS-CN2025000785$EU-Accord-498685$ACCORD$$68$YR$E$F$Y$52$KG$20250808$$MD$EU$EU
256575841$25657584$1$I$20240101$20250731$20250808$20250808$EXP$$US-AMGEN-USASP2025153670$AMGEN$Witt R.G.; Kuchimanchi N.; Gajula S. et al.. Immune Checkpoint Inhibitor-Related Dysautonomia in Merkel Cell Carcinoma: A Case Report. Cancer Reports. 2025;8 (7):1-7$57$YR$A$M$Y$$$20250808$$HP$US$US
256576741$25657674$1$I$20250101$20250203$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-493659$RANBAXY$$69$YR$E$M$Y$$$20250808$$CN$US$US
256576891$25657689$1$I$$20250106$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-489175$RANBAXY$$$$$F$Y$$$20250808$$CN$US$US
256576981$25657698$1$I$$20241210$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-485661$RANBAXY$$$$A$M$Y$$$20250808$$MD$US$US
256577001$25657700$1$I$20241118$20250106$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-481478$RANBAXY$$82$YR$E$M$Y$$$20250808$$CN$US$US
256577101$25657710$1$I$$20250401$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-485645$RANBAXY$$$$E$F$Y$$$20250808$$CN$US$US
256577331$25657733$1$I$$20250619$20250808$20250808$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-505340$RANBAXY$$$$A$M$Y$$$20250808$$CN$US$US
256579011$25657901$1$I$20250101$20250723$20250808$20250808$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-126752$ZYDUS PHARM$$$$$$Y$$$20250808$$CN$US$US
256579231$25657923$1$I$$20250731$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508001773$ELI LILLY AND COMPANY$$46$YR$A$$Y$$$20250808$$LW$US$US
256579471$25657947$1$I$$20250729$20250808$20250808$EXP$$CA-ROCHE-10000357107$ROCHE$$70$YR$E$F$Y$$$20250808$$HP$CA$CA
256579651$25657965$1$I$20240701$20250728$20250808$20250808$EXP$EU-SEMPA-2025-004872$EU-Accord-498787$ACCORD$$79$YR$E$F$Y$$$20250808$$MD$EU$EU
256580082$25658008$2$F$20250101$20250901$20250808$20250902$EXP$$ZA-ABBVIE-6406106$ABBVIE$$82$YR$$F$Y$$$20250902$$MD$ZA$ZA
256580181$25658018$1$I$20250722$20250805$20250808$20250808$EXP$GB-MHRA-MED-202508051539037820-YRDQH$GB-AMGEN-GBRSP2025156677$AMGEN$$69$YR$E$M$Y$102$KG$20250808$$HP$GB$GB
256580201$25658020$1$I$20250701$20250729$20250808$20250808$EXP$$US-TEVA-VS-3358647$TEVA$$39$YR$$F$Y$$$20250808$$CN$US$US
256580721$25658072$1$I$20250701$20250805$20250808$20250808$EXP$$GB-AMGEN-GBRSP2025155480$AMGEN$$$$$F$Y$$$20250808$$HP$GB$GB
256580741$25658074$1$I$20240101$20250731$20250808$20250808$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25051935$RADIUS PHARM$$$$$F$Y$$$20250808$$CN$US$US
256580772$25658077$2$F$20241031$20250801$20250808$20250814$EXP$EU-ALKEM LABORATORIES LIMITED-FR-ALKEM-2025-08564$EU-ALKEM LABORATORIES LIMITED-FR-ALKEM-2025-08564$ALKEM$$53$YR$$M$Y$$$20250814$$MD$EU$EU
256580912$25658091$2$F$20250101$20250826$20250808$20250901$EXP$$US-SA-2025SA231799$SANOFI AVENTIS$$85$YR$E$M$Y$$$20250901$$MD$US$US
256581121$25658112$1$I$$20250806$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508005768$ELI LILLY AND COMPANY$$60$YR$A$M$Y$$$20250808$$CN$US$US
256581691$25658169$1$I$20250101$20250804$20250808$20250808$PER$$US-SA-2025SA232713$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250808$$HP$US$US
256582172$25658217$2$F$$20250821$20250808$20250825$EXP$EU-EMA-DD-20250730-7482831-103344$EU-SA-2025SA231018$SANOFI AVENTIS$schalkwijika a, Verhagen C,  Engels Y, Hekster Y et al.. Pitfalls in the treatment of neuropathic pain in patients with cancer.. Nederlands tijdschrift voor geneeskunde. 2011;155:A2494$71$YR$E$M$Y$$$20250825$$MD$EU$EU
256583151$25658315$1$I$$20250728$20250808$20250808$EXP$$US-AUROBINDO-AUR-APL-2025-039959$AUROBINDO$Casey TJ, Mehr BP.. A novel case of aripiprazole and clomipramine-induced toxic megacolon: enough to drive anyone mad.. J-Surg-Case-Rep. 2025;6 (1-3)$49$YR$$M$Y$$$20250808$$HP$US$US
256583931$25658393$1$I$20250603$20250729$20250808$20250808$EXP$$EU-AUROBINDO-AUR-APL-2025-040319$AUROBINDO$$64$YR$$F$Y$76$KG$20250808$$MD$EU$EU
256583951$25658395$1$I$$20250729$20250808$20250808$EXP$$EU-AUROBINDO-AUR-APL-2022-030873$AUROBINDO$Pistara E, Paterno Raddusa Ms, Bellocchi B, Campanella E, Moscatt V, Ceccarelli M, Celesia BM... HIV-positive individual with myocardial infarction management: drug-to-drug interactions and therapy optimization.. Journal of HIV and Ageing. 2022;7(2):37-40$64$YR$$M$Y$$$20250808$$MD$EU$EU
256584072$25658407$2$F$20250803$20250922$20250808$20250923$EXP$$US-ABBVIE-6404818$ABBVIE$$77$YR$$M$Y$83.9$KG$20250923$$CN$US$US
256584861$25658486$1$I$20250101$20250805$20250808$20250808$EXP$$US-ABBVIE-6405143$ABBVIE$$59$YR$$F$Y$$$20250808$$CN$US$US
256585111$25658511$1$I$$20241021$20250808$20250808$EXP$$RU-ASTRAZENECA-202410RUS016656RU$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250808$$$RU$RU
256585712$25658571$2$F$20250508$20250903$20250808$20250909$PER$$US-GILEAD-2025-0723564$GILEAD$$75$YR$E$F$Y$82.54$KG$20250909$$MD$US$US
256587031$25658703$1$I$$20250728$20250808$20250808$EXP$GB-MHRA-MED-202507241518001560-KJPRQ$GB-STRIDES ARCOLAB LIMITED-2025SP009850$STRIDES$$$$$F$Y$$$20250808$$HP$GB$GB
256587041$25658704$1$I$$20250724$20250808$20250808$EXP$$IL-Renata Limited-2182095$RENATA LIMITED$Full text$76$YR$$M$Y$$$20250808$$MD$IL$IL
256587392$25658739$2$F$20250801$20250822$20250808$20250828$PER$$JP-IDORSIA-011414-2025-JP$IDORSIA PHARMACEUTICALS$$10$DEC$$F$Y$$$20250828$$HP$JP$JP
256587431$25658743$1$I$20241118$20250807$20250808$20250808$EXP$EU-AFSSAPS-PC2025000066$NVSC2025FR012892$NOVARTIS$$43$YR$$M$Y$130$KG$20250808$$PH$EU$EU
256587451$25658745$1$I$$20250804$20250808$20250808$EXP$$US-TAKEDA-2025TUS069463$TAKEDA$$$$$M$Y$$$20250808$$MD$US$US
256587651$25658765$1$I$20250415$20250805$20250808$20250808$EXP$$US-TAKEDA-2025TUS069867$TAKEDA$$38$YR$$M$Y$$$20250808$$MD$US$US
256588301$25658830$1$I$$20250804$20250808$20250808$PER$$US-BIOGEN-2025BI01319707$BIOGEN$$$$$F$Y$$$20250808$$CN$US$US
256588651$25658865$1$I$20250101$20250804$20250808$20250808$PER$$US-SA-2025SA232516$SANOFI AVENTIS$$51$YR$A$M$Y$$$20250808$$HP$US$US
256588851$25658885$1$I$20250101$20250804$20250808$20250808$PER$$US-SA-2025SA232197$SANOFI AVENTIS$$51$YR$A$F$Y$$$20250808$$HP$US$US
256589431$25658943$1$I$$20250711$20250808$20250808$PER$$US-GSK-US2025AMR092280$GLAXOSMITHKLINE$$$$$F$Y$$$20250808$$$US$US
256590991$25659099$1$I$$20250805$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508005735$ELI LILLY AND COMPANY$$43$YR$A$F$Y$$$20250808$$CN$US$US
256591381$25659138$1$I$$20250728$20250808$20250808$EXP$$EU-STERISCIENCE B.V.-2025-ST-001412$Steriscience PTE$Graafsma J, Cimic N, Dijkman M, Gresnigt FMJ, Mitrovic D, Smit C. Digoxin toxicity with therapeutic serum digoxin concentrations. Toxicol-Rep. 2025;15$76$YR$$M$Y$$$20250808$$HP$EU$EU
256591731$25659173$1$I$$20250731$20250808$20250808$EXP$$TW-ASTRAZENECA-202507ASI027944TW$ALEXION PHARMACEUTICALS$$50$YR$A$M$Y$98$KG$20250808$$MD$TW$TW
256591801$25659180$1$I$$20250801$20250808$20250808$EXP$$JP-EMD Serono-2025039840$EMD SERONO INC$$$$$M$Y$$$20250808$$MD$JP$JP
256592591$25659259$1$I$20250719$20250805$20250808$20250808$EXP$EU-AEMPS-1735941$EU-TEVA-VS-3360562$TEVA$$43$YR$$M$Y$$$20250808$$PH$EU$EU
256592801$25659280$1$I$$20250805$20250808$20250808$PER$$US-SA-2025SA232422$SANOFI AVENTIS$$16$YR$T$M$Y$$$20250808$$CN$US$US
256593531$25659353$1$I$20250321$20250807$20250807$20250807$DIR$FDA-CDER-CTU-2025-52598$$FDA-CTU$$66$YR$$F$N$$$20250807$Y$PH$US$
256593961$25659396$1$I$20250710$20250807$20250808$20250808$PER$$US-SA-2025SA233041$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250808$$CN$US$US
256594111$25659411$1$I$$20250801$20250808$20250808$EXP$$US-TAKEDA-2023TUS000724$TAKEDA$$$$$F$Y$$$20250808$$$US$US
256594121$25659412$1$I$$20250806$20250808$20250808$PER$$US-SA-2024SA356581$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250808$$CN$US$US
256594871$25659487$1$I$$20250709$20250808$20250808$PER$$US-ASTELLAS-2025-AER-038078$ASTELLAS$$$$$F$Y$$$20250808$$CN$US$US
256595931$25659593$1$I$$20250709$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508007226$ELI LILLY AND COMPANY$$$$$F$Y$$$20250808$$CN$US$US
256596101$25659610$1$I$20250101$20250731$20250808$20250808$EXP$$US-UCBSA-2025048277$UCB$$66$YR$$F$Y$$$20250808$$HP$US$US
256597071$25659707$1$I$$20250807$20250807$20250807$DIR$768907$$FDA-CTU$$$$$M$N$$$20250807$N$CN$US$
256599142$25659914$2$F$$20250821$20250808$20250827$PER$$US-BIOMARINAP-US-2025-167884$BIOMARIN$$$$A$F$Y$$$20250827$$$US$US
256599341$25659934$1$I$$20250807$20250807$20250807$DIR$768902$$FDA-CTU$$$$$$N$$$20250807$N$$US$
256599581$25659958$1$I$20250728$20250804$20250808$20250808$EXP$GB-MHRA-MED-202508041246171060-BFHKN$GB-ELI_LILLY_AND_COMPANY-GB202508004063$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250808$$CN$GB$GB
256600141$25660014$1$I$20250101$20250805$20250808$20250808$PER$$US-SA-2025SA232207$SANOFI AVENTIS$$51$YR$A$M$Y$$$20250808$$CN$US$US
256600801$25660080$1$I$20250716$20250806$20250808$20250808$EXP$EU-MINISAL02-1052328$EU-PFIZER INC-202500158254$PFIZER$$76$YR$$F$Y$$$20250808$$HP$EU$EU
256601711$25660171$1$I$$20250805$20250808$20250808$PER$$US-BAYER-2025A104734$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250808$$MD$US$US
256601761$25660176$1$I$$20250717$20250808$20250808$PER$$US-GSK-US2025AMR093084$GLAXOSMITHKLINE$$$$$F$Y$$$20250808$$$US$US
256602561$25660256$1$I$$20250731$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508000252$ELI LILLY AND COMPANY$$27$YR$A$M$Y$$$20250808$$CN$US$US
256603291$25660329$1$I$$20250806$20250808$20250808$PER$$US-SA-2025SA232460$SANOFI AVENTIS$$37$YR$A$M$Y$$$20250808$$CN$US$US
256603661$25660366$1$I$$20250731$20250808$20250808$EXP$$CA-TEVA-VS-3358759$TEVA$$$$$$Y$$$20250808$$MD$CA$CA
256604591$25660459$1$I$20250728$20250731$20250808$20250808$EXP$$US-UCBSA-2025048262$UCB$$31$YR$$M$Y$80.74$KG$20250808$$MD$US$US
256604881$25660488$1$I$$20250801$20250808$20250808$PER$$US-BAYER-2025A103915$BAYER HEALTHCARE LLC$$$$$$Y$$$20250808$$CN$US$US
256607961$25660796$1$I$20250318$20250725$20250808$20250808$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-521924$RANBAXY$$78$YR$$F$Y$$$20250808$$MD$EU$EU
256607992$25660799$2$F$$20250820$20250808$20250826$30DAY$$JP-MYLANLABS-2025M1066846$MYLAN$$$$C$$Y$$$20250826$$PH$JP$JP
256608541$25660854$1$I$20230101$20250731$20250808$20250808$EXP$EU-EMA-DD-20250730-7482650-084813$EU-BIOCON BIOLOGICS LIMITED-BBL2025004253$BIOCON$$$$$$Y$$$20250808$$MD$EU$EU
256609102$25660910$2$F$$20250904$20250808$20250911$EXP$$US-AMGEN-USASP2025155811$AMGEN$$$$$F$Y$$$20250911$$PH$US$US
256610011$25661001$1$I$20240509$20241009$20250808$20250808$EXP$$AU-ASTRAZENECA-202410GLO014268AU$ALEXION PHARMACEUTICALS$$$$I$M$Y$$$20250808$$$AU$AU
256610772$25661077$2$F$20250401$20250730$20250808$20250818$EXP$$US-SERVIER-S25011646$SERVIER$$$$$$Y$$$20250818$$CN$US$US
256611201$25661120$1$I$$20250731$20250808$20250808$PER$$US-ELI_LILLY_AND_COMPANY-US202508001985$ELI LILLY AND COMPANY$$40$YR$A$$Y$$$20250808$$LW$US$US
256612091$25661209$1$I$$20250429$20250808$20250808$PER$$US-MALLINCKRODT-MNK202502620$MALLINCKRODT$$$$$M$Y$$$20250807$$CN$US$US
256612581$25661258$1$I$20250705$20250805$20250808$20250808$EXP$EU-AFSSAPS-TO2025001159$EU-PFIZER INC-202500157426$PFIZER$$87$YR$$M$Y$61$KG$20250808$$MD$EU$EU
256612972$25661297$2$F$20190401$20250821$20250808$20250822$EXP$$AU-ABBVIE-6408319$ABBVIE$$36$YR$$F$Y$$$20250822$$MD$AU$AU
256614911$25661491$1$I$20250101$20250801$20250808$20250808$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-108211$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$90.72$KG$20250808$$CN$US$US
256614922$25661492$2$F$$20250829$20250808$20250902$30DAY$$US-PFIZER INC-202500158025$PFIZER$$6$YR$$M$Y$$$20250902$$HP$US$US
256615761$25661576$1$I$20250713$20250728$20250808$20250808$EXP$$US-FMCRTG-FMC-2507-001199$FRESENIUS MEDICAL CARE$$69$YR$E$M$Y$72$KG$20250808$$HP$US$US
256616251$25661625$1$I$$20250805$20250808$20250808$PER$$US-PURDUE PHARMA-USA-2025-0319547$PURDUE$$32$YR$$$Y$$$20250808$$CN$US$US
256616531$25661653$1$I$20230706$20250804$20250808$20250808$EXP$$CN-PAIPHARMA-2025-CN-000169$PHARMACEUTICAL ASSOC$ZHOU Lingli, ZHENG Zhiyuan, CHEN Na, et al.Analysis of serotonin syndrome caused by netupitant and palonosetron capsules..Anti-tumor Pharmacy.2025;15(1):130-136.$53$YR$$F$Y$$$20250808$$HP$CN$CN
256616592$25661659$2$F$20180401$20250912$20250808$20250918$EXP$$US-ASTRAZENECA-202508USA004644US$ALEXION PHARMACEUTICALS$$72$YR$$F$Y$120$KG$20250918$$$US$US
256616742$25661674$2$F$$20250813$20250808$20250815$PER$$US-009507513-2309645$MERCK SHARP + DOHME LLC$$$$$F$Y$70.3$KG$20250815$$CN$US$US
256617381$25661738$1$I$$20250805$20250808$20250808$EXP$$CA-HLS-202502081$HLS THERAPEUTICS$$$$$F$Y$$$20250808$$$CA$CA
256618341$25661834$1$I$20220330$20250731$20250809$20250809$EXP$$EU-CELLTRION INC.-2025ES026634$CELLTRION$$$$$$Y$$$20250809$$MD$EU$EU
256618542$25661854$2$F$20230101$20250806$20250809$20250813$EXP$$EU-CELLTRION INC.-2025AT026620$CELLTRION$$$$$$Y$$$20250813$$MD$EU$EU
256618851$25661885$1$I$$20250806$20250809$20250809$EXP$$US-ASTRAZENECA-202508USA004425US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250809$$$US$US
256619141$25661914$1$I$$20250808$20250809$20250809$EXP$$CA-TEVA-VS-3361435$TEVA$$71$YR$$M$Y$$$20250809$$HP$CA$CA
256619611$25661961$1$I$$20250730$20250809$20250809$EXP$$GE-MACLEODS PHARMA-MAC2025054551$MACLEODS$McKinney C, Sharma N, Jerath RS..Livedoid dermatitis (Nicolau syndrome) following intra-articular glucocorticoid injection.Journal of Clinical Rheumatology.SEP-2014;20(6):339-40$$$$$Y$$$20250809$$MD$GE$GE
256621611$25662161$1$I$20250605$20250801$20250810$20250810$EXP$EU-MINISAL02-1051133$EU-TEVA-VS-3359209$TEVA$$66$YR$$M$Y$83$KG$20250810$$PH$EU$EU
256621682$25662168$2$F$20250805$20250805$20250810$20250812$PER$$US-BEH-2025215465$CSL BEHRING$$12$MON$I$F$Y$14.059$KG$20250812$$HP$US$US
256623551$25662355$1$I$$20250806$20250810$20250810$PER$$US-ELI_LILLY_AND_COMPANY-US202508006375$ELI LILLY AND COMPANY$$47$YR$A$F$Y$$$20250810$$CN$US$US
256624521$25662452$1$I$20250707$20250806$20250810$20250810$EXP$$US-ABBVIE-6406671$ABBVIE$$54$YR$$M$Y$$$20250810$$CN$US$US
256625711$25662571$1$I$$20250730$20250810$20250810$EXP$$US-AMGEN-USASL2025154120$AMGEN$$71$YR$E$M$Y$103.87$KG$20250810$$MD$US$US
256625751$25662575$1$I$$20250804$20250810$20250810$PER$$US-AXS-AXS202508-001397$AXSOME THERAPEUTICS$$$$$$Y$$$20250811$$CN$US$US
256626241$25662624$1$I$$20250730$20250811$20250811$EXP$$US-AMGEN-USASP2025153807$AMGEN$Hutto S.K.; Balaban D.; Rohm Z. et al.. Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study. Journal of Neurology. 2025;272 (8):1-9$$$$$Y$$$20250810$$HP$US$US
256626611$25662661$1$I$$20250712$20250811$20250811$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0000484$RECKITT BENCKISER$$$$$M$Y$$$20250811$$CN$US$US
256626791$25662679$1$I$$20250805$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508006015$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250811$$CN$US$US
256627062$25662706$2$F$$20250826$20250811$20250903$PER$$US-Bion-015174$BIONPHARMA INC.$$11$YR$C$$Y$$$20250903$$PH$US$US
256628291$25662829$1$I$$20250805$20250811$20250811$EXP$$US-BIOGEN-2025BI01319848$BIOGEN$$$$$M$Y$$$20250811$$CN$US$US
256628383$25662838$3$F$20250718$20250820$20250811$20250825$EXP$$AU-BIOVITRUM-2025-AU-010744$BIOVITRUM$$$$$$Y$$$20250825$$MD$AU$AU
256628831$25662883$1$I$20250804$20250805$20250811$20250811$EXP$$CO-BIOVITRUM-2025-CO-010971$BIOVITRUM$$7$MON$$F$Y$$$20250811$$CN$CO$CO
256629501$25662950$1$I$$20250712$20250811$20250811$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0001399$RECKITT BENCKISER$$$$$F$Y$$$20250811$$CN$US$US
256630001$25663000$1$I$$20250808$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508008586$ELI LILLY AND COMPANY$$46$YR$A$M$Y$$$20250811$$CN$US$US
256630081$25663008$1$I$$20250729$20250811$20250811$EXP$$US-LUPIN PHARMACEUTICALS INC.-2025-06983$LUPIN$Clark E, Goudie Mp, Scivoletti N. From urine to lung - A rare case of nitrofurantoin-induced interstitial lung disease. American journal of respiratory and critical care medicine. 2025;211:A1927$77$YR$$F$Y$$$20250811$$$US$US
256630161$25663016$1$I$$20250802$20250811$20250811$EXP$$EU-CELLTRION INC.-2025FR026750$CELLTRION$$$$$$Y$$$20250811$$MD$EU$EU
256630831$25663083$1$I$20250401$20250807$20250811$20250811$EXP$EU-SEMPA-2025-005443$EU-TEVA-VS-3361575$TEVA$$67$YR$$F$Y$53.6$KG$20250811$$CN$EU$EU
256630941$25663094$1$I$20250530$20250801$20250811$20250811$EXP$EU-AFSSAPS-AM2025000578$EU-TEVA-VS-3359298$TEVA$$76$YR$$M$Y$$$20250811$$MD$EU$EU
256631051$25663105$1$I$$20250731$20250811$20250811$EXP$$AU-LUPIN PHARMACEUTICALS INC.-2025-06988$LUPIN$$$$$$Y$$$20250811$$$AU$AU
256631102$25663110$2$F$$20250820$20250811$20250828$30DAY$$US-SANDOZ INC.-SDZ2025US027070$SANDOZ$$50$YR$$F$Y$$$20250828$$CN$US$US
256631471$25663147$1$I$20250701$20250807$20250811$20250811$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-110972$BRISTOL-MYERS SQUIBB COMPANY$$84$YR$E$F$Y$$$20250811$$HP$US$US
256632681$25663268$1$I$$20250730$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508000445$ELI LILLY AND COMPANY$$$$A$$Y$$$20250811$$MD$US$US
256633291$25663329$1$I$$20250731$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508000083$ELI LILLY AND COMPANY$$$$$F$Y$$$20250811$$CN$US$US
256634361$25663436$1$I$$20250727$20250811$20250811$EXP$$EU-MankindUS-000450$MANKIND PHARMA$Torrinha G, Vieira R, Pacheco C, Vilaca C, Bernardo S. Altered Mental Status and Quadriparesis in Ambulatory Surgical Care: A Case Report. Cureus. 2025 Jun 22;17(6):e86530. doi: 10.7759/cureus.86530.$70$YR$E$M$Y$$$20250811$$HP$EU$EU
256634661$25663466$1$I$20210101$20250731$20250811$20250811$EXP$EU-AFSSAPS-AVGR2025000186$EU-ATNAHS-2025-PMNV-FR000373$Atnahs Healthcare$$$$$$Y$$$20250811$$PH$EU$EU
256634981$25663498$1$I$$20250807$20250811$20250811$EXP$$JP-ABBVIE-6408277$ABBVIE$$$$$$Y$$$20250811$$MD$JP$JP
256636051$25663605$1$I$$20250805$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508007176$ELI LILLY AND COMPANY$$$$$F$Y$$$20250811$$CN$US$US
256636281$25663628$1$I$20250116$20250807$20250811$20250811$EXP$$AU-TAKEDA-2025TUS070327$TAKEDA$$25$YR$$F$Y$$$20250811$$$AU$AU
256636881$25663688$1$I$$20250807$20250811$20250811$PER$$US-HALEON-2256938$Haleon PLC$$$$$$Y$$$20250811$$CN$US$US
256637321$25663732$1$I$$20250805$20250811$20250811$PER$$US-ABBVIE-6403962$ABBVIE$$70$YR$$F$Y$$$20250811$$MD$US$US
256637801$25663780$1$I$$20250804$20250811$20250811$EXP$$US-NOVOPROD-1494194$NOVO NORDISK$$54$YR$$$Y$$$20250808$$CN$US$US
256638272$25663827$2$F$$20250819$20250811$20250827$EXP$$US-ROCHE-10000176654$ROCHE$$64$YR$A$F$Y$41.64$KG$20250827$$MD$US$US
256638811$25663881$1$I$$20250727$20250811$20250811$EXP$$EU-HIKMA PHARMACEUTICALS-IT-H14001-25-08974$HIKMA$Zattarin E, Beninato T, Di Liberti G, Lorenzini D, Vingiani A, Leporati R et al.. Zattarin E, Beninato T, Di Liberti G, Lorenzini D, Vingiani A, Leporati R, Occhipinti M, Brambilla M. Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report. Tumori. 2025;3008916251353357$$$A$F$Y$$$20250811$$MD$EU$EU
256639261$25663926$1$I$$20250805$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508005251$ELI LILLY AND COMPANY$$67$YR$E$F$Y$$$20250811$$CN$US$US
256639321$25663932$1$I$20250805$20250805$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508004741$ELI LILLY AND COMPANY$$72$YR$E$M$Y$$$20250811$$CN$US$US
256639631$25663963$1$I$$20250807$20250811$20250811$PER$$US-JNJFOC-20250808756$JOHNSON AND JOHNSON$$17$YR$T$$Y$$$20250811$$MD$US$US
256640331$25664033$1$I$20250701$20250808$20250811$20250811$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-110901$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$F$Y$$$20250811$$CN$US$US
256640551$25664055$1$I$$20250712$20250811$20250811$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0011181$RECKITT BENCKISER$$$$$F$Y$$$20250811$$CN$US$US
256640681$25664068$1$I$$20250728$20250811$20250811$EXP$$US-STRIDES ARCOLAB LIMITED-2025SP009956$STRIDES$Gordon KS, Gordon BT, Quiros J, Samhoun J, Marin D. Not Your Typical Pneumonia: Delftia Acidovorans Pneumonia Associated With Malignant Squamous Cell Carcinoma.. Am-J-Respir-Crit-Care-Med. 2025;211 (plus Poster)$78$YR$$F$Y$$$20250811$$HP$US$US
256641021$25664102$1$I$$20250808$20250811$20250811$EXP$GB-MHRA-MED-202508080004342500-RYHKF$GB-SANDOZ INC.-SDZ2025GB057519$SANDOZ$$$$$F$Y$$$20250811$$CN$GB$GB
256641241$25664124$1$I$$20250805$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508005515$ELI LILLY AND COMPANY$$52$YR$A$F$Y$$$20250811$$CN$US$US
256641261$25664126$1$I$$20250804$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508004967$ELI LILLY AND COMPANY$$$$$$Y$$$20250811$$CN$US$US
256643831$25664383$1$I$$20250804$20250811$20250811$EXP$$AR-TEVA-VS-3360962$TEVA$Romero LCP, Caselles AV, Rius NS, Soriano E, Rosa J, Scolnik M. Tuberculosis infection in patients with dermatomyositis. Reumatismo 2025; 77 (2):.$49$YR$$F$Y$$$20250811$$HP$AR$AR
256644471$25664447$1$I$$20250801$20250811$20250811$PER$$US-ABBVIE-6401286$ABBVIE$$$$$F$Y$$$20250811$$CN$US$US
256644501$25664450$1$I$$20250728$20250811$20250811$EXP$$US-MYLANLABS-2025M1065788$MYLAN$Noh J, Lee M, Azizad-Pinto P. Stumped for the Cause: A Rare Case of EBV-negative PTSMT. Am-J-Respir-Crit-Care-Med 2025; 211 A6012 (plus Poster).$48$YR$$F$Y$$$20250811$$$US$US
256644841$25664484$1$I$$20250806$20250811$20250811$EXP$$AU-ROCHE-10000358346$ROCHE$$$$$$Y$$$20250811$$MD$AU$AU
256644882$25664488$2$F$$20250807$20250811$20250815$EXP$$US-VIIV HEALTHCARE-US2025102076$VIIV$$68$YR$$M$Y$$$20250815$$MD$US$US
256645301$25664530$1$I$$20250115$20250811$20250811$PER$$US-CHIESI-2025CHF00356$CHIESI$$$$$M$Y$$$20250811$$CN$US$US
256645631$25664563$1$I$$20250728$20250811$20250811$EXP$GB-MLMSERVICE-20230810-4478622-1$GB-STRIDES ARCOLAB LIMITED-2023SP013195$STRIDES$McGrath C, Thomas B, Duncan M, Basu T, Benjamin R, Child F.. BI11 Cutaneous presentation of Kaposi sarcoma following allogeneic haematopoietic stem cell transplantation for myeloma.. British Journal of Dermatology.. 2023;188(4):iv85-6$55$YR$$M$Y$$$20250811$$MD$GB$GB
256646221$25664622$1$I$$20250806$20250811$20250811$EXP$$IL-BEH-2025215376$CSL BEHRING$$77$YR$E$M$Y$$$20250811$$MD$IL$IL
256646261$25664626$1$I$20230101$20250801$20250811$20250811$EXP$EU-AFSSAPS-MA2025000960$EU-TEVA-VS-3359913$TEVA$$57$YR$$F$Y$$$20250811$$HP$EU$EU
256646322$25664632$2$F$20250701$20250821$20250811$20250827$EXP$$EU-ACS-20250417$ACS DOBFAR$$$$$$Y$$$20250822$$HP$EU$EU
256648081$25664808$1$I$20250721$20250805$20250811$20250811$EXP$$CN-PFIZER INC-PV202500094734$PFIZER$$49$YR$$M$Y$66.5$KG$20250811$$HP$CN$CN
256648171$25664817$1$I$20250715$20250808$20250811$20250811$PER$$US-JNJFOC-20250810028$JOHNSON AND JOHNSON$$$$$F$Y$$$20250811$$CN$US$US
256648271$25664827$1$I$$20250808$20250808$20250808$DIR$FDA-CDER-CTU-2025-52826$$FDA-CTU$$72$YR$$F$N$$$20250808$N$$US$
256648321$25664832$1$I$$20250804$20250811$20250811$PER$$US-AUCTA-000038$AUCTA PHARMACEUTICALS$$$$$M$Y$$$20250811$$MD$US$US
256649681$25664968$1$I$$20250730$20250811$20250811$EXP$AU-TGA-829247$AU-Accord-498219$ACCORD$$$$$$Y$$$20250811$$HP$AU$AU
256650111$25665011$1$I$$20250806$20250811$20250811$EXP$$SA-AMGEN-SAUSP2025157079$AMGEN$Alajlan A. H.; Algarzae N. K.; Alotaibi H. M. et al.. Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report. International Medical Case Reports Journal. 2025;18:877-881$24$YR$A$F$Y$$$20250811$$HP$SA$SA
256650761$25665076$1$I$20250728$20250808$20250811$20250811$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111127$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$M$Y$$$20250811$$HP$US$US
256650981$25665098$1$I$20241201$20250801$20250811$20250811$EXP$$GB-UCBSA-2025001162$UCB$$71$YR$$M$Y$$$20250811$$CN$GB$GB
256651061$25665106$1$I$20240301$20250805$20250811$20250811$EXP$$CN-ASTELLAS-2025-AER-043641$ASTELLAS$Zhao T, SU X. Successful Treatment of Mucormycosis and Azole-Resistant Aspergillus Coinfection in a Diabetic Patient: A Case Report. Infection and drug resistance. 2025;18: 3689-94. doi:10.2147/IDR.S530615.$52$YR$A$M$Y$75$KG$20250811$$HP$CN$CN
256651091$25665109$1$I$$20250807$20250811$20250811$PER$$US-ROCHE-10000359379$ROCHE$$28$YR$A$F$Y$$$20250811$$CN$US$US
256651293$25665129$3$F$20250729$20250822$20250811$20250828$30DAY$$US-AMGEN-USASP2025155995$AMGEN$$54$YR$A$F$Y$91.6$KG$20250828$$HP$US$US
256651862$25665186$2$F$20250723$20250804$20250811$20250813$EXP$$PE-DSJP-DS-2025-157715-PE$DAIICHI$$48$YR$$F$Y$$$20250813$$CN$PE$PE
256653051$25665305$1$I$$20250808$20250811$20250811$PER$$US-JNJFOC-20250810730$JOHNSON AND JOHNSON$$$$$$Y$$$20250811$$CN$US$US
256653611$25665361$1$I$$20250807$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508007087$ELI LILLY AND COMPANY$$39$YR$A$F$Y$$$20250811$$CN$US$US
256653911$25665391$1$I$$20250808$20250811$20250811$PER$$US-BAYER-2025A106472$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250811$$CN$US$US
256654831$25665483$1$I$$20250730$20250811$20250811$EXP$AU-TGA-832168$AU-Accord-498275$ACCORD$$68$YR$E$M$Y$$$20250811$$HP$AU$AU
256654901$25665490$1$I$20250719$20250801$20250811$20250811$EXP$$CN-KENVUE-20250802740$Kenvue$$$$$$Y$$$20250811$$HP$CN$CN
256654951$25665495$1$I$$20250808$20250811$20250811$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111342$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$M$Y$97.98$KG$20250811$$HP$US$US
256655401$25665540$1$I$$20250730$20250811$20250811$EXP$AU-TGA-836834$AU-Accord-498079$ACCORD$$30$YR$$F$Y$$$20250811$$HP$AU$AU
256655742$25665574$2$F$$20250820$20250811$20250828$EXP$$EU-TEVA-VS-3360598$TEVA$Scuppa MF, Accietto A, Corsini A, Graziosi M, Biagini E, Baldovini C, et al. End-stage heart failure and heart transplant in cardiac sarcoidosis: A case series. Eur-Heart-J-Case-Rep 2024; 8 (12): 1-10.; Scuppa MF, Accietto A, Corsini A, Graziosi M, Biagini E, Baldovini C, et al. End-stage heart failure and heart transplant in cardiac sarcoidosis: A case series. Eur-Heart-J-Case-Rep 2024; 8 (12): 1-10.; Scuppa MF, Accietto A, Corsini A, Graziosi M, Biagini E, Baldovini C, et al. End-stage hear...$36$YR$$F$Y$$$20250828$$HP$EU$EU
256655941$25665594$1$I$$20250807$20250811$20250811$EXP$$US-OTSUKA-2025_019484$OTSUKA$$$$$$Y$$$20250811$$CN$US$US
256656012$25665601$2$F$$20250813$20250811$20250818$EXP$EU-LRB-01078786$EU-FreseniusKabi-FK202510962$FRESENIUS KABI$$16$YR$T$F$Y$67.8$KG$20250818$$MD$EU$EU
256656921$25665692$1$I$20250101$20250805$20250811$20250811$EXP$$TH-ORGANON-O2508THA000616$ORGANON$$26$YR$$F$Y$$$20250811$$MD$TH$TH
256657011$25665701$1$I$$20250806$20250811$20250811$PER$$US-JNJFOC-20250811582$JOHNSON AND JOHNSON$$$$$M$Y$$$20250811$$HP$US$US
256657112$25665711$2$F$$20250808$20250811$20250812$PER$$US-PFIZER INC-202500160471$PFIZER$$22$YR$$F$Y$136.08$KG$20250812$$CN$US$US
256657281$25665728$1$I$$20250804$20250811$20250811$EXP$$US-BAYER-2025A104616$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$M$Y$$$20250811$$CN$US$US
256657692$25665769$2$F$$20250811$20250811$20250818$EXP$$IN-VANTIVE-2025VAN003647$Vantive US Healthcare$$38$YR$$F$Y$$$20250818$$CN$IN$IN
256657871$25665787$1$I$$20250730$20250811$20250811$EXP$$US-RDY-USA/2025/08/011941$DR REDDYS$Krishnaswamy S, Bhattar K, Nudelman B, Rondon E. Elizabethkingia Anophelis: A Rare Pathogen Inducing Severe Septic Shock in Respiratory Infection. Am J Respir Crit Care Med. 2025;211: A1646. DOI: 10.1164/ajrccm.2025.211.Abstracts.A1646.$40$YR$A$M$Y$$$20250811$$HP$US$US
256657951$25665795$1$I$20250730$20250730$20250811$20250811$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202508007550$ELI LILLY AND COMPANY$$80$YR$E$M$Y$$$20250811$$CN$EU$CN
256658481$25665848$1$I$20230101$20250806$20250811$20250811$EXP$$US-ABBVIE-6385458$ABBVIE$$53$YR$$F$Y$$$20250811$$CN$US$US
256658561$25665856$1$I$20250101$20250806$20250811$20250811$EXP$$US-ABBVIE-6384835$ABBVIE$$62$YR$$F$Y$$$20250811$$CN$US$US
256658881$25665888$1$I$20250628$20250804$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508003399$ELI LILLY AND COMPANY$$70$YR$E$F$Y$$$20250811$$CN$US$US
256659031$25665903$1$I$$20250806$20250811$20250811$EXP$$EU-PFIZER INC-202500158225$PFIZER$$$$$F$Y$$$20250811$$MD$EU$EU
256660941$25666094$1$I$$20250730$20250811$20250811$EXP$$US-CIPLA LTD.-2025US09980$CIPLA$Kujundzic W, Gordon KS, Walsh MJ, Quiros JR, Chaudhry A, Marin D. Rapidly fatal pulmonary arterial hypertension: Phentermine precipitating right ventricular failure in a woman with lupus.. Am J Respir Crit Care Med. 2025;211:A6492$$$$$Y$$$20250811$$HP$US$US
256661461$25666146$1$I$$20250805$20250811$20250811$EXP$$NVSC2025TW125906$NOVARTIS$$$$$M$Y$$$20250811$$CN$TW$TW
256661961$25666196$1$I$20250101$20250807$20250811$20250811$EXP$GB-MHRA-MED-202508070853116270-NVBQC$GB-ABBVIE-6406630$ABBVIE$$18$YR$$F$Y$$$20250811$$PH$GB$GB
256662342$25666234$2$F$$20250808$20250811$20250813$PER$$US-MALLINCKRODT-MNK202504909$MALLINCKRODT$$54$YR$A$F$Y$$$20250813$$CN$US$US
256662381$25666238$1$I$$20250811$20250811$20250811$DIR$769493$$FDA-CTU$$$$$$N$$$20250811$N$$US$
256663532$25666353$2$F$20250101$20250808$20250811$20250813$PER$$US-MALLINCKRODT-MNK202504732$MALLINCKRODT$$51$YR$A$F$Y$$$20250813$$CN$US$US
256663811$25666381$1$I$20250101$20250805$20250811$20250811$EXP$$US-UCBSA-2025044920$UCB$$$$$M$Y$133.81$KG$20250811$$CN$US$US
256664021$25666402$1$I$$20250804$20250811$20250811$EXP$$US-AMGEN-USASP2025154845$AMGEN$Admani, S. Successful Treatment of Palmoplantar Psoriasis With Apremilast in an Immunosuppressed Pediatric Patient on Concurrent Biologic Therapy. Pediatric Dermatology. 2025;42 (4):885-887$15$YR$T$F$Y$$$20250811$$HP$US$US
256664271$25666427$1$I$20250101$20250805$20250811$20250811$EXP$$GB-UCBSA-2025028971$UCB$$$$$M$Y$$$20250811$$CN$GB$GB
256664581$25666458$1$I$$20250801$20250811$20250811$PER$$US-SA-2025SA230613$SANOFI AVENTIS$$$$A$F$Y$$$20250811$$MD$US$US
256665331$25666533$1$I$$20250805$20250811$20250811$PER$$US-SA-2025SA232348$SANOFI AVENTIS$$79$YR$E$M$Y$$$20250811$$CN$US$US
256665381$25666538$1$I$20250101$20250806$20250811$20250811$PER$$US-SA-2025SA234353$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250811$$HP$US$US
256667121$25666712$1$I$$20250806$20250811$20250811$PER$$US-SA-2025SA233700$SANOFI AVENTIS$$$$A$M$Y$$$20250811$$HP$US$US
256667881$25666788$1$I$20250101$20250806$20250811$20250811$PER$$US-SA-2025SA232773$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250811$$CN$US$US
256668371$25666837$1$I$$20250804$20250811$20250811$PER$$US-SA-2025SA230560$SANOFI AVENTIS$$33$YR$A$F$Y$$$20250811$$MD$US$US
256668561$25666856$1$I$$20250806$20250811$20250811$PER$$US-SA-2025SA233286$SANOFI AVENTIS$$67$YR$E$F$Y$$$20250811$$CN$US$US
256668802$25666880$2$F$20250101$20250812$20250811$20250818$PER$$US-SA-2025SA233287$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250818$$MD$US$US
256668811$25666881$1$I$$20250806$20250811$20250811$PER$$US-SA-2025SA233251$SANOFI AVENTIS$$$$E$F$Y$65.91$KG$20250811$$MD$US$US
256669691$25666969$1$I$$20250807$20250811$20250811$PER$$US-SA-2025SA234748$SANOFI AVENTIS$$$$C$F$Y$$$20250811$$HP$US$US
256670401$25667040$1$I$$20250809$20250809$20250809$DIR$769214$$FDA-CTU$$$$$M$N$$$20250809$N$CN$US$
256670921$25667092$1$I$20250101$20250715$20250811$20250811$PER$$US-GALDERMA-US2025012812$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256670981$25667098$1$I$20250709$20250715$20250811$20250811$PER$$US-GALDERMA-US2025012708$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256671291$25667129$1$I$20250101$20250716$20250811$20250811$PER$$US-GALDERMA-US2025012957$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256671331$25667133$1$I$20250701$20250717$20250811$20250811$PER$$US-GALDERMA-US2025013047$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256671821$25667182$1$I$$20250729$20250811$20250811$PER$$US-INCYTE CORPORATION-2025IN008336$INCYTE$$$$$$Y$$$20250811$$$US$US
256672511$25667251$1$I$20250703$20250708$20250811$20250811$PER$$US-GALDERMA-US2025012207$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256672911$25667291$1$I$20250301$20250709$20250811$20250811$PER$$US-GALDERMA-US2025012220$GALDERMA$$$$$$Y$$$20250811$$CN$US$US
256673383$25667338$3$F$20250728$20250916$20250811$20250928$PER$$US-ALKERMES INC.-ALK-2025-002049$ALKERMES$$39$YR$$M$Y$$$20250928$$MD$US$
256673472$25667347$2$F$20250101$20250923$20250811$20250929$PER$$US-SA-2025SA179081$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250929$$HP$US$US
256673481$25667348$1$I$20250722$20250808$20250811$20250811$EXP$$NVSC2025CN125871$NOVARTIS$$50$YR$$F$Y$41$KG$20250811$$HP$CN$CN
256674281$25667428$1$I$$20250731$20250811$20250811$EXP$$EG-NOVOPROD-1492612$NOVO NORDISK$$$$$M$Y$$$20250811$$CN$EG$EG
256674501$25667450$1$I$20250806$20250806$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508007224$ELI LILLY AND COMPANY$$20$YR$A$M$Y$$$20250811$$CN$US$US
256674601$25667460$1$I$20250805$20250807$20250811$20250811$PER$$US-ELI_LILLY_AND_COMPANY-US202508007406$ELI LILLY AND COMPANY$$46$YR$A$M$Y$$$20250811$$CN$US$US
256674821$25667482$1$I$$20250805$20250811$20250811$PER$$US-JNJFOC-20250804966$JOHNSON AND JOHNSON$$$$$$Y$$$20250812$$HP$US$US
256675281$25667528$1$I$20250804$20250806$20250811$20250811$PER$$US-ABBVIE-6407391$ABBVIE$$16$YR$$F$Y$$$20250811$$HP$US$US
256675571$25667557$1$I$$20250809$20250811$20250811$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111385$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$F$Y$79.38$KG$20250812$$CN$US$US
256675762$25667576$2$F$$20250908$20250811$20250929$PER$$US-RDY-USA/2025/07/011168$DR REDDYS$$85$YR$E$M$Y$$$20250929$$PH$US$US
256676131$25667613$1$I$20250101$20250806$20250811$20250811$EXP$$US-ABBVIE-6406786$ABBVIE$$73$YR$$M$Y$$$20250811$$CN$US$US
256676801$25667680$1$I$20250704$20250805$20250811$20250811$EXP$$GB-ASTRAZENECA-202508GLO006315GB$ALEXION PHARMACEUTICALS$$29$YR$A$M$Y$$$20250811$$$GB$GB
256677011$25667701$1$I$$20250729$20250811$20250811$PER$$US-TEVA-VS-3359936$TEVA$$$$$$Y$$$20250811$$CN$US$US
256678021$25667802$1$I$$20250806$20250812$20250812$EXP$$US-ABBVIE-6408636$ABBVIE$$$$A$M$Y$$$20250812$$CN$US$US
256678091$25667809$1$I$20250730$20250804$20250812$20250812$EXP$$CN-GSK-CN2025CHI100365$GLAXOSMITHKLINE$$14$YR$$F$Y$$$20250812$$$CN$CN
256678321$25667832$1$I$20250101$20250802$20250812$20250812$PER$$US-AMGEN-USASP2025157381$AMGEN$$$$$$Y$$$20250811$$HP$US$US
256678481$25667848$1$I$$20250806$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508005843$ELI LILLY AND COMPANY$$16$YR$T$M$Y$$$20250812$$CN$US$US
256679471$25667947$1$I$20250718$20250806$20250812$20250812$EXP$GB-MHRA-MED-202508061653182810-HTBKJ$GB-TAKEDA-2025TUS070063$TAKEDA$$16$YR$$F$Y$57$KG$20250812$$$GB$GB
256680321$25668032$1$I$20250804$20250804$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508003422$ELI LILLY AND COMPANY$$63$YR$A$$Y$$$20250812$$CN$US$US
256680811$25668081$1$I$20250425$20250505$20250812$20250812$PER$$US-AUROBINDO-AUR-APL-2025-024400$AUROBINDO$$48$YR$$M$Y$70.3$KG$20250812$$CN$US$US
256680882$25668088$2$F$20250101$20250826$20250812$20250904$EXP$$US-UCBSA-2025049076$UCB$$$$$M$Y$$$20250904$$CN$US$US
256681062$25668106$2$F$$20250812$20250812$20250812$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-110810$BRISTOL-MYERS SQUIBB COMPANY$Tamaki A, et al. A case of acute erythroblastic leukemia found by low back pain. Journal of the Japanese Society of Laboratory Hematology/The 26th Annual Meeting of the Japanese Society of Laboratory Hematology. 2025;S230.$7$DEC$E$M$Y$$$20250812$$MD$JP$JP
256681091$25668109$1$I$$20250729$20250812$20250812$EXP$$US-GSK-US2025AMR099143$GLAXOSMITHKLINE$$$$$F$Y$$$20250812$$$US$US
256681211$25668121$1$I$$20250805$20250812$20250812$EXP$$EU-CELLTRION INC.-2025ES026906$CELLTRION$Robles-Alonso V, Lastiri E, Serra X, Cespedes-Martinez E, Herrera-deGuise C, Claudia L, et al.. Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD.. Gastroenterologia y Hepatologia.$$$$$Y$$$20250812$$HP$EU$EU
256683061$25668306$1$I$$20250729$20250812$20250812$EXP$$US-GSK-US2025AMR098891$GLAXOSMITHKLINE$$$$$F$Y$$$20250812$$$US$US
256683502$25668350$2$F$20250701$20250912$20250812$20250923$EXP$GB-MHRA-MED-202507311650387270-HCJFT$GB-Accord-498722$ACCORD$$13$YR$T$M$Y$37$KG$20250923$$CN$GB$GB
256684371$25668437$1$I$20250801$20250805$20250812$20250812$EXP$$US-Blueprint Medicines Corporation-2025-AER-01740$BLUEPRINT MEDICINES$$52$YR$A$F$Y$$$20250812$$CN$US$US
256684623$25668462$3$F$20250804$20250908$20250812$20250922$EXP$$EU-SANDOZ INC.-SDZ2025DE057643$SANDOZ$$$$A$F$Y$76$KG$20250922$$MD$EU$EU
256684661$25668466$1$I$20250701$20250804$20250812$20250812$EXP$$US-UCBSA-2025048976$UCB$$64$YR$$F$Y$$$20250812$$HP$US$US
256684681$25668468$1$I$20250604$20250804$20250812$20250812$EXP$EU-MINISAL02-1043270$EU-CELLTRION INC.-2025IT026967$CELLTRION$$$$$$Y$$$20250812$$MD$EU$EU
256685112$25668511$2$F$20250808$20250815$20250812$20250819$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111098$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$M$Y$69.4$KG$20250819$$CN$US$US
256685301$25668530$1$I$$20250512$20250812$20250812$PER$$US-AUROBINDO-AUR-APL-2025-025758$AUROBINDO$$62$YR$$M$Y$104.32$KG$20250812$$CN$US$US
256685383$25668538$3$F$$20250915$20250812$20250926$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA007535$SUNOVION$$56$YR$$M$Y$$$20250925$$$US$US
256685611$25668561$1$I$$20250731$20250812$20250812$EXP$$ZA-ROCHE-10000354329$ROCHE$$$$E$F$Y$$$20250812$$MD$ZA$ZA
256685721$25668572$1$I$20250611$20250808$20250812$20250812$EXP$GB-MHRA-MED-202508071554056020-LCYPJ$GB-BAXTER-2025BAX019588$BAXTER$$$$$F$Y$$$20250812$$MD$GB$GB
256686181$25668618$1$I$$20250807$20250812$20250812$EXP$$CA-SANDOZ INC.-SDZ2025CA057188$SANDOZ$$65$YR$$F$Y$66$KG$20250812$$HP$CA$CA
256686941$25668694$1$I$20200801$20250801$20250812$20250812$PER$$US-AMGEN-USASP2025155382$AMGEN$$35$YR$A$F$Y$64.6$KG$20250812$$CN$US$US
256687751$25668775$1$I$$20250807$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508007465$ELI LILLY AND COMPANY$$63$YR$A$F$Y$$$20250812$$CN$US$US
256688481$25668848$1$I$$20250805$20250812$20250812$EXP$EU-RDY-ESP/2025/08/012211$EU-RDY-ESP/2025/08/012211$DR REDDYS$Serra Font S, Lopez-Granados L, Sisinni L, Serna Berna JV, Martinez Martinez L, Fernandez de Gamarra-Martinez E, et al.. Chronic hypogammaglobulinemia after allogeneic stem cell transplantation and their treatment with subcutaneous immunoglobulin in pediatric patients. Anales de Pediatria (An- Pediatr). 2022;97(2):103-111. doi:10.1016/j.anpede.2021.08.010$3$YR$C$F$Y$$$20250812$$HP$EU$EU
256688541$25668854$1$I$$20250804$20250812$20250812$EXP$$EU-CELLTRION INC.-2025IT026873$CELLTRION$Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, et al.. Long-Term Effectiveness and Safety of Ustekinumab in Crohn^s Disease: Results from a Large Real-Life Cohort Study. J-Clin-Med. 2024;13 (23)$$$$$Y$$$20250812$$HP$EU$EU
256688911$25668891$1$I$20250101$20250723$20250812$20250812$PER$$US-Pharmobedient-000054$PHARMOBEDIENT CONSULTING, LLC$$$$E$F$Y$$$20250812$$CN$US$US
256690322$25669032$2$F$20250811$20250811$20250812$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111777$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$72.57$KG$20250813$$CN$US$US
256691471$25669147$1$I$$20250804$20250812$20250812$EXP$$CA-HIKMA PHARMACEUTICALS USA INC.-CA-H14001-25-09278$HIKMA$$$$$$Y$$$20250812$$HP$CA$CA
256691801$25669180$1$I$$20250805$20250812$20250812$EXP$$NVSC2025BR126178$NOVARTIS$$$$$F$Y$$$20250812$$CN$BR$BR
256692523$25669252$3$F$$20250917$20250812$20250918$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-088518$BOEHRINGER INGELHEIM$$83$YR$E$M$Y$$$20250918$$$JP$JP
256692843$25669284$3$F$$20250808$20250812$20250924$EXP$$JP-ASTRAZENECA-202508JPN005012JP$ALEXION PHARMACEUTICALS$$40$YR$A$F$Y$$$20250924$$MD$JP$JP
256692962$25669296$2$F$$20250814$20250812$20250821$EXP$$CA-TAKEDA-2025TUS070002$TAKEDA$$$$$F$Y$$$20250821$$$CA$CA
256693391$25669339$1$I$$20250806$20250812$20250812$EXP$$CA-APOTEX-2025AP011499$APOTEX$$63$YR$$F$Y$$$20250812$$HP$CA$CA
256693741$25669374$1$I$$20250801$20250812$20250812$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA010030$SUNOVION$$66$YR$$M$Y$$$20250808$$$US$US
256693861$25669386$1$I$20250616$20250731$20250812$20250812$EXP$EU-AFSSAPS-LL2025001245$EU-Accord-499063$ACCORD$$85$YR$E$F$Y$60$KG$20250812$$PH$EU$EU
256694341$25669434$1$I$20250501$20250805$20250812$20250812$EXP$$MX-ROCHE-10000358784$ROCHE$$20$YR$A$F$Y$$$20250812$$MD$MX$MX
256694521$25669452$1$I$$20250811$20250812$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111849$BRISTOL-MYERS SQUIBB COMPANY$$51$YR$A$F$Y$$$20250812$$CN$US$US
256694921$25669492$1$I$$20250731$20250812$20250812$EXP$$PR-MYLANLABS-2025M1066888$MYLAN$Rivera Caro A, Vazquez-Ramos D, Egozcue-Dionisi MM, Roman Carlo RI, et al. Cavitary lung lesions in immunocompromised patients: Insights from a case of nontuberculous mycobacterial (NTM) infection in CD4 lymphocytopenia. Am-J-Respir-Crit-Care-Med 2025; 211.$66$YR$$M$Y$$$20250812$$$PR$PR
256695801$25669580$1$I$$20250804$20250812$20250812$EXP$$US-SANDOZ INC.-SDZ2025US056348$SANDOZ$$$$$M$Y$$$20250812$$CN$US$US
256696001$25669600$1$I$$20250811$20250812$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111857$BRISTOL-MYERS SQUIBB COMPANY$$64$YR$A$F$Y$$$20250812$$CN$US$US
256696571$25669657$1$I$20250101$20250717$20250812$20250812$EXP$$US-GALDERMA-US2025012950$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256696881$25669688$1$I$20240612$20250805$20250812$20250812$EXP$$CN-ROCHE-10000026159$ROCHE$$58$YR$A$M$Y$$$20250812$$MD$CN$CN
256696891$25669689$1$I$$20250801$20250812$20250812$EXP$$EU-BEH-2025215378$CSL BEHRING$$$$$$Y$$$20250812$$PH$EU$EU
256697141$25669714$1$I$$20250808$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508008661$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250812$$CN$US$US
256697261$25669726$1$I$$20250808$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508009208$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250812$$CN$US$US
256697472$25669747$2$F$20250730$20250916$20250812$20250922$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009072$ACADIA PHARMACEUTICALS$$76$YR$$M$Y$$$20250922$$CN$US$US
256698641$25669864$1$I$$20250810$20250810$20250810$DIR$769308$$FDA-CTU$$$$$F$N$$$20250810$N$CN$US$
256699913$25669991$3$F$$20250813$20250812$20250818$EXP$$EU-PFIZER INC-202500159980$PFIZER$Ibai, L.. BALLOON RELEASE IN AN IMMUNOSUPPRESSED PATIENT: AN UNEXPECTED ETIOLOGY. European Journal of Case Reports in Internal Medicine. 2024;11(Supplement 1:693$88$YR$$M$Y$$$20250818$$MD$EU$EU
256700081$25670008$1$I$$20250811$20250811$20250811$DIR$769400$$FDA-CTU$$$$$M$N$$$20250811$N$CN$US$
256700461$25670046$1$I$$20250806$20250812$20250812$PER$$US-ROCHE-10000358648$ROCHE$$$$E$M$Y$$$20250812$$CN$US$US
256701881$25670188$1$I$$20250811$20250811$20250811$DIR$FDA-CDER-CTU-2025-53385$$FDA-CTU$$53$YR$$F$N$70.31$KG$20250811$N$$US$
256702161$25670216$1$I$20250802$20250805$20250812$20250812$EXP$$US-NOVOPROD-1496080$NOVO NORDISK$$49$YR$$F$Y$$$20250812$$MD$US$US
256702341$25670234$1$I$$20250807$20250812$20250812$PER$$US-BAYER-2025A105318$BAYER HEALTHCARE LLC$$$$$$Y$$$20250812$$CN$US$US
256703211$25670321$1$I$20250806$20250807$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508007424$ELI LILLY AND COMPANY$$36$YR$A$M$Y$$$20250812$$CN$US$US
256704291$25670429$1$I$$20250812$20250812$20250812$DIR$769625$$FDA-CTU$$$$$$N$$$20250812$N$$US$
256704381$25670438$1$I$20250808$20250811$20250812$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111446$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250812$$PH$US$US
256704411$25670441$1$I$$20250809$20250812$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111407$BRISTOL-MYERS SQUIBB COMPANY$$72$YR$E$F$Y$70.76$KG$20250812$$CN$US$US
256704971$25670497$1$I$20250609$20250730$20250812$20250812$EXP$GB-MHRA-MED-202507281127187860-ZHDPK$GB-ELI_LILLY_AND_COMPANY-GB202507030003$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250812$$CN$GB$GB
256705321$25670532$1$I$20250101$20250807$20250812$20250812$PER$$US-Blueprint Medicines Corporation-2025-AER-01763$BLUEPRINT MEDICINES$$35$YR$A$M$Y$$$20250812$$CN$US$US
256705361$25670536$1$I$$20250728$20250812$20250812$EXP$$US-HLS-202500288$HLS THERAPEUTICS$$58$YR$A$M$Y$$$20250812$$HP$CH$US
256705483$25670548$3$F$20250101$20250909$20250812$20250918$EXP$$US-UCBSA-2025049273$UCB$$$$$M$Y$$$20250918$$HP$US$US
256705611$25670561$1$I$$20250812$20250812$20250812$DIR$FDA-CDER-CTU-2025-53435$$FDA-CTU$$$$$F$N$$$20250812$N$HP$US$
256705691$25670569$1$I$20250712$20250811$20250812$20250812$DIR$FDA-CDER-CTU-2025-53363$$FDA-CTU$$85$YR$$F$N$69.1$KG$20250811$N$$US$
256706681$25670668$1$I$20240827$20250730$20250812$20250812$EXP$$EU-AUROBINDO-AUR-APL-2025-040274$AUROBINDO$$35$YR$$F$Y$102$KG$20250812$$MD$EU$EU
256706731$25670673$1$I$20091020$20250806$20250812$20250812$EXP$EU-EMA-20120424-ssharmap-103309610$EU-HALEON-2256732$Haleon PLC$Bouquie R,Deslandes G,Renaud C,Dailly E,Haloun A,Jolliet P. COLCHICINE-INDUCED RHABDOMYOLYSIS IN A HEART/LUNG TRANSPLANT PATIENT WITH CONCURRENT USE OF CYCLOSPORIN, PRAVASTATIN, AND AZITHROMYCIN.. JOURNAL OF CLINICAL RHEUMATOLOGY 2010 Jan;17(1):28-30.; Bouquie R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-related toxicity within therapeutic dose: Be careful to the interactions. Fundamental and Clinical Pharmacology. Conference: 15th Annual Meeting of the French Society o...$34$YR$$M$Y$62$KG$20250812$$MD$EU$EU
256707151$25670715$1$I$$20250812$20250812$20250812$DIR$769626$$FDA-CTU$$$$$$N$$$20250812$$CN$US$
256707231$25670723$1$I$$20250812$20250812$20250812$DIR$FDA-CDER-CTU-2025-53525$$FDA-CTU$$84$YR$$M$N$$$20250812$N$CN$US$
256708141$25670814$1$I$$20250808$20250812$20250812$EXP$$CA-PFIZER INC-202500159527$PFIZER$$88$YR$$F$Y$$$20250812$$HP$CA$CA
256709831$25670983$1$I$$20250807$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508009140$ELI LILLY AND COMPANY$$55$YR$A$M$Y$$$20250812$$HP$US$US
256710971$25671097$1$I$20250603$20250806$20250812$20250812$EXP$$AR-MYLANLABS-2025M1048341$MYLAN$$60$YR$$M$Y$$$20250812$$MD$AR$AR
256711141$25671114$1$I$$20250731$20250812$20250812$EXP$$US-CIPLA (EU) LIMITED-2025US09861$CIPLA$Roperia V, Kiani AZ, Jayakumar N. High-dose insulin euglycemic therapy in concomitant beta-blocker and calcium channel blocker overdose. Journal of Investigative Medicine High Impact Case Reports. 2025;13:1 to 3$$$$$Y$$$20250812$$MD$US$US
256711341$25671134$1$I$$20250723$20250812$20250812$PER$$US-RDY-USA/2025/07/011526$DR REDDYS$$$$$F$Y$$$20250812$$MD$US$US
256711781$25671178$1$I$$20250804$20250812$20250812$PER$$US-ELI_LILLY_AND_COMPANY-US202508003725$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250812$$CN$US$US
256712171$25671217$1$I$$20250806$20250812$20250812$EXP$$US-SA-2025SA234266$SANOFI AVENTIS$$$$A$F$Y$$$20250812$$HP$US$US
256712421$25671242$1$I$$20250807$20250812$20250812$EXP$$US-JNJFOC-20250808568$JOHNSON AND JOHNSON$$$$A$$Y$$$20250812$$PH$US$US
256712731$25671273$1$I$$20250716$20250812$20250812$PER$$US-RDY-USA/2025/07/011004$DR REDDYS$$$$$F$Y$$$20250812$$CN$US$US
256714151$25671415$1$I$$20250808$20250812$20250812$EXP$$US-PFIZER INC-PV202500096471$PFIZER$$$$$F$Y$$$20250812$$LW$US$US
256714482$25671448$2$F$$20250811$20250812$20250814$30DAY$$US-SANDOZ INC.-SDZ2025US056956$SANDOZ$$$$$F$Y$$$20250814$$CN$US$US
256714834$25671483$4$F$20250801$20250904$20250812$20250909$EXP$$EU-ABBVIE-6410025$ABBVIE$$72$YR$$M$Y$$$20250909$$CN$EU$EU
256715031$25671503$1$I$20240701$20250807$20250812$20250812$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-019358$JAZZ$$42$YR$$F$Y$$$20250812$$$US$US
256715081$25671508$1$I$20240405$20250808$20250812$20250812$EXP$$GB-TEVA-VS-3361835$TEVA$$49$YR$$M$Y$108$KG$20250812$$MD$GB$GB
256715441$25671544$1$I$20250101$20250808$20250812$20250812$EXP$$US-ABBVIE-6410178$ABBVIE$$70$YR$$F$Y$$$20250812$$CN$US$US
256715781$25671578$1$I$$20250808$20250812$20250812$PER$$US-PFIZER INC-202500160592$PFIZER$$72$YR$$F$Y$$$20250812$$HP$US$US
256716841$25671684$1$I$$20250804$20250812$20250812$EXP$$EU-PERRIGO-19NL020565$GALPHARM INTERNATIONAL$Broersen S, Janson J. Canceled appointment is not always good news. MEDICAL CONTACT. 2019;46:30-3$$$$F$Y$$$20250812$$HP$EU$EU
256717021$25671702$1$I$20250426$20250808$20250812$20250812$EXP$$CN-TAKEDA-2025TUS071124$TAKEDA$$2$YR$$M$Y$$$20250812$$$CN$CN
256717271$25671727$1$I$$20250811$20250812$20250812$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-111926$BRISTOL-MYERS SQUIBB COMPANY$$38$YR$A$M$Y$$$20250812$$HP$US$US
256717652$25671765$2$F$20250101$20250902$20250812$20250904$PER$$US-PFIZER INC-202500160838$PFIZER$$49$YR$$F$Y$$$20250904$$CN$US$US
256717851$25671785$1$I$20250101$20250805$20250812$20250812$EXP$$US-TEVA-VS-3360454$TEVA$$40$YR$$F$Y$$$20250812$$CN$US$US
256719052$25671905$2$F$$20250819$20250812$20250821$EXP$$GB-PFIZER INC-PV202500097576$PFIZER$$89$YR$$F$Y$$$20250821$$CN$GB$GB
256720951$25672095$1$I$20250107$20250808$20250812$20250812$EXP$EU-AFSSAPS-RS2025000787$NVSC2025FR125718$NOVARTIS$$59$YR$$F$Y$$$20250812$$MD$EU$EU
256721291$25672129$1$I$20250630$20250702$20250812$20250812$PER$$US-GALDERMA-US2025011668$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256721301$25672130$1$I$$20250702$20250812$20250812$PER$$US-GALDERMA-US2025011691$GALDERMA$$$$$$Y$$$20250812$$MD$US$US
256721351$25672135$1$I$20250101$20250701$20250812$20250812$PER$$US-GALDERMA-US2025011562$GALDERMA$$$$$$Y$$$20250812$$HP$US$US
256721401$25672140$1$I$20250703$20250703$20250812$20250812$PER$$US-GALDERMA-US2025011890$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256721641$25672164$1$I$20250101$20250702$20250812$20250812$PER$$US-GALDERMA-US2025011663$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256722181$25672218$1$I$$20250612$20250812$20250812$PER$$US-GALDERMA-US2025010116$GALDERMA$$$$$$Y$$$20250812$$MD$US$US
256722551$25672255$1$I$20250101$20250616$20250812$20250812$PER$$US-GALDERMA-US2025010460$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256722871$25672287$1$I$20250617$20250618$20250812$20250812$PER$$US-GALDERMA-US2025010613$GALDERMA$$$$$$Y$$$20250812$$CN$US$US
256723151$25672315$1$I$20240101$20250729$20250812$20250812$PER$$US-SA-2025SA228551$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250813$$HP$US$US
256723982$25672398$2$F$20250501$20250911$20250812$20250916$PER$$US-SA-2025SA234890$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250917$$HP$US$US
256724391$25672439$1$I$$20250805$20250812$20250812$PER$$US-SA-2025SA230663$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250813$$HP$US$US
256724511$25672451$1$I$20250101$20250806$20250812$20250812$PER$$US-SA-2025SA233266$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250813$$HP$US$US
256725531$25672553$1$I$$20250807$20250812$20250812$PER$$US-SA-2025SA235903$SANOFI AVENTIS$$$$$$Y$$$20250813$$MD$US$US
256726211$25672621$1$I$20250807$20250807$20250812$20250812$PER$$US-SA-2025SA236277$SANOFI AVENTIS$$68$YR$E$F$Y$$$20250813$$HP$US$US
256726251$25672625$1$I$$20250807$20250812$20250812$PER$$US-SA-2025SA235270$SANOFI AVENTIS$$$$A$F$Y$$$20250813$$HP$US$US
256726301$25672630$1$I$$20250807$20250812$20250812$PER$$US-SA-2025SA234163$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250813$$HP$US$US
256726752$25672675$2$F$20250101$20250818$20250812$20250823$PER$$US-SA-2025SA236437$SANOFI AVENTIS$$33$YR$A$F$Y$$$20250823$$HP$US$US
256727251$25672725$1$I$$20250808$20250812$20250812$PER$$US-SA-2025SA235304$SANOFI AVENTIS$$15$YR$T$F$Y$$$20250813$$CN$US$US
256728071$25672807$1$I$20250101$20250808$20250812$20250812$EXP$$AU-ABBVIE-6409523$ABBVIE$$83$YR$$F$Y$$$20250812$$CN$AU$AU
256728191$25672819$1$I$20250101$20250117$20250812$20250812$PER$$US-ANIPHARMA-2025-US-002885$ANI$$77$YR$$F$Y$61.24$KG$20250812$$HP$US$US
256728951$25672895$1$I$20250701$20250808$20250812$20250812$EXP$$US-ABBVIE-6410235$ABBVIE$$36$YR$$F$Y$$$20250812$$CN$US$US
256729051$25672905$1$I$20250721$20250721$20250812$20250812$EXP$$US-GALDERMA-US2025013353$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256729241$25672924$1$I$20250701$20250807$20250812$20250812$PER$$US-SA-2025SA234874$SANOFI AVENTIS$$17$YR$T$F$Y$$$20250813$$HP$US$US
256729821$25672982$1$I$20250724$20250808$20250812$20250812$EXP$$US-JNJFOC-20250809780$JOHNSON AND JOHNSON$$65$YR$E$$Y$98.5$KG$20250813$$HP$US$US
256731171$25673117$1$I$$20250806$20250813$20250813$PER$$US-SA-2025SA236764$SANOFI AVENTIS$$$$$M$Y$$$20250813$$CN$PH$US
256731261$25673126$1$I$20250101$20250808$20250813$20250813$EXP$$US-SA-2025SA236579$SANOFI AVENTIS$$14$YR$T$F$Y$$$20250813$$HP$US$US
256731702$25673170$2$F$20250728$20250819$20250813$20250823$EXP$$US-ABBVIE-6400370$ABBVIE$$55$YR$$M$Y$$$20250823$$CN$US$US
256734081$25673408$1$I$$20250806$20250813$20250813$EXP$$US-NOVITIUMPHARMA-2025USNVP01995$NOVITIUM PHARMA$S. Patel.Low-Risk Myelodysplastic Syndrome in Lung Transplant Candidates: Pause at Candidate Selection.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A6008$70$YR$E$M$Y$$$20250813$$HP$US$US
256735091$25673509$1$I$$20250806$20250813$20250813$EXP$$US-ASTRAZENECA-202508GLO005733US$ALEXION PHARMACEUTICALS$Arter ZH, Park C, Deng L. MET Tyrosine Kinase Domain Mutations in NSCLC: Expanding the Landscape of Acquired Resistance in Oncogene-Driven Tumors. J Thorac Oncol. 2025;20:998-1000$62$YR$A$M$Y$$$20250813$$$US$US
256735351$25673535$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236747$SANOFI AVENTIS$$$$A$F$Y$$$20250813$$HP$US$US
256735511$25673551$1$I$$20250807$20250813$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112245$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250813$$CN$US$US
256736201$25673620$1$I$$20250712$20250813$20250813$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0000318$RECKITT BENCKISER$$$$$F$Y$$$20250813$$CN$US$US
256736721$25673672$1$I$20230301$20250730$20250813$20250813$EXP$$EU-AUROBINDO-AUR-APL-2025-040199$AUROBINDO$$73$YR$$M$Y$73$KG$20250813$$MD$EU$EU
256736801$25673680$1$I$20250701$20250812$20250813$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112080$BRISTOL-MYERS SQUIBB COMPANY$$55$YR$A$F$Y$$$20250813$$CN$US$US
256736851$25673685$1$I$20250711$20250807$20250813$20250813$EXP$$CN-ROCHE-10000359134$ROCHE$$72$YR$E$F$Y$$$20250813$$HP$CN$CN
256737342$25673734$2$F$20250806$20250806$20250813$20250813$30DAY$$US-ROCHE-10000358992$ROCHE$$15$YR$T$F$Y$77.11$KG$20250813$$CN$US$US
256738311$25673831$1$I$20250726$20250809$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508010204$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250813$$CN$US$US
256739261$25673926$1$I$$20250731$20250813$20250813$EXP$$CA-TLM-TLM-2025-04923$TOLMAR$$78$YR$E$M$Y$$$20250813$$CN$CA$CA
256739293$25673929$3$F$$20250902$20250813$20250910$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA006745$SUNOVION$$48$YR$$M$Y$$$20250909$$$US$US
256739311$25673931$1$I$$20250807$20250813$20250813$EXP$$GB-JNJFOC-20250809724$JOHNSON AND JOHNSON$$$$$M$Y$$$20250813$$CN$GB$GB
256739381$25673938$1$I$$20250811$20250813$20250813$EXP$$EU-ROCHE-10000356005$ROCHE$Chavatza K, Mastrostamati E, Charalampidis C, Antonogiannaki E, Grigoropoulos I, Karofylakis E. Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes. RMD open. 2025-Jul-21;11 (3):1-6. doi:10.1136/rmdopen-2025-005756.$39$YR$A$F$Y$$$20250813$$HP$EU$EU
256739661$25673966$1$I$$20250730$20250813$20250813$EXP$$US-Appco Pharma LLC-2182387$APPCO PHARMA LLC$Initial$$$$$Y$$$20250813$$MD$US$US
256739781$25673978$1$I$20201218$20250811$20250813$20250813$EXP$$EU-SANDOZ INC.-NVSC2020ES360938$SANDOZ$$65$YR$$M$Y$73$KG$20250813$$MD$EU$EU
256740271$25674027$1$I$$20250812$20250813$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112332$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$F$Y$$$20250813$$CN$US$US
256740731$25674073$1$I$20250525$20250731$20250813$20250813$EXP$$EU-AUROBINDO-AUR-APL-2025-040610$AUROBINDO$$66$YR$$F$Y$53$KG$20250813$$PH$EU$EU
256740841$25674084$1$I$$20250811$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508011252$ELI LILLY AND COMPANY$$57$YR$A$M$Y$$$20250813$$CN$US$US
256741821$25674182$1$I$$20250528$20250813$20250813$EXP$$US-ROCHE-10000357263$ROCHE$Greenawalt P, Mendoza P, Messina I, Bouley A, Lathi E, Katz J. Real-World Experience with Ocrelizumab, 8-Year Data [Poster: DMT30]. CMSC. 2025;$42$YR$A$$Y$$$20250813$$HP$US$US
256742041$25674204$1$I$$20250812$20250813$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112203$BRISTOL-MYERS SQUIBB COMPANY$$54$YR$A$F$Y$$$20250813$$HP$US$US
256742072$25674207$2$F$$20250814$20250813$20250925$PER$$US-KENVUE-20250800053$Kenvue$$$$$F$Y$$$20250925$$HP$US$US
256742381$25674238$1$I$$20250807$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508007182$ELI LILLY AND COMPANY$$62$YR$A$F$Y$$$20250813$$CN$US$US
256742391$25674239$1$I$20250520$20250722$20250813$20250813$PER$$US-KENVUE-20250709296$Kenvue$$32$YR$$M$Y$$$20250813$$CN$US$US
256742731$25674273$1$I$$20250804$20250813$20250813$EXP$$CA-TEVA-VS-3361672$TEVA$$43$YR$$F$Y$$$20250813$$HP$CA$CA
256743571$25674357$1$I$20250601$20250811$20250813$20250813$EXP$$ZA-BEH-2025215788$CSL BEHRING$$43$YR$A$M$Y$$$20250813$$CN$ZA$ZA
256743641$25674364$1$I$20240718$20250804$20250813$20250813$EXP$$BR-RDY-BRA/2025/08/012202$DR REDDYS$$$$$F$Y$$$20250813$$CN$BR$BR
256743941$25674394$1$I$20250718$20250806$20250813$20250813$EXP$$CN-ROCHE-10000358539$ROCHE$$27$YR$A$F$Y$$$20250813$$HP$CN$CN
256744471$25674447$1$I$$20250801$20250813$20250813$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-127185$ZYDUS PHARM$Cicci CD, Theobald J, Stanton M, Feldman R.. Outcomes of benzonatate exposures reported to a single United States poison center: a 20-year review.. Clin-Toxicol-(Phila). 2025;63(7):488-494$$$$$Y$$$20250813$$HP$US$US
256745351$25674535$1$I$$20250801$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508003185$ELI LILLY AND COMPANY$$52$YR$A$$Y$$$20250813$$LW$US$US
256745551$25674555$1$I$20250806$20250806$20250813$20250813$30DAY$$US-JNJFOC-20250807187$JOHNSON AND JOHNSON$$$$$F$Y$$$20250813$$CN$US$US
256746611$25674661$1$I$20250424$20250729$20250813$20250813$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-521904$RANBAXY$$46$YR$$M$Y$83.7$KG$20250813$$MD$EU$EU
256747491$25674749$1$I$20250812$20250812$20250813$20250813$EXP$$MX-VANTIVE-2025VAN003700$Vantive US Healthcare$$$$$F$Y$$$20250813$$CN$MX$MX
256747511$25674751$1$I$$20250801$20250813$20250813$EXP$$EU-HIKMA PHARMACEUTICALS USA INC.-NL-H14001-25-09238$HIKMA$Leijtens L, Piek J, Kamps M, Oele-Egelmeer A, Dani?ls-Gooszen A, Bekkers R, et al.. Leijtens L, Piek J, Kamps M, Oele-Egelmeer A, Dani?ls-Gooszen A, Bekkers R, Cnossen J. Near-fatal saddle pulmonary embolism following chemoradiotherapy and brachytherapy for locally advanced cervical cancer: A case series.. Journal of contemporary brachytherapy. 2025;17(3):197-201$66$YR$$F$Y$$$20250813$$MD$EU$EU
256747811$25674781$1$I$20250724$20250725$20250813$20250813$PER$$US-AMGEN-USASP2025149016$AMGEN$$67$YR$E$F$Y$$$20250813$$CN$US$US
256748521$25674852$1$I$$20250812$20250813$20250813$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-088594$BOEHRINGER INGELHEIM$$77$YR$E$F$Y$$$20250813$$$JP$JP
256749801$25674980$1$I$$20250812$20250813$20250813$EXP$$US-ASTRAZENECA-202508USA008166US$ALEXION PHARMACEUTICALS$$$$E$F$Y$$$20250813$$$US$US
256750151$25675015$1$I$20250619$20250619$20250813$20250813$PER$$US-JNJFOC-20250814238$JOHNSON AND JOHNSON$$72$YR$E$M$Y$$$20250813$$HP$US$US
256750321$25675032$1$I$$20250812$20250812$20250812$DIR$769734$$FDA-CTU$$$$$F$N$45$KG$20250812$N$CN$US$
256750711$25675071$1$I$$20250811$20250813$20250813$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112296$BRISTOL-MYERS SQUIBB COMPANY$$85$YR$E$F$Y$63.96$KG$20250813$$CN$US$US
256750801$25675080$1$I$20250101$20250811$20250813$20250813$EXP$$US-ABBVIE-6411558$ABBVIE$$57$YR$$M$Y$$$20250813$$CN$US$US
256750861$25675086$1$I$20170301$20250804$20250813$20250813$EXP$$EU-PBT-010664$PANACEA BIOTEC PHARMA LIMITED$Bonazzetti C, Rinaldi M, Giovagnorio F, irkoren P, Casarini M, Cascavilla A, et al. HHV8-related diseases in Solid Organ Transplantation: a case series and systematic literature review. Clin Microbiol Infect. 2025 Jul 31:S1198-743X(25)00360-X. doi: 10.1016/j.cmi.2025.07.019.$61$YR$A$M$Y$$$20250813$$HP$EU$EU
256751131$25675113$1$I$20250724$20250805$20250813$20250813$EXP$4401031006060202500133$CN-ANIPHARMA-024119$ANI$$10$YR$C$M$Y$$$20250813$$HP$CN$CN
256752161$25675216$1$I$$20250805$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508006227$ELI LILLY AND COMPANY$$56$YR$A$M$Y$$$20250813$$MD$US$US
256753231$25675323$1$I$$20250806$20250813$20250813$EXP$$EU-MYLANLABS-2025M1068325$MYLAN$Leal EB, Ortega JAC, De La Cueva Genoves D, Romero AG, Redondo PG, Rodriguez EC. Stay close to the sun. Eur-J-Case-Rep-Intern-Med 2024; 11 (Suppl. 1) 1137 abstr. 2260.$25$YR$$F$Y$$$20250813$$$EU$EU
256754361$25675436$1$I$20250719$20250812$20250812$20250812$DIR$FDA-CDER-CTU-2025-53617$$FDA-CTU$$76$YR$$F$N$$$20250812$Y$PH$US$
256755262$25675526$2$F$20250803$20250813$20250813$20250822$PER$$CN-BRACCO-2025CN05392$BRACCO$$52$YR$$F$Y$$$20250822$$HP$CN$CN
256755661$25675566$1$I$20250501$20250725$20250813$20250813$EXP$EU-AFSSAPS-DJ2025001203$EU-GILEAD-2025-0722295$GILEAD$$44$YR$A$M$Y$78$KG$20250813$$MD$EU$EU
256758361$25675836$1$I$20250529$20250811$20250813$20250813$PER$$US-BAYER-2025A107026$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250813$$MD$US$US
256758681$25675868$1$I$20250705$20250808$20250813$20250813$EXP$CH-SM-2025-06080$CH-CHEPLA-2025009623$CHEPLAPHARM$$46$YR$$M$Y$$$20250813$$MD$COUNTRY NOT SPECIFIED$CH
256758801$25675880$1$I$$20250808$20250813$20250813$EXP$$US-CHEPLA-3000025876$CHEPLAPHARM$$$$A$F$Y$$$20250812$$MD$COUNTRY NOT SPECIFIED$US
256759892$25675989$2$F$$20250819$20250813$20250829$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202508010012$ELI LILLY AND COMPANY$$68$YR$E$M$Y$$$20250829$$CN$EU$JP
256760051$25676005$1$I$$20250811$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508010143$ELI LILLY AND COMPANY$$49$YR$A$F$Y$$$20250813$$CN$US$US
256760101$25676010$1$I$$20250808$20250813$20250813$PER$$US-ELI_LILLY_AND_COMPANY-US202508009403$ELI LILLY AND COMPANY$$$$$$Y$$$20250813$$CN$US$US
256760341$25676034$1$I$$20250813$20250813$20250813$DIR$769807$$FDA-CTU$$$$$$N$$$20250813$$CN$US$
256761041$25676104$1$I$$20250806$20250813$20250813$PER$$US-INCYTE CORPORATION-2025IN008636$INCYTE$$59$YR$$$Y$$$20250813$$$US$
256761521$25676152$1$I$20240701$20240812$20250813$20250813$PER$$US-ANIPHARMA-2024-US-043311$ANI$$70$YR$$F$Y$40.82$KG$20250813$$CN$US$US
256763221$25676322$1$I$20250701$20250808$20250813$20250813$EXP$$PH-OTSUKA-2025_019570$OTSUKA$$$$$$Y$$$20250813$$CN$PH$PH
256763351$25676335$1$I$20250812$20250813$20250813$20250813$DIR$769788$$FDA-CTU$$$$$$N$$$20250813$N$CN$US$
256763521$25676352$1$I$20250101$20250811$20250813$20250813$EXP$$CA-ABBVIE-6399614$ABBVIE$$64$YR$$F$Y$$$20250813$$CN$CA$CA
256763601$25676360$1$I$$20250730$20250813$20250813$EXP$$JP-Innogenix, LLC-2182406$INNOGENIX, LLC$Full text$8$DEC$$F$Y$$$20250813$$$JP$JP
256763661$25676366$1$I$20250101$20250605$20250813$20250813$PER$$US-GALDERMA-US2025009688$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256763911$25676391$1$I$$20250606$20250813$20250813$PER$$US-GALDERMA-US2025009736$GALDERMA$$$$$$Y$$$20250813$$HP$US$US
256764081$25676408$1$I$$20250609$20250813$20250813$PER$$US-GALDERMA-US2025009913$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256764341$25676434$1$I$20250101$20250610$20250813$20250813$PER$$US-GALDERMA-US2025010030$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256765111$25676511$1$I$20250101$20250811$20250813$20250813$EXP$$US-ABBVIE-6104213$ABBVIE$$84$YR$$M$Y$$$20250813$$CN$US$US
256765411$25676541$1$I$$20250804$20250813$20250813$EXP$$US-Imprimis NJOF, LLC-2182409$IMPRIMIS NJOF, LLC$$$$$F$Y$$$20250813$$$US$US
256765511$25676551$1$I$$20250803$20250813$20250813$EXP$$CA-Difgen-012112$DIFGEN PHARMACEUTICALS LLC$Azar P, Wong J S H, Machado J, Nikoo M, Li V W and Ignaszewski M J et al. Direct Induction of Buprenorphine Extended-Release: A Case Report. J Addict Med. 2025 Jul-Aug,19(4):490-493. doi: 10.1097/ADM.0000000000001425.$55$YR$A$M$Y$$$20250811$$MD$CA$CA
256765701$25676570$1$I$$20250804$20250813$20250813$EXP$$US-NOVOPROD-1496437$NOVO NORDISK$$$$A$F$Y$$$20250813$$CN$US$US
256765861$25676586$1$I$$20250806$20250813$20250813$EXP$$US-NOVOPROD-1495975$NOVO NORDISK$$60$YR$$$Y$$$20250813$$CN$US$US
256768071$25676807$1$I$20230501$20250811$20250813$20250813$EXP$$PH-BRISTOL-MYERS SQUIBB COMPANY-2025-111418$BRISTOL-MYERS SQUIBB COMPANY$$28$YR$A$F$Y$$$20250813$$MD$PH$PH
256768431$25676843$1$I$$20250801$20250813$20250813$PER$$US-MYLANLABS-2025M1065859$MYLAN$$87$YR$$M$Y$$$20250813$$$US$US
256769421$25676942$1$I$$20250808$20250813$20250813$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-019497$JAZZ$$$$$F$Y$$$20250813$$$US$US
256769771$25676977$1$I$20240101$20250123$20250813$20250813$PER$$US-AMERICAN REGENT INC-2025000418$AMERICAN REGENT$$$$$$Y$$$20250813$$HP$US$US
256769781$25676978$1$I$20240101$20250123$20250813$20250813$PER$$US-AMERICAN REGENT INC-2025000422$AMERICAN REGENT$$$$$$Y$$$20250813$$HP$US$US
256769861$25676986$1$I$20240101$20250123$20250813$20250813$PER$$US-AMERICAN REGENT INC-2025000424$AMERICAN REGENT$$$$$$Y$$$20250813$$HP$US$US
256770541$25677054$1$I$$20250807$20250813$20250813$PER$$US-SA-2025SA237888$SANOFI AVENTIS$$73$YR$E$F$Y$$$20250813$$MD$US$US
256770772$25677077$2$F$$20250908$20250813$20250912$PER$$US-SA-2025SA235631$SANOFI AVENTIS$$$$A$F$Y$65.91$KG$20250912$$MD$US$US
256771501$25677150$1$I$20250101$20250808$20250813$20250813$PER$$US-SA-2025SA236537$SANOFI AVENTIS$$57$YR$A$M$Y$$$20250813$$HP$US$US
256771511$25677151$1$I$20250101$20250808$20250813$20250813$PER$$US-SA-2025SA236053$SANOFI AVENTIS$$93$YR$E$M$Y$$$20250813$$MD$US$US
256771621$25677162$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236981$SANOFI AVENTIS$$$$E$F$Y$78.64$KG$20250813$$HP$US$US
256772591$25677259$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236185$SANOFI AVENTIS$$5$YR$C$M$Y$$$20250813$$HP$US$US
256772711$25677271$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236105$SANOFI AVENTIS$$9$YR$C$M$Y$24.3$KG$20250813$$CN$US$US
256773091$25677309$1$I$$20250811$20250813$20250813$PER$$US-SA-2025SA236567$SANOFI AVENTIS$$$$$M$Y$$$20250813$$CN$US$US
256773151$25677315$1$I$20250401$20250811$20250813$20250813$PER$$US-SA-2025SA236169$SANOFI AVENTIS$$$$A$F$Y$$$20250813$$CN$US$US
256773981$25677398$1$I$$20250810$20250813$20250813$PER$$US-PURDUE PHARMA-USA-2025-0319667$PURDUE$$$$$F$Y$$$20250813$$CN$US$US
256774031$25677403$1$I$20250101$20250805$20250813$20250813$EXP$$US-BIOGEN-2025BI01320002$BIOGEN$$$$$F$Y$$$20250813$$MD$US$US
256774081$25677408$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236457$SANOFI AVENTIS$$$$E$F$Y$$$20250813$$MD$US$US
256774121$25677412$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA237662$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250813$$HP$US$US
256775141$25677514$1$I$20250201$20250811$20250813$20250813$PER$$US-SA-2025SA237961$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250813$$HP$US$US
256775281$25677528$1$I$$20250813$20250813$20250813$DIR$769854$$FDA-CTU$$$$$M$N$$$20250813$N$MD$US$
256776941$25677694$1$I$$20250806$20250813$20250813$EXP$$EU-BAUSCH-BH-2025-015949$BAUSCH AND LOMB$Ronda-Roca G, Caballero-Bermejo A, Cantillana-Barrenas J, Ruiz-Antor?n B. First case reports of intentional Imepitoin overdose in humans: A case of two patients. Toxicology Reports. 2025 December 01;102098 doi: 10.1016/j.toxrep.2025.102098$31$YR$A$M$Y$$$20250813$$HP$EU$EU
256777141$25677714$1$I$20250101$20250812$20250813$20250813$PER$$US-BEH-2025215893$CSL BEHRING$$$$A$F$Y$$$20250813$$HP$US$US
256777321$25677732$1$I$$20250723$20250813$20250813$EXP$$CA-DAIICHI SANKYO, INC.-DS-2025-158628-CA$DAIICHI$$$$$F$Y$$$20250813$$MD$CA$CA
256777931$25677793$1$I$20250703$20250805$20250813$20250813$EXP$EU-AFSSAPS-GR2025001172$EU-TEVA-VS-3360207$TEVA$$83$YR$$M$Y$76$KG$20250813$$PH$EU$EU
256778411$25677841$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA236611$SANOFI AVENTIS$$9$YR$C$M$Y$$$20250813$$CN$US$US
256778521$25677852$1$I$20250604$20250806$20250813$20250813$EXP$$US-UCBSA-2025038955$UCB$$68$YR$$F$Y$$$20250813$$CN$US$US
256779061$25677906$1$I$20250101$20250530$20250813$20250813$PER$$US-GALDERMA-US2025009176$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256779311$25677931$1$I$20250101$20250602$20250813$20250813$PER$$US-GALDERMA-US2025009298$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256779671$25677967$1$I$20250101$20250605$20250813$20250813$PER$$US-GALDERMA-US2025009711$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256779821$25677982$1$I$20250803$20250804$20250813$20250813$EXP$GB-MHRA-MED-202508041017375740-RVJHB$GB-RDY-GBR/2025/08/012002$DR REDDYS$$$$$F$Y$166$KG$20250813$$HP$GB$GB
256779961$25677996$1$I$$20250808$20250813$20250813$PER$$US-SA-2025SA237908$SANOFI AVENTIS$$$$E$M$Y$$$20250813$$MD$US$US
256780251$25678025$1$I$20250701$20250812$20250813$20250813$EXP$$TW-PFIZER INC-PV202500097666$PFIZER$$71$YR$$F$Y$53$KG$20250813$$PH$TW$TW
256780431$25678043$1$I$$20250806$20250813$20250813$PER$$US-SA-2025SA237632$SANOFI AVENTIS$$21$YR$A$F$Y$$$20250813$$CN$US$US
256781051$25678105$1$I$$20250513$20250813$20250813$PER$$US-GALDERMA-US2025007944$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256781061$25678106$1$I$20250101$20250513$20250813$20250813$PER$$US-GALDERMA-US2025007981$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256781741$25678174$1$I$$20250522$20250813$20250813$PER$$US-GALDERMA-US2025008608$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256781931$25678193$1$I$$20250523$20250813$20250813$PER$$US-GALDERMA-US2025008706$GALDERMA$$$$$$Y$$$20250813$$CN$US$US
256782171$25678217$1$I$20120101$20250801$20250813$20250813$EXP$$NVSC2025CN124861$NOVARTIS$Feng X, Shen Q-B, Yuan K, Mao Y, Wang X, Min A-P.. Human papillomavirus-associated anal cancer, vulvar verrucous cancer, and cervical cancer in a post-renal transplant patient-a case report.. FRONT. ONCOL.. 2025;15:1-7$73$YR$$F$Y$$$20250813$$HP$CN$CN
256783221$25678322$1$I$20250601$20250801$20250813$20250813$EXP$EU-AEMPS-1739383$EU-ELI_LILLY_AND_COMPANY-ES202508002439$ELI LILLY AND COMPANY$$$$E$F$Y$$$20250813$$CN$EU$EU
256783621$25678362$1$I$$20250507$20250813$20250813$EXP$$US-PRINSTON PHARMACEUTICAL INC.-2025PRN00168$PRINSTON PHARMACEUTICAL$$$$A$F$Y$$$20250808$$CN$US$US
256784022$25678402$2$F$$20250819$20250813$20250821$EXP$$JP-009507513-2317889$MERCK SHARP + DOHME LLC$$82$YR$$F$Y$$$20250821$$MD$JP$JP
256784771$25678477$1$I$$20250805$20250813$20250813$EXP$$CN-BEIGENE-BGN-2025-013117$BEIGENE$$72$YR$$$Y$45$KG$20250813$$$CN$CN
256786801$25678680$1$I$20250329$20250805$20250814$20250814$EXP$$EU-ABBVIE-6411956$ABBVIE$$57$YR$$M$Y$$$20250814$$MD$EU$EU
256786891$25678689$1$I$20250101$20250807$20250814$20250814$PER$$US-BAUSCHBL-2025BNL013949$BAUSCH AND LOMB$$$$$F$Y$$$20250813$$CN$US$US
256787232$25678723$2$F$20250801$20250822$20250814$20250828$EXP$$JP-JNJFOC-20250816480$JOHNSON AND JOHNSON$$45$YR$A$M$Y$$$20250828$$PH$JP$JP
256787702$25678770$2$F$20200101$20250811$20250814$20250819$PER$$US-SA-2025SA235186$SANOFI AVENTIS$$27$YR$A$M$Y$$$20250819$$HP$US$US
256787801$25678780$1$I$$20250811$20250814$20250814$PER$$US-SA-2025SA237013$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250814$$CN$US$US
256788891$25678889$1$I$$20250807$20250814$20250814$PER$$US-SA-2025SA237906$SANOFI AVENTIS$$$$A$F$Y$72.57$KG$20250814$$HP$US$US
256790401$25679040$1$I$$20250811$20250814$20250814$PER$$US-ELI_LILLY_AND_COMPANY-US202508012337$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250814$$CN$US$US
256790641$25679064$1$I$$20250804$20250814$20250814$PER$$US-ROCHE-10000356357$ROCHE$$$$E$F$Y$50.8$KG$20250814$$CN$US$US
256791791$25679179$1$I$$20250712$20250814$20250814$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0003323$RECKITT BENCKISER$$$$$$Y$$$20250814$$CN$US$US
256791811$25679181$1$I$$20250812$20250814$20250814$EXP$$EU-SANDOZ INC.-SDZ2025PL058143$SANDOZ$$75$YR$$F$Y$$$20250814$$MD$EU$EU
256791841$25679184$1$I$$20250813$20250814$20250814$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112877$BRISTOL-MYERS SQUIBB COMPANY$$59$YR$A$M$Y$$$20250814$$CN$US$US
256793041$25679304$1$I$$20250715$20250814$20250814$PER$$US-GSK-US2025AMR093988$GLAXOSMITHKLINE$$$$$$Y$$$20250814$$$US$US
256793421$25679342$1$I$20250726$20250808$20250814$20250814$EXP$CN-NMPACDR-3717011014787202501137$CN-BAXTER-2025BAX019679$BAXTER$$54$YR$$F$Y$74$KG$20250814$$MD$CN$CN
256794061$25679406$1$I$$20250804$20250814$20250814$EXP$$EG-SA-2025SA235700$SANOFI AVENTIS$Badary HA, Ahmed R, Darweesh SK, Zakaria Z, Darweesh H, Ramadan H et al. Methotrexate induced liver fibrosis is over estimated as assessed by transient elastography, acoustic radiation force impulse and serum markers.. Arab Journal of Gastroenterology. 2025;26(3):292-9$$$A$$Y$$$20250814$$HP$EG$EG
256794731$25679473$1$I$$20250801$20250814$20250814$EXP$$US-RDY-USA/2025/08/012168$DR REDDYS$Tan E, Gharti SB. Acute on Chronic Thromboembolic Pulmonary Hypertension in a Patient With A Large, Unrepaired Atrial Septal Defect in Eisenmenger Syndrome. Am J Respir Crit Care Med. 2025;211: A6498. DOI: 10.1164/ajrccm.2025.211.Abstracts.A6498.$65$YR$E$F$Y$$$20250814$$HP$US$US
256794951$25679495$1$I$$20250811$20250814$20250814$PER$$US-ABBVIE-6414045$ABBVIE$$$$A$F$Y$$$20250814$$CN$US$US
256795191$25679519$1$I$$20250808$20250814$20250814$PER$$US-ABBVIE-6412276$ABBVIE$$$$A$M$Y$$$20250814$$CN$US$US
256795282$25679528$2$F$20250807$20250909$20250814$20250915$PER$$US-JNJFOC-20250816371$JOHNSON AND JOHNSON$$71$YR$E$M$Y$$$20250915$$CN$US$US
256795451$25679545$1$I$$20250812$20250814$20250814$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009150$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250814$$CN$US$US
256796211$25679621$1$I$$20250712$20250814$20250814$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0004246$RECKITT BENCKISER$$$$$F$Y$$$20250814$$CN$US$US
256796221$25679622$1$I$$20250807$20250814$20250814$PER$$US-009507513-2318043$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250814$$CN$US$US
256796471$25679647$1$I$$20250731$20250814$20250814$EXP$$EU-AUROBINDO-AUR-APL-2025-040995$AUROBINDO$Torrinha G, Vieira R, Pacheco C, Vila?a C, Bernardo S.. Altered Mental Status and Quadriparesis in Ambulatory Surgical Care: A Case Report.. Cureus. 2025;17(6):e86530$70$YR$$M$Y$$$20250814$$MD$EU$EU
256796651$25679665$1$I$$20250807$20250814$20250814$EXP$$CA-CELLTRION INC.-2025CA027441$CELLTRION$$$$$$Y$$$20250814$$HP$CA$CA
256796721$25679672$1$I$$20250804$20250814$20250814$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA000238$SUNOVION$$63$YR$$M$Y$$$20250813$$$US$US
256797401$25679740$1$I$$20250812$20250814$20250814$EXP$$US-ABBVIE-6415174$ABBVIE$$$$A$M$Y$$$20250814$$CN$US$US
256798261$25679826$1$I$$20250712$20250814$20250814$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0006901$RECKITT BENCKISER$$$$$$Y$$$20250814$$CN$US$US
256799601$25679960$1$I$$20250511$20250814$20250814$PER$$US-INS-BEN202505-000005$INSYS$$$$$F$Y$$$20250814$$CN$US$US
256800341$25680034$1$I$$20250801$20250814$20250814$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-127096$ZYDUS PHARM$Perez CM, Aleman-Ortiz JR.. The Dark Path From Fentanyl Use to Limb Ischemia and Necrotizing Fasciitis.. Am-J-Respir-Crit-Care-Med. 2025;211:A1633$$$$$Y$$$20250814$$HP$US$US
256800551$25680055$1$I$20250721$20250721$20250814$20250814$PER$$US-RDY-USA/2025/07/011397$DR REDDYS$$71$YR$E$F$Y$$$20250814$$CN$US$US
256801411$25680141$1$I$20250512$20250812$20250814$20250814$EXP$EU-AFSSAPS-PB2025000912$EU-TAKEDA-2025TUS071438$TAKEDA$$90$YR$$F$Y$41$KG$20250814$$MD$EU$EU
256801451$25680145$1$I$$20250808$20250814$20250814$EXP$$US-ABBVIE-6409725$ABBVIE$$$$A$F$Y$$$20250814$$CN$US$US
256802341$25680234$1$I$$20250808$20250814$20250814$EXP$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2024SPA005783$SUNOVION$$63$YR$$M$Y$$$20250814$$$US$US
256802711$25680271$1$I$20250811$20250811$20250814$20250814$PER$$US-ELI_LILLY_AND_COMPANY-US202508011648$ELI LILLY AND COMPANY$$46$YR$A$F$Y$$$20250814$$CN$US$US
256803141$25680314$1$I$$20250807$20250814$20250814$PER$$EU-TAKEDA-2025TUS071956$TAKEDA$$51$YR$$F$Y$$$20250814$$$EU$EU
256803311$25680331$1$I$$20250812$20250814$20250814$EXP$$US-009507513-2319201$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250814$$CN$US$US
256804561$25680456$1$I$$20250712$20250814$20250814$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0012930$RECKITT BENCKISER$$$$$F$Y$$$20250814$$CN$US$US
256804641$25680464$1$I$$20250811$20250814$20250814$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009129$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250814$$CN$US$US
256804712$25680471$2$F$20250607$20250909$20250814$20250916$EXP$EU-INFARMED-T202507-971$EU-HIKMA PHARMACEUTICALS USA INC.-PT-H14001-25-09191$HIKMA$$57$YR$$F$Y$50$KG$20250916$$PH$EU$EU
256805191$25680519$1$I$$20250812$20250814$20250814$EXP$$US-PFIZER INC-202500162321$PFIZER$$61$YR$$M$Y$$$20250814$$MD$US$US
256805243$25680524$3$F$20250101$20250826$20250814$20250827$EXP$$IN-PFIZER INC-PV202500098265$PFIZER$$55$YR$$M$Y$$$20250827$$CN$IN$IN
256806151$25680615$1$I$$20250729$20250813$20250813$DIR$FDA-CDER-CTU-2025-53992$$FDA-CTU$$$$$M$N$$$20250729$N$HP$US$
256806441$25680644$1$I$$20250811$20250814$20250814$PER$$US-ABBVIE-6411845$ABBVIE$$$$T$M$Y$$$20250814$$CN$US$US
256806921$25680692$1$I$$20250805$20250814$20250814$PER$$US-ALVOTECHPMS-2025-ALVOTECHPMS-004839$Alvotech$$43$YR$$F$Y$$$20250814$$MD$US$
256807721$25680772$1$I$$20250807$20250814$20250814$EXP$$EU-009507513-2300362$MERCK SHARP + DOHME LLC$$59$YR$$F$Y$83$KG$20250814$$MD$EU$EU
256808191$25680819$1$I$$20250805$20250814$20250814$EXP$$JP-MYLANLABS-2025M1068415$MYLAN$Inamura J, Taketani T, Mochida M, Goto T, Suzuki R, Igarashi S, et al. Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature. Int-J-Hematol 2025; 121 (2): 265-271.$44$YR$$F$Y$$$20250813$$$JP$JP
256808331$25680833$1$I$$20250811$20250814$20250814$EXP$EU-AFSSAPS-NY2025001174$EU-BAXTER-2025BAX019616$BAXTER$$5$YR$$M$Y$$$20250814$$PH$EU$EU
256808361$25680836$1$I$20250501$20250807$20250814$20250814$EXP$$CN-BAYER-2025A105362$BAYER HEALTHCARE PHARMACEUTICALS INC.$$48$YR$A$M$Y$$$20250814$$HP$CN$CN
256808571$25680857$1$I$$20250804$20250814$20250814$EXP$$NVSC2025DE125950$NOVARTIS$Klostermann A, Debertshauser T, Benary M, Biernath N, Erber B, Tahbaz R, et al.. Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers. ESMO OPEN. 2025;10(7):1-8$$$$$Y$$$20250814$$HP$EU$EU
256808811$25680881$1$I$$20250730$20250814$20250814$EXP$$US-RDY-USA/2025/08/012519$DR REDDYS$Philibert-Rosas S, Brace CJ, Semia S, Gidal BE, Nix BT, Josiah AF, et al. The role of cannabis in epilepsy illustrated by two case reports. Epilepsy Behav Rep. 2025;32: DOI: 10.1016/j.ebr.2025.100804.$25$YR$A$M$Y$$$20250814$$HP$US$US
256809761$25680976$1$I$$20250801$20250814$20250814$EXP$$US-AUROBINDO-AUR-APL-2025-041135$AUROBINDO$McCabe DJ, Radke JB, Wilson BZ.. Disposition, outcomes, and lengths of stay due to bupropion overdose at a tertiary care center with a medical toxicology service. American Journal of Emergency Medicine. 2022;54:269-273$16$YR$$$Y$$$20250814$$MD$US$US
256810201$25681020$1$I$20250731$20250807$20250814$20250814$PER$$US-BEH-2025215624$CSL BEHRING$$21$YR$A$F$Y$$$20250814$$HP$US$US
256810721$25681072$1$I$$20250804$20250814$20250814$EXP$$GB-MERZ PHARMACEUTICALS LLC-ACO_178630_2025$MERZ$$$$A$F$Y$$$20250814$$CN$GB$GB
256810851$25681085$1$I$20250101$20250804$20250814$20250814$EXP$$US-CYCLE PHARMACEUTICALS LTD-2025-CYC-000131$Unknown Manufacturer$$$$$$Y$$$20250813$$CN$US$US
256811131$25681113$1$I$$20250804$20250814$20250814$EXP$$US-STRIDES ARCOLAB LIMITED-2025OS000442$Onesource Specialty Pharma$Barakat S, Aldalahmeh M, Dankar R, Khamis Z, El-Hage H. Chronic Ketamine Abuse Associated With Severe Pyelonephritis and Septic Shock Requiring Bilateral Nephrostomy Tubes: A Case Report.. Am-J-Respir-Crit-Care-Med. 2025;211$31$YR$$F$Y$$$20250814$$HP$US$US
256811432$25681143$2$F$$20250916$20250814$20250929$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-07143$LUPIN$$73$YR$$$Y$52.154$KG$20250929$$$US$US
256811541$25681154$1$I$$20250717$20250814$20250814$EXP$$US-NEBO-701590$PHARMACOSMOS A/S$$$$$$Y$$$20250814$$HP$US$US
256811991$25681199$1$I$$20250803$20250814$20250814$EXP$$US-AMAROX PHARMA-HET2025US04742$HETERO$Woodard D, Boyle L, Zwiebel SJ. Concomitant Use of Dextromethorphan/ Bupropion and Escitalopram Associated With Serotonin Toxicity in an Older Adult: A Case Report. Journal of Clinical Psychopharmacology. 2025;00:1-3$79$YR$$M$Y$$$20250814$$MD$US$US
256812791$25681279$1$I$$20250804$20250814$20250814$EXP$$CA-HIKMA PHARMACEUTICALS USA INC.-CA-H14001-25-09340$HIKMA$$$$$$Y$$$20250814$$HP$CA$CA
256813121$25681312$1$I$$20250808$20250814$20250814$PER$$US-ELI_LILLY_AND_COMPANY-US202508008903$ELI LILLY AND COMPANY$$$$$F$Y$$$20250814$$CN$US$US
256814071$25681407$1$I$$20250807$20250814$20250814$PER$$US-Karo Pharma-2182483$Karo Pharma$$$$$F$Y$$$20250814$$$US$US
256814301$25681430$1$I$$20250805$20250814$20250814$EXP$$CA-BIOCON BIOLOGICS LIMITED-BBL2025004454$BIOCON$$$$$$Y$$$20250814$$HP$CA$CA
256814311$25681431$1$I$20240601$20250806$20250814$20250814$EXP$$CN-Eisai-EC-2025-194956$EISAI$$79$YR$E$M$Y$$$20250814$$$CN$CN
256815261$25681526$1$I$$20250801$20250814$20250814$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-513081$RANBAXY$Joshi S, Sanyal D, Stanley W, Prabhu M. A Double Blow: Bilateral Spontaneous Pneumothorax Due to Melioidosis in a Patient With Usual Interstitial Pneumonia-patterned Interstitial Lung Disease and Alcoholic Liver Disease. Am J Respir Crit Care Med. 2025;211 (0):A4004$69$YR$$M$Y$$$20250814$$HP$IN$IN
256815701$25681570$1$I$$20250805$20250814$20250814$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-521882$RANBAXY$$$$$F$Y$$$20250814$$CN$US$US
256816071$25681607$1$I$$20250730$20250814$20250814$EXP$$CH-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-522285$RANBAXY$Schmassmann P, Kirsch M, Zimmerli L, Breidthardt T, Bausch S. ^Toxic Shock^ due to Self-medication with Amlodipine: A Case Report. Swiss MedWkly. 2025;155 (S.285):168s/P206$58$YR$$M$Y$$$20250814$$HP$CH$CH
256816121$25681612$1$I$20250705$20250804$20250814$20250814$PER$$US-BAYER-2025A105836$BAYER HEALTHCARE PHARMACEUTICALS INC.$$31$YR$A$F$Y$$$20250814$$CN$US$US
256816371$25681637$1$I$$20250806$20250814$20250814$EXP$$US-INDIVIOR US-INDV-167701-2025$RECKITT BENCKISER$$$$$$Y$$$20250814$$CN$US$US
256816971$25681697$1$I$$20250813$20250814$20250814$PER$$US-BEH-2025215988$CSL BEHRING$$$$E$F$Y$$$20250814$$HP$US$US
256817751$25681775$1$I$$20250804$20250814$20250814$EXP$$US-RDY-USA/2025/08/012148$DR REDDYS$Cicci CD, Theobald J, Stanton M, Feldman R. Outcomes of benzonatate exposures reported to a single United States poison center: a 20-year review. Clin Toxicol. 2025;63(7): 488-94. DOI: 10.1080/15563650.2025.2512817.$25$YR$A$M$Y$$$20250814$$HP$US$US
256818141$25681814$1$I$$20250806$20250814$20250814$EXP$$US-BIOGEN-2025BI01320017$BIOGEN$$$$$F$Y$$$20250814$$CN$US$US
256819012$25681901$2$F$$20250822$20250814$20250902$EXP$$JP-JNJFOC-20250815667$JOHNSON AND JOHNSON$$$$$$Y$$$20250902$$PH$JP$JP
256819591$25681959$1$I$20250101$20250812$20250814$20250814$EXP$$CA-ABBVIE-6415228$ABBVIE$$76$YR$$M$Y$$$20250814$$CN$CA$CA
256819911$25681991$1$I$20231004$20250804$20250814$20250814$EXP$$SA-NOVOPROD-1496222$NOVO NORDISK$$$$$F$Y$$$20250814$$CN$SA$SA
256820681$25682068$1$I$$20250812$20250814$20250814$EXP$$US-BIOVITRUM-2025-US-011154$BIOVITRUM$Curet-Cervoni F, Lee H, Fayad L, Weeks B, Ighovoyivwi E, Becnel M. Retrospective Review of Two Cases of Localized Iatrogenic Anakinra-Type Amyloidosis at the University of Texas MD Anderson Cancer Center. Clinical Lymphoma, Myeloma and Leukemia. 24: S203. doi:10.1016/S2152-2650(24)02193-1.$66$YR$$M$Y$$$20250814$$HP$US$US
256821371$25682137$1$I$$20250801$20250814$20250814$EXP$$MX-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-522073$RANBAXY$Rodriguez-Cambranis S, Castillo-Espinola A-M,Fuentelzas-Rosado C-D, Salazar-Sansores P, Nunez-Solis C-G, Laviada Molina H-A, et al.. Genotype-Phenotype Correlation of EVC Variants in Ellis-Van Creveld Syndrome: A Systematic Review and Case Report. Cardiogenetics. 2025;15 (2):1-15$15$DY$$F$Y$$$20250814$$HP$MX$MX
256821503$25682150$3$F$$20250912$20250814$20250918$EXP$$CA-ATNAHS-2022-PMNV-CA000012$Atnahs Healthcare$$$$$$Y$$$20250918$$MD$CA$CA
256821731$25682173$1$I$$20250801$20250814$20250814$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI10250$NEUROCRINE BIOSCIENCES$$$$A$F$Y$$$20250814$$MD$US$US
256824151$25682415$1$I$$20250805$20250814$20250814$EXP$$US-ELI_LILLY_AND_COMPANY-US202508006428$ELI LILLY AND COMPANY$$$$$$Y$$$20250814$$CN$US$US
256824911$25682491$1$I$$20250814$20250814$20250814$DIR$FDA-CDER-CTU-2025-54185$$FDA-CTU$$49$YR$$F$N$102.06$KG$20250814$N$$US$
256825401$25682540$1$I$20250101$20250812$20250814$20250814$EXP$$US-ABBVIE-6414827$ABBVIE$$19$YR$$M$Y$$$20250814$$CN$US$US
256826491$25682649$1$I$20240101$20250804$20250814$20250814$EXP$$US-ELI_LILLY_AND_COMPANY-US202508003483$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250814$$CN$US$US
256827262$25682726$2$F$20250715$20250818$20250814$20250819$EXP$EU-AEMPS-1741813$EU-PFIZER INC-202500162429$PFIZER$$43$YR$$F$Y$$$20250819$$MD$EU$EU
256827481$25682748$1$I$$20250804$20250814$20250814$EXP$$GB-AMGEN-GBRSP2025157651$AMGEN$Black S.; Balogun F.; Makkuni D.. Disseminated tuberculosis in a patient on anti-tumour necrosis factor (anti-TNF) therapy. Clinical Medicine. 2025;25 (4):32$$$$F$Y$$$20250814$$HP$GB$GB
256828151$25682815$1$I$$20250729$20250814$20250814$PER$$US-RDY-USA/2025/08/011848$DR REDDYS$$$$$$Y$$$20250814$$MD$US$US
256828482$25682848$2$F$20250801$20250813$20250814$20250815$PER$$US-PFIZER INC-202500163113$PFIZER$$75$YR$$F$Y$$$20250815$$CN$US$US
256828511$25682851$1$I$$20250813$20250814$20250814$EXP$$NVSC2025US128110$NOVARTIS$$$$$$Y$$$20250814$$HP$US$US
256829452$25682945$2$F$20250731$20250815$20250814$20250820$EXP$$US-ABBVIE-6410029$ABBVIE$$63$YR$$M$Y$$$20250820$$CN$US$US
256829761$25682976$1$I$20250727$20250805$20250814$20250814$EXP$GB-MHRA-MED-202508051021072100-VQZPC$GB-ELI_LILLY_AND_COMPANY-GB202508005147$ELI LILLY AND COMPANY$$$$$F$Y$$$20250814$$CN$GB$GB
256830601$25683060$1$I$$20250805$20250814$20250814$EXP$$GB-ELI_LILLY_AND_COMPANY-GB202508003912$ELI LILLY AND COMPANY$$59$YR$A$M$Y$108$KG$20250814$$CN$GB$GB
256831071$25683107$1$I$20250801$20250807$20250814$20250814$PER$$US-ALKERMES INC.-ALK-2025-002156$ALKERMES$$46$YR$$M$Y$68.027$KG$20250814$$CN$US$US
256831441$25683144$1$I$20250601$20250807$20250814$20250814$EXP$$US-ELI_LILLY_AND_COMPANY-US202508008957$ELI LILLY AND COMPANY$$69$YR$E$M$Y$$$20250814$$CN$US$US
256831503$25683150$3$F$$20250818$20250814$20250923$PER$$US-ASTRAZENECA-202508USA009222US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250923$$$US$US
256831751$25683175$1$I$$20250805$20250814$20250814$EXP$$US-ELI_LILLY_AND_COMPANY-US202508005183$ELI LILLY AND COMPANY$$80$YR$E$F$Y$$$20250814$$CN$US$US
256831951$25683195$1$I$$20250811$20250814$20250814$EXP$$NVSC2025CA127263$NOVARTIS$$67$YR$$F$Y$$$20250814$$CN$CA$CA
256831961$25683196$1$I$20250730$20250811$20250814$20250814$EXP$$US-ABBVIE-6413349$ABBVIE$$52$YR$$M$Y$$$20250814$$CN$US$US
256832332$25683233$2$F$$20250915$20250814$20250917$EXP$$TR-BAUSCH-BH-2025-016268$BAUSCH AND LOMB$Karatas S, Patat Y, Gursoy S, Deniz K. IgG4-Related Disease and Treatment Approach with Two Case Reports. Turk J Gastroenterol. 2024;36(1): 89-90.$70$YR$E$M$Y$$$20250917$$MD$TR$TR
256832481$25683248$1$I$$20250811$20250814$20250814$EXP$$GB-PFIZER INC-202500161032$PFIZER$$80$YR$$F$Y$$$20250814$$HP$GB$GB
256832781$25683278$1$I$20250101$20250812$20250814$20250814$PER$$US-009507513-2319340$MERCK SHARP + DOHME LLC$$$$$M$Y$113.4$KG$20250814$$PH$US$US
256833381$25683338$1$I$$20250805$20250814$20250814$EXP$$CA-HLS-202502080$HLS THERAPEUTICS$$$$$F$Y$$$20250814$$$CA$CA
256834851$25683485$1$I$20250101$20250809$20250814$20250814$PER$$US-SA-2025SA238983$SANOFI AVENTIS$$28$YR$A$F$Y$$$20250815$$HP$US$US
256834961$25683496$1$I$20250101$20250810$20250814$20250814$PER$$US-SA-2025SA238108$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250815$$HP$US$US
256835951$25683595$1$I$$20250811$20250814$20250814$PER$$US-SA-2025SA239024$SANOFI AVENTIS$$$$E$F$Y$55$KG$20250815$$MD$US$US
256836101$25683610$1$I$20250701$20250811$20250814$20250814$PER$$US-SA-2025SA237519$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250815$$CN$US$US
256836732$25683673$2$F$20250801$20250918$20250814$20250929$PER$$US-SA-2025SA238416$SANOFI AVENTIS$$12$YR$T$F$Y$$$20250929$$HP$US$US
256836832$25683683$2$F$20250101$20250917$20250814$20250923$PER$$US-SA-2025SA238299$SANOFI AVENTIS$$47$YR$A$F$Y$$$20250923$$HP$US$US
256837201$25683720$1$I$$20250812$20250814$20250814$PER$$US-SA-2025SA238990$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250815$$CN$US$US
256837411$25683741$1$I$20220101$20250812$20250814$20250814$PER$$US-SA-2025SA239535$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250815$$HP$US$US
256837821$25683782$1$I$20250101$20250731$20250814$20250814$PER$$US-SERVIER-S25011225$SERVIER$$$$$$Y$$$20250815$$MD$US$US
256838401$25683840$1$I$20250805$20250812$20250814$20250814$EXP$$US-ABBVIE-6416109$ABBVIE$$63$YR$$F$Y$$$20250814$$CN$US$US
256838881$25683888$1$I$20250101$20250810$20250814$20250814$PER$$US-INSUD PHARMA-2508US06561$INSUD PHARMA$$$$$$Y$$$20250815$$CN$US$US
256839611$25683961$1$I$$20250807$20250815$20250815$EXP$$GB-CELLTRION INC.-2025GB027555$CELLTRION$$$$$$Y$$$20250815$$CN$GB$GB
256840511$25684051$1$I$20250812$20250812$20250815$20250815$PER$$US-SA-2025SA239735$SANOFI AVENTIS$$42$YR$A$F$Y$66.6$KG$20250815$$HP$US$US
256841671$25684167$1$I$20250722$20250724$20250815$20250815$EXP$$US-ASTRAZENECA-202507USA029687US$ALEXION PHARMACEUTICALS$$67$YR$E$M$Y$87.528$KG$20250815$$$US$US
256842201$25684220$1$I$20210101$20250807$20250815$20250815$EXP$EU-AEMPS-1699504$EU-CELLTRION INC.-2025ES027473$CELLTRION$$$$$$Y$$$20250815$$MD$EU$EU
256842352$25684235$2$F$20250801$20250908$20250815$20250910$PER$$PR-BRISTOL-MYERS SQUIBB COMPANY-2025-111649$BRISTOL-MYERS SQUIBB COMPANY$$57$YR$A$F$Y$74.84$KG$20250910$$$PR$PR
256842361$25684236$1$I$$20250807$20250815$20250815$EXP$$CA-CELLTRION INC.-2025CA027426$CELLTRION$$$$$$Y$$$20250815$$HP$CA$CA
256843191$25684319$1$I$20211206$20250813$20250815$20250815$EXP$EU-AFSSAPS-RN2025000711$EU-AMGEN-FRASP2025161480$AMGEN$$48$YR$A$F$Y$$$20250815$$MD$EU$EU
256846171$25684617$1$I$$20250805$20250815$20250815$EXP$$EU-AMGEN-ITASP2025157317$AMGEN$Stella G.M.; Bertuccio F.R.; Baio N. et al.. A Rare Case of Exophiala Dermatitidis Isolation in a Patient with Non-Cystic Fibrosis Bronchiectasis: Colonization or True Infection?. Diagnostics. 2025;15 (13):1-10$66$YR$E$F$Y$$$20250815$$HP$EU$EU
256846321$25684632$1$I$20250716$20250716$20250815$20250815$PER$$US-GSK-US2025AMR094914$GLAXOSMITHKLINE$$38$YR$$F$Y$$$20250815$$$US$US
256846671$25684667$1$I$20250809$20250812$20250815$20250815$PER$$US-GILEAD-2025-0724651$GILEAD$$33$YR$A$M$Y$$$20250815$$MD$US$US
256847151$25684715$1$I$20240823$20250802$20250815$20250815$EXP$$EU-AUROBINDO-AUR-APL-2025-041170$AUROBINDO$$76$YR$$M$Y$$$20250815$$MD$EU$EU
256847241$25684724$1$I$20250601$20250802$20250815$20250815$EXP$$EU-AUROBINDO-AUR-APL-2025-033891$AUROBINDO$$$$A$F$Y$51$KG$20250815$$MD$EU$EU
256847591$25684759$1$I$20250701$20250811$20250815$20250815$PER$$US-SA-2025SA238863$SANOFI AVENTIS$$23$YR$A$F$Y$$$20250815$$HP$US$US
256847851$25684785$1$I$20250724$20250802$20250815$20250815$EXP$$EU-AUROBINDO-AUR-APL-2025-041051$AUROBINDO$$23$YR$$M$Y$$$20250815$$MD$EU$EU
256848301$25684830$1$I$20250804$20250804$20250815$20250815$EXP$$US-ROCHE-10000356716$ROCHE$$83$YR$E$F$Y$$$20250815$$CN$US$US
256848961$25684896$1$I$$20250813$20250815$20250815$EXP$$US-ASTRAZENECA-202508USA009536US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250815$$MD$US$US
256848971$25684897$1$I$$20250805$20250815$20250815$EXP$$CA-ASTRAZENECA-202507CAN026413CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250815$$$CA$CA
256849271$25684927$1$I$20250101$20250811$20250815$20250815$EXP$$RU-BAYER-2025A107485$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250815$$CN$RU$RU
256851351$25685135$1$I$20250619$20250814$20250814$20250814$DIR$770125$$FDA-CTU$$60$YR$$F$N$64.2$KG$20250814$N$MD$US$
256852181$25685218$1$I$20250805$20250811$20250815$20250815$PER$$US-ELI_LILLY_AND_COMPANY-US202508011020$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250815$$CN$US$US
256852241$25685224$1$I$$20250803$20250815$20250815$PER$$US-ELI_LILLY_AND_COMPANY-US202508009762$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250815$$CN$US$US
256852562$25685256$2$F$20250801$20250903$20250815$20250926$PER$$US-MALLINCKRODT-MNK202505025$MALLINCKRODT$$42$YR$A$M$Y$$$20250925$$CN$US$US
256852691$25685269$1$I$$20250814$20250814$20250814$DIR$770101$$FDA-CTU$$$$$$N$$$20250814$N$CN$US$
256853031$25685303$1$I$$20250804$20250815$20250815$EXP$$CH-MACLEODS PHARMA-MAC2025054629$MACLEODS$Angel N, Hulo C, Serratrice J, Fauquex-Bopp T, Coen M.Occurrence of Gitelman^s pseudo syndrome in a patient on proton pump inhibitor and thiazide.Swiss Medical Weekly.2025;155(Supplement 285):152s$$$$$Y$$$20250815$$MD$CH$CH
256854042$25685404$2$F$$20250821$20250815$20250828$EXP$$US-ASTRAZENECA-202508USA009095US$ALEXION PHARMACEUTICALS$$$$$M$Y$98.1$KG$20250827$$MD$US$US
256854281$25685428$1$I$$20250813$20250815$20250815$EXP$$US-PFIZER INC-PV202500098482$PFIZER$$69$YR$$F$Y$$$20250815$$HP$US$US
256854301$25685430$1$I$20250522$20250813$20250815$20250815$EXP$EU-AEMPS-1742304$EU-PFIZER INC-202500162591$PFIZER$$74$YR$$F$Y$$$20250815$$MD$EU$EU
256854321$25685432$1$I$$20250812$20250815$20250815$EXP$$CA-PFIZER INC-202500162652$PFIZER$$37$YR$$F$Y$$$20250815$$CN$CA$CA
256854751$25685475$1$I$$20250815$20250815$20250815$DIR$FDA-CDER-CTU-2025-54360$$FDA-CTU$$85$YR$$M$N$$$20250815$N$CN$US$
256855231$25685523$1$I$$20250807$20250815$20250815$PER$$US-ROCHE-10000359798$ROCHE$$$$A$F$Y$$$20250815$$HP$US$US
256855711$25685571$1$I$20250801$20250815$20250815$20250815$DIR$FDA-CDER-CTU-2025-54362$$FDA-CTU$$68$YR$$M$N$260$LBS$20250815$N$CN$US$
256856211$25685621$1$I$20250801$20250812$20250815$20250815$EXP$$EU-ELI_LILLY_AND_COMPANY-CZ202508010690$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250815$$MD$EU$EU
256857501$25685750$1$I$$20250813$20250815$20250815$PER$$US-PFIZER INC-202500163132$PFIZER$$$$$$Y$$$20250815$$MD$US$US
256857971$25685797$1$I$$20250811$20250811$20250811$DIR$769527$$FDA-CTU$$$$$$N$$$20250811$N$CN$US$
256858261$25685826$1$I$$20250808$20250815$20250815$EXP$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000976$DECIPHERA PHARMACEUTICALS$$66$YR$A$M$Y$$$20250815$$CN$US$US
256858921$25685892$1$I$$20250806$20250815$20250815$EXP$$EU-NOVOPROD-1495479$NOVO NORDISK$$$$$M$Y$$$20250815$$PH$EU$EU
256859441$25685944$1$I$$20250804$20250815$20250815$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI10223$NEUROCRINE BIOSCIENCES$$45$YR$$M$Y$$$20250815$$HP$US$US
256859901$25685990$1$I$20220202$20250807$20250815$20250815$EXP$EU-URPL-DML-MLP.4401.1.1829.2022$NVSC2025PL124976$NOVARTIS$$48$YR$$F$Y$72$KG$20250815$$MD$EU$EU
256860881$25686088$1$I$$20250812$20250815$20250815$EXP$$US-Taiho Oncology Inc-2025-008611$TAIHO ONCOLOGY INC$$$$E$F$Y$50.35$KG$20250815$$CN$US$US
256861031$25686103$1$I$$20250813$20250815$20250815$EXP$$CN-TAKEDA-2025TUS072394$TAKEDA$$$$$F$Y$$$20250815$$$CN$CN
256861093$25686109$3$F$20250101$20250826$20250815$20250828$EXP$$US-009507513-2293903$MERCK SHARP + DOHME LLC$$$$$F$Y$78.925$KG$20250828$$CN$US$US
256861681$25686168$1$I$20250731$20250731$20250815$20250815$PER$$US-GE HEALTHCARE-2025CSU010474$GE HEALTHCARE$$72$YR$$M$Y$$$20250815$$HP$US$US
256861722$25686172$2$F$$20250901$20250815$20250905$PER$$EU-BIOMARINAP-DE-2025-168086$BIOMARIN$$38$YR$$M$Y$69.2$KG$20250905$$$EU$EU
256862141$25686214$1$I$$20250807$20250815$20250815$EXP$$US-NOVOPROD-1498564$NOVO NORDISK$$69$YR$$M$Y$$$20250815$$CN$US$US
256862571$25686257$1$I$$20250808$20250815$20250815$EXP$$US-NOVOPROD-1498264$NOVO NORDISK$$$$$$Y$$$20250815$$CN$US$US
256862792$25686279$2$F$20250101$20250904$20250815$20250913$EXP$$US-UCBSA-2025042538$UCB$$$$$F$Y$$$20250913$$CN$US$US
256864021$25686402$1$I$$20250814$20250815$20250815$PER$$US-PURDUE PHARMA-USA-2025-0319767$PURDUE$$31$YR$$$Y$$$20250815$$CN$US$US
256864121$25686412$1$I$$20250814$20250815$20250815$PER$$US-PURDUE PHARMA-USA-2025-0319768$PURDUE$$25$YR$$$Y$$$20250815$$CN$US$US
256864571$25686457$1$I$$20250811$20250815$20250815$EXP$GB-MHRA-MED-202508080908275970-NMZCQ$GB-ELI_LILLY_AND_COMPANY-GB202508010876$ELI LILLY AND COMPANY$$$$$F$Y$$$20250815$$CN$GB$GB
256864891$25686489$1$I$20250707$20250804$20250815$20250815$EXP$$US-ELI_LILLY_AND_COMPANY-US202508004500$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250815$$CN$US$US
256865241$25686524$1$I$20250201$20250808$20250815$20250815$PER$$US-AMGEN-USASP2025158338$AMGEN$$$$$F$Y$$$20250815$$CN$US$US
256865371$25686537$1$I$20090101$20250812$20250816$20250816$PER$$US-SA-2025SA239748$SANOFI AVENTIS$$$$E$F$Y$$$20250816$$HP$US$US
256865381$25686538$1$I$$20250807$20250816$20250816$PER$$US-UNITED THERAPEUTICS-UNT-2025-026605$UNITED THERAPEUTICS$$$$$F$Y$95.238$KG$20250816$$$US$US
256865831$25686583$1$I$$20250812$20250816$20250816$PER$$US-SA-2025SA240728$SANOFI AVENTIS$$$$E$F$Y$54.55$KG$20250816$$HP$US$US
256866791$25686679$1$I$$20250813$20250816$20250816$PER$$US-SA-2025SA240594$SANOFI AVENTIS$$44$YR$A$M$Y$$$20250816$$CN$US$US
256867052$25686705$2$F$20250101$20250813$20250816$20250823$PER$$US-AMGEN-USASP2025161767$AMGEN$$39$YR$A$F$Y$$$20250823$$CN$US$US
256867141$25686714$1$I$$20250804$20250816$20250816$EXP$$EU-AUROBINDO-AUR-APL-2025-041286$AUROBINDO$$$$$F$Y$$$20250816$$MD$EU$EU
256867411$25686741$1$I$$20250812$20250816$20250816$PER$$US-SA-2025SA238947$SANOFI AVENTIS$$$$A$F$Y$61.224$KG$20250816$$MD$US$US
256868091$25686809$1$I$20250727$20250805$20250816$20250816$EXP$$EU-AUROBINDO-AUR-APL-2025-041355$AUROBINDO$$94$YR$$F$Y$49.2$KG$20250816$$MD$EU$EU
256868572$25686857$2$F$20250813$20250812$20250816$20250818$PER$$US-SA-2025SA240479$SANOFI AVENTIS$$22$YR$A$F$Y$68.18$KG$20250818$$MD$US$US
256868761$25686876$1$I$$20250717$20250816$20250816$PER$$US-GSK-US2025AMR091595$GLAXOSMITHKLINE$$51$YR$$F$Y$$$20250816$$$US$US
256869311$25686931$1$I$$20250804$20250816$20250816$EXP$$US-ASPIRO-ASP2025US04763$ASPIRO PHARMA$Mansour M, Merten S, Gifford K, Hammoud M, Buhi P, Garg A, Shehada ER.. The Utilization of Glucagon in Refractory Anaphylactic Shock in a Patient on ? blockers. American Journal of Respiratory and Critical Care Medicine.. 2025;16;211:A5520$71$YR$$F$Y$$$20250816$$HP$US$US
256869341$25686934$1$I$20250401$20250805$20250816$20250816$EXP$$EU-AUROBINDO-AUR-APL-2025-041325$AUROBINDO$$27$YR$$F$Y$52.5$KG$20250816$$PH$EU$EU
256869511$25686951$1$I$$20250805$20250816$20250816$EXP$$US-AUROBINDO-AUR-APL-2025-041924$AUROBINDO$Tobert KE, Bos JM, Moir C, Polites SF, Ackerman MJ.. Bilateral cardiac sympathetic denervation in patients with congenital long QT syndrome. Heart-Rhythm. 2023;20(7):1033-1038$13$YR$$M$Y$$$20250816$$HP$US$US
256870202$25687020$2$F$$20250811$20250816$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508010421$ELI LILLY AND COMPANY$$77$YR$E$F$Y$$$20250818$$CN$US$US
256870941$25687094$1$I$$20250717$20250816$20250816$PER$$US-GSK-US2025AMR094518$GLAXOSMITHKLINE$$$$$F$Y$$$20250816$$$US$US
256871161$25687116$1$I$$20250804$20250816$20250816$EXP$$IN-MSNLABS-2025MSNLIT02226$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250816$$MD$IN$IN
256871201$25687120$1$I$20250201$20250807$20250816$20250816$PER$$US-SA-2025SA236198$SANOFI AVENTIS$$34$YR$A$M$Y$$$20250816$$HP$US$US
256871251$25687125$1$I$$20250804$20250816$20250816$EXP$$IN-MSNLABS-2025MSNLIT02227$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250816$$MD$IN$IN
256871831$25687183$1$I$20250730$20250808$20250816$20250816$EXP$$CN-AMGEN-CHNSP2025160589$AMGEN$$53$YR$A$M$Y$$$20250816$$HP$CN$CN
256871911$25687191$1$I$$20250811$20250816$20250816$EXP$$CA-TAKEDA-2025TUS072007$TAKEDA$$$$$F$Y$$$20250816$$$CA$CA
256872441$25687244$1$I$20250711$20250814$20250816$20250816$EXP$$NVSC2025IN128746$NOVARTIS$$84$YR$$M$Y$$$20250816$$CN$IN$IN
256873661$25687366$1$I$$20250812$20250816$20250816$PER$$US-SA-2025SA240566$SANOFI AVENTIS$$$$A$M$Y$76.36$KG$20250816$$MD$US$US
256873841$25687384$1$I$$20250812$20250816$20250816$PER$$US-SA-2025SA239285$SANOFI AVENTIS$$45$YR$A$M$Y$$$20250816$$CN$US$US
256874742$25687474$2$F$20240101$20250912$20250817$20250912$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-113570$BRISTOL-MYERS SQUIBB COMPANY$$72$YR$E$F$Y$$$20250912$$$US$US
256875881$25687588$1$I$$20250813$20250817$20250817$PER$$US-SA-2025SA240217$SANOFI AVENTIS$$73$YR$E$F$Y$$$20250817$$CN$US$US
256876411$25687641$1$I$20250704$20250718$20250817$20250817$PER$$US-GSK-US2025092515$GLAXOSMITHKLINE$$74$YR$$M$Y$$$20250817$$$US$US
256877481$25687748$1$I$$20250807$20250817$20250817$PER$$US-SA-2025SA152453$SANOFI AVENTIS$$53$YR$A$F$Y$$$20250817$$MD$US$US
256877571$25687757$1$I$$20250810$20250817$20250817$PER$$US-ELI_LILLY_AND_COMPANY-US202508009946$ELI LILLY AND COMPANY$$$$$$Y$$$20250817$$CN$US$US
256877593$25687759$3$F$20250101$20250916$20250817$20250923$PER$$US-SA-2025SA239473$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250923$$HP$US$US
256877621$25687762$1$I$$20250811$20250817$20250817$EXP$$CN-SA-2025SA238847$SANOFI AVENTIS$Zhao R, Zhou Q, Lian Y, Fu Y, Hu L, Yuan W et al.. A phase II study of short-course radiotherapy followed by sintilimab, anlotinib combined with CAPOX as neoadjuvant treatment for locally advanced MSS/pMMR rectal cancer (ZZU-1 study).. Journal of Clinical Oncology. 2025;43(16):UNKNOWN$$$$$Y$$$20250817$$HP$CN$CN
256877841$25687784$1$I$20250808$20250811$20250817$20250817$PER$$US-ELI_LILLY_AND_COMPANY-US202508010346$ELI LILLY AND COMPANY$$84$YR$E$M$Y$$$20250817$$CN$US$US
256877971$25687797$1$I$$20250805$20250817$20250817$EXP$$CA-HLS-202502063$HLS THERAPEUTICS$$45$YR$$$Y$$$20250817$$$CA$CA
256878071$25687807$1$I$$20250806$20250817$20250817$EXP$$NVSC2025ES127867$NOVARTIS$Valiente EH, Melero MG, Isasi MJC, Alvarez JD, Suarez MRC, Martin O, et al.. Persistent malaria or treatment side effect?. EUROPEAN JOURNAL OF CASE REPORTS IN INTERNAL MEDICINE. 2024;11 (Suppl. 1):507$70$YR$$F$Y$$$20250817$$HP$EU$EU
256878081$25687808$1$I$$20250805$20250817$20250817$EXP$$CA-HLS-202502062$HLS THERAPEUTICS$$27$YR$$$Y$$$20250817$$$CA$CA
256878751$25687875$1$I$20250721$20250813$20250817$20250817$EXP$$US-ABBVIE-6417084$ABBVIE$$64$YR$$M$Y$$$20250817$$CN$US$US
256879251$25687925$1$I$20250101$20250811$20250817$20250817$EXP$$US-ABBVIE-6417109$ABBVIE$$39$YR$$F$Y$88.45$KG$20250817$$CN$US$US
256880861$25688086$1$I$20250801$20250811$20250818$20250818$PER$$US-SA-2025SA240557$SANOFI AVENTIS$$36$YR$A$M$Y$$$20250818$$HP$US$US
256881311$25688131$1$I$$20250813$20250818$20250818$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112796$BRISTOL-MYERS SQUIBB COMPANY$$54$YR$A$F$Y$$$20250818$$CN$US$US
256881371$25688137$1$I$20250101$20250812$20250818$20250818$PER$$US-SA-2025SA240238$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250818$$HP$US$US
256881791$25688179$1$I$$20250810$20250818$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508010095$ELI LILLY AND COMPANY$$53$YR$A$M$Y$$$20250818$$CN$US$US
256882313$25688231$3$F$20250811$20250815$20250818$20250821$EXP$$US-ASTELLAS-2025-AER-044980$ASTELLAS$$65$YR$E$M$Y$$$20250821$$CN$US$US
256882491$25688249$1$I$20250528$20250808$20250818$20250818$EXP$EU-MINISAL02-1045573$EU-CELLTRION INC.-2025IT027878$CELLTRION$$$$$$Y$$$20250818$$MD$EU$EU
256884182$25688418$2$F$20240911$20250923$20250818$20250930$PER$$CN-TAKEDA-2025TUS071839$TAKEDA$$76$YR$$M$Y$$$20250930$$MD$CN$CN
256884361$25688436$1$I$20250101$20250204$20250818$20250818$PER$$US-WOCKHARDT LIMITED-2025WLD000022$WOCKHARDT LIMITED$$$$$$Y$$$20250818$$CN$US$US
256884771$25688477$1$I$20250705$20250709$20250818$20250818$EXP$$US-Unilever-2182680$UNILEVER$$42$YR$$M$Y$$$20250818$$$US$US
256884832$25688483$2$F$$20250912$20250818$20250919$EXP$$US-JNJFOC-20250811691$JOHNSON AND JOHNSON$$$$$F$Y$$$20250919$$LW$US$US
256885091$25688509$1$I$$20250808$20250818$20250818$EXP$$US-INTERCEPT-PM2025001707$INTERCEPT PHARMACEUTICALS$$$$$F$Y$$$20250818$$CN$US$US
256885961$25688596$1$I$20250101$20250813$20250818$20250818$EXP$$US-ABBVIE-6416554$ABBVIE$$57$YR$$M$Y$$$20250818$$CN$US$US
256886481$25688648$1$I$$20250805$20250818$20250818$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-07236$LUPIN$$$$$$Y$$$20250818$$$US$US
256886541$25688654$1$I$20250805$20250806$20250818$20250818$PER$$US-AMGEN-USASP2025155667$AMGEN$$$$$M$Y$$$20250818$$CN$US$US
256886601$25688660$1$I$$20250804$20250818$20250818$EXP$$IN-STRIDES ARCOLAB LIMITED-2025SP010408$STRIDES$Rajesh C, Thomas A, Eapen JJ, Yusuf S, John EE, Valson AT, et al.. Nocardiosis in Renal Allograft Recipients.. J-Global-Infect-Dis. 2024;16 (4):135-139$51$YR$$M$Y$$$20250818$$HP$IN$IN
256887502$25688750$2$F$$20250821$20250818$20250830$EXP$$US-TEVA-VS-3362614$TEVA$Tan EF, Gharti SB. Acute on Chronic Thromboembolic Pulmonary Hypertension in a Patient With A Large, Unrepaired Atrial Septal Defect in Eisenmenger Syndrome. Am-J-Respir-Crit-Care-Med 2025; 211 A6498.; Tan EF, Gharti SB. Acute on Chronic Thromboembolic Pulmonary Hypertension in a Patient With A Large, Unrepaired Atrial Septal Defect in Eisenmenger Syndrome. Am-J-Respir-Crit-Care-Med 2025; 211 A6498.$65$YR$$F$Y$$$20250830$$HP$US$US
256887612$25688761$2$F$20250701$20250904$20250818$20250912$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25052364$RADIUS PHARM$$79$YR$$F$Y$59.41$KG$20250912$$CN$US$US
256887941$25688794$1$I$$20250805$20250818$20250818$EXP$$US-AUROBINDO-AUR-APL-2025-041759$AUROBINDO$Kunduru M, Sultany A, Bhatia H, Siddiqui F.. Stercoral Colitis Induced Colon Ischemia Complicated by Septic Shock and Respiratory Failure.. Am-J-Respir-Crit-Care-Med. 2025;211:A1626$18$YR$$F$Y$$$20250818$$HP$US$US
256888391$25688839$1$I$$20250811$20250818$20250818$EXP$$US-ASTRAZENECA-202508USA010989US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250818$$$US$US
256889901$25688990$1$I$20250125$20250812$20250818$20250818$EXP$EU-AFSSAPS-RN2025000673$EU-TAKEDA-2025TUS071478$TAKEDA$$75$YR$$M$Y$67.5$KG$20250818$$PH$EU$EU
256890013$25689001$3$F$$20250916$20250818$20250922$EXP$$CA-APOTEX-2025AP011789$APOTEX$$36$YR$$M$Y$90$KG$20250922$$HP$CA$CA
256890051$25689005$1$I$20250203$20250808$20250818$20250818$EXP$EU-MINISAL02-1045211$EU-CELLTRION INC.-2025IT027833$CELLTRION$$$$$$Y$$$20250818$$MD$EU$EU
256890132$25689013$2$F$20240101$20250811$20250818$20250821$PER$$US-ROCHE-10000363000$ROCHE$$50$YR$A$F$Y$79.38$KG$20250821$$CN$US$US
256890482$25689048$2$F$$20200710$20250818$20250825$EXP$$IN-ROCHE-10000363921$ROCHE$$56$YR$A$M$Y$$$20250825$$CN$IN$IN
256890551$25689055$1$I$$20250806$20250818$20250818$EXP$$CN-AVS-000197$AAVIS PHARMACEUTICALS$Zhang X, Jin M, Wang M, Ma N, Gao J, Li J, et al. (SETD1B gene related epilepsy and language delay: A case report and literature review). Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2025 Jun 10;42(6):713-718. Chinese. doi: 10.3760/cma.j.cn511374-20240621-00348.$6$YR$C$F$Y$$$20250818$$HP$CN$CN
256890731$25689073$1$I$$20250803$20250818$20250818$EXP$$US-GSK-US2025AMR100406$GLAXOSMITHKLINE$$$$$F$Y$$$20250818$$$US$US
256890761$25689076$1$I$$20250805$20250818$20250818$EXP$$US-AUROBINDO-AUR-APL-2019-058900$AUROBINDO$Mostafa AMT, Ershad M, Cruz MD, Vearrier D. Fatal flecainide overdose. Clinical Toxicology. 2019;57(10):1002-1003$18$YR$$M$Y$$$20250818$$MD$US$US
256891051$25689105$1$I$20250522$20250814$20250818$20250818$EXP$EU-AEMPS-1742304$EU-ROCHE-10000364667$ROCHE$$74$YR$E$F$Y$$$20250818$$MD$EU$EU
256892051$25689205$1$I$20250101$20250813$20250818$20250818$EXP$$US-ABBVIE-6416737$ABBVIE$$34$YR$$M$Y$$$20250818$$CN$US$US
256892281$25689228$1$I$20250626$20250807$20250818$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508007876$ELI LILLY AND COMPANY$$83$YR$E$F$Y$$$20250818$$CN$US$US
256893121$25689312$1$I$$20250813$20250818$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508013323$ELI LILLY AND COMPANY$$$$$F$Y$$$20250818$$CN$US$US
256893321$25689332$1$I$20250101$20250813$20250818$20250818$EXP$$CA-ABBVIE-6418869$ABBVIE$$81$YR$$M$Y$$$20250818$$CN$CA$CA
256893361$25689336$1$I$$20250813$20250818$20250818$EXP$$AR-ABBVIE-6417846$ABBVIE$$24$YR$$M$Y$$$20250818$$CN$AR$AR
256893951$25689395$1$I$20250101$20250811$20250818$20250818$EXP$$CA-TAKEDA-2025TUS039294$TAKEDA$$80$YR$$F$Y$$$20250818$$$CA$CA
256894391$25689439$1$I$20250601$20250808$20250818$20250818$EXP$EU-AFSSAPS-AVMP2025000190$EU-TEVA-VS-3361173$TEVA$$25$YR$$M$Y$$$20250818$$MD$EU$EU
256894531$25689453$1$I$$20250805$20250818$20250818$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-127289$ZYDUS PHARM$Barritt AS, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH.. Refinement of Hy Law Using the Drug Induced Liver Injury Network Database.. Am-J-Gastroenterol. 2024;120(6):1307-1313$$$$$Y$$$20250818$$MD$US$US
256894681$25689468$1$I$20250603$20250805$20250818$20250818$EXP$$EU-AUROBINDO-AUR-APL-2025-042262$AUROBINDO$$$$A$M$Y$$$20250818$$PH$EU$EU
256894881$25689488$1$I$$20250804$20250818$20250818$EXP$$US-EPICPHARMA-US-2025EPCLIT00931$EPIC PHARM$X. Deng.Bronchial Misadventures: When Sevelamer Takes a Wrong Turn.American Journal of Respiratory and Critical Care Medicine.JAN-2025;211:A7516$75$YR$E$M$Y$$$20250818$$HP$US$US
256894922$25689492$2$F$20241031$20250918$20250818$20250929$EXP$$JP-ROCHE-10000364455$ROCHE$$75$YR$E$M$Y$53$KG$20250929$$PH$JP$JP
256894931$25689493$1$I$$20250806$20250818$20250818$EXP$$AU-009507513-2318617$MERCK SHARP + DOHME LLC$$57$YR$$M$Y$$$20250818$$CN$AU$AU
256895041$25689504$1$I$$20250718$20250818$20250818$EXP$$US-NEBO-701585$PHARMACOSMOS A/S$$$$$F$Y$$$20250818$$HP$US$US
256895081$25689508$1$I$$20250807$20250818$20250818$EXP$$EU-MYLANLABS-2025M1068889$MYLAN$Lopalco G, Antonio AD, Chimenti MS, Iannone F. Upadacitinib for the treatment of radiographic axial spondyloarthritis - case series and review of the literature. Drugs-Cont 2025; 14.$59$YR$$F$Y$$$20250818$$$EU$EU
256895691$25689569$1$I$20250527$20250808$20250818$20250818$EXP$EU-AFSSAPS-GR2025001184$EU-TEVA-VS-3361491$TEVA$$68$YR$$M$Y$$$20250818$$PH$EU$EU
256895911$25689591$1$I$20250628$20250806$20250818$20250818$EXP$EU-MINISAL02-1049080$EU-Accord-499979$ACCORD$$15$YR$T$M$Y$$$20250818$$MD$EU$EU
256896121$25689612$1$I$$20250808$20250818$20250818$EXP$$IN-DSJP-DS-2025-158975-IN$DAIICHI$$$$A$F$Y$$$20250818$$CN$IN$IN
256896321$25689632$1$I$$20250811$20250818$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508011274$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250818$$CN$US$US
256896931$25689693$1$I$$20250812$20250818$20250818$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009221$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250818$$CN$US$US
256896991$25689699$1$I$20250311$20250812$20250818$20250818$EXP$EU-AFSSAPS-PO2025000794$EU-TAKEDA-2025TUS071854$TAKEDA$$19$YR$$M$Y$63$KG$20250818$$MD$EU$EU
256897051$25689705$1$I$$20250808$20250818$20250818$EXP$GB-MHRA-MED-202508071459199700-HMCKJ$GB-AMAROX PHARMA-AMR2025GB04693$HETERO$$33$YR$$M$Y$$$20250818$$PH$GB$GB
256898261$25689826$1$I$$20250813$20250818$20250818$EXP$$CN-TAKEDA-2025TUS072670$TAKEDA$$$$$M$Y$$$20250818$$$CN$CN
256898881$25689888$1$I$$20250811$20250818$20250818$EXP$$US-TEVA-VS-3363233$TEVA$Desai D, Nohria A, Brinks AL, Needle CD, Sikora M, Anyanwu N, et al. Low-dose oral minoxidil in alopecia: evaluating blood pressure changes in patients with abnormal blood pressure-a retrospective study. Int-J-Dermatol 2025; 64 (7): 1315-1316.$$$$$Y$$$20250818$$HP$US$US
256899462$25689946$2$F$20250127$20250905$20250818$20250910$30DAY$$GB-JNJFOC-20250185351$JOHNSON AND JOHNSON$$$$$F$Y$$$20250911$$CN$GB$GB
256899541$25689954$1$I$$20250813$20250818$20250818$EXP$$CA-ROCHE-10000364020$ROCHE$Unknown ,  unknown.$42$YR$A$F$Y$$$20250818$$HP$CA$CA
256899772$25689977$2$F$$20250829$20250818$20250911$EXP$$US-TEVA-VS-3362574$TEVA$Kidwell A, Furqan F, Aschenbrenner E, Longo W, Devata S, Hamadani M, et al. Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL. Blood 2024; 144 (Suppl. 1) 2374-2375 (plus Poster).; Kidwell A, Furqan F, Aschenbrenner E, Longo W, Devata S, Hamadani M, et al. Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL. Blood 2024; 144 (Suppl. 1) 2374-2375 (plus Poster).$$$$$Y$$$20250911$$HP$US$US
256899811$25689981$1$I$20250717$20250812$20250818$20250818$EXP$$US-SANDOZ INC.-SDZ2025US058776$SANDOZ$$67$YR$$F$Y$70.3$KG$20250818$$HP$US$US
256900641$25690064$1$I$$20250813$20250818$20250818$PER$$US-PFIZER INC-PV202500098600$PFIZER$$47$YR$$F$Y$$$20250818$$CN$US$US
256901341$25690134$1$I$$20250814$20250818$20250818$PER$$US-PFIZER INC-202500164503$PFIZER$$77$YR$$F$Y$$$20250818$$HP$US$US
256901351$25690135$1$I$$20250815$20250818$20250818$PER$$US-PFIZER INC-202500164525$PFIZER$$42$YR$$F$Y$$$20250818$$MD$US$US
256901472$25690147$2$F$$20250814$20250818$20250828$PER$$US-PFIZER INC-PV202500099414$PFIZER$$76$YR$$M$Y$$$20250828$$HP$US$US
256901621$25690162$1$I$$20250812$20250818$20250818$PER$$US-ELI_LILLY_AND_COMPANY-US202508011621$ELI LILLY AND COMPANY$$59$YR$A$$Y$$$20250818$$LW$US$US
256902391$25690239$1$I$$20250804$20250818$20250818$EXP$$CA-HIKMA PHARMACEUTICALS USA INC.-CA-H14001-25-09341$HIKMA$$$$$$Y$$$20250818$$HP$CA$CA
256902601$25690260$1$I$20130101$20250808$20250818$20250818$PER$$US-BAYER-2025A106221$BAYER HEALTHCARE LLC$$72$YR$E$F$Y$$$20250818$$CN$US$US
256903091$25690309$1$I$$20250815$20250815$20250815$DIR$FDA-CDER-CTU-2025-54483$$FDA-CTU$$84$YR$$M$N$$$20250815$N$CN$US$
256903511$25690351$1$I$20250801$20250816$20250816$20250816$DIR$FDA-CDER-CTU-2025-54621$$FDA-CTU$$62$YR$$F$N$$$20250816$N$$US$
256903561$25690356$1$I$20250803$20250815$20250815$20250815$DIR$770245$$FDA-CTU$$76$YR$$M$N$$$20250815$N$HP$US$
256905712$25690571$2$F$20250101$20250815$20250818$20250825$PER$$US-MALLINCKRODT-MNK202505024$MALLINCKRODT$$$$$F$Y$$$20250825$$CN$US$US
256905911$25690591$1$I$20250101$20250811$20250818$20250818$PER$$US-MYLANLABS-2025M1068668$MYLAN$$$$$F$Y$$$20250817$$$US$US
256906101$25690610$1$I$$20250813$20250818$20250818$PER$$US-ABBVIE-6417187$ABBVIE$$$$T$M$Y$$$20250818$$CN$US$US
256906502$25690650$2$F$20250501$20250903$20250818$20250904$30DAY$$US-PFIZER INC-202500161401$PFIZER$$$$$$Y$$$20250904$$CN$US$US
256907671$25690767$1$I$20250808$20250817$20250817$20250817$DIR$770461$$FDA-CTU$$34$YR$$M$N$112.5$KG$20250817$N$CN$US$
256908061$25690806$1$I$$20250808$20250818$20250818$EXP$$SA-BAUSCH-BH-2025-016124$BAUSCH AND LOMB$Arafsha L, Samargandy SA, Alyazidi AS. Endocrine manifestations of lung adenocarcinoma with epidermal growth factor receptor mutation mimicking tuberculosis: A case report and literature review. Qatar Medical Journal. 2025 Jun 09;2: 64. doi:10.5339/qmj.2025.64.$30$YR$A$F$Y$$$20250818$$HP$SA$SA
256908521$25690852$1$I$20250618$20250811$20250818$20250818$EXP$$RU-ASTRAZENECA-202508EAF006441RU$ALEXION PHARMACEUTICALS$$50$YR$A$M$Y$83$KG$20250818$$MD$RU$RU
256908561$25690856$1$I$$20250813$20250818$20250818$EXP$$US-PFIZER INC-202500163524$PFIZER$$39$YR$$M$Y$$$20250818$$MD$US$US
256908901$25690890$1$I$20250722$20250817$20250817$20250817$DIR$770469$$FDA-CTU$$36$YR$$M$N$146.7$KG$20250817$N$CN$US$
256909351$25690935$1$I$$20250814$20250818$20250818$EXP$$CA-PFIZER INC-202500163638$PFIZER$$83$YR$$F$Y$$$20250818$$HP$CA$CA
256909951$25690995$1$I$$20250806$20250818$20250818$EXP$$US-MACLEODS PHARMA-MAC2018014270$MACLEODS$Steuber H, Williams D, Rech MA..Leave the levofloxacin? A case report of levofloxacin-induced psychosis..American Journal of Emergency Medicine..2018$$$$$Y$$$20250818$$PH$US$US
256910011$25691001$1$I$$20250806$20250818$20250818$EXP$$GB-MACLEODS PHARMA-MAC2025054692$MACLEODS$Abu-Qutaish L, Kumar R.Metformin-induced hypomagnesaemia in a patient with diabetes: a case report.Clinical Medicine, Journal of the Royal College of Physicians of London.2025;25(4):100344$$$$$Y$$$20250818$$MD$GB$GB
256910021$25691002$1$I$$20250806$20250818$20250818$EXP$$IR-MACLEODS PHARMA-MAC2025054695$MACLEODS$Mohammadpour M, Khodaparast M, Khorrami-Nejad M.Central serous chorioretinopathy following ingestion of sildenafil citrate.Clinical Optometry.8-JUL-2019;11:73-75$$$$$Y$$$20250818$$HP$IR$IR
256910301$25691030$1$I$$20250818$20250818$20250818$DIR$770525$$FDA-CTU$$$$$$N$$$20250818$N$CN$US$
256910851$25691085$1$I$20231201$20250815$20250818$20250818$EXP$GB-MHRA-MED-202508151046471060-ZCBHK$GB-ORGANON-O2508GBR001374$ORGANON$$$$$F$Y$52$KG$20250818$$CN$GB$GB
256911972$25691197$2$F$20250701$20250902$20250818$20250909$EXP$$US-CATALYST PHARMACEUTICALS-US-CATA-25-01131$CATALYST PHARMA$$16$YR$$M$Y$72.989$KG$20250909$$CN$US$US
256912212$25691221$2$F$$20250919$20250818$20250925$PER$$US-BIOMARINAP-US-2025-168049$BIOMARIN$$58$YR$$M$Y$111.97$KG$20250925$$$US$US
256912722$25691272$2$F$$20250822$20250818$20250822$PER$$US-PFIZER INC-202500164046$PFIZER$$55$YR$$M$Y$$$20250822$$HP$US$US
256912741$25691274$1$I$$20250818$20250818$20250818$DIR$770553$$FDA-CTU$$$$$F$N$$$20250818$N$CN$US$
256912971$25691297$1$I$$20250812$20250818$20250818$EXP$$CA-TEVA-VS-3363966$TEVA$$56$YR$$M$Y$$$20250818$$HP$CA$CA
256913531$25691353$1$I$$20250410$20250818$20250818$PER$$US-IMPEL-2025-US-018597$IMPEL NEUROPHARMA$$46$YR$$F$Y$$$20250818$$CN$US$US
256913621$25691362$1$I$20240301$20250818$20250818$20250818$DIR$770579$$FDA-CTU$$88$YR$$F$N$$$20250818$N$$US$
256916191$25691619$1$I$$20250724$20250818$20250818$PER$$US-KENVUE-20250710044$Kenvue$$$$$M$Y$$$20250818$$CN$US$US
256916501$25691650$1$I$$20250814$20250818$20250818$EXP$$EU-VISTAPHARM-2025-BG-000004$VISTAPHARM$Tchernev G, Kordeva S.Cheek advancement flap for BCC of the nose: the nitrosamine contamination during the combined drug intake as important skin cancer triggering factor..Acta Medica Bulgarica.2025;52(1):67-75.$74$YR$$M$Y$$$20250818$$HP$EU$EU
256916871$25691687$1$I$20240808$20250813$20250818$20250818$EXP$$CO-ASTRAZENECA-202508SAM010309CO$ALEXION PHARMACEUTICALS$$60$YR$A$F$Y$59$KG$20250818$$$CO$CO
256917011$25691701$1$I$$20250805$20250818$20250818$EXP$$US-NOVOPROD-1501216$NOVO NORDISK$$$$$M$Y$$$20250818$$HP$US$US
256917151$25691715$1$I$20250729$20250811$20250818$20250818$EXP$$CN-009507513-2319199$MERCK SHARP + DOHME LLC$$66$YR$$F$Y$$$20250818$$MD$CN$CN
256917261$25691726$1$I$20250619$20250814$20250818$20250818$EXP$EU-MINISAL02-1052517$EU-MYLANLABS-2025M1069369$MYLAN$$75$YR$$F$Y$65$KG$20250818$$MD$EU$EU
256917381$25691738$1$I$20220801$20250814$20250818$20250818$EXP$EU-DKMA-31018517$EU-TAKEDA-2025TUS072291$TAKEDA$$$$$F$Y$$$20250818$$MD$EU$EU
256917902$25691790$2$F$$20250810$20250818$20250819$30DAY$$CO-PFIZER INC-PV202500097542$PFIZER$$14$YR$$M$Y$$$20250819$$CN$CO$CO
256918551$25691855$1$I$20250413$20250414$20250818$20250818$PER$$US-IMPEL-2025-US-018793$IMPEL NEUROPHARMA$$51$YR$$F$Y$$$20250818$$CN$US$US
256918781$25691878$1$I$$20250804$20250818$20250818$EXP$$NVSC2025CA126421$NOVARTIS$Leitch HA, Buckstein RJ.. How I treat iron overload in adult MDS.. BLOOD. 2025;145 (4):383-96.$81$YR$$M$Y$$$20250818$$HP$CA$CA
256918911$25691891$1$I$$20250804$20250818$20250818$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI10336$NEUROCRINE BIOSCIENCES$$71$YR$$$Y$$$20250818$$HP$US$US
256921481$25692148$1$I$20250101$20250812$20250818$20250818$PER$$US-SA-2025SA221755$SANOFI AVENTIS$$72$YR$E$M$Y$$$20250818$$MD$US$US
256921971$25692197$1$I$$20250811$20250818$20250818$PER$$US-SA-2025SA239173$SANOFI AVENTIS$$$$T$M$Y$$$20250818$$HP$US$US
256923681$25692368$1$I$$20250812$20250818$20250818$PER$$US-SA-2025SA243738$SANOFI AVENTIS$$$$A$F$Y$$$20250818$$CN$US$US
256924231$25692423$1$I$$20250813$20250818$20250818$PER$$US-SA-2025SA239816$SANOFI AVENTIS$$$$A$F$Y$$$20250818$$CN$US$US
256925002$25692500$2$F$20250101$20250910$20250818$20250917$PER$$US-SA-2025SA243908$SANOFI AVENTIS$$72$YR$E$F$Y$$$20250917$$HP$US$US
256925061$25692506$1$I$$20250813$20250818$20250818$PER$$US-SA-2025SA240800$SANOFI AVENTIS$$$$A$F$Y$$$20250818$$HP$US$US
256925381$25692538$1$I$$20250813$20250818$20250818$PER$$US-SA-2025SA240280$SANOFI AVENTIS$$53$YR$A$M$Y$$$20250818$$CN$US$US
256925741$25692574$1$I$$20250814$20250818$20250818$PER$$US-SA-2025SA245140$SANOFI AVENTIS$$31$YR$A$M$Y$$$20250818$$PH$US$US
256926801$25692680$1$I$$20250801$20250818$20250818$PER$$US-shionogi-202500008198$SHIONOGI$Michaels H, Faris J. Outcomes in patients with thermal injury treated with cefiderocol. Burns Open. 2025;doi:https://doi.org/10.1016/j.burnso.2025.100418.$46$YR$A$M$Y$$$20250818$$HP$US$US
256926961$25692696$1$I$$20250801$20250818$20250818$PER$$US-shionogi-202500008232$SHIONOGI$Michaels H, Faris J. Outcomes in patients with thermal injury treated with cefiderocol. Burns Open. 2025;doi:https://doi.org/10.1016/j.burnso.2025.100418.$64$YR$A$M$Y$$$20250818$$HP$US$US
256936981$25693698$1$I$$20250811$20250818$20250818$EXP$$US-AMGEN-USASP2025160353$AMGEN$Karam D.; Potter A.; Al-ajmi A. et al.. Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer. Journal of Clinical Oncology. 2025;43 (16):e20120$$$$$Y$$$20250818$$HP$US$US
256974141$25697414$1$I$$20250808$20250818$20250818$EXP$$US-ELI_LILLY_AND_COMPANY-US202508011179$ELI LILLY AND COMPANY$$$$$$Y$$$20250818$$CN$US$US
256974291$25697429$1$I$$20250724$20250818$20250818$EXP$$US-GALDERMA-US2025013580$GALDERMA$$$$$$Y$$$20250819$$CN$US$US
256974831$25697483$1$I$$20250808$20250818$20250818$EXP$$US-ELI_LILLY_AND_COMPANY-US202508009010$ELI LILLY AND COMPANY$$$$$F$Y$$$20250818$$CN$US$US
256976151$25697615$1$I$$20250815$20250819$20250819$EXP$$NVSC2025US129708$NOVARTIS$$27$YR$$M$Y$$$20250819$$MD$US$US
256976311$25697631$1$I$20250812$20250813$20250819$20250819$EXP$$CA-ABBVIE-6416924$ABBVIE$$68$YR$$F$Y$90.7$KG$20250819$$CN$CA$CA
256977011$25697701$1$I$$20250812$20250819$20250819$PER$$US-GILEAD-2025-0724470$GILEAD$$$$$M$Y$$$20250818$$PH$US$US
256977543$25697754$3$F$20250101$20250908$20250819$20250910$PER$$US-UNITED THERAPEUTICS-UNT-2025-026017$UNITED THERAPEUTICS$$$$$F$Y$77.098$KG$20250910$$$US$US
256977582$25697758$2$F$20250701$20250822$20250819$20250825$PER$$EU-ASTRAZENECA-202506EEA015936FR$ALEXION PHARMACEUTICALS$$69$YR$E$M$Y$$$20250825$$$EU$EU
256978071$25697807$1$I$$20250806$20250819$20250819$PER$$US-GSK-US2025AMR102919$GLAXOSMITHKLINE$$$$$$Y$$$20250819$$$US$US
256978251$25697825$1$I$$20250811$20250819$20250819$EXP$$US-AMGEN-USASP2025161702$AMGEN$Mestres-villanueva M.; Gokun Y.; Sierra D. et al.. Real-world treatment patterns and outcomes in HER2-positive metastatic breast cancer patients with brain metastases. Journal of Clinical Oncology. 2025;43 (16):e13022$$$$$Y$$$20250818$$HP$US$US
256978911$25697891$1$I$$20250813$20250819$20250819$EXP$$CA-TEVA-VS-3363622$TEVA$$56$YR$$F$Y$$$20250819$$MD$CA$CA
256979141$25697914$1$I$20250416$20250605$20250819$20250819$PER$$US-ENDO USA, INC.-2025-001133$ENDO$$39$YR$$M$Y$$$20250819$$PH$US$US
256979601$25697960$1$I$$20250125$20250819$20250819$PER$$US-AUROBINDO-AUR-APL-2024-046446$AUROBINDO$$70$YR$$F$Y$58.9$KG$20250819$$CN$US$US
256979621$25697962$1$I$20250101$20250814$20250819$20250819$PER$$US-SA-2025SA246332$SANOFI AVENTIS$$48$YR$A$M$Y$$$20250819$$HP$US$US
256980321$25698032$1$I$20250606$20250811$20250819$20250819$EXP$EU-AFSSAPS-AM2025000613$EU-BAXTER-2025BAX019610$BAXTER$$55$YR$$F$Y$82.4$KG$20250819$$MD$EU$EU
256980741$25698074$1$I$$20250805$20250819$20250819$EXP$$US-GSK-US2025AMR101945$GLAXOSMITHKLINE$$$$$F$Y$$$20250819$$$US$US
256981581$25698158$1$I$$20250812$20250819$20250819$PER$$US-ELI_LILLY_AND_COMPANY-US202508012309$ELI LILLY AND COMPANY$$58$YR$A$M$Y$$$20250819$$HP$US$US
256981611$25698161$1$I$$20250814$20250819$20250819$PER$$US-ELI_LILLY_AND_COMPANY-US202508014349$ELI LILLY AND COMPANY$$49$YR$A$$Y$$$20250819$$LW$US$US
256981662$25698166$2$F$20250801$20250826$20250819$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202508015419$ELI LILLY AND COMPANY$$76$YR$E$F$Y$$$20250905$$CN$US$US
256982161$25698216$1$I$20250701$20250814$20250819$20250819$EXP$$CA-ABBVIE-6418835$ABBVIE$$52$YR$$M$Y$$$20250819$$CN$CA$CA
256984451$25698445$1$I$20250613$20250714$20250819$20250819$PER$$US-LIVZON-2025MPSPO00252$LIVZON PHARMA$$$$$F$Y$$$20250819$$CN$US$US
256984671$25698467$1$I$$20250805$20250819$20250819$EXP$$JP-STRIDES ARCOLAB LIMITED-2025OS000456$Onesource Specialty Pharma$Inamura J, Taketani T, Mochida M, Goto T, Suzuki R, Igarashi S, et al. Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.. Int-J-Hematol. 2025;121 (2):265-271$44$YR$$F$Y$$$20250819$$HP$JP$JP
256984701$25698470$1$I$$20250805$20250819$20250819$EXP$$CN-STRIDES ARCOLAB LIMITED-2025OS000455$Onesource Specialty Pharma$Zhang J, Chen Y, Xu D, Ma S, Gan Y, Luo Y.. Acute Generalized Exanthematous Pustulosis in a 76-year-Old Man With Neuroendocrine Carcinoma of the Lung, Responsive to Ixekizumab.. Clin-Cosmet-Invest-Dermatol. 2025;18:453-458$76$YR$$M$Y$$$20250819$$HP$CN$CN
256985051$25698505$1$I$$20250805$20250819$20250819$PER$$US-APOTEX-2025AP011567$APOTEX$Hollon N, Dang V, Eramo G, Parekh R, Boamah A, Sutton J, et al. Prevalence of dosage modifications and impact on response milestone among patients with CML treated with imatinib using RWD. Journal of Clinical Oncology. 2025;43 (16):1-3$$$A$$Y$$$20250819$$HP$US$US
256985651$25698565$1$I$$20250808$20250819$20250819$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA010337$SUNOVION$$81$YR$$M$Y$$$20250814$$$US$US
256986171$25698617$1$I$20250710$20250806$20250819$20250819$EXP$$EU-AUROBINDO-AUR-APL-2025-042371$AUROBINDO$$42$YR$$F$Y$$$20250819$$MD$EU$EU
256986451$25698645$1$I$$20250813$20250819$20250819$EXP$$CN-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-089098$BOEHRINGER INGELHEIM$$$$$$Y$$$20250819$$$CN$CN
256986691$25698669$1$I$$20241211$20250819$20250819$PER$$US-TARO PHARMACEUTICALS USA INC.-2024TAR02708$TARO$$$$$$Y$$$20250819$$CN$US$US
256986711$25698671$1$I$$20250812$20250819$20250819$EXP$$US-ABBVIE-6123906$ABBVIE$$$$A$F$Y$$$20250819$$CN$US$US
256987111$25698711$1$I$$20250725$20250819$20250819$PER$$US-ELI_LILLY_AND_COMPANY-US202507027245$ELI LILLY AND COMPANY$$$$$M$Y$$$20250819$$CN$US$US
256987761$25698776$1$I$20250101$20250805$20250819$20250819$EXP$$US-MARINUS PHARMACEUTICALS, INC.-MAR2025000187$MARINUS PHARMACEUTICALS$$$$$$Y$$$20250819$$CN$US$US
256989881$25698988$1$I$$20250812$20250819$20250819$PER$$US-CHATTEMPRD-2025OHG024915$CHATTEM$$$$$$Y$$$20250819$$CN$US$US
256990291$25699029$1$I$$20250805$20250819$20250819$EXP$$CA-TLM-TLM-2025-05798$TOLMAR$$$$A$M$Y$$$20250819$$CN$CA$CA
256990434$25699043$4$F$$20250926$20250819$20250930$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009228$ACADIA PHARMACEUTICALS$$$$$F$Y$69$KG$20250930$$CN$US$US
256991021$25699102$1$I$$20250813$20250819$20250819$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-113835$BRISTOL-MYERS SQUIBB COMPANY$$89$YR$E$F$Y$64.41$KG$20250819$$CN$US$US
256991711$25699171$1$I$20250721$20250721$20250819$20250819$PER$$US-AUROBINDO-AUR-APL-2025-038644$AUROBINDO$$50$YR$$M$Y$$$20250819$$MD$US$US
256992741$25699274$1$I$$20250809$20250819$20250819$EXP$$CA-CELLTRION INC.-2025CA027963$CELLTRION$$$$$$Y$$$20250819$$HP$CA$CA
256992912$25699291$2$F$20250801$20250820$20250819$20250825$EXP$$EU-MYLANLABS-2025M1069969$MYLAN$$42$YR$$M$Y$$$20250825$$MD$EU$EU
256993491$25699349$1$I$$20250813$20250819$20250819$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009220$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250819$$CN$US$US
256993522$25699352$2$F$20220101$20250829$20250819$20250911$EXP$$BR-TEVA-VS-3363071$TEVA$Taboada RG, Arruda Almeida MF, Santiago KM, Carraro DM, Nunes WA, Diniz AL, et al. Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review. J-Gastrointest-Can 2025; 56 1-8.; Taboada RG, Arruda Almeida MF, Santiago KM, Carraro DM, Nunes WA, Diniz AL, et al. Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Repor...$74$YR$$F$Y$$$20250911$$HP$BR$BR
256993941$25699394$1$I$$20250804$20250819$20250819$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-522750$RANBAXY$Ray U, Dutta S, Sutradhar A. Histoplasmosis - More common than we realize. ID Cases. 2025;39 (0):e02180 (1-6)$71$YR$$$Y$$$20250819$$HP$IN$IN
256994451$25699445$1$I$$20250805$20250819$20250819$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-523108$RANBAXY$$41$YR$$M$Y$69$KG$20250819$$MD$GB$GB
256994721$25699472$1$I$20231101$20250812$20250819$20250819$EXP$EU-MINISAL02-1052302$EU-ASTRAZENECA-202508GLO009687IT$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$$$20250819$$MD$EU$EU
256994901$25699490$1$I$$20250811$20250819$20250819$EXP$$MX-BAYER-2025A109841$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$$Y$$$20250819$$CN$MX$MX
256995051$25699505$1$I$$20250818$20250819$20250819$EXP$$MX-VANTIVE-2025VAN003815$Vantive US Healthcare$$$$$M$Y$$$20250819$$CN$MX$MX
256995311$25699531$1$I$20250701$20250812$20250819$20250819$EXP$$US-SANDOZ INC.-SDZ2025US058376$SANDOZ$$57$YR$$F$Y$$$20250819$$CN$US$US
256995451$25699545$1$I$$20250321$20250819$20250819$PER$$US-MC2 Therapeutics, Ltd-2182781$MC2 Therapeutics$$17$YR$$F$Y$63.5$KG$20250819$$$US$US
256995591$25699559$1$I$20250628$20250811$20250819$20250819$EXP$EU-AFSSAPS-MP2025001096$EU-BAXTER-2025BAX019658$BAXTER$$32$YR$$F$Y$$$20250819$$MD$EU$EU
256996211$25699621$1$I$20230101$20250813$20250819$20250819$EXP$$US-BIOGEN-2025BI01321013$BIOGEN$$$$$M$Y$$$20250819$$CN$US$US
256996711$25699671$1$I$$20250811$20250819$20250819$EXP$$CN-UNICHEM LABORATORIES LIMITED-UNI-2025-CN-003050$UNICHEM$Xie Q, Pak CJ, Kwon J, Chao SC and Hong JP.. Potential role of Lymphovenous bypass in mitigating Alzheimer^s disease dementia. Archives of plastic surgery. 2025;52:247-252$$$$$Y$$$20250819$$MD$CN$CN
256997001$25699700$1$I$20240701$20250714$20250819$20250819$PER$$US-BIOCRYST PHARMACEUTICALS, INC.-2025BCR00924$BIOCRYST PHARMACEUTICALS$$$$$$Y$$$20250819$$CN$US$US
256997321$25699732$1$I$20250423$20250818$20250819$20250819$EXP$$EU-SANDOZ INC.-SDZ2025CZ059543$SANDOZ$$51$YR$$M$Y$$$20250819$$HP$EU$EU
256997552$25699755$2$F$$20250912$20250819$20250915$EXP$$US-ASTRAZENECA-202508USA012942US$ALEXION PHARMACEUTICALS$$$$C$M$Y$$$20250915$$$US$US
256998072$25699807$2$F$20250706$20250820$20250819$20250821$EXP$EU-MINISAL02-1053270$EU-GILEAD-2025-0724845$GILEAD$$59$YR$A$$Y$$$20250821$$MD$EU$EU
256998751$25699875$1$I$$20250724$20250819$20250819$PER$$US-GSK-US2025AMR098812$GLAXOSMITHKLINE$$$$$F$Y$50$KG$20250819$$$US$US
256999531$25699953$1$I$20250813$20250818$20250818$20250818$DIR$770628$$FDA-CTU$$60$YR$$F$N$$$20250818$N$CN$US$
256999673$25699967$3$F$$20250908$20250819$20250918$PER$$US-SUMITOMO PHARMA SWITZERLAND GMBH-2025SPA010366$SUNOVION$$66$YR$$M$Y$$$20250917$$$US$US
257000921$25700092$1$I$$20250815$20250819$20250819$PER$$US-ELI_LILLY_AND_COMPANY-US202508016872$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250819$$CN$US$US
257000971$25700097$1$I$$20250813$20250819$20250819$PER$$US-ELI_LILLY_AND_COMPANY-US202508013975$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250819$$CN$US$US
257001651$25700165$1$I$20250808$20250811$20250819$20250819$EXP$$GB-UCBSA-2025049804$UCB$$71$YR$$F$Y$$$20250819$$CN$GB$GB
257002101$25700210$1$I$20220930$20250805$20250819$20250819$EXP$$CN-GLANDPHARMA-CN-2025GLNLIT01685$GLAND PHARMA LTD$Miaomiao Yang.Dermatomyositis following resection of thyroid and breast cancer: a case report and literature review.Frontiers in Oncology.21-JAN-2025;15:1-8$60$YR$A$F$Y$$$20250819$$HP$CN$CN
257002181$25700218$1$I$$20250729$20250819$20250819$PER$$US-009507513-2315238$MERCK SHARP + DOHME LLC$$72$YR$$M$Y$80.6$KG$20250819$$CN$US$US
257002251$25700225$1$I$20250701$20250717$20250819$20250819$PER$$US-ARCUTIS BIOTHERAPEUTICS INC-2025AER000477$ARCUTIS$$$$$$Y$$$20250818$$CN$US$US
257002531$25700253$1$I$$20250623$20250819$20250819$PER$$US-ARCUTIS BIOTHERAPEUTICS INC-2025AER000539$ARCUTIS$$$$$$Y$$$20250818$$MD$US$US
257002901$25700290$1$I$20250730$20250814$20250819$20250819$EXP$$EU-AMERICAN REGENT INC-2025003187$AMERICAN REGENT$$78$YR$$M$Y$$$20250819$$HP$EU$EU
257003392$25700339$2$F$$20250911$20250819$20250915$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009272$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250915$$CN$US$US
257003711$25700371$1$I$20250810$20250818$20250818$20250818$DIR$FDA-CDER-CTU-2025-55004$$FDA-CTU$$74$YR$$F$N$$$20250818$N$PH$US$
257003741$25700374$1$I$$20250818$20250818$20250818$DIR$FDA-CDER-CTU-2025-55009$$FDA-CTU$$14$YR$$M$N$$$20250818$N$CN$US$
257003902$25700390$2$F$20240201$20250822$20250819$20250903$EXP$$CN-Accord-500042$ACCORD$Tian Q, Shang R, Liu Y, Liu H, Zheng Y, Jian X. Case Report: Third-degree atrioventricular block and respiratory failure caused by clozapine poisoning. Front Pharmacol. 2025 Jul 18;16:1572578. doi: 10.3389/fphar.2025.1572578.$55$YR$A$M$Y$$$20250903$$HP$CN$CN
257004171$25700417$1$I$$20250809$20250819$20250819$EXP$$CA-CELLTRION INC.-2025CA027958$CELLTRION$$$$$$Y$$$20250819$$HP$CA$CA
257005531$25700553$1$I$20250221$20250813$20250819$20250819$EXP$$EU-ELI_LILLY_AND_COMPANY-FR202508014100$ELI LILLY AND COMPANY$$82$YR$E$F$Y$60$KG$20250819$$PH$EU$EU
257005731$25700573$1$I$$20250814$20250819$20250819$PER$$US-BAYER-2025A109015$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250819$$MD$US$US
257005931$25700593$1$I$20250809$20250809$20250819$20250819$EXP$$NVSC2025JO126151$NOVARTIS$$1$YR$$F$Y$$$20250819$$HP$JO$JO
257005961$25700596$1$I$$20250805$20250819$20250819$EXP$$US-ASCENT-2025ASLIT00180$ASCENT PHARMACEUTICALS INC$Chaudhary M, et al.Life-threatening ACE Inhibitor Induced Angioedema Requiring Endotracheal Intubation.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A3989$64$YR$A$M$Y$$$20250819$$HP$US$US
257006741$25700674$1$I$20250701$20250813$20250819$20250819$PER$$US-SA-2025SA245915$SANOFI AVENTIS$$27$YR$A$M$Y$$$20250819$$HP$US$US
257007731$25700773$1$I$20250101$20250813$20250819$20250819$PER$$US-SA-2025SA246020$SANOFI AVENTIS$$$$A$F$Y$$$20250819$$HP$US$US
257007891$25700789$1$I$20250813$20250813$20250819$20250819$PER$$US-SA-2025SA246066$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250819$$MD$US$US
257008092$25700809$2$F$$20250905$20250819$20250911$PER$$US-SA-2025SA240793$SANOFI AVENTIS$$$$A$F$Y$59.09$KG$20250912$$HP$US$US
257008371$25700837$1$I$$20250814$20250819$20250819$PER$$US-SA-2025SA245853$SANOFI AVENTIS$$70$YR$E$F$Y$$$20250819$$CN$US$US
257008871$25700887$1$I$$20250814$20250819$20250819$PER$$US-SA-2025SA245590$SANOFI AVENTIS$$$$A$F$Y$104.55$KG$20250819$$MD$US$US
257009291$25700929$1$I$20250101$20250814$20250819$20250819$PER$$US-SA-2025SA246116$SANOFI AVENTIS$$62$YR$A$F$Y$$$20250819$$HP$US$US
257010601$25701060$1$I$$20250815$20250818$20250818$DIR$FDA-CDER-CTU-2025-55072$$FDA-CTU$$$$$M$N$$$20250815$N$CN$US$
257010811$25701081$1$I$$20250818$20250819$20250819$PER$$US-PFIZER INC-PV202500100102$PFIZER$$70$YR$$M$Y$$$20250819$$CN$US$US
257011141$25701114$1$I$$20250811$20250819$20250819$PER$$US-SA-2025SA240753$SANOFI AVENTIS$$37$YR$A$F$Y$$$20250819$$CN$US$US
257011251$25701125$1$I$$20250814$20250819$20250819$PER$$US-PFIZER INC-PV202500099555$PFIZER$$70$YR$$M$Y$$$20250819$$CN$US$US
257011631$25701163$1$I$$20250815$20250819$20250819$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-114889$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250819$$MD$US$US
257012361$25701236$1$I$20241101$20250807$20250819$20250819$EXP$$US-ROCHE-10000359932$ROCHE$$65$YR$E$F$Y$60.8$KG$20250819$$HP$US$US
257012431$25701243$1$I$20250818$20250819$20250819$20250819$DIR$FDA-CDER-CTU-2025-55085$$FDA-CTU$$65$YR$$F$N$$$20250819$N$PH$US$
257013451$25701345$1$I$$20250807$20250819$20250819$PER$$US-JNJFOC-20250817051$JOHNSON AND JOHNSON$$$$$$Y$$$20250819$$HP$US$US
257013482$25701348$2$F$$20250814$20250819$20250901$PER$$US-KENVUE-20250805583$Kenvue$$$$$$Y$$$20250901$$CN$US$US
257014031$25701403$1$I$$20250812$20250819$20250819$EXP$$US-AMERICAN REGENT INC-2025003152$AMERICAN REGENT$Chebolu E, Gnirke M, StFrancis H, Soghoian S, Su MK.. Extravasation with methylthioninium chloride. Clinical Toxicology (Philadelphia, Pa.). 2024;62 (11):776-778$38$YR$$F$Y$$$20250819$$HP$US$US
257015252$25701525$2$F$$20250813$20250819$20250821$EXP$$CH-JNJFOC-20250822168$JOHNSON AND JOHNSON$Betz E.; Hofmann K.; Dubs L.; Sandera P.; Solimene F.. Jejunal diverticulosis: Complications and management - A case series. Journal of Surgical Case Reports. 2025;2025:7:rjaf569. doi:doi.org/10.1093/jscr/rjaf569$81$YR$E$M$Y$$$20250821$$HP$CH$CH
257015681$25701568$1$I$$20250808$20250819$20250819$EXP$GB-MHRA-MED-202508071558164840-LHFYT$GB-ELI_LILLY_AND_COMPANY-GB202508009527$ELI LILLY AND COMPANY$$$$$F$Y$$$20250819$$CN$GB$GB
257016231$25701623$1$I$20240801$20240909$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-120876$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257016371$25701637$1$I$20240822$20241219$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-123784$REGENERON$$$$$F$Y$$$20250819$$HP$US$US
257016721$25701672$1$I$20240930$20241212$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-131542$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257016801$25701680$1$I$$20241224$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-134416$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257017301$25701730$1$I$20250702$20250811$20250819$20250819$EXP$$US-ELI_LILLY_AND_COMPANY-US202508012555$ELI LILLY AND COMPANY$$65$YR$E$M$Y$$$20250819$$CN$US$US
257017601$25701760$1$I$$20250818$20250819$20250819$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-089968$BOEHRINGER INGELHEIM$$$$$$Y$$$20250819$$MD$EU$EU
257017751$25701775$1$I$$20241101$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-108433$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257018081$25701808$1$I$20240827$20241101$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-116640$REGENERON$$$$$M$Y$$$20250819$$HP$US$US
257018101$25701810$1$I$20250715$20250813$20250819$20250819$EXP$EU-AFSSAPS-LM2025000543$EU-MYLANLABS-2025M1069396$MYLAN$$73$YR$$F$Y$83.1$KG$20250819$$MD$EU$EU
257018271$25701827$1$I$$20240731$20250819$20250819$PER$$US-PERRIGO-24US007280$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250819$$CN$US$US
257018851$25701885$1$I$$20250808$20250819$20250819$EXP$$US-PERRIGO-25US010077$GALPHARM INTERNATIONAL$$$$$F$Y$$$20250819$$CN$US$US
257019151$25701915$1$I$$20250311$20250819$20250819$PER$$US-PERRIGO-25US003364$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250819$$CN$US$US
257019401$25701940$1$I$$20250310$20250819$20250819$PER$$US-PERRIGO-25US003609$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250819$$CN$US$US
257019591$25701959$1$I$$20250319$20250819$20250819$PER$$US-PERRIGO-25US003756$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250819$$CN$US$US
257019601$25701960$1$I$$20250310$20250819$20250819$PER$$US-PERRIGO-25US003738$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250819$$CN$US$US
257020011$25702001$1$I$$20250504$20250819$20250819$PER$$US-PERRIGO-25US006268$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250819$$CN$US$US
257020531$25702053$1$I$20250813$20250814$20250819$20250819$PER$$US-ABBVIE-6417472$ABBVIE$$25$YR$$F$Y$45.812$KG$20250819$$CN$US$US
257021791$25702179$1$I$20241114$20250123$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-156311$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257022201$25702220$1$I$$20241211$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-171365$REGENERON$$$$$F$Y$$$20250819$$PH$US$US
257022341$25702234$1$I$20240101$20250331$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2024-177494$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257022451$25702245$1$I$20221021$20250813$20250819$20250819$EXP$$TH-009507513-2320435$MERCK SHARP + DOHME LLC$$85$YR$$M$Y$$$20250819$$MD$TH$TH
257022551$25702255$1$I$20250102$20250306$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-011783$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257022781$25702278$1$I$$20250815$20250819$20250819$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-114858$BRISTOL-MYERS SQUIBB COMPANY$$68$YR$E$M$Y$$$20250819$$HP$US$US
257022921$25702292$1$I$$20250815$20250819$20250819$PER$$US-SA-2025SA246207$SANOFI AVENTIS$$$$A$M$Y$$$20250819$$CN$US$US
257024631$25702463$1$I$20250101$20250725$20250819$20250819$EXP$$US-GALDERMA-US2025013604$GALDERMA$$$$$$Y$$$20250819$$CN$US$US
257024641$25702464$1$I$20250407$20250407$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-061119$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257024901$25702490$1$I$$20250815$20250819$20250819$PER$$US-MTPC-MTPA2025-0014874$Unknown Manufacturer$$$$A$F$Y$$$20250819$$CN$US$US
257025241$25702524$1$I$20250801$20250815$20250819$20250819$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-114846$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$M$Y$$$20250819$$PH$US$US
257025311$25702531$1$I$20250414$20250721$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-064932$REGENERON$$$$$M$Y$$$20250819$$CN$US$US
257025381$25702538$1$I$$20250623$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-066839$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257026092$25702609$2$F$$20250910$20250819$20250915$30DAY$$CO-AMGEN-COLSP2025161287$AMGEN$$$$$$Y$$$20250915$$HP$CO$CO
257026101$25702610$1$I$20250724$20250725$20250819$20250819$EXP$$US-GALDERMA-US2025013612$GALDERMA$$$$$$Y$$$20250819$$CN$US$US
257026351$25702635$1$I$$20250721$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-078237$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257027151$25702715$1$I$20250617$20250630$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-099642$REGENERON$$$$$M$Y$$$20250819$$CN$US$US
257027871$25702787$1$I$20250101$20250724$20250819$20250819$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-118595$REGENERON$$$$$F$Y$$$20250819$$CN$US$US
257027921$25702792$1$I$20250626$20250815$20250819$20250819$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-019911$JAZZ$$43$YR$$M$Y$$$20250819$$$US$US
257028111$25702811$1$I$$20250817$20250819$20250819$PER$$US-PURDUE PHARMA-USA-2025-0319830$PURDUE$$23$YR$$M$Y$$$20250819$$CN$US$US
257029252$25702925$2$F$20240101$20250901$20250819$20250908$EXP$$US-JNJFOC-20250822851$JOHNSON AND JOHNSON$$77$YR$E$F$Y$72.109$KG$20250908$$CN$US$US
257030031$25703003$1$I$$20250725$20250819$20250819$EXP$$US-GALDERMA-US2025013611$GALDERMA$$$$$$Y$$$20250820$$CN$US$US
257030801$25703080$1$I$$20250811$20250819$20250819$EXP$$US-JNJFOC-20250812008$JOHNSON AND JOHNSON$$$$$$Y$$$20250820$$CN$US$US
257031791$25703179$1$I$20250801$20250814$20250820$20250820$PER$$US-ABBVIE-6418180$ABBVIE$$47$YR$$F$Y$55$KG$20250820$$CN$US$US
257032825$25703282$5$F$20250607$20250910$20250820$20250916$30DAY$$US-AMGEN-USASP2025162360$AMGEN$$$$$M$Y$116$KG$20250916$$PH$US$US
257033121$25703312$1$I$$20250811$20250820$20250820$PER$$US-ROCHE-10000362923$ROCHE$$$$A$M$Y$$$20250820$$CN$US$US
257033461$25703346$1$I$20250101$20250812$20250820$20250820$PER$$US-ROCHE-10000363706$ROCHE$$62$YR$A$F$Y$124.73$KG$20250820$$CN$US$US
257033531$25703353$1$I$$20250809$20250820$20250820$EXP$$CA-CELLTRION INC.-2025CA027907$CELLTRION$$$$$$Y$$$20250820$$HP$CA$CA
257034011$25703401$1$I$$20250806$20250820$20250820$EXP$GB-MHRA-TPP25652154C19354900YC1754340709905$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-08647$ALKEM$$50$YR$$M$Y$127$KG$20250820$$MD$GB$GB
257034601$25703460$1$I$20250101$20250812$20250820$20250820$EXP$$US-UCBSA-2025035555$UCB$$$$$F$Y$$$20250820$$MD$US$US
257034741$25703474$1$I$$20250721$20250820$20250820$PER$$US-GSK-US2025AMR095684$GLAXOSMITHKLINE$$$$$F$Y$$$20250820$$$US$US
257035631$25703563$1$I$$20250210$20250820$20250820$PER$$US-STRIDES ARCOLAB LIMITED-2025SP002300$STRIDES$Powers C, Corrente B, Joyce J, Stein W, Polydor S, Gunabushanam V, et al. Evolving Impact of COVID-19 on Intestinal Transplant Recipients: A Single-Center Experience. Clin-Transplant. 2025;39 (1)$44$YR$$F$Y$$$20250820$$HP$US$US
257035811$25703581$1$I$$20250617$20250820$20250820$EXP$$US-VERASTEM-2025-00217$VERASTEM$$$$$$Y$$$20250820$$HP$US$US
257036821$25703682$1$I$$20250729$20250820$20250820$EXP$$US-VERASTEM-250808US-AFCPK-00426$VERASTEM$$$$$$Y$$$20250820$$CN$US$US
257040541$25704054$1$I$$20250809$20250820$20250820$EXP$$CA-CELLTRION INC.-2025CA027822$CELLTRION$$$$$$Y$$$20250820$$HP$CA$CA
257041341$25704134$1$I$$20250813$20250820$20250820$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25052518$RADIUS PHARM$$$$$F$Y$$$20250820$$CN$US$US
257042081$25704208$1$I$$20250808$20250820$20250820$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-04454$LUPIN$$$$$$Y$$$20250820$$$US$US
257042511$25704251$1$I$$20250507$20250820$20250820$PER$$US-STRIDES ARCOLAB LIMITED-2025SP006059$STRIDES$Harada R, Kongsompong A, Carlisle R, Bindra A, Gong T, Afzal A.. Management of Paxlovid Induced Tacrolimus Neurotoxicity with Phenytoin.. J-Heart-Lung-Transplant. 2025;44 (Suppl) (4):S248 abstr. 504.$61$YR$$M$Y$$$20250820$$HP$US$US
257042911$25704291$1$I$$20250815$20250820$20250820$EXP$$US-SA-2025SA246640$SANOFI AVENTIS$$68$YR$E$M$Y$$$20250820$$MD$US$US
257043191$25704319$1$I$$20250806$20250820$20250820$EXP$$AU-CIPLA (EU) LIMITED-2025AU10204$CIPLA$$$$$$Y$$$20250820$$MD$AU$AU
257043391$25704339$1$I$$20250818$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508016954$ELI LILLY AND COMPANY$$$$$F$Y$$$20250820$$CN$US$US
257043461$25704346$1$I$$20250514$20250820$20250820$PER$$US-STRIDES ARCOLAB LIMITED-2025SP006497$STRIDES$Freyer CW, Carulli A, Frey NV, Gill SI, Hexner EO, Martin ME, et al.. Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.. Leuk-Lymphoma. 2024;65 (2):250-256$56$YR$$F$Y$$$20250820$$HP$US$US
257043551$25704355$1$I$$20250808$20250820$20250820$EXP$GB-MHRA-MED-202508071655522730-YFZQN$GB-Accord-500229$ACCORD$$25$YR$A$F$Y$80$KG$20250820$$MD$GB$GB
257043832$25704383$2$F$$20250815$20250820$20250822$EXP$GB-MHRA-MED-202508121545243940-MFRKW$GB-TEVA-VS-3364705$TEVA$$$$$M$Y$$$20250822$$CN$GB$GB
257043981$25704398$1$I$20250803$20250817$20250820$20250820$EXP$$US-SANDOZ INC.-SDZ2025US059823$SANDOZ$$67$YR$$F$Y$59.864$KG$20250820$$CN$US$US
257046321$25704632$1$I$$20250806$20250820$20250820$EXP$$TR-STRIDES ARCOLAB LIMITED-2025SP010627$STRIDES$Gokten DB, Mercan R.. Methotrexate-Associated Hypersensitivity Pneumonitis After 15 Years of Use: A Case Report and Literature Review.. Mediterr-J-Rheum. 2025;36 (2):315-320$65$YR$$F$Y$$$20250820$$HP$TR$TR
257046671$25704667$1$I$$20241010$20250820$20250820$PER$$US-STRIDES ARCOLAB LIMITED-2024SP013378$STRIDES$Cicalese L, Walton ZC, Du X, Kulkarni R, Qiu S, El Hag M, et al.. Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up.. Transpl-Int. 2024;37$7$DEC$$M$Y$$$20250820$$HP$US$US
257046934$25704693$4$F$20250708$20250828$20250820$20250901$EXP$EU-AFSSAPS-AN2025001028$EU-ROCHE-10000367344$ROCHE$$70$YR$E$M$Y$$$20250901$$MD$EU$EU
257047921$25704792$1$I$$20240912$20250820$20250820$PER$$US-STRIDES PHARMA UK LTD.-2024SP012083$STRIDES$Viacava FM, Bandres MV, Mishkin A.. A case of skin and soft tissue infection in a lung transplant recipient.. Transpl-Infect-Dis. 2024;26 (1)$$$$$Y$$$20250820$$HP$US$US
257049251$25704925$1$I$$20250814$20250820$20250820$EXP$$CA-JNJFOC-20250800482$JOHNSON AND JOHNSON$$$$A$F$Y$$$20250820$$HP$CA$CA
257049351$25704935$1$I$20250101$20250815$20250820$20250820$PER$$US-MALLINCKRODT-MNK202505112$MALLINCKRODT$$$$$F$Y$$$20250820$$CN$US$US
257049671$25704967$1$I$$20250817$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508017392$ELI LILLY AND COMPANY$$$$$$Y$$$20250820$$CN$US$US
257049811$25704981$1$I$$20250814$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508014881$ELI LILLY AND COMPANY$$78$YR$E$F$Y$$$20250820$$CN$US$US
257050651$25705065$1$I$$20250806$20250820$20250820$EXP$$US-GSK-US2025AMR102430$GLAXOSMITHKLINE$$$$$F$Y$$$20250820$$$US$US
257050672$25705067$2$F$$20250902$20250820$20250908$EXP$$US-ROCHE-10000366409$ROCHE$$$$$F$Y$$$20250908$$CN$US$US
257050781$25705078$1$I$$20250814$20250820$20250820$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009285$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250820$$CN$US$US
257051101$25705110$1$I$20250811$20250812$20250820$20250820$EXP$$IN-ROCHE-10000366013$ROCHE$$62$YR$A$M$Y$$$20250820$$CN$IN$IN
257051202$25705120$2$F$20250806$20250904$20250820$20250916$EXP$GB-MHRA-MED-202508071619212350-MWYNG$GB-Accord-500244$ACCORD$$62$YR$A$F$Y$$$20250916$$HP$GB$GB
257051601$25705160$1$I$20250816$20250819$20250819$20250819$DIR$FDA-CDER-CTU-2025-55163$$FDA-CTU$$81$YR$$F$N$$$20250819$N$HP$US$
257051721$25705172$1$I$20250101$20250728$20250820$20250820$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-127308$ZYDUS PHARM$$$$$$Y$$$20250820$$CN$US$US
257051961$25705196$1$I$$20250818$20250820$20250820$EXP$$US-JNJFOC-20250821402$JOHNSON AND JOHNSON$$$$$$Y$$$20250820$$MD$US$US
257052092$25705209$2$F$20240322$20250912$20250820$20250926$EXP$$CH-TEVA-VS-3362994$TEVA$Trottmann S, Ulrich Y, Poulose R, Bregenzer T. Shock due to a severe metformin-associated lactic acidosis during Ramadan. Swiss-Med-Wkly 2025; 155 (Suppl.) 164s.; Trottmann S, Ulrich Y, Poulose R, Bregenzer T. Shock due to a severe metformin-associated lactic acidosis during Ramadan. Swiss-Med-Wkly 2025; 155 (Suppl.) 164s.; Trottmann S, Ulrich Y, Poulose R, Bregenzer T. Shock due to a severe metformin-associated lactic acidosis during Ramadan. Swiss-Med-Wkly 2025; 155 (Suppl.) 164s.$69$YR$$M$Y$$$20250926$$MD$CH$CH
257052261$25705226$1$I$$20250721$20250820$20250820$PER$$US-GSK-US2025AMR094986$GLAXOSMITHKLINE$$$$$M$Y$$$20250820$$$US$US
257052481$25705248$1$I$$20250819$20250819$20250819$DIR$770778$$FDA-CTU$$$$$$N$$$20250819$N$CN$US$
257053751$25705375$1$I$$20250814$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508016320$ELI LILLY AND COMPANY$$$$$F$Y$$$20250820$$CN$US$US
257054101$25705410$1$I$$20250819$20250819$20250819$DIR$770757$$FDA-CTU$$$$$$N$$$20250819$$CN$US$
257054361$25705436$1$I$20250811$20250815$20250820$20250820$EXP$GB-MHRA-MED-202508152101588910-CTBSJ$GB-MYLANLABS-2025M1069849$MYLAN$$41$YR$$M$Y$110$KG$20250820$$$GB$GB
257054851$25705485$1$I$20240301$20250819$20250819$20250819$DIR$770766$$FDA-CTU$$72$YR$$M$N$$$20250819$N$$US$
257055031$25705503$1$I$$20250814$20250820$20250820$EXP$$IN-MYLANLABS-2025M1070741$MYLAN$Dhiman R, Mahajan A, Gupta V, Azad SV. Structural and anatomical changes in the retina due to sildenafil citrate overdose. BMJ-Case-Rep 2025; 18 (7):.$4$DEC$$M$Y$$$20250820$$$IN$IN
257055081$25705508$1$I$$20250728$20250820$20250820$EXP$$US-VERASTEM-250812US-AFCPK-00436$VERASTEM$$$$$$Y$$$20250820$$MD$US$US
257056021$25705602$1$I$$20250813$20250820$20250820$PER$$US-AMGEN-USASP2025162635$AMGEN$$$$E$F$Y$$$20250820$$CN$US$US
257056041$25705604$1$I$20250808$20250808$20250820$20250820$EXP$$GB-MHRA-MED-202508080610262030-WJQSM$AUROBINDO$$52$YR$$M$Y$85$KG$20250820$$MD$GB$GB
257056551$25705655$1$I$$20250812$20250820$20250820$EXP$$JP-MYLANLABS-2025M1069547$MYLAN$Yamane H, Itagaki T, Kajitani K. Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis. Case-Rep-Oncol 2025; 18 (1): 22-28.$37$YR$$F$Y$$$20250819$$$JP$JP
257058031$25705803$1$I$$20250812$20250820$20250820$EXP$$US-KOANAAP-SML-US-2025-00399$SHILPA MEDICARE$Pham D, vera A, He CB, Kronenfeld Rs, Trillo A, Dhir A. Novel Use of Bland Trans-Arterial Embolization for Hepatoblastoma: A Case Report. Pediatric Transplantation. 2025;29(5): 1-6. doi:10.1111/petr.70121.$12$MON$I$M$Y$$$20250820$$MD$US$US
257058111$25705811$1$I$20250811$20250819$20250819$20250819$DIR$770881$$FDA-CTU$$43$YR$$F$N$189$KG$20250819$N$HP$US$
257058871$25705887$1$I$$20250806$20250820$20250820$EXP$$US-GSK-US2025AMR102765$GLAXOSMITHKLINE$$$$$F$Y$$$20250820$$$US$US
257058931$25705893$1$I$20250819$20250819$20250820$20250820$EXP$$US-VANTIVE-2025VAN003860$Vantive US Healthcare$$34$YR$$M$Y$$$20250820$$HP$US$US
257058961$25705896$1$I$$20250813$20250820$20250820$PER$$US-BAYER-2025A109245$BAYER HEALTHCARE PHARMACEUTICALS INC.$$35$YR$A$F$Y$$$20250820$$HP$US$US
257058991$25705899$1$I$20231205$20250819$20250819$20250819$DIR$770933$$FDA-CTU$$34$YR$$F$N$72$KG$20250819$N$CN$US$
257059471$25705947$1$I$$20250814$20250820$20250820$EXP$$CA-UCBSA-2025051078$UCB$$$$$F$Y$$$20250820$$CN$CA$CA
257060681$25706068$1$I$$20250805$20250820$20250820$EXP$$US-GLANDPHARMA-US-2025GLNLIT01672$GLAND PHARMA LTD$T. A. D^Amico.Transient Coronary Vasospasm During Robotic Bronchoscopy.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A1678$61$YR$A$M$Y$$$20250820$$HP$US$US
257061951$25706195$1$I$$20250609$20250820$20250820$PER$$US-SPRINGWORKS THERAPEUTICS-SW-002911$SPRINGWORKS THERAPEUTIC$$$$C$M$Y$$$20250820$$CN$US$US
257062561$25706256$1$I$20250601$20250815$20250820$20250820$EXP$$US-PFIZER INC-PV202500099577$PFIZER$$59$YR$$F$Y$$$20250820$$HP$US$US
257063261$25706326$1$I$$20250810$20250820$20250820$EXP$$EU-UNITED THERAPEUTICS-UNT-2025-028037$UNITED THERAPEUTICS$Thal BR, Kremer NC, Harth S, Janetzko P, Rako ZA, Sch?fer S, et al.. A 2-decade cardiac magnetic resonance imaging journey in heritable pulmonary arterial hypertension: Reversal with sotatercept. JACC Case Rep. 2025;30(22):104494$$$A$$Y$$$20250820$$MD$EU$EU
257063501$25706350$1$I$20250409$20250630$20250820$20250820$PER$$US-CATALYST PHARMACEUTICALS-US-CATA-25-00676$CATALYST PHARMA$$5$YR$$M$Y$17.234$KG$20250820$$CN$US$US
257063671$25706367$1$I$20250814$20250819$20250820$20250820$DIR$FDA-CDER-CTU-2025-55438$$FDA-CTU$$70$YR$$M$N$102.6$KG$20250819$N$$US$
257064511$25706451$1$I$20250101$20250815$20250820$20250820$EXP$$CO-ABBVIE-6422501$ABBVIE$$74$YR$$M$Y$$$20250820$$CN$CO$CO
257064561$25706456$1$I$$20250820$20250820$20250820$DIR$770987$$FDA-CTU$$$$$$N$$$20250820$N$$US$
257065531$25706553$1$I$20250619$20250723$20250820$20250820$PER$$US-CATALYST PHARMACEUTICALS-US-CATA-25-00924$CATALYST PHARMA$$8$YR$$M$Y$22.676$KG$20250820$$CN$US$US
257066032$25706603$2$F$$20250826$20250820$20250905$EXP$$NVSC2025RU130004$NOVARTIS$$$$$$Y$$$20250905$$MD$RU$RU
257066381$25706638$1$I$$20250130$20250820$20250820$PER$$US-CIPLA LTD.-2025US01516$CIPLA$$$$$$Y$$$20250820$$CN$US$US
257067281$25706728$1$I$20250101$20250814$20250820$20250820$PER$$US-SA-2025SA246599$SANOFI AVENTIS$$51$YR$A$F$Y$$$20250820$$MD$US$US
257067511$25706751$1$I$20250801$20250814$20250820$20250820$PER$$US-SA-2025SA246745$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250820$$HP$US$US
257067612$25706761$2$F$$20250829$20250820$20250903$PER$$US-SA-2025SA246754$SANOFI AVENTIS$$75$YR$E$F$Y$$$20250903$$MD$US$US
257067801$25706780$1$I$$20250814$20250820$20250820$PER$$US-SA-2025SA245444$SANOFI AVENTIS$$46$YR$A$M$Y$$$20250820$$CN$US$US
257068201$25706820$1$I$$20250815$20250820$20250820$PER$$US-SA-2025SA247080$SANOFI AVENTIS$$88$YR$E$M$Y$$$20250820$$CN$US$US
257069931$25706993$1$I$20250815$20250819$20250820$20250820$EXP$$US-PFIZER INC-202500166231$PFIZER$$89$YR$$M$Y$89.1$KG$20250820$$HP$US$US
257070021$25707002$1$I$20250616$20250818$20250820$20250820$EXP$EU-AFSSAPS-PP2025000835$EU-PFIZER INC-202500154411$PFIZER$$70$YR$$M$Y$78$KG$20250820$$MD$EU$EU
257070481$25707048$1$I$20240101$20250812$20250820$20250820$EXP$$US-PFIZER INC-202500163887$PFIZER$$$$$$Y$$$20250820$$LW$US$US
257070681$25707068$1$I$20240101$20250818$20250820$20250820$EXP$$US-SA-2025SA247024$SANOFI AVENTIS$$50$YR$A$M$Y$$$20250820$$CN$US$US
257071571$25707157$1$I$20220801$20250819$20250820$20250820$PER$$US-PURDUE-USA-2025-0319848$PURDUE$$29$YR$$M$Y$$$20250820$$CN$US$US
257071781$25707178$1$I$$20250818$20250820$20250820$EXP$$CA-PFIZER INC-202500166313$PFIZER$$$$$M$Y$$$20250820$$CN$CA$CA
257071792$25707179$2$F$$20250902$20250820$20250910$EXP$$US-TEVA-VS-3363976$TEVA$Lee C-H, Scheinman MM. Beat-to-beat alternans. Korean-J-Intern-Med 2025; 40 (4): 687-688.; Lee C-H, Scheinman MM. Beat-to-beat alternans. Korean-J-Intern-Med 2025; 40 (4): 687-688.; Lee C-H, Scheinman MM. Beat-to-beat alternans. Korean-J-Intern-Med 2025; 40 (4): 687-688.$78$YR$$M$Y$$$20250910$$MD$US$US
257072132$25707213$2$F$20220126$20250905$20250820$20250916$EXP$$US-ALKERMES INC.-ALK-2025-002199$ALKERMES$$34$YR$$F$Y$97.052$KG$20250916$$$US$
257072292$25707229$2$F$$20250827$20250820$20250904$PER$$CA-TAKEDA-2025TUS063101$TAKEDA$$$$$M$Y$$$20250904$$$CA$CA
257072991$25707299$1$I$$20250819$20250820$20250820$PER$$US-HALEON-2258687$Haleon PLC$$$$$$Y$$$20250820$$CN$US$US
257073281$25707328$1$I$20250820$20250820$20250820$20250820$DIR$FDA-CDER-CTU-2025-55572$$FDA-CTU$$36$YR$$F$N$$$20250820$N$HP$US$
257073411$25707341$1$I$$20250812$20250820$20250820$EXP$$US-AXS-AXS202508-001444$AXSOME THERAPEUTICS$$$$$$Y$$$20250820$$CN$US$US
257073791$25707379$1$I$$20250813$20250820$20250820$30DAY$$US-SANDOZ INC.-SDZ2025US058686$SANDOZ$$$$$M$Y$$$20250820$$CN$US$US
257074911$25707491$1$I$$20250404$20250820$20250820$PER$$US-ASTELLAS-2025-AER-019599$ASTELLAS$$78$YR$E$M$Y$$$20250820$$CN$US$US
257074971$25707497$1$I$$20250421$20250820$20250820$PER$$US-ASTELLAS-2025-AER-022329$ASTELLAS$$$$$M$Y$$$20250820$$MD$US$US
257075351$25707535$1$I$$20250814$20250820$20250820$PER$$US-SA-2025SA246785$SANOFI AVENTIS$$$$A$M$Y$$$20250820$$HP$US$US
257075442$25707544$2$F$20250801$20250902$20250820$20250911$EXP$$US-ABBVIE-6421932$ABBVIE$$80$YR$$F$Y$73.48$KG$20250911$$CN$US$US
257075761$25707576$1$I$$20250814$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508015593$ELI LILLY AND COMPANY$$50$YR$A$F$Y$$$20250820$$CN$US$US
257075981$25707598$1$I$$20250811$20250820$20250820$EXP$$US-AMGEN-USASP2025161381$AMGEN$Makrakis D.; Uriel M.; Goel S. et al.. Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study. Journal of Clinical Oncology. 2025;43(16):e17044$$$$$Y$$$20250820$$HP$US$US
257076291$25707629$1$I$$20250819$20250820$20250820$EXP$$US-ASTRAZENECA-202508USA014026US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250820$$$US$US
257076583$25707658$3$F$$20250915$20250820$20250917$EXP$EU-EMA-DD-20250811-7482827-171749$EU-BAUSCH-BH-2025-016292$BAUSCH AND LOMB$Heidenreich D, Kreil S, Hofmann WK, Klein S. Akute spontane emphysematose Cholezystitis und Pankreatitis durch Clostridium perfringens bei einem Patienten mit Steroid-refraktarer akuter Graft versus Host Disease nach allogener hamatopoetischer Zelltransplantation. Oncology Research and Treatment. 2022;45(2): 140. doi:10.1159/000526456.$61$YR$A$M$Y$$$20250917$$MD$EU$EU
257077671$25707767$1$I$$20250817$20250820$20250820$PER$$US-ELI_LILLY_AND_COMPANY-US202508017482$ELI LILLY AND COMPANY$$$$$$Y$$$20250820$$CN$US$US
257078771$25707877$1$I$$20250813$20250820$20250820$PER$$US-BIOGEN-2025BI01321017$BIOGEN$$$$$F$Y$$$20250820$$HP$US$US
257079371$25707937$1$I$$20250819$20250820$20250820$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-115600$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$M$Y$$$20250820$$CN$US$US
257079582$25707958$2$F$20250801$20250910$20250820$20250912$PER$$US-BIOMARINAP-US-2025-168180$BIOMARIN$$$$C$M$Y$$$20250912$$$US$US
257079742$25707974$2$F$20250101$20250917$20250820$20250930$PER$$US-SA-2025SA248573$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250930$$MD$US$US
257079852$25707985$2$F$20250801$20250912$20250820$20250915$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-090457$BOEHRINGER INGELHEIM$$78$YR$E$F$Y$$$20250915$$$US$US
257080081$25708008$1$I$$20250818$20250820$20250820$EXP$$JP-ASTRAZENECA-202508JPN011968JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250820$$PH$JP$JP
257080101$25708010$1$I$$20250819$20250820$20250820$PER$$US-SA-2025SA248717$SANOFI AVENTIS$$$$C$F$Y$$$20250821$$CN$US$US
257081224$25708122$4$F$20250701$20250923$20250820$20250930$EXP$$EU-ABBVIE-6422550$ABBVIE$$71$YR$$M$Y$82.5$KG$20250930$$MD$EU$EU
257081332$25708133$2$F$20230101$20250926$20250820$20250930$EXP$$JP-009507513-2320518$MERCK SHARP + DOHME LLC$$59$YR$$F$Y$$$20250930$$MD$JP$JP
257081741$25708174$1$I$$20250807$20250820$20250820$EXP$$CA-HLS-202502123$HLS THERAPEUTICS$$$$E$$Y$$$20250820$$HP$CA$CA
257081931$25708193$1$I$$20250819$20250820$20250820$EXP$$US-ASTRAZENECA-202508USA014534US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250820$$$US$US
257082221$25708222$1$I$$20250808$20250821$20250821$EXP$$IN-GLENMARK PHARMACEUTICALS-2019GMK042142$GLENMARK$Kunjappa V K, Narayanan U, Khan M S, Pullockara J, Prasannan B.. MON-179 utility of clindamycin and primaquine for pneumocystis pneumonia in renal transplant recipients.. Kidney International Reports.. 2019;4 (7):S375-S376$52$YR$$M$Y$$$20250821$$MD$IN$IN
257082291$25708229$1$I$20250817$20250819$20250821$20250821$EXP$$JP-ABBVIE-6421747$ABBVIE$$67$YR$$M$Y$$$20250821$$CN$JP$JP
257082841$25708284$1$I$20230727$20230821$20250821$20250821$EXP$$US-SANDOZ INC.-SDZ2023US077493$SANDOZ$$73$YR$$F$Y$58.5$KG$20250821$$MD$US$US
257083471$25708347$1$I$$20250811$20250821$20250821$PER$$US-TEVA-VS-3364159$TEVA$$47$YR$$F$Y$$$20250821$$CN$US$US
257084511$25708451$1$I$$20250820$20250821$20250821$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-090498$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250821$$$US$US
257084791$25708479$1$I$$20250818$20250821$20250821$EXP$$NVSC2025BG130480$NOVARTIS$Gospodinova E.D. Therapeutic approach for metastatic breast cancer in old age - a clinical case. PROMEDIC. 18-21$85$YR$$F$Y$$$20250821$$HP$EU$EU
257085541$25708554$1$I$$20250806$20250821$20250821$EXP$$US-GRANULES-US-2025GRALIT00464$GRANULES PHARMACEUTICALS INC$S. Jawed.A Case of Beta Blocker and Calcium Blocker Overdose Managed With Veno-arterial Extracorporeal Circulation.American Journal of Respiratory and Critical Care Medicine.18-MAY-2025;211:A1667$40$YR$A$M$Y$$$20250821$$HP$US$US
257085861$25708586$1$I$20250807$20250817$20250821$20250821$EXP$$IN-ROCHE-10000368309$ROCHE$$70$YR$E$M$Y$$$20250821$$CN$IN$IN
257085921$25708592$1$I$$20250813$20250821$20250821$EXP$$CN-BEIGENE-BGN-2025-013642$BEIGENE$$60$YR$$$Y$48.25$KG$20250821$$$CN$CN
257086671$25708667$1$I$$20250818$20250821$20250821$PER$$US-LEO Pharma-382236$LEO PHARM$$23$YR$$F$Y$$$20250821$$PH$US$US
257086982$25708698$2$F$$20250917$20250821$20250924$EXP$$US-SMPA-2025SPA009321$SUNOVION$$64$YR$$M$Y$$$20250923$$$US$US
257087461$25708746$1$I$$20250523$20250821$20250821$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-510520$RANBAXY$$$$$$Y$$$20250821$$PH$US$US
257089762$25708976$2$F$$20250826$20250821$20250905$EXP$$NVSC2025RU129748$NOVARTIS$$$$$$Y$$$20250905$$MD$RU$RU
257090991$25709099$1$I$$20250623$20250821$20250821$PER$$US-STRIDES ARCOLAB LIMITED-2025SP008190$Onesource Specialty Pharma$Krevh R, Korman AM.. Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine.. Cutis. 2024;114 (6):188-189$28$YR$$F$Y$$$20250821$$MD$US$US
257091581$25709158$1$I$$20250725$20250821$20250821$30DAY$$US-VEROBIOTECH-2025USVEROSPO00258$VERO BIOTECH$$$$$$Y$$$20250821$$HP$US$US
257092201$25709220$1$I$$20250723$20250821$20250821$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-127193$ZYDUS PHARM$$$$$$Y$$$20250821$$CN$US$US
257092301$25709230$1$I$20230823$20250813$20250821$20250821$EXP$$CO-TAKEDA-2023TUS083492$TAKEDA$$61$YR$$F$Y$62$KG$20250821$$$CO$CO
257092321$25709232$1$I$20150301$20250807$20250821$20250821$EXP$EU-EMA-20151111-AUTODUP-450290$EU-AUROBINDO-AUR-APL-2025-042520$AUROBINDO$Palenicek L, Renke M, Debska-Slizien A, Dobies A, Wolyniec W, Rutkowski B.. Colorectal tumors diagnosed in patients after renal transplantation - case reports.. Forum Nefrologiczne (Nephrology Forum). 2015;8(3):176-80$$$E$M$Y$$$20250821$$HP$EU$EU
257092501$25709250$1$I$$20250812$20250821$20250821$PER$$US-ELI_LILLY_AND_COMPANY-US202508012406$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250821$$HP$US$US
257092601$25709260$1$I$20250621$20250816$20250821$20250821$EXP$$CN-GILEAD-2025-0725111$GILEAD$$51$YR$A$M$Y$65$KG$20250821$$HP$CN$CN
257092832$25709283$2$F$$20250819$20250821$20250901$EXP$$JP-GILEAD-2025-0725237$GILEAD$Arae H., Hoshino S., Moromi N., Tokumine K., Kohagura K.. Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease. CEN Case Reports. 2025;unk:unk. doi:10.1007/s13730-025-01024-y$59$YR$A$M$Y$$$20250901$$PH$JP$JP
257093431$25709343$1$I$$20250818$20250821$20250821$PER$$US-GILEAD-2025-0725005$GILEAD$$54$YR$A$F$Y$$$20250821$$CN$US$US
257093611$25709361$1$I$$20250818$20250821$20250821$EXP$$CN-AMGEN-CHNSP2025165596$AMGEN$Zhang Z.. Annular pustular psoriasis: A heterogeneous subtype of generalized pustular psoriasis. Chinese Medical Journal. 2025;138 (13):1630-1632$23$YR$A$F$Y$$$20250821$$HP$CN$CN
257093622$25709362$2$F$$20250821$20250821$20250826$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-07508$LUPIN$$31$YR$$$Y$$$20250826$$$US$US
257094702$25709470$2$F$$20250916$20250821$20250926$PER$$US-SMPA-2025SPA010522$SUNOVION$$69$YR$$M$Y$$$20250925$$$US$US
257096681$25709668$1$I$$20250814$20250821$20250821$PER$$US-TAKEDA-2025TUS073211$TAKEDA$$71$YR$$$Y$$$20250821$$$US$US
257096721$25709672$1$I$$20250818$20250821$20250821$EXP$$CA-Orion Corporation ORION PHARMA-25_00036199$ORION$$48$YR$A$F$Y$$$20250821$$HP$CA$
257097621$25709762$1$I$$20250722$20250821$20250821$PER$$US-GSK-US2025AMR095293$GLAXOSMITHKLINE$$$$$M$Y$$$20250821$$$US$US
257097991$25709799$1$I$$20250807$20250821$20250821$EXP$$IN-ZYDUS-IN-ZYDUS-127323$ZYDUS PHARM$Bhaskaran D, Thomas S, Scaria LM. Neurobehavioral Outcomes of Children with Antenatal Exposure to Antiseizure Medications.. Indian-J-Pediatr. 2025;92(3):252-259$$$$$Y$$$20250821$$HP$IN$IN
257098101$25709810$1$I$$20241107$20250821$20250821$PER$$US-UNICHEM LABORATORIES LIMITED-UCM202411-001517$UNICHEM$$$$$$Y$$$20250821$$CN$US$US
257098331$25709833$1$I$$20250812$20250821$20250821$PER$$US-SMPA-2025SPA010455$SUNOVION$$66$YR$$M$Y$$$20250819$$$US$US
257098691$25709869$1$I$$20250712$20250821$20250821$PER$$US-PROD-AS2-212756134-20-25-USA-RB-0003010$RECKITT BENCKISER$$$$$$Y$$$20250821$$CN$US$US
257099742$25709974$2$F$$20250826$20250821$20250904$EXP$$US-TEVA-VS-3362603$TEVA$Nawaz I. From Pneumonitis to Pneumomediastinum: A Rare Progression to Pneumomediastinum in a Keytruda-treated Patient. Am-J-Respir-Crit-Care-Med 2025; 211 (plus Poster).; Nawaz I. From Pneumonitis to Pneumomediastinum: A Rare Progression to Pneumomediastinum in a Keytruda-treated Patient. Am-J-Respir-Crit-Care-Med 2025; 211 (plus Poster).$73$YR$$M$Y$$$20250904$$HP$US$US
257099921$25709992$1$I$20250818$20250819$20250821$20250821$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009410$ACADIA PHARMACEUTICALS$$89$YR$$M$Y$$$20250821$$CN$US$US
257101112$25710111$2$F$20250212$20250827$20250821$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-523071$RANBAXY$$43$YR$$M$Y$$$20250911$$PH$EU$EU
257101571$25710157$1$I$$20250806$20250821$20250821$EXP$$BR-SA-2025SA230847$SANOFI AVENTIS$Hoff PM, Victor CR, Bonadio RC, Braghiroli MI, Bariani G, Da Fonseca LG et al.. MFOLFIRINOX efficacy as rescue regimen for patients with metastatic refractory colorectal cancer: The RE-PLAY trial.. Journal of Clinical Oncology.. 2025;43(16):unk$$$$$Y$$$20250821$$HP$BR$BR
257101671$25710167$1$I$20250224$20250806$20250821$20250821$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-523544$RANBAXY$$68$YR$$M$Y$93.5$KG$20250821$$MD$EU$EU
257102531$25710253$1$I$$20250818$20250821$20250821$PER$$US-ELI_LILLY_AND_COMPANY-US202508018196$ELI LILLY AND COMPANY$$55$YR$A$F$Y$$$20250821$$CN$US$US
257102761$25710276$1$I$$20250811$20250821$20250821$EXP$$US-ANIPHARMA-2025-US-038149$ANI$$48$YR$$M$Y$$$20250821$$HP$US$US
257102891$25710289$1$I$$20250811$20250821$20250821$PER$$NVSC2025US127469$NOVARTIS$$$$$$Y$$$20250821$$HP$US$US
257103322$25710332$2$F$$20250917$20250821$20250918$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-116233$BRISTOL-MYERS SQUIBB COMPANY$$67$YR$E$M$Y$$$20250918$$$US$US
257103741$25710374$1$I$$20250814$20250821$20250821$PER$$US-ELI_LILLY_AND_COMPANY-US202508015642$ELI LILLY AND COMPANY$$47$YR$A$$Y$$$20250821$$CN$US$US
257104221$25710422$1$I$20250819$20250820$20250820$20250820$DIR$771065$$FDA-CTU$$$$$$N$$$20250820$N$CN$US$
257104361$25710436$1$I$20250723$20250808$20250821$20250821$EXP$EU-INFARMED-J202507-1245$EU-HIKMA PHARMACEUTICALS USA INC.-PT-H14001-25-09437$HIKMA$$71$YR$$M$Y$64$KG$20250821$$PH$EU$EU
257105061$25710506$1$I$$20250808$20250821$20250821$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-09029$ALKEM$Dathe K, Benndorf C, Bergner S, Schaefer C.. Do Major Pharmacovigilance Databases Support Evidence of Second Trimester NSAID and Third Trimester Paracetamol Fetotoxicity?. Pharmaceuticals. 2024;17:1592$$$$$Y$$$20250821$$HP$EU$EU
257105321$25710532$1$I$20250102$20250818$20250821$20250821$EXP$EU-AFSSAPS-TS2025000865$EU-FreseniusKabi-FK202511524$FRESENIUS KABI$$53$YR$A$F$Y$80$KG$20250821$$MD$EU$EU
257105401$25710540$1$I$$20250819$20250821$20250821$EXP$$US-ASTRAZENECA-202508USA014394US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250821$$$US$US
257105491$25710549$1$I$$20250806$20250821$20250821$PER$$US-MSNLABS-2025MSNSPO02138$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250821$$CN$US$US
257105901$25710590$1$I$$20250811$20250821$20250821$PER$$NVSC2025US127365$NOVARTIS$$$$$F$Y$$$20250821$$CN$US$US
257106121$25710612$1$I$20250620$20250820$20250821$20250821$EXP$EU-SEMPA-2025-005719$EU-UCBSA-2025051895$UCB$$28$YR$$M$Y$$$20250821$$MD$EU$EU
257106471$25710647$1$I$$20250821$20250821$20250821$DIR$771193$$FDA-CTU$$$$$$N$$$20250821$N$$US$
257107171$25710717$1$I$20250101$20250814$20250821$20250821$PER$$US-SA-2025SA247726$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250821$$HP$US$US
257107622$25710762$2$F$20250101$20250822$20250821$20250827$PER$$US-SA-2025SA246444$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250827$$HP$US$US
257107951$25710795$1$I$20250101$20250815$20250821$20250821$PER$$US-SA-2025SA248030$SANOFI AVENTIS$$$$A$F$Y$$$20250821$$HP$US$US
257109321$25710932$1$I$20250101$20250815$20250821$20250821$PER$$US-SA-2025SA248090$SANOFI AVENTIS$$6$YR$C$F$Y$$$20250821$$CN$US$US
257109571$25710957$1$I$20250101$20250815$20250821$20250821$PER$$US-SA-2025SA249485$SANOFI AVENTIS$$83$YR$E$F$Y$$$20250821$$MD$US$US
257109672$25710967$2$F$$20250819$20250821$20250826$PER$$US-SA-2025SA248722$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250826$$MD$US$US
257109681$25710968$1$I$$20250819$20250821$20250821$PER$$US-SA-2025SA249088$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250821$$CN$US$US
257110311$25711031$1$I$$20250818$20250821$20250821$PER$$US-SA-2025SA247861$SANOFI AVENTIS$$37$YR$A$F$Y$$$20250821$$CN$US$US
257110371$25711037$1$I$$20250819$20250821$20250821$PER$$US-SA-2025SA249186$SANOFI AVENTIS$$70$YR$E$M$Y$$$20250821$$CN$US$US
257110502$25711050$2$F$20250815$20250903$20250821$20250911$PER$$US-SA-2025SA249257$SANOFI AVENTIS$$92$YR$E$F$Y$50.91$KG$20250911$$MD$US$US
257111471$25711147$1$I$$20250818$20250821$20250821$PER$$US-SA-2025SA247631$SANOFI AVENTIS$$$$E$M$Y$$$20250821$$MD$US$US
257112481$25711248$1$I$$20250725$20250821$20250821$PER$$US-GSK-US2025AMR100853$GLAXOSMITHKLINE$$$$$M$Y$$$20250821$$$US$US
257112591$25711259$1$I$$20250811$20250821$20250821$PER$$US-NPA-2025-AER-01406$NOBELPHARMA$$$$$F$Y$$$20250821$$HP$US$US
257113001$25711300$1$I$$20250712$20250821$20250821$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0014174$RECKITT BENCKISER$$$$$F$Y$$$20250821$$CN$US$US
257113841$25711384$1$I$$20250814$20250821$20250821$EXP$GB-MHRA-MED-202508140921468840-VCHDB$GB-ELI_LILLY_AND_COMPANY-GB202508014888$ELI LILLY AND COMPANY$$$$$$Y$$$20250821$$CN$GB$GB
257114851$25711485$1$I$$20250811$20250821$20250821$EXP$$US-ELI_LILLY_AND_COMPANY-US202508010443$ELI LILLY AND COMPANY$$55$YR$A$$Y$$$20250821$$LW$US$US
257114871$25711487$1$I$$20250811$20250821$20250821$EXP$$TR-ELI_LILLY_AND_COMPANY-TR202508015007$ELI LILLY AND COMPANY$$35$YR$A$M$Y$$$20250821$$CN$TR$TR
257117501$25711750$1$I$$20250814$20250821$20250821$PER$$US-ELI_LILLY_AND_COMPANY-US202508015198$ELI LILLY AND COMPANY$$54$YR$A$$Y$$$20250821$$LW$US$US
257118491$25711849$1$I$$20250820$20250821$20250821$EXP$$PH-TAKEDA-2025TUS074069$TAKEDA$$$$$M$Y$$$20250821$$$PH$PH
257119101$25711910$1$I$$20250814$20250821$20250821$EXP$$CA-TAKEDA-2025TUS067342$TAKEDA$$$$$F$Y$$$20250821$$$CA$CA
257119911$25711991$1$I$20250527$20250818$20250821$20250821$EXP$EU-AFSSAPS-PV2025000620$EU-PFIZER INC-202500164952$PFIZER$$53$YR$$F$Y$65$KG$20250821$$MD$EU$EU
257120821$25712082$1$I$$20250818$20250821$20250821$EXP$$JP-GSK-JP2025107588$GLAXOSMITHKLINE$$$$$F$Y$$$20250821$$MD$JP$JP
257121061$25712106$1$I$$20250813$20250821$20250821$EXP$$NVSC2025US131120$NOVARTIS$$$$$F$Y$$$20250821$$CN$US$US
257122321$25712232$1$I$$20250820$20250821$20250821$PER$$US-TAKEDA-2025TUS074050$TAKEDA$$$$$$Y$$$20250821$$$US$US
257122391$25712239$1$I$20250701$20250818$20250821$20250821$PER$$US-SA-2025SA248585$SANOFI AVENTIS$$80$YR$E$F$Y$$$20250821$$HP$US$US
257122561$25712256$1$I$$20250818$20250821$20250821$PER$$US-SA-2025SA248587$SANOFI AVENTIS$$24$YR$A$M$Y$$$20250821$$CN$US$US
257122831$25712283$1$I$20250801$20250813$20250821$20250821$EXP$$US-BIOGEN-2025BI01321022$BIOGEN$$32$YR$$F$Y$$$20250821$$CN$US$US
257123502$25712350$2$F$20090101$20250908$20250821$20250912$EXP$EU-BFARM-20011196$EU-MYLANLABS-2020410570$MYLAN$$24$YR$$F$Y$76$KG$20250912$$$EU$EU
257123682$25712368$2$F$20250813$20250827$20250821$20250903$EXP$$BR-BAYER-2025A110662$BAYER HEALTHCARE PHARMACEUTICALS INC.$$42$YR$A$M$Y$$$20250903$$HP$BR$BR
257123872$25712387$2$F$$20250914$20250821$20250916$30DAY$$US-ABBVIE-6420567$ABBVIE$$$$$$Y$$$20250916$$CN$US$US
257124551$25712455$1$I$$20250818$20250821$20250821$PER$$NVSC2025US131650$NOVARTIS$$$$$F$Y$$$20250821$$CN$US$US
257125031$25712503$1$I$$20250814$20250821$20250821$EXP$$EU-BAUSCH-BH-2025-016398$BAUSCH AND LOMB$Tebache J, Gudelj M. Metronidazole-induced neurotoxicity. Revue medicale de Liege. 2025;80(7-8):545-8.$43$YR$A$F$Y$$$20250821$$MD$EU$EU
257125631$25712563$1$I$20250718$20250818$20250821$20250821$EXP$EU-AFSSAPS-AM2025000656$EU-PFIZER INC-202500165059$PFIZER$$35$YR$$F$Y$57$KG$20250821$$MD$EU$EU
257127452$25712745$2$F$20250207$20250820$20250821$20250827$EXP$$US-ASTRAZENECA-202508USA015600US$ALEXION PHARMACEUTICALS$$80$YR$E$M$Y$$$20250827$$MD$US$US
257128041$25712804$1$I$$20250812$20250821$20250821$EXP$$CA-NOVOPROD-1500197$NOVO NORDISK$$$$$F$Y$$$20250821$$MD$CA$CA
257128281$25712828$1$I$$20250815$20250821$20250821$PER$$US-BIOMARINAP-US-2025-168112$BIOMARIN$$$$$M$Y$$$20250821$$$US$US
257128292$25712829$2$F$20250813$20250829$20250821$20250910$PER$$US-BIOMARINAP-US-2025-168106$BIOMARIN$$35$YR$$F$Y$$$20250910$$$US$US
257128331$25712833$1$I$20250101$20250729$20250821$20250821$PER$$US-009507513-2314688$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250821$$CN$US$US
257128451$25712845$1$I$$20250815$20250821$20250821$EXP$$IN-ELI_LILLY_AND_COMPANY-IN202508014829$ELI LILLY AND COMPANY$$23$YR$A$M$Y$$$20250821$$CN$EU$IN
257129261$25712926$1$I$20250812$20250813$20250821$20250821$PER$$US-ABBVIE-6419764$ABBVIE$$17$YR$$M$Y$$$20250821$$CN$US$US
257130641$25713064$1$I$$20250818$20250822$20250822$PER$$US-ROCHE-10000367771$ROCHE$$$$$$Y$$$20250822$$CN$US$US
257131051$25713105$1$I$20250801$20250817$20250822$20250822$EXP$$US-ABBVIE-6424060$ABBVIE$$80$YR$$F$Y$$$20250822$$CN$US$US
257131341$25713134$1$I$$20250813$20250822$20250822$EXP$$GB-BAXTER-2025BAX017365$BAXTER$$$$$F$Y$$$20250822$$CN$GB$GB
257132241$25713224$1$I$$20250814$20250822$20250822$EXP$$US-ABBVIE-6419554$ABBVIE$$$$E$M$Y$$$20250822$$CN$US$US
257132531$25713253$1$I$20250811$20250811$20250822$20250822$EXP$$GB-GLENMARK PHARMACEUTICALS-2025GMK103145$GLENMARK$$72$YR$$M$Y$89$KG$20250822$$MD$GB$GB
257132561$25713256$1$I$$20250819$20250822$20250822$EXP$$US-ABBVIE-6425608$ABBVIE$$$$A$F$Y$$$20250822$$HP$US$US
257133581$25713358$1$I$$20250818$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508017784$ELI LILLY AND COMPANY$$$$$$Y$$$20250822$$CN$US$US
257134941$25713494$1$I$$20250814$20250822$20250822$EXP$$US-GALDERMA-US2025015442$GALDERMA$$$$$$Y$$$20250822$$CN$US$US
257135212$25713521$2$F$20250619$20250822$20250822$20250823$EXP$$KR-ABBVIE-6389516$ABBVIE$$82$YR$$M$Y$66$KG$20250823$$MD$KR$KR
257135502$25713550$2$F$20250809$20250825$20250822$20250829$30DAY$$US-AMGEN-USASP2025162929$AMGEN$$57$YR$A$F$Y$62.132$KG$20250829$$HP$US$US
257135542$25713554$2$F$$20250909$20250822$20250915$EXP$$CA-ABBVIE-6369982$ABBVIE$$81$YR$$M$Y$$$20250915$$CN$CA$CA
257136203$25713620$3$F$$20250917$20250822$20250924$30DAY$$EU-JNJFOC-20250810006$JOHNSON AND JOHNSON$$68$YR$E$M$Y$$$20250924$$PH$EU$EU
257136421$25713642$1$I$20250812$20250814$20250822$20250822$PER$$US-009507513-2319968$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250822$$HP$US$US
257136881$25713688$1$I$20250811$20250811$20250822$20250822$PER$$US-ROCHE-10000363705$ROCHE$$$$$M$Y$$$20250822$$CN$US$US
257137521$25713752$1$I$20241214$20250818$20250822$20250822$EXP$EU-AFSSAPS-NY2025001210$EU-NORDICGR-063651$NORDIC PHARMA$$80$YR$$F$Y$45$KG$20250821$$MD$EU$EU
257137841$25713784$1$I$20250801$20250812$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508013678$ELI LILLY AND COMPANY$$57$YR$A$M$Y$$$20250822$$CN$US$US
257138541$25713854$1$I$20250804$20250813$20250822$20250822$EXP$CN-91110000556821568D-2025DRL001627$CN-RDY-CHN/2025/08/012689$DR REDDYS$$34$YR$A$M$Y$70$KG$20250822$$HP$CN$CN
257138662$25713866$2$F$$20250826$20250822$20250902$EXP$$GB-UCBSA-2025050939$UCB$$$$$F$Y$$$20250902$$CN$GB$GB
257138771$25713877$1$I$20250801$20250815$20250822$20250822$PER$$US-ROCHE-10000366880$ROCHE$$23$YR$A$F$Y$$$20250822$$CN$US$US
257139021$25713902$1$I$20250807$20250807$20250822$20250822$EXP$$US-GERON CORPORATION-US-GER-25-000196$GERON CORP$$82$YR$$M$Y$$$20250822$$MD$US$US
257139101$25713910$1$I$20210415$20250811$20250822$20250822$EXP$$EU-ASTELLAS-2025-AER-044329$ASTELLAS$Mrozek N, Melenotte C. Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis. Journal of Antimicrobial Chemotherapy. 2025;80(7): 2053-6. doi:10.1093/jac/dkaf158.$42$YR$A$F$Y$$$20250822$$HP$EU$EU
257139562$25713956$2$F$20250101$20250827$20250822$20250903$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009391$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250903$$CN$US$US
257140491$25714049$1$I$20240201$20250813$20250822$20250822$EXP$EU-MINISAL02-1046841$EU-CELLTRION INC.-2025IT028515$CELLTRION$$$$$$Y$$$20250822$$MD$EU$EU
257141401$25714140$1$I$$20250810$20250822$20250822$EXP$$US-Accord-500338$ACCORD$Onyirioha K, Balakrishnan M. Hemorrhagic Gastropathy From Paclitaxel-Carboplatin Combination Chemotherapy. ACG case reports journal. 2025;12(8):e01780. DOI:10.14309/crj.0000000000001780.$58$YR$A$F$Y$$$20250822$$MD$US$US
257141441$25714144$1$I$$20241115$20250822$20250822$PER$$US-IGSA-BIG0031678$GRIFOLS$$$$$F$Y$$$20250822$$MD$US$US
257142201$25714220$1$I$20250413$20250423$20250822$20250822$PER$$US-IGSA-BIG0034784$GRIFOLS$$41$YR$$F$Y$$$20250822$$CN$US$US
257142211$25714221$1$I$$20250430$20250822$20250822$PER$$US-IGSA-BIG0035003$GRIFOLS$$$$$F$Y$$$20250822$$HP$US$US
257143011$25714301$1$I$$20250818$20250822$20250822$EXP$$US-SMPA-2025SPA010754$SUNOVION$$73$YR$$M$Y$$$20250821$$$US$US
257143741$25714374$1$I$20250708$20250815$20250822$20250822$EXP$$CN-ROCHE-10000366872$ROCHE$$49$YR$A$F$Y$68$KG$20250822$$MD$CN$CN
257144812$25714481$2$F$$20250910$20250822$20250918$EXP$US-MLMSERVICE-20250804-PI601445-00329-1$US-STRIDES PHARMA UK LTD.-2025SP010797$STRIDES$Mohammed SS, Park EY, Asad R, Tadisina S. Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer.. AACE Endocrinology and Diabetes. 2025;12 (2):107-11$50$YR$$F$Y$$$20250918$$MD$US$US
257144901$25714490$1$I$$20241021$20250822$20250822$PER$$US-STRIDES ARCOLAB LIMITED-2024SP013929$STRIDES$Benenson I, Prado K.. A case of treatment-resistant hypertension.. Nurse-Pract. 2024;49 (10):13-17$58$YR$$F$Y$$$20250822$$HP$US$US
257144931$25714493$1$I$$20250625$20250822$20250822$PER$$US-STRIDES ARCOLAB LIMITED-2025SP008270$STRIDES$Hauser Chatterjee J, Monrad PA, Goldstein HE, Shaw DW, Ojemann JG, Randle SC, et al. Indomethacin-responsive refractory headache: Two case reports in children after hemispherectomy for Rasmussen^s encephalitis. Headache. 2025;65 (6):1044-1048$7$YR$$F$Y$$$20250822$$MD$US$US
257145081$25714508$1$I$20250811$20250818$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508017816$ELI LILLY AND COMPANY$$67$YR$E$F$Y$$$20250822$$CN$US$US
257145731$25714573$1$I$$20250807$20250822$20250822$EXP$$US-GSK-US2025AMR102794$GLAXOSMITHKLINE$$$$$F$Y$$$20250822$$$US$US
257145961$25714596$1$I$$20250811$20250822$20250822$30DAY$$CH-JNJFOC-20250816473$JOHNSON AND JOHNSON$$$$$$Y$$$20250822$$HP$CH$CH
257146631$25714663$1$I$20250806$20250807$20250822$20250822$EXP$$US-FreseniusKabi-FK202511164$FRESENIUS KABI$$$$$$Y$$$20250822$$PH$US$US
257146691$25714669$1$I$$20250810$20250822$20250822$EXP$$US-HETERO-HET2025US04919$HETERO$Bahar AR, Kathawa F, Le T, Farah A, Awadelkarim A, Minhas H, Afonso L. Sinoatrial nodal reentrant tachycardia a case report and literature  review. AME Case Reports.. 2025;9$45$YR$$F$Y$$$20250822$$HP$US$US
257148412$25714841$2$F$20250101$20250828$20250822$20250902$EXP$$US-ABBVIE-6424646$ABBVIE$$27$YR$$M$Y$$$20250902$$CN$US$US
257148691$25714869$1$I$20250710$20250820$20250822$20250822$EXP$GB-MHRA-MED-202508182106486820-MVPLB$GB-TEVA-VS-3364953$TEVA$$56$YR$$F$Y$101$KG$20250822$$CN$GB$GB
257151651$25715165$1$I$$20250813$20250822$20250822$EXP$$EU-CELLTRION INC.-2025FR028474$CELLTRION$Blanc A, Khouri C, Bouillet L, Chiquet C.. Retinal venous occlusion in drug-induced lupus. Therapies. 2025$$$$$Y$$$20250822$$HP$EU$EU
257152221$25715222$1$I$20250819$20250820$20250822$20250822$EXP$$IN-ROCHE-10000370322$ROCHE$$59$YR$A$M$Y$$$20250822$$CN$IN$IN
257152491$25715249$1$I$20250701$20250809$20250822$20250822$EXP$GB-MHRA-MED-202508081924126050-ZCGYK$GB-MSNLABS-2025MSNSPO02214$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250822$$CN$GB$GB
257153311$25715331$1$I$20250711$20250819$20250822$20250822$EXP$EU-AFSSAPS-TS2025000874$EU-SA-2025SA249327$SANOFI AVENTIS$$84$YR$E$F$Y$50$KG$20250822$$MD$EU$EU
257153531$25715353$1$I$20250819$20250819$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508019358$ELI LILLY AND COMPANY$$49$YR$A$F$Y$$$20250822$$CN$US$US
257154061$25715406$1$I$20250710$20250812$20250822$20250822$EXP$EU-AFSSAPS-NT2025000785$EU-TEVA-VS-3362492$TEVA$$55$YR$$M$Y$$$20250822$$MD$EU$EU
257154081$25715408$1$I$20250815$20250819$20250822$20250822$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009449$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20250822$$CN$US$US
257154331$25715433$1$I$$20250821$20250822$20250822$EXP$$US-INCYTE CORPORATION-2025IN009138$INCYTE$$55$YR$$$Y$124.72$KG$20250822$$$US$US
257154701$25715470$1$I$$20250811$20250822$20250822$EXP$$EU-MACLEODS PHARMA-MAC2025054786$MACLEODS$Santos JF, Leitao J, Santos A, Santos L.Interaction between statin and SGLT-2 inhibitor: a case report.European Journal of Case Reports in Internal Medicine.2024;11(Supplement 1):51$$$$$Y$$$20250822$$MD$EU$EU
257155141$25715514$1$I$20250801$20250819$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508019583$ELI LILLY AND COMPANY$$36$YR$A$F$Y$$$20250822$$CN$US$US
257155581$25715558$1$I$20250724$20250724$20250822$20250822$PER$$US-GSK-US2025AMR098823$GLAXOSMITHKLINE$$82$YR$$M$Y$$$20250822$$$US$US
257156532$25715653$2$F$20250627$20250826$20250822$20250909$EXP$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-09502$HIKMA$$71$YR$$F$Y$$$20250909$$HP$US$US
257156941$25715694$1$I$$20250813$20250822$20250822$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-07481$LUPIN$$65$YR$$$Y$$$20250822$$$US$US
257156991$25715699$1$I$20250325$20250811$20250822$20250822$EXP$$EU-AUROBINDO-AUR-APL-2025-042184$AUROBINDO$$70$YR$$M$Y$$$20250822$$MD$EU$EU
257157511$25715751$1$I$$20250810$20250822$20250822$EXP$$US-JNJFOC-20250823664$JOHNSON AND JOHNSON$Jaberi-Douraki M, Ramachandran RA, Xu X, Mazzoni SA, Khouri J, Williams L, et al. Comparative assessment of colitis-related adverse events in multiple myeloma patients treated with teclistamab, ciltacabtagene, and idecabtagene: Incidence, outcomes, and risk assessment.. J. Clin. Oncol.. 2025 Jun 01;(43(16)):$$$$$Y$$$20250822$$HP$US$US
257157621$25715762$1$I$$20250818$20250822$20250822$PER$$US-ABBVIE-6423543$ABBVIE$$$$$$Y$$$20250822$$CN$US$US
257157961$25715796$1$I$$20250821$20250821$20250821$DIR$771249$$FDA-CTU$$$$$$N$$$20250821$N$CN$US$
257159061$25715906$1$I$20250101$20250814$20250822$20250822$EXP$$GB-TEVA-VS-3363929$TEVA$$72$YR$$M$Y$$$20250822$$CN$GB$GB
257159891$25715989$1$I$20240708$20250818$20250822$20250822$EXP$EU-AFSSAPS-NY2025001217$EU-PFIZER INC-202500165037$PFIZER$$28$YR$$F$Y$74$KG$20250822$$MD$EU$EU
257160841$25716084$1$I$$20250820$20250822$20250822$PER$$US-BAYER-2025A111484$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250822$$MD$US$US
257161231$25716123$1$I$$20250819$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508019032$ELI LILLY AND COMPANY$$76$YR$E$$Y$$$20250822$$CN$US$US
257161471$25716147$1$I$20250701$20250820$20250822$20250822$PER$$US-ELI_LILLY_AND_COMPANY-US202508020255$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250822$$CN$US$US
257162161$25716216$1$I$20220101$20250818$20250822$20250822$EXP$$US-SA-2025SA250669$SANOFI AVENTIS$$57$YR$A$F$Y$81.82$KG$20250822$$MD$US$US
257162561$25716256$1$I$20200115$20250813$20250822$20250822$EXP$$US-NOVOPROD-1501496$NOVO NORDISK$$71$YR$$M$Y$$$20250822$$CN$US$US
257162581$25716258$1$I$$20250813$20250822$20250822$EXP$$CO-NOVOPROD-1502012$NOVO NORDISK$$76$YR$$M$Y$$$20250822$$CN$CO$CO
257162771$25716277$1$I$$20250813$20250822$20250822$EXP$GB-MHRA-MED-202508131033123880-ZPMCJ$GB-NOVOPROD-1502325$NOVO NORDISK$$$$$F$Y$$$20250822$$HP$GB$GB
257163432$25716343$2$F$$20250820$20250822$20250827$EXP$$TR-PFIZER INC-202500165960$PFIZER$Sanda, C.. KEEP IN MIND! MULTIPLE SCLEROSIS AS A RARE REASON OF SECONDARY OSTEOPOROSIS: A CASE REPORT. European Journal of Case Reports in Internal Medicine. 2024;11(Suppl 1):321-322$36$YR$$F$Y$$$20250827$$MD$TR$TR
257163461$25716346$1$I$$20250808$20250822$20250822$EXP$$US-ACORDA THERAPEUTICS IRELAND LIMITED-ACO_178667_2025$MERZ$$$$$F$Y$$$20250822$$CN$US$US
257163541$25716354$1$I$20250808$20250813$20250822$20250822$PER$$US-ROCHE-10000364836$ROCHE$$21$YR$A$F$Y$$$20250822$$CN$US$US
257163591$25716359$1$I$$20250817$20250822$20250822$EXP$$US-JNJFOC-A-CH2019-196816$JOHNSON AND JOHNSON$$32$YR$A$F$Y$$$20250822$$MD$US$US
257163901$25716390$1$I$20210808$20250814$20250822$20250822$EXP$$CA-TAKEDA-2021TUS047433$TAKEDA$$52$YR$$F$Y$$$20250822$$$CA$CA
257164601$25716460$1$I$20250820$20250820$20250822$20250822$EXP$$US-JNJFOC-20250826261$JOHNSON AND JOHNSON$$52$YR$A$M$Y$$$20250822$$MD$US$US
257166241$25716624$1$I$$20250723$20250822$20250822$PER$$US-GSK-US2025AMR096087$GLAXOSMITHKLINE$$$$$F$Y$56$KG$20250822$$$US$US
257167031$25716703$1$I$$20250819$20250822$20250822$EXP$$US-BAUSCH-BH-2025-016543$BAUSCH AND LOMB$$56$YR$A$M$Y$$$20250822$$MD$US$US
257167121$25716712$1$I$$20250822$20250822$20250822$DIR$FDA-CDER-CTU-2025-56142$$FDA-CTU$$87$YR$$F$N$$$20250822$N$HP$US$
257167511$25716751$1$I$20250817$20250820$20250822$20250822$EXP$$CN-009507513-2321986$MERCK SHARP + DOHME LLC$$87$YR$$M$Y$60$KG$20250822$$HP$CN$CN
257167761$25716776$1$I$20240731$20250814$20250822$20250822$EXP$EU-AFSSAPS-TS2025000861$EU-TEVA-VS-3363831$TEVA$$82$YR$$M$Y$$$20250822$$MD$EU$EU
257167911$25716791$1$I$20250812$20250813$20250822$20250822$EXP$$CN-KENVUE-20250807052$Kenvue$$$$$$Y$$$20250822$$HP$CN$CN
257167931$25716793$1$I$$20250812$20250822$20250822$EXP$$CA-NORDICGR-063708$NORDIC PHARMA$$62$YR$$F$Y$$$20250822$$HP$CA$CA
257168062$25716806$2$F$$20250822$20250822$20250826$PER$$US-PURDUE PHARMA-USA-2025-0319904$PURDUE$$$$$F$Y$$$20250826$$CN$US$US
257169351$25716935$1$I$$20250725$20250822$20250822$PER$$US-FMCRTG-FMC-2507-001196$FRESENIUS MEDICAL CARE$$$$$M$Y$$$20250822$$CN$US$US
257170091$25717009$1$I$20250101$20250815$20250822$20250822$PER$$US-SA-2025SA248029$SANOFI AVENTIS$$50$YR$A$F$Y$$$20250822$$HP$US$US
257171451$25717145$1$I$$20250818$20250822$20250822$PER$$US-SA-2025SA249430$SANOFI AVENTIS$$$$A$M$Y$$$20250822$$CN$US$US
257171531$25717153$1$I$$20250819$20250822$20250822$PER$$US-SA-2025SA250815$SANOFI AVENTIS$$2$YR$C$F$Y$$$20250822$$CN$US$US
257172531$25717253$1$I$20250501$20250818$20250822$20250822$PER$$US-SA-2025SA249894$SANOFI AVENTIS$$59$YR$A$M$Y$$$20250822$$HP$US$US
257172691$25717269$1$I$$20250819$20250822$20250822$PER$$US-SA-2025SA251331$SANOFI AVENTIS$$$$T$M$Y$93.18$KG$20250822$$MD$US$US
257173491$25717349$1$I$$20250819$20250822$20250822$PER$$US-SA-2025SA249975$SANOFI AVENTIS$$22$YR$A$M$Y$$$20250822$$MD$US$US
257173631$25717363$1$I$20250101$20250818$20250822$20250822$PER$$US-SA-2025SA249373$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250822$$MD$US$US
257173701$25717370$1$I$$20250811$20250822$20250822$EXP$$IN-GLENMARK PHARMACEUTICALS-2025GMK103132$GLENMARK$Arasi KV, Prasad TS, Vivek A.. Perigraft collections post renal transplantation: our institutional experience.. International Journal of Medicine and Public Health.. 2025;15(2):2357-62.$34$YR$$M$Y$$$20250822$$MD$IN$IN
257173871$25717387$1$I$$20250811$20250822$20250822$EXP$$US-ALEMBIC PHARMACUETICALS LIMITED-2025SCAL001085$ALEMBIC$Jadvani R, Juarez A, Shah CV.. CYCLOPHOSPHAMIDE-ASSOCIATED PARTIAL PROXIMAL TUBULAR DYSFUNCTION. EXCLI Journal. 2025;24:777-778$$$$$Y$$$20250822$$HP$US$US
257174271$25717427$1$I$20250701$20250819$20250822$20250822$PER$$US-SA-2025SA251029$SANOFI AVENTIS$$91$YR$E$F$Y$$$20250822$$HP$US$US
257174571$25717457$1$I$$20250818$20250822$20250822$PER$$US-SA-2025SA249736$SANOFI AVENTIS$$26$YR$A$F$Y$$$20250822$$HP$US$US
257175211$25717521$1$I$$20250818$20250822$20250822$EXP$$JP-GSK-JP2025107658$GLAXOSMITHKLINE$$$$$F$Y$$$20250822$$MD$JP$JP
257175692$25717569$2$F$20250811$20250903$20250822$20250909$PER$$JP-Eisai-EC-2025-195275$EISAI$$$$$F$Y$$$20250909$$MD$JP$JP
257175821$25717582$1$I$20220101$20250818$20250822$20250822$EXP$$EU-DSJP-DS-2025-159988-DE$DAIICHI$$$$$F$Y$$$20250822$$CN$EU$EU
257175861$25717586$1$I$20250728$20250818$20250822$20250822$EXP$$EU-DAIICHI SANKYO, INC.-DS-2025-160497-BG$DAIICHI$$$$E$F$Y$38$KG$20250822$$MD$EU$EU
257175971$25717597$1$I$$20250821$20250822$20250822$PER$$US-BAYER-2025A111351$BAYER HEALTHCARE LLC$$$$$$Y$$$20250822$$CN$US$US
257176162$25717616$2$F$20250101$20250903$20250822$20250908$EXP$$US-REGENERON PHARMACEUTICALS, INC.-2025-130190$REGENERON$$$$$M$Y$$$20250908$$CN$US$US
257176781$25717678$1$I$$20250817$20250822$20250822$EXP$$KR-JNJFOC-20250820436$JOHNSON AND JOHNSON$Shin A, Choi S, Pyo J, Ha Y, Lee Y, Lee E, et al. Risk of non-bacterial opportunistic infections associated with janus kinase inhibitors versus tumor necrosis factor inhibitors among rheumatoid arthritis patients: A cohort study. Joint Bone Spine. 2026 January 01;105945 doi: 10.1016/j.jbspin.2025.105945$$$$$Y$$$20250822$$HP$KR$KR
257177631$25717763$1$I$$20250816$20250822$20250822$PER$$US-ROCHE-10000366678$ROCHE$$$$A$F$Y$$$20250822$$CN$US$US
257177871$25717787$1$I$$20250815$20250822$20250822$EXP$$CA-AMGEN-CANSP2025167302$AMGEN$Pina P. S.; Oza A. M.; Dhani N. C. et al.. Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post- PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Journal of Clinical Oncology. 2025;43 (16)$$$$F$Y$$$20250822$$HP$CA$CA
257179301$25717930$1$I$20240417$20240531$20250822$20250822$EXP$$US-PFIZER INC-2024SGN05321$PFIZER$$62$YR$$M$Y$$$20250822$$MD$US$US
257179481$25717948$1$I$20250331$20250731$20250822$20250822$PER$$US-009507513-2316408$MERCK SHARP + DOHME LLC$$3$YR$$M$Y$$$20250822$$HP$US$US
257179502$25717950$2$F$20240521$20250922$20250822$20250929$EXP$$JP-ARDELYX-2024ARDX004931$ARDELYX$$59$YR$$M$Y$$$20250929$$MD$JP$JP
257180701$25718070$1$I$$20250812$20250823$20250823$EXP$$US-MACLEODS PHARMA-MAC2025054818$MACLEODS$Foss V, Celebi TB, Waheed R, Dhillon H.Spontaneous Psoas Hematoma Following Resistance Training in an Elderly Patient on Apixaban: A Case Report..Cureus.11-JUL-2025;17(7):e87748$$$$$Y$$$20250823$$HP$US$US
257180891$25718089$1$I$20250528$20250811$20250823$20250823$EXP$EU-MINISAL02-1050263$EU-Accord-500920$ACCORD$$75$YR$E$M$Y$$$20250823$$HP$EU$EU
257181752$25718175$2$F$$20250818$20250824$20250829$PER$$US-SA-2025SA247350$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250829$$CN$US$US
257182032$25718203$2$F$20250301$20250814$20250823$20250825$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-009317$JAZZ$$33$YR$$F$Y$$$20250825$$$US$US
257182071$25718207$1$I$$20250821$20250823$20250823$PER$$US-ELI_LILLY_AND_COMPANY-US202508021348$ELI LILLY AND COMPANY$$55$YR$A$M$Y$$$20250823$$CN$US$US
257182092$25718209$2$F$20250101$20250826$20250823$20250901$PER$$US-SA-2025SA251468$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250901$$CN$US$US
257182571$25718257$1$I$20231009$20231124$20250823$20250823$EXP$$GB-SANDOZ INC.-SDZ2023GB044163$SANDOZ$$63$YR$$M$Y$77.45$KG$20250823$$MD$GB$GB
257182761$25718276$1$I$20250801$20250819$20250824$20250824$PER$$US-SA-2025SA250632$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250824$$CN$US$US
257183611$25718361$1$I$$20250812$20250823$20250823$EXP$$US-AUROBINDO-AUR-APL-2025-043199$AUROBINDO$Isshak R, Mercado I, Habib R, Moussa H, Mohtadi M, Ebeid K, et al. When Fungus Strikes the Heart: An Exceptionally Rare Case of Lodderomyces Elongisporus Endocarditis. Am-J-Respir-Crit-Care-Med. 2025;10.1164/ajrccm.2025.211.Abstracts.A3929$29$YR$$M$Y$$$20250824$$HP$US$US
257183781$25718378$1$I$20250818$20250819$20250823$20250823$PER$$US-ELI_LILLY_AND_COMPANY-US202508018487$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250823$$CN$US$US
257183791$25718379$1$I$$20250821$20250823$20250823$PER$$US-ELI_LILLY_AND_COMPANY-US202508021467$ELI LILLY AND COMPANY$$72$YR$E$$Y$$$20250823$$CN$US$US
257183961$25718396$1$I$$20250808$20250822$20250822$EXP$GB-MHRA-MED-202508081345559910-VLTZY$GB-ELI_LILLY_AND_COMPANY-GB202508009335$ELI LILLY AND COMPANY$$$$$M$Y$$$20250822$$CN$GB$GB
257185391$25718539$1$I$$20250815$20250823$20250823$EXP$$CA-AMGEN-CANSP2025168300$AMGEN$Pina P.S.; Oza A.M.; Dhani N.C. et al.. Re-VOLVE: Phase 11 clinical trial in women with ovarian cancer progressing post- PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Journal of Clinical Oncology. 2025;43 (16)$$$$$Y$$$20250823$$HP$CA$CA
257186402$25718640$2$F$20250701$20250814$20250823$20250923$EXP$$EU-ORPHANEU-2025005865$RECORDATI$$$$$F$Y$$$20250923$$MD$EU$EU
257186961$25718696$1$I$$20250808$20250823$20250823$EXP$$CA-GSK-CA2025AMR103768$GLAXOSMITHKLINE$$59$YR$$F$Y$$$20250823$$$CA$CA
257187041$25718704$1$I$$20250821$20250822$20250822$EXP$001143020$CA-ASTRAZENECA-202508CAN016003CA$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$$$20250822$$MD$CA$CA
257187531$25718753$1$I$20250101$20250820$20250823$20250823$PER$$US-AMGEN-USASP2025167525$AMGEN$$68$YR$E$F$Y$$$20250822$$HP$US$US
257188491$25718849$1$I$$20250819$20250823$20250823$PER$$US-ELI_LILLY_AND_COMPANY-US202508019404$ELI LILLY AND COMPANY$$68$YR$E$M$Y$$$20250823$$CN$US$US
257189121$25718912$1$I$$20250819$20250822$20250822$EXP$$EU-ABBVIE-6423736$ABBVIE$$72$YR$$F$Y$$$20250822$$HP$EU$EU
257189691$25718969$1$I$$20250818$20250823$20250823$PER$$US-SA-2025SA251243$SANOFI AVENTIS$$$$A$F$Y$51.247$KG$20250823$$MD$US$US
257189721$25718972$1$I$$20250819$20250823$20250823$EXP$$US-VIIV HEALTHCARE-US2025107614$VIIV$$$$$$Y$$$20250823$$$US$US
257189991$25718999$1$I$$20250813$20250823$20250823$PER$$US-DAIICHI SANKYO, INC.-DS-2025-160601-US$DAIICHI$$$$$F$Y$$$20250823$$MD$US$US
257190031$25719003$1$I$20220316$20250812$20250823$20250823$EXP$$EU-AUROBINDO-AUR-APL-2025-042670$AUROBINDO$$72$YR$$M$Y$98$KG$20250824$$HP$EU$EU
257190371$25719037$1$I$$20250819$20250823$20250823$PER$$US-ABBVIE-6427384$ABBVIE$$$$$$Y$$$20250823$$HP$US$US
257191601$25719160$1$I$$20250814$20250823$20250823$EXP$$US-ELI_LILLY_AND_COMPANY-US202508017811$ELI LILLY AND COMPANY$$$$A$F$Y$$$20250823$$CN$US$US
257192072$25719207$2$F$20250801$20250909$20250824$20250915$PER$$US-SA-2025SA248989$SANOFI AVENTIS$$51$YR$A$M$Y$77.11$KG$20250915$$HP$US$US
257192241$25719224$1$I$20250101$20250819$20250824$20250824$EXP$$US-ORGANON-O2508USA001687$ORGANON$$$$$F$Y$87.528$KG$20250824$$MD$US$US
257192531$25719253$1$I$20250108$20250818$20250824$20250824$EXP$$JP-AMGEN-JPNSP2025167649$AMGEN$$72$YR$E$F$Y$$$20250824$$HP$JP$JP
257192601$25719260$1$I$$20250725$20250824$20250824$PER$$US-GSK-US2025AMR099128$GLAXOSMITHKLINE$$$$$F$Y$$$20250824$$$US$US
257192924$25719292$4$F$20250101$20250904$20250824$20250910$PER$$US-SA-2025SA249525$SANOFI AVENTIS$$31$YR$A$M$Y$$$20250910$$MD$US$US
257194341$25719434$1$I$20250818$20250818$20250824$20250824$PER$$US-JNJFOC-20250821249$JOHNSON AND JOHNSON$$66$YR$E$F$Y$95.25$KG$20250825$$CN$US$US
257195912$25719591$2$F$$20250821$20250825$20250825$EXP$$JP-009507513-2322023$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250825$$CN$JP$JP
257196051$25719605$1$I$20250601$20250819$20250825$20250825$PER$$US-ELI_LILLY_AND_COMPANY-US202508019688$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250825$$CN$US$US
257197241$25719724$1$I$$20250818$20250825$20250825$EXP$$NZ-SANDOZ INC.-SDZ2025NZ060797$SANDOZ$$$$$M$Y$$$20250825$$CN$NZ$NZ
257198131$25719813$1$I$20250101$20250815$20250825$20250825$EXP$$MX-UCBSA-2025050915$UCB$$$$$F$Y$23.4$KG$20250825$$MD$MX$MX
257199061$25719906$1$I$20250714$20250822$20250825$20250825$EXP$EU-JNJFOC-20250828179$EU-JNJFOC-20250828179$JOHNSON AND JOHNSON$$64$YR$A$M$Y$$$20250825$$MD$EU$EU
257199501$25719950$1$I$$20250818$20250825$20250825$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-116508$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$$$20250825$$CN$US$US
257199811$25719981$1$I$20250101$20250818$20250825$20250825$PER$$US-SA-2025SA249398$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250825$$CN$US$US
257199881$25719988$1$I$$20250819$20250825$20250825$PER$$US-SA-2025SA249059$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250825$$CN$US$US
257200001$25720000$1$I$$20250819$20250825$20250825$EXP$$CA-TEVA-VS-3365855$TEVA$$85$YR$$M$Y$$$20250825$$CN$CA$CA
257200061$25720006$1$I$$20250818$20250825$20250825$30DAY$$US-SANDOZ INC.-SDZ2025US060039$SANDOZ$$$$$M$Y$$$20250825$$CN$US$US
257200621$25720062$1$I$$20250818$20250825$20250825$PER$$US-ELI_LILLY_AND_COMPANY-US202508019911$ELI LILLY AND COMPANY$$74$YR$E$F$Y$$$20250825$$CN$US$US
257201121$25720112$1$I$$20250820$20250825$20250825$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117369$BRISTOL-MYERS SQUIBB COMPANY$$87$YR$E$$Y$$$20250825$$CN$US$US
257201351$25720135$1$I$20241113$20250818$20250825$20250825$EXP$$US-AMGEN-USASL2024227622$AMGEN$$68$YR$E$F$Y$61.315$KG$20250825$$MD$US$US
257201601$25720160$1$I$$20250812$20250825$20250825$PER$$US-GILEAD-2025-0724415$GILEAD$$83$YR$E$F$Y$$$20250825$$CN$US$US
257201891$25720189$1$I$20250812$20250821$20250825$20250825$EXP$$MX-VANTIVE-2025VAN003907$Vantive US Healthcare$$$$$F$Y$$$20250825$$CN$MX$MX
257201901$25720190$1$I$$20250820$20250825$20250825$EXP$$IN-VANTIVE-2025VAN003898$Vantive US Healthcare$$8$YR$$M$Y$$$20250825$$CN$IN$IN
257202091$25720209$1$I$20250819$20250820$20250825$20250825$30DAY$$US-SANDOZ INC.-SDZ2025US060504$SANDOZ$$38$YR$$M$Y$82.086$KG$20250825$$HP$US$US
257202412$25720241$2$F$$20250828$20250825$20250904$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009465$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250904$$CN$US$US
257203141$25720314$1$I$20220101$20250814$20250825$20250825$EXP$$CN-STERISCIENCE B.V.-2025-ST-001443$Steriscience PTE$Tang B, Meng T, Tian L, Zhong M, Dai Y, Tian R, et al. Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem. Int-J-Antimicrob-Agents. 2025;66 (4)$64$YR$$M$Y$$$20250825$$HP$CN$CN
257203221$25720322$1$I$20250101$20250816$20250825$20250825$EXP$$JP-RADIUS HEALTH INC.-JP-RADIUS-25052694$RADIUS PHARM$$92$YR$$F$Y$$$20250825$$CN$JP$JP
257203661$25720366$1$I$$20250820$20250825$20250825$EXP$$US-ABBVIE-6427854$ABBVIE$$$$E$F$Y$$$20250825$$CN$US$US
257204011$25720401$1$I$$20250816$20250825$20250825$PER$$US-SMPA-2025SPA010729$SUNOVION$$85$YR$$M$Y$$$20250822$$$US$US
257204171$25720417$1$I$20250701$20250822$20250825$20250825$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117351$BRISTOL-MYERS SQUIBB COMPANY$$68$YR$E$F$Y$$$20250825$$HP$US$US
257204271$25720427$1$I$20250804$20250819$20250825$20250825$EXP$EU-BFARM-25005706$EU-CHEPLA-2025009951$CHEPLAPHARM$$58$YR$$F$Y$55$KG$20250825$$MD$COUNTRY NOT SPECIFIED$EU
257204311$25720431$1$I$$20250812$20250825$20250825$EXP$GB-SANDOZ-SDZ2025GB056809$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-08977$ALKEM$$$$$M$Y$$$20250825$$CN$GB$GB
257204521$25720452$1$I$$20250810$20250825$20250825$EXP$$US-GSK-US2025AMR103709$GLAXOSMITHKLINE$$$$$F$Y$$$20250825$$$US$US
257204901$25720490$1$I$$20250813$20250825$20250825$EXP$$US-ROCHE-10000366041$ROCHE$$37$YR$A$F$Y$$$20250825$$HP$US$US
257206703$25720670$3$F$20250711$20250830$20250825$20250906$EXP$$EU-SANDOZ INC.-SDZ2025FR060757$SANDOZ$$53$YR$$M$Y$85$KG$20250906$$PH$EU$EU
257207392$25720739$2$F$$20250818$20250825$20250829$PER$$US-ELI_LILLY_AND_COMPANY-US202508016906$ELI LILLY AND COMPANY$$34$YR$A$F$Y$$$20250829$$CN$US$US
257207591$25720759$1$I$$20250822$20250825$20250825$EXP$$US-JNJFOC-20250828221$JOHNSON AND JOHNSON$$$$$$Y$$$20250825$$HP$US$US
257208751$25720875$1$I$$20250814$20250825$20250825$EXP$$EU-LEGACY PHARMA INC. SEZC-LGP202508-000242$LEGACY PHARMACEUTICAL PACKAGING$Rei A, Mocanu I, Pontinha C, Medeiros I.. Disturbed by a sandfly: visceral leishmaniasis in ileal Crohn^s disease under combined immunosuppression. Rev Esp Enferm Dig. 2025;117-8:457-8$44$YR$$M$Y$$$20250825$$HP$EU$EU
257208972$25720897$2$F$$20250904$20250825$20250912$PER$$US-SMPA-2025SPA010632$SUNOVION$$79$YR$$M$Y$$$20250911$$$US$US
257209191$25720919$1$I$$20250812$20250825$20250825$EXP$$US-GSK-US2025AMR105058$GLAXOSMITHKLINE$$$$$F$Y$$$20250825$$$US$US
257211151$25721115$1$I$20250822$20250822$20250822$20250822$DIR$771576$$FDA-CTU$$11$YR$$M$N$$$20250822$N$$US$
257212081$25721208$1$I$$20250819$20250825$20250825$EXP$$KR-REGENERON PHARMACEUTICALS, INC.-2025-134398$REGENERON$Kee T.E.; Choi H.G.; Kim K.L.; Kim Y;.. Retinal Occlusive Vasculitis after Intravitreal Brolucizumab Injection for Wet Age-related Macular Degeneration.. Journal of the Korean Ophthalmological Society.. 2025;66(8):346-351$73$YR$$F$Y$$$20250825$$HP$KR$KR
257212521$25721252$1$I$20250822$20250822$20250822$20250822$DIR$771518$$FDA-CTU$$48$YR$$F$N$$$20250822$N$$US$
257212771$25721277$1$I$$20250818$20250825$20250825$EXP$$GB-MYLANLABS-2025M1070869$MYLAN$$$$$M$Y$$$20250825$$PH$GB$GB
257213871$25721387$1$I$$20250814$20250825$20250825$EXP$$US-JNJFOC-20250817615$JOHNSON AND JOHNSON$$$$A$M$Y$$$20250825$$CN$US$US
257214032$25721403$2$F$$20250825$20250825$20250830$EXP$$CA-JNJFOC-20250823570$JOHNSON AND JOHNSON$$86$YR$E$F$Y$$$20250830$$CN$CA$CA
257214141$25721414$1$I$$20250824$20250825$20250825$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117637$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$100.24$KG$20250825$$CN$US$US
257216101$25721610$1$I$$20250812$20250825$20250825$PER$$US-APOTEX-2025AP011817$APOTEX$Farnsworth CW.. Commentary on Abnormal Thyroid Function Test in a Patient Taking Carbamazepine.. The journal of applied laboratory medicine. 2025$$$$F$Y$$$20250825$$HP$US$US
257218341$25721834$1$I$20250714$20250821$20250825$20250825$EXP$$US-ABBVIE-6429947$ABBVIE$$76$YR$$F$Y$$$20250825$$CN$US$US
257218721$25721872$1$I$$20250818$20250825$20250825$EXP$$EU-MYLANLABS-2025M1072731$MYLAN$Napoletano G, Treves B, De Paola L, Ghamlouch A, Del Duca F, De Matteis A, et al. Two cases of Sexual Activity-Related Deaths due to Vascular Dissection: investigating the Potential Link to phosphodiesterase type 5 inhibitor administration. [Review]. Clin-Ter 2025; 176 (Suppl.) 70-76.$61$YR$$M$Y$$$20250825$$$EU$EU
257218911$25721891$1$I$$20250819$20250825$20250825$EXP$$BR-JNJFOC-20250824933$JOHNSON AND JOHNSON$$$$$$Y$$$20250825$$MD$BR$BR
257219131$25721913$1$I$$20250822$20250823$20250823$DIR$FDA-CDER-CTU-2025-56347$$FDA-CTU$$86$YR$$M$N$$$20250822$N$$US$
257219691$25721969$1$I$$20250815$20250825$20250825$EXP$$CA-CELLTRION INC.-2025CA028830$CELLTRION$$$$$$Y$$$20250825$$HP$CA$CA
257220601$25722060$1$I$20250813$20250825$20250825$20250825$DIR$771776$$FDA-CTU$$68$YR$$F$N$83$KG$20250825$N$$US$
257221121$25722112$1$I$20180220$20250812$20250825$20250825$EXP$$US-PFIZER INC-202500163868$PFIZER$$$$$$Y$$$20250825$$LW$US$US
257222762$25722276$2$F$$20250830$20250825$20250902$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-117183$BRISTOL-MYERS SQUIBB COMPANY$Igaue S, et al. Two cases of immune-related adverse events identified following altered consciousness during postoperative management of oesophageal carcinoma. The 79th Annual Meeting of the Japan Esophageal Society. 2025;RS3-5.$57$YR$A$F$Y$$$20250902$$MD$JP$JP
257222791$25722279$1$I$20250807$20250815$20250825$20250825$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-114587$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$F$Y$72$KG$20250825$$PH$US$US
257223131$25722313$1$I$20250717$20250813$20250825$20250825$EXP$GB-MHRA-MED-202508121546338210-RCDMB$GB-ELI_LILLY_AND_COMPANY-GB202508013981$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250825$$CN$GB$GB
257223401$25722340$1$I$$20250822$20250825$20250825$PER$$US-ELI_LILLY_AND_COMPANY-US202508023424$ELI LILLY AND COMPANY$$$$$$Y$$$20250825$$CN$US$US
257223842$25722384$2$F$$20250912$20250825$20250916$30DAY$$US-PFIZER INC-202500168875$PFIZER$$$$$$Y$$$20250916$$HP$US$US
257224211$25722421$1$I$20240207$20250814$20250825$20250825$EXP$$JP-PFIZER INC-PV202500067810$PFIZER$$31$YR$$F$Y$$$20250825$$MD$JP$JP
257224431$25722443$1$I$$20250819$20250825$20250825$PER$$US-JNJFOC-20250823459$JOHNSON AND JOHNSON$$$$$F$Y$$$20250825$$HP$US$US
257224871$25722487$1$I$$20250820$20250825$20250825$EXP$$MX-VANTIVE-2025VAN003905$Vantive US Healthcare$$$$$F$Y$$$20250825$$CN$MX$MX
257225331$25722533$1$I$20250101$20250819$20250825$20250825$PER$$US-SA-2025SA253623$SANOFI AVENTIS$$62$YR$A$F$Y$89$KG$20250825$$MD$US$US
257226164$25722616$4$F$20250812$20250904$20250825$20250911$EXP$$JP-PFIZER INC-PV202500101894$PFIZER$$42$YR$$F$Y$50.1$KG$20250911$$MD$JP$JP
257226202$25722620$2$F$$20250826$20250825$20250903$PER$$US-SA-2025SA251644$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250903$$CN$US$US
257226471$25722647$1$I$20250818$20250822$20250825$20250825$EXP$$US-GILEAD-2025-0725739$GILEAD$$66$YR$E$M$Y$$$20250825$$HP$US$US
257226831$25722683$1$I$20250729$20250813$20250825$20250825$EXP$GB-MHRA-MED-202508130942069290-CTGZD$GB-Accord-500969$ACCORD$$29$YR$A$F$Y$$$20250825$$CN$GB$GB
257227091$25722709$1$I$$20250729$20250825$20250825$PER$$US-RDY-USA/2025/07/011719$DR REDDYS$$$$$M$Y$$$20250825$$HP$US$US
257227652$25722765$2$F$$20250821$20250825$20250911$EXP$$CN-ASTRAZENECA-202508GLO018615CN$ALEXION PHARMACEUTICALS$Jin Y., Ma W., Ju S., Pu X.. Risk factors and outcome analysis of osimertinib-induced cardiotoxicity in patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. China Pharmaceuticals. 2025;34 (15):94-99$81$YR$E$$Y$$$20250911$$PH$CN$CN
257229101$25722910$1$I$20250811$20250820$20250825$20250825$EXP$$CA-ABBVIE-6415221$ABBVIE$$68$YR$$F$Y$$$20250825$$CN$CA$CA
257229111$25722911$1$I$$20250819$20250825$20250825$EXP$$US-TAKEDA-2025TUS073973$TAKEDA$$$$$F$Y$$$20250825$$$US$US
257229201$25722920$1$I$$20250818$20250825$20250825$EXP$$EU-UCBSA-2025051544$UCB$$40$YR$$M$Y$$$20250825$$MD$EU$EU
257229501$25722950$1$I$$20250810$20250825$20250825$EXP$$US-GSK-US2025AMR104146$GLAXOSMITHKLINE$$$$$F$Y$$$20250825$$$US$US
257230181$25723018$1$I$20250615$20250821$20250825$20250825$EXP$$AU-PFIZER INC-202500167413$PFIZER$$65$YR$$M$Y$$$20250825$$HP$AU$AU
257231071$25723107$1$I$$20250820$20250825$20250825$EXP$GB-MHRA-MED-202508201617105640-NWJSR$GB-PFIZER INC-202500167114$PFIZER$$$$$F$Y$$$20250825$$HP$GB$GB
257231352$25723135$2$F$$20250822$20250825$20250828$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117766$BRISTOL-MYERS SQUIBB COMPANY$$20$YR$A$M$Y$$$20250828$$MD$US$US
257231431$25723143$1$I$20250728$20250820$20250825$20250825$PER$$US-ELI_LILLY_AND_COMPANY-US202508021300$ELI LILLY AND COMPANY$$50$YR$A$M$Y$$$20250825$$CN$US$US
257231541$25723154$1$I$20250710$20250730$20250825$20250825$EXP$$US-GALDERMA-US2025013964$GALDERMA$$$$$$Y$$$20250825$$CN$US$US
257232151$25723215$1$I$$20250822$20250822$20250822$DIR$771571$$FDA-CTU$$$$$F$N$$$20250822$N$CN$US$
257232371$25723237$1$I$$20250823$20250823$20250823$DIR$771637$$FDA-CTU$$$$$F$N$56.7$KG$20250823$N$CN$US$
257232381$25723238$1$I$$20250823$20250823$20250823$DIR$771638$$FDA-CTU$$$$$F$N$56.7$KG$20250823$N$CN$US$
257232971$25723297$1$I$$20250819$20250825$20250825$EXP$$EU-PFIZER INC-PV202500101593$PFIZER$Sutton, L.. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: A multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.. Blood. 2011;117(23):6109-6119$$$A$$Y$$$20250825$$HP$EU$EU
257233301$25723330$1$I$20250301$20250818$20250825$20250825$EXP$$EU-VIIV HEALTHCARE-AT2025106099$VIIV$$$$$M$Y$$$20250825$$MD$EU$EU
257233371$25723337$1$I$20250720$20250819$20250825$20250825$EXP$EU-AFSSAPS-GR2025001255$EU-MYLANLABS-2025M1070926$MYLAN$$32$YR$$F$Y$65$KG$20250825$$PH$EU$EU
257234231$25723423$1$I$$20250712$20250825$20250825$PER$$US-UniquePharma-US-2025UPLSPO00094$UNIQUE PHARMACEUTICALS$$$$$$Y$$$20250825$$CN$US$US
257234271$25723427$1$I$$20250821$20250825$20250825$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117848$BRISTOL-MYERS SQUIBB COMPANY$$81$YR$E$M$Y$$$20250825$$HP$US$US
257236501$25723650$1$I$$20240613$20250825$20250825$EXP$$US-SANDOZ INC.-SDZ2024US108048$SANDOZ$$74$YR$$F$Y$$$20250825$$CN$US$US
257236552$25723655$2$F$20250128$20250828$20250825$20250911$EXP$$US-ADMA BIOLOGICS INC.-US-2025ADM000247$ADMA BIOLOGICS$$78$YR$$F$Y$$$20250911$$CN$US$US
257237591$25723759$1$I$20250808$20250813$20250825$20250825$EXP$$NVSC2025DE129818$NOVARTIS$$$$$F$Y$$$20250825$$MD$EU$EU
257237752$25723775$2$F$20250328$20250829$20250825$20250911$EXP$$NVSC2025FR128399$NOVARTIS$$$$A$F$Y$$$20250911$$MD$EU$EU
257237911$25723791$1$I$$20250812$20250825$20250825$PER$$US-009507513-2320114$MERCK SHARP + DOHME LLC$$40$YR$$F$Y$$$20250825$$CN$US$US
257238141$25723814$1$I$$20250818$20250825$20250825$EXP$$NVSC2025US130760$NOVARTIS$Smith J, Fleet M, McKenna D, Lais J, Rehman S, Pandav J.. Transverse Myelitis: A Rare Adverse Effect of Calcineurin Inhibitors.. AM-J-TRANSPLANT. 2025;25 (supp 1) (8):S775$66$YR$$M$Y$$$20250825$$HP$US$US
257238601$25723860$1$I$$20250821$20250825$20250825$EXP$$US-ABBVIE-6429365$ABBVIE$$$$$F$Y$$$20250825$$CN$US$US
257238842$25723884$2$F$20250806$20250924$20250825$20250929$EXP$$NVSJ2025JP008404$NOVARTIS$$83$YR$$M$Y$63$KG$20250929$$PH$JP$JP
257239401$25723940$1$I$$20250820$20250825$20250825$EXP$$MX-ASTRAZENECA-202508MEX015703MX$ALEXION PHARMACEUTICALS$$53$YR$A$F$Y$$$20250825$$$MX$MX
257239541$25723954$1$I$20250801$20250812$20250825$20250825$EXP$$US-CIPLA LTD.-2025US10374$CIPLA$$$$$$Y$$$20250826$$CN$US$US
257240401$25724040$1$I$20250819$20250819$20250826$20250826$EXP$$CO-ASTRAZENECA-202508SAM014453CO$ALEXION PHARMACEUTICALS$$15$YR$T$M$Y$$$20250826$$$CO$CO
257241591$25724159$1$I$$20250821$20250826$20250826$EXP$$US-TAKEDA-2025TUS074353$TAKEDA$$$$$M$Y$$$20250826$$$US$US
257242991$25724299$1$I$$20250813$20250826$20250826$EXP$$US-BEH-2025215987$CSL BEHRING$$58$YR$A$F$Y$$$20250826$$CN$US$US
257243701$25724370$1$I$$20250819$20250826$20250826$EXP$$JP-AMGEN-JPNSP2025166996$AMGEN$$$$$$Y$$$20250825$$MD$JP$JP
257244291$25724429$1$I$$20250820$20250826$20250826$PER$$US-ELI_LILLY_AND_COMPANY-US202508020498$ELI LILLY AND COMPANY$$75$YR$E$F$Y$$$20250826$$CN$US$US
257244721$25724472$1$I$$20250813$20250826$20250826$PER$$US-ROCHE-10000364509$ROCHE$$$$E$M$Y$$$20250826$$CN$US$US
257244971$25724497$1$I$$20250819$20250826$20250826$EXP$$US-JNJFOC-20250823181$JOHNSON AND JOHNSON$$$$$F$Y$$$20250826$$CN$US$US
257245041$25724504$1$I$$20250816$20250826$20250826$EXP$$CA-BIOCON BIOLOGICS LIMITED-BBL2025004629$BIOCON$$$$$$Y$$$20250826$$CN$CA$CA
257246981$25724698$1$I$$20250818$20250826$20250826$EXP$$US-AMGEN-USASP2025166454$AMGEN$$$$$$Y$$$20250826$$LW$US$US
257247331$25724733$1$I$$20250819$20250826$20250826$EXP$$US-AMGEN-USASP2025166226$AMGEN$$$$A$M$Y$$$20250826$$MD$US$US
257247701$25724770$1$I$20220101$20250813$20250826$20250826$EXP$$EU-AUROBINDO-AUR-APL-2025-043206$AUROBINDO$Graziani L, Gori L, Manciulli T, Basile G, Campolmi I, Borchi B, et al. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19. J  Antimicrob Chemother. 2023;78:555-558$59$YR$$M$Y$$$20250826$$HP$EU$EU
257249581$25724958$1$I$$20250707$20250826$20250826$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-02480$AMNEAL$$$$$F$Y$45.351$KG$20250826$$CN$US$US
257249601$25724960$1$I$20250601$20250701$20250826$20250826$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-02527$AMNEAL$$67$YR$$F$Y$$$20250826$$CN$US$US
257249661$25724966$1$I$20250101$20250819$20250826$20250826$PER$$US-ASTELLAS-2025-AER-045646$ASTELLAS$$81$YR$E$F$Y$$$20250826$$CN$US$US
257249881$25724988$1$I$20250801$20250820$20250826$20250826$PER$$US-ROCHE-10000370145$ROCHE$$$$$$Y$$$20250826$$HP$US$US
257250031$25725003$1$I$$20250813$20250826$20250826$EXP$$GB-MHRA-MED-202508122157314670-VJGMH$AUROBINDO$$$$$F$Y$$$20250826$$CN$GB$GB
257250521$25725052$1$I$$20250711$20250826$20250826$EXP$$TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2025-07814$ALKEM$Erol Ozturk Y, Yeter O, Asliyuksek H, Oztuna A, Sezigen S, Demirel G.. The first report from Ankara on the presence of xylazine abuse in blood and urine samples using a validated LC-HRMS method. International Journal of Legal Medicine. 2025;unk:unk$23$YR$$M$Y$$$20250826$$HP$TR$TR
257250561$25725056$1$I$20250301$20250805$20250826$20250826$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-02979$AMNEAL$$67$YR$$$Y$$$20250826$$MD$US$US
257251401$25725140$1$I$$20250820$20250826$20250826$PER$$US-ROCHE-10000370891$ROCHE$$$$A$M$Y$$$20250826$$MD$US$US
257252281$25725228$1$I$20250801$20250819$20250826$20250826$EXP$EU-JNJFOC-20250822353$EU-TAKEDA-2025TUS073594$TAKEDA$$50$YR$$F$Y$93$KG$20250826$$PH$EU$EU
257253131$25725313$1$I$$20250818$20250826$20250826$PER$$US-ELI_LILLY_AND_COMPANY-US202508019445$ELI LILLY AND COMPANY$$$$$$Y$$$20250826$$CN$US$US
257253692$25725369$2$F$20250808$20250828$20250826$20250912$EXP$$US-AUROBINDO-AUR-APL-2025-043344$AUROBINDO$$63$YR$$M$Y$$$20250912$$MD$US$US
257254381$25725438$1$I$20250815$20250815$20250826$20250826$EXP$$CN-ALCON LABORATORIES-ALC2025CN004234$ALCON$$73$YR$$F$Y$70$KG$20250826$$CN$COUNTRY NOT SPECIFIED$CN
257254901$25725490$1$I$20220224$20250813$20250826$20250826$EXP$$EU-AUROBINDO-AUR-APL-2025-043124$AUROBINDO$$60$YR$$F$Y$$$20250826$$MD$EU$EU
257255122$25725512$2$F$20250101$20250825$20250826$20250905$EXP$$US-INSMED-2025-02878-USAA$INSMED$$$$$F$Y$$$20250905$$CN$US$US
257255891$25725589$1$I$20240807$20250813$20250826$20250826$EXP$$GB-MHRA-MED-202508130704052570-ZMCYR$AUROBINDO$$$$$M$Y$$$20250826$$CN$GB$GB
257255941$25725594$1$I$20250822$20250822$20250826$20250826$EXP$$US-JNJFOC-20250829530$JOHNSON AND JOHNSON$$68$YR$E$M$Y$$$20250826$$HP$US$US
257256591$25725659$1$I$20241003$20250820$20250826$20250826$EXP$$CN-ROCHE-10000369275$ROCHE$$79$YR$E$F$Y$52$KG$20250826$$MD$CN$CN
257257451$25725745$1$I$20250601$20250821$20250826$20250826$EXP$$US-SA-2025SA255287$SANOFI AVENTIS$$70$YR$E$F$Y$$$20250826$$HP$US$US
257258383$25725838$3$F$20250819$20250915$20250826$20250922$EXP$$US-BAYER-2025A111711$BAYER HEALTHCARE PHARMACEUTICALS INC.$$45$YR$A$F$Y$55.782$KG$20250922$$HP$US$US
257258591$25725859$1$I$$20250811$20250826$20250826$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-523476$RANBAXY$$14$YR$$F$Y$$$20250826$$MD$GB$GB
257258862$25725886$2$F$$20250829$20250826$20250911$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-523920$RANBAXY$$$$A$M$Y$$$20250911$$HP$US$US
257259041$25725904$1$I$$20250812$20250826$20250826$EXP$$KR-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-523020$RANBAXY$Kim TH, Youn SH, Kim MA, Kim HJ, Kwon YS, Park JS et al. Lemierre syndrome: case  presentation of a life-threatening septic pneumonia with complicated parapneumonic effusion A presentation of a life-threatening septic pneumonia with complicated parapneumonic effusion A. Medicine. 2024;103:52:4 pages$35$YR$$M$Y$$$20250826$$MD$KR$KR
257259302$25725930$2$F$20250101$20250924$20250826$20250929$EXP$$US-ABBVIE-6427907$ABBVIE$$20$YR$$F$Y$$$20250929$$CN$US$US
257261251$25726125$1$I$$20250820$20250826$20250826$EXP$$CA-TEVA-VS-3365839$TEVA$$6$DEC$$M$Y$$$20250826$$HP$CA$CA
257261441$25726144$1$I$$20250613$20250826$20250826$EXP$$EU-PHARMAESSENTIA CORPORATION-ES-2025-PEC-008033$PHARMAESSENTIA$$$$$$Y$$$20250826$$HP$EU$EU
257261561$25726156$1$I$$20250821$20250826$20250826$EXP$$CA-Eisai-EC-2025-195451$EISAI$$70$YR$E$M$Y$$$20250826$$$CA$CA
257262371$25726237$1$I$$20250819$20250826$20250826$PER$$US-SA-2025SA255031$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250826$$CN$US$US
257262491$25726249$1$I$20250101$20250820$20250826$20250826$PER$$US-SA-2025SA254222$SANOFI AVENTIS$$47$YR$A$F$Y$$$20250826$$HP$US$US
257262511$25726251$1$I$$20250820$20250826$20250826$PER$$US-SA-2025SA253884$SANOFI AVENTIS$$79$YR$E$F$Y$$$20250826$$CN$US$US
257262711$25726271$1$I$20250101$20250820$20250826$20250826$PER$$US-SA-2025SA253859$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250826$$HP$US$US
257262802$25726280$2$F$20250101$20250906$20250826$20250915$PER$$US-SA-2025SA254515$SANOFI AVENTIS$$42$YR$A$M$Y$$$20250915$$HP$US$US
257263011$25726301$1$I$$20250819$20250826$20250826$PER$$US-SA-2025SA254243$SANOFI AVENTIS$$$$A$F$Y$$$20250826$$HP$US$US
257263681$25726368$1$I$20250801$20250821$20250826$20250826$PER$$US-SA-2025SA253837$SANOFI AVENTIS$$$$$F$Y$$$20250826$$CN$US$US
257263741$25726374$1$I$20250101$20250823$20250826$20250826$PER$$US-SA-2025SA254049$SANOFI AVENTIS$$$$E$F$Y$$$20250826$$MD$US$US
257265001$25726500$1$I$$20250822$20250826$20250826$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-117913$BRISTOL-MYERS SQUIBB COMPANY$Constantinescu M, Penela O, Bhate C, Cognetta A. Delayed-onset hematomas following mohs surgery in patients taking a direct oral anticoagulant. Cureus. 2025 May 03;17(5):1-5. doi:10.7759/cureus.83408.$83$YR$E$M$Y$$$20250826$$HP$US$US
257265121$25726512$1$I$$20250815$20250826$20250826$EXP$$JP-INSMED, INC.-2025-03266-JP$INSMED$Yuki Fujiura, Kentaro Ito, Remi Inoue, Kentaro Nakanishi, Masaya Esumi, Maki Esumi, Yuta Suzuki, Nao Sakaguchi, Yoichi Nishii, Osamu Hatachi. Evaluation of Inhaled Amikacin Therapy for Refractory Nontuberculous Mycobacterial Disease at Our Institution. Kekkaku. 2025;100(5):101-105$65$YR$$F$Y$$$20250826$$MD$JP$JP
257265421$25726542$1$I$$20250801$20250826$20250826$PER$$US-Apozeal Pharmaceuticals-2183226$Apozeal Pharmaceuticals$$$$$M$Y$113.64$KG$20250826$$$US$US
257266082$25726608$2$F$$20250826$20250826$20250828$PER$$US-PFIZER INC-202500168264$PFIZER$$77$YR$$F$Y$76.2$KG$20250828$$HP$US$US
257268001$25726800$1$I$20220122$20241123$20250825$20250825$DIR$FDA-CDER-CTU-2025-56828$$FDA-CTU$$96$YR$$M$N$$$20241123$N$$US$
257268031$25726803$1$I$20220214$20241125$20250825$20250825$DIR$FDA-CDER-CTU-2025-56858$$FDA-CTU$$$$$$N$$$20241125$N$$US$
257268331$25726833$1$I$$20250821$20250826$20250826$EXP$$CA-PFIZER INC-202500169204$PFIZER$$58$YR$$F$Y$$$20250826$$MD$CA$CA
257268451$25726845$1$I$20250211$20250312$20250826$20250826$PER$$US-SAGENT PHARMACEUTICALS-2025SAG000011$SAGENT PHARMACEUTICALS$$62$YR$$M$Y$$$20250826$$PH$US$US
257269281$25726928$1$I$$20250821$20250826$20250826$PER$$US-PFIZER INC-PV202500101756$PFIZER$$54$YR$$F$Y$$$20250826$$CN$US$US
257269291$25726929$1$I$20220521$20241123$20250825$20250825$DIR$FDA-CDER-CTU-2025-56839$$FDA-CTU$$81$YR$$M$N$$$20241123$N$$US$
257269851$25726985$1$I$$20250820$20250826$20250826$PER$$US-SA-2025SA174290$SANOFI AVENTIS$$87$YR$E$F$Y$$$20250826$$MD$US$US
257270571$25727057$1$I$$20250825$20250825$20250825$DIR$FDA-CDER-CTU-2025-56745$$FDA-CTU$$62$YR$$M$N$$$20250825$N$HP$US$
257272032$25727203$2$F$20250710$20250825$20250826$20250828$30DAY$$JP-PFIZER INC-202500139627$PFIZER$$$$$$Y$$$20250828$$PH$JP$JP
257272591$25727259$1$I$20250307$20250812$20250826$20250826$EXP$EU-AFSSAPS-LY2025001170$EU-Axellia-005647$XELLIA PHARMACEUTICALS$$70$YR$E$M$Y$92$KG$20250826$$PH$EU$EU
257272821$25727282$1$I$20250817$20250821$20250826$20250826$EXP$$CO-ASTRAZENECA-202508SAM016968CO$ALEXION PHARMACEUTICALS$$76$YR$E$M$Y$$$20250826$$$CO$CO
257273042$25727304$2$F$20250801$20250811$20250826$20250918$PER$$US-IGSA-BIG0037452$GRIFOLS$$67$YR$$F$Y$54.42$KG$20250918$$CN$US$US
257273321$25727332$1$I$$20250822$20250826$20250826$PER$$US-SA-2025SA256134$SANOFI AVENTIS$$$$$F$Y$$$20250826$$CN$US$US
257273541$25727354$1$I$20250810$20250818$20250826$20250826$PER$$US-ELI_LILLY_AND_COMPANY-US202508017202$ELI LILLY AND COMPANY$$70$YR$E$M$Y$$$20250826$$CN$US$US
257273761$25727376$1$I$20250603$20250821$20250826$20250826$PER$$US-SA-2025SA255228$SANOFI AVENTIS$$53$YR$A$F$Y$$$20250826$$HP$US$US
257273811$25727381$1$I$$20250821$20250826$20250826$EXP$$JP-MSD-M2024-53480$MERCK SHARP + DOHME LLC$$65$YR$$F$Y$$$20250826$$MD$JP$JP
257276445$25727644$5$F$20250101$20250919$20250826$20250927$EXP$$US-UNITED THERAPEUTICS-UNT-2025-023259$UNITED THERAPEUTICS$$$$$M$Y$57.596$KG$20250927$$$US$US
257276941$25727694$1$I$$20250814$20250826$20250826$EXP$$US-ELI_LILLY_AND_COMPANY-US202508015171$ELI LILLY AND COMPANY$$$$$M$Y$$$20250826$$CN$US$US
257277042$25727704$2$F$$20250829$20250826$20250908$EXP$$EU-ELI_LILLY_AND_COMPANY-NL202508020858$ELI LILLY AND COMPANY$$$$$F$Y$$$20250908$$CN$EU$EU
257277352$25727735$2$F$$20250909$20250826$20250915$EXP$$US-ABBVIE-6430328$ABBVIE$$$$E$F$Y$$$20250915$$CN$US$US
257278131$25727813$1$I$20250815$20250825$20250826$20250826$DIR$FDA-CDER-CTU-2025-56739$$FDA-CTU$$65$YR$$F$N$63.3$KG$20250825$N$$US$
257278531$25727853$1$I$20250825$20250826$20250826$20250826$DIR$771953$$FDA-CTU$$$$$$N$$$20250826$N$CN$US$
257278711$25727871$1$I$$20250822$20250826$20250826$EXP$$US-INCYTE CORPORATION-2025IN009189$INCYTE$$36$YR$$$Y$$$20250826$$$US$US
257279221$25727922$1$I$20250821$20250821$20250826$20250826$PER$$US-SA-2025SA255208$SANOFI AVENTIS$$8$YR$C$$Y$27.73$KG$20250826$$HP$US$US
257279631$25727963$1$I$$20250825$20250826$20250826$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-118406$BRISTOL-MYERS SQUIBB COMPANY$$50$YR$A$M$Y$$$20250826$$CN$US$US
257279711$25727971$1$I$20250101$20250820$20250826$20250826$PER$$US-BAUSCHBL-2025BNL014747$BAUSCH AND LOMB$$76$YR$$F$Y$$$20250826$$CN$US$US
257279811$25727981$1$I$20250816$20250819$20250826$20250826$EXP$GB-MHRA-MED-202508182332078340-MPDCV$GB-ELI_LILLY_AND_COMPANY-GB202508018752$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250826$$CN$GB$GB
257279991$25727999$1$I$$20240721$20250826$20250826$PER$$US-PERRIGO-24US007005$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250826$$CN$US$US
257280591$25728059$1$I$$20250814$20250826$20250826$EXP$$US-Accord-499488$ACCORD$Ortiz J, Seif AE, States L, Mehta S, MacFarland SP, Zheng DJ. Gemcitabine and Oxaliplatin-Induced Veno-Occlusive Disease in a Pediatric Patient With Multiply Relapsed Germ Cell Tumor. Pediatr Blood Cancer. 2025 Jul 25:e31945. doi: 10.1002/pbc.31945.$10$YR$C$F$Y$40.3$KG$20250826$$HP$US$US
257281671$25728167$1$I$$20250811$20250826$20250826$EXP$$US-AMGEN-USASP2025165576$AMGEN$Safa K.; El Mouhayyar C.; Al Jurdi A. et al.. Incidence Rate of Catheter-Related Bloodstream Infection (CRBSI) Post Solid Organ Transplant: A Single Center Experience. American Journal of Transplantation. 2025;25 (8):S333$$$$$Y$$$20250826$$HP$US$US
257283411$25728341$1$I$20250627$20250821$20250826$20250826$EXP$AU-TGA-0000845128$AU-SANDOZ INC.-SDZ2025AU060982$SANDOZ$$77$YR$$M$Y$$$20250826$$HP$AU$AU
257283801$25728380$1$I$$20250822$20250826$20250826$PER$$US-PFIZER INC-202500169328$PFIZER$$$$$$Y$$$20250826$$HP$US$US
257283851$25728385$1$I$$20250822$20250826$20250826$PER$$US-PFIZER INC-202500169486$PFIZER$$86$YR$$$Y$73.9$KG$20250826$$HP$US$US
257284991$25728499$1$I$$20250822$20250826$20250826$EXP$GB-MHRA-MED-202508211719054410-DYNKF$GB-SANDOZ INC.-SDZ2025GB061213$SANDOZ$$$$$F$Y$$$20250826$$HP$GB$GB
257285491$25728549$1$I$$20250821$20250826$20250826$PER$$US-ABBVIE-6429489$ABBVIE$$$$$F$Y$$$20250826$$CN$US$US
257287611$25728761$1$I$$20250824$20250826$20250826$PER$$US-PURDUE PHARMA-USA-2025-0319967$PURDUE$$48$YR$$M$Y$$$20250826$$CN$US$US
257287731$25728773$1$I$$20250530$20250826$20250826$PER$$US-ASCENDIS PHARMA-2025US009694$ASCENDIS PHARMA$$$$$$Y$$$20250826$$CN$US$US
257287831$25728783$1$I$$20250728$20250826$20250826$PER$$US-ASCENDIS PHARMA-2025US010779$ASCENDIS PHARMA$$$$$$Y$$$20250826$$MD$US$US
257287841$25728784$1$I$$20250627$20250826$20250826$PER$$US-ASCENDIS PHARMA-2025US010192$ASCENDIS PHARMA$$$$$$Y$$$20250826$$MD$US$US
257288751$25728875$1$I$$20250821$20250826$20250826$PER$$JP-TAKEDA-2025TJP008547$TAKEDA$$$$$$Y$$$20250826$$MD$JP$JP
257289401$25728940$1$I$20240916$20250822$20250826$20250826$EXP$$EU-ABBVIE-6431515$ABBVIE$$73$YR$$F$Y$$$20250826$$MD$EU$EU
257289761$25728976$1$I$$20250818$20250826$20250826$PER$$US-ABBVIE-6424902$ABBVIE$$$$$$Y$$$20250826$$CN$US$US
257290331$25729033$1$I$$20250805$20250827$20250827$EXP$$CN-ABBVIE-6431842$ABBVIE$Cheng P, Suo X. To compare the efficacy and safety of VEN combined with DA (2+6) and DA (3+7) in the initial treatment of AML. 2025.; Cheng P, Suo X. To compare the efficacy and safety of VEN combined with DA (2+6) and DA (3+7) in the initial treatment of AML. 2025.; Cheng P, Suo X. To compare the efficacy and safety of VEN combined with DA (2+6) and DA (3+7) in the initial treatment of AML. 2025.$$$$$Y$$$20250827$$HP$CN$CN
257291571$25729157$1$I$$20250821$20250827$20250827$EXP$$US-ABBVIE-6429348$ABBVIE$$$$A$F$Y$$$20250827$$CN$US$US
257291651$25729165$1$I$$20250825$20250827$20250827$EXP$$US-ABBVIE-6433215$ABBVIE$$$$$F$Y$$$20250827$$CN$US$US
257292221$25729222$1$I$20250806$20250825$20250827$20250827$EXP$EU-AFSSAPS-TO2025001314$EU-HALEON-2259551$Haleon PLC$$16$YR$$F$Y$$$20250826$$MD$EU$EU
257292761$25729276$1$I$$20250822$20250827$20250827$PER$$US-ELI_LILLY_AND_COMPANY-US202508022970$ELI LILLY AND COMPANY$$60$YR$A$$Y$$$20250827$$CN$US$US
257293001$25729300$1$I$$20250817$20250827$20250827$EXP$$US-SANDOZ INC.-SDZ2025US061716$SANDOZ$$$$$F$Y$$$20250827$$CN$US$US
257293361$25729336$1$I$$20250819$20250827$20250827$PER$$US-JNJFOC-20250822605$JOHNSON AND JOHNSON$$$$$$Y$$$20250827$$CN$US$US
257293532$25729353$2$F$20250101$20250922$20250827$20250926$EXP$$US-REGENERON PHARMACEUTICALS, INC.-2025-134430$REGENERON$$$$$F$Y$$$20250926$$CN$US$US
257294301$25729430$1$I$20250501$20250812$20250827$20250827$PER$$US-ALKERMES INC.-ALK-2025-001900$ALKERMES$$$$$F$Y$$$20250827$$$US$
257294801$25729480$1$I$$20250815$20250827$20250827$EXP$$ZA-ROCHE-10000366133$ROCHE$$$$$$Y$$$20250827$$MD$ZA$ZA
257295101$25729510$1$I$20250822$20250822$20250827$20250827$PER$$US-ELI_LILLY_AND_COMPANY-US202508022734$ELI LILLY AND COMPANY$$52$YR$A$F$Y$$$20250827$$CN$US$US
257295821$25729582$1$I$20241101$20250821$20250827$20250827$EXP$$US-ABBVIE-6021943$ABBVIE$$78$YR$$F$Y$$$20250827$$CN$US$US
257296031$25729603$1$I$$20250820$20250827$20250827$EXP$$US-ROCHE-10000365706$ROCHE$$$$E$F$Y$125.65$KG$20250827$$MD$US$US
257296672$25729667$2$F$$20250728$20250827$20250909$EXP$$GB-ROCHE-10000349938$ROCHE$$$$C$$Y$$$20250904$$MD$GB$GB
257296741$25729674$1$I$20250622$20250818$20250827$20250827$EXP$$EU-CELLTRION INC.-2025LV029641$CELLTRION$$$$$$Y$$$20250827$$MD$EU$EU
257297171$25729717$1$I$20250501$20250820$20250827$20250827$EXP$EU-AFSSAPS-PB2025000932$EU-SAMSUNG BIOEPIS-SB-2025-28356$SAMSUNG BIOEPIS$$39$YR$A$F$Y$$$20250827$$MD$EU$EU
257297291$25729729$1$I$20250729$20250826$20250826$20250826$DIR$FDA-CDER-CTU-2025-57036$$FDA-CTU$$72$YR$$M$N$$$20250826$Y$$US$
257298601$25729860$1$I$20250707$20250820$20250827$20250827$EXP$$US-ASTELLAS-2025-AER-045982$ASTELLAS$$68$YR$E$M$Y$$$20250827$$MD$US$US
257298921$25729892$1$I$20241201$20250821$20250827$20250827$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-007023$JAZZ$$70$YR$$F$Y$$$20250827$$$US$US
257299111$25729911$1$I$$20250816$20250827$20250827$PER$$US-ROCHE-10000374851$ROCHE$Vega P, Newby R, Ignacio R, Fisher C, Oken E, Harbell J, et al. Donor-Derived Tuberculosis in 3 Solid Organ Transplant Recipients From the Same Donor. Open Forum Infectious Diseases. 2025;12 (7):1-6. doi:10.1093/ofid/ofaf372.$$$E$M$Y$$$20250827$$MD$US$US
257299301$25729930$1$I$$20250820$20250827$20250827$PER$$US-SA-2025SA253845$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250827$$CN$US$US
257299701$25729970$1$I$20250101$20250821$20250827$20250827$PER$$US-SA-2025SA255820$SANOFI AVENTIS$$29$YR$A$M$Y$$$20250827$$HP$US$US
257300341$25730034$1$I$$20250821$20250827$20250827$PER$$US-SA-2025SA255297$SANOFI AVENTIS$$64$YR$A$M$Y$$$20250827$$CN$US$US
257300461$25730046$1$I$20250101$20250822$20250827$20250827$PER$$US-SA-2025SA255859$SANOFI AVENTIS$$82$YR$E$F$Y$$$20250827$$HP$US$US
257300611$25730061$1$I$20250101$20250822$20250827$20250827$PER$$US-SA-2025SA256052$SANOFI AVENTIS$$32$YR$A$M$Y$$$20250827$$HP$US$US
257300621$25730062$1$I$$20250825$20250827$20250827$PER$$US-SA-2025SA255525$SANOFI AVENTIS$$$$$M$Y$$$20250827$$MD$US$US
257301401$25730140$1$I$20250618$20250818$20250827$20250827$EXP$EU-AFSSAPS-PV2025000614$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-127694$ZYDUS PHARM$$$$$$Y$$$20250827$$MD$EU$EU
257301501$25730150$1$I$$20250826$20250827$20250827$EXP$$US-ASTRAZENECA-202508USA020878US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250827$$$US$US
257301941$25730194$1$I$20250701$20250826$20250827$20250827$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-118704$BRISTOL-MYERS SQUIBB COMPANY$$61$YR$A$M$Y$$$20250827$$HP$US$US
257302041$25730204$1$I$20250808$20250822$20250827$20250827$EXP$$ID-ROCHE-10000373976$ROCHE$$54$YR$A$M$Y$$$20250827$$CN$ID$ID
257302701$25730270$1$I$$20250512$20250827$20250827$PER$$US-UCBSA-2025028737$UCB$$$$$F$Y$$$20250827$$HP$US$US
257303151$25730315$1$I$20250101$20250822$20250827$20250827$PER$$US-SA-2025SA255274$SANOFI AVENTIS$$43$YR$A$M$Y$$$20250827$$HP$US$US
257305621$25730562$1$I$$20250822$20250827$20250827$PER$$US-SA-2025SA255604$SANOFI AVENTIS$$$$A$M$Y$70.45$KG$20250827$$MD$US$US
257305762$25730576$2$F$$20250828$20250827$20250831$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-118715$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$$$20250901$$CN$US$US
257305821$25730582$1$I$$20250820$20250827$20250827$EXP$EU-FAMHP-DHH-N2025-124960$EU-MYE-2025M1063279AA$MYLAN$$50$YR$$F$Y$63$KG$20250826$$$EU$EU
257306221$25730622$1$I$20250822$20250825$20250825$20250825$DIR$FDA-CDER-CTU-2025-57092$$FDA-CTU$$41$YR$$F$N$59.87$KG$20250825$N$CN$US$
257306231$25730623$1$I$$20250821$20250827$20250827$30DAY$$US-SANDOZ INC.-SDZ2025US060775$SANDOZ$$$$$M$Y$$$20250827$$CN$US$US
257307421$25730742$1$I$20250808$20250815$20250827$20250827$EXP$GB-MHRA-MED-202508150903162790-PKFBM$GB-ELI_LILLY_AND_COMPANY-GB202508016095$ELI LILLY AND COMPANY$$48$YR$A$F$Y$$$20250827$$CN$GB$GB
257308041$25730804$1$I$20250801$20250820$20250827$20250827$PER$$US-SA-2025SA254640$SANOFI AVENTIS$$36$YR$A$M$Y$$$20250827$$HP$US$US
257308751$25730875$1$I$$20250822$20250827$20250827$EXP$$US-OTSUKA-2025_020650$OTSUKA$$$$$M$Y$$$20250827$$CN$US$US
257308911$25730891$1$I$$20250820$20250827$20250827$EXP$$CA-ROCHE-10000370539$ROCHE$$63$YR$A$F$Y$$$20250827$$CN$CA$CA
257309331$25730933$1$I$20250720$20250821$20250827$20250827$EXP$EU-AFSSAPS-DJ2025001382$EU-MYLANLABS-2025M1072324$MYLAN$$58$YR$$F$Y$65$KG$20250827$$MD$EU$EU
257309511$25730951$1$I$20250801$20250826$20250826$20250826$DIR$772077$$FDA-CTU$$56$YR$$F$N$$$20250826$N$$US$
257310011$25731001$1$I$$20250822$20250827$20250827$PER$$US-MALLINCKRODT-MNK202505295$MALLINCKRODT$$73$YR$E$F$Y$$$20250826$$CN$US$US
257310461$25731046$1$I$20250301$20250821$20250827$20250827$EXP$$US-Pharmaand-2025000268$pharmaAND$$67$YR$$M$Y$$$20250827$$CN$US$US
257310792$25731079$2$F$$20250923$20250827$20250925$PER$$US-MALLINCKRODT-MNK202505099$MALLINCKRODT$$54$YR$A$F$Y$$$20250925$$CN$US$US
257310851$25731085$1$I$$20250820$20250827$20250827$PER$$US-MALLINCKRODT-MNK202505200$MALLINCKRODT$$$$$M$Y$$$20250827$$CN$US$US
257311081$25731108$1$I$$20250821$20250827$20250827$EXP$$JP-UCBSA-2025052972$UCB$$$$$$Y$$$20250827$$MD$JP$JP
257311941$25731194$1$I$$20250723$20250827$20250827$PER$$US-ASCENDIS PHARMA-2025US010701$ASCENDIS PHARMA$$$$$$Y$$$20250827$$CN$US$US
257312191$25731219$1$I$$20250820$20250827$20250827$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202508019862$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250827$$CN$JP$JP
257312731$25731273$1$I$$20250818$20250827$20250827$PER$$JP-Eisai-EC-2025-195340$EISAI$Our case study of administering ICI to tumor with high tumor mutational burden (TMB-high) or high microsatellite instability (MSI-high), which were believed to highly express neoantigens.$69$YR$E$F$Y$$$20250827$$MD$JP$JP
257313162$25731316$2$F$20250805$20250826$20250827$20250829$PER$$US-PFIZER INC-202500169874$PFIZER$$43$YR$$F$Y$$$20250829$$PH$US$US
257313901$25731390$1$I$$20250827$20250827$20250827$DIR$772175$$FDA-CTU$$$$$$N$$$20250827$$CN$US$
257314461$25731446$1$I$20250815$20250825$20250827$20250827$EXP$$CN-PFIZER INC-PV202500102871$PFIZER$$70$YR$$M$Y$70$KG$20250827$$HP$CN$CN
257314683$25731468$3$F$20250801$20250901$20250827$20250908$PER$$US-SA-2025SA256136$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250908$$HP$US$US
257314911$25731491$1$I$20250827$20250827$20250827$20250827$DIR$772208$$FDA-CTU$$$$$$N$$$20250827$N$CN$US$
257315411$25731541$1$I$20250815$20250827$20250827$20250827$DIR$772231$$FDA-CTU$$74$YR$$M$N$84.6$KG$20250827$N$CN$US$
257315531$25731553$1$I$20240720$20240724$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-POI1255202400166$RVL PHARMACEUTICALS$$87$YR$E$F$Y$$$20250827$$CN$US$US
257315571$25731557$1$I$20240101$20240727$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-POI1255202400171$RVL PHARMACEUTICALS$$$$A$F$Y$$$20250827$$CN$US$US
257315731$25731573$1$I$20240811$20240815$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-POI1255202400186$RVL PHARMACEUTICALS$$63$YR$A$F$Y$$$20250827$$CN$US$US
257316061$25731606$1$I$20240925$20240926$20250827$20250827$EXP$$US-RVL_Pharmaceuticals-USA-POI1255202400220$RVL PHARMACEUTICALS$$78$YR$E$F$Y$$$20250827$$CN$US$US
257316741$25731674$1$I$20250101$20250128$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500020$RVL PHARMACEUTICALS$$$$A$F$Y$$$20250827$$CN$US$US
257316781$25731678$1$I$20250101$20250204$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500025$RVL PHARMACEUTICALS$$74$YR$E$F$Y$$$20250827$$CN$US$US
257316861$25731686$1$I$20250204$20250210$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500033$RVL PHARMACEUTICALS$$60$YR$A$F$Y$$$20250827$$CN$US$US
257317131$25731713$1$I$20250318$20250318$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500062$RVL PHARMACEUTICALS$$36$YR$A$M$Y$$$20250827$$CN$US$US
257317291$25731729$1$I$20250401$20250411$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500079$RVL PHARMACEUTICALS$$$$A$F$Y$$$20250827$$CN$US$US
257317301$25731730$1$I$20250401$20250421$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500080$RVL PHARMACEUTICALS$$64$YR$A$F$Y$$$20250827$$CN$US$US
257317341$25731734$1$I$$20250422$20250827$20250827$PER$$US-RVL_Pharmaceuticals-USA-ALL1255202500085$RVL PHARMACEUTICALS$$$$A$M$Y$$$20250827$$CN$US$US
257318661$25731866$1$I$20250624$20250821$20250827$20250827$EXP$$CN-DSJP-DS-2025-160683-CN$DAIICHI$$60$YR$$F$Y$51$KG$20250827$$HP$CN$CN
257318691$25731869$1$I$20250401$20250825$20250827$20250827$PER$$US-ABBVIE-6432877$ABBVIE$$75$YR$$F$Y$54.43$KG$20250827$$CN$US$US
257319041$25731904$1$I$20210325$20250822$20250827$20250827$EXP$EU-URPL-DML-MLP.4401.1.2918.2021$EU-TEVA-VS-3365597$TEVA$$80$YR$$M$Y$$$20250827$$MD$EU$EU
257320161$25732016$1$I$$20250821$20250827$20250827$PER$$US-SA-2025SA256328$SANOFI AVENTIS$$$$T$M$Y$$$20250827$$HP$US$US
257320523$25732052$3$F$$20250902$20250827$20250902$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-118769$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250902$$CN$US$US
257320891$25732089$1$I$20250101$20250814$20250827$20250827$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI10867$NEUROCRINE BIOSCIENCES$$$$$F$Y$$$20250827$$MD$US$US
257321091$25732109$1$I$20250101$20250821$20250827$20250827$EXP$EU-LRB-01080003$EU-009507513-2322210$MERCK SHARP + DOHME LLC$$67$YR$$F$Y$90$KG$20250827$$MD$EU$EU
257321411$25732141$1$I$$20250827$20250827$20250827$DIR$772262$$FDA-CTU$$$$$$N$$$20250827$N$$US$
257321491$25732149$1$I$20250827$20250827$20250827$20250827$DIR$772260$$FDA-CTU$$35$YR$$F$N$63$KG$20250827$N$HP$US$
257321871$25732187$1$I$$20250819$20250827$20250827$EXP$$US-NOVOPROD-1505248$NOVO NORDISK$$$$$F$Y$$$20250827$$HP$US$US
257322664$25732266$4$F$$20250925$20250827$20250929$30DAY$$CO-PFIZER INC-PV202500099179$PFIZER$$$$$F$Y$$$20250929$$CN$CO$CO
257324271$25732427$1$I$20240711$20250819$20250827$20250827$PER$$KR-Eisai-EC-2025-195345$EISAI$$62$YR$A$M$Y$61.95$KG$20250827$$PH$KR$KR
257324721$25732472$1$I$20250501$20250818$20250827$20250827$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-091742$BOEHRINGER INGELHEIM$$55$YR$A$F$Y$$$20250827$$$US$US
257325081$25732508$1$I$20250701$20250826$20250827$20250827$PER$$US-PURDUE-USA-2025-0320004$PURDUE$$19$YR$$$Y$$$20250827$$CN$US$US
257325591$25732559$1$I$$20250819$20250827$20250827$PER$$US-INCYTE CORPORATION-2025IN009066$INCYTE$$72$YR$$$Y$$$20250827$$$US$
257326931$25732693$1$I$20250815$20250820$20250827$20250827$PER$$US-BAUSCHBL-2025BNL014838$BAUSCH AND LOMB$$$$$$Y$$$20250828$$CN$US$US
257327362$25732736$2$F$20250820$20250925$20250827$20250930$EXP$$JP-ORGANON-O2508JPN001977$ORGANON$$$$$F$Y$$$20250930$$MD$JP$
257329991$25732999$1$I$20250715$20250819$20250828$20250828$EXP$EU-AEMPS-1742639$EU-TEVA-VS-3365013$TEVA$$64$YR$$F$Y$$$20250828$$MD$EU$EU
257332751$25733275$1$I$20250822$20250822$20250828$20250828$30DAY$$US-SANDOZ INC.-SDZ2025US061316$SANDOZ$$14$YR$$M$Y$$$20250828$$CN$US$US
257333081$25733308$1$I$$20250820$20250828$20250828$EXP$$NVSC2025VN133029$NOVARTIS$$$$$F$Y$$$20250828$$MD$VN$VN
257334101$25733410$1$I$$20250822$20250828$20250828$EXP$$US-ABBVIE-6046220$ABBVIE$$$$A$F$Y$$$20250828$$CN$US$US
257334191$25733419$1$I$$20250820$20250828$20250828$PER$$US-ABBVIE-6430424$ABBVIE$$72$YR$$F$Y$$$20250828$$MD$US$US
257334871$25733487$1$I$$20240617$20250828$20250828$EXP$$CA-SANDOZ INC.-SDZ2024CA108062$SANDOZ$$44$YR$$M$Y$$$20250828$$HP$CA$CA
257336001$25733600$1$I$20250701$20250818$20250828$20250828$EXP$GB-MHRA-MED-202508121607342570-KZCYJ$GB-STRIDES NORDIC APS-2025SP010852$STRIDES$$28$YR$$F$Y$$$20250828$$HP$GB$GB
257336021$25733602$1$I$$20250827$20250828$20250828$EXP$$US-JNJFOC-20250833313$JOHNSON AND JOHNSON$$$$$F$Y$$$20250828$$HP$US$US
257336111$25733611$1$I$$20250821$20250828$20250828$EXP$$US-JNJFOC-20250826852$JOHNSON AND JOHNSON$$$$$$Y$$$20250828$$CN$US$US
257337361$25733736$1$I$$20250820$20250828$20250828$EXP$$JP-Taiho Oncology Inc-2025-008843$TAIHO ONCOLOGY INC$$65$YR$E$M$Y$$$20250828$$MD$JP$JP
257337561$25733756$1$I$$20250820$20250828$20250828$PER$$US-ELI_LILLY_AND_COMPANY-US202508019919$ELI LILLY AND COMPANY$$73$YR$E$M$Y$$$20250828$$CN$US$US
257339351$25733935$1$I$$20250819$20250828$20250828$EXP$US-MLMSERVICE-20180305-1093453-1$US-RDY-USA/USA/18/0096977$DR REDDYS$Benson BC, Schwake JW. Disseminated histoplasmosis diagnosed on routine outpatient endoscopy. American Journal of Gastroenterology. 2017;112(1): S796. doi:10.1038/ ajg.2017.312..$58$YR$A$F$Y$$$20250828$$HP$US$US
257339431$25733943$1$I$20250801$20250821$20250828$20250828$PER$$US-ELI_LILLY_AND_COMPANY-US202508021966$ELI LILLY AND COMPANY$$60$YR$A$$Y$$$20250828$$CN$US$US
257339461$25733946$1$I$$20250823$20250828$20250828$PER$$US-ELI_LILLY_AND_COMPANY-US202508025459$ELI LILLY AND COMPANY$$$$$$Y$$$20250828$$CN$US$US
257339681$25733968$1$I$$20250814$20250828$20250828$PER$$US-KENVUE-20250807659$Kenvue$$$$$M$Y$$$20250828$$CN$US$US
257340831$25734083$1$I$20250501$20250816$20250828$20250828$EXP$GB-MHRA-MED-202508160648441220-VWQSY$GB-862174955-ML2025-04275$Unknown Manufacturer$$$$$F$Y$$$20250828$$CN$GB$GB
257340921$25734092$1$I$20241106$20250825$20250828$20250828$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-118095$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$$$20250828$$HP$US$US
257340991$25734099$1$I$$20250807$20250828$20250828$30DAY$$US-BECTON DICKINSON-US-BD-25-000417$BECTON DICKINSON$$$$$$Y$$$20250828$$CN$US$US
257341521$25734152$1$I$$20250811$20250828$20250828$PER$$US-KENVUE-20250804787$Kenvue$$$$$F$Y$$$20250828$$CN$US$US
257342081$25734208$1$I$20250101$20250819$20250828$20250828$EXP$$CA-CELLTRION INC.-2025CA030484$CELLTRION$$$$$$Y$$$20250828$$HP$CA$CA
257342841$25734284$1$I$$20250818$20250828$20250828$EXP$$US-ASCENDIS PHARMA-2025US011158$ASCENDIS PHARMA$$$$$$Y$$$20250828$$CN$US$US
257343691$25734369$1$I$$20250730$20250828$20250828$PER$$US-KENVUE-20250809521$Kenvue$$$$$M$Y$$$20250828$$CN$US$US
257344321$25734432$1$I$$20250822$20250828$20250828$PER$$US-ELI_LILLY_AND_COMPANY-US202508022793$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250828$$CN$US$US
257344981$25734498$1$I$$20250813$20250828$20250828$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-524811$RANBAXY$Negreira-Caamano M, Marco- Delcastillo A, Martin-Asenjo R, Ramos-Jimenez J, Rajjoub EA, Borrego-Bernabe L, et al. Single-center experience with quinidine for patients with electrical storm due to ventricular arrhythmias associated with short-coupled premature ventricular contractions. Europace. 2025;27(suppl)1:i1232$60$YR$$M$Y$$$20250828$$HP$EU$EU
257345381$25734538$1$I$$20250816$20250828$20250828$EXP$$EU-AUROBINDO-AUR-APL-2025-043524$AUROBINDO$$34$YR$$M$Y$$$20250828$$HP$EU$EU
257346821$25734682$1$I$$20250827$20250827$20250827$DIR$FDA-CDER-CTU-2025-57416$$FDA-CTU$$58$YR$$F$N$$$20250827$N$$US$
257347191$25734719$1$I$$20250825$20250828$20250828$EXP$$US-ABBVIE-6433118$ABBVIE$$$$E$F$Y$$$20250828$$CN$US$US
257347321$25734732$1$I$20250101$20250818$20250828$20250828$PER$$US-ORGANON-O2508USA001773$ORGANON$$$$$F$Y$$$20250828$$CN$US$US
257347341$25734734$1$I$20240809$20250820$20250828$20250828$EXP$$IN-AstraZeneca-2024A182976$MERCK SHARP + DOHME LLC$$40$YR$$F$Y$57$KG$20250828$$MD$IN$IN
257347592$25734759$2$F$$20250818$20250828$20250828$PER$$US-GSK-US2025AMR108668$GLAXOSMITHKLINE$$$$$$Y$$$20250828$$$US$US
257349811$25734981$1$I$20250718$20250818$20250828$20250828$EXP$GB-MHRA-MED-202508131912389510-YDQLN$GB-STRIDES NORDIC APS-2025SP010869$STRIDES$$67$YR$$M$Y$75$KG$20250828$$CN$GB$GB
257350171$25735017$1$I$$20250821$20250828$20250828$PER$$US-ROCHE-10000372128$ROCHE$$$$$M$Y$$$20250828$$MD$US$US
257350642$25735064$2$F$$20250904$20250828$20250910$PER$$US-MALLINCKRODT-MNK202505334$MALLINCKRODT$$$$$M$Y$$$20250909$$CN$US$US
257351641$25735164$1$I$20250801$20250825$20250828$20250828$EXP$$CO-BAYER-2025A113448$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$M$Y$$$20250828$$CN$CO$CO
257351891$25735189$1$I$20250701$20250825$20250828$20250828$EXP$$US-ABBVIE-6434817$ABBVIE$$65$YR$$M$Y$$$20250828$$CN$US$US
257351981$25735198$1$I$$20250827$20250828$20250828$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-119302$BRISTOL-MYERS SQUIBB COMPANY$$39$YR$A$F$Y$$$20250828$$HP$US$US
257352631$25735263$1$I$$20250827$20250828$20250828$EXP$$US-INCYTE CORPORATION-2025IN009327$INCYTE$$54$YR$$$Y$$$20250828$$$US$US
257353001$25735300$1$I$$20250819$20250828$20250828$EXP$$JP-AMGEN-JPNSP2025166104$AMGEN$$$$$$Y$$$20250828$$PH$JP$JP
257353301$25735330$1$I$$20250825$20250828$20250828$PER$$US-JNJFOC-20250832743$JOHNSON AND JOHNSON$$$$$$Y$$$20250828$$MD$US$US
257353701$25735370$1$I$$20250818$20250828$20250828$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-07706$LUPIN$$$$$$Y$$$20250828$$$US$US
257354231$25735423$1$I$20250827$20250827$20250827$20250827$DIR$FDA-CDER-CTU-2025-57567$$FDA-CTU$$30$YR$$M$N$72.57$KG$20250827$Y$$PR$
257355052$25735505$2$F$$20250908$20250828$20250922$EXP$$EU-TEVA-VS-3364921$TEVA$Taborsky J, Mickal T, Kolman P, Kraus L, Strelka M, Kamler A, et al. HAEMODIALYSIS-RESISTANT DABIGATRAN INTOXICATION. Eur-J-Case-Rep-Intern-Med 2024; 11 (Suppl. 1) 236 abstr. 0129.; Taborsky J, Mickal T, Kolman P, Kraus L, Strelka M, Kamler A, et al. HAEMODIALYSIS-RESISTANT DABIGATRAN INTOXICATION. Eur-J-Case-Rep-Intern-Med 2024; 11 (Suppl. 1) 236 abstr. 0129.$63$YR$$F$Y$$$20250916$$HP$EU$EU
257355201$25735520$1$I$$20250620$20250828$20250828$30DAY$$US-SANDOZ INC.-SDZ2025US062398$SANDOZ$$$$$$Y$$$20250828$$HP$US$US
257355751$25735575$1$I$$20250828$20250828$20250828$DIR$FDA-CDER-CTU-2025-57609$$FDA-CTU$$51$YR$$F$N$$$20250828$N$$US$
257356021$25735602$1$I$20250701$20250808$20250828$20250828$PER$$US-THERATECHNOLOGIES INC.-2025-THE-TES-000213$THERATECHNOLOGIES$$$$$$Y$$$20250826$$CN$US$US
257356031$25735603$1$I$20250601$20250728$20250828$20250828$PER$$US-THERATECHNOLOGIES INC.-2025-THE-TES-000171$Unknown Manufacturer$$$$$$Y$$$20250826$$CN$US$US
257356301$25735630$1$I$20250827$20250828$20250828$20250828$DIR$772368$$FDA-CTU$$$$$$N$$$20250828$N$CN$US$
257356331$25735633$1$I$20250816$20250819$20250828$20250828$PER$$US-THERATECHNOLOGIES INC.-2025-THE-TES-000225$THERATECHNOLOGIES$$$$$$Y$$$20250826$$CN$US$US
257356911$25735691$1$I$20250819$20250819$20250828$20250828$EXP$$IN-ROCHE-10000369565$ROCHE$$64$YR$A$F$Y$$$20250828$$CN$IN$IN
257357111$25735711$1$I$$20250828$20250828$20250828$DIR$772382$$FDA-CTU$$$$$$N$$$20250828$N$CN$US$
257357361$25735736$1$I$20250702$20250828$20250828$20250828$DIR$772406$$FDA-CTU$$52$YR$$F$N$98$KG$20250828$Y$PH$US$
257357411$25735741$1$I$20250701$20250827$20250828$20250828$PER$$US-009507513-2324020$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250828$$CN$US$US
257357991$25735799$1$I$20250101$20250825$20250828$20250828$PER$$US-PFIZER INC-PV202500102970$PFIZER$$39$YR$$F$Y$$$20250828$$HP$US$US
257358751$25735875$1$I$20250225$20250820$20250828$20250828$EXP$GB-MHRA-MED-202508200837137650-MZPRC$GB-TORRENT-00042509$TORRENT PHARMA INC.$$25$YR$A$M$Y$$$20250828$$CN$GB$GB
257359292$25735929$2$F$$20250903$20250828$20250915$EXP$$US-TEVA-VS-3364400$TEVA$Valpey R, Hale E, Kratzer I. Psychiatric Implications and Treatments for Patients Undergoing Treatment of Breast Cancer. Adv-Psychiatry-Behav-Health 2025; 5 (1): 103-116.; Valpey R, Hale E, Kratzer I. Psychiatric Implications and Treatments for Patients Undergoing Treatment of Breast Cancer. Adv-Psychiatry-Behav-Health 2025; 5 (1): 103-116.$40$YR$$F$Y$$$20250915$$MD$US$US
257359732$25735973$2$F$$20250910$20250828$20250915$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009565$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250915$$CN$US$US
257360341$25736034$1$I$20231114$20250304$20250828$20250828$PER$$US-THERATECHNOLOGIES INC.-2025-THE-IBA-000056$Unknown Manufacturer$$$$$$Y$$$20250828$$HP$US$US
257361041$25736104$1$I$$20250820$20250828$20250828$PER$$US-SA-2025SA254453$SANOFI AVENTIS$$$$A$M$Y$$$20250828$$HP$US$US
257361581$25736158$1$I$20250801$20250822$20250828$20250828$PER$$US-SA-2025SA256465$SANOFI AVENTIS$$69$YR$E$M$Y$$$20250828$$HP$US$US
257362211$25736221$1$I$20250101$20250822$20250828$20250828$PER$$US-SA-2025SA256987$SANOFI AVENTIS$$56$YR$A$F$Y$$$20250828$$HP$US$US
257362491$25736249$1$I$$20250822$20250828$20250828$PER$$US-SA-2025SA256458$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250828$$CN$US$US
257362621$25736262$1$I$20250101$20250822$20250828$20250828$PER$$US-SA-2025SA255836$SANOFI AVENTIS$$82$YR$E$M$Y$$$20250828$$HP$US$US
257362731$25736273$1$I$20250101$20250822$20250828$20250828$PER$$US-SA-2025SA256470$SANOFI AVENTIS$$$$A$F$Y$$$20250828$$HP$US$US
257363411$25736341$1$I$$20250825$20250828$20250828$PER$$US-SA-2025SA257265$SANOFI AVENTIS$$2$YR$C$M$Y$$$20250828$$CN$US$US
257363541$25736354$1$I$20250101$20250827$20250828$20250828$PER$$US-SA-2025SA257551$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250828$$CN$US$US
257364061$25736406$1$I$20250101$20250825$20250828$20250828$PER$$US-SA-2025SA257113$SANOFI AVENTIS$$6$YR$C$F$Y$$$20250828$$HP$US$US
257365141$25736514$1$I$$20250828$20250828$20250828$DIR$FDA-CDER-CTU-2025-57638$$FDA-CTU$$36$YR$$F$N$185$LBS$20250828$N$$US$
257366141$25736614$1$I$20240815$20250819$20250828$20250828$EXP$$US-SA-2025SA251065$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250828$$CN$US$US
257366321$25736632$1$I$$20250825$20250828$20250828$PER$$JP-Eisai-EC-2025-195612$EISAI$$$$$F$Y$$$20250828$$MD$JP$JP
257368221$25736822$1$I$$20250821$20250828$20250828$EXP$$CA-ROCHE-10000370622$ROCHE$$40$YR$A$F$Y$$$20250828$$HP$CA$CA
257368302$25736830$2$F$$20250828$20250828$20250829$EXP$$US-JNJFOC-20250834014$JOHNSON AND JOHNSON$$$$$M$Y$$$20250829$$HP$US$US
257368832$25736883$2$F$20250213$20250826$20250828$20250923$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US000937$DECIPHERA PHARMACEUTICALS$$77$YR$E$F$Y$$$20250923$$CN$US$US
257370062$25737006$2$F$$20250909$20250828$20250912$30DAY$$CO-PFIZER INC-202500170623$PFIZER$$$$T$F$Y$$$20250912$$CN$CO$CO
257371952$25737195$2$F$20250101$20250826$20250828$20250904$EXP$$US-UCBSA-2025051876$UCB$$$$$F$Y$$$20250904$$HP$US$US
257372241$25737224$1$I$$20250821$20250828$20250828$EXP$$US-EMD Serono-2024061640$EMD SERONO INC$$$$E$F$Y$$$20250828$$$US$US
257373181$25737318$1$I$$20250827$20250828$20250828$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-119456$BRISTOL-MYERS SQUIBB COMPANY$$52$YR$A$F$Y$$$20250828$$HP$US$US
257375111$25737511$1$I$$20250826$20250828$20250828$EXP$$JP-TAKEDA-2025TJP004632$TAKEDA$$9$DEC$$F$Y$$$20250828$$MD$JP$JP
257376711$25737671$1$I$$20250820$20250828$20250828$PER$$US-ABBVIE-6428022$ABBVIE$$$$E$M$Y$$$20250828$$CN$US$US
257376931$25737693$1$I$20240101$20241004$20250828$20250828$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-20241000827$COLLEGIUM PHARMACEUTICAL$$$$$$Y$$$20250828$$CN$US$US
257377731$25737773$1$I$$20250529$20250828$20250828$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-20250602189$COLLEGIUM PHARMACEUTICAL$$$$$M$Y$$$20250828$$CN$US$US
257378001$25737800$1$I$$20250806$20250828$20250828$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-20250802429$COLLEGIUM PHARMACEUTICAL$$$$A$M$Y$$$20250828$$MD$US$US
257378021$25737802$1$I$20250501$20250807$20250828$20250828$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-20250802431$COLLEGIUM PHARMACEUTICAL$$6$YR$$M$Y$$$20250828$$HP$US$US
257378571$25737857$1$I$$20241030$20250828$20250828$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-20241000997$COLLEGIUM PHARMACEUTICAL$$$$T$$Y$$$20250828$$HP$US$US
257379731$25737973$1$I$20250228$20250820$20250829$20250829$EXP$$CA-JNJFOC-20250314207$JOHNSON AND JOHNSON$$66$YR$E$F$Y$$$20250829$$HP$CA$CA
257379832$25737983$2$F$$20250918$20250829$20250923$30DAY$$US-JNJFOC-20250820743$JOHNSON AND JOHNSON$$$$$$Y$$$20250923$$HP$US$US
257380661$25738066$1$I$20250101$20250821$20250829$20250829$EXP$$US-GALDERMA-US2025015884$GALDERMA$$$$$$Y$$$20250829$$CN$US$US
257380811$25738081$1$I$$20250825$20250829$20250829$30DAY$$US-SANDOZ INC.-SDZ2025US061806$SANDOZ$$$$$M$Y$$$20250829$$HP$US$US
257380872$25738087$2$F$$20250912$20250829$20250922$EXP$$JP-AMGEN-JPNSP2025171390$AMGEN$$90$YR$E$F$Y$$$20250921$$PH$JP$JP
257381831$25738183$1$I$$20250828$20250829$20250829$EXP$$US-ROCHE-10000376327$ROCHE$$75$YR$E$M$Y$$$20250829$$CN$US$US
257382631$25738263$1$I$$20250203$20250829$20250829$EXP$$EU-ALKEM LABORATORIES LIMITED-DE-ALKEM-2025-01226$ALKEM$$$$$F$Y$$$20250828$$CN$EU$EU
257383002$25738300$2$F$$20250821$20250829$20250901$EXP$$US-SANDOZ INC.-SDZ2025US061304$SANDOZ$$$$$F$Y$58.513$KG$20250901$$CN$US$US
257384271$25738427$1$I$20250731$20250816$20250829$20250829$EXP$$EU-AUROBINDO-AUR-APL-2025-043528$AUROBINDO$$39$YR$$F$Y$$$20250829$$PH$EU$EU
257384281$25738428$1$I$20250701$20250819$20250829$20250829$EXP$EU-MINISAL02-1051662$EU-CELLTRION INC.-2025IT029799$CELLTRION$$$$$$Y$$$20250829$$MD$EU$EU
257384341$25738434$1$I$20250615$20250816$20250829$20250829$EXP$$EU-AUROBINDO-AUR-APL-2025-043517$AUROBINDO$$19$YR$$M$Y$85$KG$20250829$$PH$EU$EU
257384511$25738451$1$I$$20250816$20250829$20250829$EXP$$GB-MHRA-MED-202508161936169520-DZLMQ$AUROBINDO$$$$$F$Y$$$20250829$$CN$GB$GB
257384681$25738468$1$I$20250601$20250826$20250829$20250829$EXP$$CA-ABBVIE-6435369$ABBVIE$$76$YR$$M$Y$$$20250829$$CN$CA$CA
257384781$25738478$1$I$20250701$20250714$20250829$20250829$PER$$US-MDD US Operations-MDD202507-002612$MDD OPERATIONS$$67$YR$$F$Y$$$20250829$$CN$US$US
257385301$25738530$1$I$$20250827$20250829$20250829$PER$$US-JNJFOC-20250834185$JOHNSON AND JOHNSON$$$$$F$Y$$$20250829$$CN$US$US
257385372$25738537$2$F$20250801$20250905$20250829$20250911$EXP$$US-SA-2025SA253958$SANOFI AVENTIS$$62$YR$A$M$Y$126.53$KG$20250911$$HP$US$US
257385991$25738599$1$I$$20250818$20250829$20250829$EXP$$CA-ROCHE-10000373736$ROCHE$$64$YR$A$F$Y$$$20250829$$HP$CA$CA
257387361$25738736$1$I$20250201$20250309$20250829$20250829$PER$$US-COLGATE PALMOLIVE COMPANY-20250300318$COLGATE$$54$YR$$M$Y$$$20250829$$CN$US$US
257388292$25738829$2$F$$20250825$20250829$20250901$EXP$$US-ABBVIE-6433810$ABBVIE$$$$A$F$Y$$$20250901$$CN$US$US
257388791$25738879$1$I$$20250826$20250829$20250829$PER$$US-ELI_LILLY_AND_COMPANY-US202508027338$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250829$$CN$US$US
257389231$25738923$1$I$20250819$20250820$20250829$20250829$PER$$US-APOTEX-2025AP012042$APOTEX$$55$YR$A$F$Y$$$20250829$$CN$US$US
257389361$25738936$1$I$20250801$20250825$20250829$20250829$PER$$US-ABBVIE-6433859$ABBVIE$$60$YR$$F$Y$$$20250829$$CN$US$US
257389891$25738989$1$I$$20250826$20250829$20250829$EXP$$GB-TAKEDA-2025TUS076285$TAKEDA$$$$$M$Y$$$20250829$$$GB$GB
257389901$25738990$1$I$20250701$20250825$20250829$20250829$EXP$$US-ABBVIE-6433889$ABBVIE$$32$YR$$F$Y$$$20250829$$CN$US$US
257389951$25738995$1$I$20250619$20250828$20250829$20250829$PER$$US-ASTRAZENECA-202507USA010011US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250829$$$US$US
257390231$25739023$1$I$$20250825$20250829$20250829$EXP$$US-ABBVIE-6434430$ABBVIE$$$$E$M$Y$$$20250829$$CN$US$US
257390261$25739026$1$I$$20250817$20250829$20250829$EXP$$IN-Adaptis Pharma Private Limited-2183446$ADAPTIS PHARMA INDIA$Bansal A, Saini B, Rai H, Dhillon JS, Bansal P, Saini S. Dependence on ultra-high doses of gabapentinoids: A case series. Indian J Psychiatry. 2025 Jul;67(7):721-724. doi: 10.4103/indianjpsychiatry_297_25. Epub 2025 Jul 15. PMID: 40786226$48$YR$$M$Y$104$KG$20250829$$$IN$IN
257390761$25739076$1$I$$20250805$20250829$20250829$PER$$US-GALDERMA-US2025014280$GALDERMA$$$$$$Y$$$20250829$$CN$US$US
257390861$25739086$1$I$$20250825$20250829$20250829$EXP$$US-ABBVIE-6433213$ABBVIE$$$$A$F$Y$$$20250829$$CN$US$US
257391051$25739105$1$I$20250101$20250820$20250829$20250829$EXP$$US-JNJFOC-20250824363$JOHNSON AND JOHNSON$$58$YR$A$F$Y$$$20250829$$CN$US$US
257392801$25739280$1$I$$20250826$20250829$20250829$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009620$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250829$$CN$US$US
257393481$25739348$1$I$$20250818$20250829$20250829$EXP$$EU-ASTRAZENECA-202508EEA021696IT$ALEXION PHARMACEUTICALS$$$$T$M$Y$$$20250829$$$EU$EU
257393761$25739376$1$I$$20250821$20250829$20250829$EXP$$CA-CELLTRION INC.-2025CA030538$CELLTRION$$$$$$Y$$$20250829$$HP$CA$CA
257393921$25739392$1$I$$20250814$20250829$20250829$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-524637$RANBAXY$Kwiatkowski F, Lubinski M, Kowalski P, Walecka-Kapica E, Gasiorowska A, Majos A. Rare complications of Crohn^s disease - a series of three cases. Pol J Radiol. 2025;90(0):e367-e373$54$YR$$F$Y$$$20250829$$HP$EU$EU
257394261$25739426$1$I$20231119$20250814$20250829$20250829$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-524863$RANBAXY$$57$YR$$F$Y$$$20250829$$MD$EU$EU
257394431$25739443$1$I$20250815$20250816$20250829$20250829$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-524452$RANBAXY$$59$YR$$F$Y$68$KG$20250829$$CN$GB$GB
257394731$25739473$1$I$20250810$20250801$20250829$20250829$PER$$US-KENVUE-20250801301$Kenvue$$$$$$Y$$$20250829$$CN$US$US
257394831$25739483$1$I$$20250825$20250829$20250829$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009608$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250829$$CN$US$US
257394981$25739498$1$I$20250801$20250819$20250829$20250829$PER$$US-SMPA-2025SPA010792$SUNOVION$$88$YR$$F$Y$$$20250826$$$US$US
257395321$25739532$1$I$$20250822$20250829$20250829$EXP$$CA-TAKEDA-2022TUS031103$TAKEDA$$$$$M$Y$$$20250829$$$CA$CA
257396631$25739663$1$I$20250601$20250811$20250829$20250829$PER$$US-Eisai-EC-2025-194933$EISAI$$$$$$Y$$$20250829$$$US$US
257397341$25739734$1$I$20250808$20250822$20250829$20250829$EXP$$JP-BEH-2025217299$CSL BEHRING$$84$YR$E$M$Y$$$20250829$$HP$JP$JP
257397971$25739797$1$I$$20250826$20250829$20250829$PER$$US-GILEAD-2025-0726108$GILEAD$$56$YR$A$F$Y$$$20250829$$CN$US$US
257398111$25739811$1$I$20250825$20250828$20250828$20250828$DIR$FDA-CDER-CTU-2025-57713$$FDA-CTU$$73$YR$$M$N$$$20250828$N$$US$
257398461$25739846$1$I$$20250819$20250829$20250829$PER$$US-ELI_LILLY_AND_COMPANY-US202508019526$ELI LILLY AND COMPANY$$$$$$Y$$$20250829$$CN$US$US
257398511$25739851$1$I$$20250819$20250829$20250829$PER$$US-ELI_LILLY_AND_COMPANY-US202508021091$ELI LILLY AND COMPANY$$81$YR$E$$Y$$$20250829$$CN$US$US
257399651$25739965$1$I$20250101$20250825$20250829$20250829$EXP$$CA-ABBVIE-6433211$ABBVIE$$39$YR$$M$Y$$$20250829$$CN$CA$CA
257400511$25740051$1$I$$20250820$20250829$20250829$EXP$$US-MYLANLABS-2025M1073089$MYLAN$Mittman A, Busse W. Primary Ciliary Dyskinesia with subsequent Allergic Bronchopulmonary Mycosis. J-Allergy-Clin-Immunol 2025; 155 (Suppl.) (2): AB440.$19$YR$$F$Y$$$20250829$$MD$US$US
257400551$25740055$1$I$$20250821$20250829$20250829$EXP$$CN-MYLANLABS-2025M1073239$MYLAN$Yang X, Fang S, Liu Y, Li J, Kuang W. Case report: Epistaxis with electroconvulsive therapy: A report of 2 patients. Front-Psychiatry 2025; 16.$20$YR$$F$Y$$$20250829$$$CN$CN
257400821$25740082$1$I$$20250818$20250829$20250829$PER$$US-ANIPHARMA-024288$ANI$$$$$F$Y$$$20250829$$CN$US$US
257401131$25740113$1$I$$20250823$20250829$20250829$PER$$US-ROCHE-10000372421$ROCHE$$$$E$F$Y$$$20250829$$HP$US$US
257401741$25740174$1$I$$20250819$20250829$20250829$EXP$$US-KENVUE-20250807639$Kenvue$$$$$$Y$$$20250829$$CN$US$US
257401891$25740189$1$I$20250807$20250815$20250829$20250829$EXP$$CN-Hisun Pharmaceuticals USA Inc.-000648$HISUN PHARMACEUTICALS USA INC$$65$YR$E$F$Y$61$KG$20250829$$HP$CN$CN
257401901$25740190$1$I$$20250819$20250829$20250829$PER$$US-ROCHE-10000369287$ROCHE$$$$$$Y$$$20250829$$CN$US$US
257402832$25740283$2$F$$20250908$20250829$20250909$EXP$$US-ABBVIE-6435219$ABBVIE$$$$E$M$Y$$$20250909$$CN$US$US
257402941$25740294$1$I$20250628$20250828$20250828$20250828$DIR$772460$$FDA-CTU$$61$YR$$M$N$$$20250828$N$PH$US$
257405171$25740517$1$I$$20250825$20250829$20250829$EXP$$AU-PFIZER INC-PV202500103229$PFIZER$Liyanage, D.. Severe Bradyarrhythmia and Reduced Cardiac Output Due to Oral Baclofen Withdrawal in a 24-Year Old Man: A Case Report. American Journal of Case Reports. 2025;26$24$YR$$M$Y$$$20250829$$HP$AU$AU
257406691$25740669$1$I$20250701$20250825$20250829$20250829$PER$$US-SA-2025SA257379$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250829$$HP$US$US
257407101$25740710$1$I$$20250826$20250829$20250829$PER$$US-SA-2025SA258590$SANOFI AVENTIS$$44$YR$A$F$Y$66$KG$20250829$$CN$US$US
257407241$25740724$1$I$$20250822$20250829$20250829$EXP$$EU-MYLANLABS-2025M1072646$MYLAN$Ardigo M, Flenghi L, Ibatici A, Massone C, Quaglino P, Teoli M et al. Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy. Ital J Dermatol Venerol. 2025;160(2):97-108.$$$A$F$Y$$$20250829$$MD$EU$EU
257408061$25740806$1$I$20250821$20250825$20250829$20250829$PER$$US-SA-2025SA258157$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250829$$HP$US$US
257408142$25740814$2$F$20250501$20250901$20250829$20250903$PER$$US-SA-2025SA257759$SANOFI AVENTIS$$6$YR$C$M$Y$$$20250903$$MD$US$US
257409131$25740913$1$I$20250801$20250826$20250829$20250829$PER$$US-SA-2025SA258589$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250829$$HP$US$US
257410621$25741062$1$I$20250730$20250821$20250829$20250829$EXP$$US-ARDELYX-2025ARDX006422$ARDELYX$$26$YR$$F$Y$$$20250829$$HP$US$US
257410701$25741070$1$I$20241005$20241008$20250829$20250829$PER$$US-CIPLA LTD.-2024US11738$CIPLA$$$$$$Y$$$20250829$$CN$US$US
257411361$25741136$1$I$20250401$20250825$20250829$20250829$EXP$EU-INFARMED-V202508-439$EU-SANDOZ INC.-SDZ2025PT062246$SANDOZ$$64$YR$$F$Y$$$20250829$$PH$EU$EU
257411981$25741198$1$I$$20250825$20250829$20250829$PER$$US-SA-2025SA257649$SANOFI AVENTIS$$$$E$M$Y$$$20250829$$HP$US$US
257412241$25741224$1$I$20240812$20250829$20250829$20250829$EXP$EU-JNJFOC-20250836682$EU-JNJFOC-20250836682$JOHNSON AND JOHNSON$$74$YR$E$M$Y$$$20250829$$PH$EU$EU
257412501$25741250$1$I$$20250829$20250829$20250829$DIR$FDA-CDER-CTU-2025-57891$$FDA-CTU$$66$YR$$F$N$$$20250829$N$CN$US$
257412611$25741261$1$I$$20250819$20250829$20250829$EXP$$CA-NOVOPROD-1506366$NOVO NORDISK$$$$$$Y$71.2$KG$20250829$$CN$CA$CA
257413251$25741325$1$I$20250723$20250821$20250829$20250829$EXP$$US-NOVOPROD-1507188$NOVO NORDISK$$74$YR$$F$Y$$$20250829$$CN$US$US
257413801$25741380$1$I$20250821$20250821$20250829$20250829$PER$$US-BRACCO-2025US05784$BRACCO$$64$YR$$M$Y$$$20250829$$CN$US$US
257414572$25741457$2$F$20250101$20250917$20250829$20250926$PER$$US-MALLINCKRODT-MNK202505139$MALLINCKRODT$$$$$M$Y$$$20250926$$CN$US$US
257414681$25741468$1$I$20250818$20250825$20250829$20250829$EXP$$US-Blueprint Medicines Corporation-2025-AER-01875$BLUEPRINT MEDICINES$$44$YR$A$F$Y$$$20250829$$CN$US$US
257415401$25741540$1$I$$20250829$20250829$20250829$DIR$772587$$FDA-CTU$$$$$$N$$$20250829$N$$US$
257415481$25741548$1$I$$20250820$20250829$20250829$PER$$US-JNJFOC-20250826719$JOHNSON AND JOHNSON$$$$$M$Y$$$20250829$$HP$US$US
257415841$25741584$1$I$20200101$20231116$20250829$20250829$EXP$$US-SANDOZ INC.-SDZ2023US077500$SANDOZ$$56$YR$$F$Y$$$20250829$$CN$US$US
257416641$25741664$1$I$$20250818$20250829$20250829$EXP$$US-NOVAST LABORATORIES INC.-2025NOV000269$NOVAST LABORATORIES LTD$Alqawasmi M, Escobar Gil T, Shah K, Millhuff A, Parchim N.. Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH) Syndrome: A Frequently Overlooked and Underdiagnosed Condition.. Cureus. 2025;17(7): e87601$65$YR$$M$Y$$$20250829$$HP$US$US
257416752$25741675$2$F$$20250826$20250829$20250909$PER$$US-AMGEN-USASP2025171088$AMGEN$$$$A$F$Y$$$20250908$$HP$US$US
257417641$25741764$1$I$$20250826$20250829$20250829$EXP$$NVSC2025US135423$NOVARTIS$$83$YR$$F$Y$$$20250829$$CN$US$US
257417791$25741779$1$I$$20250825$20250829$20250829$PER$$US-UNITED THERAPEUTICS-UNT-2025-029780$UNITED THERAPEUTICS$$$$$F$Y$107.94$KG$20250829$$$US$US
257418281$25741828$1$I$$20250829$20250829$20250829$DIR$FDA-CDER-CTU-2025-57910$$FDA-CTU$$50$YR$$M$N$$$20250829$N$CN$US$
257419142$25741914$2$F$20231116$20250821$20250829$20250901$EXP$$EU-EXELIXIS-EXL-2025-011126$EXELIXIS$$64$YR$$M$Y$122$KG$20250901$$MD$EU$EU
257419371$25741937$1$I$20250825$20250826$20250829$20250829$EXP$$US-ABBVIE-6435012$ABBVIE$$76$YR$$F$Y$$$20250829$$CN$US$US
257420821$25742082$1$I$20250728$20250827$20250829$20250829$EXP$GB-MHRA-MED-202508272348100710-BKYQG$GB-SANDOZ INC.-SDZ2025GB062306$SANDOZ$$79$YR$$M$Y$87$KG$20250829$$MD$GB$GB
257421771$25742177$1$I$20250826$20250826$20250829$20250829$EXP$$EU-ABBVIE-6435513$ABBVIE$$73$YR$$M$Y$105$KG$20250829$$HP$EU$EU
257422261$25742226$1$I$20250803$20250825$20250829$20250829$EXP$EU-AFSSAPS-LL2025001478$EU-MYLANLABS-2025M1072804$MYLAN$$59$YR$$M$Y$110$KG$20250829$$MD$EU$EU
257422651$25742265$1$I$$20250819$20250829$20250829$EXP$$EU-TAKEDA-2025TUS076214$TAKEDA$$62$YR$$$Y$$$20250829$$$EU$EU
257422811$25742281$1$I$$20250819$20250829$20250829$PER$$NVSC2025US132176$NOVARTIS$$$$$$Y$$$20250829$$HP$US$US
257423583$25742358$3$F$20250819$20250903$20250829$20250908$30DAY$$AR-PFIZER INC-202500167764$PFIZER$$13$YR$$M$Y$49.2$KG$20250908$$HP$AR$AR
257423711$25742371$1$I$$20250828$20250829$20250829$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-120076$BRISTOL-MYERS SQUIBB COMPANY$$82$YR$E$F$Y$69.85$KG$20250829$$CN$US$US
257423731$25742373$1$I$$20250819$20250829$20250829$PER$$US-009507513-2321253$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250829$$HP$US$US
257423891$25742389$1$I$20250706$20250828$20250829$20250829$EXP$EU-AEMPS-1744285$EU-009507513-2324519$MERCK SHARP + DOHME LLC$$73$YR$$F$Y$$$20250829$$MD$EU$EU
257424351$25742435$1$I$20250101$20250826$20250829$20250829$EXP$GB-MHRA-MED-202508261237497180-BWDQJ$GB-PFIZER INC-202500170453$PFIZER$$76$YR$$F$Y$46$KG$20250829$$HP$GB$GB
257425412$25742541$2$F$$20250919$20250829$20250924$EXP$$US-ASTRAZENECA-202508USA022875US$ALEXION PHARMACEUTICALS$$62$YR$A$F$Y$55.782$KG$20250924$$MD$US$US
257425452$25742545$2$F$$20250925$20250829$20250926$EXP$$GB-ASTRAZENECA-202508GBR022771GB$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250926$$MD$GB$GB
257425821$25742582$1$I$20250628$20250822$20250829$20250829$EXP$$EU-AMGEN-FRASP2025168415$AMGEN$$58$YR$A$M$Y$$$20250829$$HP$EU$EU
257425842$25742584$2$F$$20250902$20250829$20250903$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-120056$BRISTOL-MYERS SQUIBB COMPANY$$42$YR$A$M$Y$$$20250903$$HP$US$US
257426441$25742644$1$I$$20250825$20250830$20250830$EXP$$US-ABBVIE-6435194$ABBVIE$$$$A$F$Y$$$20250830$$CN$US$US
257427631$25742763$1$I$$20250818$20250830$20250830$EXP$$US-Accord-501420$ACCORD$Dykins M, Kimura J, Tachtatzis P, Prasad R, Price J. The Utility of Serial Neuropsychological Assessment Post-Liver Transplant: A Case Study. American Journal of Transplantation. 2025;25(8)(Supplement 1):S521. DOI:10.1016/j.ajt.2025.07.1203$34$YR$A$M$Y$$$20250830$$MD$US$US
257428181$25742818$1$I$20241206$20241211$20250830$20250830$EXP$$US-AMNEAL PHARMACEUTICALS-2024-AMRX-04516$AMNEAL$$$$$F$Y$$$20250830$$CN$US$US
257429081$25742908$1$I$20250722$20250820$20250830$20250830$EXP$EU-AFSSAPS-CF2025000395$EU-CELLTRION INC.-2025FR030135$CELLTRION$$$$$$Y$$$20250830$$PH$EU$EU
257429181$25742918$1$I$$20250825$20250830$20250830$PER$$US-ELI_LILLY_AND_COMPANY-US202508024569$ELI LILLY AND COMPANY$$73$YR$E$F$Y$$$20250830$$CN$US$US
257430851$25743085$1$I$20250618$20250818$20250830$20250830$EXP$EU-OGYI-0122725$EU-Accord-501793$ACCORD$$68$YR$E$M$Y$72$KG$20250830$$PH$EU$EU
257431051$25743105$1$I$20250803$20250825$20250830$20250830$EXP$EU-AFSSAPS-LL2025001478$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-127878$ZYDUS PHARM$$$$$$Y$$$20250830$$MD$EU$EU
257431251$25743125$1$I$$20250820$20250830$20250830$EXP$$IN-ZYDUS-IN-ZYDUS-127872$ZYDUS PHARM$Ramassamy S, Chandrashekar L, Mathaiyan J, Rajappa M, Devanathan R, Selvarathinam S. Clinical relevance of thiopurine methyltransferase genotype testing for azathioprine in dermatology. Clin-Exp-Dermatol. 2025;50(7):1337-1342$$$$$Y$$$20250830$$HP$IN$IN
257431331$25743133$1$I$$20250822$20250830$20250830$PER$$US-ELI_LILLY_AND_COMPANY-US202508023694$ELI LILLY AND COMPANY$$53$YR$A$F$Y$$$20250830$$CN$US$US
257432441$25743244$1$I$$20250820$20250830$20250830$EXP$$US-AMGEN-USASP2025167386$AMGEN$Andrew L. M.; Weinstock R.; Dorfman J. et al.. Assessment and Treatment of PANS/PANDAS: A Multidisciplinary Approach and Therapeutic Considerations. Clinical Case Studies. 2025;24 (4):279-295$10$YR$C$M$Y$$$20250830$$HP$US$US
257433291$25743329$1$I$$20250825$20250830$20250830$PER$$US-JNJFOC-20250829917$JOHNSON AND JOHNSON$$$$$$Y$$$20250830$$HP$US$US
257433541$25743354$1$I$20250701$20250825$20250830$20250830$PER$$US-SA-2025SA258594$SANOFI AVENTIS$$5$YR$C$M$Y$$$20250830$$HP$US$US
257433781$25743378$1$I$$20250825$20250830$20250830$PER$$US-SA-2025SA258855$SANOFI AVENTIS$$$$E$M$Y$81.36$KG$20250830$$MD$US$US
257434551$25743455$1$I$$20250819$20250831$20250831$EXP$$BR-Accord-501469$ACCORD$Coelho E, Gueiros L, Prohaska F, Ramos I, Cavalcanti L, Correia C, et al. Gastrointestinal Histoplasmosis in a Patient With Multiple Myeloma After Autologous Bone Marrow Transplantation: Oral Ulcer Differential Diagnosis. Case Report. Clinical Lymphoma, Myeloma and Leukemia. 2024;24(Supplement 2):S105-6. DOI: 10.1016/S2152-2650(24)02012-3.$52$YR$A$M$Y$$$20250831$$MD$BR$BR
257436201$25743620$1$I$$20250825$20250831$20250831$PER$$US-SA-2025SA258930$SANOFI AVENTIS$$$$E$F$Y$$$20250831$$MD$US$US
257437131$25743713$1$I$$20250825$20250831$20250831$PER$$US-ELI_LILLY_AND_COMPANY-US202508025363$ELI LILLY AND COMPANY$$$$$$Y$$$20250831$$CN$US$US
257437501$25743750$1$I$20250701$20250826$20250831$20250831$PER$$US-SA-2025SA259237$SANOFI AVENTIS$$9$YR$C$F$Y$$$20250831$$HP$US$US
257437751$25743775$1$I$20250801$20250826$20250831$20250831$PER$$JP-Eisai-EC-2025-195758$EISAI$$$$E$F$Y$$$20250831$$MD$JP$JP
257439931$25743993$1$I$$20250727$20250831$20250831$PER$$US-SA-2025SA220716$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250730$$CN$US$US
257441141$25744114$1$I$$20250728$20250831$20250831$PER$$US-SA-2025SA221557$SANOFI AVENTIS$$$$E$F$Y$$$20250730$$MD$US$US
257441911$25744191$1$I$$20250822$20250901$20250901$PER$$US-ROCHE-10000372470$ROCHE$$$$A$F$Y$$$20250901$$CN$US$US
257442621$25744262$1$I$20240101$20250825$20250901$20250901$EXP$$AR-AMGEN-ARGSL2024209810$AMGEN$$78$YR$E$M$Y$$$20250831$$CN$AR$AR
257442673$25744267$3$F$$20250924$20250901$20250929$EXP$$US-SA-2025SA258488$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250929$$CN$US$US
257442691$25744269$1$I$$20250825$20250901$20250901$EXP$001127456$CA-ASTRAZENECA-202508CAN020326CA$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250901$$$CA$CA
257443391$25744339$1$I$$20250822$20250901$20250901$PER$$US-ROCHE-10000372256$ROCHE$$$$E$F$Y$$$20250901$$CN$US$US
257443722$25744372$2$F$20250725$20250915$20250901$20250919$EXP$EU-MINISAL02-1053852$EU-TEVA-VS-3365587$TEVA$$58$YR$$F$Y$86$KG$20250919$$MD$EU$EU
257444471$25744447$1$I$$20241105$20250901$20250901$PER$$US-ENDO USA, INC.-2024-050666$ENDO$$$$$$Y$$$20250901$$CN$US$US
257444611$25744461$1$I$20240801$20240821$20250901$20250901$PER$$US-ENDO USA, INC.-2024-003289$ENDO$$$$$F$Y$$$20250901$$CN$US$US
257445752$25744575$2$F$$20250916$20250901$20250922$30DAY$$BR-JNJFOC-20250826155$JOHNSON AND JOHNSON$$$$$$Y$$$20250922$$HP$BR$BR
257447231$25744723$1$I$20250804$20250805$20250901$20250901$PER$$US-GALDERMA-US2025014419$GALDERMA$$$$$$Y$$$20250901$$HP$US$US
257448711$25744871$1$I$$20250828$20250901$20250901$EXP$$US-JNJFOC-20250835890$JOHNSON AND JOHNSON$$$$$M$Y$$$20250901$$CN$US$US
257449311$25744931$1$I$$20250822$20250901$20250901$EXP$$JP-GALDERMA-JP2024011232$GALDERMA$$$$$$Y$$$20250901$$MD$JP$JP
257449401$25744940$1$I$20250704$20250818$20250901$20250901$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-03270$AMNEAL$$57$YR$$F$Y$79.365$KG$20250901$$CN$US$US
257449591$25744959$1$I$$20250825$20250901$20250901$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-120415$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$$$20250901$$CN$US$US
257449651$25744965$1$I$20250701$20250822$20250901$20250901$EXP$$EU-EMD Serono-2025041715$EMD SERONO INC$$54$YR$A$F$Y$$$20250901$$$EU$EU
257449741$25744974$1$I$$20250825$20250901$20250901$EXP$$US-SANDOZ INC.-SDZ2025US062439$SANDOZ$$$$$F$Y$$$20250901$$HP$US$US
257450291$25745029$1$I$20250801$20250828$20250901$20250901$EXP$EU-JNJFOC-20250900265$EU-JNJFOC-20250900265$JOHNSON AND JOHNSON$$83$YR$E$M$Y$92$KG$20250901$$PH$EU$EU
257450831$25745083$1$I$20250101$20250824$20250901$20250901$EXP$$US-SANDOZ INC.-SDZ2025US061964$SANDOZ$$$$$F$Y$$$20250901$$CN$US$US
257451022$25745102$2$F$20250822$20250826$20250901$20250903$EXP$$CA-CELLTRION INC.-2025CA030624$CELLTRION$$$$$$Y$$$20250903$$HP$CA$CA
257451031$25745103$1$I$$20250829$20250901$20250901$EXP$$CA-TEVA-VS-3367898$TEVA$$46$YR$$M$Y$$$20250901$$MD$CA$CA
257451071$25745107$1$I$20250509$20250820$20250901$20250901$EXP$$EU-AUROBINDO-AUR-APL-2025-043902$AUROBINDO$$69$YR$$M$Y$65$KG$20250901$$PH$EU$EU
257451481$25745148$1$I$$20250824$20250901$20250901$EXP$$CH-REGENERON PHARMACEUTICALS, INC.-2025-138509$REGENERON$$75$YR$$F$Y$$$20250901$$HP$CH$CH
257451711$25745171$1$I$$20250818$20250901$20250901$EXP$$CH-EPICPHARMA-CH-2025EPCLIT01004$EPIC PHARM$C. Wirth.Symptomatic Hypomagnesaemia and Hypocalcaemia after Long-Term Use of Proton Pump Inhibitors.Swiss Medical Weekly.MAY-2025;155(285):1$70$YR$E$F$Y$$$20250901$$HP$CH$CH
257452691$25745269$1$I$$20250828$20250901$20250901$EXP$$US-ASTRAZENECA-202508USA023230US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250901$$$US$US
257452801$25745280$1$I$$20250820$20250901$20250901$PER$$US-VIIV HEALTHCARE-US2025107583$VIIV$$$$$$Y$$$20250901$$PH$US$US
257453621$25745362$1$I$20250720$20250731$20250901$20250901$PER$$US-KENVUE-20250801246$Kenvue$$49$YR$$F$Y$76.6$KG$20250901$$CN$US$US
257453941$25745394$1$I$$20250818$20250901$20250901$EXP$$US-AMAROX PHARMA-HET2025US05085$HETERO$Nudelman BG, Valencia Uribe J, Bhattar K, Krishnaswamy S.. Acute Respiratory Failure Secondary to Statin induced Anti HMG CoA Reductase Myopathy A Rare Complication With Diagnostic Challenges. American Journal of Respiratory and Critical Care Medicine. 2025;211(Abstracts):A5931$74$YR$$F$Y$$$20250901$$HP$US$US
257454581$25745458$1$I$20250225$20250820$20250901$20250901$EXP$$GB-MHRA-MED-202508200837137650-MZPRC$AUROBINDO$$25$YR$$M$Y$$$20250901$$CN$GB$GB
257454691$25745469$1$I$20250426$20250820$20250901$20250901$EXP$$EU-ASTRAZENECA-202504GLO026634DE$AUROBINDO$$73$YR$$M$Y$78$KG$20250901$$MD$EU$EU
257455331$25745533$1$I$$20250819$20250901$20250901$EXP$$US-STRIDES ARCOLAB LIMITED-2025SP011135$STRIDES$Phang C, Sangwan Y, Li T.. A Rare Case of Amlodipine Overdose Leading to Acute Pulmonary Edema.. Am-J-Respir-Crit-Care-Med. 2025;211$57$YR$$F$Y$$$20250901$$HP$US$US
257456251$25745625$1$I$20250801$20250825$20250901$20250901$EXP$EU-AFSSAPS-LY2025001375$EU-CADILA HEALTHCARE LIMITED-FR-ZYDUS-127919$ZYDUS PHARM$$$$$$Y$$$20250901$$PH$EU$EU
257456681$25745668$1$I$$20241126$20250901$20250901$EXP$$US-AMNEAL PHARMACEUTICALS-2024-AMRX-04354$AMNEAL$$$$$F$Y$$$20250901$$CN$US$US
257457361$25745736$1$I$$20250825$20250901$20250901$PER$$US-JNJFOC-20250830581$JOHNSON AND JOHNSON$$$$$$Y$$$20250901$$HP$US$US
257458101$25745810$1$I$20250730$20250826$20250901$20250901$EXP$$JP-ROCHE-10000376548$ROCHE$$$$E$M$Y$$$20250901$$PH$JP$JP
257458201$25745820$1$I$$20250825$20250901$20250901$PER$$US-BIOGEN-2025BI01322054$BIOGEN$$$$$F$Y$$$20250901$$MD$US$US
257458331$25745833$1$I$$20250826$20250901$20250901$30DAY$$US-SANDOZ INC.-SDZ2025US062080$SANDOZ$$4$YR$$F$Y$$$20250901$$HP$US$US
257458571$25745857$1$I$$20250825$20250901$20250901$EXP$$SG-ROCHE-10000373565$ROCHE$$73$YR$E$M$Y$$$20250901$$CN$SG$SG
257459261$25745926$1$I$$20250822$20250901$20250901$EXP$$CA-ROCHE-10000371792$ROCHE$$$$$F$Y$$$20250901$$HP$CA$CA
257459661$25745966$1$I$$20250827$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508028259$ELI LILLY AND COMPANY$$76$YR$E$M$Y$$$20250901$$CN$US$US
257460261$25746026$1$I$$20250819$20250901$20250901$EXP$$US-STRIDES NORDIC APS-2025SP010984$STRIDES$Reddy SG, Mumber SL, Garg R.. Resolution of Colchicine-Resistant, Corticosteroid-Dependent Acute Idiopathic Recurrent Pericarditis With Rilonacept: A Case Report. Cureus. 2025;17(4):e82325$55$YR$$F$Y$$$20250901$$HP$US$US
257460921$25746092$1$I$$20250827$20250901$20250901$EXP$$US-SANDOZ INC.-PHHY2019US175631$SANDOZ$$51$YR$$F$Y$$$20250901$$HP$US$US
257461101$25746110$1$I$$20250820$20250901$20250901$PER$$US-SMPA-2025SPA010970$SUNOVION$$67$YR$$F$Y$$$20250901$$$US$US
257461711$25746171$1$I$20250101$20250825$20250901$20250901$EXP$$US-UCBSA-2025049963$UCB$$$$$F$Y$$$20250901$$MD$US$US
257462461$25746246$1$I$$20250820$20250901$20250901$EXP$$US-EMD Serono-2025022979$EMD SERONO INC$$$$A$F$Y$$$20250901$$$US$US
257463091$25746309$1$I$20250806$20250821$20250901$20250901$EXP$$EU-AUROBINDO-AUR-APL-2025-043971$AUROBINDO$$16$YR$$F$Y$$$20250901$$MD$EU$EU
257465011$25746501$1$I$$20250827$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508028263$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250901$$CN$US$US
257465341$25746534$1$I$$20250116$20250901$20250901$PER$$US-Pharmaand-2025000050$pharmaAND$$$$$$Y$$$20250901$$PH$US$US
257465501$25746550$1$I$20250813$20250822$20250901$20250901$PER$$US-AMGEN-USASP2025169021$AMGEN$$$$$$Y$$$20250901$$PH$US$US
257465613$25746561$3$F$20240601$20250919$20250901$20250926$EXP$$NVSC2025PL134329$NOVARTIS$$50$YR$$F$Y$$$20250926$$MD$EU$EU
257465871$25746587$1$I$$20250818$20250901$20250901$EXP$$US-MEITHEAL-2025MPLIT00307$MEITHEAL PHARMACEUTICALS$Carnevali M, et aL.Leukocytes in Overdrive: When Adverse Reactions Prove Fatal.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A5776$65$YR$A$M$Y$$$20250901$$HP$US$US
257466381$25746638$1$I$$20250715$20250901$20250901$PER$$US-STALCOR-2025-AER-02331$STALLERGENES$$3$YR$C$M$Y$$$20250901$$CN$US$US
257466652$25746665$2$F$$20250905$20250901$20250915$EXP$$CA-TEVA-VS-3366872$TEVA$Matheson L, White RF, Liu SSF, Rabkin SW, Bousman CA, Rafizadeh R. Clozapine discontinuation and rechallenge in suspected myocarditis: An analysis of seven cases. Schizophr-Res 2025; 276 202-204.; Matheson L, White RF, Liu SSF, Rabkin SW, Bousman CA, Rafizadeh R. Clozapine discontinuation and rechallenge in suspected myocarditis: An analysis of seven cases. Schizophr-Res 2025; 276 202-204.; Matheson L, White RF, Liu SSF, Rabkin SW, Bousman CA, Rafizadeh R. Clozapine discontinuation and rechal...$20$YR$$M$Y$$$20250915$$HP$CA$CA
257467141$25746714$1$I$$20250828$20250901$20250901$EXP$$US-ABBVIE-6438960$ABBVIE$$$$A$F$Y$$$20250901$$CN$US$US
257467453$25746745$3$F$$20250901$20250901$20250926$EXP$$EU-BAUSCH-BH-2025-016795$BAUSCH AND LOMB$Aleksandrova S, Linkova S, Benovska Y, Borisov B. ACUTE KIDNEY INJURY DUE TO METFORMIN-ASSOCIATED LACTIC ACIDOSIS. Journal of IMAB - Annual Proceeding (Scientific Papers). 2025 Aug 05;31(3): 6366-6370. doi:10.5272/jimab.2025313.6366.$72$YR$E$F$Y$$$20250926$$MD$EU$EU
257467521$25746752$1$I$20221221$20250826$20250901$20250901$EXP$$EU-BAUSCH-BL-2023-003732$BAUSCH AND LOMB$$75$YR$E$F$Y$87$KG$20250901$$MD$EU$EU
257468011$25746801$1$I$$20250821$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508025074$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250901$$CN$US$US
257468471$25746847$1$I$$20250822$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508023547$ELI LILLY AND COMPANY$$71$YR$E$M$Y$$$20250901$$CN$US$US
257468741$25746874$1$I$20250801$20250826$20250901$20250901$PER$$US-SA-2025SA260211$SANOFI AVENTIS$$42$YR$A$M$Y$$$20250901$$CN$US$US
257469081$25746908$1$I$$20250826$20250901$20250901$PER$$US-SA-2025SA259602$SANOFI AVENTIS$$77$YR$E$M$Y$$$20250901$$CN$US$US
257469531$25746953$1$I$20250801$20250826$20250901$20250901$PER$$US-SA-2025SA259581$SANOFI AVENTIS$$5$YR$C$M$Y$$$20250901$$HP$US$US
257469741$25746974$1$I$20250101$20250827$20250901$20250901$PER$$US-SA-2025SA260191$SANOFI AVENTIS$$16$YR$T$F$Y$$$20250901$$HP$US$US
257469963$25746996$3$F$20250601$20250904$20250901$20250911$PER$$US-SA-2025SA259225$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250911$$HP$US$US
257470062$25747006$2$F$20250101$20250918$20250901$20250927$PER$$US-SA-2025SA258959$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250926$$HP$US$US
257470551$25747055$1$I$20250601$20250822$20250901$20250901$EXP$$EU-GILEAD-2025-0725818$GILEAD$$63$YR$A$F$Y$$$20250901$$MD$EU$EU
257471031$25747103$1$I$20250101$20250826$20250901$20250901$PER$$US-SA-2025SA258942$SANOFI AVENTIS$$4$YR$C$F$Y$$$20250901$$HP$US$US
257471771$25747177$1$I$$20250825$20250901$20250901$EXP$$EU-TEVA-VS-3367331$TEVA$Bilbao I, Pineda Abel de la CruzI, de Asis Carmona-Torre F, Rodriguez-Mateos M, Yuste Ara JR, Del Pozo JL. Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients. J-Antimicrob-Chemother 2025; 80 (1): 102-105.$55$YR$$F$Y$$$20250901$$HP$EU$EU
257471831$25747183$1$I$$20250826$20250901$20250901$PER$$US-SA-2025SA259514$SANOFI AVENTIS$$$$A$M$Y$117$KG$20250901$$MD$US$US
257472491$25747249$1$I$20250701$20250826$20250901$20250901$PER$$US-SA-2025SA259580$SANOFI AVENTIS$$54$YR$A$M$Y$$$20250901$$HP$US$US
257472722$25747272$2$F$$20250905$20250901$20250917$PER$$US-MALLINCKRODT-MNK202505323$MALLINCKRODT$$$$$M$Y$$$20250917$$CN$US$US
257473381$25747338$1$I$$20250822$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508023977$ELI LILLY AND COMPANY$$45$YR$A$$Y$$$20250901$$CN$US$US
257474281$25747428$1$I$20250816$20250825$20250901$20250901$EXP$$CN-ROCHE-10000373621$ROCHE$$69$YR$E$F$Y$$$20250901$$HP$CN$CN
257474522$25747452$2$F$$20250902$20250901$20250906$PER$$US-AMGEN-USASP2025170450$AMGEN$$$$$F$Y$$$20250906$$CN$US$US
257474531$25747453$1$I$$20250822$20250901$20250901$PER$$US-ROCHE-10000372277$ROCHE$$$$T$M$Y$$$20250901$$CN$US$US
257474991$25747499$1$I$$20250826$20250901$20250901$EXP$$US-009507513-2324146$MERCK SHARP + DOHME LLC$Sahay S, Hernandez NV, Al Aaraj Y, et al. Pericardial Effusions And Sotatercept Therapy in Pulmonary Arterial Hypertension: A Multicenter Real-World Experience. Eur Respir J 2025; in press$45$YR$$F$Y$$$20250901$$MD$US$US
257475001$25747500$1$I$$20250729$20250901$20250901$PER$$US-STEMLINE THERAPEUTICS B.V.-2025-STML-US002674$STEMLINE THERAPEUTICS$$$$$$Y$$$20250901$$MD$US$US
257475661$25747566$1$I$$20250826$20250901$20250901$EXP$$US-009507513-2324154$MERCK SHARP + DOHME LLC$Sahay S, Hernandez NV, Al Aaraj Y, et al. Pericardial Effusions And Sotatercept Therapy in Pulmonary Arterial Hypertension: A Multicenter Real-World Experience. Eur Respir J 2025; in press$67$YR$$F$Y$$$20250901$$MD$US$US
257477071$25747707$1$I$$20250821$20250901$20250901$PER$$US-ELI_LILLY_AND_COMPANY-US202508022278$ELI LILLY AND COMPANY$$78$YR$E$F$Y$$$20250901$$CN$US$US
257477982$25747798$2$F$$20250724$20250901$20250901$30DAY$$US-SANDOZ INC.-SDZ2025US053789$SANDOZ$$$$$F$Y$$$20250901$$CN$US$US
257478201$25747820$1$I$20250101$20250825$20250901$20250901$PER$$US-ABBVIE-6434687$ABBVIE$$$$$F$Y$$$20250901$$CN$US$US
257478561$25747856$1$I$$20250828$20250901$20250901$PER$$US-SA-2025SA259971$SANOFI AVENTIS$$2$YR$C$M$Y$$$20250901$$CN$US$US
257478961$25747896$1$I$20250106$20250828$20250901$20250901$PER$$JP-TAKEDA-2025TJP008883$TAKEDA$$$$$M$Y$66.1$KG$20250901$$MD$JP$JP
257479941$25747994$1$I$$20240904$20250901$20250901$EXP$$US-HALEON-2195614$Haleon PLC$$48$YR$$F$Y$$$20240909$$HP$US$US
257481271$25748127$1$I$$20250828$20250901$20250901$EXP$$US-ABBVIE-6440736$ABBVIE$$$$E$F$Y$$$20250901$$HP$US$US
257482081$25748208$1$I$$20250829$20250902$20250902$EXP$$US-ROCHE-10000377810$ROCHE$$16$YR$T$M$Y$$$20250902$$MD$US$US
257482401$25748240$1$I$$20250819$20250902$20250902$EXP$$US-GSK-US2025AMR107825$GLAXOSMITHKLINE$$$$$F$Y$$$20250902$$$US$US
257482951$25748295$1$I$20181101$20250828$20250902$20250902$EXP$$US-ABBVIE-6439311$ABBVIE$$55$YR$$F$Y$$$20250902$$CN$US$US
257483331$25748333$1$I$$20250820$20250902$20250902$PER$$NVSC2025US132776$NOVARTIS$$$$$F$Y$$$20250902$$CN$US$US
257483741$25748374$1$I$$20250827$20250902$20250902$EXP$$JP-ASTELLAS-2025-AER-047152$ASTELLAS$$70$YR$E$M$Y$$$20250902$$MD$JP$JP
257485291$25748529$1$I$20221201$20250818$20250902$20250902$EXP$$IN-CorePharma LLC-2183633$COREPHARMA LLC$Abstract.$30$YR$$M$Y$$$20250902$$MD$IN$IN
257486171$25748617$1$I$$20250827$20250902$20250902$EXP$$JP-ASTRAZENECA-202508JPN021278JP$ALEXION PHARMACEUTICALS$$77$YR$E$F$Y$$$20250902$$PH$JP$JP
257486391$25748639$1$I$$20250825$20250902$20250902$PER$$US-ABBVIE-6434070$ABBVIE$$$$$M$Y$$$20250902$$CN$US$US
257486791$25748679$1$I$20250523$20250827$20250902$20250902$EXP$$EU-ABBVIE-6438525$ABBVIE$$61$YR$$F$Y$84$KG$20250902$$CN$EU$EU
257487511$25748751$1$I$$20250822$20250902$20250902$EXP$CA-MHPD-001137017$CA-Accord-501569$ACCORD$$49$YR$A$M$Y$$$20250902$$PH$CA$CA
257488301$25748830$1$I$$20250821$20250902$20250902$PER$$US-SA-2025SA255464$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250902$$HP$US$US
257490092$25749009$2$F$20250813$20250917$20250902$20250926$EXP$$EU-IMMUNOCORE, LTD-2025-IMC-004638$IMMUNOCORE$$$$$$Y$$$20250926$$MD$EU$EU
257491221$25749122$1$I$$20250825$20250902$20250902$PER$$US-SYNDAX PHARMACEUTICALS, INC.-2025US000656$SYNDAX$$$$$$Y$$$20250902$$MD$US$US
257491502$25749150$2$F$20250101$20250829$20250902$20250903$EXP$$US-ABBVIE-6428219$ABBVIE$$77$YR$$M$Y$$$20250903$$CN$US$US
257492071$25749207$1$I$20250810$20250824$20250902$20250902$EXP$GB-MHRA-MED-202508241655099440-CFYVD$GB-RDY-GBR/2025/08/013050$DR REDDYS$$$$$F$Y$84$KG$20250902$$CN$GB$GB
257492251$25749225$1$I$20250807$20250826$20250902$20250902$EXP$$US-ROCHE-10000374864$ROCHE$$2$YR$C$M$Y$$$20250902$$CN$US$US
257492661$25749266$1$I$$20250828$20250902$20250902$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-071361$BOEHRINGER INGELHEIM$$63$YR$A$F$Y$$$20250902$$$US$US
257493541$25749354$1$I$20250206$20250822$20250902$20250902$EXP$EU-AEMPS-1738198$EU-Accord-502431$ACCORD$$66$YR$E$M$Y$$$20250902$$MD$EU$EU
257493841$25749384$1$I$$20250806$20250902$20250902$PER$$US-KENVUE-20250802854$Kenvue$$82$YR$$F$Y$$$20250902$$CN$US$US
257493981$25749398$1$I$$20250827$20250902$20250902$EXP$$US-TAKEDA-2025TUS046276$TAKEDA$$$$$F$Y$$$20250902$$$US$US
257494061$25749406$1$I$$20250828$20250902$20250902$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25053088$RADIUS PHARM$$$$$F$Y$$$20250902$$CN$US$US
257494841$25749484$1$I$$20250818$20250902$20250902$EXP$$CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-525133$RANBAXY$Hove K, Clifford A, Ye C. Multifocal strokes in a patient with suspected CNS vasculitis : A case. Curr Opin Infect Dis. 2020;33:103 (273-78)$45$YR$$F$Y$$$20250902$$HP$CA$CA
257495061$25749506$1$I$$20250818$20250902$20250902$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-525199$RANBAXY$Vo AA, Huang E, Zhang X, Vescio R, Oveisi D, Myers C, et al. Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up. Am J Transplant. 2025;25 (Suppl.) (8):S267/OA60.5$61$YR$$F$Y$$$20250902$$HP$US$US
257495631$25749563$1$I$20250722$20250722$20250902$20250902$PER$$US-ELI_LILLY_AND_COMPANY-US202509000435$ELI LILLY AND COMPANY$$9$YR$C$F$Y$32.653$KG$20250902$$CN$US$US
257495671$25749567$1$I$20250806$20250806$20250902$20250902$PER$$US-ELI_LILLY_AND_COMPANY-US202508006565$ELI LILLY AND COMPANY$$75$YR$E$F$Y$$$20250902$$CN$US$US
257495851$25749585$1$I$$20250901$20250902$20250902$EXP$GB-MHRA-MIDB-41ef61ce-1a6d-4ca0-b589-d52950990ff6$GB-TEVA-VS-3368277$TEVA$$94$YR$$M$Y$$$20250902$$PH$GB$GB
257495981$25749598$1$I$$20250729$20250902$20250902$PER$$US-GSK-US2025098294$GLAXOSMITHKLINE$$$$$$Y$$$20250902$$$US$US
257496771$25749677$1$I$$20250826$20250902$20250902$PER$$US-AMGEN-USASP2025172696$AMGEN$$$$$F$Y$$$20250902$$HP$US$US
257497361$25749736$1$I$20250823$20250828$20250902$20250902$EXP$$MX-ABBVIE-6440080$ABBVIE$$64$YR$$M$Y$80$KG$20250902$$CN$MX$MX
257497421$25749742$1$I$20250825$20250827$20250902$20250902$EXP$$US-ABBVIE-5757658$ABBVIE$$75$YR$$F$Y$$$20250902$$CN$US$US
257497601$25749760$1$I$$20250829$20250902$20250902$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-121168$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$46.27$KG$20250902$$CN$US$US
257498501$25749850$1$I$20250312$20250826$20250902$20250902$EXP$CH-SM-2025-06572$CH-SANDOZ INC.-SDZ2025CH063021$SANDOZ$$62$YR$$F$Y$62$KG$20250902$$MD$CH$CH
257500051$25750005$1$I$20250101$20250819$20250902$20250902$EXP$$US-BAYER-2025A112217$BAYER HEALTHCARE PHARMACEUTICALS INC.$Tai J W; Young E H; Shah V D; Reed J P. Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment. Cureus. 2025;13;17(7):1-6$61$YR$A$F$Y$$$20250902$$MD$US$US
257501501$25750150$1$I$20250101$20250827$20250902$20250902$PER$$US-SA-2025SA261094$SANOFI AVENTIS$$44$YR$A$M$Y$$$20250902$$HP$US$US
257501611$25750161$1$I$$20250827$20250902$20250902$PER$$US-SA-2025SA260431$SANOFI AVENTIS$$64$YR$A$M$Y$$$20250902$$CN$US$US
257501762$25750176$2$F$20250101$20250908$20250902$20250915$PER$$US-SA-2025SA260801$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250915$$MD$US$US
257502151$25750215$1$I$20250101$20250826$20250902$20250902$PER$$US-SA-2025SA259315$SANOFI AVENTIS$$$$E$F$Y$$$20250902$$HP$US$US
257503881$25750388$1$I$$20250825$20250902$20250902$EXP$$US-PFIZER INC-PV202500103215$PFIZER$Mourad, D.. Prosthetic valve dysfunction post-bevacizumab: A transcatheter aortic valve replacement thrombosis case report. European Heart Journal - Case Reports. 2025;9 (8):10.1093/ehjcr/ytaf370$69$YR$$M$Y$$$20250902$$HP$US$US
257506161$25750616$1$I$$20250821$20250902$20250902$EXP$$KR-Accord-502777$ACCORD$Oh K, Cho SY, Lee DG, Nho D, Kim DY, Kweon HM, et al. Pathologically Confirmed Dual Coronavirus Disease 2019-Associated Tracheobronchial Aspergillosis and Pulmonary Mucormycosis in a Non-Endemic Region: A Case Report. J Clin Med. 2025 Aug 5;14(15):5526. doi: 10.3390/jcm14155526.$57$YR$A$F$Y$$$20250902$$HP$KR$KR
257506721$25750672$1$I$$20250828$20250902$20250902$PER$$US-SA-2025SA261531$SANOFI AVENTIS$$$$C$F$Y$$$20250902$$HP$US$US
257507042$25750704$2$F$20200101$20250910$20250902$20250918$EXP$$RU-TEVA-VS-3367649$TEVA$Zhuravleva JA, Fedorova LV, Lepik EE, Gusak AA, Popova MO, Lepik KV, et al. A clinical case of successful treatment of CD30-negative angioimmunoblastic T-cell lymphoma using brentuximab vedotin and lenalidomide followed by allogeneic hematopoietic stem cell transplantation. Cell-Ther-Transpl 2024; 13 (2): 41-46.; Zhuravleva JA, Fedorova LV, Lepik EE, Gusak AA, Popova MO, Lepik KV, et al. A clinical case of successful treatment of CD30-negative angioimmunoblastic T-cell lymphoma using brentuxi...$55$YR$$F$Y$$$20250918$$HP$RU$RU
257508091$25750809$1$I$20250101$20250815$20250902$20250902$PER$$US-Eisai-EC-2025-195329$EISAI$$$$$$Y$$$20250902$$$US$US
257508191$25750819$1$I$$20250829$20250902$20250902$PER$$US-SA-2025SA261635$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250902$$CN$US$US
257508221$25750822$1$I$$20250826$20250902$20250902$EXP$CA-DRL-USA-CAN/2025/08/013208$CA-RDY-CAN/2025/08/013208$DR REDDYS$$3$YR$C$F$Y$$$20250902$$PH$CA$CA
257509401$25750940$1$I$$20250828$20250902$20250902$EXP$$TR-PFIZER INC-PV202500104694$PFIZER$Akpinar, S.. A Case of Tigecycline-Associated Nonconvulsive Status Epilepticus. Anestezi Dergisi. 2025;33(3):215-219$80$YR$$F$Y$$$20250902$$HP$TR$TR
257509971$25750997$1$I$20250816$20250818$20250902$20250902$PER$$US-TEVA-VS-3365015$TEVA$$67$YR$$F$Y$$$20250902$$CN$US$US
257510121$25751012$1$I$20220915$20250830$20250830$20250830$DIR$772829$$FDA-CTU$$50$YR$$F$N$90$KG$20250830$N$CN$US$
257510361$25751036$1$I$$20250825$20250902$20250902$EXP$$NVSC2025CA134226$NOVARTIS$$52$YR$$F$Y$$$20250902$$HP$CA$CA
257510551$25751055$1$I$$20250804$20250902$20250902$PER$$US-GSK-US2025AMR102338$GLAXOSMITHKLINE$$$$$F$Y$$$20250902$$$US$US
257512491$25751249$1$I$20250812$20250815$20250831$20250831$DIR$FDA-CDER-CTU-2025-58045$$FDA-CTU$$52$YR$$F$N$107$KG$20250815$N$$US$
257513061$25751306$1$I$$20250818$20250902$20250902$EXP$$JP-Omnivium Pharmaceuticals LLC-2183649$OMNIVIUM PHARMACEUTICALS LLC$Full text$66$YR$$F$Y$$$20250902$$$JP$JP
257513251$25751325$1$I$$20250901$20250901$20250901$DIR$772981$$FDA-CTU$$$$$F$N$$$20250901$N$$US$
257513561$25751356$1$I$20250613$20250613$20250902$20250902$EXP$$US-GUERBET / LLC-US-20250115$GUERBET$$29$YR$A$M$Y$108.8$KG$20250902$$HP$US$US
257513931$25751393$1$I$20250401$20250501$20250902$20250902$PER$$US-CATALYST PHARMACEUTICALS-US-CATA-25-00657$CATALYST PHARMA$$6$YR$$M$Y$18.399$KG$20250902$$CN$US$US
257514411$25751441$1$I$20250818$20250818$20250902$20250902$PER$$US-BAYER-2025A109865$BAYER HEALTHCARE LLC$$71$YR$E$M$Y$$$20250902$$CN$US$US
257514471$25751447$1$I$$20250827$20250902$20250902$EXP$$JP-MSD-2401JPN001147J$MERCK SHARP + DOHME LLC$$65$YR$$M$Y$$$20250902$$MD$JP$JP
257514931$25751493$1$I$20200401$20250822$20250902$20250902$PER$$US-ROCHE-10000373047$ROCHE$$69$YR$E$M$Y$$$20250902$$HP$US$US
257516782$25751678$2$F$$20250828$20250902$20250905$EXP$$EU-PFIZER INC-202500171056$PFIZER$Terrier, B.. Symptomatic Occlusive Retinal Vasculitis as an Unusual Presentation of Biopsy-Proven Sarcoidosis: A Case Series.. Ocular Immunology and Inflammation. 2025;33(6):1042-1045$19$YR$$M$Y$$$20250905$$MD$EU$EU
257517631$25751763$1$I$20150506$20250821$20250902$20250902$EXP$$US-AMGEN-USASP2025168335$AMGEN$$59$YR$A$M$Y$82.993$KG$20250902$$MD$US$US
257517671$25751767$1$I$20250825$20250825$20250902$20250902$EXP$$CA-ABBVIE-6435078$ABBVIE$$34$YR$$M$Y$$$20250902$$CN$CA$CA
257517702$25751770$2$F$20250801$20250924$20250902$20250929$EXP$$US-ABBVIE-6439647$ABBVIE$$76$YR$$M$Y$$$20250929$$CN$US$US
257518841$25751884$1$I$20250830$20250901$20250901$20250901$DIR$772936$$FDA-CTU$$40$YR$$F$N$103.5$KG$20250901$N$CN$US$
257520431$25752043$1$I$20220101$20250821$20250902$20250902$EXP$$US-NOVOPROD-1507589$NOVO NORDISK$$74$YR$$M$Y$$$20250902$$CN$US$US
257520641$25752064$1$I$$20250826$20250902$20250902$EXP$$JP-PFIZER INC-202500170293$PFIZER$$96$YR$$F$Y$$$20250902$$MD$JP$JP
257521181$25752118$1$I$20250626$20250821$20250902$20250902$EXP$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI10371$NEUROCRINE BIOSCIENCES$$57$YR$$F$Y$$$20250902$$MD$US$US
257521291$25752129$1$I$$20250829$20250902$20250902$PER$$US-PURDUE-USA-2025-0320087$PURDUE$$55$YR$$M$Y$$$20250902$$CN$US$US
257521741$25752174$1$I$$20250902$20250902$20250902$DIR$773050$$FDA-CTU$$$$$$N$$$20250902$N$CN$US$
257521871$25752187$1$I$$20250826$20250902$20250902$PER$$US-BAYER-2025A114366$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250902$$HP$US$US
257522051$25752205$1$I$$20250902$20250902$20250902$DIR$773017$$FDA-CTU$$$$$$N$$$20250902$N$CN$US$
257522541$25752254$1$I$$20250819$20250902$20250902$EXP$$US-AIPING-2025AILIT00139$AIPING PHARMACEUTICAL$Burns AJ, et al..Delayed Bupropion Cardiotoxicity Treated With Intravenous Lipid Emulsion: A Case Report.American Journal of Respiratory and Critical Care Medicine.may-2025;211:A1198$51$YR$A$M$Y$$$20250902$$HP$US$US
257522771$25752277$1$I$20240118$20250827$20250902$20250902$EXP$$US-OTSUKA-2025_021212$OTSUKA$$45$YR$$M$Y$$$20250902$$CN$US$US
257522792$25752279$2$F$$20250826$20250902$20250905$30DAY$$US-SANDOZ INC.-SDZ2025US062149$SANDOZ$$$$$M$Y$$$20250905$$CN$US$US
257523121$25752312$1$I$$20250828$20250902$20250902$EXP$$US-ASTRAZENECA-202508USA022973US$ALEXION PHARMACEUTICALS$$$$$F$Y$83$KG$20250902$$$US$US
257523401$25752340$1$I$$20250827$20250902$20250902$EXP$$JP-MSD-2401JPN001182J$MERCK SHARP + DOHME LLC$$68$YR$$M$Y$$$20250902$$MD$JP$JP
257523791$25752379$1$I$$20250827$20250902$20250902$EXP$$TH-ASTRAZENECA-202508ASI021412TH$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250902$$$TH$TH
257524031$25752403$1$I$$20250828$20250902$20250902$EXP$$CN-AMGEN-CHNSP2025173029$AMGEN$Tang Y.; Xu X.; Yan W. et al.. Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancer medicine. 2025;14 (6):1-8$$$$$Y$$$20250902$$HP$CN$CN
257524701$25752470$1$I$$20250828$20250902$20250902$EXP$$CN-AMGEN-CHNSP2025173193$AMGEN$Tang Y.; Xu X.; Yan W. et al.. Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancer Medicine. 2025;14 (16):1-8$$$$$Y$$$20250902$$HP$CN$CN
257525591$25752559$1$I$$20250826$20250902$20250902$EXP$$US-009507513-2325154$MERCK SHARP + DOHME LLC$Larson J, Cuttica M, Mylvaganam R. Sotatercept and the Development of Pericardial Effusions: An Emerging Safety Signal. Chest. 2025.$60$YR$$F$Y$$$20250902$$MD$US$US
257525871$25752587$1$I$20250819$20250828$20250902$20250902$EXP$GB-MHRA-MED-202508281531417530-JZVFB$GB-ELI_LILLY_AND_COMPANY-GB202508029207$ELI LILLY AND COMPANY$$61$YR$A$M$Y$92$KG$20250902$$CN$GB$GB
257526453$25752645$3$F$$20250903$20250902$20250911$PER$$US-SA-2025SA262866$SANOFI AVENTIS$$40$YR$A$F$Y$$$20250911$$CN$US$US
257526521$25752652$1$I$$20250827$20250902$20250902$PER$$US-PFIZER INC-PV202500104149$PFIZER$$41$YR$$M$Y$$$20250902$$CN$US$US
257526591$25752659$1$I$20250715$20250827$20250902$20250902$EXP$EU-AFSSAPS-AN2025001028$EU-MYLANLABS-2025M1069963$MYLAN$$70$YR$$M$Y$$$20250902$$MD$EU$EU
257527371$25752737$1$I$$20250828$20250902$20250902$EXP$$CA-PFIZER INC-202500172696$PFIZER$$81$YR$$M$Y$$$20250902$$HP$CA$CA
257528031$25752803$1$I$$20250820$20250902$20250902$EXP$$US-009507513-2321932$MERCK SHARP + DOHME LLC$$61$YR$$M$Y$$$20250902$$MD$US$US
257528581$25752858$1$I$$20250825$20250902$20250902$EXP$$BR-ELI_LILLY_AND_COMPANY-BR202508023431$ELI LILLY AND COMPANY$$38$YR$A$F$Y$$$20250902$$CN$BR$BR
257528681$25752868$1$I$$20250827$20250902$20250902$PER$$US-ABBVIE-6441486$ABBVIE$$57$YR$$F$Y$$$20250902$$PH$US$US
257528761$25752876$1$I$$20250827$20250902$20250902$PER$$US-ABBVIE-6438478$ABBVIE$$$$$F$Y$$$20250902$$CN$US$US
257529211$25752921$1$I$$20250825$20250902$20250902$EXP$GB-MHRA-MED-202508250352125930-KVYPG$GB-ELI_LILLY_AND_COMPANY-GB202508025052$ELI LILLY AND COMPANY$$21$YR$A$F$Y$153$KG$20250902$$CN$GB$GB
257529231$25752923$1$I$$20250826$20250902$20250902$EXP$$EU-ELI_LILLY_AND_COMPANY-FR202508018170$ELI LILLY AND COMPANY$$80$YR$E$M$Y$$$20250902$$PH$EU$EU
257529401$25752940$1$I$20250814$20250822$20250902$20250902$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202508024242$ELI LILLY AND COMPANY$$76$YR$E$F$Y$68$KG$20250902$$CN$CN$CN
257529481$25752948$1$I$$20250827$20250902$20250902$EXP$$US-ELI_LILLY_AND_COMPANY-US202508027607$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250902$$CN$US$US
257529691$25752969$1$I$20250716$20250718$20250902$20250902$PER$$US-ELI_LILLY_AND_COMPANY-US202509000431$ELI LILLY AND COMPANY$$$$$F$Y$136.05$KG$20250902$$CN$US$US
257530221$25753022$1$I$$20250827$20250902$20250902$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-120152$BRISTOL-MYERS SQUIBB COMPANY$$45$YR$A$M$Y$$$20250902$$HP$US$US
257531182$25753118$2$F$20250828$20250901$20250902$20250909$EXP$$EU-ABBVIE-6441523$ABBVIE$$80$YR$$M$Y$$$20250908$$HP$EU$EU
257532281$25753228$1$I$20240626$20250828$20250903$20250903$EXP$$EU-AMGEN-FRASP2025172448$AMGEN$$28$YR$A$M$Y$90.9$KG$20250902$$MD$EU$EU
257533101$25753310$1$I$$20250822$20250903$20250903$EXP$$US-NOVOPROD-1506820$NOVO NORDISK$$62$YR$$$Y$$$20250902$$CN$US$US
257533311$25753331$1$I$20250825$20250825$20250903$20250903$EXP$$BR-JNJFOC-20250832289$JOHNSON AND JOHNSON$$46$YR$A$M$Y$74$KG$20250902$$MD$BR$BR
257533611$25753361$1$I$$20250828$20250903$20250903$PER$$US-SA-2025SA262308$SANOFI AVENTIS$$$$A$F$Y$$$20250903$$HP$US$US
257534872$25753487$2$F$$20250901$20250903$20250909$EXP$$CN-BEIGENE-BGN-2025-014544$BEIGENE$$49$YR$$$Y$68$KG$20250909$$$CN$CN
257536121$25753612$1$I$$20250828$20250903$20250903$PER$$US-PFIZER INC-PV202500105263$PFIZER$$69$YR$$M$Y$$$20250902$$MD$US$US
257536722$25753672$2$F$$20250904$20250903$20250908$PER$$US-PFIZER INC-202500172869$PFIZER$$$$$F$Y$$$20250908$$PH$US$US
257536741$25753674$1$I$$20250828$20250903$20250903$PER$$US-PFIZER INC-202500172060$PFIZER$$$$$M$Y$$$20250902$$HP$US$US
257536952$25753695$2$F$20250501$20250904$20250903$20250911$EXP$$JP-JNJFOC-20250900063$JOHNSON AND JOHNSON$$$$$$Y$$$20250912$$PH$JP$JP
257537161$25753716$1$I$$20250822$20250903$20250903$EXP$GB-MHRA-MED-202508211719054410-DYNKF$GB-Accord-502137$ACCORD$$$$$F$Y$$$20250903$$HP$GB$GB
257537451$25753745$1$I$$20250224$20250903$20250903$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-497442$RANBAXY$$$$A$M$Y$$$20250903$$CN$US$US
257538201$25753820$1$I$20220801$20250828$20250903$20250903$EXP$EU-SEMPA-2025-005914$EU-ASTELLAS-2025-AER-047504$ASTELLAS$$59$YR$A$F$Y$$$20250903$$PH$EU$EU
257539561$25753956$1$I$$20250825$20250903$20250903$EXP$$US-BAYER-2025A115708$BAYER HEALTHCARE LLC$Barisano D.; Nance G.; Gleason M.; Chai P.; Fundora M.P.; Woods G.; Rosenblum J.M.; Branstetter J.W.. Safety of direct oral anticoagulants in surgical bioprosthetic heart valves: a paediatric institution^s experience. Cardiology in the Young. 2025;1-6$13$YR$T$$Y$52$KG$20250903$$HP$US$US
257539691$25753969$1$I$$20250826$20250903$20250903$PER$$US-BAYER-2025A114565$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250903$$CN$US$US
257540531$25754053$1$I$20250728$20250827$20250903$20250903$EXP$GB-MHRA-MED-202508272348100710-BKYQG$GB-RDY-GBR/2025/08/013356$DR REDDYS$$79$YR$E$M$Y$87$KG$20250903$$MD$GB$GB
257541271$25754127$1$I$$20250825$20250903$20250903$EXP$$CA-CELLTRION INC.-2025CA030582$CELLTRION$$$$$$Y$$$20250903$$HP$CA$CA
257541641$25754164$1$I$20250101$20250822$20250903$20250903$EXP$EU-AFSSAPS-BX2025001174$EU-Accord-502393$ACCORD$$75$YR$E$M$Y$100$KG$20250903$$MD$EU$EU
257543341$25754334$1$I$$20241118$20250903$20250903$PER$$US-STRIDES ARCOLAB LIMITED-2024SP015250$STRIDES$Broome DT, Kodali A, Phillips D, Makin V, Mendlovic D, Zimmerman RS.. Combined Dipeptidyl Peptidase 4 Inhibitor and a-Glucosidase Inhibitor Treatment in Postprandial Hypoglycemia.. Clin-Diabet. 2022;40 (1):116-119.$3$DEC$$F$Y$$$20250903$$HP$US$US
257543581$25754358$1$I$$20250826$20250903$20250903$EXP$$US-RDY-USA/2025/08/013298$DR REDDYS$Azad F, Frisch A, Cuevo R. TCL-822: A Case of Hepatosplenic T-Cell Lymphoma: A Rare and Aggressive Subtype of Peripheral T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2025;S872. DOI: 10.1016/S2152-2650(25)02512-1.$31$YR$A$M$Y$$$20250903$$HP$US$US
257543712$25754371$2$F$$20250902$20250903$20250904$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-121779$BRISTOL-MYERS SQUIBB COMPANY$$53$YR$A$F$Y$$$20250904$$CN$US$US
257544051$25754405$1$I$20250829$20250829$20250903$20250903$EXP$$GB-ASTRAZENECA-202508GLO024774GB$ALEXION PHARMACEUTICALS$$51$YR$A$M$Y$106$KG$20250903$$MD$GB$GB
257544691$25754469$1$I$20250724$20250822$20250903$20250903$EXP$$JP-PHATHOM PHARMACEUTICALS INC.-2025PHT02412$Phathom Pharmaceuticals$$76$YR$$M$Y$$$20250903$$MD$JP$JP
257545091$25754509$1$I$$20250826$20250903$20250903$EXP$$JP-BEH-2025217159$CSL BEHRING$$5$DEC$A$F$Y$$$20250903$$MD$JP$JP
257545111$25754511$1$I$20250821$20250822$20250903$20250903$EXP$$GB-MHRA-MED-202508221055003190-CDTRS$AUROBINDO$$59$YR$$M$Y$70$KG$20250903$$HP$GB$GB
257545551$25754555$1$I$$20250826$20250903$20250903$EXP$GB-drreddys-LIT/UKI/22/0158193$GB-RDY-LIT/UKI/22/0158193$DR REDDYS$Rice K, Hikin L, Lawson A, Smith PR, Morley S. Quantification of Flualprazolam in Blood by LC-MS-MS: A Case Series of Nine Deaths. J Anal Toxicol. 2021;45(4): 410-6. doi:10.1093/jat/bkaa098.$40$YR$A$M$Y$$$20250903$$HP$GB$GB
257545971$25754597$1$I$$20250216$20250903$20250903$EXP$GB-MHRA-MED-202502140909102170-VDWLY$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-01792$ALKEM$$$$$M$Y$$$20250903$$HP$GB$GB
257546061$25754606$1$I$$20250717$20250903$20250903$EXP$GB-TEVA-VS-3350155$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-07892$ALKEM$$$$$M$Y$$$20250903$$CN$GB$GB
257546471$25754647$1$I$$20250625$20250903$20250903$EXP$$IN-ALKEM LABORATORIES LIMITED-IN-ALKEM-2025-07173$ALKEM$Bala A, Ghai B, George A, Banerjee S, Kumar M, Dayal D.. Caudal epidural steroid injection as a novel therapy for treatment-induced neuropathy of diabetes in children: report of two cases. J Pediatr Endocrinol Metab. 2025;unk:1-4$16$YR$$F$Y$$$20250903$$HP$IN$IN
257547071$25754707$1$I$20250825$20250825$20250903$20250903$EXP$$JP-EMD Serono-2025044058$EMD SERONO INC$$62$YR$A$M$Y$63$KG$20250903$$MD$JP$JP
257547161$25754716$1$I$$20250825$20250903$20250903$EXP$$US-LEX-000803$LEXICON PHARMACEUTICALS$$81$YR$$F$Y$$$20250902$$CN$US$US
257549081$25754908$1$I$$20250820$20250903$20250903$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-524454$RANBAXY$Benyahia R, Roques O, Ysebaert L, Berge Y, Mazieres J, Syrykh C, et al.. Pivotal role for typing of renal infiltrates: kidney localisation of a lymphoma presenting as pembrolizumab-associated nephritis. A lesson for the clinical nephrologist. J Nephrol. 2025;38 (5):1487-1491$77$YR$$F$Y$$$20250903$$HP$EU$EU
257550821$25755082$1$I$20250825$20250826$20250903$20250903$EXP$$CN-ORGANON-O2508CHN002189$ORGANON$$35$YR$$M$Y$90$KG$20250903$$HP$CN$CN
257551001$25755100$1$I$$20250820$20250903$20250903$EXP$$US-HETERO-HET2025US05078$HETERO$Alqawasmi M, Escobar Gil T, Shah K, Millhuff A, Parchim N.. Bradycardia Renal Failure Atrioventricular Nodal Blockade Shock and Hyperkalemia (BRASH) Syndrome A Frequently Overlooked and Underdiagnosed Condition. Cureus. 2025;17(7):e87601$65$YR$$M$Y$$$20250903$$HP$US$US
257551161$25755116$1$I$$20250825$20250903$20250903$PER$$US-SMPA-2025SPA011055$SUNOVION$$83$YR$$M$Y$$$20250902$$$US$US
257551261$25755126$1$I$$20250829$20250903$20250903$EXP$$US-SA-2025SA261715$SANOFI AVENTIS$$$$A$F$Y$61.36$KG$20250903$$HP$US$US
257551451$25755145$1$I$20250827$20250828$20250903$20250903$PER$$US-ELI_LILLY_AND_COMPANY-US202508029419$ELI LILLY AND COMPANY$$67$YR$E$M$Y$$$20250903$$CN$US$US
257552771$25755277$1$I$20250721$20250721$20250903$20250903$PER$$US-ELI_LILLY_AND_COMPANY-US202509000204$ELI LILLY AND COMPANY$$63$YR$A$F$Y$83.9$KG$20250903$$CN$US$US
257554061$25755406$1$I$$20250828$20250903$20250903$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009749$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250903$$CN$US$US
257554361$25755436$1$I$$20250829$20250903$20250903$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009741$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250903$$CN$US$US
257554511$25755451$1$I$20250808$20250829$20250903$20250903$EXP$EU-NOMAADVRE-RELISV-2025-Va9jpk$EU-SAMSUNG BIOEPIS-SB-2025-29414$SAMSUNG BIOEPIS$$47$YR$A$F$Y$$$20250903$$MD$EU$EU
257554701$25755470$1$I$20250825$20250829$20250903$20250903$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009753$ACADIA PHARMACEUTICALS$$77$YR$$F$Y$$$20250903$$CN$US$US
257555061$25755506$1$I$20250101$20250829$20250903$20250903$EXP$$US-JNJFOC-20250837602$JOHNSON AND JOHNSON$$45$YR$A$M$Y$$$20250903$$HP$US$US
257555941$25755594$1$I$$20250829$20250903$20250903$PER$$US-ELI_LILLY_AND_COMPANY-US202509001032$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250903$$CN$US$US
257556943$25755694$3$F$20240101$20250910$20250903$20250918$EXP$$NVSC2025DE117092$NOVARTIS$$$$A$F$Y$56$KG$20250918$$CN$EU$EU
257558321$25755832$1$I$$20250823$20250903$20250903$EXP$$GB-MHRA-MED-202508231211554650-ZMCVG$AUROBINDO$$26$YR$$F$Y$$$20250903$$CN$GB$GB
257560051$25756005$1$I$$20250902$20250903$20250903$EXP$$IN-ROCHE-10000379142$ROCHE$$$$E$M$Y$$$20250903$$MD$IN$IN
257560941$25756094$1$I$20250811$20250825$20250903$20250903$EXP$CN-91110000556821568D-2025DRL001709$CN-RDY-CHN/2025/08/013225$DR REDDYS$$68$YR$E$M$Y$60$KG$20250903$$HP$CN$CN
257561291$25756129$1$I$20250802$20250902$20250902$20250902$DIR$773210$$FDA-CTU$$59$YR$$F$N$78.75$KG$20250902$N$HP$PR$
257561781$25756178$1$I$20240701$20250901$20250903$20250903$EXP$EU-AFSSAPS-PA2025000172$EU-SA-2025SA262761$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250903$$PH$EU$EU
257561941$25756194$1$I$20250828$20250903$20250903$20250903$EXP$EU-JNJFOC-20250902961$EU-JNJFOC-20250902961$JOHNSON AND JOHNSON$$67$YR$E$M$Y$$$20250903$$MD$EU$EU
257562041$25756204$1$I$20240101$20250822$20250903$20250903$EXP$$US-NOVOPROD-1507931$NOVO NORDISK$$55$YR$$F$Y$$$20250903$$CN$US$US
257562101$25756210$1$I$$20250825$20250903$20250903$PER$$JP-Eisai-EC-2025-195687$EISAI$$$$$F$Y$$$20250903$$MD$JP$JP
257562221$25756222$1$I$$20250822$20250903$20250903$EXP$$US-NOVOPROD-1508232$NOVO NORDISK$$49$YR$$$Y$$$20250903$$CN$US$US
257562231$25756223$1$I$$20250822$20250903$20250903$EXP$$CO-NOVOPROD-1507627$NOVO NORDISK$$$$$F$Y$$$20250903$$MD$CO$CO
257562351$25756235$1$I$20241001$20250822$20250903$20250903$EXP$$US-NOVOPROD-1508282$NOVO NORDISK$$74$YR$$M$Y$$$20250903$$CN$US$US
257562681$25756268$1$I$$20250902$20250902$20250902$DIR$773178$$FDA-CTU$$$$$$N$$$20250902$N$$US$
257562971$25756297$1$I$20250101$20250826$20250903$20250903$EXP$$US-Genus_Lifesciences-USA-ALL0580202500134$GENUS LIFESCIENCES$Stephanos K, Hayes BD. Caffeine Overdose Resulting in Seizure Like Activity and Rhabdomyolysis in a Child A Case Report. J Emerg Med. 2025 Aug;75(C): 323-6.$4$YR$C$F$Y$$$20250903$$MD$US$US
257563141$25756314$1$I$20250731$20250829$20250903$20250903$EXP$EU-CADRBFARM-2025338104$EU-TEVA-VS-3367869$TEVA$$75$YR$$F$Y$72$KG$20250903$$CN$EU$EU
257564131$25756413$1$I$$20250902$20250902$20250902$DIR$773217$$FDA-CTU$$$$$M$N$$$20250902$N$HP$US$
257564761$25756476$1$I$$20250824$20250903$20250903$EXP$$US-HQ-20250062$HQ SPECIALTY$Blake RJ, Frye BM, Lastinger AM. Linezolid-Induced Glossitis and Papillitis in Orthopedic Patients With Postoperative Infection: A Case Report. Case Rep Infect Dis. 2025 Aug 10;2025:9036606. doi: 10.1155/crdi/9036606.$68$YR$$F$Y$$$20250828$$MD$US$
257565501$25756550$1$I$20250101$20250828$20250903$20250903$PER$$US-SA-2025SA262626$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250903$$HP$US$US
257565852$25756585$2$F$20250101$20250916$20250903$20250923$PER$$US-SA-2025SA262433$SANOFI AVENTIS$$9$YR$C$M$Y$$$20250923$$HP$US$US
257566121$25756612$1$I$$20250828$20250903$20250903$PER$$US-SA-2025SA262725$SANOFI AVENTIS$$$$E$F$Y$$$20250903$$HP$US$US
257566161$25756616$1$I$20250801$20250828$20250903$20250903$PER$$US-SA-2025SA262250$SANOFI AVENTIS$$59$YR$A$F$Y$$$20250903$$HP$US$US
257566191$25756619$1$I$20250101$20250828$20250903$20250903$PER$$US-SA-2025SA261023$SANOFI AVENTIS$$33$YR$A$F$Y$$$20250903$$HP$US$US
257566451$25756645$1$I$20250808$20250828$20250903$20250903$PER$$US-SA-2025SA260657$SANOFI AVENTIS$$34$YR$A$M$Y$$$20250903$$MD$US$US
257566551$25756655$1$I$$20250828$20250903$20250903$PER$$US-SA-2025SA261855$SANOFI AVENTIS$$$$A$F$Y$$$20250903$$HP$US$US
257567781$25756778$1$I$20250701$20250829$20250903$20250903$PER$$US-SA-2025SA263864$SANOFI AVENTIS$$71$YR$E$F$Y$$$20250903$$HP$US$US
257568072$25756807$2$F$$20250903$20250903$20250908$EXP$EU-ROM-ROU/2025/08/012360$EU-SANDOZ INC.-SDZ2025RO062775$SANDOZ$$24$YR$$M$Y$$$20250908$$HP$EU$EU
257569531$25756953$1$I$$20250828$20250903$20250903$PER$$US-ABBVIE-6441050$ABBVIE$$$$C$M$Y$$$20250903$$CN$US$US
257569541$25756954$1$I$20211004$20250901$20250903$20250903$EXP$CH-SM-2025-07025$CH-SA-2025SA263187$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250903$$PH$CH$CH
257570121$25757012$1$I$$20250901$20250903$20250903$EXP$$IN-BRISTOL-MYERS SQUIBB COMPANY-2025-121753$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$$Y$$$20250903$$MD$IN$IN
257570271$25757027$1$I$20250815$20250828$20250903$20250903$EXP$EU-AFSSAPS-TS2025000930$EU-ARGENX-2025-ARGX-FR011675$ARGENX BVBA$$$$$$Y$$$20250903$$MD$EU$EU
257570311$25757031$1$I$$20250828$20250903$20250903$PER$$US-ROCHE-10000376784$ROCHE$$$$$$Y$$$20250903$$CN$US$US
257570711$25757071$1$I$$20250828$20250903$20250903$PER$$US-SA-2025SA260666$SANOFI AVENTIS$$55$YR$A$$Y$$$20250903$$CN$US$US
257573341$25757334$1$I$20250814$20250829$20250903$20250903$EXP$$EU-AMERICAN REGENT INC-2025003342$AMERICAN REGENT$$33$YR$$F$Y$58$KG$20250903$$HP$EU$EU
257574751$25757475$1$I$$20250902$20250903$20250903$PER$$US-PFIZER INC-PV202500106229$PFIZER$$$$$F$Y$$$20250903$$CN$US$US
257574892$25757489$2$F$20250817$20250905$20250903$20250909$EXP$$CN-PFIZER INC-PV202500105076$PFIZER$$36$YR$$F$Y$52$KG$20250909$$HP$CN$CN
257575702$25757570$2$F$$20250902$20250903$20250904$EXP$$IN-PFIZER INC-PV202500104676$PFIZER$$56$YR$$F$Y$$$20250904$$CN$IN$IN
257577091$25757709$1$I$$20250827$20250903$20250903$PER$$US-ABBVIE-6439061$ABBVIE$$$$$$Y$$$20250903$$CN$US$US
257577141$25757714$1$I$$20250828$20250903$20250903$EXP$$US-NOVOPROD-1510266$NOVO NORDISK$$65$YR$$M$Y$$$20250903$$CN$US$US
257577251$25757725$1$I$20230301$20250820$20250903$20250903$EXP$$IN-SCIEGENP-2025SCLIT00250$SCIEGEN PHARMACEUTICALS INC$Shah M, et al.The next gen poison- a case series of amlodipine overdose.Asia Pacific Journal of Medical Toxicology.sep-2024;13(03):125-130$20$YR$A$F$Y$$$20250903$$HP$IN$IN
257577761$25757776$1$I$$20250827$20250903$20250903$EXP$$JP-MSD-2401JPN001165J$MERCK SHARP + DOHME LLC$$78$YR$$F$Y$$$20250903$$HP$JP$JP
257578841$25757884$1$I$$20250826$20250903$20250903$PER$$US-BIOGEN-2025BI01322393$BIOGEN$$$$$F$Y$$$20250903$$MD$US$US
257579091$25757909$1$I$$20250822$20250903$20250903$PER$$NVSC2025US133892$NOVARTIS$$$$$F$Y$$$20250904$$PH$US$US
257579221$25757922$1$I$$20250828$20250903$20250903$EXP$$NVSC2025CN137038$NOVARTIS$$72$YR$$M$Y$$$20250904$$CN$CN$CN
257579451$25757945$1$I$20250829$20250829$20250903$20250903$PER$$US-SA-2025SA262975$SANOFI AVENTIS$$$$$M$Y$$$20250904$$CN$US$US
257579911$25757991$1$I$$20250826$20250903$20250903$EXP$$CN-BEIGENE-BGN-2025-014538$BEIGENE$$59$YR$$$Y$$$20250903$$$CN$CN
257581241$25758124$1$I$20250727$20250728$20250903$20250903$PER$$US-ELI_LILLY_AND_COMPANY-US202509000214$ELI LILLY AND COMPANY$$81$YR$E$M$Y$113.38$KG$20250903$$CN$US$US
257582961$25758296$1$I$$20250820$20250904$20250904$EXP$GB-MHRA-MED-202508191520107880-TWSQY$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-09268$ALKEM$$$$$F$Y$$$20250904$$HP$GB$GB
257583111$25758311$1$I$$20250826$20250904$20250904$PER$$US-Encube-002215$ENCUBE ETHICALS PVT. LTD.$$$$$M$Y$$$20250903$$CN$US$
257583391$25758339$1$I$$20250902$20250904$20250904$EXP$$CA-APOTEX-2025AP029537$APOTEX$$70$YR$$M$Y$$$20250904$$CN$CA$CA
257584612$25758461$2$F$20190109$20250812$20250904$20250918$EXP$$EU-AstraZeneca-2021A836990$ALEXION PHARMACEUTICALS$$52$YR$A$F$Y$70$KG$20250918$$MD$EU$EU
257584671$25758467$1$I$$20250901$20250904$20250904$EXP$$EU-SANDOZ INC.-SDZ2025FR063525$SANDOZ$$40$YR$$F$Y$$$20250904$$MD$EU$EU
257585201$25758520$1$I$$20250825$20250904$20250904$EXP$$CA-SANDOZ INC.-SDZ2025CA063804$SANDOZ$$52$YR$$F$Y$$$20250904$$HP$CA$CA
257585361$25758536$1$I$$20250823$20250904$20250904$EXP$AU-TGA-844129$AU-Accord-501750$ACCORD$$17$YR$T$F$Y$$$20250904$$HP$AU$
257585481$25758548$1$I$20250830$20250830$20250904$20250904$EXP$$EU-ABBVIE-6442765$ABBVIE$$83$YR$$F$Y$$$20250904$$HP$EU$EU
257585621$25758562$1$I$$20250829$20250904$20250904$EXP$$US-JNJFOC-20250838058$JOHNSON AND JOHNSON$$$$$M$Y$$$20250904$$HP$US$US
257585691$25758569$1$I$20241118$20250821$20250904$20250904$EXP$GB-MHRA-MED-202507102000144930-NHMRT$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-07485$ALKEM$$$$$F$Y$$$20250904$$MD$GB$GB
257586601$25758660$1$I$$20250827$20250904$20250904$PER$$US-SA-2025SA260553$SANOFI AVENTIS$$$$A$F$Y$68.18$KG$20250904$$HP$US$US
257586851$25758685$1$I$$20250902$20250904$20250904$PER$$US-SA-2025SA263840$SANOFI AVENTIS$$24$YR$A$F$Y$$$20250904$$CN$US$US
257586982$25758698$2$F$20250801$20250919$20250904$20250927$PER$$US-SA-2025SA263000$SANOFI AVENTIS$$32$YR$A$F$Y$$$20250926$$HP$US$US
257588281$25758828$1$I$$20250903$20250904$20250904$EXP$$US-SANDOZ INC.-SDZ2025US063986$SANDOZ$$63$YR$$M$Y$$$20250904$$MD$US$US
257588691$25758869$1$I$$20250822$20250904$20250904$EXP$$VN-STRIDES ARCOLAB LIMITED-2025SP011103$STRIDES$Nguyen TD, Lam HT, Vo TD. Invasive Klebsiella Syndrome with Liver Abscess and Endogenous Endophthalmitis. Int Med Case Rep J. 2025;18:559-565$$$$$Y$$$20250904$$HP$VN$VN
257589581$25758958$1$I$20250801$20250902$20250904$20250904$PER$$US-Blueprint Medicines Corporation-2025-AER-01924$BLUEPRINT MEDICINES$$62$YR$A$F$Y$$$20250904$$CN$US$US
257589821$25758982$1$I$20250801$20250828$20250904$20250904$PER$$US-SA-2025SA262142$SANOFI AVENTIS$$59$YR$A$M$Y$$$20250904$$CN$US$US
257589851$25758985$1$I$$20250829$20250904$20250904$PER$$US-SA-2025SA263233$SANOFI AVENTIS$$32$YR$A$$Y$$$20250904$$CN$US$US
257590711$25759071$1$I$$20250903$20250904$20250904$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-122341$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$F$Y$$$20250904$$CN$US$US
257592361$25759236$1$I$$20250902$20250904$20250904$PER$$US-JNJFOC-20250902632$JOHNSON AND JOHNSON$$$$$$Y$$$20250904$$CN$US$US
257592641$25759264$1$I$20250818$20250829$20250904$20250904$EXP$$CN-EMD Serono-2025044513$EMD SERONO INC$$18$YR$A$M$Y$$$20250904$$$CN$CN
257592681$25759268$1$I$$20250820$20250904$20250904$EXP$$US-GRANULES-US-2025GRALIT00495$GRANULES PHARMACEUTICALS INC$T. Grover.Metformin Associated Lactic Acidosis - A Critical Diagnostic Priority.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A3870$70$YR$E$F$Y$$$20250904$$HP$US$US
257593621$25759362$1$I$$20250828$20250904$20250904$EXP$$CA-CELLTRION INC.-2025CA031177$CELLTRION$$$$$$Y$$$20250904$$CN$CA$CA
257593841$25759384$1$I$$20250721$20250904$20250904$PER$$US-ASCENT-2025ASSPO00138$ASCENT PHARMACEUTICALS INC$$$$$M$Y$$$20250904$$CN$US$US
257594291$25759429$1$I$20200721$20241023$20250904$20250904$PER$$US-CHIESI-2024CHF06292$CHIESI$$6$YR$$F$Y$27$KG$20250904$$CN$US$US
257594801$25759480$1$I$$20250312$20250904$20250904$PER$$US-BSC-2025000021$BOSTON SCIENTIFIC$$32$YR$$F$Y$$$20250904$$CN$US$US
257595091$25759509$1$I$20250805$20250826$20250904$20250904$EXP$EU-AFSSAPS-TS2025000903$EU-TEVA-VS-3367123$TEVA$$61$YR$$F$Y$79$KG$20250904$$MD$EU$EU
257595892$25759589$2$F$20250801$20250909$20250904$20250917$PER$$US-UNITED THERAPEUTICS-UNT-2025-028447$UNITED THERAPEUTICS$$63$YR$$F$Y$89.796$KG$20250917$$$US$US
257596521$25759652$1$I$$20250805$20250904$20250904$PER$$US-TLM-TLM-2025-05552$TOLMAR$$$$$F$Y$$$20250902$$HP$US$US
257596741$25759674$1$I$20250815$20250901$20250904$20250904$EXP$$CN-ROCHE-10000378662$ROCHE$$48$YR$A$M$Y$$$20250904$$HP$CN$CN
257597561$25759756$1$I$$20250829$20250904$20250904$PER$$US-SA-2025SA263739$SANOFI AVENTIS$$$$A$M$Y$$$20250904$$HP$US$US
257597961$25759796$1$I$20250812$20250812$20250904$20250904$PER$$US-GALDERMA-US2025014981$GALDERMA$$$$$$Y$$$20250904$$CN$US$US
257598391$25759839$1$I$$20250829$20250904$20250904$EXP$$EU-IPCA LABORATORIES LIMITED-IPC-2025-PT-002384$IPCA$Rodrigues R, Amador P, Rassi L, Seixo F, Parreira L, Fonseca N and Soares L. Brugada pattern in a patient medicated with lamotrigine. Portuguese Journal of Cardiology. 2013;32(10):807-10$$$$$Y$$$20250904$$HP$EU$EU
257598881$25759888$1$I$20210604$20250820$20250904$20250904$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-525455$RANBAXY$$$$$M$Y$3.2$KG$20250904$$MD$EU$EU
257599901$25759990$1$I$$20250901$20250904$20250904$EXP$$CA-Orion Corporation ORION PHARMA-25_00036389$ORION$$63$YR$A$M$Y$$$20250904$$HP$CA$
257600221$25760022$1$I$20250101$20250826$20250904$20250904$EXP$$US-UCBSA-2025053673$UCB$$$$$F$Y$66.304$KG$20250904$$HP$US$US
257600272$25760027$2$F$20250101$20250919$20250904$20250927$PER$$US-SA-2025SA264042$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250927$$HP$US$US
257600331$25760033$1$I$$20250829$20250904$20250904$PER$$US-SA-2025SA262892$SANOFI AVENTIS$$55$YR$A$M$Y$$$20250904$$CN$US$US
257600421$25760042$1$I$$20250820$20250904$20250904$EXP$$US-GRANULES-US-2025GRALIT00493$GRANULES PHARMACEUTICALS INC$B. Singh.Managing Page Kidney in a Patient With Underlying Renal Cell Carcinoma: A Case Report.American Journal of Respiratory and Critical Care Medicine.MAY-2025;211:A7550$48$YR$A$M$Y$$$20250904$$HP$US$US
257601561$25760156$1$I$20250806$20250902$20250904$20250904$EXP$$US-ASTRAZENECA-202509USA001043US$ALEXION PHARMACEUTICALS$$68$YR$E$M$Y$$$20250904$$MD$US$US
257601601$25760160$1$I$$20250903$20250904$20250904$PER$$US-JNJFOC-20250904066$JOHNSON AND JOHNSON$$$$$$Y$$$20250904$$HP$US$US
257601621$25760162$1$I$$20250822$20250904$20250904$PER$$US-APOTEX-2025AP012375$APOTEX$Taylor AB, Masich AM, Fulco PP. Evaluation of Drug-Drug Interactions of Modafinil and Armodafinil with Concurrent Antiretroviral Therapies: A Case Series. The Annals of pharmacotherapy. 2025;106002802513615:1-4$53$YR$$$Y$$$20250904$$PH$US$US
257601891$25760189$1$I$$20250826$20250904$20250904$PER$$US-TAKEDA-2025TUS075872$TAKEDA$$59$YR$$F$Y$131.5$KG$20250904$$$US$US
257602221$25760222$1$I$$20250821$20250904$20250904$PER$$US-ROCHE-10000372340$ROCHE$$$$A$F$Y$$$20250904$$HP$US$US
257602491$25760249$1$I$20250801$20250903$20250903$20250903$DIR$FDA-CDER-CTU-2025-58790$$FDA-CTU$$67$YR$$M$N$$$20250903$N$PH$US$
257602571$25760257$1$I$20250827$20250829$20250904$20250904$EXP$CN-NMPACDR-3413021511544202500256$CN-BAXTER-2025BAX020613$BAXTER$$48$YR$$F$Y$65$KG$20250904$$MD$CN$CN
257603171$25760317$1$I$$20250903$20250903$20250903$DIR$FDA-CDER-CTU-2025-58767$$FDA-CTU$$$$$M$N$$$20250903$N$$US$
257603831$25760383$1$I$20241223$20250825$20250904$20250904$EXP$$EU-TEVA-VS-3366612$TEVA$$79$YR$$M$Y$$$20250904$$HP$EU$EU
257604021$25760402$1$I$$20250825$20250904$20250904$EXP$$US-TEVA-VS-3366878$TEVA$Patel S, Jeurling S, Albayda J, Tiniakou E, Kang J. Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series. Rheumatology 2025;.; Patel S, Jeurling S, Albayda J, Tiniakou E, Kang J. Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series. Rheumatology 2025;.$50$YR$$M$Y$$$20250904$$HP$US$US
257604311$25760431$1$I$$20250825$20250904$20250904$EXP$$US-UNITED THERAPEUTICS-UNT-2025-030216$UNITED THERAPEUTICS$$$$$F$Y$$$20250904$$$US$US
257604751$25760475$1$I$20250101$20250902$20250904$20250904$PER$$US-SA-2025SA264079$SANOFI AVENTIS$$69$YR$E$M$Y$$$20250904$$HP$US$US
257605271$25760527$1$I$20150817$20250828$20250904$20250904$EXP$$BR-BIOGEN-2025BI01322699$BIOGEN$$36$YR$$F$Y$67$KG$20250904$$CN$BR$BR
257606261$25760626$1$I$$20250828$20250904$20250904$EXP$$US-SANDOZ INC.-SDZ2025US063284$SANDOZ$$66$YR$$F$Y$102$KG$20250904$$CN$US$US
257606441$25760644$1$I$$20250822$20250904$20250904$EXP$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-09835$HIKMA$$$$$M$Y$$$20250904$$MD$US$US
257606691$25760669$1$I$$20250902$20250904$20250904$PER$$US-SA-2025SA264549$SANOFI AVENTIS$$43$YR$A$M$Y$$$20250904$$CN$US$US
257607171$25760717$1$I$$20250829$20250904$20250904$PER$$US-ELI_LILLY_AND_COMPANY-US202509001658$ELI LILLY AND COMPANY$$53$YR$A$M$Y$$$20250904$$CN$US$US
257608351$25760835$1$I$$20250820$20250904$20250904$EXP$$JP-ASTRAZENECA-202508GLO018655JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250904$$PH$JP$JP
257609871$25760987$1$I$$20250902$20250904$20250904$EXP$$GB-GILEAD-2025-0726835$GILEAD$$7$DEC$E$M$Y$$$20250904$$MD$GB$GB
257610511$25761051$1$I$20250101$20250902$20250904$20250904$EXP$$GB-VERTEX PHARMACEUTICALS-2025-014514$VERTEX$$$$A$M$Y$$$20250904$$CN$GB$GB
257611341$25761134$1$I$20250818$20250826$20250904$20250904$EXP$$EU-EMD Serono-2025044050$EMD SERONO INC$$73$YR$E$M$Y$$$20250904$$MD$EU$EU
257611361$25761136$1$I$$20250902$20250904$20250904$PER$$US-JNJFOC-20250902301$JOHNSON AND JOHNSON$$$$$$Y$$$20250904$$HP$US$US
257611861$25761186$1$I$20250718$20250902$20250904$20250904$EXP$EU-MINISAL02-1055093$EU-SA-2025SA264138$SANOFI AVENTIS$$49$YR$A$F$Y$$$20250904$$MD$EU$EU
257611941$25761194$1$I$20240901$20250903$20250904$20250904$DIR$FDA-CDER-CTU-2025-58897$$FDA-CTU$$72$YR$$F$N$$$20250903$N$$US$
257612281$25761228$1$I$$20250829$20250904$20250904$EXP$$US-AMGEN-USASP2025173484$AMGEN$$$$$F$Y$$$20250904$$CN$US$US
257612621$25761262$1$I$$20240717$20250904$20250904$PER$$US-BRAINTREE LABORATORIES, INC.-2024BTE00460$BRAINTREE$$$$$F$Y$$$20250903$$CN$US$US
257612701$25761270$1$I$20240901$20240915$20250904$20250904$PER$$US-BRAINTREE LABORATORIES, INC.-2024BTE00603$BRAINTREE$$$$$M$Y$$$20250903$$CN$US$US
257612771$25761277$1$I$20241101$20241202$20250904$20250904$PER$$US-BRAINTREE LABORATORIES, INC.-2024BTE00788$BRAINTREE$$70$YR$$M$Y$64.853$KG$20250903$$CN$US$US
257612832$25761283$2$F$20250101$20250829$20250904$20250910$EXP$$CA-ADVANZ PHARMA-202508007586$ADVANZ PHARMA$$$$$$Y$$$20250910$$PH$CA$CA
257613381$25761338$1$I$20250402$20250901$20250904$20250904$EXP$EU-AEMPS-1744934$EU-PFIZER INC-202500173351$PFIZER$$60$YR$$M$Y$$$20250904$$MD$EU$EU
257613811$25761381$1$I$20230101$20250901$20250904$20250904$EXP$EU-AFSSAPS-MA2025001156$EU-FreseniusKabi-FK202512141$FRESENIUS KABI$$42$YR$A$F$Y$$$20250904$$HP$EU$EU
257613872$25761387$2$F$20250811$20250902$20250904$20250908$EXP$EU-AFSSAPS-AM2025000677$EU-PFIZER INC-202500173406$PFIZER$$48$YR$$M$Y$131$KG$20250908$$PH$EU$EU
257613921$25761392$1$I$20230419$20230717$20250904$20250904$EXP$$US-SANDOZ INC.-NVSC2023US106936$SANDOZ$$53$YR$$F$Y$$$20250904$$MD$US$US
257614352$25761435$2$F$20250824$20250909$20250904$20250910$30DAY$$US-PFIZER INC-202500170859$PFIZER$$12$YR$$F$Y$$$20250910$$CN$US$US
257614981$25761498$1$I$20241209$20241209$20250904$20250904$PER$$US-MEDEXUS PHARMA, INC.-2024MED00495$MEDEXUS PHARMA$$90$YR$$F$Y$68.946$KG$20250730$$CN$US$US
257615121$25761512$1$I$20240101$20241003$20250904$20250904$PER$$US-MEDEXUS PHARMA, INC.-2024MED00419$MEDEXUS PHARMA$$$$$F$Y$$$20250730$$CN$US$US
257615131$25761513$1$I$20230101$20241016$20250904$20250904$PER$$US-MEDEXUS PHARMA, INC.-2024MED00431$MEDEXUS PHARMA$$$$$F$Y$$$20250730$$CN$US$US
257615451$25761545$1$I$20250818$20250903$20250903$20250903$DIR$773336$$FDA-CTU$$48$YR$$F$N$72$KG$20250903$N$CN$US$
257616431$25761643$1$I$$20250829$20250904$20250904$EXP$$EU-SANDOZ INC.-SDZ2025DE063383$SANDOZ$$$$$M$Y$$$20250904$$MD$EU$EU
257616711$25761671$1$I$$20250828$20250904$20250904$EXP$$IN-ELI_LILLY_AND_COMPANY-IN202509000503$ELI LILLY AND COMPANY$$$$$$Y$$$20250904$$MD$IN$IN
257616871$25761687$1$I$20240101$20250826$20250904$20250904$EXP$$CO-EXELIXIS-EXL-2025-011235$EXELIXIS$$31$YR$$M$Y$$$20250904$$MD$CO$CO
257617341$25761734$1$I$$20250820$20250904$20250904$PER$$US-RDY-USA/2025/08/012938$DR REDDYS$$$$$F$Y$$$20250904$$CN$US$US
257618291$25761829$1$I$$20250811$20250904$20250904$PER$$US-GALDERMA-US2025014999$GALDERMA$$$$$$Y$$$20250904$$CN$US$US
257619042$25761904$2$F$$20250906$20250904$20250916$PER$$US-LUNDBECK-DKLU4018880$LUNDBECK$$$$$$Y$$$20250916$$CN$US$US
257619111$25761911$1$I$$20250829$20250904$20250904$PER$$US-PURDUE-USA-2025-0320184$PURDUE$$$$$$Y$$$20250904$$CN$US$US
257619611$25761961$1$I$20230101$20250829$20250904$20250904$EXP$EU-AFSSAPS-MA2025000977$EU-MYLANLABS-2025M1074885$MYLAN$$56$YR$$F$Y$$$20250904$$$EU$EU
257621391$25762139$1$I$20250402$20250903$20250904$20250904$PER$$US-BAYER-2025A117466$BAYER HEALTHCARE PHARMACEUTICALS INC.$$57$YR$A$F$Y$$$20250904$$CN$US$US
257622273$25762227$3$F$$20250827$20250904$20250911$PER$$NVSC2025US135604$NOVARTIS$$$$$$Y$$$20250911$$CN$US$US
257622801$25762280$1$I$$20250902$20250904$20250904$EXP$$MA-PFIZER INC-202500174699$PFIZER$$$$$M$Y$$$20250904$$CN$MA$MA
257624331$25762433$1$I$20250808$20250808$20250904$20250904$PER$$US-ELI_LILLY_AND_COMPANY-US202509002130$ELI LILLY AND COMPANY$$14$YR$T$F$Y$70.2$KG$20250904$$CN$US$US
257624581$25762458$1$I$20250818$20250903$20250904$20250904$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-122638$BRISTOL-MYERS SQUIBB COMPANY$$73$YR$E$F$Y$$$20250904$$PH$US$US
257625242$25762524$2$F$$20250908$20250904$20250916$EXP$$TR-TEVA-VS-3364915$TEVA$Gezegen CE, Bugdayci ZG, Ok Kurt AM. ABIRATERONE-INDUCED SEVERE HYPOKALEMIA IN A PROSTATE CANCER PATIENT: A RARE SIDE EFFECT. Eur-J-Case-Rep-Intern-Med 2024; 11 (Suppl.) 302 abstr. 1192.; Gezegen CE, Bugdayci ZG, Ok Kurt AM. ABIRATERONE-INDUCED SEVERE HYPOKALEMIA IN A PROSTATE CANCER PATIENT: A RARE SIDE EFFECT. Eur-J-Case-Rep-Intern-Med 2024; 11 (Suppl.) 302 abstr. 1192.; Gezegen CE, Bugdayci ZG, Ok Kurt AM. ABIRATERONE-INDUCED SEVERE HYPOKALEMIA IN A PROSTATE CANCER PATIENT: A RARE SIDE EFF...$73$YR$$M$Y$$$20250916$$HP$TR$TR
257625391$25762539$1$I$20250819$20250901$20250904$20250904$EXP$$JP-PFIZER INC-202500174849$PFIZER$$$$E$$Y$$$20250904$$PH$JP$JP
257625921$25762592$1$I$$20250902$20250904$20250904$PER$$US-SA-2025SA264155$SANOFI AVENTIS$$3$YR$C$F$Y$$$20250904$$CN$US$US
257626001$25762600$1$I$20250827$20250827$20250904$20250904$PER$$NVSC2025US136087$NOVARTIS$$$$$F$Y$$$20250904$$MD$US$US
257626191$25762619$1$I$20250819$20250825$20250904$20250904$PER$$US-PHARMING-PHAUS2025001223$PHARMING GROUP$$$$$$Y$$$20250904$$MD$US$US
257626531$25762653$1$I$$20250901$20250904$20250904$PER$$US-ELI_LILLY_AND_COMPANY-US202509002223$ELI LILLY AND COMPANY$$51$YR$A$M$Y$$$20250904$$CN$US$US
257627991$25762799$1$I$$20250829$20250904$20250904$PER$$US-PURDUE-USA-2025-0320211$PURDUE$$$$$$Y$$$20250904$$CN$US$US
257629261$25762926$1$I$20241010$20250904$20250904$20250904$EXP$GB-MHRA-MED-202509040905017090-ZPGQH$GB-TEVA-VS-3369538$TEVA$$77$YR$$M$Y$90$KG$20250904$$CN$GB$GB
257629591$25762959$1$I$$20250903$20250904$20250904$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-122497$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$$$20250905$$CN$US$US
257630141$25763014$1$I$$20250902$20250904$20250904$EXP$$JP-ASTRAZENECA-202509JPN001310JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250904$$MD$JP$JP
257630341$25763034$1$I$20250825$20250903$20250904$20250904$EXP$$EU-ABBVIE-6445407$ABBVIE$$70$YR$$M$Y$$$20250904$$CN$EU$EU
257630842$25763084$2$F$$20250828$20250904$20250915$EXP$$US-JNJFOC-20250836081$JOHNSON AND JOHNSON$$87$YR$E$M$Y$$$20250915$$CN$US$US
257632101$25763210$1$I$$20250902$20250905$20250905$PER$$US-SA-2025SA263625$SANOFI AVENTIS$$$$A$M$Y$$$20250905$$CN$US$US
257632641$25763264$1$I$$20250902$20250905$20250905$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-122078$BRISTOL-MYERS SQUIBB COMPANY$Pham A, Alvarez D, Leon D, Ghasemi-Rad M, Wynne D. Arterial injury from transjugular liver biopsy with delayed hemorrhage. Journal of Vascular and Interventional Radiology. 2025;36(9):1468-70. doi:10.1016/j.jvir.2025.05.021.$67$YR$E$M$Y$$$20250905$$HP$US$US
257632712$25763271$2$F$$20250923$20250905$20250930$PER$$US-ROCHE-10000378119$ROCHE$Zeigler G, Quinlan M, Varelas P, Collin M, Molho E. Anti-IgLON-5 disease presenting with axial dystonia and acetazolamide-responsive apnea. Clinical Neurology and Neurosurgery. 2025;257:1-4. doi:10.1016/j.clineuro.2025.109117.$66$YR$E$M$Y$$$20250930$$HP$US$US
257632871$25763287$1$I$$20250822$20250905$20250905$EXP$$US-GSK-US2025AMR109609$GLAXOSMITHKLINE$$$$$F$Y$$$20250905$$$US$US
257634401$25763440$1$I$$20250828$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202508029200$ELI LILLY AND COMPANY$$55$YR$A$M$Y$$$20250905$$CN$US$US
257634681$25763468$1$I$20250701$20250902$20250905$20250905$EXP$$RU-JNJFOC-20250903154$JOHNSON AND JOHNSON$$72$YR$E$M$Y$75$KG$20250905$$MD$RU$RU
257635121$25763512$1$I$$20250826$20250905$20250905$EXP$$GB-SA-2016SA228253$SANOFI AVENTIS$Szeto MCH, Yalcin MD, Khan A, Piotrowicz A.. Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis.. Case Reports in Immunology. 2016;unk:4$53$YR$A$F$Y$$$20250905$$MD$GB$GB
257635761$25763576$1$I$$20241024$20250905$20250905$PER$$US-FARMAPROD-202410-3738$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250818$$CN$US$US
257635771$25763577$1$I$$20241105$20250905$20250905$PER$$US-FARMAPROD-202410-3721$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250818$$CN$US$US
257636261$25763626$1$I$$20241113$20250905$20250905$PER$$US-FARMAPROD-202411-3937$DOMPE FARMACEUTICI$$$$A$M$Y$$$20250818$$CN$US$US
257636341$25763634$1$I$$20241017$20250905$20250905$PER$$US-FARMAPROD-202410-3645$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250818$$CN$US$US
257636451$25763645$1$I$$20241018$20250905$20250905$PER$$US-FARMAPROD-202410-3657$DOMPE FARMACEUTICI$$$$$M$Y$$$20250818$$CN$US$US
257636731$25763673$1$I$$20241114$20250905$20250905$PER$$US-FARMAPROD-202411-3969$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257637001$25763700$1$I$$20241127$20250905$20250905$PER$$US-FARMAPROD-202411-3934$DOMPE FARMACEUTICI$$$$E$F$Y$48.99$KG$20250818$$CN$US$US
257637491$25763749$1$I$$20241126$20250905$20250905$PER$$US-FARMAPROD-202411-4080$DOMPE FARMACEUTICI$$$$E$F$Y$70.31$KG$20250818$$CN$US$US
257637671$25763767$1$I$$20241129$20250905$20250905$PER$$US-FARMAPROD-202411-4059$DOMPE FARMACEUTICI$$$$E$M$Y$108.41$KG$20250818$$CN$US$US
257637701$25763770$1$I$20241117$20241117$20250905$20250905$PER$$US-FARMAPROD-202411-3817$DOMPE FARMACEUTICI$$51$YR$A$F$Y$$$20250818$$CN$US$US
257637921$25763792$1$I$20241206$20241206$20250905$20250905$PER$$US-FARMAPROD-202412-4159$DOMPE FARMACEUTICI$$80$YR$E$F$Y$$$20250818$$CN$US$US
257638071$25763807$1$I$$20241209$20250905$20250905$PER$$US-FARMAPROD-202412-4166$DOMPE FARMACEUTICI$$$$E$F$Y$95.25$KG$20250818$$CN$US$US
257638111$25763811$1$I$$20241209$20250905$20250905$PER$$US-FARMAPROD-202412-4173$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257638391$25763839$1$I$20241114$20241203$20250905$20250905$PER$$US-FARMAPROD-202411-3984$DOMPE FARMACEUTICI$$78$YR$E$F$Y$$$20250818$$CN$US$US
257639511$25763951$1$I$20241119$20241120$20250905$20250905$PER$$US-FARMAPROD-202411-4038$DOMPE FARMACEUTICI$$45$YR$A$F$Y$$$20250818$$CN$US$US
257639561$25763956$1$I$$20241220$20250905$20250905$PER$$US-FARMAPROD-202411-4040$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257639821$25763982$1$I$20210101$20250826$20250905$20250905$EXP$$US-HBP-2024US030586$HELSINN HEALTHCARE$$$$$M$Y$$$20250905$$CN$US$US
257641321$25764132$1$I$$20250828$20250905$20250905$EXP$$CA-CELLTRION INC.-2025CA031209$CELLTRION$$$$$$Y$$$20250905$$HP$CA$CA
257641761$25764176$1$I$$20250828$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202508028945$ELI LILLY AND COMPANY$$36$YR$A$F$Y$$$20250905$$CN$US$US
257641781$25764178$1$I$20250821$20250901$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202509003091$ELI LILLY AND COMPANY$$41$YR$A$M$Y$$$20250905$$CN$US$US
257641981$25764198$1$I$20241211$20241211$20250905$20250905$PER$$US-FARMAPROD-202412-4192$DOMPE FARMACEUTICI$$32$YR$A$F$Y$$$20250819$$CN$US$US
257642221$25764222$1$I$20241218$20241230$20250905$20250905$PER$$US-FARMAPROD-202501-0006$DOMPE FARMACEUTICI$$65$YR$E$M$Y$$$20250819$$CN$US$US
257642311$25764231$1$I$20241216$20250106$20250905$20250905$PER$$US-FARMAPROD-202412-4189$DOMPE FARMACEUTICI$$72$YR$E$F$Y$95.71$KG$20250819$$CN$US$US
257642441$25764244$1$I$$20241219$20250905$20250905$EXP$$US-FARMAPROD-202412-4276$DOMPE FARMACEUTICI$$$$T$M$Y$$$20250819$$CN$US$US
257642551$25764255$1$I$20250105$20250109$20250905$20250905$PER$$US-FARMAPROD-202412-4303$DOMPE FARMACEUTICI$$62$YR$A$F$Y$$$20250819$$CN$US$US
257642611$25764261$1$I$20241219$20250103$20250905$20250905$PER$$US-FARMAPROD-202412-4281$DOMPE FARMACEUTICI$$86$YR$E$F$Y$$$20250819$$CN$US$US
257642621$25764262$1$I$$20241218$20250905$20250905$PER$$US-FARMAPROD-202412-4269$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250819$$CN$US$US
257643271$25764327$1$I$$20241213$20250905$20250905$PER$$US-FARMAPROD-202412-4221$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250819$$CN$US$US
257643821$25764382$1$I$$20250225$20250905$20250905$PER$$US-FARMAPROD-202501-0267$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250819$$CN$US$US
257644151$25764415$1$I$$20250122$20250905$20250905$PER$$US-FARMAPROD-202501-0091$DOMPE FARMACEUTICI$$$$E$F$Y$45.31$KG$20250819$$CN$US$US
257644411$25764441$1$I$20250129$20250130$20250905$20250905$PER$$US-FARMAPROD-202501-0104$DOMPE FARMACEUTICI$$78$YR$E$F$Y$$$20250819$$CN$US$US
257644871$25764487$1$I$20250102$20250116$20250905$20250905$PER$$US-FARMAPROD-202501-0050$DOMPE FARMACEUTICI$$80$YR$E$F$Y$$$20250819$$MD$US$US
257645641$25764564$1$I$20250116$20250116$20250905$20250905$PER$$US-FARMAPROD-202501-0191$DOMPE FARMACEUTICI$$71$YR$E$M$Y$$$20250824$$CN$US$US
257645821$25764582$1$I$$20250822$20250905$20250905$EXP$$US-ALVOGEN-2025098618$ALVOGEN$Abruzzo AR, Harris MTH, Sroussi HY, Suzuki J, Kass JI, Rettig EM. Oral cavity cancer after sublingual buprenorphine use. Oral Oncology. 2025;168:107573. doi:https://doi.org/10.1016/j.oraloncology.2025.107573$53$YR$$F$Y$$$20250905$$HP$US$US
257646311$25764631$1$I$$20250903$20250905$20250905$EXP$$US-ABBVIE-6445626$ABBVIE$$$$A$F$Y$$$20250905$$CN$US$US
257646441$25764644$1$I$20241008$20241014$20250905$20250905$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2024R1-473699$RANBAXY$$6$YR$C$M$Y$$$20250905$$CN$US$US
257647601$25764760$1$I$20240101$20241016$20250905$20250905$PER$$US-ULTRAGENYX PHARMACEUTICAL INC.-US-UGX-24-01982$ULTRAGENYX PHARMACEUTICAL$$$$$M$Y$$$20250905$$CN$US$US
257648451$25764845$1$I$$20250829$20250905$20250905$EXP$$CA-CELLTRION INC.-2025CA031342$CELLTRION$$$$$$Y$$$20250905$$HP$CA$CA
257649161$25764916$1$I$$20250106$20250905$20250905$PER$$US-TARO PHARMACEUTICALS USA INC.-2025TAR00107$TARO$$$$$$Y$$$20250905$$CN$US$US
257649871$25764987$1$I$20250101$20250902$20250905$20250905$EXP$$US-ABBVIE-6443312$ABBVIE$$72$YR$$M$Y$$$20250905$$CN$US$US
257650041$25765004$1$I$20250829$20250829$20250905$20250905$PER$$US-JNJFOC-20250837648$JOHNSON AND JOHNSON$$$$$$Y$$$20250905$$HP$US$US
257650301$25765030$1$I$$20250829$20250905$20250905$EXP$$CA-TAKEDA-2025TUS077312$TAKEDA$$$$$F$Y$$$20250905$$MD$CA$CA
257650871$25765087$1$I$$20250825$20250905$20250905$EXP$$US-STRIDES NORDIC APS-2025SP011259$STRIDES$Levine O, Mitra S. beta-Blocker and Colchicine Coingestion in the Setting of Cocaine Intoxication. Prim-Care-Companion-CNS-Disord. 2025;27 (3)$$$$M$Y$$$20250905$$MD$US$US
257651112$25765111$2$F$20250101$20250911$20250905$20250917$EXP$$JP-BEH-2025217795$CSL BEHRING$$89$YR$E$F$Y$$$20250917$$HP$JP$JP
257651311$25765131$1$I$$20250828$20250905$20250905$EXP$$US-CELLTRION INC.-2025US031504$CELLTRION$$$$$$Y$$$20250905$$HP$US$US
257651582$25765158$2$F$20250801$20250922$20250905$20250929$EXP$$NVSJ2025JP008803$NOVARTIS$$$$$$Y$$$20250929$$MD$JP$JP
257652501$25765250$1$I$20220605$20250821$20250905$20250905$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-525262$RANBAXY$$$$A$F$Y$84$KG$20250905$$HP$GB$GB
257653312$25765331$2$F$20250101$20250905$20250905$20250911$EXP$$US-ABBVIE-6445458$ABBVIE$$29$YR$$F$Y$$$20250911$$CN$US$US
257653401$25765340$1$I$$20250901$20250905$20250905$EXP$GB-MHRA-MED-202509011045459050-HMGQY$GB-TAKEDA-2025TUS076945$TAKEDA$$16$YR$$F$Y$48$KG$20250905$$$GB$GB
257654511$25765451$1$I$20250201$20250418$20250905$20250905$PER$$US-AUROBINDO-AUR-APL-2025-022062$AUROBINDO$$$$$$Y$$$20250905$$HP$US$US
257654662$25765466$2$F$$20250918$20250905$20250927$PER$$US-TLM-TLM-2025-05563$TOLMAR$$$$$$Y$$$20250923$$MD$US$US
257654721$25765472$1$I$20250601$20250904$20250905$20250905$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-093404$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250905$$$US$US
257655261$25765526$1$I$$20250825$20250905$20250905$EXP$$JP-BEH-2025217826$CSL BEHRING$$$$$$Y$$$20250905$$HP$JP$JP
257656101$25765610$1$I$20250101$20250805$20250905$20250905$PER$$US-P+L Devolo-2183904$PL DEVELOPMENTS$$$$$F$Y$$$20250905$$$US$US
257656811$25765681$1$I$$20250825$20250905$20250905$EXP$$JP-BEH-2025217824$CSL BEHRING$$$$$$Y$$$20250905$$HP$JP$JP
257657131$25765713$1$I$20250903$20250904$20250905$20250905$EXP$$TH-ROCHE-10000381104$ROCHE$$82$YR$E$M$Y$$$20250905$$CN$TH$TH
257657171$25765717$1$I$$20250822$20250905$20250905$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-526196$RANBAXY$Ma X, Yu N, Ying X, Dai X, Chen X.. Adrenal cortical adenoma-induced cushing^s syndrome in pregnancy: a multidisciplinary approach to diagnosis and management. Curr Probl Surg. 2025;70:1-8;101851$$$N$F$Y$1.15$KG$20250905$$HP$CN$CN
257657381$25765738$1$I$20250701$20250901$20250905$20250905$EXP$$BR-BIOGEN-2025BI01323019$BIOGEN$$36$YR$$F$Y$109$KG$20250905$$CN$BR$BR
257659001$25765900$1$I$$20240801$20250905$20250905$PER$$US-FARMAPROD-202407-2604$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250817$$CN$US$US
257659191$25765919$1$I$20240716$20240717$20250905$20250905$PER$$US-FARMAPROD-202407-2649$DOMPE FARMACEUTICI$$66$YR$E$F$Y$$$20250817$$CN$US$US
257659671$25765967$1$I$20240718$20240725$20250905$20250905$PER$$US-FARMAPROD-202407-2671$DOMPE FARMACEUTICI$$45$YR$A$F$Y$$$20250817$$CN$US$US
257659681$25765968$1$I$$20240718$20250905$20250905$PER$$US-FARMAPROD-202407-2670$DOMPE FARMACEUTICI$$$$E$M$Y$$$20250817$$CN$US$US
257659741$25765974$1$I$$20240812$20250905$20250905$PER$$US-FARMAPROD-202407-2702$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250817$$CN$US$US
257660061$25766006$1$I$$20240724$20250905$20250905$PER$$US-FARMAPROD-202407-2734$DOMPE FARMACEUTICI$$$$A$F$Y$53.07$KG$20250817$$CN$US$US
257660271$25766027$1$I$$20250825$20250905$20250905$EXP$$JP-BEH-2025217804$CSL BEHRING$$$$$F$Y$$$20250905$$HP$JP$JP
257660591$25766059$1$I$20250801$20250822$20250905$20250905$PER$$US-MYLANLABS-2025M1073027$MYLAN$$89$YR$$M$Y$$$20250904$$$US$US
257660631$25766063$1$I$20250301$20250902$20250905$20250905$EXP$$US-ABBVIE-6282863$ABBVIE$$58$YR$$M$Y$$$20250905$$CN$US$US
257660971$25766097$1$I$$20250827$20250905$20250905$PER$$US-SMPA-2025SPA011189$SUNOVION$$63$YR$$M$Y$$$20250904$$$US$US
257660981$25766098$1$I$$20250827$20250905$20250905$PER$$US-SMPA-2025SPA011165$SUNOVION$$73$YR$$M$Y$$$20250905$$$US$US
257661371$25766137$1$I$$20240830$20250905$20250905$PER$$US-FARMAPROD-202408-2820$DOMPE FARMACEUTICI$$$$E$M$Y$$$20250817$$MD$US$US
257661971$25766197$1$I$$20250826$20250905$20250905$PER$$US-SMPA-2025SPA011102$SUNOVION$$70$YR$$M$Y$$$20250904$$$US$US
257662841$25766284$1$I$$20250902$20250905$20250905$EXP$$US-PFIZER INC-PV202500106519$PFIZER$Varma, S.. Autoimmune Hemolytic Anemia Associated With Tyrosine Kinase Inhibitors in a Case of CML. Clinical Lymphoma, Myeloma and Leukemia. 2025;25(Supple 1):S578$$$$$Y$$$20250905$$MD$US$US
257663062$25766306$2$F$20230301$20250909$20250905$20250915$EXP$$EU-MYLANLABS-2025M1074657$MYLAN$Chillaron MM, Gonzalez A, Garcia-Herrera A, Larque AB, Olle Grau J, Morantes L, et al. . Factor B inhibition with iptacopan in C3 glomerulopathy recurrence after transplantation: a case presentation. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2024;39:2677-8$38$YR$$M$Y$77$KG$20250915$$MD$EU$EU
257663661$25766366$1$I$$20250905$20250905$20250905$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-123096$BRISTOL-MYERS SQUIBB COMPANY$$67$YR$E$F$Y$$$20250905$$CN$US$US
257663871$25766387$1$I$20250101$20250830$20250905$20250905$EXP$$CA-SAMSUNG BIOEPIS-SB-2025-20770$SAMSUNG BIOEPIS$$73$YR$E$F$Y$$$20250905$$MD$CA$CA
257663931$25766393$1$I$$20250905$20250905$20250905$DIR$773732$$FDA-CTU$$$$$F$N$$$20250905$N$$US$
257665601$25766560$1$I$$20250903$20250903$20250903$DIR$773368$$FDA-CTU$$$$$$N$$$20250903$N$$US$
257666121$25766612$1$I$$20250905$20250905$20250905$DIR$FDA-CDER-CTU-2025-59363$$FDA-CTU$$60$YR$$F$N$$$20250905$N$$US$
257666661$25766666$1$I$$20250829$20250905$20250905$PER$$US-ABBVIE-6444739$ABBVIE$$$$$F$Y$$$20250905$$CN$US$US
257666921$25766692$1$I$$20250826$20250905$20250905$PER$$US-ASTELLAS-2025-AER-047130$ASTELLAS$$$$$$Y$$$20250905$$PH$US$US
257667071$25766707$1$I$20250824$20250829$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202509001063$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250905$$CN$US$US
257667171$25766717$1$I$$20250904$20250905$20250905$EXP$$CH-BRISTOL-MYERS SQUIBB COMPANY-2025-122764$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250905$$MD$CH$CH
257667811$25766781$1$I$20250814$20250902$20250905$20250905$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009859$ACADIA PHARMACEUTICALS$$80$YR$$F$Y$$$20250905$$CN$US$US
257667891$25766789$1$I$$20250828$20250905$20250905$EXP$$EU-009507513-2325132$MERCK SHARP + DOHME LLC$$63$YR$$$Y$$$20250905$$MD$EU$EU
257668311$25766831$1$I$20250822$20250904$20250905$20250905$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-123082$BRISTOL-MYERS SQUIBB COMPANY$$66$YR$E$F$Y$$$20250905$$HP$US$US
257668791$25766879$1$I$$20250812$20250905$20250905$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-112304$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$$$20250905$$MD$US$US
257669551$25766955$1$I$$20250828$20250905$20250905$PER$$US-INCYTE CORPORATION-2025IN009391$INCYTE$$$$$$Y$$$20250905$$$US$
257670291$25767029$1$I$$20250903$20250905$20250905$EXP$$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-122159$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250905$$MD$EU$EU
257670781$25767078$1$I$$20250903$20250905$20250905$PER$$US-SA-2025SA265117$SANOFI AVENTIS$$17$YR$T$F$Y$56$KG$20250905$$CN$US$US
257671001$25767100$1$I$20250801$20250902$20250905$20250905$PER$$US-SA-2025SA265106$SANOFI AVENTIS$$62$YR$A$F$Y$$$20250905$$HP$US$US
257671251$25767125$1$I$$20250903$20250905$20250905$PER$$US-SA-2025SA265260$SANOFI AVENTIS$$18$YR$A$F$Y$$$20250905$$CN$US$US
257672281$25767228$1$I$20250801$20250902$20250905$20250905$PER$$US-SA-2025SA264852$SANOFI AVENTIS$$28$YR$A$M$Y$$$20250905$$HP$US$US
257672571$25767257$1$I$20250904$20250904$20250904$20250904$DIR$773682$$FDA-CTU$$$$$$N$$$20250904$N$CN$US$
257673521$25767352$1$I$$20250904$20250904$20250904$DIR$773485$$FDA-CTU$$$$$$N$$$20250904$N$CN$US$
257673571$25767357$1$I$20250904$20250904$20250904$20250904$DIR$773658$$FDA-CTU$$77$YR$$F$N$$$20250904$N$$US$
257674441$25767444$1$I$20230810$20250826$20250905$20250905$EXP$EU-SEMPA-2025-005807$EU-NOVOPROD-1511749$NOVO NORDISK$$48$YR$$F$Y$79$KG$20250905$$CN$EU$EU
257674471$25767447$1$I$20250813$20250826$20250905$20250905$EXP$$US-NOVOPROD-1510363$NOVO NORDISK$$66$YR$$F$Y$$$20250905$$CN$US$US
257674801$25767480$1$I$20250628$20250828$20250905$20250905$EXP$CH-SM-2025-05889$CH-PFIZER INC-202500176203$PFIZER$$47$YR$$M$Y$$$20250905$$MD$CH$CH
257675831$25767583$1$I$20250601$20250902$20250905$20250905$PER$$US-ORGANON-O2509USA000204$ORGANON$$$$$F$Y$$$20250905$$CN$US$US
257675941$25767594$1$I$20250827$20250827$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202508028605$ELI LILLY AND COMPANY$$75$YR$E$F$Y$$$20250905$$CN$US$US
257677151$25767715$1$I$$20250905$20250905$20250905$DIR$773769$$FDA-CTU$$$$$F$N$$$20250905$N$CN$US$
257678341$25767834$1$I$20240820$20250827$20250905$20250905$PER$$US-MYLANLABS-2025M1073909$MYLAN$$$$$M$Y$$$20250905$$$US$US
257679581$25767958$1$I$$20250530$20250905$20250905$PER$$US-FARMAPROD-202505-1651$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257679602$25767960$2$F$20250626$20250910$20250905$20250912$EXP$$EU-STEMLINE THERAPEUTICS, INC-2025-STML-DE002323$STEMLINE THERAPEUTICS$$$$$$Y$$$20250912$$MD$EU$EU
257679761$25767976$1$I$$20250521$20250905$20250905$PER$$US-FARMAPROD-202505-1722$DOMPE FARMACEUTICI$$$$$$Y$$$20250821$$HP$US$US
257679941$25767994$1$I$$20250830$20250905$20250905$EXP$GB-MHRA-MED-202508291745575190-CVQSB$GB-ELI_LILLY_AND_COMPANY-GB202509000995$ELI LILLY AND COMPANY$$$$$F$Y$$$20250905$$CN$GB$GB
257679981$25767998$1$I$$20250519$20250905$20250905$PER$$US-FARMAPROD-202505-1698$DOMPE FARMACEUTICI$$$$A$M$Y$$$20250821$$CN$US$US
257680001$25768000$1$I$$20250623$20250905$20250905$PER$$US-FARMAPROD-202505-1714$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257680471$25768047$1$I$$20250521$20250905$20250905$PER$$US-FARMAPROD-202505-1737$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250821$$CN$US$US
257680621$25768062$1$I$$20250613$20250905$20250905$PER$$US-FARMAPROD-202505-1731$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257680831$25768083$1$I$$20250905$20250905$20250905$DIR$773827$$FDA-CTU$$$$$$N$$$20250905$N$CN$US$
257681581$25768158$1$I$$20250602$20250905$20250905$PER$$US-FARMAPROD-202506-1862$DOMPE FARMACEUTICI$$$$$$Y$$$20250822$$MD$US$US
257682791$25768279$1$I$$20250624$20250905$20250905$PER$$US-FARMAPROD-202506-1990$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250821$$CN$US$US
257683141$25768314$1$I$$20250614$20250905$20250905$PER$$US-FARMAPROD-202506-2028$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257683191$25768319$1$I$$20250822$20250905$20250905$EXP$$US-GSK-US2025AMR109552$GLAXOSMITHKLINE$$$$$F$Y$$$20250905$$$US$US
257683241$25768324$1$I$$20250620$20250905$20250905$PER$$US-FARMAPROD-202506-2016$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257683931$25768393$1$I$$20250106$20250905$20250905$PER$$US-AZURITY PHARMACEUTICALS, INC.-AZR202501-000015$AZURITY PHARMACEUTICALS$$$$$M$Y$$$20250905$$HP$US$US
257684591$25768459$1$I$$20250904$20250905$20250905$PER$$US-PFIZER INC-202500175840$PFIZER$$$$$F$Y$$$20250905$$CN$US$US
257685022$25768502$2$F$$20250908$20250905$20250916$EXP$$US-UCBSA-2025053881$UCB$$$$$F$Y$$$20250916$$MD$US$US
257685781$25768578$1$I$$20250901$20250905$20250905$EXP$$NVSC2025CN139294$NOVARTIS$$62$YR$$F$Y$$$20250905$$HP$CN$CN
257686341$25768634$1$I$20250829$20250829$20250905$20250905$EXP$$US-UCBSA-2025054277$UCB$$67$YR$$M$Y$$$20250905$$CN$US$US
257686391$25768639$1$I$20250101$20250822$20250905$20250905$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009560$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250905$$HP$US$US
257686402$25768640$2$F$$20250922$20250905$20250930$EXP$$EU-REGENERON PHARMACEUTICALS, INC.-2025-140709$REGENERON$$59$YR$$M$Y$$$20250930$$MD$EU$EU
257686921$25768692$1$I$$20250729$20250905$20250905$PER$$US-GSK-US2025AMR099372$GLAXOSMITHKLINE$$$$$M$Y$$$20250905$$$US$US
257687051$25768705$1$I$$20250807$20250905$20250905$PER$$US-GSK-US2025AMR102844$GLAXOSMITHKLINE$$$$$F$Y$$$20250905$$$US$US
257687451$25768745$1$I$$20250828$20250905$20250905$EXP$$US-ARDELYX-2025ARDX006575$ARDELYX$$$$$F$Y$$$20250905$$HP$US$US
257687691$25768769$1$I$$20250825$20250905$20250905$PER$$NVSC2025US134450$NOVARTIS$$$$A$F$Y$$$20250905$$CN$US$US
257688111$25768811$1$I$20250821$20250828$20250905$20250905$EXP$$US-UCBSA-2025053630$UCB$$44$YR$$M$Y$$$20250905$$CN$US$US
257688172$25768817$2$F$20250701$20250903$20250905$20250909$EXP$$TW-BRISTOL-MYERS SQUIBB COMPANY-2025-122801$BRISTOL-MYERS SQUIBB COMPANY$$52$YR$A$F$Y$58.9$KG$20250909$$MD$TW$TW
257688941$25768894$1$I$$20250905$20250905$20250905$DIR$773844$$FDA-CTU$$$$$$N$$$20250905$N$CN$US$
257689301$25768930$1$I$$20250825$20250905$20250905$EXP$$NVSC2025US134349$NOVARTIS$$4$YR$$F$Y$$$20250905$$CN$US$US
257689371$25768937$1$I$20240601$20250903$20250905$20250905$PER$$US-009507513-2326238$MERCK SHARP + DOHME LLC$$54$YR$$F$Y$$$20250905$$HP$US$US
257690461$25769046$1$I$$20250825$20250905$20250905$PER$$US-ELI_LILLY_AND_COMPANY-US202508024835$ELI LILLY AND COMPANY$$51$YR$A$M$Y$$$20250905$$CN$US$US
257691123$25769112$3$F$20250901$20250916$20250905$20250922$PER$$US-AMGEN-USASP2025175806$AMGEN$$50$YR$A$M$Y$$$20250922$$CN$US$US
257691421$25769142$1$I$20250801$20250903$20250905$20250905$PER$$US-AMGEN-USASP2025176053$AMGEN$$$$$M$Y$$$20250905$$CN$US$US
257694721$25769472$1$I$$20250902$20250906$20250906$PER$$US-ASTRAZENECA-202509USA001116US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250906$$$US$US
257695061$25769506$1$I$$20250807$20250906$20250906$PER$$US-GSK-US2025AMR102935$GLAXOSMITHKLINE$$34$YR$$M$Y$$$20250906$$$US$US
257695882$25769588$2$F$20250101$20250917$20250906$20250926$PER$$US-UNITED THERAPEUTICS-UNT-2025-022766$UNITED THERAPEUTICS$$$$$F$Y$43.084$KG$20250926$$$US$US
257696081$25769608$1$I$$20250825$20250906$20250906$EXP$$GB-Accord-502478$ACCORD$Nwankwo L, Lewis White P, Barry S, Cass LM, Murray AB, Berman L, et al. Successful treatment of an allergic bronchopulmonary aspergillosis patient with inhaled antifungal opelconazole. Journal of Allergy and Clinical Immunology: In Practice. 2025;13(8):2171-3.e1. DOI: 10.1016/j.jaip.2025.05.018.$$$A$F$Y$$$20250906$$PH$GB$GB
257696302$25769630$2$F$20250101$20250829$20250906$20250907$EXP$$US-UNITED THERAPEUTICS-UNT-2025-026453$UNITED THERAPEUTICS$$$$$F$Y$62.132$KG$20250907$$$US$US
257696561$25769656$1$I$$20250903$20250906$20250906$PER$$US-ELI_LILLY_AND_COMPANY-US202509004271$ELI LILLY AND COMPANY$$62$YR$A$M$Y$$$20250906$$CN$US$US
257696611$25769661$1$I$$20250828$20250906$20250906$EXP$$US-RDY-USA/2025/09/013619$DR REDDYS$$26$YR$A$M$Y$$$20250906$$CN$US$US
257697451$25769745$1$I$$20250904$20250907$20250907$EXP$GB-MHRA-MED-202509030932502270-CQPBK$GB-DEXPHARM-2025-4481$DEXCEL LTD.$$64$YR$A$F$Y$$$20250907$$HP$GB$GB
257697831$25769783$1$I$$20250903$20250907$20250907$PER$$US-ELI_LILLY_AND_COMPANY-US202509004193$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250907$$CN$US$US
257698041$25769804$1$I$$20250901$20250907$20250907$EXP$$JP-009507513-2325200$MERCK SHARP + DOHME LLC$$7$DEC$$M$Y$$$20250907$$MD$JP$JP
257698521$25769852$1$I$$20250901$20250907$20250907$EXP$$EU-JNJFOC-20250901110$JOHNSON AND JOHNSON$$$$$$Y$$$20250907$$MD$EU$EU
257698941$25769894$1$I$$20250902$20250907$20250907$PER$$US-ELI_LILLY_AND_COMPANY-US202509004811$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250907$$CN$US$US
257699471$25769947$1$I$$20250904$20250907$20250907$PER$$US-SA-2025SA266492$SANOFI AVENTIS$$53$YR$A$F$Y$$$20250907$$CN$US$US
257699861$25769986$1$I$$20250812$20250907$20250907$PER$$US-GALDERMA-US2025015151$GALDERMA$$$$$$Y$$$20250907$$CN$US$US
257700391$25770039$1$I$20250101$20250903$20250907$20250907$PER$$US-SA-2025SA266097$SANOFI AVENTIS$$58$YR$A$F$Y$$$20250907$$CN$US$US
257701291$25770129$1$I$$20250902$20250907$20250907$EXP$$CA-ABBVIE-6444074$ABBVIE$$$$E$M$Y$$$20250907$$CN$CA$CA
257701371$25770137$1$I$$20250828$20250907$20250907$PER$$US-TEVA-VS-3368845$TEVA$$38$YR$$F$Y$$$20250907$$CN$US$US
257701391$25770139$1$I$$20250903$20250907$20250907$EXP$$CA-JNJFOC-20250907604$JOHNSON AND JOHNSON$$46$YR$A$M$Y$$$20250908$$CN$CA$CA
257701841$25770184$1$I$20250101$20250902$20250907$20250907$PER$$US-SA-2025SA265467$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250908$$MD$US$US
257702441$25770244$1$I$$20250902$20250907$20250907$EXP$$US-ASTRAZENECA-202509USA001035US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250907$$$US$US
257702721$25770272$1$I$20250821$20250825$20250907$20250907$EXP$$US-MDD US Operations-MDD202508-003355$MDD OPERATIONS$$70$YR$$F$Y$$$20250908$$HP$US$US
257702801$25770280$1$I$$20250828$20250907$20250907$EXP$$US-PIRAMAL CRITICAL CARE LIMITED-2025-PPL-000495$PIRAMAL$Saha A.; Fisher M.; Sanchez J.; Chen S.; Pinyavat T.. Malignant Hyperthermia in a Patient with RYR1 c.528G}T; p.Glu176Asp. A and A Practice. 2025;19:5:354-355$$$$$Y$$$20250908$$HP$US$US
257702902$25770290$2$F$20250724$20250903$20250907$20250911$EXP$$EU-JNJFOC-20250906386$JOHNSON AND JOHNSON$$68$YR$E$F$Y$$$20250911$$HP$EU$EU
257703641$25770364$1$I$20250828$20250828$20250908$20250908$30DAY$$US-SANDOZ INC.-SDZ2025US062822$SANDOZ$$50$YR$$M$Y$$$20250908$$CN$US$US
257704491$25770449$1$I$$20250829$20250908$20250908$EXP$$CA-TEVA-VS-3370155$TEVA$$28$YR$$F$Y$$$20250908$$CN$CA$CA
257705741$25770574$1$I$$20250905$20250908$20250908$EXP$$JP-ASTRAZENECA-202509JPN003467JP$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250908$$PH$JP$JP
257706031$25770603$1$I$20250813$20250825$20250908$20250908$EXP$$CN-Hisun Pharmaceuticals USA Inc.-000677$HISUN PHARMACEUTICALS USA INC$$51$YR$A$M$Y$104$KG$20250908$$HP$CN$CN
257706181$25770618$1$I$20231221$20241122$20250908$20250908$PER$$US-CHIESI-2024CHF07661$CHIESI$$22$YR$$F$Y$53$KG$20250908$$CN$US$US
257706211$25770621$1$I$20240101$20241127$20250908$20250908$PER$$US-CHIESI-2024CHF07781$CHIESI$$$$$F$Y$50$KG$20250908$$CN$US$US
257706371$25770637$1$I$$20241223$20250908$20250908$PER$$US-GLENMARK PHARMACEUTICALS-2024GMK096798$GLENMARK$$$$$$Y$$$20250908$$CN$US$US
257706471$25770647$1$I$$20250627$20250908$20250908$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK101762$GLENMARK$$$$$F$Y$$$20250908$$CN$US$US
257706651$25770665$1$I$20250821$20250822$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202508024089$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250908$$CN$US$US
257707541$25770754$1$I$$20241028$20250908$20250908$PER$$US-AIMMUNE THERAPEUTICS, INC.-2024AIMT01341$AIMMUNE$$$$$$Y$$$20250908$$CN$US$US
257707741$25770774$1$I$$20250829$20250908$20250908$EXP$$CA-CELLTRION INC.-2025CA031421$CELLTRION$$$$$$Y$$$20250908$$HP$CA$CA
257708621$25770862$1$I$$20250604$20250908$20250908$PER$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00550$AIMMUNE$$$$$$Y$$$20250908$$CN$US$US
257708641$25770864$1$I$$20250506$20250908$20250908$PER$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00457$AIMMUNE$$$$$$Y$$$20250908$$MD$US$US
257708831$25770883$1$I$20250617$20250718$20250908$20250908$PER$$US-AIMMUNE THERAPEUTICS, INC.-2025AIMT00621$AIMMUNE$$$$$$Y$$$20250908$$HP$US$US
257708931$25770893$1$I$$20250904$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202509005660$ELI LILLY AND COMPANY$$$$$$Y$$$20250908$$CN$US$US
257709491$25770949$1$I$$20250825$20250908$20250908$EXP$$EU-MSNLABS-2025MSNLIT02562$MSN LABORATORIES PRIVATE LIMITED$Limongiello MA, Metafuni E, Giammarco S, Galli E, Sora F, Autore F, Baroni S, Chiusolo P, Sica S..High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation.International Journal of Hematology .2025;122(3):368-371,DOI: 10.1007/s12185-025-04032-x$$$$$Y$$$20250908$$HP$EU$EU
257709891$25770989$1$I$20250831$20250902$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202509002175$ELI LILLY AND COMPANY$$39$YR$A$F$Y$$$20250908$$CN$US$US
257712021$25771202$1$I$$20250401$20250908$20250908$PER$$US-FARMAPROD-202504-1109$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250820$$CN$US$US
257712051$25771205$1$I$$20250331$20250908$20250908$PER$$US-FARMAPROD-202504-1092$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250820$$CN$US$US
257712071$25771207$1$I$$20250402$20250908$20250908$PER$$US-FARMAPROD-202504-1123$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250820$$CN$US$US
257712961$25771296$1$I$$20250425$20250908$20250908$PER$$US-FARMAPROD-202504-1163$DOMPE FARMACEUTICI$$$$E$F$Y$54.16$KG$20250821$$CN$US$US
257713141$25771314$1$I$$20250429$20250908$20250908$PER$$US-FARMAPROD-202504-1214$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250820$$CN$US$US
257713781$25771378$1$I$20250411$20250411$20250908$20250908$PER$$US-FARMAPROD-202504-1251$DOMPE FARMACEUTICI$$77$YR$E$F$Y$$$20250820$$CN$US$US
257714171$25771417$1$I$$20250519$20250908$20250908$PER$$US-FARMAPROD-202504-1311$DOMPE FARMACEUTICI$$$$E$M$Y$77.97$KG$20250820$$CN$US$US
257714381$25771438$1$I$$20250415$20250908$20250908$PER$$US-FARMAPROD-202504-1291$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250820$$CN$US$US
257715441$25771544$1$I$$20250425$20250908$20250908$PER$$US-FARMAPROD-202504-1410$DOMPE FARMACEUTICI$$$$E$M$Y$$$20250820$$CN$US$US
257715861$25771586$1$I$$20250501$20250908$20250908$PER$$US-FARMAPROD-202505-1465$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250821$$CN$US$US
257716221$25771622$1$I$$20250505$20250908$20250908$PER$$US-FARMAPROD-202505-1519$DOMPE FARMACEUTICI$$$$A$M$Y$77.11$KG$20250821$$CN$US$US
257717081$25771708$1$I$$20250509$20250908$20250908$PER$$US-FARMAPROD-202505-1577$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250820$$CN$US$US
257717501$25771750$1$I$$20250106$20250908$20250908$PER$$US-TEYRO-2025-TY-000014$Teyro Labs$Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Herrera AF, et.al.Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma..Haematologica.2025;110:142-152$$$$$Y$$$20250908$$HP$US$US
257718311$25771831$1$I$$20250818$20250908$20250908$PER$$US-STRIDES ARCOLAB LIMITED-2025SP010937$STRIDES$Cotiguala L, Przybylski A, Yu T, Lopez-Soler R, Trotter C, Mahoney E, et al. Addition of Belatacept to Tacrolimus-Mycophenolate-Prednisone (Quadruple Immunosuppression) in Kidney Transplant Recipients with Donor Specific Antibodies and/or Antibody Mediated Rejection. Am-J-Transplant. 2025;25 (Suppl. 1) (8):S644 abstr. P2.07.51$$$$M$Y$$$20250908$$HP$US$US
257718721$25771872$1$I$$20250829$20250908$20250908$EXP$$US-SMPA-2025SPA011277$SUNOVION$$62$YR$$M$Y$$$20250905$$$US$US
257718731$25771873$1$I$$20250829$20250908$20250908$EXP$$US-SMPA-2025SPA011279$SUNOVION$$71$YR$$M$Y$$$20250905$$$US$US
257719511$25771951$1$I$$20250702$20250908$20250908$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-01980$AMNEAL$$$$$M$Y$$$20250908$$CN$US$US
257720091$25772009$1$I$$20250905$20250908$20250908$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-123467$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250908$$$US$US
257720742$25772074$2$F$$20250909$20250908$20250923$EXP$IR-MLMSERVICE-20250821-PI614748-00232-1$IR-ALKEM LABORATORIES LIMITED-IR-ALKEM-2025-09479$ALKEM$Shadravan MM, Farshchian F, Rajaei A, Alavi Darazam I, Naseri R, Maghsudloo F.. Post Varicella-Zoster virus transverse myelitis: Diagnostic and therapeutic challenges- A case report and literature review. IDCases. 2025;41:e02336$61$YR$$F$Y$$$20250923$$MD$IR$IR
257720831$25772083$1$I$20250831$20250903$20250908$20250908$PER$$US-SA-2025SA265253$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250908$$PH$US$US
257721221$25772122$1$I$$20250829$20250908$20250908$EXP$$US-EMD Serono-2025044598$EMD SERONO INC$$$$$F$Y$$$20250908$$MD$US$US
257721701$25772170$1$I$20250820$20250903$20250908$20250908$PER$$US-SA-2025SA264696$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250908$$CN$US$US
257721851$25772185$1$I$$20250904$20250908$20250908$PER$$US-SA-2025SA266615$SANOFI AVENTIS$$36$YR$A$F$Y$$$20250908$$CN$US$US
257722461$25772246$1$I$$20250717$20250908$20250908$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009416$STRIDES$Davis L, Park S, Woods J, Matulonis R.. Monthly High-dose Methylprednisolone and Daily Mycophenolate Mofetil for Chronic Immune Checkpoint Inhibitor Pneumonitis.. Am-J-Respir-Crit-Care-Med. 2025;211$77$YR$$M$Y$$$20250908$$HP$US$US
257722872$25772287$2$F$$20250926$20250908$20250930$PER$$US-ELI_LILLY_AND_COMPANY-US202508022756$ELI LILLY AND COMPANY$$74$YR$E$M$Y$$$20250930$$CN$US$US
257723372$25772337$2$F$$20250908$20250908$20250920$EXP$$JP-PBT-010729$PANACEA BIOTEC PHARMA LIMITED$Fujimori K, Sakamoto K, Tsujimoto S, Yamada M, Gocho Y, Deguchi T, et al. Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide for Pediatric Chronic Active Epstein-Barr Virus Infection. Pediatr Transplant. 2025 Sep;29(6):e70165. doi: 10.1111/petr.70165.$7$YR$C$F$Y$$$20250920$$MD$JP$JP
257724321$25772432$1$I$$20250903$20250908$20250908$EXP$$US-SA-2025SA266456$SANOFI AVENTIS$$69$YR$E$$Y$$$20250908$$CN$US$US
257725631$25772563$1$I$$20250127$20250908$20250908$PER$$US-TEYRO-2025-TY-000074$Teyro Labs$Wong K, Khanna M, Wu R..Gemcitabine-induced acute myositis in a patient  with duodenal cancer..Clin Oncol (R Coll Radiol).2011;23:492-3$$$$$Y$$$20250908$$HP$US$US
257726741$25772674$1$I$$20250826$20250908$20250908$EXP$$US-CIPLA (EU) LIMITED-2025US11099$CIPLA$Jones FJS, Liewluck T, Mirman I, Milone M.. Exposure to Sertraline and ranolazine is common among adult patients with genetically uncharacterized lipid storage myopathy.. Journal of the Neurological Sciences.. 2025;475 (123599):1 to 5$$$$$Y$$$20250908$$HP$US$US
257727021$25772702$1$I$$20250127$20250908$20250908$PER$$US-CIPLA LTD.-2025US01452$CIPLA$$$$$$Y$$$20250908$$CN$US$US
257727271$25772727$1$I$20250816$20250901$20250908$20250908$EXP$$CN-ROCHE-10000378661$ROCHE$$73$YR$E$F$Y$$$20250908$$HP$CN$CN
257727691$25772769$1$I$$20250903$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202509004350$ELI LILLY AND COMPANY$$73$YR$E$M$Y$$$20250908$$CN$US$US
257728411$25772841$1$I$20250701$20250906$20250906$20250906$DIR$773970$$FDA-CTU$$32$YR$$M$N$77.85$KG$20250906$N$CN$US$
257729561$25772956$1$I$20250824$20250903$20250908$20250908$EXP$$CA-MYLANLABS-2025M1075612$MYLAN$$84$YR$$F$Y$$$20250906$$$CA$CA
257729991$25772999$1$I$$20250903$20250908$20250908$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009850$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250908$$CN$US$US
257730481$25773048$1$I$$20250902$20250908$20250908$EXP$$GB-ABBVIE-6445545$ABBVIE$$61$YR$$F$Y$$$20250908$$CN$GB$GB
257730571$25773057$1$I$20160101$20250825$20250908$20250908$EXP$$EU-AUROBINDO-AUR-APL-2019-008847$AUROBINDO$Matei Palimariciuc, Elena R. Popescu, Roxana Chiri??.. Therapeutic particularities of the psychopathological manifestations in DiGeorge.. Bulletin of Integrative Psychiatry. 2018;24:87-94$34$YR$$F$Y$$$20250908$$MD$EU$EU
257730941$25773094$1$I$$20250903$20250908$20250908$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-092927$BOEHRINGER INGELHEIM$$$$E$F$Y$$$20250908$$MD$EU$EU
257731171$25773117$1$I$$20250903$20250908$20250908$EXP$$US-SA-2025SA265543$SANOFI AVENTIS$$80$YR$E$F$Y$$$20250908$$CN$US$US
257732061$25773206$1$I$$20250901$20250908$20250908$PER$$US-ROCHE-10000379060$ROCHE$$$$A$F$Y$$$20250908$$CN$US$US
257732381$25773238$1$I$20250626$20250709$20250905$20250905$DIR$FDA-CDER-CTU-2025-59749$$FDA-CTU$$69$YR$$F$N$84.37$KG$20250709$N$CN$US$
257732511$25773251$1$I$20250828$20250902$20250908$20250908$PER$$US-ROCHE-10000380522$ROCHE$$41$YR$A$M$Y$83.91$KG$20250908$$CN$US$US
257732701$25773270$1$I$$20250904$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202509005994$ELI LILLY AND COMPANY$$77$YR$E$F$Y$$$20250908$$CN$US$US
257733001$25773300$1$I$$20250904$20250908$20250908$PER$$US-SA-2025SA266539$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250908$$CN$US$US
257733971$25773397$1$I$$20250904$20250908$20250908$EXP$$US-ABBVIE-6447521$ABBVIE$$$$$M$Y$$$20250908$$CN$US$US
257734811$25773481$1$I$20241221$20250825$20250908$20250908$EXP$$EU-AUROBINDO-AUR-APL-2025-044381$AUROBINDO$$69$YR$$M$Y$$$20250908$$PH$EU$EU
257735731$25773573$1$I$$20250908$20250908$20250908$DIR$FDA-CDER-CTU-2025-59793$$FDA-CTU$$70$YR$$F$N$$$20250908$N$$US$
257735961$25773596$1$I$$20250903$20250908$20250908$EXP$$GB-TEVA-VS-3369097$TEVA$$$$$$Y$$$20250908$$CN$GB$GB
257736431$25773643$1$I$$20250902$20250908$20250908$EXP$$JP-OTSUKA-2025_021666$OTSUKA$$80$YR$$$Y$$$20250908$$MD$JP$JP
257736471$25773647$1$I$20250610$20250902$20250908$20250908$EXP$$EG-ROCHE-10000380091$ROCHE$$57$YR$A$F$Y$74$KG$20250908$$CN$EG$EG
257736781$25773678$1$I$20250101$20250728$20250908$20250908$PER$$US-CHIESI-2025CHF04236$CHIESI$$$$$F$Y$44$KG$20250908$$CN$US$US
257737141$25773714$1$I$$20250905$20250908$20250908$EXP$$JP-PFIZER INC-PV202500107756$PFIZER$$$$E$$Y$$$20250908$$MD$JP$JP
257737351$25773735$1$I$20250707$20250827$20250908$20250908$EXP$$US-ELI_LILLY_AND_COMPANY-US202508029658$ELI LILLY AND COMPANY$$$$$F$Y$$$20250908$$CN$US$US
257737431$25773743$1$I$20250301$20250831$20250908$20250908$EXP$$EG-ELI_LILLY_AND_COMPANY-EG202509003546$ELI LILLY AND COMPANY$$30$YR$A$M$Y$$$20250908$$CN$EG$EG
257738141$25773814$1$I$$20250905$20250908$20250908$PER$$US-PFIZER INC-202500177389$PFIZER$$12$YR$$M$Y$$$20250908$$MD$US$US
257739271$25773927$1$I$$20250902$20250908$20250908$EXP$$EU-ELI_LILLY_AND_COMPANY-DE202509001657$ELI LILLY AND COMPANY$$71$YR$E$M$Y$$$20250908$$CN$EU$EU
257739751$25773975$1$I$$20250902$20250908$20250908$EXP$$US-ASTRAZENECA-202509USA000732US$ALEXION PHARMACEUTICALS$$$$C$M$Y$$$20250908$$$US$US
257740011$25774001$1$I$20240101$20250827$20250908$20250908$EXP$$US-NOVOPROD-1513885$NOVO NORDISK$$72$YR$$M$Y$$$20250908$$CN$US$US
257740121$25774012$1$I$$20250829$20250908$20250908$EXP$$US-TEVA-VS-3368741$TEVA$$$$$M$Y$$$20250908$$CN$US$US
257740221$25774022$1$I$20250403$20250905$20250905$20250905$DIR$773921$$FDA-CTU$$19$YR$$F$N$79.2$KG$20250905$N$$US$
257740551$25774055$1$I$20250101$20250903$20250908$20250908$PER$$US-SA-2025SA266747$SANOFI AVENTIS$$74$YR$E$M$Y$$$20250908$$HP$US$US
257740961$25774096$1$I$20200101$20250904$20250908$20250908$PER$$US-ABBVIE-6448959$ABBVIE$$67$YR$$F$Y$$$20250908$$CN$US$US
257741091$25774109$1$I$20230101$20250829$20250908$20250908$EXP$EU-AFSSAPS-MA2025000978$EU-009507513-2325304$MERCK SHARP + DOHME LLC$$68$YR$$F$Y$$$20250908$$HP$EU$EU
257741371$25774137$1$I$$20250820$20250908$20250908$EXP$$US-TORRENT-00014510$TORRENT PHARMA INC.$$$$$F$Y$$$20250908$$HP$US$US
257741851$25774185$1$I$20240902$20250828$20250908$20250908$EXP$$US-NOVOPROD-1512440$NOVO NORDISK$$$$$F$Y$$$20250908$$CN$US$US
257743121$25774312$1$I$$20250828$20250908$20250908$EXP$$US-JNJFOC-20250836065$JOHNSON AND JOHNSON$$$$$$Y$$$20250908$$CN$US$US
257743431$25774343$1$I$20250711$20250903$20250908$20250908$EXP$GB-MHRA-MED-202509031057160050-HBWPG$GB-DSJP-DS-2025-162927-GB$DAIICHI$$67$YR$$F$Y$78$KG$20250908$$PH$GB$GB
257743761$25774376$1$I$$20250903$20250908$20250908$PER$$US-ELI_LILLY_AND_COMPANY-US202509004228$ELI LILLY AND COMPANY$$36$YR$A$M$Y$$$20250908$$CN$US$US
257743992$25774399$2$F$$20250911$20250908$20250912$EXP$$US-INCYTE CORPORATION-2025IN009658$INCYTE$$64$YR$$$Y$$$20250912$$$US$US
257744071$25774407$1$I$$20250908$20250908$20250908$DIR$FDA-CDER-CTU-2025-59872$$FDA-CTU$$58$YR$$M$N$$$20250908$N$$US$
257744482$25774448$2$F$20250824$20250918$20250908$20250923$EXP$$CO-BIOVITRUM-2025-CO-012247$BIOVITRUM$$6$MON$$F$Y$$$20250923$$CN$CO$CO
257745051$25774505$1$I$$20250905$20250908$20250908$EXP$$US-ASTRAZENECA-202509USA004172US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250908$$MD$US$US
257745171$25774517$1$I$$20250904$20250908$20250908$PER$$NVSC2025US139662$NOVARTIS$$$$$F$Y$$$20250908$$CN$US$US
257745341$25774534$1$I$20240731$20250828$20250908$20250908$EXP$$CA-JNJFOC-20240760221$JOHNSON AND JOHNSON$$9$YR$C$M$Y$32$KG$20250908$$HP$CA$CA
257745471$25774547$1$I$$20250821$20250908$20250908$PER$$US-RDY-USA/2025/08/013245$DR REDDYS$$$$$$Y$$$20250908$$MD$US$US
257746071$25774607$1$I$$20250903$20250908$20250908$PER$$US-SA-2025SA264808$SANOFI AVENTIS$$$$A$F$Y$$$20250908$$CN$US$US
257746181$25774618$1$I$20250827$20250828$20250908$20250908$EXP$$BR-BAYER-2025A115639$BAYER HEALTHCARE PHARMACEUTICALS INC.$$88$YR$E$M$Y$65$KG$20250908$$CN$BR$BR
257748001$25774800$1$I$$20250117$20250908$20250908$PER$$US-CIPLA LTD.-2025US01230$CIPLA$$$$$$Y$$$20250908$$CN$US$US
257748111$25774811$1$I$$20250903$20250908$20250908$EXP$$CA-MYLANLABS-2025M1076138$MYLAN$$$$$M$Y$$$20250908$$$CA$CA
257748281$25774828$1$I$20250825$20250829$20250908$20250908$PER$$US-MYLANLABS-2025M1074727$MYLAN$$53$YR$$F$Y$$$20250908$$$US$US
257748391$25774839$1$I$$20250904$20250908$20250908$PER$$US-BAYER-2025A118356$BAYER HEALTHCARE LLC$$$$$$Y$$$20250908$$CN$US$US
257748741$25774874$1$I$20230214$20250908$20250908$20250908$EXP$$NVSC2025FR139906$NOVARTIS$$73$YR$$M$Y$74$KG$20250908$$MD$EU$EU
257749231$25774923$1$I$20250701$20250908$20250908$20250908$DIR$774169$$FDA-CTU$$61$YR$$F$N$$$20250908$N$CN$US$
257749791$25774979$1$I$20250801$20250828$20250908$20250908$EXP$CN-NMPA-5301221033465202500035$CN-NOVOPROD-1512806$NOVO NORDISK$$45$YR$$F$Y$58$KG$20250908$$HP$CN$CN
257750101$25775010$1$I$$20250829$20250908$20250908$EXP$$JP-OTSUKA-2025_021530$OTSUKA$A case of schizophrenia in which improvement was noted during the clinical course on treatment, although cooccurrence of personality disorder had been diagnosed. SEMINAR$5$DEC$$F$Y$$$20250908$$MD$JP$JP
257750261$25775026$1$I$20250101$20250904$20250909$20250909$EXP$$EU-ABBVIE-6448005$ABBVIE$$$$$$Y$$$20250908$$MD$EU$EU
257750591$25775059$1$I$$20250901$20250909$20250909$EXP$$GB-ELI_LILLY_AND_COMPANY-GB202509000731$ELI LILLY AND COMPANY$$$$$F$Y$$$20250908$$CN$GB$GB
257750951$25775095$1$I$20230601$20250903$20250909$20250909$EXP$$US-ABBVIE-6354354$ABBVIE$$63$YR$$M$Y$$$20250908$$MD$US$US
257751473$25775147$3$F$$20250923$20250909$20250926$30DAY$$US-JNJFOC-20250829901$JOHNSON AND JOHNSON$$$$$F$Y$$$20250926$$CN$US$US
257752311$25775231$1$I$20250101$20250904$20250909$20250909$EXP$$US-ABBVIE-6448596$ABBVIE$$73$YR$$M$Y$$$20250908$$CN$US$US
257752362$25775236$2$F$20250711$20250905$20250909$20250910$EXP$$CN-ABBVIE-6442075$ABBVIE$$67$YR$$M$Y$58$KG$20250910$$MD$CN$CN
257752621$25775262$1$I$20250101$20250903$20250909$20250909$PER$$US-AMGEN-USASP2025176216$AMGEN$$16$YR$T$F$Y$$$20250908$$HP$US$US
257752901$25775290$1$I$20250829$20250901$20250909$20250909$PER$$US-SA-2025SA265793$SANOFI AVENTIS$$53$YR$A$F$Y$90.45$KG$20250909$$MD$US$US
257753011$25775301$1$I$20250904$20250904$20250909$20250909$EXP$$US-ABBVIE-6448266$ABBVIE$$40$YR$$M$Y$$$20250909$$CN$US$US
257753341$25775334$1$I$$20250903$20250909$20250909$EXP$$EU-VIIV HEALTHCARE-FR2025EME114021$VIIV$$$$$$Y$$$20250909$$MD$EU$EU
257753481$25775348$1$I$20250701$20250903$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202509004375$ELI LILLY AND COMPANY$$60$YR$A$F$Y$$$20250909$$CN$US$US
257753931$25775393$1$I$20231124$20250904$20250909$20250909$EXP$$JP-ABBVIE-5867182$ABBVIE$$49$YR$$M$Y$75$KG$20250909$$MD$JP$JP
257754641$25775464$1$I$$20250903$20250909$20250909$EXP$$EU-HALEON-2011204503$Haleon PLC$Vrabec-matkovic D e tal. Failure in long-term treatment of chronic pain in cervical spondylotic myelopathy.^ 10 cases have been identified for the same patient, different drug.. Medicinski Glasnik. 2011;8 (2):309-11; Vrabec-Matkovic D, Budisin V, Pahic R.. Failure in longterm treatment of chronic pain in cervical spondylotic  myelopathy. Med Glas Ljek Komore Zenicko-doboj kantona. 2011;8 (2):309-311; Vrabec Matkovic D, Budisin V, Pahic R. Failure in long term treatment of chronic pain in cerv...$31$YR$$F$Y$$$20250908$$MD$EU$EU
257755171$25775517$1$I$$20250827$20250909$20250909$EXP$$GB-Accord-503063$ACCORD$Black L, Mitchell-Gears S, Bines E, Parmar P, O Neill M. Case-based learning: frailty. Pharm J. 2025;315(8000). doi:10.1211/PJ.2025.1.366577.$90$YR$E$M$Y$56$KG$20250909$$PH$GB$GB
257756771$25775677$1$I$20250801$20250825$20250909$20250909$30DAY$$US-CIPLA LTD.-2025US10940$CIPLA$$$$$$Y$$$20250909$$HP$US$US
257757051$25775705$1$I$$20250904$20250909$20250909$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-009942$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250909$$HP$US$US
257757481$25775748$1$I$$20250903$20250909$20250909$EXP$$CA-ROCHE-10000380557$ROCHE$$62$YR$A$M$Y$$$20250909$$HP$CA$CA
257757682$25775768$2$F$20250903$20250908$20250909$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509006556$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250911$$CN$US$US
257759841$25775984$1$I$20250106$20250905$20250909$20250909$EXP$$JP-ASTELLAS-2025-AER-048884$ASTELLAS$$63$YR$A$M$Y$46$KG$20250909$$MD$JP$JP
257760102$25776010$2$F$$20250910$20250909$20250912$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-2025-122908$BRISTOL-MYERS SQUIBB COMPANY$$$$$M$Y$$$20250912$$MD$JP$JP
257760261$25776026$1$I$$20250708$20250909$20250909$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2025-07507$ALKEM$Lammer J, Hein R, Roenneberg S, et al.. Drug-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature. Acta Derm Venereol. 2019;99:508-515$$$$$Y$$$20250909$$HP$US$US
257760491$25776049$1$I$$20250825$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202508027516$ELI LILLY AND COMPANY$$54$YR$A$F$Y$$$20250909$$CN$US$US
257761191$25776119$1$I$$20240917$20250909$20250909$PER$$US-FARMAPROD-202408-2922$DOMPE FARMACEUTICI$$$$A$M$Y$$$20250817$$CN$US$US
257762451$25776245$1$I$$20250212$20250909$20250909$PER$$US-FARMAPROD-202502-0503$DOMPE FARMACEUTICI$$$$A$F$Y$$$20250819$$CN$US$US
257762991$25776299$1$I$$20250219$20250909$20250909$PER$$US-FARMAPROD-202502-0565$DOMPE FARMACEUTICI$$$$$$Y$$$20250819$$HP$US$US
257763001$25776300$1$I$20250208$20250218$20250909$20250909$PER$$US-FARMAPROD-202502-0569$DOMPE FARMACEUTICI$$1$YR$C$M$Y$$$20250819$$CN$US$US
257763761$25776376$1$I$20240820$20240907$20250909$20250909$PER$$US-FARMAPROD-202408-3018$DOMPE FARMACEUTICI$$41$YR$A$F$Y$$$20250817$$CN$US$US
257763841$25776384$1$I$20240822$20240919$20250909$20250909$PER$$US-FARMAPROD-202408-3047$DOMPE FARMACEUTICI$$81$YR$E$F$Y$$$20250817$$CN$US$US
257763981$25776398$1$I$$20240917$20250909$20250909$PER$$US-FARMAPROD-202408-3010$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250817$$CN$US$US
257764501$25776450$1$I$$20250325$20250909$20250909$PER$$US-FARMAPROD-202502-0655$DOMPE FARMACEUTICI$$$$E$M$Y$87.09$KG$20250819$$CN$US$US
257765332$25776533$2$F$$20250225$20250909$20250909$PER$$US-FARMAPROD-202502-0640$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250819$$CN$US$US
257765631$25776563$1$I$$20250304$20250909$20250909$PER$$US-FARMAPROD-202503-0731$DOMPE FARMACEUTICI$$$$A$M$Y$$$20250819$$CN$US$US
257765881$25776588$1$I$$20250306$20250909$20250909$PER$$US-FARMAPROD-202503-0773$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250819$$CN$US$US
257765961$25776596$1$I$$20250304$20250909$20250909$PER$$US-FARMAPROD-202503-0732$DOMPE FARMACEUTICI$$$$E$M$Y$96.21$KG$20250819$$CN$US$US
257766541$25776654$1$I$20250309$20250505$20250909$20250909$PER$$US-FARMAPROD-202503-0814$DOMPE FARMACEUTICI$$85$YR$E$F$Y$56.25$KG$20250819$$CN$US$US
257768221$25776822$1$I$20250317$20250325$20250909$20250909$PER$$US-FARMAPROD-202503-1002$DOMPE FARMACEUTICI$$36$YR$A$F$Y$$$20250819$$CN$US$US
257769281$25776928$1$I$$20240912$20250909$20250909$PER$$US-FARMAPROD-202409-3274$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257769411$25776941$1$I$$20240916$20250909$20250909$PER$$US-FARMAPROD-202409-3301$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257769872$25776987$2$F$$20250905$20250909$20250917$EXP$$ZA-ASTRAZENECA-202509SSA003714ZA$ALEXION PHARMACEUTICALS$$79$YR$E$F$Y$$$20250917$$$ZA$ZA
257769891$25776989$1$I$20240917$20241022$20250909$20250909$PER$$US-FARMAPROD-202409-3344$DOMPE FARMACEUTICI$$86$YR$E$F$Y$$$20250818$$CN$US$US
257769912$25776991$2$F$20250101$20250902$20250909$20250916$PER$$US-AMGEN-USASP2025175528$AMGEN$$81$YR$E$F$Y$$$20250915$$CN$US$US
257770391$25777039$1$I$20210101$20250826$20250909$20250909$EXP$$CN-GLANDPHARMA-CN-2025GLNLIT01801$GLAND PHARMA LTD$Nuoni Wang.Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report..Frontiers in Immunology.30-JUN-2025;16:01-09$45$YR$A$F$Y$$$20250909$$HP$CN$CN
257770681$25777068$1$I$$20241004$20250909$20250909$PER$$US-FARMAPROD-202410-3485$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257770961$25777096$1$I$$20250826$20250909$20250909$EXP$$US-AUROBINDO-AUR-APL-2025-044703$AUROBINDO$Mize BM, Laskey E, Damhorst GL, Kraft CS, Escobar GA. Two Cases of Mycotic Aneurysms Caused by Brucella suis Infection of Aortic Graft Material. Open Forum Infectious Diseases. 2025;12. No .7:1-4$48$YR$$M$Y$$$20250909$$MD$US$US
257771241$25777124$1$I$20230101$20250903$20250909$20250909$EXP$$BR-ABBVIE-6445986$ABBVIE$$69$YR$$F$Y$95$KG$20250909$$CN$BR$BR
257771261$25777126$1$I$$20241001$20250909$20250909$PER$$US-FARMAPROD-202410-3437$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250818$$CN$US$US
257775461$25777546$1$I$$20241122$20250909$20250909$EXP$$US-AMNEAL PHARMACEUTICALS-2024-AMRX-03718$AMNEAL$$$$$F$Y$$$20250909$$CN$US$US
257776531$25777653$1$I$$20250904$20250909$20250909$EXP$$US-ABBVIE-6447660$ABBVIE$$$$$F$Y$$$20250909$$CN$US$US
257777031$25777703$1$I$$20250901$20250909$20250909$EXP$$US-ROCHE-10000379084$ROCHE$Duarte-Celada W, Rivas K, Suppakitjanusant P, Davila-Siliezar P, Vijil M, Gamboa X, et al. Safety of thrombolysis in acute ischemic stroke patients with previous aortic abdominal aneurysm repair. Journal of Stroke and Cerebrovascular Diseases. 2025;34 (10):1-5. doi:10.1016/j.jstrokecerebrovasdis.2025.108421.$95$YR$E$M$Y$$$20250909$$HP$US$US
257778331$25777833$1$I$$20250905$20250909$20250909$PER$$US-ASTRAZENECA-202509USA005400US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250909$$$US$US
257778351$25777835$1$I$$20250712$20250909$20250909$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0012710$RECKITT BENCKISER$$$$$$Y$$$20250909$$CN$US$US
257779661$25777966$1$I$20250823$20250906$20250906$20250906$DIR$773999$$FDA-CTU$$45$YR$$M$N$63.45$KG$20250906$N$CN$US$
257779881$25777988$1$I$$20250825$20250909$20250909$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-526107$RANBAXY$Illari V, Tedeschi A, Di Cinto V, Guerra A,Di Spigno F, Orlandi E, et al.. NEVER LET YOUR GUARD DOWN WITH IMMUNE CHECKPOINT INHIBITOR RELATED MYOTOXICITY. Eur Heart J Suppl. 2025;27 (Suppl.):v110-v111.;suaf076.247$58$YR$$F$Y$$$20250909$$HP$EU$EU
257780311$25778031$1$I$$20250825$20250909$20250909$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526091$RANBAXY$Horiuchi K, Nakamura S, Yamada K. Tocilizumab for Rheumatoid Meningitis in Elderly Patients: A Report of Two Cases. Intern Med. 2025;0 (0):no pagination$80$YR$$M$Y$$$20250909$$MD$JP$JP
257781041$25778104$1$I$$20250901$20250909$20250909$EXP$$JP-MYLANLABS-2025M1075965$MYLAN$Sadaga Y, Watanabe D, Najima Y, Sadato D, Hirama C, Kato K, et al. Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation. Hematology 2025; 30 (1):.$57$YR$$F$Y$$$20250908$$$JP$JP
257781511$25778151$1$I$$20250903$20250909$20250909$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-009864$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250909$$CN$US$US
257782041$25778204$1$I$$20250905$20250909$20250909$EXP$$NZ-ROCHE-10000382123$ROCHE$$$$A$M$Y$$$20250909$$MD$NZ$NZ
257784281$25778428$1$I$$20250829$20250909$20250909$EXP$$US-MACLEODS PHARMA-MAC2025055123$MACLEODS$Haroon N, Singh A, Bhat ZY.Tacrolimus toxicity with minimal clinical manifestations: A case report and literature review..American Journal of Therapeutics.2016;23(2):e631- e634$$$$$Y$$$20250909$$MD$US$US
257784301$25778430$1$I$$20250618$20250909$20250909$PER$$US-NOVEN PHARMACEUTICALS, INC.-2025-NOV-US001145$NOVEN$$$$$F$Y$$$20250909$$CN$US$US
257784321$25778432$1$I$20250101$20250818$20250909$20250909$PER$$US-NOVEN PHARMACEUTICALS, INC.-2025-NOV-US001255$NOVEN$$$$$F$Y$$$20250909$$CN$US$US
257785061$25778506$1$I$$20250904$20250909$20250909$EXP$$US-PFIZER INC-PV202500107427$PFIZER$Siddika, A.. Fulminant CNS Aspergillosis Presenting as Unilateral Headache: A Case of Rapid Progression and Neurovascular Complications (P5-10.003). Neurology. 2025;104(7Supple1):10.1212/WNL.0000000000208597$64$YR$$M$Y$$$20250909$$HP$US$US
257785302$25778530$2$F$20250814$20250908$20250909$20250918$EXP$$EU-AUROBINDO-AUR-APL-2025-044454$AUROBINDO$$51$YR$$M$Y$19.7$KG$20250918$$HP$EU$EU
257785411$25778541$1$I$$20250831$20250909$20250909$PER$$US-INCYTE CORPORATION-2025IN009449$INCYTE$$67$YR$$$Y$$$20250909$$$US$
257785731$25778573$1$I$$20250908$20250909$20250909$EXP$$TH-JNJFOC-20250908955$JOHNSON AND JOHNSON$$96$YR$E$M$Y$$$20250909$$CN$TH$TH
257786411$25778641$1$I$$20250908$20250908$20250908$DIR$FDA-CDER-CTU-2025-59913$$FDA-CTU$$72$YR$$M$N$$$20250908$N$CN$US$
257787251$25778725$1$I$$20250904$20250909$20250909$EXP$$CA-APOTEX-2025AP029679$APOTEX$$56$YR$$M$Y$$$20250909$$CN$CA$CA
257787691$25778769$1$I$20250515$20250905$20250905$20250905$DIR$773956$$FDA-CTU$$43$YR$$F$N$$$20250905$N$CN$US$
257788361$25778836$1$I$20250722$20250904$20250909$20250909$PER$$US-PFIZER INC-202500176232$PFIZER$$64$YR$$F$Y$$$20250909$$CN$US$US
257788601$25778860$1$I$$20250904$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202509005988$ELI LILLY AND COMPANY$$$$$F$Y$$$20250909$$CN$US$US
257788911$25778891$1$I$20250101$20250903$20250909$20250909$PER$$US-ABBVIE-6447427$ABBVIE$$$$$$Y$$$20250909$$HP$US$US
257789311$25778931$1$I$20250825$20250908$20250908$20250908$DIR$774248$$FDA-CTU$$57$YR$$M$N$127.8$KG$20250908$N$CN$US$
257789561$25778956$1$I$20250827$20250903$20250909$20250909$EXP$$CN-SA-2025SA265773$SANOFI AVENTIS$$63$YR$A$F$Y$68$KG$20250909$$HP$CN$CN
257790201$25779020$1$I$$20250901$20250909$20250909$EXP$$AU-EMD Serono-2025044578$EMD SERONO INC$$$$$M$Y$$$20250909$$$AU$AU
257790671$25779067$1$I$20250801$20250904$20250909$20250909$EXP$$US-PFIZER INC-PV202500107697$PFIZER$$49$YR$$F$Y$$$20250909$$HP$US$US
257791051$25779105$1$I$20250908$20250908$20250908$20250908$DIR$774279$$FDA-CTU$$31$YR$$F$N$$$20250908$N$CN$US$
257791781$25779178$1$I$$20250908$20250908$20250908$DIR$774225$$FDA-CTU$$$$$$N$$$20250908$$CN$US$
257791961$25779196$1$I$20250901$20250909$20250909$20250909$DIR$774315$$FDA-CTU$$71$YR$$F$N$$$20250909$N$CN$US$
257792761$25779276$1$I$$20250901$20250909$20250909$EXP$$CO-ELI_LILLY_AND_COMPANY-CO202509001567$ELI LILLY AND COMPANY$$82$YR$E$F$Y$$$20250909$$CN$CO$CO
257793001$25779300$1$I$20250903$20250909$20250909$20250909$DIR$FDA-CDER-CTU-2025-60141$$FDA-CTU$$73$YR$$M$N$201$KG$20250909$N$$US$
257794181$25779418$1$I$$20250903$20250909$20250909$PER$$US-ABBVIE-6446327$ABBVIE$$$$$M$Y$$$20250909$$CN$US$US
257794421$25779442$1$I$20250829$20250905$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202509006210$ELI LILLY AND COMPANY$$62$YR$A$M$Y$$$20250909$$CN$US$US
257795171$25779517$1$I$$20250903$20250909$20250909$EXP$GB-MHRA-EMIS-3200-6da7ac2c-aeea-431b-96e0-f92bc3069c9c$GB-RDY-GBR/2025/09/013679$DR REDDYS$$22$YR$A$M$Y$70$KG$20250909$$HP$GB$GB
257795301$25779530$1$I$$20250904$20250909$20250909$EXP$$EU-INCYTE CORPORATION-2025IN009756$INCYTE$$65$YR$$$Y$$$20250909$$MD$EU$EU
257795571$25779557$1$I$20250814$20250901$20250909$20250909$EXP$EU-INFARMED-R202508-549$EU-FreseniusKabi-FK202512116$FRESENIUS KABI$$58$YR$A$F$Y$91.5$KG$20250909$$PH$EU$EU
257795651$25779565$1$I$20210913$20250129$20250909$20250909$EXP$$EU-TAKEDA-2025TUS078896$TAKEDA$$86$YR$$F$Y$$$20250909$$$EU$EU
257796391$25779639$1$I$$20250908$20250909$20250909$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-124382$BRISTOL-MYERS SQUIBB COMPANY$$73$YR$E$F$Y$60.33$KG$20250909$$$US$US
257796632$25779663$2$F$20250101$20250925$20250909$20250930$EXP$$US-ABBVIE-6446723$ABBVIE$$65$YR$$M$Y$$$20250930$$CN$US$US
257796831$25779683$1$I$$20250908$20250908$20250908$DIR$774118$$FDA-CTU$$$$$$N$$$20250908$N$$US$
257796981$25779698$1$I$$20250906$20250909$20250909$PER$$US-PURDUE-USA-2025-0320330$PURDUE$$$$A$F$Y$$$20250909$$CN$US$US
257797631$25779763$1$I$$20250905$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202509006221$ELI LILLY AND COMPANY$$$$$$Y$$$20250909$$CN$US$US
257797971$25779797$1$I$20250101$20250908$20250909$20250909$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-124397$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$M$Y$$$20250909$$$US$US
257798391$25779839$1$I$$20250903$20250909$20250909$PER$$US-ABBVIE-6448771$ABBVIE$$$$$F$Y$$$20250909$$HP$US$US
257798491$25779849$1$I$$20250903$20250909$20250909$EXP$$EU-ELI_LILLY_AND_COMPANY-GR202509002612$ELI LILLY AND COMPANY$$55$YR$A$M$Y$$$20250909$$CN$EU$EU
257798811$25779881$1$I$20210917$20250129$20250909$20250909$EXP$$EU-TAKEDA-2025TUS078877$TAKEDA$$75$YR$$F$Y$$$20250909$$$EU$EU
257799281$25779928$1$I$20230707$20250908$20250908$20250908$DIR$774156$$FDA-CTU$$22$YR$$F$N$117$KG$20250908$N$CN$US$
257800971$25780097$1$I$$20250903$20250909$20250909$EXP$EU-LRB-01081353$EU-MYLANLABS-2025M1075844$MYLAN$$85$YR$$M$Y$86$KG$20250909$$$EU$EU
257801022$25780102$2$F$20250818$20250904$20250909$20250915$EXP$$BR-NOVOPROD-1512934$NOVO NORDISK$$33$YR$$M$Y$$$20250915$$CN$BR$BR
257802272$25780227$2$F$$20250829$20250909$20250923$PER$$US-SA-2025SA266769$SANOFI AVENTIS$$$$A$$Y$$$20250923$$CN$US$US
257802841$25780284$1$I$$20250903$20250909$20250909$PER$$US-SA-2025SA267005$SANOFI AVENTIS$$67$YR$E$M$Y$$$20250909$$MD$US$US
257803401$25780340$1$I$20250801$20250902$20250909$20250909$PER$$US-SA-2025SA266919$SANOFI AVENTIS$$55$YR$A$F$Y$50.91$KG$20250909$$HP$US$US
257803511$25780351$1$I$$20250903$20250909$20250909$PER$$US-SA-2025SA266885$SANOFI AVENTIS$$56$YR$A$M$Y$$$20250909$$HP$US$US
257803601$25780360$1$I$20250801$20250903$20250909$20250909$PER$$US-SA-2025SA267117$SANOFI AVENTIS$$29$YR$A$F$Y$$$20250909$$HP$US$US
257804011$25780401$1$I$$20250903$20250909$20250909$PER$$US-SA-2025SA267349$SANOFI AVENTIS$$$$A$F$Y$73.64$KG$20250909$$MD$US$US
257804511$25780451$1$I$$20250903$20250909$20250909$EXP$$BR-AMGEN-BRASP2025176799$AMGEN$Ramos L. H.; Piazera F. Z.; Tolentino P. D. et al.. Retrospective Analysis of Patients With Hairy-Cell Leukemia Treated at a Public Reference Hospital in Brazil. Clinical Lymphoma Myeloma and Leukemia. 2025;25:S825-S826$$$$$Y$$$20250909$$MD$BR$BR
257804751$25780475$1$I$20250101$20250904$20250909$20250909$PER$$US-SA-2025SA269382$SANOFI AVENTIS$$79$YR$E$F$Y$$$20250909$$HP$US$US
257804851$25780485$1$I$$20250904$20250909$20250909$PER$$US-SA-2025SA266448$SANOFI AVENTIS$$60$YR$A$M$Y$$$20250909$$CN$US$US
257805811$25780581$1$I$$20250905$20250909$20250909$PER$$US-SA-2025SA267552$SANOFI AVENTIS$$$$A$F$Y$$$20250909$$CN$US$US
257806681$25780668$1$I$$20250904$20250909$20250909$PER$$NVSC2025US140323$NOVARTIS$$$$$$Y$$$20250909$$MD$US$US
257807351$25780735$1$I$$20250908$20250909$20250909$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-124344$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250909$$$US$US
257807821$25780782$1$I$$20250908$20250909$20250909$EXP$$EU-BAUSCH-BH-2025-017243$BAUSCH AND LOMB$Lim M, Abou-lsmail M, Branch W. Differential diagnosis and management of rare thrombotic microangiopathies in pregnant and postpartum women. Medycyna Praktyczna - Ginekologia i Poloznictwo. 2025;(3):$$$$$Y$$$20250909$$MD$EU$EU
257808181$25780818$1$I$$20250905$20250909$20250909$PER$$US-PFIZER INC-PV202500107979$PFIZER$$74$YR$$M$Y$$$20250909$$HP$US$US
257809821$25780982$1$I$$20250908$20250909$20250909$PER$$US-ELI_LILLY_AND_COMPANY-US202509008617$ELI LILLY AND COMPANY$$$$$F$Y$$$20250909$$CN$US$US
257813131$25781313$1$I$$20250908$20250909$20250909$EXP$$CA-HLS-202502366$HLS THERAPEUTICS$$$$$F$Y$$$20250909$$$CA$CA
257823832$25782383$2$F$20250801$20250915$20250909$20250919$EXP$$BR-BIOGEN-2025BI01323371$BIOGEN$$36$YR$$F$Y$$$20250919$$CN$BR$BR
257825111$25782511$1$I$20200101$20250905$20250909$20250909$PER$$US-SA-2025SA268480$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250910$$MD$US$US
257828683$25782868$3$F$$20250905$20250909$20250919$EXP$$JP-ASTRAZENECA-202509JPN004655JP$ALEXION PHARMACEUTICALS$$66$YR$E$F$Y$$$20250919$$MD$JP$JP
257828701$25782870$1$I$$20250901$20250909$20250909$EXP$$CN-BEIGENE-BGN-2025-014923$BEIGENE$$64$YR$$$Y$55$KG$20250909$$$CN$CN
257829431$25782943$1$I$$20250905$20250909$20250909$PER$$US-SA-2025SA268909$SANOFI AVENTIS$$$$E$M$Y$$$20250910$$HP$US$US
257830151$25783015$1$I$20250901$20250904$20250910$20250910$30DAY$$US-SANDOZ INC.-SDZ2025US064640$SANDOZ$$$$$F$Y$$$20250909$$CN$US$US
257832281$25783228$1$I$$20241205$20250910$20250910$PER$$US-CIPLA LTD.-2024US14698$CIPLA$$$$$$Y$$$20250910$$CN$US$US
257835141$25783514$1$I$$20250731$20250910$20250910$PER$$US-GSK-US2025AMR099637$GLAXOSMITHKLINE$$$$$F$Y$$$20250910$$MD$US$US
257837021$25783702$1$I$20250825$20250825$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509001638$ELI LILLY AND COMPANY$$67$YR$E$M$Y$143.76$KG$20250910$$CN$US$US
257838021$25783802$1$I$$20250712$20250910$20250910$PER$$US-PROD-AS2-212756134-20-24-USA-RB-0016377$RECKITT BENCKISER$$$$$M$Y$$$20250910$$CN$US$US
257840601$25784060$1$I$20250801$20250904$20250910$20250910$PER$$US-SA-2025SA268384$SANOFI AVENTIS$$57$YR$A$F$Y$$$20250910$$HP$US$US
257842441$25784244$1$I$$20250903$20250910$20250910$EXP$$US-JNJFOC-20250903562$JOHNSON AND JOHNSON$$$$$$Y$$$20250910$$PH$US$US
257842751$25784275$1$I$$20250815$20250910$20250910$PER$$US-GALDERMA-US2025015418$GALDERMA$$$$$$Y$$$20250910$$MD$US$US
257843792$25784379$2$F$20250731$20250903$20250910$20250914$EXP$$EU-AUROBINDO-AUR-APL-2025-044660$AUROBINDO$$$$A$F$Y$65$KG$20250914$$MD$EU$EU
257844731$25784473$1$I$$20250902$20250910$20250910$EXP$$US-APOTEX-2025AP029667$APOTEX$Aggarwal A, Wadhwani A, Loscalzo S, McSherry M, Lockman J, Brandsema J, McGuire J, Matesanz S.. ICU Management of Severe Myotonic Crisis in the Setting of Beta- Adrenergic Agonist Use: A Case Report. Neurology. 2025;104:7(Suppl. 1)$10$YR$$F$Y$$$20250910$$HP$US$US
257845991$25784599$1$I$$20250908$20250910$20250910$PER$$US-ASTRAZENECA-202509USA005099US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250910$$$US$US
257846231$25784623$1$I$$20250828$20250910$20250910$EXP$$CA-AUROBINDO-AUR-APL-2025-045632$AUROBINDO$$76$YR$$F$Y$73$KG$20250910$$PH$CA$CA
257847181$25784718$1$I$$20250905$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509006482$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250910$$CN$US$US
257848041$25784804$1$I$$20250901$20250910$20250910$EXP$$US-ROCHE-10000379983$ROCHE$Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, et al. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver International. 2025;45 (9):1-13. doi:10.1111/liv.70255.$59$YR$A$M$Y$$$20250910$$HP$US$US
257848331$25784833$1$I$20220101$20250903$20250910$20250910$EXP$$US-ABBVIE-6137419$ABBVIE$$73$YR$$F$Y$81.64$KG$20250910$$CN$US$US
257848451$25784845$1$I$$20250826$20250910$20250910$PER$$US-COSETTE-CP2025US000850$COSETTE PHARMACEUTICALS INC$$$$$F$Y$$$20250910$$CN$US$US
257848461$25784846$1$I$$20250905$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509006721$ELI LILLY AND COMPANY$$72$YR$E$M$Y$$$20250910$$CN$US$US
257848882$25784888$2$F$20250630$20250909$20250910$20250911$PER$$US-AMGEN-USASP2025179283$AMGEN$$71$YR$E$F$Y$$$20250911$$PH$US$US
257850351$25785035$1$I$$20250902$20250910$20250910$EXP$$US-GILEAD-2025-0726917$GILEAD$$$$T$F$Y$$$20250910$$CN$US$US
257852531$25785253$1$I$$20250906$20250910$20250910$PER$$US-KENVUE-20250903465$Kenvue$$$$A$F$Y$$$20250910$$CN$US$US
257853011$25785301$1$I$20240314$20250217$20250910$20250910$PER$$US-CHIESI-2025CHF01269$CHIESI$$7$YR$$M$Y$30$KG$20250910$$CN$US$US
257853331$25785333$1$I$$20250905$20250910$20250910$EXP$$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-123103$BRISTOL-MYERS SQUIBB COMPANY$Saraullo S, Rossi D, Giordano B, Palermi A, Scollo C, Magnano R, et al. Chemotherapy-induced cardiotoxicity with a shark fin presentation. Eur Heart J Suppl. 2025;27(1):v114. doi:10.1093/eurheartjsupp/suaf076.257.$87$YR$E$F$Y$$$20250910$$$EU$EU
257854771$25785477$1$I$$20250902$20250910$20250910$PER$$US-ABBVIE-6445627$ABBVIE$$$$$$Y$$$20250910$$CN$US$US
257855121$25785512$1$I$$20250826$20250910$20250910$EXP$$GB-AUROBINDO-AUR-APL-2022-051834$AUROBINDO$Rice K, Hikin L, Lawson A, Smith PR, Morley S.. Quantification of Flualprazolam in Blood by LC?MS-MS: A Case Series of Nine Deaths.. Journal of Analytical Toxicology.. 2021;45(4):410-6$40$YR$$M$Y$$$20250910$$MD$GB$GB
257855971$25785597$1$I$$20250902$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509003095$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250910$$CN$US$US
257857111$25785711$1$I$$20250904$20250910$20250910$EXP$$CA-009507513-2326590$MERCK SHARP + DOHME LLC$$84$YR$$M$Y$$$20250910$$HP$CA$CA
257857391$25785739$1$I$20250905$20250909$20250909$20250909$DIR$FDA-CDER-CTU-2025-60394$$FDA-CTU$$33$YR$$F$N$$$20250909$Y$HP$US$
257858241$25785824$1$I$$20250909$20250909$20250909$DIR$774480$$FDA-CTU$$$$$F$N$$$20250909$N$$US$
257859261$25785926$1$I$$20250826$20250910$20250910$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-524628$RANBAXY$Tchernev G, Broshtilova V, Lozev I, Kordeva S, Pidakev I, Ivanova V, et al. NITROSAMINES IN METFORMIN AND HYDROCHLOROTHIAZIDE: ^HUMAN SAFE PHOTOCARCINOGENS^ WITHIN THE POLYPHARMACY AS GENERATOR FOR PHOTOTOXICITY/ PHOTOCARCINOGENICITY AND THE SUBSEQUENT DEVELOPMENT OF MULTIPLE KERATINOCYTE CARCINOMAS. DOUBLE HATCHET FLAP AS OPTIMAL AND NECESSARY DERMATOSURGICAL DECISION IN TWO NEW PATIENTS. Georgian Med News. 2025;Apr;(361):80-89$78$YR$$F$Y$$$20250910$$HP$EU$EU
257859331$25785933$1$I$$20250905$20250910$20250910$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-123885$BRISTOL-MYERS SQUIBB COMPANY$$62$YR$A$M$Y$$$20250910$$$US$US
257861001$25786100$1$I$$20250909$20250910$20250910$EXP$$CN-PFIZER INC-PV202500108622$PFIZER$$$$A$M$Y$$$20250910$$CN$CN$CN
257861311$25786131$1$I$$20250901$20250910$20250910$EXP$$US-STRIDES ARCOLAB LIMITED-2025SP011489$STRIDES$Shayegan LH, Shaw KS, Wieschhoff GG, Ezeh N, Kim YJ, Shahriari N, et al.. Improvement in dermatomyositis-associated muscle disease with anifrolumab.. Br-J-Dermatol. 2025;192 (6):1126-1128$25$YR$$F$Y$$$20250910$$HP$US$US
257864281$25786428$1$I$$20250905$20250910$20250910$PER$$US-SA-2025SA269116$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250910$$CN$US$US
257865071$25786507$1$I$20250101$20250904$20250910$20250910$PER$$US-SA-2025SA268253$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250910$$HP$US$US
257865431$25786543$1$I$$20250905$20250910$20250910$PER$$US-SA-2025SA269012$SANOFI AVENTIS$$42$YR$A$F$Y$104.33$KG$20250910$$HP$US$US
257865801$25786580$1$I$20250101$20250905$20250910$20250910$EXP$$CA-PFIZER INC-PV202500108351$PFIZER$$54$YR$$F$Y$$$20250910$$HP$CA$CA
257866211$25786621$1$I$$20250905$20250910$20250910$PER$$US-SA-2025SA268392$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250910$$CN$US$US
257867881$25786788$1$I$$20250908$20250910$20250910$EXP$$US-ABBVIE-6451997$ABBVIE$$$$A$F$Y$$$20250910$$CN$US$US
257868131$25786813$1$I$$20250901$20250910$20250910$EXP$$US-STRIDES PHARMA UK LTD.-2025SP011533$STRIDES$DoDoo A, Cregan M, Remien KA, Patel A.. Sevoflurane-induction via the Flow-i ventilator in the pediatric intensive care unit for the treatment of status asthmaticus: a case report and literature review.. J-Asthma. 2025;62 (8):1450-1457$14$YR$$M$Y$54.2$KG$20250910$$MD$US$US
257868342$25786834$2$F$20250825$20250919$20250910$20250929$EXP$$JP-GALDERMA-JP2025017091$GALDERMA$$$$$$Y$$$20250929$$MD$JP$JP
257868371$25786837$1$I$$20250905$20250910$20250910$PER$$US-SA-2025SA268725$SANOFI AVENTIS$$9$YR$C$F$Y$$$20250910$$HP$US$US
257868611$25786861$1$I$$20250909$20250910$20250910$PER$$US-PFIZER INC-PV202500109263$PFIZER$$79$YR$$M$Y$$$20250910$$CN$US$US
257869021$25786902$1$I$20250306$20250308$20250910$20250910$PER$$US-ANIPHARMA-2025-PR-000014$ANI$$69$YR$$F$Y$57.61$KG$20250910$$HP$US$PR
257870021$25787002$1$I$$20250818$20250910$20250910$PER$$US-Merz Pharmaceuticals GmbH-2025080000098$MERZ$$$$$$Y$$$20250910$$MD$US$US
257870281$25787028$1$I$20250901$20250905$20250910$20250910$PER$$US-SA-2025SA269076$SANOFI AVENTIS$$54$YR$A$F$Y$$$20250910$$HP$US$US
257871921$25787192$1$I$20250903$20250910$20250910$20250910$DIR$FDA-CDER-CTU-2025-60544$$FDA-CTU$$24$YR$$M$N$108.86$KG$20250910$N$$US$
257872491$25787249$1$I$$20250910$20250910$20250910$DIR$774552$$FDA-CTU$$$$$$N$$$20250910$N$$US$
257872761$25787276$1$I$$20250902$20250910$20250910$EXP$$RU-BAYER-2025A118102$BAYER HEALTHCARE PHARMACEUTICALS INC.$$40$YR$A$F$Y$$$20250910$$MD$RU$RU
257872881$25787288$1$I$$20250901$20250910$20250910$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202509007382$ELI LILLY AND COMPANY$$74$YR$E$M$Y$$$20250910$$CN$EU$JP
257874151$25787415$1$I$20250701$20250829$20250910$20250910$EXP$$US-NOVOPROD-1514901$NOVO NORDISK$$49$YR$$F$Y$$$20250910$$CN$US$US
257875061$25787506$1$I$20250827$20250903$20250910$20250910$PER$$US-SA-2025SA265545$SANOFI AVENTIS$$$$A$M$Y$$$20250910$$CN$US$US
257875491$25787549$1$I$$20250828$20250910$20250910$PER$$US-ABBVIE-6453557$ABBVIE$$$$E$M$Y$$$20250910$$MD$US$US
257875771$25787577$1$I$$20241218$20250910$20250910$PER$$US-FARMAPROD-202412-4265$DOMPE FARMACEUTICI$$$$E$F$Y$$$20250909$$CN$US$US
257877641$25787764$1$I$$20250905$20250910$20250910$EXP$$US-ABBVIE-6450163$ABBVIE$$$$E$F$Y$$$20250910$$CN$US$US
257877831$25787783$1$I$20250701$20250905$20250910$20250910$EXP$$US-ABBVIE-6411192$ABBVIE$$70$YR$$M$Y$$$20250910$$CN$US$US
257879821$25787982$1$I$$20250819$20250910$20250910$PER$$US-009507513-2321225$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250910$$PH$US$US
257880561$25788056$1$I$$20250908$20250910$20250910$EXP$$CA-HLS-202502351$HLS THERAPEUTICS$$91$YR$E$F$Y$$$20250910$$$CA$CA
257880611$25788061$1$I$$20250903$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202507023568$ELI LILLY AND COMPANY$$56$YR$A$F$Y$$$20250910$$CN$US$US
257881311$25788131$1$I$$20250908$20250910$20250910$PER$$US-SA-2025SA269596$SANOFI AVENTIS$$$$$M$Y$$$20250910$$CN$US$US
257881411$25788141$1$I$$20250828$20250910$20250910$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI11464$NEUROCRINE BIOSCIENCES$$43$YR$$M$Y$$$20250910$$HP$US$US
257881711$25788171$1$I$$20250905$20250910$20250910$EXP$$IN-ROCHE-10000382846$ROCHE$$70$YR$E$M$Y$90.3$KG$20250910$$CN$IN$IN
257881841$25788184$1$I$20250709$20250902$20250910$20250910$EXP$$US-NOVOPROD-1515998$NOVO NORDISK$$79$YR$$M$Y$$$20250910$$CN$US$US
257882121$25788212$1$I$$20250829$20250910$20250910$EXP$$US-ELI_LILLY_AND_COMPANY-US202509003444$ELI LILLY AND COMPANY$$$$$$Y$$$20250910$$CN$US$US
257883011$25788301$1$I$20230101$20250903$20250910$20250910$EXP$EU-AFSSAPS-MA2025001158$EU-009507513-2326320$MERCK SHARP + DOHME LLC$$72$YR$$F$Y$$$20250910$$HP$EU$EU
257883051$25788305$1$I$$20250908$20250910$20250910$PER$$US-ROCHE-10000384018$ROCHE$$$$A$F$Y$$$20250910$$CN$US$US
257883191$25788319$1$I$20250830$20250905$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509007471$ELI LILLY AND COMPANY$$51$YR$A$$Y$$$20250910$$CN$US$US
257883251$25788325$1$I$$20250829$20250910$20250910$PER$$US-ELI_LILLY_AND_COMPANY-US202509000923$ELI LILLY AND COMPANY$$71$YR$E$M$Y$$$20250910$$CN$US$US
257883881$25788388$1$I$$20250905$20250910$20250910$EXP$$GB-PFIZER INC-PV202500108235$PFIZER$$$$A$F$Y$$$20250910$$MD$GB$GB
257884282$25788428$2$F$20250829$20250902$20250910$20250915$30DAY$$US-JNJFOC-20250902497$JOHNSON AND JOHNSON$$36$YR$A$F$Y$$$20250915$$PH$US$US
257885302$25788530$2$F$20250829$20250908$20250910$20250918$EXP$$US-DELCATH SYSTEMS-DELC-000022$DELCATH SYSTEMS$$68$YR$$M$Y$$$20250918$$MD$US$US
257885661$25788566$1$I$20250501$20250905$20250910$20250910$EXP$$US-ABBVIE-6450216$ABBVIE$$61$YR$$M$Y$$$20250910$$CN$US$US
257886461$25788646$1$I$$20250908$20250910$20250910$PER$$US-TAKEDA-2025TUS078734$TAKEDA$$$$$M$Y$75$KG$20250910$$$US$US
257886491$25788649$1$I$20250101$20250908$20250910$20250910$EXP$$US-ABBVIE-6451756$ABBVIE$$70$YR$$M$Y$$$20250910$$CN$US$US
257887281$25788728$1$I$$20250819$20250910$20250910$30DAY$$US-BAXTER-2025BAX020982$BAXTER$$$$$$Y$$$20250910$$PH$US$US
257887461$25788746$1$I$$20250902$20250910$20250910$EXP$$CN-BEIGENE-BGN-2025-015089$BEIGENE$$66$YR$$$Y$$$20250910$$$CN$CN
257887631$25788763$1$I$$20250905$20250910$20250910$EXP$$US-ABBVIE-6451495$ABBVIE$$$$E$F$Y$$$20250910$$CN$US$US
257887731$25788773$1$I$$20250829$20250911$20250911$EXP$$IN-CIPLA LTD.-2025IN11114$CIPLA$Durairaj T, Porchezhian M, Kumar M, Britto De JRJ, K M, Saravanan A. Beyond seizure control: A case series on Levetiracetam associated psychiatric manifestations. Indian journal of psychological medicine. 2025;1 to 4$$$$$Y$$$20250911$$HP$IN$IN
257888041$25788804$1$I$20250818$20250905$20250911$20250911$PER$$US-VIIV HEALTHCARE-US2025114564$VIIV$$35$YR$$M$Y$$$20250911$$$US$US
257888381$25788838$1$I$20211205$20250904$20250911$20250911$EXP$EU-URPL-DML-MLP.4401.2.13214.2021$EU-GSK-PL2025114976$GLAXOSMITHKLINE$$$$A$M$Y$76$KG$20250911$$$EU$EU
257888741$25788874$1$I$20250701$20250901$20250911$20250911$PER$$AU-TAKEDA-2025TUS079343$TAKEDA$$87$YR$$M$Y$$$20250911$$$AU$AU
257889691$25788969$1$I$$20250827$20250911$20250911$PER$$US-GSK-US2025110342$GLAXOSMITHKLINE$$78$YR$$F$Y$$$20250911$$MD$US$US
257891101$25789110$1$I$$20250903$20250911$20250911$PER$$NVSC2025US138870$NOVARTIS$$$$$$Y$$$20250911$$HP$US$US
257892541$25789254$1$I$$20250909$20250911$20250911$EXP$$EU-SANDOZ INC.-SDZ2025PL065886$SANDOZ$$$$$F$Y$$$20250911$$MD$EU$EU
257892621$25789262$1$I$20250101$20250815$20250911$20250911$PER$$US-GALDERMA-US2025015525$GALDERMA$$$$$$Y$$$20250911$$CN$US$US
257893631$25789363$1$I$20250801$20250902$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509003647$ELI LILLY AND COMPANY$$49$YR$A$M$Y$$$20250911$$CN$US$US
257893651$25789365$1$I$$20250829$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509001182$ELI LILLY AND COMPANY$$65$YR$E$F$Y$$$20250911$$CN$US$US
257893671$25789367$1$I$$20250909$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509008903$ELI LILLY AND COMPANY$$78$YR$E$F$Y$$$20250911$$CN$US$US
257893792$25789379$2$F$20250830$20250911$20250911$20250918$EXP$$CA-ROCHE-10000383995$ROCHE$$66$YR$E$M$Y$$$20250918$$CN$CA$CA
257893823$25789382$3$F$$20250922$20250911$20250926$EXP$$EU-TLM-25DE056043$TOLMAR$Sauerbruch T. Enzalutamide: Hepatotoxicity and DILI. Drug Prescription in Practice. 2024;51(4):339-343$78$YR$E$F$Y$$$20250925$$MD$EU$EU
257894001$25789400$1$I$20250312$20250910$20250911$20250911$EXP$EU-AFSSAPS-RN2025000828$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-124923$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$$$20250911$$MD$EU$EU
257896151$25789615$1$I$$20250724$20250911$20250911$EXP$$EU-ASTELLAS-2025-AER-038386$ASTELLAS$Kelleher A. A rare dermatomyositis with significant lung involvement. American Journal of Respiratory and Critical Care Medicine. 2025; 211: A3580-Unknown.$33$YR$A$F$Y$$$20250911$$HP$EU$EU
257896471$25789647$1$I$$20250907$20250911$20250911$PER$$US-ASTRAZENECA-202509USA005902US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250911$$$US$US
257897421$25789742$1$I$$20250902$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509004163$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250911$$CN$US$US
257897781$25789778$1$I$20250901$20250904$20250911$20250911$30DAY$$GB-JNJFOC-20250902774$JOHNSON AND JOHNSON$$55$YR$A$M$Y$$$20250911$$CN$GB$GB
257899421$25789942$1$I$$20250909$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509009385$ELI LILLY AND COMPANY$$$$$$Y$$$20250911$$CN$US$US
257900882$25790088$2$F$20250114$20250919$20250911$20250929$EXP$$JP-UCBSA-2025055062$UCB$$27$YR$$M$Y$67$KG$20250928$$MD$JP$JP
257902311$25790231$1$I$20250903$20250908$20250911$20250911$EXP$$CO-ASTRAZENECA-202509SAM006576CO$ALEXION PHARMACEUTICALS$$62$YR$A$M$Y$66$KG$20250911$$$CO$CO
257902581$25790258$1$I$20250803$20250827$20250911$20250911$EXP$$CN-COSETTE-CP2025CN000899$COSETTE PHARMACEUTICALS INC$$42$YR$A$M$Y$$$20250911$$HP$CN$CN
257903281$25790328$1$I$20250502$20250827$20250911$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526228$RANBAXY$$82$YR$$F$Y$$$20250911$$CN$EU$EU
257903361$25790336$1$I$20250412$20250827$20250911$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526230$RANBAXY$$41$YR$$M$Y$79$KG$20250911$$MD$EU$EU
257903451$25790345$1$I$20250509$20250827$20250911$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526075$RANBAXY$$69$YR$$F$Y$109$KG$20250911$$MD$EU$EU
257903461$25790346$1$I$20250612$20250828$20250911$20250911$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526406$RANBAXY$$50$YR$$F$Y$62$KG$20250911$$MD$GB$GB
257903981$25790398$1$I$20250424$20250829$20250911$20250911$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-526392$RANBAXY$$31$YR$$M$Y$$$20250911$$MD$EU$EU
257904931$25790493$1$I$$20250320$20250911$20250911$EXP$$TW-BAYER-2025A120326$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$$Y$$$20250911$$HP$TW$TW
257905011$25790501$1$I$$20250904$20250911$20250911$EXP$$US-SANDOZ INC.-SDZ2025US066021$SANDOZ$$$$$F$Y$$$20250911$$MD$US$US
257905021$25790502$1$I$$20250828$20250911$20250911$EXP$$US-Lepu Pharmaceutical Technology Co., Ltd.-2184277$LEPU PHARMACEUTICAL TECHNOLOGY CO., LTD.$Full text$74$YR$$F$Y$$$20250911$$MD$US$US
257905231$25790523$1$I$20250724$20250910$20250910$20250910$DIR$FDA-CDER-CTU-2025-60661$$FDA-CTU$$76$YR$$F$N$$$20250910$Y$PH$US$
257905462$25790546$2$F$$20250917$20250911$20250925$EXP$$US-TEVA-VS-3368665$TEVA$Adhan IK, Martin J, Strombeck T, Chisholm SAM, Stiff H. Neurotoxic Implications of Vincristine in Pediatric Ophthalmology: A Case Series. J-Pediatr-Ophthalmol-Strabismus 2025; 62 (4): e51-e53.; Adhan IK, Martin J, Strombeck T, Chisholm SAM, Stiff H. Neurotoxic Implications of Vincristine in Pediatric Ophthalmology: A Case Series. J-Pediatr-Ophthalmol-Strabismus 2025; 62 (4): e51-e53.$14$MON$$F$Y$$$20250925$$MD$US$US
257905531$25790553$1$I$20250831$20250831$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509005486$ELI LILLY AND COMPANY$$60$YR$A$F$Y$60.771$KG$20250911$$CN$US$US
257905881$25790588$1$I$$20250910$20250910$20250910$DIR$774652$$FDA-CTU$$$$$M$N$$$20250910$N$$US$
257906041$25790604$1$I$$20250905$20250911$20250911$EXP$$AU-SAMSUNG BIOEPIS-SB-2025-30373$SAMSUNG BIOEPIS$$$$$$Y$74$KG$20250911$$MD$AU$AU
257907511$25790751$1$I$$20250828$20250911$20250911$EXP$$US-GSK-US2025AMR110605$GLAXOSMITHKLINE$$$$$F$Y$$$20250911$$$US$US
257907581$25790758$1$I$$20250910$20250911$20250911$PER$$US-PFIZER INC-PV202500109522$PFIZER$$65$YR$$F$Y$$$20250911$$HP$US$US
257907841$25790784$1$I$$20250910$20250911$20250911$PER$$US-PFIZER INC-PV202500109676$PFIZER$$72$YR$$F$Y$$$20250911$$HP$US$US
257907871$25790787$1$I$$20231130$20250911$20250911$PER$$US-TEVA-VS-3371521$TEVA$$71$YR$$F$Y$$$20250911$$CN$US$US
257908071$25790807$1$I$20250905$20250910$20250910$20250910$DIR$FDA-CDER-CTU-2025-60660$$FDA-CTU$$74$YR$$F$N$$$20250910$Y$PH$US$
257908272$25790827$2$F$20250828$20250904$20250911$20250918$EXP$$US-ADMA BIOLOGICS INC.-US-2025ADM000266$ADMA BIOLOGICS$$69$YR$$M$Y$$$20250918$$PH$US$US
257908641$25790864$1$I$20180101$20250905$20250911$20250911$EXP$$EU-SA-2025SA267857$SANOFI AVENTIS$Paulik A.. Successful treatment of metastatic breast cancer in a man with the combination of abemaciclib with fulvestrant - case report / Uspesna lecba metastazujiciho karcinomu prsu u muze kombinaci abemaciklibu s fulvestrantem - kazuistika.. Onkologicka revue.. 2025;12(4):224-8$74$YR$E$M$Y$$$20250911$$MD$EU$EU
257909071$25790907$1$I$$20250908$20250911$20250911$30DAY$$CO-PFIZER INC-202500177838$PFIZER$$$$C$F$Y$$$20250911$$CN$CO$CO
257910281$25791028$1$I$20250816$20250909$20250911$20250911$EXP$$CA-MYLANLABS-2025M1077331$MYLAN$$52$YR$$M$Y$$$20250911$$$CA$CA
257910681$25791068$1$I$$20250908$20250911$20250911$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-125594$BRISTOL-MYERS SQUIBB COMPANY$$$$$$Y$$$20250911$$PH$US$US
257910972$25791097$2$F$20250125$20250917$20250911$20250930$EXP$EU-HPRA-2025-123319$EU-MSNLABS-2025MSNSPO02502$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250930$$CN$EU$EU
257911011$25791101$1$I$20250909$20250911$20250911$20250911$EXP$GB-MHRA-MED-202509110950382230-GVWYB$GB-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-094771$BOEHRINGER INGELHEIM$$55$YR$A$M$Y$$$20250911$$MD$GB$GB
257911361$25791136$1$I$20250905$20250908$20250911$20250911$EXP$$GB-Ipsen Biopharmaceuticals, Inc.-2025-22261$IPSEN BIOPHARMACEUTICALS, INC.$$51$YR$A$F$Y$$$20250911$$$GB$GB
257912681$25791268$1$I$$20250911$20250911$20250911$DIR$774704$$FDA-CTU$$$$$$N$$$20250911$N$CN$US$
257913231$25791323$1$I$$20250909$20250911$20250911$EXP$$EC-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-094558$BOEHRINGER INGELHEIM$$$$$M$Y$$$20250911$$MD$EC$EC
257913251$25791325$1$I$$20250817$20250911$20250911$PER$$US-GRANULES-US-2025GRASPO00474$GRANULES PHARMACEUTICALS INC$$$$$F$Y$$$20250911$$CN$US$US
257914001$25791400$1$I$$20250902$20250911$20250911$EXP$$US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-25-10234$HIKMA$$34$YR$$M$Y$$$20250911$$CN$US$US
257914131$25791413$1$I$20250818$20250818$20250911$20250911$PER$$US-GALDERMA-US2025015502$GALDERMA$$$$$$Y$$$20250911$$CN$US$US
257914441$25791444$1$I$$20250902$20250911$20250911$EXP$$US-NOVOPROD-1514307$NOVO NORDISK$$45$YR$$$Y$$$20250911$$CN$US$US
257914871$25791487$1$I$20250827$20250828$20250911$20250911$DIR$FDA-CDER-CTU-2025-60803$$FDA-CTU$$43$YR$$M$N$$$20250828$N$$US$
257915271$25791527$1$I$20250301$20250901$20250911$20250911$EXP$GB-MHRA-36550039$GB-TORRENT-00042619$TORRENT PHARMA INC.$$$$$F$Y$$$20250911$$CN$GB$GB
257916471$25791647$1$I$20250101$20250904$20250911$20250911$EXP$$US-ABBVIE-6447773$ABBVIE$$54$YR$$M$Y$$$20250911$$CN$US$US
257916821$25791682$1$I$20250601$20250905$20250911$20250911$EXP$$CA-GILEAD-2025-0727572$GILEAD$$76$YR$E$M$Y$$$20250911$$CN$CA$CA
257918971$25791897$1$I$$20250904$20250911$20250911$PER$$US-SA-2025SA268531$SANOFI AVENTIS$$$$A$M$Y$$$20250911$$MD$US$US
257919831$25791983$1$I$20250101$20250905$20250911$20250911$PER$$US-SA-2025SA269992$SANOFI AVENTIS$$3$YR$C$F$Y$$$20250911$$HP$US$US
257920381$25792038$1$I$20250801$20250905$20250911$20250911$PER$$US-SA-2025SA270317$SANOFI AVENTIS$$61$YR$A$F$Y$$$20250911$$HP$US$US
257920642$25792064$2$F$20250101$20250909$20250911$20250915$PER$$US-SA-2025SA270083$SANOFI AVENTIS$$34$YR$A$F$Y$$$20250915$$HP$US$US
257921011$25792101$1$I$$20250905$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509008790$ELI LILLY AND COMPANY$$52$YR$A$M$Y$$$20250911$$CN$US$US
257921571$25792157$1$I$20250801$20250907$20250911$20250911$PER$$US-SA-2025SA270093$SANOFI AVENTIS$$51$YR$A$F$Y$$$20250911$$HP$US$US
257921601$25792160$1$I$$20250909$20250911$20250911$PER$$US-SA-2025SA270611$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250911$$CN$US$US
257922181$25792218$1$I$20250801$20250908$20250911$20250911$PER$$US-SA-2025SA270302$SANOFI AVENTIS$$55$YR$A$M$Y$$$20250911$$HP$US$US
257922431$25792243$1$I$$20250908$20250911$20250911$PER$$US-SA-2025SA269439$SANOFI AVENTIS$$$$$M$Y$$$20250911$$CN$US$US
257922501$25792250$1$I$$20250909$20250911$20250911$PER$$US-SA-2025SA270267$SANOFI AVENTIS$$52$YR$A$M$Y$$$20250911$$CN$US$US
257922671$25792267$1$I$$20250909$20250911$20250911$PER$$US-SA-2025SA270255$SANOFI AVENTIS$$18$YR$A$M$Y$$$20250911$$CN$US$US
257922911$25792291$1$I$20250823$20250908$20250911$20250911$EXP$$CN-PFIZER INC-PV202500108515$PFIZER$$65$YR$$F$Y$69$KG$20250911$$HP$CN$CN
257923281$25792328$1$I$$20250909$20250911$20250911$EXP$$CA-PFIZER INC-202500179337$PFIZER$$77$YR$$M$Y$70$KG$20250911$$HP$CA$CA
257923431$25792343$1$I$$20250908$20250911$20250911$EXP$$CA-TAKEDA-2025TUS079373$TAKEDA$$$$$F$Y$$$20250911$$MD$CA$CA
257923522$25792352$2$F$$20250911$20250911$20250916$EXP$$GB-MYLANLABS-2025M1077016$MYLAN$$$$$M$Y$$$20250916$$$GB$GB
257923851$25792385$1$I$20250101$20250908$20250911$20250911$PER$$US-AMGEN-USASP2025180085$AMGEN$$$$$$Y$$$20250911$$CN$US$US
257924581$25792458$1$I$20250831$20250903$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509007188$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250911$$CN$US$US
257925701$25792570$1$I$$20250905$20250911$20250911$PER$$US-AMGEN-USASP2025178406$AMGEN$$$$$F$Y$$$20250911$$HP$US$US
257925911$25792591$1$I$20250903$20250904$20250911$20250911$PER$$US-SA-2025SA267865$SANOFI AVENTIS$$72$YR$E$F$Y$$$20250911$$CN$US$US
257925951$25792595$1$I$$20250908$20250911$20250911$PER$$US-SA-2025SA269566$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250911$$HP$US$US
257926071$25792607$1$I$$20250903$20250911$20250911$PER$$US-BIOVITRUM-2025-US-012089$BIOVITRUM$$85$YR$$M$Y$$$20250911$$HP$US$US
257926081$25792608$1$I$$20250908$20250911$20250911$PER$$US-HALEON-2261867$Haleon PLC$$$$$$Y$$$20250911$$CN$US$US
257926621$25792662$1$I$$20250911$20250911$20250911$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-125738$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$M$Y$$$20250911$$$US$US
257926951$25792695$1$I$20250101$20250909$20250911$20250911$PER$$US-MALLINCKRODT-MNK202505670$MALLINCKRODT$$68$YR$E$M$Y$$$20250911$$CN$US$US
257927701$25792770$1$I$20231109$20250901$20250911$20250911$EXP$$CN-NOVOPROD-1515609$NOVO NORDISK$WANG, Yujuan et al. Care report and literature analysis of exogenous insulin autoimmune syndrome. China Pharmacy. 2025$65$YR$$M$Y$55$KG$20250911$$PH$CN$CN
257927781$25792778$1$I$$20250902$20250911$20250911$PER$$US-INCYTE CORPORATION-2025IN009521$INCYTE$$$$$$Y$$$20250911$$PH$US$US
257927821$25792782$1$I$$20250908$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509007804$ELI LILLY AND COMPANY$$62$YR$A$$Y$$$20250911$$CN$US$US
257928121$25792812$1$I$20250101$20250904$20250911$20250911$PER$$US-SA-2025SA269247$SANOFI AVENTIS$$72$YR$E$M$Y$112.02$KG$20250911$$HP$US$US
257928201$25792820$1$I$20250801$20250910$20250911$20250911$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-125548$BRISTOL-MYERS SQUIBB COMPANY$$87$YR$E$F$Y$$$20250911$$$US$US
257928801$25792880$1$I$20250101$20250829$20250911$20250911$PER$$US-MYLANLABS-2025M1074319$MYLAN$$68$YR$$M$Y$$$20250905$$$US$US
257929751$25792975$1$I$$20250909$20250911$20250911$PER$$US-PFIZER INC-202500178823$PFIZER$$$$$$Y$$$20250911$$CN$US$US
257930011$25793001$1$I$$20250901$20250911$20250911$EXP$$US-AMGEN-USASP2025174857$AMGEN$Matarneh A.; Sardar S.; Akkari A. et al.. Infective endocarditis mimicking antineutrophil-cytoplasmic-antibody-associated vasculitis with glomerulonephritis: a case report. Journal of Medical Case Reports. 2025;19 (1):1-5$77$YR$E$M$Y$$$20250911$$HP$US$US
257930221$25793022$1$I$$20250908$20250911$20250911$EXP$$US-ABBVIE-6451818$ABBVIE$$$$A$M$Y$$$20250911$$CN$US$US
257930321$25793032$1$I$20240901$20250905$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509008489$ELI LILLY AND COMPANY$$51$YR$A$$Y$$$20250911$$CN$US$US
257930731$25793073$1$I$20250907$20250910$20250911$20250911$EXP$$US-UNITED THERAPEUTICS-UNT-2025-031489$UNITED THERAPEUTICS$$89$YR$$F$Y$$$20250911$$$US$US
257932981$25793298$1$I$$20250908$20250911$20250911$EXP$$US-ASTRAZENECA-202509USA005751US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250911$$$US$US
257933101$25793310$1$I$$20250905$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509006346$ELI LILLY AND COMPANY$$84$YR$E$F$Y$$$20250911$$CN$US$US
257933361$25793336$1$I$$20250906$20250911$20250911$PER$$US-ELI_LILLY_AND_COMPANY-US202509007729$ELI LILLY AND COMPANY$$45$YR$A$M$Y$$$20250911$$CN$US$US
257933701$25793370$1$I$20250101$20250815$20250911$20250911$PER$$US-GALDERMA-US2025015580$GALDERMA$$$$$$Y$$$20250912$$CN$US$US
257934531$25793453$1$I$20250717$20250909$20250911$20250911$EXP$$US-ABBVIE-6401420$ABBVIE$$69$YR$$F$Y$79.378$KG$20250911$$CN$US$US
257934921$25793492$1$I$$20250908$20250911$20250911$PER$$US-SA-2025SA270578$SANOFI AVENTIS$$$$E$F$Y$60$KG$20250912$$HP$US$US
257935371$25793537$1$I$20250801$20250905$20250911$20250911$PER$$US-SA-2025SA269669$SANOFI AVENTIS$$71$YR$E$F$Y$$$20250912$$HP$US$US
257936441$25793644$1$I$$20250317$20250912$20250912$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-500567$RANBAXY$$$$E$F$Y$85.275$KG$20250912$$CN$US$US
257936592$25793659$2$F$$20250910$20250912$20250919$EXP$$JP-ASTRAZENECA-202509JPN006159JP$ALEXION PHARMACEUTICALS$$74$YR$E$M$Y$$$20250919$$MD$JP$JP
257939531$25793953$1$I$$20250903$20250912$20250912$EXP$$US-KYOWAKIRIN-2025KK017356$KYOWA$$$$$$Y$$$20250912$$HP$US$US
257939651$25793965$1$I$$20250909$20250912$20250912$EXP$$US-SA-2025SA270328$SANOFI AVENTIS$$$$A$$Y$$$20250912$$CN$US$US
257939802$25793980$2$F$$20250925$20250912$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-126030$BRISTOL-MYERS SQUIBB COMPANY$$78$YR$E$M$Y$78.47$KG$20250926$$$US$US
257940261$25794026$1$I$20250101$20250908$20250912$20250912$EXP$$US-ABBVIE-6451798$ABBVIE$$76$YR$$M$Y$$$20250912$$CN$US$US
257940531$25794053$1$I$20250801$20250908$20250912$20250912$EXP$$US-ABBVIE-6454676$ABBVIE$$18$YR$$M$Y$$$20250912$$CN$US$US
257940741$25794074$1$I$$20250908$20250912$20250912$PER$$US-BIOGEN-2025BI01323543$BIOGEN$$$$$F$Y$$$20250912$$CN$US$US
257941761$25794176$1$I$20250519$20250903$20250912$20250912$EXP$EU-AFSSAPS-ST2025000969$EU-TEVA-VS-3369284$TEVA$$56$YR$$F$Y$72$KG$20250912$$PH$EU$EU
257942831$25794283$1$I$$20250909$20250912$20250912$PER$$US-KENVUE-20250905195$Kenvue$$$$$F$Y$$$20250912$$CN$US$US
257942911$25794291$1$I$20250501$20250904$20250912$20250912$PER$$US-AVET LIFESCIENCES LTD-2025-AVET-000286$EMCURE PHARMACEUTICALS LTD$$$$$F$Y$$$20250912$$CN$US$US
257943591$25794359$1$I$$20250906$20250912$20250912$EXP$$US-SMPA-2025SPA011528$SUNOVION$$86$YR$$M$Y$$$20250911$$$US$US
257943831$25794383$1$I$$20250901$20250912$20250912$EXP$$JP-ROCHE-10000385540$ROCHE$Suzuki Y, Kuzuya T, Osawa L, Komiyama Y, Takada H, Matsuda S, et al. Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma. Hepatology Research. 2025-Jan;1-8. doi:10.1111/hepr.70024.$$$$$Y$$$20250912$$HP$JP$JP
257944481$25794448$1$I$$20250902$20250912$20250912$PER$$US-SMPA-2025SPA005651$SUNOVION$$75$YR$$M$Y$$$20250911$$$US$US
257946081$25794608$1$I$$20250829$20250912$20250912$PER$$US-JNJFOC-20250910345$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20250912$$HP$US$US
257947321$25794732$1$I$$20241107$20250912$20250912$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2024008247$BIOCON$$$$$$Y$$$20250912$$CN$US$US
257948051$25794805$1$I$$20250911$20250912$20250912$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-126193$BRISTOL-MYERS SQUIBB COMPANY$$85$YR$E$F$Y$$$20250912$$$US$US
257949981$25794998$1$I$$20250904$20250912$20250912$PER$$US-SMPA-2025SPA000232$SUNOVION$$78$YR$$M$Y$$$20250911$$$US$US
257950531$25795053$1$I$$20250820$20250912$20250912$PER$$US-009507513-2321425$MERCK SHARP + DOHME LLC$$$$$$Y$$$20250912$$CN$US$US
257951601$25795160$1$I$$20250908$20250912$20250912$PER$$US-KENVUE-20250904813$Kenvue$$$$$F$Y$$$20250912$$CN$US$US
257951851$25795185$1$I$20250806$20250812$20250912$20250912$EXP$GB-MHRA-MED-202508080957110420-YBJVF$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-08874$ALKEM$$63$YR$$F$Y$82$KG$20250912$$CN$GB$GB
257955311$25795531$1$I$$20250818$20250912$20250912$PER$$US-GALDERMA-US2025015661$GALDERMA$$$$$$Y$$$20250912$$CN$US$US
257956141$25795614$1$I$$20250908$20250912$20250912$PER$$US-ELI_LILLY_AND_COMPANY-US202509009025$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250912$$CN$US$US
257956611$25795661$1$I$$20241028$20250912$20250912$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2024007987$BIOCON$$$$$$Y$$$20250912$$CN$US$US
257958132$25795813$2$F$20250901$20250918$20250912$20250920$PER$$US-ABBVIE-6451661$ABBVIE$$38$YR$$F$Y$$$20250920$$HP$US$US
257958801$25795880$1$I$$20250903$20250912$20250912$EXP$$IN-STRIDES ARCOLAB LIMITED-2025SP011583$STRIDES$Patel JM, Rajvanshi A, Chandra N, Udwadia ZF.. A case of refractory antisynthetase syndrome - Interstitial lung disease.. Lung-India. 2025;42 (Suppl. 1):S54-S55 abstr. 127.$23$YR$$F$Y$$$20250912$$HP$IN$IN
257958831$25795883$1$I$20250101$20250904$20250912$20250912$EXP$$EU-ESPERIONTHERAPEUTICS-2025DEU01185$ESPERION THERAPEUTICS$$$$$$Y$$$20250912$$CN$EU$EU
257959261$25795926$1$I$$20250901$20250912$20250912$EXP$$CN-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-526988$RANBAXY$Li S, Zhang S. A case report of Chinese medicine combined with neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 breast cancer. Medicine. 2025;104 (33):e43387$54$YR$$F$Y$50$KG$20250912$$HP$CN$CN
257960291$25796029$1$I$$20250908$20250912$20250912$EXP$$US-ASTRAZENECA-202509USA005692US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250912$$$US$US
257960691$25796069$1$I$$20250530$20250912$20250912$EXP$$BR-Ipsen Biopharmaceuticals, Inc.-2025-22414$IPSEN BIOPHARMACEUTICALS, INC.$$$$$F$Y$82$KG$20250912$$$BR$BR
257960751$25796075$1$I$20250605$20250911$20250912$20250912$EXP$$EU-SANDOZ INC.-SDZ2025DE066487$SANDOZ$$66$YR$$M$Y$$$20250912$$MD$EU$EU
257960891$25796089$1$I$$20250911$20250912$20250912$EXP$$PH-ASTRAZENECA-202509ASI008719PH$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250912$$$PH$PH
257963101$25796310$1$I$$20250908$20250912$20250912$EXP$$AU-ROCHE-10000384563$ROCHE$Scott E, Brown D, Rohleder C, Shin M, Park S, Hickie I. A Case Series of Young People Receiving Adjunctive Immunotherapy for Neuroimmune-Mediated Major Mood or Psychotic Syndromes. Biological Psychiatry Global Open Science. 2025;5 (6):1-12. doi:10.1016/j.bpsgos.2025.100564.$$$$$Y$$$20250912$$HP$AU$AU
257963611$25796361$1$I$$20250909$20250912$20250912$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-126349$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$F$Y$$$20250912$$$US$US
257964702$25796470$2$F$20250801$20250926$20250912$20250930$PER$$US-SA-2025SA270074$SANOFI AVENTIS$$30$YR$A$M$Y$$$20250930$$HP$US$US
257965531$25796553$1$I$$20250908$20250912$20250912$PER$$US-SA-2025SA270787$SANOFI AVENTIS$$82$YR$E$F$Y$$$20250912$$CN$US$US
257965801$25796580$1$I$$20250908$20250912$20250912$PER$$US-SA-2025SA271383$SANOFI AVENTIS$$13$YR$T$F$Y$$$20250912$$CN$US$US
257966781$25796678$1$I$20250101$20250908$20250912$20250912$PER$$US-SA-2025SA271948$SANOFI AVENTIS$$33$YR$A$M$Y$$$20250912$$HP$US$US
257968131$25796813$1$I$$20250904$20250912$20250912$EXP$$RU-CHEPLA-2025010650$CHEPLAPHARM$$$$$$Y$$$20250912$$CN$COUNTRY NOT SPECIFIED$RU
257968421$25796842$1$I$$20250908$20250912$20250912$PER$$US-SA-2025SA271951$SANOFI AVENTIS$$$$E$F$Y$$$20250912$$HP$US$US
257968641$25796864$1$I$$20250908$20250912$20250912$PER$$US-SA-2025SA271938$SANOFI AVENTIS$$$$A$F$Y$96.36$KG$20250912$$MD$US$US
257968871$25796887$1$I$$20250904$20250912$20250912$PER$$US-AMGEN-USASP2025178209$AMGEN$$40$YR$A$M$Y$$$20250912$$PH$US$US
257968881$25796888$1$I$20250909$20250910$20250912$20250912$PER$$US-AMGEN-USASP2025181171$AMGEN$$31$YR$A$$Y$$$20250912$$HP$US$US
257968941$25796894$1$I$20250805$20250901$20250912$20250912$EXP$EU-AFSSAPS-RE2025000731$EU-GLENMARK PHARMACEUTICALS-2025GMK103669$GLENMARK$$62$YR$$F$Y$70$KG$20250912$$PH$EU$EU
257969811$25796981$1$I$20220101$20250909$20250912$20250912$EXP$$US-PFIZER INC-PV202500109191$PFIZER$$$$$F$Y$$$20250912$$LW$US$US
257969991$25796999$1$I$$20250902$20250912$20250912$EXP$$US-RADIUS HEALTH INC.-US-RADIUS-25053214$RADIUS PHARM$$$$$F$Y$$$20250912$$CN$US$US
257970581$25797058$1$I$20250904$20250904$20250912$20250912$PER$$US-ORYZAPHARMA-2025ORYSPO-00010$ORYZA PHARMACEUTICALS$$$$$M$Y$$$20250912$$CN$US$US
257970821$25797082$1$I$$20250906$20250912$20250912$EXP$$US-SANDOZ INC.-SDZ2025US065876$SANDOZ$$$$$$Y$$$20250912$$HP$US$US
257972001$25797200$1$I$$20250909$20250912$20250912$PER$$US-ELI_LILLY_AND_COMPANY-US202509010627$ELI LILLY AND COMPANY$$$$$$Y$$$20250912$$CN$US$US
257973361$25797336$1$I$20250801$20250904$20250912$20250912$PER$$US-LEX-000806$LEXICON PHARMACEUTICALS$$69$YR$$F$Y$$$20250912$$CN$US$US
257974251$25797425$1$I$$20250910$20250912$20250912$EXP$GB-MHRA-MED-202509100904487230-FHVBD$GB-ELI_LILLY_AND_COMPANY-GB202509010643$ELI LILLY AND COMPANY$$$$$F$Y$$$20250912$$CN$GB$GB
257974561$25797456$1$I$20210601$20250912$20250912$20250912$DIR$774909$$FDA-CTU$$36$YR$$F$N$90$KG$20250912$N$CN$US$
257975171$25797517$1$I$$20250904$20250912$20250912$EXP$$US-FreseniusKabi-FK202512295$FRESENIUS KABI$$$$A$F$Y$113.64$KG$20250912$$CN$US$US
257975291$25797529$1$I$$20250905$20250912$20250912$PER$$US-SA-2025SA269369$SANOFI AVENTIS$$$$E$M$Y$89.82$KG$20250912$$MD$US$US
257975381$25797538$1$I$20250701$20250905$20250912$20250912$EXP$$US-SA-2024SA173089$SANOFI AVENTIS$$61$YR$A$F$Y$108$KG$20250912$$MD$US$US
257976001$25797600$1$I$20250828$20250828$20250912$20250912$EXP$$GB-AUROBINDO-AUR-APL-2025-044792$AUROBINDO$$65$YR$$M$Y$131$KG$20250912$$MD$GB$GB
257976371$25797637$1$I$20250901$20250908$20250912$20250912$EXP$$US-ARDELYX-2025ARDX006848$ARDELYX$$$$A$F$Y$$$20250912$$HP$US$US
257976731$25797673$1$I$20250610$20250811$20250912$20250912$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-094456$REGENERON$$$$$$Y$$$20250912$$HP$US$US
257976821$25797682$1$I$$20250623$20250912$20250912$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-101613$REGENERON$$$$$M$Y$$$20250912$$HP$US$US
257977031$25797703$1$I$20250101$20250717$20250912$20250912$5DAY$$US-REGENERON PHARMACEUTICALS, INC.-2025-114904$REGENERON$$$$$F$Y$$$20250912$$HP$US$US
257977081$25797708$1$I$$20250902$20250912$20250912$30DAY$$US-SANDOZ INC.-SDZ2025US066761$SANDOZ$$$$$F$Y$$$20250912$$CN$US$US
257977962$25797796$2$F$20250909$20250911$20250912$20250923$EXP$$EU-ASTRAZENECA-202509EEA009055BE$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250923$$MD$EU$EU
257978061$25797806$1$I$$20250909$20250912$20250912$EXP$$US-ABBVIE-6456785$ABBVIE$$$$E$M$Y$$$20250912$$CN$US$US
257978081$25797808$1$I$$20250908$20250912$20250912$EXP$$EU-MYLANLABS-2025M1077089$MYLAN$$77$YR$$M$Y$66$KG$20250912$$$EU$EU
257978871$25797887$1$I$$20250910$20250910$20250910$DIR$FDA-CDER-CTU-2025-60697$$FDA-CTU$$$$$$N$$$20250910$N$$US$
257978981$25797898$1$I$$20250912$20250912$20250912$DIR$774947$$FDA-CTU$$$$$$N$$$20250912$$CN$US$
257980161$25798016$1$I$20250910$20250910$20250912$20250912$EXP$$JP-ASTRAZENECA-202509JPN007588JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250912$$MD$JP$JP
257981101$25798110$1$I$$20250909$20250912$20250912$PER$$US-PFIZER INC-PV202500109015$PFIZER$$61$YR$$F$Y$$$20250912$$HP$US$US
257981861$25798186$1$I$$20250904$20250912$20250912$EXP$$US-RIGEL-20250900056$RIGEL PHARMACEUTICALS$$$$$F$Y$$$20250912$$CN$US$US
257982041$25798204$1$I$20250909$20250909$20250912$20250912$PER$$US-ELI_LILLY_AND_COMPANY-US202509010252$ELI LILLY AND COMPANY$$41$YR$A$F$Y$$$20250912$$CN$US$US
257982951$25798295$1$I$$20250911$20250912$20250912$PER$$US-ELI_LILLY_AND_COMPANY-US202509012654$ELI LILLY AND COMPANY$$88$YR$E$$Y$$$20250912$$CN$US$US
257983021$25798302$1$I$20240101$20250905$20250912$20250912$EXP$$CA-ABBVIE-6451654$ABBVIE$$61$YR$$M$Y$$$20250912$$CN$CA$CA
257983051$25798305$1$I$$20250911$20250912$20250912$PER$$US-ASTRAZENECA-202509USA009220US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250912$$$US$US
257984241$25798424$1$I$20250101$20250909$20250913$20250913$PER$$US-SA-2025SA274190$SANOFI AVENTIS$$52$YR$A$F$Y$$$20250913$$HP$US$US
257985111$25798511$1$I$$20250910$20250913$20250913$PER$$US-ELI_LILLY_AND_COMPANY-US202509010777$ELI LILLY AND COMPANY$$$$$M$Y$$$20250913$$CN$US$US
257985471$25798547$1$I$20220126$20250905$20250913$20250913$EXP$$CA-CELLTRION INC.-2025CA008343$CELLTRION$$$$$$Y$$$20250913$$HP$CA$CA
257986142$25798614$2$F$$20250910$20250913$20250917$PER$$US-SA-2025SA273560$SANOFI AVENTIS$$35$YR$A$F$Y$$$20250917$$CN$US$US
257986483$25798648$3$F$20250814$20250911$20250913$20250918$EXP$$AU-ASTRAZENECA-202509OCE008451AU$ALEXION PHARMACEUTICALS$$58$YR$A$F$Y$$$20250918$$$AU$AU
257987291$25798729$1$I$$20250821$20250913$20250913$PER$$US-GRANULES-US-2025GRASPO00481$GRANULES PHARMACEUTICALS INC$$$$$$Y$$$20250913$$CN$US$US
257988211$25798821$1$I$20250307$20250829$20250913$20250913$EXP$$EU-AUROBINDO-AUR-APL-2025-045294$AUROBINDO$$69$YR$$F$Y$$$20250913$$MD$EU$EU
257988261$25798826$1$I$$20250911$20250913$20250913$PER$$US-ASTRAZENECA-202509USA009295US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250913$$$US$US
257988451$25798845$1$I$20250301$20250910$20250913$20250913$PER$$US-ABBVIE-6455246$ABBVIE$$46$YR$$F$Y$78.925$KG$20250913$$CN$US$US
257988531$25798853$1$I$$20250906$20250913$20250913$PER$$US-ELI_LILLY_AND_COMPANY-US202509010474$ELI LILLY AND COMPANY$$$$$$Y$$$20250913$$CN$US$US
257988821$25798882$1$I$20250827$20250829$20250913$20250913$EXP$$EU-AUROBINDO-AUR-APL-2025-045246$AUROBINDO$$75$YR$$F$Y$59$KG$20250913$$PH$EU$EU
257990351$25799035$1$I$20250601$20250910$20250913$20250913$EXP$$US-ABBVIE-6457319$ABBVIE$$85$YR$$F$Y$$$20250913$$CN$US$US
257990621$25799062$1$I$20250201$20250904$20250913$20250913$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-006883$JAZZ$$68$YR$$F$Y$$$20250913$$$US$US
257991821$25799182$1$I$20250101$20250905$20250913$20250913$PER$$US-UNITED THERAPEUTICS-UNT-2025-031220$UNITED THERAPEUTICS$$$$$F$Y$54.422$KG$20250913$$$US$US
257992261$25799226$1$I$$20250903$20250913$20250913$PER$$US-UNITED THERAPEUTICS-UNT-2025-031331$UNITED THERAPEUTICS$$$$$F$Y$$$20250913$$$US$US
257992441$25799244$1$I$20240801$20250908$20250913$20250913$PER$$US-SA-2025SA272757$SANOFI AVENTIS$$1$YR$I$M$Y$$$20250913$$HP$US$US
257993141$25799314$1$I$$20250908$20250913$20250913$PER$$US-SA-2025SA271555$SANOFI AVENTIS$$$$A$F$Y$$$20250913$$HP$US$US
257993241$25799324$1$I$$20250909$20250913$20250913$PER$$US-SA-2025SA272590$SANOFI AVENTIS$$39$YR$A$F$Y$$$20250913$$CN$US$US
257993341$25799334$1$I$$20250903$20250913$20250913$EXP$$US-UCBSA-2025055653$UCB$$$$$$Y$$$20250913$$CN$US$US
257993831$25799383$1$I$$20250904$20250913$20250913$EXP$$EU-Medicap-000048$Medicap Laboratories$Andreasen JB, Akkaoui KK, Andersen LV, Norgaard MA. Surviving cardiac arrest from severe metformin-associated lactic acidosis using extracorporeal membrane oxygenation and double continuous venovenous haemodialysis. BMJ Case Rep. 2023 Aug 16:16(8):e254649. doi: 10.1136/bcr-2023-254649$$$$M$Y$$$20250908$$MD$EU$EU
257993841$25799384$1$I$$20250902$20250913$20250913$EXP$$GB-Medicap-000045$Medicap Laboratories$Tyler M, Ward L and Grosse S. Chemsex-related deaths in the United Kingdom (2017-2022): A review of the Forensic Toxicology data. Forensic Sci Int. 2025 Oct: 375:112553. Doi: 10.1016/j.forsciint.2025.112553$54$YR$A$M$Y$$$20250903$$HP$GB$GB
257994911$25799491$1$I$$20250904$20250914$20250914$PER$$NVSC2025US139388$NOVARTIS$$$$$F$Y$$$20250914$$CN$US$US
257995021$25799502$1$I$$20250910$20250914$20250914$PER$$US-SA-2025SA272895$SANOFI AVENTIS$$$$$$Y$$$20250914$$HP$US$US
257995051$25799505$1$I$20250801$20250908$20250914$20250914$PER$$US-SA-2025SA273096$SANOFI AVENTIS$$$$$M$Y$$$20250914$$CN$US$US
257995232$25799523$2$F$$20250911$20250914$20250916$PER$$US-SA-2025SA269745$SANOFI AVENTIS$$$$A$F$Y$$$20250917$$CN$US$US
257995611$25799561$1$I$$20250902$20250914$20250914$EXP$$US-AUROBINDO-AUR-APL-2025-046263$AUROBINDO$$$$$M$Y$$$20250914$$MD$US$US
257996201$25799620$1$I$20250101$20250909$20250914$20250914$PER$$US-SA-2025SA273119$SANOFI AVENTIS$$30$YR$A$F$Y$$$20250914$$HP$US$US
257996291$25799629$1$I$$20250903$20250914$20250914$EXP$$CA-AUROBINDO-AUR-APL-2025-046264$AUROBINDO$$57$YR$$F$Y$$$20250914$$MD$CA$CA
257996351$25799635$1$I$$20250911$20250914$20250914$PER$$US-ELI_LILLY_AND_COMPANY-US202509012120$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250914$$CN$US$US
257997521$25799752$1$I$$20250909$20250914$20250914$PER$$US-SA-2025SA273791$SANOFI AVENTIS$$$$A$F$Y$$$20250914$$HP$US$US
257997591$25799759$1$I$20250910$20250911$20250914$20250914$PER$$US-ELI_LILLY_AND_COMPANY-US202509012100$ELI LILLY AND COMPANY$$64$YR$A$M$Y$$$20250914$$CN$US$US
257997661$25799766$1$I$$20250909$20250914$20250914$PER$$US-SA-2025SA271198$SANOFI AVENTIS$$76$YR$E$F$Y$$$20250914$$CN$US$US
257997771$25799777$1$I$$20250909$20250914$20250914$PER$$US-ELI_LILLY_AND_COMPANY-US202509011255$ELI LILLY AND COMPANY$$$$$$Y$$$20250914$$CN$US$US
257998161$25799816$1$I$$20250906$20250914$20250914$PER$$US-SA-2025SA271746$SANOFI AVENTIS$$82$YR$E$F$Y$$$20250914$$CN$US$US
257998271$25799827$1$I$20250911$20250911$20250914$20250914$PER$$US-SA-2025SA273989$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250914$$CN$US$US
257998431$25799843$1$I$20250101$20250908$20250914$20250914$PER$$US-SA-2025SA273183$SANOFI AVENTIS$$28$YR$A$F$Y$$$20250914$$HP$US$US
257999722$25799972$2$F$$20250908$20250914$20250914$30DAY$$US-SANDOZ INC.-SDZ2025US065397$SANDOZ$$$$$M$Y$$$20250914$$CN$US$US
257999921$25799992$1$I$20250903$20250909$20250914$20250914$PER$$US-ABBVIE-6453808$ABBVIE$$60$YR$$F$Y$$$20250914$$HP$US$US
258000081$25800008$1$I$20250101$20250911$20250914$20250914$EXP$$US-ABBVIE-6458216$ABBVIE$$62$YR$$F$Y$$$20250914$$CN$US$US
258000431$25800043$1$I$20240801$20250905$20250914$20250914$PER$$US-ABBVIE-6451187$ABBVIE$$71$YR$$F$Y$70$KG$20250914$$CN$US$US
258000811$25800081$1$I$$20250909$20250914$20250914$EXP$$CA-ABBVIE-6455611$ABBVIE$$$$A$F$Y$$$20250914$$CN$CA$CA
258000981$25800098$1$I$20250901$20250909$20250915$20250915$PER$$US-ELI_LILLY_AND_COMPANY-US202509010313$ELI LILLY AND COMPANY$$49$YR$A$F$Y$$$20250914$$CN$US$US
258001491$25800149$1$I$20250101$20250909$20250915$20250915$EXP$$US-ABBVIE-6451906$ABBVIE$$64$YR$$F$Y$$$20250915$$CN$US$US
258002681$25800268$1$I$20250729$20250905$20250915$20250915$PER$$US-VIIV HEALTHCARE-US2025114437$VIIV$$$$$M$Y$$$20250915$$$US$US
258003241$25800324$1$I$$20250909$20250915$20250915$EXP$$US-COLLEGIUM PHARMACEUTICAL, INC.-20250902525$COLLEGIUM PHARMACEUTICAL$$76$YR$$M$Y$63.946$KG$20250914$$CN$US$US
258003301$25800330$1$I$20250101$20250908$20250915$20250915$PER$$US-SA-2025SA274061$SANOFI AVENTIS$$3$YR$C$F$Y$$$20250915$$MD$US$US
258003861$25800386$1$I$$20250821$20250915$20250915$PER$$US-GSK-US2025AMR110095$GLAXOSMITHKLINE$$$$$$Y$$$20250915$$$US$US
258004801$25800480$1$I$$20250902$20250915$20250915$EXP$$US-INTRA-CELLULAR THERAPIES, INC.-2025ICT01789$INTRA-CELLULAR THERAPIES$$$$A$F$Y$$$20250915$$HP$US$US
258005951$25800595$1$I$$20250905$20250915$20250915$EXP$GB-MHRA-EMIS-1694-18290a1f-9df2-4639-bddb-bd0c06fdfd60$GB-RDY-GBR/2025/07/011430$DR REDDYS$$52$YR$A$M$Y$94$KG$20250915$$HP$GB$GB
258006171$25800617$1$I$$20250912$20250915$20250915$EXP$$CA-ASTRAZENECA-202509CAN010036CA$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250915$$$CA$CA
258007081$25800708$1$I$20250801$20250905$20250915$20250915$EXP$$ZA-AMGEN-ZAFSP2025181012$AMGEN$$$$$$Y$$$20250915$$CN$ZA$ZA
258008141$25800814$1$I$$20250908$20250915$20250915$EXP$$TW-ROCHE-10000383197$ROCHE$$47$YR$A$F$Y$$$20250915$$CN$TW$TW
258008841$25800884$1$I$$20250910$20250915$20250915$PER$$US-SA-2025SA272014$SANOFI AVENTIS$$31$YR$A$M$Y$$$20250915$$HP$US$US
258009021$25800902$1$I$20240101$20250904$20250915$20250915$PER$$US-ASTELLAS-2025-AER-049190$ASTELLAS$$$$$F$Y$$$20250915$$MD$US$US
258009341$25800934$1$I$20250122$20250910$20250915$20250915$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-093017$BOEHRINGER INGELHEIM$$74$YR$E$F$Y$$$20250915$$$US$US
258009761$25800976$1$I$$20250912$20250915$20250915$EXP$$US-ASTRAZENECA-202509USA010141US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250915$$$US$US
258010381$25801038$1$I$$20250909$20250915$20250915$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010137$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250915$$CN$US$US
258011881$25801188$1$I$20250202$20250203$20250915$20250915$PER$$US-BIOCON BIOLOGICS LIMITED-BBL2025000707$BIOCON$$$$$$Y$$$20250915$$CN$US$US
258012181$25801218$1$I$$20250908$20250915$20250915$EXP$$CA-ROCHE-10000385630$ROCHE$$49$YR$A$F$Y$68$KG$20250915$$PH$CA$CA
258013551$25801355$1$I$$20250915$20250915$20250915$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-095287$BOEHRINGER INGELHEIM$$$$$M$Y$$$20250915$$MD$EU$EU
258013901$25801390$1$I$$20250905$20250915$20250915$EXP$CN-MLMSERVICE-20250901-PI629537-00189-2$CN-STRIDES ARCOLAB LIMITED-2025SP011686$STRIDES$Li D, Huang Y, Tian J.. Atypical presentation of valproic acid-induced hyperammonemic encephalopathy with hemiparesis following craniotomy: A case report.. Asian Journal of Surgery.. 2025$27$YR$$M$Y$$$20250915$$HP$CN$CN
258014541$25801454$1$I$$20250827$20250915$20250915$PER$$US-ALVOGEN-2025098435$ALVOGEN$$$$$$Y$$$20250915$$CN$US$US
258014631$25801463$1$I$20250830$20250903$20250915$20250915$PER$$US-ELI_LILLY_AND_COMPANY-US202509003935$ELI LILLY AND COMPANY$$23$YR$A$M$Y$$$20250915$$CN$US$US
258015291$25801529$1$I$20250101$20250908$20250915$20250915$PER$$US-UNITED THERAPEUTICS-UNT-2025-031546$UNITED THERAPEUTICS$$$$$F$Y$62.585$KG$20250915$$$US$US
258015751$25801575$1$I$$20250821$20250915$20250915$PER$$US-GSK-US2025AMR110096$GLAXOSMITHKLINE$$$$$$Y$$$20250915$$$US$US
258015901$25801590$1$I$20250215$20250909$20250915$20250915$EXP$$EU-AMGEN-FRANI2025048018$AMGEN$$49$YR$A$F$Y$65$KG$20250915$$MD$EU$EU
258016051$25801605$1$I$20250826$20250905$20250915$20250915$EXP$$CN-ROCHE-10000382243$ROCHE$$55$YR$A$F$Y$$$20250915$$HP$CN$CN
258016411$25801641$1$I$20240101$20250807$20250915$20250915$PER$$US-ALVOGEN-2024095885$ALVOGEN$$$$$M$Y$$$20250915$$CN$US$US
258016591$25801659$1$I$20250825$20250912$20250912$20250912$DIR$774979$$FDA-CTU$$4$YR$$M$N$$$20250912$N$PH$US$
258016781$25801678$1$I$20250911$20250912$20250912$20250912$DIR$774965$$FDA-CTU$$61$YR$$M$N$90.8$KG$20250912$N$$US$
258016801$25801680$1$I$20250912$20250912$20250912$20250912$DIR$774986$$FDA-CTU$$75$YR$$M$N$87.3$KG$20250912$N$$US$
258017181$25801718$1$I$20250808$20250905$20250915$20250915$EXP$EU-AFSSAPS-TO2025001321$EU-TEVA-VS-3370657$TEVA$$97$YR$$M$Y$$$20250915$$MD$EU$EU
258017201$25801720$1$I$$20250910$20250915$20250915$PER$$US-SA-2025SA274383$SANOFI AVENTIS$$$$A$F$Y$49.09$KG$20250915$$HP$US$US
258017301$25801730$1$I$20250101$20250829$20250915$20250915$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US001132$DECIPHERA PHARMACEUTICALS$$39$YR$A$F$Y$80.635$KG$20250915$$CN$US$US
258019191$25801919$1$I$$20250902$20250915$20250915$EXP$$US-AUROBINDO-AUR-APL-2025-046164$AUROBINDO$Cicci CD, Theobalda J, Stantona M, Feldman R.. Outcomes of benzonatate exposures reported to a single United States  poison center: a 20-year review. Clinical Toxicology. 2025;63, NO. 7:488-494$33$YR$$F$Y$$$20250915$$HP$US$US
258019611$25801961$1$I$$20250301$20250915$20250915$EXP$$IN-ROCHE-10000365110$ROCHE$$72$YR$E$M$Y$$$20250915$$CN$IN$IN
258020441$25802044$1$I$$20250910$20250915$20250915$EXP$$EU-MYLANLABS-2025M1078346$MYLAN$Hudak V. 2025. Acute abdomen as a non-traumatic life-threatening complication of anticoagulant treatment. LEK?RSKY OBZOR;74 (9):355-359$74$YR$$M$Y$$$20250914$$MD$EU$EU
258020481$25802048$1$I$20250809$20250905$20250915$20250915$EXP$EU-AFSSAPS-MA2025001218$EU-TEVA-VS-3370203$TEVA$$1$DY$$F$Y$1.03$KG$20250915$$MD$EU$EU
258021111$25802111$1$I$$20250820$20250915$20250915$PER$$US-GALDERMA-US2025015906$GALDERMA$$$$$$Y$$$20250915$$CN$US$US
258021871$25802187$1$I$$20250825$20250915$20250915$PER$$US-GSK-US2025AMR110223$GLAXOSMITHKLINE$$$$$F$Y$$$20250915$$$US$US
258022311$25802231$1$I$$20250901$20250915$20250915$EXP$$US-MSNLABS-2025MSNLIT02655$MSN LABORATORIES PRIVATE LIMITED$Restrepo JA, Rosenbaum BL, Harris D, Gift T, Freudenreich O..Clozapine in Solid Organ Transplant: A Literature Review and Case Series.Journal of the Academy of Consultation-Liaison Psychiatry.2025;66 (4):331-340,DOI:10.1016/j.jaclp.2025.05.007$$$$$Y$$$20250915$$MD$US$US
258023651$25802365$1$I$$20250903$20250915$20250915$EXP$$EU-EXELTIS PHARMACEUTICAL HOLDING, S.L.-2509PT07417$INSUD PHARMA$Baltazar AM, Savka L, Carreira NR.. Porphyria Cutanea Tarda: A Multifactorial Disease.. Cureus. 2025;17:7$39$YR$$F$Y$$$20250915$$MD$EU$EU
258024111$25802411$1$I$20230101$20250901$20250915$20250915$EXP$$CN-PBT-010748$PANACEA BIOTEC PHARMA LIMITED$Chen J, Fang J, Sun L, Zhang Z, Ma Q, Wu J, et al. Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report. Virulence. 2025 Dec;16(1):2545570. doi: 10.1080/21505594.2025.2545570.$45$YR$A$M$Y$$$20250915$$HP$CN$CN
258024331$25802433$1$I$20250101$20250822$20250915$20250915$PER$$US-009507513-2322589$MERCK SHARP + DOHME LLC$$$$$F$Y$78$KG$20250915$$CN$US$US
258024701$25802470$1$I$$20250912$20250912$20250912$DIR$FDA-CDER-CTU-2025-61404$$FDA-CTU$$72$YR$$F$N$$$20250912$N$CN$US$
258025441$25802544$1$I$20250801$20250904$20250915$20250915$PER$$US-SA-2025SA272159$SANOFI AVENTIS$$$$$$Y$$$20250915$$HP$US$US
258025932$25802593$2$F$20250101$20250910$20250915$20250922$EXP$$US-NOVOPROD-1520258$NOVO NORDISK$$$$$M$Y$$$20250922$$CN$US$US
258026221$25802622$1$I$$20250909$20250915$20250915$PER$$US-JNJFOC-20250913049$JOHNSON AND JOHNSON$$33$YR$A$M$Y$$$20250915$$CN$US$US
258028351$25802835$1$I$20250101$20250911$20250915$20250915$PER$$US-AMGEN-USASP2025182568$AMGEN$$58$YR$A$F$Y$$$20250915$$CN$US$US
258029861$25802986$1$I$$20250902$20250915$20250915$EXP$GB-MHRA-MED-202509021613311730-RVCSY$GB-ELI_LILLY_AND_COMPANY-GB202509002871$ELI LILLY AND COMPANY$$34$YR$A$F$Y$$$20250915$$CN$GB$GB
258029871$25802987$1$I$20250828$20250901$20250915$20250915$EXP$$CN-ELI_LILLY_AND_COMPANY-CN202509001711$ELI LILLY AND COMPANY$$40$YR$A$F$Y$100$KG$20250915$$CN$CN$CN
258030151$25803015$1$I$20241206$20241230$20250915$20250915$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-005371$SAREPTA THERAPEUTICS$$14$YR$$M$Y$59.9$KG$20250915$$HP$US$US
258030281$25803028$1$I$20241220$20250123$20250915$20250915$PER$$US-SAREPTA THERAPEUTICS INC.-SRP2024-005422$SAREPTA THERAPEUTICS$$16$YR$$M$Y$42.7$KG$20250915$$HP$US$US
258031081$25803108$1$I$20250601$20250911$20250915$20250915$PER$$US-SA-2025SA275801$SANOFI AVENTIS$$50$YR$A$F$Y$$$20250915$$HP$US$US
258033271$25803327$1$I$20250818$20250902$20250915$20250915$EXP$CN-NMPA-3201271025975202501405$CN-NOVOPROD-1515710$NOVO NORDISK$$73$YR$$M$Y$73$KG$20250915$$HP$CN$CN
258033671$25803367$1$I$20200101$20250901$20250915$20250915$EXP$$EU-EPICPHARMA-IT-2025EPCLIT01081$EPIC PHARM$Gabriella Gentile.Management of fertility preservation in young female patients  with gastrointestinal cancer: A case series and systematic  literature review.Current Problems in Cancer.17-JUN-2025;57:1-9$23$YR$A$F$Y$$$20250915$$HP$EU$EU
258033791$25803379$1$I$20250801$20250904$20250915$20250915$EXP$CN-NMPA-5325221013218202500632$CN-NOVOPROD-1517666$NOVO NORDISK$$69$YR$$F$Y$68$KG$20250915$$HP$CN$CN
258033811$25803381$1$I$$20250904$20250915$20250915$EXP$$IL-NOVOPROD-1517334$NOVO NORDISK$$60$YR$$M$Y$$$20250915$$HP$IL$IL
258034321$25803432$1$I$$20250901$20250915$20250915$EXP$$PE-EPICPHARMA-PE-2025EPCLIT01075$EPIC PHARM$Johan Azanero-Haro.Paracoccidioidomycosis and HTLV-1 infection: incidental coexistence? A case report.Horizonte Medico.17-FEB-2025;25(2):1-5$68$YR$E$M$Y$$$20250915$$HP$PE$PE
258034741$25803474$1$I$20250310$20250317$20250915$20250915$PER$$US-PERRIGO-25US003526$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250915$$CN$US$US
258035061$25803506$1$I$20250907$20250908$20250915$20250915$PER$$US-ELI_LILLY_AND_COMPANY-US202509008351$ELI LILLY AND COMPANY$$74$YR$E$F$Y$$$20250915$$PH$US$US
258037031$25803703$1$I$$20250908$20250915$20250915$EXP$$HK-OTSUKA-2025_022458$OTSUKA$Lam TK, Liu S, Hui CF. Aripiprazole overdose in Hong Kong: A 10-year retrospective cohort. Hong Kong Journal of Emergency Medicine. 2025;32(5):1-9$6$YR$$M$Y$$$20250915$$HP$HK$HK
258038482$25803848$2$F$$20250919$20250915$20250923$EXP$$US-PFIZER INC-202500181271$PFIZER$$44$YR$$F$Y$$$20250923$$CN$US$US
258038751$25803875$1$I$$20250911$20250915$20250915$PER$$US-PFIZER INC-PV202500110961$PFIZER$$69$YR$$M$Y$$$20250915$$CN$US$US
258038891$25803889$1$I$$20250911$20250915$20250915$PER$$US-PFIZER INC-PV202500110935$PFIZER$$81$YR$$M$Y$$$20250915$$MD$US$US
258038961$25803896$1$I$$20250914$20250915$20250915$PER$$US-PFIZER INC-PV202500111056$PFIZER$$26$YR$$F$Y$$$20250915$$HP$US$US
258039731$25803973$1$I$20250904$20250909$20250915$20250915$PER$$US-BIOMARINAP-US-2025-168712$BIOMARIN$$8$YR$$M$Y$19.048$KG$20250915$$$US$US
258040511$25804051$1$I$20250910$20250910$20250915$20250915$EXP$$RS-JNJFOC-20250914391$JOHNSON AND JOHNSON$$65$YR$E$M$Y$$$20250915$$MD$RS$RS
258041911$25804191$1$I$$20250901$20250915$20250915$EXP$$EG-NOVOPROD-1513949$NOVO NORDISK$$668$MON$$F$Y$$$20250915$$CN$EG$EG
258041951$25804195$1$I$$20250905$20250915$20250915$PER$$US-AXS-AXS202509-001568$AXSOME THERAPEUTICS$$$$A$M$Y$$$20250915$$MD$US$US
258042772$25804277$2$F$20250101$20250911$20250915$20250925$PER$$US-MALLINCKRODT-MNK202505156$MALLINCKRODT$$54$YR$A$F$Y$$$20250925$$CN$US$US
258042871$25804287$1$I$20250910$20250911$20250915$20250915$PER$$US-MALLINCKRODT-MNK202505718$MALLINCKRODT$$63$YR$A$M$Y$$$20250915$$CN$US$US
258043801$25804380$1$I$$20250912$20250915$20250915$EXP$$KW-PFIZER INC-PV202500110451$PFIZER$$37$YR$$F$Y$$$20250915$$CN$KW$KW
258043981$25804398$1$I$20250815$20250911$20250915$20250915$EXP$$CN-PFIZER INC-PV202500110186$PFIZER$$37$YR$$F$Y$60$KG$20250915$$HP$CN$CN
258044381$25804438$1$I$$20250910$20250915$20250915$EXP$$US-ABBVIE-6458413$ABBVIE$$$$$$Y$$$20250915$$MD$US$US
258044391$25804439$1$I$$20250908$20250915$20250915$EXP$$NVSC2025CA140991$NOVARTIS$$34$YR$$F$Y$$$20250915$$PH$CA$CA
258044741$25804474$1$I$$20250909$20250915$20250915$PER$$US-ELI_LILLY_AND_COMPANY-US202509009118$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250915$$CN$US$US
258045061$25804506$1$I$$20250912$20250915$20250915$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-126645$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250915$$$US$US
258045301$25804530$1$I$20160101$20250901$20250915$20250915$EXP$$NVSC2025RO138691$NOVARTIS$$54$YR$$$Y$$$20250915$$MD$EU$EU
258046641$25804664$1$I$$20250909$20250915$20250915$EXP$$JP-GENMAB-2025-02716$GENMAB$$$$$$Y$$$20250916$$MD$JP$JP
258047631$25804763$1$I$20250408$20250910$20250915$20250915$EXP$$US-ABBVIE-6228504$ABBVIE$$64$YR$$F$Y$$$20250915$$CN$US$US
258048141$25804814$1$I$$20250912$20250915$20250915$EXP$$US-ABBVIE-6460257$ABBVIE$$$$A$F$Y$$$20250915$$CN$US$US
258048361$25804836$1$I$20250901$20250911$20250915$20250915$EXP$$US-ABBVIE-6459205$ABBVIE$$73$YR$$M$Y$$$20250915$$CN$US$US
258048621$25804862$1$I$$20250911$20250916$20250916$EXP$$BR-JNJFOC-20250918687$JOHNSON AND JOHNSON$$81$YR$E$F$Y$75$KG$20250916$$CN$BR$BR
258050261$25805026$1$I$20250301$20250910$20250916$20250916$PER$$US-ASTELLAS-2025-AER-016948$ASTELLAS$$$$E$F$Y$$$20250916$$CN$US$US
258055971$25805597$1$I$20250701$20250910$20250916$20250916$PER$$US-JNJFOC-20250913293$JOHNSON AND JOHNSON$$58$YR$A$M$Y$$$20250916$$CN$US$US
258057161$25805716$1$I$$20250911$20250916$20250916$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-010158$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250916$$CN$US$US
258058021$25805802$1$I$$20250820$20250916$20250916$PER$$US-GALDERMA-US2025015792$GALDERMA$$$$$$Y$$$20250916$$CN$US$US
258058141$25805814$1$I$$20250903$20250916$20250916$EXP$$JP-Accord-504162$ACCORD$Sato D, Sawa N, Matuoka S, Ikuma D, Oba Y, Mizuno H, et al. Sarcoidosis Induced by Metal Particles From a Left Elbow Prosthesis. Kidney Medicine. 2025;7(9):101066. DOI: 10.1016/ j.xkme.2025.101066.$74$YR$E$F$Y$46$KG$20250916$$MD$JP$JP
258058421$25805842$1$I$20250901$20250909$20250916$20250916$EXP$$JP-ROCHE-10000386215$ROCHE$$8$DEC$E$M$Y$$$20250916$$MD$JP$JP
258058661$25805866$1$I$$20250904$20250916$20250916$EXP$CA-MHPD-E2B_07863198$CA-Accord-503867$ACCORD$$68$YR$E$F$Y$$$20250916$$HP$CA$CA
258059141$25805914$1$I$$20250909$20250916$20250916$EXP$$US-RIGEL-20250900079$RIGEL PHARMACEUTICALS$$$$$M$Y$$$20250916$$CN$US$US
258059431$25805943$1$I$20250301$20250908$20250916$20250916$PER$$US-TRIS PHARMA, INC.-25US012092$TRIS PHARMA, INC.$$$$$$Y$$$20250916$$MD$US$US
258059821$25805982$1$I$$20250903$20250916$20250916$EXP$EU-EMA-DD-20250828-7482675-073225$EU-MSNLABS-2025MSNLIT02634$MSN LABORATORIES PRIVATE LIMITED$$$$$$Y$$$20250916$$MD$EU$EU
258059871$25805987$1$I$20250522$20250903$20250916$20250916$EXP$$GB-AUROBINDO-AUR-APL-2025-045723$AUROBINDO$$44$YR$$F$Y$66$KG$20250916$$MD$GB$GB
258060051$25806005$1$I$20250904$20250912$20250916$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-127242$BRISTOL-MYERS SQUIBB COMPANY$$54$YR$A$F$Y$62.6$KG$20250916$$PH$US$US
258060081$25806008$1$I$20250101$20250911$20250916$20250916$EXP$$US-ABBVIE-6459510$ABBVIE$$45$YR$$F$Y$$$20250916$$CN$US$US
258060701$25806070$1$I$20250908$20250915$20250916$20250916$PER$$US-ASTRAZENECA-202509USA011536US$ALEXION PHARMACEUTICALS$$64$YR$A$F$Y$$$20250916$$$US$US
258061131$25806113$1$I$$20250904$20250916$20250916$EXP$$CN-Medicap-000062$Medicap Laboratories$Kuang W, Lu W and Li J. Dramatic toothache related to venlafaxine: a case report. 2024 Jul.24(4):1036-1037. Doi: 10.1111/psyg.13135.$68$YR$E$F$Y$$$20250910$$MD$CN$CN
258061801$25806180$1$I$$20250912$20250916$20250916$EXP$$US-ASTRAZENECA-202509USA010108US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250916$$$US$US
258062151$25806215$1$I$$20250904$20250916$20250916$PER$$US-SMPA-2025SPA011539$SUNOVION$$66$YR$$M$Y$$$20250912$$$US$US
258064461$25806446$1$I$20250101$20250910$20250916$20250916$EXP$$CA-ABBVIE-6456612$ABBVIE$$81$YR$$M$Y$77.5$KG$20250916$$CN$CA$CA
258064701$25806470$1$I$$20250910$20250916$20250916$PER$$US-KENVUE-20250907585$Kenvue$$$$$F$Y$$$20250916$$CN$US$US
258065242$25806524$2$F$20250902$20250918$20250916$20250926$EXP$$IN-EMD Serono-2025046099$EMD SERONO INC$$61$YR$A$M$Y$$$20250926$$MD$IN$IN
258066261$25806626$1$I$$20250912$20250916$20250916$EXP$$GB-DSJP-DS-2025-164874-GB$DAIICHI$$56$YR$$$Y$$$20250916$$MD$GB$GB
258066511$25806651$1$I$$20250909$20250916$20250916$PER$$US-KENVUE-20250906973$Kenvue$$$$$F$Y$$$20250916$$CN$US$US
258067011$25806701$1$I$20250630$20250912$20250916$20250916$EXP$$US-TAKEDA-2025TUS039493$TAKEDA$$69$YR$$F$Y$$$20250916$$$US$US
258067331$25806733$1$I$20250910$20250915$20250915$20250915$DIR$775354$$FDA-CTU$$91$YR$$M$N$68.1$KG$20250915$N$PH$US$
258067571$25806757$1$I$$20250902$20250916$20250916$EXP$$CA-AUROBINDO-AUR-APL-2024-018198$AUROBINDO$Youssef DE, Averin K, Richards S, Sheppard C, Seaman C, Pietrosanu M, et al.. A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients. Frontiers in -Pediatrics. 2023;11:1073336$9$YR$$F$Y$70$KG$20250916$$HP$CA$CA
258068712$25806871$2$F$20250828$20250912$20250916$20250923$30DAY$$US-AMGEN-USASL2025176821$AMGEN$$57$YR$A$F$Y$59.7$KG$20250923$$PH$US$US
258068731$25806873$1$I$20250912$20250912$20250916$20250916$PER$$US-ELI_LILLY_AND_COMPANY-US202509013778$ELI LILLY AND COMPANY$$33$YR$A$F$Y$$$20250916$$CN$US$US
258069231$25806923$1$I$20250501$20250602$20250916$20250916$PER$$US-BRAEBURN PHARMACEUTICALS-US-BRA-25-000492$BRAEBURN PHARMACEUTICALS$$$$$M$Y$$$20250916$$CN$US$US
258070681$25807068$1$I$20250901$20250910$20250916$20250916$EXP$$US-BEH-2025218648$CSL BEHRING$$44$YR$A$M$Y$$$20250916$$HP$US$US
258071081$25807108$1$I$$20250908$20250916$20250916$EXP$$CA-TEVA-VS-3370548$TEVA$$$$$F$Y$$$20250916$$HP$CA$CA
258071431$25807143$1$I$$20250904$20250916$20250916$EXP$$US-GSK-US2025AMR114377$GLAXOSMITHKLINE$$$$$F$Y$$$20250916$$$US$US
258071491$25807149$1$I$$20250902$20250916$20250916$EXP$$US-GSK-US2025AMR113493$GLAXOSMITHKLINE$$$$$F$Y$$$20250916$$$US$US
258072351$25807235$1$I$$20250908$20250916$20250916$PER$$US-ELI_LILLY_AND_COMPANY-US202509013341$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250916$$CN$US$US
258073401$25807340$1$I$20250901$20250915$20250915$20250915$DIR$FDA-CDER-CTU-2025-61723$$FDA-CTU$$81$YR$$M$N$$$20250915$N$$US$
258073701$25807370$1$I$20170101$20250908$20250916$20250916$EXP$$EU-STRIDES PHARMA UK LTD.-2025SP011600$STRIDES$$6$YR$$F$Y$$$20250916$$CN$EU$EU
258073822$25807382$2$F$$20250915$20250916$20250922$EXP$$AU-ABBVIE-6461733$ABBVIE$$58$YR$$F$Y$$$20250922$$HP$AU$AU
258073981$25807398$1$I$20250907$20250915$20250916$20250916$DIR$FDA-CDER-CTU-2025-61756$$FDA-CTU$$39$YR$$M$N$155.6$KG$20250915$N$$US$
258074061$25807406$1$I$$20250916$20250916$20250916$DIR$FDA-CDER-CTU-2025-61803$$FDA-CTU$$42$YR$$F$N$$$20250916$N$CN$US$
258075051$25807505$1$I$20250101$20250911$20250916$20250916$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-095021$BOEHRINGER INGELHEIM$$77$YR$E$F$Y$$$20250916$$$US$US
258075291$25807529$1$I$$20250912$20250916$20250916$EXP$$US-PFIZER INC-PV202500111034$PFIZER$$$$$F$Y$$$20250916$$LW$US$US
258076571$25807657$1$I$20240101$20250910$20250916$20250916$PER$$US-PFIZER INC-202500180505$PFIZER$$37$YR$$M$Y$$$20250916$$HP$US$US
258076771$25807677$1$I$20250101$20250910$20250916$20250916$PER$$US-PFIZER INC-202500180309$PFIZER$$67$YR$$F$Y$$$20250916$$HP$US$US
258077301$25807730$1$I$20250815$20250909$20250916$20250916$PER$$US-AMGEN-USASP2025180247$AMGEN$$55$YR$A$$Y$$$20250916$$CN$US$US
258077361$25807736$1$I$20230601$20250905$20250916$20250916$EXP$CN-NMPA-3401011026912202500732$CN-NOVOPROD-1518429$NOVO NORDISK$$50$YR$$F$Y$67$KG$20250916$$HP$CN$CN
258077591$25807759$1$I$20250607$20250807$20250916$20250916$EXP$$US-ELI_LILLY_AND_COMPANY-US202508024911$ELI LILLY AND COMPANY$$81$YR$E$F$Y$59.41$KG$20250916$$MD$US$US
258080143$25808014$3$F$20250825$20250911$20250916$20250923$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-021550$JAZZ$$34$YR$$F$Y$$$20250923$$$US$US
258080321$25808032$1$I$$20250905$20250916$20250916$EXP$$US-NOVOPROD-1518522$NOVO NORDISK$$$$$M$Y$$$20250916$$CN$US$US
258081621$25808162$1$I$$20250904$20250916$20250916$EXP$$TR-GILEAD-2025-0727499$GILEAD$$46$YR$A$F$Y$$$20250916$$HP$TR$TR
258081962$25808196$2$F$$20250919$20250916$20250922$EXP$$IN-PFIZER INC-PV202500111645$PFIZER$$60$YR$$F$Y$$$20250922$$CN$IN$IN
258082101$25808210$1$I$20240101$20250905$20250916$20250916$EXP$$EU-NOVOPROD-1519517$NOVO NORDISK$$70$YR$$M$Y$$$20250916$$MD$EU$EU
258082532$25808253$2$F$20250901$20250910$20250916$20250930$PER$$US-BAYER-2025A121887$BAYER HEALTHCARE PHARMACEUTICALS INC.$$43$YR$A$F$Y$$$20250930$$MD$US$US
258083551$25808355$1$I$$20250916$20250916$20250916$DIR$FDA-CDER-CTU-2025-61836$$FDA-CTU$$76$YR$$M$N$$$20250916$N$$US$
258083731$25808373$1$I$20250901$20250915$20250916$20250916$EXP$$US-ABBVIE-6461604$ABBVIE$$89$YR$$M$Y$$$20250916$$CN$US$US
258084251$25808425$1$I$$20250902$20250916$20250916$EXP$$EU-SCIEGENP-2025SCLIT00266$SCIEGEN PHARMACEUTICALS INC$Lautrou-cabasson N, et al.Persistent signs of poisoning after massive drug ingestion: move the ultrasound probe to the stomach.Intensive Care Medicine.15-MAY-2025;51(06):1179-1180$73$YR$E$$Y$$$20250916$$HP$EU$EU
258084341$25808434$1$I$$20250909$20250916$20250916$PER$$US-KENVUE-20250906374$Kenvue$$$$$F$Y$$$20250916$$CN$US$US
258085191$25808519$1$I$20250801$20250909$20250916$20250916$EXP$$US-Blueprint Medicines Corporation-2025-AER-01968$BLUEPRINT MEDICINES$$53$YR$A$F$Y$$$20250916$$CN$US$US
258086271$25808627$1$I$20250515$20250910$20250916$20250916$EXP$$US-ABBVIE-6302254$ABBVIE$$80$YR$$F$Y$$$20250916$$CN$US$US
258087811$25808781$1$I$$20250908$20250916$20250916$EXP$$US-ASTRAZENECA-202509USA010611US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250916$$$US$US
258087841$25808784$1$I$20250401$20250909$20250916$20250916$EXP$$CH-ABBVIE-6456111$ABBVIE$$53$YR$$F$Y$90$KG$20250916$$HP$CH$CH
258087961$25808796$1$I$$20250905$20250916$20250916$EXP$$EU-MYLANLABS-2025M1077694$MYLAN$Grasu D, Pirvu E, Malenda D, Bacanu M, Vasile A, Popov V, et al. HL-699: Case report: complex management of relapsed/refractory classical hodgkin lymphoma complicated by pregnancy and chronic pulmonary aspergillosis. Clin-Lymphoma-Myeloma-Leuk 2025; 25 (Suppl.) S707 abstr. HL-699.$37$YR$$F$Y$$$20250916$$MD$EU$EU
258088311$25808831$1$I$$20250911$20250916$20250916$EXP$$US-SA-2025SA274888$SANOFI AVENTIS$$4$YR$C$M$Y$$$20250916$$CN$US$US
258089041$25808904$1$I$$20250908$20250916$20250916$EXP$$US-B. Braun Medical Inc.-US-BBM-202503526$B. BRAUN MEDICAL INC.$Selective Radiological Vulnerability and Neuropsychiatric Challenges in Anti-DPPX Antibody-Associated Encephalitis. Neurology. 2025 Apr 07;doi:o0g/1_0.1212NA L.0000000000212005.$27$YR$A$F$Y$$$20250916$$MD$US$US
258089331$25808933$1$I$$20250910$20250916$20250916$PER$$US-PHARMING-PHAUS2025001315$PHARMING GROUP$$$$$$Y$$$20250916$$CN$US$US
258089401$25808940$1$I$20250101$20250912$20250916$20250916$PER$$US-MALLINCKRODT-MNK202505763$MALLINCKRODT$$70$YR$E$F$Y$130$KG$20250915$$CN$US$US
258089721$25808972$1$I$$20250905$20250916$20250916$EXP$$EU-AMGEN-SWENI2025184431$AMGEN$Gunnarsson I, Lindholm A., Petkovic M., Brolin S., Borjesson O., AzzawI I. et. al. Avacopan in a compassionate use program for severe ANCA-Associated Vasculitis - Experiences from rheumatology and nephrology in Sweden. 2021$34$YR$A$M$Y$$$20250916$$HP$EU$EU
258090741$25809074$1$I$20250801$20250905$20250916$20250916$EXP$$US-UCBSA-2025056073$UCB$$53$YR$$F$Y$$$20250916$$HP$US$US
258091201$25809120$1$I$20250903$20250910$20250916$20250916$EXP$$CA-LUNDBECK-DKLU4018584$LUNDBECK$$48$YR$A$F$Y$$$20250916$$CN$CA$CA
258091421$25809142$1$I$20250916$20250916$20250916$20250916$DIR$775551$$FDA-CTU$$68$YR$$$N$$$20250916$N$PH$US$
258091582$25809158$2$F$20250711$20250922$20250916$20250930$EXP$$EU-UCBSA-2025056285$UCB$$28$YR$$F$Y$100$KG$20250930$$MD$EU$EU
258091721$25809172$1$I$$20250910$20250916$20250916$EXP$$GB-009507513-2328983$MERCK SHARP + DOHME LLC$$60$YR$$F$Y$$$20250916$$MD$GB$GB
258092581$25809258$1$I$20250101$20250915$20250916$20250916$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-127458$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$M$Y$$$20250916$$$US$US
258094141$25809414$1$I$$20250910$20250916$20250916$PER$$US-SA-2025SA275469$SANOFI AVENTIS$$$$C$F$Y$$$20250917$$HP$US$US
258094221$25809422$1$I$20250101$20250910$20250916$20250916$PER$$US-SA-2025SA274624$SANOFI AVENTIS$$3$YR$C$F$Y$$$20250917$$HP$US$US
258094241$25809424$1$I$20250101$20250909$20250916$20250916$PER$$US-SA-2025SA239331$SANOFI AVENTIS$$36$YR$A$M$Y$$$20250917$$CN$US$US
258094601$25809460$1$I$20250801$20250910$20250916$20250916$PER$$US-SA-2025SA275244$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250917$$HP$US$US
258095041$25809504$1$I$$20250911$20250916$20250916$PER$$US-SA-2025SA275878$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250917$$CN$US$US
258095441$25809544$1$I$20250801$20250911$20250916$20250916$PER$$US-SA-2025SA275650$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250917$$HP$US$US
258095481$25809548$1$I$$20250911$20250916$20250916$PER$$US-SA-2025SA274847$SANOFI AVENTIS$$$$$F$Y$$$20250917$$CN$US$US
258095681$25809568$1$I$20250911$20250911$20250916$20250916$PER$$US-SA-2025SA275142$SANOFI AVENTIS$$47$YR$A$F$Y$$$20250917$$MD$US$US
258096801$25809680$1$I$20250701$20250709$20250916$20250916$PER$$US-OSMOTICA PHARMACEUTICALS-2025ALO02349$Alora Pharma$$13$YR$$F$Y$55.782$KG$20250912$$CN$US$US
258096831$25809683$1$I$$20250908$20250916$20250916$EXP$$CA-SANDOZ INC.-NVSC2020CA224902$SANDOZ$$43$YR$$F$Y$$$20250916$$CN$CA$CA
258097411$25809741$1$I$$20250916$20250916$20250916$EXP$EU-LRB-01084127$EU-JNJFOC-20250923920$JOHNSON AND JOHNSON$$67$YR$E$M$Y$109$KG$20250917$$MD$EU$EU
258098001$25809800$1$I$20250910$20250910$20250916$20250916$EXP$$US-ABBVIE-6461422$ABBVIE$$53$YR$$F$Y$$$20250916$$CN$US$US
258098381$25809838$1$I$20250701$20250910$20250916$20250916$EXP$$TR-ASTELLAS-2025-AER-050270$ASTELLAS$$69$YR$E$F$Y$$$20250917$$MD$TR$TR
258098572$25809857$2$F$$20250912$20250917$20250925$30DAY$$US-JNJFOC-20250917999$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20250925$$CN$US$US
258099091$25809909$1$I$20250827$20250908$20250917$20250917$EXP$EU-AEMPS-1747434$EU-GSK-ES2025115818$GLAXOSMITHKLINE$$65$YR$$F$Y$57$KG$20250917$$PH$EU$EU
258099841$25809984$1$I$$20250915$20250917$20250917$EXP$$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-127469$BRISTOL-MYERS SQUIBB COMPANY$$$$$M$Y$$$20250917$$MD$EU$EU
258100121$25810012$1$I$20201201$20250908$20250917$20250917$EXP$$JP-AMGEN-JPNSP2025073118$AMGEN$$83$YR$E$F$Y$$$20250916$$MD$JP$JP
258101301$25810130$1$I$$20250905$20250917$20250917$EXP$GB-MHRA-EMIS-1694-18290a1f-9df2-4639-bddb-bd0c06fdfd60$GB-Accord-497192$ACCORD$$52$YR$A$M$Y$94$KG$20250917$$HP$GB$GB
258101611$25810161$1$I$20250601$20250911$20250917$20250917$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010225$ACADIA PHARMACEUTICALS$$69$YR$$M$Y$$$20250917$$CN$US$US
258101881$25810188$1$I$$20250913$20250917$20250917$PER$$US-KARYOPHARM-2025KPT100732$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20250917$$MD$US$US
258101961$25810196$1$I$$20250908$20250917$20250917$EXP$$US-BAXTER-2025BAX021187$BAXTER$$4$DEC$$F$Y$$$20250917$$HP$US$US
258102241$25810224$1$I$$20250904$20250917$20250917$EXP$$US-ALEMBIC PHARMACUETICALS LIMITED-2025SCAL001186$ALEMBIC$Ambati S, Jakoby M, Williams V. Idiopathic Intracranial Hypertension-Associated Secondary Adrenal Insufficiency Masking Diabetes Mellitus. Endocrine Practice. 2025;31 (9) (S48)$$$$$Y$$$20250917$$MD$US$US
258102811$25810281$1$I$20210511$20250905$20250917$20250917$EXP$EU-URPL-DML-MLP.4401.1.3222.2021$EU-Accord-504598$ACCORD$$66$YR$E$F$Y$84$KG$20250917$$MD$EU$EU
258102982$25810298$2$F$$20250918$20250917$20250925$EXP$$GB-ROCHE-10000386885$ROCHE$$$$E$F$Y$$$20250925$$CN$GB$GB
258103401$25810340$1$I$$20250912$20250917$20250917$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-127295$BRISTOL-MYERS SQUIBB COMPANY$$$$E$$Y$$$20250917$$MD$US$US
258104612$25810461$2$F$20250530$20250915$20250917$20250919$EXP$$NZ-009507513-2329669$MERCK SHARP + DOHME LLC$$72$YR$$F$Y$$$20250919$$MD$NZ$NZ
258104961$25810496$1$I$20230101$20250909$20250917$20250917$EXP$$EU-AMGEN-DEUSP2025185450$AMGEN$$57$YR$A$F$Y$63$KG$20250917$$CN$EU$EU
258105561$25810556$1$I$20250808$20250912$20250917$20250917$EXP$$PK-ROCHE-10000387742$ROCHE$$85$YR$E$F$Y$$$20250917$$CN$PK$PK
258106102$25810610$2$F$$20250919$20250917$20250924$PER$$US-LUPIN PHARMACEUTICALS INC.-2025-08230$LUPIN$$65$YR$$$Y$77.098$KG$20250924$$$US$US
258106821$25810682$1$I$20250818$20250910$20250917$20250917$EXP$EU-AFSSAPS-PV2025000690$EU-TEVA-VS-3371627$TEVA$$14$YR$$M$Y$57$KG$20250917$$MD$EU$EU
258107321$25810732$1$I$$20250908$20250917$20250917$EXP$$CA-CELLTRION INC.-2025CA033311$CELLTRION$$$$$$Y$$$20250917$$HP$CA$CA
258107521$25810752$1$I$20250627$20250905$20250917$20250917$EXP$EU-SEMPA-2025-005616$EU-Accord-504826$ACCORD$$75$YR$E$F$Y$$$20250917$$MD$EU$EU
258107611$25810761$1$I$$20250903$20250917$20250917$EXP$$EU-GRANULES-IT-2025GRALIT00521$GRANULES PHARMACEUTICALS INC$Biancamaria Treves.Two cases of Sexual Activity-Related Deaths due to Vascular  Dissection: investigating the Potential Link to phosphodiesterase type 5 inhibitor administration. Clinica Terapeutica.JAN-2025;176 S1(2):70-76$58$YR$A$M$Y$$$20250917$$HP$EU$EU
258108441$25810844$1$I$20250630$20250910$20250917$20250917$EXP$EU-AFSSAPS-NY2025001304$EU-TEVA-VS-3371810$TEVA$$84$YR$$F$Y$70$KG$20250917$$MD$EU$EU
258108591$25810859$1$I$20250912$20250912$20250917$20250917$EXP$$IN-ASTRAZENECA-202509IND010659IN$ALEXION PHARMACEUTICALS$$52$YR$A$M$Y$$$20250917$$$IN$IN
258109511$25810951$1$I$20250901$20250915$20250917$20250917$EXP$$EU-ABBVIE-6462560$ABBVIE$$76$YR$$M$Y$$$20250917$$CN$EU$EU
258109611$25810961$1$I$$20250821$20250917$20250917$PER$$US-GALDERMA-US2025015982$GALDERMA$$$$$$Y$$$20250917$$CN$US$US
258109662$25810966$2$F$20250101$20250921$20250917$20250925$EXP$$US-JNJFOC-20250913438$JOHNSON AND JOHNSON$$60$YR$A$M$Y$$$20250925$$CN$US$US
258109731$25810973$1$I$20250223$20250910$20250917$20250917$EXP$EU-AFSSAPS-TO2025001403$EU-TEVA-VS-3371379$TEVA$$76$YR$$M$Y$$$20250917$$MD$EU$EU
258110091$25811009$1$I$$20250912$20250917$20250917$EXP$$US-AMGEN-USASP2025183093$AMGEN$Chen Z.; Zhu J.; Nahm J. et al.. Improving Median Overall Survival (OS) of Glioblastoma (GBM) Patients by Optimizing Standard of Care (SOC) Through Multidisciplinary Team Work and Combination Therapies Including Tumor Treating Fields (TTF). Neurology. 2025;104 (7)$$$$$Y$$$20250917$$MD$US$US
258110291$25811029$1$I$$20250912$20250917$20250917$EXP$$US-REGENERON PHARMACEUTICALS, INC.-2025-145733$REGENERON$$$$$F$Y$$$20250917$$CN$US$US
258110681$25811068$1$I$20250808$20250909$20250917$20250917$EXP$EU-AFSSAPS-AN2025001116$EU-TEVA-VS-3371225$TEVA$$30$YR$$M$Y$83$KG$20250917$$HP$EU$EU
258111331$25811133$1$I$$20250912$20250917$20250917$PER$$US-JNJFOC-20250918629$JOHNSON AND JOHNSON$$$$$$Y$$$20250917$$HP$US$US
258111841$25811184$1$I$20250301$20250912$20250917$20250917$EXP$$NVSC2025GB050188$NOVARTIS$$$$$F$Y$$$20250917$$CN$GB$GB
258111871$25811187$1$I$20250827$20250915$20250917$20250917$EXP$GB-MHRA-MED-202509151633418390-BCMJN$GB-TEVA-VS-3372924$TEVA$$73$YR$$M$Y$$$20250917$$PH$GB$GB
258111971$25811197$1$I$20250907$20250910$20250917$20250917$EXP$$GB-ABBVIE-6457628$ABBVIE$$40$YR$$M$Y$$$20250917$$MD$GB$GB
258112031$25811203$1$I$$20250908$20250917$20250917$PER$$US-KENVUE-20250905895$Kenvue$$$$$F$Y$$$20250917$$CN$US$US
258112511$25811251$1$I$20250225$20250903$20250917$20250917$EXP$EU-MINISAL02-1055076$EU-HIKMA PHARMACEUTICALS USA INC.-IT-H14001-25-10176$HIKMA$$35$YR$$M$Y$88$KG$20250917$$PH$EU$EU
258113421$25811342$1$I$$20250725$20250917$20250917$PER$$US-BRAEBURN PHARMACEUTICALS-US-BRA-25-000669$BRAEBURN PHARMACEUTICALS$$$$$M$Y$$$20250917$$HP$US$US
258113751$25811375$1$I$20250801$20250813$20250917$20250917$PER$$US-BRAEBURN PHARMACEUTICALS-US-BRA-25-000721$BRAEBURN PHARMACEUTICALS$$$$$M$Y$$$20250917$$HP$US$US
258113941$25811394$1$I$$20250905$20250917$20250917$PER$$US-SMPA-2025SPA011568$SUNOVION$$55$YR$$M$Y$$$20250914$$$US$US
258115051$25811505$1$I$$20250905$20250917$20250917$EXP$CA-MHPD-E2B_07882194$CA-Accord-503900$ACCORD$$$$$F$Y$$$20250917$$CN$CA$CA
258115281$25811528$1$I$$20250911$20250917$20250917$EXP$$CA-TEVA-VS-3372161$TEVA$$54$YR$$F$Y$99$KG$20250917$$HP$CA$CA
258116611$25811661$1$I$20250910$20250910$20250917$20250917$EXP$$CA-TEVA-VS-3372757$TEVA$$61$YR$$M$Y$116$KG$20250917$$HP$CA$CA
258116841$25811684$1$I$$20250910$20250917$20250917$EXP$$US-UPSHER-SMITH LABORATORIES, LLC-20250901192$UPSHER SMITH LABORATORIES$$$$$$Y$$$20250917$$MD$US$US
258117211$25811721$1$I$$20250902$20250917$20250917$EXP$$US-GSK-US2025AMR111807$GLAXOSMITHKLINE$$$$$F$Y$$$20250917$$$US$US
258119711$25811971$1$I$20250913$20250915$20250917$20250917$PER$$US-PFIZER INC-202500182678$PFIZER$$48$YR$$M$Y$$$20250917$$CN$US$US
258119942$25811994$2$F$20250101$20250918$20250917$20250923$EXP$$CA-PFIZER INC-202500181480$PFIZER$$47$YR$$F$Y$48$KG$20250923$$HP$CA$CA
258121231$25812123$1$I$$20250916$20250916$20250916$DIR$775571$$FDA-CTU$$61$YR$$M$N$87.75$KG$20250916$Y$PH$US$
258121331$25812133$1$I$20250906$20250916$20250917$20250917$DIR$FDA-CDER-CTU-2025-62054$$FDA-CTU$$82$YR$$F$N$54$KG$20250916$N$$US$
258121501$25812150$1$I$20250916$20250916$20250916$20250916$DIR$775575$$FDA-CTU$$81$YR$$M$N$$$20250916$N$$US$
258121601$25812160$1$I$20250327$20250911$20250917$20250917$EXP$EU-SEMPA-2025-006562$EU-TEVA-VS-3372173$TEVA$$94$YR$$F$Y$$$20250917$$MD$EU$EU
258122001$25812200$1$I$$20250912$20250917$20250917$EXP$$US-PFIZER INC-202500182304$PFIZER$$67$YR$$F$Y$$$20250917$$HP$US$US
258122021$25812202$1$I$$20250916$20250917$20250917$EXP$$CA-PFIZER INC-202500182965$PFIZER$$$$$$Y$$$20250917$$MD$CA$CA
258122071$25812207$1$I$$20250911$20250917$20250917$EXP$$CA-TEVA-VS-3372124$TEVA$$$$$F$Y$$$20250917$$CN$CA$CA
258122171$25812217$1$I$20250401$20250905$20250917$20250917$EXP$GB-MHRA-MED-202509031149408390-CKBYL$GB-MACLEODS PHARMA-MAC2025055232$MACLEODS$$$$$$Y$$$20250917$$CN$GB$GB
258122611$25812261$1$I$20220620$20250913$20250917$20250917$EXP$$US-PFIZER INC-202500181456$PFIZER$$$$$F$Y$$$20250917$$LW$US$US
258123531$25812353$1$I$20250101$20250915$20250917$20250917$EXP$$EU-ABBVIE-6462839$ABBVIE$$85$YR$$M$Y$$$20250917$$MD$EU$EU
258123761$25812376$1$I$$20250915$20250917$20250917$PER$$US-TAKEDA-2025TUS081205$TAKEDA$$$$$$Y$$$20250917$$$US$US
258123901$25812390$1$I$20250901$20250915$20250917$20250917$EXP$$US-SA-2025SA277770$SANOFI AVENTIS$$80$YR$E$F$Y$$$20250917$$CN$US$US
258123941$25812394$1$I$$20250917$20250917$20250917$DIR$775455$$FDA-CTU$$$$$$N$$$20250917$$CN$US$
258124331$25812433$1$I$$20250822$20250917$20250917$PER$$US-GLANDPHARMA-US-2025GLNSPO01749$GLAND PHARMA LTD$$$$$M$Y$$$20250917$$CN$US$US
258125061$25812506$1$I$$20250912$20250917$20250917$PER$$US-ELI_LILLY_AND_COMPANY-US202509003080$ELI LILLY AND COMPANY$$51$YR$A$F$Y$$$20250917$$CN$US$US
258125601$25812560$1$I$$20250830$20250917$20250917$PER$$US-GLANDPHARMA-US-2025GLNSPO01790$GLAND PHARMA LTD$$$$$$Y$$$20250917$$CN$US$US
258125621$25812562$1$I$20250904$20250915$20250917$20250917$EXP$$CO-JNJFOC-20250924130$JOHNSON AND JOHNSON$$62$YR$A$F$Y$61$KG$20250917$$CN$CO$CO
258125791$25812579$1$I$$20250917$20250917$20250917$DIR$FDA-CDER-CTU-2025-62153$$FDA-CTU$$87$YR$$F$N$$$20250917$N$$US$
258126001$25812600$1$I$20000101$20250912$20250917$20250917$EXP$$US-ATNAHS-2025-PMNV-US000828$Atnahs Healthcare$$$$$$Y$$$20250917$$CN$US$US
258126371$25812637$1$I$$20250912$20250917$20250917$PER$$US-ABBVIE-6459609$ABBVIE$$$$A$F$Y$$$20250917$$HP$US$US
258127281$25812728$1$I$$20250910$20250917$20250917$PER$$US-SA-2025SA275002$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250917$$CN$US$US
258127411$25812741$1$I$20250901$20250910$20250917$20250917$PER$$US-SA-2025SA276059$SANOFI AVENTIS$$53$YR$A$M$Y$$$20250917$$HP$US$US
258128211$25812821$1$I$$20250911$20250917$20250917$PER$$US-SA-2025SA274841$SANOFI AVENTIS$$$$E$F$Y$75.45$KG$20250917$$MD$US$US
258128591$25812859$1$I$20250101$20250911$20250917$20250917$PER$$US-SA-2025SA276649$SANOFI AVENTIS$$64$YR$A$M$Y$$$20250917$$HP$US$US
258128881$25812888$1$I$$20250911$20250917$20250917$PER$$US-SA-2025SA277717$SANOFI AVENTIS$$$$A$M$Y$63.492$KG$20250917$$HP$US$US
258129601$25812960$1$I$20250912$20250912$20250917$20250917$PER$$US-SA-2025SA276128$SANOFI AVENTIS$$47$YR$A$F$Y$$$20250917$$MD$US$US
258130381$25813038$1$I$$20250903$20250917$20250917$EXP$$US-ELI_LILLY_AND_COMPANY-US202509013928$ELI LILLY AND COMPANY$$$$N$$Y$7$KG$20250917$$CN$US$US
258130441$25813044$1$I$$20250915$20250917$20250917$PER$$US-ELI_LILLY_AND_COMPANY-US202509015203$ELI LILLY AND COMPANY$$$$$$Y$$$20250917$$CN$US$US
258130771$25813077$1$I$20250529$20250609$20250917$20250917$EXP$$US-FERRINGPH-2025FE02966$FERRING$$33$YR$$F$Y$75.8$KG$20250917$$HP$US$US
258131511$25813151$1$I$$20250904$20250917$20250917$PER$$US-Calliditas-2025CAL02814$CALLIDITAS THERAPEUTICS AB$$40$YR$A$M$Y$$$20250917$$CN$US$US
258131611$25813161$1$I$$20250912$20250917$20250917$EXP$$GB-ABBVIE-6462745$ABBVIE$$$$A$M$Y$$$20250917$$CN$GB$GB
258132551$25813255$1$I$20170111$20250913$20250917$20250917$EXP$$US-PFIZER INC-202500181453$PFIZER$$$$$F$Y$$$20250917$$LW$US$US
258133071$25813307$1$I$$20250825$20250917$20250917$PER$$US-GSK-US2025AMR110585$GLAXOSMITHKLINE$$$$$M$Y$$$20250917$$$US$US
258135221$25813522$1$I$$20250903$20250917$20250917$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-527457$RANBAXY$Lal A, Khan M, Rath S, Yadav S. MCL-651: Mantle Cell Lymphoma With Bilateral Uveitis and Progressive Neuropathy: An Atypical Presentation of the Blastic Variant. Clin Lymphoma Myeloma Leuk. 2025;25 (Suppl:S852$33$YR$$M$Y$$$20250917$$HP$US$US
258135401$25813540$1$I$$20250902$20250917$20250917$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-527677$RANBAXY$Restrepo JA, Rosenbaum BL, Harris D, Gift T, Freudenreich O. Clozapine in Solid Organ Transplant: A Literature Review and Case Series. J Acad Consult Liaison Psychiatry. 2025;66:331-340$70$YR$$$Y$$$20250917$$MD$US$US
258135501$25813550$1$I$20250101$20250911$20250917$20250917$PER$$US-SA-2025SA277007$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250917$$CN$US$US
258135552$25813555$2$F$$20250904$20250917$20250919$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-527594$RANBAXY$$$$$F$Y$75$KG$20250919$$MD$EU$EU
258135652$25813565$2$F$20250910$20250911$20250917$20250920$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-126868$BRISTOL-MYERS SQUIBB COMPANY$$52$YR$A$F$Y$$$20250920$$$US$US
258135661$25813566$1$I$$20250904$20250917$20250917$PER$$US-BAYER-2025A118815$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$M$Y$$$20250917$$CN$US$US
258136261$25813626$1$I$$20250818$20250917$20250917$PER$$US-ETHYPHARM-2025002587$ETHYPHARM$Ahern T, Ashenburg N,Park J,Ognian I, Lee J. Low-Dose Buprenorphine for Acute Pain Management in the Emergency Department: A Prospective Observational Study. Annals of Emergency Medicine. 2005 Sep;86 (3 Supp 1):S62.$$$$$Y$$$20250917$$HP$US$US
258136501$25813650$1$I$$20250912$20250917$20250917$PER$$US-HALEON-2262749$Haleon PLC$$$$$$Y$$$20250917$$CN$US$US
258137401$25813740$1$I$$20250908$20250917$20250917$EXP$$US-UCBSA-2025056644$UCB$Sayali FU, Bhavsar D, Nickerson D, Slater J, Golson K, Nazir N et al. Safety and Efficacy of Multiple Monitored Anesthesia Care During Burn Dressing Change: Three Case Series. American Burn Association 57th Annual Meeting. 2025;S292-3$$$$M$Y$$$20250917$$MD$US$US
258139201$25813920$1$I$$20250828$20250917$20250917$PER$$US-ARDELYX-2025ARDX006615$ARDELYX$$$$$M$Y$$$20250917$$CN$US$US
258139311$25813931$1$I$$20250823$20250917$20250917$PER$$US-ARDELYX-2025ARDX006518$ARDELYX$$29$YR$$F$Y$$$20250917$$HP$US$US
258139511$25813951$1$I$20250101$20250813$20250917$20250917$PER$$US-ARDELYX-2025ARDX006211$ARDELYX$$$$$F$Y$$$20250917$$HP$US$US
258140821$25814082$1$I$20250831$20250909$20250917$20250917$EXP$$HN-BRISTOL-MYERS SQUIBB COMPANY-2025-127361$BRISTOL-MYERS SQUIBB COMPANY$$17$YR$T$F$Y$$$20250917$$MD$HN$HN
258141781$25814178$1$I$$20250908$20250917$20250917$EXP$$EU-BAYER-2025A121525$BAYER HEALTHCARE PHARMACEUTICALS INC.$$58$YR$A$$Y$102$KG$20250917$$HP$EU$EU
258142681$25814268$1$I$$20250915$20250917$20250917$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-128076$BRISTOL-MYERS SQUIBB COMPANY$$58$YR$A$M$Y$$$20250917$$$US$US
258143071$25814307$1$I$20250829$20250911$20250917$20250917$PER$$CN-Eisai-EC-2025-196633$EISAI$$45$YR$A$F$Y$55$KG$20250917$$$CN$CN
258143161$25814316$1$I$20250905$20250912$20250917$20250917$PER$$US-ELI_LILLY_AND_COMPANY-US202509013218$ELI LILLY AND COMPANY$$$$$F$Y$$$20250917$$CN$US$US
258143661$25814366$1$I$20250819$20250917$20250917$20250917$DIR$775684$$FDA-CTU$$70$YR$$F$N$72$KG$20250917$N$CN$US$
258143771$25814377$1$I$$20250917$20250917$20250917$DIR$775704$$FDA-CTU$$$$$$N$$$20250917$N$$US$
258143951$25814395$1$I$20250902$20250908$20250917$20250917$EXP$$US-NOVOPROD-1521124$NOVO NORDISK$$51$YR$$F$Y$$$20250917$$CN$US$US
258143961$25814396$1$I$$20250908$20250917$20250917$EXP$$US-NOVOPROD-1521143$NOVO NORDISK$$$$$M$Y$$$20250917$$CN$US$US
258144701$25814470$1$I$$20250905$20250917$20250917$EXP$$BR-ELI_LILLY_AND_COMPANY-BR202509007157$ELI LILLY AND COMPANY$$46$YR$A$F$Y$106$KG$20250917$$CN$BR$BR
258146241$25814624$1$I$$20250911$20250917$20250917$EXP$$AU-SANDOZ INC.-SDZ2025AU067625$SANDOZ$$72$YR$$M$Y$$$20250917$$MD$AU$AU
258146411$25814641$1$I$$20250910$20250917$20250917$EXP$$CN-BEIGENE-BGN-2025-015624$BEIGENE$$73$YR$$$Y$50$KG$20250917$$$CN$CN
258146541$25814654$1$I$$20250912$20250917$20250917$PER$$US-SA-2025SA277169$SANOFI AVENTIS$$$$E$M$Y$$$20250918$$HP$US$US
258146631$25814663$1$I$20250822$20250913$20250917$20250917$EXP$$CR-ASTRAZENECA-202509CAM010588CR$ALEXION PHARMACEUTICALS$$49$YR$A$F$Y$90$KG$20250917$$$CR$CR
258147391$25814739$1$I$$20250911$20250917$20250917$EXP$$US-BEIGENE-BGN-2025-015126$BEIGENE$Chemotherapy-associated, Atypical Hemorrhagic Posterior Reversible Encephalopathy Syndrome (PRES)in a Patient with Non-Hodgkin^s Lymphoma: A Case Report. Annual Meeting American Academy of Neurology (AAN). 2025$59$YR$$$Y$$$20250917$$$US$US
258147441$25814744$1$I$20250101$20250909$20250917$20250917$PER$$US-UNITED THERAPEUTICS-UNT-2025-031452$UNITED THERAPEUTICS$$$$$F$Y$58.957$KG$20250917$$$US$US
258147631$25814763$1$I$$20250909$20250917$20250917$PER$$US-ELI_LILLY_AND_COMPANY-US202509009151$ELI LILLY AND COMPANY$$52$YR$A$F$Y$$$20250917$$CN$US$US
258149821$25814982$1$I$20250907$20250910$20250918$20250918$PER$$US-AMGEN-USASP2025181381$AMGEN$$66$YR$E$$Y$$$20250917$$CN$US$US
258150041$25815004$1$I$20250910$20250910$20250918$20250918$30DAY$$US-SANDOZ INC.-SDZ2025US066478$SANDOZ$$$$$F$Y$$$20250918$$MD$US$US
258150241$25815024$1$I$20250101$20250908$20250918$20250918$PER$$US-ROCHE-10000384571$ROCHE$$38$YR$A$F$Y$92.53$KG$20250918$$CN$US$US
258150491$25815049$1$I$$20240916$20250918$20250918$PER$$US-AUROBINDO-AUR-APL-2024-040445$AUROBINDO$$$$$F$Y$$$20250918$$CN$US$US
258150581$25815058$1$I$20240826$20240928$20250918$20250918$PER$$US-AUROBINDO-AUR-APL-2024-044093$AUROBINDO$$85$YR$$F$Y$$$20250918$$CN$US$US
258151341$25815134$1$I$$20240930$20250918$20250918$PER$$US-AUROBINDO-AUR-APL-2024-048900$AUROBINDO$$$$$F$Y$$$20250918$$CN$US$US
258151501$25815150$1$I$20250528$20250915$20250918$20250918$EXP$$EU-SANDOZ INC.-SDZ2025DE067639$SANDOZ$$75$YR$$M$Y$79.4$KG$20250918$$MD$EU$EU
258152021$25815202$1$I$$20250904$20250918$20250918$EXP$$CA-AUROBINDO-AUR-APL-2025-046328$AUROBINDO$$74$YR$$F$Y$70$KG$20250918$$MD$CA$CA
258153311$25815331$1$I$$20250903$20250918$20250918$EXP$$EU-AUROBINDO-AUR-APL-2025-045816$AUROBINDO$$$$$M$Y$$$20250918$$MD$EU$EU
258154951$25815495$1$I$$20250916$20250918$20250918$EXP$$NZ-ASTRAZENECA-202509OCE012088NZ$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250918$$$NZ$NZ
258156871$25815687$1$I$20250101$20250823$20250918$20250918$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-128350$ZYDUS PHARM$$$$$$Y$$$20250918$$CN$US$US
258158111$25815811$1$I$$20240906$20250918$20250918$PER$$US-CATALYSTPHARMACEUTICALPARTNERS-US-CATA-24-00996$CATALYST PHARMA$$$$$M$Y$$$20250918$$CN$US$US
258159321$25815932$1$I$$20250717$20250918$20250918$PER$$US-CATALYSTPHARMACEUTICALPARTNERS-US-CATA-25-01042$CATALYST PHARMA$$$$$$Y$$$20250918$$CN$US$US
258159781$25815978$1$I$20250701$20250905$20250918$20250918$PER$$US-GE HEALTHCARE-2025CSU012430$GE HEALTHCARE$$63$YR$$F$Y$$$20250918$$MD$US$US
258160141$25816014$1$I$20250901$20250904$20250918$20250918$30DAY$$US-CIPLA LTD.-2025US11331$CIPLA$$$$$$Y$$$20250918$$CN$US$US
258160491$25816049$1$I$20250819$20250819$20250918$20250918$PER$$US-GSK-US2025106816$GLAXOSMITHKLINE$$67$YR$$M$Y$$$20250918$$$US$US
258160571$25816057$1$I$$20250519$20250918$20250918$PER$$US-STRIDES ARCOLAB LIMITED-2025SP006604$STRIDES$$$$$$Y$$$20250918$$CN$US$US
258161081$25816108$1$I$20250101$20250912$20250918$20250918$PER$$US-AMGEN-USASP2025183603$AMGEN$$67$YR$E$F$Y$$$20250918$$CN$US$US
258161311$25816131$1$I$$20250909$20250918$20250918$PER$$US-Bion-015252$BIONPHARMA INC.$$$$$M$Y$$$20250918$$CN$US$US
258161501$25816150$1$I$$20250917$20250918$20250918$EXP$$NZ-ASTRAZENECA-202509OCE013242NZ$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250918$$$NZ$NZ
258161541$25816154$1$I$$20250719$20250918$20250918$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009432$STRIDES$$$$$$Y$$$20250918$$CN$US$US
258161551$25816155$1$I$$20250905$20250918$20250918$EXP$$EU-AUROBINDO-AUR-APL-2025-046242$AUROBINDO$$86$YR$$M$Y$71$KG$20250918$$CN$EU$EU
258161711$25816171$1$I$$20250728$20250918$20250918$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009864$STRIDES$$$$$$Y$$$20250918$$CN$US$US
258162531$25816253$1$I$$20250909$20250918$20250918$EXP$$US-JNJFOC-20250911819$JOHNSON AND JOHNSON$$54$YR$A$M$Y$$$20250918$$MD$US$US
258165191$25816519$1$I$20250909$20250910$20250918$20250918$PER$$US-ASTELLAS-2025-AER-050234$ASTELLAS$$66$YR$E$F$Y$$$20250918$$HP$US$US
258165501$25816550$1$I$20250101$20250916$20250918$20250918$EXP$$US-ABBVIE-6463630$ABBVIE$$67$YR$$M$Y$$$20250918$$CN$US$US
258167341$25816734$1$I$$20250819$20250918$20250918$PER$$US-GSK-US2025106742$GLAXOSMITHKLINE$$$$$F$Y$$$20250918$$$US$US
258167801$25816780$1$I$$20250904$20250918$20250918$EXP$$EU-AUROBINDO-AUR-APL-2025-045977$AUROBINDO$$69$YR$$F$Y$$$20250918$$MD$EU$EU
258167891$25816789$1$I$$20250910$20250918$20250918$EXP$$US-LUPIN PHARMACEUTICALS INC.-2025-08413$LUPIN$Omar H, Swords A, Horani M. Patient with thyroid storm caused by levothyroxine overdose treated with plasmapheresis. Endocrine Practice. 2025;31 (9):S97-S98$70$YR$$M$Y$$$20250918$$$US$US
258169741$25816974$1$I$$20250916$20250918$20250918$PER$$US-ELI_LILLY_AND_COMPANY-US202509015608$ELI LILLY AND COMPANY$$85$YR$E$F$Y$$$20250918$$CN$US$US
258171111$25817111$1$I$$20250910$20250918$20250918$EXP$$EU-STRIDES ARCOLAB LIMITED-2025SP011763$STRIDES$Van Hove K, D^heygere E, Vanderdonckt P, D^heygere F. An unusual cause of neurological symptoms. [Dutch]. Tijdschr-Geneeskd. 2025;81 (6):484-492$54$YR$$M$Y$$$20250918$$HP$EU$EU
258171381$25817138$1$I$20250818$20250917$20250917$20250917$DIR$FDA-CDER-CTU-2025-62265$$FDA-CTU$$71$YR$$M$N$$$20250917$Y$PH$US$
258171471$25817147$1$I$20250910$20250911$20250918$20250918$PER$$US-ROCHE-10000387621$ROCHE$$15$YR$T$F$Y$49.89$KG$20250918$$CN$US$US
258171751$25817175$1$I$$20250910$20250918$20250918$EXP$EU-URPL-DML-MLP.4401.1.3148.2021$EU-RDY-POL/2025/09/013969$DR REDDYS$$49$YR$A$F$Y$62$KG$20250918$$MD$EU$EU
258172081$25817208$1$I$$20250915$20250918$20250918$PER$$US-GILEAD-2025-0728557$GILEAD$$$$A$F$Y$$$20250918$$HP$US$US
258172231$25817223$1$I$20250912$20250917$20250917$20250917$DIR$775698$$FDA-CTU$$$$$$N$$$20250917$Y$PH$US$
258172291$25817229$1$I$$20250917$20250917$20250917$DIR$FDA-CDER-CTU-2025-62228$$FDA-CTU$$69$YR$$F$N$$$20250917$N$$US$
258172811$25817281$1$I$20250904$20250916$20250918$20250918$EXP$$CN-PFIZER INC-PV202500111962$PFIZER$$29$YR$$F$Y$49.5$KG$20250918$$HP$CN$CN
258173661$25817366$1$I$$20250807$20250918$20250918$PER$$US-Innogenix, LLC-2184763$INNOGENIX, LLC$$$$$$Y$$$20250918$$$US$US
258173771$25817377$1$I$$20250911$20250918$20250918$EXP$$EU-MYLANLABS-2025M1077994$MYLAN$Padron LT, Egger EK. Targeted therapies in primary vaginal cancer. Journal of Cancer Research and Clinical Oncology. 11-Aug-2025;151(8): 228$65$YR$$F$Y$$$20250918$$$EU$EU
258173791$25817379$1$I$20250101$20250912$20250918$20250918$PER$$US-PHARMING-PHAUS2025001322$PHARMING GROUP$$$$$$Y$$$20250918$$CN$US$US
258174091$25817409$1$I$$20250915$20250918$20250918$EXP$$US-INCYTE CORPORATION-2025IN010088$INCYTE$$$$$$Y$$$20250918$$$US$US
258174751$25817475$1$I$$20250904$20250918$20250918$EXP$$EU-AMNEAL PHARMACEUTICALS-2025-AMRX-03464$AMNEAL$Tchernev G, Kordeva S.. Basal cell carcinoma development after use of metformin-potential role of nitrosamines as enhancing factors.. Port J Dermatol Venereol.. 2023;81(1):65-68$61$YR$$M$Y$$$20250918$$HP$EU$EU
258174821$25817482$1$I$$20250908$20250918$20250918$EXP$$US-AUROBINDO-AUR-APL-2025-046668$AUROBINDO$Marinov M, Gonzalez DD, George S, Ahmed A, Keeney S, Danhof M. CML-1058: Parallel Paths: The Coexistence of JAK2 and BCRABL Mutations Causing Disease Acceleration. Clin-LymphomaMyeloma-Leuk. 2025;25 (Suppl. 1):S590 abstr$$$$$Y$$$20250918$$MD$US$US
258175671$25817567$1$I$$20250911$20250918$20250918$EXP$$CN-BEIGENE-BGN-2025-015713$BEIGENE$$59$YR$$$Y$51$KG$20250918$$$CN$CN
258175991$25817599$1$I$$20250909$20250918$20250918$EXP$$CA-JNJFOC-20250915574$JOHNSON AND JOHNSON$$61$YR$A$M$Y$$$20250918$$CN$CA$CA
258176131$25817613$1$I$$20250723$20250918$20250918$PER$$US-TRAVERE-2025TVT01266$TRAVERE THERAPEUTICS$$52$YR$A$$Y$$$20250918$$CN$US$US
258176171$25817617$1$I$$20250723$20250918$20250918$PER$$US-TRAVERE-2025TVT01263$TRAVERE THERAPEUTICS$$38$YR$A$F$Y$$$20250918$$CN$US$US
258176411$25817641$1$I$20250101$20250915$20250918$20250918$EXP$$US-PFIZER INC-PV202500111790$PFIZER$$86$YR$$M$Y$$$20250918$$HP$US$US
258177111$25817711$1$I$20250915$20250915$20250918$20250918$EXP$$US-ABBVIE-6464061$ABBVIE$$61$YR$$F$Y$$$20250918$$CN$US$US
258177301$25817730$1$I$$20250910$20250918$20250918$EXP$$IN-AMGEN-INDSP2025184991$AMGEN$Bhadada S.K.; Shetty A.J.; Singhal M. et al.. Assessment of Cardiovascular Risks by CT-Derived Calcium Scoring and FGF-23 in Patients with Renal Hyperparathyroidism Undergoing Near-Total Parathyroidectomy and Cinacalcet Therapy: A Prospective Pilot Study. Indian Journal of  Endocrinology and Metabolism. 2025;29 (4):446-452$$$A$$Y$$$20250918$$MD$IN$IN
258177941$25817794$1$I$$20250911$20250918$20250918$EXP$$US-AMGEN-USASP2025182808$AMGEN$$$$$F$Y$$$20250918$$HP$US$US
258178721$25817872$1$I$$20250913$20250918$20250918$PER$$US-VERTEX PHARMACEUTICALS-2025-015349$VERTEX$$$$$F$Y$$$20250918$$MD$US$US
258178771$25817877$1$I$$20250911$20250918$20250918$PER$$US-VERTEX PHARMACEUTICALS-2025-015137$VERTEX$$$$$F$Y$$$20250918$$MD$US$US
258178931$25817893$1$I$$20250915$20250918$20250918$PER$$US-ELI_LILLY_AND_COMPANY-US202509015598$ELI LILLY AND COMPANY$$$$$$Y$$$20250918$$CN$US$US
258179741$25817974$1$I$$20250916$20250918$20250918$EXP$$GB-MYLANLABS-2025M1048429$MYLAN$$$$$M$Y$$$20250918$$$GB$GB
258181681$25818168$1$I$$20250905$20250918$20250918$PER$$NVSC2025US140262$NOVARTIS$$$$$F$Y$$$20250918$$HP$US$US
258181691$25818169$1$I$$20250914$20250918$20250918$EXP$$NVSC2025IL144638$NOVARTIS$$68$YR$$F$Y$$$20250918$$HP$IL$IL
258181781$25818178$1$I$$20250910$20250918$20250918$PER$$US-ASTELLAS-2025-AER-050547$ASTELLAS$$73$YR$E$M$Y$$$20250918$$CN$US$US
258182211$25818221$1$I$20231228$20250911$20250918$20250918$EXP$$EU-AstraZeneca-2024A071529$ALEXION PHARMACEUTICALS$$73$YR$E$F$Y$46$KG$20250918$$MD$EU$EU
258182311$25818231$1$I$20250907$20250909$20250918$20250918$EXP$$US-NOVOPROD-1521912$NOVO NORDISK$$59$YR$$F$Y$$$20250918$$MD$US$US
258182591$25818259$1$I$$20250916$20250918$20250918$PER$$US-ELI_LILLY_AND_COMPANY-US202509016210$ELI LILLY AND COMPANY$$$$$F$Y$$$20250918$$CN$US$US
258182991$25818299$1$I$$20250918$20250918$20250918$DIR$FDA-CDER-CTU-2025-62443$$FDA-CTU$$58$YR$$F$N$$$20250918$N$CN$US$
258184831$25818483$1$I$$20250909$20250918$20250918$PER$$US-INCYTE CORPORATION-2025IN009841$INCYTE$$$$$$Y$98.866$KG$20250918$$$US$
258185371$25818537$1$I$20240201$20250912$20250918$20250918$EXP$$EU-MYLANLABS-2025M1078644$MYLAN$$$$$M$Y$2.42$KG$20250918$$MD$EU$EU
258186572$25818657$2$F$$20250907$20250918$20250920$EXP$$US-ABBVIE-6464281$ABBVIE$Siddika A, Kapoor G. Fulminant cns aspergillosis presenting as unilateral headache: a case of rapid progression and neurovascular complications(P5-10.003). Neurology. 2025;104(7_Suppl_1):1536. //www.neurology.org/doi/10.1212/WNL.0000000000208597$64$YR$$M$Y$$$20250920$$HP$US$US
258186931$25818693$1$I$$20250908$20250918$20250918$30DAY$$US-SANDOZ INC.-SDZ2025US065551$SANDOZ$$$$$$Y$$$20250918$$MD$US$US
258187101$25818710$1$I$20250821$20250912$20250918$20250918$EXP$EU-HPRA-2025-123686$EU-AMGEN-IRLSP2025186407$AMGEN$$64$YR$A$F$Y$57$KG$20250918$$MD$EU$EU
258187181$25818718$1$I$$20250917$20250918$20250918$EXP$$CA-PFIZER INC-202500183784$PFIZER$$59$YR$$M$Y$$$20250918$$HP$CA$CA
258187641$25818764$1$I$20250808$20250909$20250918$20250918$EXP$$US-SPRINGWORKS THERAPEUTICS-SW-003226$SPRINGWORKS THERAPEUTIC$$20$YR$$M$Y$$$20250918$$CN$US$US
258188071$25818807$1$I$20250101$20250911$20250918$20250918$EXP$$JP-009507513-2286205$MERCK SHARP + DOHME LLC$$7$DEC$$F$Y$$$20250918$$MD$JP$JP
258188301$25818830$1$I$$20250905$20250918$20250918$PER$$NVSC2025US140090$NOVARTIS$$$$$F$Y$$$20250918$$PH$US$US
258188961$25818896$1$I$$20250909$20250918$20250918$PER$$NVSC2025US141441$NOVARTIS$$$$$F$Y$$$20250918$$CN$US$US
258189081$25818908$1$I$20250916$20250916$20250918$20250918$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-128735$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$$Y$$$20250918$$$US$US
258190071$25819007$1$I$20250703$20250909$20250918$20250918$PER$$US-SA-2025SA275151$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250918$$HP$US$US
258191161$25819116$1$I$20250101$20250911$20250918$20250918$PER$$US-SA-2025SA277188$SANOFI AVENTIS$$49$YR$A$M$Y$$$20250918$$HP$US$US
258191411$25819141$1$I$20250101$20250911$20250918$20250918$PER$$US-SA-2025SA277490$SANOFI AVENTIS$$60$YR$A$F$Y$$$20250918$$HP$US$US
258192661$25819266$1$I$20230101$20250912$20250918$20250918$PER$$US-SA-2025SA277741$SANOFI AVENTIS$$$$T$F$Y$$$20250918$$HP$US$US
258193772$25819377$2$F$$20250919$20250918$20250927$PER$$US-SA-2025SA278339$SANOFI AVENTIS$$28$YR$A$F$Y$$$20250926$$CN$US$US
258193781$25819378$1$I$$20250913$20250918$20250918$PER$$US-SA-2025SA278865$SANOFI AVENTIS$$$$A$F$Y$76.36$KG$20250918$$MD$US$US
258194371$25819437$1$I$20250701$20250915$20250918$20250918$PER$$US-SA-2025SA278049$SANOFI AVENTIS$$17$YR$T$F$Y$$$20250918$$HP$US$US
258194922$25819492$2$F$20250101$20250922$20250918$20250925$PER$$US-SA-2025SA278637$SANOFI AVENTIS$$25$YR$A$F$Y$$$20250925$$HP$US$US
258195061$25819506$1$I$$20250915$20250918$20250918$PER$$US-SA-2025SA278213$SANOFI AVENTIS$$$$A$F$Y$$$20250918$$HP$US$US
258195281$25819528$1$I$20250801$20250915$20250918$20250918$PER$$US-SA-2025SA278761$SANOFI AVENTIS$$24$YR$A$M$Y$$$20250918$$HP$US$US
258196151$25819615$1$I$20250906$20250915$20250918$20250918$EXP$$US-OTSUKA-2025_022853$OTSUKA$$80$YR$$F$Y$$$20250918$$CN$US$US
258196962$25819696$2$F$20250208$20250911$20250918$20250922$EXP$$CA-UCBSA-2025008611$UCB$$65$YR$$M$Y$$$20250922$$CN$CA$CA
258197081$25819708$1$I$$20250916$20250918$20250918$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202509016739$ELI LILLY AND COMPANY$$$$$$Y$$$20250918$$CN$JP$JP
258197171$25819717$1$I$20250819$20250910$20250918$20250918$EXP$EU-AFSSAPS-LL2025001599$EU-ELI_LILLY_AND_COMPANY-FR202509014683$ELI LILLY AND COMPANY$$86$YR$E$F$Y$$$20250918$$CN$EU$EU
258197571$25819757$1$I$$20250918$20250918$20250918$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-128846$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$$Y$$$20250918$$$US$US
258198331$25819833$1$I$$20250917$20250918$20250918$EXP$$EU-ASTRAZENECA-202509EEA013505PL$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250918$$MD$EU$EU
258198601$25819860$1$I$$20250623$20250918$20250918$PER$$US-KVK-TECH, INC-20250600098$KVK-TECH$$$$$$Y$$$20250918$$CN$US$US
258198911$25819891$1$I$20240905$20240909$20250918$20250918$PER$$US-KVK-TECH, INC-20240900134$KVK-TECH$$$$$$Y$$$20250918$$CN$US$US
258199301$25819930$1$I$20250911$20250912$20250918$20250918$PER$$US-SA-2025SA277097$SANOFI AVENTIS$$46$YR$A$F$Y$$$20250919$$HP$US$US
258199621$25819962$1$I$20250101$20250916$20250918$20250918$EXP$$US-ABBVIE-6465110$ABBVIE$$75$YR$$M$Y$$$20250918$$CN$US$US
258199701$25819970$1$I$20250731$20250912$20250918$20250918$EXP$$JP-AMGEN-JPNSP2025158067$AMGEN$$6$DEC$A$F$Y$$$20250918$$PH$JP$JP
258200601$25820060$1$I$$20250915$20250918$20250918$EXP$$US-ABBVIE-6463458$ABBVIE$$$$E$F$Y$$$20250918$$CN$US$US
258201251$25820125$1$I$$20250916$20250919$20250919$EXP$$US-ABBVIE-6465747$ABBVIE$$$$A$F$Y$$$20250919$$CN$US$US
258203331$25820333$1$I$$20250915$20250919$20250919$PER$$US-BEH-2025219093$CSL BEHRING$$$$E$M$Y$$$20250919$$CN$US$US
258203621$25820362$1$I$$20250915$20250919$20250919$EXP$$SA-ANIPHARMA-030575$ANI$$35$YR$A$F$Y$$$20250919$$HP$SA$SA
258203901$25820390$1$I$20250908$20250909$20250919$20250919$EXP$$AR-ELI_LILLY_AND_COMPANY-AR202509014473$ELI LILLY AND COMPANY$$50$YR$A$M$Y$$$20250919$$CN$EU$AR
258204141$25820414$1$I$$20250818$20250919$20250919$PER$$US-GSK-US2025AMR107497$GLAXOSMITHKLINE$$$$$M$Y$$$20250918$$$US$US
258205521$25820552$1$I$$20250910$20250919$20250919$PER$$US-TEVA-VS-3372451$TEVA$$62$YR$$F$Y$$$20250919$$HP$US$US
258205831$25820583$1$I$$20250915$20250919$20250919$EXP$$US-ASTRAZENECA-202509USA011588US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250919$$$US$US
258206501$25820650$1$I$20250101$20250911$20250919$20250919$PER$$US-AMGEN-USASP2025182859$AMGEN$$67$YR$E$M$Y$$$20250919$$CN$US$US
258206511$25820651$1$I$$20250908$20250919$20250919$PER$$US-SMPA-2025SPA011607$SUNOVION$$71$YR$$M$Y$$$20250917$$$US$US
258207701$25820770$1$I$$20250911$20250919$20250919$PER$$US-SA-2025SA277098$SANOFI AVENTIS$$$$A$F$Y$$$20250919$$HP$US$US
258208311$25820831$1$I$$20250909$20250919$20250919$EXP$$CA-AUROBINDO-AUR-APL-2025-047288$AUROBINDO$$38$YR$$M$Y$$$20250919$$HP$CA$CA
258210481$25821048$1$I$$20250909$20250919$20250919$EXP$$CA-AUROBINDO-AUR-APL-2025-047353$AUROBINDO$$86$YR$$M$Y$90$KG$20250919$$PH$CA$CA
258211171$25821117$1$I$20250111$20250319$20250919$20250919$EXP$$AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2025-03437$ALKEM$$52$YR$$F$Y$$$20250919$$HP$AU$AU
258211381$25821138$1$I$$20250317$20250919$20250919$EXP$$JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2025-02885$ALKEM$Fukuya Y, Funatogawa T, Inoue A, Yamaguchi T, Katagiri N, Nemoto T. Parkinsonism induced by Duloxetine in a patient with Schizoafective disorder: A case report.. Psychiatry Research Case Reports. 2022;1:100004$41$YR$$M$Y$$$20250919$$HP$JP$JP
258211421$25821142$1$I$$20250723$20250919$20250919$EXP$$CA-ALKEM LABORATORIES LIMITED-CA-ALKEM-2025-07853$ALKEM$Rosenblat JD, Leon-Carlyle M, Ali, Husain MI, McIntyre RS.. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. Am J Psychiatry. 2023;180(5):395-396$45$YR$$M$Y$$$20250919$$MD$CA$CA
258213241$25821324$1$I$20250819$20250916$20250919$20250919$EXP$$CN-SANDOZ INC.-SDZ2025CN067866$SANDOZ$$53$YR$$F$Y$69.5$KG$20250919$$HP$CN$CN
258213541$25821354$1$I$$20250915$20250919$20250919$PER$$US-ABBVIE-6463463$ABBVIE$$$$E$F$Y$$$20250919$$CN$US$US
258213711$25821371$1$I$$20250909$20250919$20250919$PER$$US-SMPA-2025SPA011728$SUNOVION$$68$YR$$M$Y$$$20250917$$$US$US
258214141$25821414$1$I$$20250909$20250919$20250919$EXP$$US-GSK-US2025AMR116344$GLAXOSMITHKLINE$$$$$F$Y$$$20250919$$$US$US
258214411$25821441$1$I$$20250916$20250919$20250919$EXP$$CA-TAKEDA-2025TUS054493$TAKEDA$$$$$F$Y$$$20250919$$$CA$US
258214921$25821492$1$I$$20250916$20250919$20250919$EXP$$EU-SANDOZ INC.-SDZ2025IT068078$SANDOZ$$$$$F$Y$$$20250919$$MD$EU$EU
258215551$25821555$1$I$20250915$20250915$20250919$20250919$PER$$US-EMD Serono-2025047543$EMD SERONO INC$$41$YR$A$F$Y$$$20250919$$$US$US
258215631$25821563$1$I$20250414$20250414$20250919$20250919$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-505069$RANBAXY$$$$$F$Y$$$20250919$$CN$US$US
258216271$25821627$1$I$$20250910$20250919$20250919$EXP$$CN-STRIDES ARCOLAB LIMITED-2025OS000716$Onesource Specialty Pharma$Wang R, Li N, Tian J, Zeng X.. Amnesia and sensation disorders induced by the combination of midazolam and fentanyl.. Advers-Drug-React-J. 2025;27 (7):443-445$62$YR$$F$Y$45$KG$20250919$$HP$CN$CN
258216311$25821631$1$I$$20250909$20250919$20250919$EXP$$US-KENVUE-20250906596$Kenvue$$$$$F$Y$$$20250919$$CN$US$US
258217181$25821718$1$I$20250701$20250916$20250919$20250919$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010350$ACADIA PHARMACEUTICALS$$79$YR$$M$Y$$$20250919$$CN$US$US
258218261$25821826$1$I$$20250916$20250919$20250919$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-010328$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250919$$CN$US$US
258218351$25821835$1$I$$20250918$20250919$20250919$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-128917$BRISTOL-MYERS SQUIBB COMPANY$$77$YR$E$M$Y$$$20250919$$$US$US
258218501$25821850$1$I$$20250909$20250919$20250919$PER$$US-SMPA-2025SPA010781$SUNOVION$$74$YR$$M$Y$$$20250918$$$US$US
258218671$25821867$1$I$$20250912$20250919$20250919$EXP$$IN-ROCHE-10000336227$ROCHE$$67$YR$E$M$Y$70$KG$20250919$$CN$IN$IN
258219531$25821953$1$I$20250101$20250912$20250919$20250919$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-128599$ZYDUS PHARM$$$$$$Y$$$20250919$$CN$US$US
258219911$25821991$1$I$$20250916$20250919$20250919$EXP$$US-NOVITIUMPHARMA-2025USNVP02388$NOVITIUM PHARMA$Maria Barbara Grimberg.Diagnosing Neurosyphilis in Patients Taking Immune Suppressive Medications: A Cautionary Tale.Neurology 2025.08-APR-2025;104 (7_Supplement_1):NA$38$YR$A$F$Y$$$20250919$$HP$US$US
258220601$25822060$1$I$$20240916$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001133$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258220821$25822082$1$I$20240901$20241003$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001203$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258221121$25822112$1$I$$20241009$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001237$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258221352$25822135$2$F$20241011$20241014$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001250$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258221471$25822147$1$I$$20241008$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001224$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258222381$25822238$1$I$$20241108$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001355$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258223281$25822328$1$I$$20240813$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001014$VIVUS$$$$$$Y$$$20250902$$CN$US$US
258223991$25822399$1$I$20250701$20250916$20250919$20250919$PER$$US-ELI_LILLY_AND_COMPANY-US202509016797$ELI LILLY AND COMPANY$$$$$$Y$$$20250919$$MD$US$US
258224621$25822462$1$I$20250910$20250917$20250919$20250919$EXP$GB-MHRA-MED-202509121910103780-BYQSF$GB-ATNAHS-2025-PMNV-GB000874$Atnahs Healthcare$$$$$$Y$$$20250919$$CN$GB$GB
258225131$25822513$1$I$$20250905$20250919$20250919$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-527796$RANBAXY$Khosla H, Soliman S, Rafaeli N, Alam ST, Rios A. Patients With Lymphoma Requiring Colectomy. Clin Lymphoma Myeloma Leuk. 2025;25 (Suppl.):S772-S773;ABCL-968$33$YR$$M$Y$$$20250919$$MD$US$US
258225221$25822522$1$I$$20250904$20250919$20250919$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-527562$RANBAXY$Conti MA, Angelozzi A, Serra P, Imparato L, De Remigis F, Santarelli F. MULTIMODALITY APPROACH IN THE TREATMENT OF AN ARRHYTHMIC STORM. Eur Heart J Suppl. 2025;27 (Suppl.):v44-v45$74$YR$$F$Y$$$20250919$$HP$EU$EU
258225271$25822527$1$I$$20250102$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000007$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258225441$25822544$1$I$$20250424$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000049$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258226141$25822614$1$I$$20250506$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000092$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258226451$25822645$1$I$$20250530$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000209$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258226471$25822647$1$I$$20250530$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000211$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258226731$25822673$1$I$$20250604$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000226$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258228271$25822827$1$I$$20250707$20250919$20250919$EXP$$US-VIVUS LLC-2025V10000377$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258228981$25822898$1$I$$20241223$20250919$20250919$EXP$$US-VIVUS LLC-2024V1001569$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258229181$25822918$1$I$$20250912$20250919$20250919$EXP$$CA-TEVA-VS-3373127$TEVA$$83$YR$$F$Y$$$20250919$$HP$CA$CA
258229671$25822967$1$I$$20250909$20250919$20250919$EXP$$US-KENVUE-20250905890$Kenvue$$$$$$Y$$$20250919$$CN$US$US
258229761$25822976$1$I$20250609$20250917$20250919$20250919$EXP$$US-ASTRAZENECA-202509USA014318US$ALEXION PHARMACEUTICALS$$72$YR$E$F$Y$$$20250919$$$US$US
258230591$25823059$1$I$20250907$20250909$20250919$20250919$PER$$US-TAKEDA-2025TUS079455$TAKEDA$$11$YR$$F$Y$46.03$KG$20250919$$PH$US$US
258230951$25823095$1$I$$20250908$20250919$20250919$EXP$$CO-AUROBINDO-AUR-APL-2025-046879$AUROBINDO$Monica De Avila-Gomez M, Bayona-Pedraza JM, Upegui-Jimenez D, Benavides-Cruz J.. Hepatotoxicity due to chemotherapy in magnetic resonance imaging: experience in a health institution in Colombia. Austral-J-imaging. 2025;31 (1):18-23$76$YR$$F$Y$$$20250919$$HP$CO$CO
258231111$25823111$1$I$$20250916$20250919$20250919$EXP$$GB-MYLANLABS-2025M1079677$MYLAN$$$$$F$Y$$$20250918$$$GB$GB
258231811$25823181$1$I$$20250913$20250919$20250919$PER$$US-AMGEN-USASP2025184065$AMGEN$$$$A$$Y$$$20250919$$CN$US$US
258232081$25823208$1$I$$20250915$20250919$20250919$PER$$US-ROCHE-10000389141$ROCHE$$$$E$F$Y$$$20250919$$CN$US$US
258232321$25823232$1$I$$20250109$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000046$VIVUS$$$$$$Y$$$20250902$$CN$US$US
258232421$25823242$1$I$$20250117$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000098$VIVUS$$$$$$Y$$$20250902$$CN$US$US
258232731$25823273$1$I$$20250909$20250919$20250919$EXP$$US-KENVUE-20250906578$Kenvue$$$$$$Y$$$20250919$$CN$US$US
258233641$25823364$1$I$$20250205$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000202$VIVUS$$$$$F$Y$$$20250902$$CN$US$US
258233711$25823371$1$I$$20250204$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000193$VIVUS$$$$$F$Y$$$20250902$$CN$US$US
258233801$25823380$1$I$$20250206$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000218$VIVUS$$$$$F$Y$$$20250902$$CN$US$US
258234071$25823407$1$I$$20250129$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000170$VIVUS$$$$$$Y$$$20250902$$CN$US$US
258234231$25823423$1$I$$20250312$20250919$20250919$EXP$$US-VIVUS LLC-2025V1000416$VIVUS$$$$$$Y$$$20250903$$CN$US$US
258234571$25823457$1$I$$20250908$20250919$20250919$EXP$$US-AUROBINDO-AUR-APL-2025-046644$AUROBINDO$Janakiram M, Liu L, Goldsmith S, Borogovac A, Lee S, Nathwani N, et al.. GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series. Blood Cancer Journal. 2025;15No. 1:135$$$A$F$Y$$$20250919$$HP$US$US
258234751$25823475$1$I$$20250918$20250919$20250919$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-128919$BRISTOL-MYERS SQUIBB COMPANY$$82$YR$E$F$Y$$$20250919$$$US$US
258234991$25823499$1$I$20250915$20250918$20250918$20250918$DIR$FDA-CDER-CTU-2025-62566$$FDA-CTU$$83$YR$$M$N$80$KG$20250918$Y$PH$US$
258235431$25823543$1$I$20210715$20250910$20250919$20250919$EXP$$CA-JNJFOC-20250915918$JOHNSON AND JOHNSON$$60$YR$A$F$Y$$$20250919$$HP$CA$CA
258236161$25823616$1$I$20250815$20250915$20250919$20250919$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010280$ACADIA PHARMACEUTICALS$$81$YR$$M$Y$$$20250919$$CN$US$US
258236451$25823645$1$I$$20250916$20250919$20250919$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010399$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250919$$CN$US$US
258237191$25823719$1$I$$20250917$20250919$20250919$PER$$US-BAYER-2025A124553$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250919$$MD$US$US
258237481$25823748$1$I$20250905$20250905$20250919$20250919$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-03481$AMNEAL$$92$YR$$F$Y$$$20250919$$CN$US$US
258237621$25823762$1$I$20231119$20250918$20250918$20250918$DIR$775934$$FDA-CTU$$37$YR$$F$N$54$KG$20250918$N$CN$US$
258237861$25823786$1$I$20190614$20250904$20250919$20250919$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-528215$RANBAXY$$24$YR$$M$Y$77$KG$20250919$$CN$GB$GB
258238072$25823807$2$F$$20250916$20250919$20250922$EXP$$EU-JNJFOC-20250913636$JOHNSON AND JOHNSON$$52$YR$A$M$Y$$$20250922$$HP$EU$EU
258238101$25823810$1$I$$20250913$20250919$20250919$PER$$US-CHATTEMPRD-2025OHG027892$CHATTEM$$$$$$Y$$$20250919$$CN$US$US
258238891$25823889$1$I$$20250910$20250919$20250919$PER$$US-MYLANLABS-2025M1077964$MYLAN$$$$$F$Y$$$20250919$$$US$US
258239091$25823909$1$I$$20250804$20250919$20250919$EXP$$NZ-SANDOZ INC.-SDZ2025NZ067759$SANDOZ$$$$$$Y$$$20250919$$CN$NZ$NZ
258239591$25823959$1$I$$20250916$20250919$20250919$EXP$$US-TAKEDA-2025TUS082211$TAKEDA$$$$$F$Y$$$20250919$$$US$US
258239631$25823963$1$I$20250101$20250917$20250919$20250919$EXP$$US-ABBVIE-6465701$ABBVIE$$51$YR$$F$Y$$$20250919$$CN$US$US
258240291$25824029$1$I$$20250909$20250919$20250919$PER$$US-ALKERMES INC.-ALK-2025-002484$ALKERMES$$$$$M$Y$98$KG$20250919$$PH$US$
258241061$25824106$1$I$20250914$20250915$20250919$20250919$PER$$US-ELI_LILLY_AND_COMPANY-US202509015140$ELI LILLY AND COMPANY$$68$YR$E$F$Y$$$20250919$$CN$US$US
258241341$25824134$1$I$20250828$20250910$20250919$20250919$DIR$FDA-CDER-CTU-2025-62648$$FDA-CTU$$69$YR$$F$N$170$LBS$20250910$N$CN$US$
258241461$25824146$1$I$20241101$20250908$20250919$20250919$EXP$$US-NOVOPROD-1519505$NOVO NORDISK$$$$E$F$Y$$$20250919$$CN$US$US
258243551$25824355$1$I$20250101$20250912$20250919$20250919$PER$$US-SA-2025SA250805$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250919$$HP$US$US
258243661$25824366$1$I$20250101$20250912$20250919$20250919$PER$$US-SA-2025SA279536$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250919$$HP$US$US
258244112$25824411$2$F$$20250916$20250919$20250923$PER$$US-SA-2025SA278913$SANOFI AVENTIS$$55$YR$A$M$Y$$$20250923$$CN$US$US
258245631$25824563$1$I$20250101$20250915$20250919$20250919$PER$$US-SA-2025SA279301$SANOFI AVENTIS$$80$YR$E$F$Y$$$20250919$$HP$US$US
258246451$25824645$1$I$20250101$20250915$20250919$20250919$PER$$US-SA-2025SA279665$SANOFI AVENTIS$$50$YR$A$M$Y$$$20250919$$HP$US$US
258246811$25824681$1$I$$20250909$20250919$20250919$EXP$$US-MARINUS PHARMACEUTICALS, INC.-MAR2025000214$MARINUS PHARMACEUTICALS$$$$$$Y$$$20250919$$CN$US$US
258247181$25824718$1$I$$20250909$20250919$20250919$EXP$$CA-AUROBINDO-AUR-APL-2025-047390$AUROBINDO$$54$YR$$M$Y$94$KG$20250919$$HP$CA$CA
258247301$25824730$1$I$$20250707$20250919$20250919$PER$$US-TRAVERE-2025TVT01118$TRAVERE THERAPEUTICS$$$$$M$Y$$$20250919$$CN$US$US
258247901$25824790$1$I$20250912$20250919$20250919$20250919$DIR$776071$$FDA-CTU$$20$YR$$F$N$$$20250919$N$$US$
258248431$25824843$1$I$$20250919$20250919$20250919$DIR$776060$$FDA-CTU$$$$$M$N$$$20250919$N$HP$US$
258249811$25824981$1$I$$20250916$20250919$20250919$PER$$US-AMGEN-USASP2025186899$AMGEN$$$$E$F$Y$$$20250919$$MD$US$US
258251031$25825103$1$I$$20250909$20250919$20250919$PER$$US-LGM Pharma Solutions, LLC-2184878$LGM PHARMA SOLUTIONS, LLC$$$$$F$Y$$$20250919$$$A1$US
258251851$25825185$1$I$$20250910$20250919$20250919$PER$$US-TEVA-VS-3371721$TEVA$$$$$M$Y$$$20250919$$HP$US$US
258252391$25825239$1$I$$20250919$20250919$20250919$DIR$FDA-CDER-CTU-2025-62785$$FDA-CTU$$57$YR$$M$N$$$20250919$N$CN$US$
258252541$25825254$1$I$20250901$20250916$20250919$20250919$EXP$$CA-Taiho Oncology Inc-2025-010050$TAIHO ONCOLOGY INC$$54$YR$A$M$Y$$$20250919$$CN$CA$CA
258252951$25825295$1$I$20250401$20250911$20250919$20250919$EXP$$JP-JNJFOC-20250929910$JOHNSON AND JOHNSON$$69$YR$E$M$Y$$$20250919$$PH$JP$JP
258253291$25825329$1$I$$20250916$20250919$20250919$EXP$$JP-Eisai-EC-2025-196907$EISAI$$$$$F$Y$$$20250919$$MD$JP$JP
258253351$25825335$1$I$20250901$20250910$20250919$20250919$EXP$$US-UCBSA-2025058052$UCB$$19$YR$$F$Y$$$20250919$$HP$US$US
258254611$25825461$1$I$20250909$20250916$20250919$20250919$EXP$$CN-PFIZER INC-PV202500111905$PFIZER$$70$YR$$F$Y$60$KG$20250919$$HP$CN$CN
258255111$25825511$1$I$20250701$20250915$20250919$20250919$PER$$US-SA-2025SA279863$SANOFI AVENTIS$$44$YR$A$F$Y$$$20250919$$HP$US$US
258255151$25825515$1$I$$20250909$20250919$20250919$EXP$$US-KENVUE-20250907559$Kenvue$$$$$$Y$$$20250919$$CN$US$US
258255361$25825536$1$I$$20250915$20250919$20250919$EXP$$GB-MYLANLABS-2025M1046048$MYLAN$$30$YR$$M$Y$$$20250919$$PH$GB$GB
258255621$25825562$1$I$$20250909$20250919$20250919$EXP$GB-MHRA-MED-202509090926171850-CJFLN$GB-ELI_LILLY_AND_COMPANY-GB202509009379$ELI LILLY AND COMPANY$$$$$F$Y$$$20250919$$CN$GB$GB
258256121$25825612$1$I$20250801$20250916$20250919$20250919$EXP$$US-ABBVIE-6466597$ABBVIE$$72$YR$$F$Y$$$20250919$$CN$US$US
258257451$25825745$1$I$20240701$20241127$20250919$20250919$PER$$US-PERRIGO-24US011151$GALPHARM INTERNATIONAL$$77$YR$$F$Y$74.83$KG$20250919$$CN$US$US
258257801$25825780$1$I$$20250916$20250919$20250919$EXP$$US-PFIZER INC-202500184806$PFIZER$Cuzzo, B.. Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant.. Blood Neoplasia. 2025;2(2):100094:10.1016/j.bneo.2025.100094$69$YR$$$Y$$$20250919$$HP$US$US
258258191$25825819$1$I$20080101$20250918$20250919$20250919$EXP$$CA-ORGANON-O2503CAN002653$ORGANON$$$$$M$Y$$$20250919$$LW$CA$CA
258258631$25825863$1$I$$20250918$20250919$20250919$PER$$US-ASTRAZENECA-202509USA015288US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250919$$$US$US
258258831$25825883$1$I$$20250903$20250919$20250919$PER$$US-MALLINCKRODT-MNK202505547$MALLINCKRODT$$$$$F$Y$$$20250918$$CN$US$US
258258881$25825888$1$I$20240510$20250912$20250919$20250919$EXP$$US-MALLINCKRODT-MNK202505803$MALLINCKRODT$$$$$$Y$$$20250918$$HP$US$US
258258961$25825896$1$I$20250911$20250912$20250919$20250919$EXP$$US-MALLINCKRODT-MNK202505797$MALLINCKRODT$$$$N$M$Y$$$20250919$$HP$US$US
258259061$25825906$1$I$20250801$20250910$20250919$20250919$EXP$$US-UCBSA-2025057437$UCB$$55$YR$$F$Y$$$20250919$$HP$US$US
258259441$25825944$1$I$$20250915$20250919$20250919$EXP$$EU-REGENERON PHARMACEUTICALS, INC.-2025-148220$REGENERON$Oelbrandt F, Marignier R, Dubois B. Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab. Clinical Neurology and Neurosurgery. 2025;257:109120:1-3$54$YR$$F$Y$$$20250919$$MD$EU$EU
258260181$25826018$1$I$20250729$20250729$20250919$20250919$PER$$US-Armstrong Pharmaceuticals, Inc.-2184904$ARMSTRONG PHARMACEUTICALS, INC.$$$$$F$Y$$$20250919$$$US$US
258260821$25826082$1$I$20240801$20250613$20250919$20250919$PER$$US-HARROW-HAR-2025-US-00300$Harrow Health$$72$YR$$M$Y$$$20250919$$CN$US$
258261001$25826100$1$I$20250101$20250908$20250919$20250919$PER$$US-SERVIER-S25013221$SERVIER$$$$$$Y$$$20250919$$PH$US$US
258261671$25826167$1$I$$20250916$20250919$20250919$EXP$$US-ABBVIE-6464698$ABBVIE$$$$E$M$Y$$$20250919$$CN$US$US
258262441$25826244$1$I$$20250917$20250919$20250919$EXP$$US-ABBVIE-6465588$ABBVIE$$64$YR$$F$Y$$$20250919$$CN$US$US
258263121$25826312$1$I$$20250909$20250919$20250919$EXP$$US-KENVUE-20250908800$Kenvue$$$$$$Y$$$20250920$$CN$US$US
258263291$25826329$1$I$$20250915$20250919$20250919$PER$$US-SA-2025SA279286$SANOFI AVENTIS$$12$YR$T$M$Y$$$20250920$$CN$US$US
258263521$25826352$1$I$$20250910$20250920$20250920$EXP$$US-KENVUE-20250909808$Kenvue$$$$$F$Y$$$20250920$$CN$US$US
258263781$25826378$1$I$$20250915$20250920$20250920$EXP$$EU-ABBVIE-6465374$ABBVIE$$$$$F$Y$$$20250920$$MD$EU$EU
258264131$25826413$1$I$20250101$20250917$20250920$20250920$EXP$$EU-ABBVIE-6467623$ABBVIE$$49$YR$$M$Y$$$20250920$$CN$EU$EU
258264391$25826439$1$I$$20250910$20250920$20250920$EXP$$US-KENVUE-20250909531$Kenvue$$$$$$Y$$$20250920$$CN$US$US
258265351$25826535$1$I$20250801$20250910$20250920$20250920$EXP$$IL-RECORDATI RARE DISEASE INC.-2025006496$RECORDATI$$86$YR$$M$Y$$$20250920$$MD$IL$IL
258265391$25826539$1$I$$20250918$20250920$20250920$PER$$US-ASTRAZENECA-202509USA015337US$ALEXION PHARMACEUTICALS$$$$E$M$Y$$$20250920$$MD$US$US
258265551$25826555$1$I$$20250909$20250920$20250920$PER$$US-ABBVIE-6455411$ABBVIE$$$$$$Y$$$20250920$$CN$US$US
258266771$25826677$1$I$20250101$20250916$20250920$20250920$EXP$$US-ABBVIE-6465217$ABBVIE$$59$YR$$M$Y$$$20250920$$CN$US$US
258267021$25826702$1$I$20241001$20250916$20250920$20250920$EXP$$JP-ABBVIE-5991766$ABBVIE$$70$YR$$F$Y$40$KG$20250920$$CN$JP$JP
258267182$25826718$2$F$$20250918$20250920$20250926$EXP$$CA-CELLTRION INC.-2025CA028098$CELLTRION$$$$$$Y$$$20250926$$CN$CA$CA
258267711$25826771$1$I$20250613$20250917$20250920$20250920$EXP$$US-ABBVIE-6403660$ABBVIE$$57$YR$$M$Y$134$KG$20250920$$CN$US$US
258268351$25826835$1$I$$20250908$20250920$20250920$EXP$$US-AUROBINDO-AUR-APL-2025-046588$AUROBINDO$He S, Davick J, Rastogi P, Kuppachi S. Primary Ewing Sarcoma Within an Autosomal Dominant Polycystic Kidney:A Case Report. Kidney-Med. 2025;Vol 7 | Iss 9:101064$44$YR$$M$Y$$$20250920$$MD$US$US
258268481$25826848$1$I$$20250917$20250920$20250920$EXP$$EU-ABBVIE-6468718$ABBVIE$$$$E$M$Y$$$20250920$$MD$EU$EU
258269491$25826949$1$I$20250831$20250908$20250920$20250920$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-03530$AMNEAL$$80$YR$$F$Y$$$20250920$$CN$US$US
258270131$25827013$1$I$20220301$20250909$20250920$20250920$EXP$$AE-MACLEODS PHARMA-MAC2023043081$MACLEODS$Anouassi Z, Abril C, Ismail G, El Nekidy WS, Al-Hadeethi A, Bafadel A, et al..A Case of Hemorrhagic Cholecystitis in a Patient on Apixaban After COVID-19 Infection.American Journal of Case Reports.2023;24:e939677$$$$$Y$$$20250920$$PH$AE$AE
258270761$25827076$1$I$$20250910$20250920$20250920$EXP$$US-UCBSA-2025057330$UCB$$$$$M$Y$131.5$KG$20250920$$HP$US$US
258270981$25827098$1$I$$20250910$20250920$20250920$EXP$$NVSC2025GR143366$NOVARTIS$$$$$$Y$$$20250920$$MD$EU$EU
258271262$25827126$2$F$$20250923$20250920$20250930$EXP$$CA-TLM-TLM-2025-06897$TOLMAR$$$$E$M$Y$$$20250929$$MD$CA$CA
258271381$25827138$1$I$20250101$20250916$20250920$20250920$PER$$US-SA-2025SA279603$SANOFI AVENTIS$$33$YR$A$M$Y$$$20250920$$CN$US$US
258272431$25827243$1$I$$20250630$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00378$Harrow Health$$$$$F$Y$$$20250920$$CN$US$
258272981$25827298$1$I$20250530$20250701$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00386$Harrow Health$$74$YR$E$F$Y$$$20250920$$CN$US$US
258273011$25827301$1$I$20250601$20250701$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00387$Harrow Health$$76$YR$$F$Y$$$20250920$$CN$US$US
258273292$25827329$2$F$$20250911$20250920$20250926$EXP$$CA-ASTRAZENECA-202508CAN011621CA$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250926$$$CA$CA
258273501$25827350$1$I$20250101$20250917$20250920$20250920$EXP$$US-ABBVIE-6466567$ABBVIE$$68$YR$$F$Y$$$20250920$$CN$US$US
258274031$25827403$1$I$$20250725$20250920$20250920$PER$$US-TRAVERE-2025TVT01290$TRAVERE THERAPEUTICS$$$$$F$Y$$$20250920$$CN$US$US
258274661$25827466$1$I$$20250715$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00474$Harrow Health$$75$YR$E$F$Y$$$20250919$$CN$US$
258274781$25827478$1$I$$20250917$20250920$20250920$EXP$$CA-TEVA-VS-3374066$TEVA$$71$YR$$M$Y$$$20250920$$CN$CA$CA
258275311$25827531$1$I$20250723$20250725$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00531$Harrow Health$$80$YR$E$F$Y$$$20250920$$CN$US$
258275381$25827538$1$I$$20250725$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00535$Harrow Health$$$$$F$Y$$$20250920$$CN$US$
258275691$25827569$1$I$20250525$20250728$20250920$20250920$PER$$US-HARROW-HAR-2025-US-00547$Harrow Health$$81$YR$E$F$Y$$$20250920$$CN$US$
258276171$25827617$1$I$$20250916$20250921$20250921$PER$$US-SA-2025SA280548$SANOFI AVENTIS$$$$E$F$Y$$$20250921$$MD$US$US
258276321$25827632$1$I$$20250805$20250921$20250921$PER$$US-HARROW-HAR-2025-US-00602$Harrow Health$$$$$F$Y$$$20250920$$CN$US$
258276681$25827668$1$I$$20250917$20250921$20250921$PER$$US-ELI_LILLY_AND_COMPANY-US202509017737$ELI LILLY AND COMPANY$$$$$$Y$$$20250921$$CN$US$US
258277641$25827764$1$I$$20250910$20250921$20250921$EXP$$AU-GSK-AU2025117096$GLAXOSMITHKLINE$$35$YR$$F$Y$$$20250921$$MD$AU$AU
258277731$25827773$1$I$20250807$20250915$20250921$20250921$PER$$US-009507513-2318211$MERCK SHARP + DOHME LLC$$16$YR$$M$Y$$$20250921$$HP$US$US
258278061$25827806$1$I$$20250916$20250921$20250921$PER$$US-SA-2025SA280479$SANOFI AVENTIS$$12$YR$T$M$Y$$$20250921$$CN$US$US
258279091$25827909$1$I$$20250812$20250921$20250921$PER$$US-TRAVERE-2025TVT01423$TRAVERE THERAPEUTICS$$$$$F$Y$$$20250921$$MD$US$US
258279111$25827911$1$I$$20250910$20250921$20250921$PER$$US-ELI_LILLY_AND_COMPANY-US202509010488$ELI LILLY AND COMPANY$$15$YR$T$F$Y$$$20250921$$CN$US$US
258279211$25827921$1$I$$20250808$20250921$20250921$PER$$US-HARROW-HAR-2025-US-00640$Harrow Health$$$$$F$Y$$$20250920$$CN$US$
258279271$25827927$1$I$20250809$20250819$20250921$20250921$PER$$US-HARROW-HAR-2025-US-00649$Harrow Health$$73$YR$$F$Y$$$20250920$$CN$US$
258279381$25827938$1$I$$20250813$20250921$20250921$PER$$US-TRAVERE-2025TVT01426$TRAVERE THERAPEUTICS$$$$$F$Y$$$20250921$$CN$US$US
258279961$25827996$1$I$20220101$20250916$20250921$20250921$EXP$$TH-009507513-2331344$MERCK SHARP + DOHME LLC$$28$YR$$M$Y$$$20250921$$MD$TH$TH
258281461$25828146$1$I$20250101$20250827$20250921$20250921$PER$$US-GALDERMA-US2025016379$GALDERMA$$$$$$Y$$$20250921$$CN$US$US
258281761$25828176$1$I$20250303$20250825$20250921$20250921$PER$$US-HARROW-HAR-2025-US-00787$Harrow Health$$66$YR$E$F$Y$$$20250919$$CN$US$
258282191$25828219$1$I$$20250828$20250921$20250921$PER$$US-HARROW-HAR-2025-US-00820$Harrow Health$$$$$F$Y$$$20250919$$CN$US$
258282881$25828288$1$I$20240701$20250916$20250921$20250921$EXP$$CO-ABBVIE-6354167$ABBVIE$$53$YR$$F$Y$85$KG$20250921$$CN$CO$CO
258285641$25828564$1$I$$20250917$20250922$20250922$PER$$US-ROCHE-10000392140$ROCHE$$$$A$F$Y$$$20250922$$MD$US$US
258285991$25828599$1$I$$20250903$20250922$20250922$EXP$$US-GSK-US2025113792$GLAXOSMITHKLINE$$$$$F$Y$$$20250919$$$US$US
258286631$25828663$1$I$$20250916$20250922$20250922$PER$$US-SA-2025SA280441$SANOFI AVENTIS$$21$YR$A$F$Y$$$20250922$$CN$US$US
258286871$25828687$1$I$20250901$20250910$20250922$20250922$EXP$GB-MHRA-MED-202509101100572160-QCRNL$GB-Accord-504655$ACCORD$$50$YR$A$F$Y$$$20250922$$PH$GB$GB
258287511$25828751$1$I$$20250915$20250922$20250922$PER$$US-JNJFOC-20250920200$JOHNSON AND JOHNSON$$61$YR$A$F$Y$$$20250922$$CN$US$US
258287711$25828771$1$I$$20250908$20250922$20250922$EXP$$CA-GSK-CA2025AMR116202$GLAXOSMITHKLINE$$54$YR$$F$Y$$$20250922$$$CA$CA
258289021$25828902$1$I$$20250918$20250922$20250922$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-129438$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$81.65$KG$20250922$$$US$US
258290291$25829029$1$I$$20250730$20250922$20250922$PER$$US-TRAVERE-2025TVT01312$TRAVERE THERAPEUTICS$$$$$M$Y$$$20250922$$MD$US$US
258290941$25829094$1$I$$20250916$20250922$20250922$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010401$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250922$$CN$US$US
258291211$25829121$1$I$$20250909$20250922$20250922$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-03558$AMNEAL$$$$$M$Y$$$20250922$$CN$US$US
258291901$25829190$1$I$$20250916$20250922$20250922$PER$$US-ELI_LILLY_AND_COMPANY-US202509016666$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250922$$CN$US$US
258292721$25829272$1$I$20250101$20250912$20250922$20250922$EXP$$GB-TEVA-VS-3373979$TEVA$$52$YR$$M$Y$$$20250922$$HP$GB$GB
258292831$25829283$1$I$$20250917$20250922$20250922$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-129262$BRISTOL-MYERS SQUIBB COMPANY$$65$YR$E$M$Y$$$20250922$$$US$US
258293841$25829384$1$I$$20250908$20250922$20250922$EXP$$US-IPCA LABORATORIES LIMITED-IPC-2025-US-002536$IPCA$Vo-Ba D, Steinhauer M, Mostagh-Sisan F, Hirabayashi E, Rahmanzai S, Luu A, Jacob J, et al.. Concurrent metformin and sulfonylurea toxicity due to acute urinary retention. Endocrine Practice. 2025;31:S161$$$$$Y$$$20250922$$HP$US$US
258293951$25829395$1$I$$20250916$20250922$20250922$PER$$US-ROCHE-10000390291$ROCHE$$$$$$Y$$$20250922$$CN$US$US
258295301$25829530$1$I$20250603$20250801$20250922$20250922$PER$$US-TRAVERE-2025TVT01337$TRAVERE THERAPEUTICS$$76$YR$E$M$Y$$$20250922$$MD$US$US
258296471$25829647$1$I$20250620$20250915$20250922$20250922$EXP$$EU-ROCHE-10000389792$ROCHE$$78$YR$E$F$Y$$$20250922$$MD$EU$EU
258297241$25829724$1$I$20240301$20250918$20250922$20250922$EXP$$EU-ASTELLAS-2025-AER-051731$ASTELLAS$$68$YR$E$M$Y$$$20250922$$MD$EU$EU
258297801$25829780$1$I$$20250918$20250922$20250922$EXP$$US-GSK-US2025AMR120281$GLAXOSMITHKLINE$$$$$F$Y$$$20250922$$$US$US
258298661$25829866$1$I$$20250916$20250922$20250922$PER$$US-SA-2025SA280717$SANOFI AVENTIS$$16$YR$T$F$Y$$$20250922$$HP$US$US
258299731$25829973$1$I$$20250919$20250922$20250922$EXP$$US-ASTRAZENECA-202509USA016568US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250922$$$US$US
258300801$25830080$1$I$$20250916$20250922$20250922$EXP$$AU-ASTELLAS-2025-AER-052232$ASTELLAS$Kerkham A, Weltman M, Jennings Z., Liem H. Disseminated Histoplasmosis as a Cause of a Small Bowel Mass and Cholestatic Liver Injury in an Immunocompetent Host: A Case Report. Case Reports in Gastroenterology. 2025;19(1):568-573. doi:10.1159/000545824$50$YR$A$M$Y$$$20250922$$HP$AU$AU
258301362$25830136$2$F$$20250923$20250922$20250930$EXP$$US-GSK-US2025AMR117193$GLAXOSMITHKLINE$$$$$F$Y$$$20250930$$$US$US
258301951$25830195$1$I$$20250915$20250922$20250922$EXP$$CA-TAKEDA-2024TUS092276$TAKEDA$$$$$M$Y$$$20250922$$MD$CA$CA
258302711$25830271$1$I$20210917$20250911$20250922$20250922$EXP$$EU-AUROBINDO-AUR-APL-2025-047048$AUROBINDO$$75$YR$$F$Y$$$20250922$$HP$EU$EU
258305181$25830518$1$I$$20250916$20250922$20250922$EXP$$US-CHEPLA-2025010996$CHEPLAPHARM$Gonzalez J, Avellan R, Barreto Lopez C, Bedran K, Del Pilar Bonilla L. Acute Meningitis/Encephalitis Presumably Secondary to Human Herpesvirus 6: A Case Report. Cureus part of Springer Nature.2025;7(8):e89609. doi: 10.7759/cureus.89609.$39$YR$$F$Y$$$20250922$$HP$COUNTRY NOT SPECIFIED$US
258305981$25830598$1$I$$20250916$20250922$20250922$PER$$US-SA-2025SA281677$SANOFI AVENTIS$$$$A$M$Y$117.73$KG$20250922$$MD$US$US
258306221$25830622$1$I$20250910$20250910$20250922$20250922$EXP$$EU-BAYER-2025A122970$BAYER HEALTHCARE PHARMACEUTICALS INC.$$70$YR$E$F$Y$$$20250922$$HP$EU$EU
258306721$25830672$1$I$20250908$20250919$20250922$20250922$EXP$$CN-ROCHE-10000393921$ROCHE$$44$YR$A$F$Y$$$20250922$$HP$CN$CN
258307871$25830787$1$I$20250901$20250915$20250922$20250922$EXP$$GB-MYLANLABS-2025M1079355$MYLAN$$$$A$M$Y$$$20250922$$MD$GB$GB
258308121$25830812$1$I$$20250917$20250922$20250922$PER$$US-SA-2025SA280947$SANOFI AVENTIS$$$$E$M$Y$$$20250922$$CN$US$US
258308661$25830866$1$I$$20250910$20250922$20250922$EXP$$US-KENVUE-20250909650$Kenvue$$$$$$Y$$$20250922$$CN$US$US
258308881$25830888$1$I$20250101$20250916$20250922$20250922$PER$$US-SA-2025SA280733$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250922$$HP$US$US
258309181$25830918$1$I$$20250910$20250922$20250922$EXP$$US-KENVUE-20250909439$Kenvue$$$$$F$Y$$$20250922$$CN$US$US
258309311$25830931$1$I$$20250918$20250922$20250922$PER$$US-SA-2025SA282715$SANOFI AVENTIS$$$$$$Y$$$20250922$$CN$US$US
258309531$25830953$1$I$$20250910$20250922$20250922$EXP$$US-KENVUE-20250909321$Kenvue$$$$$M$Y$$$20250922$$CN$US$US
258310032$25831003$2$F$$20250919$20250922$20250929$EXP$$CA-TAKEDA-2025TUS058397AA$TAKEDA$$63$YR$$F$Y$$$20250929$$$CA$CA
258310581$25831058$1$I$$20250918$20250919$20250919$DIR$FDA-CDER-CTU-2025-63045$$FDA-CTU$$51$YR$$F$N$$$20250918$N$$US$
258310651$25831065$1$I$$20250919$20250919$20250919$DIR$FDA-CDER-CTU-2025-62861$$FDA-CTU$$57$YR$$F$N$$$20250919$N$$US$
258310831$25831083$1$I$$20250911$20250922$20250922$EXP$$EU-PADAGIS-2025PAD01147$PADAGIS$Kluger N. A giant patch of dermatoporosis secondary to inappropriate topical corticosteroid use. Annales de Dermatologie et de V?n?r?ologie. 2025;152(2):103348$$$$$Y$$$20250922$$HP$EU$EU
258311001$25831100$1$I$20250701$20250812$20250922$20250922$EXP$$US-AMNEAL PHARMACEUTICALS-2025-AMRX-02507$AMNEAL$$$$$$Y$$$20250922$$CN$US$US
258311731$25831173$1$I$$20250919$20250919$20250919$DIR$FDA-CDER-CTU-2025-62859$$FDA-CTU$$73$YR$$F$N$$$20250919$N$CN$US$
258312391$25831239$1$I$20250828$20250912$20250922$20250922$EXP$$CN-PFIZER INC-202500183771$PFIZER$$72$YR$$M$Y$67$KG$20250922$$HP$CN$CN
258313031$25831303$1$I$20240401$20250912$20250922$20250922$EXP$$EU-EMD Serono-2025047105$EMD SERONO INC$Geni D, Irina N, Amanda C, Mihaela A. Unusual association between Multiple Sclerosis and Myasthenia Gravis ? A case report and systematic literature minireview. JOURNAL OF NEUROLOGY AND CHILD AND ADOLESCENT PSYCHIATRY IN ROMANIA. 2025;31(2): 43-45.$26$YR$A$F$Y$$$20250922$$MD$EU$EU
258313231$25831323$1$I$$20250917$20250922$20250922$PER$$US-SA-2025SA281468$SANOFI AVENTIS$$52$YR$A$M$Y$$$20250922$$MD$US$US
258314861$25831486$1$I$$20250909$20250922$20250922$EXP$$BR-NOVOPROD-1520439$NOVO NORDISK$$$$$M$Y$$$20250922$$CN$BR$BR
258316411$25831641$1$I$$20250919$20250919$20250919$DIR$776148$$FDA-CTU$$$$$M$N$$$20250919$N$$US$
258316671$25831667$1$I$20250808$20250918$20250922$20250922$PER$$US-SA-2025SA282172$SANOFI AVENTIS$$63$YR$A$F$Y$$$20250922$$CN$US$US
258317062$25831706$2$F$$20250919$20250922$20250922$PER$$US-PFIZER INC-202500184679$PFIZER$$25$YR$$M$Y$$$20250922$$HP$US$US
258317081$25831708$1$I$$20250918$20250922$20250922$PER$$US-PFIZER INC-202500186492$PFIZER$$$$A$F$Y$$$20250922$$HP$US$US
258317341$25831734$1$I$20250821$20250916$20250922$20250922$EXP$EU-AFSSAPS-BX2025001391$EU-009507513-2330673$MERCK SHARP + DOHME LLC$$72$YR$$M$Y$68$KG$20250922$$PH$EU$EU
258317361$25831736$1$I$20250903$20250909$20250922$20250922$EXP$$US-NOVOPROD-1522002$NOVO NORDISK$$46$YR$$F$Y$$$20250922$$CN$US$US
258317601$25831760$1$I$20250701$20250918$20250922$20250922$EXP$EU-AFSSAPS-BX2025001430$EU-PFIZER INC-202500184353$PFIZER$$56$YR$$M$Y$$$20250922$$MD$EU$EU
258318451$25831845$1$I$20250902$20250921$20250921$20250921$DIR$776493$$FDA-CTU$$58$YR$$M$N$58.5$KG$20250921$N$HP$US$
258319791$25831979$1$I$$20250916$20250922$20250922$EXP$$US-SA-2025SA202354$SANOFI AVENTIS$$$$A$F$Y$56.82$KG$20250922$$HP$US$US
258320101$25832010$1$I$20250101$20250911$20250922$20250922$EXP$$US-UCBSA-2025058338$UCB$$$$$F$Y$$$20250922$$HP$US$US
258320561$25832056$1$I$$20250919$20250919$20250919$DIR$776239$$FDA-CTU$$$$$F$N$$$20250919$N$$US$
258320621$25832062$1$I$20250902$20250919$20250919$20250919$DIR$776262$$FDA-CTU$$47$YR$$F$N$$$20250919$N$CN$US$
258321341$25832134$1$I$$20250918$20250922$20250922$EXP$$US-PFIZER INC-202500186317$PFIZER$$53$YR$$F$Y$$$20250922$$HP$US$US
258322221$25832222$1$I$$20250919$20250919$20250919$DIR$776332$$FDA-CTU$$$$$F$N$$$20250919$N$CN$US$
258322251$25832225$1$I$$20250922$20250922$20250922$DIR$776511$$FDA-CTU$$$$$$N$$$20250922$N$CN$US$
258323821$25832382$1$I$$20250908$20250922$20250922$EXP$$RU-TAKEDA-2025TUS080166$TAKEDA$$27$YR$$M$Y$$$20250922$$$RU$RU
258324092$25832409$2$F$$20250919$20250922$20250925$EXP$$US-PFIZER INC-202500185052$PFIZER$Sharma, N.. SOX1-Positive Encephalitis Presenting as New-Onset Refractory Status Epilepticus (NORSE): A Rare Paraneoplastic Manifestation ; : abstr. P3-8.012.. Neurology. 2025;104(Suppl.1)(7):3-8$70$YR$$F$Y$$$20250925$$HP$US$US
258324921$25832492$1$I$$20250921$20250921$20250921$DIR$776449$$FDA-CTU$$$$$F$N$$$20250921$N$CN$US$
258324931$25832493$1$I$$20250921$20250921$20250921$DIR$776450$$FDA-CTU$$$$$F$N$$$20250921$N$CN$US$
258325201$25832520$1$I$$20250918$20250922$20250922$PER$$US-ABBVIE-6469807$ABBVIE$$$$$$Y$$$20250922$$HP$US$US
258325541$25832554$1$I$$20250917$20250922$20250922$EXP$$JP-JNJFOC-20250927455$JOHNSON AND JOHNSON$$77$YR$E$F$Y$$$20250922$$PH$JP$JP
258325771$25832577$1$I$$20250917$20250922$20250922$EXP$$JP-KYOWAKIRIN-2025KK018179$KYOWA$$$$$$Y$$$20250922$$HP$JP$JP
258326141$25832614$1$I$20250904$20250922$20250922$20250922$DIR$FDA-CDER-CTU-2025-63108$$FDA-CTU$$74$YR$$F$N$95.25$KG$20250922$N$$US$
258328281$25832828$1$I$$20250917$20250922$20250922$PER$$US-TAKEDA-2025TUS082265$TAKEDA$$$$$$Y$$$20250922$$$US$US
258328531$25832853$1$I$20250409$20250916$20250922$20250922$EXP$EU-AFSSAPS-CN2025001003$EU-MYLANLABS-2025M1079230$MYLAN$$47$YR$$M$Y$96$KG$20250922$$MD$EU$EU
258328801$25832880$1$I$$20250922$20250922$20250922$DIR$776636$$FDA-CTU$$$$$$N$$$20250922$N$CN$US$
258329341$25832934$1$I$20250615$20250615$20250922$20250922$PER$$US-BRAINTREE LABORATORIES, INC.-2025BTE00417$BRAINTREE$$$$A$M$Y$$$20250922$$CN$US$US
258329481$25832948$1$I$20240929$20240929$20250922$20250922$PER$$US-BRAINTREE LABORATORIES, INC.-2024BTE00659$BRAINTREE$$56$YR$$M$Y$$$20250922$$CN$US$US
258329901$25832990$1$I$20190701$20250916$20250922$20250922$EXP$$EU-MYLANLABS-2025M1079043$MYLAN$$50$YR$$M$Y$$$20250922$$$EU$EU
258329931$25832993$1$I$$20250917$20250922$20250922$PER$$US-ABBVIE-6467362$ABBVIE$$$$$$Y$$$20250922$$HP$US$US
258330131$25833013$1$I$20210526$20250915$20250922$20250922$EXP$EU-URPL-DML-MLP.4401.1.6152.2021$EU-ELI_LILLY_AND_COMPANY-PL202509014785$ELI LILLY AND COMPANY$$49$YR$A$F$Y$69$KG$20250922$$CN$EU$EU
258331621$25833162$1$I$$20250922$20250922$20250922$DIR$776671$$FDA-CTU$$73$YR$$M$N$$$20250922$N$PH$US$
258331631$25833163$1$I$20250919$20250922$20250922$20250922$DIR$776692$$FDA-CTU$$9$WK$$M$N$4.445$KG$20250922$Y$$US$
258333481$25833348$1$I$20220801$20250915$20250922$20250922$EXP$EU-AFSSAPS-PA20224167$EU-AFSSAPS-PA20224167$MERCK SHARP + DOHME LLC$$50$YR$$F$Y$81$KG$20250922$$MD$EU$EU
258333741$25833374$1$I$20250725$20250910$20250922$20250922$PER$$US-009507513-2328696$MERCK SHARP + DOHME LLC$$76$YR$$M$Y$78.471$KG$20250922$$CN$US$US
258333801$25833380$1$I$20250101$20250918$20250922$20250922$EXP$$EU-ASTELLAS-2025-AER-052118$ASTELLAS$$$$E$M$Y$$$20250922$$MD$EU$EU
258335201$25833520$1$I$$20250915$20250922$20250922$EXP$$US-ASTRAZENECA-202509USA012665US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250922$$$US$US
258335401$25833540$1$I$20250717$20250919$20250922$20250922$PER$$US-DAIICHI SANKYO, INC.-DS-2025-154160-US$DAIICHI$$59$YR$$M$Y$$$20250922$$HP$US$US
258335541$25833554$1$I$20250907$20250911$20250922$20250922$EXP$$JP-009507513-2330089$MERCK SHARP + DOHME LLC$$76$YR$$M$Y$$$20250922$$MD$JP$JP
258335831$25833583$1$I$$20250918$20250922$20250922$EXP$$US-ASTRAZENECA-202509USA015469US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250922$$$US$US
258336371$25833637$1$I$20250910$20250918$20250922$20250922$EXP$$US-ABBVIE-6470303$ABBVIE$$78$YR$$F$Y$$$20250922$$CN$US$US
258336851$25833685$1$I$$20250917$20250922$20250922$EXP$$BR-ASTRAZENECA-202509SAM014117BR$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250922$$$BR$BR
258337091$25833709$1$I$$20250915$20250922$20250922$EXP$$CA-CELLTRION INC.-2025CA033595$CELLTRION$$$$$$Y$$$20250923$$HP$CA$CA
258337271$25833727$1$I$20250915$20250918$20250923$20250923$EXP$$EU-ABBVIE-6469297$ABBVIE$$$$$M$Y$$$20250922$$MD$EU$EU
258337711$25833771$1$I$$20250909$20250923$20250923$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2025-10215$ALKEM$Levine B, Jufer RA, Smialek JE.. Lamotrigine distribution in two postmortem cases. J Anal Toxicol. 2000;24:635-637$$$$$Y$$$20250923$$HP$US$US
258338271$25833827$1$I$20250826$20250917$20250923$20250923$PER$$US-ELI_LILLY_AND_COMPANY-US202509018301$ELI LILLY AND COMPANY$$72$YR$E$F$Y$$$20250923$$CN$US$US
258338581$25833858$1$I$$20250916$20250923$20250923$EXP$$CN-BEIGENE-BGN-2025-016002$BEIGENE$$77$YR$$$Y$45$KG$20250923$$$CN$CN
258339891$25833989$1$I$$20250918$20250923$20250923$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-TRF-010435$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250923$$CN$US$US
258340031$25834003$1$I$$20250818$20250923$20250923$EXP$$US-GSK-US2025106089$GLAXOSMITHKLINE$$$$$M$Y$$$20250922$$$US$US
258340561$25834056$1$I$20250606$20250922$20250923$20250923$EXP$GB-MHRA-MED-202509201042230350-VZFMY$GB-TEVA-VS-3374808$TEVA$$75$YR$$F$Y$43$KG$20250923$$CN$GB$GB
258341291$25834129$1$I$$20250917$20250923$20250923$PER$$US-UNITED THERAPEUTICS-UNT-2025-032614$UNITED THERAPEUTICS$$$$$F$Y$71.655$KG$20250923$$$US$US
258341331$25834133$1$I$$20250912$20250923$20250923$PER$$US-JNJFOC-20250919594$JOHNSON AND JOHNSON$$$$$F$Y$$$20250923$$HP$US$US
258341921$25834192$1$I$20250704$20250918$20250923$20250923$EXP$$GB-Ipsen Biopharmaceuticals, Inc.-2025-16939$IPSEN BIOPHARMACEUTICALS, INC.$$80$YR$E$F$Y$$$20250923$$$GB$GB
258343181$25834318$1$I$$20250918$20250923$20250923$EXP$$IN-ROCHE-10000392849$ROCHE$$79$YR$E$F$Y$$$20250923$$CN$IN$IN
258345011$25834501$1$I$$20250918$20250923$20250923$PER$$US-SA-2025SA283186$SANOFI AVENTIS$$71$YR$E$M$Y$$$20250923$$CN$US$US
258346191$25834619$1$I$20250429$20250911$20250923$20250923$PER$$US-GSK-US2025117123$GLAXOSMITHKLINE$$60$YR$$M$Y$$$20250923$$$US$US
258346402$25834640$2$F$$20240808$20250923$20250923$PER$$US-LEADIANT BIOSCIENCES, INC.-2024LBI000305$SIGMA TAU$$$$$M$Y$$$20250923$$CN$US$US
258346651$25834665$1$I$$20250911$20250923$20250923$EXP$$US-KENVUE-20250909419$Kenvue$$$$$$Y$$$20250923$$CN$US$US
258346671$25834667$1$I$$20250915$20250923$20250923$EXP$$JP-TAKEDA-2025TUS081174$TAKEDA$Tazuke Y, Kimura T, Ueno T, Nakahata K, Deguchi K, Uga N, et al. Three-year experience with glp-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome. Pediatric Surgery International. 2025;41(1):1-7. doi:10.1007/s00383-025-06154-z$$$A$$Y$$$20250923$$$JP$JP
258347621$25834762$1$I$20250919$20250922$20250923$20250923$EXP$GB-MHRA-MED-202509220342045440-RVKBG$GB-TEVA-VS-3374563$TEVA$$$$$F$Y$$$20250923$$CN$GB$GB
258347711$25834771$1$I$$20250915$20250923$20250923$EXP$$RU-BAUSCH-BH-2025-017646$BAUSCH AND LOMB$Bodryagina E, Odintsova A, Cheremina N, Blatt N, Akberova D, Abdulganieva D. Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis. BioNanoScience. 2022 Sep 23;(12): 1394-1396. doi:10.1007/s12668-022-01027-4.$16$YR$T$F$Y$$$20250923$$HP$RU$RU
258347831$25834783$1$I$20250915$20250919$20250923$20250923$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-129940$BRISTOL-MYERS SQUIBB COMPANY$$79$YR$E$M$Y$$$20250923$$$US$US
258348541$25834854$1$I$$20250918$20250923$20250923$EXP$$US-BEH-2025219542$CSL BEHRING$$$$E$F$Y$$$20250923$$HP$US$US
258348871$25834887$1$I$$20250910$20250923$20250923$EXP$$US-GSK-US2025AMR117765$GLAXOSMITHKLINE$$$$$F$Y$$$20250923$$$US$US
258349171$25834917$1$I$$20250912$20250923$20250923$PER$$US-ELI_LILLY_AND_COMPANY-US202509013220$ELI LILLY AND COMPANY$$$$$$Y$$$20250923$$CN$US$US
258349281$25834928$1$I$$20250911$20250923$20250923$EXP$$AU-CIPLA (EU) LIMITED-2025AU11837$CIPLA$$$$$$Y$$$20250923$$HP$AU$AU
258349571$25834957$1$I$$20250917$20250923$20250923$PER$$US-LEO Pharma-382978$LEO PHARM$$40$YR$$F$Y$$$20250923$$PH$US$US
258349861$25834986$1$I$$20250917$20250923$20250923$EXP$$JP-009507513-2302931$MERCK SHARP + DOHME LLC$$8$DEC$$F$Y$$$20250923$$MD$JP$JP
258349891$25834989$1$I$20240308$20250913$20250923$20250923$EXP$$CA-CELLTRION INC.-2024CA008168$CELLTRION$$$$$$Y$$$20250923$$CN$CA$CA
258350591$25835059$1$I$$20250916$20250923$20250923$PER$$US-SA-2025SA282070$SANOFI AVENTIS$$65$YR$E$F$Y$77.73$KG$20250923$$MD$US$US
258350881$25835088$1$I$$20250911$20250923$20250923$EXP$$US-KENVUE-20250909069$Kenvue$$$$$$Y$$$20250923$$CN$US$US
258351441$25835144$1$I$20241101$20250915$20250923$20250923$EXP$$EU-IMMUNOCORE, LTD-2025-IMC-004759$IMMUNOCORE$$$$$$Y$$$20250923$$MD$EU$EU
258351501$25835150$1$I$$20250908$20250923$20250923$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-527405$RANBAXY$Kanda T, Ishikawa M, Techigawara K, Saginoya T, Hamada K, Saito M, et al. Pimitespib therapy for a patient with PDGFRA D842V-mutant gastrointestinal stromal tumor. Clin J Gastroenterol. 2025;18 (4):595-600$67$YR$$M$Y$$$20250923$$HP$JP$JP
258351811$25835181$1$I$20250112$20250908$20250923$20250923$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-527935$RANBAXY$$68$YR$$M$Y$$$20250923$$MD$EU$EU
258352091$25835209$1$I$20240701$20250908$20250923$20250923$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-527619$RANBAXY$$36$YR$$F$Y$$$20250923$$MD$EU$EU
258352391$25835239$1$I$20250101$20250828$20250923$20250923$PER$$US-GALDERMA-US2025016536$GALDERMA$$$$$$Y$$$20250923$$CN$US$US
258352431$25835243$1$I$$20250910$20250923$20250923$EXP$$EU-ROCHE-10000388809$ROCHE$$$$E$M$Y$$$20250923$$MD$EU$EU
258353941$25835394$1$I$$20210309$20250923$20250923$EXP$$CA-ATNAHS-2021-PMNV-CA000026$Atnahs Healthcare$$$$$$Y$$$20250923$$HP$CA$CA
258354221$25835422$1$I$20250915$20250919$20250923$20250923$PER$$US-GRUNENTHAL-2025-122709$AVERITAS$$53$YR$$M$Y$$$20250923$$CN$US$US
258354411$25835441$1$I$$20250918$20250923$20250923$EXP$$US-GSK-US2025AMR121286$GLAXOSMITHKLINE$$$$$F$Y$$$20250923$$$US$US
258356651$25835665$1$I$$20250902$20250923$20250923$PER$$US-ALCON LABORATORIES-ALC2025US004388$ALCON$$$$$F$Y$$$20250923$$CN$US$US
258358211$25835821$1$I$$20250917$20250923$20250923$PER$$US-ABBVIE-6472012$ABBVIE$$$$$$Y$$$20250923$$MD$US$US
258359431$25835943$1$I$$20250916$20250923$20250923$EXP$$US-MYLANLABS-2025M1080468$MYLAN$Gonzalez M, Sudheendra M, Das A, Risen S. Unraveling pediatric rcvs: a hidden cause of headaches and infarcts. Neurology 2025; 104 (Suppl. 1) (7):.$10$YR$$F$Y$$$20250923$$$US$US
258359511$25835951$1$I$20230619$20250915$20250923$20250923$EXP$$AR-SANDOZ INC.-SDZ2024AR096520$SANDOZ$$40$YR$$F$Y$$$20250923$$CN$AR$AR
258359861$25835986$1$I$$20250912$20250923$20250923$EXP$$US-RDY-USA/2025/09/014379$DR REDDYS$Pile PT, Mirza F. A Cardiac Cure, A Thyroid Curse: Myxedema Coma Induced by Amiodarone. Endocr Pract. 2025;31: S71. DOI: 10.1016/j.eprac.2025.05.198.$91$YR$E$F$Y$$$20250923$$HP$US$US
258360971$25836097$1$I$$20250916$20250923$20250923$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-130446$BRISTOL-MYERS SQUIBB COMPANY$$61$YR$A$M$Y$$$20250923$$$US$US
258361651$25836165$1$I$$20250917$20250923$20250923$PER$$US-ELI_LILLY_AND_COMPANY-US202509017611$ELI LILLY AND COMPANY$$66$YR$E$F$Y$$$20250923$$CN$US$US
258362131$25836213$1$I$$20250922$20250922$20250922$DIR$FDA-CDER-CTU-2025-63469$$FDA-CTU$$43$YR$$M$N$$$20250922$N$$US$
258362171$25836217$1$I$$20250917$20250923$20250923$EXP$$US-GSK-US2025120825$GLAXOSMITHKLINE$$$$$F$Y$$$20250923$$$US$US
258362192$25836219$2$F$$20250922$20250923$20250925$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010512$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250925$$CN$US$US
258363161$25836316$1$I$$20250916$20250923$20250923$PER$$US-ABBVIE-6465419$ABBVIE$$$$$F$Y$$$20250923$$HP$US$US
258363371$25836337$1$I$$20250916$20250923$20250923$PER$$US-SA-2025SA280956$SANOFI AVENTIS$$$$T$M$Y$$$20250923$$HP$US$US
258363591$25836359$1$I$$20250916$20250923$20250923$EXP$$US-AMGEN-USASP2025185976$AMGEN$$$$$$Y$$$20250923$$HP$US$US
258363981$25836398$1$I$$20250918$20250923$20250923$PER$$US-ABBVIE-6471392$ABBVIE$$$$$M$Y$$$20250923$$HP$US$US
258364141$25836414$1$I$$20250920$20250923$20250923$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010501$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20250923$$CN$US$US
258365211$25836521$1$I$$20250911$20250923$20250923$EXP$US-MLMSERVICE-20250905-PI637172-00273-1$US-RDY-USA/2025/09/014236$DR REDDYS$Schartz CM, Folsom ML. Laying it all out on the Table: A Case Report. Kansas journal of medicine. 2025;18(4):97-8. DOI:10.17161/kjm.vol18.24069.$74$YR$E$M$Y$$$20250923$$MD$US$US
258365381$25836538$1$I$$20250915$20250923$20250923$EXP$$EU-ROCHE-10000392237$ROCHE$Bitzanakis N, Fragkiskos P, Garnavou-Xirou Ch, Xirou T, Kampanarou S. The use of intravitreal faricimab in a patient with choroidal neovascularization on the background of neovascular age-related macular degeneration and coexisting angioid streaks. 58TH PANHELLENIC OPHTHALMOLOGY CONGRESS. 2025;15-7$58$YR$A$F$Y$$$20250923$$HP$EU$EU
258365531$25836553$1$I$20250922$20250922$20250922$20250922$DIR$776749$$FDA-CTU$$34$YR$$F$N$$$20250922$N$$US$
258365791$25836579$1$I$20250101$20250919$20250923$20250923$EXP$$US-ABBVIE-6470624$ABBVIE$$21$YR$$F$Y$$$20250923$$CN$US$US
258365871$25836587$1$I$$20250917$20250923$20250923$PER$$US-SA-2025SA282431$SANOFI AVENTIS$$$$A$F$Y$$$20250923$$CN$US$US
258365881$25836588$1$I$20250101$20250916$20250923$20250923$PER$$US-SA-2025SA281789$SANOFI AVENTIS$$73$YR$E$M$Y$$$20250923$$HP$US$US
258366551$25836655$1$I$20250101$20250915$20250923$20250923$EXP$$US-SA-2025SA278597$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250923$$CN$US$US
258366641$25836664$1$I$$20250922$20250923$20250923$EXP$$US-ASTRAZENECA-202509USA018348US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250923$$$US$US
258367201$25836720$1$I$$20240828$20250923$20250923$PER$$US-LEADIANT BIOSCIENCES, INC.-2024LBI000337$SIGMA TAU$$$$$M$Y$$$20250923$$CN$US$US
258367431$25836743$1$I$20250101$20250919$20250923$20250923$PER$$US-PFIZER INC-PV202500113606$PFIZER$$48$YR$$M$Y$$$20250923$$HP$US$US
258368551$25836855$1$I$$20250916$20250923$20250923$EXP$$CA-PFIZER INC-PV202500048018$PFIZER$$64$YR$$M$Y$$$20250923$$CN$CA$CA
258368791$25836879$1$I$20250101$20250917$20250923$20250923$EXP$$CA-PFIZER INC-PV202500113353$PFIZER$$64$YR$$M$Y$$$20250923$$HP$CA$CA
258369391$25836939$1$I$20250101$20250916$20250923$20250923$PER$$US-SA-2025SA282579$SANOFI AVENTIS$$22$YR$A$F$Y$$$20250923$$HP$US$US
258369711$25836971$1$I$20250828$20250910$20250923$20250923$PER$$US-ELI_LILLY_AND_COMPANY-US202509011275$ELI LILLY AND COMPANY$$$$$$Y$$$20250923$$CN$US$US
258369871$25836987$1$I$$20250916$20250923$20250923$EXP$$JP-PFIZER INC-PV202500112212$PFIZER$Kawaguchi, M.. A case of patient who experienced fulminant hemolytic streptococcal infection during palbociclib administration but whose life was saved. The 22nd Chubu Regional Meeting of the Japanese Breast Cancer Society. 2025;22nd:81$68$YR$$F$Y$$$20250923$$HP$JP$JP
258370781$25837078$1$I$20250831$20250918$20250923$20250923$EXP$$US-OTSUKA-2025_023285$OTSUKA$$76$YR$$M$Y$$$20250923$$CN$US$US
258371241$25837124$1$I$20240713$20250915$20250923$20250923$EXP$$NVSC2021IN026058$NOVARTIS$$61$YR$$F$Y$93.6$KG$20250923$$CN$IN$IN
258372091$25837209$1$I$20250917$20250917$20250923$20250923$EXP$$CN-SA-2025SA282116$SANOFI AVENTIS$$$$A$$Y$$$20250923$$HP$CN$CN
258372831$25837283$1$I$$20250917$20250923$20250923$EXP$$US-TEVA-VS-3374226$TEVA$$$$$$Y$$$20250923$$CN$US$US
258373711$25837371$1$I$$20250915$20250923$20250923$PER$$US-INCYTE CORPORATION-2025IN010106$INCYTE$$$$$$Y$$$20250923$$$US$US
258374631$25837463$1$I$$20250923$20250923$20250923$DIR$776865$$FDA-CTU$$$$$$N$$$20250923$$CN$US$
258376211$25837621$1$I$20231110$20250910$20250923$20250923$PER$$US-BAYER-2025A120892$BAYER HEALTHCARE PHARMACEUTICALS INC.$$0$YR$$$Y$$$20250923$$MD$US$US
258376251$25837625$1$I$$20250916$20250923$20250923$PER$$US-BIOGEN-2025BI01324234$BIOGEN$$$$$F$Y$$$20250923$$CN$US$US
258376461$25837646$1$I$$20250917$20250923$20250923$EXP$$EU-AMGEN-ITASP2025187262$AMGEN$Contaldi C.; Montesarchio V.; Daniello C. et al.. Myocardial work and atrial strain for the early detection of subclinical cardiac dysfunction in bevacizumab treated colorectal cancer patients. European Heart Journal. 2025;27 (SUPPL_6):vi315 - vi316$$$$$Y$$$20250923$$HP$EU$EU
258376761$25837676$1$I$20250101$20250911$20250923$20250923$EXP$$US-LIQUIDIA TECHNOLOGIES, INC.-LIQ-2025-000625$LIQUIDIA TECHNOLOGIES$$$$$$Y$$$20250923$$CN$US$US
258376901$25837690$1$I$20250516$20250815$20250923$20250923$EXP$$US-ELI_LILLY_AND_COMPANY-US202509001257$ELI LILLY AND COMPANY$$39$YR$A$M$Y$95.238$KG$20250923$$CN$US$US
258377011$25837701$1$I$20250717$20250726$20250923$20250923$EXP$$US-ELI_LILLY_AND_COMPANY-US202509000217$ELI LILLY AND COMPANY$$52$YR$A$M$Y$$$20250923$$CN$US$US
258377121$25837712$1$I$20250725$20250729$20250923$20250923$EXP$$US-ELI_LILLY_AND_COMPANY-US202509000046$ELI LILLY AND COMPANY$$52$YR$A$M$Y$67$KG$20250923$$CN$US$US
258378412$25837841$2$F$$20250929$20250923$20250930$30DAY$$US-PFIZER INC-202500092559$PFIZER$$7$YR$$F$Y$$$20250930$$CN$US$US
258378661$25837866$1$I$$20250915$20250923$20250923$EXP$$US-MYLANLABS-2025M1080742$MYLAN$Chen B, Kanjilal D, Beigel M, Ibrahim R. Delayed Post-hypoxic Leukoencephalopathy: An Elusive Diagnosis. Neurology 2025; 104 (Suppl.) (7):.$61$YR$$F$Y$$$20250923$$$US$US
258379031$25837903$1$I$$20250917$20250923$20250923$EXP$$EU-MYLANLABS-2025M1079317$MYLAN$Limongiello MA, Metafuni E, Giammarco S, Galli E, Sora F, Autore F et al. High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation. Int J Hematol. 2025 Jul 14. Online ahead of print.$70$YR$$M$Y$$$20250923$$MD$EU$EU
258379091$25837909$1$I$20250101$20250917$20250923$20250923$EXP$$US-ABBVIE-6472231$ABBVIE$$78$YR$$M$Y$$$20250923$$CN$US$US
258379161$25837916$1$I$20250613$20250923$20250923$20250923$DIR$776931$$FDA-CTU$$64$YR$$F$N$60.3$KG$20250923$N$CN$US$
258379591$25837959$1$I$20250911$20250923$20250923$20250923$DIR$776946$$FDA-CTU$$$$$$N$$$20250923$N$PH$US$
258380801$25838080$1$I$20250101$20250914$20250923$20250923$EXP$$US-UCBSA-2025058970$UCB$$$$$F$Y$$$20250923$$HP$US$US
258381451$25838145$1$I$$20250910$20250923$20250923$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI12048$NEUROCRINE BIOSCIENCES$$72$YR$$F$Y$$$20250923$$HP$US$US
258382211$25838221$1$I$20101130$20250916$20250923$20250923$EXP$$CA-JNJFOC-20250924998$JOHNSON AND JOHNSON$$45$YR$A$M$Y$87$KG$20250923$$HP$CA$CA
258382231$25838223$1$I$$20250915$20250923$20250923$PER$$US-JNJFOC-20250921661$JOHNSON AND JOHNSON$$$$$$Y$$$20250923$$HP$US$US
258382652$25838265$2$F$20250729$20250919$20250923$20250930$EXP$$CN-009507513-2332059$MERCK SHARP + DOHME LLC$$77$YR$$M$Y$80$KG$20250930$$HP$CN$CN
258383021$25838302$1$I$$20250916$20250923$20250923$PER$$US-MALLINCKRODT-MNK202505833$MALLINCKRODT$$$$$M$Y$$$20250922$$CN$US$US
258383531$25838353$1$I$20250908$20250912$20250923$20250923$EXP$$JP-EAGLE PHARMACEUTICALS, INC.-JP-2025EAG000115$EAGLE$$$$$$Y$$$20250923$$PH$JP$JP
258384021$25838402$1$I$20250910$20250910$20250923$20250923$EXP$$US-FMCRTG-FMC-2509-001478$FRESENIUS MEDICAL CARE$$$$$M$Y$$$20250923$$CN$US$US
258385451$25838545$1$I$20250917$20250919$20250923$20250923$EXP$$EU-ABBVIE-6472264$ABBVIE$$78$YR$$F$Y$$$20250923$$CN$EU$EU
258385751$25838575$1$I$20230427$20250704$20250923$20250923$EXP$$VN-SANDOZ INC.-SDZ2025VN069536$SANDOZ$$52$YR$$F$Y$$$20250923$$CN$VN$VN
258386341$25838634$1$I$20250828$20250829$20250924$20250924$PER$$US-GALDERMA-US2025016517$GALDERMA$$$$$$Y$$$20250924$$CN$US$US
258386911$25838691$1$I$$20250916$20250924$20250924$EXP$$CA-CELLTRION INC.-2025CA033832$CELLTRION$$$$$$Y$$$20250924$$HP$CA$CA
258387231$25838723$1$I$$20250723$20250924$20250924$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009914$STRIDES$Chaudhuri U, Forrest J R, Sastry K, Reagans R, Agrawal S. Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine. Cureus. 2025;17(5):e84405$$$$M$Y$$$20250924$$HP$US$US
258387621$25838762$1$I$$20250910$20250924$20250924$EXP$GB-NAPPMUNDI-GBR-2025-0128580$GB-PTA-006286$BANNER$$$$$F$Y$$$20250922$$CN$GB$GB
258387851$25838785$1$I$20250911$20250916$20250924$20250924$EXP$$US-GSK-US2025AMR120280$GLAXOSMITHKLINE$$53$YR$$M$Y$$$20250924$$$US$US
258388141$25838814$1$I$$20250919$20250924$20250924$EXP$$US-ABBVIE-6470437$ABBVIE$$$$E$F$Y$$$20250924$$CN$US$US
258389371$25838937$1$I$$20250918$20250924$20250924$PER$$US-ROCHE-10000393036$ROCHE$$$$A$F$Y$$$20250924$$CN$US$US
258389641$25838964$1$I$20250806$20250912$20250924$20250924$EXP$EU-AFSSAPS-AN2025001065$EU-Accord-505549$ACCORD$$66$YR$E$F$Y$83$KG$20250924$$MD$EU$EU
258389691$25838969$1$I$$20250915$20250924$20250924$EXP$$US-SA-2025SA268752$SANOFI AVENTIS$Ambat S, Jakoby M, Williams V.. Idiopathic Intracranial Hypertension-Associated Secondary Adrenal Insufficiency Masking Diabetes Mellitus.. Endocrine Practice.. 2025;31(9):S48$39$YR$A$F$Y$$$20250924$$MD$US$US
258389941$25838994$1$I$$20250918$20250924$20250924$PER$$US-ROCHE-10000392219$ROCHE$$$$$$Y$$$20250924$$HP$US$US
258390071$25839007$1$I$$20250918$20250924$20250924$PER$$US-ROCHE-10000392487$ROCHE$$$$E$F$Y$$$20250924$$CN$US$US
258390191$25839019$1$I$$20250828$20250924$20250924$PER$$US-TLM-TLM-2025-06311$TOLMAR$$$$$F$Y$$$20250923$$HP$US$US
258390961$25839096$1$I$20250808$20250919$20250924$20250924$EXP$$NVSC2025GB147794$NOVARTIS$$46$YR$$M$Y$$$20250924$$CN$GB$GB
258391101$25839110$1$I$$20250919$20250924$20250924$EXP$$CA-ROCHE-10000392553$ROCHE$$37$YR$A$F$Y$$$20250924$$HP$CA$CA
258391261$25839126$1$I$20250620$20250915$20250924$20250924$EXP$$US-ROCHE-10000389247$ROCHE$$67$YR$E$F$Y$$$20250924$$CN$US$US
258392272$25839227$2$F$20250101$20250919$20250924$20250924$EXP$$JP-SA-2025SA282511$SANOFI AVENTIS$$$$$M$Y$$$20250924$$MD$JP$JP
258393141$25839314$1$I$$20250904$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509005998$ELI LILLY AND COMPANY$$19$YR$A$F$Y$$$20250924$$CN$US$US
258394941$25839494$1$I$20250922$20250922$20250924$20250924$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-130880$BRISTOL-MYERS SQUIBB COMPANY$$83$YR$E$F$Y$68.04$KG$20250924$$$US$US
258395231$25839523$1$I$$20250919$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509021117$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250924$$CN$US$US
258395241$25839524$1$I$20250801$20250919$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509020023$ELI LILLY AND COMPANY$$76$YR$E$F$Y$$$20250924$$CN$US$US
258396301$25839630$1$I$$20250919$20250924$20250924$PER$$US-ABBVIE-6472415$ABBVIE$$$$$$Y$$$20250924$$HP$US$US
258396781$25839678$1$I$$20250922$20250924$20250924$EXP$$JP-BEIGENE-BGN-2025-016399$BEIGENE$$40$YR$$$Y$$$20250924$$MD$JP$JP
258396851$25839685$1$I$$20250909$20250924$20250924$EXP$$US-AUROBINDO-AUR-APL-2025-048789$AUROBINDO$Houdu J, Jankowski R, Nguyen D-T. Ectopic ACTH Secretion Induced by an Olfactory Neuroblastoma: A Case Report.. Case-Rep-Endocrinol 2025. 2025;1:1-6$65$YR$$M$Y$$$20250924$$HP$US$EU
258397801$25839780$1$I$$20250912$20250924$20250924$PER$$US-SMPA-2025SPA011928$SUNOVION$$74$YR$$M$Y$$$20250922$$$US$US
258397851$25839785$1$I$$20250912$20250924$20250924$PER$$US-SMPA-2025SPA011940$SUNOVION$$89$YR$$M$Y$$$20250923$$$US$US
258398871$25839887$1$I$20211129$20250919$20250924$20250924$EXP$EU-URPL-DML-MLP.4401.1.6091.2021$EU-SAMSUNG BIOEPIS-SB-2025-31770$SAMSUNG BIOEPIS$$56$YR$A$F$Y$98$KG$20250924$$MD$EU$EU
258399631$25839963$1$I$$20250606$20250924$20250924$PER$$US-STRIDES ARCOLAB LIMITED-2025SP007320$STRIDES$Rust HP, Donovan A, Leick M, Henry M, Merani S.. Ursodiol Prophylaxis in Recipients of Liver Transplant From Donors After Cardiac Death.. Experimental and Clinical Transplantation. 2024;6:465-470$$$$$Y$$$20250924$$HP$US$US
258401481$25840148$1$I$$20250919$20250924$20250924$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-129533$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$M$Y$$$20250924$$$US$US
258401631$25840163$1$I$$20250918$20250924$20250924$EXP$$JP-GSK-JP2025120538$GLAXOSMITHKLINE$$$$$$Y$$$20250924$$MD$JP$JP
258401911$25840191$1$I$$20250916$20250924$20250924$EXP$$JP-CATALYSTPHARMACEUTICALPARTNERS-JP-CATA-25-01426$CATALYST PHARMA$Runa Shimizu et al.. A Case of Anti-NMDA Receptor Encephalitis with Intractable Convulsion Successfully Treated with Multidisciplinary Treatment Including Early Tumourectomy. The 75th Kanto Regional Meeting of the Japanese Association for Acute Medicine/The 62nd Paramedic Academic Research Meeting General Topics (Abstracts).. 2025$28$YR$$F$Y$$$20250924$$MD$JP$JP
258402351$25840235$1$I$$20250915$20250924$20250924$EXP$$BR-CHEPLA-2025011083$CHEPLAPHARM$$35$YR$$M$Y$$$20250924$$CN$COUNTRY NOT SPECIFIED$BR
258402921$25840292$1$I$$20250909$20250924$20250924$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2025RR-527290$RANBAXY$$$$$F$Y$$$20250924$$CN$GB$GB
258403001$25840300$1$I$20240915$20250916$20250924$20250924$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES INC-2025RR-527821$RANBAXY$$40$YR$$M$Y$$$20250924$$MD$EU$EU
258403531$25840353$1$I$$20250916$20250924$20250924$EXP$$JP-AMGEN-JPNSP2025185715$AMGEN$Takahashi M.. Phase I study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. International Journal of Hematology. 2025;122 (3):421-433$$$$$Y$$$20250924$$HP$JP$JP
258403731$25840373$1$I$$20250919$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509020233$ELI LILLY AND COMPANY$$33$YR$A$F$Y$$$20250924$$CN$US$US
258404781$25840478$1$I$$20250911$20250924$20250924$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI12201$NEUROCRINE BIOSCIENCES$$67$YR$$$Y$$$20250924$$PH$US$US
258404881$25840488$1$I$20250801$20250917$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509018105$ELI LILLY AND COMPANY$$63$YR$A$F$Y$$$20250924$$CN$US$US
258405831$25840583$1$I$$20250923$20250923$20250923$DIR$FDA-CDER-CTU-2025-63831$$FDA-CTU$$44$YR$$F$N$$$20250923$N$$US$
258406221$25840622$1$I$$20250915$20250924$20250924$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-127550$BRISTOL-MYERS SQUIBB COMPANY$$76$YR$E$F$Y$$$20250924$$$US$US
258406711$25840671$1$I$20250821$20250911$20250924$20250924$EXP$$CN-VIIV HEALTHCARE-CN2025CHI117633$VIIV$$62$YR$$M$Y$65$KG$20250924$$$CN$CN
258407131$25840713$1$I$$20250923$20250923$20250923$DIR$FDA-CDER-CTU-2025-63758$$FDA-CTU$$90$YR$$M$N$$$20250923$N$CN$US$
258408141$25840814$1$I$$20250807$20250924$20250924$PER$$US-CELLTRION INC.-2025US027410$CELLTRION$$$$$$Y$$$20250924$$HP$US$US
258408691$25840869$1$I$$20250922$20250924$20250924$EXP$$CA-TEVA-VS-3375662$TEVA$$64$YR$$M$Y$$$20250924$$HP$CA$CA
258411201$25841120$1$I$$20250919$20250924$20250924$EXP$$US-ABBVIE-6472425$ABBVIE$$$$E$F$Y$$$20250924$$CN$US$US
258411582$25841158$2$F$20241217$20250919$20250924$20250929$EXP$$US-ALIMERA SCIENCES INC.-US-A16013-25-000298$ALIMERA$$$$$$Y$$$20250929$$MD$US$US
258412441$25841244$1$I$20240101$20250721$20250924$20250924$PER$$US-MADRIGAL PHARMACEUTICALS, INC-2025REZ8663$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250924$$HP$US$US
258412591$25841259$1$I$$20250919$20250924$20250924$EXP$$IQ-ANIPHARMA-030690$ANI$$28$YR$A$M$Y$$$20250924$$HP$IQ$IQ
258413061$25841306$1$I$20250915$20250922$20250924$20250924$EXP$$CN-PFIZER INC-PV202500114168$PFIZER$$8$YR$$M$Y$38.7$KG$20250924$$HP$CN$CN
258413631$25841363$1$I$$20250918$20250924$20250924$EXP$$US-GSK-US2025AMR121179$GLAXOSMITHKLINE$$$$$F$Y$$$20250924$$$US$US
258413751$25841375$1$I$20250101$20250811$20250924$20250924$PER$$US-MADRIGAL PHARMACEUTICALS, INC-2025USREZ09465$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250924$$MD$US$US
258414421$25841442$1$I$20250903$20250919$20250924$20250924$EXP$$US-OTSUKA-2025_023283$OTSUKA$$$$$$Y$$$20250924$$CN$US$US
258414541$25841454$1$I$$20250912$20250924$20250924$EXP$$US-KENVUE-20250909440$Kenvue$$$$$M$Y$$$20250924$$CN$US$US
258414581$25841458$1$I$$20250911$20250924$20250924$EXP$$US-NOVOPROD-1523778$NOVO NORDISK$$$$A$M$Y$$$20250924$$CN$US$US
258414761$25841476$1$I$$20250912$20250924$20250924$EXP$$US-KENVUE-20250909546$Kenvue$$$$$$Y$$$20250924$$CN$US$US
258415961$25841596$1$I$20250923$20250924$20250924$20250924$DIR$777088$$FDA-CTU$$64$YR$$F$N$71.1$KG$20250924$N$CN$US$
258416111$25841611$1$I$$20250916$20250924$20250924$EXP$$TR-AMGEN-TURSP2025187722$AMGEN$Ali Kaan G.; Polat H.; Coban E. et al.. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study. Annals of Saudi medicine. 2025;45(4):249-255$$$A$$Y$$$20250924$$MD$TR$TR
258416531$25841653$1$I$20250911$20250917$20250924$20250924$EXP$$CN-SA-2025SA280714$SANOFI AVENTIS$$79$YR$E$M$Y$65$KG$20250924$$HP$CN$CN
258416541$25841654$1$I$$20250919$20250924$20250924$EXP$$US-Taiho Oncology Inc-2025-010045$TAIHO ONCOLOGY INC$$77$YR$E$M$Y$84.82$KG$20250924$$CN$US$US
258416791$25841679$1$I$$20250916$20250924$20250924$PER$$US-BIOMARINAP-US-2025-168944$BIOMARIN$$$$C$F$Y$36.281$KG$20250924$$MD$US$US
258417261$25841726$1$I$$20250911$20250924$20250924$EXP$$GB-BAYER-2025A121185$BAYER HEALTHCARE LLC$$$$$F$Y$$$20250924$$CN$GB$GB
258417451$25841745$1$I$$20250918$20250924$20250924$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010451$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250924$$CN$US$US
258418151$25841815$1$I$$20250919$20250924$20250924$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-130899$BRISTOL-MYERS SQUIBB COMPANY$$91$YR$E$F$Y$$$20250924$$$US$US
258418731$25841873$1$I$$20250922$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509021494$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250924$$CN$US$US
258419831$25841983$1$I$$20250913$20250924$20250924$EXP$GB-MHRA-MED-202509131049503430-DSVQH$GB-ELI_LILLY_AND_COMPANY-GB202509013809$ELI LILLY AND COMPANY$$$$$F$Y$$$20250924$$CN$GB$GB
258419901$25841990$1$I$$20250912$20250924$20250924$EXP$$US-ELI_LILLY_AND_COMPANY-US202509016407$ELI LILLY AND COMPANY$$75$YR$E$M$Y$$$20250924$$CN$US$US
258420861$25842086$1$I$$20250120$20250924$20250924$PER$$US-LEADIANT GMBH-2025LBI000004$SIGMA TAU$$$$$F$Y$$$20250924$$CN$US$US
258420971$25842097$1$I$$20250918$20250924$20250924$PER$$US-ROCHE-10000394587$ROCHE$$$$$F$Y$$$20250924$$MD$US$US
258421261$25842126$1$I$$20250918$20250924$20250924$EXP$$JP-Taiho Oncology Inc-2025-008180$TAIHO ONCOLOGY INC$$56$YR$A$F$Y$$$20250924$$PH$JP$JP
258421491$25842149$1$I$$20250912$20250924$20250924$EXP$$US-KENVUE-20250909590$Kenvue$$$$$F$Y$$$20250924$$CN$US$US
258423141$25842314$1$I$20220101$20250917$20250924$20250924$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-096545$BOEHRINGER INGELHEIM$Lorsch AM, Lange S, Jung J, Funke D, Honikl L, Fischer C. Afatinib and temozolomide in recurrent glioblastoma with EGFR mutation and amplification: a case report considering the molecular profile with long-term response. Die Onkologie. 2025 Sep 03;2025: 1-4. doi:10.1007/s00761-025-01818-w.$50$YR$A$M$Y$$$20250924$$$EU$EU
258423781$25842378$1$I$20250910$20250924$20250924$20250924$DIR$777185$$FDA-CTU$$82$YR$$F$N$80.1$KG$20250924$N$CN$US$
258424281$25842428$1$I$$20250922$20250924$20250924$EXP$$US-ASTRAZENECA-202509GLO018889US$ALEXION PHARMACEUTICALS$Vo KM., Goss N., Adams M., Young P.. Severe Esophagitis Induced by Durvalumab in the Treatment of Advanced Urothelial Cancer: A Case Report. 2025 ANNUAL SCIENTIFIC MEETING AND POSTGRADUATE COURSE OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG). 2025$58$YR$A$M$Y$$$20250924$$MD$US$US
258424301$25842430$1$I$$20250917$20250924$20250924$EXP$$US-SA-2025SA283895$SANOFI AVENTIS$$56$YR$A$M$Y$65$KG$20250924$$MD$US$US
258424452$25842445$2$F$$20250918$20250924$20250927$EXP$$US-SA-2025SA284119$SANOFI AVENTIS$$$$A$F$Y$63.5$KG$20250926$$MD$US$US
258424591$25842459$1$I$$20250921$20250924$20250924$EXP$$US-SA-2025SA284999$SANOFI AVENTIS$$$$E$M$Y$$$20250924$$HP$US$US
258425811$25842581$1$I$20250913$20250913$20250924$20250924$PER$$US-ELI_LILLY_AND_COMPANY-US202509014765$ELI LILLY AND COMPANY$$45$YR$A$F$Y$$$20250924$$CN$US$US
258425981$25842598$1$I$$20250918$20250924$20250924$EXP$$EU-MYLANLABS-2025M1079974$MYLAN$$57$YR$$$Y$$$20250924$$$EU$EU
258426711$25842671$1$I$20250915$20250916$20250924$20250924$PER$$US-IGSA-BIG0038062$GRIFOLS$$25$YR$$M$Y$94$KG$20250924$$HP$US$US
258427241$25842724$1$I$$20250918$20250924$20250924$PER$$US-ABBVIE-6469452$ABBVIE$$$$$F$Y$$$20250924$$CN$US$US
258427581$25842758$1$I$20250101$20250911$20250924$20250924$PER$$US-MYLANLABS-2025M1078760$MYLAN$$$$$F$Y$$$20250921$$$US$US
258427861$25842786$1$I$20250901$20250922$20250924$20250924$EXP$$US-ABBVIE-6474227$ABBVIE$$57$YR$$M$Y$$$20250924$$CN$US$US
258427871$25842787$1$I$$20250924$20250924$20250924$PER$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-097443$BOEHRINGER INGELHEIM$$$$$$Y$$$20250924$$$US$US
258428111$25842811$1$I$$20250910$20250924$20250924$EXP$$US-SCIEGENP-2025SCLIT00296$SCIEGEN PHARMACEUTICALS INC$Berg M, et al.Rivastigmine as an alternative treatment for anticholinergic toxidrome in light of the physostigmine shortage: A case series.American Journal of Emergency Medicine .AUG-2025;94:144-147$$$$$Y$$$20250924$$MD$US$US
258428641$25842864$1$I$20220801$20250916$20250924$20250924$EXP$$VN-BAYER-2025A123920$BAYER HEALTHCARE PHARMACEUTICALS INC.$$55$YR$A$$Y$$$20250924$$MD$VN$VN
258428981$25842898$1$I$20240501$20250917$20250924$20250924$EXP$EU-AFSSAPS-RE2024001305$EU-AFSSAPS-RE2024001305$MERCK SHARP + DOHME LLC$$71$YR$$M$Y$58.3$KG$20250924$$MD$EU$EU
258429911$25842991$1$I$$20250914$20250924$20250924$PER$$US-SA-2025SA280838$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250924$$CN$US$US
258430211$25843021$1$I$$20250917$20250924$20250924$PER$$US-SA-2025SA284158$SANOFI AVENTIS$$$$A$F$Y$$$20250924$$HP$US$US
258430681$25843068$1$I$$20250917$20250924$20250924$PER$$US-SA-2025SA283736$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250924$$HP$US$US
258430932$25843093$2$F$20250915$20250924$20250924$20250927$PER$$US-SA-2025SA279781$SANOFI AVENTIS$$64$YR$A$M$Y$122.47$KG$20250926$$MD$US$US
258431601$25843160$1$I$20241201$20250918$20250924$20250924$PER$$US-SA-2025SA282456$SANOFI AVENTIS$$16$YR$T$M$Y$$$20250924$$HP$US$US
258432751$25843275$1$I$20250101$20250918$20250924$20250924$PER$$US-SA-2025SA284702$SANOFI AVENTIS$$43$YR$A$F$Y$$$20250924$$HP$US$US
258432921$25843292$1$I$$20250918$20250924$20250924$PER$$US-SA-2025SA283573$SANOFI AVENTIS$$$$A$M$Y$102.04$KG$20250924$$HP$US$US
258433341$25843334$1$I$20250101$20250919$20250924$20250924$PER$$US-SA-2025SA284537$SANOFI AVENTIS$$$$I$F$Y$$$20250924$$HP$US$US
258433411$25843341$1$I$$20250919$20250924$20250924$PER$$US-SA-2025SA283775$SANOFI AVENTIS$$78$YR$E$F$Y$$$20250924$$CN$US$US
258433751$25843375$1$I$20250913$20250919$20250924$20250924$PER$$US-SA-2025SA284387$SANOFI AVENTIS$$69$YR$E$F$Y$$$20250924$$HP$US$US
258434561$25843456$1$I$$20250920$20250924$20250924$PER$$US-SA-2025SA284148$SANOFI AVENTIS$$45$YR$A$F$Y$$$20250925$$CN$US$US
258436631$25843663$1$I$$20250909$20250924$20250924$PER$$US-KENVUE-20250907230$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258436671$25843667$1$I$$20250910$20250924$20250924$PER$$US-KENVUE-20250907233$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258437261$25843726$1$I$20250101$20250916$20250924$20250924$EXP$$US-ABBVIE-6473960$ABBVIE$$51$YR$$F$Y$109.31$KG$20250924$$CN$US$US
258437481$25843748$1$I$20250907$20250917$20250924$20250924$PER$$US-ABBVIE-6469217$ABBVIE$$72$YR$$F$Y$72.575$KG$20250924$$CN$US$US
258437751$25843775$1$I$$20250908$20250924$20250924$PER$$US-KENVUE-20250905091$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258437981$25843798$1$I$$20250909$20250924$20250924$PER$$US-KENVUE-20250907593$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258438121$25843812$1$I$$20250909$20250924$20250924$PER$$US-KENVUE-20250905266$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258438341$25843834$1$I$$20250917$20250924$20250924$EXP$$CA-CELLTRION INC.-2025CA033959$CELLTRION$$$$$$Y$$$20250925$$HP$CA$CA
258438551$25843855$1$I$20250809$20250912$20250925$20250925$EXP$$CN-NUVATION BIO INC.-2025NUV000202$NUVATION BIO$$75$YR$$M$Y$$$20250925$$$CN$CN
258439971$25843997$1$I$20250101$20250922$20250925$20250925$EXP$$US-SA-2025SA284531$SANOFI AVENTIS$$62$YR$A$M$Y$$$20250925$$CN$US$US
258440131$25844013$1$I$$20250915$20250925$20250925$EXP$$CO-IPCA LABORATORIES LIMITED-IPC-2025-CO-002581$IPCA$Galvez LA, Espinosa K, Grisales MP and Cantor JF. Acute toxic leukoencephalopathy due to use of tramadol, diagnosis, and treatment. Neurology India. 2025;1-3$$$$$Y$$$20250925$$MD$CO$CO
258440191$25844019$1$I$$20250922$20250925$20250925$EXP$$CA-TEVA-VS-3375648$TEVA$$74$YR$$M$Y$$$20250925$$HP$CA$CA
258440601$25844060$1$I$$20250915$20250925$20250925$EXP$CA-MHPD-E2B_07934484$CA-Accord-505481$ACCORD$$48$YR$A$F$Y$$$20250925$$HP$CA$CA
258441031$25844103$1$I$20250826$20250922$20250925$20250925$EXP$CN-NMPACDR-3101101027955202500641$CN-BAXTER-2025BAX021743$BAXTER$$11$YR$$F$Y$$$20250925$$MD$CN$CN
258441131$25844113$1$I$$20250919$20250925$20250925$EXP$$US-GSK-US2025AMR121005$GLAXOSMITHKLINE$$$$$M$Y$$$20250925$$$US$US
258441241$25844124$1$I$$20250916$20250925$20250925$EXP$$US-GALDERMA-US2025018140$GALDERMA$$$$$$Y$$$20250925$$CN$US$US
258442181$25844218$1$I$20250818$20250919$20250925$20250925$EXP$EU-AEMPS-1749032$EU-BRISTOL-MYERS SQUIBB COMPANY-2025-129679$BRISTOL-MYERS SQUIBB COMPANY$$49$YR$A$F$Y$$$20250925$$$EU$EU
258442431$25844243$1$I$$20250923$20250925$20250925$EXP$$US-JNJFOC-20250936174$JOHNSON AND JOHNSON$$$$$$Y$$$20250925$$CN$US$US
258442521$25844252$1$I$20250801$20250921$20250925$20250925$PER$$US-SA-2025SA286017$SANOFI AVENTIS$$65$YR$E$M$Y$$$20250925$$HP$US$US
258444611$25844461$1$I$$20250915$20250925$20250925$EXP$$CN-UCBSA-2025058197$UCB$An R, Wang X, Xiong L, Yang Y, Li P. A case series on TNF-? inhibitors for APS- induced high-risk pregnancies. Journal of Clinical and Translational Science. 2025;9:e186:1-6$1$DY$$M$Y$2.35$KG$20250925$$HP$CN$CN
258445101$25844510$1$I$$20250910$20250925$20250925$EXP$$JP-AMGEN-JPNSP2025191576$AMGEN$$63$YR$A$M$Y$$$20250925$$MD$JP$JP
258445491$25844549$1$I$$20250910$20250925$20250925$EXP$$US-GSK-US2025AMR117645$GLAXOSMITHKLINE$$$$$F$Y$$$20250925$$$US$US
258445991$25844599$1$I$$20250915$20250925$20250925$EXP$CA-MHPD-E2B_07923269$CA-Accord-505395$ACCORD$$79$YR$E$F$Y$60$KG$20250925$$HP$CA$CA
258446091$25844609$1$I$$20250919$20250925$20250925$EXP$$US-009507513-2331582$MERCK SHARP + DOHME LLC$$63$YR$$M$Y$$$20250925$$CN$US$US
258446681$25844668$1$I$20250101$20250923$20250925$20250925$EXP$$GB-JNJFOC-20250939816$JOHNSON AND JOHNSON$$$$$F$Y$$$20250925$$CN$GB$GB
258447781$25844778$1$I$20250916$20250918$20250925$20250925$EXP$$US-AMGEN-USASP2025187691$AMGEN$$76$YR$E$M$Y$$$20250925$$CN$US$US
258448421$25844842$1$I$20250918$20250919$20250925$20250925$PER$$US-ELI_LILLY_AND_COMPANY-US202509020601$ELI LILLY AND COMPANY$$43$YR$A$M$Y$$$20250925$$PH$US$US
258449981$25844998$1$I$$20250915$20250925$20250925$PER$$US-ELI_LILLY_AND_COMPANY-US202509016491$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250925$$CN$US$US
258451104$25845110$4$F$$20241104$20250925$20250925$EXP$$US-LEADIANT BIOSCIENCES, INC.-2024LBI000443$SIGMA TAU$LOPEZ VJ, VELEZ PS, EL HOSSEN J, LOPEZ FJ, RASSI N.. A RARE CASE OF CHRONIC GRANULOMATOUS INVASIVE ASPERGILLOSIS MASQUERADING AS A PARANASAL-MAXILLARY SINUS CARCINOMA IN AN ELDERLY PATIENT.. Chest Journal. 2024;166 (4):A5040-A5041$$$E$M$Y$$$20250925$$HP$US$US
258451491$25845149$1$I$20250918$20250923$20250925$20250925$EXP$$US-ABBVIE-6474485$ABBVIE$$71$YR$$F$Y$$$20250925$$CN$US$US
258451811$25845181$1$I$20250101$20250918$20250925$20250925$EXP$$EU-ABBVIE-6475335$ABBVIE$$81$YR$$M$Y$$$20250925$$MD$EU$EU
258452131$25845213$1$I$$20250909$20250925$20250925$PER$$US-KENVUE-20250905345$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258452301$25845230$1$I$$20250916$20250925$20250925$EXP$$CN-STRIDES ARCOLAB LIMITED-2025SP012077$STRIDES$Feng L, Hong Y, Fan J, Yang C, Huang Y, Xu Y, et al.. Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study.. J-Antimicrob-Chemother. 2025;80 (7):1980-1987$$$$$Y$$$20250925$$HP$CN$CN
258452642$25845264$2$F$20250201$20250926$20250925$20250930$EXP$$US-VIIV HEALTHCARE-US2025121019$VIIV$$31$YR$$M$Y$46.85$KG$20250930$$MD$US$US
258453361$25845336$1$I$$20250919$20250925$20250925$EXP$$GB-BAXTER-2025BAX021720$BAXTER$$63$YR$$F$Y$$$20250925$$MD$GB$GB
258453391$25845339$1$I$$20250922$20250925$20250925$PER$$US-ASTRAZENECA-202509USA019848US$ALEXION PHARMACEUTICALS$$$$$$Y$$$20250925$$$US$US
258453492$25845349$2$F$$20250918$20250925$20250925$EXP$$SG-REGENERON PHARMACEUTICALS, INC.-2025-150982$REGENERON$$$$$$Y$$$20250925$$MD$SG$SG
258453581$25845358$1$I$$20250911$20250925$20250925$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2025-10224$ALKEM$Choe J, Al Saedy S, Miotke K, De Lisle J.. Differentiating between a prasugrel-induced hypersensitivity reaction and an atorvastatin-induced DRESS syndrome in the post-percutaneous coronary intervention setting.. JAAD CASE REPORTS. 2025;63:50-52$74$YR$$F$Y$$$20250925$$MD$US$US
258454901$25845490$1$I$$20250922$20250925$20250925$PER$$US-TAKEDA-2025TUS083203$TAKEDA$$$$$$Y$$$20250925$$$US$US
258455131$25845513$1$I$20250904$20250922$20250925$20250925$PER$$US-ABBVIE-6473981$ABBVIE$$43$YR$$F$Y$$$20250925$$MD$US$US
258455681$25845568$1$I$20140914$20250914$20250925$20250925$EXP$GB-MHRA-MED-202509140309163610-MGLBQ$GB-MACLEODS PHARMA-MAC2025055374$MACLEODS$$$$$$Y$$$20250925$$CN$GB$GB
258455841$25845584$1$I$$20250918$20250925$20250925$PER$$US-ABBVIE-6468704$ABBVIE$$$$$F$Y$$$20250925$$CN$US$US
258457101$25845710$1$I$$20250909$20250925$20250925$PER$$US-KENVUE-20250905740$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258457841$25845784$1$I$20250820$20250915$20250925$20250925$EXP$$US-009507513-2329850$MERCK SHARP + DOHME LLC$$84$YR$$F$Y$68$KG$20250925$$PH$US$US
258458572$25845857$2$F$$20250915$20250925$20250930$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-527682$RANBAXY$Inoue R, Weinandy E, Maturu S, Khandker N. Modifed Atkins Diet Therapy during Pregnancy for Refractory Epilepsy. Neurology. 2025;Apr8;104(s)(7):1-4/P1-9.017$25$YR$$F$Y$$$20250930$$HP$US$US
258458961$25845896$1$I$$20250910$20250925$20250925$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES INC-2025R1-527644$RANBAXY$Daichang C, Rutkowski E, Ali Z.. A case of delirious mania in the context of concurrent cardiac comorbidities and autonomic instability. Bipolar Disord. 2025;27 (1):77-80$26$YR$$M$Y$$$20250925$$HP$US$US
258459471$25845947$1$I$20250924$20250924$20250925$20250925$EXP$GB-MHRA-MED-202509242202410450-LNMHP$GB-TEVA-VS-3376005$TEVA$$41$YR$$F$Y$140$KG$20250925$$CN$GB$GB
258459501$25845950$1$I$20250101$20250922$20250925$20250925$EXP$$US-SA-2025SA284519$SANOFI AVENTIS$$64$YR$A$F$Y$$$20250925$$CN$US$US
258459591$25845959$1$I$$20250916$20250925$20250925$EXP$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-128755$ZYDUS PHARM$Demmy T, Abdelhady S, Tomaszewski G, Petroziello M, Hasan O, Hennon M, et al. Pulmonary Suffusion Refinements for Primary and Secondary Malignancies: Preliminary Analyses of Phase I Safety and Drug Delivery Data. Cancers. 2025;17$$$$$Y$$$20250925$$HP$US$US
258459641$25845964$1$I$20250701$20250919$20250925$20250925$EXP$$IN-CIPLA LTD.-2025IN11045$CIPLA$$$$$$Y$$$20250925$$CN$IN$IN
258460181$25846018$1$I$$20250922$20250925$20250925$EXP$$CA-ASTRAZENECA-202509CAN018274CA$ALEXION PHARMACEUTICALS$$41$YR$A$F$Y$$$20250925$$$CA$CA
258460481$25846048$1$I$$20250924$20250924$20250924$DIR$FDA-CDER-CTU-2025-64012$$FDA-CTU$$$$$F$N$$$20250924$N$$US$
258460951$25846095$1$I$$20250910$20250925$20250925$EXP$$EU-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-528094$RANBAXY$Bidiga L, Csonka T, Mehes G, Markoth C, Hutkai D and Matyus J. Case Report: Toxic tubulointerstitial nephropathy with lipofuscin deposition - the potential cause of occupational Bisphenol-A exposition. Pathol Oncol. 2025;31:1612046$72$YR$$M$Y$$$20250925$$HP$EU$EU
258461041$25846104$1$I$$20250908$20250925$20250925$PER$$US-DECIPHERA PHARMACEUTICALS LLC-2025US001136$DECIPHERA PHARMACEUTICALS$$82$YR$E$M$Y$$$20250925$$CN$US$US
258461061$25846106$1$I$$20250909$20250925$20250925$PER$$US-KENVUE-20250906696$Kenvue$$$$$F$Y$$$20250925$$CN$US$US
258461131$25846113$1$I$20250801$20250924$20250925$20250925$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-131704$BRISTOL-MYERS SQUIBB COMPANY$$69$YR$E$F$Y$$$20250925$$$US$US
258461381$25846138$1$I$20250409$20250912$20250925$20250925$EXP$$EU-AUROBINDO-AUR-APL-2025-047741$AUROBINDO$$47$YR$$M$Y$96$KG$20250925$$MD$EU$EU
258462052$25846205$2$F$$20250922$20250925$20250928$PER$$US-SA-2025SA283575$SANOFI AVENTIS$$$$$$Y$$$20250928$$CN$US$US
258462261$25846226$1$I$20241001$20250918$20250925$20250925$PER$$US-SA-2025SA283783$SANOFI AVENTIS$$23$YR$A$M$Y$$$20250925$$$US$US
258462341$25846234$1$I$$20250918$20250925$20250925$PER$$US-SA-2025SA283689$SANOFI AVENTIS$$$$$M$Y$$$20250925$$CN$US$US
258462891$25846289$1$I$$20250919$20250925$20250925$PER$$US-SA-2025SA284039$SANOFI AVENTIS$$26$YR$A$F$Y$$$20250925$$CN$US$US
258463271$25846327$1$I$$20250922$20250925$20250925$PER$$US-SA-2025SA285915$SANOFI AVENTIS$$20$YR$A$F$Y$$$20250925$$CN$US$US
258463412$25846341$2$F$20250101$20250922$20250925$20250930$PER$$US-SA-2025SA284583$SANOFI AVENTIS$$63$YR$A$M$Y$$$20250930$$MD$US$US
258464221$25846422$1$I$20250909$20250922$20250925$20250925$EXP$EU-AFSSAPS-LL2025001653$EU-PFIZER INC-202500186790$PFIZER$$63$YR$$M$Y$$$20250925$$PH$EU$EU
258464261$25846426$1$I$20250101$20250917$20250925$20250925$EXP$$JP-PFIZER INC-202500184961$PFIZER$$6$DEC$$F$Y$$$20250925$$MD$JP$JP
258464371$25846437$1$I$20250820$20250922$20250925$20250925$EXP$EU-AEMPS-1750937$EU-PFIZER INC-202500186760$PFIZER$$48$YR$$$Y$59$KG$20250925$$MD$EU$EU
258466171$25846617$1$I$$20250913$20250925$20250925$EXP$$VN-SANDOZ INC.-SDZ2025VN069995$SANDOZ$$$$A$M$Y$$$20250925$$MD$VN$VN
258466401$25846640$1$I$20250501$20250918$20250925$20250925$PER$$EU-TAKEDA-2025TUS083812$TAKEDA$$50$YR$$M$Y$$$20250925$$MD$EU$EU
258466511$25846651$1$I$20250101$20250922$20250925$20250925$EXP$$US-SA-2025SA284553$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250925$$MD$US$US
258466661$25846666$1$I$20250101$20250920$20250925$20250925$PER$$US-SA-2025SA285976$SANOFI AVENTIS$$23$YR$A$F$Y$$$20250925$$CN$US$US
258467821$25846782$1$I$$20250916$20250925$20250925$EXP$$EU-AUROBINDO-AUR-APL-2025-048952$AUROBINDO$Laroche M, Labetoulle M, Jouanjus E, Kroger E, Zongo E.. Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France.. Fundamental and Clinical Pharmacology. 2025;39:1-13$$$A$$Y$$$20250925$$HP$EU$EU
258468111$25846811$1$I$20250828$20250923$20250925$20250925$EXP$GB-MHRA-MED-202509231436145170-DJHKS$GB-HALEON-2264663$Haleon PLC$$59$YR$$M$Y$$$20250925$$PH$GB$GB
258468891$25846889$1$I$$20250812$20250925$20250925$PER$$US-GLENMARK PHARMACEUTICALS-2025GMK103181$GLENMARK$$$$$$Y$$$20250925$$HP$US$US
258468911$25846891$1$I$$20250914$20250925$20250925$EXP$$BR-NOVOPROD-1525620$NOVO NORDISK$Ivan Rodrigues Barros Godoy, Tatiane Cantarelli Rodrigues, Andre Fukunishi Yamada, Abdalla Skaf. Atypical ^opened-bottle^ proximal tibial fractures in young male patients with growth hormone and aromatase inhibitor treatment: case series. Skeletal Radiology. 2025;1-6$12$YR$$M$Y$$$20250925$$HP$BR$BR
258469441$25846944$1$I$20250701$20250912$20250925$20250925$EXP$$US-NOVOPROD-1525727$NOVO NORDISK$$93$YR$$F$Y$$$20250925$$CN$US$US
258470031$25847003$1$I$$20250923$20250925$20250925$PER$$US-ASTRAZENECA-202509USA019543US$ALEXION PHARMACEUTICALS$$$$A$F$Y$$$20250925$$MD$US$US
258471292$25847129$2$F$$20250924$20250925$20250927$PER$$US-SA-2025SA285242$SANOFI AVENTIS$$$$E$F$Y$90.91$KG$20250927$$MD$US$US
258472391$25847239$1$I$$20250923$20250923$20250923$DIR$776924$$FDA-CTU$$$$$F$N$$$20250923$N$$US$
258473471$25847347$1$I$20250619$20250619$20250925$20250925$PER$$US-INDIVIOR US-INDV-164977-2025$RECKITT BENCKISER$$$$$F$Y$$$20250925$$PH$US$US
258473861$25847386$1$I$$20250919$20250925$20250925$EXP$$US-PFIZER INC-PV202500113596$PFIZER$$$$$F$Y$$$20250925$$LW$US$US
258473951$25847395$1$I$20250823$20250923$20250925$20250925$EXP$$CN-PFIZER INC-PV202500114473$PFIZER$$38$YR$$F$Y$50.1$KG$20250925$$HP$CN$CN
258474071$25847407$1$I$$20250918$20250925$20250925$EXP$GB-MHRA-MED-202509181110136160-JCDQF$GB-ELI_LILLY_AND_COMPANY-GB202509018754$ELI LILLY AND COMPANY$$$$$F$Y$$$20250925$$CN$GB$GB
258474111$25847411$1$I$$20250919$20250925$20250925$EXP$$US-PFIZER INC-PV202500113562$PFIZER$$$$$F$Y$$$20250925$$LW$US$US
258476201$25847620$1$I$20250101$20250919$20250925$20250925$PER$$US-BAYER-2025A125769$BAYER HEALTHCARE PHARMACEUTICALS INC.$$32$YR$A$F$Y$$$20250925$$CN$US$US
258476291$25847629$1$I$$20250916$20250925$20250925$30DAY$$KW-PFIZER INC-202500187090$PFIZER$$$$$$Y$$$20250925$$CN$KW$KW
258477241$25847724$1$I$$20250918$20250925$20250925$PER$$US-AMGEN-USASP2025187523$AMGEN$$$$$F$Y$$$20250925$$CN$US$US
258478051$25847805$1$I$$20250922$20250925$20250925$PER$$US-ABBVIE-6473605$ABBVIE$$$$$F$Y$$$20250925$$CN$US$US
258479711$25847971$1$I$$20250922$20250925$20250925$PER$$US-SA-2025SA286465$SANOFI AVENTIS$$$$A$F$Y$$$20250925$$HP$US$US
258479731$25847973$1$I$$20250918$20250925$20250925$PER$$US-ABBVIE-6472970$ABBVIE$$$$$$Y$$$20250925$$CN$US$US
258480731$25848073$1$I$20250101$20250919$20250925$20250925$EXP$$US-SA-2025SA285833$SANOFI AVENTIS$$65$YR$E$F$Y$$$20250925$$HP$US$US
258480811$25848081$1$I$20250901$20250919$20250925$20250925$PER$$US-SA-2025SA283588$SANOFI AVENTIS$$16$YR$T$M$Y$$$20250925$$HP$US$US
258480971$25848097$1$I$20240101$20250917$20250925$20250925$EXP$$US-ELI_LILLY_AND_COMPANY-US202509018923$ELI LILLY AND COMPANY$$$$$F$Y$$$20250925$$CN$US$US
258481511$25848151$1$I$$20250909$20250925$20250925$PER$$US-INSUD PHARMA-2509US07461$INSUD PHARMA$$$$$$Y$$$20250925$$CN$US$US
258481711$25848171$1$I$$20250922$20250925$20250925$PER$$US-JNJFOC-20250936153$JOHNSON AND JOHNSON$$$$$$Y$$$20250925$$HP$US$US
258481831$25848183$1$I$$20250924$20250925$20250925$PER$$US-PURDUE-USA-2025-0320835$PURDUE$$43$YR$$M$Y$$$20250925$$CN$US$US
258482471$25848247$1$I$20250101$20250918$20250925$20250925$EXP$$US-UCBSA-2025059196$UCB$$$$$F$Y$$$20250925$$HP$US$US
258483741$25848374$1$I$20250913$20250924$20250924$20250924$DIR$777167$$FDA-CTU$$81$YR$$M$N$$$20250924$N$CN$US$
258485601$25848560$1$I$$20250923$20250925$20250925$EXP$$EU-PFIZER INC-PV202500114311$PFIZER$$71$YR$$F$Y$$$20250925$$MD$EU$EU
258486101$25848610$1$I$$20250922$20250925$20250925$PER$$US-LUNDBECK-DKLU4019721$LUNDBECK$$$$$F$Y$$$20250925$$CN$US$US
258486131$25848613$1$I$$20250918$20250925$20250925$PER$$US-JNJFOC-20250929794$JOHNSON AND JOHNSON$$$$$F$Y$$$20250925$$HP$US$US
258486451$25848645$1$I$20250801$20250916$20250925$20250925$EXP$$US-UCBSA-2025059097$UCB$$75$YR$$F$Y$$$20250925$$HP$US$US
258486781$25848678$1$I$20250821$20250923$20250925$20250925$EXP$$US-ASTRAZENECA-202509USA020635US$ALEXION PHARMACEUTICALS$$67$YR$E$F$Y$92$KG$20250925$$$US$US
258487201$25848720$1$I$20250912$20250925$20250925$20250925$DIR$777416$$FDA-CTU$$78$YR$$F$N$$$20250925$N$$US$
258487661$25848766$1$I$20220101$20250922$20250925$20250925$EXP$$KR-MYLANLABS-2025M1081237$MYLAN$$42$YR$$F$Y$$$20250925$$PH$KR$KR
258488201$25848820$1$I$20250101$20250912$20250925$20250925$PER$$US-MALLINCKRODT-MNK202505753$MALLINCKRODT$$60$YR$A$F$Y$$$20250924$$CN$US$US
258488561$25848856$1$I$$20250917$20250925$20250925$30DAY$$US-PFIZER INC-202500189600$PFIZER$$$$$$Y$$$20250925$$HP$US$US
258488661$25848866$1$I$$20250917$20250925$20250925$EXP$$US-EMD Serono-2025047781$EMD SERONO INC$$$$A$F$Y$$$20250925$$$US$US
258488921$25848892$1$I$20240718$20240724$20250925$20250925$EXP$$US-VIVUS LLC-2024V1000944$VIVUS$$$$$$Y$$$20250925$$CN$US$US
258489181$25848918$1$I$$20250211$20250925$20250925$EXP$$US-VIVUS LLC-2025V1000246$VIVUS$$$$$$Y$$$20250925$$CN$US$US
258489721$25848972$1$I$$20250306$20250925$20250925$EXP$$US-VIVUS LLC-2025V1000387$VIVUS$$$$$$Y$$$20250925$$CN$US$US
258490811$25849081$1$I$20160101$20250915$20250925$20250925$EXP$$US-ABBVIE-6447327$ABBVIE$$$$$M$Y$79.378$KG$20250925$$CN$US$US
258491001$25849100$1$I$20250916$20250923$20250925$20250925$EXP$$CN-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-097284$BOEHRINGER INGELHEIM$$74$YR$E$M$Y$52$KG$20250925$$$CN$CN
258491661$25849166$1$I$$20250916$20250925$20250925$EXP$$US-ZENPEP LLC-2025AIMT00888$AIMMUNE$$$$$$Y$$$20250925$$CN$US$US
258492091$25849209$1$I$$20250924$20250925$20250925$EXP$$US-ASTRAZENECA-202509USA020498US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250925$$$US$US
258492321$25849232$1$I$$20250902$20250925$20250925$PER$$US-GALDERMA-US2025016767$GALDERMA$$$$$$Y$$$20250926$$CN$US$US
258492751$25849275$1$I$20250909$20250924$20250925$20250925$PER$$US-ELI_LILLY_AND_COMPANY-US202509024525$ELI LILLY AND COMPANY$$24$YR$A$F$Y$$$20250925$$CN$US$US
258493071$25849307$1$I$20241111$20250918$20250925$20250925$EXP$$EG-EMD Serono-2025048563$EMD SERONO INC$$0$YR$N$M$Y$$$20250925$$$EG$EG
258493211$25849321$1$I$$20250915$20250925$20250925$EXP$$CN-JNJFOC-20250922935$JOHNSON AND JOHNSON$$$$$$Y$$$20250926$$MD$CN$CN
258493371$25849337$1$I$20250101$20250922$20250925$20250925$EXP$$CN-JNJFOC-20250940644$JOHNSON AND JOHNSON$$85$YR$E$F$Y$$$20250926$$HP$CN$CN
258494241$25849424$1$I$20250801$20250922$20250925$20250925$EXP$$US-ABBVIE-6474368$ABBVIE$$65$YR$$M$Y$$$20250925$$CN$US$US
258494391$25849439$1$I$$20250920$20250925$20250925$EXP$$CN-ABBVIE-6475383$ABBVIE$$$$$$Y$$$20250925$$MD$CN$CN
258494711$25849471$1$I$20250521$20250925$20250926$20250926$EXP$GB-MHRA-MED-202509251849362210-YFBLJ$GB-TEVA-VS-3376505$TEVA$$67$YR$$F$Y$59$KG$20250926$$CN$GB$GB
258494951$25849495$1$I$$20250923$20250926$20250926$EXP$$US-ABBVIE-6475950$ABBVIE$$$$A$F$Y$$$20250926$$CN$US$US
258495931$25849593$1$I$$20250919$20250926$20250926$EXP$$EU-AMGEN-ESPSP2025190340$AMGEN$$26$YR$A$F$Y$$$20250925$$MD$EU$EU
258496291$25849629$1$I$$20250918$20250926$20250926$EXP$$EU-EMD Serono-2025047766$EMD SERONO INC$$$$$F$Y$$$20250926$$$EU$EU
258497031$25849703$1$I$$20250919$20250926$20250926$30DAY$$US-SANDOZ INC.-SDZ2025US069294$SANDOZ$$$$$F$Y$$$20250926$$CN$US$US
258497171$25849717$1$I$$20250920$20250926$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132039$BRISTOL-MYERS SQUIBB COMPANY$$75$YR$E$F$Y$$$20250926$$$US$US
258497281$25849728$1$I$20250911$20250925$20250926$20250926$EXP$GB-MHRA-MED-202509251320059170-FTDWN$GB-TEVA-VS-3376527$TEVA$$75$YR$$F$Y$$$20250926$$CN$GB$GB
258497401$25849740$1$I$20250910$20250923$20250926$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-131342$BRISTOL-MYERS SQUIBB COMPANY$$19$YR$A$M$Y$$$20250926$$$US$US
258497961$25849796$1$I$$20250922$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509022036$ELI LILLY AND COMPANY$$40$YR$A$F$Y$$$20250926$$CN$US$US
258497981$25849798$1$I$$20250916$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509017399$ELI LILLY AND COMPANY$$$$$$Y$$$20250926$$CN$US$US
258499041$25849904$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250905293$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258500541$25850054$1$I$$20250920$20250926$20250926$PER$$US-ROCHE-10000394248$ROCHE$$$$A$F$Y$$$20250926$$CN$US$US
258501561$25850156$1$I$$20250910$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509010522$ELI LILLY AND COMPANY$$69$YR$E$F$Y$$$20250926$$CN$US$US
258501621$25850162$1$I$$20250919$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509020422$ELI LILLY AND COMPANY$$41$YR$A$M$Y$$$20250926$$CN$US$US
258502041$25850204$1$I$$20250925$20250926$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132120$BRISTOL-MYERS SQUIBB COMPANY$$66$YR$E$M$Y$$$20250926$$$US$US
258503011$25850301$1$I$$20250919$20250926$20250926$EXP$$EU-ABBVIE-6472166$ABBVIE$$$$E$M$Y$$$20250926$$CN$EU$EU
258503521$25850352$1$I$20250603$20250918$20250926$20250926$EXP$$GB-CELLTRION INC.-2025GB018215$CELLTRION$$$$$$Y$$$20250926$$PH$GB$GB
258505231$25850523$1$I$$20250915$20250926$20250926$PER$$US-SMPA-2025SPA010060$SUNOVION$$82$YR$$M$Y$$$20250925$$$US$US
258505461$25850546$1$I$$20250922$20250926$20250926$EXP$$US-ABBVIE-6472604$ABBVIE$$$$$F$Y$$$20250926$$MD$US$US
258505891$25850589$1$I$$20250925$20250926$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132231$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$M$Y$$$20250926$$$US$US
258506201$25850620$1$I$$20250915$20250926$20250926$EXP$CA-MHPD-E2B_07940163$CA-Accord-505531$ACCORD$$67$YR$E$F$Y$$$20250926$$CN$CA$CA
258506301$25850630$1$I$20250901$20250922$20250926$20250926$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010583$ACADIA PHARMACEUTICALS$$66$YR$$M$Y$$$20250926$$CN$US$US
258506631$25850663$1$I$$20250715$20250926$20250926$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009227$STRIDES$Wang Z, Tanco K, Liu E, Madireddy S, Renee Warner K, Smith TJ.. A case report: Treating insomnia with olanzapine in cancer patients.. Palliat-Support-Care. 2025;23:e121$7$DEC$$F$Y$$$20250926$$MD$US$US
258508091$25850809$1$I$$20250910$20250926$20250926$PER$$US-KENVUE-20250907658$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258508211$25850821$1$I$20250801$20250902$20250926$20250926$PER$$US-GALDERMA-US2025016882$GALDERMA$$$$$$Y$$$20250926$$CN$US$US
258508842$25850884$2$F$$20250925$20250926$20250930$PER$$CA-TAKEDA-2025TUS084359$TAKEDA$$73$YR$$M$Y$$$20250930$$$CA$CA
258509121$25850912$1$I$$20250924$20250926$20250926$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-097853$BOEHRINGER INGELHEIM$$$$$F$Y$$$20250926$$$US$US
258510051$25851005$1$I$19950101$20250922$20250926$20250926$PER$$US-KENVUE-20250913161$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258510301$25851030$1$I$$20250911$20250926$20250926$PER$$US-GSK-US2025AMR118171$GLAXOSMITHKLINE$$$$$F$Y$$$20250926$$$US$US
258510861$25851086$1$I$$20250922$20250926$20250926$EXP$$US-ABBVIE-6472008$ABBVIE$$$$A$F$Y$$$20250926$$MD$US$US
258511171$25851117$1$I$$20250909$20250926$20250926$PER$US-KENVUE-20250906545$US-KENVUE-20250906545$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258511231$25851123$1$I$$20250908$20250926$20250926$PER$$US-KENVUE-20250904814$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258511311$25851131$1$I$$20250910$20250926$20250926$PER$$US-KENVUE-20250907828$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258511911$25851191$1$I$$20250910$20250926$20250926$PER$$US-KENVUE-20250905669$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258512051$25851205$1$I$$20250918$20250926$20250926$EXP$$EU-CELLTRION INC.-2025HU031849$CELLTRION$Ranjbar Y, Arokszallasi T, Szinay D, Nagy E.B, Tarr T, Nagy-Vincze M.. The Way Back from Tetraplegia or, Rare Neurological Manifestations of Eosinophil Granulomatosis with Polyangiitis. Journal of Clinical Medicine. 2025;14(16):5652$$$$$Y$$$20250926$$HP$EU$EU
258512311$25851231$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250906978$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258512931$25851293$1$I$$20200311$20250926$20250926$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-053174$ZYDUS PHARM$$$$$$Y$$$20250926$$CN$US$US
258513491$25851349$1$I$$20250923$20250926$20250926$EXP$$CA-ASTELLAS-2025-AER-052805$ASTELLAS$$96$YR$E$M$Y$$$20250926$$HP$CA$CA
258513581$25851358$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250907754$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258513661$25851366$1$I$20250924$20250925$20250925$20250925$DIR$777378$$FDA-CTU$$48$YR$$F$N$64.8$KG$20250925$N$PH$US$
258514561$25851456$1$I$20250920$20250922$20250926$20250926$EXP$GB-MHRA-MED-202509221716107780-WPGTH$GB-BEH-2025219772$CSL BEHRING$$$$$F$Y$$$20250926$$MD$GB$GB
258515041$25851504$1$I$20250210$20250918$20250926$20250926$EXP$EU-MINISAL02-1056930$EU-HIKMA PHARMACEUTICALS USA INC.-IT-H14001-25-10589$HIKMA$$$$$$Y$$$20250926$$MD$EU$EU
258515831$25851583$1$I$$20250911$20250926$20250926$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2025R1-528125$RANBAXY$$$$$M$Y$$$20250926$$HP$US$US
258516651$25851665$1$I$$20250922$20250926$20250926$EXP$$BR-JNJFOC-20250936698$JOHNSON AND JOHNSON$$87$YR$E$F$Y$70$KG$20250926$$HP$BR$BR
258516671$25851667$1$I$20250822$20250923$20250926$20250926$EXP$EU-AFSSAPS-LL2025001627$EU-ORGANON-O2509FRA001998$ORGANON$$80$YR$$M$Y$63$KG$20250926$$HP$EU$EU
258517221$25851722$1$I$$20250919$20250926$20250926$PER$$EU-TAKEDA-2025TUS083225$TAKEDA$$64$YR$$M$Y$85$KG$20250926$$$EU$EU
258517251$25851725$1$I$$20250908$20250926$20250926$PER$$US-CHATTEMPRD-2025OHG028729$CHATTEM$$$$$M$Y$$$20250926$$CN$US$US
258517341$25851734$1$I$$20250908$20250926$20250926$PER$$US-CHATTEMPRD-2025OHG028803$CHATTEM$$$$$M$Y$$$20250926$$CN$US$US
258517391$25851739$1$I$$20250923$20250926$20250926$PER$$US-ROCHE-10000396272$ROCHE$$$$$$Y$$$20250926$$CN$US$US
258518671$25851867$1$I$$20250625$20250926$20250926$PER$$US-LEADIANT BIOSCIENCES, INC.-2025LBI000238$SIGMA TAU$$$$$F$Y$$$20250926$$CN$US$US
258519221$25851922$1$I$$20250917$20250926$20250926$EXP$$CA-CELLTRION INC.-2025CA033915$CELLTRION$$$$$$Y$$$20250926$$HP$CA$CA
258519901$25851990$1$I$$20250917$20250926$20250926$EXP$$CA-CELLTRION INC.-2025CA033937$CELLTRION$$$$$$Y$$$20250926$$HP$CA$CA
258520031$25852003$1$I$20250601$20250915$20250926$20250926$EXP$$US-NOVOPROD-1525775$NOVO NORDISK$$$$$M$Y$$$20250926$$CN$US$US
258520701$25852070$1$I$$20250924$20250925$20250925$DIR$FDA-CDER-CTU-2025-64502$$FDA-CTU$$$$$F$N$$$20250924$N$$US$
258521301$25852130$1$I$$20250922$20250926$20250926$PER$$US-ABBVIE-6474431$ABBVIE$$$$$M$Y$$$20250926$$CN$US$US
258521911$25852191$1$I$$20250924$20250926$20250926$EXP$$EU-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-097693$BOEHRINGER INGELHEIM$$$$$$Y$$$20250926$$MD$EU$EU
258522141$25852214$1$I$$20250923$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509023824$ELI LILLY AND COMPANY$$75$YR$E$F$Y$$$20250926$$CN$US$US
258522311$25852231$1$I$20250915$20250916$20250926$20250926$DIR$FDA-CDER-CTU-2025-64551$$FDA-CTU$$69$YR$$M$N$73.5$KG$20250916$N$$US$
258522741$25852274$1$I$$20250912$20250926$20250926$EXP$$US-QUAGEN-2025QUALIT00643$QUAGEN PHARMACEUTICALS$Jamie Nassur.Adverse Events Associated with Injection of Suprachoroidal Triamcinolone Acetonide in the Real-World Setting.Investigative Ophthalmology + Visual Science.JUN-2025;66$$$$$Y$$$20250926$$HP$US$US
258523081$25852308$1$I$$20250916$20250926$20250926$PER$$US-ABBVIE-6465936$ABBVIE$$$$$F$Y$$$20250926$$CN$US$US
258523401$25852340$1$I$$20250923$20250926$20250926$PER$$US-PFIZER INC-202500188636$PFIZER$$72$YR$$M$Y$$$20250926$$MD$US$US
258524351$25852435$1$I$$20250922$20250926$20250926$PER$$US-BAYER-2025A127567$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$$F$Y$$$20250926$$CN$US$US
258525111$25852511$1$I$$20250915$20250926$20250926$EXP$$CA-AUROBINDO-AUR-APL-2025-048593$AUROBINDO$$33$YR$$M$Y$$$20250926$$CN$CA$CA
258525251$25852525$1$I$$20250912$20250926$20250926$EXP$$EU-AUROBINDO-AUR-APL-2025-047496$AUROBINDO$Gerritsma AM, Hagdorn QA, Geurkink TH, Groothuis JG, van Ofwegen-Hanekamp CE, Lagas JS. Dietary lifestyle changes unexpectedly causing digoxin intoxication with cardiogenic shock: a grand round case report.. European Heart Journal - Case Reports. 2025;9:8:1-6$66$YR$$M$Y$$$20250926$$HP$EU$EU
258525271$25852527$1$I$20250817$20250915$20250926$20250926$EXP$$EU-AUROBINDO-AUR-APL-2025-048334$AUROBINDO$$61$YR$$F$Y$69.5$KG$20250926$$MD$EU$EU
258526411$25852641$1$I$20250625$20250922$20250926$20250926$EXP$EU-AFSSAPS-TO2025001267$EU-009507513-2322520$MERCK SHARP + DOHME LLC$$63$YR$$M$Y$99$KG$20250926$$PH$EU$EU
258526851$25852685$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250904754$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258527081$25852708$1$I$$20250916$20250926$20250926$EXP$EU-FAMHP-DHH-N2025-125441$EU-COSETTE-CP2025BE000949$COSETTE PHARMACEUTICALS INC$$$$$F$Y$$$20250926$$PH$EU$EU
258527241$25852724$1$I$$20250924$20250926$20250926$PER$$US-ASTRAZENECA-202509USA020550US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250926$$$US$US
258527461$25852746$1$I$$20250918$20250926$20250926$PER$$US-APOTEX-2025AP012180$APOTEX$$44$YR$$M$Y$$$20250926$$CN$US$US
258527571$25852757$1$I$$20250210$20250926$20250926$PER$$US-Lavipharm SA-2185366$LAVIPHARM$$67$YR$$F$Y$$$20250926$$$US$US
258528621$25852862$1$I$20250903$20250924$20250926$20250926$EXP$$US-PFIZER INC-PV202500115076$PFIZER$$52$YR$$F$Y$$$20250926$$HP$US$US
258529001$25852900$1$I$20250924$20250924$20250926$20250926$EXP$$JP-PFIZER INC-202500188787$PFIZER$$51$YR$$F$Y$$$20250926$$PH$JP$JP
258529341$25852934$1$I$20230808$20250922$20250926$20250926$EXP$$US-PFIZER INC-PV202500114034$PFIZER$$$$$F$Y$$$20250926$$LW$US$US
258529591$25852959$1$I$$20250917$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509017853$ELI LILLY AND COMPANY$$40$YR$A$F$Y$$$20250926$$CN$US$US
258530621$25853062$1$I$20250816$20250925$20250925$20250925$DIR$777558$$FDA-CTU$$44$YR$$F$N$$$20250925$N$$US$
258531231$25853123$1$I$$20250825$20250926$20250926$PER$$US-GLANDPHARMA-US-2025GLNSPO01797$GLAND PHARMA LTD$$$$$$Y$$$20250926$$CN$US$US
258531751$25853175$1$I$$20250925$20250926$20250926$EXP$$US-PURDUE PHARMA-USA-2025-0320889$PURDUE$$82$YR$$M$Y$$$20250926$$CN$US$US
258532611$25853261$1$I$20250424$20250916$20250926$20250926$EXP$$GT-ELI_LILLY_AND_COMPANY-GT202504024842$ELI LILLY AND COMPANY$$65$YR$E$F$Y$62.4$KG$20250926$$CN$GT$GT
258532921$25853292$1$I$$20250917$20250926$20250926$EXP$$US-SYNDAX PHARMACEUTICALS, INC.-2025US000725$SYNDAX$$$$$$Y$$$20250926$$MD$US$US
258532941$25853294$1$I$$20250828$20250926$20250926$PER$$US-GLANDPHARMA-US-2025GLNSPO01810$GLAND PHARMA LTD$$46$YR$A$$Y$$$20250926$$CN$US$US
258533741$25853374$1$I$20250925$20250926$20250926$20250926$DIR$777650$$FDA-CTU$$$$$$N$$$20250926$N$CN$US$
258534601$25853460$1$I$20250817$20250918$20250926$20250926$EXP$EU-AFSSAPS-MP2025001215$EU-TEVA-VS-3374126$TEVA$$88$YR$$F$Y$51$KG$20250926$$PH$EU$EU
258535662$25853566$2$F$$20250916$20250926$20250930$EXP$$NVSC2025US145139$NOVARTIS$$$$$M$Y$$$20250930$$HP$US$US
258536091$25853609$1$I$$20250922$20250926$20250926$EXP$$IN-ROCHE-10000395857$ROCHE$$77$YR$E$M$Y$$$20250926$$CN$IN$IN
258536971$25853697$1$I$20250901$20250918$20250926$20250926$EXP$$US-BAYER-2025A124558$BAYER HEALTHCARE PHARMACEUTICALS INC.$$53$YR$A$M$Y$$$20250926$$CN$US$US
258537091$25853709$1$I$20230201$20250911$20250926$20250926$EXP$$US-PARI RESPIRATORY EQUIPMENT, INC.-2025PAR00072$PARI RESPIRATORY EQUIPMENT$$3$YR$$M$Y$$$20250926$$HP$US$US
258537131$25853713$1$I$$20250910$20250926$20250926$PER$$US-RDY-USA/2025/09/014247$DR REDDYS$$$$$F$Y$$$20250926$$CN$US$US
258538191$25853819$1$I$$20250924$20250926$20250926$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132408$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$$$20250926$$$US$US
258538791$25853879$1$I$$20250918$20250926$20250926$PER$$US-ABBVIE-6471809$ABBVIE$$$$$$Y$$$20250926$$HP$US$US
258538961$25853896$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250907956$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258539241$25853924$1$I$$20250909$20250926$20250926$PER$$US-KENVUE-20250908316$Kenvue$$$$$F$Y$$$20250926$$CN$US$US
258539621$25853962$1$I$$20250915$20250926$20250926$EXP$$US-SCIEGENP-2025SCLIT00297$SCIEGEN PHARMACEUTICALS INC$Conner S, et al.Use of Single-Pass Albumin Dialysis in an Adolescent with Refractory Vasoplegic Shock Secondary to Combined Calcium Channel Blocker and Angiotensin Converting Enzyme Inhibitor Overdose.ASAIO Journal.apr-2025;71(01):13$17$YR$T$F$Y$77$KG$20250926$$HP$US$US
258540321$25854032$1$I$$20250915$20250926$20250926$EXP$$EUPVG-2025-002012$SK LIFE SCIENCE$$$$$$Y$$$20250926$$HP$CA$CA
258541031$25854103$1$I$$20250924$20250926$20250926$PER$$US-PFIZER INC-202500191911$PFIZER$$62$YR$$F$Y$$$20250926$$HP$US$US
258541671$25854167$1$I$20230807$20230809$20250926$20250926$PER$$US-PFIZER INC-202300272745$PFIZER$$49$YR$$F$Y$$$20250926$$PH$US$US
258541891$25854189$1$I$20231001$20231025$20250926$20250926$PER$$US-PFIZER INC-202300348040$PFIZER$$82$YR$$M$Y$$$20250926$$CN$US$US
258542251$25854225$1$I$$20250922$20250926$20250926$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-022746$JAZZ$$11$YR$$M$Y$$$20250926$$$US$US
258542441$25854244$1$I$$20250919$20250926$20250926$PER$$US-ELI_LILLY_AND_COMPANY-US202509024464$ELI LILLY AND COMPANY$$$$$F$Y$$$20250926$$CN$US$US
258542711$25854271$1$I$$20250923$20250926$20250926$EXP$GB-MHRA-MED-202509231211454500-VHSQM$GB-ELI_LILLY_AND_COMPANY-GB202509023739$ELI LILLY AND COMPANY$$$$$$Y$$$20250926$$CN$GB$GB
258542941$25854294$1$I$20250815$20250924$20250927$20250927$EXP$$US-ABBVIE-6478799$ABBVIE$$79$YR$$F$Y$$$20250927$$CN$US$US
258543411$25854341$1$I$20250923$20250923$20250927$20250927$EXP$$US-ABBVIE-6475401$ABBVIE$$28$YR$$M$Y$$$20250926$$CN$US$US
258543852$25854385$2$F$$20250707$20250927$20250927$30DAY$$US-SANDOZ INC.-SDZ2025US065047$SANDOZ$$$$$M$Y$$$20250927$$CN$US$US
258544761$25854476$1$I$$20250916$20250927$20250927$EXP$$GB-862174955-ML2025-04877$MICRO LABS$Shakanti Y, Irhouma A, Hassan A. Kounis Syndrome Triggered by Intravenous Co-Amoxiclav: A Case of Transient ST Elevation in the Context of Anaphylaxis. Cureus. 2025 Aug 08;17(8): 1-7. doi:10.7759/cureus.89641.$9$DEC$E$F$Y$$$20250927$$HP$GB$GB
258545421$25854542$1$I$20250906$20250915$20250927$20250927$PER$$US-GSK-US2025118501$GLAXOSMITHKLINE$$79$YR$$F$Y$$$20250927$$$US$US
258545471$25854547$1$I$$20250915$20250927$20250927$PER$$US-SA-2025SA282561$SANOFI AVENTIS$$$$E$F$Y$68.41$KG$20250926$$MD$US$US
258546071$25854607$1$I$$20250922$20250927$20250927$PER$$US-SA-2025SA287185$SANOFI AVENTIS$$$$A$M$Y$$$20250926$$MD$US$US
258547151$25854715$1$I$$20250915$20250927$20250927$EXP$$CN-SA-2025SA277774$SANOFI AVENTIS$$$$$M$Y$$$20250926$$CN$CN$CN
258547931$25854793$1$I$$20250924$20250927$20250927$PER$$US-SA-2025SA286640$SANOFI AVENTIS$$$$A$F$Y$$$20250926$$HP$US$US
258547941$25854794$1$I$20250101$20250918$20250927$20250927$PER$$US-SA-2025SA283960$SANOFI AVENTIS$$9$YR$C$F$Y$$$20250926$$HP$US$US
258548511$25854851$1$I$20250101$20250922$20250927$20250927$EXP$$BR-SA-2025SA271225$SANOFI AVENTIS$$83$YR$E$M$Y$$$20250926$$MD$BR$BR
258550291$25855029$1$I$20250901$20250919$20250927$20250927$PER$$US-SA-2025SA285864$SANOFI AVENTIS$$37$YR$A$F$Y$$$20250926$$HP$US$US
258550381$25855038$1$I$20250101$20250923$20250927$20250927$PER$$US-SA-2025SA288345$SANOFI AVENTIS$$12$YR$T$F$Y$$$20250927$$HP$US$US
258550891$25855089$1$I$$20250903$20250927$20250927$PER$$US-GSK-US2025114380$GLAXOSMITHKLINE$$$$$M$Y$$$20250927$$$US$US
258551371$25855137$1$I$$20250924$20250927$20250927$PER$$US-ASTRAZENECA-202509USA020713US$ALEXION PHARMACEUTICALS$$$$$F$Y$79.832$KG$20250927$$MD$US$US
258551471$25855147$1$I$$20250924$20250927$20250927$PER$$US-SA-2025SA288574$SANOFI AVENTIS$$$$$F$Y$$$20250927$$HP$US$US
258554161$25855416$1$I$20250101$20250923$20250927$20250927$PER$$US-SA-2025SA288326$SANOFI AVENTIS$$2$YR$C$F$Y$$$20250927$$HP$US$US
258554201$25855420$1$I$$20250917$20250927$20250927$EXP$$US-CHIESI-2025CHF06685$CHIESI$$36$YR$$M$Y$$$20250927$$CN$US$US
258554371$25855437$1$I$$20250924$20250927$20250927$PER$$US-ABBVIE-6479825$ABBVIE$$$$$F$Y$$$20250927$$CN$US$US
258554971$25855497$1$I$$20250924$20250927$20250927$EXP$$JP-ASTRAZENECA-202509JPN020009JP$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250927$$$JP$
258557131$25855713$1$I$20200901$20250919$20250928$20250928$EXP$$US-GSK-US2025AMR121902$GLAXOSMITHKLINE$$67$YR$$F$Y$$$20250928$$$US$US
258557491$25855749$1$I$$20250919$20250928$20250928$EXP$$CN-BEIGENE-BGN-2025-016247$BEIGENE$$79$YR$$$Y$58$KG$20250928$$$CN$CN
258557501$25855750$1$I$20250903$20250923$20250928$20250928$EXP$$EU-ASTRAZENECA-202509EEA005201IE$ALEXION PHARMACEUTICALS$$42$YR$A$F$Y$$$20250928$$$EU$EU
258557961$25855796$1$I$$20250925$20250928$20250928$PER$$US-ELI_LILLY_AND_COMPANY-US202509026219$ELI LILLY AND COMPANY$$$$$F$Y$$$20250928$$CN$US$US
258559721$25855972$1$I$$20250924$20250928$20250928$PER$$US-ELI_LILLY_AND_COMPANY-US202509024773$ELI LILLY AND COMPANY$$60$YR$A$M$Y$$$20250928$$CN$US$US
258561211$25856121$1$I$20250101$20250923$20250928$20250928$EXP$$US-SA-2025SA288042$SANOFI AVENTIS$$74$YR$E$F$Y$$$20250928$$HP$US$US
258562121$25856212$1$I$20250828$20250918$20250928$20250928$PER$$US-ELI_LILLY_AND_COMPANY-US202509020090$ELI LILLY AND COMPANY$$61$YR$A$F$Y$$$20250928$$CN$US$US
258562701$25856270$1$I$20250901$20250917$20250928$20250928$EXP$$US-SERVIER-S25013777$SERVIER$$$$$$Y$$$20250928$$CN$US$US
258563291$25856329$1$I$$20250919$20250928$20250928$EXP$$EU-009507513-2333802$MERCK SHARP + DOHME LLC$M. Spisarova; J. Vymetal; H. Studentova; B. Melichar; K. Hola; A. Zemankova. Cardiac dysfunction in patients with kidney cancer receiving immunotherapy. European Heart Journal Supplements 2025, Volume 27, Suppl 6.$58$YR$$$Y$$$20250928$$HP$EU$EU
258563391$25856339$1$I$20240616$20250922$20250928$20250928$EXP$$KR-009507513-2332582$MERCK SHARP + DOHME LLC$$75$YR$$M$Y$51.3$KG$20250928$$HP$KR$KR
258563411$25856341$1$I$$20250925$20250928$20250928$EXP$$EU-BEIGENE-BGN-2025-016694$BEIGENE$$78$YR$$$Y$$$20250928$$PH$EU$EU
258564491$25856449$1$I$$20250919$20250929$20250929$PER$$US-AMGEN-USASP2025188985$AMGEN$$$$$F$Y$$$20250928$$HP$US$US
258564501$25856450$1$I$20250101$20250924$20250929$20250929$EXP$$US-ABBVIE-6477000$ABBVIE$$48$YR$$M$Y$$$20250929$$CN$US$US
258565521$25856552$1$I$20250101$20250917$20250929$20250929$EXP$$US-UCBSA-2025049921$UCB$$$$$M$Y$94.331$KG$20250926$$HP$US$US
258567061$25856706$1$I$$20250827$20250929$20250929$PER$$US-GSK-US2025AMR110604$GLAXOSMITHKLINE$$$$$F$Y$$$20250927$$$US$US
258567641$25856764$1$I$$20250821$20250929$20250929$PER$$US-GSK-US2025AMR110120$GLAXOSMITHKLINE$$$$$$Y$$$20250928$$$US$US
258567951$25856795$1$I$$20250922$20250929$20250929$PER$$US-ABBVIE-6478314$ABBVIE$$$$$$Y$$$20250929$$HP$US$US
258569401$25856940$1$I$$20250923$20250929$20250929$PER$$US-GSK-US2025AMR122558$GLAXOSMITHKLINE$$$$$$Y$$$20250929$$$US$US
258569541$25856954$1$I$$20241121$20250929$20250929$PER$$US-STRIDES ARCOLAB LIMITED-2024SP015641$STRIDES$Duehlmeyer S, Meier E, Oermann C.. Successful treatment of Stenotrophomonas maltophilia with ceftazidime-avibactam and aztreonam in an individual with cystic fibrosis: A case report.. Pediatr-Pulmonol. 2024$2$DEC$$F$Y$$$20250929$$PH$US$US
258569571$25856957$1$I$20250912$20250919$20250929$20250929$PER$$US-009507513-2331589$MERCK SHARP + DOHME LLC$$15$MON$$$Y$$$20250929$$HP$US$US
258569762$25856976$2$F$$20250926$20250929$20250930$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132763$BRISTOL-MYERS SQUIBB COMPANY$$63$YR$A$F$Y$$$20250930$$$US$US
258569891$25856989$1$I$$20250915$20250929$20250929$EXP$$ID-AUROBINDO-AUR-APL-2025-049997$AUROBINDO$Riswati HP, Rizal A.. Fatal dysfunction of cardiac pacemaker on hyperkalemia patient.. Indones-J-Cardiol. 2023;44 (Suppl.):61$69$YR$$F$Y$$$20250929$$HP$ID$ID
258570231$25857023$1$I$$20250923$20250929$20250929$PER$$US-ABBVIE-6478033$ABBVIE$$$$A$F$Y$$$20250929$$CN$US$US
258570241$25857024$1$I$$20250924$20250929$20250929$EXP$$JP-ASTRAZENECA-202509JPN020172JP$ALEXION PHARMACEUTICALS$$60$YR$A$M$Y$$$20250929$$MD$JP$JP
258570351$25857035$1$I$20250924$20250926$20250929$20250929$PER$$US-ASTRAZENECA-202509USA023478US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250929$$MD$US$US
258570771$25857077$1$I$$20250915$20250929$20250929$EXP$CA-MHPD-E2B_07895654$CA-Accord-505214$ACCORD$$$$$F$Y$58$KG$20250929$$HP$CA$CA
258571591$25857159$1$I$$20250925$20250929$20250929$PER$$US-ASTRAZENECA-202509USA022232US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250929$$$US$US
258571721$25857172$1$I$20240301$20250925$20250929$20250929$EXP$$US-ABBVIE-6478231$ABBVIE$$49$YR$$M$Y$$$20250929$$CN$US$US
258574061$25857406$1$I$20250923$20250924$20250929$20250929$PER$$US-ELI_LILLY_AND_COMPANY-US202509025411$ELI LILLY AND COMPANY$$41$YR$A$F$Y$$$20250929$$CN$US$US
258575351$25857535$1$I$$20250925$20250929$20250929$PER$$US-BIOVITRUM-2025-US-011442$BIOVITRUM$$72$YR$$M$Y$$$20250929$$CN$US$US
258575561$25857556$1$I$$20250925$20250929$20250929$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132647$BRISTOL-MYERS SQUIBB COMPANY$$70$YR$E$M$Y$$$20250929$$$US$US
258575921$25857592$1$I$$20250923$20250929$20250929$PER$$US-009507513-2333067$MERCK SHARP + DOHME LLC$$$$$F$Y$$$20250929$$CN$US$US
258576081$25857608$1$I$20250408$20250926$20250929$20250929$PER$$US-ELI_LILLY_AND_COMPANY-US202509027702$ELI LILLY AND COMPANY$$59$YR$A$F$Y$$$20250929$$CN$US$US
258576711$25857671$1$I$$20241212$20250929$20250929$PER$$US-STRIDES ARCOLAB LIMITED-2024SP016659$STRIDES$Kowalczyk M, Rubinstein PG, Aboulafia DM.. Initial Experience with Thrombopoetin Receptor Agonists (TRA) in 5 Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura (ITP).. Blood. 2014;124 (21):5014$$$A$$Y$$$20250929$$HP$US$US
258576951$25857695$1$I$20250908$20250915$20250929$20250929$EXP$$GB-AUROBINDO-AUR-APL-2025-048169$AUROBINDO$$54$YR$$F$Y$$$20250929$$CN$GB$GB
258577731$25857773$1$I$20240101$20250919$20250929$20250929$EXP$$EU-TORRENT-00029443$TORRENT PHARMA INC.$$28$YR$A$F$Y$$$20250929$$MD$EU$EU
258577841$25857784$1$I$20240926$20250922$20250929$20250929$EXP$$CA-TAKEDA-2024TUS079548$TAKEDA$$70$YR$$M$Y$$$20250929$$MD$CA$CA
258578951$25857895$1$I$20250601$20250916$20250929$20250929$EXP$GB-AUROBINDO-AUR-APL-2025-041944$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2025-10407$ALKEM$$70$YR$$F$Y$$$20250929$$CN$GB$GB
258579671$25857967$1$I$20250901$20250924$20250929$20250929$PER$$US-ABBVIE-6476786$ABBVIE$$78$YR$$F$Y$$$20250929$$CN$US$US
258580741$25858074$1$I$$20250923$20250929$20250929$EXP$$CA-APOTEX-2025AP030516$APOTEX$$81$YR$$M$Y$$$20250929$$CN$CA$CA
258580911$25858091$1$I$20250101$20250924$20250929$20250929$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132134$BRISTOL-MYERS SQUIBB COMPANY$$80$YR$E$M$Y$92.08$KG$20250929$$$US$US
258581491$25858149$1$I$$20250915$20250929$20250929$EXP$$US-AUROBINDO-AUR-APL-2025-047572$AUROBINDO$Creechan P, Lockwood M, Weber BN, Klein A, Haider SW. Use of an IL-1 Inhibitor for Refractory Steroid-Dependent Lupus Pericarditis With Constrictive Physiology. JACC Case Rep. 2025$33$YR$$F$Y$$$20250929$$MD$US$US
258581721$25858172$1$I$$20250923$20250929$20250929$EXP$$US-TAKEDA-2024TUS064906$TAKEDA$$$$$F$Y$$$20250929$$$US$US
258581771$25858177$1$I$20250903$20250904$20250929$20250929$PER$$US-GALDERMA-US2025017036$GALDERMA$$$$$$Y$$$20250929$$CN$US$US
258582221$25858222$1$I$$20250922$20250929$20250929$EXP$$US-ASTELLAS-2025-AER-052600$ASTELLAS$Pearce R. Clinical Variability of Pneumatosis Intestinalis in Cancer Patients: A Case Series. Infectious Diseases in Clinical Practice. 2025 Sep;33(5): 1-4.$68$YR$E$M$Y$$$20250929$$MD$US$US
258583171$25858317$1$I$20140201$20250922$20250929$20250929$PER$$US-TAKEDA-2025TUS083413$TAKEDA$$41$YR$$F$Y$$$20250929$$$US$US
258583661$25858366$1$I$$20250926$20250929$20250929$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-132975$BRISTOL-MYERS SQUIBB COMPANY$$$$$F$Y$$$20250929$$MD$US$US
258584831$25858483$1$I$20160601$20250918$20250929$20250929$EXP$$US-COOPERSURGICAL, INC.-2025CPS006943$COOPERSURGICAL$$35$YR$$F$Y$58.957$KG$20250929$$CN$US$US
258585201$25858520$1$I$20240601$20250917$20250929$20250929$EXP$$BR-ROCHE-10000391972$ROCHE$$68$YR$E$M$Y$$$20250929$$MD$BR$BR
258585351$25858535$1$I$$20250924$20250929$20250929$EXP$$NVSJ2025JP009636$NOVARTIS$$44$YR$$M$Y$$$20250929$$MD$JP$JP
258586501$25858650$1$I$$20250917$20250929$20250929$EXP$$NVSC2025TW146883$NOVARTIS$$$$$M$Y$$$20250929$$MD$TW$TW
258586841$25858684$1$I$20250923$20250924$20250929$20250929$PER$$US-ABBVIE-6477760$ABBVIE$$$$$M$Y$$$20250929$$CN$US$US
258586901$25858690$1$I$$20250923$20250929$20250929$EXP$$US-DSJP-DS-2025-166499-US$DAIICHI$$76$YR$$F$Y$$$20250929$$CN$US$US
258587281$25858728$1$I$20250922$20250926$20250927$20250927$DIR$FDA-CDER-CTU-2025-64925$$FDA-CTU$$75$YR$$F$N$58$KG$20250926$N$$US$
258588001$25858800$1$I$$20250926$20250928$20250928$DIR$FDA-CDER-CTU-2025-64910$$FDA-CTU$$$$$M$N$$$20250926$N$CN$US$
258588091$25858809$1$I$$20250928$20250928$20250928$DIR$FDA-CDER-CTU-2025-64908$$FDA-CTU$$52$YR$$M$N$$$20250928$N$CN$US$
258589401$25858940$1$I$20210101$20250908$20250929$20250929$EXP$$EU-TAKEDA-2025TUS084747$TAKEDA$$76$YR$$M$Y$$$20250929$$MD$EU$EU
258589511$25858951$1$I$$20250922$20250929$20250929$PER$$US-ASTRAZENECA-202509GLO024218US$ALEXION PHARMACEUTICALS$$$$$M$Y$$$20250929$$$US$US
258589621$25858962$1$I$20250922$20250922$20250929$20250929$EXP$$EU-MYLANLABS-2025M1081528$MYLAN$$$$$M$Y$$$20250929$$$EU$EU
258590211$25859021$1$I$20250912$20250919$20250929$20250929$EXP$$JP-JAZZ PHARMACEUTICALS-2025-JP-022803$JAZZ$$$$$F$Y$$$20250929$$MD$JP$JP
258590332$25859033$2$F$$20250929$20250929$20250930$PER$$US-BIOVITRUM-2025-US-013317$BIOVITRUM$$68$YR$$F$Y$$$20250930$$CN$US$US
258590861$25859086$1$I$20210101$20250923$20250929$20250929$EXP$$US-TAKEDA-2025TUS083920$TAKEDA$$$$$F$Y$$$20250929$$$US$US
258590891$25859089$1$I$$20250909$20250929$20250929$PER$$US-KENVUE-20250906317$Kenvue$$$$$F$Y$$$20250929$$CN$US$US
258590931$25859093$1$I$$20250918$20250929$20250929$PER$$US-BAYER-2025A124630$BAYER HEALTHCARE LLC$$$$$$Y$$$20250929$$CN$US$US
258591811$25859181$1$I$20250916$20250917$20250929$20250929$PER$$US-GSK-US2025119740$GLAXOSMITHKLINE$$66$YR$$M$Y$$$20250929$$$US$US
258592031$25859203$1$I$$20250918$20250929$20250929$PER$$US-NEUROCRINE BIOSCIENCES INC.-2025NBI12505$NEUROCRINE BIOSCIENCES$$$$$$Y$$$20250929$$HP$US$US
258593061$25859306$1$I$20250916$20250925$20250929$20250929$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010746$ACADIA PHARMACEUTICALS$$78$YR$$M$Y$$$20250929$$CN$US$US
258593261$25859326$1$I$$20250922$20250929$20250929$EXP$$VN-ROCHE-10000397343$ROCHE$Nguyen L, Le D, Trinh T, Tran Q. Treatment outcomes of waldenstrom macroglobulinemia at the blood transfusion and hematology hospital: A report of 10 clinical cases [Abstract number: 326]. Vietnam medical journal. 2025-Jul;326-34.$$$$$Y$$$20250929$$HP$VN$VN
258594581$25859458$1$I$$20250923$20250929$20250929$EXP$$US-ELI_LILLY_AND_COMPANY-US202509024446$ELI LILLY AND COMPANY$$67$YR$E$F$Y$$$20250929$$CN$US$US
258595341$25859534$1$I$$20250920$20250929$20250929$DIR$FDA-CDER-CTU-2025-64979$$FDA-CTU$$$$$M$N$$$20250920$N$$US$
258595521$25859552$1$I$20250801$20250926$20250929$20250929$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-133075$BRISTOL-MYERS SQUIBB COMPANY$$58$YR$A$$Y$$$20250929$$$US$US
258595611$25859561$1$I$20250301$20250924$20250929$20250929$EXP$$US-ABBVIE-6446390$ABBVIE$$70$YR$$M$Y$$$20250929$$CN$US$US
258596291$25859629$1$I$$20250922$20250929$20250929$PER$$US-ROCHE-10000394631$ROCHE$$$$$$Y$$$20250929$$CN$US$US
258597031$25859703$1$I$20250912$20250926$20250926$20250926$DIR$777796$$FDA-CTU$$19$YR$$M$N$103.8$KG$20250926$N$PH$US$
258597161$25859716$1$I$$20250417$20250929$20250929$PER$$US-PERRIGO-25US005496$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250929$$CN$US$US
258597871$25859787$1$I$20250901$20250923$20250929$20250929$EXP$$CA-SAMSUNG BIOEPIS-SB-2025-32399$SAMSUNG BIOEPIS$$35$YR$A$F$Y$60$KG$20250929$$CN$CA$CA
258598291$25859829$1$I$$20250918$20250929$20250929$EXP$$JP-ROCHE-10000395688$ROCHE$$$$$F$Y$$$20250929$$CN$JP$JP
258598731$25859873$1$I$20200601$20200608$20250929$20250929$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-052176$ZYDUS PHARM$$$$$$Y$$$20250929$$PH$US$US
258599341$25859934$1$I$$20250924$20250929$20250929$PER$$US-BAYER-2025A127914$BAYER HEALTHCARE PHARMACEUTICALS INC.$$$$A$F$Y$$$20250929$$MD$US$US
258600741$25860074$1$I$$20250926$20250929$20250929$EXP$$CN-ASTRAZENECA-202509CHN022552CN$ALEXION PHARMACEUTICALS$$66$YR$E$M$Y$$$20250929$$$CN$CN
258600781$25860078$1$I$$20250723$20250929$20250929$PER$$US-STRIDES ARCOLAB LIMITED-2025SP009926$STRIDES$Gamm DM, Harris A, Mehran RJ, Wood M, Foster CS, Mootha VV.. Mucous membrane pemphigoid with fatal bronchial involvement in a  Seventeen-Year-Old Girl. Cornea. 2006;25:474-478$17$YR$$F$Y$$$20250929$$HP$US$US
258601161$25860116$1$I$20250817$20250819$20250929$20250929$PER$$US-PERRIGO-25US010597$GALPHARM INTERNATIONAL$$$$A$$Y$$$20250929$$CN$US$US
258601571$25860157$1$I$$20250919$20250929$20250929$EXP$$CA-AMGEN-CANSP2025193269$AMGEN$$$$$$Y$$$20250929$$CN$CA$CA
258603981$25860398$1$I$$20250920$20250929$20250929$PER$$US-JNJFOC-20250932609$JOHNSON AND JOHNSON$$$$$F$Y$$$20250929$$HP$US$US
258605521$25860552$1$I$$20250821$20250929$20250929$PER$US-MLMSERVICE-20250814-PI613666-00270-1$US-STRIDES ARCOLAB LIMITED-2025SP011168$STRIDES$Cohen K, Oza V, Malaga-Dieguez L.. Severe Striae Distensae in the Setting of Pediatric Nephrotic Syndrome. Pediatric dermatology. 2025;1-4$12$YR$$F$Y$$$20250929$$MD$US$US
258606211$25860621$1$I$20250929$20250929$20250929$20250929$DIR$778068$$FDA-CTU$$69$YR$$M$N$92$KG$20250929$N$PH$US$
258608921$25860892$1$I$$20250924$20250929$20250929$PER$$US-SA-2025SA289340$SANOFI AVENTIS$$$$A$M$Y$$$20250929$$HP$US$US
258608971$25860897$1$I$20250101$20250922$20250929$20250929$PER$$US-SA-2025SA287298$SANOFI AVENTIS$$12$YR$T$M$Y$$$20250929$$HP$US$US
258609021$25860902$1$I$20250101$20250924$20250929$20250929$PER$$US-SA-2025SA289634$SANOFI AVENTIS$$29$YR$A$M$Y$$$20250929$$HP$US$US
258609041$25860904$1$I$20250801$20250924$20250929$20250929$PER$$US-SA-2025SA289246$SANOFI AVENTIS$$66$YR$E$M$Y$$$20250929$$HP$US$US
258609331$25860933$1$I$$20250922$20250929$20250929$PER$$US-SA-2025SA284577$SANOFI AVENTIS$$73$YR$E$F$Y$$$20250929$$CN$US$US
258609911$25860991$1$I$20250801$20250922$20250929$20250929$PER$$US-SA-2025SA286706$SANOFI AVENTIS$$11$YR$C$F$Y$$$20250929$$HP$US$US
258609951$25860995$1$I$$20250924$20250929$20250929$PER$$US-SA-2025SA289123$SANOFI AVENTIS$$14$YR$T$M$Y$81.6$KG$20250929$$HP$US$US
258610041$25861004$1$I$20250101$20250922$20250929$20250929$PER$$US-SA-2025SA286789$SANOFI AVENTIS$$8$YR$C$F$Y$$$20250929$$HP$US$US
258610121$25861012$1$I$20250901$20250922$20250929$20250929$PER$$US-SA-2025SA284546$SANOFI AVENTIS$$28$YR$A$M$Y$$$20250929$$MD$US$US
258610191$25861019$1$I$20250101$20250923$20250929$20250929$PER$$US-SA-2025SA289223$SANOFI AVENTIS$$39$YR$A$M$Y$$$20250929$$HP$US$US
258612191$25861219$1$I$20250101$20250919$20250929$20250929$EXP$$US-MADRIGAL PHARMACEUTICALS, INC-2025USREZ11611$MADRIGAL PHARMACEUTICALS$$$$$$Y$$$20250929$$CN$US$US
258612282$25861228$2$F$$20250923$20250929$20250929$EXP$$US-AMGEN-USASP2025190968$AMGEN$$$$$$Y$$$20250929$$HP$US$US
258612891$25861289$1$I$20250923$20250923$20250929$20250929$PER$$US-ELI_LILLY_AND_COMPANY-US202509026130$ELI LILLY AND COMPANY$$33$YR$A$M$Y$$$20250929$$CN$US$US
258613781$25861378$1$I$$20250925$20250929$20250929$PER$$US-ASTRAZENECA-202509USA023042US$ALEXION PHARMACEUTICALS$$$$$F$Y$$$20250929$$MD$US$US
258614481$25861448$1$I$$20250922$20250929$20250929$30DAY$$US-SANDOZ INC.-SDZ2025US069778$SANDOZ$$$$$F$Y$$$20250929$$CN$US$US
258615591$25861559$1$I$$20250822$20250930$20250930$PER$$US-GSK-US2025AMR109682$GLAXOSMITHKLINE$$$$$$Y$$$20250929$$$US$US
258615781$25861578$1$I$$20250919$20250930$20250930$EXP$$US-JNJFOC-20250931527$JOHNSON AND JOHNSON$$$$$M$Y$$$20250930$$CN$US$US
258616221$25861622$1$I$$20250918$20250930$20250930$PER$$US-ELI_LILLY_AND_COMPANY-US202509018955$ELI LILLY AND COMPANY$$57$YR$A$F$Y$$$20250930$$CN$US$US
258616781$25861678$1$I$20250606$20250924$20250930$20250930$EXP$EU-MINISAL02-1057486$EU-TEVA-VS-3375810$TEVA$$67$YR$$F$Y$$$20250930$$MD$EU$EU
258618531$25861853$1$I$20250101$20250813$20250930$20250930$PER$$US-CHIESI-2025CHF05741$CHIESI$$$$$F$Y$65$KG$20250930$$CN$US$US
258620141$25862014$1$I$$20250923$20250930$20250930$EXP$$EU-ASTELLAS-2025-AER-052914$ASTELLAS$$$$$F$Y$$$20250930$$MD$EU$EU
258621401$25862140$1$I$$20250926$20250930$20250930$PER$$US-SA-2025SA290119$SANOFI AVENTIS$$61$YR$A$M$Y$$$20250930$$PH$US$US
258622821$25862282$1$I$$20250922$20250930$20250930$EXP$$ID-TEVA-VS-3376630$TEVA$Kadafi SN, Putra GB. Atrial Fibrillation Rapid Ventricular Response in A 55-years-old Woman Followed by ST Elevation Myocardial Infarction: A Case Report. Indones-J-Cardiol 2022; 43 (Suppl.).$55$YR$$F$Y$$$20250930$$HP$ID$ID
258623621$25862362$1$I$$20250924$20250930$20250930$EXP$$GB-ASTRAZENECA-202509GBR022622GB$ALEXION PHARMACEUTICALS$$$$A$M$Y$$$20250930$$$GB$GB
258624381$25862438$1$I$20230301$20250922$20250930$20250930$EXP$GB-MHRA-MED-202410301815169700-WQSLM$GB-TORRENT-00038565$TORRENT PHARMA INC.$$81$YR$E$M$Y$$$20250930$$CN$GB$GB
258624611$25862461$1$I$$20250924$20250930$20250930$EXP$$CA-SAMSUNG BIOEPIS-SB-2025-32470$SAMSUNG BIOEPIS$$55$YR$A$M$Y$$$20250930$$CN$CA$CA
258624661$25862466$1$I$$20250925$20250930$20250930$EXP$$US-JAZZ PHARMACEUTICALS-2025-US-022917$JAZZ$$$$$M$Y$$$20250930$$$US$US
258625021$25862502$1$I$$20250924$20250930$20250930$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2025-PIM-010709$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20250930$$CN$US$US
258627041$25862704$1$I$$20250925$20250930$20250930$EXP$$US-AMGEN-USASP2025193133$AMGEN$$$$$M$Y$$$20250930$$HP$US$US
258627521$25862752$1$I$$20250923$20250930$20250930$EXP$$CA-TAKEDA-2025TUS084243$TAKEDA$$54$YR$$M$Y$$$20250930$$$CA$CA
258627791$25862779$1$I$$20250909$20250930$20250930$PER$$US-KENVUE-20250905190$Kenvue$$$$$F$Y$$$20250930$$CN$US$US
258628921$25862892$1$I$20250101$20250912$20250930$20250930$PER$$US-PYROS PHARMACEUTICALS, INC-20250901203$Pyros Pharmaceuticals$$$$$$Y$$$20250930$$$US$US
258629451$25862945$1$I$20250901$20250928$20250930$20250930$EXP$$CN-ASTRAZENECA-202509CHN024346CN$ALEXION PHARMACEUTICALS$$66$YR$E$F$Y$65$KG$20250930$$$CN$CN
258629731$25862973$1$I$$20250916$20250930$20250930$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2025-10427$ALKEM$Ferreira Felix I, Karlinski Vizentin V, Neves R, Bains S, Bos JM, Giudicessi JR, Ackerman MJ. The Risk of Breakthrough Cardiac Events Associated With Psychiatric Medications in Patients With Diagnosed and Clinically Treated Long QT Syndrome. JACC: Clinical Electrophysiology. 2025;2405-500X:1-10$31$YR$$F$Y$$$20250930$$MD$US$US
258629741$25862974$1$I$$20250918$20250930$20250930$PER$$NVSC2025US146779$NOVARTIS$$$$$M$Y$$$20250930$$HP$US$US
258630621$25863062$1$I$$20250923$20250930$20250930$PER$$US-KENVUE-20250913370$Kenvue$$$$$F$Y$$$20250930$$CN$US$US
258630791$25863079$1$I$20250902$20250930$20250930$20250930$EXP$$SG-B.I. Pharmaceuticals,Inc./Ridgefield-2025-BI-098573$BOEHRINGER INGELHEIM$$82$YR$E$F$Y$$$20250930$$$SG$SG
258632591$25863259$1$I$20250801$20250925$20250930$20250930$EXP$$US-ABBVIE-6478593$ABBVIE$$40$YR$$M$Y$$$20250930$$CN$US$US
258633451$25863345$1$I$$20250922$20250930$20250930$PER$$US-KENVUE-20250913219$Kenvue$$$$$F$Y$$$20250930$$CN$US$US
258634221$25863422$1$I$20250802$20250926$20250930$20250930$PER$$US-LUNDBECK-DKLU4019898$LUNDBECK$$52$YR$A$F$Y$$$20250930$$CN$US$US
258635061$25863506$1$I$$20250919$20250930$20250930$EXP$$EU-JNJFOC-20250932030$JOHNSON AND JOHNSON$Gonzalez-Calle V, Rosi?ol L, Puig N, Ocio E, Bua B, Sureda A, et al. Efficacy and Safety of Iberdomide, Daratumumab, and Dexamethasone, in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: Initial Analysis of the GEM-IBERDARAX trial. 22nd International Myeloma Society Annual Meeting. 2025 Sep;63-64.$$$E$F$Y$$$20250930$$MD$EU$EU
258635681$25863568$1$I$$20250923$20250930$20250930$EXP$$US-GSK-US2025123795$GLAXOSMITHKLINE$$$$$M$Y$$$20250930$$$US$US
258637331$25863733$1$I$$20250924$20250930$20250930$EXP$$EU-MYLANLABS-2025M1083019$MYLAN$Karakaya M, Ragab I, Riehmer V, Erger F, Aly NH, Ryu SW, et al. ELMO2-related intraosseous vascular malformation: new cases with novel pathogenic variants, clinical follow-up and therapeutic approaches. Eur-J-Hum-Genet 2025; 33 (3): 334-343.$7$YR$$M$Y$$$20250930$$$EU$EU
258637841$25863784$1$I$20250924$20250929$20250929$20250929$DIR$778210$$FDA-CTU$$$$$$N$$$20250929$N$CN$US$
258637911$25863791$1$I$$20250908$20250930$20250930$PER$$US-GSK-US2025AMR115909$GLAXOSMITHKLINE$$$$$F$Y$$$20250930$$$US$US
258638201$25863820$1$I$$20250924$20250930$20250930$EXP$$US-JNJFOC-20250939190$JOHNSON AND JOHNSON$$$$$F$Y$$$20250930$$HP$US$US
258638441$25863844$1$I$$20250923$20250930$20250930$EXP$$EU-MYLANLABS-2025M1083049$MYLAN$Smaguc A, Mackovic M, Maric N, Udiljak N. Acute pancreatitis associated with tacrolimus in a lung transplant recipient: a case report and review of literature. Eur-J-Case-Rep-Intern-Med 2025; 12 (9):.$60$YR$$M$Y$$$20250930$$$EU$EU
258640271$25864027$1$I$$20250922$20250930$20250930$PER$$US-KENVUE-20250913695$Kenvue$$$$$F$Y$$$20250930$$CN$US$US
258640591$25864059$1$I$$20250922$20250930$20250930$PER$$US-ABBVIE-6472959$ABBVIE$$$$$$Y$$$20250930$$HP$US$US
258640741$25864074$1$I$$20250927$20250929$20250929$DIR$FDA-CDER-CTU-2025-65340$$FDA-CTU$$$$$M$N$$$20250927$N$CN$US$
258640821$25864082$1$I$20250623$20250929$20250929$20250929$DIR$FDA-CDER-CTU-2025-65308$$FDA-CTU$$38$YR$$F$N$$$20250929$N$$US$
258641271$25864127$1$I$$20250922$20250930$20250930$EXP$$US-MYLANLABS-2025M1082572$MYLAN$Lagos-Villaseca A, Koshkin VS, Kinet MJ, Rosen CA. Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment. J-Voice 2025; 39 (4): 890-895.$84$YR$$M$Y$$$20250930$$$US$US
258641291$25864129$1$I$$20250925$20250930$20250930$EXP$$CA-ABBVIE-6480761$ABBVIE$$$$E$F$Y$$$20250930$$MD$CA$CA
258641501$25864150$1$I$20250811$20250924$20250930$20250930$EXP$$EU-AUROBINDO-AUR-APL-2025-050174$AUROBINDO$$60$YR$$M$Y$88$KG$20250930$$MD$EU$EU
258641531$25864153$1$I$20200811$20200827$20250930$20250930$PER$$US-CADILA HEALTHCARE LIMITED-US-ZYDUS-055355$ZYDUS PHARM$$$$$$Y$$$20250930$$CN$US$US
258642161$25864216$1$I$$20250926$20250930$20250930$PER$$US-ELI_LILLY_AND_COMPANY-US202509028091$ELI LILLY AND COMPANY$$58$YR$A$$Y$$$20250930$$CN$US$US
258642261$25864226$1$I$20250925$20250926$20250930$20250930$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-133637$BRISTOL-MYERS SQUIBB COMPANY$$71$YR$E$M$Y$94.8$KG$20250930$$PH$US$US
258642891$25864289$1$I$$20250922$20250930$20250930$EXP$$US-TEVA-VS-3375451$TEVA$Zaghloul TM, Pio L, Mostafa AG, Halepota H, Mothid SS, Abdelhafeez AH, et al. Nutritional support in children treated for advanced adrenocortical carcinoma. Pediatr-Surg-Int 2025; 41 (1):.$$$I$F$Y$$$20250930$$HP$US$US
258643471$25864347$1$I$$20250926$20250930$20250930$EXP$$US-JNJFOC-20250944464$JOHNSON AND JOHNSON$$6$DEC$A$F$Y$$$20250930$$HP$US$US
258645521$25864552$1$I$20250611$20250929$20250929$20250929$DIR$778000$$FDA-CTU$$69$YR$$F$N$$$20250929$N$CN$US$
258645561$25864556$1$I$$20250922$20250930$20250930$EXP$$US-JUBILANT RADIOPHARMA-2025US000027$Jubilant Radiopharma$Adeel Riaz. Myofibroblastic Proliferation as a Secondary Malignancy From Radioactive Iodine Treatment for Thyroid Carcinoma: A Case Report. Cureus, Springer Nature. 2025$$$$$Y$$$20250930$$MD$US$US
258646761$25864676$1$I$$20250929$20250929$20250929$DIR$778156$$FDA-CTU$$$$$$N$$$20250929$N$CN$US$
258647161$25864716$1$I$20250901$20250925$20250930$20250930$30DAY$$US-PFIZER INC-202500192236$PFIZER$$$$T$M$Y$52.16$KG$20250930$$CN$US$US
258647511$25864751$1$I$20250523$20250918$20250930$20250930$EXP$$GB-GLENMARK PHARMACEUTICALS-2025GMK104143$GLENMARK$$39$YR$$F$Y$62$KG$20250930$$HP$GB$GB
258647531$25864753$1$I$$20250922$20250930$20250930$PER$$US-CHATTEMPRD-2025OHG028927$CHATTEM$$$$$M$Y$$$20250930$$CN$US$US
258648001$25864800$1$I$$20250929$20250929$20250929$DIR$778021$$FDA-CTU$$$$$F$N$$$20250929$N$CN$US$
258648081$25864808$1$I$20240801$20250930$20250930$20250930$DIR$778246$$FDA-CTU$$31$YR$$F$N$189$KG$20250930$N$CN$US$
258649051$25864905$1$I$$20250917$20250930$20250930$EXP$$US-SCIEGENP-2025SCLIT00309$SCIEGEN PHARMACEUTICALS INC$Quizon MR, et al.Hydralazine-induced antineutrophil cytoplasmic antibody-associated glomerulonephritis.Clinical Kidney Journal.AUG-2025;18(08):1-3$88$YR$E$M$Y$$$20250930$$HP$US$US
258649211$25864921$1$I$20250908$20250908$20250930$20250930$PER$$US-GSK-US2025115415$GLAXOSMITHKLINE$$94$YR$$F$Y$$$20250930$$$US$US
258649641$25864964$1$I$$20250928$20250930$20250930$PER$$US-AMGEN-USASP2025194379$AMGEN$$$$$M$Y$$$20250930$$CN$US$US
258649941$25864994$1$I$20250924$20250924$20250930$20250930$PER$$US-ELI_LILLY_AND_COMPANY-US202509025331$ELI LILLY AND COMPANY$$58$YR$A$F$Y$$$20250930$$CN$US$US
258650371$25865037$1$I$20250101$20250924$20250930$20250930$EXP$$EU-MYLANLABS-2025M1082483$MYLAN$Kerner M, Todoroff J, von Schnakenburg C, Amann K, Muller-Kuhnle J. Fatigue, Polyuria, and Hidden Uveitis: A Case of Tubulointerstitial Nephritis and Uveitis Syndrome Diagnosed in Primary Care. Cureus. 2025 Aug 2;17(8):e89245.$15$YR$$F$Y$82$KG$20250930$$MD$EU$EU
258650731$25865073$1$I$$20250917$20250930$20250930$EXP$$CN-NOVITIUMPHARMA-2025CNNVP02396$NOVITIUM PHARMA$Guzailinuer Sailaiajimu.Cerebral Nocardia Infections Following Lung Abscesses in a Kidney Transplant Recipient: A Case Report and Literature Review.Transplantation Proceedings.21-AUG-2025;57 (7):1338-1343$60$YR$A$M$Y$$$20250930$$HP$CN$CN
258651071$25865107$1$I$$20250929$20250929$20250929$DIR$778078$$FDA-CTU$$$$$M$N$$$20250929$N$CN$US$
258651091$25865109$1$I$$20250926$20250930$20250930$EXP$$US-JNJFOC-20250943525$JOHNSON AND JOHNSON$$$$$$Y$$$20250930$$HP$US$US
258651641$25865164$1$I$$20250916$20250930$20250930$EXP$$EU-BAYER-2025A126802$BAYER HEALTHCARE LLC$Dragomir AS, Taujan GC, Dragan MV, Gavrizi-Zafiu L, Chiriac DD, Geru DL, et al.. A rare form of endogenous hypoglycemia uncovered after corticosteroid treatment. Endocrinology, Diabetes and Metabolism Case Reports. 2025;2025:e240149. DOI:10.1530/EDM-24-0149. Endocrinology, Diabetes and Metabolism Case Reports. 2025;2025:3:e240149$52$YR$A$F$Y$$$20250930$$MD$EU$EU
258652961$25865296$1$I$$20250930$20250930$20250930$DIR$FDA-CDER-CTU-2025-65604$$FDA-CTU$$63$YR$$F$N$$$20250930$N$CN$US$
258653991$25865399$1$I$$20250925$20250930$20250930$EXP$$US-GSK-US2025AMR123323$GLAXOSMITHKLINE$$$$$F$Y$$$20250930$$$US$US
258654331$25865433$1$I$20250101$20250924$20250930$20250930$PER$$US-SA-2025SA290419$SANOFI AVENTIS$$66$YR$E$F$Y$$$20250930$$HP$US$US
258654371$25865437$1$I$$20250924$20250930$20250930$PER$$US-SA-2025SA289866$SANOFI AVENTIS$$48$YR$A$F$Y$$$20250930$$HP$US$US
258655381$25865538$1$I$$20250925$20250930$20250930$PER$$US-SA-2025SA290707$SANOFI AVENTIS$$77$YR$E$F$Y$$$20250930$$CN$US$US
258655521$25865552$1$I$20250901$20250925$20250930$20250930$PER$$US-SA-2025SA290606$SANOFI AVENTIS$$20$YR$A$M$Y$$$20250930$$HP$US$US
258655691$25865569$1$I$20250101$20250925$20250930$20250930$PER$$US-SA-2025SA290788$SANOFI AVENTIS$$40$YR$A$M$Y$$$20250930$$HP$US$US
258656381$25865638$1$I$20250901$20250926$20250930$20250930$PER$$US-SA-2025SA290769$SANOFI AVENTIS$$$$$M$Y$$$20250930$$CN$US$US
258658231$25865823$1$I$20250910$20250919$20250930$20250930$EXP$EU-MINISAL02-1057984$EU-ELI_LILLY_AND_COMPANY-IT202509020696$ELI LILLY AND COMPANY$$42$YR$A$F$Y$$$20250930$$CN$EU$EU
258658511$25865851$1$I$20250204$20250923$20250930$20250930$EXP$$EU-ASTRAZENECA-202509GLO020054DE$ALEXION PHARMACEUTICALS$$$$$M$Y$90$KG$20250930$$MD$EU$EU
258660791$25866079$1$I$$20250925$20250930$20250930$PER$$US-BIOGEN-2025BI01325118$BIOGEN$$$$$F$Y$$$20250930$$CN$US$US
258661801$25866180$1$I$20250917$20250930$20250930$20250930$DIR$778342$$FDA-CTU$$57$YR$$F$N$62$KG$20250930$Y$$US$
258662861$25866286$1$I$$20250925$20250930$20250930$EXP$$CA-PFIZER INC-2021702211$MYLAN$$40$YR$$F$Y$96$KG$20250930$$$CA$CA
258663541$25866354$1$I$20250911$20250925$20250930$20250930$EXP$EU-AFSSAPS-MP2025001323$EU-ELI_LILLY_AND_COMPANY-FR202509026664$ELI LILLY AND COMPANY$$44$YR$A$F$Y$78.7$KG$20250930$$CN$EU$EU
258664311$25866431$1$I$20250827$20250917$20250930$20250930$EXP$EU-AFSSAPS-PP2025000981$EU-NOVOPROD-1527074$NOVO NORDISK$$72$YR$$M$Y$80$KG$20250930$$HP$EU$EU
258664931$25866493$1$I$$20250924$20250930$20250930$PER$$US-PFIZER INC-PV202500115592$PFIZER$$62$YR$$F$Y$$$20250930$$MD$US$US
258665071$25866507$1$I$$20250926$20250930$20250930$PER$$US-PFIZER INC-PV202500116568$PFIZER$$68$YR$$F$Y$$$20250930$$HP$US$US
258665111$25866511$1$I$$20250925$20250930$20250930$EXP$$US-SA-2025SA290829$SANOFI AVENTIS$$$$E$M$Y$72.73$KG$20250930$$HP$US$US
258665241$25866524$1$I$20250901$20250918$20250930$20250930$PER$$US-JNJFOC-20250944586$JOHNSON AND JOHNSON$$$$$F$Y$$$20250930$$PH$US$US
258665321$25866532$1$I$$20250924$20250930$20250930$EXP$GB-MHRA-MED-202509242012444050-FTMGR$GB-ELI_LILLY_AND_COMPANY-GB202509025283$ELI LILLY AND COMPANY$$$$$F$Y$$$20250930$$CN$GB$GB
258665621$25866562$1$I$$20250929$20250930$20250930$EXP$$ZA-ASTRAZENECA-202509SSA024283ZA$ALEXION PHARMACEUTICALS$$67$YR$E$M$Y$$$20250930$$$ZA$ZA
258667211$25866721$1$I$$20250925$20250930$20250930$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-2025-133013$BRISTOL-MYERS SQUIBB COMPANY$$43$YR$A$F$Y$$$20250930$$$US$US
258689811$25868981$1$I$20250907$20250930$20250930$20250930$DIR$FDA-CDER-CTU-2025-65651$$FDA-CTU$$70$YR$$M$N$$$20250930$Y$$US$
258697111$25869711$1$I$20250930$20250930$20250930$20250930$DIR$778454$$FDA-CTU$$67$YR$$M$N$$$20250930$N$HP$US$
258698431$25869843$1$I$$20250930$20250930$20250930$DIR$778399$$FDA-CTU$$$$$M$N$$$20250930$N$CN$US$
69804953$6980495$3$F$$20250703$20090429$20250802$EXP$$EU-AstraZeneca-2009AC01116$ALEXION PHARMACEUTICALS$Fuentes EJ, Garcia S, Garrido M, Lorenzo C, Iglesias JM, Sola JE. Succesfull Treatment of Propofol-inducted Priapism With Distal Glans to Corporal Cavernosal Shunt. Journal of Urology (Pediatric Case Report) Elsevier Inc.. 2009;74:113-115$7$YR$C$M$Y$$$20250802$$MD$US$EU
71395843$7139584$3$F$20090708$20250806$20091005$20250814$EXP$$GB-MERCK-0910GBR00002$MERCK SHARP + DOHME LLC$KIDD I MICHAEL, JIM DOWN, ELENI NASTOULI, ROB SHULMAN, PAUL R GRANT, DAVID CJ HOWELL, MERVYN SINGER. H1 N1 pneumonitis treated with intravenous zanamivir. LANCET. 2009; 374: Pg:1036$22$YR$$F$Y$$$20250814$$MD$GB$GB
72753233$7275323$3$F$20091222$20250901$20100210$20250902$EXP$$EU-ELI_LILLY_AND_COMPANY-ES201001005831$ELI LILLY AND COMPANY$$80$YR$E$F$Y$$$20250902$$HP$EU$EU
